[{"header": {"dataset": "BioASQ", "split": "dev"}}]
{"context": "To evaluate short- and mid-term level of imbalance after vestibular schwannoma (VS) microsurgery by the transpetrosal approach, to search for factors predictive of vestibular compensation, and to determine which patient categories need a postoperative vestibular rehabilitation program. Prospective cohort study at a tertiary referral center. Between 2010 and 2011, patients aged 18 to 75 operated on for VS by transpetrosal approaches were included. VS was characterized by its size (Koos classification) and the presence or not of a cystic component. Hearing was classified according to the Gardner Robertson grading. The preoperative workup included an audiogram, computerized video nystagmography (VNG) with caloric testing, gaze study, rotatory tests, click-evoked cervical vestibular evoked myogenic potential measurements (cVEMPs), and subjective visual vertical test. Patients were asked to complete a Dizziness Handicap Inventory (DHI). Postoperatively, patients were reevaluated on D7 (clinical status), D90 (VNG and DHI), and D180 (DHI). Timing and duration of vestibular rehabilitation were also recorded. Forty-eight patients were included. Preoperatively, 77% experienced mild instability problems with a mean DHI score of 14.1 (range 4-32). Postoperatively, 71% reported stable or even improved perceived stability. Mean DHI scores were 28.1 on D90 and 19.8 on D180. Serviceable hearing, cystic transformation, normal cVEMPs, diplopia, and vestibular syndrome on D7 were found to be predictive of worse equilibrium outcome than when absent. A preoperative caloric deficit greater than 75% seemed to be a good prognostic factor. Vestibular rehabilitation was conducted in 56% of patients. Starting it early (<1 mo) seemed to be beneficial for final equilibrium outcome. VS microsurgery provides good stability results. Some preoperative parameters may be predictive of worse or improved balance recovery, as is clinical status on D7.", "qas": [{"question": "Which disease can be categorized using the Koos grading system?", "answers": ["vestibular schwannoma"], "qid": "44cd890f1a1b4d6a9b055e363d1c3221", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["categorized", 21], ["using", 33], ["the", 39], ["Koos", 43], ["grading", 48], ["system", 56], ["?", 62]], "detected_answers": [{"text": "vestibular schwannoma", "token_spans": [[11, 12]], "char_spans": [[57, 77]]}]}], "context_tokens": [["To", 0], ["evaluate", 3], ["short-", 12], ["and", 19], ["mid", 23], ["-", 26], ["term", 27], ["level", 32], ["of", 38], ["imbalance", 41], ["after", 51], ["vestibular", 57], ["schwannoma", 68], ["(", 79], ["VS", 80], [")", 82], ["microsurgery", 84], ["by", 97], ["the", 100], ["transpetrosal", 104], ["approach", 118], [",", 126], ["to", 128], ["search", 131], ["for", 138], ["factors", 142], ["predictive", 150], ["of", 161], ["vestibular", 164], ["compensation", 175], [",", 187], ["and", 189], ["to", 193], ["determine", 196], ["which", 206], ["patient", 212], ["categories", 220], ["need", 231], ["a", 236], ["postoperative", 238], ["vestibular", 252], ["rehabilitation", 263], ["program", 278], [".", 285], ["Prospective", 287], ["cohort", 299], ["study", 306], ["at", 312], ["a", 315], ["tertiary", 317], ["referral", 326], ["center", 335], [".", 341], ["Between", 343], ["2010", 351], ["and", 356], ["2011", 360], [",", 364], ["patients", 366], ["aged", 375], ["18", 380], ["to", 383], ["75", 386], ["operated", 389], ["on", 398], ["for", 401], ["VS", 405], ["by", 408], ["transpetrosal", 411], ["approaches", 425], ["were", 436], ["included", 441], [".", 449], ["VS", 451], ["was", 454], ["characterized", 458], ["by", 472], ["its", 475], ["size", 479], ["(", 484], ["Koos", 485], ["classification", 490], [")", 504], ["and", 506], ["the", 510], ["presence", 514], ["or", 523], ["not", 526], ["of", 530], ["a", 533], ["cystic", 535], ["component", 542], [".", 551], ["Hearing", 553], ["was", 561], ["classified", 565], ["according", 576], ["to", 586], ["the", 589], ["Gardner", 593], ["Robertson", 601], ["grading", 611], [".", 618], ["The", 620], ["preoperative", 624], ["workup", 637], ["included", 644], ["an", 653], ["audiogram", 656], [",", 665], ["computerized", 667], ["video", 680], ["nystagmography", 686], ["(", 701], ["VNG", 702], [")", 705], ["with", 707], ["caloric", 712], ["testing", 720], [",", 727], ["gaze", 729], ["study", 734], [",", 739], ["rotatory", 741], ["tests", 750], [",", 755], ["click", 757], ["-", 762], ["evoked", 763], ["cervical", 770], ["vestibular", 779], ["evoked", 790], ["myogenic", 797], ["potential", 806], ["measurements", 816], ["(", 829], ["cVEMPs", 830], [")", 836], [",", 837], ["and", 839], ["subjective", 843], ["visual", 854], ["vertical", 861], ["test", 870], [".", 874], ["Patients", 876], ["were", 885], ["asked", 890], ["to", 896], ["complete", 899], ["a", 908], ["Dizziness", 910], ["Handicap", 920], ["Inventory", 929], ["(", 939], ["DHI", 940], [")", 943], [".", 944], ["Postoperatively", 946], [",", 961], ["patients", 963], ["were", 972], ["reevaluated", 977], ["on", 989], ["D7", 992], ["(", 995], ["clinical", 996], ["status", 1005], [")", 1011], [",", 1012], ["D90", 1014], ["(", 1018], ["VNG", 1019], ["and", 1023], ["DHI", 1027], [")", 1030], [",", 1031], ["and", 1033], ["D180", 1037], ["(", 1042], ["DHI", 1043], [")", 1046], [".", 1047], ["Timing", 1049], ["and", 1056], ["duration", 1060], ["of", 1069], ["vestibular", 1072], ["rehabilitation", 1083], ["were", 1098], ["also", 1103], ["recorded", 1108], [".", 1116], ["Forty", 1118], ["-", 1123], ["eight", 1124], ["patients", 1130], ["were", 1139], ["included", 1144], [".", 1152], ["Preoperatively", 1154], [",", 1168], ["77", 1170], ["%", 1172], ["experienced", 1174], ["mild", 1186], ["instability", 1191], ["problems", 1203], ["with", 1212], ["a", 1217], ["mean", 1219], ["DHI", 1224], ["score", 1228], ["of", 1234], ["14.1", 1237], ["(", 1242], ["range", 1243], ["4", 1249], ["-", 1250], ["32", 1251], [")", 1253], [".", 1254], ["Postoperatively", 1256], [",", 1271], ["71", 1273], ["%", 1275], ["reported", 1277], ["stable", 1286], ["or", 1293], ["even", 1296], ["improved", 1301], ["perceived", 1310], ["stability", 1320], [".", 1329], ["Mean", 1331], ["DHI", 1336], ["scores", 1340], ["were", 1347], ["28.1", 1352], ["on", 1357], ["D90", 1360], ["and", 1364], ["19.8", 1368], ["on", 1373], ["D180", 1376], [".", 1380], ["Serviceable", 1382], ["hearing", 1394], [",", 1401], ["cystic", 1403], ["transformation", 1410], [",", 1424], ["normal", 1426], ["cVEMPs", 1433], [",", 1439], ["diplopia", 1441], [",", 1449], ["and", 1451], ["vestibular", 1455], ["syndrome", 1466], ["on", 1475], ["D7", 1478], ["were", 1481], ["found", 1486], ["to", 1492], ["be", 1495], ["predictive", 1498], ["of", 1509], ["worse", 1512], ["equilibrium", 1518], ["outcome", 1530], ["than", 1538], ["when", 1543], ["absent", 1548], [".", 1554], ["A", 1556], ["preoperative", 1558], ["caloric", 1571], ["deficit", 1579], ["greater", 1587], ["than", 1595], ["75", 1600], ["%", 1602], ["seemed", 1604], ["to", 1611], ["be", 1614], ["a", 1617], ["good", 1619], ["prognostic", 1624], ["factor", 1635], [".", 1641], ["Vestibular", 1643], ["rehabilitation", 1654], ["was", 1669], ["conducted", 1673], ["in", 1683], ["56", 1686], ["%", 1688], ["of", 1690], ["patients", 1693], [".", 1701], ["Starting", 1703], ["it", 1712], ["early", 1715], ["(", 1721], ["<", 1722], ["1", 1723], ["mo", 1725], [")", 1727], ["seemed", 1729], ["to", 1736], ["be", 1739], ["beneficial", 1742], ["for", 1753], ["final", 1757], ["equilibrium", 1763], ["outcome", 1775], [".", 1782], ["VS", 1784], ["microsurgery", 1787], ["provides", 1800], ["good", 1809], ["stability", 1814], ["results", 1824], [".", 1831], ["Some", 1833], ["preoperative", 1838], ["parameters", 1851], ["may", 1862], ["be", 1866], ["predictive", 1869], ["of", 1880], ["worse", 1883], ["or", 1889], ["improved", 1892], ["balance", 1901], ["recovery", 1909], [",", 1917], ["as", 1919], ["is", 1922], ["clinical", 1925], ["status", 1934], ["on", 1941], ["D7", 1944], [".", 1946]]}
{"context": "The efficacy of the BD GeneOhm methicillin-resistant Staphylococcus aureus (MRSA) assay was assessed by analyzing nasal swabs and swabs from other body sites for the presence of MRSA in a low-prevalence area. From 681 patients with a high risk for MRSA carriage, 1,601 specimens were collected and transported in Amies agar. After discordant analysis, the sensitivity, specificity, positive predictive value, and negative predictive value of the BD GeneOhm MRSA assay were 84.3%, 99.2%, 88.4%, and 98.9%, respectively, compared to culture.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "746d6125a1ae4b47b8868da9703ff04b", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[81, 81], [47, 47], [12, 12], [31, 31]], "char_spans": [[457, 460], [248, 251], [76, 79], [178, 181]]}]}], "context_tokens": [["The", 0], ["efficacy", 4], ["of", 13], ["the", 16], ["BD", 20], ["GeneOhm", 23], ["methicillin", 31], ["-", 42], ["resistant", 43], ["Staphylococcus", 53], ["aureus", 68], ["(", 75], ["MRSA", 76], [")", 80], ["assay", 82], ["was", 88], ["assessed", 92], ["by", 101], ["analyzing", 104], ["nasal", 114], ["swabs", 120], ["and", 126], ["swabs", 130], ["from", 136], ["other", 141], ["body", 147], ["sites", 152], ["for", 158], ["the", 162], ["presence", 166], ["of", 175], ["MRSA", 178], ["in", 183], ["a", 186], ["low", 188], ["-", 191], ["prevalence", 192], ["area", 203], [".", 207], ["From", 209], ["681", 214], ["patients", 218], ["with", 227], ["a", 232], ["high", 234], ["risk", 239], ["for", 244], ["MRSA", 248], ["carriage", 253], [",", 261], ["1,601", 263], ["specimens", 269], ["were", 279], ["collected", 284], ["and", 294], ["transported", 298], ["in", 310], ["Amies", 313], ["agar", 319], [".", 323], ["After", 325], ["discordant", 331], ["analysis", 342], [",", 350], ["the", 352], ["sensitivity", 356], [",", 367], ["specificity", 369], [",", 380], ["positive", 382], ["predictive", 391], ["value", 402], [",", 407], ["and", 409], ["negative", 413], ["predictive", 422], ["value", 433], ["of", 439], ["the", 442], ["BD", 446], ["GeneOhm", 449], ["MRSA", 457], ["assay", 462], ["were", 468], ["84.3", 473], ["%", 477], [",", 478], ["99.2", 480], ["%", 484], [",", 485], ["88.4", 487], ["%", 491], [",", 492], ["and", 494], ["98.9", 498], ["%", 502], [",", 503], ["respectively", 505], [",", 517], ["compared", 519], ["to", 528], ["culture", 531], [".", 538]]}
{"context": "To investigate whether gender is an independent factor associated with disease expression in early rheumatoid arthritis (RA) patients. 438 patients with early RA (disease duration less than one year) were studied. They all were patients with early RA who presented at the Rheumatology Clinic of the University Hospital of Ioannina during the period 1991-2000. All patients fulfilled the American College of Rheumatology criteria for RA. The demographic, clinical, laboratory, radiological and therapeutic characteristics of the disease at diagnosis, and at the last follow-up were analyzed according to gender. We studied 312 women and 126 men with early RA. The female to male ratio was 2.5:1 and the mean age at diagnosis was 49.4 +/- 14.9 years for women and 55.3 +/-15.6 years for men (P < 0.0003). Women had a longer duration of follow-up (P < 0.0003). There were no differences between genders in the general symptoms or the simmetricity of joint involvement at at disease onset. However at disease onset women had a higher erythrocyte sedimentation rate (ESR) (> 30 mm/1st hour), although there were no significant differences between the two groups concerninig the rest of the clinical, laboratory and radiological findings. At the last follow-up women still had a higher ESR (>30 min/1st hour), but no significant differences were found between the two groups concerning the rest of the parameters investigated independently of the follow-up duration. Finally, women and men showed the same degree of radiological changes and functional ability and were treated similarly except for the more frequent use of hydroxychloroquine in women. It seems that gender does not signficantly influence the expression of RA.", "qas": [{"question": "Is Rheumatoid Arthritis more common in men or women?", "answers": ["Women"], "qid": "b3aff0ff72834de8bbd3a3ca13a60532", "question_tokens": [["Is", 0], ["Rheumatoid", 3], ["Arthritis", 14], ["more", 24], ["common", 29], ["in", 36], ["men", 39], ["or", 43], ["women", 46], ["?", 51]], "detected_answers": [{"text": "Women", "token_spans": [[235, 235], [275, 275], [150, 150], [301, 301], [108, 108], [136, 136], [190, 190]], "char_spans": [[1255, 1259], [1470, 1474], [803, 807], [1639, 1643], [626, 630], [752, 756], [1011, 1015]]}]}], "context_tokens": [["To", 0], ["investigate", 3], ["whether", 15], ["gender", 23], ["is", 30], ["an", 33], ["independent", 36], ["factor", 48], ["associated", 55], ["with", 66], ["disease", 71], ["expression", 79], ["in", 90], ["early", 93], ["rheumatoid", 99], ["arthritis", 110], ["(", 120], ["RA", 121], [")", 123], ["patients", 125], [".", 133], ["438", 135], ["patients", 139], ["with", 148], ["early", 153], ["RA", 159], ["(", 162], ["disease", 163], ["duration", 171], ["less", 180], ["than", 185], ["one", 190], ["year", 194], [")", 198], ["were", 200], ["studied", 205], [".", 212], ["They", 214], ["all", 219], ["were", 223], ["patients", 228], ["with", 237], ["early", 242], ["RA", 248], ["who", 251], ["presented", 255], ["at", 265], ["the", 268], ["Rheumatology", 272], ["Clinic", 285], ["of", 292], ["the", 295], ["University", 299], ["Hospital", 310], ["of", 319], ["Ioannina", 322], ["during", 331], ["the", 338], ["period", 342], ["1991", 349], ["-", 353], ["2000", 354], [".", 358], ["All", 360], ["patients", 364], ["fulfilled", 373], ["the", 383], ["American", 387], ["College", 396], ["of", 404], ["Rheumatology", 407], ["criteria", 420], ["for", 429], ["RA", 433], [".", 435], ["The", 437], ["demographic", 441], [",", 452], ["clinical", 454], [",", 462], ["laboratory", 464], [",", 474], ["radiological", 476], ["and", 489], ["therapeutic", 493], ["characteristics", 505], ["of", 521], ["the", 524], ["disease", 528], ["at", 536], ["diagnosis", 539], [",", 548], ["and", 550], ["at", 554], ["the", 557], ["last", 561], ["follow", 566], ["-", 572], ["up", 573], ["were", 576], ["analyzed", 581], ["according", 590], ["to", 600], ["gender", 603], [".", 609], ["We", 611], ["studied", 614], ["312", 622], ["women", 626], ["and", 632], ["126", 636], ["men", 640], ["with", 644], ["early", 649], ["RA", 655], [".", 657], ["The", 659], ["female", 663], ["to", 670], ["male", 673], ["ratio", 678], ["was", 684], ["2.5:1", 688], ["and", 694], ["the", 698], ["mean", 702], ["age", 707], ["at", 711], ["diagnosis", 714], ["was", 724], ["49.4", 728], ["+", 733], ["/-", 734], ["14.9", 737], ["years", 742], ["for", 748], ["women", 752], ["and", 758], ["55.3", 762], ["+", 767], ["/-15.6", 768], ["years", 775], ["for", 781], ["men", 785], ["(", 789], ["P", 790], ["<", 792], ["0.0003", 794], [")", 800], [".", 801], ["Women", 803], ["had", 809], ["a", 813], ["longer", 815], ["duration", 822], ["of", 831], ["follow", 834], ["-", 840], ["up", 841], ["(", 844], ["P", 845], ["<", 847], ["0.0003", 849], [")", 855], [".", 856], ["There", 858], ["were", 864], ["no", 869], ["differences", 872], ["between", 884], ["genders", 892], ["in", 900], ["the", 903], ["general", 907], ["symptoms", 915], ["or", 924], ["the", 927], ["simmetricity", 931], ["of", 944], ["joint", 947], ["involvement", 953], ["at", 965], ["at", 968], ["disease", 971], ["onset", 979], [".", 984], ["However", 986], ["at", 994], ["disease", 997], ["onset", 1005], ["women", 1011], ["had", 1017], ["a", 1021], ["higher", 1023], ["erythrocyte", 1030], ["sedimentation", 1042], ["rate", 1056], ["(", 1061], ["ESR", 1062], [")", 1065], ["(", 1067], [">", 1068], ["30", 1070], ["mm/1st", 1073], ["hour", 1080], [")", 1084], [",", 1085], ["although", 1087], ["there", 1096], ["were", 1102], ["no", 1107], ["significant", 1110], ["differences", 1122], ["between", 1134], ["the", 1142], ["two", 1146], ["groups", 1150], ["concerninig", 1157], ["the", 1169], ["rest", 1173], ["of", 1178], ["the", 1181], ["clinical", 1185], [",", 1193], ["laboratory", 1195], ["and", 1206], ["radiological", 1210], ["findings", 1223], [".", 1231], ["At", 1233], ["the", 1236], ["last", 1240], ["follow", 1245], ["-", 1251], ["up", 1252], ["women", 1255], ["still", 1261], ["had", 1267], ["a", 1271], ["higher", 1273], ["ESR", 1280], ["(", 1284], [">", 1285], ["30", 1286], ["min/1st", 1289], ["hour", 1297], [")", 1301], [",", 1302], ["but", 1304], ["no", 1308], ["significant", 1311], ["differences", 1323], ["were", 1335], ["found", 1340], ["between", 1346], ["the", 1354], ["two", 1358], ["groups", 1362], ["concerning", 1369], ["the", 1380], ["rest", 1384], ["of", 1389], ["the", 1392], ["parameters", 1396], ["investigated", 1407], ["independently", 1420], ["of", 1434], ["the", 1437], ["follow", 1441], ["-", 1447], ["up", 1448], ["duration", 1451], [".", 1459], ["Finally", 1461], [",", 1468], ["women", 1470], ["and", 1476], ["men", 1480], ["showed", 1484], ["the", 1491], ["same", 1495], ["degree", 1500], ["of", 1507], ["radiological", 1510], ["changes", 1523], ["and", 1531], ["functional", 1535], ["ability", 1546], ["and", 1554], ["were", 1558], ["treated", 1563], ["similarly", 1571], ["except", 1581], ["for", 1588], ["the", 1592], ["more", 1596], ["frequent", 1601], ["use", 1610], ["of", 1614], ["hydroxychloroquine", 1617], ["in", 1636], ["women", 1639], [".", 1644], ["It", 1646], ["seems", 1649], ["that", 1655], ["gender", 1660], ["does", 1667], ["not", 1672], ["signficantly", 1676], ["influence", 1689], ["the", 1699], ["expression", 1703], ["of", 1714], ["RA", 1717], [".", 1719]]}
{"context": "ZFHX1B encodes Smad-interacting protein 1, a transcriptional corepressor involved in the transforming growth factors beta (TGFbeta) signaling pathway. ZFHX1B mutations cause a complex developmental phenotype characterized by severe mental retardation (MR) and multiple congenital defects. We compared the distribution of ZFHX1B transcripts during mouse and human embryogenesis as well as in adult mice and humans. This showed that this gene is strongly transcribed at an early stage in the developing peripheral and central nervous systems of both mice and humans, in all neuronal regions of the brains of 25-week human fetuses and adult mice, and at varying levels in numerous nonneural tissues. Northern blot analysis suggested that ZFHX1B undergoes tissue-specific alternative splicing in both species. These results strongly suggest that ZFHX1B determines the transcriptional levels of target genes in various tissues through the combinatorial interactions of its isoforms with different Smad proteins. Thus, as well as causing neural defects, ZFHX1B mutations may also cause other malformations.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "8870a7ba64174735af9856e72fd82aaa", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZFHX1B", "token_spans": [[0, 0], [24, 24], [120, 120], [136, 136], [168, 168], [49, 49]], "char_spans": [[0, 5], [151, 156], [735, 740], [842, 847], [1048, 1053], [321, 326]]}]}], "context_tokens": [["ZFHX1B", 0], ["encodes", 7], ["Smad", 15], ["-", 19], ["interacting", 20], ["protein", 32], ["1", 40], [",", 41], ["a", 43], ["transcriptional", 45], ["corepressor", 61], ["involved", 73], ["in", 82], ["the", 85], ["transforming", 89], ["growth", 102], ["factors", 109], ["beta", 117], ["(", 122], ["TGFbeta", 123], [")", 130], ["signaling", 132], ["pathway", 142], [".", 149], ["ZFHX1B", 151], ["mutations", 158], ["cause", 168], ["a", 174], ["complex", 176], ["developmental", 184], ["phenotype", 198], ["characterized", 208], ["by", 222], ["severe", 225], ["mental", 232], ["retardation", 239], ["(", 251], ["MR", 252], [")", 254], ["and", 256], ["multiple", 260], ["congenital", 269], ["defects", 280], [".", 287], ["We", 289], ["compared", 292], ["the", 301], ["distribution", 305], ["of", 318], ["ZFHX1B", 321], ["transcripts", 328], ["during", 340], ["mouse", 347], ["and", 353], ["human", 357], ["embryogenesis", 363], ["as", 377], ["well", 380], ["as", 385], ["in", 388], ["adult", 391], ["mice", 397], ["and", 402], ["humans", 406], [".", 412], ["This", 414], ["showed", 419], ["that", 426], ["this", 431], ["gene", 436], ["is", 441], ["strongly", 444], ["transcribed", 453], ["at", 465], ["an", 468], ["early", 471], ["stage", 477], ["in", 483], ["the", 486], ["developing", 490], ["peripheral", 501], ["and", 512], ["central", 516], ["nervous", 524], ["systems", 532], ["of", 540], ["both", 543], ["mice", 548], ["and", 553], ["humans", 557], [",", 563], ["in", 565], ["all", 568], ["neuronal", 572], ["regions", 581], ["of", 589], ["the", 592], ["brains", 596], ["of", 603], ["25-week", 606], ["human", 614], ["fetuses", 620], ["and", 628], ["adult", 632], ["mice", 638], [",", 642], ["and", 644], ["at", 648], ["varying", 651], ["levels", 659], ["in", 666], ["numerous", 669], ["nonneural", 678], ["tissues", 688], [".", 695], ["Northern", 697], ["blot", 706], ["analysis", 711], ["suggested", 720], ["that", 730], ["ZFHX1B", 735], ["undergoes", 742], ["tissue", 752], ["-", 758], ["specific", 759], ["alternative", 768], ["splicing", 780], ["in", 789], ["both", 792], ["species", 797], [".", 804], ["These", 806], ["results", 812], ["strongly", 820], ["suggest", 829], ["that", 837], ["ZFHX1B", 842], ["determines", 849], ["the", 860], ["transcriptional", 864], ["levels", 880], ["of", 887], ["target", 890], ["genes", 897], ["in", 903], ["various", 906], ["tissues", 914], ["through", 922], ["the", 930], ["combinatorial", 934], ["interactions", 948], ["of", 961], ["its", 964], ["isoforms", 968], ["with", 977], ["different", 982], ["Smad", 992], ["proteins", 997], [".", 1005], ["Thus", 1007], [",", 1011], ["as", 1013], ["well", 1016], ["as", 1021], ["causing", 1024], ["neural", 1032], ["defects", 1039], [",", 1046], ["ZFHX1B", 1048], ["mutations", 1055], ["may", 1065], ["also", 1069], ["cause", 1074], ["other", 1080], ["malformations", 1086], [".", 1099]]}
{"context": "The reactive oxygen-generating NADPH oxidases (Noxes) function in a variety of biological roles, and can be broadly classified into those that are regulated by subunit interactions and those that are regulated by calcium. The prototypical subunit-regulated Nox, Nox2, is the membrane-associated catalytic subunit of the phagocyte NADPH-oxidase. Nox2 forms a heterodimer with the integral membrane protein, p22phox, and this heterodimer binds to the regulatory subunits p47phox, p67phox, p40phox and the small GTPase Rac, triggering superoxide generation. Nox-organizer protein 1 (NOXO1) and Nox-activator 1 (NOXA1), respective homologs of p47phox and p67phox, together with p22phox and Rac, activate Nox1, a non-phagocytic homolog of Nox2. NOXO1 and p22phox also regulate Nox3, whereas Nox4 requires only p22phox. In this study, we have assembled and analyzed amino acid sequences of Nox regulatory subunit orthologs from vertebrates, a urochordate, an echinoderm, a mollusc, a cnidarian, a choanoflagellate, fungi and a slime mold amoeba to investigate the evolutionary history of these subunits. Ancestral p47phox, p67phox, and p22phox genes are broadly seen in the metazoa, except for the ecdysozoans. The choanoflagellate Monosiga brevicollis, the unicellular organism that is the closest relatives of multicellular animals, encodes early prototypes of p22phox, p47phox as well as the earliest known Nox2-like ancestor of the Nox1-3 subfamily. p67phox- and p47phox-like genes are seen in the sea urchin Strongylocentrotus purpuratus and the limpet Lottia gigantea that also possess Nox2-like co-orthologs of vertebrate Nox1-3. Duplication of primordial p47phox and p67phox genes occurred in vertebrates, with the duplicated branches evolving into NOXO1 and NOXA1. Analysis of characteristic domains of regulatory subunits suggests a novel view of the evolution of Nox: in fish, p40phox participated in regulating both Nox1 and Nox2, but after the appearance of mammals, Nox1 (but not Nox2) became independent of p40phox. In the fish Oryzias latipes, a NOXO1 ortholog retains an autoinhibitory region that is characteristic of mammalian p47phox, and this was subsequently lost from NOXO1 in later vertebrates. Detailed amino acid sequence comparisons identified both putative key residues conserved in characteristic domains and previously unidentified conserved regions. Also, candidate organizer/activator proteins in fungi and amoeba are identified and hypothetical activation models are suggested. This is the first report to provide the comprehensive view of the molecular evolution of regulatory subunits for Nox enzymes. This approach provides clues for understanding the evolution of biochemical and physiological functions for regulatory-subunit-dependent Nox enzymes.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "c9411266b7014dedb3a042e1c5632fa7", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[128, 128], [288, 288], [349, 349], [338, 338], [255, 255]], "char_spans": [[700, 703], [1623, 1626], [1974, 1977], [1922, 1925], [1430, 1433]]}]}], "context_tokens": [["The", 0], ["reactive", 4], ["oxygen", 13], ["-", 19], ["generating", 20], ["NADPH", 31], ["oxidases", 37], ["(", 46], ["Noxes", 47], [")", 52], ["function", 54], ["in", 63], ["a", 66], ["variety", 68], ["of", 76], ["biological", 79], ["roles", 90], [",", 95], ["and", 97], ["can", 101], ["be", 105], ["broadly", 108], ["classified", 116], ["into", 127], ["those", 132], ["that", 138], ["are", 143], ["regulated", 147], ["by", 157], ["subunit", 160], ["interactions", 168], ["and", 181], ["those", 185], ["that", 191], ["are", 196], ["regulated", 200], ["by", 210], ["calcium", 213], [".", 220], ["The", 222], ["prototypical", 226], ["subunit", 239], ["-", 246], ["regulated", 247], ["Nox", 257], [",", 260], ["Nox2", 262], [",", 266], ["is", 268], ["the", 271], ["membrane", 275], ["-", 283], ["associated", 284], ["catalytic", 295], ["subunit", 305], ["of", 313], ["the", 316], ["phagocyte", 320], ["NADPH", 330], ["-", 335], ["oxidase", 336], [".", 343], ["Nox2", 345], ["forms", 350], ["a", 356], ["heterodimer", 358], ["with", 370], ["the", 375], ["integral", 379], ["membrane", 388], ["protein", 397], [",", 404], ["p22phox", 406], [",", 413], ["and", 415], ["this", 419], ["heterodimer", 424], ["binds", 436], ["to", 442], ["the", 445], ["regulatory", 449], ["subunits", 460], ["p47phox", 469], [",", 476], ["p67phox", 478], [",", 485], ["p40phox", 487], ["and", 495], ["the", 499], ["small", 503], ["GTPase", 509], ["Rac", 516], [",", 519], ["triggering", 521], ["superoxide", 532], ["generation", 543], [".", 553], ["Nox", 555], ["-", 558], ["organizer", 559], ["protein", 569], ["1", 577], ["(", 579], ["NOXO1", 580], [")", 585], ["and", 587], ["Nox", 591], ["-", 594], ["activator", 595], ["1", 605], ["(", 607], ["NOXA1", 608], [")", 613], [",", 614], ["respective", 616], ["homologs", 627], ["of", 636], ["p47phox", 639], ["and", 647], ["p67phox", 651], [",", 658], ["together", 660], ["with", 669], ["p22phox", 674], ["and", 682], ["Rac", 686], [",", 689], ["activate", 691], ["Nox1", 700], [",", 704], ["a", 706], ["non", 708], ["-", 711], ["phagocytic", 712], ["homolog", 723], ["of", 731], ["Nox2", 734], [".", 738], ["NOXO1", 740], ["and", 746], ["p22phox", 750], ["also", 758], ["regulate", 763], ["Nox3", 772], [",", 776], ["whereas", 778], ["Nox4", 786], ["requires", 791], ["only", 800], ["p22phox", 805], [".", 812], ["In", 814], ["this", 817], ["study", 822], [",", 827], ["we", 829], ["have", 832], ["assembled", 837], ["and", 847], ["analyzed", 851], ["amino", 860], ["acid", 866], ["sequences", 871], ["of", 881], ["Nox", 884], ["regulatory", 888], ["subunit", 899], ["orthologs", 907], ["from", 917], ["vertebrates", 922], [",", 933], ["a", 935], ["urochordate", 937], [",", 948], ["an", 950], ["echinoderm", 953], [",", 963], ["a", 965], ["mollusc", 967], [",", 974], ["a", 976], ["cnidarian", 978], [",", 987], ["a", 989], ["choanoflagellate", 991], [",", 1007], ["fungi", 1009], ["and", 1015], ["a", 1019], ["slime", 1021], ["mold", 1027], ["amoeba", 1032], ["to", 1039], ["investigate", 1042], ["the", 1054], ["evolutionary", 1058], ["history", 1071], ["of", 1079], ["these", 1082], ["subunits", 1088], [".", 1096], ["Ancestral", 1098], ["p47phox", 1108], [",", 1115], ["p67phox", 1117], [",", 1124], ["and", 1126], ["p22phox", 1130], ["genes", 1138], ["are", 1144], ["broadly", 1148], ["seen", 1156], ["in", 1161], ["the", 1164], ["metazoa", 1168], [",", 1175], ["except", 1177], ["for", 1184], ["the", 1188], ["ecdysozoans", 1192], [".", 1203], ["The", 1205], ["choanoflagellate", 1209], ["Monosiga", 1226], ["brevicollis", 1235], [",", 1246], ["the", 1248], ["unicellular", 1252], ["organism", 1264], ["that", 1273], ["is", 1278], ["the", 1281], ["closest", 1285], ["relatives", 1293], ["of", 1303], ["multicellular", 1306], ["animals", 1320], [",", 1327], ["encodes", 1329], ["early", 1337], ["prototypes", 1343], ["of", 1354], ["p22phox", 1357], [",", 1364], ["p47phox", 1366], ["as", 1374], ["well", 1377], ["as", 1382], ["the", 1385], ["earliest", 1389], ["known", 1398], ["Nox2-like", 1404], ["ancestor", 1414], ["of", 1423], ["the", 1426], ["Nox1", 1430], ["-", 1434], ["3", 1435], ["subfamily", 1437], [".", 1446], ["p67phox-", 1448], ["and", 1457], ["p47phox", 1461], ["-", 1468], ["like", 1469], ["genes", 1474], ["are", 1480], ["seen", 1484], ["in", 1489], ["the", 1492], ["sea", 1496], ["urchin", 1500], ["Strongylocentrotus", 1507], ["purpuratus", 1526], ["and", 1537], ["the", 1541], ["limpet", 1545], ["Lottia", 1552], ["gigantea", 1559], ["that", 1568], ["also", 1573], ["possess", 1578], ["Nox2-like", 1586], ["co", 1596], ["-", 1598], ["orthologs", 1599], ["of", 1609], ["vertebrate", 1612], ["Nox1", 1623], ["-", 1627], ["3", 1628], [".", 1629], ["Duplication", 1631], ["of", 1643], ["primordial", 1646], ["p47phox", 1657], ["and", 1665], ["p67phox", 1669], ["genes", 1677], ["occurred", 1683], ["in", 1692], ["vertebrates", 1695], [",", 1706], ["with", 1708], ["the", 1713], ["duplicated", 1717], ["branches", 1728], ["evolving", 1737], ["into", 1746], ["NOXO1", 1751], ["and", 1757], ["NOXA1", 1761], [".", 1766], ["Analysis", 1768], ["of", 1777], ["characteristic", 1780], ["domains", 1795], ["of", 1803], ["regulatory", 1806], ["subunits", 1817], ["suggests", 1826], ["a", 1835], ["novel", 1837], ["view", 1843], ["of", 1848], ["the", 1851], ["evolution", 1855], ["of", 1865], ["Nox", 1868], [":", 1871], ["in", 1873], ["fish", 1876], [",", 1880], ["p40phox", 1882], ["participated", 1890], ["in", 1903], ["regulating", 1906], ["both", 1917], ["Nox1", 1922], ["and", 1927], ["Nox2", 1931], [",", 1935], ["but", 1937], ["after", 1941], ["the", 1947], ["appearance", 1951], ["of", 1962], ["mammals", 1965], [",", 1972], ["Nox1", 1974], ["(", 1979], ["but", 1980], ["not", 1984], ["Nox2", 1988], [")", 1992], ["became", 1994], ["independent", 2001], ["of", 2013], ["p40phox", 2016], [".", 2023], ["In", 2025], ["the", 2028], ["fish", 2032], ["Oryzias", 2037], ["latipes", 2045], [",", 2052], ["a", 2054], ["NOXO1", 2056], ["ortholog", 2062], ["retains", 2071], ["an", 2079], ["autoinhibitory", 2082], ["region", 2097], ["that", 2104], ["is", 2109], ["characteristic", 2112], ["of", 2127], ["mammalian", 2130], ["p47phox", 2140], [",", 2147], ["and", 2149], ["this", 2153], ["was", 2158], ["subsequently", 2162], ["lost", 2175], ["from", 2180], ["NOXO1", 2185], ["in", 2191], ["later", 2194], ["vertebrates", 2200], [".", 2211], ["Detailed", 2213], ["amino", 2222], ["acid", 2228], ["sequence", 2233], ["comparisons", 2242], ["identified", 2254], ["both", 2265], ["putative", 2270], ["key", 2279], ["residues", 2283], ["conserved", 2292], ["in", 2302], ["characteristic", 2305], ["domains", 2320], ["and", 2328], ["previously", 2332], ["unidentified", 2343], ["conserved", 2356], ["regions", 2366], [".", 2373], ["Also", 2375], [",", 2379], ["candidate", 2381], ["organizer", 2391], ["/", 2400], ["activator", 2401], ["proteins", 2411], ["in", 2420], ["fungi", 2423], ["and", 2429], ["amoeba", 2433], ["are", 2440], ["identified", 2444], ["and", 2455], ["hypothetical", 2459], ["activation", 2472], ["models", 2483], ["are", 2490], ["suggested", 2494], [".", 2503], ["This", 2505], ["is", 2510], ["the", 2513], ["first", 2517], ["report", 2523], ["to", 2530], ["provide", 2533], ["the", 2541], ["comprehensive", 2545], ["view", 2559], ["of", 2564], ["the", 2567], ["molecular", 2571], ["evolution", 2581], ["of", 2591], ["regulatory", 2594], ["subunits", 2605], ["for", 2614], ["Nox", 2618], ["enzymes", 2622], [".", 2629], ["This", 2631], ["approach", 2636], ["provides", 2645], ["clues", 2654], ["for", 2660], ["understanding", 2664], ["the", 2678], ["evolution", 2682], ["of", 2692], ["biochemical", 2695], ["and", 2707], ["physiological", 2711], ["functions", 2725], ["for", 2735], ["regulatory", 2739], ["-", 2749], ["subunit", 2750], ["-", 2757], ["dependent", 2758], ["Nox", 2768], ["enzymes", 2772], [".", 2779]]}
{"context": "In melanoma, transition to the vertical growth phase is the critical step in conversion to a deadly malignant disease. Here, we offer the first evidence that an antioxidant enzyme has a key role in this transition. We found that the antioxidant enzyme peroxiredoxin-2 (Prx2) inversely correlated with the metastatic capacity of human melanoma cells. Silencing Prx2 expression stimulated proliferation and migration, whereas ectopic expression of Prx2 produced the opposite effect. Mechanistic investigations indicated that Prx2 negatively regulated Src/ERK activation status, which in turn fortified adherens junctions function by increasing E-cadherin expression and phospho-Y654-dependent retention of \u03b2-catenin in the plasma membrane. In murine melanoma cells, Prx2 silencing enhanced lung metastasis in vivo. Interestingly, the natural compound gliotoxin, which is known to exert a Prx-like activity, inhibited proliferation and migration as well as lung metastasis of Prx2-deficient melanoma cells. Overall, our findings reveal that Prx2 is a key regulator of invasion and metastasis in melanoma, and also suggest a pharmacologic strategy to effectively decrease deadly malignant forms of this disease.", "qas": [{"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?", "answers": ["antioxidant"], "qid": "4725ab4959074b2b82db8e9b8383de5d", "question_tokens": [["What", 0], ["type", 5], ["of", 10], ["enzyme", 13], ["is", 20], ["peroxiredoxin", 23], ["2", 37], ["(", 39], ["PRDX2", 40], [")", 45], ["?", 46]], "detected_answers": [{"text": "antioxidant", "token_spans": [[44, 44], [30, 30]], "char_spans": [[233, 243], [161, 171]]}]}], "context_tokens": [["In", 0], ["melanoma", 3], [",", 11], ["transition", 13], ["to", 24], ["the", 27], ["vertical", 31], ["growth", 40], ["phase", 47], ["is", 53], ["the", 56], ["critical", 60], ["step", 69], ["in", 74], ["conversion", 77], ["to", 88], ["a", 91], ["deadly", 93], ["malignant", 100], ["disease", 110], [".", 117], ["Here", 119], [",", 123], ["we", 125], ["offer", 128], ["the", 134], ["first", 138], ["evidence", 144], ["that", 153], ["an", 158], ["antioxidant", 161], ["enzyme", 173], ["has", 180], ["a", 184], ["key", 186], ["role", 190], ["in", 195], ["this", 198], ["transition", 203], [".", 213], ["We", 215], ["found", 218], ["that", 224], ["the", 229], ["antioxidant", 233], ["enzyme", 245], ["peroxiredoxin-2", 252], ["(", 268], ["Prx2", 269], [")", 273], ["inversely", 275], ["correlated", 285], ["with", 296], ["the", 301], ["metastatic", 305], ["capacity", 316], ["of", 325], ["human", 328], ["melanoma", 334], ["cells", 343], [".", 348], ["Silencing", 350], ["Prx2", 360], ["expression", 365], ["stimulated", 376], ["proliferation", 387], ["and", 401], ["migration", 405], [",", 414], ["whereas", 416], ["ectopic", 424], ["expression", 432], ["of", 443], ["Prx2", 446], ["produced", 451], ["the", 460], ["opposite", 464], ["effect", 473], [".", 479], ["Mechanistic", 481], ["investigations", 493], ["indicated", 508], ["that", 518], ["Prx2", 523], ["negatively", 528], ["regulated", 539], ["Src", 549], ["/", 552], ["ERK", 553], ["activation", 557], ["status", 568], [",", 574], ["which", 576], ["in", 582], ["turn", 585], ["fortified", 590], ["adherens", 600], ["junctions", 609], ["function", 619], ["by", 628], ["increasing", 631], ["E", 642], ["-", 643], ["cadherin", 644], ["expression", 653], ["and", 664], ["phospho", 668], ["-", 675], ["Y654-dependent", 676], ["retention", 691], ["of", 701], ["\u03b2", 704], ["-", 705], ["catenin", 706], ["in", 714], ["the", 717], ["plasma", 721], ["membrane", 728], [".", 736], ["In", 738], ["murine", 741], ["melanoma", 748], ["cells", 757], [",", 762], ["Prx2", 764], ["silencing", 769], ["enhanced", 779], ["lung", 788], ["metastasis", 793], ["in", 804], ["vivo", 807], [".", 811], ["Interestingly", 813], [",", 826], ["the", 828], ["natural", 832], ["compound", 840], ["gliotoxin", 849], [",", 858], ["which", 860], ["is", 866], ["known", 869], ["to", 875], ["exert", 878], ["a", 884], ["Prx", 886], ["-", 889], ["like", 890], ["activity", 895], [",", 903], ["inhibited", 905], ["proliferation", 915], ["and", 929], ["migration", 933], ["as", 943], ["well", 946], ["as", 951], ["lung", 954], ["metastasis", 959], ["of", 970], ["Prx2-deficient", 973], ["melanoma", 988], ["cells", 997], [".", 1002], ["Overall", 1004], [",", 1011], ["our", 1013], ["findings", 1017], ["reveal", 1026], ["that", 1033], ["Prx2", 1038], ["is", 1043], ["a", 1046], ["key", 1048], ["regulator", 1052], ["of", 1062], ["invasion", 1065], ["and", 1074], ["metastasis", 1078], ["in", 1089], ["melanoma", 1092], [",", 1100], ["and", 1102], ["also", 1106], ["suggest", 1111], ["a", 1119], ["pharmacologic", 1121], ["strategy", 1135], ["to", 1144], ["effectively", 1147], ["decrease", 1159], ["deadly", 1168], ["malignant", 1175], ["forms", 1185], ["of", 1191], ["this", 1194], ["disease", 1199], [".", 1206]]}
{"context": "CADASIL is the most prominent inherited form of vascular dementia. The main clinical features include migraine with aura, stroke, mood disturbances, and cognitive decline, with a mid-life (30s-60s) adult onset. Genetic testing is the gold standard for the diagnosis. CADASIL is caused mostly by missense mutations in the NOTCH3 gene, invariably involving a cysteine residue. Only a couple of splice site mutations have been reported. In a few pathologically defined patients, genetic mutations remain unidentified. We report a family with late-onset CADASIL phenotype carrying a novel intronic deletion in the NOTCH3 gene (c.341-26_24delAAC). Transcript analysis revealed a splicing alteration, with the complete intron 3 retention. The insertion was in-frame and encoded an extra 25 amino acids, including 1 cysteine. This is the first report of an aberrant splicing event of the NOTCH3 gene associated with a mutation far away from the canonical splice site. Our finding suggests that the assays used to evaluate splicing should be mandatory in the diagnostic setting of genetically undefined CADASIL cases.", "qas": [{"question": "Which amino acid residue appears mutated in most of the cases reported with  cadasil syndrome?", "answers": ["Cysteine"], "qid": "dabfffc898254535a9a607a6650d2562", "question_tokens": [["Which", 0], ["amino", 6], ["acid", 12], ["residue", 17], ["appears", 25], ["mutated", 33], ["in", 41], ["most", 44], ["of", 49], ["the", 52], ["cases", 56], ["reported", 62], ["with", 71], [" ", 76], ["cadasil", 77], ["syndrome", 85], ["?", 93]], "detected_answers": [{"text": "Cysteine", "token_spans": [[65, 65], [146, 146]], "char_spans": [[357, 364], [809, 816]]}]}], "context_tokens": [["CADASIL", 0], ["is", 8], ["the", 11], ["most", 15], ["prominent", 20], ["inherited", 30], ["form", 40], ["of", 45], ["vascular", 48], ["dementia", 57], [".", 65], ["The", 67], ["main", 71], ["clinical", 76], ["features", 85], ["include", 94], ["migraine", 102], ["with", 111], ["aura", 116], [",", 120], ["stroke", 122], [",", 128], ["mood", 130], ["disturbances", 135], [",", 147], ["and", 149], ["cognitive", 153], ["decline", 163], [",", 170], ["with", 172], ["a", 177], ["mid", 179], ["-", 182], ["life", 183], ["(", 188], ["30s-60s", 189], [")", 196], ["adult", 198], ["onset", 204], [".", 209], ["Genetic", 211], ["testing", 219], ["is", 227], ["the", 230], ["gold", 234], ["standard", 239], ["for", 248], ["the", 252], ["diagnosis", 256], [".", 265], ["CADASIL", 267], ["is", 275], ["caused", 278], ["mostly", 285], ["by", 292], ["missense", 295], ["mutations", 304], ["in", 314], ["the", 317], ["NOTCH3", 321], ["gene", 328], [",", 332], ["invariably", 334], ["involving", 345], ["a", 355], ["cysteine", 357], ["residue", 366], [".", 373], ["Only", 375], ["a", 380], ["couple", 382], ["of", 389], ["splice", 392], ["site", 399], ["mutations", 404], ["have", 414], ["been", 419], ["reported", 424], [".", 432], ["In", 434], ["a", 437], ["few", 439], ["pathologically", 443], ["defined", 458], ["patients", 466], [",", 474], ["genetic", 476], ["mutations", 484], ["remain", 494], ["unidentified", 501], [".", 513], ["We", 515], ["report", 518], ["a", 525], ["family", 527], ["with", 534], ["late", 539], ["-", 543], ["onset", 544], ["CADASIL", 550], ["phenotype", 558], ["carrying", 568], ["a", 577], ["novel", 579], ["intronic", 585], ["deletion", 594], ["in", 603], ["the", 606], ["NOTCH3", 610], ["gene", 617], ["(", 622], ["c.341", 623], ["-", 628], ["26_24delAAC", 629], [")", 640], [".", 641], ["Transcript", 643], ["analysis", 654], ["revealed", 663], ["a", 672], ["splicing", 674], ["alteration", 683], [",", 693], ["with", 695], ["the", 700], ["complete", 704], ["intron", 713], ["3", 720], ["retention", 722], [".", 731], ["The", 733], ["insertion", 737], ["was", 747], ["in", 751], ["-", 753], ["frame", 754], ["and", 760], ["encoded", 764], ["an", 772], ["extra", 775], ["25", 781], ["amino", 784], ["acids", 790], [",", 795], ["including", 797], ["1", 807], ["cysteine", 809], [".", 817], ["This", 819], ["is", 824], ["the", 827], ["first", 831], ["report", 837], ["of", 844], ["an", 847], ["aberrant", 850], ["splicing", 859], ["event", 868], ["of", 874], ["the", 877], ["NOTCH3", 881], ["gene", 888], ["associated", 893], ["with", 904], ["a", 909], ["mutation", 911], ["far", 920], ["away", 924], ["from", 929], ["the", 934], ["canonical", 938], ["splice", 948], ["site", 955], [".", 959], ["Our", 961], ["finding", 965], ["suggests", 973], ["that", 982], ["the", 987], ["assays", 991], ["used", 998], ["to", 1003], ["evaluate", 1006], ["splicing", 1015], ["should", 1024], ["be", 1031], ["mandatory", 1034], ["in", 1044], ["the", 1047], ["diagnostic", 1051], ["setting", 1062], ["of", 1070], ["genetically", 1073], ["undefined", 1085], ["CADASIL", 1095], ["cases", 1103], [".", 1108]]}
{"context": "To review available studies of empagliflozin, a sodium glucose co-transporter-2 (SGLT2) inhibitor approved in 2014 by the European Commission and the United States Food and Drug Administration for the treatment of type 2 diabetes mellitus (T2DM). PubMed was searched using the search terms empagliflozin, BI 10773, and BI10773, for entries between January 1, 2000, and December 1, 2014. Reference lists from retrieved articles were searched manually for additional peer-reviewed publications. All publications reporting clinical trials of empagliflozin were eligible for inclusion. Empagliflozin is a new once-daily oral SGLT2 inhibitor with a mechanism of action that is independent of \u03b2-cell function and the insulin pathway. Data from a comprehensive phase III clinical trial program have demonstrated its efficacy as monotherapy, as add-on to other glucose-lowering agents, and in different patient populations. In these studies, empagliflozin resulted in improvements in blood glucose levels as well as reductions in body weight and blood pressure. Empagliflozin was well tolerated and was not associated with an increased risk of hypoglycemia versus placebo. The oral antidiabetes agent, empagliflozin, can be used as monotherapy or alongside other glucose-lowering treatments, including insulin, to treat T2DM.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "8e4362d962304849af0e9a9cf344f780", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[108, 108], [14, 14]], "char_spans": [[621, 625], [81, 85]]}]}], "context_tokens": [["To", 0], ["review", 3], ["available", 10], ["studies", 20], ["of", 28], ["empagliflozin", 31], [",", 44], ["a", 46], ["sodium", 48], ["glucose", 55], ["co", 63], ["-", 65], ["transporter-2", 66], ["(", 80], ["SGLT2", 81], [")", 86], ["inhibitor", 88], ["approved", 98], ["in", 107], ["2014", 110], ["by", 115], ["the", 118], ["European", 122], ["Commission", 131], ["and", 142], ["the", 146], ["United", 150], ["States", 157], ["Food", 164], ["and", 169], ["Drug", 173], ["Administration", 178], ["for", 193], ["the", 197], ["treatment", 201], ["of", 211], ["type", 214], ["2", 219], ["diabetes", 221], ["mellitus", 230], ["(", 239], ["T2DM", 240], [")", 244], [".", 245], ["PubMed", 247], ["was", 254], ["searched", 258], ["using", 267], ["the", 273], ["search", 277], ["terms", 284], ["empagliflozin", 290], [",", 303], ["BI", 305], ["10773", 308], [",", 313], ["and", 315], ["BI10773", 319], [",", 326], ["for", 328], ["entries", 332], ["between", 340], ["January", 348], ["1", 356], [",", 357], ["2000", 359], [",", 363], ["and", 365], ["December", 369], ["1", 378], [",", 379], ["2014", 381], [".", 385], ["Reference", 387], ["lists", 397], ["from", 403], ["retrieved", 408], ["articles", 418], ["were", 427], ["searched", 432], ["manually", 441], ["for", 450], ["additional", 454], ["peer", 465], ["-", 469], ["reviewed", 470], ["publications", 479], [".", 491], ["All", 493], ["publications", 497], ["reporting", 510], ["clinical", 520], ["trials", 529], ["of", 536], ["empagliflozin", 539], ["were", 553], ["eligible", 558], ["for", 567], ["inclusion", 571], [".", 580], ["Empagliflozin", 582], ["is", 596], ["a", 599], ["new", 601], ["once", 605], ["-", 609], ["daily", 610], ["oral", 616], ["SGLT2", 621], ["inhibitor", 627], ["with", 637], ["a", 642], ["mechanism", 644], ["of", 654], ["action", 657], ["that", 664], ["is", 669], ["independent", 672], ["of", 684], ["\u03b2", 687], ["-", 688], ["cell", 689], ["function", 694], ["and", 703], ["the", 707], ["insulin", 711], ["pathway", 719], [".", 726], ["Data", 728], ["from", 733], ["a", 738], ["comprehensive", 740], ["phase", 754], ["III", 760], ["clinical", 764], ["trial", 773], ["program", 779], ["have", 787], ["demonstrated", 792], ["its", 805], ["efficacy", 809], ["as", 818], ["monotherapy", 821], [",", 832], ["as", 834], ["add", 837], ["-", 840], ["on", 841], ["to", 844], ["other", 847], ["glucose", 853], ["-", 860], ["lowering", 861], ["agents", 870], [",", 876], ["and", 878], ["in", 882], ["different", 885], ["patient", 895], ["populations", 903], [".", 914], ["In", 916], ["these", 919], ["studies", 925], [",", 932], ["empagliflozin", 934], ["resulted", 948], ["in", 957], ["improvements", 960], ["in", 973], ["blood", 976], ["glucose", 982], ["levels", 990], ["as", 997], ["well", 1000], ["as", 1005], ["reductions", 1008], ["in", 1019], ["body", 1022], ["weight", 1027], ["and", 1034], ["blood", 1038], ["pressure", 1044], [".", 1052], ["Empagliflozin", 1054], ["was", 1068], ["well", 1072], ["tolerated", 1077], ["and", 1087], ["was", 1091], ["not", 1095], ["associated", 1099], ["with", 1110], ["an", 1115], ["increased", 1118], ["risk", 1128], ["of", 1133], ["hypoglycemia", 1136], ["versus", 1149], ["placebo", 1156], [".", 1163], ["The", 1165], ["oral", 1169], ["antidiabetes", 1174], ["agent", 1187], [",", 1192], ["empagliflozin", 1194], [",", 1207], ["can", 1209], ["be", 1213], ["used", 1216], ["as", 1221], ["monotherapy", 1224], ["or", 1236], ["alongside", 1239], ["other", 1249], ["glucose", 1255], ["-", 1262], ["lowering", 1263], ["treatments", 1272], [",", 1282], ["including", 1284], ["insulin", 1294], [",", 1301], ["to", 1303], ["treat", 1306], ["T2DM", 1312], [".", 1316]]}
{"context": "While Clostridium difficile epidemiology is well documented in many European countries, data are largely missing for South Eastern European region. Here we report the PCR ribotype distribution of 249 C.\u00a0difficile isolates received for typing from six hospital settings from Croatia, Bosnia and Herzegovina, Republic of Macedonia and Serbia in time period from 2008 to 2015. Twenty-four PCR ribotypes were detected. The majority of strains from Bosnia and Herzegovina and Serbia belonged to PCR ribotype 027 (65.8%). Other three dominating PCR ribotypes were 176 (18 strains; Croatia), 001/072 (15 strains; all countries) and 014/020 (15 strains; all countries).", "qas": [{"question": "Which main ribotype of Clostridium difficile is responsible of the recent outbreak?", "answers": ["Ribotype 027"], "qid": "7bfea0506db945dca07567f46a77be7c", "question_tokens": [["Which", 0], ["main", 6], ["ribotype", 11], ["of", 20], ["Clostridium", 23], ["difficile", 35], ["is", 45], ["responsible", 48], ["of", 60], ["the", 63], ["recent", 67], ["outbreak", 74], ["?", 82]], "detected_answers": [{"text": "Ribotype 027", "token_spans": [[82, 83]], "char_spans": [[494, 505]]}]}], "context_tokens": [["While", 0], ["Clostridium", 6], ["difficile", 18], ["epidemiology", 28], ["is", 41], ["well", 44], ["documented", 49], ["in", 60], ["many", 63], ["European", 68], ["countries", 77], [",", 86], ["data", 88], ["are", 93], ["largely", 97], ["missing", 105], ["for", 113], ["South", 117], ["Eastern", 123], ["European", 131], ["region", 140], [".", 146], ["Here", 148], ["we", 153], ["report", 156], ["the", 163], ["PCR", 167], ["ribotype", 171], ["distribution", 180], ["of", 193], ["249", 196], ["C.", 200], ["difficile", 203], ["isolates", 213], ["received", 222], ["for", 231], ["typing", 235], ["from", 242], ["six", 247], ["hospital", 251], ["settings", 260], ["from", 269], ["Croatia", 274], [",", 281], ["Bosnia", 283], ["and", 290], ["Herzegovina", 294], [",", 305], ["Republic", 307], ["of", 316], ["Macedonia", 319], ["and", 329], ["Serbia", 333], ["in", 340], ["time", 343], ["period", 348], ["from", 355], ["2008", 360], ["to", 365], ["2015", 368], [".", 372], ["Twenty", 374], ["-", 380], ["four", 381], ["PCR", 386], ["ribotypes", 390], ["were", 400], ["detected", 405], [".", 413], ["The", 415], ["majority", 419], ["of", 428], ["strains", 431], ["from", 439], ["Bosnia", 444], ["and", 451], ["Herzegovina", 455], ["and", 467], ["Serbia", 471], ["belonged", 478], ["to", 487], ["PCR", 490], ["ribotype", 494], ["027", 503], ["(", 507], ["65.8", 508], ["%", 512], [")", 513], [".", 514], ["Other", 516], ["three", 522], ["dominating", 528], ["PCR", 539], ["ribotypes", 543], ["were", 553], ["176", 558], ["(", 562], ["18", 563], ["strains", 566], [";", 573], ["Croatia", 575], [")", 582], [",", 583], ["001/072", 585], ["(", 593], ["15", 594], ["strains", 597], [";", 604], ["all", 606], ["countries", 610], [")", 619], ["and", 621], ["014/020", 625], ["(", 633], ["15", 634], ["strains", 637], [";", 644], ["all", 646], ["countries", 650], [")", 659], [".", 660]]}
{"context": "LHCII, the most abundant membrane protein on earth, is the major light-harvesting complex of plants. It is generally accepted that LHCII is associated with Photosystem II and only as a short-term response to overexcitation of PSII a subset moves to Photosystem I, triggered by its phosphorylation (state1 to state2 transition). However, here we show that in most natural light conditions LHCII serves as an antenna of both Photosystem I and Photosystem II and it is quantitatively demonstrated that this is required to achieve excitation balance between the two photosystems. This allows for acclimation to different light intensities simply by regulating the expression of LHCII genes only. It is demonstrated that indeed the amount of LHCII that is bound to both photosystems decreases when growth light intensity increases and vice versa. Finally, time-resolved fluorescence measurements on the photosynthetic thylakoid membranes show that LHCII is even a more efficient light harvester when associated with Photosystem I than with Photosystem II.", "qas": [{"question": "Which is the most abundant membrane protein on Earth?", "answers": ["Light-harvesting pigment-protein complex of Photosystem II", "LHCII"], "qid": "60b7c837674146058fe26d85952d6ef1", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["abundant", 18], ["membrane", 27], ["protein", 36], ["on", 44], ["Earth", 47], ["?", 52]], "detected_answers": [{"text": "LHCII", "token_spans": [[0, 0], [128, 128], [116, 116], [25, 25], [72, 72], [159, 159]], "char_spans": [[0, 4], [737, 741], [674, 678], [131, 135], [388, 392], [943, 947]]}]}], "context_tokens": [["LHCII", 0], [",", 5], ["the", 7], ["most", 11], ["abundant", 16], ["membrane", 25], ["protein", 34], ["on", 42], ["earth", 45], [",", 50], ["is", 52], ["the", 55], ["major", 59], ["light", 65], ["-", 70], ["harvesting", 71], ["complex", 82], ["of", 90], ["plants", 93], [".", 99], ["It", 101], ["is", 104], ["generally", 107], ["accepted", 117], ["that", 126], ["LHCII", 131], ["is", 137], ["associated", 140], ["with", 151], ["Photosystem", 156], ["II", 168], ["and", 171], ["only", 175], ["as", 180], ["a", 183], ["short", 185], ["-", 190], ["term", 191], ["response", 196], ["to", 205], ["overexcitation", 208], ["of", 223], ["PSII", 226], ["a", 231], ["subset", 233], ["moves", 240], ["to", 246], ["Photosystem", 249], ["I", 261], [",", 262], ["triggered", 264], ["by", 274], ["its", 277], ["phosphorylation", 281], ["(", 297], ["state1", 298], ["to", 305], ["state2", 308], ["transition", 315], [")", 325], [".", 326], ["However", 328], [",", 335], ["here", 337], ["we", 342], ["show", 345], ["that", 350], ["in", 355], ["most", 358], ["natural", 363], ["light", 371], ["conditions", 377], ["LHCII", 388], ["serves", 394], ["as", 401], ["an", 404], ["antenna", 407], ["of", 415], ["both", 418], ["Photosystem", 423], ["I", 435], ["and", 437], ["Photosystem", 441], ["II", 453], ["and", 456], ["it", 460], ["is", 463], ["quantitatively", 466], ["demonstrated", 481], ["that", 494], ["this", 499], ["is", 504], ["required", 507], ["to", 516], ["achieve", 519], ["excitation", 527], ["balance", 538], ["between", 546], ["the", 554], ["two", 558], ["photosystems", 562], [".", 574], ["This", 576], ["allows", 581], ["for", 588], ["acclimation", 592], ["to", 604], ["different", 607], ["light", 617], ["intensities", 623], ["simply", 635], ["by", 642], ["regulating", 645], ["the", 656], ["expression", 660], ["of", 671], ["LHCII", 674], ["genes", 680], ["only", 686], [".", 690], ["It", 692], ["is", 695], ["demonstrated", 698], ["that", 711], ["indeed", 716], ["the", 723], ["amount", 727], ["of", 734], ["LHCII", 737], ["that", 743], ["is", 748], ["bound", 751], ["to", 757], ["both", 760], ["photosystems", 765], ["decreases", 778], ["when", 788], ["growth", 793], ["light", 800], ["intensity", 806], ["increases", 816], ["and", 826], ["vice", 830], ["versa", 835], [".", 840], ["Finally", 842], [",", 849], ["time", 851], ["-", 855], ["resolved", 856], ["fluorescence", 865], ["measurements", 878], ["on", 891], ["the", 894], ["photosynthetic", 898], ["thylakoid", 913], ["membranes", 923], ["show", 933], ["that", 938], ["LHCII", 943], ["is", 949], ["even", 952], ["a", 957], ["more", 959], ["efficient", 964], ["light", 974], ["harvester", 980], ["when", 990], ["associated", 995], ["with", 1006], ["Photosystem", 1011], ["I", 1023], ["than", 1025], ["with", 1030], ["Photosystem", 1035], ["II", 1047], [".", 1049]]}
{"context": "Highly conserved sequences at the 5' splice site and branch site of U12-dependent introns are important determinants for splicing by U12-dependent spliceosomes. This study investigates the in vivo splicing phenotypes of mutations in the branch site consensus sequence of the U12-dependent intron F from a human NOL1 (P120) minigene. Intron F contains a fully consensus branch site sequence (UUCCUUAAC). Mutations at each position were analyzed for their effects on U12-dependent splicing in vivo. Mutations at most positions resulted in a significant reduction of correct U12-dependent splicing. Defects observed included increased unspliced RNA levels, the activation of cryptic U2-dependent 5' and 3' splice sites, and the activation of cryptic U12-dependent branch/3' splice sites. A strong correlation was observed between the predicted thermodynamic stability of the branch site: U12 snRNA interaction and correct U12-dependent splicing. The lack of a polypyrimidine tract between the branch site and 3' splice site of U12-dependent introns and the observed reliance on base-pairing interactions for correct U12-dependent splicing emphasize the importance of RNA/RNA interactions during U12-dependent intron recognition and proper splice site selection.", "qas": [{"question": "Which is the branch site consensus sequence in U12-dependent introns?", "answers": ["UUCCUUAAC"], "qid": "b43e2230834144e38cbeb13c23ffd134", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["branch", 13], ["site", 20], ["consensus", 25], ["sequence", 35], ["in", 44], ["U12-dependent", 47], ["introns", 61], ["?", 68]], "detected_answers": [{"text": "UUCCUUAAC", "token_spans": [[64, 64]], "char_spans": [[391, 399]]}]}], "context_tokens": [["Highly", 0], ["conserved", 7], ["sequences", 17], ["at", 27], ["the", 30], ["5", 34], ["'", 35], ["splice", 37], ["site", 44], ["and", 49], ["branch", 53], ["site", 60], ["of", 65], ["U12-dependent", 68], ["introns", 82], ["are", 90], ["important", 94], ["determinants", 104], ["for", 117], ["splicing", 121], ["by", 130], ["U12-dependent", 133], ["spliceosomes", 147], [".", 159], ["This", 161], ["study", 166], ["investigates", 172], ["the", 185], ["in", 189], ["vivo", 192], ["splicing", 197], ["phenotypes", 206], ["of", 217], ["mutations", 220], ["in", 230], ["the", 233], ["branch", 237], ["site", 244], ["consensus", 249], ["sequence", 259], ["of", 268], ["the", 271], ["U12-dependent", 275], ["intron", 289], ["F", 296], ["from", 298], ["a", 303], ["human", 305], ["NOL1", 311], ["(", 316], ["P120", 317], [")", 321], ["minigene", 323], [".", 331], ["Intron", 333], ["F", 340], ["contains", 342], ["a", 351], ["fully", 353], ["consensus", 359], ["branch", 369], ["site", 376], ["sequence", 381], ["(", 390], ["UUCCUUAAC", 391], [")", 400], [".", 401], ["Mutations", 403], ["at", 413], ["each", 416], ["position", 421], ["were", 430], ["analyzed", 435], ["for", 444], ["their", 448], ["effects", 454], ["on", 462], ["U12-dependent", 465], ["splicing", 479], ["in", 488], ["vivo", 491], [".", 495], ["Mutations", 497], ["at", 507], ["most", 510], ["positions", 515], ["resulted", 525], ["in", 534], ["a", 537], ["significant", 539], ["reduction", 551], ["of", 561], ["correct", 564], ["U12-dependent", 572], ["splicing", 586], [".", 594], ["Defects", 596], ["observed", 604], ["included", 613], ["increased", 622], ["unspliced", 632], ["RNA", 642], ["levels", 646], [",", 652], ["the", 654], ["activation", 658], ["of", 669], ["cryptic", 672], ["U2-dependent", 680], ["5", 693], ["'", 694], ["and", 696], ["3", 700], ["'", 701], ["splice", 703], ["sites", 710], [",", 715], ["and", 717], ["the", 721], ["activation", 725], ["of", 736], ["cryptic", 739], ["U12-dependent", 747], ["branch/3", 761], ["'", 769], ["splice", 771], ["sites", 778], [".", 783], ["A", 785], ["strong", 787], ["correlation", 794], ["was", 806], ["observed", 810], ["between", 819], ["the", 827], ["predicted", 831], ["thermodynamic", 841], ["stability", 855], ["of", 865], ["the", 868], ["branch", 872], ["site", 879], [":", 883], ["U12", 885], ["snRNA", 889], ["interaction", 895], ["and", 907], ["correct", 911], ["U12-dependent", 919], ["splicing", 933], [".", 941], ["The", 943], ["lack", 947], ["of", 952], ["a", 955], ["polypyrimidine", 957], ["tract", 972], ["between", 978], ["the", 986], ["branch", 990], ["site", 997], ["and", 1002], ["3", 1006], ["'", 1007], ["splice", 1009], ["site", 1016], ["of", 1021], ["U12-dependent", 1024], ["introns", 1038], ["and", 1046], ["the", 1050], ["observed", 1054], ["reliance", 1063], ["on", 1072], ["base", 1075], ["-", 1079], ["pairing", 1080], ["interactions", 1088], ["for", 1101], ["correct", 1105], ["U12-dependent", 1113], ["splicing", 1127], ["emphasize", 1136], ["the", 1146], ["importance", 1150], ["of", 1161], ["RNA", 1164], ["/", 1167], ["RNA", 1168], ["interactions", 1172], ["during", 1185], ["U12-dependent", 1192], ["intron", 1206], ["recognition", 1213], ["and", 1225], ["proper", 1229], ["splice", 1236], ["site", 1243], ["selection", 1248], [".", 1257]]}
{"context": "Restless Legs Syndrome (RLS) or Willis-Ekbom Disease (WED) is highly prevalent, but patients and healthcare providers alike know little about it. Furthermore, controversy persists as to the best way of diagnosing this nosological entity. To verify whether the term used to refer to this disease entity (Restless Legs Syndrome or Willis-Ekbom Disease) affects the prevalence of self-diagnosed RLS/WED in a sample of newly graduated physicians. Newly graduated physicians were asked to self-evaluate for the presence of RLS/WED. Briefly, participants were allocated randomly across two groups. One was asked to self-assess for RLS, while the other was asked to self-assess for WED. The evaluation form given to one group asked 'Do you have Restless Legs Syndrome?' whereas the form given to participants in the other group asked 'Do you have Willis-Ekbom Disease?'. Both forms also contained the four criteria for diagnosing RLS proposed by the International Restless Legs Syndrome Study Group (IRLSSG) and instructions for self-diagnosis according to these criteria. The study sample comprised 1413 newly graduated physicians. Of the 708 participants who were given the form that used the term RLS, 87 (12.28%) diagnosed themselves with the condition. Conversely, of 705 physicians given the form with the term WED, 13 (1.84%) diagnosed themselves with the condition (p\u2009<0.0001). A greater proportion of newly graduated physicians diagnosed themselves with RLS/WED when presented with the term Restless Legs Syndrome than when presented with the term Willis-Ekbom Disease. This suggests that the term Restless Legs Syndrome may not be the most appropriate term to denote this nosological entity.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "16a25da84839436a89074d9ddedd979f", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[145, 147], [306, 308], [186, 188], [57, 59], [0, 2], [287, 289]], "char_spans": [[738, 759], [1600, 1621], [957, 978], [303, 324], [0, 21], [1493, 1514]]}]}], "context_tokens": [["Restless", 0], ["Legs", 9], ["Syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], ["or", 29], ["Willis", 32], ["-", 38], ["Ekbom", 39], ["Disease", 45], ["(", 53], ["WED", 54], [")", 57], ["is", 59], ["highly", 62], ["prevalent", 69], [",", 78], ["but", 80], ["patients", 84], ["and", 93], ["healthcare", 97], ["providers", 108], ["alike", 118], ["know", 124], ["little", 129], ["about", 136], ["it", 142], [".", 144], ["Furthermore", 146], [",", 157], ["controversy", 159], ["persists", 171], ["as", 180], ["to", 183], ["the", 186], ["best", 190], ["way", 195], ["of", 199], ["diagnosing", 202], ["this", 213], ["nosological", 218], ["entity", 230], [".", 236], ["To", 238], ["verify", 241], ["whether", 248], ["the", 256], ["term", 260], ["used", 265], ["to", 270], ["refer", 273], ["to", 279], ["this", 282], ["disease", 287], ["entity", 295], ["(", 302], ["Restless", 303], ["Legs", 312], ["Syndrome", 317], ["or", 326], ["Willis", 329], ["-", 335], ["Ekbom", 336], ["Disease", 342], [")", 349], ["affects", 351], ["the", 359], ["prevalence", 363], ["of", 374], ["self", 377], ["-", 381], ["diagnosed", 382], ["RLS", 392], ["/", 395], ["WED", 396], ["in", 400], ["a", 403], ["sample", 405], ["of", 412], ["newly", 415], ["graduated", 421], ["physicians", 431], [".", 441], ["Newly", 443], ["graduated", 449], ["physicians", 459], ["were", 470], ["asked", 475], ["to", 481], ["self", 484], ["-", 488], ["evaluate", 489], ["for", 498], ["the", 502], ["presence", 506], ["of", 515], ["RLS", 518], ["/", 521], ["WED", 522], [".", 525], ["Briefly", 527], [",", 534], ["participants", 536], ["were", 549], ["allocated", 554], ["randomly", 564], ["across", 573], ["two", 580], ["groups", 584], [".", 590], ["One", 592], ["was", 596], ["asked", 600], ["to", 606], ["self", 609], ["-", 613], ["assess", 614], ["for", 621], ["RLS", 625], [",", 628], ["while", 630], ["the", 636], ["other", 640], ["was", 646], ["asked", 650], ["to", 656], ["self", 659], ["-", 663], ["assess", 664], ["for", 671], ["WED", 675], [".", 678], ["The", 680], ["evaluation", 684], ["form", 695], ["given", 700], ["to", 706], ["one", 709], ["group", 713], ["asked", 719], ["'", 725], ["Do", 726], ["you", 729], ["have", 733], ["Restless", 738], ["Legs", 747], ["Syndrome", 752], ["?", 760], ["'", 761], ["whereas", 763], ["the", 771], ["form", 775], ["given", 780], ["to", 786], ["participants", 789], ["in", 802], ["the", 805], ["other", 809], ["group", 815], ["asked", 821], ["'", 827], ["Do", 828], ["you", 831], ["have", 835], ["Willis", 840], ["-", 846], ["Ekbom", 847], ["Disease", 853], ["?", 860], ["'", 861], [".", 862], ["Both", 864], ["forms", 869], ["also", 875], ["contained", 880], ["the", 890], ["four", 894], ["criteria", 899], ["for", 908], ["diagnosing", 912], ["RLS", 923], ["proposed", 927], ["by", 936], ["the", 939], ["International", 943], ["Restless", 957], ["Legs", 966], ["Syndrome", 971], ["Study", 980], ["Group", 986], ["(", 992], ["IRLSSG", 993], [")", 999], ["and", 1001], ["instructions", 1005], ["for", 1018], ["self", 1022], ["-", 1026], ["diagnosis", 1027], ["according", 1037], ["to", 1047], ["these", 1050], ["criteria", 1056], [".", 1064], ["The", 1066], ["study", 1070], ["sample", 1076], ["comprised", 1083], ["1413", 1093], ["newly", 1098], ["graduated", 1104], ["physicians", 1114], [".", 1124], ["Of", 1126], ["the", 1129], ["708", 1133], ["participants", 1137], ["who", 1150], ["were", 1154], ["given", 1159], ["the", 1165], ["form", 1169], ["that", 1174], ["used", 1179], ["the", 1184], ["term", 1188], ["RLS", 1193], [",", 1196], ["87", 1198], ["(", 1201], ["12.28", 1202], ["%", 1207], [")", 1208], ["diagnosed", 1210], ["themselves", 1220], ["with", 1231], ["the", 1236], ["condition", 1240], [".", 1249], ["Conversely", 1251], [",", 1261], ["of", 1263], ["705", 1266], ["physicians", 1270], ["given", 1281], ["the", 1287], ["form", 1291], ["with", 1296], ["the", 1301], ["term", 1305], ["WED", 1310], [",", 1313], ["13", 1315], ["(", 1318], ["1.84", 1319], ["%", 1323], [")", 1324], ["diagnosed", 1326], ["themselves", 1336], ["with", 1347], ["the", 1352], ["condition", 1356], ["(", 1366], ["p", 1367], ["<", 1369], ["0.0001", 1370], [")", 1376], [".", 1377], ["A", 1379], ["greater", 1381], ["proportion", 1389], ["of", 1400], ["newly", 1403], ["graduated", 1409], ["physicians", 1419], ["diagnosed", 1430], ["themselves", 1440], ["with", 1451], ["RLS", 1456], ["/", 1459], ["WED", 1460], ["when", 1464], ["presented", 1469], ["with", 1479], ["the", 1484], ["term", 1488], ["Restless", 1493], ["Legs", 1502], ["Syndrome", 1507], ["than", 1516], ["when", 1521], ["presented", 1526], ["with", 1536], ["the", 1541], ["term", 1545], ["Willis", 1550], ["-", 1556], ["Ekbom", 1557], ["Disease", 1563], [".", 1570], ["This", 1572], ["suggests", 1577], ["that", 1586], ["the", 1591], ["term", 1595], ["Restless", 1600], ["Legs", 1609], ["Syndrome", 1614], ["may", 1623], ["not", 1627], ["be", 1631], ["the", 1634], ["most", 1638], ["appropriate", 1643], ["term", 1655], ["to", 1660], ["denote", 1663], ["this", 1670], ["nosological", 1675], ["entity", 1687], [".", 1693]]}
{"context": "Restless legs syndrome (RLS), also known as Willis-Ekbom disease, is characterised by abnormal sensations in the legs as well as dysaesthesia. Although the aetiology of RLS has not yet been determined, it may be associated with systemic inflammation. The neutrophil-to-lymphocyte ratio (NLR) is a new and simple marker indicating systemic inflammation. The present study aimed to investigate the relationship between systemic inflammation and RLS through the use of the NLR. A total of 75 newly diagnosed patients with RLS and 56 healthy control subjects were included in the study. Baseline NLR was calculated by dividing the absolute neutrophil count by the absolute lymphocyte count. The NLRs of the two groups were compared. There were no significant differences in gender and age between the two groups. The NLR was 1.96 \u00b1 0.66 in the patient group and 1.67 \u00b1 0.68 in the control group (p = 0.005). Receiver operating characteristic analysis was performed to determine the cut-off value of NLR to predict RLS. The NLR was predictive at 1.58 with a 64% sensitivity and 50% specificity (95% confidence interval 0.55-0.74, area under curve 0.648 \u00b1 0.05). The NLR was found to be statistically higher in patients with RLS and may be used to predict RLS. The aetiology of RLS remains undetermined. The present study showed that systemic inflammation may play a role in RLS. However, RLS could also be associated with systemic inflammatory diseases. This relationship is supported by high NLR values, which are related to chronic systemic inflammation.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "10121cea2cf84ddb98d1d1e853f2f446", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], [",", 28], ["also", 30], ["known", 35], ["as", 41], ["Willis", 44], ["-", 50], ["Ekbom", 51], ["disease", 57], [",", 64], ["is", 66], ["characterised", 69], ["by", 83], ["abnormal", 86], ["sensations", 95], ["in", 106], ["the", 109], ["legs", 113], ["as", 118], ["well", 121], ["as", 126], ["dysaesthesia", 129], [".", 141], ["Although", 143], ["the", 152], ["aetiology", 156], ["of", 166], ["RLS", 169], ["has", 173], ["not", 177], ["yet", 181], ["been", 185], ["determined", 190], [",", 200], ["it", 202], ["may", 205], ["be", 209], ["associated", 212], ["with", 223], ["systemic", 228], ["inflammation", 237], [".", 249], ["The", 251], ["neutrophil", 255], ["-", 265], ["to", 266], ["-", 268], ["lymphocyte", 269], ["ratio", 280], ["(", 286], ["NLR", 287], [")", 290], ["is", 292], ["a", 295], ["new", 297], ["and", 301], ["simple", 305], ["marker", 312], ["indicating", 319], ["systemic", 330], ["inflammation", 339], [".", 351], ["The", 353], ["present", 357], ["study", 365], ["aimed", 371], ["to", 377], ["investigate", 380], ["the", 392], ["relationship", 396], ["between", 409], ["systemic", 417], ["inflammation", 426], ["and", 439], ["RLS", 443], ["through", 447], ["the", 455], ["use", 459], ["of", 463], ["the", 466], ["NLR", 470], [".", 473], ["A", 475], ["total", 477], ["of", 483], ["75", 486], ["newly", 489], ["diagnosed", 495], ["patients", 505], ["with", 514], ["RLS", 519], ["and", 523], ["56", 527], ["healthy", 530], ["control", 538], ["subjects", 546], ["were", 555], ["included", 560], ["in", 569], ["the", 572], ["study", 576], [".", 581], ["Baseline", 583], ["NLR", 592], ["was", 596], ["calculated", 600], ["by", 611], ["dividing", 614], ["the", 623], ["absolute", 627], ["neutrophil", 636], ["count", 647], ["by", 653], ["the", 656], ["absolute", 660], ["lymphocyte", 669], ["count", 680], [".", 685], ["The", 687], ["NLRs", 691], ["of", 696], ["the", 699], ["two", 703], ["groups", 707], ["were", 714], ["compared", 719], [".", 727], ["There", 729], ["were", 735], ["no", 740], ["significant", 743], ["differences", 755], ["in", 767], ["gender", 770], ["and", 777], ["age", 781], ["between", 785], ["the", 793], ["two", 797], ["groups", 801], [".", 807], ["The", 809], ["NLR", 813], ["was", 817], ["1.96", 821], ["\u00b1", 826], ["0.66", 828], ["in", 833], ["the", 836], ["patient", 840], ["group", 848], ["and", 854], ["1.67", 858], ["\u00b1", 863], ["0.68", 865], ["in", 870], ["the", 873], ["control", 877], ["group", 885], ["(", 891], ["p", 892], ["=", 894], ["0.005", 896], [")", 901], [".", 902], ["Receiver", 904], ["operating", 913], ["characteristic", 923], ["analysis", 938], ["was", 947], ["performed", 951], ["to", 961], ["determine", 964], ["the", 974], ["cut", 978], ["-", 981], ["off", 982], ["value", 986], ["of", 992], ["NLR", 995], ["to", 999], ["predict", 1002], ["RLS", 1010], [".", 1013], ["The", 1015], ["NLR", 1019], ["was", 1023], ["predictive", 1027], ["at", 1038], ["1.58", 1041], ["with", 1046], ["a", 1051], ["64", 1053], ["%", 1055], ["sensitivity", 1057], ["and", 1069], ["50", 1073], ["%", 1075], ["specificity", 1077], ["(", 1089], ["95", 1090], ["%", 1092], ["confidence", 1094], ["interval", 1105], ["0.55", 1114], ["-", 1118], ["0.74", 1119], [",", 1123], ["area", 1125], ["under", 1130], ["curve", 1136], ["0.648", 1142], ["\u00b1", 1148], ["0.05", 1150], [")", 1154], [".", 1155], ["The", 1157], ["NLR", 1161], ["was", 1165], ["found", 1169], ["to", 1175], ["be", 1178], ["statistically", 1181], ["higher", 1195], ["in", 1202], ["patients", 1205], ["with", 1214], ["RLS", 1219], ["and", 1223], ["may", 1227], ["be", 1231], ["used", 1234], ["to", 1239], ["predict", 1242], ["RLS", 1250], [".", 1253], ["The", 1255], ["aetiology", 1259], ["of", 1269], ["RLS", 1272], ["remains", 1276], ["undetermined", 1284], [".", 1296], ["The", 1298], ["present", 1302], ["study", 1310], ["showed", 1316], ["that", 1323], ["systemic", 1328], ["inflammation", 1337], ["may", 1350], ["play", 1354], ["a", 1359], ["role", 1361], ["in", 1366], ["RLS", 1369], [".", 1372], ["However", 1374], [",", 1381], ["RLS", 1383], ["could", 1387], ["also", 1393], ["be", 1398], ["associated", 1401], ["with", 1412], ["systemic", 1417], ["inflammatory", 1426], ["diseases", 1439], [".", 1447], ["This", 1449], ["relationship", 1454], ["is", 1467], ["supported", 1470], ["by", 1480], ["high", 1483], ["NLR", 1488], ["values", 1492], [",", 1498], ["which", 1500], ["are", 1506], ["related", 1510], ["to", 1518], ["chronic", 1521], ["systemic", 1529], ["inflammation", 1538], [".", 1550]]}
{"context": "Peripheral neuropathy (PN) has been reported in idiopathic and hereditary forms of parkinsonism, but the pathogenic mechanisms are unclear and likely heterogeneous. Levodopa-induced vitamin B12 deficiency has been discussed as a causal factor of PN in idiopathic Parkinson's disease, but peripheral nervous system involvement might also be a consequence of the underlying neurodegenerative process. Occurrence of PN with parkinsonism has been associated with a panel of mitochondrial cytopathies, more frequently related to a nuclear gene defect and mainly polymerase gamma (POLG1) gene. Parkin (PARK2) gene mutations are responsible for juvenile parkinsonism, and possible peripheral nervous system involvement has been reported. Rarely, an association of parkinsonism with PN may be encountered in other neurodegenerative diseases such as fragile X-associated tremor and ataxia syndrome related to premutation CGG repeat expansion in the fragile X mental retardation (FMR1) gene, Machado-Joseph disease related to an abnormal CAG repeat expansion in ataxin-3 (ATXN3) gene, Kufor-Rakeb syndrome caused by mutations in ATP13A2 gene, or in hereditary systemic disorders such as Gaucher disease due to mutations in the \u03b2-glucocerebrosidase (GBA) gene and Chediak-Higashi syndrome due to LYST gene mutations. This article reviews conditions in which PN may coexist with parkinsonism.", "qas": [{"question": "Which mutated gene causes the Ch\u00e9diak\u2013Higashi Syndrome?", "answers": ["lysosomal trafficking regulator gene", "LYST gene"], "qid": "ccaf40e8947045dbb86dafd325b2f626", "question_tokens": [["Which", 0], ["mutated", 6], ["gene", 14], ["causes", 19], ["the", 26], ["Ch\u00e9diak", 30], ["\u2013", 37], ["Higashi", 38], ["Syndrome", 46], ["?", 54]], "detected_answers": [{"text": "LYST gene", "token_spans": [[216, 217]], "char_spans": [[1285, 1293]]}]}], "context_tokens": [["Peripheral", 0], ["neuropathy", 11], ["(", 22], ["PN", 23], [")", 25], ["has", 27], ["been", 31], ["reported", 36], ["in", 45], ["idiopathic", 48], ["and", 59], ["hereditary", 63], ["forms", 74], ["of", 80], ["parkinsonism", 83], [",", 95], ["but", 97], ["the", 101], ["pathogenic", 105], ["mechanisms", 116], ["are", 127], ["unclear", 131], ["and", 139], ["likely", 143], ["heterogeneous", 150], [".", 163], ["Levodopa", 165], ["-", 173], ["induced", 174], ["vitamin", 182], ["B12", 190], ["deficiency", 194], ["has", 205], ["been", 209], ["discussed", 214], ["as", 224], ["a", 227], ["causal", 229], ["factor", 236], ["of", 243], ["PN", 246], ["in", 249], ["idiopathic", 252], ["Parkinson", 263], ["'s", 272], ["disease", 275], [",", 282], ["but", 284], ["peripheral", 288], ["nervous", 299], ["system", 307], ["involvement", 314], ["might", 326], ["also", 332], ["be", 337], ["a", 340], ["consequence", 342], ["of", 354], ["the", 357], ["underlying", 361], ["neurodegenerative", 372], ["process", 390], [".", 397], ["Occurrence", 399], ["of", 410], ["PN", 413], ["with", 416], ["parkinsonism", 421], ["has", 434], ["been", 438], ["associated", 443], ["with", 454], ["a", 459], ["panel", 461], ["of", 467], ["mitochondrial", 470], ["cytopathies", 484], [",", 495], ["more", 497], ["frequently", 502], ["related", 513], ["to", 521], ["a", 524], ["nuclear", 526], ["gene", 534], ["defect", 539], ["and", 546], ["mainly", 550], ["polymerase", 557], ["gamma", 568], ["(", 574], ["POLG1", 575], [")", 580], ["gene", 582], [".", 586], ["Parkin", 588], ["(", 595], ["PARK2", 596], [")", 601], ["gene", 603], ["mutations", 608], ["are", 618], ["responsible", 622], ["for", 634], ["juvenile", 638], ["parkinsonism", 647], [",", 659], ["and", 661], ["possible", 665], ["peripheral", 674], ["nervous", 685], ["system", 693], ["involvement", 700], ["has", 712], ["been", 716], ["reported", 721], [".", 729], ["Rarely", 731], [",", 737], ["an", 739], ["association", 742], ["of", 754], ["parkinsonism", 757], ["with", 770], ["PN", 775], ["may", 778], ["be", 782], ["encountered", 785], ["in", 797], ["other", 800], ["neurodegenerative", 806], ["diseases", 824], ["such", 833], ["as", 838], ["fragile", 841], ["X", 849], ["-", 850], ["associated", 851], ["tremor", 862], ["and", 869], ["ataxia", 873], ["syndrome", 880], ["related", 889], ["to", 897], ["premutation", 900], ["CGG", 912], ["repeat", 916], ["expansion", 923], ["in", 933], ["the", 936], ["fragile", 940], ["X", 948], ["mental", 950], ["retardation", 957], ["(", 969], ["FMR1", 970], [")", 974], ["gene", 976], [",", 980], ["Machado", 982], ["-", 989], ["Joseph", 990], ["disease", 997], ["related", 1005], ["to", 1013], ["an", 1016], ["abnormal", 1019], ["CAG", 1028], ["repeat", 1032], ["expansion", 1039], ["in", 1049], ["ataxin-3", 1052], ["(", 1061], ["ATXN3", 1062], [")", 1067], ["gene", 1069], [",", 1073], ["Kufor", 1075], ["-", 1080], ["Rakeb", 1081], ["syndrome", 1087], ["caused", 1096], ["by", 1103], ["mutations", 1106], ["in", 1116], ["ATP13A2", 1119], ["gene", 1127], [",", 1131], ["or", 1133], ["in", 1136], ["hereditary", 1139], ["systemic", 1150], ["disorders", 1159], ["such", 1169], ["as", 1174], ["Gaucher", 1177], ["disease", 1185], ["due", 1193], ["to", 1197], ["mutations", 1200], ["in", 1210], ["the", 1213], ["\u03b2", 1217], ["-", 1218], ["glucocerebrosidase", 1219], ["(", 1238], ["GBA", 1239], [")", 1242], ["gene", 1244], ["and", 1249], ["Chediak", 1253], ["-", 1260], ["Higashi", 1261], ["syndrome", 1269], ["due", 1278], ["to", 1282], ["LYST", 1285], ["gene", 1290], ["mutations", 1295], [".", 1304], ["This", 1306], ["article", 1311], ["reviews", 1319], ["conditions", 1327], ["in", 1338], ["which", 1341], ["PN", 1347], ["may", 1350], ["coexist", 1354], ["with", 1362], ["parkinsonism", 1367], [".", 1379]]}
{"context": "Restless legs syndrome/Willis-Ekbom disease (RLS/WED) is commonly seen in patients with end-stage renal disease (ESRD), but this condition has not been properly recognized. The prevalence of RLS/WED in ESRD shows the ethnic variation (7%-68%), with the similar tendency of primary RLS/WED. Although RLS/WED in ESRD is defined in secondary RLS/WED, the factors of ESRD that are involved in the genesis of RLS/WED remain unknown. Even after renal transplantation, RLS/WED symptoms do not completely disappear, and genetic predisposition to RLS/WED may play an important role in causing RLS/WED. Long-term intervention for RLS/WED and ESRD will be necessary.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "bad640c274d449bc9a202b19f0948118", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["/", 22], ["Willis", 23], ["-", 29], ["Ekbom", 30], ["disease", 36], ["(", 44], ["RLS", 45], ["/", 48], ["WED", 49], [")", 52], ["is", 54], ["commonly", 57], ["seen", 66], ["in", 71], ["patients", 74], ["with", 83], ["end", 88], ["-", 91], ["stage", 92], ["renal", 98], ["disease", 104], ["(", 112], ["ESRD", 113], [")", 117], [",", 118], ["but", 120], ["this", 124], ["condition", 129], ["has", 139], ["not", 143], ["been", 147], ["properly", 152], ["recognized", 161], [".", 171], ["The", 173], ["prevalence", 177], ["of", 188], ["RLS", 191], ["/", 194], ["WED", 195], ["in", 199], ["ESRD", 202], ["shows", 207], ["the", 213], ["ethnic", 217], ["variation", 224], ["(", 234], ["7%-68", 235], ["%", 240], [")", 241], [",", 242], ["with", 244], ["the", 249], ["similar", 253], ["tendency", 261], ["of", 270], ["primary", 273], ["RLS", 281], ["/", 284], ["WED", 285], [".", 288], ["Although", 290], ["RLS", 299], ["/", 302], ["WED", 303], ["in", 307], ["ESRD", 310], ["is", 315], ["defined", 318], ["in", 326], ["secondary", 329], ["RLS", 339], ["/", 342], ["WED", 343], [",", 346], ["the", 348], ["factors", 352], ["of", 360], ["ESRD", 363], ["that", 368], ["are", 373], ["involved", 377], ["in", 386], ["the", 389], ["genesis", 393], ["of", 401], ["RLS", 404], ["/", 407], ["WED", 408], ["remain", 412], ["unknown", 419], [".", 426], ["Even", 428], ["after", 433], ["renal", 439], ["transplantation", 445], [",", 460], ["RLS", 462], ["/", 465], ["WED", 466], ["symptoms", 470], ["do", 479], ["not", 482], ["completely", 486], ["disappear", 497], [",", 506], ["and", 508], ["genetic", 512], ["predisposition", 520], ["to", 535], ["RLS", 538], ["/", 541], ["WED", 542], ["may", 546], ["play", 550], ["an", 555], ["important", 558], ["role", 568], ["in", 573], ["causing", 576], ["RLS", 584], ["/", 587], ["WED", 588], [".", 591], ["Long", 593], ["-", 597], ["term", 598], ["intervention", 603], ["for", 616], ["RLS", 620], ["/", 623], ["WED", 624], ["and", 628], ["ESRD", 632], ["will", 637], ["be", 642], ["necessary", 645], [".", 654]]}
{"context": "Stress-induced mutagenesis describes the accumulation of mutations that occur in nongrowing cells, in contrast to mutagenesis that occurs in actively dividing populations, and has been referred to as stationary-phase or adaptive mutagenesis. The most widely studied system for stress-induced mutagenesis involves monitoring the appearance of Lac(+) revertants of the strain FC40 under starvation conditions in Escherichia coli. The SOS-inducible translesion DNA polymerase DinB plays an important role in this phenomenon. Loss of DinB (DNA pol IV) function results in a severe reduction of Lac(+) revertants. We previously reported that NusA, an essential component of elongating RNA polymerases, interacts with DinB. Here we report our unexpected observation that wild-type NusA function is required for stress-induced mutagenesis. We present evidence that this effect is unlikely to be due to defects in transcription of lac genes but rather is due to an inability to adapt and mutate in response to environmental stress. Furthermore, we extended our analysis to the formation of stress-induced mutants in response to antibiotic treatment, observing the same striking abolition of mutagenesis under entirely different conditions. Our results are the first to implicate NusA as a crucial participant in the phenomenon of stress-induced mutagenesis.", "qas": [{"question": "In which phase of cell cycle does  stress-induced transcription-associated mutagenesis (TAM) occur?", "answers": ["stationary phase", "stationary-phase"], "qid": "1daf44d1e59d499da16d3746bd6277c2", "question_tokens": [["In", 0], ["which", 3], ["phase", 9], ["of", 15], ["cell", 18], ["cycle", 23], ["does", 29], [" ", 34], ["stress", 35], ["-", 41], ["induced", 42], ["transcription", 50], ["-", 63], ["associated", 64], ["mutagenesis", 75], ["(", 87], ["TAM", 88], [")", 91], ["occur", 93], ["?", 98]], "detected_answers": [{"text": "stationary phase", "token_spans": [[32, 34]], "char_spans": [[200, 215]]}]}], "context_tokens": [["Stress", 0], ["-", 6], ["induced", 7], ["mutagenesis", 15], ["describes", 27], ["the", 37], ["accumulation", 41], ["of", 54], ["mutations", 57], ["that", 67], ["occur", 72], ["in", 78], ["nongrowing", 81], ["cells", 92], [",", 97], ["in", 99], ["contrast", 102], ["to", 111], ["mutagenesis", 114], ["that", 126], ["occurs", 131], ["in", 138], ["actively", 141], ["dividing", 150], ["populations", 159], [",", 170], ["and", 172], ["has", 176], ["been", 180], ["referred", 185], ["to", 194], ["as", 197], ["stationary", 200], ["-", 210], ["phase", 211], ["or", 217], ["adaptive", 220], ["mutagenesis", 229], [".", 240], ["The", 242], ["most", 246], ["widely", 251], ["studied", 258], ["system", 266], ["for", 273], ["stress", 277], ["-", 283], ["induced", 284], ["mutagenesis", 292], ["involves", 304], ["monitoring", 313], ["the", 324], ["appearance", 328], ["of", 339], ["Lac(+", 342], [")", 347], ["revertants", 349], ["of", 360], ["the", 363], ["strain", 367], ["FC40", 374], ["under", 379], ["starvation", 385], ["conditions", 396], ["in", 407], ["Escherichia", 410], ["coli", 422], [".", 426], ["The", 428], ["SOS", 432], ["-", 435], ["inducible", 436], ["translesion", 446], ["DNA", 458], ["polymerase", 462], ["DinB", 473], ["plays", 478], ["an", 484], ["important", 487], ["role", 497], ["in", 502], ["this", 505], ["phenomenon", 510], [".", 520], ["Loss", 522], ["of", 527], ["DinB", 530], ["(", 535], ["DNA", 536], ["pol", 540], ["IV", 544], [")", 546], ["function", 548], ["results", 557], ["in", 565], ["a", 568], ["severe", 570], ["reduction", 577], ["of", 587], ["Lac(+", 590], [")", 595], ["revertants", 597], [".", 607], ["We", 609], ["previously", 612], ["reported", 623], ["that", 632], ["NusA", 637], [",", 641], ["an", 643], ["essential", 646], ["component", 656], ["of", 666], ["elongating", 669], ["RNA", 680], ["polymerases", 684], [",", 695], ["interacts", 697], ["with", 707], ["DinB.", 712], ["Here", 718], ["we", 723], ["report", 726], ["our", 733], ["unexpected", 737], ["observation", 748], ["that", 760], ["wild", 765], ["-", 769], ["type", 770], ["NusA", 775], ["function", 780], ["is", 789], ["required", 792], ["for", 801], ["stress", 805], ["-", 811], ["induced", 812], ["mutagenesis", 820], [".", 831], ["We", 833], ["present", 836], ["evidence", 844], ["that", 853], ["this", 858], ["effect", 863], ["is", 870], ["unlikely", 873], ["to", 882], ["be", 885], ["due", 888], ["to", 892], ["defects", 895], ["in", 903], ["transcription", 906], ["of", 920], ["lac", 923], ["genes", 927], ["but", 933], ["rather", 937], ["is", 944], ["due", 947], ["to", 951], ["an", 954], ["inability", 957], ["to", 967], ["adapt", 970], ["and", 976], ["mutate", 980], ["in", 987], ["response", 990], ["to", 999], ["environmental", 1002], ["stress", 1016], [".", 1022], ["Furthermore", 1024], [",", 1035], ["we", 1037], ["extended", 1040], ["our", 1049], ["analysis", 1053], ["to", 1062], ["the", 1065], ["formation", 1069], ["of", 1079], ["stress", 1082], ["-", 1088], ["induced", 1089], ["mutants", 1097], ["in", 1105], ["response", 1108], ["to", 1117], ["antibiotic", 1120], ["treatment", 1131], [",", 1140], ["observing", 1142], ["the", 1152], ["same", 1156], ["striking", 1161], ["abolition", 1170], ["of", 1180], ["mutagenesis", 1183], ["under", 1195], ["entirely", 1201], ["different", 1210], ["conditions", 1220], [".", 1230], ["Our", 1232], ["results", 1236], ["are", 1244], ["the", 1248], ["first", 1252], ["to", 1258], ["implicate", 1261], ["NusA", 1271], ["as", 1276], ["a", 1279], ["crucial", 1281], ["participant", 1289], ["in", 1301], ["the", 1304], ["phenomenon", 1308], ["of", 1319], ["stress", 1322], ["-", 1328], ["induced", 1329], ["mutagenesis", 1337], [".", 1348]]}
{"context": "A 60-year-old man diagnosed clinically with Becker's muscular dystrophy 20 years ago by another physician presented with gradually progressive proximal muscle weakness since teenage years. Family history revealed a strong paternal familial inheritance pattern of similar distribution of weakness-face, forearm flexion, knee extension and foot dorsiflexion. Work-ups revealed B12 deficiency and allele 1 deletion in fascioscapulohumeral muscular dystrophy (FSHD) DNA testing. FSHD is the third most common muscular dystrophy. Clinical diagnosis is made from the distinctive pattern of weakness, autosomal-dominant inheritance, and confirmed by genetic testing. This case strongly demonstrates the importance of a thorough and careful clinical evaluation even in a case with a long standing diagnosis.", "qas": [{"question": "What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?", "answers": ["autosomal-dominant", "autosomal dominant"], "qid": "ff8ede38609d4622af0f985023a70e89", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Facioscapulohumeral", 35], ["muscular", 55], ["dystrophy", 64], ["(", 74], ["FSHD", 75], [")", 79], ["?", 80]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[95, 97]], "char_spans": [[594, 611]]}]}], "context_tokens": [["A", 0], ["60-year", 2], ["-", 9], ["old", 10], ["man", 14], ["diagnosed", 18], ["clinically", 28], ["with", 39], ["Becker", 44], ["'s", 50], ["muscular", 53], ["dystrophy", 62], ["20", 72], ["years", 75], ["ago", 81], ["by", 85], ["another", 88], ["physician", 96], ["presented", 106], ["with", 116], ["gradually", 121], ["progressive", 131], ["proximal", 143], ["muscle", 152], ["weakness", 159], ["since", 168], ["teenage", 174], ["years", 182], [".", 187], ["Family", 189], ["history", 196], ["revealed", 204], ["a", 213], ["strong", 215], ["paternal", 222], ["familial", 231], ["inheritance", 240], ["pattern", 252], ["of", 260], ["similar", 263], ["distribution", 271], ["of", 284], ["weakness", 287], ["-", 295], ["face", 296], [",", 300], ["forearm", 302], ["flexion", 310], [",", 317], ["knee", 319], ["extension", 324], ["and", 334], ["foot", 338], ["dorsiflexion", 343], [".", 355], ["Work", 357], ["-", 361], ["ups", 362], ["revealed", 366], ["B12", 375], ["deficiency", 379], ["and", 390], ["allele", 394], ["1", 401], ["deletion", 403], ["in", 412], ["fascioscapulohumeral", 415], ["muscular", 436], ["dystrophy", 445], ["(", 455], ["FSHD", 456], [")", 460], ["DNA", 462], ["testing", 466], [".", 473], ["FSHD", 475], ["is", 480], ["the", 483], ["third", 487], ["most", 493], ["common", 498], ["muscular", 505], ["dystrophy", 514], [".", 523], ["Clinical", 525], ["diagnosis", 534], ["is", 544], ["made", 547], ["from", 552], ["the", 557], ["distinctive", 561], ["pattern", 573], ["of", 581], ["weakness", 584], [",", 592], ["autosomal", 594], ["-", 603], ["dominant", 604], ["inheritance", 613], [",", 624], ["and", 626], ["confirmed", 630], ["by", 640], ["genetic", 643], ["testing", 651], [".", 658], ["This", 660], ["case", 665], ["strongly", 670], ["demonstrates", 679], ["the", 692], ["importance", 696], ["of", 707], ["a", 710], ["thorough", 712], ["and", 721], ["careful", 725], ["clinical", 733], ["evaluation", 742], ["even", 753], ["in", 758], ["a", 761], ["case", 763], ["with", 768], ["a", 773], ["long", 775], ["standing", 780], ["diagnosis", 789], [".", 798]]}
{"context": "Although alpha-synuclein (alpha-syn) has been implicated as a major component of the abnormal filaments that form glial cytoplasmic inclusions (GCIs) in multiple system atrophy (MSA), it is uncertain if GCIs are homogenous and contain full-length alpha-syn. Since this has implications for hypotheses about the pathogenesis of GCIs, we used a novel panel of antibodies to defined regions throughout alpha-syn in immunohistochemical epitope mapping studies of GCIs in MSA brains. Although the immunostaining profile of GCIs with these antibodies was similar for all MSA brains, there were significant differences in the immunoreactivity of the alpha-syn epitopes detected in GCIs. Notably, carboxy-terminal alpha-syn epitopes were immunodominant in GCIs, but the entire panel of antibodies immunostained cortical Lewy bodies (LBs) in dementia with LBs brain with similar intensity. While the distribution of alpha-syn labeled GCIs paralleled that previously reported using silver stains, antibodies to carboxy-terminal alpha-syn epitopes revealed a previously undescribed burden of GCIs in the MSA hippocampal formation. Finally, Western blots demonstrated detergent insoluble monomeric and high-molecular weight alpha-syn species in GCI rich MSA cerebellar white matter. Collectively, these data indicate that alpha-syn is a prominent component of GCIs in MSA, and that GCIs and LBs may result from cell type specific conformational or post-translational permutations in alpha-syn.", "qas": [{"question": "Against which protein is the antibody used for immonostaining of Lewy bodies raised?", "answers": ["alpha-Synuclein"], "qid": "6bb8ed04d3334d21be1d6007dec1ca83", "question_tokens": [["Against", 0], ["which", 8], ["protein", 14], ["is", 22], ["the", 25], ["antibody", 29], ["used", 38], ["for", 43], ["immonostaining", 47], ["of", 62], ["Lewy", 65], ["bodies", 70], ["raised", 77], ["?", 83]], "detected_answers": [{"text": "alpha-Synuclein", "token_spans": [[1, 3]], "char_spans": [[9, 23]]}]}], "context_tokens": [["Although", 0], ["alpha", 9], ["-", 14], ["synuclein", 15], ["(", 25], ["alpha", 26], ["-", 31], ["syn", 32], [")", 35], ["has", 37], ["been", 41], ["implicated", 46], ["as", 57], ["a", 60], ["major", 62], ["component", 68], ["of", 78], ["the", 81], ["abnormal", 85], ["filaments", 94], ["that", 104], ["form", 109], ["glial", 114], ["cytoplasmic", 120], ["inclusions", 132], ["(", 143], ["GCIs", 144], [")", 148], ["in", 150], ["multiple", 153], ["system", 162], ["atrophy", 169], ["(", 177], ["MSA", 178], [")", 181], [",", 182], ["it", 184], ["is", 187], ["uncertain", 190], ["if", 200], ["GCIs", 203], ["are", 208], ["homogenous", 212], ["and", 223], ["contain", 227], ["full", 235], ["-", 239], ["length", 240], ["alpha", 247], ["-", 252], ["syn", 253], [".", 256], ["Since", 258], ["this", 264], ["has", 269], ["implications", 273], ["for", 286], ["hypotheses", 290], ["about", 301], ["the", 307], ["pathogenesis", 311], ["of", 324], ["GCIs", 327], [",", 331], ["we", 333], ["used", 336], ["a", 341], ["novel", 343], ["panel", 349], ["of", 355], ["antibodies", 358], ["to", 369], ["defined", 372], ["regions", 380], ["throughout", 388], ["alpha", 399], ["-", 404], ["syn", 405], ["in", 409], ["immunohistochemical", 412], ["epitope", 432], ["mapping", 440], ["studies", 448], ["of", 456], ["GCIs", 459], ["in", 464], ["MSA", 467], ["brains", 471], [".", 477], ["Although", 479], ["the", 488], ["immunostaining", 492], ["profile", 507], ["of", 515], ["GCIs", 518], ["with", 523], ["these", 528], ["antibodies", 534], ["was", 545], ["similar", 549], ["for", 557], ["all", 561], ["MSA", 565], ["brains", 569], [",", 575], ["there", 577], ["were", 583], ["significant", 588], ["differences", 600], ["in", 612], ["the", 615], ["immunoreactivity", 619], ["of", 636], ["the", 639], ["alpha", 643], ["-", 648], ["syn", 649], ["epitopes", 653], ["detected", 662], ["in", 671], ["GCIs", 674], [".", 678], ["Notably", 680], [",", 687], ["carboxy", 689], ["-", 696], ["terminal", 697], ["alpha", 706], ["-", 711], ["syn", 712], ["epitopes", 716], ["were", 725], ["immunodominant", 730], ["in", 745], ["GCIs", 748], [",", 752], ["but", 754], ["the", 758], ["entire", 762], ["panel", 769], ["of", 775], ["antibodies", 778], ["immunostained", 789], ["cortical", 803], ["Lewy", 812], ["bodies", 817], ["(", 824], ["LBs", 825], [")", 828], ["in", 830], ["dementia", 833], ["with", 842], ["LBs", 847], ["brain", 851], ["with", 857], ["similar", 862], ["intensity", 870], [".", 879], ["While", 881], ["the", 887], ["distribution", 891], ["of", 904], ["alpha", 907], ["-", 912], ["syn", 913], ["labeled", 917], ["GCIs", 925], ["paralleled", 930], ["that", 941], ["previously", 946], ["reported", 957], ["using", 966], ["silver", 972], ["stains", 979], [",", 985], ["antibodies", 987], ["to", 998], ["carboxy", 1001], ["-", 1008], ["terminal", 1009], ["alpha", 1018], ["-", 1023], ["syn", 1024], ["epitopes", 1028], ["revealed", 1037], ["a", 1046], ["previously", 1048], ["undescribed", 1059], ["burden", 1071], ["of", 1078], ["GCIs", 1081], ["in", 1086], ["the", 1089], ["MSA", 1093], ["hippocampal", 1097], ["formation", 1109], [".", 1118], ["Finally", 1120], [",", 1127], ["Western", 1129], ["blots", 1137], ["demonstrated", 1143], ["detergent", 1156], ["insoluble", 1166], ["monomeric", 1176], ["and", 1186], ["high", 1190], ["-", 1194], ["molecular", 1195], ["weight", 1205], ["alpha", 1212], ["-", 1217], ["syn", 1218], ["species", 1222], ["in", 1230], ["GCI", 1233], ["rich", 1237], ["MSA", 1242], ["cerebellar", 1246], ["white", 1257], ["matter", 1263], [".", 1269], ["Collectively", 1271], [",", 1283], ["these", 1285], ["data", 1291], ["indicate", 1296], ["that", 1305], ["alpha", 1310], ["-", 1315], ["syn", 1316], ["is", 1320], ["a", 1323], ["prominent", 1325], ["component", 1335], ["of", 1345], ["GCIs", 1348], ["in", 1353], ["MSA", 1356], [",", 1359], ["and", 1361], ["that", 1365], ["GCIs", 1370], ["and", 1375], ["LBs", 1379], ["may", 1383], ["result", 1387], ["from", 1394], ["cell", 1399], ["type", 1404], ["specific", 1409], ["conformational", 1418], ["or", 1433], ["post", 1436], ["-", 1440], ["translational", 1441], ["permutations", 1455], ["in", 1468], ["alpha", 1471], ["-", 1476], ["syn", 1477], [".", 1480]]}
{"context": "Patisiran is an investigational RNA interference (RNAi) therapeutic in development for the treatment of hereditary ATTR (hATTR) amyloidosis, a progressive disease associated with significant disability, morbidity, and mortality. Here we describe the rationale and design of the Phase 3 APOLLO study, a randomized, double-blind, placebo-controlled, global study to evaluate the efficacy and safety of patisiran in patients with hATTR amyloidosis with polyneuropathy. Eligible patients are 18-85\u00a0years old with hATTR amyloidosis, investigator-estimated survival of \u22652\u00a0years, Neuropathy Impairment Score (NIS) of 5-130, and polyneuropathy disability score\u00a0\u2264IIIb. Patients are randomized 2:1 to receive either intravenous patisiran 0.3\u00a0mg/kg or placebo once every 3\u00a0weeks. The primary objective is to determine the efficacy of patisiran at 18\u00a0months based on the difference in the change in modified NIS+7 (a composite measure of motor strength, sensation, reflexes, nerve conduction, and autonomic function) between the patisiran and placebo groups. Secondary objectives are to evaluate the effect of patisiran on Norfolk-Diabetic Neuropathy quality of life questionnaire score, nutritional status (as evaluated by modified body mass index), motor function (as measured by NIS-weakness and timed 10-m walk test), and autonomic symptoms (as measured by the Composite Autonomic Symptom Score-31 questionnaire). Exploratory objectives include assessment of cardiac function and pathologic evaluation to assess nerve fiber innervation and amyloid burden. Safety of patisiran will be assessed throughout the study. APOLLO represents the largest randomized, Phase 3 study to date in patients with hATTR amyloidosis, with endpoints that capture the multisystemic nature of this disease. This trial is registered at clinicaltrials.gov ( NCT01960348 ); October 9, 2013.", "qas": [{"question": "What is the name of the RNAi investigational drug being developed against hereditary amyloidosis?", "answers": ["Patisiran"], "qid": "f6d7e1841db1466093bc4a2667512ecc", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["RNAi", 24], ["investigational", 29], ["drug", 45], ["being", 50], ["developed", 56], ["against", 66], ["hereditary", 74], ["amyloidosis", 85], ["?", 96]], "detected_answers": [{"text": "Patisiran", "token_spans": [[0, 0], [269, 269], [70, 70], [180, 180], [124, 124], [193, 193], [145, 145]], "char_spans": [[0, 8], [1558, 1566], [400, 408], [1017, 1025], [718, 726], [1098, 1106], [823, 831]]}]}], "context_tokens": [["Patisiran", 0], ["is", 10], ["an", 13], ["investigational", 16], ["RNA", 32], ["interference", 36], ["(", 49], ["RNAi", 50], [")", 54], ["therapeutic", 56], ["in", 68], ["development", 71], ["for", 83], ["the", 87], ["treatment", 91], ["of", 101], ["hereditary", 104], ["ATTR", 115], ["(", 120], ["hATTR", 121], [")", 126], ["amyloidosis", 128], [",", 139], ["a", 141], ["progressive", 143], ["disease", 155], ["associated", 163], ["with", 174], ["significant", 179], ["disability", 191], [",", 201], ["morbidity", 203], [",", 212], ["and", 214], ["mortality", 218], [".", 227], ["Here", 229], ["we", 234], ["describe", 237], ["the", 246], ["rationale", 250], ["and", 260], ["design", 264], ["of", 271], ["the", 274], ["Phase", 278], ["3", 284], ["APOLLO", 286], ["study", 293], [",", 298], ["a", 300], ["randomized", 302], [",", 312], ["double", 314], ["-", 320], ["blind", 321], [",", 326], ["placebo", 328], ["-", 335], ["controlled", 336], [",", 346], ["global", 348], ["study", 355], ["to", 361], ["evaluate", 364], ["the", 373], ["efficacy", 377], ["and", 386], ["safety", 390], ["of", 397], ["patisiran", 400], ["in", 410], ["patients", 413], ["with", 422], ["hATTR", 427], ["amyloidosis", 433], ["with", 445], ["polyneuropathy", 450], [".", 464], ["Eligible", 466], ["patients", 475], ["are", 484], ["18", 488], ["-", 490], ["85", 491], ["years", 494], ["old", 500], ["with", 504], ["hATTR", 509], ["amyloidosis", 515], [",", 526], ["investigator", 528], ["-", 540], ["estimated", 541], ["survival", 551], ["of", 560], ["\u22652", 563], ["years", 566], [",", 571], ["Neuropathy", 573], ["Impairment", 584], ["Score", 595], ["(", 601], ["NIS", 602], [")", 605], ["of", 607], ["5", 610], ["-", 611], ["130", 612], [",", 615], ["and", 617], ["polyneuropathy", 621], ["disability", 636], ["score", 647], ["\u2264IIIb", 653], [".", 658], ["Patients", 660], ["are", 669], ["randomized", 673], ["2:1", 684], ["to", 688], ["receive", 691], ["either", 699], ["intravenous", 706], ["patisiran", 718], ["0.3", 728], ["mg", 732], ["/", 734], ["kg", 735], ["or", 738], ["placebo", 741], ["once", 749], ["every", 754], ["3", 760], ["weeks", 762], [".", 767], ["The", 769], ["primary", 773], ["objective", 781], ["is", 791], ["to", 794], ["determine", 797], ["the", 807], ["efficacy", 811], ["of", 820], ["patisiran", 823], ["at", 833], ["18", 836], ["months", 839], ["based", 846], ["on", 852], ["the", 855], ["difference", 859], ["in", 870], ["the", 873], ["change", 877], ["in", 884], ["modified", 887], ["NIS+7", 896], ["(", 902], ["a", 903], ["composite", 905], ["measure", 915], ["of", 923], ["motor", 926], ["strength", 932], [",", 940], ["sensation", 942], [",", 951], ["reflexes", 953], [",", 961], ["nerve", 963], ["conduction", 969], [",", 979], ["and", 981], ["autonomic", 985], ["function", 995], [")", 1003], ["between", 1005], ["the", 1013], ["patisiran", 1017], ["and", 1027], ["placebo", 1031], ["groups", 1039], [".", 1045], ["Secondary", 1047], ["objectives", 1057], ["are", 1068], ["to", 1072], ["evaluate", 1075], ["the", 1084], ["effect", 1088], ["of", 1095], ["patisiran", 1098], ["on", 1108], ["Norfolk", 1111], ["-", 1118], ["Diabetic", 1119], ["Neuropathy", 1128], ["quality", 1139], ["of", 1147], ["life", 1150], ["questionnaire", 1155], ["score", 1169], [",", 1174], ["nutritional", 1176], ["status", 1188], ["(", 1195], ["as", 1196], ["evaluated", 1199], ["by", 1209], ["modified", 1212], ["body", 1221], ["mass", 1226], ["index", 1231], [")", 1236], [",", 1237], ["motor", 1239], ["function", 1245], ["(", 1254], ["as", 1255], ["measured", 1258], ["by", 1267], ["NIS", 1270], ["-", 1273], ["weakness", 1274], ["and", 1283], ["timed", 1287], ["10-m", 1293], ["walk", 1298], ["test", 1303], [")", 1307], [",", 1308], ["and", 1310], ["autonomic", 1314], ["symptoms", 1324], ["(", 1333], ["as", 1334], ["measured", 1337], ["by", 1346], ["the", 1349], ["Composite", 1353], ["Autonomic", 1363], ["Symptom", 1373], ["Score-31", 1381], ["questionnaire", 1390], [")", 1403], [".", 1404], ["Exploratory", 1406], ["objectives", 1418], ["include", 1429], ["assessment", 1437], ["of", 1448], ["cardiac", 1451], ["function", 1459], ["and", 1468], ["pathologic", 1472], ["evaluation", 1483], ["to", 1494], ["assess", 1497], ["nerve", 1504], ["fiber", 1510], ["innervation", 1516], ["and", 1528], ["amyloid", 1532], ["burden", 1540], [".", 1546], ["Safety", 1548], ["of", 1555], ["patisiran", 1558], ["will", 1568], ["be", 1573], ["assessed", 1576], ["throughout", 1585], ["the", 1596], ["study", 1600], [".", 1605], ["APOLLO", 1607], ["represents", 1614], ["the", 1625], ["largest", 1629], ["randomized", 1637], [",", 1647], ["Phase", 1649], ["3", 1655], ["study", 1657], ["to", 1663], ["date", 1666], ["in", 1671], ["patients", 1674], ["with", 1683], ["hATTR", 1688], ["amyloidosis", 1694], [",", 1705], ["with", 1707], ["endpoints", 1712], ["that", 1722], ["capture", 1727], ["the", 1735], ["multisystemic", 1739], ["nature", 1753], ["of", 1760], ["this", 1763], ["disease", 1768], [".", 1775], ["This", 1777], ["trial", 1782], ["is", 1788], ["registered", 1791], ["at", 1802], ["clinicaltrials.gov", 1805], ["(", 1824], ["NCT01960348", 1826], [")", 1838], [";", 1839], ["October", 1841], ["9", 1849], [",", 1850], ["2013", 1852], [".", 1856]]}
{"context": "The dynamin-related protein Opa1 is localized to the mitochondrial intermembrane space, where it facilitates fusion between mitochondria. Apoptosis causes Opa1 release into the cytosol and causes mitochondria to fragment. Loss of mitochondrial membrane potential also causes mitochondrial fragmentation but not Opa1 release into the cytosol. Both conditions induce the proteolytic cleavage of Opa1, suggesting that mitochondrial fragmentation is triggered by Opa1 inactivation. The opposite effect was observed with knockdown of the mitochondrial intermembrane space protease Yme1. Knockdown of Yme1 prevents the constitutive cleavage of a subset of Opa1 splice variants but does not affect carbonyl cyanide m-chlorophenyl hydrazone or apoptosis-induced cleavage. Knockdown of Yme1 also increases mitochondrial connectivity, but this effect is independent of Opa1 because it also occurs in Opa1 knockdown cells. We conclude that Yme1 constitutively regulates a subset of Opa1 isoforms and an unknown mitochondrial morphology protein, whereas the loss of membrane potential induces the further proteolysis of Opa1.", "qas": [{"question": "Which is the cellular localization of the protein Opa1?", "answers": ["mitochondrial intermembrane space"], "qid": "06ee6c4a1f9d4cd19afcd49b8dd40d16", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["cellular", 13], ["localization", 22], ["of", 35], ["the", 38], ["protein", 42], ["Opa1", 50], ["?", 54]], "detected_answers": [{"text": "mitochondrial intermembrane space", "token_spans": [[10, 12], [79, 81]], "char_spans": [[53, 85], [533, 565]]}]}], "context_tokens": [["The", 0], ["dynamin", 4], ["-", 11], ["related", 12], ["protein", 20], ["Opa1", 28], ["is", 33], ["localized", 36], ["to", 46], ["the", 49], ["mitochondrial", 53], ["intermembrane", 67], ["space", 81], [",", 86], ["where", 88], ["it", 94], ["facilitates", 97], ["fusion", 109], ["between", 116], ["mitochondria", 124], [".", 136], ["Apoptosis", 138], ["causes", 148], ["Opa1", 155], ["release", 160], ["into", 168], ["the", 173], ["cytosol", 177], ["and", 185], ["causes", 189], ["mitochondria", 196], ["to", 209], ["fragment", 212], [".", 220], ["Loss", 222], ["of", 227], ["mitochondrial", 230], ["membrane", 244], ["potential", 253], ["also", 263], ["causes", 268], ["mitochondrial", 275], ["fragmentation", 289], ["but", 303], ["not", 307], ["Opa1", 311], ["release", 316], ["into", 324], ["the", 329], ["cytosol", 333], [".", 340], ["Both", 342], ["conditions", 347], ["induce", 358], ["the", 365], ["proteolytic", 369], ["cleavage", 381], ["of", 390], ["Opa1", 393], [",", 397], ["suggesting", 399], ["that", 410], ["mitochondrial", 415], ["fragmentation", 429], ["is", 443], ["triggered", 446], ["by", 456], ["Opa1", 459], ["inactivation", 464], [".", 476], ["The", 478], ["opposite", 482], ["effect", 491], ["was", 498], ["observed", 502], ["with", 511], ["knockdown", 516], ["of", 526], ["the", 529], ["mitochondrial", 533], ["intermembrane", 547], ["space", 561], ["protease", 567], ["Yme1", 576], [".", 580], ["Knockdown", 582], ["of", 592], ["Yme1", 595], ["prevents", 600], ["the", 609], ["constitutive", 613], ["cleavage", 626], ["of", 635], ["a", 638], ["subset", 640], ["of", 647], ["Opa1", 650], ["splice", 655], ["variants", 662], ["but", 671], ["does", 675], ["not", 680], ["affect", 684], ["carbonyl", 691], ["cyanide", 700], ["m", 708], ["-", 709], ["chlorophenyl", 710], ["hydrazone", 723], ["or", 733], ["apoptosis", 736], ["-", 745], ["induced", 746], ["cleavage", 754], [".", 762], ["Knockdown", 764], ["of", 774], ["Yme1", 777], ["also", 782], ["increases", 787], ["mitochondrial", 797], ["connectivity", 811], [",", 823], ["but", 825], ["this", 829], ["effect", 834], ["is", 841], ["independent", 844], ["of", 856], ["Opa1", 859], ["because", 864], ["it", 872], ["also", 875], ["occurs", 880], ["in", 887], ["Opa1", 890], ["knockdown", 895], ["cells", 905], [".", 910], ["We", 912], ["conclude", 915], ["that", 924], ["Yme1", 929], ["constitutively", 934], ["regulates", 949], ["a", 959], ["subset", 961], ["of", 968], ["Opa1", 971], ["isoforms", 976], ["and", 985], ["an", 989], ["unknown", 992], ["mitochondrial", 1000], ["morphology", 1014], ["protein", 1025], [",", 1032], ["whereas", 1034], ["the", 1042], ["loss", 1046], ["of", 1051], ["membrane", 1054], ["potential", 1063], ["induces", 1073], ["the", 1081], ["further", 1085], ["proteolysis", 1093], ["of", 1105], ["Opa1", 1108], [".", 1112]]}
{"context": "Three isoforms of human plasma apolipoprotein E (apoE) are ligands to lipoprotein receptors and influence in different manner the synthesis and catabolism of pro-atherogenic triglyceride-rich lipoproteins. Among three isoforms, the apoE4 isoform is associated with increased frequency of atherosclerosis and Alzheimer's disease (AD). The conformational transitions of beta-amyloid (Abeta) influenced by apoE and serum amyloid P (SAP) component are key events in AD development, the accumulation of intermediate diffusible and soluble oligomers of Abeta being of particular significance. SAP and apoE, in a different manner for the three isoforms, serve as \"pathological\" chaperones during the aggregation of Abeta considered as a conformation-prone process. In turn, apoE consisting of two domains self-associates in solution and intermediate structures differently populated for the three isoforms exist. The different structures of the three isoforms determine their different distribution among various plasma lipoproteins. The structural and metabolic consideration of the common apoE pathway(s) in two pathologies assumes four molecular targets for AD correction: (i) inhibition of the accumulation of diffusible soluble Abeta oligomers; (ii) inhibition of apoE synthesis and secretion by astrocytes, in particular, under lipid-lowering therapy; (iii) inhibition of the binding of apoE and/or SAP to Abeta; (iv) stimulation of the expression of cholesterol transporter ABCA1.", "qas": [{"question": "Which ApoE isoform is associated with atherosclerosis and Alzheimer's disease?", "answers": ["ApoE4 isoform", "Apolipoprotein E4 isoform"], "qid": "d2affbf1297d4be7a210c9cbf1cccbba", "question_tokens": [["Which", 0], ["ApoE", 6], ["isoform", 11], ["is", 19], ["associated", 22], ["with", 33], ["atherosclerosis", 38], ["and", 54], ["Alzheimer", 58], ["'s", 67], ["disease", 70], ["?", 77]], "detected_answers": [{"text": "ApoE4 isoform", "token_spans": [[38, 39]], "char_spans": [[232, 244]]}]}], "context_tokens": [["Three", 0], ["isoforms", 6], ["of", 15], ["human", 18], ["plasma", 24], ["apolipoprotein", 31], ["E", 46], ["(", 48], ["apoE", 49], [")", 53], ["are", 55], ["ligands", 59], ["to", 67], ["lipoprotein", 70], ["receptors", 82], ["and", 92], ["influence", 96], ["in", 106], ["different", 109], ["manner", 119], ["the", 126], ["synthesis", 130], ["and", 140], ["catabolism", 144], ["of", 155], ["pro", 158], ["-", 161], ["atherogenic", 162], ["triglyceride", 174], ["-", 186], ["rich", 187], ["lipoproteins", 192], [".", 204], ["Among", 206], ["three", 212], ["isoforms", 218], [",", 226], ["the", 228], ["apoE4", 232], ["isoform", 238], ["is", 246], ["associated", 249], ["with", 260], ["increased", 265], ["frequency", 275], ["of", 285], ["atherosclerosis", 288], ["and", 304], ["Alzheimer", 308], ["'s", 317], ["disease", 320], ["(", 328], ["AD", 329], [")", 331], [".", 332], ["The", 334], ["conformational", 338], ["transitions", 353], ["of", 365], ["beta", 368], ["-", 372], ["amyloid", 373], ["(", 381], ["Abeta", 382], [")", 387], ["influenced", 389], ["by", 400], ["apoE", 403], ["and", 408], ["serum", 412], ["amyloid", 418], ["P", 426], ["(", 428], ["SAP", 429], [")", 432], ["component", 434], ["are", 444], ["key", 448], ["events", 452], ["in", 459], ["AD", 462], ["development", 465], [",", 476], ["the", 478], ["accumulation", 482], ["of", 495], ["intermediate", 498], ["diffusible", 511], ["and", 522], ["soluble", 526], ["oligomers", 534], ["of", 544], ["Abeta", 547], ["being", 553], ["of", 559], ["particular", 562], ["significance", 573], [".", 585], ["SAP", 587], ["and", 591], ["apoE", 595], [",", 599], ["in", 601], ["a", 604], ["different", 606], ["manner", 616], ["for", 623], ["the", 627], ["three", 631], ["isoforms", 637], [",", 645], ["serve", 647], ["as", 653], ["\"", 656], ["pathological", 657], ["\"", 669], ["chaperones", 671], ["during", 682], ["the", 689], ["aggregation", 693], ["of", 705], ["Abeta", 708], ["considered", 714], ["as", 725], ["a", 728], ["conformation", 730], ["-", 742], ["prone", 743], ["process", 749], [".", 756], ["In", 758], ["turn", 761], [",", 765], ["apoE", 767], ["consisting", 772], ["of", 783], ["two", 786], ["domains", 790], ["self", 798], ["-", 802], ["associates", 803], ["in", 814], ["solution", 817], ["and", 826], ["intermediate", 830], ["structures", 843], ["differently", 854], ["populated", 866], ["for", 876], ["the", 880], ["three", 884], ["isoforms", 890], ["exist", 899], [".", 904], ["The", 906], ["different", 910], ["structures", 920], ["of", 931], ["the", 934], ["three", 938], ["isoforms", 944], ["determine", 953], ["their", 963], ["different", 969], ["distribution", 979], ["among", 992], ["various", 998], ["plasma", 1006], ["lipoproteins", 1013], [".", 1025], ["The", 1027], ["structural", 1031], ["and", 1042], ["metabolic", 1046], ["consideration", 1056], ["of", 1070], ["the", 1073], ["common", 1077], ["apoE", 1084], ["pathway(s", 1089], [")", 1098], ["in", 1100], ["two", 1103], ["pathologies", 1107], ["assumes", 1119], ["four", 1127], ["molecular", 1132], ["targets", 1142], ["for", 1150], ["AD", 1154], ["correction", 1157], [":", 1167], ["(", 1169], ["i", 1170], [")", 1171], ["inhibition", 1173], ["of", 1184], ["the", 1187], ["accumulation", 1191], ["of", 1204], ["diffusible", 1207], ["soluble", 1218], ["Abeta", 1226], ["oligomers", 1232], [";", 1241], ["(", 1243], ["ii", 1244], [")", 1246], ["inhibition", 1248], ["of", 1259], ["apoE", 1262], ["synthesis", 1267], ["and", 1277], ["secretion", 1281], ["by", 1291], ["astrocytes", 1294], [",", 1304], ["in", 1306], ["particular", 1309], [",", 1319], ["under", 1321], ["lipid", 1327], ["-", 1332], ["lowering", 1333], ["therapy", 1342], [";", 1349], ["(", 1351], ["iii", 1352], [")", 1355], ["inhibition", 1357], ["of", 1368], ["the", 1371], ["binding", 1375], ["of", 1383], ["apoE", 1386], ["and/or", 1391], ["SAP", 1398], ["to", 1402], ["Abeta", 1405], [";", 1410], ["(", 1412], ["iv", 1413], [")", 1415], ["stimulation", 1417], ["of", 1429], ["the", 1432], ["expression", 1436], ["of", 1447], ["cholesterol", 1450], ["transporter", 1462], ["ABCA1", 1474], [".", 1479]]}
{"context": "The membranous structure of vestibular schwannoma is an important factor in its surgical treatment. Herein, we report intraoperative and microscopic findings relating to an outermost dura-like membrane in cases of vestibular schwannoma and the importance of these findings. Intraoperative findings of 16 cases of vestibular schwannoma treated with an initial surgery were studied with an aim to determine if the cases had a dura-like membrane. Then we studied microscopic findings of the dura-like membrane using hematoxylin and eosin, Masson trichrome, and immunohistochemical staining in 2 cases. The dura-like membrane was observed in 8 out of 16 cases. The average tumor size of the cases that had a dura-like membrane was 30 \u00b1 8.1 mm, and Koos grading 4 was in 7 out of 8 cases, and one was grade 3. In cases without a dura-like membrane, these values were significantly smaller, with an average tumor size of 12.8 \u00b1 5.2 mm, and Koos grading 4 was only in 1 of 8 cases, grade 3 was in 2 cases, and other 5 cases were grade 2. The outermost dura-like membrane enveloped the vestibular schwannoma around the internal acoustic meatus and was continuous with the dura mater. Reactive angiogenesis was observed in the dura mater. Microscopic findings proved its continuity with the dura mater. In one case, the facial nerve was damaged before it was identified during subcapsular dissection. In that case, the dura-like membrane negatively affected our ability to identify the facial nerve. A dura-like membrane sometimes envelops vestibular schwannoma around the internal acoustic meatus. Recognition of this membranous structure is important for the surgical preservation of facial and acoustic nerves.", "qas": [{"question": "Which disease can be categorized using the Koos grading system?", "answers": ["vestibular schwannoma"], "qid": "49b937d0ed614da79079221407d48ab8", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["categorized", 21], ["using", 33], ["the", 39], ["Koos", 43], ["grading", 48], ["system", 56], ["?", 62]], "detected_answers": [{"text": "vestibular schwannoma", "token_spans": [[49, 50], [289, 290], [4, 5], [212, 213], [34, 35]], "char_spans": [[313, 333], [1531, 1551], [28, 48], [1078, 1098], [214, 234]]}]}], "context_tokens": [["The", 0], ["membranous", 4], ["structure", 15], ["of", 25], ["vestibular", 28], ["schwannoma", 39], ["is", 50], ["an", 53], ["important", 56], ["factor", 66], ["in", 73], ["its", 76], ["surgical", 80], ["treatment", 89], [".", 98], ["Herein", 100], [",", 106], ["we", 108], ["report", 111], ["intraoperative", 118], ["and", 133], ["microscopic", 137], ["findings", 149], ["relating", 158], ["to", 167], ["an", 170], ["outermost", 173], ["dura", 183], ["-", 187], ["like", 188], ["membrane", 193], ["in", 202], ["cases", 205], ["of", 211], ["vestibular", 214], ["schwannoma", 225], ["and", 236], ["the", 240], ["importance", 244], ["of", 255], ["these", 258], ["findings", 264], [".", 272], ["Intraoperative", 274], ["findings", 289], ["of", 298], ["16", 301], ["cases", 304], ["of", 310], ["vestibular", 313], ["schwannoma", 324], ["treated", 335], ["with", 343], ["an", 348], ["initial", 351], ["surgery", 359], ["were", 367], ["studied", 372], ["with", 380], ["an", 385], ["aim", 388], ["to", 392], ["determine", 395], ["if", 405], ["the", 408], ["cases", 412], ["had", 418], ["a", 422], ["dura", 424], ["-", 428], ["like", 429], ["membrane", 434], [".", 442], ["Then", 444], ["we", 449], ["studied", 452], ["microscopic", 460], ["findings", 472], ["of", 481], ["the", 484], ["dura", 488], ["-", 492], ["like", 493], ["membrane", 498], ["using", 507], ["hematoxylin", 513], ["and", 525], ["eosin", 529], [",", 534], ["Masson", 536], ["trichrome", 543], [",", 552], ["and", 554], ["immunohistochemical", 558], ["staining", 578], ["in", 587], ["2", 590], ["cases", 592], [".", 597], ["The", 599], ["dura", 603], ["-", 607], ["like", 608], ["membrane", 613], ["was", 622], ["observed", 626], ["in", 635], ["8", 638], ["out", 640], ["of", 644], ["16", 647], ["cases", 650], [".", 655], ["The", 657], ["average", 661], ["tumor", 669], ["size", 675], ["of", 680], ["the", 683], ["cases", 687], ["that", 693], ["had", 698], ["a", 702], ["dura", 704], ["-", 708], ["like", 709], ["membrane", 714], ["was", 723], ["30", 727], ["\u00b1", 730], ["8.1", 732], ["mm", 736], [",", 738], ["and", 740], ["Koos", 744], ["grading", 749], ["4", 757], ["was", 759], ["in", 763], ["7", 766], ["out", 768], ["of", 772], ["8", 775], ["cases", 777], [",", 782], ["and", 784], ["one", 788], ["was", 792], ["grade", 796], ["3", 802], [".", 803], ["In", 805], ["cases", 808], ["without", 814], ["a", 822], ["dura", 824], ["-", 828], ["like", 829], ["membrane", 834], [",", 842], ["these", 844], ["values", 850], ["were", 857], ["significantly", 862], ["smaller", 876], [",", 883], ["with", 885], ["an", 890], ["average", 893], ["tumor", 901], ["size", 907], ["of", 912], ["12.8", 915], ["\u00b1", 920], ["5.2", 922], ["mm", 926], [",", 928], ["and", 930], ["Koos", 934], ["grading", 939], ["4", 947], ["was", 949], ["only", 953], ["in", 958], ["1", 961], ["of", 963], ["8", 966], ["cases", 968], [",", 973], ["grade", 975], ["3", 981], ["was", 983], ["in", 987], ["2", 990], ["cases", 992], [",", 997], ["and", 999], ["other", 1003], ["5", 1009], ["cases", 1011], ["were", 1017], ["grade", 1022], ["2", 1028], [".", 1029], ["The", 1031], ["outermost", 1035], ["dura", 1045], ["-", 1049], ["like", 1050], ["membrane", 1055], ["enveloped", 1064], ["the", 1074], ["vestibular", 1078], ["schwannoma", 1089], ["around", 1100], ["the", 1107], ["internal", 1111], ["acoustic", 1120], ["meatus", 1129], ["and", 1136], ["was", 1140], ["continuous", 1144], ["with", 1155], ["the", 1160], ["dura", 1164], ["mater", 1169], [".", 1174], ["Reactive", 1176], ["angiogenesis", 1185], ["was", 1198], ["observed", 1202], ["in", 1211], ["the", 1214], ["dura", 1218], ["mater", 1223], [".", 1228], ["Microscopic", 1230], ["findings", 1242], ["proved", 1251], ["its", 1258], ["continuity", 1262], ["with", 1273], ["the", 1278], ["dura", 1282], ["mater", 1287], [".", 1292], ["In", 1294], ["one", 1297], ["case", 1301], [",", 1305], ["the", 1307], ["facial", 1311], ["nerve", 1318], ["was", 1324], ["damaged", 1328], ["before", 1336], ["it", 1343], ["was", 1346], ["identified", 1350], ["during", 1361], ["subcapsular", 1368], ["dissection", 1380], [".", 1390], ["In", 1392], ["that", 1395], ["case", 1400], [",", 1404], ["the", 1406], ["dura", 1410], ["-", 1414], ["like", 1415], ["membrane", 1420], ["negatively", 1429], ["affected", 1440], ["our", 1449], ["ability", 1453], ["to", 1461], ["identify", 1464], ["the", 1473], ["facial", 1477], ["nerve", 1484], [".", 1489], ["A", 1491], ["dura", 1493], ["-", 1497], ["like", 1498], ["membrane", 1503], ["sometimes", 1512], ["envelops", 1522], ["vestibular", 1531], ["schwannoma", 1542], ["around", 1553], ["the", 1560], ["internal", 1564], ["acoustic", 1573], ["meatus", 1582], [".", 1588], ["Recognition", 1590], ["of", 1602], ["this", 1605], ["membranous", 1610], ["structure", 1621], ["is", 1631], ["important", 1634], ["for", 1644], ["the", 1648], ["surgical", 1652], ["preservation", 1661], ["of", 1674], ["facial", 1677], ["and", 1684], ["acoustic", 1688], ["nerves", 1697], [".", 1703]]}
{"context": "In recent years, we have seen remarkable progress in our understanding of the disease mechanism underlying facioscapulohumeral muscular dystrophy (FSHD). The purpose of this review is to provide a comprehensive overview of our current understanding of the disease mechanism and to discuss the observations supporting the possibility of a developmental defect in this disorder. In the majority of cases, FSHD is caused by contraction of the D4Z4 repeat array (FSHD1). This results in local chromatin relaxation and stable expression of the DUX4 retrogene in skeletal muscle, but only when a polymorphic DUX4 polyadenylation signal is present. In some cases (FSHD2), D4Z4 chromatin relaxation and stable DUX4 expression occur in the absence of D4Z4 array contraction. DUX4 is a germline transcription factor and its expression in skeletal muscle leads to activation of early stem cell and germline programs and transcriptional activation of retroelements. Recent studies have provided a plausible disease mechanism for FSHD in which FSHD results from inappropriate expression of the germline transcription factor DUX4. The genes regulated by DUX4 suggest several mechanisms of muscle damage, and provide potential biomarkers and therapeutic targets that should be investigated in future studies.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "942b79bc7d384edd901fe2769f46512d", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[65, 65], [167, 167], [21, 21], [170, 170]], "char_spans": [[403, 406], [1017, 1020], [147, 150], [1031, 1034]]}]}], "context_tokens": [["In", 0], ["recent", 3], ["years", 10], [",", 15], ["we", 17], ["have", 20], ["seen", 25], ["remarkable", 30], ["progress", 41], ["in", 50], ["our", 53], ["understanding", 57], ["of", 71], ["the", 74], ["disease", 78], ["mechanism", 86], ["underlying", 96], ["facioscapulohumeral", 107], ["muscular", 127], ["dystrophy", 136], ["(", 146], ["FSHD", 147], [")", 151], [".", 152], ["The", 154], ["purpose", 158], ["of", 166], ["this", 169], ["review", 174], ["is", 181], ["to", 184], ["provide", 187], ["a", 195], ["comprehensive", 197], ["overview", 211], ["of", 220], ["our", 223], ["current", 227], ["understanding", 235], ["of", 249], ["the", 252], ["disease", 256], ["mechanism", 264], ["and", 274], ["to", 278], ["discuss", 281], ["the", 289], ["observations", 293], ["supporting", 306], ["the", 317], ["possibility", 321], ["of", 333], ["a", 336], ["developmental", 338], ["defect", 352], ["in", 359], ["this", 362], ["disorder", 367], [".", 375], ["In", 377], ["the", 380], ["majority", 384], ["of", 393], ["cases", 396], [",", 401], ["FSHD", 403], ["is", 408], ["caused", 411], ["by", 418], ["contraction", 421], ["of", 433], ["the", 436], ["D4Z4", 440], ["repeat", 445], ["array", 452], ["(", 458], ["FSHD1", 459], [")", 464], [".", 465], ["This", 467], ["results", 472], ["in", 480], ["local", 483], ["chromatin", 489], ["relaxation", 499], ["and", 510], ["stable", 514], ["expression", 521], ["of", 532], ["the", 535], ["DUX4", 539], ["retrogene", 544], ["in", 554], ["skeletal", 557], ["muscle", 566], [",", 572], ["but", 574], ["only", 578], ["when", 583], ["a", 588], ["polymorphic", 590], ["DUX4", 602], ["polyadenylation", 607], ["signal", 623], ["is", 630], ["present", 633], [".", 640], ["In", 642], ["some", 645], ["cases", 650], ["(", 656], ["FSHD2", 657], [")", 662], [",", 663], ["D4Z4", 665], ["chromatin", 670], ["relaxation", 680], ["and", 691], ["stable", 695], ["DUX4", 702], ["expression", 707], ["occur", 718], ["in", 724], ["the", 727], ["absence", 731], ["of", 739], ["D4Z4", 742], ["array", 747], ["contraction", 753], [".", 764], ["DUX4", 766], ["is", 771], ["a", 774], ["germline", 776], ["transcription", 785], ["factor", 799], ["and", 806], ["its", 810], ["expression", 814], ["in", 825], ["skeletal", 828], ["muscle", 837], ["leads", 844], ["to", 850], ["activation", 853], ["of", 864], ["early", 867], ["stem", 873], ["cell", 878], ["and", 883], ["germline", 887], ["programs", 896], ["and", 905], ["transcriptional", 909], ["activation", 925], ["of", 936], ["retroelements", 939], [".", 952], ["Recent", 954], ["studies", 961], ["have", 969], ["provided", 974], ["a", 983], ["plausible", 985], ["disease", 995], ["mechanism", 1003], ["for", 1013], ["FSHD", 1017], ["in", 1022], ["which", 1025], ["FSHD", 1031], ["results", 1036], ["from", 1044], ["inappropriate", 1049], ["expression", 1063], ["of", 1074], ["the", 1077], ["germline", 1081], ["transcription", 1090], ["factor", 1104], ["DUX4", 1111], [".", 1115], ["The", 1117], ["genes", 1121], ["regulated", 1127], ["by", 1137], ["DUX4", 1140], ["suggest", 1145], ["several", 1153], ["mechanisms", 1161], ["of", 1172], ["muscle", 1175], ["damage", 1182], [",", 1188], ["and", 1190], ["provide", 1194], ["potential", 1202], ["biomarkers", 1212], ["and", 1223], ["therapeutic", 1227], ["targets", 1239], ["that", 1247], ["should", 1252], ["be", 1259], ["investigated", 1262], ["in", 1275], ["future", 1278], ["studies", 1285], [".", 1292]]}
{"context": "A study was carried out on 200 patients of ages 20-40 years suffering from acute viral hepatitis. Sera were tested for markers of hepatitis B (HBsAg, and IgM anti-HBc) and hepatitis A (IgM-anti-HAV) by the ELISA technique. Sera negative for the markers of both viruses: Hepatitis A (HAV) and Hepatitis B (HBV) were subsequently tested for IGM Heterophil antibodies against Epstein-Barr virus (EBV) by the Monospot slide test to diagnose acute infectious mononucleosis and tested for anti-CMV (IgM) by ELISA technique for the diagnosis of acute Cytomegalovirus (CMV) infection. Non-A, non-B hepatitis (NANB) was diagnosed by exclusion. The results of the study showed that 133 (66.5%) patients had evidence of HBV infection, while only 9(4.5%) were diagnosed as HAV infection. EBV and CMV were the possible etiological agents of acute viral hepatitis in (3.5%) and 1%) respectively. Accordingly the Non-A, non-B hepatitis in this study amounts to (24.5%) of the acute viral hepatitis.", "qas": [{"question": "Which virus can be diagnosed with the monospot test?", "answers": ["Epstein-Barr virus"], "qid": "c5f3d85f9a094b98b72b423fbde816d2", "question_tokens": [["Which", 0], ["virus", 6], ["can", 12], ["be", 16], ["diagnosed", 19], ["with", 29], ["the", 34], ["monospot", 38], ["test", 47], ["?", 51]], "detected_answers": [{"text": "Epstein-Barr virus", "token_spans": [[80, 83]], "char_spans": [[373, 390]]}]}], "context_tokens": [["A", 0], ["study", 2], ["was", 8], ["carried", 12], ["out", 20], ["on", 24], ["200", 27], ["patients", 31], ["of", 40], ["ages", 43], ["20", 48], ["-", 50], ["40", 51], ["years", 54], ["suffering", 60], ["from", 70], ["acute", 75], ["viral", 81], ["hepatitis", 87], [".", 96], ["Sera", 98], ["were", 103], ["tested", 108], ["for", 115], ["markers", 119], ["of", 127], ["hepatitis", 130], ["B", 140], ["(", 142], ["HBsAg", 143], [",", 148], ["and", 150], ["IgM", 154], ["anti", 158], ["-", 162], ["HBc", 163], [")", 166], ["and", 168], ["hepatitis", 172], ["A", 182], ["(", 184], ["IgM", 185], ["-", 188], ["anti", 189], ["-", 193], ["HAV", 194], [")", 197], ["by", 199], ["the", 202], ["ELISA", 206], ["technique", 212], [".", 221], ["Sera", 223], ["negative", 228], ["for", 237], ["the", 241], ["markers", 245], ["of", 253], ["both", 256], ["viruses", 261], [":", 268], ["Hepatitis", 270], ["A", 280], ["(", 282], ["HAV", 283], [")", 286], ["and", 288], ["Hepatitis", 292], ["B", 302], ["(", 304], ["HBV", 305], [")", 308], ["were", 310], ["subsequently", 315], ["tested", 328], ["for", 335], ["IGM", 339], ["Heterophil", 343], ["antibodies", 354], ["against", 365], ["Epstein", 373], ["-", 380], ["Barr", 381], ["virus", 386], ["(", 392], ["EBV", 393], [")", 396], ["by", 398], ["the", 401], ["Monospot", 405], ["slide", 414], ["test", 420], ["to", 425], ["diagnose", 428], ["acute", 437], ["infectious", 443], ["mononucleosis", 454], ["and", 468], ["tested", 472], ["for", 479], ["anti", 483], ["-", 487], ["CMV", 488], ["(", 492], ["IgM", 493], [")", 496], ["by", 498], ["ELISA", 501], ["technique", 507], ["for", 517], ["the", 521], ["diagnosis", 525], ["of", 535], ["acute", 538], ["Cytomegalovirus", 544], ["(", 560], ["CMV", 561], [")", 564], ["infection", 566], [".", 575], ["Non", 577], ["-", 580], ["A", 581], [",", 582], ["non", 584], ["-", 587], ["B", 588], ["hepatitis", 590], ["(", 600], ["NANB", 601], [")", 605], ["was", 607], ["diagnosed", 611], ["by", 621], ["exclusion", 624], [".", 633], ["The", 635], ["results", 639], ["of", 647], ["the", 650], ["study", 654], ["showed", 660], ["that", 667], ["133", 672], ["(", 676], ["66.5", 677], ["%", 681], [")", 682], ["patients", 684], ["had", 693], ["evidence", 697], ["of", 706], ["HBV", 709], ["infection", 713], [",", 722], ["while", 724], ["only", 730], ["9(4.5", 735], ["%", 740], [")", 741], ["were", 743], ["diagnosed", 748], ["as", 758], ["HAV", 761], ["infection", 765], [".", 774], ["EBV", 776], ["and", 780], ["CMV", 784], ["were", 788], ["the", 793], ["possible", 797], ["etiological", 806], ["agents", 818], ["of", 825], ["acute", 828], ["viral", 834], ["hepatitis", 840], ["in", 850], ["(", 853], ["3.5", 854], ["%", 857], [")", 858], ["and", 860], ["1", 864], ["%", 865], [")", 866], ["respectively", 868], [".", 880], ["Accordingly", 882], ["the", 894], ["Non", 898], ["-", 901], ["A", 902], [",", 903], ["non", 905], ["-", 908], ["B", 909], ["hepatitis", 911], ["in", 921], ["this", 924], ["study", 929], ["amounts", 935], ["to", 943], ["(", 946], ["24.5", 947], ["%", 951], [")", 952], ["of", 954], ["the", 957], ["acute", 961], ["viral", 967], ["hepatitis", 973], [".", 982]]}
{"context": "Neuronal loss in specific brain regions and neurons with intracellular inclusions termed Lewy bodies are the pathologic hallmark in both Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Lewy bodies comprise of aggregated intracellular vesicles and proteins and \u03b1-synuclein is reported to be a major protein component. Using human brain tissue from control, PD and DLB and light and confocal immunohistochemistry with antibodies to superoxide dismutase 2 as a marker for mitochondria, \u03b1-synuclein for Lewy bodies and \u03b2III Tubulin for microtubules we have examined the relationship between Lewy bodies and mitochondrial loss. We have shown microtubule regression and mitochondrial and nuclear degradation in neurons with developing Lewy bodies. In PD, multiple Lewy bodies were often observed with \u03b1-synuclein interacting with DNA to cause marked nuclear degradation. In DLB, the mitochondria are drawn into the Lewy body and the mitochondrial integrity is lost. This work suggests that Lewy bodies are cytotoxic. In DLB, we suggest that microtubule regression and mitochondrial loss results in decreased cellular energy and axonal transport that leads to cell death. In PD, \u03b1-synuclein aggregations are associated with intact mitochondria but interacts with and causes nuclear degradation which may be the major cause of cell death.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "a26bb24d46114aeaa1d54858c6340119", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[134, 136], [201, 203], [45, 47], [84, 86]], "char_spans": [[809, 819], [1186, 1196], [274, 284], [497, 507]]}]}], "context_tokens": [["Neuronal", 0], ["loss", 9], ["in", 14], ["specific", 17], ["brain", 26], ["regions", 32], ["and", 40], ["neurons", 44], ["with", 52], ["intracellular", 57], ["inclusions", 71], ["termed", 82], ["Lewy", 89], ["bodies", 94], ["are", 101], ["the", 105], ["pathologic", 109], ["hallmark", 120], ["in", 129], ["both", 132], ["Parkinson", 137], ["'s", 146], ["disease", 149], ["(", 157], ["PD", 158], [")", 160], ["and", 162], ["dementia", 166], ["with", 175], ["Lewy", 180], ["bodies", 185], ["(", 192], ["DLB", 193], [")", 196], [".", 197], ["Lewy", 199], ["bodies", 204], ["comprise", 211], ["of", 220], ["aggregated", 223], ["intracellular", 234], ["vesicles", 248], ["and", 257], ["proteins", 261], ["and", 270], ["\u03b1", 274], ["-", 275], ["synuclein", 276], ["is", 286], ["reported", 289], ["to", 298], ["be", 301], ["a", 304], ["major", 306], ["protein", 312], ["component", 320], [".", 329], ["Using", 331], ["human", 337], ["brain", 343], ["tissue", 349], ["from", 356], ["control", 361], [",", 368], ["PD", 370], ["and", 373], ["DLB", 377], ["and", 381], ["light", 385], ["and", 391], ["confocal", 395], ["immunohistochemistry", 404], ["with", 425], ["antibodies", 430], ["to", 441], ["superoxide", 444], ["dismutase", 455], ["2", 465], ["as", 467], ["a", 470], ["marker", 472], ["for", 479], ["mitochondria", 483], [",", 495], ["\u03b1", 497], ["-", 498], ["synuclein", 499], ["for", 509], ["Lewy", 513], ["bodies", 518], ["and", 525], ["\u03b2III", 529], ["Tubulin", 534], ["for", 542], ["microtubules", 546], ["we", 559], ["have", 562], ["examined", 567], ["the", 576], ["relationship", 580], ["between", 593], ["Lewy", 601], ["bodies", 606], ["and", 613], ["mitochondrial", 617], ["loss", 631], [".", 635], ["We", 637], ["have", 640], ["shown", 645], ["microtubule", 651], ["regression", 663], ["and", 674], ["mitochondrial", 678], ["and", 692], ["nuclear", 696], ["degradation", 704], ["in", 716], ["neurons", 719], ["with", 727], ["developing", 732], ["Lewy", 743], ["bodies", 748], [".", 754], ["In", 756], ["PD", 759], [",", 761], ["multiple", 763], ["Lewy", 772], ["bodies", 777], ["were", 784], ["often", 789], ["observed", 795], ["with", 804], ["\u03b1", 809], ["-", 810], ["synuclein", 811], ["interacting", 821], ["with", 833], ["DNA", 838], ["to", 842], ["cause", 845], ["marked", 851], ["nuclear", 858], ["degradation", 866], [".", 877], ["In", 879], ["DLB", 882], [",", 885], ["the", 887], ["mitochondria", 891], ["are", 904], ["drawn", 908], ["into", 914], ["the", 919], ["Lewy", 923], ["body", 928], ["and", 933], ["the", 937], ["mitochondrial", 941], ["integrity", 955], ["is", 965], ["lost", 968], [".", 972], ["This", 974], ["work", 979], ["suggests", 984], ["that", 993], ["Lewy", 998], ["bodies", 1003], ["are", 1010], ["cytotoxic", 1014], [".", 1023], ["In", 1025], ["DLB", 1028], [",", 1031], ["we", 1033], ["suggest", 1036], ["that", 1044], ["microtubule", 1049], ["regression", 1061], ["and", 1072], ["mitochondrial", 1076], ["loss", 1090], ["results", 1095], ["in", 1103], ["decreased", 1106], ["cellular", 1116], ["energy", 1125], ["and", 1132], ["axonal", 1136], ["transport", 1143], ["that", 1153], ["leads", 1158], ["to", 1164], ["cell", 1167], ["death", 1172], [".", 1177], ["In", 1179], ["PD", 1182], [",", 1184], ["\u03b1", 1186], ["-", 1187], ["synuclein", 1188], ["aggregations", 1198], ["are", 1211], ["associated", 1215], ["with", 1226], ["intact", 1231], ["mitochondria", 1238], ["but", 1251], ["interacts", 1255], ["with", 1265], ["and", 1270], ["causes", 1274], ["nuclear", 1281], ["degradation", 1289], ["which", 1301], ["may", 1307], ["be", 1311], ["the", 1314], ["major", 1318], ["cause", 1324], ["of", 1330], ["cell", 1333], ["death", 1338], [".", 1343]]}
{"context": "Cep135 is a 135-kDa, coiled-coil centrosome protein important for microtubule organization in mammalian cells [Ohta et al., 2002: J. Cell Biol. 156:87-99]. To identify Cep135-interacting molecules, we screened yeast two-hybrid libraries. One clone encoded dynamitin, a p50 dynactin subunit, which localized at the centrosome and has been shown to be involved in anchoring microtubules to centrosomes. The central domain of p50 binds to the C-terminal sequence of Cep135; this was further confirmed by immunoprecipitation and immunostaining of CHO cells co-expressing the binding domains for Cep135 and p50. Exogenous p50 lacking the Cep 135-binding domain failed to locate at the centrosome, suggesting that Cep135 is required for initial targeting of the centrosome. Altered levels of Cep135 and p50 by RNAi and protein overexpression caused the release of endogenous partner molecules from centrosomes. This also resulted in dislocation of other centrosomal molecules, such as gamma-tubulin and pericentrin, ultimately leading to disorganization of microtubule patterns. These results suggest that Cep135 and p50 play an important role in assembly and maintenance of functional microtubule-organizing centers.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "08c3aa54125445ca90f9fe4a6632bcf7", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[134, 134], [8, 8], [59, 59], [122, 122]], "char_spans": [[756, 765], [33, 42], [314, 323], [680, 689]]}]}], "context_tokens": [["Cep135", 0], ["is", 7], ["a", 10], ["135-kDa", 12], [",", 19], ["coiled", 21], ["-", 27], ["coil", 28], ["centrosome", 33], ["protein", 44], ["important", 52], ["for", 62], ["microtubule", 66], ["organization", 78], ["in", 91], ["mammalian", 94], ["cells", 104], ["[", 110], ["Ohta", 111], ["et", 116], ["al", 119], [".", 121], [",", 122], ["2002", 124], [":", 128], ["J.", 130], ["Cell", 133], ["Biol", 138], [".", 142], ["156:87", 144], ["-", 150], ["99].", 151], ["To", 156], ["identify", 159], ["Cep135-interacting", 168], ["molecules", 187], [",", 196], ["we", 198], ["screened", 201], ["yeast", 210], ["two", 216], ["-", 219], ["hybrid", 220], ["libraries", 227], [".", 236], ["One", 238], ["clone", 242], ["encoded", 248], ["dynamitin", 256], [",", 265], ["a", 267], ["p50", 269], ["dynactin", 273], ["subunit", 282], [",", 289], ["which", 291], ["localized", 297], ["at", 307], ["the", 310], ["centrosome", 314], ["and", 325], ["has", 329], ["been", 333], ["shown", 338], ["to", 344], ["be", 347], ["involved", 350], ["in", 359], ["anchoring", 362], ["microtubules", 372], ["to", 385], ["centrosomes", 388], [".", 399], ["The", 401], ["central", 405], ["domain", 413], ["of", 420], ["p50", 423], ["binds", 427], ["to", 433], ["the", 436], ["C", 440], ["-", 441], ["terminal", 442], ["sequence", 451], ["of", 460], ["Cep135", 463], [";", 469], ["this", 471], ["was", 476], ["further", 480], ["confirmed", 488], ["by", 498], ["immunoprecipitation", 501], ["and", 521], ["immunostaining", 525], ["of", 540], ["CHO", 543], ["cells", 547], ["co", 553], ["-", 555], ["expressing", 556], ["the", 567], ["binding", 571], ["domains", 579], ["for", 587], ["Cep135", 591], ["and", 598], ["p50", 602], [".", 605], ["Exogenous", 607], ["p50", 617], ["lacking", 621], ["the", 629], ["Cep", 633], ["135-binding", 637], ["domain", 649], ["failed", 656], ["to", 663], ["locate", 666], ["at", 673], ["the", 676], ["centrosome", 680], [",", 690], ["suggesting", 692], ["that", 703], ["Cep135", 708], ["is", 715], ["required", 718], ["for", 727], ["initial", 731], ["targeting", 739], ["of", 749], ["the", 752], ["centrosome", 756], [".", 766], ["Altered", 768], ["levels", 776], ["of", 783], ["Cep135", 786], ["and", 793], ["p50", 797], ["by", 801], ["RNAi", 804], ["and", 809], ["protein", 813], ["overexpression", 821], ["caused", 836], ["the", 843], ["release", 847], ["of", 855], ["endogenous", 858], ["partner", 869], ["molecules", 877], ["from", 887], ["centrosomes", 892], [".", 903], ["This", 905], ["also", 910], ["resulted", 915], ["in", 924], ["dislocation", 927], ["of", 939], ["other", 942], ["centrosomal", 948], ["molecules", 960], [",", 969], ["such", 971], ["as", 976], ["gamma", 979], ["-", 984], ["tubulin", 985], ["and", 993], ["pericentrin", 997], [",", 1008], ["ultimately", 1010], ["leading", 1021], ["to", 1029], ["disorganization", 1032], ["of", 1048], ["microtubule", 1051], ["patterns", 1063], [".", 1071], ["These", 1073], ["results", 1079], ["suggest", 1087], ["that", 1095], ["Cep135", 1100], ["and", 1107], ["p50", 1111], ["play", 1115], ["an", 1120], ["important", 1123], ["role", 1133], ["in", 1138], ["assembly", 1141], ["and", 1150], ["maintenance", 1154], ["of", 1166], ["functional", 1169], ["microtubule", 1180], ["-", 1191], ["organizing", 1192], ["centers", 1203], [".", 1210]]}
{"context": "Small supernumerary marker chromosomes (sSMC) can be present in numerically abnormal karyotypes like in a 'Turner-syndrome karyotype' mos 45,X/46,X,+mar. Here we report the first case of an sSMC found in Turner syndrome karyotypes (sSMCT) derived from chromosome 14 in a Turner syndrome patient. According to cytogenetic and molecular cytogenetic characterization the karyotype was 46,X,+del(14)(q11.1). The present case is the third Turner syndrome case with an sSMCT not derived from the X- or the Y-chromosome. More comprehensive characterization of such sSMCT might identify them to be more frequent than only ~0.6% in Turner syndrome cases according to available data.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "d691510d9c1e401ebf6364b876537b48", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[82, 82]], "char_spans": [[490, 491]]}]}], "context_tokens": [["Small", 0], ["supernumerary", 6], ["marker", 20], ["chromosomes", 27], ["(", 39], ["sSMC", 40], [")", 44], ["can", 46], ["be", 50], ["present", 53], ["in", 61], ["numerically", 64], ["abnormal", 76], ["karyotypes", 85], ["like", 96], ["in", 101], ["a", 104], ["'", 106], ["Turner", 107], ["-", 113], ["syndrome", 114], ["karyotype", 123], ["'", 132], ["mos", 134], ["45,X/46,X,+mar", 138], [".", 152], ["Here", 154], ["we", 159], ["report", 162], ["the", 169], ["first", 173], ["case", 179], ["of", 184], ["an", 187], ["sSMC", 190], ["found", 195], ["in", 201], ["Turner", 204], ["syndrome", 211], ["karyotypes", 220], ["(", 231], ["sSMCT", 232], [")", 237], ["derived", 239], ["from", 247], ["chromosome", 252], ["14", 263], ["in", 266], ["a", 269], ["Turner", 271], ["syndrome", 278], ["patient", 287], [".", 294], ["According", 296], ["to", 306], ["cytogenetic", 309], ["and", 321], ["molecular", 325], ["cytogenetic", 335], ["characterization", 347], ["the", 364], ["karyotype", 368], ["was", 378], ["46,X,+del(14)(q11.1", 382], [")", 401], [".", 402], ["The", 404], ["present", 408], ["case", 416], ["is", 421], ["the", 424], ["third", 428], ["Turner", 434], ["syndrome", 441], ["case", 450], ["with", 455], ["an", 460], ["sSMCT", 463], ["not", 469], ["derived", 473], ["from", 481], ["the", 486], ["X-", 490], ["or", 493], ["the", 496], ["Y", 500], ["-", 501], ["chromosome", 502], [".", 512], ["More", 514], ["comprehensive", 519], ["characterization", 533], ["of", 550], ["such", 553], ["sSMCT", 558], ["might", 564], ["identify", 570], ["them", 579], ["to", 584], ["be", 587], ["more", 590], ["frequent", 595], ["than", 604], ["only", 609], ["~0.6", 614], ["%", 618], ["in", 620], ["Turner", 623], ["syndrome", 630], ["cases", 639], ["according", 645], ["to", 655], ["available", 658], ["data", 668], [".", 672]]}
{"context": "Deubiquitinating enzymes (DUbs) play important roles in many ubiquitin-dependent pathways, yet how DUbs themselves are regulated is not well understood. Here, we provide insight into the mechanism by which ubiquitination directly enhances the activity of ataxin-3, a DUb implicated in protein quality control and the disease protein in the polyglutamine neurodegenerative disorder, Spinocerebellar Ataxia Type 3. We identify Lys-117, which resides near the catalytic triad, as the primary site of ubiquitination in wild type and pathogenic ataxin-3. Further studies indicate that ubiquitin-dependent activation of ataxin-3 at Lys-117 is important for its ability to reduce high molecular weight ubiquitinated species in cells. Ubiquitination at Lys-117 also facilitates the ability of ataxin-3 to induce aggresome formation in cells. Finally, structure-function studies support a model of activation whereby ubiquitination at Lys-117 enhances ataxin-3 activity independent of the known ubiquitin-binding sites in ataxin-3, most likely through a direct conformational change in or near the catalytic domain.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "76df6ea078eb43ef838474f8a30b5d15", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[160, 160], [149, 149], [99, 99], [125, 125], [42, 42], [88, 88]], "char_spans": [[1013, 1020], [943, 950], [614, 621], [785, 792], [255, 262], [540, 547]]}]}], "context_tokens": [["Deubiquitinating", 0], ["enzymes", 17], ["(", 25], ["DUbs", 26], [")", 30], ["play", 32], ["important", 37], ["roles", 47], ["in", 53], ["many", 56], ["ubiquitin", 61], ["-", 70], ["dependent", 71], ["pathways", 81], [",", 89], ["yet", 91], ["how", 95], ["DUbs", 99], ["themselves", 104], ["are", 115], ["regulated", 119], ["is", 129], ["not", 132], ["well", 136], ["understood", 141], [".", 151], ["Here", 153], [",", 157], ["we", 159], ["provide", 162], ["insight", 170], ["into", 178], ["the", 183], ["mechanism", 187], ["by", 197], ["which", 200], ["ubiquitination", 206], ["directly", 221], ["enhances", 230], ["the", 239], ["activity", 243], ["of", 252], ["ataxin-3", 255], [",", 263], ["a", 265], ["DUb", 267], ["implicated", 271], ["in", 282], ["protein", 285], ["quality", 293], ["control", 301], ["and", 309], ["the", 313], ["disease", 317], ["protein", 325], ["in", 333], ["the", 336], ["polyglutamine", 340], ["neurodegenerative", 354], ["disorder", 372], [",", 380], ["Spinocerebellar", 382], ["Ataxia", 398], ["Type", 405], ["3", 410], [".", 411], ["We", 413], ["identify", 416], ["Lys-117", 425], [",", 432], ["which", 434], ["resides", 440], ["near", 448], ["the", 453], ["catalytic", 457], ["triad", 467], [",", 472], ["as", 474], ["the", 477], ["primary", 481], ["site", 489], ["of", 494], ["ubiquitination", 497], ["in", 512], ["wild", 515], ["type", 520], ["and", 525], ["pathogenic", 529], ["ataxin-3", 540], [".", 548], ["Further", 550], ["studies", 558], ["indicate", 566], ["that", 575], ["ubiquitin", 580], ["-", 589], ["dependent", 590], ["activation", 600], ["of", 611], ["ataxin-3", 614], ["at", 623], ["Lys-117", 626], ["is", 634], ["important", 637], ["for", 647], ["its", 651], ["ability", 655], ["to", 663], ["reduce", 666], ["high", 673], ["molecular", 678], ["weight", 688], ["ubiquitinated", 695], ["species", 709], ["in", 717], ["cells", 720], [".", 725], ["Ubiquitination", 727], ["at", 742], ["Lys-117", 745], ["also", 753], ["facilitates", 758], ["the", 770], ["ability", 774], ["of", 782], ["ataxin-3", 785], ["to", 794], ["induce", 797], ["aggresome", 804], ["formation", 814], ["in", 824], ["cells", 827], [".", 832], ["Finally", 834], [",", 841], ["structure", 843], ["-", 852], ["function", 853], ["studies", 862], ["support", 870], ["a", 878], ["model", 880], ["of", 886], ["activation", 889], ["whereby", 900], ["ubiquitination", 908], ["at", 923], ["Lys-117", 926], ["enhances", 934], ["ataxin-3", 943], ["activity", 952], ["independent", 961], ["of", 973], ["the", 976], ["known", 980], ["ubiquitin", 986], ["-", 995], ["binding", 996], ["sites", 1004], ["in", 1010], ["ataxin-3", 1013], [",", 1021], ["most", 1023], ["likely", 1028], ["through", 1035], ["a", 1043], ["direct", 1045], ["conformational", 1052], ["change", 1067], ["in", 1074], ["or", 1077], ["near", 1080], ["the", 1085], ["catalytic", 1089], ["domain", 1099], [".", 1105]]}
{"context": "Both non-Group A streptococcal (non-GAS) pharyngitis and Group A streptococcal (GAS) pharyngitis are commonly found in patients with sore throat. It is not known whether or not they present with similar signs and symptoms compared to patients with non-streptococcal pharyngitis. MEDLINE was searched for prospective studies that reported throat culture for both GAS and non-GAS as a reference standard, and reported at least one sign, symptom, or the Centor score. Summary estimates of sensitivity, specificity, likelihood ratios (LR+ and LR-), and diagnostic odds ratios (DOR) were calculated using a bivariate random effects model. Summary receiver operating characteristic (ROC) curves were created for key signs and symptoms. Eight studies met our inclusion criteria. Tonsillar exudate had the highest LR+ for both GAS and non-GAS pharyngitis (1.53 versus 1.71). The confidence intervals of sensitivity, LR+, LR-, and DOR for all signs, symptoms, and the Centor score between two groups overlapped, with the relative difference between sensitivities within 15% for arthralgia or myalgia, fever, injected throat, tonsillar enlargement, and tonsillar exudate. Larger differences in sensitivities were observed for sore throat, cervical adenopathy, and lack of a cough, although the difference for lack of a cough largely due to a single outlier. Signs and symptoms of patients with GAS and non-GAS pharyngitis are generally similar. No signs or symptoms clearly distinguish GAS from non-GAS infection. Further work is needed to determine whether Group C streptococcus is a pathogen that should be treated.", "qas": [{"question": "Centor criteria are used for which disease?", "answers": ["streptococcal pharyngitis"], "qid": "6952c83e31114a20b979dc5962329901", "question_tokens": [["Centor", 0], ["criteria", 7], ["are", 16], ["used", 20], ["for", 25], ["which", 29], ["disease", 35], ["?", 42]], "detected_answers": [{"text": "streptococcal pharyngitis", "token_spans": [[49, 50]], "char_spans": [[252, 276]]}]}], "context_tokens": [["Both", 0], ["non", 5], ["-", 8], ["Group", 9], ["A", 15], ["streptococcal", 17], ["(", 31], ["non", 32], ["-", 35], ["GAS", 36], [")", 39], ["pharyngitis", 41], ["and", 53], ["Group", 57], ["A", 63], ["streptococcal", 65], ["(", 79], ["GAS", 80], [")", 83], ["pharyngitis", 85], ["are", 97], ["commonly", 101], ["found", 110], ["in", 116], ["patients", 119], ["with", 128], ["sore", 133], ["throat", 138], [".", 144], ["It", 146], ["is", 149], ["not", 152], ["known", 156], ["whether", 162], ["or", 170], ["not", 173], ["they", 177], ["present", 182], ["with", 190], ["similar", 195], ["signs", 203], ["and", 209], ["symptoms", 213], ["compared", 222], ["to", 231], ["patients", 234], ["with", 243], ["non", 248], ["-", 251], ["streptococcal", 252], ["pharyngitis", 266], [".", 277], ["MEDLINE", 279], ["was", 287], ["searched", 291], ["for", 300], ["prospective", 304], ["studies", 316], ["that", 324], ["reported", 329], ["throat", 338], ["culture", 345], ["for", 353], ["both", 357], ["GAS", 362], ["and", 366], ["non", 370], ["-", 373], ["GAS", 374], ["as", 378], ["a", 381], ["reference", 383], ["standard", 393], [",", 401], ["and", 403], ["reported", 407], ["at", 416], ["least", 419], ["one", 425], ["sign", 429], [",", 433], ["symptom", 435], [",", 442], ["or", 444], ["the", 447], ["Centor", 451], ["score", 458], [".", 463], ["Summary", 465], ["estimates", 473], ["of", 483], ["sensitivity", 486], [",", 497], ["specificity", 499], [",", 510], ["likelihood", 512], ["ratios", 523], ["(", 530], ["LR+", 531], ["and", 535], ["LR-", 539], [")", 542], [",", 543], ["and", 545], ["diagnostic", 549], ["odds", 560], ["ratios", 565], ["(", 572], ["DOR", 573], [")", 576], ["were", 578], ["calculated", 583], ["using", 594], ["a", 600], ["bivariate", 602], ["random", 612], ["effects", 619], ["model", 627], [".", 632], ["Summary", 634], ["receiver", 642], ["operating", 651], ["characteristic", 661], ["(", 676], ["ROC", 677], [")", 680], ["curves", 682], ["were", 689], ["created", 694], ["for", 702], ["key", 706], ["signs", 710], ["and", 716], ["symptoms", 720], [".", 728], ["Eight", 730], ["studies", 736], ["met", 744], ["our", 748], ["inclusion", 752], ["criteria", 762], [".", 770], ["Tonsillar", 772], ["exudate", 782], ["had", 790], ["the", 794], ["highest", 798], ["LR+", 806], ["for", 810], ["both", 814], ["GAS", 819], ["and", 823], ["non", 827], ["-", 830], ["GAS", 831], ["pharyngitis", 835], ["(", 847], ["1.53", 848], ["versus", 853], ["1.71", 860], [")", 864], [".", 865], ["The", 867], ["confidence", 871], ["intervals", 882], ["of", 892], ["sensitivity", 895], [",", 906], ["LR+", 908], [",", 911], ["LR-", 913], [",", 916], ["and", 918], ["DOR", 922], ["for", 926], ["all", 930], ["signs", 934], [",", 939], ["symptoms", 941], [",", 949], ["and", 951], ["the", 955], ["Centor", 959], ["score", 966], ["between", 972], ["two", 980], ["groups", 984], ["overlapped", 991], [",", 1001], ["with", 1003], ["the", 1008], ["relative", 1012], ["difference", 1021], ["between", 1032], ["sensitivities", 1040], ["within", 1054], ["15", 1061], ["%", 1063], ["for", 1065], ["arthralgia", 1069], ["or", 1080], ["myalgia", 1083], [",", 1090], ["fever", 1092], [",", 1097], ["injected", 1099], ["throat", 1108], [",", 1114], ["tonsillar", 1116], ["enlargement", 1126], [",", 1137], ["and", 1139], ["tonsillar", 1143], ["exudate", 1153], [".", 1160], ["Larger", 1162], ["differences", 1169], ["in", 1181], ["sensitivities", 1184], ["were", 1198], ["observed", 1203], ["for", 1212], ["sore", 1216], ["throat", 1221], [",", 1227], ["cervical", 1229], ["adenopathy", 1238], [",", 1248], ["and", 1250], ["lack", 1254], ["of", 1259], ["a", 1262], ["cough", 1264], [",", 1269], ["although", 1271], ["the", 1280], ["difference", 1284], ["for", 1295], ["lack", 1299], ["of", 1304], ["a", 1307], ["cough", 1309], ["largely", 1315], ["due", 1323], ["to", 1327], ["a", 1330], ["single", 1332], ["outlier", 1339], [".", 1346], ["Signs", 1348], ["and", 1354], ["symptoms", 1358], ["of", 1367], ["patients", 1370], ["with", 1379], ["GAS", 1384], ["and", 1388], ["non", 1392], ["-", 1395], ["GAS", 1396], ["pharyngitis", 1400], ["are", 1412], ["generally", 1416], ["similar", 1426], [".", 1433], ["No", 1435], ["signs", 1438], ["or", 1444], ["symptoms", 1447], ["clearly", 1456], ["distinguish", 1464], ["GAS", 1476], ["from", 1480], ["non", 1485], ["-", 1488], ["GAS", 1489], ["infection", 1493], [".", 1502], ["Further", 1504], ["work", 1512], ["is", 1517], ["needed", 1520], ["to", 1527], ["determine", 1530], ["whether", 1540], ["Group", 1548], ["C", 1554], ["streptococcus", 1556], ["is", 1570], ["a", 1573], ["pathogen", 1575], ["that", 1584], ["should", 1589], ["be", 1596], ["treated", 1599], [".", 1606]]}
{"context": "Autosomal dominant facioscapulohumeral muscular dystrophy (FSHD) has an unusual pathogenic mechanism. FSHD is caused by deletion of a subset of D4Z4 macrosatellite repeat units in the subtelomere of chromosome 4q. Recent studies provide compelling evidence that a retrotransposed gene in the D4Z4 repeat, DUX4, is expressed in the human germline and then epigenetically silenced in somatic tissues. In FSHD, the combination of inefficient chromatin silencing of the D4Z4 repeat and polymorphisms on the FSHD-permissive alleles that stabilize the DUX4 mRNAs emanating from the repeat result in inappropriate DUX4 protein expression in muscle cells. FSHD is thereby the first example of a human disease caused by the inefficient repression of a retrogene in a macrosatellite repeat array.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "fb6050311b794585986ab4a8b17b564e", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[6, 6], [65, 65], [104, 104], [14, 14], [81, 81]], "char_spans": [[59, 62], [402, 405], [648, 651], [102, 105], [503, 506]]}]}], "context_tokens": [["Autosomal", 0], ["dominant", 10], ["facioscapulohumeral", 19], ["muscular", 39], ["dystrophy", 48], ["(", 58], ["FSHD", 59], [")", 63], ["has", 65], ["an", 69], ["unusual", 72], ["pathogenic", 80], ["mechanism", 91], [".", 100], ["FSHD", 102], ["is", 107], ["caused", 110], ["by", 117], ["deletion", 120], ["of", 129], ["a", 132], ["subset", 134], ["of", 141], ["D4Z4", 144], ["macrosatellite", 149], ["repeat", 164], ["units", 171], ["in", 177], ["the", 180], ["subtelomere", 184], ["of", 196], ["chromosome", 199], ["4q", 210], [".", 212], ["Recent", 214], ["studies", 221], ["provide", 229], ["compelling", 237], ["evidence", 248], ["that", 257], ["a", 262], ["retrotransposed", 264], ["gene", 280], ["in", 285], ["the", 288], ["D4Z4", 292], ["repeat", 297], [",", 303], ["DUX4", 305], [",", 309], ["is", 311], ["expressed", 314], ["in", 324], ["the", 327], ["human", 331], ["germline", 337], ["and", 346], ["then", 350], ["epigenetically", 355], ["silenced", 370], ["in", 379], ["somatic", 382], ["tissues", 390], [".", 397], ["In", 399], ["FSHD", 402], [",", 406], ["the", 408], ["combination", 412], ["of", 424], ["inefficient", 427], ["chromatin", 439], ["silencing", 449], ["of", 459], ["the", 462], ["D4Z4", 466], ["repeat", 471], ["and", 478], ["polymorphisms", 482], ["on", 496], ["the", 499], ["FSHD", 503], ["-", 507], ["permissive", 508], ["alleles", 519], ["that", 527], ["stabilize", 532], ["the", 542], ["DUX4", 546], ["mRNAs", 551], ["emanating", 557], ["from", 567], ["the", 572], ["repeat", 576], ["result", 583], ["in", 590], ["inappropriate", 593], ["DUX4", 607], ["protein", 612], ["expression", 620], ["in", 631], ["muscle", 634], ["cells", 641], [".", 646], ["FSHD", 648], ["is", 653], ["thereby", 656], ["the", 664], ["first", 668], ["example", 674], ["of", 682], ["a", 685], ["human", 687], ["disease", 693], ["caused", 701], ["by", 708], ["the", 711], ["inefficient", 715], ["repression", 727], ["of", 738], ["a", 741], ["retrogene", 743], ["in", 753], ["a", 756], ["macrosatellite", 758], ["repeat", 773], ["array", 780], [".", 785]]}
{"context": "Understanding the pathogenesis of CLL has uncovered a plethora of novel targets for human application of monoclonal antibodies, engineered T cells, or inhibitors of signal transduction pathways. The B-cell receptor signaling pathway is being actively explored as a therapeutic target in CLL. Ibrutinib, an inhibitor of Bruton's tyrosine kinase is showing impressive responses in heavily pre-treated high-risk CLL, whether alone or in combination with MoAbs or chemotherapy. Other key components of the BCR pathway, namely PI3K-\u03b4, are also being targeted with novel therapies with promising results as well. Future trials would likely evaluate ibrutinib in the front-line setting. Moreover, improvements in allogeneic HCT mostly by continuing to reduce associated toxicity as well as incorporating cellular therapies such as autologous CLL tumor vaccines, among others, will continue to expand. This is also the case for the next generation of chimeric antigen receptor therapy for CLL once genetically modified T cells are available at broad scale and with improved efficacy. As our ability to further refine and integrate these therapies continues to improve, and we gain further knowledge from gene sequencing, we anticipate that treatment algorithms will continue to be revised to a more personalized approach to treat this disease with improved efficacy and devoid of unnecessary toxicity.", "qas": [{"question": "What is the name of Bruton's tyrosine kinase inhibitor that can be used for treatment of chronic lymphocytic leukemia?", "answers": ["Ibrutinib"], "qid": "e34cd287534b4fd788442be110013bba", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["Bruton", 20], ["'s", 26], ["tyrosine", 29], ["kinase", 38], ["inhibitor", 45], ["that", 55], ["can", 60], ["be", 64], ["used", 67], ["for", 72], ["treatment", 76], ["of", 86], ["chronic", 89], ["lymphocytic", 97], ["leukemia", 109], ["?", 117]], "detected_answers": [{"text": "Ibrutinib", "token_spans": [[48, 48], [112, 112]], "char_spans": [[292, 300], [643, 651]]}]}], "context_tokens": [["Understanding", 0], ["the", 14], ["pathogenesis", 18], ["of", 31], ["CLL", 34], ["has", 38], ["uncovered", 42], ["a", 52], ["plethora", 54], ["of", 63], ["novel", 66], ["targets", 72], ["for", 80], ["human", 84], ["application", 90], ["of", 102], ["monoclonal", 105], ["antibodies", 116], [",", 126], ["engineered", 128], ["T", 139], ["cells", 141], [",", 146], ["or", 148], ["inhibitors", 151], ["of", 162], ["signal", 165], ["transduction", 172], ["pathways", 185], [".", 193], ["The", 195], ["B", 199], ["-", 200], ["cell", 201], ["receptor", 206], ["signaling", 215], ["pathway", 225], ["is", 233], ["being", 236], ["actively", 242], ["explored", 251], ["as", 260], ["a", 263], ["therapeutic", 265], ["target", 277], ["in", 284], ["CLL", 287], [".", 290], ["Ibrutinib", 292], [",", 301], ["an", 303], ["inhibitor", 306], ["of", 316], ["Bruton", 319], ["'s", 325], ["tyrosine", 328], ["kinase", 337], ["is", 344], ["showing", 347], ["impressive", 355], ["responses", 366], ["in", 376], ["heavily", 379], ["pre", 387], ["-", 390], ["treated", 391], ["high", 399], ["-", 403], ["risk", 404], ["CLL", 409], [",", 412], ["whether", 414], ["alone", 422], ["or", 428], ["in", 431], ["combination", 434], ["with", 446], ["MoAbs", 451], ["or", 457], ["chemotherapy", 460], [".", 472], ["Other", 474], ["key", 480], ["components", 484], ["of", 495], ["the", 498], ["BCR", 502], ["pathway", 506], [",", 513], ["namely", 515], ["PI3K", 522], ["-", 526], ["\u03b4", 527], [",", 528], ["are", 530], ["also", 534], ["being", 539], ["targeted", 545], ["with", 554], ["novel", 559], ["therapies", 565], ["with", 575], ["promising", 580], ["results", 590], ["as", 598], ["well", 601], [".", 605], ["Future", 607], ["trials", 614], ["would", 621], ["likely", 627], ["evaluate", 634], ["ibrutinib", 643], ["in", 653], ["the", 656], ["front", 660], ["-", 665], ["line", 666], ["setting", 671], [".", 678], ["Moreover", 680], [",", 688], ["improvements", 690], ["in", 703], ["allogeneic", 706], ["HCT", 717], ["mostly", 721], ["by", 728], ["continuing", 731], ["to", 742], ["reduce", 745], ["associated", 752], ["toxicity", 763], ["as", 772], ["well", 775], ["as", 780], ["incorporating", 783], ["cellular", 797], ["therapies", 806], ["such", 816], ["as", 821], ["autologous", 824], ["CLL", 835], ["tumor", 839], ["vaccines", 845], [",", 853], ["among", 855], ["others", 861], [",", 867], ["will", 869], ["continue", 874], ["to", 883], ["expand", 886], [".", 892], ["This", 894], ["is", 899], ["also", 902], ["the", 907], ["case", 911], ["for", 916], ["the", 920], ["next", 924], ["generation", 929], ["of", 940], ["chimeric", 943], ["antigen", 952], ["receptor", 960], ["therapy", 969], ["for", 977], ["CLL", 981], ["once", 985], ["genetically", 990], ["modified", 1002], ["T", 1011], ["cells", 1013], ["are", 1019], ["available", 1023], ["at", 1033], ["broad", 1036], ["scale", 1042], ["and", 1048], ["with", 1052], ["improved", 1057], ["efficacy", 1066], [".", 1074], ["As", 1076], ["our", 1079], ["ability", 1083], ["to", 1091], ["further", 1094], ["refine", 1102], ["and", 1109], ["integrate", 1113], ["these", 1123], ["therapies", 1129], ["continues", 1139], ["to", 1149], ["improve", 1152], [",", 1159], ["and", 1161], ["we", 1165], ["gain", 1168], ["further", 1173], ["knowledge", 1181], ["from", 1191], ["gene", 1196], ["sequencing", 1201], [",", 1211], ["we", 1213], ["anticipate", 1216], ["that", 1227], ["treatment", 1232], ["algorithms", 1242], ["will", 1253], ["continue", 1258], ["to", 1267], ["be", 1270], ["revised", 1273], ["to", 1281], ["a", 1284], ["more", 1286], ["personalized", 1291], ["approach", 1304], ["to", 1313], ["treat", 1316], ["this", 1322], ["disease", 1327], ["with", 1335], ["improved", 1340], ["efficacy", 1349], ["and", 1358], ["devoid", 1362], ["of", 1369], ["unnecessary", 1372], ["toxicity", 1384], [".", 1392]]}
{"context": "Chronic lymphocytic leukemia (CLL) is characterized by constitutive activation of the B-cell receptor (BCR) signaling pathway, but variable responsiveness of the BCR to antigen ligation. Bruton's tyrosine kinase (BTK) shows constitutive activity in CLL and is the target of irreversible inhibition by ibrutinib, an orally bioavailable kinase inhibitor that has shown outstanding activity in CLL. Early clinical results in CLL with other reversible and irreversible BTK inhibitors have been less promising, however, raising the question of whether BTK kinase activity is an important target of ibrutinib and also in CLL. To determine the role of BTK in CLL, we used patient samples and the E\u03bc-TCL1 (TCL1) transgenic mouse model of CLL, which results in spontaneous leukemia development. Inhibition of BTK in primary human CLL cells by small interfering RNA promotes apoptosis. Inhibition of BTK kinase activity through either targeted genetic inactivation or ibrutinib in the TCL1 mouse significantly delays the development of CLL, demonstrating that BTK is a critical kinase for CLL development and expansion and thus an important target of ibrutinib. Collectively, our data confirm the importance of kinase-functional BTK in CLL.", "qas": [{"question": "What is the name of Bruton's tyrosine kinase inhibitor that can be used for treatment of chronic lymphocytic leukemia?", "answers": ["Ibrutinib"], "qid": "6696f9c425644649871fb87ff9a6ff0d", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["Bruton", 20], ["'s", 26], ["tyrosine", 29], ["kinase", 38], ["inhibitor", 45], ["that", 55], ["can", 60], ["be", 64], ["used", 67], ["for", 72], ["treatment", 76], ["of", 86], ["chronic", 89], ["lymphocytic", 97], ["leukemia", 109], ["?", 117]], "detected_answers": [{"text": "Ibrutinib", "token_spans": [[196, 196], [100, 100], [53, 53], [166, 166]], "char_spans": [[1141, 1149], [593, 601], [301, 309], [958, 966]]}]}], "context_tokens": [["Chronic", 0], ["lymphocytic", 8], ["leukemia", 20], ["(", 29], ["CLL", 30], [")", 33], ["is", 35], ["characterized", 38], ["by", 52], ["constitutive", 55], ["activation", 68], ["of", 79], ["the", 82], ["B", 86], ["-", 87], ["cell", 88], ["receptor", 93], ["(", 102], ["BCR", 103], [")", 106], ["signaling", 108], ["pathway", 118], [",", 125], ["but", 127], ["variable", 131], ["responsiveness", 140], ["of", 155], ["the", 158], ["BCR", 162], ["to", 166], ["antigen", 169], ["ligation", 177], [".", 185], ["Bruton", 187], ["'s", 193], ["tyrosine", 196], ["kinase", 205], ["(", 212], ["BTK", 213], [")", 216], ["shows", 218], ["constitutive", 224], ["activity", 237], ["in", 246], ["CLL", 249], ["and", 253], ["is", 257], ["the", 260], ["target", 264], ["of", 271], ["irreversible", 274], ["inhibition", 287], ["by", 298], ["ibrutinib", 301], [",", 310], ["an", 312], ["orally", 315], ["bioavailable", 322], ["kinase", 335], ["inhibitor", 342], ["that", 352], ["has", 357], ["shown", 361], ["outstanding", 367], ["activity", 379], ["in", 388], ["CLL", 391], [".", 394], ["Early", 396], ["clinical", 402], ["results", 411], ["in", 419], ["CLL", 422], ["with", 426], ["other", 431], ["reversible", 437], ["and", 448], ["irreversible", 452], ["BTK", 465], ["inhibitors", 469], ["have", 480], ["been", 485], ["less", 490], ["promising", 495], [",", 504], ["however", 506], [",", 513], ["raising", 515], ["the", 523], ["question", 527], ["of", 536], ["whether", 539], ["BTK", 547], ["kinase", 551], ["activity", 558], ["is", 567], ["an", 570], ["important", 573], ["target", 583], ["of", 590], ["ibrutinib", 593], ["and", 603], ["also", 607], ["in", 612], ["CLL", 615], [".", 618], ["To", 620], ["determine", 623], ["the", 633], ["role", 637], ["of", 642], ["BTK", 645], ["in", 649], ["CLL", 652], [",", 655], ["we", 657], ["used", 660], ["patient", 665], ["samples", 673], ["and", 681], ["the", 685], ["E\u03bc", 689], ["-", 691], ["TCL1", 692], ["(", 697], ["TCL1", 698], [")", 702], ["transgenic", 704], ["mouse", 715], ["model", 721], ["of", 727], ["CLL", 730], [",", 733], ["which", 735], ["results", 741], ["in", 749], ["spontaneous", 752], ["leukemia", 764], ["development", 773], [".", 784], ["Inhibition", 786], ["of", 797], ["BTK", 800], ["in", 804], ["primary", 807], ["human", 815], ["CLL", 821], ["cells", 825], ["by", 831], ["small", 834], ["interfering", 840], ["RNA", 852], ["promotes", 856], ["apoptosis", 865], [".", 874], ["Inhibition", 876], ["of", 887], ["BTK", 890], ["kinase", 894], ["activity", 901], ["through", 910], ["either", 918], ["targeted", 925], ["genetic", 934], ["inactivation", 942], ["or", 955], ["ibrutinib", 958], ["in", 968], ["the", 971], ["TCL1", 975], ["mouse", 980], ["significantly", 986], ["delays", 1000], ["the", 1007], ["development", 1011], ["of", 1023], ["CLL", 1026], [",", 1029], ["demonstrating", 1031], ["that", 1045], ["BTK", 1050], ["is", 1054], ["a", 1057], ["critical", 1059], ["kinase", 1068], ["for", 1075], ["CLL", 1079], ["development", 1083], ["and", 1095], ["expansion", 1099], ["and", 1109], ["thus", 1113], ["an", 1118], ["important", 1121], ["target", 1131], ["of", 1138], ["ibrutinib", 1141], [".", 1150], ["Collectively", 1152], [",", 1164], ["our", 1166], ["data", 1170], ["confirm", 1175], ["the", 1183], ["importance", 1187], ["of", 1198], ["kinase", 1201], ["-", 1207], ["functional", 1208], ["BTK", 1219], ["in", 1223], ["CLL", 1226], [".", 1229]]}
{"context": "Mutations in the ribosomal protein (RP)S19 gene have been found in about 25% of the cases of Diamond-Blackfan anemia (DBA), a rare congenital hypoplastic anemia that includes variable physical malformations. Various mutations have been identified in the RPS19 gene, but no investigations regarding the effect of these alterations on RPS19 mRNA levels have been performed. It is well established that mutated mRNA containing a premature stop codon (PTC) or lacking a stop codon can be rapidly degraded by specific mechanisms called nonsense mediated decay (NMD) and nonstop decay. To study the involvement of such mechanisms in DBA, we analyzed immortalized lymphoblastoid cells and primary fibroblasts from patients presenting different kinds of mutations in the RPS19 gene, generating allelic deletion, missense, nonsense, and nonstop messengers. We found that RPS19 mRNA levels are decreased in the cells with allelic deletion and, to a variable extent, also in all the cell lines with PTC or nonstop mutations. Further analysis showed that translation inhibition causes a stabilization of the mutated RPS19 mRNA. Our findings indicate that NMD and nonstop decay affect the expression of mutated RPS19 genes; this may help to clarify genotype-phenotype correlations in DBA.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "141cca4558cd4f99b00b0fe5066754ca", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[19, 22]], "char_spans": [[93, 115]]}, {"text": "DBA", "token_spans": [[219, 219], [24, 24], [111, 111]], "char_spans": [[1271, 1273], [118, 120], [627, 629]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["the", 13], ["ribosomal", 17], ["protein", 27], ["(", 35], ["RP)S19", 36], ["gene", 43], ["have", 48], ["been", 53], ["found", 58], ["in", 64], ["about", 67], ["25", 73], ["%", 75], ["of", 77], ["the", 80], ["cases", 84], ["of", 90], ["Diamond", 93], ["-", 100], ["Blackfan", 101], ["anemia", 110], ["(", 117], ["DBA", 118], [")", 121], [",", 122], ["a", 124], ["rare", 126], ["congenital", 131], ["hypoplastic", 142], ["anemia", 154], ["that", 161], ["includes", 166], ["variable", 175], ["physical", 184], ["malformations", 193], [".", 206], ["Various", 208], ["mutations", 216], ["have", 226], ["been", 231], ["identified", 236], ["in", 247], ["the", 250], ["RPS19", 254], ["gene", 260], [",", 264], ["but", 266], ["no", 270], ["investigations", 273], ["regarding", 288], ["the", 298], ["effect", 302], ["of", 309], ["these", 312], ["alterations", 318], ["on", 330], ["RPS19", 333], ["mRNA", 339], ["levels", 344], ["have", 351], ["been", 356], ["performed", 361], [".", 370], ["It", 372], ["is", 375], ["well", 378], ["established", 383], ["that", 395], ["mutated", 400], ["mRNA", 408], ["containing", 413], ["a", 424], ["premature", 426], ["stop", 436], ["codon", 441], ["(", 447], ["PTC", 448], [")", 451], ["or", 453], ["lacking", 456], ["a", 464], ["stop", 466], ["codon", 471], ["can", 477], ["be", 481], ["rapidly", 484], ["degraded", 492], ["by", 501], ["specific", 504], ["mechanisms", 513], ["called", 524], ["nonsense", 531], ["mediated", 540], ["decay", 549], ["(", 555], ["NMD", 556], [")", 559], ["and", 561], ["nonstop", 565], ["decay", 573], [".", 578], ["To", 580], ["study", 583], ["the", 589], ["involvement", 593], ["of", 605], ["such", 608], ["mechanisms", 613], ["in", 624], ["DBA", 627], [",", 630], ["we", 632], ["analyzed", 635], ["immortalized", 644], ["lymphoblastoid", 657], ["cells", 672], ["and", 678], ["primary", 682], ["fibroblasts", 690], ["from", 702], ["patients", 707], ["presenting", 716], ["different", 727], ["kinds", 737], ["of", 743], ["mutations", 746], ["in", 756], ["the", 759], ["RPS19", 763], ["gene", 769], [",", 773], ["generating", 775], ["allelic", 786], ["deletion", 794], [",", 802], ["missense", 804], [",", 812], ["nonsense", 814], [",", 822], ["and", 824], ["nonstop", 828], ["messengers", 836], [".", 846], ["We", 848], ["found", 851], ["that", 857], ["RPS19", 862], ["mRNA", 868], ["levels", 873], ["are", 880], ["decreased", 884], ["in", 894], ["the", 897], ["cells", 901], ["with", 907], ["allelic", 912], ["deletion", 920], ["and", 929], [",", 932], ["to", 934], ["a", 937], ["variable", 939], ["extent", 948], [",", 954], ["also", 956], ["in", 961], ["all", 964], ["the", 968], ["cell", 972], ["lines", 977], ["with", 983], ["PTC", 988], ["or", 992], ["nonstop", 995], ["mutations", 1003], [".", 1012], ["Further", 1014], ["analysis", 1022], ["showed", 1031], ["that", 1038], ["translation", 1043], ["inhibition", 1055], ["causes", 1066], ["a", 1073], ["stabilization", 1075], ["of", 1089], ["the", 1092], ["mutated", 1096], ["RPS19", 1104], ["mRNA", 1110], [".", 1114], ["Our", 1116], ["findings", 1120], ["indicate", 1129], ["that", 1138], ["NMD", 1143], ["and", 1147], ["nonstop", 1151], ["decay", 1159], ["affect", 1165], ["the", 1172], ["expression", 1176], ["of", 1187], ["mutated", 1190], ["RPS19", 1198], ["genes", 1204], [";", 1209], ["this", 1211], ["may", 1216], ["help", 1220], ["to", 1225], ["clarify", 1228], ["genotype", 1236], ["-", 1244], ["phenotype", 1245], ["correlations", 1255], ["in", 1268], ["DBA", 1271], [".", 1274]]}
{"context": "Imatinib mesylate (IM) binds to the BCR-ABL protein, inhibiting its kinase activity and effectively controlling diseases driven by this kinase. IM resistance has been associated with kinase mutations or increased BCR-ABL expression. However, disease progression may be mediated by other mechanisms that render tumor cells independent of BCR-ABL. To demonstrate this potential, IM-resistant cells were found in chronic myelogenous leukemia patients with continuous BCR-ABL gene expression but undetectable BCR-ABL protein expression. These cells were unresponsive to IM and acquired BCR-ABL-independent signaling characteristics. IM resistance in some patients may be mediated through loss of kinase target dependence.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "7887f12a541643aebe9893f82a5f0c28", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[86, 88], [36, 38], [100, 102], [8, 10], [57, 59], [79, 81]], "char_spans": [[505, 511], [213, 219], [582, 588], [36, 42], [337, 343], [464, 470]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], ["(", 18], ["IM", 19], [")", 21], ["binds", 23], ["to", 29], ["the", 32], ["BCR", 36], ["-", 39], ["ABL", 40], ["protein", 44], [",", 51], ["inhibiting", 53], ["its", 64], ["kinase", 68], ["activity", 75], ["and", 84], ["effectively", 88], ["controlling", 100], ["diseases", 112], ["driven", 121], ["by", 128], ["this", 131], ["kinase", 136], [".", 142], ["IM", 144], ["resistance", 147], ["has", 158], ["been", 162], ["associated", 167], ["with", 178], ["kinase", 183], ["mutations", 190], ["or", 200], ["increased", 203], ["BCR", 213], ["-", 216], ["ABL", 217], ["expression", 221], [".", 231], ["However", 233], [",", 240], ["disease", 242], ["progression", 250], ["may", 262], ["be", 266], ["mediated", 269], ["by", 278], ["other", 281], ["mechanisms", 287], ["that", 298], ["render", 303], ["tumor", 310], ["cells", 316], ["independent", 322], ["of", 334], ["BCR", 337], ["-", 340], ["ABL", 341], [".", 344], ["To", 346], ["demonstrate", 349], ["this", 361], ["potential", 366], [",", 375], ["IM", 377], ["-", 379], ["resistant", 380], ["cells", 390], ["were", 396], ["found", 401], ["in", 407], ["chronic", 410], ["myelogenous", 418], ["leukemia", 430], ["patients", 439], ["with", 448], ["continuous", 453], ["BCR", 464], ["-", 467], ["ABL", 468], ["gene", 472], ["expression", 477], ["but", 488], ["undetectable", 492], ["BCR", 505], ["-", 508], ["ABL", 509], ["protein", 513], ["expression", 521], [".", 531], ["These", 533], ["cells", 539], ["were", 545], ["unresponsive", 550], ["to", 563], ["IM", 566], ["and", 569], ["acquired", 573], ["BCR", 582], ["-", 585], ["ABL", 586], ["-", 589], ["independent", 590], ["signaling", 602], ["characteristics", 612], [".", 627], ["IM", 629], ["resistance", 632], ["in", 643], ["some", 646], ["patients", 651], ["may", 660], ["be", 664], ["mediated", 667], ["through", 676], ["loss", 684], ["of", 689], ["kinase", 692], ["target", 699], ["dependence", 706], [".", 716]]}
{"context": "Alpha-synuclein is phosphorylated at serine 129 (Ser129) in intracellular protein aggregates called Lewy bodies. These inclusion bodies are the characteristic pathologic lesions of Parkinson disease. Here we define the role of phosphorylation of Ser129 in alpha-synuclein toxicity and inclusion formation using a Drosophila model of Parkinson disease. Mutation of Ser129 to alanine to prevent phosphorylation completely suppresses dopaminergic neuronal loss produced by expression of human alpha-synuclein. In contrast, altering Ser129 to the negatively charged residue aspartate, to mimic phosphorylation, significantly enhances alpha-synuclein toxicity. The G protein-coupled receptor kinase 2 (Gprk2) phosphorylates Ser129 in vivo and enhances alpha-synuclein toxicity. Blocking phosphorylation at Ser129 substantially increases aggregate formation. Thus Ser129 phosphorylation status is crucial in mediating alpha-synuclein neurotoxicity and inclusion formation. Because increased number of inclusion bodies correlates with reduced toxicity, inclusion bodies may protect neurons from alpha-synuclein toxicity.", "qas": [{"question": "Which residue of alpha-synuclein was found to be phosphorylated in Lewy bodies?", "answers": ["Serine 129"], "qid": "7161d325e39f4f4884391fb5e3adb5db", "question_tokens": [["Which", 0], ["residue", 6], ["of", 14], ["alpha", 17], ["-", 22], ["synuclein", 23], ["was", 33], ["found", 37], ["to", 43], ["be", 46], ["phosphorylated", 49], ["in", 64], ["Lewy", 67], ["bodies", 72], ["?", 78]], "detected_answers": [{"text": "Serine 129", "token_spans": [[6, 7]], "char_spans": [[37, 46]]}]}], "context_tokens": [["Alpha", 0], ["-", 5], ["synuclein", 6], ["is", 16], ["phosphorylated", 19], ["at", 34], ["serine", 37], ["129", 44], ["(", 48], ["Ser129", 49], [")", 55], ["in", 57], ["intracellular", 60], ["protein", 74], ["aggregates", 82], ["called", 93], ["Lewy", 100], ["bodies", 105], [".", 111], ["These", 113], ["inclusion", 119], ["bodies", 129], ["are", 136], ["the", 140], ["characteristic", 144], ["pathologic", 159], ["lesions", 170], ["of", 178], ["Parkinson", 181], ["disease", 191], [".", 198], ["Here", 200], ["we", 205], ["define", 208], ["the", 215], ["role", 219], ["of", 224], ["phosphorylation", 227], ["of", 243], ["Ser129", 246], ["in", 253], ["alpha", 256], ["-", 261], ["synuclein", 262], ["toxicity", 272], ["and", 281], ["inclusion", 285], ["formation", 295], ["using", 305], ["a", 311], ["Drosophila", 313], ["model", 324], ["of", 330], ["Parkinson", 333], ["disease", 343], [".", 350], ["Mutation", 352], ["of", 361], ["Ser129", 364], ["to", 371], ["alanine", 374], ["to", 382], ["prevent", 385], ["phosphorylation", 393], ["completely", 409], ["suppresses", 420], ["dopaminergic", 431], ["neuronal", 444], ["loss", 453], ["produced", 458], ["by", 467], ["expression", 470], ["of", 481], ["human", 484], ["alpha", 490], ["-", 495], ["synuclein", 496], [".", 505], ["In", 507], ["contrast", 510], [",", 518], ["altering", 520], ["Ser129", 529], ["to", 536], ["the", 539], ["negatively", 543], ["charged", 554], ["residue", 562], ["aspartate", 570], [",", 579], ["to", 581], ["mimic", 584], ["phosphorylation", 590], [",", 605], ["significantly", 607], ["enhances", 621], ["alpha", 630], ["-", 635], ["synuclein", 636], ["toxicity", 646], [".", 654], ["The", 656], ["G", 660], ["protein", 662], ["-", 669], ["coupled", 670], ["receptor", 678], ["kinase", 687], ["2", 694], ["(", 696], ["Gprk2", 697], [")", 702], ["phosphorylates", 704], ["Ser129", 719], ["in", 726], ["vivo", 729], ["and", 734], ["enhances", 738], ["alpha", 747], ["-", 752], ["synuclein", 753], ["toxicity", 763], [".", 771], ["Blocking", 773], ["phosphorylation", 782], ["at", 798], ["Ser129", 801], ["substantially", 808], ["increases", 822], ["aggregate", 832], ["formation", 842], [".", 851], ["Thus", 853], ["Ser129", 858], ["phosphorylation", 865], ["status", 881], ["is", 888], ["crucial", 891], ["in", 899], ["mediating", 902], ["alpha", 912], ["-", 917], ["synuclein", 918], ["neurotoxicity", 928], ["and", 942], ["inclusion", 946], ["formation", 956], [".", 965], ["Because", 967], ["increased", 975], ["number", 985], ["of", 992], ["inclusion", 995], ["bodies", 1005], ["correlates", 1012], ["with", 1023], ["reduced", 1028], ["toxicity", 1036], [",", 1044], ["inclusion", 1046], ["bodies", 1056], ["may", 1063], ["protect", 1067], ["neurons", 1075], ["from", 1083], ["alpha", 1088], ["-", 1093], ["synuclein", 1094], ["toxicity", 1104], [".", 1112]]}
{"context": "Since the publication of the first European Federation of Neurological Societies (EFNS) guidelines in 2005 on the management of restless legs syndrome (RLS; also known as Willis-Ekbom disease), there have been major therapeutic advances in the field. Furthermore, the management of RLS is now a part of routine neurological practice in Europe. New drugs have also become available, and further randomized controlled trials have been undertaken. These guidelines were undertaken by the EFNS in collaboration with the European Neurological Society and the European Sleep Research Society. To provide an evidence-based update of new treatments published since 2005 for the management of RLS. First, we determined what the objectives of management of primary and secondary RLS should be. We developed the search strategy and conducted a review of the scientific literature up to 31 December 2011 (print and electronic publications) for the drug classes and interventions employed in RLS treatment. Previous guidelines were consulted. All trials were analysed according to class of evidence, and recommendations made according to the 2004 EFNS criteria for rating. Level A recommendations can be made for rotigotine, ropinirole, pramipexole, gabapentin enacarbil, gabapentin and pregabalin, which are all considered effective for the short-term treatment for RLS. However, for the long-term treatment for RLS, rotigotine is considered effective, gabapentin enacarbil is probably effective, and ropinirole, pramipexole and gabapentin are considered possibly effective. Cabergoline has according to our criteria a level A recommendation, but the taskforce cannot recommend this drug because of its serious adverse events.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "de513d59252e439c8c943b250eba9f14", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[21, 23]], "char_spans": [[128, 149]]}]}], "context_tokens": [["Since", 0], ["the", 6], ["publication", 10], ["of", 22], ["the", 25], ["first", 29], ["European", 35], ["Federation", 44], ["of", 55], ["Neurological", 58], ["Societies", 71], ["(", 81], ["EFNS", 82], [")", 86], ["guidelines", 88], ["in", 99], ["2005", 102], ["on", 107], ["the", 110], ["management", 114], ["of", 125], ["restless", 128], ["legs", 137], ["syndrome", 142], ["(", 151], ["RLS", 152], [";", 155], ["also", 157], ["known", 162], ["as", 168], ["Willis", 171], ["-", 177], ["Ekbom", 178], ["disease", 184], [")", 191], [",", 192], ["there", 194], ["have", 200], ["been", 205], ["major", 210], ["therapeutic", 216], ["advances", 228], ["in", 237], ["the", 240], ["field", 244], [".", 249], ["Furthermore", 251], [",", 262], ["the", 264], ["management", 268], ["of", 279], ["RLS", 282], ["is", 286], ["now", 289], ["a", 293], ["part", 295], ["of", 300], ["routine", 303], ["neurological", 311], ["practice", 324], ["in", 333], ["Europe", 336], [".", 342], ["New", 344], ["drugs", 348], ["have", 354], ["also", 359], ["become", 364], ["available", 371], [",", 380], ["and", 382], ["further", 386], ["randomized", 394], ["controlled", 405], ["trials", 416], ["have", 423], ["been", 428], ["undertaken", 433], [".", 443], ["These", 445], ["guidelines", 451], ["were", 462], ["undertaken", 467], ["by", 478], ["the", 481], ["EFNS", 485], ["in", 490], ["collaboration", 493], ["with", 507], ["the", 512], ["European", 516], ["Neurological", 525], ["Society", 538], ["and", 546], ["the", 550], ["European", 554], ["Sleep", 563], ["Research", 569], ["Society", 578], [".", 585], ["To", 587], ["provide", 590], ["an", 598], ["evidence", 601], ["-", 609], ["based", 610], ["update", 616], ["of", 623], ["new", 626], ["treatments", 630], ["published", 641], ["since", 651], ["2005", 657], ["for", 662], ["the", 666], ["management", 670], ["of", 681], ["RLS", 684], [".", 687], ["First", 689], [",", 694], ["we", 696], ["determined", 699], ["what", 710], ["the", 715], ["objectives", 719], ["of", 730], ["management", 733], ["of", 744], ["primary", 747], ["and", 755], ["secondary", 759], ["RLS", 769], ["should", 773], ["be", 780], [".", 782], ["We", 784], ["developed", 787], ["the", 797], ["search", 801], ["strategy", 808], ["and", 817], ["conducted", 821], ["a", 831], ["review", 833], ["of", 840], ["the", 843], ["scientific", 847], ["literature", 858], ["up", 869], ["to", 872], ["31", 875], ["December", 878], ["2011", 887], ["(", 892], ["print", 893], ["and", 899], ["electronic", 903], ["publications", 914], [")", 926], ["for", 928], ["the", 932], ["drug", 936], ["classes", 941], ["and", 949], ["interventions", 953], ["employed", 967], ["in", 976], ["RLS", 979], ["treatment", 983], [".", 992], ["Previous", 994], ["guidelines", 1003], ["were", 1014], ["consulted", 1019], [".", 1028], ["All", 1030], ["trials", 1034], ["were", 1041], ["analysed", 1046], ["according", 1055], ["to", 1065], ["class", 1068], ["of", 1074], ["evidence", 1077], [",", 1085], ["and", 1087], ["recommendations", 1091], ["made", 1107], ["according", 1112], ["to", 1122], ["the", 1125], ["2004", 1129], ["EFNS", 1134], ["criteria", 1139], ["for", 1148], ["rating", 1152], [".", 1158], ["Level", 1160], ["A", 1166], ["recommendations", 1168], ["can", 1184], ["be", 1188], ["made", 1191], ["for", 1196], ["rotigotine", 1200], [",", 1210], ["ropinirole", 1212], [",", 1222], ["pramipexole", 1224], [",", 1235], ["gabapentin", 1237], ["enacarbil", 1248], [",", 1257], ["gabapentin", 1259], ["and", 1270], ["pregabalin", 1274], [",", 1284], ["which", 1286], ["are", 1292], ["all", 1296], ["considered", 1300], ["effective", 1311], ["for", 1321], ["the", 1325], ["short", 1329], ["-", 1334], ["term", 1335], ["treatment", 1340], ["for", 1350], ["RLS", 1354], [".", 1357], ["However", 1359], [",", 1366], ["for", 1368], ["the", 1372], ["long", 1376], ["-", 1380], ["term", 1381], ["treatment", 1386], ["for", 1396], ["RLS", 1400], [",", 1403], ["rotigotine", 1405], ["is", 1416], ["considered", 1419], ["effective", 1430], [",", 1439], ["gabapentin", 1441], ["enacarbil", 1452], ["is", 1462], ["probably", 1465], ["effective", 1474], [",", 1483], ["and", 1485], ["ropinirole", 1489], [",", 1499], ["pramipexole", 1501], ["and", 1513], ["gabapentin", 1517], ["are", 1528], ["considered", 1532], ["possibly", 1543], ["effective", 1552], [".", 1561], ["Cabergoline", 1563], ["has", 1575], ["according", 1579], ["to", 1589], ["our", 1592], ["criteria", 1596], ["a", 1605], ["level", 1607], ["A", 1613], ["recommendation", 1615], [",", 1629], ["but", 1631], ["the", 1635], ["taskforce", 1639], ["can", 1649], ["not", 1652], ["recommend", 1656], ["this", 1666], ["drug", 1671], ["because", 1676], ["of", 1684], ["its", 1687], ["serious", 1691], ["adverse", 1699], ["events", 1707], [".", 1713]]}
{"context": "A dedicated excision repair pathway, termed transcription-coupled repair (TCR), targets the removal of DNA lesions from transcribed strands of expressed genes. Transcription arrest at the site of the lesion has been proposed as the first step for initiation of TCR. In support of this model, a strong correlation between arrest of transcription by a lesion in vitro and TCR of that lesion in vivo has been found in most cases analyzed. TCR has been reported for oxidative DNA damage; however, very little is known about how frequently occurring and spontaneous DNA damage, such as depurination and base deamination, affects progression of the transcription complex. We have previously determined that the oxidative lesion, thymine glycol, is a significant block to transcription by T7 RNA polymerase (T7 RNAP) but has no detectable effect on transcription by RNA polymerase II (RNAP II) in a reconstituted system with all of the required factors. Another oxidative lesion, 8-oxoguanine, only slightly blocked T7 RNAP and caused RNAP II to briefly pause at the lesion before bypassing it. Because an abasic site is an intermediate in the repair of oxidative damage, it was of interest to learn whether it arrested transcription. Using in vitro transcription assays and substrates containing a specifically positioned lesion, we found that an abasic site in the transcribed strand is a 60% block to transcription by T7 RNAP but nearly a complete block to transcription by mammalian RNAP II. An abasic site in the nontranscribed strand did not block either polymerase. Our results clearly indicate that an abasic site is a much stronger block to transcription than either a thymine glycol or an 8-oxoguanine. Because the predominant model for TCR postulates that only lesions that block RNAP will be subject to TCR, our findings suggest that the abasic site may be sufficient to initiate TCR in vivo.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "6960bdbb74c3432a83bd3a3c0a6c30f1", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[242, 243]], "char_spans": [[1360, 1377]]}]}], "context_tokens": [["A", 0], ["dedicated", 2], ["excision", 12], ["repair", 21], ["pathway", 28], [",", 35], ["termed", 37], ["transcription", 44], ["-", 57], ["coupled", 58], ["repair", 66], ["(", 73], ["TCR", 74], [")", 77], [",", 78], ["targets", 80], ["the", 88], ["removal", 92], ["of", 100], ["DNA", 103], ["lesions", 107], ["from", 115], ["transcribed", 120], ["strands", 132], ["of", 140], ["expressed", 143], ["genes", 153], [".", 158], ["Transcription", 160], ["arrest", 174], ["at", 181], ["the", 184], ["site", 188], ["of", 193], ["the", 196], ["lesion", 200], ["has", 207], ["been", 211], ["proposed", 216], ["as", 225], ["the", 228], ["first", 232], ["step", 238], ["for", 243], ["initiation", 247], ["of", 258], ["TCR", 261], [".", 264], ["In", 266], ["support", 269], ["of", 277], ["this", 280], ["model", 285], [",", 290], ["a", 292], ["strong", 294], ["correlation", 301], ["between", 313], ["arrest", 321], ["of", 328], ["transcription", 331], ["by", 345], ["a", 348], ["lesion", 350], ["in", 357], ["vitro", 360], ["and", 366], ["TCR", 370], ["of", 374], ["that", 377], ["lesion", 382], ["in", 389], ["vivo", 392], ["has", 397], ["been", 401], ["found", 406], ["in", 412], ["most", 415], ["cases", 420], ["analyzed", 426], [".", 434], ["TCR", 436], ["has", 440], ["been", 444], ["reported", 449], ["for", 458], ["oxidative", 462], ["DNA", 472], ["damage", 476], [";", 482], ["however", 484], [",", 491], ["very", 493], ["little", 498], ["is", 505], ["known", 508], ["about", 514], ["how", 520], ["frequently", 524], ["occurring", 535], ["and", 545], ["spontaneous", 549], ["DNA", 561], ["damage", 565], [",", 571], ["such", 573], ["as", 578], ["depurination", 581], ["and", 594], ["base", 598], ["deamination", 603], [",", 614], ["affects", 616], ["progression", 624], ["of", 636], ["the", 639], ["transcription", 643], ["complex", 657], [".", 664], ["We", 666], ["have", 669], ["previously", 674], ["determined", 685], ["that", 696], ["the", 701], ["oxidative", 705], ["lesion", 715], [",", 721], ["thymine", 723], ["glycol", 731], [",", 737], ["is", 739], ["a", 742], ["significant", 744], ["block", 756], ["to", 762], ["transcription", 765], ["by", 779], ["T7", 782], ["RNA", 785], ["polymerase", 789], ["(", 800], ["T7", 801], ["RNAP", 804], [")", 808], ["but", 810], ["has", 814], ["no", 818], ["detectable", 821], ["effect", 832], ["on", 839], ["transcription", 842], ["by", 856], ["RNA", 859], ["polymerase", 863], ["II", 874], ["(", 877], ["RNAP", 878], ["II", 883], [")", 885], ["in", 887], ["a", 890], ["reconstituted", 892], ["system", 906], ["with", 913], ["all", 918], ["of", 922], ["the", 925], ["required", 929], ["factors", 938], [".", 945], ["Another", 947], ["oxidative", 955], ["lesion", 965], [",", 971], ["8-oxoguanine", 973], [",", 985], ["only", 987], ["slightly", 992], ["blocked", 1001], ["T7", 1009], ["RNAP", 1012], ["and", 1017], ["caused", 1021], ["RNAP", 1028], ["II", 1033], ["to", 1036], ["briefly", 1039], ["pause", 1047], ["at", 1053], ["the", 1056], ["lesion", 1060], ["before", 1067], ["bypassing", 1074], ["it", 1084], [".", 1086], ["Because", 1088], ["an", 1096], ["abasic", 1099], ["site", 1106], ["is", 1111], ["an", 1114], ["intermediate", 1117], ["in", 1130], ["the", 1133], ["repair", 1137], ["of", 1144], ["oxidative", 1147], ["damage", 1157], [",", 1163], ["it", 1165], ["was", 1168], ["of", 1172], ["interest", 1175], ["to", 1184], ["learn", 1187], ["whether", 1193], ["it", 1201], ["arrested", 1204], ["transcription", 1213], [".", 1226], ["Using", 1228], ["in", 1234], ["vitro", 1237], ["transcription", 1243], ["assays", 1257], ["and", 1264], ["substrates", 1268], ["containing", 1279], ["a", 1290], ["specifically", 1292], ["positioned", 1305], ["lesion", 1316], [",", 1322], ["we", 1324], ["found", 1327], ["that", 1333], ["an", 1338], ["abasic", 1341], ["site", 1348], ["in", 1353], ["the", 1356], ["transcribed", 1360], ["strand", 1372], ["is", 1379], ["a", 1382], ["60", 1384], ["%", 1386], ["block", 1388], ["to", 1394], ["transcription", 1397], ["by", 1411], ["T7", 1414], ["RNAP", 1417], ["but", 1422], ["nearly", 1426], ["a", 1433], ["complete", 1435], ["block", 1444], ["to", 1450], ["transcription", 1453], ["by", 1467], ["mammalian", 1470], ["RNAP", 1480], ["II", 1485], [".", 1487], ["An", 1489], ["abasic", 1492], ["site", 1499], ["in", 1504], ["the", 1507], ["nontranscribed", 1511], ["strand", 1526], ["did", 1533], ["not", 1537], ["block", 1541], ["either", 1547], ["polymerase", 1554], [".", 1564], ["Our", 1566], ["results", 1570], ["clearly", 1578], ["indicate", 1586], ["that", 1595], ["an", 1600], ["abasic", 1603], ["site", 1610], ["is", 1615], ["a", 1618], ["much", 1620], ["stronger", 1625], ["block", 1634], ["to", 1640], ["transcription", 1643], ["than", 1657], ["either", 1662], ["a", 1669], ["thymine", 1671], ["glycol", 1679], ["or", 1686], ["an", 1689], ["8-oxoguanine", 1692], [".", 1704], ["Because", 1706], ["the", 1714], ["predominant", 1718], ["model", 1730], ["for", 1736], ["TCR", 1740], ["postulates", 1744], ["that", 1755], ["only", 1760], ["lesions", 1765], ["that", 1773], ["block", 1778], ["RNAP", 1784], ["will", 1789], ["be", 1794], ["subject", 1797], ["to", 1805], ["TCR", 1808], [",", 1811], ["our", 1813], ["findings", 1817], ["suggest", 1826], ["that", 1834], ["the", 1839], ["abasic", 1843], ["site", 1850], ["may", 1855], ["be", 1859], ["sufficient", 1862], ["to", 1873], ["initiate", 1876], ["TCR", 1885], ["in", 1889], ["vivo", 1892], [".", 1896]]}
{"context": "Ehlers-Danlos syndrome denotes a group of inherited connective tissue diseases comprising nine types. Type IV Ehlers-Danlos syndrome is the most life-threatening form. It is characterized by a type III collagen deficiency resulting in arterial fragility and death from vascular rupture or bowel perforation. This disease involves a col 3A1 gene mutation. We report the case of a 44 year-old woman with type IV Ehlers-Danlos syndrome. The medical history of our patient included bowel necrosis and two vascular ruptures. We indicate data required to establish Ehlers-Danlos syndrome diagnosis and guidelines for patient management.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "549476d728754e0e979168d1b056eae7", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[9, 10]], "char_spans": [[52, 68]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndrome", 14], ["denotes", 23], ["a", 31], ["group", 33], ["of", 39], ["inherited", 42], ["connective", 52], ["tissue", 63], ["diseases", 70], ["comprising", 79], ["nine", 90], ["types", 95], [".", 100], ["Type", 102], ["IV", 107], ["Ehlers", 110], ["-", 116], ["Danlos", 117], ["syndrome", 124], ["is", 133], ["the", 136], ["most", 140], ["life", 145], ["-", 149], ["threatening", 150], ["form", 162], [".", 166], ["It", 168], ["is", 171], ["characterized", 174], ["by", 188], ["a", 191], ["type", 193], ["III", 198], ["collagen", 202], ["deficiency", 211], ["resulting", 222], ["in", 232], ["arterial", 235], ["fragility", 244], ["and", 254], ["death", 258], ["from", 264], ["vascular", 269], ["rupture", 278], ["or", 286], ["bowel", 289], ["perforation", 295], [".", 306], ["This", 308], ["disease", 313], ["involves", 321], ["a", 330], ["col", 332], ["3A1", 336], ["gene", 340], ["mutation", 345], [".", 353], ["We", 355], ["report", 358], ["the", 365], ["case", 369], ["of", 374], ["a", 377], ["44", 379], ["year", 382], ["-", 386], ["old", 387], ["woman", 391], ["with", 397], ["type", 402], ["IV", 407], ["Ehlers", 410], ["-", 416], ["Danlos", 417], ["syndrome", 424], [".", 432], ["The", 434], ["medical", 438], ["history", 446], ["of", 454], ["our", 457], ["patient", 461], ["included", 469], ["bowel", 478], ["necrosis", 484], ["and", 493], ["two", 497], ["vascular", 501], ["ruptures", 510], [".", 518], ["We", 520], ["indicate", 523], ["data", 532], ["required", 537], ["to", 546], ["establish", 549], ["Ehlers", 559], ["-", 565], ["Danlos", 566], ["syndrome", 573], ["diagnosis", 582], ["and", 592], ["guidelines", 596], ["for", 607], ["patient", 611], ["management", 619], [".", 629]]}
{"context": "Mowat-Wilson syndrome is a genetic disease caused by heterozygous mutations or deletions of the zinc finger E-box-binding homeobox 2 (ZEB2) gene. The syndrome is characterized by typical facial features, moderate-to-severe mental retardation, epilepsy and variable congenital malformations, including Hirschsprung disease, genital anomalies, congenital heart disease, agenesis of the corpus callosum, and eye defects. The prevalence of Mowat-Wilson syndrome is currently unknown, but it seems that Mowat-Wilson syndrome is underdiagnosed, particularly in patients without Hirschsprung disease. We report here the first Egyptian case of Mowat-Wilson syndrome who was conceived by intracytoplasmic sperm injection. The patient manifested bilateral sensorineural hearing loss--a new feature not previously reported in cases of Mowat-Wilson syndrome. This report describes the first Egyptian patient of Mowat-Wilson syndrome who was conceived after intracytoplasmic sperm injection, and provides a new evidence for the inclusion of deafness among the congenital defects of the syndrome.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "c3272be6bdea40c9ac22dfe5337dc311", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZEB2", "token_spans": [[26, 26]], "char_spans": [[134, 137]]}]}], "context_tokens": [["Mowat", 0], ["-", 5], ["Wilson", 6], ["syndrome", 13], ["is", 22], ["a", 25], ["genetic", 27], ["disease", 35], ["caused", 43], ["by", 50], ["heterozygous", 53], ["mutations", 66], ["or", 76], ["deletions", 79], ["of", 89], ["the", 92], ["zinc", 96], ["finger", 101], ["E", 108], ["-", 109], ["box", 110], ["-", 113], ["binding", 114], ["homeobox", 122], ["2", 131], ["(", 133], ["ZEB2", 134], [")", 138], ["gene", 140], [".", 144], ["The", 146], ["syndrome", 150], ["is", 159], ["characterized", 162], ["by", 176], ["typical", 179], ["facial", 187], ["features", 194], [",", 202], ["moderate", 204], ["-", 212], ["to", 213], ["-", 215], ["severe", 216], ["mental", 223], ["retardation", 230], [",", 241], ["epilepsy", 243], ["and", 252], ["variable", 256], ["congenital", 265], ["malformations", 276], [",", 289], ["including", 291], ["Hirschsprung", 301], ["disease", 314], [",", 321], ["genital", 323], ["anomalies", 331], [",", 340], ["congenital", 342], ["heart", 353], ["disease", 359], [",", 366], ["agenesis", 368], ["of", 377], ["the", 380], ["corpus", 384], ["callosum", 391], [",", 399], ["and", 401], ["eye", 405], ["defects", 409], [".", 416], ["The", 418], ["prevalence", 422], ["of", 433], ["Mowat", 436], ["-", 441], ["Wilson", 442], ["syndrome", 449], ["is", 458], ["currently", 461], ["unknown", 471], [",", 478], ["but", 480], ["it", 484], ["seems", 487], ["that", 493], ["Mowat", 498], ["-", 503], ["Wilson", 504], ["syndrome", 511], ["is", 520], ["underdiagnosed", 523], [",", 537], ["particularly", 539], ["in", 552], ["patients", 555], ["without", 564], ["Hirschsprung", 572], ["disease", 585], [".", 592], ["We", 594], ["report", 597], ["here", 604], ["the", 609], ["first", 613], ["Egyptian", 619], ["case", 628], ["of", 633], ["Mowat", 636], ["-", 641], ["Wilson", 642], ["syndrome", 649], ["who", 658], ["was", 662], ["conceived", 666], ["by", 676], ["intracytoplasmic", 679], ["sperm", 696], ["injection", 702], [".", 711], ["The", 713], ["patient", 717], ["manifested", 725], ["bilateral", 736], ["sensorineural", 746], ["hearing", 760], ["loss", 768], ["--", 772], ["a", 774], ["new", 776], ["feature", 780], ["not", 788], ["previously", 792], ["reported", 803], ["in", 812], ["cases", 815], ["of", 821], ["Mowat", 824], ["-", 829], ["Wilson", 830], ["syndrome", 837], [".", 845], ["This", 847], ["report", 852], ["describes", 859], ["the", 869], ["first", 873], ["Egyptian", 879], ["patient", 888], ["of", 896], ["Mowat", 899], ["-", 904], ["Wilson", 905], ["syndrome", 912], ["who", 921], ["was", 925], ["conceived", 929], ["after", 939], ["intracytoplasmic", 945], ["sperm", 962], ["injection", 968], [",", 977], ["and", 979], ["provides", 983], ["a", 992], ["new", 994], ["evidence", 998], ["for", 1007], ["the", 1011], ["inclusion", 1015], ["of", 1025], ["deafness", 1028], ["among", 1037], ["the", 1043], ["congenital", 1047], ["defects", 1058], ["of", 1066], ["the", 1069], ["syndrome", 1073], [".", 1081]]}
{"context": "Facioscapulohumeral muscular dystrophy (FSHD) is a dominant disease linked to contraction of an array of tandem 3.3-kb repeats (D4Z4) at 4q35. Within each repeat unit is a gene, DUX4, that can encode a protein containing two homeodomains. A DUX4 transcript derived from the last repeat unit in a contracted array is associated with pathogenesis but it is unclear how. Using exon-based microarrays, the expression profiles of myogenic precursor cells were determined. Both undifferentiated myoblasts and myoblasts differentiated to myotubes derived from FSHD patients and controls were studied after immunocytochemical verification of the quality of the cultures. To further our understanding of FSHD and normal myogenesis, the expression profiles obtained were compared to those of 19 non-muscle cell types analyzed by identical methods. Many of the ~17,000 examined genes were differentially expressed (>2-fold, p<0.01) in control myoblasts or myotubes vs. non-muscle cells (2185 and 3006, respectively) or in FSHD vs. control myoblasts or myotubes (295 and 797, respectively). Surprisingly, despite the morphologically normal differentiation of FSHD myoblasts to myotubes, most of the disease-related dysregulation was seen as dampening of normal myogenesis-specific expression changes, including in genes for muscle structure, mitochondrial function, stress responses, and signal transduction. Other classes of genes, including those encoding extracellular matrix or pro-inflammatory proteins, were upregulated in FSHD myogenic cells independent of an inverse myogenesis association. Importantly, the disease-linked DUX4 RNA isoform was detected by RT-PCR in FSHD myoblast and myotube preparations only at extremely low levels. Unique insights into myogenesis-specific gene expression were also obtained. For example, all four Argonaute genes involved in RNA-silencing were significantly upregulated during normal (but not FSHD) myogenesis relative to non-muscle cell types. DUX4's pathogenic effect in FSHD may occur transiently at or before the stage of myoblast formation to establish a cascade of gene dysregulation. This contrasts with the current emphasis on toxic effects of experimentally upregulated DUX4 expression at the myoblast or myotube stages. Our model could explain why DUX4's inappropriate expression was barely detectable in myoblasts and myotubes but nonetheless linked to FSHD.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "7d7dfb5ece1846bc8fab1c8af7bcce92", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[256, 256], [115, 115], [325, 325], [282, 282], [341, 341], [196, 196], [4, 4], [174, 174], [402, 402], [94, 94]], "char_spans": [[1517, 1520], [695, 698], [1926, 1929], [1662, 1665], [2006, 2009], [1147, 1150], [40, 43], [1011, 1014], [2397, 2400], [553, 556]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["muscular", 20], ["dystrophy", 29], ["(", 39], ["FSHD", 40], [")", 44], ["is", 46], ["a", 49], ["dominant", 51], ["disease", 60], ["linked", 68], ["to", 75], ["contraction", 78], ["of", 90], ["an", 93], ["array", 96], ["of", 102], ["tandem", 105], ["3.3-kb", 112], ["repeats", 119], ["(", 127], ["D4Z4", 128], [")", 132], ["at", 134], ["4q35", 137], [".", 141], ["Within", 143], ["each", 150], ["repeat", 155], ["unit", 162], ["is", 167], ["a", 170], ["gene", 172], [",", 176], ["DUX4", 178], [",", 182], ["that", 184], ["can", 189], ["encode", 193], ["a", 200], ["protein", 202], ["containing", 210], ["two", 221], ["homeodomains", 225], [".", 237], ["A", 239], ["DUX4", 241], ["transcript", 246], ["derived", 257], ["from", 265], ["the", 270], ["last", 274], ["repeat", 279], ["unit", 286], ["in", 291], ["a", 294], ["contracted", 296], ["array", 307], ["is", 313], ["associated", 316], ["with", 327], ["pathogenesis", 332], ["but", 345], ["it", 349], ["is", 352], ["unclear", 355], ["how", 363], [".", 366], ["Using", 368], ["exon", 374], ["-", 378], ["based", 379], ["microarrays", 385], [",", 396], ["the", 398], ["expression", 402], ["profiles", 413], ["of", 422], ["myogenic", 425], ["precursor", 434], ["cells", 444], ["were", 450], ["determined", 455], [".", 465], ["Both", 467], ["undifferentiated", 472], ["myoblasts", 489], ["and", 499], ["myoblasts", 503], ["differentiated", 513], ["to", 528], ["myotubes", 531], ["derived", 540], ["from", 548], ["FSHD", 553], ["patients", 558], ["and", 567], ["controls", 571], ["were", 580], ["studied", 585], ["after", 593], ["immunocytochemical", 599], ["verification", 618], ["of", 631], ["the", 634], ["quality", 638], ["of", 646], ["the", 649], ["cultures", 653], [".", 661], ["To", 663], ["further", 666], ["our", 674], ["understanding", 678], ["of", 692], ["FSHD", 695], ["and", 700], ["normal", 704], ["myogenesis", 711], [",", 721], ["the", 723], ["expression", 727], ["profiles", 738], ["obtained", 747], ["were", 756], ["compared", 761], ["to", 770], ["those", 773], ["of", 779], ["19", 782], ["non", 785], ["-", 788], ["muscle", 789], ["cell", 796], ["types", 801], ["analyzed", 807], ["by", 816], ["identical", 819], ["methods", 829], [".", 836], ["Many", 838], ["of", 843], ["the", 846], ["~17,000", 850], ["examined", 858], ["genes", 867], ["were", 873], ["differentially", 878], ["expressed", 893], ["(", 903], [">", 904], ["2-fold", 905], [",", 911], ["p<0.01", 913], [")", 919], ["in", 921], ["control", 924], ["myoblasts", 932], ["or", 942], ["myotubes", 945], ["vs.", 954], ["non", 958], ["-", 961], ["muscle", 962], ["cells", 969], ["(", 975], ["2185", 976], ["and", 981], ["3006", 985], [",", 989], ["respectively", 991], [")", 1003], ["or", 1005], ["in", 1008], ["FSHD", 1011], ["vs.", 1016], ["control", 1020], ["myoblasts", 1028], ["or", 1038], ["myotubes", 1041], ["(", 1050], ["295", 1051], ["and", 1055], ["797", 1059], [",", 1062], ["respectively", 1064], [")", 1076], [".", 1077], ["Surprisingly", 1079], [",", 1091], ["despite", 1093], ["the", 1101], ["morphologically", 1105], ["normal", 1121], ["differentiation", 1128], ["of", 1144], ["FSHD", 1147], ["myoblasts", 1152], ["to", 1162], ["myotubes", 1165], [",", 1173], ["most", 1175], ["of", 1180], ["the", 1183], ["disease", 1187], ["-", 1194], ["related", 1195], ["dysregulation", 1203], ["was", 1217], ["seen", 1221], ["as", 1226], ["dampening", 1229], ["of", 1239], ["normal", 1242], ["myogenesis", 1249], ["-", 1259], ["specific", 1260], ["expression", 1269], ["changes", 1280], [",", 1287], ["including", 1289], ["in", 1299], ["genes", 1302], ["for", 1308], ["muscle", 1312], ["structure", 1319], [",", 1328], ["mitochondrial", 1330], ["function", 1344], [",", 1352], ["stress", 1354], ["responses", 1361], [",", 1370], ["and", 1372], ["signal", 1376], ["transduction", 1383], [".", 1395], ["Other", 1397], ["classes", 1403], ["of", 1411], ["genes", 1414], [",", 1419], ["including", 1421], ["those", 1431], ["encoding", 1437], ["extracellular", 1446], ["matrix", 1460], ["or", 1467], ["pro", 1470], ["-", 1473], ["inflammatory", 1474], ["proteins", 1487], [",", 1495], ["were", 1497], ["upregulated", 1502], ["in", 1514], ["FSHD", 1517], ["myogenic", 1522], ["cells", 1531], ["independent", 1537], ["of", 1549], ["an", 1552], ["inverse", 1555], ["myogenesis", 1563], ["association", 1574], [".", 1585], ["Importantly", 1587], [",", 1598], ["the", 1600], ["disease", 1604], ["-", 1611], ["linked", 1612], ["DUX4", 1619], ["RNA", 1624], ["isoform", 1628], ["was", 1636], ["detected", 1640], ["by", 1649], ["RT", 1652], ["-", 1654], ["PCR", 1655], ["in", 1659], ["FSHD", 1662], ["myoblast", 1667], ["and", 1676], ["myotube", 1680], ["preparations", 1688], ["only", 1701], ["at", 1706], ["extremely", 1709], ["low", 1719], ["levels", 1723], [".", 1729], ["Unique", 1731], ["insights", 1738], ["into", 1747], ["myogenesis", 1752], ["-", 1762], ["specific", 1763], ["gene", 1772], ["expression", 1777], ["were", 1788], ["also", 1793], ["obtained", 1798], [".", 1806], ["For", 1808], ["example", 1812], [",", 1819], ["all", 1821], ["four", 1825], ["Argonaute", 1830], ["genes", 1840], ["involved", 1846], ["in", 1855], ["RNA", 1858], ["-", 1861], ["silencing", 1862], ["were", 1872], ["significantly", 1877], ["upregulated", 1891], ["during", 1903], ["normal", 1910], ["(", 1917], ["but", 1918], ["not", 1922], ["FSHD", 1926], [")", 1930], ["myogenesis", 1932], ["relative", 1943], ["to", 1952], ["non", 1955], ["-", 1958], ["muscle", 1959], ["cell", 1966], ["types", 1971], [".", 1976], ["DUX4", 1978], ["'s", 1982], ["pathogenic", 1985], ["effect", 1996], ["in", 2003], ["FSHD", 2006], ["may", 2011], ["occur", 2015], ["transiently", 2021], ["at", 2033], ["or", 2036], ["before", 2039], ["the", 2046], ["stage", 2050], ["of", 2056], ["myoblast", 2059], ["formation", 2068], ["to", 2078], ["establish", 2081], ["a", 2091], ["cascade", 2093], ["of", 2101], ["gene", 2104], ["dysregulation", 2109], [".", 2122], ["This", 2124], ["contrasts", 2129], ["with", 2139], ["the", 2144], ["current", 2148], ["emphasis", 2156], ["on", 2165], ["toxic", 2168], ["effects", 2174], ["of", 2182], ["experimentally", 2185], ["upregulated", 2200], ["DUX4", 2212], ["expression", 2217], ["at", 2228], ["the", 2231], ["myoblast", 2235], ["or", 2244], ["myotube", 2247], ["stages", 2255], [".", 2261], ["Our", 2263], ["model", 2267], ["could", 2273], ["explain", 2279], ["why", 2287], ["DUX4", 2291], ["'s", 2295], ["inappropriate", 2298], ["expression", 2312], ["was", 2323], ["barely", 2327], ["detectable", 2334], ["in", 2345], ["myoblasts", 2348], ["and", 2358], ["myotubes", 2362], ["but", 2371], ["nonetheless", 2375], ["linked", 2387], ["to", 2394], ["FSHD", 2397], [".", 2401]]}
{"context": "{4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid (ACT-333679) is the main metabolite of the selective prostacyclin (PGI(2)) receptor (IP receptor) agonist selexipag. The goal of this study was to determine the influence of IP receptor selectivity on the vasorelaxant efficacy of ACT-333679 and the PGI(2) analog treprostinil in pulmonary artery under conditions associated with pulmonary arterial hypertension (PAH). Selexipag and ACT-333679 evoked full relaxation of pulmonary artery from control and monocrotaline (MCT)-PAH rats, and ACT-333679 relaxed normal pulmonary artery contracted with either endothelin-1 (ET-1) or phenylephrine. In contrast, treprostinil evoked weaker relaxation than ACT-333679 of control pulmonary artery and failed to induce relaxation of pulmonary artery from MCT-PAH rats. Treprostinil did not evoke relaxation of normal pulmonary artery contracted with either ET-1 or phenylephrine. Expression of prostaglandin E(3) (EP(3)) receptor mRNA was increased in pulmonary artery from MCT-PAH rats. In contraction experiments, the selective EP(3) receptor agonist sulprostone evoked significantly greater contraction of pulmonary artery from MCT-PAH rats compared with control rats. The presence of a threshold concentration of ET-1 significantly augmented the contractile response to sulprostone in normal pulmonary artery. ACT-333679 did not evoke direct contraction of rat pulmonary artery, whereas treprostinil evoked concentration-dependent contraction that was inhibited by the EP(3) receptor antagonist (2E)-3-(3',4'-dichlorobiphenyl-2-yl)-N-(2-thienylsulfonyl)acrylamide. Antagonism of EP(3) receptors also revealed a relaxant response to treprostinil in normal pulmonary artery contracted with ET-1. These data demonstrate that the relaxant efficacy of the selective IP receptor agonist selexipag and its metabolite ACT-333679 is not modified under conditions associated with PAH, whereas relaxation to treprostinil may be limited in the presence of mediators of disease.", "qas": [{"question": "Selexipag is used for which disease?", "answers": ["pulmonary arterial hypertension"], "qid": "69acbdb73b2c414cb48a711bb6da31f1", "question_tokens": [["Selexipag", 0], ["is", 10], ["used", 13], ["for", 18], ["which", 22], ["disease", 28], ["?", 35]], "detected_answers": [{"text": "pulmonary arterial hypertension", "token_spans": [[59, 61]], "char_spans": [[395, 425]]}]}], "context_tokens": [["{", 0], ["4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic", 1], ["acid", 61], ["(", 66], ["ACT-333679", 67], [")", 77], ["is", 79], ["the", 82], ["main", 86], ["metabolite", 91], ["of", 102], ["the", 105], ["selective", 109], ["prostacyclin", 119], ["(", 132], ["PGI(2", 133], [")", 138], [")", 139], ["receptor", 141], ["(", 150], ["IP", 151], ["receptor", 154], [")", 162], ["agonist", 164], ["selexipag", 172], [".", 181], ["The", 183], ["goal", 187], ["of", 192], ["this", 195], ["study", 200], ["was", 206], ["to", 210], ["determine", 213], ["the", 223], ["influence", 227], ["of", 237], ["IP", 240], ["receptor", 243], ["selectivity", 252], ["on", 264], ["the", 267], ["vasorelaxant", 271], ["efficacy", 284], ["of", 293], ["ACT-333679", 296], ["and", 307], ["the", 311], ["PGI(2", 315], [")", 320], ["analog", 322], ["treprostinil", 329], ["in", 342], ["pulmonary", 345], ["artery", 355], ["under", 362], ["conditions", 368], ["associated", 379], ["with", 390], ["pulmonary", 395], ["arterial", 405], ["hypertension", 414], ["(", 427], ["PAH", 428], [")", 431], [".", 432], ["Selexipag", 434], ["and", 444], ["ACT-333679", 448], ["evoked", 459], ["full", 466], ["relaxation", 471], ["of", 482], ["pulmonary", 485], ["artery", 495], ["from", 502], ["control", 507], ["and", 515], ["monocrotaline", 519], ["(", 533], ["MCT)-PAH", 534], ["rats", 543], [",", 547], ["and", 549], ["ACT-333679", 553], ["relaxed", 564], ["normal", 572], ["pulmonary", 579], ["artery", 589], ["contracted", 596], ["with", 607], ["either", 612], ["endothelin-1", 619], ["(", 632], ["ET-1", 633], [")", 637], ["or", 639], ["phenylephrine", 642], [".", 655], ["In", 657], ["contrast", 660], [",", 668], ["treprostinil", 670], ["evoked", 683], ["weaker", 690], ["relaxation", 697], ["than", 708], ["ACT-333679", 713], ["of", 724], ["control", 727], ["pulmonary", 735], ["artery", 745], ["and", 752], ["failed", 756], ["to", 763], ["induce", 766], ["relaxation", 773], ["of", 784], ["pulmonary", 787], ["artery", 797], ["from", 804], ["MCT", 809], ["-", 812], ["PAH", 813], ["rats", 817], [".", 821], ["Treprostinil", 823], ["did", 836], ["not", 840], ["evoke", 844], ["relaxation", 850], ["of", 861], ["normal", 864], ["pulmonary", 871], ["artery", 881], ["contracted", 888], ["with", 899], ["either", 904], ["ET-1", 911], ["or", 916], ["phenylephrine", 919], [".", 932], ["Expression", 934], ["of", 945], ["prostaglandin", 948], ["E(3", 962], [")", 965], ["(", 967], ["EP(3", 968], [")", 972], [")", 973], ["receptor", 975], ["mRNA", 984], ["was", 989], ["increased", 993], ["in", 1003], ["pulmonary", 1006], ["artery", 1016], ["from", 1023], ["MCT", 1028], ["-", 1031], ["PAH", 1032], ["rats", 1036], [".", 1040], ["In", 1042], ["contraction", 1045], ["experiments", 1057], [",", 1068], ["the", 1070], ["selective", 1074], ["EP(3", 1084], [")", 1088], ["receptor", 1090], ["agonist", 1099], ["sulprostone", 1107], ["evoked", 1119], ["significantly", 1126], ["greater", 1140], ["contraction", 1148], ["of", 1160], ["pulmonary", 1163], ["artery", 1173], ["from", 1180], ["MCT", 1185], ["-", 1188], ["PAH", 1189], ["rats", 1193], ["compared", 1198], ["with", 1207], ["control", 1212], ["rats", 1220], [".", 1224], ["The", 1226], ["presence", 1230], ["of", 1239], ["a", 1242], ["threshold", 1244], ["concentration", 1254], ["of", 1268], ["ET-1", 1271], ["significantly", 1276], ["augmented", 1290], ["the", 1300], ["contractile", 1304], ["response", 1316], ["to", 1325], ["sulprostone", 1328], ["in", 1340], ["normal", 1343], ["pulmonary", 1350], ["artery", 1360], [".", 1366], ["ACT-333679", 1368], ["did", 1379], ["not", 1383], ["evoke", 1387], ["direct", 1393], ["contraction", 1400], ["of", 1412], ["rat", 1415], ["pulmonary", 1419], ["artery", 1429], [",", 1435], ["whereas", 1437], ["treprostinil", 1445], ["evoked", 1458], ["concentration", 1465], ["-", 1478], ["dependent", 1479], ["contraction", 1489], ["that", 1501], ["was", 1506], ["inhibited", 1510], ["by", 1520], ["the", 1523], ["EP(3", 1527], [")", 1531], ["receptor", 1533], ["antagonist", 1542], ["(", 1553], ["2E)-3-(3',4'-dichlorobiphenyl-2-yl)-N-(2-thienylsulfonyl)acrylamide", 1554], [".", 1621], ["Antagonism", 1623], ["of", 1634], ["EP(3", 1637], [")", 1641], ["receptors", 1643], ["also", 1653], ["revealed", 1658], ["a", 1667], ["relaxant", 1669], ["response", 1678], ["to", 1687], ["treprostinil", 1690], ["in", 1703], ["normal", 1706], ["pulmonary", 1713], ["artery", 1723], ["contracted", 1730], ["with", 1741], ["ET-1", 1746], [".", 1750], ["These", 1752], ["data", 1758], ["demonstrate", 1763], ["that", 1775], ["the", 1780], ["relaxant", 1784], ["efficacy", 1793], ["of", 1802], ["the", 1805], ["selective", 1809], ["IP", 1819], ["receptor", 1822], ["agonist", 1831], ["selexipag", 1839], ["and", 1849], ["its", 1853], ["metabolite", 1857], ["ACT-333679", 1868], ["is", 1879], ["not", 1882], ["modified", 1886], ["under", 1895], ["conditions", 1901], ["associated", 1912], ["with", 1923], ["PAH", 1928], [",", 1931], ["whereas", 1933], ["relaxation", 1941], ["to", 1952], ["treprostinil", 1955], ["may", 1968], ["be", 1972], ["limited", 1975], ["in", 1983], ["the", 1986], ["presence", 1990], ["of", 1999], ["mediators", 2002], ["of", 2012], ["disease", 2015], [".", 2022]]}
{"context": "Non-vitamin K anticoagulants (NOAC) such as dabigatran have become important therapeutic options for the prevention of stroke. Until recently, there were only nonspecific agents to reverse their anticoagulant effects in a case of emergency. Idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a NOAC to be approved, but real-world experience is limited. We report two cases of patients on dabigatran with acute intracerebral hemorrhage who received idarucizumab. In both cases, idarucizumab promptly reversed the anticoagulant effect of dabigatran and there was no hematoma expansion in follow-up imaging. In addition to clinical and preclinical studies, our cases add to the experience regarding the safety and efficacy of idarucizumab. They show that idarucizumab may be an important safety option for patients on dabigatran in emergency situations.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "0f0142c6d85345b6ad31f47e1f7b98d4", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[144, 144], [96, 96], [10, 10], [76, 76], [47, 47]], "char_spans": [[856, 865], [577, 586], [44, 53], [429, 438], [286, 295]]}]}], "context_tokens": [["Non", 0], ["-", 3], ["vitamin", 4], ["K", 12], ["anticoagulants", 14], ["(", 29], ["NOAC", 30], [")", 34], ["such", 36], ["as", 41], ["dabigatran", 44], ["have", 55], ["become", 60], ["important", 67], ["therapeutic", 77], ["options", 89], ["for", 97], ["the", 101], ["prevention", 105], ["of", 116], ["stroke", 119], [".", 125], ["Until", 127], ["recently", 133], [",", 141], ["there", 143], ["were", 149], ["only", 154], ["nonspecific", 159], ["agents", 171], ["to", 178], ["reverse", 181], ["their", 189], ["anticoagulant", 195], ["effects", 209], ["in", 217], ["a", 220], ["case", 222], ["of", 227], ["emergency", 230], [".", 239], ["Idarucizumab", 241], [",", 253], ["an", 255], ["antibody", 258], ["fragment", 267], ["targeting", 276], ["dabigatran", 286], [",", 296], ["is", 298], ["the", 301], ["first", 305], ["specific", 311], ["antidote", 320], ["for", 329], ["a", 333], ["NOAC", 335], ["to", 340], ["be", 343], ["approved", 346], [",", 354], ["but", 356], ["real", 360], ["-", 364], ["world", 365], ["experience", 371], ["is", 382], ["limited", 385], [".", 392], ["We", 394], ["report", 397], ["two", 404], ["cases", 408], ["of", 414], ["patients", 417], ["on", 426], ["dabigatran", 429], ["with", 440], ["acute", 445], ["intracerebral", 451], ["hemorrhage", 465], ["who", 476], ["received", 480], ["idarucizumab", 489], [".", 501], ["In", 503], ["both", 506], ["cases", 511], [",", 516], ["idarucizumab", 518], ["promptly", 531], ["reversed", 540], ["the", 549], ["anticoagulant", 553], ["effect", 567], ["of", 574], ["dabigatran", 577], ["and", 588], ["there", 592], ["was", 598], ["no", 602], ["hematoma", 605], ["expansion", 614], ["in", 624], ["follow", 627], ["-", 633], ["up", 634], ["imaging", 637], [".", 644], ["In", 646], ["addition", 649], ["to", 658], ["clinical", 661], ["and", 670], ["preclinical", 674], ["studies", 686], [",", 693], ["our", 695], ["cases", 699], ["add", 705], ["to", 709], ["the", 712], ["experience", 716], ["regarding", 727], ["the", 737], ["safety", 741], ["and", 748], ["efficacy", 752], ["of", 761], ["idarucizumab", 764], [".", 776], ["They", 778], ["show", 783], ["that", 788], ["idarucizumab", 793], ["may", 806], ["be", 810], ["an", 813], ["important", 816], ["safety", 826], ["option", 833], ["for", 840], ["patients", 844], ["on", 853], ["dabigatran", 856], ["in", 867], ["emergency", 870], ["situations", 880], [".", 890]]}
{"context": "Spectrins comprise \u03b1- and \u03b2-subunits made up predominantly of a series of homologous repeating units of about 106 amino acids; the \u03b1- and \u03b2-chains form antiparallel dimers by lateral association, and tetramers through head-to-head contacts between the dimers. Here we consider the first of these interactions. (1) We confirm earlier observations, showing that the first two paired repeats (\u03b2IR1 with \u03b1IR21, and \u03b2IR2 with \u03b1RI20) at one end of the erythroid spectrin (\u03b1I\u03b2I) dimer are necessary and sufficient to unite the chains; (2) we resolve a conflict in published reports by showing that the strength of the interaction is considerably increased on adding the adjoining pair of repeats (\u03b2IR3-\u03b1IR19); (3) in brain (\u03b1II\u03b2II) spectrin the first two pairs of repeats are similarly essential and sufficient for heterodimer formation; (4) this interaction is ~60-fold stronger than that in the erythroid counterpart, but no enhancement can be detected on addition of three further pairs of repeats; (5) formation of a tight \u03b1I\u03b2I dimer probably depends on structural coupling of the first two repeats in each chain; (6) an analysis of the sequences of the strongly interacting repeats, \u03b2IR1, \u03b2IIR1, \u03b1IR21 and \u03b1IIR20 and repeats in \u03b1-actinin, which also interact very strongly in forming an antiparallel dimer, affords a possible explanation for the different properties of the two spectrin isoforms in respect of the stability of the inter-chain interactions, and also suggests the evolutionary path by which the erythroid and non-erythroid sequences diverged.", "qas": [{"question": "Alpha-spectrin and beta-spectrin subunits form parallel or antiparallel heterodimers?", "answers": ["antiparallel"], "qid": "0cf3e09ca48743ab8afcd531f7b306e9", "question_tokens": [["Alpha", 0], ["-", 5], ["spectrin", 6], ["and", 15], ["beta", 19], ["-", 23], ["spectrin", 24], ["subunits", 33], ["form", 42], ["parallel", 47], ["or", 56], ["antiparallel", 59], ["heterodimers", 72], ["?", 84]], "detected_answers": [{"text": "antiparallel", "token_spans": [[248, 248], [30, 30]], "char_spans": [[1285, 1296], [152, 163]]}]}], "context_tokens": [["Spectrins", 0], ["comprise", 10], ["\u03b1-", 19], ["and", 22], ["\u03b2", 26], ["-", 27], ["subunits", 28], ["made", 37], ["up", 42], ["predominantly", 45], ["of", 59], ["a", 62], ["series", 64], ["of", 71], ["homologous", 74], ["repeating", 85], ["units", 95], ["of", 101], ["about", 104], ["106", 110], ["amino", 114], ["acids", 120], [";", 125], ["the", 127], ["\u03b1-", 131], ["and", 134], ["\u03b2", 138], ["-", 139], ["chains", 140], ["form", 147], ["antiparallel", 152], ["dimers", 165], ["by", 172], ["lateral", 175], ["association", 183], [",", 194], ["and", 196], ["tetramers", 200], ["through", 210], ["head", 218], ["-", 222], ["to", 223], ["-", 225], ["head", 226], ["contacts", 231], ["between", 240], ["the", 248], ["dimers", 252], [".", 258], ["Here", 260], ["we", 265], ["consider", 268], ["the", 277], ["first", 281], ["of", 287], ["these", 290], ["interactions", 296], [".", 308], ["(", 310], ["1", 311], [")", 312], ["We", 314], ["confirm", 317], ["earlier", 325], ["observations", 333], [",", 345], ["showing", 347], ["that", 355], ["the", 360], ["first", 364], ["two", 370], ["paired", 374], ["repeats", 381], ["(", 389], ["\u03b2IR1", 390], ["with", 395], ["\u03b1IR21", 400], [",", 405], ["and", 407], ["\u03b2IR2", 411], ["with", 416], ["\u03b1RI20", 421], [")", 426], ["at", 428], ["one", 431], ["end", 435], ["of", 439], ["the", 442], ["erythroid", 446], ["spectrin", 456], ["(", 465], ["\u03b1I\u03b2I", 466], [")", 470], ["dimer", 472], ["are", 478], ["necessary", 482], ["and", 492], ["sufficient", 496], ["to", 507], ["unite", 510], ["the", 516], ["chains", 520], [";", 526], ["(", 528], ["2", 529], [")", 530], ["we", 532], ["resolve", 535], ["a", 543], ["conflict", 545], ["in", 554], ["published", 557], ["reports", 567], ["by", 575], ["showing", 578], ["that", 586], ["the", 591], ["strength", 595], ["of", 604], ["the", 607], ["interaction", 611], ["is", 623], ["considerably", 626], ["increased", 639], ["on", 649], ["adding", 652], ["the", 659], ["adjoining", 663], ["pair", 673], ["of", 678], ["repeats", 681], ["(", 689], ["\u03b2IR3-\u03b1IR19", 690], [")", 700], [";", 701], ["(", 703], ["3", 704], [")", 705], ["in", 707], ["brain", 710], ["(", 716], ["\u03b1II\u03b2II", 717], [")", 723], ["spectrin", 725], ["the", 734], ["first", 738], ["two", 744], ["pairs", 748], ["of", 754], ["repeats", 757], ["are", 765], ["similarly", 769], ["essential", 779], ["and", 789], ["sufficient", 793], ["for", 804], ["heterodimer", 808], ["formation", 820], [";", 829], ["(", 831], ["4", 832], [")", 833], ["this", 835], ["interaction", 840], ["is", 852], ["~60-fold", 855], ["stronger", 864], ["than", 873], ["that", 878], ["in", 883], ["the", 886], ["erythroid", 890], ["counterpart", 900], [",", 911], ["but", 913], ["no", 917], ["enhancement", 920], ["can", 932], ["be", 936], ["detected", 939], ["on", 948], ["addition", 951], ["of", 960], ["three", 963], ["further", 969], ["pairs", 977], ["of", 983], ["repeats", 986], [";", 993], ["(", 995], ["5", 996], [")", 997], ["formation", 999], ["of", 1009], ["a", 1012], ["tight", 1014], ["\u03b1I\u03b2I", 1020], ["dimer", 1025], ["probably", 1031], ["depends", 1040], ["on", 1048], ["structural", 1051], ["coupling", 1062], ["of", 1071], ["the", 1074], ["first", 1078], ["two", 1084], ["repeats", 1088], ["in", 1096], ["each", 1099], ["chain", 1104], [";", 1109], ["(", 1111], ["6", 1112], [")", 1113], ["an", 1115], ["analysis", 1118], ["of", 1127], ["the", 1130], ["sequences", 1134], ["of", 1144], ["the", 1147], ["strongly", 1151], ["interacting", 1160], ["repeats", 1172], [",", 1179], ["\u03b2IR1", 1181], [",", 1185], ["\u03b2IIR1", 1187], [",", 1192], ["\u03b1IR21", 1194], ["and", 1200], ["\u03b1IIR20", 1204], ["and", 1211], ["repeats", 1215], ["in", 1223], ["\u03b1", 1226], ["-", 1227], ["actinin", 1228], [",", 1235], ["which", 1237], ["also", 1243], ["interact", 1248], ["very", 1257], ["strongly", 1262], ["in", 1271], ["forming", 1274], ["an", 1282], ["antiparallel", 1285], ["dimer", 1298], [",", 1303], ["affords", 1305], ["a", 1313], ["possible", 1315], ["explanation", 1324], ["for", 1336], ["the", 1340], ["different", 1344], ["properties", 1354], ["of", 1365], ["the", 1368], ["two", 1372], ["spectrin", 1376], ["isoforms", 1385], ["in", 1394], ["respect", 1397], ["of", 1405], ["the", 1408], ["stability", 1412], ["of", 1422], ["the", 1425], ["inter", 1429], ["-", 1434], ["chain", 1435], ["interactions", 1441], [",", 1453], ["and", 1455], ["also", 1459], ["suggests", 1464], ["the", 1473], ["evolutionary", 1477], ["path", 1490], ["by", 1495], ["which", 1498], ["the", 1504], ["erythroid", 1508], ["and", 1518], ["non", 1522], ["-", 1525], ["erythroid", 1526], ["sequences", 1536], ["diverged", 1546], [".", 1554]]}
{"context": "Two forms of neurofibromatosis, type 1 (NF1) and type 2 (NF2) are connected with genes localized on chromosomes 17 and 22, respectively. The genes that are inactivated in neurofibromatosis code for the proteins neurofibromine and merline, respectively. Since inactivation leads to neoplasia, they are called tumour suppressor genes. Neurofibromine shows resemblances to proteins that serve to inactivate oncogenes. Merline has a relationship with proteins that connect the cytoskeleton and the cell membrane. The precise function of the proteins is still unknown. The NF1 gene is characterized by extraordinarily high sensitivity to mutation; half the NF1 patients have not inherited the disease. In the familial form of neurofibromatosis, a mutated gene is inherited and the normal allele in the tumour is inactivated, making tumour growth possible. In the sporadic form of neurofibromatosis, both normal alleles are inactivated locally in the tissue so that a tumour develops in that place.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "02a0b88b776d4b2d90874b4cebd2bc40", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[8, 8], [96, 96], [109, 109]], "char_spans": [[40, 42], [568, 570], [652, 654]]}]}], "context_tokens": [["Two", 0], ["forms", 4], ["of", 10], ["neurofibromatosis", 13], [",", 30], ["type", 32], ["1", 37], ["(", 39], ["NF1", 40], [")", 43], ["and", 45], ["type", 49], ["2", 54], ["(", 56], ["NF2", 57], [")", 60], ["are", 62], ["connected", 66], ["with", 76], ["genes", 81], ["localized", 87], ["on", 97], ["chromosomes", 100], ["17", 112], ["and", 115], ["22", 119], [",", 121], ["respectively", 123], [".", 135], ["The", 137], ["genes", 141], ["that", 147], ["are", 152], ["inactivated", 156], ["in", 168], ["neurofibromatosis", 171], ["code", 189], ["for", 194], ["the", 198], ["proteins", 202], ["neurofibromine", 211], ["and", 226], ["merline", 230], [",", 237], ["respectively", 239], [".", 251], ["Since", 253], ["inactivation", 259], ["leads", 272], ["to", 278], ["neoplasia", 281], [",", 290], ["they", 292], ["are", 297], ["called", 301], ["tumour", 308], ["suppressor", 315], ["genes", 326], [".", 331], ["Neurofibromine", 333], ["shows", 348], ["resemblances", 354], ["to", 367], ["proteins", 370], ["that", 379], ["serve", 384], ["to", 390], ["inactivate", 393], ["oncogenes", 404], [".", 413], ["Merline", 415], ["has", 423], ["a", 427], ["relationship", 429], ["with", 442], ["proteins", 447], ["that", 456], ["connect", 461], ["the", 469], ["cytoskeleton", 473], ["and", 486], ["the", 490], ["cell", 494], ["membrane", 499], [".", 507], ["The", 509], ["precise", 513], ["function", 521], ["of", 530], ["the", 533], ["proteins", 537], ["is", 546], ["still", 549], ["unknown", 555], [".", 562], ["The", 564], ["NF1", 568], ["gene", 572], ["is", 577], ["characterized", 580], ["by", 594], ["extraordinarily", 597], ["high", 613], ["sensitivity", 618], ["to", 630], ["mutation", 633], [";", 641], ["half", 643], ["the", 648], ["NF1", 652], ["patients", 656], ["have", 665], ["not", 670], ["inherited", 674], ["the", 684], ["disease", 688], [".", 695], ["In", 697], ["the", 700], ["familial", 704], ["form", 713], ["of", 718], ["neurofibromatosis", 721], [",", 738], ["a", 740], ["mutated", 742], ["gene", 750], ["is", 755], ["inherited", 758], ["and", 768], ["the", 772], ["normal", 776], ["allele", 783], ["in", 790], ["the", 793], ["tumour", 797], ["is", 804], ["inactivated", 807], [",", 818], ["making", 820], ["tumour", 827], ["growth", 834], ["possible", 841], [".", 849], ["In", 851], ["the", 854], ["sporadic", 858], ["form", 867], ["of", 872], ["neurofibromatosis", 875], [",", 892], ["both", 894], ["normal", 899], ["alleles", 906], ["are", 914], ["inactivated", 918], ["locally", 930], ["in", 938], ["the", 941], ["tissue", 945], ["so", 952], ["that", 955], ["a", 960], ["tumour", 962], ["develops", 969], ["in", 978], ["that", 981], ["place", 986], [".", 991]]}
{"context": "Parkinson's disease (PD) and dementia with Lewy bodies are common disorders of the aging population and characterized by the progressive accumulation of \u03b1-synuclein (\u03b1-syn) in the central nervous system. Aggregation of \u03b1-syn into oligomers with a ring-like appearance has been proposed to play a role in toxicity. However, the molecular mechanisms and the potential sequence of events involved in the formation of pore-like structures are unclear. We utilized computer modeling and cell-based studies to investigate the process of oligomerization of wild-type and A53T mutant \u03b1-syn in membranes. The studies suggest that \u03b1-syn penetrates the membrane rapidly, changing its conformation from \u03b1-helical towards a coiled structure. This penetration facilitates the incorporation of additional \u03b1-syn monomers in the complex, and the subsequent displacement of phospholipids and the formation of oligomers in the membrane. This process occurred more rapidly, and with a more favorable energy of interaction, for mutant A53T compared with wild-type \u03b1-syn. After 4 ns of simulation of the protein-membrane model, \u03b1-syn had penetrated through two-thirds of the membrane. By 9 ns, the penetration of the annular \u03b1-syn oligomers can result in the formation of pore-like structures that fully perforate the lipid bilayer. Experimental incubation of recombinant \u03b1-syn in synthetic membranes resulted in the formation of similar pore-like complexes. Moreover, mutant (A53T) \u03b1-syn had a greater tendency to accumulate in neuronal membrane fractions in cell cultures, resulting in greater neuronal permeability, as demonstrated with the calcein efflux assay. These studies provide a sequential molecular explanation for the process of \u03b1-syn oligomerization in the membrane, and support the role of formation of pore-like structures in the pathogenesis of the neurodegenerative process in PD.", "qas": [{"question": "Which disease of the central nervous system is characterized by the presence of Lewy bodies?", "answers": ["Parkinson's disease (PD)"], "qid": "c042537f3aac4a97a4633fcf4c88fc5b", "question_tokens": [["Which", 0], ["disease", 6], ["of", 14], ["the", 17], ["central", 21], ["nervous", 29], ["system", 37], ["is", 44], ["characterized", 47], ["by", 61], ["the", 64], ["presence", 68], ["of", 77], ["Lewy", 80], ["bodies", 85], ["?", 91]], "detected_answers": [{"text": "Parkinson's disease (PD)", "token_spans": [[0, 4]], "char_spans": [[0, 22]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["and", 25], ["dementia", 29], ["with", 38], ["Lewy", 43], ["bodies", 48], ["are", 55], ["common", 59], ["disorders", 66], ["of", 76], ["the", 79], ["aging", 83], ["population", 89], ["and", 100], ["characterized", 104], ["by", 118], ["the", 121], ["progressive", 125], ["accumulation", 137], ["of", 150], ["\u03b1", 153], ["-", 154], ["synuclein", 155], ["(", 165], ["\u03b1", 166], ["-", 167], ["syn", 168], [")", 171], ["in", 173], ["the", 176], ["central", 180], ["nervous", 188], ["system", 196], [".", 202], ["Aggregation", 204], ["of", 216], ["\u03b1", 219], ["-", 220], ["syn", 221], ["into", 225], ["oligomers", 230], ["with", 240], ["a", 245], ["ring", 247], ["-", 251], ["like", 252], ["appearance", 257], ["has", 268], ["been", 272], ["proposed", 277], ["to", 286], ["play", 289], ["a", 294], ["role", 296], ["in", 301], ["toxicity", 304], [".", 312], ["However", 314], [",", 321], ["the", 323], ["molecular", 327], ["mechanisms", 337], ["and", 348], ["the", 352], ["potential", 356], ["sequence", 366], ["of", 375], ["events", 378], ["involved", 385], ["in", 394], ["the", 397], ["formation", 401], ["of", 411], ["pore", 414], ["-", 418], ["like", 419], ["structures", 424], ["are", 435], ["unclear", 439], [".", 446], ["We", 448], ["utilized", 451], ["computer", 460], ["modeling", 469], ["and", 478], ["cell", 482], ["-", 486], ["based", 487], ["studies", 493], ["to", 501], ["investigate", 504], ["the", 516], ["process", 520], ["of", 528], ["oligomerization", 531], ["of", 547], ["wild", 550], ["-", 554], ["type", 555], ["and", 560], ["A53", 564], ["T", 567], ["mutant", 569], ["\u03b1", 576], ["-", 577], ["syn", 578], ["in", 582], ["membranes", 585], [".", 594], ["The", 596], ["studies", 600], ["suggest", 608], ["that", 616], ["\u03b1", 621], ["-", 622], ["syn", 623], ["penetrates", 627], ["the", 638], ["membrane", 642], ["rapidly", 651], [",", 658], ["changing", 660], ["its", 669], ["conformation", 673], ["from", 686], ["\u03b1", 691], ["-", 692], ["helical", 693], ["towards", 701], ["a", 709], ["coiled", 711], ["structure", 718], [".", 727], ["This", 729], ["penetration", 734], ["facilitates", 746], ["the", 758], ["incorporation", 762], ["of", 776], ["additional", 779], ["\u03b1", 790], ["-", 791], ["syn", 792], ["monomers", 796], ["in", 805], ["the", 808], ["complex", 812], [",", 819], ["and", 821], ["the", 825], ["subsequent", 829], ["displacement", 840], ["of", 853], ["phospholipids", 856], ["and", 870], ["the", 874], ["formation", 878], ["of", 888], ["oligomers", 891], ["in", 901], ["the", 904], ["membrane", 908], [".", 916], ["This", 918], ["process", 923], ["occurred", 931], ["more", 940], ["rapidly", 945], [",", 952], ["and", 954], ["with", 958], ["a", 963], ["more", 965], ["favorable", 970], ["energy", 980], ["of", 987], ["interaction", 990], [",", 1001], ["for", 1003], ["mutant", 1007], ["A53", 1014], ["T", 1017], ["compared", 1019], ["with", 1028], ["wild", 1033], ["-", 1037], ["type", 1038], ["\u03b1", 1043], ["-", 1044], ["syn", 1045], [".", 1048], ["After", 1050], ["4", 1056], ["ns", 1058], ["of", 1061], ["simulation", 1064], ["of", 1075], ["the", 1078], ["protein", 1082], ["-", 1089], ["membrane", 1090], ["model", 1099], [",", 1104], ["\u03b1", 1106], ["-", 1107], ["syn", 1108], ["had", 1112], ["penetrated", 1116], ["through", 1127], ["two", 1135], ["-", 1138], ["thirds", 1139], ["of", 1146], ["the", 1149], ["membrane", 1153], [".", 1161], ["By", 1163], ["9", 1166], ["ns", 1168], [",", 1170], ["the", 1172], ["penetration", 1176], ["of", 1188], ["the", 1191], ["annular", 1195], ["\u03b1", 1203], ["-", 1204], ["syn", 1205], ["oligomers", 1209], ["can", 1219], ["result", 1223], ["in", 1230], ["the", 1233], ["formation", 1237], ["of", 1247], ["pore", 1250], ["-", 1254], ["like", 1255], ["structures", 1260], ["that", 1271], ["fully", 1276], ["perforate", 1282], ["the", 1292], ["lipid", 1296], ["bilayer", 1302], [".", 1309], ["Experimental", 1311], ["incubation", 1324], ["of", 1335], ["recombinant", 1338], ["\u03b1", 1350], ["-", 1351], ["syn", 1352], ["in", 1356], ["synthetic", 1359], ["membranes", 1369], ["resulted", 1379], ["in", 1388], ["the", 1391], ["formation", 1395], ["of", 1405], ["similar", 1408], ["pore", 1416], ["-", 1420], ["like", 1421], ["complexes", 1426], [".", 1435], ["Moreover", 1437], [",", 1445], ["mutant", 1447], ["(", 1454], ["A53", 1455], ["T", 1458], [")", 1459], ["\u03b1", 1461], ["-", 1462], ["syn", 1463], ["had", 1467], ["a", 1471], ["greater", 1473], ["tendency", 1481], ["to", 1490], ["accumulate", 1493], ["in", 1504], ["neuronal", 1507], ["membrane", 1516], ["fractions", 1525], ["in", 1535], ["cell", 1538], ["cultures", 1543], [",", 1551], ["resulting", 1553], ["in", 1563], ["greater", 1566], ["neuronal", 1574], ["permeability", 1583], [",", 1595], ["as", 1597], ["demonstrated", 1600], ["with", 1613], ["the", 1618], ["calcein", 1622], ["efflux", 1630], ["assay", 1637], [".", 1642], ["These", 1644], ["studies", 1650], ["provide", 1658], ["a", 1666], ["sequential", 1668], ["molecular", 1679], ["explanation", 1689], ["for", 1701], ["the", 1705], ["process", 1709], ["of", 1717], ["\u03b1", 1720], ["-", 1721], ["syn", 1722], ["oligomerization", 1726], ["in", 1742], ["the", 1745], ["membrane", 1749], [",", 1757], ["and", 1759], ["support", 1763], ["the", 1771], ["role", 1775], ["of", 1780], ["formation", 1783], ["of", 1793], ["pore", 1796], ["-", 1800], ["like", 1801], ["structures", 1806], ["in", 1817], ["the", 1820], ["pathogenesis", 1824], ["of", 1837], ["the", 1840], ["neurodegenerative", 1844], ["process", 1862], ["in", 1870], ["PD", 1873], [".", 1875]]}
{"context": "To develop a clinical prediction rule to identify patients who can be safely discharged one hour after the administration of naloxone for presumed opioid overdose. Patients who received naloxone for known or presumed opioid overdose were formally evaluated one hour later for multiple potential predictor variables. Patients were classified into two groups: those with adverse events within 24 hours and those without. Using classification and regression tree methodology, a decision rule was developed to predict safe discharge. Clinical findings from 573 patients allowed us to develop a clinical prediction rule with a sensitivity of 99% (95% CI = 96% to 100%) and a specificity of 40% (95% CI = 36% to 45%). Patients with presumed opioid overdose can be safely discharged one hour after naloxone administration if they: 1) can mobilize as usual; 2) have oxygen saturation on room air of >92%; 3) have a respiratory rate >10 breaths/min and <20 breaths/min; 4) have a temperature of >35.0 degrees C and <37.5 degrees C; 5) have a heart rate >50 beats/min and <100 beats/min; and 6) have a Glasgow Coma Scale score of 15. This prediction rule for safe early discharge of patients with presumed opioid overdose performs well in this derivation set but requires validation followed by confirmation of safe implementation.", "qas": [{"question": "Which medication should be administered when managing patients with suspected acute opioid overdose?", "answers": ["naloxone"], "qid": "70d7878277804532b313a72e5e20e286", "question_tokens": [["Which", 0], ["medication", 6], ["should", 17], ["be", 24], ["administered", 27], ["when", 40], ["managing", 45], ["patients", 54], ["with", 63], ["suspected", 68], ["acute", 78], ["opioid", 84], ["overdose", 91], ["?", 99]], "detected_answers": [{"text": "naloxone", "token_spans": [[20, 20], [29, 29], [143, 143]], "char_spans": [[125, 132], [186, 193], [791, 798]]}]}], "context_tokens": [["To", 0], ["develop", 3], ["a", 11], ["clinical", 13], ["prediction", 22], ["rule", 33], ["to", 38], ["identify", 41], ["patients", 50], ["who", 59], ["can", 63], ["be", 67], ["safely", 70], ["discharged", 77], ["one", 88], ["hour", 92], ["after", 97], ["the", 103], ["administration", 107], ["of", 122], ["naloxone", 125], ["for", 134], ["presumed", 138], ["opioid", 147], ["overdose", 154], [".", 162], ["Patients", 164], ["who", 173], ["received", 177], ["naloxone", 186], ["for", 195], ["known", 199], ["or", 205], ["presumed", 208], ["opioid", 217], ["overdose", 224], ["were", 233], ["formally", 238], ["evaluated", 247], ["one", 257], ["hour", 261], ["later", 266], ["for", 272], ["multiple", 276], ["potential", 285], ["predictor", 295], ["variables", 305], [".", 314], ["Patients", 316], ["were", 325], ["classified", 330], ["into", 341], ["two", 346], ["groups", 350], [":", 356], ["those", 358], ["with", 364], ["adverse", 369], ["events", 377], ["within", 384], ["24", 391], ["hours", 394], ["and", 400], ["those", 404], ["without", 410], [".", 417], ["Using", 419], ["classification", 425], ["and", 440], ["regression", 444], ["tree", 455], ["methodology", 460], [",", 471], ["a", 473], ["decision", 475], ["rule", 484], ["was", 489], ["developed", 493], ["to", 503], ["predict", 506], ["safe", 514], ["discharge", 519], [".", 528], ["Clinical", 530], ["findings", 539], ["from", 548], ["573", 553], ["patients", 557], ["allowed", 566], ["us", 574], ["to", 577], ["develop", 580], ["a", 588], ["clinical", 590], ["prediction", 599], ["rule", 610], ["with", 615], ["a", 620], ["sensitivity", 622], ["of", 634], ["99", 637], ["%", 639], ["(", 641], ["95", 642], ["%", 644], ["CI", 646], ["=", 649], ["96", 651], ["%", 653], ["to", 655], ["100", 658], ["%", 661], [")", 662], ["and", 664], ["a", 668], ["specificity", 670], ["of", 682], ["40", 685], ["%", 687], ["(", 689], ["95", 690], ["%", 692], ["CI", 694], ["=", 697], ["36", 699], ["%", 701], ["to", 703], ["45", 706], ["%", 708], [")", 709], [".", 710], ["Patients", 712], ["with", 721], ["presumed", 726], ["opioid", 735], ["overdose", 742], ["can", 751], ["be", 755], ["safely", 758], ["discharged", 765], ["one", 776], ["hour", 780], ["after", 785], ["naloxone", 791], ["administration", 800], ["if", 815], ["they", 818], [":", 822], ["1", 824], [")", 825], ["can", 827], ["mobilize", 831], ["as", 840], ["usual", 843], [";", 848], ["2", 850], [")", 851], ["have", 853], ["oxygen", 858], ["saturation", 865], ["on", 876], ["room", 879], ["air", 884], ["of", 888], [">", 891], ["92", 892], ["%", 894], [";", 895], ["3", 897], [")", 898], ["have", 900], ["a", 905], ["respiratory", 907], ["rate", 919], [">", 924], ["10", 925], ["breaths", 928], ["/", 935], ["min", 936], ["and", 940], ["<", 944], ["20", 945], ["breaths", 948], ["/", 955], ["min", 956], [";", 959], ["4", 961], [")", 962], ["have", 964], ["a", 969], ["temperature", 971], ["of", 983], [">", 986], ["35.0", 987], ["degrees", 992], ["C", 1000], ["and", 1002], ["<", 1006], ["37.5", 1007], ["degrees", 1012], ["C", 1020], [";", 1021], ["5", 1023], [")", 1024], ["have", 1026], ["a", 1031], ["heart", 1033], ["rate", 1039], [">", 1044], ["50", 1045], ["beats", 1048], ["/", 1053], ["min", 1054], ["and", 1058], ["<", 1062], ["100", 1063], ["beats", 1067], ["/", 1072], ["min", 1073], [";", 1076], ["and", 1078], ["6", 1082], [")", 1083], ["have", 1085], ["a", 1090], ["Glasgow", 1092], ["Coma", 1100], ["Scale", 1105], ["score", 1111], ["of", 1117], ["15", 1120], [".", 1122], ["This", 1124], ["prediction", 1129], ["rule", 1140], ["for", 1145], ["safe", 1149], ["early", 1154], ["discharge", 1160], ["of", 1170], ["patients", 1173], ["with", 1182], ["presumed", 1187], ["opioid", 1196], ["overdose", 1203], ["performs", 1212], ["well", 1221], ["in", 1226], ["this", 1229], ["derivation", 1234], ["set", 1245], ["but", 1249], ["requires", 1253], ["validation", 1262], ["followed", 1273], ["by", 1282], ["confirmation", 1285], ["of", 1298], ["safe", 1301], ["implementation", 1306], [".", 1320]]}
{"context": "The carpal tunnel syndrome is a neuropathy due to trapping (focal lesion of the peripheral nerve due to a local cause); in this case, the median nerve is the most commonly involved. Its presentation is characteristic in females about 40 years of age. The diagnosis is mainly based on clinical features and is confirmed by electrical criteria. In the anamnesis it is important to consider systemic diseases as causing the abnormality. Treatment depends on the etiology. It may be medical or surgical. In the present article we report three cases with different etiology and treatment. We also review the syndrome.", "qas": [{"question": "What nerve is involved in carpal tunnel syndrome?", "answers": ["median"], "qid": "944fef283f4a45c0b0e909cc2f35bb32", "question_tokens": [["What", 0], ["nerve", 5], ["is", 11], ["involved", 14], ["in", 23], ["carpal", 26], ["tunnel", 33], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "median", "token_spans": [[29, 29]], "char_spans": [[138, 143]]}]}], "context_tokens": [["The", 0], ["carpal", 4], ["tunnel", 11], ["syndrome", 18], ["is", 27], ["a", 30], ["neuropathy", 32], ["due", 43], ["to", 47], ["trapping", 50], ["(", 59], ["focal", 60], ["lesion", 66], ["of", 73], ["the", 76], ["peripheral", 80], ["nerve", 91], ["due", 97], ["to", 101], ["a", 104], ["local", 106], ["cause", 112], [")", 117], [";", 118], ["in", 120], ["this", 123], ["case", 128], [",", 132], ["the", 134], ["median", 138], ["nerve", 145], ["is", 151], ["the", 154], ["most", 158], ["commonly", 163], ["involved", 172], [".", 180], ["Its", 182], ["presentation", 186], ["is", 199], ["characteristic", 202], ["in", 217], ["females", 220], ["about", 228], ["40", 234], ["years", 237], ["of", 243], ["age", 246], [".", 249], ["The", 251], ["diagnosis", 255], ["is", 265], ["mainly", 268], ["based", 275], ["on", 281], ["clinical", 284], ["features", 293], ["and", 302], ["is", 306], ["confirmed", 309], ["by", 319], ["electrical", 322], ["criteria", 333], [".", 341], ["In", 343], ["the", 346], ["anamnesis", 350], ["it", 360], ["is", 363], ["important", 366], ["to", 376], ["consider", 379], ["systemic", 388], ["diseases", 397], ["as", 406], ["causing", 409], ["the", 417], ["abnormality", 421], [".", 432], ["Treatment", 434], ["depends", 444], ["on", 452], ["the", 455], ["etiology", 459], [".", 467], ["It", 469], ["may", 472], ["be", 476], ["medical", 479], ["or", 487], ["surgical", 490], [".", 498], ["In", 500], ["the", 503], ["present", 507], ["article", 515], ["we", 523], ["report", 526], ["three", 533], ["cases", 539], ["with", 545], ["different", 550], ["etiology", 560], ["and", 569], ["treatment", 573], [".", 582], ["We", 584], ["also", 587], ["review", 592], ["the", 599], ["syndrome", 603], [".", 611]]}
{"context": "We have recently shown that the Na(+)/Ca(2+) exchanger (NCX) is involved in nitric oxide (NO)-induced cytotoxicity in cultured astrocytes and neurons. However, there is no in vivo evidence suggesting the role of NCX in neurodegenerative disorders associated with NO. NO is implicated in the pathogenesis of neurodegenerative disorders such as Parkinson's disease. This study examined the effect of SEA0400, the specific NCX inhibitor, on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity, a model of Parkinson's disease, in C57BL/6J mice. MPTP treatment (10 mg/kg, four times at 2-h intervals) decreased dopamine levels in the midbrain and impaired motor coordination, and these effects were counteracted by S-methylthiocitrulline, a selective neuronal NO synthase inhibitor. SEA0400 protected against the dopaminergic neurotoxicity (determined by dopamine levels in the midbrain and striatum, tyrosine hydroxylase immunoreactivity in the substantia nigra and striatum, striatal dopamine release, and motor deficits) in MPTP-treated mice. SEA0400 had no radical-scavenging activity. SEA0400 did not affect MPTP metabolism and MPTP-induced NO production and microglial activation, while it attenuated MPTP-induced increases in extracellular signal-regulated kinase (ERK) phosphorylation and lipid peroxidation product, thiobarbituric acid reactive substance. These findings suggest that SEA0400 protects against MPTP-induced neurotoxicity probably by blocking ERK phosphorylation and lipid peroxidation which are downstream of NCX-mediated Ca(2+) influx.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "da32f12980d845719c03c2c03494afe1", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "Na(+)/Ca(2+) exchanger", "token_spans": [[6, 9]], "char_spans": [[32, 53]]}, {"text": "NCX", "token_spans": [[72, 72], [39, 39], [11, 11], [250, 250]], "char_spans": [[420, 422], [212, 214], [56, 58], [1563, 1565]]}]}], "context_tokens": [["We", 0], ["have", 3], ["recently", 8], ["shown", 17], ["that", 23], ["the", 28], ["Na(+)/Ca(2", 32], ["+", 42], [")", 43], ["exchanger", 45], ["(", 55], ["NCX", 56], [")", 59], ["is", 61], ["involved", 64], ["in", 73], ["nitric", 76], ["oxide", 83], ["(", 89], ["NO)-induced", 90], ["cytotoxicity", 102], ["in", 115], ["cultured", 118], ["astrocytes", 127], ["and", 138], ["neurons", 142], [".", 149], ["However", 151], [",", 158], ["there", 160], ["is", 166], ["no", 169], ["in", 172], ["vivo", 175], ["evidence", 180], ["suggesting", 189], ["the", 200], ["role", 204], ["of", 209], ["NCX", 212], ["in", 216], ["neurodegenerative", 219], ["disorders", 237], ["associated", 247], ["with", 258], ["NO", 263], [".", 265], ["NO", 267], ["is", 270], ["implicated", 273], ["in", 284], ["the", 287], ["pathogenesis", 291], ["of", 304], ["neurodegenerative", 307], ["disorders", 325], ["such", 335], ["as", 340], ["Parkinson", 343], ["'s", 352], ["disease", 355], [".", 362], ["This", 364], ["study", 369], ["examined", 375], ["the", 384], ["effect", 388], ["of", 395], ["SEA0400", 398], [",", 405], ["the", 407], ["specific", 411], ["NCX", 420], ["inhibitor", 424], [",", 433], ["on", 435], ["1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", 438], ["(", 483], ["MPTP)-induced", 484], ["dopaminergic", 498], ["neurotoxicity", 511], [",", 524], ["a", 526], ["model", 528], ["of", 534], ["Parkinson", 537], ["'s", 546], ["disease", 549], [",", 556], ["in", 558], ["C57BL/6J", 561], ["mice", 570], [".", 574], ["MPTP", 576], ["treatment", 581], ["(", 591], ["10", 592], ["mg", 595], ["/", 597], ["kg", 598], [",", 600], ["four", 602], ["times", 607], ["at", 613], ["2-h", 616], ["intervals", 620], [")", 629], ["decreased", 631], ["dopamine", 641], ["levels", 650], ["in", 657], ["the", 660], ["midbrain", 664], ["and", 673], ["impaired", 677], ["motor", 686], ["coordination", 692], [",", 704], ["and", 706], ["these", 710], ["effects", 716], ["were", 724], ["counteracted", 729], ["by", 742], ["S", 745], ["-", 746], ["methylthiocitrulline", 747], [",", 767], ["a", 769], ["selective", 771], ["neuronal", 781], ["NO", 790], ["synthase", 793], ["inhibitor", 802], [".", 811], ["SEA0400", 813], ["protected", 821], ["against", 831], ["the", 839], ["dopaminergic", 843], ["neurotoxicity", 856], ["(", 870], ["determined", 871], ["by", 882], ["dopamine", 885], ["levels", 894], ["in", 901], ["the", 904], ["midbrain", 908], ["and", 917], ["striatum", 921], [",", 929], ["tyrosine", 931], ["hydroxylase", 940], ["immunoreactivity", 952], ["in", 969], ["the", 972], ["substantia", 976], ["nigra", 987], ["and", 993], ["striatum", 997], [",", 1005], ["striatal", 1007], ["dopamine", 1016], ["release", 1025], [",", 1032], ["and", 1034], ["motor", 1038], ["deficits", 1044], [")", 1052], ["in", 1054], ["MPTP", 1057], ["-", 1061], ["treated", 1062], ["mice", 1070], [".", 1074], ["SEA0400", 1076], ["had", 1084], ["no", 1088], ["radical", 1091], ["-", 1098], ["scavenging", 1099], ["activity", 1110], [".", 1118], ["SEA0400", 1120], ["did", 1128], ["not", 1132], ["affect", 1136], ["MPTP", 1143], ["metabolism", 1148], ["and", 1159], ["MPTP", 1163], ["-", 1167], ["induced", 1168], ["NO", 1176], ["production", 1179], ["and", 1190], ["microglial", 1194], ["activation", 1205], [",", 1215], ["while", 1217], ["it", 1223], ["attenuated", 1226], ["MPTP", 1237], ["-", 1241], ["induced", 1242], ["increases", 1250], ["in", 1260], ["extracellular", 1263], ["signal", 1277], ["-", 1283], ["regulated", 1284], ["kinase", 1294], ["(", 1301], ["ERK", 1302], [")", 1305], ["phosphorylation", 1307], ["and", 1323], ["lipid", 1327], ["peroxidation", 1333], ["product", 1346], [",", 1353], ["thiobarbituric", 1355], ["acid", 1370], ["reactive", 1375], ["substance", 1384], [".", 1393], ["These", 1395], ["findings", 1401], ["suggest", 1410], ["that", 1418], ["SEA0400", 1423], ["protects", 1431], ["against", 1440], ["MPTP", 1448], ["-", 1452], ["induced", 1453], ["neurotoxicity", 1461], ["probably", 1475], ["by", 1484], ["blocking", 1487], ["ERK", 1496], ["phosphorylation", 1500], ["and", 1516], ["lipid", 1520], ["peroxidation", 1526], ["which", 1539], ["are", 1545], ["downstream", 1549], ["of", 1560], ["NCX", 1563], ["-", 1566], ["mediated", 1567], ["Ca(2", 1576], ["+", 1580], [")", 1581], ["influx", 1583], [".", 1589]]}
{"context": "Previous X-ray crystal structures have shown that linkers of five amino acid residues connecting pairs of chicken brain alpha-spectrin and human erythroid beta-spectrin repeats can undergo bending without losing their alpha-helical structure. To test whether bending at one linker can influence bending at an adjacent linker, the structures of two and three repeat fragments of chicken brain alpha-spectrin have been determined by X-ray crystallography. The structure of the three-repeat fragment clearly shows that bending at one linker can occur independently of bending at an adjacent linker. This observation increases the possible trajectories of modeled chains of spectrin repeats. Furthermore, the three-repeat molecule crystallized as an antiparallel dimer with a significantly smaller buried interfacial area than that of alpha-actinin, a spectrin-related molecule, but large enough and of a type indicating biological specificity. Comparison of the structures of the spectrin and alpha-actinin dimers supports weak association of the former, which could not be detected by analytical ultracentrifugation, versus strong association of the latter, which has been observed by others. To correlate features of the structure with solution properties and to test a previous model of stable spectrin and dystrophin repeats, the number of inter-helical interactions in each repeat of several spectrin structures were counted and compared to their thermal stabilities. Inter-helical interactions, but not all interactions, increased in parallel with measured thermal stabilities of each repeat and in agreement with the thermal stabilities of two and three repeats and also partial repeats of spectrin.", "qas": [{"question": "Alpha-spectrin and beta-spectrin subunits form parallel or antiparallel heterodimers?", "answers": ["antiparallel"], "qid": "159e2ef1d3ca4a3b889fd3fd5ef2acb9", "question_tokens": [["Alpha", 0], ["-", 5], ["spectrin", 6], ["and", 15], ["beta", 19], ["-", 23], ["spectrin", 24], ["subunits", 33], ["form", 42], ["parallel", 47], ["or", 56], ["antiparallel", 59], ["heterodimers", 72], ["?", 84]], "detected_answers": [{"text": "antiparallel", "token_spans": [[127, 127]], "char_spans": [[746, 757]]}]}], "context_tokens": [["Previous", 0], ["X", 9], ["-", 10], ["ray", 11], ["crystal", 15], ["structures", 23], ["have", 34], ["shown", 39], ["that", 45], ["linkers", 50], ["of", 58], ["five", 61], ["amino", 66], ["acid", 72], ["residues", 77], ["connecting", 86], ["pairs", 97], ["of", 103], ["chicken", 106], ["brain", 114], ["alpha", 120], ["-", 125], ["spectrin", 126], ["and", 135], ["human", 139], ["erythroid", 145], ["beta", 155], ["-", 159], ["spectrin", 160], ["repeats", 169], ["can", 177], ["undergo", 181], ["bending", 189], ["without", 197], ["losing", 205], ["their", 212], ["alpha", 218], ["-", 223], ["helical", 224], ["structure", 232], [".", 241], ["To", 243], ["test", 246], ["whether", 251], ["bending", 259], ["at", 267], ["one", 270], ["linker", 274], ["can", 281], ["influence", 285], ["bending", 295], ["at", 303], ["an", 306], ["adjacent", 309], ["linker", 318], [",", 324], ["the", 326], ["structures", 330], ["of", 341], ["two", 344], ["and", 348], ["three", 352], ["repeat", 358], ["fragments", 365], ["of", 375], ["chicken", 378], ["brain", 386], ["alpha", 392], ["-", 397], ["spectrin", 398], ["have", 407], ["been", 412], ["determined", 417], ["by", 428], ["X", 431], ["-", 432], ["ray", 433], ["crystallography", 437], [".", 452], ["The", 454], ["structure", 458], ["of", 468], ["the", 471], ["three", 475], ["-", 480], ["repeat", 481], ["fragment", 488], ["clearly", 497], ["shows", 505], ["that", 511], ["bending", 516], ["at", 524], ["one", 527], ["linker", 531], ["can", 538], ["occur", 542], ["independently", 548], ["of", 562], ["bending", 565], ["at", 573], ["an", 576], ["adjacent", 579], ["linker", 588], [".", 594], ["This", 596], ["observation", 601], ["increases", 613], ["the", 623], ["possible", 627], ["trajectories", 636], ["of", 649], ["modeled", 652], ["chains", 660], ["of", 667], ["spectrin", 670], ["repeats", 679], [".", 686], ["Furthermore", 688], [",", 699], ["the", 701], ["three", 705], ["-", 710], ["repeat", 711], ["molecule", 718], ["crystallized", 727], ["as", 740], ["an", 743], ["antiparallel", 746], ["dimer", 759], ["with", 765], ["a", 770], ["significantly", 772], ["smaller", 786], ["buried", 794], ["interfacial", 801], ["area", 813], ["than", 818], ["that", 823], ["of", 828], ["alpha", 831], ["-", 836], ["actinin", 837], [",", 844], ["a", 846], ["spectrin", 848], ["-", 856], ["related", 857], ["molecule", 865], [",", 873], ["but", 875], ["large", 879], ["enough", 885], ["and", 892], ["of", 896], ["a", 899], ["type", 901], ["indicating", 906], ["biological", 917], ["specificity", 928], [".", 939], ["Comparison", 941], ["of", 952], ["the", 955], ["structures", 959], ["of", 970], ["the", 973], ["spectrin", 977], ["and", 986], ["alpha", 990], ["-", 995], ["actinin", 996], ["dimers", 1004], ["supports", 1011], ["weak", 1020], ["association", 1025], ["of", 1037], ["the", 1040], ["former", 1044], [",", 1050], ["which", 1052], ["could", 1058], ["not", 1064], ["be", 1068], ["detected", 1071], ["by", 1080], ["analytical", 1083], ["ultracentrifugation", 1094], [",", 1113], ["versus", 1115], ["strong", 1122], ["association", 1129], ["of", 1141], ["the", 1144], ["latter", 1148], [",", 1154], ["which", 1156], ["has", 1162], ["been", 1166], ["observed", 1171], ["by", 1180], ["others", 1183], [".", 1189], ["To", 1191], ["correlate", 1194], ["features", 1204], ["of", 1213], ["the", 1216], ["structure", 1220], ["with", 1230], ["solution", 1235], ["properties", 1244], ["and", 1255], ["to", 1259], ["test", 1262], ["a", 1267], ["previous", 1269], ["model", 1278], ["of", 1284], ["stable", 1287], ["spectrin", 1294], ["and", 1303], ["dystrophin", 1307], ["repeats", 1318], [",", 1325], ["the", 1327], ["number", 1331], ["of", 1338], ["inter", 1341], ["-", 1346], ["helical", 1347], ["interactions", 1355], ["in", 1368], ["each", 1371], ["repeat", 1376], ["of", 1383], ["several", 1386], ["spectrin", 1394], ["structures", 1403], ["were", 1414], ["counted", 1419], ["and", 1427], ["compared", 1431], ["to", 1440], ["their", 1443], ["thermal", 1449], ["stabilities", 1457], [".", 1468], ["Inter", 1470], ["-", 1475], ["helical", 1476], ["interactions", 1484], [",", 1496], ["but", 1498], ["not", 1502], ["all", 1506], ["interactions", 1510], [",", 1522], ["increased", 1524], ["in", 1534], ["parallel", 1537], ["with", 1546], ["measured", 1551], ["thermal", 1560], ["stabilities", 1568], ["of", 1580], ["each", 1583], ["repeat", 1588], ["and", 1595], ["in", 1599], ["agreement", 1602], ["with", 1612], ["the", 1617], ["thermal", 1621], ["stabilities", 1629], ["of", 1641], ["two", 1644], ["and", 1648], ["three", 1652], ["repeats", 1658], ["and", 1666], ["also", 1670], ["partial", 1675], ["repeats", 1683], ["of", 1691], ["spectrin", 1694], [".", 1702]]}
{"context": "Tardive dyskinesia (TD) is a movement disorder characterized by abnormal involuntary facial movements induced by chronic therapy with classical antipsychotic medications. Currently, there is no satisfactory pharmacotherapy for TD, which represents a major limitation to therapy with classical antipsychotics. In order to develop or optimize therapies for TD, and to develop new APDs with lower indices of motor side effects, the pathology underlying TD must first be understood. The use of animal models has been used to further this objective. Here, we review different preparations that have been used to model TD and discuss the contribution of neuroimaging studies conducted in these models. Studies in animal models have lead to several hypotheses of TD pathology, although none has yet emerged as the ultimate underlying cause of this syndrome. We discuss alterations in functional indices, neuron and synapse morphology and changes in specific neurotransmitter systems that have been described in animal models of TD, and outline how these findings have contributed to our understanding of antipsychotic-induced dyskinesias. We conclude that several non-mutually exclusive theories of TD are supported by animal studies, including increases in oxidative stress leading to structural and functional changes in specific neurotransmitter systems. Elucidating the mechanisms underlying TD neuropathology partly through the use of animal models will lead to the development of APDs with superior side effect profiles or more effective therapies for TD.", "qas": [{"question": "What is the cause of Tardive dyskinesia?", "answers": ["Tardive dyskinesia (TD) is a movement disorder characterized by abnormal involuntary facial movements induced by chronic therapy with classical antipsychotic medications."], "qid": "b0f3562cb2574620ba46ae33c88d65b3", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["cause", 12], ["of", 18], ["Tardive", 21], ["dyskinesia", 29], ["?", 39]], "detected_answers": [{"text": "Tardive dyskinesia (TD) is a movement disorder characterized by abnormal involuntary facial movements induced by chronic therapy with classical antipsychotic medications.", "token_spans": [[0, 22]], "char_spans": [[0, 168]]}]}], "context_tokens": [["Tardive", 0], ["dyskinesia", 8], ["(", 19], ["TD", 20], [")", 22], ["is", 24], ["a", 27], ["movement", 29], ["disorder", 38], ["characterized", 47], ["by", 61], ["abnormal", 64], ["involuntary", 73], ["facial", 85], ["movements", 92], ["induced", 102], ["by", 110], ["chronic", 113], ["therapy", 121], ["with", 129], ["classical", 134], ["antipsychotic", 144], ["medications", 158], [".", 169], ["Currently", 171], [",", 180], ["there", 182], ["is", 188], ["no", 191], ["satisfactory", 194], ["pharmacotherapy", 207], ["for", 223], ["TD", 227], [",", 229], ["which", 231], ["represents", 237], ["a", 248], ["major", 250], ["limitation", 256], ["to", 267], ["therapy", 270], ["with", 278], ["classical", 283], ["antipsychotics", 293], [".", 307], ["In", 309], ["order", 312], ["to", 318], ["develop", 321], ["or", 329], ["optimize", 332], ["therapies", 341], ["for", 351], ["TD", 355], [",", 357], ["and", 359], ["to", 363], ["develop", 366], ["new", 374], ["APDs", 378], ["with", 383], ["lower", 388], ["indices", 394], ["of", 402], ["motor", 405], ["side", 411], ["effects", 416], [",", 423], ["the", 425], ["pathology", 429], ["underlying", 439], ["TD", 450], ["must", 453], ["first", 458], ["be", 464], ["understood", 467], [".", 477], ["The", 479], ["use", 483], ["of", 487], ["animal", 490], ["models", 497], ["has", 504], ["been", 508], ["used", 513], ["to", 518], ["further", 521], ["this", 529], ["objective", 534], [".", 543], ["Here", 545], [",", 549], ["we", 551], ["review", 554], ["different", 561], ["preparations", 571], ["that", 584], ["have", 589], ["been", 594], ["used", 599], ["to", 604], ["model", 607], ["TD", 613], ["and", 616], ["discuss", 620], ["the", 628], ["contribution", 632], ["of", 645], ["neuroimaging", 648], ["studies", 661], ["conducted", 669], ["in", 679], ["these", 682], ["models", 688], [".", 694], ["Studies", 696], ["in", 704], ["animal", 707], ["models", 714], ["have", 721], ["lead", 726], ["to", 731], ["several", 734], ["hypotheses", 742], ["of", 753], ["TD", 756], ["pathology", 759], [",", 768], ["although", 770], ["none", 779], ["has", 784], ["yet", 788], ["emerged", 792], ["as", 800], ["the", 803], ["ultimate", 807], ["underlying", 816], ["cause", 827], ["of", 833], ["this", 836], ["syndrome", 841], [".", 849], ["We", 851], ["discuss", 854], ["alterations", 862], ["in", 874], ["functional", 877], ["indices", 888], [",", 895], ["neuron", 897], ["and", 904], ["synapse", 908], ["morphology", 916], ["and", 927], ["changes", 931], ["in", 939], ["specific", 942], ["neurotransmitter", 951], ["systems", 968], ["that", 976], ["have", 981], ["been", 986], ["described", 991], ["in", 1001], ["animal", 1004], ["models", 1011], ["of", 1018], ["TD", 1021], [",", 1023], ["and", 1025], ["outline", 1029], ["how", 1037], ["these", 1041], ["findings", 1047], ["have", 1056], ["contributed", 1061], ["to", 1073], ["our", 1076], ["understanding", 1080], ["of", 1094], ["antipsychotic", 1097], ["-", 1110], ["induced", 1111], ["dyskinesias", 1119], [".", 1130], ["We", 1132], ["conclude", 1135], ["that", 1144], ["several", 1149], ["non", 1157], ["-", 1160], ["mutually", 1161], ["exclusive", 1170], ["theories", 1180], ["of", 1189], ["TD", 1192], ["are", 1195], ["supported", 1199], ["by", 1209], ["animal", 1212], ["studies", 1219], [",", 1226], ["including", 1228], ["increases", 1238], ["in", 1248], ["oxidative", 1251], ["stress", 1261], ["leading", 1268], ["to", 1276], ["structural", 1279], ["and", 1290], ["functional", 1294], ["changes", 1305], ["in", 1313], ["specific", 1316], ["neurotransmitter", 1325], ["systems", 1342], [".", 1349], ["Elucidating", 1351], ["the", 1363], ["mechanisms", 1367], ["underlying", 1378], ["TD", 1389], ["neuropathology", 1392], ["partly", 1407], ["through", 1414], ["the", 1422], ["use", 1426], ["of", 1430], ["animal", 1433], ["models", 1440], ["will", 1447], ["lead", 1452], ["to", 1457], ["the", 1460], ["development", 1464], ["of", 1476], ["APDs", 1479], ["with", 1484], ["superior", 1489], ["side", 1498], ["effect", 1503], ["profiles", 1510], ["or", 1519], ["more", 1522], ["effective", 1527], ["therapies", 1537], ["for", 1547], ["TD", 1551], [".", 1553]]}
{"context": "Kx is lacking in the RBCs of patients with the McLeod syndrome. This condition is sometimes associated with chronic granulomatous disease (CGD). If given allogeneic RBCs, CGD patients with the McLeod phenotype may produce anti-Kx and anti-Km, and only phenotypically matched McLeod blood would be compatible. McLeod phenotype persons without CGD have made anti-Km but not anti-Kx (2 examples), and thus both McLeod and K(O) blood would be compatible. RBCs from a transfused patient with the McLeod phenotype but not with CGD (non-CGD McLeod) were typed for the Kell blood group antigens, and the plasma was analyzed for the presence of antibody by agglutination. The molecular basis was determined by analyzing for XK protein on RBC membranes by Western immunoblotting, by sequencing the XK gene, and by RFLP. The RBCs did not react with anti-Kx + anti-Km and showed weakening of Kell system antigens. The patient's plasma reacted moderately (2+) with RBCs of common Kell type and strongly (4+) with K(O) RBCs and RBCs of common Kell type treated with dithiothreitol, and did not react with McLeod RBCs. XK protein was absent from the RBC membranes. The XK gene had a point mutation in the donor splice site of intron 1 (G>C). This is the first report describing the molecular alteration in a non-CGD McLeod patient who has made anti-Kx. The immune response of people with the McLeod phenotype can vary, and K(O) blood may not always be compatible.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "ae5bb34ab378486298ab61b3973ece7b", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[232, 232], [150, 150], [222, 222], [138, 138]], "char_spans": [[1154, 1155], [788, 789], [1104, 1105], [715, 716]]}]}], "context_tokens": [["Kx", 0], ["is", 3], ["lacking", 6], ["in", 14], ["the", 17], ["RBCs", 21], ["of", 26], ["patients", 29], ["with", 38], ["the", 43], ["McLeod", 47], ["syndrome", 54], [".", 62], ["This", 64], ["condition", 69], ["is", 79], ["sometimes", 82], ["associated", 92], ["with", 103], ["chronic", 108], ["granulomatous", 116], ["disease", 130], ["(", 138], ["CGD", 139], [")", 142], [".", 143], ["If", 145], ["given", 148], ["allogeneic", 154], ["RBCs", 165], [",", 169], ["CGD", 171], ["patients", 175], ["with", 184], ["the", 189], ["McLeod", 193], ["phenotype", 200], ["may", 210], ["produce", 214], ["anti", 222], ["-", 226], ["Kx", 227], ["and", 230], ["anti", 234], ["-", 238], ["Km", 239], [",", 241], ["and", 243], ["only", 247], ["phenotypically", 252], ["matched", 267], ["McLeod", 275], ["blood", 282], ["would", 288], ["be", 294], ["compatible", 297], [".", 307], ["McLeod", 309], ["phenotype", 316], ["persons", 326], ["without", 334], ["CGD", 342], ["have", 346], ["made", 351], ["anti", 356], ["-", 360], ["Km", 361], ["but", 364], ["not", 368], ["anti", 372], ["-", 376], ["Kx", 377], ["(", 380], ["2", 381], ["examples", 383], [")", 391], [",", 392], ["and", 394], ["thus", 398], ["both", 403], ["McLeod", 408], ["and", 415], ["K(O", 419], [")", 422], ["blood", 424], ["would", 430], ["be", 436], ["compatible", 439], [".", 449], ["RBCs", 451], ["from", 456], ["a", 461], ["transfused", 463], ["patient", 474], ["with", 482], ["the", 487], ["McLeod", 491], ["phenotype", 498], ["but", 508], ["not", 512], ["with", 516], ["CGD", 521], ["(", 525], ["non", 526], ["-", 529], ["CGD", 530], ["McLeod", 534], [")", 540], ["were", 542], ["typed", 547], ["for", 553], ["the", 557], ["Kell", 561], ["blood", 566], ["group", 572], ["antigens", 578], [",", 586], ["and", 588], ["the", 592], ["plasma", 596], ["was", 603], ["analyzed", 607], ["for", 616], ["the", 620], ["presence", 624], ["of", 633], ["antibody", 636], ["by", 645], ["agglutination", 648], [".", 661], ["The", 663], ["molecular", 667], ["basis", 677], ["was", 683], ["determined", 687], ["by", 698], ["analyzing", 701], ["for", 711], ["XK", 715], ["protein", 718], ["on", 726], ["RBC", 729], ["membranes", 733], ["by", 743], ["Western", 746], ["immunoblotting", 754], [",", 768], ["by", 770], ["sequencing", 773], ["the", 784], ["XK", 788], ["gene", 791], [",", 795], ["and", 797], ["by", 801], ["RFLP", 804], [".", 808], ["The", 810], ["RBCs", 814], ["did", 819], ["not", 823], ["react", 827], ["with", 833], ["anti", 838], ["-", 842], ["Kx", 843], ["+", 846], ["anti", 848], ["-", 852], ["Km", 853], ["and", 856], ["showed", 860], ["weakening", 867], ["of", 877], ["Kell", 880], ["system", 885], ["antigens", 892], [".", 900], ["The", 902], ["patient", 906], ["'s", 913], ["plasma", 916], ["reacted", 923], ["moderately", 931], ["(", 942], ["2", 943], ["+", 944], [")", 945], ["with", 947], ["RBCs", 952], ["of", 957], ["common", 960], ["Kell", 967], ["type", 972], ["and", 977], ["strongly", 981], ["(", 990], ["4", 991], ["+", 992], [")", 993], ["with", 995], ["K(O", 1000], [")", 1003], ["RBCs", 1005], ["and", 1010], ["RBCs", 1014], ["of", 1019], ["common", 1022], ["Kell", 1029], ["type", 1034], ["treated", 1039], ["with", 1047], ["dithiothreitol", 1052], [",", 1066], ["and", 1068], ["did", 1072], ["not", 1076], ["react", 1080], ["with", 1086], ["McLeod", 1091], ["RBCs", 1098], [".", 1102], ["XK", 1104], ["protein", 1107], ["was", 1115], ["absent", 1119], ["from", 1126], ["the", 1131], ["RBC", 1135], ["membranes", 1139], [".", 1148], ["The", 1150], ["XK", 1154], ["gene", 1157], ["had", 1162], ["a", 1166], ["point", 1168], ["mutation", 1174], ["in", 1183], ["the", 1186], ["donor", 1190], ["splice", 1196], ["site", 1203], ["of", 1208], ["intron", 1211], ["1", 1218], ["(", 1220], ["G", 1221], [">", 1222], ["C", 1223], [")", 1224], [".", 1225], ["This", 1227], ["is", 1232], ["the", 1235], ["first", 1239], ["report", 1245], ["describing", 1252], ["the", 1263], ["molecular", 1267], ["alteration", 1277], ["in", 1288], ["a", 1291], ["non", 1293], ["-", 1296], ["CGD", 1297], ["McLeod", 1301], ["patient", 1308], ["who", 1316], ["has", 1320], ["made", 1324], ["anti", 1329], ["-", 1333], ["Kx", 1334], [".", 1336], ["The", 1338], ["immune", 1342], ["response", 1349], ["of", 1358], ["people", 1361], ["with", 1368], ["the", 1373], ["McLeod", 1377], ["phenotype", 1384], ["can", 1394], ["vary", 1398], [",", 1402], ["and", 1404], ["K(O", 1408], [")", 1411], ["blood", 1413], ["may", 1419], ["not", 1423], ["always", 1427], ["be", 1434], ["compatible", 1437], [".", 1447]]}
{"context": "Parkinson's disease (PD) is a neurodegenerative disorder characterized by the appearance of intracytoplasmic inclusions called Lewy bodies (LB) in dopamine neurons in the substantia nigra and the progressive loss of these neurons. Recently, mutations in the alpha-synuclein gene have been identified in early-onset familial PD, and alpha-synuclein has been shown to be a major component of LB in all patients. Yet, the pathophysiological function of alpha-synuclein remains unknown. In this report, we have investigated the toxic effects of adenovirus-mediated alpha-synuclein overexpression on dopamine neurons in rat primary mesencephalic cultures and in a rat dopaminergic cell line - the large T-antigen immortalized, mesencephalon-derived 1RB3AN27 (N27). Adenovirus-transduced cultures showed high-level expression of alpha-synuclein within the cells. Overexpression of human mutant alpha-synuclein (Ala(53)Thr) selectively induced apoptotic programmed cell death of primary dopamine neurons as well as N27 cells. The mutant protein also potentiated the neurotoxicity of 6-hydroxydopamine (6-OHDA). By contrast, overexpression of wild-type human alpha-synuclein was not directly neurotoxic but did increase cell death after 6-OHDA. Overexpression of wild-type rat alpha-synuclein had no effect on dopamine cell survival or 6-OHDA neurotoxicity. These results indicate that overexpression of human mutant alpha-synuclein directly leads to dopamine neuron death, and overexpression of either human mutant or human wild-type alpha-synuclein renders dopamine neurons more vulnerable to neurotoxic insults.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "d46479c4ece34bc181a6026e994a86e9", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[81, 83], [222, 224], [244, 246], [101, 103], [157, 159], [58, 60], [201, 203], [265, 267], [146, 148], [43, 45]], "char_spans": [[450, 464], [1269, 1283], [1409, 1423], [561, 575], [888, 902], [332, 346], [1151, 1165], [1527, 1541], [823, 837], [258, 272]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["is", 25], ["a", 28], ["neurodegenerative", 30], ["disorder", 48], ["characterized", 57], ["by", 71], ["the", 74], ["appearance", 78], ["of", 89], ["intracytoplasmic", 92], ["inclusions", 109], ["called", 120], ["Lewy", 127], ["bodies", 132], ["(", 139], ["LB", 140], [")", 142], ["in", 144], ["dopamine", 147], ["neurons", 156], ["in", 164], ["the", 167], ["substantia", 171], ["nigra", 182], ["and", 188], ["the", 192], ["progressive", 196], ["loss", 208], ["of", 213], ["these", 216], ["neurons", 222], [".", 229], ["Recently", 231], [",", 239], ["mutations", 241], ["in", 251], ["the", 254], ["alpha", 258], ["-", 263], ["synuclein", 264], ["gene", 274], ["have", 279], ["been", 284], ["identified", 289], ["in", 300], ["early", 303], ["-", 308], ["onset", 309], ["familial", 315], ["PD", 324], [",", 326], ["and", 328], ["alpha", 332], ["-", 337], ["synuclein", 338], ["has", 348], ["been", 352], ["shown", 357], ["to", 363], ["be", 366], ["a", 369], ["major", 371], ["component", 377], ["of", 387], ["LB", 390], ["in", 393], ["all", 396], ["patients", 400], [".", 408], ["Yet", 410], [",", 413], ["the", 415], ["pathophysiological", 419], ["function", 438], ["of", 447], ["alpha", 450], ["-", 455], ["synuclein", 456], ["remains", 466], ["unknown", 474], [".", 481], ["In", 483], ["this", 486], ["report", 491], [",", 497], ["we", 499], ["have", 502], ["investigated", 507], ["the", 520], ["toxic", 524], ["effects", 530], ["of", 538], ["adenovirus", 541], ["-", 551], ["mediated", 552], ["alpha", 561], ["-", 566], ["synuclein", 567], ["overexpression", 577], ["on", 592], ["dopamine", 595], ["neurons", 604], ["in", 612], ["rat", 615], ["primary", 619], ["mesencephalic", 627], ["cultures", 641], ["and", 650], ["in", 654], ["a", 657], ["rat", 659], ["dopaminergic", 663], ["cell", 676], ["line", 681], ["-", 686], ["the", 688], ["large", 692], ["T", 698], ["-", 699], ["antigen", 700], ["immortalized", 708], [",", 720], ["mesencephalon", 722], ["-", 735], ["derived", 736], ["1RB3AN27", 744], ["(", 753], ["N27", 754], [")", 757], [".", 758], ["Adenovirus", 760], ["-", 770], ["transduced", 771], ["cultures", 782], ["showed", 791], ["high", 798], ["-", 802], ["level", 803], ["expression", 809], ["of", 820], ["alpha", 823], ["-", 828], ["synuclein", 829], ["within", 839], ["the", 846], ["cells", 850], [".", 855], ["Overexpression", 857], ["of", 872], ["human", 875], ["mutant", 881], ["alpha", 888], ["-", 893], ["synuclein", 894], ["(", 904], ["Ala(53)Thr", 905], [")", 915], ["selectively", 917], ["induced", 929], ["apoptotic", 937], ["programmed", 947], ["cell", 958], ["death", 963], ["of", 969], ["primary", 972], ["dopamine", 980], ["neurons", 989], ["as", 997], ["well", 1000], ["as", 1005], ["N27", 1008], ["cells", 1012], [".", 1017], ["The", 1019], ["mutant", 1023], ["protein", 1030], ["also", 1038], ["potentiated", 1043], ["the", 1055], ["neurotoxicity", 1059], ["of", 1073], ["6-hydroxydopamine", 1076], ["(", 1094], ["6-OHDA", 1095], [")", 1101], [".", 1102], ["By", 1104], ["contrast", 1107], [",", 1115], ["overexpression", 1117], ["of", 1132], ["wild", 1135], ["-", 1139], ["type", 1140], ["human", 1145], ["alpha", 1151], ["-", 1156], ["synuclein", 1157], ["was", 1167], ["not", 1171], ["directly", 1175], ["neurotoxic", 1184], ["but", 1195], ["did", 1199], ["increase", 1203], ["cell", 1212], ["death", 1217], ["after", 1223], ["6-OHDA", 1229], [".", 1235], ["Overexpression", 1237], ["of", 1252], ["wild", 1255], ["-", 1259], ["type", 1260], ["rat", 1265], ["alpha", 1269], ["-", 1274], ["synuclein", 1275], ["had", 1285], ["no", 1289], ["effect", 1292], ["on", 1299], ["dopamine", 1302], ["cell", 1311], ["survival", 1316], ["or", 1325], ["6-OHDA", 1328], ["neurotoxicity", 1335], [".", 1348], ["These", 1350], ["results", 1356], ["indicate", 1364], ["that", 1373], ["overexpression", 1378], ["of", 1393], ["human", 1396], ["mutant", 1402], ["alpha", 1409], ["-", 1414], ["synuclein", 1415], ["directly", 1425], ["leads", 1434], ["to", 1440], ["dopamine", 1443], ["neuron", 1452], ["death", 1459], [",", 1464], ["and", 1466], ["overexpression", 1470], ["of", 1485], ["either", 1488], ["human", 1495], ["mutant", 1501], ["or", 1508], ["human", 1511], ["wild", 1517], ["-", 1521], ["type", 1522], ["alpha", 1527], ["-", 1532], ["synuclein", 1533], ["renders", 1543], ["dopamine", 1551], ["neurons", 1560], ["more", 1568], ["vulnerable", 1573], ["to", 1584], ["neurotoxic", 1587], ["insults", 1598], [".", 1605]]}
{"context": "Flumazenil is a competitive benzodiazepine antagonist that acts to reverse their sedative and hypnotic effects. It is indicated in the management of benzodiazepine overdose, but its role in the routine reversal of endoscopic conscious sedation has not been defined. Patients undergoing diagnostic upper endoscopy who received sedation with either diazepam or midazolam alone were given flumazenil 0.2 mg incrementally immediately following the procedure until awake. They were then asked to repeat three psychomotor tests measuring cognitive and motor skills, with their baseline scores compared with postprocedure scores over a 3-hour period. Full psychomotor function was restored to baseline values within 30 minutes after flumazenil in 79% of patients, with no differences in the reversal of psychomotor skill impairment observed between diazepam and midazolam sedation. There was no evidence of rebound sedation seen for up to 3 hours. No significant anterograde amnesia was evident in 78% of individuals. These results demonstrate that flumazenil's effects on reversing psychomotor impairment are similar when midazolam or diazepam are used for conscious sedation. However, the potential usefulness of routine flumazenil reversal of conscious sedation will require further evaluation of specific psychomotor performance skills (such as driving a car) before we lift the admonition against leaving the endoscopic suite unattended, driving a vehicle, or operating complicated machinery for several hours.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "8c08be9367e44a248f7e98941e6d911d", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[0, 0], [163, 163], [189, 189], [109, 109], [58, 58]], "char_spans": [[0, 9], [1042, 1051], [1216, 1225], [726, 735], [386, 395]]}]}], "context_tokens": [["Flumazenil", 0], ["is", 11], ["a", 14], ["competitive", 16], ["benzodiazepine", 28], ["antagonist", 43], ["that", 54], ["acts", 59], ["to", 64], ["reverse", 67], ["their", 75], ["sedative", 81], ["and", 90], ["hypnotic", 94], ["effects", 103], [".", 110], ["It", 112], ["is", 115], ["indicated", 118], ["in", 128], ["the", 131], ["management", 135], ["of", 146], ["benzodiazepine", 149], ["overdose", 164], [",", 172], ["but", 174], ["its", 178], ["role", 182], ["in", 187], ["the", 190], ["routine", 194], ["reversal", 202], ["of", 211], ["endoscopic", 214], ["conscious", 225], ["sedation", 235], ["has", 244], ["not", 248], ["been", 252], ["defined", 257], [".", 264], ["Patients", 266], ["undergoing", 275], ["diagnostic", 286], ["upper", 297], ["endoscopy", 303], ["who", 313], ["received", 317], ["sedation", 326], ["with", 335], ["either", 340], ["diazepam", 347], ["or", 356], ["midazolam", 359], ["alone", 369], ["were", 375], ["given", 380], ["flumazenil", 386], ["0.2", 397], ["mg", 401], ["incrementally", 404], ["immediately", 418], ["following", 430], ["the", 440], ["procedure", 444], ["until", 454], ["awake", 460], [".", 465], ["They", 467], ["were", 472], ["then", 477], ["asked", 482], ["to", 488], ["repeat", 491], ["three", 498], ["psychomotor", 504], ["tests", 516], ["measuring", 522], ["cognitive", 532], ["and", 542], ["motor", 546], ["skills", 552], [",", 558], ["with", 560], ["their", 565], ["baseline", 571], ["scores", 580], ["compared", 587], ["with", 596], ["postprocedure", 601], ["scores", 615], ["over", 622], ["a", 627], ["3-hour", 629], ["period", 636], [".", 642], ["Full", 644], ["psychomotor", 649], ["function", 661], ["was", 670], ["restored", 674], ["to", 683], ["baseline", 686], ["values", 695], ["within", 702], ["30", 709], ["minutes", 712], ["after", 720], ["flumazenil", 726], ["in", 737], ["79", 740], ["%", 742], ["of", 744], ["patients", 747], [",", 755], ["with", 757], ["no", 762], ["differences", 765], ["in", 777], ["the", 780], ["reversal", 784], ["of", 793], ["psychomotor", 796], ["skill", 808], ["impairment", 814], ["observed", 825], ["between", 834], ["diazepam", 842], ["and", 851], ["midazolam", 855], ["sedation", 865], [".", 873], ["There", 875], ["was", 881], ["no", 885], ["evidence", 888], ["of", 897], ["rebound", 900], ["sedation", 908], ["seen", 917], ["for", 922], ["up", 926], ["to", 929], ["3", 932], ["hours", 934], [".", 939], ["No", 941], ["significant", 944], ["anterograde", 956], ["amnesia", 968], ["was", 976], ["evident", 980], ["in", 988], ["78", 991], ["%", 993], ["of", 995], ["individuals", 998], [".", 1009], ["These", 1011], ["results", 1017], ["demonstrate", 1025], ["that", 1037], ["flumazenil", 1042], ["'s", 1052], ["effects", 1055], ["on", 1063], ["reversing", 1066], ["psychomotor", 1076], ["impairment", 1088], ["are", 1099], ["similar", 1103], ["when", 1111], ["midazolam", 1116], ["or", 1126], ["diazepam", 1129], ["are", 1138], ["used", 1142], ["for", 1147], ["conscious", 1151], ["sedation", 1161], [".", 1169], ["However", 1171], [",", 1178], ["the", 1180], ["potential", 1184], ["usefulness", 1194], ["of", 1205], ["routine", 1208], ["flumazenil", 1216], ["reversal", 1227], ["of", 1236], ["conscious", 1239], ["sedation", 1249], ["will", 1258], ["require", 1263], ["further", 1271], ["evaluation", 1279], ["of", 1290], ["specific", 1293], ["psychomotor", 1302], ["performance", 1314], ["skills", 1326], ["(", 1333], ["such", 1334], ["as", 1339], ["driving", 1342], ["a", 1350], ["car", 1352], [")", 1355], ["before", 1357], ["we", 1364], ["lift", 1367], ["the", 1372], ["admonition", 1376], ["against", 1387], ["leaving", 1395], ["the", 1403], ["endoscopic", 1407], ["suite", 1418], ["unattended", 1424], [",", 1434], ["driving", 1436], ["a", 1444], ["vehicle", 1446], [",", 1453], ["or", 1455], ["operating", 1458], ["complicated", 1468], ["machinery", 1480], ["for", 1490], ["several", 1494], ["hours", 1502], [".", 1507]]}
{"context": "Inherited ventricular arrhythmias such as the long QT syndrome (LQTS), Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia (CPVT), idiopathic ventricular fibrillation (VF), and arrhythmogenic right ventricular cardiomyopathy (ARVC) account for a relevant proportion of sudden cardiac death cases in young patients cohorts. The detailed pathogenetic mechanisms of inherited ventricular arrhythmias are still poorly understood because systematic investigations are difficult to perform due to low patient numbers and the lack of appropriate experimental models. However, recent advances in research and science have identified a genetic background for many of these diseases. In LQTS, various mutations in different genes encoding for cardiac potassium and sodium channel proteins have been identified (\"channelopathy\"), and initial progress in genotype-phenotype correlation is made. Mutations in the cardiac sodium channel gene have also been identified in a subset of patients with Brugada syndrome, whereas a genetic background has not yet been demonstrated in idiopathic VF and right ventricular outflow-tract tachycardia (RVO-VT). Very recently, mutations in the cardiac ryanodine receptor gene have been identified in CPVT and in a subgroup of patients with ARVC. Although several chromosomal loci were suggested, no other responsible genes or mutations have been found in autosomal dominant forms of ARVC. However, in Naxos disease, a recessive form of ARVC with coexpression of palmoplantar keratoderma and woolly hair, a mutation in the plakoglobin gene has recently been discovered, thus underscoring the potential role of genetic alterations in cytoskeletal proteins in ARVC. In the next years, significant progress in the genetic diagnosis pathophysiologic understanding of disease mechanisms, genotype-phenotype correlation, and the development of gene- or target-directed treatment strategies can be expected in the field of inherited ventricular arrhythmias. This review summarizes the current knowledge of the molecular mechanisms, including aspects of pathoanatomy, autonomic innervation, genetics, and genotype-phenotype correlations with their potential implications for diagnosis and treatment of inherited ventricular arrhythmias.", "qas": [{"question": "Which gene is mutated in a subtype of arrhythmogenic right ventricular cardiomyopathy known as Naxos disease?", "answers": ["The Plakoglobin gene", "plakoglobin[jup]"], "qid": "82cb45ef0dce4731bfd7549461b332ab", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["mutated", 14], ["in", 22], ["a", 25], ["subtype", 27], ["of", 35], ["arrhythmogenic", 38], ["right", 53], ["ventricular", 59], ["cardiomyopathy", 71], ["known", 86], ["as", 92], ["Naxos", 95], ["disease", 101], ["?", 108]], "detected_answers": [{"text": "The Plakoglobin gene", "token_spans": [[257, 258]], "char_spans": [[1565, 1580]]}]}], "context_tokens": [["Inherited", 0], ["ventricular", 10], ["arrhythmias", 22], ["such", 34], ["as", 39], ["the", 42], ["long", 46], ["QT", 51], ["syndrome", 54], ["(", 63], ["LQTS", 64], [")", 68], [",", 69], ["Brugada", 71], ["syndrome", 79], [",", 87], ["catecholaminergic", 89], ["polymorphic", 107], ["ventricular", 119], ["tachycardia", 131], ["(", 143], ["CPVT", 144], [")", 148], [",", 149], ["idiopathic", 151], ["ventricular", 162], ["fibrillation", 174], ["(", 187], ["VF", 188], [")", 190], [",", 191], ["and", 193], ["arrhythmogenic", 197], ["right", 212], ["ventricular", 218], ["cardiomyopathy", 230], ["(", 245], ["ARVC", 246], [")", 250], ["account", 252], ["for", 260], ["a", 264], ["relevant", 266], ["proportion", 275], ["of", 286], ["sudden", 289], ["cardiac", 296], ["death", 304], ["cases", 310], ["in", 316], ["young", 319], ["patients", 325], ["cohorts", 334], [".", 341], ["The", 343], ["detailed", 347], ["pathogenetic", 356], ["mechanisms", 369], ["of", 380], ["inherited", 383], ["ventricular", 393], ["arrhythmias", 405], ["are", 417], ["still", 421], ["poorly", 427], ["understood", 434], ["because", 445], ["systematic", 453], ["investigations", 464], ["are", 479], ["difficult", 483], ["to", 493], ["perform", 496], ["due", 504], ["to", 508], ["low", 511], ["patient", 515], ["numbers", 523], ["and", 531], ["the", 535], ["lack", 539], ["of", 544], ["appropriate", 547], ["experimental", 559], ["models", 572], [".", 578], ["However", 580], [",", 587], ["recent", 589], ["advances", 596], ["in", 605], ["research", 608], ["and", 617], ["science", 621], ["have", 629], ["identified", 634], ["a", 645], ["genetic", 647], ["background", 655], ["for", 666], ["many", 670], ["of", 675], ["these", 678], ["diseases", 684], [".", 692], ["In", 694], ["LQTS", 697], [",", 701], ["various", 703], ["mutations", 711], ["in", 721], ["different", 724], ["genes", 734], ["encoding", 740], ["for", 749], ["cardiac", 753], ["potassium", 761], ["and", 771], ["sodium", 775], ["channel", 782], ["proteins", 790], ["have", 799], ["been", 804], ["identified", 809], ["(", 820], ["\"", 821], ["channelopathy", 822], ["\"", 835], [")", 836], [",", 837], ["and", 839], ["initial", 843], ["progress", 851], ["in", 860], ["genotype", 863], ["-", 871], ["phenotype", 872], ["correlation", 882], ["is", 894], ["made", 897], [".", 901], ["Mutations", 903], ["in", 913], ["the", 916], ["cardiac", 920], ["sodium", 928], ["channel", 935], ["gene", 943], ["have", 948], ["also", 953], ["been", 958], ["identified", 963], ["in", 974], ["a", 977], ["subset", 979], ["of", 986], ["patients", 989], ["with", 998], ["Brugada", 1003], ["syndrome", 1011], [",", 1019], ["whereas", 1021], ["a", 1029], ["genetic", 1031], ["background", 1039], ["has", 1050], ["not", 1054], ["yet", 1058], ["been", 1062], ["demonstrated", 1067], ["in", 1080], ["idiopathic", 1083], ["VF", 1094], ["and", 1097], ["right", 1101], ["ventricular", 1107], ["outflow", 1119], ["-", 1126], ["tract", 1127], ["tachycardia", 1133], ["(", 1145], ["RVO", 1146], ["-", 1149], ["VT", 1150], [")", 1152], [".", 1153], ["Very", 1155], ["recently", 1160], [",", 1168], ["mutations", 1170], ["in", 1180], ["the", 1183], ["cardiac", 1187], ["ryanodine", 1195], ["receptor", 1205], ["gene", 1214], ["have", 1219], ["been", 1224], ["identified", 1229], ["in", 1240], ["CPVT", 1243], ["and", 1248], ["in", 1252], ["a", 1255], ["subgroup", 1257], ["of", 1266], ["patients", 1269], ["with", 1278], ["ARVC", 1283], [".", 1287], ["Although", 1289], ["several", 1298], ["chromosomal", 1306], ["loci", 1318], ["were", 1323], ["suggested", 1328], [",", 1337], ["no", 1339], ["other", 1342], ["responsible", 1348], ["genes", 1360], ["or", 1366], ["mutations", 1369], ["have", 1379], ["been", 1384], ["found", 1389], ["in", 1395], ["autosomal", 1398], ["dominant", 1408], ["forms", 1417], ["of", 1423], ["ARVC", 1426], [".", 1430], ["However", 1432], [",", 1439], ["in", 1441], ["Naxos", 1444], ["disease", 1450], [",", 1457], ["a", 1459], ["recessive", 1461], ["form", 1471], ["of", 1476], ["ARVC", 1479], ["with", 1484], ["coexpression", 1489], ["of", 1502], ["palmoplantar", 1505], ["keratoderma", 1518], ["and", 1530], ["woolly", 1534], ["hair", 1541], [",", 1545], ["a", 1547], ["mutation", 1549], ["in", 1558], ["the", 1561], ["plakoglobin", 1565], ["gene", 1577], ["has", 1582], ["recently", 1586], ["been", 1595], ["discovered", 1600], [",", 1610], ["thus", 1612], ["underscoring", 1617], ["the", 1630], ["potential", 1634], ["role", 1644], ["of", 1649], ["genetic", 1652], ["alterations", 1660], ["in", 1672], ["cytoskeletal", 1675], ["proteins", 1688], ["in", 1697], ["ARVC", 1700], [".", 1704], ["In", 1706], ["the", 1709], ["next", 1713], ["years", 1718], [",", 1723], ["significant", 1725], ["progress", 1737], ["in", 1746], ["the", 1749], ["genetic", 1753], ["diagnosis", 1761], ["pathophysiologic", 1771], ["understanding", 1788], ["of", 1802], ["disease", 1805], ["mechanisms", 1813], [",", 1823], ["genotype", 1825], ["-", 1833], ["phenotype", 1834], ["correlation", 1844], [",", 1855], ["and", 1857], ["the", 1861], ["development", 1865], ["of", 1877], ["gene-", 1880], ["or", 1886], ["target", 1889], ["-", 1895], ["directed", 1896], ["treatment", 1905], ["strategies", 1915], ["can", 1926], ["be", 1930], ["expected", 1933], ["in", 1942], ["the", 1945], ["field", 1949], ["of", 1955], ["inherited", 1958], ["ventricular", 1968], ["arrhythmias", 1980], [".", 1991], ["This", 1993], ["review", 1998], ["summarizes", 2005], ["the", 2016], ["current", 2020], ["knowledge", 2028], ["of", 2038], ["the", 2041], ["molecular", 2045], ["mechanisms", 2055], [",", 2065], ["including", 2067], ["aspects", 2077], ["of", 2085], ["pathoanatomy", 2088], [",", 2100], ["autonomic", 2102], ["innervation", 2112], [",", 2123], ["genetics", 2125], [",", 2133], ["and", 2135], ["genotype", 2139], ["-", 2147], ["phenotype", 2148], ["correlations", 2158], ["with", 2171], ["their", 2176], ["potential", 2182], ["implications", 2192], ["for", 2205], ["diagnosis", 2209], ["and", 2219], ["treatment", 2223], ["of", 2233], ["inherited", 2236], ["ventricular", 2246], ["arrhythmias", 2258], [".", 2269]]}
{"context": "Delamanid (Deltyba(\u00ae)), a nitroimidazo-oxazole derivative, is a new anti-tuberculosis (TB) drug which exhibits potent in vitro and in vivo antitubercular activity against drug-susceptible and -resistant strains of Mycobacterium tuberculosis. It is approved in several countries, including Japan and those of the EU, for use as part of an appropriate combination regimen in adults with multidrug-resistant tuberculosis (MDR-TB) when an effective treatment regimen cannot otherwise be composed due to resistance or tolerability. In a robust phase\u00a0II trial in adult patients with MDR-TB, oral delamanid 100\u00a0mg twice daily for 2\u00a0months plus an optimized background regimen improved sputum culture conversion rates to a significantly greater extent than placebo. In a 6-month extension study, long-term (\u22648\u00a0months) treatment with delamanid was associated with a higher incidence of favourable outcomes (i.e. cured or completed all treatment) than short-term (\u22642\u00a0months) treatment, with an accompanying reduction inunfavourable outcomes as defined by the WHO (i.e. pre-specified proportion of TB-positive sputum cultures, death or treatment discontinuation for \u22652\u00a0months without medical approval). Delamanid was not associated with clinically relevant drug-drug interactions, including with antiretroviral drugs and those commonly used in treating TB. Delamanid was generally well tolerated in patients with MDR-TB, with gastrointestinal adverse events and insomnia reported most commonly. Although the incidence of QT interval prolongation was higher with delamanid-based therapy, it was not associated with clinical symptoms such as syncope and arrhythmia. In conclusion, delamanid is a useful addition to the treatment options currently available for patients with MDR-TB.", "qas": [{"question": "Which disease can be treated with Delamanid?", "answers": ["tuberculosis"], "qid": "cffa38bb217641c08713c8debdecf88f", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["treated", 21], ["with", 29], ["Delamanid", 34], ["?", 43]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[75, 75], [19, 19], [43, 43]], "char_spans": [[405, 416], [73, 84], [228, 239]]}]}], "context_tokens": [["Delamanid", 0], ["(", 10], ["Deltyba", 11], ["(", 18], ["\u00ae", 19], [")", 20], [")", 21], [",", 22], ["a", 24], ["nitroimidazo", 26], ["-", 38], ["oxazole", 39], ["derivative", 47], [",", 57], ["is", 59], ["a", 62], ["new", 64], ["anti", 68], ["-", 72], ["tuberculosis", 73], ["(", 86], ["TB", 87], [")", 89], ["drug", 91], ["which", 96], ["exhibits", 102], ["potent", 111], ["in", 118], ["vitro", 121], ["and", 127], ["in", 131], ["vivo", 134], ["antitubercular", 139], ["activity", 154], ["against", 163], ["drug", 171], ["-", 175], ["susceptible", 176], ["and", 188], ["-resistant", 192], ["strains", 203], ["of", 211], ["Mycobacterium", 214], ["tuberculosis", 228], [".", 240], ["It", 242], ["is", 245], ["approved", 248], ["in", 257], ["several", 260], ["countries", 268], [",", 277], ["including", 279], ["Japan", 289], ["and", 295], ["those", 299], ["of", 305], ["the", 308], ["EU", 312], [",", 314], ["for", 316], ["use", 320], ["as", 324], ["part", 327], ["of", 332], ["an", 335], ["appropriate", 338], ["combination", 350], ["regimen", 362], ["in", 370], ["adults", 373], ["with", 380], ["multidrug", 385], ["-", 394], ["resistant", 395], ["tuberculosis", 405], ["(", 418], ["MDR", 419], ["-", 422], ["TB", 423], [")", 425], ["when", 427], ["an", 432], ["effective", 435], ["treatment", 445], ["regimen", 455], ["can", 463], ["not", 466], ["otherwise", 470], ["be", 480], ["composed", 483], ["due", 492], ["to", 496], ["resistance", 499], ["or", 510], ["tolerability", 513], [".", 525], ["In", 527], ["a", 530], ["robust", 532], ["phase", 539], ["II", 545], ["trial", 548], ["in", 554], ["adult", 557], ["patients", 563], ["with", 572], ["MDR", 577], ["-", 580], ["TB", 581], [",", 583], ["oral", 585], ["delamanid", 590], ["100", 600], ["mg", 604], ["twice", 607], ["daily", 613], ["for", 619], ["2", 623], ["months", 625], ["plus", 632], ["an", 637], ["optimized", 640], ["background", 650], ["regimen", 661], ["improved", 669], ["sputum", 678], ["culture", 685], ["conversion", 693], ["rates", 704], ["to", 710], ["a", 713], ["significantly", 715], ["greater", 729], ["extent", 737], ["than", 744], ["placebo", 749], [".", 756], ["In", 758], ["a", 761], ["6-month", 763], ["extension", 771], ["study", 781], [",", 786], ["long", 788], ["-", 792], ["term", 793], ["(", 798], ["\u22648", 799], ["months", 802], [")", 808], ["treatment", 810], ["with", 820], ["delamanid", 825], ["was", 835], ["associated", 839], ["with", 850], ["a", 855], ["higher", 857], ["incidence", 864], ["of", 874], ["favourable", 877], ["outcomes", 888], ["(", 897], ["i.e.", 898], ["cured", 903], ["or", 909], ["completed", 912], ["all", 922], ["treatment", 926], [")", 935], ["than", 937], ["short", 942], ["-", 947], ["term", 948], ["(", 953], ["\u22642", 954], ["months", 957], [")", 963], ["treatment", 965], [",", 974], ["with", 976], ["an", 981], ["accompanying", 984], ["reduction", 997], ["inunfavourable", 1007], ["outcomes", 1022], ["as", 1031], ["defined", 1034], ["by", 1042], ["the", 1045], ["WHO", 1049], ["(", 1053], ["i.e.", 1054], ["pre", 1059], ["-", 1062], ["specified", 1063], ["proportion", 1073], ["of", 1084], ["TB", 1087], ["-", 1089], ["positive", 1090], ["sputum", 1099], ["cultures", 1106], [",", 1114], ["death", 1116], ["or", 1122], ["treatment", 1125], ["discontinuation", 1135], ["for", 1151], ["\u22652", 1155], ["months", 1158], ["without", 1165], ["medical", 1173], ["approval", 1181], [")", 1189], [".", 1190], ["Delamanid", 1192], ["was", 1202], ["not", 1206], ["associated", 1210], ["with", 1221], ["clinically", 1226], ["relevant", 1237], ["drug", 1246], ["-", 1250], ["drug", 1251], ["interactions", 1256], [",", 1268], ["including", 1270], ["with", 1280], ["antiretroviral", 1285], ["drugs", 1300], ["and", 1306], ["those", 1310], ["commonly", 1316], ["used", 1325], ["in", 1330], ["treating", 1333], ["TB", 1342], [".", 1344], ["Delamanid", 1346], ["was", 1356], ["generally", 1360], ["well", 1370], ["tolerated", 1375], ["in", 1385], ["patients", 1388], ["with", 1397], ["MDR", 1402], ["-", 1405], ["TB", 1406], [",", 1408], ["with", 1410], ["gastrointestinal", 1415], ["adverse", 1432], ["events", 1440], ["and", 1447], ["insomnia", 1451], ["reported", 1460], ["most", 1469], ["commonly", 1474], [".", 1482], ["Although", 1484], ["the", 1493], ["incidence", 1497], ["of", 1507], ["QT", 1510], ["interval", 1513], ["prolongation", 1522], ["was", 1535], ["higher", 1539], ["with", 1546], ["delamanid", 1551], ["-", 1560], ["based", 1561], ["therapy", 1567], [",", 1574], ["it", 1576], ["was", 1579], ["not", 1583], ["associated", 1587], ["with", 1598], ["clinical", 1603], ["symptoms", 1612], ["such", 1621], ["as", 1626], ["syncope", 1629], ["and", 1637], ["arrhythmia", 1641], [".", 1651], ["In", 1653], ["conclusion", 1656], [",", 1666], ["delamanid", 1668], ["is", 1678], ["a", 1681], ["useful", 1683], ["addition", 1690], ["to", 1699], ["the", 1702], ["treatment", 1706], ["options", 1716], ["currently", 1724], ["available", 1734], ["for", 1744], ["patients", 1748], ["with", 1757], ["MDR", 1762], ["-", 1765], ["TB", 1766], [".", 1768]]}
{"context": "To assess the efficacy and safety of R788 (fostamatinib disodium), an inhibitor of spleen tyrosine kinase (Syk), in patients with active rheumatoid arthritis (RA) that did not respond to biologic therapies. A total of 219 patients with active RA in whom treatment with biologic agents had failed were enrolled in a 3-month multicenter, randomized, double-blind, placebo-controlled trial of R788. The primary end point was the percentage of patients who met the American College of Rheumatology 20% improvement criteria (achieved an ACR20 response) at month 3. Secondary end points included changes in inflammation and damage, as assessed by magnetic resonance imaging (MRI), and changes in the Disease Activity Score. The ACR20 response in the R788 100 mg twice daily group was 38%, versus 37% in the placebo group, at month 3. No significant differences were achieved in the ACR20, ACR50, or ACR70 response levels at 3 months. There were differences between the groups from baseline to month 3 in the secondary end points C-reactive protein (CRP) level and synovitis score on MRI. There were baseline differences in steroid use, prior biologic use, and synovitis score on MRI between the R788 group and the placebo group that may have affected the outcomes. A high placebo response rate was seen in this trial, and exploratory analysis suggested that this may in part have been driven by patients who entered the trial with an elevated erythrocyte sedimentation rate but normal CRP level. Our findings indicate that there were no differences in the primary end point between the R788 and placebo groups. Differences were observed between the R788 and placebo groups in secondary end points, particularly in those patients who entered the study with an elevated CRP level.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "da2a8dc6772a49fb956f810030d12b53", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[16, 18]], "char_spans": [[83, 104]]}]}], "context_tokens": [["To", 0], ["assess", 3], ["the", 10], ["efficacy", 14], ["and", 23], ["safety", 27], ["of", 34], ["R788", 37], ["(", 42], ["fostamatinib", 43], ["disodium", 56], [")", 64], [",", 65], ["an", 67], ["inhibitor", 70], ["of", 80], ["spleen", 83], ["tyrosine", 90], ["kinase", 99], ["(", 106], ["Syk", 107], [")", 110], [",", 111], ["in", 113], ["patients", 116], ["with", 125], ["active", 130], ["rheumatoid", 137], ["arthritis", 148], ["(", 158], ["RA", 159], [")", 161], ["that", 163], ["did", 168], ["not", 172], ["respond", 176], ["to", 184], ["biologic", 187], ["therapies", 196], [".", 205], ["A", 207], ["total", 209], ["of", 215], ["219", 218], ["patients", 222], ["with", 231], ["active", 236], ["RA", 243], ["in", 246], ["whom", 249], ["treatment", 254], ["with", 264], ["biologic", 269], ["agents", 278], ["had", 285], ["failed", 289], ["were", 296], ["enrolled", 301], ["in", 310], ["a", 313], ["3-month", 315], ["multicenter", 323], [",", 334], ["randomized", 336], [",", 346], ["double", 348], ["-", 354], ["blind", 355], [",", 360], ["placebo", 362], ["-", 369], ["controlled", 370], ["trial", 381], ["of", 387], ["R788", 390], [".", 394], ["The", 396], ["primary", 400], ["end", 408], ["point", 412], ["was", 418], ["the", 422], ["percentage", 426], ["of", 437], ["patients", 440], ["who", 449], ["met", 453], ["the", 457], ["American", 461], ["College", 470], ["of", 478], ["Rheumatology", 481], ["20", 494], ["%", 496], ["improvement", 498], ["criteria", 510], ["(", 519], ["achieved", 520], ["an", 529], ["ACR20", 532], ["response", 538], [")", 546], ["at", 548], ["month", 551], ["3", 557], [".", 558], ["Secondary", 560], ["end", 570], ["points", 574], ["included", 581], ["changes", 590], ["in", 598], ["inflammation", 601], ["and", 614], ["damage", 618], [",", 624], ["as", 626], ["assessed", 629], ["by", 638], ["magnetic", 641], ["resonance", 650], ["imaging", 660], ["(", 668], ["MRI", 669], [")", 672], [",", 673], ["and", 675], ["changes", 679], ["in", 687], ["the", 690], ["Disease", 694], ["Activity", 702], ["Score", 711], [".", 716], ["The", 718], ["ACR20", 722], ["response", 728], ["in", 737], ["the", 740], ["R788", 744], ["100", 749], ["mg", 753], ["twice", 756], ["daily", 762], ["group", 768], ["was", 774], ["38", 778], ["%", 780], [",", 781], ["versus", 783], ["37", 790], ["%", 792], ["in", 794], ["the", 797], ["placebo", 801], ["group", 809], [",", 814], ["at", 816], ["month", 819], ["3", 825], [".", 826], ["No", 828], ["significant", 831], ["differences", 843], ["were", 855], ["achieved", 860], ["in", 869], ["the", 872], ["ACR20", 876], [",", 881], ["ACR50", 883], [",", 888], ["or", 890], ["ACR70", 893], ["response", 899], ["levels", 908], ["at", 915], ["3", 918], ["months", 920], [".", 926], ["There", 928], ["were", 934], ["differences", 939], ["between", 951], ["the", 959], ["groups", 963], ["from", 970], ["baseline", 975], ["to", 984], ["month", 987], ["3", 993], ["in", 995], ["the", 998], ["secondary", 1002], ["end", 1012], ["points", 1016], ["C", 1023], ["-", 1024], ["reactive", 1025], ["protein", 1034], ["(", 1042], ["CRP", 1043], [")", 1046], ["level", 1048], ["and", 1054], ["synovitis", 1058], ["score", 1068], ["on", 1074], ["MRI", 1077], [".", 1080], ["There", 1082], ["were", 1088], ["baseline", 1093], ["differences", 1102], ["in", 1114], ["steroid", 1117], ["use", 1125], [",", 1128], ["prior", 1130], ["biologic", 1136], ["use", 1145], [",", 1148], ["and", 1150], ["synovitis", 1154], ["score", 1164], ["on", 1170], ["MRI", 1173], ["between", 1177], ["the", 1185], ["R788", 1189], ["group", 1194], ["and", 1200], ["the", 1204], ["placebo", 1208], ["group", 1216], ["that", 1222], ["may", 1227], ["have", 1231], ["affected", 1236], ["the", 1245], ["outcomes", 1249], [".", 1257], ["A", 1259], ["high", 1261], ["placebo", 1266], ["response", 1274], ["rate", 1283], ["was", 1288], ["seen", 1292], ["in", 1297], ["this", 1300], ["trial", 1305], [",", 1310], ["and", 1312], ["exploratory", 1316], ["analysis", 1328], ["suggested", 1337], ["that", 1347], ["this", 1352], ["may", 1357], ["in", 1361], ["part", 1364], ["have", 1369], ["been", 1374], ["driven", 1379], ["by", 1386], ["patients", 1389], ["who", 1398], ["entered", 1402], ["the", 1410], ["trial", 1414], ["with", 1420], ["an", 1425], ["elevated", 1428], ["erythrocyte", 1437], ["sedimentation", 1449], ["rate", 1463], ["but", 1468], ["normal", 1472], ["CRP", 1479], ["level", 1483], [".", 1488], ["Our", 1490], ["findings", 1494], ["indicate", 1503], ["that", 1512], ["there", 1517], ["were", 1523], ["no", 1528], ["differences", 1531], ["in", 1543], ["the", 1546], ["primary", 1550], ["end", 1558], ["point", 1562], ["between", 1568], ["the", 1576], ["R788", 1580], ["and", 1585], ["placebo", 1589], ["groups", 1597], [".", 1603], ["Differences", 1605], ["were", 1617], ["observed", 1622], ["between", 1631], ["the", 1639], ["R788", 1643], ["and", 1648], ["placebo", 1652], ["groups", 1660], ["in", 1667], ["secondary", 1670], ["end", 1680], ["points", 1684], [",", 1690], ["particularly", 1692], ["in", 1705], ["those", 1708], ["patients", 1714], ["who", 1723], ["entered", 1727], ["the", 1735], ["study", 1739], ["with", 1745], ["an", 1750], ["elevated", 1753], ["CRP", 1762], ["level", 1766], [".", 1771]]}
{"context": "Mutations in FOXP2 cause developmental verbal dyspraxia (DVD), but only a few cases have been described. We characterize 13 patients with DVD--5 with hemizygous paternal deletions spanning the FOXP2 gene, 1 with a translocation interrupting FOXP2, and the remaining 7 with maternal uniparental disomy of chromosome 7 (UPD7), who were also given a diagnosis of Silver-Russell Syndrome (SRS). Of these individuals with DVD, all 12 for whom parental DNA was available showed absence of a paternal copy of FOXP2. Five other individuals with deletions of paternally inherited FOXP2 but with incomplete clinical information or phenotypes too complex to properly assess are also described. Four of the patients with DVD also meet criteria for autism spectrum disorder. Individuals with paternal UPD7 or with partial maternal UPD7 or deletion starting downstream of FOXP2 do not have DVD. Using quantitative real-time polymerase chain reaction, we show the maternally inherited FOXP2 to be comparatively underexpressed. Our results indicate that absence of paternal FOXP2 is the cause of DVD in patients with SRS with maternal UPD7. The data also point to a role for differential parent-of-origin expression of FOXP2 in human speech development.", "qas": [{"question": "Which gene is responsible for proper speech development?", "answers": ["FOXP2"], "qid": "a5597097671740739398b8d4cab19549", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["proper", 30], ["speech", 37], ["development", 44], ["?", 55]], "detected_answers": [{"text": "FOXP2", "token_spans": [[32, 32], [93, 93], [181, 181], [211, 211], [148, 148], [103, 103], [40, 40], [168, 168], [2, 2]], "char_spans": [[193, 197], [502, 506], [1058, 1062], [1203, 1207], [858, 862], [571, 575], [241, 245], [970, 974], [13, 17]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["FOXP2", 13], ["cause", 19], ["developmental", 25], ["verbal", 39], ["dyspraxia", 46], ["(", 56], ["DVD", 57], [")", 60], [",", 61], ["but", 63], ["only", 67], ["a", 72], ["few", 74], ["cases", 78], ["have", 84], ["been", 89], ["described", 94], [".", 103], ["We", 105], ["characterize", 108], ["13", 121], ["patients", 124], ["with", 133], ["DVD--5", 138], ["with", 145], ["hemizygous", 150], ["paternal", 161], ["deletions", 170], ["spanning", 180], ["the", 189], ["FOXP2", 193], ["gene", 199], [",", 203], ["1", 205], ["with", 207], ["a", 212], ["translocation", 214], ["interrupting", 228], ["FOXP2", 241], [",", 246], ["and", 248], ["the", 252], ["remaining", 256], ["7", 266], ["with", 268], ["maternal", 273], ["uniparental", 282], ["disomy", 294], ["of", 301], ["chromosome", 304], ["7", 315], ["(", 317], ["UPD7", 318], [")", 322], [",", 323], ["who", 325], ["were", 329], ["also", 334], ["given", 339], ["a", 345], ["diagnosis", 347], ["of", 357], ["Silver", 360], ["-", 366], ["Russell", 367], ["Syndrome", 375], ["(", 384], ["SRS", 385], [")", 388], [".", 389], ["Of", 391], ["these", 394], ["individuals", 400], ["with", 412], ["DVD", 417], [",", 420], ["all", 422], ["12", 426], ["for", 429], ["whom", 433], ["parental", 438], ["DNA", 447], ["was", 451], ["available", 455], ["showed", 465], ["absence", 472], ["of", 480], ["a", 483], ["paternal", 485], ["copy", 494], ["of", 499], ["FOXP2", 502], [".", 507], ["Five", 509], ["other", 514], ["individuals", 520], ["with", 532], ["deletions", 537], ["of", 547], ["paternally", 550], ["inherited", 561], ["FOXP2", 571], ["but", 577], ["with", 581], ["incomplete", 586], ["clinical", 597], ["information", 606], ["or", 618], ["phenotypes", 621], ["too", 632], ["complex", 636], ["to", 644], ["properly", 647], ["assess", 656], ["are", 663], ["also", 667], ["described", 672], [".", 681], ["Four", 683], ["of", 688], ["the", 691], ["patients", 695], ["with", 704], ["DVD", 709], ["also", 713], ["meet", 718], ["criteria", 723], ["for", 732], ["autism", 736], ["spectrum", 743], ["disorder", 752], [".", 760], ["Individuals", 762], ["with", 774], ["paternal", 779], ["UPD7", 788], ["or", 793], ["with", 796], ["partial", 801], ["maternal", 809], ["UPD7", 818], ["or", 823], ["deletion", 826], ["starting", 835], ["downstream", 844], ["of", 855], ["FOXP2", 858], ["do", 864], ["not", 867], ["have", 871], ["DVD", 876], [".", 879], ["Using", 881], ["quantitative", 887], ["real", 900], ["-", 904], ["time", 905], ["polymerase", 910], ["chain", 921], ["reaction", 927], [",", 935], ["we", 937], ["show", 940], ["the", 945], ["maternally", 949], ["inherited", 960], ["FOXP2", 970], ["to", 976], ["be", 979], ["comparatively", 982], ["underexpressed", 996], [".", 1010], ["Our", 1012], ["results", 1016], ["indicate", 1024], ["that", 1033], ["absence", 1038], ["of", 1046], ["paternal", 1049], ["FOXP2", 1058], ["is", 1064], ["the", 1067], ["cause", 1071], ["of", 1077], ["DVD", 1080], ["in", 1084], ["patients", 1087], ["with", 1096], ["SRS", 1101], ["with", 1105], ["maternal", 1110], ["UPD7", 1119], [".", 1123], ["The", 1125], ["data", 1129], ["also", 1134], ["point", 1139], ["to", 1145], ["a", 1148], ["role", 1150], ["for", 1155], ["differential", 1159], ["parent", 1172], ["-", 1178], ["of", 1179], ["-", 1181], ["origin", 1182], ["expression", 1189], ["of", 1200], ["FOXP2", 1203], ["in", 1209], ["human", 1212], ["speech", 1218], ["development", 1225], [".", 1236]]}
{"context": "Atrial fibrillation (AF), a common cardiac arrhythmia associated with increased risk of heart failure, thromboembolic phenomena and death, is a leading cause of hospitalization of adults. A major complication of AF is an increased risk of ischemic stroke leading to long-term disability and in severe cases, death. Historically, Coumadin has been the drug of choice for chronic anticoagulation and stroke prevention in AF patients however, given the need for constant monitoring and multiple drug interactions, newer anticoagulants have been developed. One such drug is dabigatran, with the promise of less frequent monitoring and decreased bleeding tendencies as compared to Coumadin. The main disadvantage of dabigatran has been the lack of a reversal agent in case of severe bleeding or emergent surgical intervention. This was until the recent The Food and Drug Administration approval of idarucizumab, a potential reversal agent for dabigatran. In this article, we discuss the evidence addressing idarucizumab safety, tolerability and its efficacy for reversing effect of dabigatran.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "d6e9cee2def349948db2eae4577d1aaa", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[158, 158], [120, 120], [180, 180], [98, 98]], "char_spans": [[938, 947], [711, 720], [1077, 1086], [570, 579]]}]}], "context_tokens": [["Atrial", 0], ["fibrillation", 7], ["(", 20], ["AF", 21], [")", 23], [",", 24], ["a", 26], ["common", 28], ["cardiac", 35], ["arrhythmia", 43], ["associated", 54], ["with", 65], ["increased", 70], ["risk", 80], ["of", 85], ["heart", 88], ["failure", 94], [",", 101], ["thromboembolic", 103], ["phenomena", 118], ["and", 128], ["death", 132], [",", 137], ["is", 139], ["a", 142], ["leading", 144], ["cause", 152], ["of", 158], ["hospitalization", 161], ["of", 177], ["adults", 180], [".", 186], ["A", 188], ["major", 190], ["complication", 196], ["of", 209], ["AF", 212], ["is", 215], ["an", 218], ["increased", 221], ["risk", 231], ["of", 236], ["ischemic", 239], ["stroke", 248], ["leading", 255], ["to", 263], ["long", 266], ["-", 270], ["term", 271], ["disability", 276], ["and", 287], ["in", 291], ["severe", 294], ["cases", 301], [",", 306], ["death", 308], [".", 313], ["Historically", 315], [",", 327], ["Coumadin", 329], ["has", 338], ["been", 342], ["the", 347], ["drug", 351], ["of", 356], ["choice", 359], ["for", 366], ["chronic", 370], ["anticoagulation", 378], ["and", 394], ["stroke", 398], ["prevention", 405], ["in", 416], ["AF", 419], ["patients", 422], ["however", 431], [",", 438], ["given", 440], ["the", 446], ["need", 450], ["for", 455], ["constant", 459], ["monitoring", 468], ["and", 479], ["multiple", 483], ["drug", 492], ["interactions", 497], [",", 509], ["newer", 511], ["anticoagulants", 517], ["have", 532], ["been", 537], ["developed", 542], [".", 551], ["One", 553], ["such", 557], ["drug", 562], ["is", 567], ["dabigatran", 570], [",", 580], ["with", 582], ["the", 587], ["promise", 591], ["of", 599], ["less", 602], ["frequent", 607], ["monitoring", 616], ["and", 627], ["decreased", 631], ["bleeding", 641], ["tendencies", 650], ["as", 661], ["compared", 664], ["to", 673], ["Coumadin", 676], [".", 684], ["The", 686], ["main", 690], ["disadvantage", 695], ["of", 708], ["dabigatran", 711], ["has", 722], ["been", 726], ["the", 731], ["lack", 735], ["of", 740], ["a", 743], ["reversal", 745], ["agent", 754], ["in", 760], ["case", 763], ["of", 768], ["severe", 771], ["bleeding", 778], ["or", 787], ["emergent", 790], ["surgical", 799], ["intervention", 808], [".", 820], ["This", 822], ["was", 827], ["until", 831], ["the", 837], ["recent", 841], ["The", 848], ["Food", 852], ["and", 857], ["Drug", 861], ["Administration", 866], ["approval", 881], ["of", 890], ["idarucizumab", 893], [",", 905], ["a", 907], ["potential", 909], ["reversal", 919], ["agent", 928], ["for", 934], ["dabigatran", 938], [".", 948], ["In", 950], ["this", 953], ["article", 958], [",", 965], ["we", 967], ["discuss", 970], ["the", 978], ["evidence", 982], ["addressing", 991], ["idarucizumab", 1002], ["safety", 1015], [",", 1021], ["tolerability", 1023], ["and", 1036], ["its", 1040], ["efficacy", 1044], ["for", 1053], ["reversing", 1057], ["effect", 1067], ["of", 1074], ["dabigatran", 1077], [".", 1087]]}
{"context": "The Sotos syndrome gene product, NSD1, is a SET domain histone methyltransferase that primarily dimethylates nucleosomal histone H3 lysine 36 (H3K36). To date, the intrinsic properties of NSD1 that determine its nucleosomal substrate selectivity and dimethyl H3K36 product specificity remain unknown. The 1.7 \u00c5 structure of the catalytic domain of NSD1 presented here shows that a regulatory loop adopts a conformation that prevents free access of H3K36 to the bound S-adenosyl-L-methionine. Molecular dynamics simulation and computational docking revealed that this normally inhibitory loop can adopt an active conformation, allowing H3K36 access to the active site, and that the nucleosome may stabilize the active conformation of the regulatory loop. Hence, our study reveals an autoregulatory mechanism of NSD1 and provides insight into the molecular mechanism of the nucleosomal substrate selectivity of this disease-related H3K36 methyltransferase.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "d8dc6dcb02604df98e1a216e74a229fa", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[10, 11]], "char_spans": [[44, 53]]}]}], "context_tokens": [["The", 0], ["Sotos", 4], ["syndrome", 10], ["gene", 19], ["product", 24], [",", 31], ["NSD1", 33], [",", 37], ["is", 39], ["a", 42], ["SET", 44], ["domain", 48], ["histone", 55], ["methyltransferase", 63], ["that", 81], ["primarily", 86], ["dimethylates", 96], ["nucleosomal", 109], ["histone", 121], ["H3", 129], ["lysine", 132], ["36", 139], ["(", 142], ["H3K36", 143], [")", 148], [".", 149], ["To", 151], ["date", 154], [",", 158], ["the", 160], ["intrinsic", 164], ["properties", 174], ["of", 185], ["NSD1", 188], ["that", 193], ["determine", 198], ["its", 208], ["nucleosomal", 212], ["substrate", 224], ["selectivity", 234], ["and", 246], ["dimethyl", 250], ["H3K36", 259], ["product", 265], ["specificity", 273], ["remain", 285], ["unknown", 292], [".", 299], ["The", 301], ["1.7", 305], ["\u00c5", 309], ["structure", 311], ["of", 321], ["the", 324], ["catalytic", 328], ["domain", 338], ["of", 345], ["NSD1", 348], ["presented", 353], ["here", 363], ["shows", 368], ["that", 374], ["a", 379], ["regulatory", 381], ["loop", 392], ["adopts", 397], ["a", 404], ["conformation", 406], ["that", 419], ["prevents", 424], ["free", 433], ["access", 438], ["of", 445], ["H3K36", 448], ["to", 454], ["the", 457], ["bound", 461], ["S", 467], ["-", 468], ["adenosyl", 469], ["-", 477], ["L", 478], ["-", 479], ["methionine", 480], [".", 490], ["Molecular", 492], ["dynamics", 502], ["simulation", 511], ["and", 522], ["computational", 526], ["docking", 540], ["revealed", 548], ["that", 557], ["this", 562], ["normally", 567], ["inhibitory", 576], ["loop", 587], ["can", 592], ["adopt", 596], ["an", 602], ["active", 605], ["conformation", 612], [",", 624], ["allowing", 626], ["H3K36", 635], ["access", 641], ["to", 648], ["the", 651], ["active", 655], ["site", 662], [",", 666], ["and", 668], ["that", 672], ["the", 677], ["nucleosome", 681], ["may", 692], ["stabilize", 696], ["the", 706], ["active", 710], ["conformation", 717], ["of", 730], ["the", 733], ["regulatory", 737], ["loop", 748], [".", 752], ["Hence", 754], [",", 759], ["our", 761], ["study", 765], ["reveals", 771], ["an", 779], ["autoregulatory", 782], ["mechanism", 797], ["of", 807], ["NSD1", 810], ["and", 815], ["provides", 819], ["insight", 828], ["into", 836], ["the", 841], ["molecular", 845], ["mechanism", 855], ["of", 865], ["the", 868], ["nucleosomal", 872], ["substrate", 884], ["selectivity", 894], ["of", 906], ["this", 909], ["disease", 914], ["-", 921], ["related", 922], ["H3K36", 930], ["methyltransferase", 936], [".", 953]]}
{"context": "We have investigated the contribution of Ca2+/calmodulin-dependent protein kinase II (CaM kinase II) and mitogen-activated protein kinase (MAP kinase) in norepinephrine (NE)-induced arachidonic acid (AA) release in rabbit aortic vascular smooth muscle cells (VSMC). NE enhanced release of AA via activation of cytosolic phospholipase A2 (cPLA2) but not secretory PLA2 in VSMC prelabeled with [3H]AA. NE (10 microM) enhanced CaM kinase II and MAP kinase activity. In cells transiently transfected with antisense oligonucleotides complementary to the translation initiation sites of CaM kinase II and MAP kinase, NE-induced AA release was inhibited by 100 and 35% respectively. Treatment of cells with PD-098059, a MAP kinase kinase inhibitor, or with MAP kinase antisense oligonucleotide reduced NE-induced activation of MAP kinase and cPLA2. NE-induced MAP kinase and cPLA2 activation was also inhibited in cells treated with a CaM kinase II inhibitor, KN-93, or with CaM kinase II antisense oligonucleotide. On the other hand, inhibition of MAP kinase kinase with PD-098059 or of MAP kinase with antisense oligonucleotides did not alter the NE-induced increase in CaM kinase II activity. Phosphorylation of MAP kinase and CaM kinase II by NE, studied by 32P incorporation and immune complex kinase assays, was inhibited by KN-93. Collectively, these data suggest that CaM kinase II can activate MAP kinase, which in turn activates cPLA2 to release AA for prostacyclin synthesis in the rabbit VSMC. This novel pathway for activation of MAP kinase by CaM kinase II appears to be mediated through stimulation of MAP kinase kinase. Activation of adrenergic receptors with NE in VSMC caused translocation of CaM kinase II, MAP kinase, and cPLA2 to the nuclear envelope only in the presence of extracellular Ca2+. Okadaic acid, which increased phosphorylation and activity, did not translocate these enzymes. Therefore, it appears that in rabbit VSMC, NE, by promoting extracellular Ca2+ influx, increases CaM kinase II activity, leading to activation of MAP kinase and cPLA2 and translocation to the nuclear envelope, resulting in release of AA from the nuclear envelope for prostacyclin synthesis.", "qas": [{"question": "Which kinase is inhibited by the small molecule KN-93?", "answers": ["The calcium/calmodulin-dependent protein kinase-II", "CaM kinase II", "CAMK2"], "qid": "4c1e2ae7b3044ebdbc54ebb2645c4732", "question_tokens": [["Which", 0], ["kinase", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["the", 29], ["small", 33], ["molecule", 39], ["KN-93", 48], ["?", 53]], "detected_answers": [{"text": "CaM kinase II", "token_spans": [[247, 249], [305, 307], [220, 222], [101, 103], [13, 15], [210, 212], [280, 282], [79, 81], [361, 363], [176, 178], [167, 169]], "char_spans": [[1369, 1381], [1704, 1716], [1223, 1235], [581, 593], [86, 98], [1165, 1177], [1550, 1562], [424, 436], [2001, 2013], [968, 980], [928, 940]]}]}], "context_tokens": [["We", 0], ["have", 3], ["investigated", 8], ["the", 21], ["contribution", 25], ["of", 38], ["Ca2+/calmodulin", 41], ["-", 56], ["dependent", 57], ["protein", 67], ["kinase", 75], ["II", 82], ["(", 85], ["CaM", 86], ["kinase", 90], ["II", 97], [")", 99], ["and", 101], ["mitogen", 105], ["-", 112], ["activated", 113], ["protein", 123], ["kinase", 131], ["(", 138], ["MAP", 139], ["kinase", 143], [")", 149], ["in", 151], ["norepinephrine", 154], ["(", 169], ["NE)-induced", 170], ["arachidonic", 182], ["acid", 194], ["(", 199], ["AA", 200], [")", 202], ["release", 204], ["in", 212], ["rabbit", 215], ["aortic", 222], ["vascular", 229], ["smooth", 238], ["muscle", 245], ["cells", 252], ["(", 258], ["VSMC", 259], [")", 263], [".", 264], ["NE", 266], ["enhanced", 269], ["release", 278], ["of", 286], ["AA", 289], ["via", 292], ["activation", 296], ["of", 307], ["cytosolic", 310], ["phospholipase", 320], ["A2", 334], ["(", 337], ["cPLA2", 338], [")", 343], ["but", 345], ["not", 349], ["secretory", 353], ["PLA2", 363], ["in", 368], ["VSMC", 371], ["prelabeled", 376], ["with", 387], ["[", 392], ["3H]AA", 393], [".", 398], ["NE", 400], ["(", 403], ["10", 404], ["microM", 407], [")", 413], ["enhanced", 415], ["CaM", 424], ["kinase", 428], ["II", 435], ["and", 438], ["MAP", 442], ["kinase", 446], ["activity", 453], [".", 461], ["In", 463], ["cells", 466], ["transiently", 472], ["transfected", 484], ["with", 496], ["antisense", 501], ["oligonucleotides", 511], ["complementary", 528], ["to", 542], ["the", 545], ["translation", 549], ["initiation", 561], ["sites", 572], ["of", 578], ["CaM", 581], ["kinase", 585], ["II", 592], ["and", 595], ["MAP", 599], ["kinase", 603], [",", 609], ["NE", 611], ["-", 613], ["induced", 614], ["AA", 622], ["release", 625], ["was", 633], ["inhibited", 637], ["by", 647], ["100", 650], ["and", 654], ["35", 658], ["%", 660], ["respectively", 662], [".", 674], ["Treatment", 676], ["of", 686], ["cells", 689], ["with", 695], ["PD-098059", 700], [",", 709], ["a", 711], ["MAP", 713], ["kinase", 717], ["kinase", 724], ["inhibitor", 731], [",", 740], ["or", 742], ["with", 745], ["MAP", 750], ["kinase", 754], ["antisense", 761], ["oligonucleotide", 771], ["reduced", 787], ["NE", 795], ["-", 797], ["induced", 798], ["activation", 806], ["of", 817], ["MAP", 820], ["kinase", 824], ["and", 831], ["cPLA2", 835], [".", 840], ["NE", 842], ["-", 844], ["induced", 845], ["MAP", 853], ["kinase", 857], ["and", 864], ["cPLA2", 868], ["activation", 874], ["was", 885], ["also", 889], ["inhibited", 894], ["in", 904], ["cells", 907], ["treated", 913], ["with", 921], ["a", 926], ["CaM", 928], ["kinase", 932], ["II", 939], ["inhibitor", 942], [",", 951], ["KN-93", 953], [",", 958], ["or", 960], ["with", 963], ["CaM", 968], ["kinase", 972], ["II", 979], ["antisense", 982], ["oligonucleotide", 992], [".", 1007], ["On", 1009], ["the", 1012], ["other", 1016], ["hand", 1022], [",", 1026], ["inhibition", 1028], ["of", 1039], ["MAP", 1042], ["kinase", 1046], ["kinase", 1053], ["with", 1060], ["PD-098059", 1065], ["or", 1075], ["of", 1078], ["MAP", 1081], ["kinase", 1085], ["with", 1092], ["antisense", 1097], ["oligonucleotides", 1107], ["did", 1124], ["not", 1128], ["alter", 1132], ["the", 1138], ["NE", 1142], ["-", 1144], ["induced", 1145], ["increase", 1153], ["in", 1162], ["CaM", 1165], ["kinase", 1169], ["II", 1176], ["activity", 1179], [".", 1187], ["Phosphorylation", 1189], ["of", 1205], ["MAP", 1208], ["kinase", 1212], ["and", 1219], ["CaM", 1223], ["kinase", 1227], ["II", 1234], ["by", 1237], ["NE", 1240], [",", 1242], ["studied", 1244], ["by", 1252], ["32P", 1255], ["incorporation", 1259], ["and", 1273], ["immune", 1277], ["complex", 1284], ["kinase", 1292], ["assays", 1299], [",", 1305], ["was", 1307], ["inhibited", 1311], ["by", 1321], ["KN-93", 1324], [".", 1329], ["Collectively", 1331], [",", 1343], ["these", 1345], ["data", 1351], ["suggest", 1356], ["that", 1364], ["CaM", 1369], ["kinase", 1373], ["II", 1380], ["can", 1383], ["activate", 1387], ["MAP", 1396], ["kinase", 1400], [",", 1406], ["which", 1408], ["in", 1414], ["turn", 1417], ["activates", 1422], ["cPLA2", 1432], ["to", 1438], ["release", 1441], ["AA", 1449], ["for", 1452], ["prostacyclin", 1456], ["synthesis", 1469], ["in", 1479], ["the", 1482], ["rabbit", 1486], ["VSMC", 1493], [".", 1497], ["This", 1499], ["novel", 1504], ["pathway", 1510], ["for", 1518], ["activation", 1522], ["of", 1533], ["MAP", 1536], ["kinase", 1540], ["by", 1547], ["CaM", 1550], ["kinase", 1554], ["II", 1561], ["appears", 1564], ["to", 1572], ["be", 1575], ["mediated", 1578], ["through", 1587], ["stimulation", 1595], ["of", 1607], ["MAP", 1610], ["kinase", 1614], ["kinase", 1621], [".", 1627], ["Activation", 1629], ["of", 1640], ["adrenergic", 1643], ["receptors", 1654], ["with", 1664], ["NE", 1669], ["in", 1672], ["VSMC", 1675], ["caused", 1680], ["translocation", 1687], ["of", 1701], ["CaM", 1704], ["kinase", 1708], ["II", 1715], [",", 1717], ["MAP", 1719], ["kinase", 1723], [",", 1729], ["and", 1731], ["cPLA2", 1735], ["to", 1741], ["the", 1744], ["nuclear", 1748], ["envelope", 1756], ["only", 1765], ["in", 1770], ["the", 1773], ["presence", 1777], ["of", 1786], ["extracellular", 1789], ["Ca2", 1803], ["+", 1806], [".", 1807], ["Okadaic", 1809], ["acid", 1817], [",", 1821], ["which", 1823], ["increased", 1829], ["phosphorylation", 1839], ["and", 1855], ["activity", 1859], [",", 1867], ["did", 1869], ["not", 1873], ["translocate", 1877], ["these", 1889], ["enzymes", 1895], [".", 1902], ["Therefore", 1904], [",", 1913], ["it", 1915], ["appears", 1918], ["that", 1926], ["in", 1931], ["rabbit", 1934], ["VSMC", 1941], [",", 1945], ["NE", 1947], [",", 1949], ["by", 1951], ["promoting", 1954], ["extracellular", 1964], ["Ca2", 1978], ["+", 1981], ["influx", 1983], [",", 1989], ["increases", 1991], ["CaM", 2001], ["kinase", 2005], ["II", 2012], ["activity", 2015], [",", 2023], ["leading", 2025], ["to", 2033], ["activation", 2036], ["of", 2047], ["MAP", 2050], ["kinase", 2054], ["and", 2061], ["cPLA2", 2065], ["and", 2071], ["translocation", 2075], ["to", 2089], ["the", 2092], ["nuclear", 2096], ["envelope", 2104], [",", 2112], ["resulting", 2114], ["in", 2124], ["release", 2127], ["of", 2135], ["AA", 2138], ["from", 2141], ["the", 2146], ["nuclear", 2150], ["envelope", 2158], ["for", 2167], ["prostacyclin", 2171], ["synthesis", 2184], [".", 2193]]}
{"context": "Long QT and short QT syndromes (LQTS and SQTS) are cardiac repolarization abnormalities that are characterized by length perturbations of the QT interval as measured on electrocardiogram (ECG). Prolonged QT interval and a propensity for ventricular tachycardia of the torsades de pointes (TdP) type are characteristic of LQTS, while SQTS is characterized by shortened QT interval with tall peaked T-waves and a propensity for atrial fibrillation. Both syndromes represent a high risk for syncope and sudden death. LQTS exists as a congenital genetic disease (cLQTS) with more than 700 mutations described in 12 genes (LQT1-12), but can also be acquired (aLQTS). The genetic forms of LQTS include Romano-Ward syndrome (RWS), which is characterized by isolated LQTS and an autosomal dominant pattern of inheritance, and syndromes with LQTS in association with other conditions. The latter includes Jervell and Lange-Nielsen syndrome (JLNS), Andersen syndrome (AS), and Timothy syndrome (TS). The genetics are further complicated by the occurrence of double and triple heterozygotes in LQTS and a considerable number of nonpathogenic rare polymorphisms in the involved genes. SQTS is a very rare condition, caused by mutations in five genes (SQTS1-5). The present mutation update is a comprehensive description of all known LQTS- and SQTS-associated mutations.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal dominant"], "qid": "857f5bd2ba3140ffa45bbf468805dfa3", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[145, 146]], "char_spans": [[771, 788]]}]}], "context_tokens": [["Long", 0], ["QT", 5], ["and", 8], ["short", 12], ["QT", 18], ["syndromes", 21], ["(", 31], ["LQTS", 32], ["and", 37], ["SQTS", 41], [")", 45], ["are", 47], ["cardiac", 51], ["repolarization", 59], ["abnormalities", 74], ["that", 88], ["are", 93], ["characterized", 97], ["by", 111], ["length", 114], ["perturbations", 121], ["of", 135], ["the", 138], ["QT", 142], ["interval", 145], ["as", 154], ["measured", 157], ["on", 166], ["electrocardiogram", 169], ["(", 187], ["ECG", 188], [")", 191], [".", 192], ["Prolonged", 194], ["QT", 204], ["interval", 207], ["and", 216], ["a", 220], ["propensity", 222], ["for", 233], ["ventricular", 237], ["tachycardia", 249], ["of", 261], ["the", 264], ["torsades", 268], ["de", 277], ["pointes", 280], ["(", 288], ["TdP", 289], [")", 292], ["type", 294], ["are", 299], ["characteristic", 303], ["of", 318], ["LQTS", 321], [",", 325], ["while", 327], ["SQTS", 333], ["is", 338], ["characterized", 341], ["by", 355], ["shortened", 358], ["QT", 368], ["interval", 371], ["with", 380], ["tall", 385], ["peaked", 390], ["T", 397], ["-", 398], ["waves", 399], ["and", 405], ["a", 409], ["propensity", 411], ["for", 422], ["atrial", 426], ["fibrillation", 433], [".", 445], ["Both", 447], ["syndromes", 452], ["represent", 462], ["a", 472], ["high", 474], ["risk", 479], ["for", 484], ["syncope", 488], ["and", 496], ["sudden", 500], ["death", 507], [".", 512], ["LQTS", 514], ["exists", 519], ["as", 526], ["a", 529], ["congenital", 531], ["genetic", 542], ["disease", 550], ["(", 558], ["cLQTS", 559], [")", 564], ["with", 566], ["more", 571], ["than", 576], ["700", 581], ["mutations", 585], ["described", 595], ["in", 605], ["12", 608], ["genes", 611], ["(", 617], ["LQT1", 618], ["-", 622], ["12", 623], [")", 625], [",", 626], ["but", 628], ["can", 632], ["also", 636], ["be", 641], ["acquired", 644], ["(", 653], ["aLQTS", 654], [")", 659], [".", 660], ["The", 662], ["genetic", 666], ["forms", 674], ["of", 680], ["LQTS", 683], ["include", 688], ["Romano", 696], ["-", 702], ["Ward", 703], ["syndrome", 708], ["(", 717], ["RWS", 718], [")", 721], [",", 722], ["which", 724], ["is", 730], ["characterized", 733], ["by", 747], ["isolated", 750], ["LQTS", 759], ["and", 764], ["an", 768], ["autosomal", 771], ["dominant", 781], ["pattern", 790], ["of", 798], ["inheritance", 801], [",", 812], ["and", 814], ["syndromes", 818], ["with", 828], ["LQTS", 833], ["in", 838], ["association", 841], ["with", 853], ["other", 858], ["conditions", 864], [".", 874], ["The", 876], ["latter", 880], ["includes", 887], ["Jervell", 896], ["and", 904], ["Lange", 908], ["-", 913], ["Nielsen", 914], ["syndrome", 922], ["(", 931], ["JLNS", 932], [")", 936], [",", 937], ["Andersen", 939], ["syndrome", 948], ["(", 957], ["AS", 958], [")", 960], [",", 961], ["and", 963], ["Timothy", 967], ["syndrome", 975], ["(", 984], ["TS", 985], [")", 987], [".", 988], ["The", 990], ["genetics", 994], ["are", 1003], ["further", 1007], ["complicated", 1015], ["by", 1027], ["the", 1030], ["occurrence", 1034], ["of", 1045], ["double", 1048], ["and", 1055], ["triple", 1059], ["heterozygotes", 1066], ["in", 1080], ["LQTS", 1083], ["and", 1088], ["a", 1092], ["considerable", 1094], ["number", 1107], ["of", 1114], ["nonpathogenic", 1117], ["rare", 1131], ["polymorphisms", 1136], ["in", 1150], ["the", 1153], ["involved", 1157], ["genes", 1166], [".", 1171], ["SQTS", 1173], ["is", 1178], ["a", 1181], ["very", 1183], ["rare", 1188], ["condition", 1193], [",", 1202], ["caused", 1204], ["by", 1211], ["mutations", 1214], ["in", 1224], ["five", 1227], ["genes", 1232], ["(", 1238], ["SQTS1", 1239], ["-", 1244], ["5", 1245], [")", 1246], [".", 1247], ["The", 1249], ["present", 1253], ["mutation", 1261], ["update", 1270], ["is", 1277], ["a", 1280], ["comprehensive", 1282], ["description", 1296], ["of", 1308], ["all", 1311], ["known", 1315], ["LQTS-", 1321], ["and", 1327], ["SQTS", 1331], ["-", 1335], ["associated", 1336], ["mutations", 1347], [".", 1356]]}
{"context": "Human alpha-galactosidase A (EC 3.2.1.22; alpha-Gal A) is the lysosomal exoglycosidase responsible for the hydrolysis of terminal alpha-galactosyl residues from glycoconjugates and is the defective enzyme causing Fabry disease (McKusick 301500). An unusally elevated level of plasma alpha-Gal A activity (> 2.5 times the normal mean) was detected in two unrelated normal males and the elevated activities were inherited as X-linked traits in their families. Sequencing of the alpha-Gal A coding region, intron/exon boundaries and 5'-flanking region from the proband identified a single mutation, a G-->A transition 30 nt upstream from the initiation of translation codon in exon 1. The -30G-->A mutation occurred in a putative NF kappa B/Ets consensus binding site that was recently shown to inhibit protein binding to the 5'-untranslated region of the gene, providing a possible explanation for its high activity. To further characterize the mutation, the mRNA and protein expressed by this variant allele were studied. Purified plasma and lymphoblast alpha-Gal A activity from individuals with the -30G-->A mutation had normal physical and kinetic properties. In vitro translation of mRNAs from the cloned normal and high plasma activity alleles resulted in similar levels of alpha-Gal A protein, indicating that this mutation did not enhance translation. These findings suggest that the -30G-->A mutation in the 5'-untranslated region of the alpha-Gal A gene enhances transcription, presumably by interfering with the binding of negatively-acting transcription factors which normally decrease alpha-Gal A expression in various cells. Preliminary studies of the frequency of the -30G-->A mutation in 395 unrelated normal males of mixed ancestry revealed two additional unrelated individuals who had high plasma enzymatic activity and the mutation, confirming the effect of this mutation on enzyme expression and suggesting that about 0.5% of normal individuals have high plasma alpha-Gal A activity due to this variant allele.", "qas": [{"question": "Which is the defective protein causing the lysosomal storage disease Fabry?", "answers": ["alpha-galactosidase A"], "qid": "cd3dcbcaf34943d0be36358f319a997a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["defective", 13], ["protein", 23], ["causing", 31], ["the", 39], ["lysosomal", 43], ["storage", 53], ["disease", 61], ["Fabry", 69], ["?", 74]], "detected_answers": [{"text": "alpha-galactosidase A", "token_spans": [[1, 3]], "char_spans": [[6, 24]]}]}], "context_tokens": [["Human", 0], ["alpha", 6], ["-", 11], ["galactosidase", 12], ["A", 26], ["(", 28], ["EC", 29], ["3.2.1.22", 32], [";", 40], ["alpha", 42], ["-", 47], ["Gal", 48], ["A", 52], [")", 53], ["is", 55], ["the", 58], ["lysosomal", 62], ["exoglycosidase", 72], ["responsible", 87], ["for", 99], ["the", 103], ["hydrolysis", 107], ["of", 118], ["terminal", 121], ["alpha", 130], ["-", 135], ["galactosyl", 136], ["residues", 147], ["from", 156], ["glycoconjugates", 161], ["and", 177], ["is", 181], ["the", 184], ["defective", 188], ["enzyme", 198], ["causing", 205], ["Fabry", 213], ["disease", 219], ["(", 227], ["McKusick", 228], ["301500", 237], [")", 243], [".", 244], ["An", 246], ["unusally", 249], ["elevated", 258], ["level", 267], ["of", 273], ["plasma", 276], ["alpha", 283], ["-", 288], ["Gal", 289], ["A", 293], ["activity", 295], ["(", 304], [">", 305], ["2.5", 307], ["times", 311], ["the", 317], ["normal", 321], ["mean", 328], [")", 332], ["was", 334], ["detected", 338], ["in", 347], ["two", 350], ["unrelated", 354], ["normal", 364], ["males", 371], ["and", 377], ["the", 381], ["elevated", 385], ["activities", 394], ["were", 405], ["inherited", 410], ["as", 420], ["X", 423], ["-", 424], ["linked", 425], ["traits", 432], ["in", 439], ["their", 442], ["families", 448], [".", 456], ["Sequencing", 458], ["of", 469], ["the", 472], ["alpha", 476], ["-", 481], ["Gal", 482], ["A", 486], ["coding", 488], ["region", 495], [",", 501], ["intron", 503], ["/", 509], ["exon", 510], ["boundaries", 515], ["and", 526], ["5'-flanking", 530], ["region", 542], ["from", 549], ["the", 554], ["proband", 558], ["identified", 566], ["a", 577], ["single", 579], ["mutation", 586], [",", 594], ["a", 596], ["G-->A", 598], ["transition", 604], ["30", 615], ["nt", 618], ["upstream", 621], ["from", 630], ["the", 635], ["initiation", 639], ["of", 650], ["translation", 653], ["codon", 665], ["in", 671], ["exon", 674], ["1", 679], [".", 680], ["The", 682], ["-30G-->A", 686], ["mutation", 695], ["occurred", 704], ["in", 713], ["a", 716], ["putative", 718], ["NF", 727], ["kappa", 730], ["B", 736], ["/", 737], ["Ets", 738], ["consensus", 742], ["binding", 752], ["site", 760], ["that", 765], ["was", 770], ["recently", 774], ["shown", 783], ["to", 789], ["inhibit", 792], ["protein", 800], ["binding", 808], ["to", 816], ["the", 819], ["5'-untranslated", 823], ["region", 839], ["of", 846], ["the", 849], ["gene", 853], [",", 857], ["providing", 859], ["a", 869], ["possible", 871], ["explanation", 880], ["for", 892], ["its", 896], ["high", 900], ["activity", 905], [".", 913], ["To", 915], ["further", 918], ["characterize", 926], ["the", 939], ["mutation", 943], [",", 951], ["the", 953], ["mRNA", 957], ["and", 962], ["protein", 966], ["expressed", 974], ["by", 984], ["this", 987], ["variant", 992], ["allele", 1000], ["were", 1007], ["studied", 1012], [".", 1019], ["Purified", 1021], ["plasma", 1030], ["and", 1037], ["lymphoblast", 1041], ["alpha", 1053], ["-", 1058], ["Gal", 1059], ["A", 1063], ["activity", 1065], ["from", 1074], ["individuals", 1079], ["with", 1091], ["the", 1096], ["-30G-->A", 1100], ["mutation", 1109], ["had", 1118], ["normal", 1122], ["physical", 1129], ["and", 1138], ["kinetic", 1142], ["properties", 1150], [".", 1160], ["In", 1162], ["vitro", 1165], ["translation", 1171], ["of", 1183], ["mRNAs", 1186], ["from", 1192], ["the", 1197], ["cloned", 1201], ["normal", 1208], ["and", 1215], ["high", 1219], ["plasma", 1224], ["activity", 1231], ["alleles", 1240], ["resulted", 1248], ["in", 1257], ["similar", 1260], ["levels", 1268], ["of", 1275], ["alpha", 1278], ["-", 1283], ["Gal", 1284], ["A", 1288], ["protein", 1290], [",", 1297], ["indicating", 1299], ["that", 1310], ["this", 1315], ["mutation", 1320], ["did", 1329], ["not", 1333], ["enhance", 1337], ["translation", 1345], [".", 1356], ["These", 1358], ["findings", 1364], ["suggest", 1373], ["that", 1381], ["the", 1386], ["-30G-->A", 1390], ["mutation", 1399], ["in", 1408], ["the", 1411], ["5'-untranslated", 1415], ["region", 1431], ["of", 1438], ["the", 1441], ["alpha", 1445], ["-", 1450], ["Gal", 1451], ["A", 1455], ["gene", 1457], ["enhances", 1462], ["transcription", 1471], [",", 1484], ["presumably", 1486], ["by", 1497], ["interfering", 1500], ["with", 1512], ["the", 1517], ["binding", 1521], ["of", 1529], ["negatively", 1532], ["-", 1542], ["acting", 1543], ["transcription", 1550], ["factors", 1564], ["which", 1572], ["normally", 1578], ["decrease", 1587], ["alpha", 1596], ["-", 1601], ["Gal", 1602], ["A", 1606], ["expression", 1608], ["in", 1619], ["various", 1622], ["cells", 1630], [".", 1635], ["Preliminary", 1637], ["studies", 1649], ["of", 1657], ["the", 1660], ["frequency", 1664], ["of", 1674], ["the", 1677], ["-30G-->A", 1681], ["mutation", 1690], ["in", 1699], ["395", 1702], ["unrelated", 1706], ["normal", 1716], ["males", 1723], ["of", 1729], ["mixed", 1732], ["ancestry", 1738], ["revealed", 1747], ["two", 1756], ["additional", 1760], ["unrelated", 1771], ["individuals", 1781], ["who", 1793], ["had", 1797], ["high", 1801], ["plasma", 1806], ["enzymatic", 1813], ["activity", 1823], ["and", 1832], ["the", 1836], ["mutation", 1840], [",", 1848], ["confirming", 1850], ["the", 1861], ["effect", 1865], ["of", 1872], ["this", 1875], ["mutation", 1880], ["on", 1889], ["enzyme", 1892], ["expression", 1899], ["and", 1910], ["suggesting", 1914], ["that", 1925], ["about", 1930], ["0.5", 1936], ["%", 1939], ["of", 1941], ["normal", 1944], ["individuals", 1951], ["have", 1963], ["high", 1968], ["plasma", 1973], ["alpha", 1980], ["-", 1985], ["Gal", 1986], ["A", 1990], ["activity", 1992], ["due", 2001], ["to", 2005], ["this", 2008], ["variant", 2013], ["allele", 2021], [".", 2027]]}
{"context": "For dozens of years, a variety of pathological findings have been revealed through previous observations on surgically resected lesions from patients with intractable epilepsy, including excessive number of neurons in the molecular layer of cortices, unexpected existence of white matter neurons, and persistent columnar structure. These findings have sometimes been referred to as microdysgenesis (MD) or mild malformation of cortical development (mMCD), which is defined as microscopic abnormalities of brain formations with no macroscopical and neuroradiological findings. Taylor et al. (1971) described surgical cases with giant neurons and bizarre, grotesque cells as \"focal dysplasia of the cerebral cortices with epilepsy.\" Since 1997, such malformations have subsequently been referred to as focal cortical dysplasia (FCD), in Greenfield's Neuropathology. Since early 2000, the definition of FCD has gradually been given a broader interpretation than the case described by Taylor et al., as shown in Palmini's classification (2004) or the newest classification (2011) proposed by the Neuropathology Task Force of the International League Against Epilepsy (ILAE). The ILAE classification describes 3 types of disease: Type I, Type II, and Type III. Type I is equivalent to some, but not all, pathological phenotypes of MD or mMCD. Type II is Taylor's FCD alone. Type III, which was not included in Palmini's classification, merges brain malformation and other pathological findings. However, the reproducibility of pathological diagnosis by using the ILAE classification was low, except for Type IIb. Hence, future studies are necessary to provide further reliable criteria for the pathological diagnosis of epilepsy patients.", "qas": [{"question": "Which disorder is rated by Palmini classification?", "answers": ["focal cortical dysplasia"], "qid": "71df3d8251d84f0f8c452651b470a6ec", "question_tokens": [["Which", 0], ["disorder", 6], ["is", 15], ["rated", 18], ["by", 24], ["Palmini", 27], ["classification", 35], ["?", 49]], "detected_answers": [{"text": "focal cortical dysplasia", "token_spans": [[129, 131]], "char_spans": [[800, 823]]}]}], "context_tokens": [["For", 0], ["dozens", 4], ["of", 11], ["years", 14], [",", 19], ["a", 21], ["variety", 23], ["of", 31], ["pathological", 34], ["findings", 47], ["have", 56], ["been", 61], ["revealed", 66], ["through", 75], ["previous", 83], ["observations", 92], ["on", 105], ["surgically", 108], ["resected", 119], ["lesions", 128], ["from", 136], ["patients", 141], ["with", 150], ["intractable", 155], ["epilepsy", 167], [",", 175], ["including", 177], ["excessive", 187], ["number", 197], ["of", 204], ["neurons", 207], ["in", 215], ["the", 218], ["molecular", 222], ["layer", 232], ["of", 238], ["cortices", 241], [",", 249], ["unexpected", 251], ["existence", 262], ["of", 272], ["white", 275], ["matter", 281], ["neurons", 288], [",", 295], ["and", 297], ["persistent", 301], ["columnar", 312], ["structure", 321], [".", 330], ["These", 332], ["findings", 338], ["have", 347], ["sometimes", 352], ["been", 362], ["referred", 367], ["to", 376], ["as", 379], ["microdysgenesis", 382], ["(", 398], ["MD", 399], [")", 401], ["or", 403], ["mild", 406], ["malformation", 411], ["of", 424], ["cortical", 427], ["development", 436], ["(", 448], ["mMCD", 449], [")", 453], [",", 454], ["which", 456], ["is", 462], ["defined", 465], ["as", 473], ["microscopic", 476], ["abnormalities", 488], ["of", 502], ["brain", 505], ["formations", 511], ["with", 522], ["no", 527], ["macroscopical", 530], ["and", 544], ["neuroradiological", 548], ["findings", 566], [".", 574], ["Taylor", 576], ["et", 583], ["al", 586], [".", 588], ["(", 590], ["1971", 591], [")", 595], ["described", 597], ["surgical", 607], ["cases", 616], ["with", 622], ["giant", 627], ["neurons", 633], ["and", 641], ["bizarre", 645], [",", 652], ["grotesque", 654], ["cells", 664], ["as", 670], ["\"", 673], ["focal", 674], ["dysplasia", 680], ["of", 690], ["the", 693], ["cerebral", 697], ["cortices", 706], ["with", 715], ["epilepsy", 720], [".", 728], ["\"", 729], ["Since", 731], ["1997", 737], [",", 741], ["such", 743], ["malformations", 748], ["have", 762], ["subsequently", 767], ["been", 780], ["referred", 785], ["to", 794], ["as", 797], ["focal", 800], ["cortical", 806], ["dysplasia", 815], ["(", 825], ["FCD", 826], [")", 829], [",", 830], ["in", 832], ["Greenfield", 835], ["'s", 845], ["Neuropathology", 848], [".", 862], ["Since", 864], ["early", 870], ["2000", 876], [",", 880], ["the", 882], ["definition", 886], ["of", 897], ["FCD", 900], ["has", 904], ["gradually", 908], ["been", 918], ["given", 923], ["a", 929], ["broader", 931], ["interpretation", 939], ["than", 954], ["the", 959], ["case", 963], ["described", 968], ["by", 978], ["Taylor", 981], ["et", 988], ["al", 991], [".", 993], [",", 994], ["as", 996], ["shown", 999], ["in", 1005], ["Palmini", 1008], ["'s", 1015], ["classification", 1018], ["(", 1033], ["2004", 1034], [")", 1038], ["or", 1040], ["the", 1043], ["newest", 1047], ["classification", 1054], ["(", 1069], ["2011", 1070], [")", 1074], ["proposed", 1076], ["by", 1085], ["the", 1088], ["Neuropathology", 1092], ["Task", 1107], ["Force", 1112], ["of", 1118], ["the", 1121], ["International", 1125], ["League", 1139], ["Against", 1146], ["Epilepsy", 1154], ["(", 1163], ["ILAE", 1164], [")", 1168], [".", 1169], ["The", 1171], ["ILAE", 1175], ["classification", 1180], ["describes", 1195], ["3", 1205], ["types", 1207], ["of", 1213], ["disease", 1216], [":", 1223], ["Type", 1225], ["I", 1230], [",", 1231], ["Type", 1233], ["II", 1238], [",", 1240], ["and", 1242], ["Type", 1246], ["III", 1251], [".", 1254], ["Type", 1256], ["I", 1261], ["is", 1263], ["equivalent", 1266], ["to", 1277], ["some", 1280], [",", 1284], ["but", 1286], ["not", 1290], ["all", 1294], [",", 1297], ["pathological", 1299], ["phenotypes", 1312], ["of", 1323], ["MD", 1326], ["or", 1329], ["mMCD", 1332], [".", 1336], ["Type", 1338], ["II", 1343], ["is", 1346], ["Taylor", 1349], ["'s", 1355], ["FCD", 1358], ["alone", 1362], [".", 1367], ["Type", 1369], ["III", 1374], [",", 1377], ["which", 1379], ["was", 1385], ["not", 1389], ["included", 1393], ["in", 1402], ["Palmini", 1405], ["'s", 1412], ["classification", 1415], [",", 1429], ["merges", 1431], ["brain", 1438], ["malformation", 1444], ["and", 1457], ["other", 1461], ["pathological", 1467], ["findings", 1480], [".", 1488], ["However", 1490], [",", 1497], ["the", 1499], ["reproducibility", 1503], ["of", 1519], ["pathological", 1522], ["diagnosis", 1535], ["by", 1545], ["using", 1548], ["the", 1554], ["ILAE", 1558], ["classification", 1563], ["was", 1578], ["low", 1582], [",", 1585], ["except", 1587], ["for", 1594], ["Type", 1598], ["IIb", 1603], [".", 1606], ["Hence", 1608], [",", 1613], ["future", 1615], ["studies", 1622], ["are", 1630], ["necessary", 1634], ["to", 1644], ["provide", 1647], ["further", 1655], ["reliable", 1663], ["criteria", 1672], ["for", 1681], ["the", 1685], ["pathological", 1689], ["diagnosis", 1702], ["of", 1712], ["epilepsy", 1715], ["patients", 1724], [".", 1732]]}
{"context": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) represents a quite poorly understood and inadequately defined phenotype of methicillin resistance. BORSA strains show low, borderline resistance to penicillinase-resistant penicillins (PRPs), with oxacillin MICs typically equal to 1-8\u2009\u00b5g\u2009ml", "qas": [{"question": "What is BORSA?", "answers": ["Borderline oxacillin-resistant Staphylococcus aureus"], "qid": "6bf60ce1cd73408f93464f39ccdb6be4", "question_tokens": [["What", 0], ["is", 5], ["BORSA", 8], ["?", 13]], "detected_answers": [{"text": "Borderline oxacillin-resistant Staphylococcus aureus", "token_spans": [[0, 5]], "char_spans": [[0, 51]]}]}], "context_tokens": [["Borderline", 0], ["oxacillin", 11], ["-", 20], ["resistant", 21], ["Staphylococcus", 31], ["aureus", 46], ["(", 53], ["BORSA", 54], [")", 59], ["represents", 61], ["a", 72], ["quite", 74], ["poorly", 80], ["understood", 87], ["and", 98], ["inadequately", 102], ["defined", 115], ["phenotype", 123], ["of", 133], ["methicillin", 136], ["resistance", 148], [".", 158], ["BORSA", 160], ["strains", 166], ["show", 174], ["low", 179], [",", 182], ["borderline", 184], ["resistance", 195], ["to", 206], ["penicillinase", 209], ["-", 222], ["resistant", 223], ["penicillins", 233], ["(", 245], ["PRPs", 246], [")", 250], [",", 251], ["with", 253], ["oxacillin", 258], ["MICs", 268], ["typically", 273], ["equal", 283], ["to", 289], ["1", 292], ["-", 293], ["8", 294], ["\u00b5g", 296], ["ml", 299]]}
{"context": "The authors discuss the clinical and molecular genetic aspects of genetically determined neuromuscular disorders of some Roma families living in Hungary. Among the autosomal recessively inherited spinal muscular atrophic (SMA) group, 8 Caucasian children had the typical 7-8 exonal deletions of the SMA gene, but only 2 patients belonged to the Roma population. There was no difference in the molecular genetic findings among the Caucasian and the Roma SMA patients. All of them had 7-8 exonal deletions of the SMA gene. We wanted to call attention to the founder mutation of the Roma population in 7 patients suffering from congenital myasthenia (CMS) from 3 Roma families. The 1267G deletion for CMS was detected by molecular genetic method. Clinical onset was pubertal and relatively slow progression of specific and phenotypic features for this founder mutation of acetyl-cholin receptor epsylon gene. In 2 patients (sister and brother) the sarcoglycanopathy 2C type C283Q mutation was proven in one Roma family suffering from limb-girdle muscular dystrophy (LGMD). Two out of the three facioscapular-humeral dystrophy (FSHD) Roma families carried 21.8 kb and 18.5 kb alleles in FSHD A1 gene (D4S139). In one family together with prenatal diagnosis founder mutation in FSHD A1 gene was detected, according to the autosomal dominant (AD) inheritance. In (F2) prenatal diagnosis was carried out, 18.5 kb/18.5 kb homozygosity was proven in the fetus, so the pregnancy was interrupted. In the CMS, LGMD and FSHD Roma patients ancient typical Roma founder mutations were found.", "qas": [{"question": "What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?", "answers": ["autosomal dominant"], "qid": "0219464e052f47129d0aa71da3738b73", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Facioscapulohumeral", 35], ["muscular", 55], ["dystrophy", 64], ["(", 74], ["FSHD", 75], [")", 79], ["?", 80]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[238, 239]], "char_spans": [[1317, 1334]]}]}], "context_tokens": [["The", 0], ["authors", 4], ["discuss", 12], ["the", 20], ["clinical", 24], ["and", 33], ["molecular", 37], ["genetic", 47], ["aspects", 55], ["of", 63], ["genetically", 66], ["determined", 78], ["neuromuscular", 89], ["disorders", 103], ["of", 113], ["some", 116], ["Roma", 121], ["families", 126], ["living", 135], ["in", 142], ["Hungary", 145], [".", 152], ["Among", 154], ["the", 160], ["autosomal", 164], ["recessively", 174], ["inherited", 186], ["spinal", 196], ["muscular", 203], ["atrophic", 212], ["(", 221], ["SMA", 222], [")", 225], ["group", 227], [",", 232], ["8", 234], ["Caucasian", 236], ["children", 246], ["had", 255], ["the", 259], ["typical", 263], ["7", 271], ["-", 272], ["8", 273], ["exonal", 275], ["deletions", 282], ["of", 292], ["the", 295], ["SMA", 299], ["gene", 303], [",", 307], ["but", 309], ["only", 313], ["2", 318], ["patients", 320], ["belonged", 329], ["to", 338], ["the", 341], ["Roma", 345], ["population", 350], [".", 360], ["There", 362], ["was", 368], ["no", 372], ["difference", 375], ["in", 386], ["the", 389], ["molecular", 393], ["genetic", 403], ["findings", 411], ["among", 420], ["the", 426], ["Caucasian", 430], ["and", 440], ["the", 444], ["Roma", 448], ["SMA", 453], ["patients", 457], [".", 465], ["All", 467], ["of", 471], ["them", 474], ["had", 479], ["7", 483], ["-", 484], ["8", 485], ["exonal", 487], ["deletions", 494], ["of", 504], ["the", 507], ["SMA", 511], ["gene", 515], [".", 519], ["We", 521], ["wanted", 524], ["to", 531], ["call", 534], ["attention", 539], ["to", 549], ["the", 552], ["founder", 556], ["mutation", 564], ["of", 573], ["the", 576], ["Roma", 580], ["population", 585], ["in", 596], ["7", 599], ["patients", 601], ["suffering", 610], ["from", 620], ["congenital", 625], ["myasthenia", 636], ["(", 647], ["CMS", 648], [")", 651], ["from", 653], ["3", 658], ["Roma", 660], ["families", 665], [".", 673], ["The", 675], ["1267", 679], ["G", 683], ["deletion", 685], ["for", 694], ["CMS", 698], ["was", 702], ["detected", 706], ["by", 715], ["molecular", 718], ["genetic", 728], ["method", 736], [".", 742], ["Clinical", 744], ["onset", 753], ["was", 759], ["pubertal", 763], ["and", 772], ["relatively", 776], ["slow", 787], ["progression", 792], ["of", 804], ["specific", 807], ["and", 816], ["phenotypic", 820], ["features", 831], ["for", 840], ["this", 844], ["founder", 849], ["mutation", 857], ["of", 866], ["acetyl", 869], ["-", 875], ["cholin", 876], ["receptor", 883], ["epsylon", 892], ["gene", 900], [".", 904], ["In", 906], ["2", 909], ["patients", 911], ["(", 920], ["sister", 921], ["and", 928], ["brother", 932], [")", 939], ["the", 941], ["sarcoglycanopathy", 945], ["2C", 963], ["type", 966], ["C283Q", 971], ["mutation", 977], ["was", 986], ["proven", 990], ["in", 997], ["one", 1000], ["Roma", 1004], ["family", 1009], ["suffering", 1016], ["from", 1026], ["limb", 1031], ["-", 1035], ["girdle", 1036], ["muscular", 1043], ["dystrophy", 1052], ["(", 1062], ["LGMD", 1063], [")", 1067], [".", 1068], ["Two", 1070], ["out", 1074], ["of", 1078], ["the", 1081], ["three", 1085], ["facioscapular", 1091], ["-", 1104], ["humeral", 1105], ["dystrophy", 1113], ["(", 1123], ["FSHD", 1124], [")", 1128], ["Roma", 1130], ["families", 1135], ["carried", 1144], ["21.8", 1152], ["kb", 1157], ["and", 1160], ["18.5", 1164], ["kb", 1169], ["alleles", 1172], ["in", 1180], ["FSHD", 1183], ["A1", 1188], ["gene", 1191], ["(", 1196], ["D4S139", 1197], [")", 1203], [".", 1204], ["In", 1206], ["one", 1209], ["family", 1213], ["together", 1220], ["with", 1229], ["prenatal", 1234], ["diagnosis", 1243], ["founder", 1253], ["mutation", 1261], ["in", 1270], ["FSHD", 1273], ["A1", 1278], ["gene", 1281], ["was", 1286], ["detected", 1290], [",", 1298], ["according", 1300], ["to", 1310], ["the", 1313], ["autosomal", 1317], ["dominant", 1327], ["(", 1336], ["AD", 1337], [")", 1339], ["inheritance", 1341], [".", 1352], ["In", 1354], ["(", 1357], ["F2", 1358], [")", 1360], ["prenatal", 1362], ["diagnosis", 1371], ["was", 1381], ["carried", 1385], ["out", 1393], [",", 1396], ["18.5", 1398], ["kb/18.5", 1403], ["kb", 1411], ["homozygosity", 1414], ["was", 1427], ["proven", 1431], ["in", 1438], ["the", 1441], ["fetus", 1445], [",", 1450], ["so", 1452], ["the", 1455], ["pregnancy", 1459], ["was", 1469], ["interrupted", 1473], [".", 1484], ["In", 1486], ["the", 1489], ["CMS", 1493], [",", 1496], ["LGMD", 1498], ["and", 1503], ["FSHD", 1507], ["Roma", 1512], ["patients", 1517], ["ancient", 1526], ["typical", 1534], ["Roma", 1542], ["founder", 1547], ["mutations", 1555], ["were", 1565], ["found", 1570], [".", 1575]]}
{"context": "Alpha-synuclein (\u03b1-Syn) is the principal protein component of Lewy bodies, a pathological hallmark of Parkinson's disease (PD). This protein may regulate protein phosphatase 2A (PP2A) activity, although the molecular mechanisms for \u03b1-Syn-mediated regulation of PP2A and the potential neuroprotective actions of PP2A against PD-associated pathology remain largely unexplored. We found that \u03b1-Syn gene overexpression in SK-N-SH cells and primary neurons led to PP2A/C phosphorylation at Y307, a known target of Src kinase, and consequent phosphatase inhibition. In addition, phospho-activated Src (p-Y416 Src, pSrc) was higher in SK-N-SH cells and primary neurons overexpressing \u03b1-Syn. Thus, \u03b1-Syn may promote Src activation and PP2A inactivation, leading to hyperphosphorylation of proteins. Immunoprecipitation revealed higher calmodulin/Src complex formation in \u03b1-Syn-overexpressing cells and \u03b1-Syn transgenic mice. A TUNEL apoptosis assay and an MTT cell viability assay demonstrated that the PP2A activator C2-ceramide protected neurons against \u03b1-Syn-induced cell injury. Buffering the Ca(2+) elevations induced by \u03b1-Syn overexpression ameliorated the cytotoxicity of \u03b1-Syn. Our findings define a potential molecular mechanism for \u03b1-Syn-mediated regulation of PP2A through formation of the calmodulin/Src complex, activation of Src, and Src-mediated phospho-inhibition of PP2A. Overexpression of \u03b1-Syn may lead to neurodegeneration in PD in part by suppressing the endogenous neuroprotective activity of PP2A.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "cf97c5fcf3d94305a47f705ecb7271f5", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[0, 2]], "char_spans": [[0, 14]]}]}], "context_tokens": [["Alpha", 0], ["-", 5], ["synuclein", 6], ["(", 16], ["\u03b1", 17], ["-", 18], ["Syn", 19], [")", 22], ["is", 24], ["the", 27], ["principal", 31], ["protein", 41], ["component", 49], ["of", 59], ["Lewy", 62], ["bodies", 67], [",", 73], ["a", 75], ["pathological", 77], ["hallmark", 90], ["of", 99], ["Parkinson", 102], ["'s", 111], ["disease", 114], ["(", 122], ["PD", 123], [")", 125], [".", 126], ["This", 128], ["protein", 133], ["may", 141], ["regulate", 145], ["protein", 154], ["phosphatase", 162], ["2A", 174], ["(", 177], ["PP2A", 178], [")", 182], ["activity", 184], [",", 192], ["although", 194], ["the", 203], ["molecular", 207], ["mechanisms", 217], ["for", 228], ["\u03b1", 232], ["-", 233], ["Syn", 234], ["-", 237], ["mediated", 238], ["regulation", 247], ["of", 258], ["PP2A", 261], ["and", 266], ["the", 270], ["potential", 274], ["neuroprotective", 284], ["actions", 300], ["of", 308], ["PP2A", 311], ["against", 316], ["PD", 324], ["-", 326], ["associated", 327], ["pathology", 338], ["remain", 348], ["largely", 355], ["unexplored", 363], [".", 373], ["We", 375], ["found", 378], ["that", 384], ["\u03b1", 389], ["-", 390], ["Syn", 391], ["gene", 395], ["overexpression", 400], ["in", 415], ["SK", 418], ["-", 420], ["N", 421], ["-", 422], ["SH", 423], ["cells", 426], ["and", 432], ["primary", 436], ["neurons", 444], ["led", 452], ["to", 456], ["PP2A", 459], ["/", 463], ["C", 464], ["phosphorylation", 466], ["at", 482], ["Y307", 485], [",", 489], ["a", 491], ["known", 493], ["target", 499], ["of", 506], ["Src", 509], ["kinase", 513], [",", 519], ["and", 521], ["consequent", 525], ["phosphatase", 536], ["inhibition", 548], [".", 558], ["In", 560], ["addition", 563], [",", 571], ["phospho", 573], ["-", 580], ["activated", 581], ["Src", 591], ["(", 595], ["p", 596], ["-", 597], ["Y416", 598], ["Src", 603], [",", 606], ["pSrc", 608], [")", 612], ["was", 614], ["higher", 618], ["in", 625], ["SK", 628], ["-", 630], ["N", 631], ["-", 632], ["SH", 633], ["cells", 636], ["and", 642], ["primary", 646], ["neurons", 654], ["overexpressing", 662], ["\u03b1", 677], ["-", 678], ["Syn", 679], [".", 682], ["Thus", 684], [",", 688], ["\u03b1", 690], ["-", 691], ["Syn", 692], ["may", 696], ["promote", 700], ["Src", 708], ["activation", 712], ["and", 723], ["PP2A", 727], ["inactivation", 732], [",", 744], ["leading", 746], ["to", 754], ["hyperphosphorylation", 757], ["of", 778], ["proteins", 781], [".", 789], ["Immunoprecipitation", 791], ["revealed", 811], ["higher", 820], ["calmodulin", 827], ["/", 837], ["Src", 838], ["complex", 842], ["formation", 850], ["in", 860], ["\u03b1", 863], ["-", 864], ["Syn", 865], ["-", 868], ["overexpressing", 869], ["cells", 884], ["and", 890], ["\u03b1", 894], ["-", 895], ["Syn", 896], ["transgenic", 900], ["mice", 911], [".", 915], ["A", 917], ["TUNEL", 919], ["apoptosis", 925], ["assay", 935], ["and", 941], ["an", 945], ["MTT", 948], ["cell", 952], ["viability", 957], ["assay", 967], ["demonstrated", 973], ["that", 986], ["the", 991], ["PP2A", 995], ["activator", 1000], ["C2-ceramide", 1010], ["protected", 1022], ["neurons", 1032], ["against", 1040], ["\u03b1", 1048], ["-", 1049], ["Syn", 1050], ["-", 1053], ["induced", 1054], ["cell", 1062], ["injury", 1067], [".", 1073], ["Buffering", 1075], ["the", 1085], ["Ca(2", 1089], ["+", 1093], [")", 1094], ["elevations", 1096], ["induced", 1107], ["by", 1115], ["\u03b1", 1118], ["-", 1119], ["Syn", 1120], ["overexpression", 1124], ["ameliorated", 1139], ["the", 1151], ["cytotoxicity", 1155], ["of", 1168], ["\u03b1", 1171], ["-", 1172], ["Syn", 1173], [".", 1176], ["Our", 1178], ["findings", 1182], ["define", 1191], ["a", 1198], ["potential", 1200], ["molecular", 1210], ["mechanism", 1220], ["for", 1230], ["\u03b1", 1234], ["-", 1235], ["Syn", 1236], ["-", 1239], ["mediated", 1240], ["regulation", 1249], ["of", 1260], ["PP2A", 1263], ["through", 1268], ["formation", 1276], ["of", 1286], ["the", 1289], ["calmodulin", 1293], ["/", 1303], ["Src", 1304], ["complex", 1308], [",", 1315], ["activation", 1317], ["of", 1328], ["Src", 1331], [",", 1334], ["and", 1336], ["Src", 1340], ["-", 1343], ["mediated", 1344], ["phospho", 1353], ["-", 1360], ["inhibition", 1361], ["of", 1372], ["PP2A.", 1375], ["Overexpression", 1381], ["of", 1396], ["\u03b1", 1399], ["-", 1400], ["Syn", 1401], ["may", 1405], ["lead", 1409], ["to", 1414], ["neurodegeneration", 1417], ["in", 1435], ["PD", 1438], ["in", 1441], ["part", 1444], ["by", 1449], ["suppressing", 1452], ["the", 1464], ["endogenous", 1468], ["neuroprotective", 1479], ["activity", 1495], ["of", 1504], ["PP2A.", 1507]]}
{"context": "Chediak-Higashi syndrome (CHS) is a rare autosomal recessive disease characterized by variable degrees of oculocutaneous albinism, recurrent infections, and a mild bleeding tendency, with late neurologic dysfunction. Most patients also undergo an accelerated phase of lymphohistiocytosis and die at an early age unless they receive an allogeneic hematopoietic stem cell transplant (SCT). Mutations in the CHS1 (LYST) gene result in CHS. Here, we describe an adopted infant who is compound heterozygous for two novel CHS1 gene mutations, both of which are predicted to result in truncated proteins. The two mutations are a nonsense mutation (c.1540 C>T, CGA>TGA, R514X) in exon 5 and a one base pair deletion (del c.9893T, F3298fsX3304) in exon 43, coding for part of the CHS1 protein's BEACH domain. These two newly described mutations are expected to give rise to a severe phenotype and, indeed, the patient had absolutely no cytotoxicity by natural killer cells or cytotoxic lymphocytes prior to his allogeneic SCT.", "qas": [{"question": "Which syndrome is associated with mutations in the LYST gene?", "answers": ["Chediak-Higashi syndrome"], "qid": "08de58bba59d48acbc705a1f43e25d57", "question_tokens": [["Which", 0], ["syndrome", 6], ["is", 15], ["associated", 18], ["with", 29], ["mutations", 34], ["in", 44], ["the", 47], ["LYST", 51], ["gene", 56], ["?", 60]], "detected_answers": [{"text": "Chediak-Higashi syndrome", "token_spans": [[0, 3]], "char_spans": [[0, 23]]}]}], "context_tokens": [["Chediak", 0], ["-", 7], ["Higashi", 8], ["syndrome", 16], ["(", 25], ["CHS", 26], [")", 29], ["is", 31], ["a", 34], ["rare", 36], ["autosomal", 41], ["recessive", 51], ["disease", 61], ["characterized", 69], ["by", 83], ["variable", 86], ["degrees", 95], ["of", 103], ["oculocutaneous", 106], ["albinism", 121], [",", 129], ["recurrent", 131], ["infections", 141], [",", 151], ["and", 153], ["a", 157], ["mild", 159], ["bleeding", 164], ["tendency", 173], [",", 181], ["with", 183], ["late", 188], ["neurologic", 193], ["dysfunction", 204], [".", 215], ["Most", 217], ["patients", 222], ["also", 231], ["undergo", 236], ["an", 244], ["accelerated", 247], ["phase", 259], ["of", 265], ["lymphohistiocytosis", 268], ["and", 288], ["die", 292], ["at", 296], ["an", 299], ["early", 302], ["age", 308], ["unless", 312], ["they", 319], ["receive", 324], ["an", 332], ["allogeneic", 335], ["hematopoietic", 346], ["stem", 360], ["cell", 365], ["transplant", 370], ["(", 381], ["SCT", 382], [")", 385], [".", 386], ["Mutations", 388], ["in", 398], ["the", 401], ["CHS1", 405], ["(", 410], ["LYST", 411], [")", 415], ["gene", 417], ["result", 422], ["in", 429], ["CHS", 432], [".", 435], ["Here", 437], [",", 441], ["we", 443], ["describe", 446], ["an", 455], ["adopted", 458], ["infant", 466], ["who", 473], ["is", 477], ["compound", 480], ["heterozygous", 489], ["for", 502], ["two", 506], ["novel", 510], ["CHS1", 516], ["gene", 521], ["mutations", 526], [",", 535], ["both", 537], ["of", 542], ["which", 545], ["are", 551], ["predicted", 555], ["to", 565], ["result", 568], ["in", 575], ["truncated", 578], ["proteins", 588], [".", 596], ["The", 598], ["two", 602], ["mutations", 606], ["are", 616], ["a", 620], ["nonsense", 622], ["mutation", 631], ["(", 640], ["c.1540", 641], ["C", 648], [">", 649], ["T", 650], [",", 651], ["CGA", 653], [">", 656], ["TGA", 657], [",", 660], ["R514X", 662], [")", 667], ["in", 669], ["exon", 672], ["5", 677], ["and", 679], ["a", 683], ["one", 685], ["base", 689], ["pair", 694], ["deletion", 699], ["(", 708], ["del", 709], ["c.9893", 713], ["T", 719], [",", 720], ["F3298fsX3304", 722], [")", 734], ["in", 736], ["exon", 739], ["43", 744], [",", 746], ["coding", 748], ["for", 755], ["part", 759], ["of", 764], ["the", 767], ["CHS1", 771], ["protein", 776], ["'s", 783], ["BEACH", 786], ["domain", 792], [".", 798], ["These", 800], ["two", 806], ["newly", 810], ["described", 816], ["mutations", 826], ["are", 836], ["expected", 840], ["to", 849], ["give", 852], ["rise", 857], ["to", 862], ["a", 865], ["severe", 867], ["phenotype", 874], ["and", 884], [",", 887], ["indeed", 889], [",", 895], ["the", 897], ["patient", 901], ["had", 909], ["absolutely", 913], ["no", 924], ["cytotoxicity", 927], ["by", 940], ["natural", 943], ["killer", 951], ["cells", 958], ["or", 964], ["cytotoxic", 967], ["lymphocytes", 977], ["prior", 989], ["to", 995], ["his", 998], ["allogeneic", 1002], ["SCT", 1013], [".", 1016]]}
{"context": "We describe the clinical characteristics and epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) in children with cystic fibrosis (CF) from the U.S. CF center with the highest MRSA prevalence. Medical records of children with CF were retrospectively reviewed from 1997-2009. MRSA clinical isolates from 2007-2009 were analyzed by polymerase chain reaction and pulsed field gel electrophoresis. The prevalence of MRSA was 1% in 1997 and 49% in 2009. Fifty-five children (26%) had persistent MRSA infection. Sixty-eight percent of MRSA isolates were hospital-associated (HA) MRSA, of which 52% were pulsed-field type USA 100. Ninety-three percent of HA MRSA isolates were clindamycin resistant. Twelve children acquired MRSA before 1 year of age, 83% of whom were hospitalized prior to acquisition of MRSA. Ten of 11 sibling pairs carried indistinguishable MRSA strains. Children with persistent MRSA were hospitalized more often (P\u2009=\u2009.01), required inhaled medications more frequently (P\u2009=\u2009.01), and had higher rates of Pseudomonas aeruginosa coinfection (P\u2009<\u2009.001). MRSA prevalence in children with CF is increasing, and most children are infected with HA MRSA. Exposure to health care facilities and gastrointestinal surgeries may facilitate early acquisition of MRSA. Siblings carry indistinguishable MRSA strains, indicating household transmission of MRSA. Children with persistent MRSA had worse pulmonary morbidity. Coinfection with MRSA and P aeruginosa is likely associated with further increased pulmonary morbidity.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "4e1c49bbf28c4f2e9198848bf13a61dc", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[32, 32], [139, 139], [171, 171], [243, 243], [250, 250], [71, 71], [263, 263], [14, 14], [130, 130], [255, 255], [207, 207], [49, 49], [110, 110], [93, 93], [101, 101], [165, 165], [156, 156], [238, 238], [223, 223]], "char_spans": [[191, 194], [733, 736], [909, 912], [1318, 1321], [1369, 1372], [427, 430], [1453, 1456], [106, 109], [666, 669], [1400, 1403], [1081, 1084], [290, 293], [588, 591], [505, 508], [544, 547], [870, 873], [814, 817], [1279, 1282], [1171, 1174]]}]}], "context_tokens": [["We", 0], ["describe", 3], ["the", 12], ["clinical", 16], ["characteristics", 25], ["and", 41], ["epidemiology", 45], ["of", 58], ["methicillin", 61], ["-", 72], ["resistant", 73], ["Staphylococcus", 83], ["aureus", 98], ["(", 105], ["MRSA", 106], [")", 110], ["in", 112], ["children", 115], ["with", 124], ["cystic", 129], ["fibrosis", 136], ["(", 145], ["CF", 146], [")", 148], ["from", 150], ["the", 155], ["U.S.", 159], ["CF", 164], ["center", 167], ["with", 174], ["the", 179], ["highest", 183], ["MRSA", 191], ["prevalence", 196], [".", 206], ["Medical", 208], ["records", 216], ["of", 224], ["children", 227], ["with", 236], ["CF", 241], ["were", 244], ["retrospectively", 249], ["reviewed", 265], ["from", 274], ["1997", 279], ["-", 283], ["2009", 284], [".", 288], ["MRSA", 290], ["clinical", 295], ["isolates", 304], ["from", 313], ["2007", 318], ["-", 322], ["2009", 323], ["were", 328], ["analyzed", 333], ["by", 342], ["polymerase", 345], ["chain", 356], ["reaction", 362], ["and", 371], ["pulsed", 375], ["field", 382], ["gel", 388], ["electrophoresis", 392], [".", 407], ["The", 409], ["prevalence", 413], ["of", 424], ["MRSA", 427], ["was", 432], ["1", 436], ["%", 437], ["in", 439], ["1997", 442], ["and", 447], ["49", 451], ["%", 453], ["in", 455], ["2009", 458], [".", 462], ["Fifty", 464], ["-", 469], ["five", 470], ["children", 475], ["(", 484], ["26", 485], ["%", 487], [")", 488], ["had", 490], ["persistent", 494], ["MRSA", 505], ["infection", 510], [".", 519], ["Sixty", 521], ["-", 526], ["eight", 527], ["percent", 533], ["of", 541], ["MRSA", 544], ["isolates", 549], ["were", 558], ["hospital", 563], ["-", 571], ["associated", 572], ["(", 583], ["HA", 584], [")", 586], ["MRSA", 588], [",", 592], ["of", 594], ["which", 597], ["52", 603], ["%", 605], ["were", 607], ["pulsed", 612], ["-", 618], ["field", 619], ["type", 625], ["USA", 630], ["100", 634], [".", 637], ["Ninety", 639], ["-", 645], ["three", 646], ["percent", 652], ["of", 660], ["HA", 663], ["MRSA", 666], ["isolates", 671], ["were", 680], ["clindamycin", 685], ["resistant", 697], [".", 706], ["Twelve", 708], ["children", 715], ["acquired", 724], ["MRSA", 733], ["before", 738], ["1", 745], ["year", 747], ["of", 752], ["age", 755], [",", 758], ["83", 760], ["%", 762], ["of", 764], ["whom", 767], ["were", 772], ["hospitalized", 777], ["prior", 790], ["to", 796], ["acquisition", 799], ["of", 811], ["MRSA", 814], [".", 818], ["Ten", 820], ["of", 824], ["11", 827], ["sibling", 830], ["pairs", 838], ["carried", 844], ["indistinguishable", 852], ["MRSA", 870], ["strains", 875], [".", 882], ["Children", 884], ["with", 893], ["persistent", 898], ["MRSA", 909], ["were", 914], ["hospitalized", 919], ["more", 932], ["often", 937], ["(", 943], ["P", 944], ["=", 946], [".01", 948], [")", 951], [",", 952], ["required", 954], ["inhaled", 963], ["medications", 971], ["more", 983], ["frequently", 988], ["(", 999], ["P", 1000], ["=", 1002], [".01", 1004], [")", 1007], [",", 1008], ["and", 1010], ["had", 1014], ["higher", 1018], ["rates", 1025], ["of", 1031], ["Pseudomonas", 1034], ["aeruginosa", 1046], ["coinfection", 1057], ["(", 1069], ["P", 1070], ["<", 1072], [".001", 1074], [")", 1078], [".", 1079], ["MRSA", 1081], ["prevalence", 1086], ["in", 1097], ["children", 1100], ["with", 1109], ["CF", 1114], ["is", 1117], ["increasing", 1120], [",", 1130], ["and", 1132], ["most", 1136], ["children", 1141], ["are", 1150], ["infected", 1154], ["with", 1163], ["HA", 1168], ["MRSA", 1171], [".", 1175], ["Exposure", 1177], ["to", 1186], ["health", 1189], ["care", 1196], ["facilities", 1201], ["and", 1212], ["gastrointestinal", 1216], ["surgeries", 1233], ["may", 1243], ["facilitate", 1247], ["early", 1258], ["acquisition", 1264], ["of", 1276], ["MRSA", 1279], [".", 1283], ["Siblings", 1285], ["carry", 1294], ["indistinguishable", 1300], ["MRSA", 1318], ["strains", 1323], [",", 1330], ["indicating", 1332], ["household", 1343], ["transmission", 1353], ["of", 1366], ["MRSA", 1369], [".", 1373], ["Children", 1375], ["with", 1384], ["persistent", 1389], ["MRSA", 1400], ["had", 1405], ["worse", 1409], ["pulmonary", 1415], ["morbidity", 1425], [".", 1434], ["Coinfection", 1436], ["with", 1448], ["MRSA", 1453], ["and", 1458], ["P", 1462], ["aeruginosa", 1464], ["is", 1475], ["likely", 1478], ["associated", 1485], ["with", 1496], ["further", 1501], ["increased", 1509], ["pulmonary", 1519], ["morbidity", 1529], [".", 1538]]}
{"context": "McLeod syndrome and chorea-acanthocytosis are classified with the so-called neuroacanthocytosis group of syndromes. Both lead to progressive basal ganglia degeneration and were not easily distinguished in the past. With the discovery of their molecular bases, mutations of the X-linked gene XK and autosomal recessive mutations of the gene coding for chorein, respectively, the two phenotypes can now be differentiated and extend the diagnostic spectrum in patients presenting with chorea. The present review compares the two conditions and proposes a practical approach to diagnosis and treatment. Better-defined disease concepts should eventually replace the umbrella term of \"neuroacanthocytosis.\" Animal models are needed to understand the underlying mechanisms. A final common pathway is likely for the pathogenesis of these conditions and is most probably shared with Huntington's disease.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "4678fd2baf4f4fc2a3d6a5f6d70178ed", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[49, 49]], "char_spans": [[291, 292]]}]}], "context_tokens": [["McLeod", 0], ["syndrome", 7], ["and", 16], ["chorea", 20], ["-", 26], ["acanthocytosis", 27], ["are", 42], ["classified", 46], ["with", 57], ["the", 62], ["so", 66], ["-", 68], ["called", 69], ["neuroacanthocytosis", 76], ["group", 96], ["of", 102], ["syndromes", 105], [".", 114], ["Both", 116], ["lead", 121], ["to", 126], ["progressive", 129], ["basal", 141], ["ganglia", 147], ["degeneration", 155], ["and", 168], ["were", 172], ["not", 177], ["easily", 181], ["distinguished", 188], ["in", 202], ["the", 205], ["past", 209], [".", 213], ["With", 215], ["the", 220], ["discovery", 224], ["of", 234], ["their", 237], ["molecular", 243], ["bases", 253], [",", 258], ["mutations", 260], ["of", 270], ["the", 273], ["X", 277], ["-", 278], ["linked", 279], ["gene", 286], ["XK", 291], ["and", 294], ["autosomal", 298], ["recessive", 308], ["mutations", 318], ["of", 328], ["the", 331], ["gene", 335], ["coding", 340], ["for", 347], ["chorein", 351], [",", 358], ["respectively", 360], [",", 372], ["the", 374], ["two", 378], ["phenotypes", 382], ["can", 393], ["now", 397], ["be", 401], ["differentiated", 404], ["and", 419], ["extend", 423], ["the", 430], ["diagnostic", 434], ["spectrum", 445], ["in", 454], ["patients", 457], ["presenting", 466], ["with", 477], ["chorea", 482], [".", 488], ["The", 490], ["present", 494], ["review", 502], ["compares", 509], ["the", 518], ["two", 522], ["conditions", 526], ["and", 537], ["proposes", 541], ["a", 550], ["practical", 552], ["approach", 562], ["to", 571], ["diagnosis", 574], ["and", 584], ["treatment", 588], [".", 597], ["Better", 599], ["-", 605], ["defined", 606], ["disease", 614], ["concepts", 622], ["should", 631], ["eventually", 638], ["replace", 649], ["the", 657], ["umbrella", 661], ["term", 670], ["of", 675], ["\"", 678], ["neuroacanthocytosis", 679], [".", 698], ["\"", 699], ["Animal", 701], ["models", 708], ["are", 715], ["needed", 719], ["to", 726], ["understand", 729], ["the", 740], ["underlying", 744], ["mechanisms", 755], [".", 765], ["A", 767], ["final", 769], ["common", 775], ["pathway", 782], ["is", 790], ["likely", 793], ["for", 800], ["the", 804], ["pathogenesis", 808], ["of", 821], ["these", 824], ["conditions", 830], ["and", 841], ["is", 845], ["most", 848], ["probably", 853], ["shared", 862], ["with", 869], ["Huntington", 874], ["'s", 884], ["disease", 887], [".", 894]]}
{"context": "We previously identified a mammalian Set1A complex analogous to the yeast Set1/COMPASS histone H3-Lys4 methyltransferase complex (Lee, J.-H., and Skalnik, D. G. (2005) J. Biol. Chem. 280, 41725-41731). Data base analysis indicates that human Set1A protein shares 39% identity with an uncharacterized SET domain protein, KIAA1076, hereafter denoted Set1B. Immunoprecipitation and mass spectrometry reveal that Set1B associates with a approximately 450 kDa complex that contains all five non-catalytic components of the Set1A complex, including CFP1, Rbbp5, Ash2, Wdr5, and Wdr82. These data reveal two human protein complexes that differ only in the identity of the catalytic histone methyltransferase. In vitro assays demonstrate that the Set1B complex is a histone methyltransferase that produces trimethylated histone H3 at Lys(4). Both Set1A and Set1B are widely expressed. Inducible expression of the carboxyl terminus of either Set1A or Set1B decreases steady-state levels of both endogenous Set1A and Set1B protein, but does not alter the expression of the non-catalytic components of the Set1 complexes. A 123-amino acid fragment upstream of the Set1A SET domain is necessary for interaction with CFP1, Ash2, Rbbp5, and Wdr5. This protein domain is also required to mediate feedback inhibition of Set1A and Set1B expression, which is a consequence of reduced Set1A and Set1B stability when not associated with the methyltransferase complex. Confocal microscopy reveals that Set1A and Set1B each localize to a largely non-overlapping set of euchromatic nuclear speckles, suggesting that Set1A and Set1B each bind to a unique set of target genes and thus make non-redundant contributions to the epigenetic control of chromatin structure and gene expression.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "7b483c4cbcd8422c8a975ae0c76fa06c", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[56, 57], [201, 202]], "char_spans": [[300, 309], [1159, 1168]]}]}], "context_tokens": [["We", 0], ["previously", 3], ["identified", 14], ["a", 25], ["mammalian", 27], ["Set1A", 37], ["complex", 43], ["analogous", 51], ["to", 61], ["the", 64], ["yeast", 68], ["Set1/COMPASS", 74], ["histone", 87], ["H3-Lys4", 95], ["methyltransferase", 103], ["complex", 121], ["(", 129], ["Lee", 130], [",", 133], ["J.-H.", 135], [",", 140], ["and", 142], ["Skalnik", 146], [",", 153], ["D.", 155], ["G.", 158], ["(", 161], ["2005", 162], [")", 166], ["J.", 168], ["Biol", 171], [".", 175], ["Chem", 177], [".", 181], ["280", 183], [",", 186], ["41725", 188], ["-", 193], ["41731", 194], [")", 199], [".", 200], ["Data", 202], ["base", 207], ["analysis", 212], ["indicates", 221], ["that", 231], ["human", 236], ["Set1A", 242], ["protein", 248], ["shares", 256], ["39", 263], ["%", 265], ["identity", 267], ["with", 276], ["an", 281], ["uncharacterized", 284], ["SET", 300], ["domain", 304], ["protein", 311], [",", 318], ["KIAA1076", 320], [",", 328], ["hereafter", 330], ["denoted", 340], ["Set1B.", 348], ["Immunoprecipitation", 355], ["and", 375], ["mass", 379], ["spectrometry", 384], ["reveal", 397], ["that", 404], ["Set1B", 409], ["associates", 415], ["with", 426], ["a", 431], ["approximately", 433], ["450", 447], ["kDa", 451], ["complex", 455], ["that", 463], ["contains", 468], ["all", 477], ["five", 481], ["non", 486], ["-", 489], ["catalytic", 490], ["components", 500], ["of", 511], ["the", 514], ["Set1A", 518], ["complex", 524], [",", 531], ["including", 533], ["CFP1", 543], [",", 547], ["Rbbp5", 549], [",", 554], ["Ash2", 556], [",", 560], ["Wdr5", 562], [",", 566], ["and", 568], ["Wdr82", 572], [".", 577], ["These", 579], ["data", 585], ["reveal", 590], ["two", 597], ["human", 601], ["protein", 607], ["complexes", 615], ["that", 625], ["differ", 630], ["only", 637], ["in", 642], ["the", 645], ["identity", 649], ["of", 658], ["the", 661], ["catalytic", 665], ["histone", 675], ["methyltransferase", 683], [".", 700], ["In", 702], ["vitro", 705], ["assays", 711], ["demonstrate", 718], ["that", 730], ["the", 735], ["Set1B", 739], ["complex", 745], ["is", 753], ["a", 756], ["histone", 758], ["methyltransferase", 766], ["that", 784], ["produces", 789], ["trimethylated", 798], ["histone", 812], ["H3", 820], ["at", 823], ["Lys(4", 826], [")", 831], [".", 832], ["Both", 834], ["Set1A", 839], ["and", 845], ["Set1B", 849], ["are", 855], ["widely", 859], ["expressed", 866], [".", 875], ["Inducible", 877], ["expression", 887], ["of", 898], ["the", 901], ["carboxyl", 905], ["terminus", 914], ["of", 923], ["either", 926], ["Set1A", 933], ["or", 939], ["Set1B", 942], ["decreases", 948], ["steady", 958], ["-", 964], ["state", 965], ["levels", 971], ["of", 978], ["both", 981], ["endogenous", 986], ["Set1A", 997], ["and", 1003], ["Set1B", 1007], ["protein", 1013], [",", 1020], ["but", 1022], ["does", 1026], ["not", 1031], ["alter", 1035], ["the", 1041], ["expression", 1045], ["of", 1056], ["the", 1059], ["non", 1063], ["-", 1066], ["catalytic", 1067], ["components", 1077], ["of", 1088], ["the", 1091], ["Set1", 1095], ["complexes", 1100], [".", 1109], ["A", 1111], ["123-amino", 1113], ["acid", 1123], ["fragment", 1128], ["upstream", 1137], ["of", 1146], ["the", 1149], ["Set1A", 1153], ["SET", 1159], ["domain", 1163], ["is", 1170], ["necessary", 1173], ["for", 1183], ["interaction", 1187], ["with", 1199], ["CFP1", 1204], [",", 1208], ["Ash2", 1210], [",", 1214], ["Rbbp5", 1216], [",", 1221], ["and", 1223], ["Wdr5", 1227], [".", 1231], ["This", 1233], ["protein", 1238], ["domain", 1246], ["is", 1253], ["also", 1256], ["required", 1261], ["to", 1270], ["mediate", 1273], ["feedback", 1281], ["inhibition", 1290], ["of", 1301], ["Set1A", 1304], ["and", 1310], ["Set1B", 1314], ["expression", 1320], [",", 1330], ["which", 1332], ["is", 1338], ["a", 1341], ["consequence", 1343], ["of", 1355], ["reduced", 1358], ["Set1A", 1366], ["and", 1372], ["Set1B", 1376], ["stability", 1382], ["when", 1392], ["not", 1397], ["associated", 1401], ["with", 1412], ["the", 1417], ["methyltransferase", 1421], ["complex", 1439], [".", 1446], ["Confocal", 1448], ["microscopy", 1457], ["reveals", 1468], ["that", 1476], ["Set1A", 1481], ["and", 1487], ["Set1B", 1491], ["each", 1497], ["localize", 1502], ["to", 1511], ["a", 1514], ["largely", 1516], ["non", 1524], ["-", 1527], ["overlapping", 1528], ["set", 1540], ["of", 1544], ["euchromatic", 1547], ["nuclear", 1559], ["speckles", 1567], [",", 1575], ["suggesting", 1577], ["that", 1588], ["Set1A", 1593], ["and", 1599], ["Set1B", 1603], ["each", 1609], ["bind", 1614], ["to", 1619], ["a", 1622], ["unique", 1624], ["set", 1631], ["of", 1635], ["target", 1638], ["genes", 1645], ["and", 1651], ["thus", 1655], ["make", 1660], ["non", 1665], ["-", 1668], ["redundant", 1669], ["contributions", 1679], ["to", 1693], ["the", 1696], ["epigenetic", 1700], ["control", 1711], ["of", 1719], ["chromatin", 1722], ["structure", 1732], ["and", 1742], ["gene", 1746], ["expression", 1751], [".", 1761]]}
{"context": "To validate the presence and demonstrate the clinical value of the type I interferon (IFN)-signature during arthritis development. In 115 seropositive arthralgia patients who were followed for the development of arthritis (Amsterdam Reade cohort), and 25 presymptomatic individuals who developed rheumatoid arthritis (RA) later, and 45 population-based controls (Northern Sweden cohort), the expression levels of 7 type I IFN response genes were determined with multiplex qPCR and an IFN-score was calculated. The diagnostic performance of the IFN-score was evaluated using Cox regression and Receiver Operating Characteristics (ROC)-curve analysis. In 44 of the 115 at-risk individuals (38%) from the Amsterdam Reade cohort, arthritis developed after a median period of 8 months (IQR 5-13). Stratification of these individuals based on the IFN-score revealed that 15 out of 25 IFN(high) individuals converted to arthritis, compared with 29 out of 90 IFN(low) individuals (p=0.011). In the Northern Sweden cohort, the level of the IFN-score was also significantly increased in presymptomatic individuals who developed RA compared with population-based controls (p=0.002). Cox regression analysis of the Amsterdam Reade cohort showed that the hazard ratio (HR) for development of arthritis was 2.38 (p=0.008) for IFN(high) at-risk individuals after correction for anticitrullinated protein antibodies (ACPA) and rheumatoid factor (RF). The ROC-curve area under the curve (AUC) for the IFN-score combined with ACPA and RF in the prediction of arthritis was 78.5% (p=0.0001, 95% CI 0.70 to 0.87). The results demonstrated clinical utility for the IFN-signature as a biomarker in the prediction of arthritis development.", "qas": [{"question": "Which is the most common gene signature in Rheumatoid Arthritis patients?", "answers": ["IFN-signature", "Interferon signature", "IFN signature"], "qid": "78f9bca0ee664b74b0be699e63138b9b", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["common", 18], ["gene", 25], ["signature", 30], ["in", 40], ["Rheumatoid", 43], ["Arthritis", 54], ["patients", 64], ["?", 72]], "detected_answers": [{"text": "IFN signature", "token_spans": [[307, 309]], "char_spans": [[1644, 1656]]}]}], "context_tokens": [["To", 0], ["validate", 3], ["the", 12], ["presence", 16], ["and", 25], ["demonstrate", 29], ["the", 41], ["clinical", 45], ["value", 54], ["of", 60], ["the", 63], ["type", 67], ["I", 72], ["interferon", 74], ["(", 85], ["IFN)-signature", 86], ["during", 101], ["arthritis", 108], ["development", 118], [".", 129], ["In", 131], ["115", 134], ["seropositive", 138], ["arthralgia", 151], ["patients", 162], ["who", 171], ["were", 175], ["followed", 180], ["for", 189], ["the", 193], ["development", 197], ["of", 209], ["arthritis", 212], ["(", 222], ["Amsterdam", 223], ["Reade", 233], ["cohort", 239], [")", 245], [",", 246], ["and", 248], ["25", 252], ["presymptomatic", 255], ["individuals", 270], ["who", 282], ["developed", 286], ["rheumatoid", 296], ["arthritis", 307], ["(", 317], ["RA", 318], [")", 320], ["later", 322], [",", 327], ["and", 329], ["45", 333], ["population", 336], ["-", 346], ["based", 347], ["controls", 353], ["(", 362], ["Northern", 363], ["Sweden", 372], ["cohort", 379], [")", 385], [",", 386], ["the", 388], ["expression", 392], ["levels", 403], ["of", 410], ["7", 413], ["type", 415], ["I", 420], ["IFN", 422], ["response", 426], ["genes", 435], ["were", 441], ["determined", 446], ["with", 457], ["multiplex", 462], ["qPCR", 472], ["and", 477], ["an", 481], ["IFN", 484], ["-", 487], ["score", 488], ["was", 494], ["calculated", 498], [".", 508], ["The", 510], ["diagnostic", 514], ["performance", 525], ["of", 537], ["the", 540], ["IFN", 544], ["-", 547], ["score", 548], ["was", 554], ["evaluated", 558], ["using", 568], ["Cox", 574], ["regression", 578], ["and", 589], ["Receiver", 593], ["Operating", 602], ["Characteristics", 612], ["(", 628], ["ROC)-curve", 629], ["analysis", 640], [".", 648], ["In", 650], ["44", 653], ["of", 656], ["the", 659], ["115", 663], ["at", 667], ["-", 669], ["risk", 670], ["individuals", 675], ["(", 687], ["38", 688], ["%", 690], [")", 691], ["from", 693], ["the", 698], ["Amsterdam", 702], ["Reade", 712], ["cohort", 718], [",", 724], ["arthritis", 726], ["developed", 736], ["after", 746], ["a", 752], ["median", 754], ["period", 761], ["of", 768], ["8", 771], ["months", 773], ["(", 780], ["IQR", 781], ["5", 785], ["-", 786], ["13", 787], [")", 789], [".", 790], ["Stratification", 792], ["of", 807], ["these", 810], ["individuals", 816], ["based", 828], ["on", 834], ["the", 837], ["IFN", 841], ["-", 844], ["score", 845], ["revealed", 851], ["that", 860], ["15", 865], ["out", 868], ["of", 872], ["25", 875], ["IFN(high", 878], [")", 886], ["individuals", 888], ["converted", 900], ["to", 910], ["arthritis", 913], [",", 922], ["compared", 924], ["with", 933], ["29", 938], ["out", 941], ["of", 945], ["90", 948], ["IFN(low", 951], [")", 958], ["individuals", 960], ["(", 972], ["p=0.011", 973], [")", 980], [".", 981], ["In", 983], ["the", 986], ["Northern", 990], ["Sweden", 999], ["cohort", 1006], [",", 1012], ["the", 1014], ["level", 1018], ["of", 1024], ["the", 1027], ["IFN", 1031], ["-", 1034], ["score", 1035], ["was", 1041], ["also", 1045], ["significantly", 1050], ["increased", 1064], ["in", 1074], ["presymptomatic", 1077], ["individuals", 1092], ["who", 1104], ["developed", 1108], ["RA", 1118], ["compared", 1121], ["with", 1130], ["population", 1135], ["-", 1145], ["based", 1146], ["controls", 1152], ["(", 1161], ["p=0.002", 1162], [")", 1169], [".", 1170], ["Cox", 1172], ["regression", 1176], ["analysis", 1187], ["of", 1196], ["the", 1199], ["Amsterdam", 1203], ["Reade", 1213], ["cohort", 1219], ["showed", 1226], ["that", 1233], ["the", 1238], ["hazard", 1242], ["ratio", 1249], ["(", 1255], ["HR", 1256], [")", 1258], ["for", 1260], ["development", 1264], ["of", 1276], ["arthritis", 1279], ["was", 1289], ["2.38", 1293], ["(", 1298], ["p=0.008", 1299], [")", 1306], ["for", 1308], ["IFN(high", 1312], [")", 1320], ["at", 1322], ["-", 1324], ["risk", 1325], ["individuals", 1330], ["after", 1342], ["correction", 1348], ["for", 1359], ["anticitrullinated", 1363], ["protein", 1381], ["antibodies", 1389], ["(", 1400], ["ACPA", 1401], [")", 1405], ["and", 1407], ["rheumatoid", 1411], ["factor", 1422], ["(", 1429], ["RF", 1430], [")", 1432], [".", 1433], ["The", 1435], ["ROC", 1439], ["-", 1442], ["curve", 1443], ["area", 1449], ["under", 1454], ["the", 1460], ["curve", 1464], ["(", 1470], ["AUC", 1471], [")", 1474], ["for", 1476], ["the", 1480], ["IFN", 1484], ["-", 1487], ["score", 1488], ["combined", 1494], ["with", 1503], ["ACPA", 1508], ["and", 1513], ["RF", 1517], ["in", 1520], ["the", 1523], ["prediction", 1527], ["of", 1538], ["arthritis", 1541], ["was", 1551], ["78.5", 1555], ["%", 1559], ["(", 1561], ["p=0.0001", 1562], [",", 1570], ["95", 1572], ["%", 1574], ["CI", 1576], ["0.70", 1579], ["to", 1584], ["0.87", 1587], [")", 1591], [".", 1592], ["The", 1594], ["results", 1598], ["demonstrated", 1606], ["clinical", 1619], ["utility", 1628], ["for", 1636], ["the", 1640], ["IFN", 1644], ["-", 1647], ["signature", 1648], ["as", 1658], ["a", 1661], ["biomarker", 1663], ["in", 1673], ["the", 1676], ["prediction", 1680], ["of", 1691], ["arthritis", 1694], ["development", 1704], [".", 1715]]}
{"context": "Ehlers-Danlos syndrome is an inherited connective tissue disorder. Clinical manifestations of this syndrome are due to fragile connective tissue. Though many cardiovascular disorders in association with it have been reported, myocardial infarction is quite rare. In this report, two cases with type 4 Ehlers-Danlos syndrome and myocardial infarction are described. Patient 1 was a 30-year-old woman. She was diagnosed as having myocardial infarction on the basis of typical changes in electrocardiograms and serum enzymes (CPK, SGOT and LDH). The diagnosis of type 4 Ehlers-Danlos syndrome was made by the microscopic examination of her connective tissue. Patient 2 was a 32-year-old man. He was also diagnosed as having acute myocardial infarction. His fibroblasts were cultured and they could not synthesize type 3 collagen. Type 4 Ehlers-Danlos syndrome was diagnosed. It was likely that myocardial infarction might have resulted from the fragility of their coronary arteries in type 4 Ehlers-Danlos syndrome.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "2400eadb605d444e87f69ff530a1856c", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[20, 21], [7, 8], [112, 113]], "char_spans": [[127, 143], [39, 55], [637, 653]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndrome", 14], ["is", 23], ["an", 26], ["inherited", 29], ["connective", 39], ["tissue", 50], ["disorder", 57], [".", 65], ["Clinical", 67], ["manifestations", 76], ["of", 91], ["this", 94], ["syndrome", 99], ["are", 108], ["due", 112], ["to", 116], ["fragile", 119], ["connective", 127], ["tissue", 138], [".", 144], ["Though", 146], ["many", 153], ["cardiovascular", 158], ["disorders", 173], ["in", 183], ["association", 186], ["with", 198], ["it", 203], ["have", 206], ["been", 211], ["reported", 216], [",", 224], ["myocardial", 226], ["infarction", 237], ["is", 248], ["quite", 251], ["rare", 257], [".", 261], ["In", 263], ["this", 266], ["report", 271], [",", 277], ["two", 279], ["cases", 283], ["with", 289], ["type", 294], ["4", 299], ["Ehlers", 301], ["-", 307], ["Danlos", 308], ["syndrome", 315], ["and", 324], ["myocardial", 328], ["infarction", 339], ["are", 350], ["described", 354], [".", 363], ["Patient", 365], ["1", 373], ["was", 375], ["a", 379], ["30-year", 381], ["-", 388], ["old", 389], ["woman", 393], [".", 398], ["She", 400], ["was", 404], ["diagnosed", 408], ["as", 418], ["having", 421], ["myocardial", 428], ["infarction", 439], ["on", 450], ["the", 453], ["basis", 457], ["of", 463], ["typical", 466], ["changes", 474], ["in", 482], ["electrocardiograms", 485], ["and", 504], ["serum", 508], ["enzymes", 514], ["(", 522], ["CPK", 523], [",", 526], ["SGOT", 528], ["and", 533], ["LDH", 537], [")", 540], [".", 541], ["The", 543], ["diagnosis", 547], ["of", 557], ["type", 560], ["4", 565], ["Ehlers", 567], ["-", 573], ["Danlos", 574], ["syndrome", 581], ["was", 590], ["made", 594], ["by", 599], ["the", 602], ["microscopic", 606], ["examination", 618], ["of", 630], ["her", 633], ["connective", 637], ["tissue", 648], [".", 654], ["Patient", 656], ["2", 664], ["was", 666], ["a", 670], ["32-year", 672], ["-", 679], ["old", 680], ["man", 684], [".", 687], ["He", 689], ["was", 692], ["also", 696], ["diagnosed", 701], ["as", 711], ["having", 714], ["acute", 721], ["myocardial", 727], ["infarction", 738], [".", 748], ["His", 750], ["fibroblasts", 754], ["were", 766], ["cultured", 771], ["and", 780], ["they", 784], ["could", 789], ["not", 795], ["synthesize", 799], ["type", 810], ["3", 815], ["collagen", 817], [".", 825], ["Type", 827], ["4", 832], ["Ehlers", 834], ["-", 840], ["Danlos", 841], ["syndrome", 848], ["was", 857], ["diagnosed", 861], [".", 870], ["It", 872], ["was", 875], ["likely", 879], ["that", 886], ["myocardial", 891], ["infarction", 902], ["might", 913], ["have", 919], ["resulted", 924], ["from", 933], ["the", 938], ["fragility", 942], ["of", 952], ["their", 955], ["coronary", 961], ["arteries", 970], ["in", 979], ["type", 982], ["4", 987], ["Ehlers", 989], ["-", 995], ["Danlos", 996], ["syndrome", 1003], [".", 1011]]}
{"context": "Suppression subtractive hybridization performed on Down syndrome (DS) versus control fetal brains revealed differential expression of peroxiredoxin 2 (PRDX2), mapped at 13q12. Peroxiredoxins are antioxidant enzymes involved in protein and lipid protection against oxidative injury and in cellular signalling pathways regulating apoptosis. The under-expression of PRDX2 observed in DS samples was confirmed by real-time PCR (0.73-fold). To test whether decreased expression is associated with enhanced sensitivity of DS neurons to reactive oxygen species, we down-regulated PRDX2 through stable transfections of SH-SY5Y neuroblastoma cells with antisense contructs of the complete PRDX2 coding sequence. In addition, we over-expressed SOD1 and compared the effects of the two genes on cell viability. Cells transfected with either construct showed similar sensitivity to oxidative stress in addition to increased apoptosis under basal conditions and after treatment with oxidative cytotoxic agents. This suggests that the decreased expression of PRDX2 may contribute to the altered redox state in DS at levels comparable to that of the increased expression of SOD1.", "qas": [{"question": "What type of enzyme is peroxiredoxin 2 (PRDX2)?", "answers": ["antioxidant"], "qid": "733e977ad4f14caf9148b8dbb151fd8c", "question_tokens": [["What", 0], ["type", 5], ["of", 10], ["enzyme", 13], ["is", 20], ["peroxiredoxin", 23], ["2", 37], ["(", 39], ["PRDX2", 40], [")", 45], ["?", 46]], "detected_answers": [{"text": "antioxidant", "token_spans": [[30, 30]], "char_spans": [[195, 205]]}]}], "context_tokens": [["Suppression", 0], ["subtractive", 12], ["hybridization", 24], ["performed", 38], ["on", 48], ["Down", 51], ["syndrome", 56], ["(", 65], ["DS", 66], [")", 68], ["versus", 70], ["control", 77], ["fetal", 85], ["brains", 91], ["revealed", 98], ["differential", 107], ["expression", 120], ["of", 131], ["peroxiredoxin", 134], ["2", 148], ["(", 150], ["PRDX2", 151], [")", 156], [",", 157], ["mapped", 159], ["at", 166], ["13q12", 169], [".", 174], ["Peroxiredoxins", 176], ["are", 191], ["antioxidant", 195], ["enzymes", 207], ["involved", 215], ["in", 224], ["protein", 227], ["and", 235], ["lipid", 239], ["protection", 245], ["against", 256], ["oxidative", 264], ["injury", 274], ["and", 281], ["in", 285], ["cellular", 288], ["signalling", 297], ["pathways", 308], ["regulating", 317], ["apoptosis", 328], [".", 337], ["The", 339], ["under", 343], ["-", 348], ["expression", 349], ["of", 360], ["PRDX2", 363], ["observed", 369], ["in", 378], ["DS", 381], ["samples", 384], ["was", 392], ["confirmed", 396], ["by", 406], ["real", 409], ["-", 413], ["time", 414], ["PCR", 419], ["(", 423], ["0.73-fold", 424], [")", 433], [".", 434], ["To", 436], ["test", 439], ["whether", 444], ["decreased", 452], ["expression", 462], ["is", 473], ["associated", 476], ["with", 487], ["enhanced", 492], ["sensitivity", 501], ["of", 513], ["DS", 516], ["neurons", 519], ["to", 527], ["reactive", 530], ["oxygen", 539], ["species", 546], [",", 553], ["we", 555], ["down", 558], ["-", 562], ["regulated", 563], ["PRDX2", 573], ["through", 579], ["stable", 587], ["transfections", 594], ["of", 608], ["SH", 611], ["-", 613], ["SY5Y", 614], ["neuroblastoma", 619], ["cells", 633], ["with", 639], ["antisense", 644], ["contructs", 654], ["of", 664], ["the", 667], ["complete", 671], ["PRDX2", 680], ["coding", 686], ["sequence", 693], [".", 701], ["In", 703], ["addition", 706], [",", 714], ["we", 716], ["over", 719], ["-", 723], ["expressed", 724], ["SOD1", 734], ["and", 739], ["compared", 743], ["the", 752], ["effects", 756], ["of", 764], ["the", 767], ["two", 771], ["genes", 775], ["on", 781], ["cell", 784], ["viability", 789], [".", 798], ["Cells", 800], ["transfected", 806], ["with", 818], ["either", 823], ["construct", 830], ["showed", 840], ["similar", 847], ["sensitivity", 855], ["to", 867], ["oxidative", 870], ["stress", 880], ["in", 887], ["addition", 890], ["to", 899], ["increased", 902], ["apoptosis", 912], ["under", 922], ["basal", 928], ["conditions", 934], ["and", 945], ["after", 949], ["treatment", 955], ["with", 965], ["oxidative", 970], ["cytotoxic", 980], ["agents", 990], [".", 996], ["This", 998], ["suggests", 1003], ["that", 1012], ["the", 1017], ["decreased", 1021], ["expression", 1031], ["of", 1042], ["PRDX2", 1045], ["may", 1051], ["contribute", 1055], ["to", 1066], ["the", 1069], ["altered", 1073], ["redox", 1081], ["state", 1087], ["in", 1093], ["DS", 1096], ["at", 1099], ["levels", 1102], ["comparable", 1109], ["to", 1120], ["that", 1123], ["of", 1128], ["the", 1131], ["increased", 1135], ["expression", 1145], ["of", 1156], ["SOD1", 1159], [".", 1163]]}
{"context": "Systemic autoinflammatory diseases are caused by mutations in genes that function in innate immunity. Here, we report an autoinflammatory disease caused by loss-of-function mutations in OTULIN (FAM105B), encoding a deubiquitinase with linear linkage specificity. We identified two missense and one frameshift mutations in one Pakistani and two Turkish families with four affected patients. Patients presented with neonatal-onset fever, neutrophilic dermatitis/panniculitis, and failure to thrive, but without obvious primary immunodeficiency. HEK293 cells transfected with mutated OTULIN had decreased enzyme activity relative to cells transfected with WT OTULIN, and showed a substantial defect in the linear deubiquitination of target molecules. Stimulated patients' fibroblasts and peripheral blood mononuclear cells showed evidence for increased signaling in the canonical NF-\u03baB pathway and accumulated linear ubiquitin aggregates. Levels of proinflammatory cytokines were significantly increased in the supernatants of stimulated primary cells and serum samples. This discovery adds to the emerging spectrum of human diseases caused by defects in the ubiquitin pathway and suggests a role for targeted cytokine therapies.", "qas": [{"question": "Which is the enzymatic activity of OTULIN?", "answers": ["deubiquitination"], "qid": "f85c2449871b49c598f41e1f233256be", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["enzymatic", 13], ["activity", 23], ["of", 32], ["OTULIN", 35], ["?", 41]], "detected_answers": [{"text": "deubiquitination", "token_spans": [[114, 114]], "char_spans": [[710, 725]]}]}], "context_tokens": [["Systemic", 0], ["autoinflammatory", 9], ["diseases", 26], ["are", 35], ["caused", 39], ["by", 46], ["mutations", 49], ["in", 59], ["genes", 62], ["that", 68], ["function", 73], ["in", 82], ["innate", 85], ["immunity", 92], [".", 100], ["Here", 102], [",", 106], ["we", 108], ["report", 111], ["an", 118], ["autoinflammatory", 121], ["disease", 138], ["caused", 146], ["by", 153], ["loss", 156], ["-", 160], ["of", 161], ["-", 163], ["function", 164], ["mutations", 173], ["in", 183], ["OTULIN", 186], ["(", 193], ["FAM105B", 194], [")", 201], [",", 202], ["encoding", 204], ["a", 213], ["deubiquitinase", 215], ["with", 230], ["linear", 235], ["linkage", 242], ["specificity", 250], [".", 261], ["We", 263], ["identified", 266], ["two", 277], ["missense", 281], ["and", 290], ["one", 294], ["frameshift", 298], ["mutations", 309], ["in", 319], ["one", 322], ["Pakistani", 326], ["and", 336], ["two", 340], ["Turkish", 344], ["families", 352], ["with", 361], ["four", 366], ["affected", 371], ["patients", 380], [".", 388], ["Patients", 390], ["presented", 399], ["with", 409], ["neonatal", 414], ["-", 422], ["onset", 423], ["fever", 429], [",", 434], ["neutrophilic", 436], ["dermatitis", 449], ["/", 459], ["panniculitis", 460], [",", 472], ["and", 474], ["failure", 478], ["to", 486], ["thrive", 489], [",", 495], ["but", 497], ["without", 501], ["obvious", 509], ["primary", 517], ["immunodeficiency", 525], [".", 541], ["HEK293", 543], ["cells", 550], ["transfected", 556], ["with", 568], ["mutated", 573], ["OTULIN", 581], ["had", 588], ["decreased", 592], ["enzyme", 602], ["activity", 609], ["relative", 618], ["to", 627], ["cells", 630], ["transfected", 636], ["with", 648], ["WT", 653], ["OTULIN", 656], [",", 662], ["and", 664], ["showed", 668], ["a", 675], ["substantial", 677], ["defect", 689], ["in", 696], ["the", 699], ["linear", 703], ["deubiquitination", 710], ["of", 727], ["target", 730], ["molecules", 737], [".", 746], ["Stimulated", 748], ["patients", 759], ["'", 767], ["fibroblasts", 769], ["and", 781], ["peripheral", 785], ["blood", 796], ["mononuclear", 802], ["cells", 814], ["showed", 820], ["evidence", 827], ["for", 836], ["increased", 840], ["signaling", 850], ["in", 860], ["the", 863], ["canonical", 867], ["NF", 877], ["-", 879], ["\u03baB", 880], ["pathway", 883], ["and", 891], ["accumulated", 895], ["linear", 907], ["ubiquitin", 914], ["aggregates", 924], [".", 934], ["Levels", 936], ["of", 943], ["proinflammatory", 946], ["cytokines", 962], ["were", 972], ["significantly", 977], ["increased", 991], ["in", 1001], ["the", 1004], ["supernatants", 1008], ["of", 1021], ["stimulated", 1024], ["primary", 1035], ["cells", 1043], ["and", 1049], ["serum", 1053], ["samples", 1059], [".", 1066], ["This", 1068], ["discovery", 1073], ["adds", 1083], ["to", 1088], ["the", 1091], ["emerging", 1095], ["spectrum", 1104], ["of", 1113], ["human", 1116], ["diseases", 1122], ["caused", 1131], ["by", 1138], ["defects", 1141], ["in", 1149], ["the", 1152], ["ubiquitin", 1156], ["pathway", 1166], ["and", 1174], ["suggests", 1178], ["a", 1187], ["role", 1189], ["for", 1194], ["targeted", 1198], ["cytokine", 1207], ["therapies", 1216], [".", 1225]]}
{"context": "Lack of specific antidotes is a major concern in intracerebral hemorrhage (ICH) related to direct anticoagulants including dabigatran (OAC-ICH). We examined the efficacy of idarucizumab, an antibody fragment binding to dabigatran, in a mouse model of OAC-ICH. Dabigatran etexilate (DE) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab. Pretreatment with DE increased intracerebral hematoma volume and cerebral hemoglobin content. Idarucizumab in equimolar dose prevented excess hematoma expansion for both DE doses. In more extensive ICH, idarucizumab significantly reduced mortality. Thus, idarucizumab prevents excess intracerebral hematoma formation in mice anticoagulated with dabigatran and reduces mortality.", "qas": [{"question": "Idarucizumab is an antidote of which drug?", "answers": ["dabigatran"], "qid": "37ea67d513cc47e680a8cad150662beb", "question_tokens": [["Idarucizumab", 0], ["is", 13], ["an", 16], ["antidote", 19], ["of", 28], ["which", 31], ["drug", 37], ["?", 41]], "detected_answers": [{"text": "dabigatran", "token_spans": [[121, 121], [19, 19], [49, 49], [38, 38]], "char_spans": [[746, 755], [123, 132], [260, 269], [219, 228]]}]}], "context_tokens": [["Lack", 0], ["of", 5], ["specific", 8], ["antidotes", 17], ["is", 27], ["a", 30], ["major", 32], ["concern", 38], ["in", 46], ["intracerebral", 49], ["hemorrhage", 63], ["(", 74], ["ICH", 75], [")", 78], ["related", 80], ["to", 88], ["direct", 91], ["anticoagulants", 98], ["including", 113], ["dabigatran", 123], ["(", 134], ["OAC", 135], ["-", 138], ["ICH", 139], [")", 142], [".", 143], ["We", 145], ["examined", 148], ["the", 157], ["efficacy", 161], ["of", 170], ["idarucizumab", 173], [",", 185], ["an", 187], ["antibody", 190], ["fragment", 199], ["binding", 208], ["to", 216], ["dabigatran", 219], [",", 229], ["in", 231], ["a", 234], ["mouse", 236], ["model", 242], ["of", 248], ["OAC", 251], ["-", 254], ["ICH", 255], [".", 258], ["Dabigatran", 260], ["etexilate", 271], ["(", 281], ["DE", 282], [")", 284], ["dose", 286], ["-", 290], ["dependently", 291], ["prolonged", 303], ["diluted", 313], ["thrombin", 321], ["time", 330], ["and", 335], ["tail", 339], ["-", 343], ["vein", 344], ["bleeding", 349], ["time", 358], [",", 362], ["which", 364], ["were", 370], ["reversed", 375], ["by", 384], ["idarucizumab", 387], [".", 399], ["Pretreatment", 401], ["with", 414], ["DE", 419], ["increased", 422], ["intracerebral", 432], ["hematoma", 446], ["volume", 455], ["and", 462], ["cerebral", 466], ["hemoglobin", 475], ["content", 486], [".", 493], ["Idarucizumab", 495], ["in", 508], ["equimolar", 511], ["dose", 521], ["prevented", 526], ["excess", 536], ["hematoma", 543], ["expansion", 552], ["for", 562], ["both", 566], ["DE", 571], ["doses", 574], [".", 579], ["In", 581], ["more", 584], ["extensive", 589], ["ICH", 599], [",", 602], ["idarucizumab", 604], ["significantly", 617], ["reduced", 631], ["mortality", 639], [".", 648], ["Thus", 650], [",", 654], ["idarucizumab", 656], ["prevents", 669], ["excess", 678], ["intracerebral", 685], ["hematoma", 699], ["formation", 708], ["in", 718], ["mice", 721], ["anticoagulated", 726], ["with", 741], ["dabigatran", 746], ["and", 757], ["reduces", 761], ["mortality", 769], [".", 778]]}
{"context": "Lewy bodies and coarse Lewy neurites are the pathological hallmarks of degenerating neurons in the brains of patients suffering from Parkinson's disease (PD). Recently, the presynaptic protein alpha-synuclein was shown to be a major component of Lewy bodies and Lewy neurites. This study demonstrates for the first time that extensive and thin alpha-synuclein-immunoreactive inclusions are present in the axonal processes of neurons.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "62d0c93b45ca401ca522395ff2d09c8b", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[60, 62], [32, 34]], "char_spans": [[344, 358], [193, 207]]}]}], "context_tokens": [["Lewy", 0], ["bodies", 5], ["and", 12], ["coarse", 16], ["Lewy", 23], ["neurites", 28], ["are", 37], ["the", 41], ["pathological", 45], ["hallmarks", 58], ["of", 68], ["degenerating", 71], ["neurons", 84], ["in", 92], ["the", 95], ["brains", 99], ["of", 106], ["patients", 109], ["suffering", 118], ["from", 128], ["Parkinson", 133], ["'s", 142], ["disease", 145], ["(", 153], ["PD", 154], [")", 156], [".", 157], ["Recently", 159], [",", 167], ["the", 169], ["presynaptic", 173], ["protein", 185], ["alpha", 193], ["-", 198], ["synuclein", 199], ["was", 209], ["shown", 213], ["to", 219], ["be", 222], ["a", 225], ["major", 227], ["component", 233], ["of", 243], ["Lewy", 246], ["bodies", 251], ["and", 258], ["Lewy", 262], ["neurites", 267], [".", 275], ["This", 277], ["study", 282], ["demonstrates", 288], ["for", 301], ["the", 305], ["first", 309], ["time", 315], ["that", 320], ["extensive", 325], ["and", 335], ["thin", 339], ["alpha", 344], ["-", 349], ["synuclein", 350], ["-", 359], ["immunoreactive", 360], ["inclusions", 375], ["are", 386], ["present", 390], ["in", 398], ["the", 401], ["axonal", 405], ["processes", 412], ["of", 422], ["neurons", 425], [".", 432]]}
{"context": "Sodium-glucose cotransporter 2 (SGLT2) inhibitors lower glycemia by enhancing urinary glucose excretion. The physiologic response to pharmacologically induced acute or chronic glycosuria has not been investigated in human diabetes. We evaluated 66 patients with type 2 diabetes (62 \u00b1 7 years, BMI = 31.6 \u00b1 4.6 kg/m(2), HbA1c = 55 \u00b1 8 mmol/mol, mean \u00b1 SD) at baseline, after a single dose, and following 4-week treatment with empagliflozin (25 mg). At each time point, patients received a mixed meal coupled with dual-tracer glucose administration and indirect calorimetry. Both single-dose and chronic empagliflozin treatment caused glycosuria during fasting (median, 7.8 [interquartile range {IQR}, 4.4] g/3 hours and 9.2 [IQR, 5.2] g/3 hours) and after meal ingestion (median, 29.0 [IQR, 12.5] g/5 hours and 28.2 [IQR, 15.4] g/5 hours). After 3 hours of fasting, endogenous glucose production (EGP) was increased 25%, while glycemia was 0.9 \u00b1 0.7 mmol/l lower (P < 0.0001 vs. baseline). After meal ingestion, glucose and insulin AUC decreased, whereas the glucagon response increased (all P < 0.001). While oral glucose appearance was unchanged, EGP was increased (median, 40 [IQR, 14] g and 37 [IQR, 11] g vs. 34 [IQR, 11] g, both P < 0.01). Tissue glucose disposal was reduced (median, 75 [IQR, 16] g and 70 [IQR, 21] g vs. 93 [IQR, 18] g, P < 0.0001), due to a decrease in both glucose oxidation and nonoxidative glucose disposal, with a concomitant rise in lipid oxidation after chronic administration (all P < 0.01). \u03b2 Cell glucose sensitivity increased (median, 55 [IQR, 35] pmol \u2022 min(-1) \u2022 m(-2) \u2022 mM(-1) and 55 [IQR, 39] pmol \u2022 min(-1) \u2022 m(-2) \u2022 mM(-1) vs. 44 [IQR, 32] pmol \u2022 min(-1) \u2022 m(-2) \u2022 mM(-1), P < 0.0001), and insulin sensitivity was improved. Resting energy expenditure rates and those after meal ingestion were unchanged. In patients with type 2 diabetes, empagliflozin-induced glycosuria improved \u03b2 cell function and insulin sensitivity, despite the fall in insulin secretion and tissue glucose disposal and the rise in EGP after one dose, thereby lowering fasting and postprandial glycemia. Chronic dosing shifted substrate utilization from carbohydrate to lipid. Trial registration. ClinicalTrials.Gov NCT01248364 (EudraCT no. 2010-018708-99). Funding. This study was funded by Boehringer Ingelheim.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "b5538b30d15c497e8eafc6e1d38b50cf", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[6, 6]], "char_spans": [[32, 36]]}]}], "context_tokens": [["Sodium", 0], ["-", 6], ["glucose", 7], ["cotransporter", 15], ["2", 29], ["(", 31], ["SGLT2", 32], [")", 37], ["inhibitors", 39], ["lower", 50], ["glycemia", 56], ["by", 65], ["enhancing", 68], ["urinary", 78], ["glucose", 86], ["excretion", 94], [".", 103], ["The", 105], ["physiologic", 109], ["response", 121], ["to", 130], ["pharmacologically", 133], ["induced", 151], ["acute", 159], ["or", 165], ["chronic", 168], ["glycosuria", 176], ["has", 187], ["not", 191], ["been", 195], ["investigated", 200], ["in", 213], ["human", 216], ["diabetes", 222], [".", 230], ["We", 232], ["evaluated", 235], ["66", 245], ["patients", 248], ["with", 257], ["type", 262], ["2", 267], ["diabetes", 269], ["(", 278], ["62", 279], ["\u00b1", 282], ["7", 284], ["years", 286], [",", 291], ["BMI", 293], ["=", 297], ["31.6", 299], ["\u00b1", 304], ["4.6", 306], ["kg", 310], ["/", 312], ["m(2", 313], [")", 316], [",", 317], ["HbA1c", 319], ["=", 325], ["55", 327], ["\u00b1", 330], ["8", 332], ["mmol", 334], ["/", 338], ["mol", 339], [",", 342], ["mean", 344], ["\u00b1", 349], ["SD", 351], [")", 353], ["at", 355], ["baseline", 358], [",", 366], ["after", 368], ["a", 374], ["single", 376], ["dose", 383], [",", 387], ["and", 389], ["following", 393], ["4-week", 403], ["treatment", 410], ["with", 420], ["empagliflozin", 425], ["(", 439], ["25", 440], ["mg", 443], [")", 445], [".", 446], ["At", 448], ["each", 451], ["time", 456], ["point", 461], [",", 466], ["patients", 468], ["received", 477], ["a", 486], ["mixed", 488], ["meal", 494], ["coupled", 499], ["with", 507], ["dual", 512], ["-", 516], ["tracer", 517], ["glucose", 524], ["administration", 532], ["and", 547], ["indirect", 551], ["calorimetry", 560], [".", 571], ["Both", 573], ["single", 578], ["-", 584], ["dose", 585], ["and", 590], ["chronic", 594], ["empagliflozin", 602], ["treatment", 616], ["caused", 626], ["glycosuria", 633], ["during", 644], ["fasting", 651], ["(", 659], ["median", 660], [",", 666], ["7.8", 668], ["[", 672], ["interquartile", 673], ["range", 687], ["{", 693], ["IQR", 694], ["}", 697], [",", 698], ["4.4", 700], ["]", 703], ["g/3", 705], ["hours", 709], ["and", 715], ["9.2", 719], ["[", 723], ["IQR", 724], [",", 727], ["5.2", 729], ["]", 732], ["g/3", 734], ["hours", 738], [")", 743], ["and", 745], ["after", 749], ["meal", 755], ["ingestion", 760], ["(", 770], ["median", 771], [",", 777], ["29.0", 779], ["[", 784], ["IQR", 785], [",", 788], ["12.5", 790], ["]", 794], ["g/5", 796], ["hours", 800], ["and", 806], ["28.2", 810], ["[", 815], ["IQR", 816], [",", 819], ["15.4", 821], ["]", 825], ["g/5", 827], ["hours", 831], [")", 836], [".", 837], ["After", 839], ["3", 845], ["hours", 847], ["of", 853], ["fasting", 856], [",", 863], ["endogenous", 865], ["glucose", 876], ["production", 884], ["(", 895], ["EGP", 896], [")", 899], ["was", 901], ["increased", 905], ["25", 915], ["%", 917], [",", 918], ["while", 920], ["glycemia", 926], ["was", 935], ["0.9", 939], ["\u00b1", 943], ["0.7", 945], ["mmol", 949], ["/", 953], ["l", 954], ["lower", 956], ["(", 962], ["P", 963], ["<", 965], ["0.0001", 967], ["vs.", 974], ["baseline", 978], [")", 986], [".", 987], ["After", 989], ["meal", 995], ["ingestion", 1000], [",", 1009], ["glucose", 1011], ["and", 1019], ["insulin", 1023], ["AUC", 1031], ["decreased", 1035], [",", 1044], ["whereas", 1046], ["the", 1054], ["glucagon", 1058], ["response", 1067], ["increased", 1076], ["(", 1086], ["all", 1087], ["P", 1091], ["<", 1093], ["0.001", 1095], [")", 1100], [".", 1101], ["While", 1103], ["oral", 1109], ["glucose", 1114], ["appearance", 1122], ["was", 1133], ["unchanged", 1137], [",", 1146], ["EGP", 1148], ["was", 1152], ["increased", 1156], ["(", 1166], ["median", 1167], [",", 1173], ["40", 1175], ["[", 1178], ["IQR", 1179], [",", 1182], ["14", 1184], ["]", 1186], ["g", 1188], ["and", 1190], ["37", 1194], ["[", 1197], ["IQR", 1198], [",", 1201], ["11", 1203], ["]", 1205], ["g", 1207], ["vs.", 1209], ["34", 1213], ["[", 1216], ["IQR", 1217], [",", 1220], ["11", 1222], ["]", 1224], ["g", 1226], [",", 1227], ["both", 1229], ["P", 1234], ["<", 1236], ["0.01", 1238], [")", 1242], [".", 1243], ["Tissue", 1245], ["glucose", 1252], ["disposal", 1260], ["was", 1269], ["reduced", 1273], ["(", 1281], ["median", 1282], [",", 1288], ["75", 1290], ["[", 1293], ["IQR", 1294], [",", 1297], ["16", 1299], ["]", 1301], ["g", 1303], ["and", 1305], ["70", 1309], ["[", 1312], ["IQR", 1313], [",", 1316], ["21", 1318], ["]", 1320], ["g", 1322], ["vs.", 1324], ["93", 1328], ["[", 1331], ["IQR", 1332], [",", 1335], ["18", 1337], ["]", 1339], ["g", 1341], [",", 1342], ["P", 1344], ["<", 1346], ["0.0001", 1348], [")", 1354], [",", 1355], ["due", 1357], ["to", 1361], ["a", 1364], ["decrease", 1366], ["in", 1375], ["both", 1378], ["glucose", 1383], ["oxidation", 1391], ["and", 1401], ["nonoxidative", 1405], ["glucose", 1418], ["disposal", 1426], [",", 1434], ["with", 1436], ["a", 1441], ["concomitant", 1443], ["rise", 1455], ["in", 1460], ["lipid", 1463], ["oxidation", 1469], ["after", 1479], ["chronic", 1485], ["administration", 1493], ["(", 1508], ["all", 1509], ["P", 1513], ["<", 1515], ["0.01", 1517], [")", 1521], [".", 1522], ["\u03b2", 1524], ["Cell", 1526], ["glucose", 1531], ["sensitivity", 1539], ["increased", 1551], ["(", 1561], ["median", 1562], [",", 1568], ["55", 1570], ["[", 1573], ["IQR", 1574], [",", 1577], ["35", 1579], ["]", 1581], ["pmol", 1583], ["\u2022", 1588], ["min(-1", 1590], [")", 1596], ["\u2022", 1598], ["m(-2", 1600], [")", 1604], ["\u2022", 1606], ["mM(-1", 1608], [")", 1613], ["and", 1615], ["55", 1619], ["[", 1622], ["IQR", 1623], [",", 1626], ["39", 1628], ["]", 1630], ["pmol", 1632], ["\u2022", 1637], ["min(-1", 1639], [")", 1645], ["\u2022", 1647], ["m(-2", 1649], [")", 1653], ["\u2022", 1655], ["mM(-1", 1657], [")", 1662], ["vs.", 1664], ["44", 1668], ["[", 1671], ["IQR", 1672], [",", 1675], ["32", 1677], ["]", 1679], ["pmol", 1681], ["\u2022", 1686], ["min(-1", 1688], [")", 1694], ["\u2022", 1696], ["m(-2", 1698], [")", 1702], ["\u2022", 1704], ["mM(-1", 1706], [")", 1711], [",", 1712], ["P", 1714], ["<", 1716], ["0.0001", 1718], [")", 1724], [",", 1725], ["and", 1727], ["insulin", 1731], ["sensitivity", 1739], ["was", 1751], ["improved", 1755], [".", 1763], ["Resting", 1765], ["energy", 1773], ["expenditure", 1780], ["rates", 1792], ["and", 1798], ["those", 1802], ["after", 1808], ["meal", 1814], ["ingestion", 1819], ["were", 1829], ["unchanged", 1834], [".", 1843], ["In", 1845], ["patients", 1848], ["with", 1857], ["type", 1862], ["2", 1867], ["diabetes", 1869], [",", 1877], ["empagliflozin", 1879], ["-", 1892], ["induced", 1893], ["glycosuria", 1901], ["improved", 1912], ["\u03b2", 1921], ["cell", 1923], ["function", 1928], ["and", 1937], ["insulin", 1941], ["sensitivity", 1949], [",", 1960], ["despite", 1962], ["the", 1970], ["fall", 1974], ["in", 1979], ["insulin", 1982], ["secretion", 1990], ["and", 2000], ["tissue", 2004], ["glucose", 2011], ["disposal", 2019], ["and", 2028], ["the", 2032], ["rise", 2036], ["in", 2041], ["EGP", 2044], ["after", 2048], ["one", 2054], ["dose", 2058], [",", 2062], ["thereby", 2064], ["lowering", 2072], ["fasting", 2081], ["and", 2089], ["postprandial", 2093], ["glycemia", 2106], [".", 2114], ["Chronic", 2116], ["dosing", 2124], ["shifted", 2131], ["substrate", 2139], ["utilization", 2149], ["from", 2161], ["carbohydrate", 2166], ["to", 2179], ["lipid", 2182], [".", 2187], ["Trial", 2189], ["registration", 2195], [".", 2207], ["ClinicalTrials", 2209], [".", 2223], ["Gov", 2224], ["NCT01248364", 2228], ["(", 2240], ["EudraCT", 2241], ["no", 2249], [".", 2251], ["2010", 2253], ["-", 2257], ["018708", 2258], ["-", 2264], ["99", 2265], [")", 2267], [".", 2268], ["Funding", 2270], [".", 2277], ["This", 2279], ["study", 2284], ["was", 2290], ["funded", 2294], ["by", 2301], ["Boehringer", 2304], ["Ingelheim", 2315], [".", 2324]]}
{"context": "Six persons with the classical Angelman syndrome (AS) phenotype and de novo deletions of chromosome 15q11-q13 were studied to determine the parental origin of the chromosome deletion. Four of the 6 patients had informative cytogenetic studies and all demonstrated maternal inheritance of the deletion. These findings, together with other reported cases of the origin of the chromosome 15 deletion in AS, suggest that deletion of the maternally contributed chromosome leads to the AS phenotype. This contrasts with the Prader-Willi syndrome (PWS) in which a similar deletion of the paternally contributed chromosome 15 is observed. In deletion cases, a parental gamete effect such as genomic imprinting may be the best model to explain why apparently identical 15q11-q13 deletions may develop the different phenotypes of AS or PWS.", "qas": [{"question": "Angelman syndrome is associated with deletion of a part of Chromosome 15 but if the deletion occurs in the paternally inherited chromosome 15, what is the disease?", "answers": ["Prader-Willi syndrome"], "qid": "03aa34b985ac43f7b28e110d51d52e44", "question_tokens": [["Angelman", 0], ["syndrome", 9], ["is", 18], ["associated", 21], ["with", 32], ["deletion", 37], ["of", 46], ["a", 49], ["part", 51], ["of", 56], ["Chromosome", 59], ["15", 70], ["but", 73], ["if", 77], ["the", 80], ["deletion", 84], ["occurs", 93], ["in", 100], ["the", 103], ["paternally", 107], ["inherited", 118], ["chromosome", 128], ["15", 139], [",", 141], ["what", 143], ["is", 148], ["the", 151], ["disease", 155], ["?", 162]], "detected_answers": [{"text": "Prader-Willi syndrome", "token_spans": [[85, 88]], "char_spans": [[518, 538]]}]}], "context_tokens": [["Six", 0], ["persons", 4], ["with", 12], ["the", 17], ["classical", 21], ["Angelman", 31], ["syndrome", 40], ["(", 49], ["AS", 50], [")", 52], ["phenotype", 54], ["and", 64], ["de", 68], ["novo", 71], ["deletions", 76], ["of", 86], ["chromosome", 89], ["15q11-q13", 100], ["were", 110], ["studied", 115], ["to", 123], ["determine", 126], ["the", 136], ["parental", 140], ["origin", 149], ["of", 156], ["the", 159], ["chromosome", 163], ["deletion", 174], [".", 182], ["Four", 184], ["of", 189], ["the", 192], ["6", 196], ["patients", 198], ["had", 207], ["informative", 211], ["cytogenetic", 223], ["studies", 235], ["and", 243], ["all", 247], ["demonstrated", 251], ["maternal", 264], ["inheritance", 273], ["of", 285], ["the", 288], ["deletion", 292], [".", 300], ["These", 302], ["findings", 308], [",", 316], ["together", 318], ["with", 327], ["other", 332], ["reported", 338], ["cases", 347], ["of", 353], ["the", 356], ["origin", 360], ["of", 367], ["the", 370], ["chromosome", 374], ["15", 385], ["deletion", 388], ["in", 397], ["AS", 400], [",", 402], ["suggest", 404], ["that", 412], ["deletion", 417], ["of", 426], ["the", 429], ["maternally", 433], ["contributed", 444], ["chromosome", 456], ["leads", 467], ["to", 473], ["the", 476], ["AS", 480], ["phenotype", 483], [".", 492], ["This", 494], ["contrasts", 499], ["with", 509], ["the", 514], ["Prader", 518], ["-", 524], ["Willi", 525], ["syndrome", 531], ["(", 540], ["PWS", 541], [")", 544], ["in", 546], ["which", 549], ["a", 555], ["similar", 557], ["deletion", 565], ["of", 574], ["the", 577], ["paternally", 581], ["contributed", 592], ["chromosome", 604], ["15", 615], ["is", 618], ["observed", 621], [".", 629], ["In", 631], ["deletion", 634], ["cases", 643], [",", 648], ["a", 650], ["parental", 652], ["gamete", 661], ["effect", 668], ["such", 675], ["as", 680], ["genomic", 683], ["imprinting", 691], ["may", 702], ["be", 706], ["the", 709], ["best", 713], ["model", 718], ["to", 724], ["explain", 727], ["why", 735], ["apparently", 739], ["identical", 750], ["15q11-q13", 760], ["deletions", 770], ["may", 780], ["develop", 784], ["the", 792], ["different", 796], ["phenotypes", 806], ["of", 817], ["AS", 820], ["or", 823], ["PWS", 826], [".", 829]]}
{"context": "Chronic myeloid leukemia cells contain a BCR-ABL oncoprotein with an enhanced tyrosine kinase activity, which is considered to be the principal 'cause' of the leukemia. Though the precise mechanisms underlying the leukemogenesis remains enigmatic, the use of imatinib to inhibit the dysregulated kinase activity has proved remarkably successful in clinical practice. Imatinib was the first small molecule developed to inhibit BCR-ABL tyrosine kinase activity and its success introduced the current era of molecularly targeted therapies for a number of other malignancies. In patients with chronic myeloid leukaemia who develop resistance to imatinib, the Bcr-Abl signaling pathway is often re-established. This has led to the emergence of a number of alternative treatment strategies designed to target the leukemic cell which are resistant to imatinib.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "34f1609a5e28421ea7ca56e3a8591062", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[104, 106], [6, 8], [67, 69]], "char_spans": [[655, 661], [41, 47], [426, 432]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["cells", 25], ["contain", 31], ["a", 39], ["BCR", 41], ["-", 44], ["ABL", 45], ["oncoprotein", 49], ["with", 61], ["an", 66], ["enhanced", 69], ["tyrosine", 78], ["kinase", 87], ["activity", 94], [",", 102], ["which", 104], ["is", 110], ["considered", 113], ["to", 124], ["be", 127], ["the", 130], ["principal", 134], ["'cause", 144], ["'", 150], ["of", 152], ["the", 155], ["leukemia", 159], [".", 167], ["Though", 169], ["the", 176], ["precise", 180], ["mechanisms", 188], ["underlying", 199], ["the", 210], ["leukemogenesis", 214], ["remains", 229], ["enigmatic", 237], [",", 246], ["the", 248], ["use", 252], ["of", 256], ["imatinib", 259], ["to", 268], ["inhibit", 271], ["the", 279], ["dysregulated", 283], ["kinase", 296], ["activity", 303], ["has", 312], ["proved", 316], ["remarkably", 323], ["successful", 334], ["in", 345], ["clinical", 348], ["practice", 357], [".", 365], ["Imatinib", 367], ["was", 376], ["the", 380], ["first", 384], ["small", 390], ["molecule", 396], ["developed", 405], ["to", 415], ["inhibit", 418], ["BCR", 426], ["-", 429], ["ABL", 430], ["tyrosine", 434], ["kinase", 443], ["activity", 450], ["and", 459], ["its", 463], ["success", 467], ["introduced", 475], ["the", 486], ["current", 490], ["era", 498], ["of", 502], ["molecularly", 505], ["targeted", 517], ["therapies", 526], ["for", 536], ["a", 540], ["number", 542], ["of", 549], ["other", 552], ["malignancies", 558], [".", 570], ["In", 572], ["patients", 575], ["with", 584], ["chronic", 589], ["myeloid", 597], ["leukaemia", 605], ["who", 615], ["develop", 619], ["resistance", 627], ["to", 638], ["imatinib", 641], [",", 649], ["the", 651], ["Bcr", 655], ["-", 658], ["Abl", 659], ["signaling", 663], ["pathway", 673], ["is", 681], ["often", 684], ["re", 690], ["-", 692], ["established", 693], [".", 704], ["This", 706], ["has", 711], ["led", 715], ["to", 719], ["the", 722], ["emergence", 726], ["of", 736], ["a", 739], ["number", 741], ["of", 748], ["alternative", 751], ["treatment", 763], ["strategies", 773], ["designed", 784], ["to", 793], ["target", 796], ["the", 803], ["leukemic", 807], ["cell", 816], ["which", 821], ["are", 827], ["resistant", 831], ["to", 841], ["imatinib", 844], [".", 852]]}
{"context": "Restless legs syndrome (RLS) is a clinically important, common disease and should be diagnosed and treated early and adequately. At present, there have been no clinical biomarkers or methodologies that can contribute to the correct diagnosis of RLS, RLS should be diagnosed on the basis of 4 essential criteria: urge to move the legs, improvement after movement, and worsening or occurrence of symptoms in the evening and at rest. When applying the criteria, RLS mimics should be ruled out and comorbid diseases should be taken into account. The origin and pathogenesis of RLS are still under investigation; however, iron deficiency in the brain has been observed on imaging and cerebrospinal fluid analyses of patients with RLS. In contrast, the results of neuroimaging studies evaluating brain dopaminergic functions in patients with RLS have yielded inconclusive results, although involvement of the hypothalamus (A11) is thought to cause impaired dopaminergic modulation in the dorsal horn and intermediolateral nucleus, resulting in the restlessness of legs.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "f86ef5e1ac664cb0a799f69a2e54f94d", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[112, 112]], "char_spans": [[617, 620]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], ["is", 29], ["a", 32], ["clinically", 34], ["important", 45], [",", 54], ["common", 56], ["disease", 63], ["and", 71], ["should", 75], ["be", 82], ["diagnosed", 85], ["and", 95], ["treated", 99], ["early", 107], ["and", 113], ["adequately", 117], [".", 127], ["At", 129], ["present", 132], [",", 139], ["there", 141], ["have", 147], ["been", 152], ["no", 157], ["clinical", 160], ["biomarkers", 169], ["or", 180], ["methodologies", 183], ["that", 197], ["can", 202], ["contribute", 206], ["to", 217], ["the", 220], ["correct", 224], ["diagnosis", 232], ["of", 242], ["RLS", 245], [",", 248], ["RLS", 250], ["should", 254], ["be", 261], ["diagnosed", 264], ["on", 274], ["the", 277], ["basis", 281], ["of", 287], ["4", 290], ["essential", 292], ["criteria", 302], [":", 310], ["urge", 312], ["to", 317], ["move", 320], ["the", 325], ["legs", 329], [",", 333], ["improvement", 335], ["after", 347], ["movement", 353], [",", 361], ["and", 363], ["worsening", 367], ["or", 377], ["occurrence", 380], ["of", 391], ["symptoms", 394], ["in", 403], ["the", 406], ["evening", 410], ["and", 418], ["at", 422], ["rest", 425], [".", 429], ["When", 431], ["applying", 436], ["the", 445], ["criteria", 449], [",", 457], ["RLS", 459], ["mimics", 463], ["should", 470], ["be", 477], ["ruled", 480], ["out", 486], ["and", 490], ["comorbid", 494], ["diseases", 503], ["should", 512], ["be", 519], ["taken", 522], ["into", 528], ["account", 533], [".", 540], ["The", 542], ["origin", 546], ["and", 553], ["pathogenesis", 557], ["of", 570], ["RLS", 573], ["are", 577], ["still", 581], ["under", 587], ["investigation", 593], [";", 606], ["however", 608], [",", 615], ["iron", 617], ["deficiency", 622], ["in", 633], ["the", 636], ["brain", 640], ["has", 646], ["been", 650], ["observed", 655], ["on", 664], ["imaging", 667], ["and", 675], ["cerebrospinal", 679], ["fluid", 693], ["analyses", 699], ["of", 708], ["patients", 711], ["with", 720], ["RLS", 725], [".", 728], ["In", 730], ["contrast", 733], [",", 741], ["the", 743], ["results", 747], ["of", 755], ["neuroimaging", 758], ["studies", 771], ["evaluating", 779], ["brain", 790], ["dopaminergic", 796], ["functions", 809], ["in", 819], ["patients", 822], ["with", 831], ["RLS", 836], ["have", 840], ["yielded", 845], ["inconclusive", 853], ["results", 866], [",", 873], ["although", 875], ["involvement", 884], ["of", 896], ["the", 899], ["hypothalamus", 903], ["(", 916], ["A11", 917], [")", 920], ["is", 922], ["thought", 925], ["to", 933], ["cause", 936], ["impaired", 942], ["dopaminergic", 951], ["modulation", 964], ["in", 975], ["the", 978], ["dorsal", 982], ["horn", 989], ["and", 994], ["intermediolateral", 998], ["nucleus", 1016], [",", 1023], ["resulting", 1025], ["in", 1035], ["the", 1038], ["restlessness", 1042], ["of", 1055], ["legs", 1058], [".", 1062]]}
{"context": "MicroRNAs (miRNAs) constitute a large family of noncoding RNAs that function as guide molecules in diverse gene silencing pathways. Current efforts are focused on the regulatory function of miRNAs, while little is known about how these unusual genes themselves are regulated. Here we present the first direct evidence that miRNA genes are transcribed by RNA polymerase II (pol II). The primary miRNA transcripts (pri-miRNAs) contain cap structures as well as poly(A) tails, which are the unique properties of class II gene transcripts. The treatment of human cells with alpha-amanitin decreased the level of pri-miRNAs at a concentration that selectively inhibits pol II activity. Furthermore, chromatin immunoprecipitation analyses show that pol II is physically associated with a miRNA promoter. We also describe, for the first time, the detailed structure of a miRNA gene by determining the promoter and the terminator of mir-23a approximately 27a approximately 24-2. These data indicate that pol II is the main, if not the only, RNA polymerase for miRNA gene transcription. Our study offers a basis for understanding the structure and regulation of miRNA genes.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "bfbcb1b432584aff8df5bc3c70e56f62", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[59, 61]], "char_spans": [[354, 370]]}]}], "context_tokens": [["MicroRNAs", 0], ["(", 10], ["miRNAs", 11], [")", 17], ["constitute", 19], ["a", 30], ["large", 32], ["family", 38], ["of", 45], ["noncoding", 48], ["RNAs", 58], ["that", 63], ["function", 68], ["as", 77], ["guide", 80], ["molecules", 86], ["in", 96], ["diverse", 99], ["gene", 107], ["silencing", 112], ["pathways", 122], [".", 130], ["Current", 132], ["efforts", 140], ["are", 148], ["focused", 152], ["on", 160], ["the", 163], ["regulatory", 167], ["function", 178], ["of", 187], ["miRNAs", 190], [",", 196], ["while", 198], ["little", 204], ["is", 211], ["known", 214], ["about", 220], ["how", 226], ["these", 230], ["unusual", 236], ["genes", 244], ["themselves", 250], ["are", 261], ["regulated", 265], [".", 274], ["Here", 276], ["we", 281], ["present", 284], ["the", 292], ["first", 296], ["direct", 302], ["evidence", 309], ["that", 318], ["miRNA", 323], ["genes", 329], ["are", 335], ["transcribed", 339], ["by", 351], ["RNA", 354], ["polymerase", 358], ["II", 369], ["(", 372], ["pol", 373], ["II", 377], [")", 379], [".", 380], ["The", 382], ["primary", 386], ["miRNA", 394], ["transcripts", 400], ["(", 412], ["pri", 413], ["-", 416], ["miRNAs", 417], [")", 423], ["contain", 425], ["cap", 433], ["structures", 437], ["as", 448], ["well", 451], ["as", 456], ["poly(A", 459], [")", 465], ["tails", 467], [",", 472], ["which", 474], ["are", 480], ["the", 484], ["unique", 488], ["properties", 495], ["of", 506], ["class", 509], ["II", 515], ["gene", 518], ["transcripts", 523], [".", 534], ["The", 536], ["treatment", 540], ["of", 550], ["human", 553], ["cells", 559], ["with", 565], ["alpha", 570], ["-", 575], ["amanitin", 576], ["decreased", 585], ["the", 595], ["level", 599], ["of", 605], ["pri", 608], ["-", 611], ["miRNAs", 612], ["at", 619], ["a", 622], ["concentration", 624], ["that", 638], ["selectively", 643], ["inhibits", 655], ["pol", 664], ["II", 668], ["activity", 671], [".", 679], ["Furthermore", 681], [",", 692], ["chromatin", 694], ["immunoprecipitation", 704], ["analyses", 724], ["show", 733], ["that", 738], ["pol", 743], ["II", 747], ["is", 750], ["physically", 753], ["associated", 764], ["with", 775], ["a", 780], ["miRNA", 782], ["promoter", 788], [".", 796], ["We", 798], ["also", 801], ["describe", 806], [",", 814], ["for", 816], ["the", 820], ["first", 824], ["time", 830], [",", 834], ["the", 836], ["detailed", 840], ["structure", 849], ["of", 859], ["a", 862], ["miRNA", 864], ["gene", 870], ["by", 875], ["determining", 878], ["the", 890], ["promoter", 894], ["and", 903], ["the", 907], ["terminator", 911], ["of", 922], ["mir-23a", 925], ["approximately", 933], ["27a", 947], ["approximately", 951], ["24", 965], ["-", 967], ["2", 968], [".", 969], ["These", 971], ["data", 977], ["indicate", 982], ["that", 991], ["pol", 996], ["II", 1000], ["is", 1003], ["the", 1006], ["main", 1010], [",", 1014], ["if", 1016], ["not", 1019], ["the", 1023], ["only", 1027], [",", 1031], ["RNA", 1033], ["polymerase", 1037], ["for", 1048], ["miRNA", 1052], ["gene", 1058], ["transcription", 1063], [".", 1076], ["Our", 1078], ["study", 1082], ["offers", 1088], ["a", 1095], ["basis", 1097], ["for", 1103], ["understanding", 1107], ["the", 1121], ["structure", 1125], ["and", 1135], ["regulation", 1139], ["of", 1150], ["miRNA", 1153], ["genes", 1159], [".", 1164]]}
{"context": "Trimethylation of histone H3 Lys4 (H3K4) is associated with transcriptional activation. One of the chief effectors of H3K4 methylation is mixed-lineage leukemia 1 (MLL1), a gene that is disrupted by chromosomal translocation in acute leukemia and a master regulator of Hox and other genes. In a recent paper, core components of the human MLL histone methyltransferase (MT) complex were found to form a structural platform, with one component (WDR5) mediating association between the specific histone H3K4 substrate and the MT. This novel regulatory mechanism, which is conserved from yeast to human, is required for both methylation and downstream target gene transcription.", "qas": [{"question": "Which is the histone residue methylated by MLL1?", "answers": ["H3K4"], "qid": "f5a528ae5c1742e2a05b03ecd56fb554", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["histone", 13], ["residue", 21], ["methylated", 29], ["by", 40], ["MLL1", 43], ["?", 47]], "detected_answers": [{"text": "H3K4", "token_spans": [[20, 20], [90, 90], [6, 6]], "char_spans": [[118, 121], [500, 503], [35, 38]]}]}], "context_tokens": [["Trimethylation", 0], ["of", 15], ["histone", 18], ["H3", 26], ["Lys4", 29], ["(", 34], ["H3K4", 35], [")", 39], ["is", 41], ["associated", 44], ["with", 55], ["transcriptional", 60], ["activation", 76], [".", 86], ["One", 88], ["of", 92], ["the", 95], ["chief", 99], ["effectors", 105], ["of", 115], ["H3K4", 118], ["methylation", 123], ["is", 135], ["mixed", 138], ["-", 143], ["lineage", 144], ["leukemia", 152], ["1", 161], ["(", 163], ["MLL1", 164], [")", 168], [",", 169], ["a", 171], ["gene", 173], ["that", 178], ["is", 183], ["disrupted", 186], ["by", 196], ["chromosomal", 199], ["translocation", 211], ["in", 225], ["acute", 228], ["leukemia", 234], ["and", 243], ["a", 247], ["master", 249], ["regulator", 256], ["of", 266], ["Hox", 269], ["and", 273], ["other", 277], ["genes", 283], [".", 288], ["In", 290], ["a", 293], ["recent", 295], ["paper", 302], [",", 307], ["core", 309], ["components", 314], ["of", 325], ["the", 328], ["human", 332], ["MLL", 338], ["histone", 342], ["methyltransferase", 350], ["(", 368], ["MT", 369], [")", 371], ["complex", 373], ["were", 381], ["found", 386], ["to", 392], ["form", 395], ["a", 400], ["structural", 402], ["platform", 413], [",", 421], ["with", 423], ["one", 428], ["component", 432], ["(", 442], ["WDR5", 443], [")", 447], ["mediating", 449], ["association", 459], ["between", 471], ["the", 479], ["specific", 483], ["histone", 492], ["H3K4", 500], ["substrate", 505], ["and", 515], ["the", 519], ["MT", 523], [".", 525], ["This", 527], ["novel", 532], ["regulatory", 538], ["mechanism", 549], [",", 558], ["which", 560], ["is", 566], ["conserved", 569], ["from", 579], ["yeast", 584], ["to", 590], ["human", 593], [",", 598], ["is", 600], ["required", 603], ["for", 612], ["both", 616], ["methylation", 621], ["and", 633], ["downstream", 637], ["target", 648], ["gene", 655], ["transcription", 660], [".", 673]]}
{"context": "The actin-cross-linking protein spectrin is a prominent component of the membrane cytoskeleton. Spectrin is a tetramer of two antiparallel alphabeta-dimers which share a unique and ancient gene structure. The alpha-spectrin and beta-spectrin genes are composed primarily of tandemly repeated 106-amino-acid segments, each of which forms a triple alpha-helical coiled coil. Both the genes and the repeats themselves are homologous. The two genes are thought to be the result of a gene duplication event, and each gene is the product of duplications of the 106-amino-acid repeats. In this work we compare the process of molecular evolution across the repeated segments of the alpha- and beta-spectrin genes. We find that the alpha-spectrin segments have, for the most part, evolved in a homogeneous fashion, while considerable heterogeneity is found among beta-spectrin segments. Several segments with unique known functions are found to have evolved differently than the others. On the basis of heterogeneity of the evolutionary process, we suggest that at least one repeat has a unique function that has yet to be documented. We also present new statistical methods for comparing the evolutionary process between different regions of DNA sequences.", "qas": [{"question": "Alpha-spectrin and beta-spectrin subunits form parallel or antiparallel heterodimers?", "answers": ["antiparallel"], "qid": "b37db289ef2948e9b5e75fbc0cbd66bf", "question_tokens": [["Alpha", 0], ["-", 5], ["spectrin", 6], ["and", 15], ["beta", 19], ["-", 23], ["spectrin", 24], ["subunits", 33], ["form", 42], ["parallel", 47], ["or", 56], ["antiparallel", 59], ["heterodimers", 72], ["?", 84]], "detected_answers": [{"text": "antiparallel", "token_spans": [[23, 23]], "char_spans": [[126, 137]]}]}], "context_tokens": [["The", 0], ["actin", 4], ["-", 9], ["cross", 10], ["-", 15], ["linking", 16], ["protein", 24], ["spectrin", 32], ["is", 41], ["a", 44], ["prominent", 46], ["component", 56], ["of", 66], ["the", 69], ["membrane", 73], ["cytoskeleton", 82], [".", 94], ["Spectrin", 96], ["is", 105], ["a", 108], ["tetramer", 110], ["of", 119], ["two", 122], ["antiparallel", 126], ["alphabeta", 139], ["-", 148], ["dimers", 149], ["which", 156], ["share", 162], ["a", 168], ["unique", 170], ["and", 177], ["ancient", 181], ["gene", 189], ["structure", 194], [".", 203], ["The", 205], ["alpha", 209], ["-", 214], ["spectrin", 215], ["and", 224], ["beta", 228], ["-", 232], ["spectrin", 233], ["genes", 242], ["are", 248], ["composed", 252], ["primarily", 261], ["of", 271], ["tandemly", 274], ["repeated", 283], ["106-amino", 292], ["-", 301], ["acid", 302], ["segments", 307], [",", 315], ["each", 317], ["of", 322], ["which", 325], ["forms", 331], ["a", 337], ["triple", 339], ["alpha", 346], ["-", 351], ["helical", 352], ["coiled", 360], ["coil", 367], [".", 371], ["Both", 373], ["the", 378], ["genes", 382], ["and", 388], ["the", 392], ["repeats", 396], ["themselves", 404], ["are", 415], ["homologous", 419], [".", 429], ["The", 431], ["two", 435], ["genes", 439], ["are", 445], ["thought", 449], ["to", 457], ["be", 460], ["the", 463], ["result", 467], ["of", 474], ["a", 477], ["gene", 479], ["duplication", 484], ["event", 496], [",", 501], ["and", 503], ["each", 507], ["gene", 512], ["is", 517], ["the", 520], ["product", 524], ["of", 532], ["duplications", 535], ["of", 548], ["the", 551], ["106-amino", 555], ["-", 564], ["acid", 565], ["repeats", 570], [".", 577], ["In", 579], ["this", 582], ["work", 587], ["we", 592], ["compare", 595], ["the", 603], ["process", 607], ["of", 615], ["molecular", 618], ["evolution", 628], ["across", 638], ["the", 645], ["repeated", 649], ["segments", 658], ["of", 667], ["the", 670], ["alpha-", 674], ["and", 681], ["beta", 685], ["-", 689], ["spectrin", 690], ["genes", 699], [".", 704], ["We", 706], ["find", 709], ["that", 714], ["the", 719], ["alpha", 723], ["-", 728], ["spectrin", 729], ["segments", 738], ["have", 747], [",", 751], ["for", 753], ["the", 757], ["most", 761], ["part", 766], [",", 770], ["evolved", 772], ["in", 780], ["a", 783], ["homogeneous", 785], ["fashion", 797], [",", 804], ["while", 806], ["considerable", 812], ["heterogeneity", 825], ["is", 839], ["found", 842], ["among", 848], ["beta", 854], ["-", 858], ["spectrin", 859], ["segments", 868], [".", 876], ["Several", 878], ["segments", 886], ["with", 895], ["unique", 900], ["known", 907], ["functions", 913], ["are", 923], ["found", 927], ["to", 933], ["have", 936], ["evolved", 941], ["differently", 949], ["than", 961], ["the", 966], ["others", 970], [".", 976], ["On", 978], ["the", 981], ["basis", 985], ["of", 991], ["heterogeneity", 994], ["of", 1008], ["the", 1011], ["evolutionary", 1015], ["process", 1028], [",", 1035], ["we", 1037], ["suggest", 1040], ["that", 1048], ["at", 1053], ["least", 1056], ["one", 1062], ["repeat", 1066], ["has", 1073], ["a", 1077], ["unique", 1079], ["function", 1086], ["that", 1095], ["has", 1100], ["yet", 1104], ["to", 1108], ["be", 1111], ["documented", 1114], [".", 1124], ["We", 1126], ["also", 1129], ["present", 1134], ["new", 1142], ["statistical", 1146], ["methods", 1158], ["for", 1166], ["comparing", 1170], ["the", 1180], ["evolutionary", 1184], ["process", 1197], ["between", 1205], ["different", 1213], ["regions", 1223], ["of", 1231], ["DNA", 1234], ["sequences", 1238], [".", 1247]]}
{"context": "Mutations in NOTCH3 are the cause of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a hereditary angiopathy causing stroke and vascular dementia. All CADASIL mutations identified so far result in the loss or gain of one cysteine residue within epidermal growth factor (EGF)-like repeat domains. Here an in-frame deletion causing a loss of three cysteine residues within EGF repeat 6 is reported. These data are consistent with the hypothesis that the change toward an odd number of cysteine residues within a given EGF repeat and therefore an unpaired, reactive cysteine residue is the common and critical molecular event in CADASIL.", "qas": [{"question": "Which amino acid residue appears mutated in most of the cases reported with  cadasil syndrome?", "answers": ["Cysteine"], "qid": "04da2c70e07e4c2581afe158af0e1759", "question_tokens": [["Which", 0], ["amino", 6], ["acid", 12], ["residue", 17], ["appears", 25], ["mutated", 33], ["in", 41], ["most", 44], ["of", 49], ["the", 52], ["cases", 56], ["reported", 62], ["with", 71], [" ", 76], ["cadasil", 77], ["syndrome", 85], ["?", 93]], "detected_answers": [{"text": "Cysteine", "token_spans": [[65, 65], [89, 89], [43, 43], [102, 102]], "char_spans": [[400, 407], [537, 544], [275, 282], [617, 624]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["NOTCH3", 13], ["are", 20], ["the", 24], ["cause", 28], ["of", 34], ["cerebral", 37], ["autosomal", 46], ["dominant", 56], ["arteriopathy", 65], ["with", 78], ["subcortical", 83], ["infarcts", 95], ["and", 104], ["leukoencephalopathy", 108], ["(", 128], ["CADASIL", 129], [")", 136], [",", 137], ["a", 139], ["hereditary", 141], ["angiopathy", 152], ["causing", 163], ["stroke", 171], ["and", 178], ["vascular", 182], ["dementia", 191], [".", 199], ["All", 201], ["CADASIL", 205], ["mutations", 213], ["identified", 223], ["so", 234], ["far", 237], ["result", 241], ["in", 248], ["the", 251], ["loss", 255], ["or", 260], ["gain", 263], ["of", 268], ["one", 271], ["cysteine", 275], ["residue", 284], ["within", 292], ["epidermal", 299], ["growth", 309], ["factor", 316], ["(", 323], ["EGF)-like", 324], ["repeat", 334], ["domains", 341], [".", 348], ["Here", 350], ["an", 355], ["in", 358], ["-", 360], ["frame", 361], ["deletion", 367], ["causing", 376], ["a", 384], ["loss", 386], ["of", 391], ["three", 394], ["cysteine", 400], ["residues", 409], ["within", 418], ["EGF", 425], ["repeat", 429], ["6", 436], ["is", 438], ["reported", 441], [".", 449], ["These", 451], ["data", 457], ["are", 462], ["consistent", 466], ["with", 477], ["the", 482], ["hypothesis", 486], ["that", 497], ["the", 502], ["change", 506], ["toward", 513], ["an", 520], ["odd", 523], ["number", 527], ["of", 534], ["cysteine", 537], ["residues", 546], ["within", 555], ["a", 562], ["given", 564], ["EGF", 570], ["repeat", 574], ["and", 581], ["therefore", 585], ["an", 595], ["unpaired", 598], [",", 606], ["reactive", 608], ["cysteine", 617], ["residue", 626], ["is", 634], ["the", 637], ["common", 641], ["and", 648], ["critical", 652], ["molecular", 661], ["event", 671], ["in", 677], ["CADASIL", 680], [".", 687]]}
{"context": "The Shprintzen-Goldberg syndrome (SGS) is a disorder of unknown cause comprising craniosynostosis, a marfanoid habitus and skeletal, neurological, cardiovascular, and connective-tissue anomalies. There are no pathognomonic signs of SGS and diagnosis depends on recognition of a characteristic combination of anomalies. Here, we describe 14 persons with SGS and compare their clinical findings with those of 23 previously reported individuals, including two families with more than one affected individual. Our analysis suggests that there is a characteristic facial appearance, with more than two thirds of all individuals having hypertelorism, down-slanting palpebral fissures, a high-arched palate, micrognathia, and apparently low-set and posteriorly rotated ears. Other commonly reported manifestations include hypotonia in at least the neonatal period, developmental delay, and inguinal or umbilical hernia. The degree of reported intellectual impairment ranges from mild to severe. The most common skeletal manifestations in SGS were arachnodactyly, pectus deformity, camptodactyly, scoliosis, and joint hypermobility. None of the skeletal signs alone is specific for SGS. Our study includes 14 mainly German individuals with SGS evaluated over a period of 10 years. Given that only 23 other persons with SGS have been reported to date worldwide, we suggest that SGS may be more common than previously assumed.", "qas": [{"question": "Which disease is included as an additional feature in the Goldberg-Shprintzen syndrome?", "answers": ["Craniosynostosis"], "qid": "2406a794568840628014804927e40975", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["included", 17], ["as", 26], ["an", 29], ["additional", 32], ["feature", 43], ["in", 51], ["the", 54], ["Goldberg", 58], ["-", 66], ["Shprintzen", 67], ["syndrome", 78], ["?", 86]], "detected_answers": [{"text": "Craniosynostosis", "token_spans": [[15, 15]], "char_spans": [[81, 96]]}]}], "context_tokens": [["The", 0], ["Shprintzen", 4], ["-", 14], ["Goldberg", 15], ["syndrome", 24], ["(", 33], ["SGS", 34], [")", 37], ["is", 39], ["a", 42], ["disorder", 44], ["of", 53], ["unknown", 56], ["cause", 64], ["comprising", 70], ["craniosynostosis", 81], [",", 97], ["a", 99], ["marfanoid", 101], ["habitus", 111], ["and", 119], ["skeletal", 123], [",", 131], ["neurological", 133], [",", 145], ["cardiovascular", 147], [",", 161], ["and", 163], ["connective", 167], ["-", 177], ["tissue", 178], ["anomalies", 185], [".", 194], ["There", 196], ["are", 202], ["no", 206], ["pathognomonic", 209], ["signs", 223], ["of", 229], ["SGS", 232], ["and", 236], ["diagnosis", 240], ["depends", 250], ["on", 258], ["recognition", 261], ["of", 273], ["a", 276], ["characteristic", 278], ["combination", 293], ["of", 305], ["anomalies", 308], [".", 317], ["Here", 319], [",", 323], ["we", 325], ["describe", 328], ["14", 337], ["persons", 340], ["with", 348], ["SGS", 353], ["and", 357], ["compare", 361], ["their", 369], ["clinical", 375], ["findings", 384], ["with", 393], ["those", 398], ["of", 404], ["23", 407], ["previously", 410], ["reported", 421], ["individuals", 430], [",", 441], ["including", 443], ["two", 453], ["families", 457], ["with", 466], ["more", 471], ["than", 476], ["one", 481], ["affected", 485], ["individual", 494], [".", 504], ["Our", 506], ["analysis", 510], ["suggests", 519], ["that", 528], ["there", 533], ["is", 539], ["a", 542], ["characteristic", 544], ["facial", 559], ["appearance", 566], [",", 576], ["with", 578], ["more", 583], ["than", 588], ["two", 593], ["thirds", 597], ["of", 604], ["all", 607], ["individuals", 611], ["having", 623], ["hypertelorism", 630], [",", 643], ["down", 645], ["-", 649], ["slanting", 650], ["palpebral", 659], ["fissures", 669], [",", 677], ["a", 679], ["high", 681], ["-", 685], ["arched", 686], ["palate", 693], [",", 699], ["micrognathia", 701], [",", 713], ["and", 715], ["apparently", 719], ["low", 730], ["-", 733], ["set", 734], ["and", 738], ["posteriorly", 742], ["rotated", 754], ["ears", 762], [".", 766], ["Other", 768], ["commonly", 774], ["reported", 783], ["manifestations", 792], ["include", 807], ["hypotonia", 815], ["in", 825], ["at", 828], ["least", 831], ["the", 837], ["neonatal", 841], ["period", 850], [",", 856], ["developmental", 858], ["delay", 872], [",", 877], ["and", 879], ["inguinal", 883], ["or", 892], ["umbilical", 895], ["hernia", 905], [".", 911], ["The", 913], ["degree", 917], ["of", 924], ["reported", 927], ["intellectual", 936], ["impairment", 949], ["ranges", 960], ["from", 967], ["mild", 972], ["to", 977], ["severe", 980], [".", 986], ["The", 988], ["most", 992], ["common", 997], ["skeletal", 1004], ["manifestations", 1013], ["in", 1028], ["SGS", 1031], ["were", 1035], ["arachnodactyly", 1040], [",", 1054], ["pectus", 1056], ["deformity", 1063], [",", 1072], ["camptodactyly", 1074], [",", 1087], ["scoliosis", 1089], [",", 1098], ["and", 1100], ["joint", 1104], ["hypermobility", 1110], [".", 1123], ["None", 1125], ["of", 1130], ["the", 1133], ["skeletal", 1137], ["signs", 1146], ["alone", 1152], ["is", 1158], ["specific", 1161], ["for", 1170], ["SGS", 1174], [".", 1177], ["Our", 1179], ["study", 1183], ["includes", 1189], ["14", 1198], ["mainly", 1201], ["German", 1208], ["individuals", 1215], ["with", 1227], ["SGS", 1232], ["evaluated", 1236], ["over", 1246], ["a", 1251], ["period", 1253], ["of", 1260], ["10", 1263], ["years", 1266], [".", 1271], ["Given", 1273], ["that", 1279], ["only", 1284], ["23", 1289], ["other", 1292], ["persons", 1298], ["with", 1306], ["SGS", 1311], ["have", 1315], ["been", 1320], ["reported", 1325], ["to", 1334], ["date", 1337], ["worldwide", 1342], [",", 1351], ["we", 1353], ["suggest", 1356], ["that", 1364], ["SGS", 1369], ["may", 1373], ["be", 1377], ["more", 1380], ["common", 1385], ["than", 1392], ["previously", 1397], ["assumed", 1408], [".", 1415]]}
{"context": "Epigenomic mapping of enhancer-associated chromatin modifications facilitates the genome-wide discovery of tissue-specific enhancers in vivo. However, reliance on single chromatin marks leads to high rates of false-positive predictions. More sophisticated, integrative methods have been described, but commonly suffer from limited accessibility to the resulting predictions and reduced biological interpretability. Here we present the Limb-Enhancer Genie (LEG), a collection of highly accurate, genome-wide predictions of enhancers in the developing limb, available through a user-friendly online interface. We predict limb enhancers using a combination of >50 published limb-specific datasets and clusters of evolutionarily conserved transcription factor binding sites, taking advantage of the patterns observed at previously in vivo validated elements. By combining different statistical models, our approach outperforms current state-of-the-art methods and provides interpretable measures of feature importance. Our results indicate that including a previously unappreciated score that quantifies tissue-specific nuclease accessibility significantly improves prediction performance. We demonstrate the utility of our approach through in vivo validation of newly predicted elements. Moreover, we describe general features that can guide the type of datasets to include when predicting tissue-specific enhancers genome-wide, while providing an accessible resource to the general biological community and facilitating the functional interpretation of genetic studies of limb malformations.", "qas": [{"question": "Which resource contains accurate enhancer predictions in the developing limb?", "answers": ["Limb-Enhancer Genie (LEG)"], "qid": "a1f4e0c1a4c84385836fb9879b463d73", "question_tokens": [["Which", 0], ["resource", 6], ["contains", 15], ["accurate", 24], ["enhancer", 33], ["predictions", 42], ["in", 54], ["the", 57], ["developing", 61], ["limb", 72], ["?", 76]], "detected_answers": [{"text": "Limb-Enhancer Genie (LEG)", "token_spans": [[67, 72]], "char_spans": [[435, 458]]}]}], "context_tokens": [["Epigenomic", 0], ["mapping", 11], ["of", 19], ["enhancer", 22], ["-", 30], ["associated", 31], ["chromatin", 42], ["modifications", 52], ["facilitates", 66], ["the", 78], ["genome", 82], ["-", 88], ["wide", 89], ["discovery", 94], ["of", 104], ["tissue", 107], ["-", 113], ["specific", 114], ["enhancers", 123], ["in", 133], ["vivo", 136], [".", 140], ["However", 142], [",", 149], ["reliance", 151], ["on", 160], ["single", 163], ["chromatin", 170], ["marks", 180], ["leads", 186], ["to", 192], ["high", 195], ["rates", 200], ["of", 206], ["false", 209], ["-", 214], ["positive", 215], ["predictions", 224], [".", 235], ["More", 237], ["sophisticated", 242], [",", 255], ["integrative", 257], ["methods", 269], ["have", 277], ["been", 282], ["described", 287], [",", 296], ["but", 298], ["commonly", 302], ["suffer", 311], ["from", 318], ["limited", 323], ["accessibility", 331], ["to", 345], ["the", 348], ["resulting", 352], ["predictions", 362], ["and", 374], ["reduced", 378], ["biological", 386], ["interpretability", 397], [".", 413], ["Here", 415], ["we", 420], ["present", 423], ["the", 431], ["Limb", 435], ["-", 439], ["Enhancer", 440], ["Genie", 449], ["(", 455], ["LEG", 456], [")", 459], [",", 460], ["a", 462], ["collection", 464], ["of", 475], ["highly", 478], ["accurate", 485], [",", 493], ["genome", 495], ["-", 501], ["wide", 502], ["predictions", 507], ["of", 519], ["enhancers", 522], ["in", 532], ["the", 535], ["developing", 539], ["limb", 550], [",", 554], ["available", 556], ["through", 566], ["a", 574], ["user", 576], ["-", 580], ["friendly", 581], ["online", 590], ["interface", 597], [".", 606], ["We", 608], ["predict", 611], ["limb", 619], ["enhancers", 624], ["using", 634], ["a", 640], ["combination", 642], ["of", 654], [">", 657], ["50", 658], ["published", 661], ["limb", 671], ["-", 675], ["specific", 676], ["datasets", 685], ["and", 694], ["clusters", 698], ["of", 707], ["evolutionarily", 710], ["conserved", 725], ["transcription", 735], ["factor", 749], ["binding", 756], ["sites", 764], [",", 769], ["taking", 771], ["advantage", 778], ["of", 788], ["the", 791], ["patterns", 795], ["observed", 804], ["at", 813], ["previously", 816], ["in", 827], ["vivo", 830], ["validated", 835], ["elements", 845], [".", 853], ["By", 855], ["combining", 858], ["different", 868], ["statistical", 878], ["models", 890], [",", 896], ["our", 898], ["approach", 902], ["outperforms", 911], ["current", 923], ["state", 931], ["-", 936], ["of", 937], ["-", 939], ["the", 940], ["-", 943], ["art", 944], ["methods", 948], ["and", 956], ["provides", 960], ["interpretable", 969], ["measures", 983], ["of", 992], ["feature", 995], ["importance", 1003], [".", 1013], ["Our", 1015], ["results", 1019], ["indicate", 1027], ["that", 1036], ["including", 1041], ["a", 1051], ["previously", 1053], ["unappreciated", 1064], ["score", 1078], ["that", 1084], ["quantifies", 1089], ["tissue", 1100], ["-", 1106], ["specific", 1107], ["nuclease", 1116], ["accessibility", 1125], ["significantly", 1139], ["improves", 1153], ["prediction", 1162], ["performance", 1173], [".", 1184], ["We", 1186], ["demonstrate", 1189], ["the", 1201], ["utility", 1205], ["of", 1213], ["our", 1216], ["approach", 1220], ["through", 1229], ["in", 1237], ["vivo", 1240], ["validation", 1245], ["of", 1256], ["newly", 1259], ["predicted", 1265], ["elements", 1275], [".", 1283], ["Moreover", 1285], [",", 1293], ["we", 1295], ["describe", 1298], ["general", 1307], ["features", 1315], ["that", 1324], ["can", 1329], ["guide", 1333], ["the", 1339], ["type", 1343], ["of", 1348], ["datasets", 1351], ["to", 1360], ["include", 1363], ["when", 1371], ["predicting", 1376], ["tissue", 1387], ["-", 1393], ["specific", 1394], ["enhancers", 1403], ["genome", 1413], ["-", 1419], ["wide", 1420], [",", 1424], ["while", 1426], ["providing", 1432], ["an", 1442], ["accessible", 1445], ["resource", 1456], ["to", 1465], ["the", 1468], ["general", 1472], ["biological", 1480], ["community", 1491], ["and", 1501], ["facilitating", 1505], ["the", 1518], ["functional", 1522], ["interpretation", 1533], ["of", 1548], ["genetic", 1551], ["studies", 1559], ["of", 1567], ["limb", 1570], ["malformations", 1575], [".", 1588]]}
{"context": "To assess the efficacy, usefulness, safety, and dosages of flumazenil required when flumazenil is used in the diagnosis of benzodiazepine-induced coma (vs. other drug-induced coma), and to reverse or prevent the recurrence of unconsciousness. A two-phase study: a controlled, randomized, double-blind study followed by a prospective, open study. An 800-bed, teaching, university-affiliated hospital. Unconscious patients (n = 110) suspected of benzodiazepine overdose, graded 2 to 4 on the Matthew and Lawson coma scale, were treated with flumazenil, the specific benzodiazepine receptor antagonist. The first 31 patients were studied in a double-blind fashion, while the rest of the patients were given flumazenil according to an open protocol. INTERVENTIONS; All patients received supplemental oxygen; endotracheal intubation was performed, and synchronized intermittent mandatory ventilation was initiated whenever it was deemed necessary. A peripheral intravenous cannula was inserted, as were indwelling arterial and urinary bladder catheters. Blood pressure, electrocardiogram, respiratory rate, end-tidal CO2, and core temperature were continuously monitored. The first 31 double-blind patients received either intravenous flumazenil (to a maximum of 1 mg) or saline, while the rest of the patients were given flumazenil until either regaining consciousness or a maximum of 2.5 mg was injected. Patients remaining unconscious among double-blind patients or those patients relapsing into coma after the first dose were later treated in the open phase of the study. Treatment continued by boluses or infusion as long as efficacious. Fourteen of 17 double-blind, flumazenil-treated patients woke after a mean of 0.8 +/- 0.3 (SD) mg vs. one of 14 placebo patients (p < .001). Seventy-five percent of the aggregated controlled and uncontrolled patients awoke from coma scores of 3.1 +/- 0.6 to 0.4 +/- 0.5 (p < .01) after the injection of 0.7 +/- 0.3 mg of flumazenil. These patients had high benzodiazepine serum blood concentrations. Twenty-five percent of the patients did not regain consciousness. These patients had very high serum concentrations of nonbenzodiazepine drugs. Sixty percent of the responders who had primarily ingested benzodiazepines remained awake for 72 +/- 37 mins after flumazenil administration; 40% relapsed into coma after 18 +/- 7 mins and various central nervous system depressant drugs were detected in their blood in addition to benzodiazepines. Seventy-one percent of the patients had ingested tricyclic antidepressants. Seventy-eight percent of the responders were continually and efficaciously treated for < or = 8 days. Fourteen (25%) of the intubated patients were extubated safely while 12 patients, who had shown increased respiratory insufficiency, resumed satisfactory respiration after flumazenil injection. Five cases of transient increase in blood pressure and heart rate were encountered. There were 27 mildly unpleasant \"waking\" episodes, such as anxiety, restlessness, and aggression, but no patient had benzodiazepine withdrawal signs, convulsions, or dysrhythmia, most noticeably absent in tricyclic antidepressant-intoxicated patients. Flumazenil is a valid diagnostic tool for distinguishing pure benzodiazepine from mixed-drug intoxication or nondrug-induced coma. Flumazenil is effective in preventing recurrence of benzodiazepine-induced coma. Respiratory insufficiency is reversed after its administration. Flumazenil is safe when administered cautiously, even in patients with coma caused by a mixed overdose of benzodiazepine plus tricyclic antidepressants.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "703c26f6e3614fc3ad84fedea34fc7ed", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[416, 416], [213, 213], [363, 363], [134, 134], [294, 294], [605, 605], [12, 12], [564, 564], [105, 105], [233, 233], [505, 505], [585, 585], [15, 15]], "char_spans": [[2297, 2306], [1230, 1239], [1959, 1968], [704, 713], [1667, 1676], [3464, 3473], [59, 68], [3188, 3197], [539, 548], [1317, 1326], [2830, 2839], [3319, 3328], [84, 93]]}]}], "context_tokens": [["To", 0], ["assess", 3], ["the", 10], ["efficacy", 14], [",", 22], ["usefulness", 24], [",", 34], ["safety", 36], [",", 42], ["and", 44], ["dosages", 48], ["of", 56], ["flumazenil", 59], ["required", 70], ["when", 79], ["flumazenil", 84], ["is", 95], ["used", 98], ["in", 103], ["the", 106], ["diagnosis", 110], ["of", 120], ["benzodiazepine", 123], ["-", 137], ["induced", 138], ["coma", 146], ["(", 151], ["vs.", 152], ["other", 156], ["drug", 162], ["-", 166], ["induced", 167], ["coma", 175], [")", 179], [",", 180], ["and", 182], ["to", 186], ["reverse", 189], ["or", 197], ["prevent", 200], ["the", 208], ["recurrence", 212], ["of", 223], ["unconsciousness", 226], [".", 241], ["A", 243], ["two", 245], ["-", 248], ["phase", 249], ["study", 255], [":", 260], ["a", 262], ["controlled", 264], [",", 274], ["randomized", 276], [",", 286], ["double", 288], ["-", 294], ["blind", 295], ["study", 301], ["followed", 307], ["by", 316], ["a", 319], ["prospective", 321], [",", 332], ["open", 334], ["study", 339], [".", 344], ["An", 346], ["800-bed", 349], [",", 356], ["teaching", 358], [",", 366], ["university", 368], ["-", 378], ["affiliated", 379], ["hospital", 390], [".", 398], ["Unconscious", 400], ["patients", 412], ["(", 421], ["n", 422], ["=", 424], ["110", 426], [")", 429], ["suspected", 431], ["of", 441], ["benzodiazepine", 444], ["overdose", 459], [",", 467], ["graded", 469], ["2", 476], ["to", 478], ["4", 481], ["on", 483], ["the", 486], ["Matthew", 490], ["and", 498], ["Lawson", 502], ["coma", 509], ["scale", 514], [",", 519], ["were", 521], ["treated", 526], ["with", 534], ["flumazenil", 539], [",", 549], ["the", 551], ["specific", 555], ["benzodiazepine", 564], ["receptor", 579], ["antagonist", 588], [".", 598], ["The", 600], ["first", 604], ["31", 610], ["patients", 613], ["were", 622], ["studied", 627], ["in", 635], ["a", 638], ["double", 640], ["-", 646], ["blind", 647], ["fashion", 653], [",", 660], ["while", 662], ["the", 668], ["rest", 672], ["of", 677], ["the", 680], ["patients", 684], ["were", 693], ["given", 698], ["flumazenil", 704], ["according", 715], ["to", 725], ["an", 728], ["open", 731], ["protocol", 736], [".", 744], ["INTERVENTIONS", 746], [";", 759], ["All", 761], ["patients", 765], ["received", 774], ["supplemental", 783], ["oxygen", 796], [";", 802], ["endotracheal", 804], ["intubation", 817], ["was", 828], ["performed", 832], [",", 841], ["and", 843], ["synchronized", 847], ["intermittent", 860], ["mandatory", 873], ["ventilation", 883], ["was", 895], ["initiated", 899], ["whenever", 909], ["it", 918], ["was", 921], ["deemed", 925], ["necessary", 932], [".", 941], ["A", 943], ["peripheral", 945], ["intravenous", 956], ["cannula", 968], ["was", 976], ["inserted", 980], [",", 988], ["as", 990], ["were", 993], ["indwelling", 998], ["arterial", 1009], ["and", 1018], ["urinary", 1022], ["bladder", 1030], ["catheters", 1038], [".", 1047], ["Blood", 1049], ["pressure", 1055], [",", 1063], ["electrocardiogram", 1065], [",", 1082], ["respiratory", 1084], ["rate", 1096], [",", 1100], ["end", 1102], ["-", 1105], ["tidal", 1106], ["CO2", 1112], [",", 1115], ["and", 1117], ["core", 1121], ["temperature", 1126], ["were", 1138], ["continuously", 1143], ["monitored", 1156], [".", 1165], ["The", 1167], ["first", 1171], ["31", 1177], ["double", 1180], ["-", 1186], ["blind", 1187], ["patients", 1193], ["received", 1202], ["either", 1211], ["intravenous", 1218], ["flumazenil", 1230], ["(", 1241], ["to", 1242], ["a", 1245], ["maximum", 1247], ["of", 1255], ["1", 1258], ["mg", 1260], [")", 1262], ["or", 1264], ["saline", 1267], [",", 1273], ["while", 1275], ["the", 1281], ["rest", 1285], ["of", 1290], ["the", 1293], ["patients", 1297], ["were", 1306], ["given", 1311], ["flumazenil", 1317], ["until", 1328], ["either", 1334], ["regaining", 1341], ["consciousness", 1351], ["or", 1365], ["a", 1368], ["maximum", 1370], ["of", 1378], ["2.5", 1381], ["mg", 1385], ["was", 1388], ["injected", 1392], [".", 1400], ["Patients", 1402], ["remaining", 1411], ["unconscious", 1421], ["among", 1433], ["double", 1439], ["-", 1445], ["blind", 1446], ["patients", 1452], ["or", 1461], ["those", 1464], ["patients", 1470], ["relapsing", 1479], ["into", 1489], ["coma", 1494], ["after", 1499], ["the", 1505], ["first", 1509], ["dose", 1515], ["were", 1520], ["later", 1525], ["treated", 1531], ["in", 1539], ["the", 1542], ["open", 1546], ["phase", 1551], ["of", 1557], ["the", 1560], ["study", 1564], [".", 1569], ["Treatment", 1571], ["continued", 1581], ["by", 1591], ["boluses", 1594], ["or", 1602], ["infusion", 1605], ["as", 1614], ["long", 1617], ["as", 1622], ["efficacious", 1625], [".", 1636], ["Fourteen", 1638], ["of", 1647], ["17", 1650], ["double", 1653], ["-", 1659], ["blind", 1660], [",", 1665], ["flumazenil", 1667], ["-", 1677], ["treated", 1678], ["patients", 1686], ["woke", 1695], ["after", 1700], ["a", 1706], ["mean", 1708], ["of", 1713], ["0.8", 1716], ["+", 1720], ["/-", 1721], ["0.3", 1724], ["(", 1728], ["SD", 1729], [")", 1731], ["mg", 1733], ["vs.", 1736], ["one", 1740], ["of", 1744], ["14", 1747], ["placebo", 1750], ["patients", 1758], ["(", 1767], ["p", 1768], ["<", 1770], [".001", 1772], [")", 1776], [".", 1777], ["Seventy", 1779], ["-", 1786], ["five", 1787], ["percent", 1792], ["of", 1800], ["the", 1803], ["aggregated", 1807], ["controlled", 1818], ["and", 1829], ["uncontrolled", 1833], ["patients", 1846], ["awoke", 1855], ["from", 1861], ["coma", 1866], ["scores", 1871], ["of", 1878], ["3.1", 1881], ["+", 1885], ["/-", 1886], ["0.6", 1889], ["to", 1893], ["0.4", 1896], ["+", 1900], ["/-", 1901], ["0.5", 1904], ["(", 1908], ["p", 1909], ["<", 1911], [".01", 1913], [")", 1916], ["after", 1918], ["the", 1924], ["injection", 1928], ["of", 1938], ["0.7", 1941], ["+", 1945], ["/-", 1946], ["0.3", 1949], ["mg", 1953], ["of", 1956], ["flumazenil", 1959], [".", 1969], ["These", 1971], ["patients", 1977], ["had", 1986], ["high", 1990], ["benzodiazepine", 1995], ["serum", 2010], ["blood", 2016], ["concentrations", 2022], [".", 2036], ["Twenty", 2038], ["-", 2044], ["five", 2045], ["percent", 2050], ["of", 2058], ["the", 2061], ["patients", 2065], ["did", 2074], ["not", 2078], ["regain", 2082], ["consciousness", 2089], [".", 2102], ["These", 2104], ["patients", 2110], ["had", 2119], ["very", 2123], ["high", 2128], ["serum", 2133], ["concentrations", 2139], ["of", 2154], ["nonbenzodiazepine", 2157], ["drugs", 2175], [".", 2180], ["Sixty", 2182], ["percent", 2188], ["of", 2196], ["the", 2199], ["responders", 2203], ["who", 2214], ["had", 2218], ["primarily", 2222], ["ingested", 2232], ["benzodiazepines", 2241], ["remained", 2257], ["awake", 2266], ["for", 2272], ["72", 2276], ["+", 2279], ["/-", 2280], ["37", 2283], ["mins", 2286], ["after", 2291], ["flumazenil", 2297], ["administration", 2308], [";", 2322], ["40", 2324], ["%", 2326], ["relapsed", 2328], ["into", 2337], ["coma", 2342], ["after", 2347], ["18", 2353], ["+", 2356], ["/-", 2357], ["7", 2360], ["mins", 2362], ["and", 2367], ["various", 2371], ["central", 2379], ["nervous", 2387], ["system", 2395], ["depressant", 2402], ["drugs", 2413], ["were", 2419], ["detected", 2424], ["in", 2433], ["their", 2436], ["blood", 2442], ["in", 2448], ["addition", 2451], ["to", 2460], ["benzodiazepines", 2463], [".", 2478], ["Seventy", 2480], ["-", 2487], ["one", 2488], ["percent", 2492], ["of", 2500], ["the", 2503], ["patients", 2507], ["had", 2516], ["ingested", 2520], ["tricyclic", 2529], ["antidepressants", 2539], [".", 2554], ["Seventy", 2556], ["-", 2563], ["eight", 2564], ["percent", 2570], ["of", 2578], ["the", 2581], ["responders", 2585], ["were", 2596], ["continually", 2601], ["and", 2613], ["efficaciously", 2617], ["treated", 2631], ["for", 2639], ["<", 2643], ["or", 2645], ["=", 2648], ["8", 2650], ["days", 2652], [".", 2656], ["Fourteen", 2658], ["(", 2667], ["25", 2668], ["%", 2670], [")", 2671], ["of", 2673], ["the", 2676], ["intubated", 2680], ["patients", 2690], ["were", 2699], ["extubated", 2704], ["safely", 2714], ["while", 2721], ["12", 2727], ["patients", 2730], [",", 2738], ["who", 2740], ["had", 2744], ["shown", 2748], ["increased", 2754], ["respiratory", 2764], ["insufficiency", 2776], [",", 2789], ["resumed", 2791], ["satisfactory", 2799], ["respiration", 2812], ["after", 2824], ["flumazenil", 2830], ["injection", 2841], [".", 2850], ["Five", 2852], ["cases", 2857], ["of", 2863], ["transient", 2866], ["increase", 2876], ["in", 2885], ["blood", 2888], ["pressure", 2894], ["and", 2903], ["heart", 2907], ["rate", 2913], ["were", 2918], ["encountered", 2923], [".", 2934], ["There", 2936], ["were", 2942], ["27", 2947], ["mildly", 2950], ["unpleasant", 2957], ["\"", 2968], ["waking", 2969], ["\"", 2975], ["episodes", 2977], [",", 2985], ["such", 2987], ["as", 2992], ["anxiety", 2995], [",", 3002], ["restlessness", 3004], [",", 3016], ["and", 3018], ["aggression", 3022], [",", 3032], ["but", 3034], ["no", 3038], ["patient", 3041], ["had", 3049], ["benzodiazepine", 3053], ["withdrawal", 3068], ["signs", 3079], [",", 3084], ["convulsions", 3086], [",", 3097], ["or", 3099], ["dysrhythmia", 3102], [",", 3113], ["most", 3115], ["noticeably", 3120], ["absent", 3131], ["in", 3138], ["tricyclic", 3141], ["antidepressant", 3151], ["-", 3165], ["intoxicated", 3166], ["patients", 3178], [".", 3186], ["Flumazenil", 3188], ["is", 3199], ["a", 3202], ["valid", 3204], ["diagnostic", 3210], ["tool", 3221], ["for", 3226], ["distinguishing", 3230], ["pure", 3245], ["benzodiazepine", 3250], ["from", 3265], ["mixed", 3270], ["-", 3275], ["drug", 3276], ["intoxication", 3281], ["or", 3294], ["nondrug", 3297], ["-", 3304], ["induced", 3305], ["coma", 3313], [".", 3317], ["Flumazenil", 3319], ["is", 3330], ["effective", 3333], ["in", 3343], ["preventing", 3346], ["recurrence", 3357], ["of", 3368], ["benzodiazepine", 3371], ["-", 3385], ["induced", 3386], ["coma", 3394], [".", 3398], ["Respiratory", 3400], ["insufficiency", 3412], ["is", 3426], ["reversed", 3429], ["after", 3438], ["its", 3444], ["administration", 3448], [".", 3462], ["Flumazenil", 3464], ["is", 3475], ["safe", 3478], ["when", 3483], ["administered", 3488], ["cautiously", 3501], [",", 3511], ["even", 3513], ["in", 3518], ["patients", 3521], ["with", 3530], ["coma", 3535], ["caused", 3540], ["by", 3547], ["a", 3550], ["mixed", 3552], ["overdose", 3558], ["of", 3567], ["benzodiazepine", 3570], ["plus", 3585], ["tricyclic", 3590], ["antidepressants", 3600], [".", 3615]]}
{"context": "1. In order to investigate the biological function of the human CLN3 gene that is defective in Batten disease, we created a yeast strain by PCR-targeted disruption of the yeast gene (YHC3), which is a homologue of the human CLN3 gene. 2. The phenotypic characterization revealed that the yhc3 delta mutants are more sensitive to combined heat and alkaline stress than the wild-type strains as determined by inhibition of cell proliferation. 3. This suggests that the yhc3 delta mutant is a good model to investigate the biological function of human CLN3 gene in mammalian cells and to understand the pathophysiology of juvenile Batten disease.", "qas": [{"question": "What is the effect of a defective CLN3 gene?", "answers": ["Batten disease", "juvenile-onset neuronal ceroid lipofuscinosis", "JNCL"], "qid": "9bb5d9f90f804b34971f0a239f63343b", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["effect", 12], ["of", 19], ["a", 22], ["defective", 24], ["CLN3", 34], ["gene", 39], ["?", 43]], "detected_answers": [{"text": "Batten disease", "token_spans": [[18, 19], [115, 116]], "char_spans": [[95, 108], [628, 641]]}]}], "context_tokens": [["1", 0], [".", 1], ["In", 3], ["order", 6], ["to", 12], ["investigate", 15], ["the", 27], ["biological", 31], ["function", 42], ["of", 51], ["the", 54], ["human", 58], ["CLN3", 64], ["gene", 69], ["that", 74], ["is", 79], ["defective", 82], ["in", 92], ["Batten", 95], ["disease", 102], [",", 109], ["we", 111], ["created", 114], ["a", 122], ["yeast", 124], ["strain", 130], ["by", 137], ["PCR", 140], ["-", 143], ["targeted", 144], ["disruption", 153], ["of", 164], ["the", 167], ["yeast", 171], ["gene", 177], ["(", 182], ["YHC3", 183], [")", 187], [",", 188], ["which", 190], ["is", 196], ["a", 199], ["homologue", 201], ["of", 211], ["the", 214], ["human", 218], ["CLN3", 224], ["gene", 229], [".", 233], ["2", 235], [".", 236], ["The", 238], ["phenotypic", 242], ["characterization", 253], ["revealed", 270], ["that", 279], ["the", 284], ["yhc3", 288], ["delta", 293], ["mutants", 299], ["are", 307], ["more", 311], ["sensitive", 316], ["to", 326], ["combined", 329], ["heat", 338], ["and", 343], ["alkaline", 347], ["stress", 356], ["than", 363], ["the", 368], ["wild", 372], ["-", 376], ["type", 377], ["strains", 382], ["as", 390], ["determined", 393], ["by", 404], ["inhibition", 407], ["of", 418], ["cell", 421], ["proliferation", 426], [".", 439], ["3", 441], [".", 442], ["This", 444], ["suggests", 449], ["that", 458], ["the", 463], ["yhc3", 467], ["delta", 472], ["mutant", 478], ["is", 485], ["a", 488], ["good", 490], ["model", 495], ["to", 501], ["investigate", 504], ["the", 516], ["biological", 520], ["function", 531], ["of", 540], ["human", 543], ["CLN3", 549], ["gene", 554], ["in", 559], ["mammalian", 562], ["cells", 572], ["and", 578], ["to", 582], ["understand", 585], ["the", 596], ["pathophysiology", 600], ["of", 616], ["juvenile", 619], ["Batten", 628], ["disease", 635], [".", 642]]}
{"context": "With an ageing population and improving cancer therapies, the two most common benign and malignant bone diseases, osteoporosis and bone metastases, will continue to affect an increasing number of patients. Our expanding knowledge of the molecular processes underlying these conditions has resulted in novel bone targets that are currently being explored in clinical trials. Clearly, the approval of denosumab, a monoclonal antibody directed against RANKL, has just marked the beginning of a new era for bone therapy with several additional new therapies lining up for clinical approval in the coming years. Potential agents targeting the osteoclast include cathepsin K, currently in phase 3 trials, and src inhibitors. Amongst anabolic agents, inhibitors of the Wnt-inhibitor sclerostin and dickkopf-1 are promising in clinical trials. Here, we will provide a comprehensive overview of the most promising agents currently explored for the treatment of bone diseases.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "ba391f992ee74328aaba8df43265479c", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[71, 71]], "char_spans": [[449, 453]]}]}], "context_tokens": [["With", 0], ["an", 5], ["ageing", 8], ["population", 15], ["and", 26], ["improving", 30], ["cancer", 40], ["therapies", 47], [",", 56], ["the", 58], ["two", 62], ["most", 66], ["common", 71], ["benign", 78], ["and", 85], ["malignant", 89], ["bone", 99], ["diseases", 104], [",", 112], ["osteoporosis", 114], ["and", 127], ["bone", 131], ["metastases", 136], [",", 146], ["will", 148], ["continue", 153], ["to", 162], ["affect", 165], ["an", 172], ["increasing", 175], ["number", 186], ["of", 193], ["patients", 196], [".", 204], ["Our", 206], ["expanding", 210], ["knowledge", 220], ["of", 230], ["the", 233], ["molecular", 237], ["processes", 247], ["underlying", 257], ["these", 268], ["conditions", 274], ["has", 285], ["resulted", 289], ["in", 298], ["novel", 301], ["bone", 307], ["targets", 312], ["that", 320], ["are", 325], ["currently", 329], ["being", 339], ["explored", 345], ["in", 354], ["clinical", 357], ["trials", 366], [".", 372], ["Clearly", 374], [",", 381], ["the", 383], ["approval", 387], ["of", 396], ["denosumab", 399], [",", 408], ["a", 410], ["monoclonal", 412], ["antibody", 423], ["directed", 432], ["against", 441], ["RANKL", 449], [",", 454], ["has", 456], ["just", 460], ["marked", 465], ["the", 472], ["beginning", 476], ["of", 486], ["a", 489], ["new", 491], ["era", 495], ["for", 499], ["bone", 503], ["therapy", 508], ["with", 516], ["several", 521], ["additional", 529], ["new", 540], ["therapies", 544], ["lining", 554], ["up", 561], ["for", 564], ["clinical", 568], ["approval", 577], ["in", 586], ["the", 589], ["coming", 593], ["years", 600], [".", 605], ["Potential", 607], ["agents", 617], ["targeting", 624], ["the", 634], ["osteoclast", 638], ["include", 649], ["cathepsin", 657], ["K", 667], [",", 668], ["currently", 670], ["in", 680], ["phase", 683], ["3", 689], ["trials", 691], [",", 697], ["and", 699], ["src", 703], ["inhibitors", 707], [".", 717], ["Amongst", 719], ["anabolic", 727], ["agents", 736], [",", 742], ["inhibitors", 744], ["of", 755], ["the", 758], ["Wnt", 762], ["-", 765], ["inhibitor", 766], ["sclerostin", 776], ["and", 787], ["dickkopf-1", 791], ["are", 802], ["promising", 806], ["in", 816], ["clinical", 819], ["trials", 828], [".", 834], ["Here", 836], [",", 840], ["we", 842], ["will", 845], ["provide", 850], ["a", 858], ["comprehensive", 860], ["overview", 874], ["of", 883], ["the", 886], ["most", 890], ["promising", 895], ["agents", 905], ["currently", 912], ["explored", 922], ["for", 931], ["the", 935], ["treatment", 939], ["of", 949], ["bone", 952], ["diseases", 957], [".", 965]]}
{"context": "Nestin is a unique intermediate filament protein. While it is robustly expressed in developing brain, postnatal expression is limited to the brain's subventricular zone (SVZ) and endothelial cells. Reexpression occurs, however, under several pathological conditions, including injury and neoplasia. We hypothesized that nestin would be a sensitive marker of early neoplasia after transplacental exposure of rats to ethylnitrosourea (ENU). Rats of various ages were administered bromodeoxyuridine (BudR) before sacrifice, and brain sections were examined for proliferative cells and several immunohistochemical markers, including nestin. Additional rats were examined after a stab wound injury to assess the expression of two of these markers, GFAP and nestin, in reactive astrocytes. All ENU-induced brain tumors (n = 9) were classified as gliomas (astrocytomas or oligoastrocytomas) based on their histology and immunophenotype. Nestin expression was noted in all tumors examined and was present in tumor cells as well as endothelial cells. During tumor development, we consistently noted nestin-expressing cells bearing multiple processes distributed throughout brain parenchyma. Both single cells and multiple cell clusters were observed as early as postnatal day 30 in all ENU-exposed brains examined (n = 11). Such distinctive nestin-expressing cells were not seen in nestin-stained control brains or ENU-exposed brains stained for GFAP or vimentin, nor was such a cell seen in a stab wound model used to assess reactive astrocytosis. While the number of these clusters was highly variable among rats, their size increased between 30 and 90 days. The data suggest that these nestin-expressing cells represent an early stage of the neoplastic process. It remains to be determined whether these cells become apparent at 30 days of age due to \"dedifferentiation\" of a local resident astrocyte or astrocyte precursor cell or migration of a relatively undifferentiated precursor/stem cell from the SVZ.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "36dc5cbeedc44c65ab77495e3f481e0d", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[0, 0], [224, 224], [99, 99], [155, 155], [122, 122], [182, 182], [291, 291], [52, 52], [232, 232]], "char_spans": [[0, 5], [1332, 1337], [629, 634], [930, 935], [752, 757], [1090, 1095], [1680, 1685], [320, 325], [1373, 1378]]}]}], "context_tokens": [["Nestin", 0], ["is", 7], ["a", 10], ["unique", 12], ["intermediate", 19], ["filament", 32], ["protein", 41], [".", 48], ["While", 50], ["it", 56], ["is", 59], ["robustly", 62], ["expressed", 71], ["in", 81], ["developing", 84], ["brain", 95], [",", 100], ["postnatal", 102], ["expression", 112], ["is", 123], ["limited", 126], ["to", 134], ["the", 137], ["brain", 141], ["'s", 146], ["subventricular", 149], ["zone", 164], ["(", 169], ["SVZ", 170], [")", 173], ["and", 175], ["endothelial", 179], ["cells", 191], [".", 196], ["Reexpression", 198], ["occurs", 211], [",", 217], ["however", 219], [",", 226], ["under", 228], ["several", 234], ["pathological", 242], ["conditions", 255], [",", 265], ["including", 267], ["injury", 277], ["and", 284], ["neoplasia", 288], [".", 297], ["We", 299], ["hypothesized", 302], ["that", 315], ["nestin", 320], ["would", 327], ["be", 333], ["a", 336], ["sensitive", 338], ["marker", 348], ["of", 355], ["early", 358], ["neoplasia", 364], ["after", 374], ["transplacental", 380], ["exposure", 395], ["of", 404], ["rats", 407], ["to", 412], ["ethylnitrosourea", 415], ["(", 432], ["ENU", 433], [")", 436], [".", 437], ["Rats", 439], ["of", 444], ["various", 447], ["ages", 455], ["were", 460], ["administered", 465], ["bromodeoxyuridine", 478], ["(", 496], ["BudR", 497], [")", 501], ["before", 503], ["sacrifice", 510], [",", 519], ["and", 521], ["brain", 525], ["sections", 531], ["were", 540], ["examined", 545], ["for", 554], ["proliferative", 558], ["cells", 572], ["and", 578], ["several", 582], ["immunohistochemical", 590], ["markers", 610], [",", 617], ["including", 619], ["nestin", 629], [".", 635], ["Additional", 637], ["rats", 648], ["were", 653], ["examined", 658], ["after", 667], ["a", 673], ["stab", 675], ["wound", 680], ["injury", 686], ["to", 693], ["assess", 696], ["the", 703], ["expression", 707], ["of", 718], ["two", 721], ["of", 725], ["these", 728], ["markers", 734], [",", 741], ["GFAP", 743], ["and", 748], ["nestin", 752], [",", 758], ["in", 760], ["reactive", 763], ["astrocytes", 772], [".", 782], ["All", 784], ["ENU", 788], ["-", 791], ["induced", 792], ["brain", 800], ["tumors", 806], ["(", 813], ["n", 814], ["=", 816], ["9", 818], [")", 819], ["were", 821], ["classified", 826], ["as", 837], ["gliomas", 840], ["(", 848], ["astrocytomas", 849], ["or", 862], ["oligoastrocytomas", 865], [")", 882], ["based", 884], ["on", 890], ["their", 893], ["histology", 899], ["and", 909], ["immunophenotype", 913], [".", 928], ["Nestin", 930], ["expression", 937], ["was", 948], ["noted", 952], ["in", 958], ["all", 961], ["tumors", 965], ["examined", 972], ["and", 981], ["was", 985], ["present", 989], ["in", 997], ["tumor", 1000], ["cells", 1006], ["as", 1012], ["well", 1015], ["as", 1020], ["endothelial", 1023], ["cells", 1035], [".", 1040], ["During", 1042], ["tumor", 1049], ["development", 1055], [",", 1066], ["we", 1068], ["consistently", 1071], ["noted", 1084], ["nestin", 1090], ["-", 1096], ["expressing", 1097], ["cells", 1108], ["bearing", 1114], ["multiple", 1122], ["processes", 1131], ["distributed", 1141], ["throughout", 1153], ["brain", 1164], ["parenchyma", 1170], [".", 1180], ["Both", 1182], ["single", 1187], ["cells", 1194], ["and", 1200], ["multiple", 1204], ["cell", 1213], ["clusters", 1218], ["were", 1227], ["observed", 1232], ["as", 1241], ["early", 1244], ["as", 1250], ["postnatal", 1253], ["day", 1263], ["30", 1267], ["in", 1270], ["all", 1273], ["ENU", 1277], ["-", 1280], ["exposed", 1281], ["brains", 1289], ["examined", 1296], ["(", 1305], ["n", 1306], ["=", 1308], ["11", 1310], [")", 1312], [".", 1313], ["Such", 1315], ["distinctive", 1320], ["nestin", 1332], ["-", 1338], ["expressing", 1339], ["cells", 1350], ["were", 1356], ["not", 1361], ["seen", 1365], ["in", 1370], ["nestin", 1373], ["-", 1379], ["stained", 1380], ["control", 1388], ["brains", 1396], ["or", 1403], ["ENU", 1406], ["-", 1409], ["exposed", 1410], ["brains", 1418], ["stained", 1425], ["for", 1433], ["GFAP", 1437], ["or", 1442], ["vimentin", 1445], [",", 1453], ["nor", 1455], ["was", 1459], ["such", 1463], ["a", 1468], ["cell", 1470], ["seen", 1475], ["in", 1480], ["a", 1483], ["stab", 1485], ["wound", 1490], ["model", 1496], ["used", 1502], ["to", 1507], ["assess", 1510], ["reactive", 1517], ["astrocytosis", 1526], [".", 1538], ["While", 1540], ["the", 1546], ["number", 1550], ["of", 1557], ["these", 1560], ["clusters", 1566], ["was", 1575], ["highly", 1579], ["variable", 1586], ["among", 1595], ["rats", 1601], [",", 1605], ["their", 1607], ["size", 1613], ["increased", 1618], ["between", 1628], ["30", 1636], ["and", 1639], ["90", 1643], ["days", 1646], [".", 1650], ["The", 1652], ["data", 1656], ["suggest", 1661], ["that", 1669], ["these", 1674], ["nestin", 1680], ["-", 1686], ["expressing", 1687], ["cells", 1698], ["represent", 1704], ["an", 1714], ["early", 1717], ["stage", 1723], ["of", 1729], ["the", 1732], ["neoplastic", 1736], ["process", 1747], [".", 1754], ["It", 1756], ["remains", 1759], ["to", 1767], ["be", 1770], ["determined", 1773], ["whether", 1784], ["these", 1792], ["cells", 1798], ["become", 1804], ["apparent", 1811], ["at", 1820], ["30", 1823], ["days", 1826], ["of", 1831], ["age", 1834], ["due", 1838], ["to", 1842], ["\"", 1845], ["dedifferentiation", 1846], ["\"", 1863], ["of", 1865], ["a", 1868], ["local", 1870], ["resident", 1876], ["astrocyte", 1885], ["or", 1895], ["astrocyte", 1898], ["precursor", 1908], ["cell", 1918], ["or", 1923], ["migration", 1926], ["of", 1936], ["a", 1939], ["relatively", 1941], ["undifferentiated", 1952], ["precursor", 1969], ["/", 1978], ["stem", 1979], ["cell", 1984], ["from", 1989], ["the", 1994], ["SVZ", 1998], [".", 2001]]}
{"context": "Parkinson's disease (PD) is a neurodegnerative disorder that is pathologically characterized by the presence of Lewy bodies in the brain. We show that Lewy bodies in PD are strongly immunoreactive for torsinA, the protein product of the DYT1 gene, which is associated with primary generalized dystonia. In the substantia nigra, torsinA immunoreactivity is localized to the periphery of Lewy bodies, whereas, in cortical Lewy bodies it is uniformly distributed. The significance of this finding is unknown, but may implicate torsinA in neuronal dysfunction that occurs in PD as well as in primary dystonia.", "qas": [{"question": "Which disease of the central nervous system is characterized by the presence of Lewy bodies?", "answers": ["Parkinson's disease (PD)"], "qid": "630e6932bb704bc7a85107087e4dd2ea", "question_tokens": [["Which", 0], ["disease", 6], ["of", 14], ["the", 17], ["central", 21], ["nervous", 29], ["system", 37], ["is", 44], ["characterized", 47], ["by", 61], ["the", 64], ["presence", 68], ["of", 77], ["Lewy", 80], ["bodies", 85], ["?", 91]], "detected_answers": [{"text": "Parkinson's disease (PD)", "token_spans": [[0, 4]], "char_spans": [[0, 22]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["is", 25], ["a", 28], ["neurodegnerative", 30], ["disorder", 47], ["that", 56], ["is", 61], ["pathologically", 64], ["characterized", 79], ["by", 93], ["the", 96], ["presence", 100], ["of", 109], ["Lewy", 112], ["bodies", 117], ["in", 124], ["the", 127], ["brain", 131], [".", 136], ["We", 138], ["show", 141], ["that", 146], ["Lewy", 151], ["bodies", 156], ["in", 163], ["PD", 166], ["are", 169], ["strongly", 173], ["immunoreactive", 182], ["for", 197], ["torsinA", 201], [",", 208], ["the", 210], ["protein", 214], ["product", 222], ["of", 230], ["the", 233], ["DYT1", 237], ["gene", 242], [",", 246], ["which", 248], ["is", 254], ["associated", 257], ["with", 268], ["primary", 273], ["generalized", 281], ["dystonia", 293], [".", 301], ["In", 303], ["the", 306], ["substantia", 310], ["nigra", 321], [",", 326], ["torsinA", 328], ["immunoreactivity", 336], ["is", 353], ["localized", 356], ["to", 366], ["the", 369], ["periphery", 373], ["of", 383], ["Lewy", 386], ["bodies", 391], [",", 397], ["whereas", 399], [",", 406], ["in", 408], ["cortical", 411], ["Lewy", 420], ["bodies", 425], ["it", 432], ["is", 435], ["uniformly", 438], ["distributed", 448], [".", 459], ["The", 461], ["significance", 465], ["of", 478], ["this", 481], ["finding", 486], ["is", 494], ["unknown", 497], [",", 504], ["but", 506], ["may", 510], ["implicate", 514], ["torsinA", 524], ["in", 532], ["neuronal", 535], ["dysfunction", 544], ["that", 556], ["occurs", 561], ["in", 568], ["PD", 571], ["as", 574], ["well", 577], ["as", 582], ["in", 585], ["primary", 588], ["dystonia", 596], [".", 604]]}
{"context": "Chronic myelogenous leukemia (CML) is characterized by a molecular aberration, a fusion BCR-ABL gene encoding for aberrant tyrosine kinase activity, which is crucial in the pathogenesis of CML. In vitro, inhibition of BCR-ABL protein tyrosine kinase activity by a tyrosine kinase inhibitor, Imatinib mesylate (STI571; formerly CGP57148B), successfully suppressed proliferation/survival of the BCR-ABL positive clones. In clinical studies, hematologic and cytogenetic remissions have been achieved in most patients with chronic phase CML; in accelerated and blastic phases of CML, STI571 appeared less effective. In the current study, the authors tested combinations of STI571 and cytarabine and homoharringtonine (HHT), drugs with documented activity in CML. The single agents and their combinations were studied for in vitro effect on proliferation of BCR-ABL positive cell lines KBM5 and KBM7 by 3(4,5-dimethylthiazol-2yl)-2,5 diphenyl-tetrazolium bromide assay and on primary patient-derived BCR-ABL cells by clonogenic assays. The in vitro additive, synergistic, or antagonistic effects of cytarabine and HHT with STI571 were then investigated by computer-assisted analysis using the CalcuSyn software. STI571 consistently suppressed BCR-ABL positive cell proliferation with a dose-effect correlation. In the model system used, STI571/cytarabine and STI571/HHT combinations were more effective in inhibiting KBM5 and KBM7 cell growth than each drug as single agent. These results were also verified in primary CML-derived clonogenic cells in semisolid cultures. In this experimental system, our studies documented additive or synergistic effects with STI571 plus cytarabine or HHT, supporting the future use of STI571 combinations in clinical trials in patients with Philadelphia chromosome-positive leukemias.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "ee0fc9bc759e4496ab701a203ebb0a81", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[148, 150], [69, 71], [170, 172], [40, 42], [210, 212], [15, 17]], "char_spans": [[853, 859], [393, 399], [995, 1001], [218, 224], [1238, 1244], [88, 94]]}]}], "context_tokens": [["Chronic", 0], ["myelogenous", 8], ["leukemia", 20], ["(", 29], ["CML", 30], [")", 33], ["is", 35], ["characterized", 38], ["by", 52], ["a", 55], ["molecular", 57], ["aberration", 67], [",", 77], ["a", 79], ["fusion", 81], ["BCR", 88], ["-", 91], ["ABL", 92], ["gene", 96], ["encoding", 101], ["for", 110], ["aberrant", 114], ["tyrosine", 123], ["kinase", 132], ["activity", 139], [",", 147], ["which", 149], ["is", 155], ["crucial", 158], ["in", 166], ["the", 169], ["pathogenesis", 173], ["of", 186], ["CML", 189], [".", 192], ["In", 194], ["vitro", 197], [",", 202], ["inhibition", 204], ["of", 215], ["BCR", 218], ["-", 221], ["ABL", 222], ["protein", 226], ["tyrosine", 234], ["kinase", 243], ["activity", 250], ["by", 259], ["a", 262], ["tyrosine", 264], ["kinase", 273], ["inhibitor", 280], [",", 289], ["Imatinib", 291], ["mesylate", 300], ["(", 309], ["STI571", 310], [";", 316], ["formerly", 318], ["CGP57148B", 327], [")", 336], [",", 337], ["successfully", 339], ["suppressed", 352], ["proliferation", 363], ["/", 376], ["survival", 377], ["of", 386], ["the", 389], ["BCR", 393], ["-", 396], ["ABL", 397], ["positive", 401], ["clones", 410], [".", 416], ["In", 418], ["clinical", 421], ["studies", 430], [",", 437], ["hematologic", 439], ["and", 451], ["cytogenetic", 455], ["remissions", 467], ["have", 478], ["been", 483], ["achieved", 488], ["in", 497], ["most", 500], ["patients", 505], ["with", 514], ["chronic", 519], ["phase", 527], ["CML", 533], [";", 536], ["in", 538], ["accelerated", 541], ["and", 553], ["blastic", 557], ["phases", 565], ["of", 572], ["CML", 575], [",", 578], ["STI571", 580], ["appeared", 587], ["less", 596], ["effective", 601], [".", 610], ["In", 612], ["the", 615], ["current", 619], ["study", 627], [",", 632], ["the", 634], ["authors", 638], ["tested", 646], ["combinations", 653], ["of", 666], ["STI571", 669], ["and", 676], ["cytarabine", 680], ["and", 691], ["homoharringtonine", 695], ["(", 713], ["HHT", 714], [")", 717], [",", 718], ["drugs", 720], ["with", 726], ["documented", 731], ["activity", 742], ["in", 751], ["CML", 754], [".", 757], ["The", 759], ["single", 763], ["agents", 770], ["and", 777], ["their", 781], ["combinations", 787], ["were", 800], ["studied", 805], ["for", 813], ["in", 817], ["vitro", 820], ["effect", 826], ["on", 833], ["proliferation", 836], ["of", 850], ["BCR", 853], ["-", 856], ["ABL", 857], ["positive", 861], ["cell", 870], ["lines", 875], ["KBM5", 881], ["and", 886], ["KBM7", 890], ["by", 895], ["3(4,5-dimethylthiazol-2yl)-2,5", 898], ["diphenyl", 929], ["-", 937], ["tetrazolium", 938], ["bromide", 950], ["assay", 958], ["and", 964], ["on", 968], ["primary", 971], ["patient", 979], ["-", 986], ["derived", 987], ["BCR", 995], ["-", 998], ["ABL", 999], ["cells", 1003], ["by", 1009], ["clonogenic", 1012], ["assays", 1023], [".", 1029], ["The", 1031], ["in", 1035], ["vitro", 1038], ["additive", 1044], [",", 1052], ["synergistic", 1054], [",", 1065], ["or", 1067], ["antagonistic", 1070], ["effects", 1083], ["of", 1091], ["cytarabine", 1094], ["and", 1105], ["HHT", 1109], ["with", 1113], ["STI571", 1118], ["were", 1125], ["then", 1130], ["investigated", 1135], ["by", 1148], ["computer", 1151], ["-", 1159], ["assisted", 1160], ["analysis", 1169], ["using", 1178], ["the", 1184], ["CalcuSyn", 1188], ["software", 1197], [".", 1205], ["STI571", 1207], ["consistently", 1214], ["suppressed", 1227], ["BCR", 1238], ["-", 1241], ["ABL", 1242], ["positive", 1246], ["cell", 1255], ["proliferation", 1260], ["with", 1274], ["a", 1279], ["dose", 1281], ["-", 1285], ["effect", 1286], ["correlation", 1293], [".", 1304], ["In", 1306], ["the", 1309], ["model", 1313], ["system", 1319], ["used", 1326], [",", 1330], ["STI571/cytarabine", 1332], ["and", 1350], ["STI571/HHT", 1354], ["combinations", 1365], ["were", 1378], ["more", 1383], ["effective", 1388], ["in", 1398], ["inhibiting", 1401], ["KBM5", 1412], ["and", 1417], ["KBM7", 1421], ["cell", 1426], ["growth", 1431], ["than", 1438], ["each", 1443], ["drug", 1448], ["as", 1453], ["single", 1456], ["agent", 1463], [".", 1468], ["These", 1470], ["results", 1476], ["were", 1484], ["also", 1489], ["verified", 1494], ["in", 1503], ["primary", 1506], ["CML", 1514], ["-", 1517], ["derived", 1518], ["clonogenic", 1526], ["cells", 1537], ["in", 1543], ["semisolid", 1546], ["cultures", 1556], [".", 1564], ["In", 1566], ["this", 1569], ["experimental", 1574], ["system", 1587], [",", 1593], ["our", 1595], ["studies", 1599], ["documented", 1607], ["additive", 1618], ["or", 1627], ["synergistic", 1630], ["effects", 1642], ["with", 1650], ["STI571", 1655], ["plus", 1662], ["cytarabine", 1667], ["or", 1678], ["HHT", 1681], [",", 1684], ["supporting", 1686], ["the", 1697], ["future", 1701], ["use", 1708], ["of", 1712], ["STI571", 1715], ["combinations", 1722], ["in", 1735], ["clinical", 1738], ["trials", 1747], ["in", 1754], ["patients", 1757], ["with", 1766], ["Philadelphia", 1771], ["chromosome", 1784], ["-", 1794], ["positive", 1795], ["leukemias", 1804], [".", 1813]]}
{"context": "Linkage analysis and DNA sequencing in a family exhibiting an X-linked mental retardation (XLMR) syndrome, characterized by microcephaly, epilepsy, ataxia, and absent speech and resembling Angelman syndrome, identified a deletion in the SLC9A6 gene encoding the Na(+)/H(+) exchanger NHE6. Subsequently, other mutations were found in a male with mental retardation (MR) who had been investigated for Angelman syndrome and in two XLMR families with epilepsy and ataxia, including the family designated as having Christianson syndrome. Therefore, mutations in SLC9A6 cause X-linked mental retardation. Additionally, males with findings suggestive of unexplained Angelman syndrome should be considered as potential candidates for SLC9A6 mutations.", "qas": [{"question": "Mutation of which gene is implicated in the Christianson syndrome?", "answers": ["SLC9A6"], "qid": "b926d6e0091141cb9a74f555ced0e3ae", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["implicated", 26], ["in", 37], ["the", 40], ["Christianson", 44], ["syndrome", 57], ["?", 65]], "detected_answers": [{"text": "SLC9A6", "token_spans": [[95, 95], [120, 120], [41, 41]], "char_spans": [[557, 562], [726, 731], [237, 242]]}]}], "context_tokens": [["Linkage", 0], ["analysis", 8], ["and", 17], ["DNA", 21], ["sequencing", 25], ["in", 36], ["a", 39], ["family", 41], ["exhibiting", 48], ["an", 59], ["X", 62], ["-", 63], ["linked", 64], ["mental", 71], ["retardation", 78], ["(", 90], ["XLMR", 91], [")", 95], ["syndrome", 97], [",", 105], ["characterized", 107], ["by", 121], ["microcephaly", 124], [",", 136], ["epilepsy", 138], [",", 146], ["ataxia", 148], [",", 154], ["and", 156], ["absent", 160], ["speech", 167], ["and", 174], ["resembling", 178], ["Angelman", 189], ["syndrome", 198], [",", 206], ["identified", 208], ["a", 219], ["deletion", 221], ["in", 230], ["the", 233], ["SLC9A6", 237], ["gene", 244], ["encoding", 249], ["the", 258], ["Na(+)/H(+", 262], [")", 271], ["exchanger", 273], ["NHE6", 283], [".", 287], ["Subsequently", 289], [",", 301], ["other", 303], ["mutations", 309], ["were", 319], ["found", 324], ["in", 330], ["a", 333], ["male", 335], ["with", 340], ["mental", 345], ["retardation", 352], ["(", 364], ["MR", 365], [")", 367], ["who", 369], ["had", 373], ["been", 377], ["investigated", 382], ["for", 395], ["Angelman", 399], ["syndrome", 408], ["and", 417], ["in", 421], ["two", 424], ["XLMR", 428], ["families", 433], ["with", 442], ["epilepsy", 447], ["and", 456], ["ataxia", 460], [",", 466], ["including", 468], ["the", 478], ["family", 482], ["designated", 489], ["as", 500], ["having", 503], ["Christianson", 510], ["syndrome", 523], [".", 531], ["Therefore", 533], [",", 542], ["mutations", 544], ["in", 554], ["SLC9A6", 557], ["cause", 564], ["X", 570], ["-", 571], ["linked", 572], ["mental", 579], ["retardation", 586], [".", 597], ["Additionally", 599], [",", 611], ["males", 613], ["with", 619], ["findings", 624], ["suggestive", 633], ["of", 644], ["unexplained", 647], ["Angelman", 659], ["syndrome", 668], ["should", 677], ["be", 684], ["considered", 687], ["as", 698], ["potential", 701], ["candidates", 711], ["for", 722], ["SLC9A6", 726], ["mutations", 733], [".", 742]]}
{"context": "Fluorescence in situ hybridization (FISH) technique has been successfully used to detect the BCR-ABL gene fusion in chronic myeloid leukemia (CML) with the classic form of the Philadelphia chromosome (Ph). We applied FISH to study three CML patients showing variant Ph chromosome (either complex or simple type). The results demonstrate that the use of a yeast artificial chromosome (YAC)-derived probe (D107F9) and a cosmid probe (cos-abl 8), specific for BCR and ABL genes respectively, allows also the detection of the BCR-ABL fusion in CML patients with variant Ph.", "qas": [{"question": "Which gene fusion is the result of the \"philadelphia translocation\" or the \"philadelphia chromosome\" mutation?", "answers": ["The BCR/ABL gene fusion", "ABL/BCR fusion"], "qid": "97cb4d97afcb4eb2952fd63b3de90dbf", "question_tokens": [["Which", 0], ["gene", 6], ["fusion", 11], ["is", 18], ["the", 21], ["result", 25], ["of", 32], ["the", 35], ["\"", 39], ["philadelphia", 40], ["translocation", 53], ["\"", 66], ["or", 68], ["the", 71], ["\"", 75], ["philadelphia", 76], ["chromosome", 89], ["\"", 99], ["mutation", 101], ["?", 109]], "detected_answers": [{"text": "The BCR/ABL gene fusion", "token_spans": [[15, 19]], "char_spans": [[93, 111]]}]}], "context_tokens": [["Fluorescence", 0], ["in", 13], ["situ", 16], ["hybridization", 21], ["(", 35], ["FISH", 36], [")", 40], ["technique", 42], ["has", 52], ["been", 56], ["successfully", 61], ["used", 74], ["to", 79], ["detect", 82], ["the", 89], ["BCR", 93], ["-", 96], ["ABL", 97], ["gene", 101], ["fusion", 106], ["in", 113], ["chronic", 116], ["myeloid", 124], ["leukemia", 132], ["(", 141], ["CML", 142], [")", 145], ["with", 147], ["the", 152], ["classic", 156], ["form", 164], ["of", 169], ["the", 172], ["Philadelphia", 176], ["chromosome", 189], ["(", 200], ["Ph", 201], [")", 203], [".", 204], ["We", 206], ["applied", 209], ["FISH", 217], ["to", 222], ["study", 225], ["three", 231], ["CML", 237], ["patients", 241], ["showing", 250], ["variant", 258], ["Ph", 266], ["chromosome", 269], ["(", 280], ["either", 281], ["complex", 288], ["or", 296], ["simple", 299], ["type", 306], [")", 310], [".", 311], ["The", 313], ["results", 317], ["demonstrate", 325], ["that", 337], ["the", 342], ["use", 346], ["of", 350], ["a", 353], ["yeast", 355], ["artificial", 361], ["chromosome", 372], ["(", 383], ["YAC)-derived", 384], ["probe", 397], ["(", 403], ["D107F9", 404], [")", 410], ["and", 412], ["a", 416], ["cosmid", 418], ["probe", 425], ["(", 431], ["cos", 432], ["-", 435], ["abl", 436], ["8)", 440], [",", 442], ["specific", 444], ["for", 453], ["BCR", 457], ["and", 461], ["ABL", 465], ["genes", 469], ["respectively", 475], [",", 487], ["allows", 489], ["also", 496], ["the", 501], ["detection", 505], ["of", 515], ["the", 518], ["BCR", 522], ["-", 525], ["ABL", 526], ["fusion", 530], ["in", 537], ["CML", 540], ["patients", 544], ["with", 553], ["variant", 558], ["Ph", 566], [".", 568]]}
{"context": "The Ehlers-Danlos Syndrome (EDS) is a rare connective tissue disorder characterised by fragility of the soft connective tissues and widespread manifestations in skin, ligaments, joints, blood vessels and internal organs. We report a case of a 12-year-old boy, previously diagnosed with kyphoscoliosis-type EDS (type VI), presenting with a left brachial artery pseudo-aneursym with history of multiple spontaneous and post-traumatic arterial ruptures. Surgical management of this patient was performed successfully by primary repair of brachial artery lesion.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "151aa629d0054dd180576c092fb49055", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[11, 12]], "char_spans": [[43, 59]]}]}], "context_tokens": [["The", 0], ["Ehlers", 4], ["-", 10], ["Danlos", 11], ["Syndrome", 18], ["(", 27], ["EDS", 28], [")", 31], ["is", 33], ["a", 36], ["rare", 38], ["connective", 43], ["tissue", 54], ["disorder", 61], ["characterised", 70], ["by", 84], ["fragility", 87], ["of", 97], ["the", 100], ["soft", 104], ["connective", 109], ["tissues", 120], ["and", 128], ["widespread", 132], ["manifestations", 143], ["in", 158], ["skin", 161], [",", 165], ["ligaments", 167], [",", 176], ["joints", 178], [",", 184], ["blood", 186], ["vessels", 192], ["and", 200], ["internal", 204], ["organs", 213], [".", 219], ["We", 221], ["report", 224], ["a", 231], ["case", 233], ["of", 238], ["a", 241], ["12-year", 243], ["-", 250], ["old", 251], ["boy", 255], [",", 258], ["previously", 260], ["diagnosed", 271], ["with", 281], ["kyphoscoliosis", 286], ["-", 300], ["type", 301], ["EDS", 306], ["(", 310], ["type", 311], ["VI", 316], [")", 318], [",", 319], ["presenting", 321], ["with", 332], ["a", 337], ["left", 339], ["brachial", 344], ["artery", 353], ["pseudo", 360], ["-", 366], ["aneursym", 367], ["with", 376], ["history", 381], ["of", 389], ["multiple", 392], ["spontaneous", 401], ["and", 413], ["post", 417], ["-", 421], ["traumatic", 422], ["arterial", 432], ["ruptures", 441], [".", 449], ["Surgical", 451], ["management", 460], ["of", 471], ["this", 474], ["patient", 479], ["was", 487], ["performed", 491], ["successfully", 501], ["by", 514], ["primary", 517], ["repair", 525], ["of", 532], ["brachial", 535], ["artery", 544], ["lesion", 551], [".", 557]]}
{"context": "Mutations in rfx6 were recently associated with Mitchell-Riley syndrome, which involves neonatal diabetes, and other digestive system defects. To better define the function of Rfx6 in early endoderm development we cloned the Xenopus homologue. Expression of rfx6 begins early, showing broad expression throughout the anterior endoderm; at later stages rfx6 expression becomes restricted to the endocrine cells of the gut and pancreas. Morpholino knockdown of rfx6 caused a loss of pancreas marker expression, as well as other abnormalities. Co-injection of exogenous wild-type rfx6 rescued the morpholino phenotype in Xenopus tadpoles, whereas attempts to rescue the loss-of-function phenotype using mutant rfx6 based on Mitchell-Riley patients were unsuccessful. To better define the pleiotropic effects, we performed microarray analyses of gene expression in knockdown foregut tissue. In addition to pancreatic defects, the microarray analyses revealed downregulation of lung, stomach and heart markers and an upregulation of kidney markers. We verified these results using RT-PCR and in situ hybridization. Based on the different rfx6 expression patterns and our functional analyses, we propose that rfx6 has both early and late functions. In early development Rfx6 plays a broad role, being essential for development of most anterior endodermal organs. At later stages however, Rfx6 function is restricted to endocrine cells.", "qas": [{"question": "Which gene is associated with the Mitchell-Riley syndrome?", "answers": ["RFX6"], "qid": "23231ba1735c46b7b4dbacd35b95a111", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["associated", 14], ["with", 25], ["the", 30], ["Mitchell", 34], ["-", 42], ["Riley", 43], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "RFX6", "token_spans": [[29, 29], [42, 42], [74, 74], [212, 212], [57, 57], [119, 119], [201, 201], [233, 233], [190, 190], [2, 2], [97, 97]], "char_spans": [[176, 179], [258, 261], [459, 462], [1264, 1267], [352, 355], [707, 710], [1203, 1206], [1382, 1385], [1133, 1136], [13, 16], [577, 580]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["rfx6", 13], ["were", 18], ["recently", 23], ["associated", 32], ["with", 43], ["Mitchell", 48], ["-", 56], ["Riley", 57], ["syndrome", 63], [",", 71], ["which", 73], ["involves", 79], ["neonatal", 88], ["diabetes", 97], [",", 105], ["and", 107], ["other", 111], ["digestive", 117], ["system", 127], ["defects", 134], [".", 141], ["To", 143], ["better", 146], ["define", 153], ["the", 160], ["function", 164], ["of", 173], ["Rfx6", 176], ["in", 181], ["early", 184], ["endoderm", 190], ["development", 199], ["we", 211], ["cloned", 214], ["the", 221], ["Xenopus", 225], ["homologue", 233], [".", 242], ["Expression", 244], ["of", 255], ["rfx6", 258], ["begins", 263], ["early", 270], [",", 275], ["showing", 277], ["broad", 285], ["expression", 291], ["throughout", 302], ["the", 313], ["anterior", 317], ["endoderm", 326], [";", 334], ["at", 336], ["later", 339], ["stages", 345], ["rfx6", 352], ["expression", 357], ["becomes", 368], ["restricted", 376], ["to", 387], ["the", 390], ["endocrine", 394], ["cells", 404], ["of", 410], ["the", 413], ["gut", 417], ["and", 421], ["pancreas", 425], [".", 433], ["Morpholino", 435], ["knockdown", 446], ["of", 456], ["rfx6", 459], ["caused", 464], ["a", 471], ["loss", 473], ["of", 478], ["pancreas", 481], ["marker", 490], ["expression", 497], [",", 507], ["as", 509], ["well", 512], ["as", 517], ["other", 520], ["abnormalities", 526], [".", 539], ["Co", 541], ["-", 543], ["injection", 544], ["of", 554], ["exogenous", 557], ["wild", 567], ["-", 571], ["type", 572], ["rfx6", 577], ["rescued", 582], ["the", 590], ["morpholino", 594], ["phenotype", 605], ["in", 615], ["Xenopus", 618], ["tadpoles", 626], [",", 634], ["whereas", 636], ["attempts", 644], ["to", 653], ["rescue", 656], ["the", 663], ["loss", 667], ["-", 671], ["of", 672], ["-", 674], ["function", 675], ["phenotype", 684], ["using", 694], ["mutant", 700], ["rfx6", 707], ["based", 712], ["on", 718], ["Mitchell", 721], ["-", 729], ["Riley", 730], ["patients", 736], ["were", 745], ["unsuccessful", 750], [".", 762], ["To", 764], ["better", 767], ["define", 774], ["the", 781], ["pleiotropic", 785], ["effects", 797], [",", 804], ["we", 806], ["performed", 809], ["microarray", 819], ["analyses", 830], ["of", 839], ["gene", 842], ["expression", 847], ["in", 858], ["knockdown", 861], ["foregut", 871], ["tissue", 879], [".", 885], ["In", 887], ["addition", 890], ["to", 899], ["pancreatic", 902], ["defects", 913], [",", 920], ["the", 922], ["microarray", 926], ["analyses", 937], ["revealed", 946], ["downregulation", 955], ["of", 970], ["lung", 973], [",", 977], ["stomach", 979], ["and", 987], ["heart", 991], ["markers", 997], ["and", 1005], ["an", 1009], ["upregulation", 1012], ["of", 1025], ["kidney", 1028], ["markers", 1035], [".", 1042], ["We", 1044], ["verified", 1047], ["these", 1056], ["results", 1062], ["using", 1070], ["RT", 1076], ["-", 1078], ["PCR", 1079], ["and", 1083], ["in", 1087], ["situ", 1090], ["hybridization", 1095], [".", 1108], ["Based", 1110], ["on", 1116], ["the", 1119], ["different", 1123], ["rfx6", 1133], ["expression", 1138], ["patterns", 1149], ["and", 1158], ["our", 1162], ["functional", 1166], ["analyses", 1177], [",", 1185], ["we", 1187], ["propose", 1190], ["that", 1198], ["rfx6", 1203], ["has", 1208], ["both", 1212], ["early", 1217], ["and", 1223], ["late", 1227], ["functions", 1232], [".", 1241], ["In", 1243], ["early", 1246], ["development", 1252], ["Rfx6", 1264], ["plays", 1269], ["a", 1275], ["broad", 1277], ["role", 1283], [",", 1287], ["being", 1289], ["essential", 1295], ["for", 1305], ["development", 1309], ["of", 1321], ["most", 1324], ["anterior", 1329], ["endodermal", 1338], ["organs", 1349], [".", 1355], ["At", 1357], ["later", 1360], ["stages", 1366], ["however", 1373], [",", 1380], ["Rfx6", 1382], ["function", 1387], ["is", 1396], ["restricted", 1399], ["to", 1410], ["endocrine", 1413], ["cells", 1423], [".", 1428]]}
{"context": "RNA editing by deamination of specific adenosine bases to inosines during pre-mRNA processing generates edited isoforms of proteins. Recoding RNA editing is more widespread in Drosophila than in vertebrates. Editing levels rise strongly at metamorphosis, and Adar(5G1) null mutant flies lack editing events in hundreds of CNS transcripts; mutant flies have reduced viability, severely defective locomotion and age-dependent neurodegeneration. On the other hand, overexpressing an adult dADAR isoform with high enzymatic activity ubiquitously during larval and pupal stages is lethal. Advantage was taken of this to screen for genetic modifiers; Adar overexpression lethality is rescued by reduced dosage of the Rdl (Resistant to dieldrin), gene encoding a subunit of inhibitory GABA receptors. Reduced dosage of the Gad1 gene encoding the GABA synthetase also rescues Adar overexpression lethality. Drosophila Adar(5G1) mutant phenotypes are ameliorated by feeding GABA modulators. We demonstrate that neuronal excitability is linked to dADAR expression levels in individual neurons; Adar-overexpressing larval motor neurons show reduced excitability whereas Adar(5G1) null mutant or targeted Adar knockdown motor neurons exhibit increased excitability. GABA inhibitory signalling is impaired in human epileptic and autistic conditions, and vertebrate ADARs may have a relevant evolutionarily conserved control over neuronal excitability.", "qas": [{"question": "Which is the major RNA editing enzyme in Drosophila melanogaster?", "answers": ["ADAR", "adenosine deaminase, RNA-specific"], "qid": "8c9513c5db4344709452efcb0a8fca01", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["major", 13], ["RNA", 19], ["editing", 23], ["enzyme", 31], ["in", 38], ["Drosophila", 41], ["melanogaster", 52], ["?", 64]], "detected_answers": [{"text": "ADAR", "token_spans": [[104, 104], [189, 189], [173, 173], [142, 142]], "char_spans": [[645, 648], [1193, 1196], [1084, 1087], [868, 871]]}]}], "context_tokens": [["RNA", 0], ["editing", 4], ["by", 12], ["deamination", 15], ["of", 27], ["specific", 30], ["adenosine", 39], ["bases", 49], ["to", 55], ["inosines", 58], ["during", 67], ["pre", 74], ["-", 77], ["mRNA", 78], ["processing", 83], ["generates", 94], ["edited", 104], ["isoforms", 111], ["of", 120], ["proteins", 123], [".", 131], ["Recoding", 133], ["RNA", 142], ["editing", 146], ["is", 154], ["more", 157], ["widespread", 162], ["in", 173], ["Drosophila", 176], ["than", 187], ["in", 192], ["vertebrates", 195], [".", 206], ["Editing", 208], ["levels", 216], ["rise", 223], ["strongly", 228], ["at", 237], ["metamorphosis", 240], [",", 253], ["and", 255], ["Adar(5G1", 259], [")", 267], ["null", 269], ["mutant", 274], ["flies", 281], ["lack", 287], ["editing", 292], ["events", 300], ["in", 307], ["hundreds", 310], ["of", 319], ["CNS", 322], ["transcripts", 326], [";", 337], ["mutant", 339], ["flies", 346], ["have", 352], ["reduced", 357], ["viability", 365], [",", 374], ["severely", 376], ["defective", 385], ["locomotion", 395], ["and", 406], ["age", 410], ["-", 413], ["dependent", 414], ["neurodegeneration", 424], [".", 441], ["On", 443], ["the", 446], ["other", 450], ["hand", 456], [",", 460], ["overexpressing", 462], ["an", 477], ["adult", 480], ["dADAR", 486], ["isoform", 492], ["with", 500], ["high", 505], ["enzymatic", 510], ["activity", 520], ["ubiquitously", 529], ["during", 542], ["larval", 549], ["and", 556], ["pupal", 560], ["stages", 566], ["is", 573], ["lethal", 576], [".", 582], ["Advantage", 584], ["was", 594], ["taken", 598], ["of", 604], ["this", 607], ["to", 612], ["screen", 615], ["for", 622], ["genetic", 626], ["modifiers", 634], [";", 643], ["Adar", 645], ["overexpression", 650], ["lethality", 665], ["is", 675], ["rescued", 678], ["by", 686], ["reduced", 689], ["dosage", 697], ["of", 704], ["the", 707], ["Rdl", 711], ["(", 715], ["Resistant", 716], ["to", 726], ["dieldrin", 729], [")", 737], [",", 738], ["gene", 740], ["encoding", 745], ["a", 754], ["subunit", 756], ["of", 764], ["inhibitory", 767], ["GABA", 778], ["receptors", 783], [".", 792], ["Reduced", 794], ["dosage", 802], ["of", 809], ["the", 812], ["Gad1", 816], ["gene", 821], ["encoding", 826], ["the", 835], ["GABA", 839], ["synthetase", 844], ["also", 855], ["rescues", 860], ["Adar", 868], ["overexpression", 873], ["lethality", 888], [".", 897], ["Drosophila", 899], ["Adar(5G1", 910], [")", 918], ["mutant", 920], ["phenotypes", 927], ["are", 938], ["ameliorated", 942], ["by", 954], ["feeding", 957], ["GABA", 965], ["modulators", 970], [".", 980], ["We", 982], ["demonstrate", 985], ["that", 997], ["neuronal", 1002], ["excitability", 1011], ["is", 1024], ["linked", 1027], ["to", 1034], ["dADAR", 1037], ["expression", 1043], ["levels", 1054], ["in", 1061], ["individual", 1064], ["neurons", 1075], [";", 1082], ["Adar", 1084], ["-", 1088], ["overexpressing", 1089], ["larval", 1104], ["motor", 1111], ["neurons", 1117], ["show", 1125], ["reduced", 1130], ["excitability", 1138], ["whereas", 1151], ["Adar(5G1", 1159], [")", 1167], ["null", 1169], ["mutant", 1174], ["or", 1181], ["targeted", 1184], ["Adar", 1193], ["knockdown", 1198], ["motor", 1208], ["neurons", 1214], ["exhibit", 1222], ["increased", 1230], ["excitability", 1240], [".", 1252], ["GABA", 1254], ["inhibitory", 1259], ["signalling", 1270], ["is", 1281], ["impaired", 1284], ["in", 1293], ["human", 1296], ["epileptic", 1302], ["and", 1312], ["autistic", 1316], ["conditions", 1325], [",", 1335], ["and", 1337], ["vertebrate", 1341], ["ADARs", 1352], ["may", 1358], ["have", 1362], ["a", 1367], ["relevant", 1369], ["evolutionarily", 1378], ["conserved", 1393], ["control", 1403], ["over", 1411], ["neuronal", 1416], ["excitability", 1425], [".", 1437]]}
{"context": "Parkinson's disease (PD) and dementia with Lewy bodies (DLB) are characterized by abnormal deposition of \u03b1-synuclein aggregates in many regions of the central and peripheral nervous systems. Accumulating evidence suggests that the \u03b1-synuclein pathology initiates in a few discrete regions and spreads to larger areas in the nervous system. Recent pathological studies of PD patients have raised the possibility that the enteric nervous system is one of the initial sites of \u03b1-synuclein aggregation and propagation. Here, we evaluated the induction and propagation of \u03b1-synuclein aggregates in the enteric nervous system of the A53T \u03b1-synuclein transgenic mice after injection of human brain tissue extracts into the gastric walls of the mice. Western analysis of the brain extracts showed that the DLB extract contained detergent-stable \u03b1-synuclein aggregates, but the normal brain extract did not. Injection of the DLB extract resulted in an increased deposition of \u03b1-synuclein in the myenteric neurons, in which \u03b1-synuclein formed punctate aggregates over time up to 4 months. In these mice, inflammatory responses were increased transiently at early time points. None of these changes were observed in the A53T mice injected with saline or the normal brain extract, nor were these found in the wild type mice injected with the DLB extract. These results demonstrate that pathological \u03b1-synuclein aggregates present in the brain of DLB patient can induce the aggregation of endogenous \u03b1-synuclein in the myenteric neurons in A53T mice, suggesting the transmission of synucleinopathy lesions in the enteric nervous system.", "qas": [{"question": "Which disease of the central nervous system is characterized by the presence of Lewy bodies?", "answers": ["Parkinson's disease (PD)"], "qid": "9a225d6aa2034d27a58fc2dea42dbe40", "question_tokens": [["Which", 0], ["disease", 6], ["of", 14], ["the", 17], ["central", 21], ["nervous", 29], ["system", 37], ["is", 44], ["characterized", 47], ["by", 61], ["the", 64], ["presence", 68], ["of", 77], ["Lewy", 80], ["bodies", 85], ["?", 91]], "detected_answers": [{"text": "Parkinson's disease (PD)", "token_spans": [[0, 4]], "char_spans": [[0, 22]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["and", 25], ["dementia", 29], ["with", 38], ["Lewy", 43], ["bodies", 48], ["(", 55], ["DLB", 56], [")", 59], ["are", 61], ["characterized", 65], ["by", 79], ["abnormal", 82], ["deposition", 91], ["of", 102], ["\u03b1", 105], ["-", 106], ["synuclein", 107], ["aggregates", 117], ["in", 128], ["many", 131], ["regions", 136], ["of", 144], ["the", 147], ["central", 151], ["and", 159], ["peripheral", 163], ["nervous", 174], ["systems", 182], [".", 189], ["Accumulating", 191], ["evidence", 204], ["suggests", 213], ["that", 222], ["the", 227], ["\u03b1", 231], ["-", 232], ["synuclein", 233], ["pathology", 243], ["initiates", 253], ["in", 263], ["a", 266], ["few", 268], ["discrete", 272], ["regions", 281], ["and", 289], ["spreads", 293], ["to", 301], ["larger", 304], ["areas", 311], ["in", 317], ["the", 320], ["nervous", 324], ["system", 332], [".", 338], ["Recent", 340], ["pathological", 347], ["studies", 360], ["of", 368], ["PD", 371], ["patients", 374], ["have", 383], ["raised", 388], ["the", 395], ["possibility", 399], ["that", 411], ["the", 416], ["enteric", 420], ["nervous", 428], ["system", 436], ["is", 443], ["one", 446], ["of", 450], ["the", 453], ["initial", 457], ["sites", 465], ["of", 471], ["\u03b1", 474], ["-", 475], ["synuclein", 476], ["aggregation", 486], ["and", 498], ["propagation", 502], [".", 513], ["Here", 515], [",", 519], ["we", 521], ["evaluated", 524], ["the", 534], ["induction", 538], ["and", 548], ["propagation", 552], ["of", 564], ["\u03b1", 567], ["-", 568], ["synuclein", 569], ["aggregates", 579], ["in", 590], ["the", 593], ["enteric", 597], ["nervous", 605], ["system", 613], ["of", 620], ["the", 623], ["A53", 627], ["T", 630], ["\u03b1", 632], ["-", 633], ["synuclein", 634], ["transgenic", 644], ["mice", 655], ["after", 660], ["injection", 666], ["of", 676], ["human", 679], ["brain", 685], ["tissue", 691], ["extracts", 698], ["into", 707], ["the", 712], ["gastric", 716], ["walls", 724], ["of", 730], ["the", 733], ["mice", 737], [".", 741], ["Western", 743], ["analysis", 751], ["of", 760], ["the", 763], ["brain", 767], ["extracts", 773], ["showed", 782], ["that", 789], ["the", 794], ["DLB", 798], ["extract", 802], ["contained", 810], ["detergent", 820], ["-", 829], ["stable", 830], ["\u03b1", 837], ["-", 838], ["synuclein", 839], ["aggregates", 849], [",", 859], ["but", 861], ["the", 865], ["normal", 869], ["brain", 876], ["extract", 882], ["did", 890], ["not", 894], [".", 897], ["Injection", 899], ["of", 909], ["the", 912], ["DLB", 916], ["extract", 920], ["resulted", 928], ["in", 937], ["an", 940], ["increased", 943], ["deposition", 953], ["of", 964], ["\u03b1", 967], ["-", 968], ["synuclein", 969], ["in", 979], ["the", 982], ["myenteric", 986], ["neurons", 996], [",", 1003], ["in", 1005], ["which", 1008], ["\u03b1", 1014], ["-", 1015], ["synuclein", 1016], ["formed", 1026], ["punctate", 1033], ["aggregates", 1042], ["over", 1053], ["time", 1058], ["up", 1063], ["to", 1066], ["4", 1069], ["months", 1071], [".", 1077], ["In", 1079], ["these", 1082], ["mice", 1088], [",", 1092], ["inflammatory", 1094], ["responses", 1107], ["were", 1117], ["increased", 1122], ["transiently", 1132], ["at", 1144], ["early", 1147], ["time", 1153], ["points", 1158], [".", 1164], ["None", 1166], ["of", 1171], ["these", 1174], ["changes", 1180], ["were", 1188], ["observed", 1193], ["in", 1202], ["the", 1205], ["A53", 1209], ["T", 1212], ["mice", 1214], ["injected", 1219], ["with", 1228], ["saline", 1233], ["or", 1240], ["the", 1243], ["normal", 1247], ["brain", 1254], ["extract", 1260], [",", 1267], ["nor", 1269], ["were", 1273], ["these", 1278], ["found", 1284], ["in", 1290], ["the", 1293], ["wild", 1297], ["type", 1302], ["mice", 1307], ["injected", 1312], ["with", 1321], ["the", 1326], ["DLB", 1330], ["extract", 1334], [".", 1341], ["These", 1343], ["results", 1349], ["demonstrate", 1357], ["that", 1369], ["pathological", 1374], ["\u03b1", 1387], ["-", 1388], ["synuclein", 1389], ["aggregates", 1399], ["present", 1410], ["in", 1418], ["the", 1421], ["brain", 1425], ["of", 1431], ["DLB", 1434], ["patient", 1438], ["can", 1446], ["induce", 1450], ["the", 1457], ["aggregation", 1461], ["of", 1473], ["endogenous", 1476], ["\u03b1", 1487], ["-", 1488], ["synuclein", 1489], ["in", 1499], ["the", 1502], ["myenteric", 1506], ["neurons", 1516], ["in", 1524], ["A53", 1527], ["T", 1530], ["mice", 1532], [",", 1536], ["suggesting", 1538], ["the", 1549], ["transmission", 1553], ["of", 1566], ["synucleinopathy", 1569], ["lesions", 1585], ["in", 1593], ["the", 1596], ["enteric", 1600], ["nervous", 1608], ["system", 1616], [".", 1622]]}
{"context": "A monoclonal antibody (mAb) has been produced which reacts with human mitofilin, a mitochondrial inner membrane protein. This mAb immunocaptures its target protein in association with six other proteins, metaxins 1 and 2, SAM50, CHCHD3, CHCHD6 and DnaJC11, respectively. The first three are outer membrane proteins, CHCHD3 has been assigned to the matrix space, and the other two proteins have not been described in mitochondria previously. The functional role of this new complex is uncertain. However, a role in protein import related to maintenance of mitochondrial structure is suggested as mitofilin helps regulate mitochondrial morphology and at least four of the associated proteins (metaxins 1 and 2, SAM50 and CHCHD3) have been implicated in protein import, while DnaJC11 is a chaperone-like protein that may have a similar role.", "qas": [{"question": "What is the localization of the protein encoded by the gene DNAJC11?", "answers": ["mitochondrial inner membrane"], "qid": "8c2a0605602f461d93cb146b331734aa", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["localization", 12], ["of", 25], ["the", 28], ["protein", 32], ["encoded", 40], ["by", 48], ["the", 51], ["gene", 55], ["DNAJC11", 60], ["?", 67]], "detected_answers": [{"text": "mitochondrial inner membrane", "token_spans": [[16, 18]], "char_spans": [[83, 110]]}]}], "context_tokens": [["A", 0], ["monoclonal", 2], ["antibody", 13], ["(", 22], ["mAb", 23], [")", 26], ["has", 28], ["been", 32], ["produced", 37], ["which", 46], ["reacts", 52], ["with", 59], ["human", 64], ["mitofilin", 70], [",", 79], ["a", 81], ["mitochondrial", 83], ["inner", 97], ["membrane", 103], ["protein", 112], [".", 119], ["This", 121], ["mAb", 126], ["immunocaptures", 130], ["its", 145], ["target", 149], ["protein", 156], ["in", 164], ["association", 167], ["with", 179], ["six", 184], ["other", 188], ["proteins", 194], [",", 202], ["metaxins", 204], ["1", 213], ["and", 215], ["2", 219], [",", 220], ["SAM50", 222], [",", 227], ["CHCHD3", 229], [",", 235], ["CHCHD6", 237], ["and", 244], ["DnaJC11", 248], [",", 255], ["respectively", 257], [".", 269], ["The", 271], ["first", 275], ["three", 281], ["are", 287], ["outer", 291], ["membrane", 297], ["proteins", 306], [",", 314], ["CHCHD3", 316], ["has", 323], ["been", 327], ["assigned", 332], ["to", 341], ["the", 344], ["matrix", 348], ["space", 355], [",", 360], ["and", 362], ["the", 366], ["other", 370], ["two", 376], ["proteins", 380], ["have", 389], ["not", 394], ["been", 398], ["described", 403], ["in", 413], ["mitochondria", 416], ["previously", 429], [".", 439], ["The", 441], ["functional", 445], ["role", 456], ["of", 461], ["this", 464], ["new", 469], ["complex", 473], ["is", 481], ["uncertain", 484], [".", 493], ["However", 495], [",", 502], ["a", 504], ["role", 506], ["in", 511], ["protein", 514], ["import", 522], ["related", 529], ["to", 537], ["maintenance", 540], ["of", 552], ["mitochondrial", 555], ["structure", 569], ["is", 579], ["suggested", 582], ["as", 592], ["mitofilin", 595], ["helps", 605], ["regulate", 611], ["mitochondrial", 620], ["morphology", 634], ["and", 645], ["at", 649], ["least", 652], ["four", 658], ["of", 663], ["the", 666], ["associated", 670], ["proteins", 681], ["(", 690], ["metaxins", 691], ["1", 700], ["and", 702], ["2", 706], [",", 707], ["SAM50", 709], ["and", 715], ["CHCHD3", 719], [")", 725], ["have", 727], ["been", 732], ["implicated", 737], ["in", 748], ["protein", 751], ["import", 759], [",", 765], ["while", 767], ["DnaJC11", 773], ["is", 781], ["a", 784], ["chaperone", 786], ["-", 795], ["like", 796], ["protein", 801], ["that", 809], ["may", 814], ["have", 818], ["a", 823], ["similar", 825], ["role", 833], [".", 837]]}
{"context": "Osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand (RANKL) are dominant regulators of bone resorption. Many hormones, cytokines and growth factors mediate bone resorption by altering the ratio of RANKL to OPG. RANKL and OPG expression is also altered in numerous bone diseases, and these changes can reflect disease etiology or compensatory responses to disease. RANKL stimulates osteoclast formation, function and survival, and each of these effects is inhibited by OPG. OPG suppresses bone resorption and increases the density, area and strength of both cancellous and cortical bone. Denosumab (AMG 162), a fully human monoclonal antibody to RANKL, shares the pharmacologic attributes of OPG but has a significantly longer half-life that allows less frequent administration.", "qas": [{"question": "To the ligand of which receptors does Denosumab (Prolia) bind?", "answers": ["RANKL"], "qid": "bd9c8ec49b8446ba9d107c61a8280a06", "question_tokens": [["To", 0], ["the", 3], ["ligand", 7], ["of", 14], ["which", 17], ["receptors", 23], ["does", 33], ["Denosumab", 38], ["(", 48], ["Prolia", 49], [")", 55], ["bind", 57], ["?", 61]], "detected_answers": [{"text": "RANKL", "token_spans": [[117, 117], [67, 67], [42, 42], [38, 38], [14, 14]], "char_spans": [[670, 674], [389, 393], [236, 240], [222, 226], [78, 82]]}]}], "context_tokens": [["Osteoprotegerin", 0], ["(", 16], ["OPG", 17], [")", 20], ["and", 22], ["receptor", 26], ["activator", 35], ["of", 45], ["nuclear", 48], ["factor", 56], ["-", 62], ["kappaB", 63], ["ligand", 70], ["(", 77], ["RANKL", 78], [")", 83], ["are", 85], ["dominant", 89], ["regulators", 98], ["of", 109], ["bone", 112], ["resorption", 117], [".", 127], ["Many", 129], ["hormones", 134], [",", 142], ["cytokines", 144], ["and", 154], ["growth", 158], ["factors", 165], ["mediate", 173], ["bone", 181], ["resorption", 186], ["by", 197], ["altering", 200], ["the", 209], ["ratio", 213], ["of", 219], ["RANKL", 222], ["to", 228], ["OPG", 231], [".", 234], ["RANKL", 236], ["and", 242], ["OPG", 246], ["expression", 250], ["is", 261], ["also", 264], ["altered", 269], ["in", 277], ["numerous", 280], ["bone", 289], ["diseases", 294], [",", 302], ["and", 304], ["these", 308], ["changes", 314], ["can", 322], ["reflect", 326], ["disease", 334], ["etiology", 342], ["or", 351], ["compensatory", 354], ["responses", 367], ["to", 377], ["disease", 380], [".", 387], ["RANKL", 389], ["stimulates", 395], ["osteoclast", 406], ["formation", 417], [",", 426], ["function", 428], ["and", 437], ["survival", 441], [",", 449], ["and", 451], ["each", 455], ["of", 460], ["these", 463], ["effects", 469], ["is", 477], ["inhibited", 480], ["by", 490], ["OPG", 493], [".", 496], ["OPG", 498], ["suppresses", 502], ["bone", 513], ["resorption", 518], ["and", 529], ["increases", 533], ["the", 543], ["density", 547], [",", 554], ["area", 556], ["and", 561], ["strength", 565], ["of", 574], ["both", 577], ["cancellous", 582], ["and", 593], ["cortical", 597], ["bone", 606], [".", 610], ["Denosumab", 612], ["(", 622], ["AMG", 623], ["162", 627], [")", 630], [",", 631], ["a", 633], ["fully", 635], ["human", 641], ["monoclonal", 647], ["antibody", 658], ["to", 667], ["RANKL", 670], [",", 675], ["shares", 677], ["the", 684], ["pharmacologic", 688], ["attributes", 702], ["of", 713], ["OPG", 716], ["but", 720], ["has", 724], ["a", 728], ["significantly", 730], ["longer", 744], ["half", 751], ["-", 755], ["life", 756], ["that", 761], ["allows", 766], ["less", 773], ["frequent", 778], ["administration", 787], [".", 801]]}
{"context": "Imatinib mesylate, a selective Bcr-Abl tyrosine kinase inhibitor, has proved to be most effective therapy of Philadelphia chromosome-positive chronic myelogenous leukemia. Imatinib induces complete haematological and cytogenetic response in high percentage of patients. The aim of this study was to identify potential prognostic factors before beginning treatment with imatinib associated with complete cytogenetic response. We analyzed 20 patients with newly diagnosed Philadelphia positive chronic myelogenous leukemia treated at our institution from June 2006 until May 2009. These patients were treated with imatinib mesylate in oral dose of 400 to 800 mg daily. Complete blood counts were performed every month, while serum chemistry evaluations and bone marrow evaluations including morphology and cytogenetics were performed every 6 months. Of the 20 patients analyzed in this study, 19 (95%) achieved complete haematologic response within three months. In all patients cytogenetic analyses were done and all have achieved absolute cytogenetic response. The best cytogenetic response rate at any time during study treatment among 20 patients was: complete cytogenetic response in 15, partial cytogenetic response in three and minor cytogenetic response in two patients. Among 11 observed base-line patients' characteristics five were independent predictors of a high rate of complete cytogenetic response; the absence of blasts and basophils in peripheral blood, the presence of less than 5 percent of bone marrow blasts, white blood cell count less than 10 x 10(9)/L and the absence of splenomegaly (p < 0.01). Our results showed that some pre-treatment characteristics of patients might be the cause of differences in treatment outcome. On the basis of this analysis, we identified several pre-treatment patients' characteristics to be independent prognostic factors for achievement of complete cytogenetic response.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "6a2e5c9b921c417c892010de2379c6d7", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[5, 7]], "char_spans": [[31, 37]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], [",", 17], ["a", 19], ["selective", 21], ["Bcr", 31], ["-", 34], ["Abl", 35], ["tyrosine", 39], ["kinase", 48], ["inhibitor", 55], [",", 64], ["has", 66], ["proved", 70], ["to", 77], ["be", 80], ["most", 83], ["effective", 88], ["therapy", 98], ["of", 106], ["Philadelphia", 109], ["chromosome", 122], ["-", 132], ["positive", 133], ["chronic", 142], ["myelogenous", 150], ["leukemia", 162], [".", 170], ["Imatinib", 172], ["induces", 181], ["complete", 189], ["haematological", 198], ["and", 213], ["cytogenetic", 217], ["response", 229], ["in", 238], ["high", 241], ["percentage", 246], ["of", 257], ["patients", 260], [".", 268], ["The", 270], ["aim", 274], ["of", 278], ["this", 281], ["study", 286], ["was", 292], ["to", 296], ["identify", 299], ["potential", 308], ["prognostic", 318], ["factors", 329], ["before", 337], ["beginning", 344], ["treatment", 354], ["with", 364], ["imatinib", 369], ["associated", 378], ["with", 389], ["complete", 394], ["cytogenetic", 403], ["response", 415], [".", 423], ["We", 425], ["analyzed", 428], ["20", 437], ["patients", 440], ["with", 449], ["newly", 454], ["diagnosed", 460], ["Philadelphia", 470], ["positive", 483], ["chronic", 492], ["myelogenous", 500], ["leukemia", 512], ["treated", 521], ["at", 529], ["our", 532], ["institution", 536], ["from", 548], ["June", 553], ["2006", 558], ["until", 563], ["May", 569], ["2009", 573], [".", 577], ["These", 579], ["patients", 585], ["were", 594], ["treated", 599], ["with", 607], ["imatinib", 612], ["mesylate", 621], ["in", 630], ["oral", 633], ["dose", 638], ["of", 643], ["400", 646], ["to", 650], ["800", 653], ["mg", 657], ["daily", 660], [".", 665], ["Complete", 667], ["blood", 676], ["counts", 682], ["were", 689], ["performed", 694], ["every", 704], ["month", 710], [",", 715], ["while", 717], ["serum", 723], ["chemistry", 729], ["evaluations", 739], ["and", 751], ["bone", 755], ["marrow", 760], ["evaluations", 767], ["including", 779], ["morphology", 789], ["and", 800], ["cytogenetics", 804], ["were", 817], ["performed", 822], ["every", 832], ["6", 838], ["months", 840], [".", 846], ["Of", 848], ["the", 851], ["20", 855], ["patients", 858], ["analyzed", 867], ["in", 876], ["this", 879], ["study", 884], [",", 889], ["19", 891], ["(", 894], ["95", 895], ["%", 897], [")", 898], ["achieved", 900], ["complete", 909], ["haematologic", 918], ["response", 931], ["within", 940], ["three", 947], ["months", 953], [".", 959], ["In", 961], ["all", 964], ["patients", 968], ["cytogenetic", 977], ["analyses", 989], ["were", 998], ["done", 1003], ["and", 1008], ["all", 1012], ["have", 1016], ["achieved", 1021], ["absolute", 1030], ["cytogenetic", 1039], ["response", 1051], [".", 1059], ["The", 1061], ["best", 1065], ["cytogenetic", 1070], ["response", 1082], ["rate", 1091], ["at", 1096], ["any", 1099], ["time", 1103], ["during", 1108], ["study", 1115], ["treatment", 1121], ["among", 1131], ["20", 1137], ["patients", 1140], ["was", 1149], [":", 1152], ["complete", 1154], ["cytogenetic", 1163], ["response", 1175], ["in", 1184], ["15", 1187], [",", 1189], ["partial", 1191], ["cytogenetic", 1199], ["response", 1211], ["in", 1220], ["three", 1223], ["and", 1229], ["minor", 1233], ["cytogenetic", 1239], ["response", 1251], ["in", 1260], ["two", 1263], ["patients", 1267], [".", 1275], ["Among", 1277], ["11", 1283], ["observed", 1286], ["base", 1295], ["-", 1299], ["line", 1300], ["patients", 1305], ["'", 1313], ["characteristics", 1315], ["five", 1331], ["were", 1336], ["independent", 1341], ["predictors", 1353], ["of", 1364], ["a", 1367], ["high", 1369], ["rate", 1374], ["of", 1379], ["complete", 1382], ["cytogenetic", 1391], ["response", 1403], [";", 1411], ["the", 1413], ["absence", 1417], ["of", 1425], ["blasts", 1428], ["and", 1435], ["basophils", 1439], ["in", 1449], ["peripheral", 1452], ["blood", 1463], [",", 1468], ["the", 1470], ["presence", 1474], ["of", 1483], ["less", 1486], ["than", 1491], ["5", 1496], ["percent", 1498], ["of", 1506], ["bone", 1509], ["marrow", 1514], ["blasts", 1521], [",", 1527], ["white", 1529], ["blood", 1535], ["cell", 1541], ["count", 1546], ["less", 1552], ["than", 1557], ["10", 1562], ["x", 1565], ["10(9)/L", 1567], ["and", 1575], ["the", 1579], ["absence", 1583], ["of", 1591], ["splenomegaly", 1594], ["(", 1607], ["p", 1608], ["<", 1610], ["0.01", 1612], [")", 1616], [".", 1617], ["Our", 1619], ["results", 1623], ["showed", 1631], ["that", 1638], ["some", 1643], ["pre", 1648], ["-", 1651], ["treatment", 1652], ["characteristics", 1662], ["of", 1678], ["patients", 1681], ["might", 1690], ["be", 1696], ["the", 1699], ["cause", 1703], ["of", 1709], ["differences", 1712], ["in", 1724], ["treatment", 1727], ["outcome", 1737], [".", 1744], ["On", 1746], ["the", 1749], ["basis", 1753], ["of", 1759], ["this", 1762], ["analysis", 1767], [",", 1775], ["we", 1777], ["identified", 1780], ["several", 1791], ["pre", 1799], ["-", 1802], ["treatment", 1803], ["patients", 1813], ["'", 1821], ["characteristics", 1823], ["to", 1839], ["be", 1842], ["independent", 1845], ["prognostic", 1857], ["factors", 1868], ["for", 1876], ["achievement", 1880], ["of", 1892], ["complete", 1895], ["cytogenetic", 1904], ["response", 1916], [".", 1924]]}
{"context": "Epidemiology of Clostridium difficile is characterized by worldwide increase of C. difficile infections (CDI) and the emergence of new epidemic outbreak strains with the capacity for global spreading. Long-term local surveillance at the University of Saarland Medical Center between 2000 and 2013 shows that the incidence rate of laboratory-confirmed CDI was influenced by local epidemiology as well as by testing strategies. Since 2008, molecular typing of C. difficile was regularly performed for symptomatic hospitalized patients by surface-layer protein A sequence typing (slpAST), which is an established highly standardized technique for genotyping of C. difficile. The results were assigned to known ribotypes for better comparison to international data. It could be demonstrated that distribution of genotypes was different between age groups. Older patients were predominantly infected with ribotype 001 and 027, whereas ribotype 027 was not detected in the pediatric population. Molecular typing of German isolates sent to the advisory laboratory between 2011 and 2013 revealed that ribotype 027 is present with high percentages in most German regions except for the very North. In conclusion, optimized testing of all hospitalized patients with diarrhea should be generally implemented to avoid under-diagnosis of C. difficile infection. Ribotype 027 is highly prevalent in Germany, but its infections are restricted to older patients, while absent in children. Molecular typing of suspected hospital outbreaks and of patients with severe or recurrent disease may help to better understand virulence and epidemic spreading of C. difficile.", "qas": [{"question": "Which main ribotype of Clostridium difficile is responsible of the recent outbreak?", "answers": ["Ribotype 027"], "qid": "e08396e636f94ad19455f09fad2df0c8", "question_tokens": [["Which", 0], ["main", 6], ["ribotype", 11], ["of", 20], ["Clostridium", 23], ["difficile", 35], ["is", 45], ["responsible", 48], ["of", 60], ["the", 63], ["recent", 67], ["outbreak", 74], ["?", 82]], "detected_answers": [{"text": "Ribotype 027", "token_spans": [[149, 150], [175, 176], [217, 218]], "char_spans": [[930, 941], [1093, 1104], [1349, 1360]]}]}], "context_tokens": [["Epidemiology", 0], ["of", 13], ["Clostridium", 16], ["difficile", 28], ["is", 38], ["characterized", 41], ["by", 55], ["worldwide", 58], ["increase", 68], ["of", 77], ["C.", 80], ["difficile", 83], ["infections", 93], ["(", 104], ["CDI", 105], [")", 108], ["and", 110], ["the", 114], ["emergence", 118], ["of", 128], ["new", 131], ["epidemic", 135], ["outbreak", 144], ["strains", 153], ["with", 161], ["the", 166], ["capacity", 170], ["for", 179], ["global", 183], ["spreading", 190], [".", 199], ["Long", 201], ["-", 205], ["term", 206], ["local", 211], ["surveillance", 217], ["at", 230], ["the", 233], ["University", 237], ["of", 248], ["Saarland", 251], ["Medical", 260], ["Center", 268], ["between", 275], ["2000", 283], ["and", 288], ["2013", 292], ["shows", 297], ["that", 303], ["the", 308], ["incidence", 312], ["rate", 322], ["of", 327], ["laboratory", 330], ["-", 340], ["confirmed", 341], ["CDI", 351], ["was", 355], ["influenced", 359], ["by", 370], ["local", 373], ["epidemiology", 379], ["as", 392], ["well", 395], ["as", 400], ["by", 403], ["testing", 406], ["strategies", 414], [".", 424], ["Since", 426], ["2008", 432], [",", 436], ["molecular", 438], ["typing", 448], ["of", 455], ["C.", 458], ["difficile", 461], ["was", 471], ["regularly", 475], ["performed", 485], ["for", 495], ["symptomatic", 499], ["hospitalized", 511], ["patients", 524], ["by", 533], ["surface", 536], ["-", 543], ["layer", 544], ["protein", 550], ["A", 558], ["sequence", 560], ["typing", 569], ["(", 576], ["slpAST", 577], [")", 583], [",", 584], ["which", 586], ["is", 592], ["an", 595], ["established", 598], ["highly", 610], ["standardized", 617], ["technique", 630], ["for", 640], ["genotyping", 644], ["of", 655], ["C.", 658], ["difficile", 661], [".", 670], ["The", 672], ["results", 676], ["were", 684], ["assigned", 689], ["to", 698], ["known", 701], ["ribotypes", 707], ["for", 717], ["better", 721], ["comparison", 728], ["to", 739], ["international", 742], ["data", 756], [".", 760], ["It", 762], ["could", 765], ["be", 771], ["demonstrated", 774], ["that", 787], ["distribution", 792], ["of", 805], ["genotypes", 808], ["was", 818], ["different", 822], ["between", 832], ["age", 840], ["groups", 844], [".", 850], ["Older", 852], ["patients", 858], ["were", 867], ["predominantly", 872], ["infected", 886], ["with", 895], ["ribotype", 900], ["001", 909], ["and", 913], ["027", 917], [",", 920], ["whereas", 922], ["ribotype", 930], ["027", 939], ["was", 943], ["not", 947], ["detected", 951], ["in", 960], ["the", 963], ["pediatric", 967], ["population", 977], [".", 987], ["Molecular", 989], ["typing", 999], ["of", 1006], ["German", 1009], ["isolates", 1016], ["sent", 1025], ["to", 1030], ["the", 1033], ["advisory", 1037], ["laboratory", 1046], ["between", 1057], ["2011", 1065], ["and", 1070], ["2013", 1074], ["revealed", 1079], ["that", 1088], ["ribotype", 1093], ["027", 1102], ["is", 1106], ["present", 1109], ["with", 1117], ["high", 1122], ["percentages", 1127], ["in", 1139], ["most", 1142], ["German", 1147], ["regions", 1154], ["except", 1162], ["for", 1169], ["the", 1173], ["very", 1177], ["North", 1182], [".", 1187], ["In", 1189], ["conclusion", 1192], [",", 1202], ["optimized", 1204], ["testing", 1214], ["of", 1222], ["all", 1225], ["hospitalized", 1229], ["patients", 1242], ["with", 1251], ["diarrhea", 1256], ["should", 1265], ["be", 1272], ["generally", 1275], ["implemented", 1285], ["to", 1297], ["avoid", 1300], ["under", 1306], ["-", 1311], ["diagnosis", 1312], ["of", 1322], ["C.", 1325], ["difficile", 1328], ["infection", 1338], [".", 1347], ["Ribotype", 1349], ["027", 1358], ["is", 1362], ["highly", 1365], ["prevalent", 1372], ["in", 1382], ["Germany", 1385], [",", 1392], ["but", 1394], ["its", 1398], ["infections", 1402], ["are", 1413], ["restricted", 1417], ["to", 1428], ["older", 1431], ["patients", 1437], [",", 1445], ["while", 1447], ["absent", 1453], ["in", 1460], ["children", 1463], [".", 1471], ["Molecular", 1473], ["typing", 1483], ["of", 1490], ["suspected", 1493], ["hospital", 1503], ["outbreaks", 1512], ["and", 1522], ["of", 1526], ["patients", 1529], ["with", 1538], ["severe", 1543], ["or", 1550], ["recurrent", 1553], ["disease", 1563], ["may", 1571], ["help", 1575], ["to", 1580], ["better", 1583], ["understand", 1590], ["virulence", 1601], ["and", 1611], ["epidemic", 1615], ["spreading", 1624], ["of", 1634], ["C.", 1637], ["difficile", 1640], [".", 1649]]}
{"context": "Past studies have documented a crosstalk between H2B ubiquitylation (H2Bub) and H3K4 methylation, but little (if any) direct evidence exists explaining the mechanism underlying H2Bub-dependent H3K4 methylation on chromatin templates. Here, we took advantage of an in vitro histone methyltransferase assay employing a reconstituted yeast Set1 complex (ySet1C) and a recombinant chromatin template containing fully ubiquitylated H2B to gain valuable insights. Combined with genetic analyses, we demonstrate that the n-SET domain within Set1, but not Swd2, is essential for H2Bub-dependent H3K4 methylation. Spp1, a homolog of human CFP1, is conditionally involved in this crosstalk. Our findings extend to the human Set1 complex, underscoring the conserved nature of this disease-relevant crosstalk pathway. As not all members of the H3K4 methyltransferase family contain n-SET domains, our studies draw attention to the n-SET domain as a predictor of an H2B ubiquitylation-sensing mechanism that leads to downstream H3K4 methylation.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "0e9ad5ae9db7422d92338cea8e52e210", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[84, 85], [161, 162]], "char_spans": [[516, 525], [921, 930]]}]}], "context_tokens": [["Past", 0], ["studies", 5], ["have", 13], ["documented", 18], ["a", 29], ["crosstalk", 31], ["between", 41], ["H2B", 49], ["ubiquitylation", 53], ["(", 68], ["H2Bub", 69], [")", 74], ["and", 76], ["H3K4", 80], ["methylation", 85], [",", 96], ["but", 98], ["little", 102], ["(", 109], ["if", 110], ["any", 113], [")", 116], ["direct", 118], ["evidence", 125], ["exists", 134], ["explaining", 141], ["the", 152], ["mechanism", 156], ["underlying", 166], ["H2Bub", 177], ["-", 182], ["dependent", 183], ["H3K4", 193], ["methylation", 198], ["on", 210], ["chromatin", 213], ["templates", 223], [".", 232], ["Here", 234], [",", 238], ["we", 240], ["took", 243], ["advantage", 248], ["of", 258], ["an", 261], ["in", 264], ["vitro", 267], ["histone", 273], ["methyltransferase", 281], ["assay", 299], ["employing", 305], ["a", 315], ["reconstituted", 317], ["yeast", 331], ["Set1", 337], ["complex", 342], ["(", 350], ["ySet1C", 351], [")", 357], ["and", 359], ["a", 363], ["recombinant", 365], ["chromatin", 377], ["template", 387], ["containing", 396], ["fully", 407], ["ubiquitylated", 413], ["H2B", 427], ["to", 431], ["gain", 434], ["valuable", 439], ["insights", 448], [".", 456], ["Combined", 458], ["with", 467], ["genetic", 472], ["analyses", 480], [",", 488], ["we", 490], ["demonstrate", 493], ["that", 505], ["the", 510], ["n", 514], ["-", 515], ["SET", 516], ["domain", 520], ["within", 527], ["Set1", 534], [",", 538], ["but", 540], ["not", 544], ["Swd2", 548], [",", 552], ["is", 554], ["essential", 557], ["for", 567], ["H2Bub", 571], ["-", 576], ["dependent", 577], ["H3K4", 587], ["methylation", 592], [".", 603], ["Spp1", 605], [",", 609], ["a", 611], ["homolog", 613], ["of", 621], ["human", 624], ["CFP1", 630], [",", 634], ["is", 636], ["conditionally", 639], ["involved", 653], ["in", 662], ["this", 665], ["crosstalk", 670], [".", 679], ["Our", 681], ["findings", 685], ["extend", 694], ["to", 701], ["the", 704], ["human", 708], ["Set1", 714], ["complex", 719], [",", 726], ["underscoring", 728], ["the", 741], ["conserved", 745], ["nature", 755], ["of", 762], ["this", 765], ["disease", 770], ["-", 777], ["relevant", 778], ["crosstalk", 787], ["pathway", 797], [".", 804], ["As", 806], ["not", 809], ["all", 813], ["members", 817], ["of", 825], ["the", 828], ["H3K4", 832], ["methyltransferase", 837], ["family", 855], ["contain", 862], ["n", 870], ["-", 871], ["SET", 872], ["domains", 876], [",", 883], ["our", 885], ["studies", 889], ["draw", 897], ["attention", 902], ["to", 912], ["the", 915], ["n", 919], ["-", 920], ["SET", 921], ["domain", 925], ["as", 932], ["a", 935], ["predictor", 937], ["of", 947], ["an", 950], ["H2B", 953], ["ubiquitylation", 957], ["-", 971], ["sensing", 972], ["mechanism", 980], ["that", 990], ["leads", 995], ["to", 1001], ["downstream", 1004], ["H3K4", 1015], ["methylation", 1020], [".", 1031]]}
{"context": "Sotos syndrome is an overgrowth syndrome with characteristic facial gestalt and mental retardation of variable severity. Haploinsufficiency of the NSD1 gene has been implicated as the major cause of Sotos syndrome, with a predominance of microdeletions reported in Japanese patients. This study was conducted to investigate into the spectrum of NSD1 gene mutations in southern Chinese patients with Sotos syndrome. Thirty-six Chinese patients with Sotos syndrome and two patients with Weaver syndrome were subject to molecular testing. NSD1 gene mutations were detected in 26 (72%) Sotos patients. Microdeletion was found in only 3 patients, while the other 23 had point mutations (6 frameshift, 8 nonsense, 2 spice site, and 7 missense). Of these, 19 mutations were never reported. NSD1 gene mutations were not found in the two patients with Weaver syndrome. Most cases of Sotos syndrome are caused by NSD1 gene defects, but the spectrum of mutations is different from that of Japanese patients. Genotype-phenotype correlation showed that patients with microdeletions might be more prone to congenital heart disease but less likely to have somatic overgrowth. The two patients with Weaver syndrome were not found to have NSD1 gene mutations, but the number was too small for any conclusion to be drawn.", "qas": [{"question": "Which gene is responsible for the development of Sotos syndrome?", "answers": ["NSD1 gene"], "qid": "2cf9e36ee549421b84170a93d439b69d", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["Sotos", 49], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "NSD1 gene", "token_spans": [[160, 161], [138, 139], [20, 21], [84, 85], [53, 54], [213, 214]], "char_spans": [[903, 911], [783, 791], [147, 155], [536, 544], [345, 353], [1222, 1230]]}]}], "context_tokens": [["Sotos", 0], ["syndrome", 6], ["is", 15], ["an", 18], ["overgrowth", 21], ["syndrome", 32], ["with", 41], ["characteristic", 46], ["facial", 61], ["gestalt", 68], ["and", 76], ["mental", 80], ["retardation", 87], ["of", 99], ["variable", 102], ["severity", 111], [".", 119], ["Haploinsufficiency", 121], ["of", 140], ["the", 143], ["NSD1", 147], ["gene", 152], ["has", 157], ["been", 161], ["implicated", 166], ["as", 177], ["the", 180], ["major", 184], ["cause", 190], ["of", 196], ["Sotos", 199], ["syndrome", 205], [",", 213], ["with", 215], ["a", 220], ["predominance", 222], ["of", 235], ["microdeletions", 238], ["reported", 253], ["in", 262], ["Japanese", 265], ["patients", 274], [".", 282], ["This", 284], ["study", 289], ["was", 295], ["conducted", 299], ["to", 309], ["investigate", 312], ["into", 324], ["the", 329], ["spectrum", 333], ["of", 342], ["NSD1", 345], ["gene", 350], ["mutations", 355], ["in", 365], ["southern", 368], ["Chinese", 377], ["patients", 385], ["with", 394], ["Sotos", 399], ["syndrome", 405], [".", 413], ["Thirty", 415], ["-", 421], ["six", 422], ["Chinese", 426], ["patients", 434], ["with", 443], ["Sotos", 448], ["syndrome", 454], ["and", 463], ["two", 467], ["patients", 471], ["with", 480], ["Weaver", 485], ["syndrome", 492], ["were", 501], ["subject", 506], ["to", 514], ["molecular", 517], ["testing", 527], [".", 534], ["NSD1", 536], ["gene", 541], ["mutations", 546], ["were", 556], ["detected", 561], ["in", 570], ["26", 573], ["(", 576], ["72", 577], ["%", 579], [")", 580], ["Sotos", 582], ["patients", 588], [".", 596], ["Microdeletion", 598], ["was", 612], ["found", 616], ["in", 622], ["only", 625], ["3", 630], ["patients", 632], [",", 640], ["while", 642], ["the", 648], ["other", 652], ["23", 658], ["had", 661], ["point", 665], ["mutations", 671], ["(", 681], ["6", 682], ["frameshift", 684], [",", 694], ["8", 696], ["nonsense", 698], [",", 706], ["2", 708], ["spice", 710], ["site", 716], [",", 720], ["and", 722], ["7", 726], ["missense", 728], [")", 736], [".", 737], ["Of", 739], ["these", 742], [",", 747], ["19", 749], ["mutations", 752], ["were", 762], ["never", 767], ["reported", 773], [".", 781], ["NSD1", 783], ["gene", 788], ["mutations", 793], ["were", 803], ["not", 808], ["found", 812], ["in", 818], ["the", 821], ["two", 825], ["patients", 829], ["with", 838], ["Weaver", 843], ["syndrome", 850], [".", 858], ["Most", 860], ["cases", 865], ["of", 871], ["Sotos", 874], ["syndrome", 880], ["are", 889], ["caused", 893], ["by", 900], ["NSD1", 903], ["gene", 908], ["defects", 913], [",", 920], ["but", 922], ["the", 926], ["spectrum", 930], ["of", 939], ["mutations", 942], ["is", 952], ["different", 955], ["from", 965], ["that", 970], ["of", 975], ["Japanese", 978], ["patients", 987], [".", 995], ["Genotype", 997], ["-", 1005], ["phenotype", 1006], ["correlation", 1016], ["showed", 1028], ["that", 1035], ["patients", 1040], ["with", 1049], ["microdeletions", 1054], ["might", 1069], ["be", 1075], ["more", 1078], ["prone", 1083], ["to", 1089], ["congenital", 1092], ["heart", 1103], ["disease", 1109], ["but", 1117], ["less", 1121], ["likely", 1126], ["to", 1133], ["have", 1136], ["somatic", 1141], ["overgrowth", 1149], [".", 1159], ["The", 1161], ["two", 1165], ["patients", 1169], ["with", 1178], ["Weaver", 1183], ["syndrome", 1190], ["were", 1199], ["not", 1204], ["found", 1208], ["to", 1214], ["have", 1217], ["NSD1", 1222], ["gene", 1227], ["mutations", 1232], [",", 1241], ["but", 1243], ["the", 1247], ["number", 1251], ["was", 1258], ["too", 1262], ["small", 1266], ["for", 1272], ["any", 1276], ["conclusion", 1280], ["to", 1291], ["be", 1294], ["drawn", 1297], [".", 1302]]}
{"context": "The RTS,S/AS01(E) candidate malaria vaccine is being developed for immunisation of infants in Africa through the expanded programme on immunisation (EPI). 8 month follow-up data have been reported for safety and immunogenicity of RTS,S/AS01(E) when integrated into the EPI. We report extended follow-up to 19 months, including efficacy results. We did a randomised, open-label, phase 2 trial of safety and efficacy of the RTS,S/AS01(E) candidate malaria vaccine given with EPI vaccines between April 30, 2007, and Oct 7, 2009, in Ghana, Tanzania, and Gabon. Eligible children were 6-10 weeks of age at first vaccination, without serious acute or chronic illness. All children received the EPI diphtheria, tetanus, pertussis (inactivated whole-cell), and hepatitis-B vaccines, Haemophilus influenzae type b vaccine, and oral polio vaccine at study months 0, 1, and 2, and measles vaccine and yellow fever vaccines at study month 7. Participants were randomly assigned (1:1:1) to receive three doses of RTS,S/AS01(E) at 6, 10, and 14 weeks (0, 1, 2 month schedule) or at 6 weeks, 10 weeks, and 9 months (0, 2, 7 month schedule) or placebo. Randomisation was according to a predefined block list with a computer-generated randomisation code. Detection of serious adverse events and malaria was by passive case detection. Antibodies against Plasmodium falciparum circumsporozoite protein and HBsAg were monitored for 19 months. This study is registered with ClinicalTrials.gov, number NCT00436007. 511 children were enrolled. Serious adverse events occurred in 57 participants in the RTS,S/AS01(E) 0, 1, 2 month group (34%, 95% CI 27-41), 47 in the 0, 1, 7 month group (28%, 21-35), and 49 (29%, 22-36) in the control group; none were judged to be related to study vaccination. At month 19, anticircumsporozoite immune responses were significantly higher in the RTS,S/AS01(E) groups than in the control group. Vaccine efficacy for the 0, 1, 2 month schedule (2 weeks after dose three to month 19, site-adjusted according-to-protocol analysis) was 53% (95% CI 26-70; p=0\u00b70012) against first malaria episodes and 59% (36-74; p=0\u00b70001) against all malaria episodes. For the entire study period, (total vaccinated cohort) vaccine efficacy against all malaria episodes was higher with the 0, 1, 2 month schedule (57%, 95% CI 33-73; p=0\u00b70002) than with the 0, 1, 7 month schedule (32% CI 16-45; p=0\u00b70003). 1 year after dose three, vaccine efficacy against first malaria episodes was similar for both schedules (0, 1, 2 month group, 61\u00b76% [95% CI 35\u00b76-77\u00b71], p<0\u00b7001; 0, 1, 7 month group, 63\u00b78% [40\u00b74-78\u00b70], p<0\u00b7001, according-to-protocol cohort). Vaccine efficacy was consistent with the target put forward by the WHO-sponsored malaria vaccine technology roadmap for a first-generation malaria vaccine. The 0, 1, 2 month vaccine schedule has been selected for phase 3 candidate vaccine assessment. Program for Appropriate Technology in Health Malaria Vaccine Initiative; GlaxoSmithKline Biologicals.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "e902e6f0d961453ba6bc3e8ea9ab9588", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[275, 275], [549, 549], [474, 474], [618, 618], [627, 627], [460, 460], [492, 492], [8, 8], [94, 94], [655, 655]], "char_spans": [[1279, 1285], [2452, 2458], [2141, 2147], [2718, 2724], [2776, 2782], [2086, 2092], [2243, 2249], [28, 34], [446, 452], [2933, 2939]]}]}], "context_tokens": [["The", 0], ["RTS", 4], [",", 7], ["S", 8], ["/", 9], ["AS01(E", 10], [")", 16], ["candidate", 18], ["malaria", 28], ["vaccine", 36], ["is", 44], ["being", 47], ["developed", 53], ["for", 63], ["immunisation", 67], ["of", 80], ["infants", 83], ["in", 91], ["Africa", 94], ["through", 101], ["the", 109], ["expanded", 113], ["programme", 122], ["on", 132], ["immunisation", 135], ["(", 148], ["EPI", 149], [")", 152], [".", 153], ["8", 155], ["month", 157], ["follow", 163], ["-", 169], ["up", 170], ["data", 173], ["have", 178], ["been", 183], ["reported", 188], ["for", 197], ["safety", 201], ["and", 208], ["immunogenicity", 212], ["of", 227], ["RTS", 230], [",", 233], ["S", 234], ["/", 235], ["AS01(E", 236], [")", 242], ["when", 244], ["integrated", 249], ["into", 260], ["the", 265], ["EPI", 269], [".", 272], ["We", 274], ["report", 277], ["extended", 284], ["follow", 293], ["-", 299], ["up", 300], ["to", 303], ["19", 306], ["months", 309], [",", 315], ["including", 317], ["efficacy", 327], ["results", 336], [".", 343], ["We", 345], ["did", 348], ["a", 352], ["randomised", 354], [",", 364], ["open", 366], ["-", 370], ["label", 371], [",", 376], ["phase", 378], ["2", 384], ["trial", 386], ["of", 392], ["safety", 395], ["and", 402], ["efficacy", 406], ["of", 415], ["the", 418], ["RTS", 422], [",", 425], ["S", 426], ["/", 427], ["AS01(E", 428], [")", 434], ["candidate", 436], ["malaria", 446], ["vaccine", 454], ["given", 462], ["with", 468], ["EPI", 473], ["vaccines", 477], ["between", 486], ["April", 494], ["30", 500], [",", 502], ["2007", 504], [",", 508], ["and", 510], ["Oct", 514], ["7", 518], [",", 519], ["2009", 521], [",", 525], ["in", 527], ["Ghana", 530], [",", 535], ["Tanzania", 537], [",", 545], ["and", 547], ["Gabon", 551], [".", 556], ["Eligible", 558], ["children", 567], ["were", 576], ["6", 581], ["-", 582], ["10", 583], ["weeks", 586], ["of", 592], ["age", 595], ["at", 599], ["first", 602], ["vaccination", 608], [",", 619], ["without", 621], ["serious", 629], ["acute", 637], ["or", 643], ["chronic", 646], ["illness", 654], [".", 661], ["All", 663], ["children", 667], ["received", 676], ["the", 685], ["EPI", 689], ["diphtheria", 693], [",", 703], ["tetanus", 705], [",", 712], ["pertussis", 714], ["(", 724], ["inactivated", 725], ["whole", 737], ["-", 742], ["cell", 743], [")", 747], [",", 748], ["and", 750], ["hepatitis", 754], ["-", 763], ["B", 764], ["vaccines", 766], [",", 774], ["Haemophilus", 776], ["influenzae", 788], ["type", 799], ["b", 804], ["vaccine", 806], [",", 813], ["and", 815], ["oral", 819], ["polio", 824], ["vaccine", 830], ["at", 838], ["study", 841], ["months", 847], ["0", 854], [",", 855], ["1", 857], [",", 858], ["and", 860], ["2", 864], [",", 865], ["and", 867], ["measles", 871], ["vaccine", 879], ["and", 887], ["yellow", 891], ["fever", 898], ["vaccines", 904], ["at", 913], ["study", 916], ["month", 922], ["7", 928], [".", 929], ["Participants", 931], ["were", 944], ["randomly", 949], ["assigned", 958], ["(", 967], ["1:1:1", 968], [")", 973], ["to", 975], ["receive", 978], ["three", 986], ["doses", 992], ["of", 998], ["RTS", 1001], [",", 1004], ["S", 1005], ["/", 1006], ["AS01(E", 1007], [")", 1013], ["at", 1015], ["6", 1018], [",", 1019], ["10", 1021], [",", 1023], ["and", 1025], ["14", 1029], ["weeks", 1032], ["(", 1038], ["0", 1039], [",", 1040], ["1", 1042], [",", 1043], ["2", 1045], ["month", 1047], ["schedule", 1053], [")", 1061], ["or", 1063], ["at", 1066], ["6", 1069], ["weeks", 1071], [",", 1076], ["10", 1078], ["weeks", 1081], [",", 1086], ["and", 1088], ["9", 1092], ["months", 1094], ["(", 1101], ["0", 1102], [",", 1103], ["2", 1105], [",", 1106], ["7", 1108], ["month", 1110], ["schedule", 1116], [")", 1124], ["or", 1126], ["placebo", 1129], [".", 1136], ["Randomisation", 1138], ["was", 1152], ["according", 1156], ["to", 1166], ["a", 1169], ["predefined", 1171], ["block", 1182], ["list", 1188], ["with", 1193], ["a", 1198], ["computer", 1200], ["-", 1208], ["generated", 1209], ["randomisation", 1219], ["code", 1233], [".", 1237], ["Detection", 1239], ["of", 1249], ["serious", 1252], ["adverse", 1260], ["events", 1268], ["and", 1275], ["malaria", 1279], ["was", 1287], ["by", 1291], ["passive", 1294], ["case", 1302], ["detection", 1307], [".", 1316], ["Antibodies", 1318], ["against", 1329], ["Plasmodium", 1337], ["falciparum", 1348], ["circumsporozoite", 1359], ["protein", 1376], ["and", 1384], ["HBsAg", 1388], ["were", 1394], ["monitored", 1399], ["for", 1409], ["19", 1413], ["months", 1416], [".", 1422], ["This", 1424], ["study", 1429], ["is", 1435], ["registered", 1438], ["with", 1449], ["ClinicalTrials.gov", 1454], [",", 1472], ["number", 1474], ["NCT00436007", 1481], [".", 1492], ["511", 1494], ["children", 1498], ["were", 1507], ["enrolled", 1512], [".", 1520], ["Serious", 1522], ["adverse", 1530], ["events", 1538], ["occurred", 1545], ["in", 1554], ["57", 1557], ["participants", 1560], ["in", 1573], ["the", 1576], ["RTS", 1580], [",", 1583], ["S", 1584], ["/", 1585], ["AS01(E", 1586], [")", 1592], ["0", 1594], [",", 1595], ["1", 1597], [",", 1598], ["2", 1600], ["month", 1602], ["group", 1608], ["(", 1614], ["34", 1615], ["%", 1617], [",", 1618], ["95", 1620], ["%", 1622], ["CI", 1624], ["27", 1627], ["-", 1629], ["41", 1630], [")", 1632], [",", 1633], ["47", 1635], ["in", 1638], ["the", 1641], ["0", 1645], [",", 1646], ["1", 1648], [",", 1649], ["7", 1651], ["month", 1653], ["group", 1659], ["(", 1665], ["28", 1666], ["%", 1668], [",", 1669], ["21", 1671], ["-", 1673], ["35", 1674], [")", 1676], [",", 1677], ["and", 1679], ["49", 1683], ["(", 1686], ["29", 1687], ["%", 1689], [",", 1690], ["22", 1692], ["-", 1694], ["36", 1695], [")", 1697], ["in", 1699], ["the", 1702], ["control", 1706], ["group", 1714], [";", 1719], ["none", 1721], ["were", 1726], ["judged", 1731], ["to", 1738], ["be", 1741], ["related", 1744], ["to", 1752], ["study", 1755], ["vaccination", 1761], [".", 1772], ["At", 1774], ["month", 1777], ["19", 1783], [",", 1785], ["anticircumsporozoite", 1787], ["immune", 1808], ["responses", 1815], ["were", 1825], ["significantly", 1830], ["higher", 1844], ["in", 1851], ["the", 1854], ["RTS", 1858], [",", 1861], ["S", 1862], ["/", 1863], ["AS01(E", 1864], [")", 1870], ["groups", 1872], ["than", 1879], ["in", 1884], ["the", 1887], ["control", 1891], ["group", 1899], [".", 1904], ["Vaccine", 1906], ["efficacy", 1914], ["for", 1923], ["the", 1927], ["0", 1931], [",", 1932], ["1", 1934], [",", 1935], ["2", 1937], ["month", 1939], ["schedule", 1945], ["(", 1954], ["2", 1955], ["weeks", 1957], ["after", 1963], ["dose", 1969], ["three", 1974], ["to", 1980], ["month", 1983], ["19", 1989], [",", 1991], ["site", 1993], ["-", 1997], ["adjusted", 1998], ["according", 2007], ["-", 2016], ["to", 2017], ["-", 2019], ["protocol", 2020], ["analysis", 2029], [")", 2037], ["was", 2039], ["53", 2043], ["%", 2045], ["(", 2047], ["95", 2048], ["%", 2050], ["CI", 2052], ["26", 2055], ["-", 2057], ["70", 2058], [";", 2060], ["p=0\u00b70012", 2062], [")", 2070], ["against", 2072], ["first", 2080], ["malaria", 2086], ["episodes", 2094], ["and", 2103], ["59", 2107], ["%", 2109], ["(", 2111], ["36", 2112], ["-", 2114], ["74", 2115], [";", 2117], ["p=0\u00b70001", 2119], [")", 2127], ["against", 2129], ["all", 2137], ["malaria", 2141], ["episodes", 2149], [".", 2157], ["For", 2159], ["the", 2163], ["entire", 2167], ["study", 2174], ["period", 2180], [",", 2186], ["(", 2188], ["total", 2189], ["vaccinated", 2195], ["cohort", 2206], [")", 2212], ["vaccine", 2214], ["efficacy", 2222], ["against", 2231], ["all", 2239], ["malaria", 2243], ["episodes", 2251], ["was", 2260], ["higher", 2264], ["with", 2271], ["the", 2276], ["0", 2280], [",", 2281], ["1", 2283], [",", 2284], ["2", 2286], ["month", 2288], ["schedule", 2294], ["(", 2303], ["57", 2304], ["%", 2306], [",", 2307], ["95", 2309], ["%", 2311], ["CI", 2313], ["33", 2316], ["-", 2318], ["73", 2319], [";", 2321], ["p=0\u00b70002", 2323], [")", 2331], ["than", 2333], ["with", 2338], ["the", 2343], ["0", 2347], [",", 2348], ["1", 2350], [",", 2351], ["7", 2353], ["month", 2355], ["schedule", 2361], ["(", 2370], ["32", 2371], ["%", 2373], ["CI", 2375], ["16", 2378], ["-", 2380], ["45", 2381], [";", 2383], ["p=0\u00b70003", 2385], [")", 2393], [".", 2394], ["1", 2396], ["year", 2398], ["after", 2403], ["dose", 2409], ["three", 2414], [",", 2419], ["vaccine", 2421], ["efficacy", 2429], ["against", 2438], ["first", 2446], ["malaria", 2452], ["episodes", 2460], ["was", 2469], ["similar", 2473], ["for", 2481], ["both", 2485], ["schedules", 2490], ["(", 2500], ["0", 2501], [",", 2502], ["1", 2504], [",", 2505], ["2", 2507], ["month", 2509], ["group", 2515], [",", 2520], ["61\u00b76", 2522], ["%", 2526], ["[", 2528], ["95", 2529], ["%", 2531], ["CI", 2533], ["35\u00b76", 2536], ["-", 2540], ["77\u00b71", 2541], ["]", 2545], [",", 2546], ["p<0\u00b7001", 2548], [";", 2555], ["0", 2557], [",", 2558], ["1", 2560], [",", 2561], ["7", 2563], ["month", 2565], ["group", 2571], [",", 2576], ["63\u00b78", 2578], ["%", 2582], ["[", 2584], ["40\u00b74", 2585], ["-", 2589], ["78\u00b70", 2590], ["]", 2594], [",", 2595], ["p<0\u00b7001", 2597], [",", 2604], ["according", 2606], ["-", 2615], ["to", 2616], ["-", 2618], ["protocol", 2619], ["cohort", 2628], [")", 2634], [".", 2635], ["Vaccine", 2637], ["efficacy", 2645], ["was", 2654], ["consistent", 2658], ["with", 2669], ["the", 2674], ["target", 2678], ["put", 2685], ["forward", 2689], ["by", 2697], ["the", 2700], ["WHO", 2704], ["-", 2707], ["sponsored", 2708], ["malaria", 2718], ["vaccine", 2726], ["technology", 2734], ["roadmap", 2745], ["for", 2753], ["a", 2757], ["first", 2759], ["-", 2764], ["generation", 2765], ["malaria", 2776], ["vaccine", 2784], [".", 2791], ["The", 2793], ["0", 2797], [",", 2798], ["1", 2800], [",", 2801], ["2", 2803], ["month", 2805], ["vaccine", 2811], ["schedule", 2819], ["has", 2828], ["been", 2832], ["selected", 2837], ["for", 2846], ["phase", 2850], ["3", 2856], ["candidate", 2858], ["vaccine", 2868], ["assessment", 2876], [".", 2886], ["Program", 2888], ["for", 2896], ["Appropriate", 2900], ["Technology", 2912], ["in", 2923], ["Health", 2926], ["Malaria", 2933], ["Vaccine", 2941], ["Initiative", 2949], [";", 2959], ["GlaxoSmithKline", 2961], ["Biologicals", 2977], [".", 2988]]}
{"context": "Imatinib mesylate, a tyrosine kinase inhibitor with specific activity against the breakpoint cluster region--Abelson murine leukemia (BCR-ABL) tyrosine kinase has been developed for treatment of chronic myelogenous leukemia (CML). Its hematologic and cytogenetic effects have been evaluated in a series of clinical trials. The aim of this study was to report hematologic and cytogenetic response in CML patients during the treatment with imatinib mesylate. A total of 21 patients were treated and observed from July 2006 to December 2008. The median time from CML diagnosis was no more than 12 months, so all the patients received previous treatment with hydroxyurea for which the median time was 3 months. The patients received imatinib mesylate in an effective oral dose of 400 to 800 mg daily, which was followed with peripheral blood counts, bone marrow examination, and cytogenetic studies at 6, 12, 18 and 24 months. Complete hematologic responses were reported for 19 (90.48%) of 21 patients studied. Among 19 patients who had a response, 16 (86%) did so within 3 months. The best cytogenetic response rate at any time during the study treatment with imatinib mesylate, among 14 patients in which cytogenetic response evaluated was: complete cytogenetic response in 7 (50%) patients, partial cytogenetic response in 6 (42.9%) patients and minor cytogenetic response in 1 (7.1%) patient. No patients had progressed to accelerated or blastic phase. The most frequent adverse effects that seemed to be related to treatment with imatinib mesylate were edema and musculoskeletal pain; overall, most were mild. Only one patient discontinued treatment because of hematologic toxic effects. The results obtained in this study confirm that imatinib mesylate induces a complete hematological and cytogenetic response in a high percentage of patients with chronic-phase CML.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "6a1078ce36c74d609a098b1b566be822", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[20, 22]], "char_spans": [[134, 140]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], [",", 17], ["a", 19], ["tyrosine", 21], ["kinase", 30], ["inhibitor", 37], ["with", 47], ["specific", 52], ["activity", 61], ["against", 70], ["the", 78], ["breakpoint", 82], ["cluster", 93], ["region", 101], ["--", 107], ["Abelson", 109], ["murine", 117], ["leukemia", 124], ["(", 133], ["BCR", 134], ["-", 137], ["ABL", 138], [")", 141], ["tyrosine", 143], ["kinase", 152], ["has", 159], ["been", 163], ["developed", 168], ["for", 178], ["treatment", 182], ["of", 192], ["chronic", 195], ["myelogenous", 203], ["leukemia", 215], ["(", 224], ["CML", 225], [")", 228], [".", 229], ["Its", 231], ["hematologic", 235], ["and", 247], ["cytogenetic", 251], ["effects", 263], ["have", 271], ["been", 276], ["evaluated", 281], ["in", 291], ["a", 294], ["series", 296], ["of", 303], ["clinical", 306], ["trials", 315], [".", 321], ["The", 323], ["aim", 327], ["of", 331], ["this", 334], ["study", 339], ["was", 345], ["to", 349], ["report", 352], ["hematologic", 359], ["and", 371], ["cytogenetic", 375], ["response", 387], ["in", 396], ["CML", 399], ["patients", 403], ["during", 412], ["the", 419], ["treatment", 423], ["with", 433], ["imatinib", 438], ["mesylate", 447], [".", 455], ["A", 457], ["total", 459], ["of", 465], ["21", 468], ["patients", 471], ["were", 480], ["treated", 485], ["and", 493], ["observed", 497], ["from", 506], ["July", 511], ["2006", 516], ["to", 521], ["December", 524], ["2008", 533], [".", 537], ["The", 539], ["median", 543], ["time", 550], ["from", 555], ["CML", 560], ["diagnosis", 564], ["was", 574], ["no", 578], ["more", 581], ["than", 586], ["12", 591], ["months", 594], [",", 600], ["so", 602], ["all", 605], ["the", 609], ["patients", 613], ["received", 622], ["previous", 631], ["treatment", 640], ["with", 650], ["hydroxyurea", 655], ["for", 667], ["which", 671], ["the", 677], ["median", 681], ["time", 688], ["was", 693], ["3", 697], ["months", 699], [".", 705], ["The", 707], ["patients", 711], ["received", 720], ["imatinib", 729], ["mesylate", 738], ["in", 747], ["an", 750], ["effective", 753], ["oral", 763], ["dose", 768], ["of", 773], ["400", 776], ["to", 780], ["800", 783], ["mg", 787], ["daily", 790], [",", 795], ["which", 797], ["was", 803], ["followed", 807], ["with", 816], ["peripheral", 821], ["blood", 832], ["counts", 838], [",", 844], ["bone", 846], ["marrow", 851], ["examination", 858], [",", 869], ["and", 871], ["cytogenetic", 875], ["studies", 887], ["at", 895], ["6", 898], [",", 899], ["12", 901], [",", 903], ["18", 905], ["and", 908], ["24", 912], ["months", 915], [".", 921], ["Complete", 923], ["hematologic", 932], ["responses", 944], ["were", 954], ["reported", 959], ["for", 968], ["19", 972], ["(", 975], ["90.48", 976], ["%", 981], [")", 982], ["of", 984], ["21", 987], ["patients", 990], ["studied", 999], [".", 1006], ["Among", 1008], ["19", 1014], ["patients", 1017], ["who", 1026], ["had", 1030], ["a", 1034], ["response", 1036], [",", 1044], ["16", 1046], ["(", 1049], ["86", 1050], ["%", 1052], [")", 1053], ["did", 1055], ["so", 1059], ["within", 1062], ["3", 1069], ["months", 1071], [".", 1077], ["The", 1079], ["best", 1083], ["cytogenetic", 1088], ["response", 1100], ["rate", 1109], ["at", 1114], ["any", 1117], ["time", 1121], ["during", 1126], ["the", 1133], ["study", 1137], ["treatment", 1143], ["with", 1153], ["imatinib", 1158], ["mesylate", 1167], [",", 1175], ["among", 1177], ["14", 1183], ["patients", 1186], ["in", 1195], ["which", 1198], ["cytogenetic", 1204], ["response", 1216], ["evaluated", 1225], ["was", 1235], [":", 1238], ["complete", 1240], ["cytogenetic", 1249], ["response", 1261], ["in", 1270], ["7", 1273], ["(", 1275], ["50", 1276], ["%", 1278], [")", 1279], ["patients", 1281], [",", 1289], ["partial", 1291], ["cytogenetic", 1299], ["response", 1311], ["in", 1320], ["6", 1323], ["(", 1325], ["42.9", 1326], ["%", 1330], [")", 1331], ["patients", 1333], ["and", 1342], ["minor", 1346], ["cytogenetic", 1352], ["response", 1364], ["in", 1373], ["1", 1376], ["(", 1378], ["7.1", 1379], ["%", 1382], [")", 1383], ["patient", 1385], [".", 1392], ["No", 1394], ["patients", 1397], ["had", 1406], ["progressed", 1410], ["to", 1421], ["accelerated", 1424], ["or", 1436], ["blastic", 1439], ["phase", 1447], [".", 1452], ["The", 1454], ["most", 1458], ["frequent", 1463], ["adverse", 1472], ["effects", 1480], ["that", 1488], ["seemed", 1493], ["to", 1500], ["be", 1503], ["related", 1506], ["to", 1514], ["treatment", 1517], ["with", 1527], ["imatinib", 1532], ["mesylate", 1541], ["were", 1550], ["edema", 1555], ["and", 1561], ["musculoskeletal", 1565], ["pain", 1581], [";", 1585], ["overall", 1587], [",", 1594], ["most", 1596], ["were", 1601], ["mild", 1606], [".", 1610], ["Only", 1612], ["one", 1617], ["patient", 1621], ["discontinued", 1629], ["treatment", 1642], ["because", 1652], ["of", 1660], ["hematologic", 1663], ["toxic", 1675], ["effects", 1681], [".", 1688], ["The", 1690], ["results", 1694], ["obtained", 1702], ["in", 1711], ["this", 1714], ["study", 1719], ["confirm", 1725], ["that", 1733], ["imatinib", 1738], ["mesylate", 1747], ["induces", 1756], ["a", 1764], ["complete", 1766], ["hematological", 1775], ["and", 1789], ["cytogenetic", 1793], ["response", 1805], ["in", 1814], ["a", 1817], ["high", 1819], ["percentage", 1824], ["of", 1835], ["patients", 1838], ["with", 1847], ["chronic", 1852], ["-", 1859], ["phase", 1860], ["CML", 1866], [".", 1869]]}
{"context": "Coexpression of PU.1 and GATA-1 is required for proper specification of the mast cell lineage; however, in the myeloid and erythroid lineages, PU.1 and GATA-1 are functionally antagonistic. In this study, we report a transcriptional network in which PU.1 positively regulates GATA-1 expression in mast cell development. We isolated a variant mRNA isoform of GATA-1 in murine mast cells that is significantly upregulated during mast cell differentiation. This isoform contains an alternatively spliced first exon (IB) that is distinct from the first exon (IE) incorporated in the major erythroid mRNA transcript. In contrast to erythroid and megakaryocyte cells, in mast cells we show that PU.1 and GATA-2 predominantly occupy potential cis-regulatory elements in the IB exon region in vivo. Using reporter assays, we identify an enhancer flanking the IB exon that is activated by PU.1. Furthermore, we observe that in PU.1(-/-) fetal liver cells, low levels of the IE GATA-1 isoform is expressed, but the variant IB isoform is absent. Reintroduction of PU.1 restores variant IB isoform and upregulates total GATA-1 protein expression, which is concurrent with mast cell differentiation. Our results are consistent with a transcriptional hierarchy in which PU.1, possibly in concert with GATA-2, activates GATA-1 expression in mast cells in a pathway distinct from that seen in the erythroid and megakaryocytic lineages.", "qas": [{"question": "Which gene controls the expression of GATA-1 isoforms?", "answers": ["PU.1"], "qid": "f6516640f1d44d11963b1679aae29f07", "question_tokens": [["Which", 0], ["gene", 6], ["controls", 11], ["the", 20], ["expression", 24], ["of", 35], ["GATA-1", 38], ["isoforms", 45], ["?", 53]], "detected_answers": [{"text": "PU.1", "token_spans": [[117, 117], [43, 43], [151, 151], [25, 25], [185, 185], [215, 215], [2, 2], [159, 159]], "char_spans": [[689, 692], [250, 253], [880, 883], [143, 146], [1053, 1056], [1256, 1259], [16, 19], [918, 925]]}]}], "context_tokens": [["Coexpression", 0], ["of", 13], ["PU.1", 16], ["and", 21], ["GATA-1", 25], ["is", 32], ["required", 35], ["for", 44], ["proper", 48], ["specification", 55], ["of", 69], ["the", 72], ["mast", 76], ["cell", 81], ["lineage", 86], [";", 93], ["however", 95], [",", 102], ["in", 104], ["the", 107], ["myeloid", 111], ["and", 119], ["erythroid", 123], ["lineages", 133], [",", 141], ["PU.1", 143], ["and", 148], ["GATA-1", 152], ["are", 159], ["functionally", 163], ["antagonistic", 176], [".", 188], ["In", 190], ["this", 193], ["study", 198], [",", 203], ["we", 205], ["report", 208], ["a", 215], ["transcriptional", 217], ["network", 233], ["in", 241], ["which", 244], ["PU.1", 250], ["positively", 255], ["regulates", 266], ["GATA-1", 276], ["expression", 283], ["in", 294], ["mast", 297], ["cell", 302], ["development", 307], [".", 318], ["We", 320], ["isolated", 323], ["a", 332], ["variant", 334], ["mRNA", 342], ["isoform", 347], ["of", 355], ["GATA-1", 358], ["in", 365], ["murine", 368], ["mast", 375], ["cells", 380], ["that", 386], ["is", 391], ["significantly", 394], ["upregulated", 408], ["during", 420], ["mast", 427], ["cell", 432], ["differentiation", 437], [".", 452], ["This", 454], ["isoform", 459], ["contains", 467], ["an", 476], ["alternatively", 479], ["spliced", 493], ["first", 501], ["exon", 507], ["(", 512], ["IB", 513], [")", 515], ["that", 517], ["is", 522], ["distinct", 525], ["from", 534], ["the", 539], ["first", 543], ["exon", 549], ["(", 554], ["IE", 555], [")", 557], ["incorporated", 559], ["in", 572], ["the", 575], ["major", 579], ["erythroid", 585], ["mRNA", 595], ["transcript", 600], [".", 610], ["In", 612], ["contrast", 615], ["to", 624], ["erythroid", 627], ["and", 637], ["megakaryocyte", 641], ["cells", 655], [",", 660], ["in", 662], ["mast", 665], ["cells", 670], ["we", 676], ["show", 679], ["that", 684], ["PU.1", 689], ["and", 694], ["GATA-2", 698], ["predominantly", 705], ["occupy", 719], ["potential", 726], ["cis", 736], ["-", 739], ["regulatory", 740], ["elements", 751], ["in", 760], ["the", 763], ["IB", 767], ["exon", 770], ["region", 775], ["in", 782], ["vivo", 785], [".", 789], ["Using", 791], ["reporter", 797], ["assays", 806], [",", 812], ["we", 814], ["identify", 817], ["an", 826], ["enhancer", 829], ["flanking", 838], ["the", 847], ["IB", 851], ["exon", 854], ["that", 859], ["is", 864], ["activated", 867], ["by", 877], ["PU.1", 880], [".", 884], ["Furthermore", 886], [",", 897], ["we", 899], ["observe", 902], ["that", 910], ["in", 915], ["PU.1(-/-", 918], [")", 926], ["fetal", 928], ["liver", 934], ["cells", 940], [",", 945], ["low", 947], ["levels", 951], ["of", 958], ["the", 961], ["IE", 965], ["GATA-1", 968], ["isoform", 975], ["is", 983], ["expressed", 986], [",", 995], ["but", 997], ["the", 1001], ["variant", 1005], ["IB", 1013], ["isoform", 1016], ["is", 1024], ["absent", 1027], [".", 1033], ["Reintroduction", 1035], ["of", 1050], ["PU.1", 1053], ["restores", 1058], ["variant", 1067], ["IB", 1075], ["isoform", 1078], ["and", 1086], ["upregulates", 1090], ["total", 1102], ["GATA-1", 1108], ["protein", 1115], ["expression", 1123], [",", 1133], ["which", 1135], ["is", 1141], ["concurrent", 1144], ["with", 1155], ["mast", 1160], ["cell", 1165], ["differentiation", 1170], [".", 1185], ["Our", 1187], ["results", 1191], ["are", 1199], ["consistent", 1203], ["with", 1214], ["a", 1219], ["transcriptional", 1221], ["hierarchy", 1237], ["in", 1247], ["which", 1250], ["PU.1", 1256], [",", 1260], ["possibly", 1262], ["in", 1271], ["concert", 1274], ["with", 1282], ["GATA-2", 1287], [",", 1293], ["activates", 1295], ["GATA-1", 1305], ["expression", 1312], ["in", 1323], ["mast", 1326], ["cells", 1331], ["in", 1337], ["a", 1340], ["pathway", 1342], ["distinct", 1350], ["from", 1359], ["that", 1364], ["seen", 1369], ["in", 1374], ["the", 1377], ["erythroid", 1381], ["and", 1391], ["megakaryocytic", 1395], ["lineages", 1410], [".", 1418]]}
{"context": "Turner syndrome (TS) is the most common genetic problem affecting women and occurs when an X chromosome is completely deleted, portions of an X chromosome are deleted, or chromosomal mosaicism occurs. Girls with TS may also have occult Y chromosome sequences. Whereas some girls with TS are identified in infancy or early childhood, many girls with TS are not detected until after 10 yr of age, resulting in delayed evaluation and treatment. To prevent the delayed recognition and treatment of TS, a quantitative method of genotyping that can be performed as part of newborn screening is needed. To screen for sex chromosome abnormalities, we assembled a panel of informative single nucleotide polymorphism (SNP) markers that span the X chromosome from the dbSNP database. Pyrosequencing assays suitable for quantitative assessment of signal strength from single nucleotides were designed and used to genotype 46,XX; 46,XY; 45,X; and TS mosaics, examining zygosity and signal strength for individual alleles. Pyrosequencing assays were also designed for the detection of Y chromosome material. With just four informative SNP markers for the X chromosome, all TS girls with 45,X, partial X chromosome deletions, or mosaicism were identified with 100% sensitivity. In mosaic individuals, Y chromosomal material was detected with 100% sensitivity. These results suggest that inexpensive high-throughput screening is possible for TS and other sex chromosome disorders using quantitative genotyping approaches.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "4d9adbc83c164890a231325d350c9a93", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[131, 131], [26, 26], [196, 196], [206, 206], [17, 17]], "char_spans": [[735, 735], [142, 142], [1141, 1141], [1187, 1187], [91, 91]]}]}], "context_tokens": [["Turner", 0], ["syndrome", 7], ["(", 16], ["TS", 17], [")", 19], ["is", 21], ["the", 24], ["most", 28], ["common", 33], ["genetic", 40], ["problem", 48], ["affecting", 56], ["women", 66], ["and", 72], ["occurs", 76], ["when", 83], ["an", 88], ["X", 91], ["chromosome", 93], ["is", 104], ["completely", 107], ["deleted", 118], [",", 125], ["portions", 127], ["of", 136], ["an", 139], ["X", 142], ["chromosome", 144], ["are", 155], ["deleted", 159], [",", 166], ["or", 168], ["chromosomal", 171], ["mosaicism", 183], ["occurs", 193], [".", 199], ["Girls", 201], ["with", 207], ["TS", 212], ["may", 215], ["also", 219], ["have", 224], ["occult", 229], ["Y", 236], ["chromosome", 238], ["sequences", 249], [".", 258], ["Whereas", 260], ["some", 268], ["girls", 273], ["with", 279], ["TS", 284], ["are", 287], ["identified", 291], ["in", 302], ["infancy", 305], ["or", 313], ["early", 316], ["childhood", 322], [",", 331], ["many", 333], ["girls", 338], ["with", 344], ["TS", 349], ["are", 352], ["not", 356], ["detected", 360], ["until", 369], ["after", 375], ["10", 381], ["yr", 384], ["of", 387], ["age", 390], [",", 393], ["resulting", 395], ["in", 405], ["delayed", 408], ["evaluation", 416], ["and", 427], ["treatment", 431], [".", 440], ["To", 442], ["prevent", 445], ["the", 453], ["delayed", 457], ["recognition", 465], ["and", 477], ["treatment", 481], ["of", 491], ["TS", 494], [",", 496], ["a", 498], ["quantitative", 500], ["method", 513], ["of", 520], ["genotyping", 523], ["that", 534], ["can", 539], ["be", 543], ["performed", 546], ["as", 556], ["part", 559], ["of", 564], ["newborn", 567], ["screening", 575], ["is", 585], ["needed", 588], [".", 594], ["To", 596], ["screen", 599], ["for", 606], ["sex", 610], ["chromosome", 614], ["abnormalities", 625], [",", 638], ["we", 640], ["assembled", 643], ["a", 653], ["panel", 655], ["of", 661], ["informative", 664], ["single", 676], ["nucleotide", 683], ["polymorphism", 694], ["(", 707], ["SNP", 708], [")", 711], ["markers", 713], ["that", 721], ["span", 726], ["the", 731], ["X", 735], ["chromosome", 737], ["from", 748], ["the", 753], ["dbSNP", 757], ["database", 763], [".", 771], ["Pyrosequencing", 773], ["assays", 788], ["suitable", 795], ["for", 804], ["quantitative", 808], ["assessment", 821], ["of", 832], ["signal", 835], ["strength", 842], ["from", 851], ["single", 856], ["nucleotides", 863], ["were", 875], ["designed", 880], ["and", 889], ["used", 893], ["to", 898], ["genotype", 901], ["46,XX", 910], [";", 915], ["46,XY", 917], [";", 922], ["45,X", 924], [";", 928], ["and", 930], ["TS", 934], ["mosaics", 937], [",", 944], ["examining", 946], ["zygosity", 956], ["and", 965], ["signal", 969], ["strength", 976], ["for", 985], ["individual", 989], ["alleles", 1000], [".", 1007], ["Pyrosequencing", 1009], ["assays", 1024], ["were", 1031], ["also", 1036], ["designed", 1041], ["for", 1050], ["the", 1054], ["detection", 1058], ["of", 1068], ["Y", 1071], ["chromosome", 1073], ["material", 1084], [".", 1092], ["With", 1094], ["just", 1099], ["four", 1104], ["informative", 1109], ["SNP", 1121], ["markers", 1125], ["for", 1133], ["the", 1137], ["X", 1141], ["chromosome", 1143], [",", 1153], ["all", 1155], ["TS", 1159], ["girls", 1162], ["with", 1168], ["45,X", 1173], [",", 1177], ["partial", 1179], ["X", 1187], ["chromosome", 1189], ["deletions", 1200], [",", 1209], ["or", 1211], ["mosaicism", 1214], ["were", 1224], ["identified", 1229], ["with", 1240], ["100", 1245], ["%", 1248], ["sensitivity", 1250], [".", 1261], ["In", 1263], ["mosaic", 1266], ["individuals", 1273], [",", 1284], ["Y", 1286], ["chromosomal", 1288], ["material", 1300], ["was", 1309], ["detected", 1313], ["with", 1322], ["100", 1327], ["%", 1330], ["sensitivity", 1332], [".", 1343], ["These", 1345], ["results", 1351], ["suggest", 1359], ["that", 1367], ["inexpensive", 1372], ["high", 1384], ["-", 1388], ["throughput", 1389], ["screening", 1400], ["is", 1410], ["possible", 1413], ["for", 1422], ["TS", 1426], ["and", 1429], ["other", 1433], ["sex", 1439], ["chromosome", 1443], ["disorders", 1454], ["using", 1464], ["quantitative", 1470], ["genotyping", 1483], ["approaches", 1494], [".", 1504]]}
{"context": "Patients receiving tumor necrosis factor alpha inhibitors for the treatment of rheumatic diseases (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis) are at high risk of developing tuberculosis during treatment. This article gives the recommendations for the prevention and management of tuberculosis in patients with rheumatic diseases before initiating therapy with tumor necrosis factor alpha inhibitors. They are adapted considering the high prevalence of tuberculosis, high drug resistance of Mycobacterium tuberculosis, and extensive bacille Calmette-Gu\u00e9rin vaccination against tuberculosis in Lithuania. In order to reduce the risk of tuberculosis, the screening should be done before starting antitumor necrosis factor alpha therapy. This includes complete medical history and posterior-anterior, lateral chest radiography. Tuberculin skin test using the Mantoux method with 5 tuberculin units and interferon-gamma release assay should be performed in patients without posttuberculous radiological lesions. If Ghon's complex or untreated posttuberculous lesions are present, or if the results the Mantoux test or interferon-gamma release assay are positive, the patient should be treated for latent tuberculosis. For the treatment of latent tuberculosis, isoniazid and rifampicin are given for 3 months, and the introduction of antitumor necrosis factor alpha therapy is delayed at least for one month. In cases of suspected active Mycobacterium tuberculosis infection, tuberculosis should be confirmed microbiologically or morphologically, and adequate antituberculosis treatment should be initiated.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "a96c132fbe5e40d5a762f6f9583a5c81", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[96, 96], [75, 75], [29, 29], [85, 85], [186, 186], [227, 227], [230, 230], [68, 68], [44, 44], [193, 193]], "char_spans": [[658, 669], [528, 539], [197, 208], [600, 611], [1223, 1234], [1470, 1481], [1494, 1505], [476, 487], [304, 315], [1265, 1276]]}]}], "context_tokens": [["Patients", 0], ["receiving", 9], ["tumor", 19], ["necrosis", 25], ["factor", 34], ["alpha", 41], ["inhibitors", 47], ["for", 58], ["the", 62], ["treatment", 66], ["of", 76], ["rheumatic", 79], ["diseases", 89], ["(", 98], ["rheumatoid", 99], ["arthritis", 110], [",", 119], ["psoriatic", 121], ["arthritis", 131], [",", 140], ["ankylosing", 142], ["spondylitis", 153], [")", 164], ["are", 166], ["at", 170], ["high", 173], ["risk", 178], ["of", 183], ["developing", 186], ["tuberculosis", 197], ["during", 210], ["treatment", 217], [".", 226], ["This", 228], ["article", 233], ["gives", 241], ["the", 247], ["recommendations", 251], ["for", 267], ["the", 271], ["prevention", 275], ["and", 286], ["management", 290], ["of", 301], ["tuberculosis", 304], ["in", 317], ["patients", 320], ["with", 329], ["rheumatic", 334], ["diseases", 344], ["before", 353], ["initiating", 360], ["therapy", 371], ["with", 379], ["tumor", 384], ["necrosis", 390], ["factor", 399], ["alpha", 406], ["inhibitors", 412], [".", 422], ["They", 424], ["are", 429], ["adapted", 433], ["considering", 441], ["the", 453], ["high", 457], ["prevalence", 462], ["of", 473], ["tuberculosis", 476], [",", 488], ["high", 490], ["drug", 495], ["resistance", 500], ["of", 511], ["Mycobacterium", 514], ["tuberculosis", 528], [",", 540], ["and", 542], ["extensive", 546], ["bacille", 556], ["Calmette", 564], ["-", 572], ["Gu\u00e9rin", 573], ["vaccination", 580], ["against", 592], ["tuberculosis", 600], ["in", 613], ["Lithuania", 616], [".", 625], ["In", 627], ["order", 630], ["to", 636], ["reduce", 639], ["the", 646], ["risk", 650], ["of", 655], ["tuberculosis", 658], [",", 670], ["the", 672], ["screening", 676], ["should", 686], ["be", 693], ["done", 696], ["before", 701], ["starting", 708], ["antitumor", 717], ["necrosis", 727], ["factor", 736], ["alpha", 743], ["therapy", 749], [".", 756], ["This", 758], ["includes", 763], ["complete", 772], ["medical", 781], ["history", 789], ["and", 797], ["posterior", 801], ["-", 810], ["anterior", 811], [",", 819], ["lateral", 821], ["chest", 829], ["radiography", 835], [".", 846], ["Tuberculin", 848], ["skin", 859], ["test", 864], ["using", 869], ["the", 875], ["Mantoux", 879], ["method", 887], ["with", 894], ["5", 899], ["tuberculin", 901], ["units", 912], ["and", 918], ["interferon", 922], ["-", 932], ["gamma", 933], ["release", 939], ["assay", 947], ["should", 953], ["be", 960], ["performed", 963], ["in", 973], ["patients", 976], ["without", 985], ["posttuberculous", 993], ["radiological", 1009], ["lesions", 1022], [".", 1029], ["If", 1031], ["Ghon", 1034], ["'s", 1038], ["complex", 1041], ["or", 1049], ["untreated", 1052], ["posttuberculous", 1062], ["lesions", 1078], ["are", 1086], ["present", 1090], [",", 1097], ["or", 1099], ["if", 1102], ["the", 1105], ["results", 1109], ["the", 1117], ["Mantoux", 1121], ["test", 1129], ["or", 1134], ["interferon", 1137], ["-", 1147], ["gamma", 1148], ["release", 1154], ["assay", 1162], ["are", 1168], ["positive", 1172], [",", 1180], ["the", 1182], ["patient", 1186], ["should", 1194], ["be", 1201], ["treated", 1204], ["for", 1212], ["latent", 1216], ["tuberculosis", 1223], [".", 1235], ["For", 1237], ["the", 1241], ["treatment", 1245], ["of", 1255], ["latent", 1258], ["tuberculosis", 1265], [",", 1277], ["isoniazid", 1279], ["and", 1289], ["rifampicin", 1293], ["are", 1304], ["given", 1308], ["for", 1314], ["3", 1318], ["months", 1320], [",", 1326], ["and", 1328], ["the", 1332], ["introduction", 1336], ["of", 1349], ["antitumor", 1352], ["necrosis", 1362], ["factor", 1371], ["alpha", 1378], ["therapy", 1384], ["is", 1392], ["delayed", 1395], ["at", 1403], ["least", 1406], ["for", 1412], ["one", 1416], ["month", 1420], [".", 1425], ["In", 1427], ["cases", 1430], ["of", 1436], ["suspected", 1439], ["active", 1449], ["Mycobacterium", 1456], ["tuberculosis", 1470], ["infection", 1483], [",", 1492], ["tuberculosis", 1494], ["should", 1507], ["be", 1514], ["confirmed", 1517], ["microbiologically", 1527], ["or", 1545], ["morphologically", 1548], [",", 1563], ["and", 1565], ["adequate", 1569], ["antituberculosis", 1578], ["treatment", 1595], ["should", 1605], ["be", 1612], ["initiated", 1615], [".", 1624]]}
{"context": "Community-associated methicillin-resistant Staphylococcus aureus-(CA-MRSA) strains have emerged in Argentina. We investigated the clinical and molecular evolution of community-onset MRSA infections (CO-MRSA) in children of C\u00f3rdoba, Argentina, 2005-2008. Additionally, data from 2007 were compared with the epidemiology of these infections in other regions of the country. Two datasets were used: i) lab-based prospective surveillance of CA-MRSA isolates from 3 C\u00f3rdoba pediatric hospitals-(CBAH1-H3) in 2007-2008 (compared to previously published data of 2005) and ii) a sampling of CO-MRSA from a study involving both, healthcare-associated community-onset-(HACO) infections in children with risk-factors for healthcare-associated infections-(HRFs), and CA-MRSA infections in patients without HRFs detected in multiple centers of Argentina in 2007. Molecular typing was performed on the CA-MRSA-(n: 99) isolates from the CBAH1-H3-dataset and on the HACO-MRSA-(n: 51) and CA-MRSA-(n: 213) isolates from other regions. Between 2005-2008, the annual proportion of CA-MRSA/CA-S. aureus in C\u00f3rdoba hospitals increased from 25% to 49%, P<0.01. Total CA-MRSA infections increased 3.6 fold-(5.1 to 18.6 cases/100,000 annual-visits, P<0.0001), associated with an important increase of invasive CA-MRSA infections-(8.5 fold). In all regions analyzed, a single genotype prevailed in both CA-MRSA (82%) and HACO-MRSA(57%), which showed pulsed-field-gel electrophoresis-(PFGE)-type-\"I\", sequence-type-5-(ST5), SCCmec-type-IVa, spa-t311, and was positive for PVL. The second clone, pulsotype-N/ST30/CC30/SCCmecIVc/t019/PVL(+), accounted for 11.5% of total CA-MRSA infections. Importantly, the first 4 isolates of Argentina belonging to South American-USA300 clone-(USA300/ST8/CC8/SCCmecIVc/t008/PVL(+)/ACME(-)) were detected. We also demonstrated that a HA-MRSA clone-(pulsotype-C/ST100/CC5) caused 2% and 10% of CA-MRSA and HACO-MRSA infections respectively and was associated with a SCCmec type closely related to SCCmecIV(2B&5). The dissemination of epidemic MRSA clone, ST5-IV-PVL(+) was the main cause of increasing staphylococcal community-onset infections in Argentinean children (2003-2008), conversely to other countries. The predominance of this clone, which has capacity to express the h-VISA phenotype, in healthcare-associated community-onset cases suggests that it has infiltrated into hospital-settings.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "e471eaad8b7f456298a4d3d189d07e9f", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[226, 226], [384, 384], [141, 141], [250, 250], [28, 28], [204, 204], [9, 9], [268, 268], [332, 332], [364, 364], [380, 380], [404, 404], [110, 110], [33, 33], [81, 81]], "char_spans": [[1148, 1151], [1917, 1920], [758, 761], [1289, 1292], [182, 185], [1065, 1068], [69, 72], [1381, 1384], [1646, 1649], [1844, 1847], [1903, 1906], [2049, 2052], [586, 589], [202, 205], [440, 443]]}]}], "context_tokens": [["Community", 0], ["-", 9], ["associated", 10], ["methicillin", 21], ["-", 32], ["resistant", 33], ["Staphylococcus", 43], ["aureus-(CA", 58], ["-", 68], ["MRSA", 69], [")", 73], ["strains", 75], ["have", 83], ["emerged", 88], ["in", 96], ["Argentina", 99], [".", 108], ["We", 110], ["investigated", 113], ["the", 126], ["clinical", 130], ["and", 139], ["molecular", 143], ["evolution", 153], ["of", 163], ["community", 166], ["-", 175], ["onset", 176], ["MRSA", 182], ["infections", 187], ["(", 198], ["CO", 199], ["-", 201], ["MRSA", 202], [")", 206], ["in", 208], ["children", 211], ["of", 220], ["C\u00f3rdoba", 223], [",", 230], ["Argentina", 232], [",", 241], ["2005", 243], ["-", 247], ["2008", 248], [".", 252], ["Additionally", 254], [",", 266], ["data", 268], ["from", 273], ["2007", 278], ["were", 283], ["compared", 288], ["with", 297], ["the", 302], ["epidemiology", 306], ["of", 319], ["these", 322], ["infections", 328], ["in", 339], ["other", 342], ["regions", 348], ["of", 356], ["the", 359], ["country", 363], [".", 370], ["Two", 372], ["datasets", 376], ["were", 385], ["used", 390], [":", 394], ["i", 396], [")", 397], ["lab", 399], ["-", 402], ["based", 403], ["prospective", 409], ["surveillance", 421], ["of", 434], ["CA", 437], ["-", 439], ["MRSA", 440], ["isolates", 445], ["from", 454], ["3", 459], ["C\u00f3rdoba", 461], ["pediatric", 469], ["hospitals-(CBAH1-H3", 479], [")", 498], ["in", 500], ["2007", 503], ["-", 507], ["2008", 508], ["(", 513], ["compared", 514], ["to", 523], ["previously", 526], ["published", 537], ["data", 547], ["of", 552], ["2005", 555], [")", 559], ["and", 561], ["ii", 565], [")", 567], ["a", 569], ["sampling", 571], ["of", 580], ["CO", 583], ["-", 585], ["MRSA", 586], ["from", 591], ["a", 596], ["study", 598], ["involving", 604], ["both", 614], [",", 618], ["healthcare", 620], ["-", 630], ["associated", 631], ["community", 642], ["-", 651], ["onset-(HACO", 652], [")", 663], ["infections", 665], ["in", 676], ["children", 679], ["with", 688], ["risk", 693], ["-", 697], ["factors", 698], ["for", 706], ["healthcare", 710], ["-", 720], ["associated", 721], ["infections-(HRFs", 732], [")", 748], [",", 749], ["and", 751], ["CA", 755], ["-", 757], ["MRSA", 758], ["infections", 763], ["in", 774], ["patients", 777], ["without", 786], ["HRFs", 794], ["detected", 799], ["in", 808], ["multiple", 811], ["centers", 820], ["of", 828], ["Argentina", 831], ["in", 841], ["2007", 844], [".", 848], ["Molecular", 850], ["typing", 860], ["was", 867], ["performed", 871], ["on", 881], ["the", 884], ["CA", 888], ["-", 890], ["MRSA-(n", 891], [":", 898], ["99", 900], [")", 902], ["isolates", 904], ["from", 913], ["the", 918], ["CBAH1-H3-dataset", 922], ["and", 939], ["on", 943], ["the", 946], ["HACO", 950], ["-", 954], ["MRSA-(n", 955], [":", 962], ["51", 964], [")", 966], ["and", 968], ["CA", 972], ["-", 974], ["MRSA-(n", 975], [":", 982], ["213", 984], [")", 987], ["isolates", 989], ["from", 998], ["other", 1003], ["regions", 1009], [".", 1016], ["Between", 1018], ["2005", 1026], ["-", 1030], ["2008", 1031], [",", 1035], ["the", 1037], ["annual", 1041], ["proportion", 1048], ["of", 1059], ["CA", 1062], ["-", 1064], ["MRSA", 1065], ["/", 1069], ["CA", 1070], ["-", 1072], ["S.", 1073], ["aureus", 1076], ["in", 1083], ["C\u00f3rdoba", 1086], ["hospitals", 1094], ["increased", 1104], ["from", 1114], ["25", 1119], ["%", 1121], ["to", 1123], ["49", 1126], ["%", 1128], [",", 1129], ["P<0.01", 1131], [".", 1137], ["Total", 1139], ["CA", 1145], ["-", 1147], ["MRSA", 1148], ["infections", 1153], ["increased", 1164], ["3.6", 1174], ["fold-(5.1", 1178], ["to", 1188], ["18.6", 1191], ["cases/100,000", 1196], ["annual", 1210], ["-", 1216], ["visits", 1217], [",", 1223], ["P<0.0001", 1225], [")", 1233], [",", 1234], ["associated", 1236], ["with", 1247], ["an", 1252], ["important", 1255], ["increase", 1265], ["of", 1274], ["invasive", 1277], ["CA", 1286], ["-", 1288], ["MRSA", 1289], ["infections-(8.5", 1294], ["fold", 1310], [")", 1314], [".", 1315], ["In", 1317], ["all", 1320], ["regions", 1324], ["analyzed", 1332], [",", 1340], ["a", 1342], ["single", 1344], ["genotype", 1351], ["prevailed", 1360], ["in", 1370], ["both", 1373], ["CA", 1378], ["-", 1380], ["MRSA", 1381], ["(", 1386], ["82", 1387], ["%", 1389], [")", 1390], ["and", 1392], ["HACO", 1396], ["-", 1400], ["MRSA(57", 1401], ["%", 1408], [")", 1409], [",", 1410], ["which", 1412], ["showed", 1418], ["pulsed", 1425], ["-", 1431], ["field", 1432], ["-", 1437], ["gel", 1438], ["electrophoresis-(PFGE)-type-\"I", 1442], ["\"", 1472], [",", 1473], ["sequence", 1475], ["-", 1483], ["type-5-(ST5", 1484], [")", 1495], [",", 1496], ["SCCmec", 1498], ["-", 1504], ["type", 1505], ["-", 1509], ["IVa", 1510], [",", 1513], ["spa", 1515], ["-", 1518], ["t311", 1519], [",", 1523], ["and", 1525], ["was", 1529], ["positive", 1533], ["for", 1542], ["PVL", 1546], [".", 1549], ["The", 1551], ["second", 1555], ["clone", 1562], [",", 1567], ["pulsotype", 1569], ["-", 1578], ["N", 1579], ["/", 1580], ["ST30/CC30/SCCmecIVc", 1581], ["/", 1600], ["t019/PVL(+", 1601], [")", 1611], [",", 1612], ["accounted", 1614], ["for", 1624], ["11.5", 1628], ["%", 1632], ["of", 1634], ["total", 1637], ["CA", 1643], ["-", 1645], ["MRSA", 1646], ["infections", 1651], [".", 1661], ["Importantly", 1663], [",", 1674], ["the", 1676], ["first", 1680], ["4", 1686], ["isolates", 1688], ["of", 1697], ["Argentina", 1700], ["belonging", 1710], ["to", 1720], ["South", 1723], ["American", 1729], ["-", 1737], ["USA300", 1738], ["clone-(USA300/ST8/CC8/SCCmecIVc", 1745], ["/", 1776], ["t008/PVL(+)/ACME(-", 1777], [")", 1795], [")", 1796], ["were", 1798], ["detected", 1803], [".", 1811], ["We", 1813], ["also", 1816], ["demonstrated", 1821], ["that", 1834], ["a", 1839], ["HA", 1841], ["-", 1843], ["MRSA", 1844], ["clone-(pulsotype", 1849], ["-", 1865], ["C", 1866], ["/", 1867], ["ST100/CC5", 1868], [")", 1877], ["caused", 1879], ["2", 1886], ["%", 1887], ["and", 1889], ["10", 1893], ["%", 1895], ["of", 1897], ["CA", 1900], ["-", 1902], ["MRSA", 1903], ["and", 1908], ["HACO", 1912], ["-", 1916], ["MRSA", 1917], ["infections", 1922], ["respectively", 1933], ["and", 1946], ["was", 1950], ["associated", 1954], ["with", 1965], ["a", 1970], ["SCCmec", 1972], ["type", 1979], ["closely", 1984], ["related", 1992], ["to", 2000], ["SCCmecIV(2B&5", 2003], [")", 2016], [".", 2017], ["The", 2019], ["dissemination", 2023], ["of", 2037], ["epidemic", 2040], ["MRSA", 2049], ["clone", 2054], [",", 2059], ["ST5-IV", 2061], ["-", 2067], ["PVL(+", 2068], [")", 2073], ["was", 2075], ["the", 2079], ["main", 2083], ["cause", 2088], ["of", 2094], ["increasing", 2097], ["staphylococcal", 2108], ["community", 2123], ["-", 2132], ["onset", 2133], ["infections", 2139], ["in", 2150], ["Argentinean", 2153], ["children", 2165], ["(", 2174], ["2003", 2175], ["-", 2179], ["2008", 2180], [")", 2184], [",", 2185], ["conversely", 2187], ["to", 2198], ["other", 2201], ["countries", 2207], [".", 2216], ["The", 2218], ["predominance", 2222], ["of", 2235], ["this", 2238], ["clone", 2243], [",", 2248], ["which", 2250], ["has", 2256], ["capacity", 2260], ["to", 2269], ["express", 2272], ["the", 2280], ["h", 2284], ["-", 2285], ["VISA", 2286], ["phenotype", 2291], [",", 2300], ["in", 2302], ["healthcare", 2305], ["-", 2315], ["associated", 2316], ["community", 2327], ["-", 2336], ["onset", 2337], ["cases", 2343], ["suggests", 2349], ["that", 2358], ["it", 2363], ["has", 2366], ["infiltrated", 2370], ["into", 2382], ["hospital", 2387], ["-", 2395], ["settings", 2396], [".", 2404]]}
{"context": "A 50-year-old man presented with worsening, virtually lifelong, chorea and progressive behavioural disturbance, involving disinhibition and hoarding, over 10 years. Clinical assessment revealed chorea, dysarthria, areflexia, an inappropriately jovial, impulsive manner and neuropsychological evidence of frontosubcortical dysfunction. Investigation results included an elevated creatine kinase, caudate atrophy and hypoperfusion, acanthocytes in the peripheral blood and the McLeod phenotype. DNA studies demonstrated a single-base deletion at position 172 in exon 1 of the XK gene, giving rise to a premature stop codon at position 129 in exon 2.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "c44de3a52803425c8e515bdb5fb039ac", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[88, 88]], "char_spans": [[574, 575]]}]}], "context_tokens": [["A", 0], ["50-year", 2], ["-", 9], ["old", 10], ["man", 14], ["presented", 18], ["with", 28], ["worsening", 33], [",", 42], ["virtually", 44], ["lifelong", 54], [",", 62], ["chorea", 64], ["and", 71], ["progressive", 75], ["behavioural", 87], ["disturbance", 99], [",", 110], ["involving", 112], ["disinhibition", 122], ["and", 136], ["hoarding", 140], [",", 148], ["over", 150], ["10", 155], ["years", 158], [".", 163], ["Clinical", 165], ["assessment", 174], ["revealed", 185], ["chorea", 194], [",", 200], ["dysarthria", 202], [",", 212], ["areflexia", 214], [",", 223], ["an", 225], ["inappropriately", 228], ["jovial", 244], [",", 250], ["impulsive", 252], ["manner", 262], ["and", 269], ["neuropsychological", 273], ["evidence", 292], ["of", 301], ["frontosubcortical", 304], ["dysfunction", 322], [".", 333], ["Investigation", 335], ["results", 349], ["included", 357], ["an", 366], ["elevated", 369], ["creatine", 378], ["kinase", 387], [",", 393], ["caudate", 395], ["atrophy", 403], ["and", 411], ["hypoperfusion", 415], [",", 428], ["acanthocytes", 430], ["in", 443], ["the", 446], ["peripheral", 450], ["blood", 461], ["and", 467], ["the", 471], ["McLeod", 475], ["phenotype", 482], [".", 491], ["DNA", 493], ["studies", 497], ["demonstrated", 505], ["a", 518], ["single", 520], ["-", 526], ["base", 527], ["deletion", 532], ["at", 541], ["position", 544], ["172", 553], ["in", 557], ["exon", 560], ["1", 565], ["of", 567], ["the", 570], ["XK", 574], ["gene", 577], [",", 581], ["giving", 583], ["rise", 590], ["to", 595], ["a", 598], ["premature", 600], ["stop", 610], ["codon", 615], ["at", 621], ["position", 624], ["129", 633], ["in", 637], ["exon", 640], ["2", 645], [".", 646]]}
{"context": "Ubiquilin proteins facilitate delivery of ubiquitinated proteins to the proteasome for degradation. Interest in the proteins has been heightened by the discovery that gene mutations in UBQLN2 cause dominant inheritance of amyotrophic lateral sclerosis (ALS). However, the mechanisms by which the mutations cause ALS are not known. Here we report on the underlying defect of ubiquilin-2 proteins containing ALS-linked mutations in affecting proteasome-mediated degradation. We found that overexpression of ubiquilin-2 proteins containing any one of five different ALS mutations slow degradation of Myc, a prototypic proteasome substrate. Examination of coprecipitating proteins indicated that the mutant proteins are generally capable of binding polyubiquitinated proteins, but defective in binding the proteasome. GST-pulldown studies revealed that many of the mutants bind weaker to the S5a subunit of the proteasome, compared with wild type (WT) ubiquilin-2 protein. The results suggest the mutant proteins are unable to deliver their captured cargo to the proteasome for degradation, which presumably leads to toxicity. Quantification of cell death is consistent with this idea. Measurement of protein turnover further indicated the mutant proteins have longer half-lives than WT ubiquilin-2. Our studies provide novel insight into the mechanism by which ALS-linked mutations in UBQLN2 interfere with protein degradation.", "qas": [{"question": "Which human disease is associated with mutated UBQLN2", "answers": ["ALS", "amyotrophic lateral sclerosis"], "qid": "512ddca4bf4d4b0b858b5f2fc87b8f28", "question_tokens": [["Which", 0], ["human", 6], ["disease", 12], ["is", 20], ["associated", 23], ["with", 34], ["mutated", 39], ["UBQLN2", 47]], "detected_answers": [{"text": "ALS", "token_spans": [[48, 48], [64, 64], [36, 36], [217, 217], [88, 88]], "char_spans": [[312, 314], [406, 408], [253, 255], [1358, 1360], [563, 565]]}, {"text": "amyotrophic lateral sclerosis", "token_spans": [[32, 34]], "char_spans": [[222, 250]]}]}], "context_tokens": [["Ubiquilin", 0], ["proteins", 10], ["facilitate", 19], ["delivery", 30], ["of", 39], ["ubiquitinated", 42], ["proteins", 56], ["to", 65], ["the", 68], ["proteasome", 72], ["for", 83], ["degradation", 87], [".", 98], ["Interest", 100], ["in", 109], ["the", 112], ["proteins", 116], ["has", 125], ["been", 129], ["heightened", 134], ["by", 145], ["the", 148], ["discovery", 152], ["that", 162], ["gene", 167], ["mutations", 172], ["in", 182], ["UBQLN2", 185], ["cause", 192], ["dominant", 198], ["inheritance", 207], ["of", 219], ["amyotrophic", 222], ["lateral", 234], ["sclerosis", 242], ["(", 252], ["ALS", 253], [")", 256], [".", 257], ["However", 259], [",", 266], ["the", 268], ["mechanisms", 272], ["by", 283], ["which", 286], ["the", 292], ["mutations", 296], ["cause", 306], ["ALS", 312], ["are", 316], ["not", 320], ["known", 324], [".", 329], ["Here", 331], ["we", 336], ["report", 339], ["on", 346], ["the", 349], ["underlying", 353], ["defect", 364], ["of", 371], ["ubiquilin-2", 374], ["proteins", 386], ["containing", 395], ["ALS", 406], ["-", 409], ["linked", 410], ["mutations", 417], ["in", 427], ["affecting", 430], ["proteasome", 440], ["-", 450], ["mediated", 451], ["degradation", 460], [".", 471], ["We", 473], ["found", 476], ["that", 482], ["overexpression", 487], ["of", 502], ["ubiquilin-2", 505], ["proteins", 517], ["containing", 526], ["any", 537], ["one", 541], ["of", 545], ["five", 548], ["different", 553], ["ALS", 563], ["mutations", 567], ["slow", 577], ["degradation", 582], ["of", 594], ["Myc", 597], [",", 600], ["a", 602], ["prototypic", 604], ["proteasome", 615], ["substrate", 626], [".", 635], ["Examination", 637], ["of", 649], ["coprecipitating", 652], ["proteins", 668], ["indicated", 677], ["that", 687], ["the", 692], ["mutant", 696], ["proteins", 703], ["are", 712], ["generally", 716], ["capable", 726], ["of", 734], ["binding", 737], ["polyubiquitinated", 745], ["proteins", 763], [",", 771], ["but", 773], ["defective", 777], ["in", 787], ["binding", 790], ["the", 798], ["proteasome", 802], [".", 812], ["GST", 814], ["-", 817], ["pulldown", 818], ["studies", 827], ["revealed", 835], ["that", 844], ["many", 849], ["of", 854], ["the", 857], ["mutants", 861], ["bind", 869], ["weaker", 874], ["to", 881], ["the", 884], ["S5a", 888], ["subunit", 892], ["of", 900], ["the", 903], ["proteasome", 907], [",", 917], ["compared", 919], ["with", 928], ["wild", 933], ["type", 938], ["(", 943], ["WT", 944], [")", 946], ["ubiquilin-2", 948], ["protein", 960], [".", 967], ["The", 969], ["results", 973], ["suggest", 981], ["the", 989], ["mutant", 993], ["proteins", 1000], ["are", 1009], ["unable", 1013], ["to", 1020], ["deliver", 1023], ["their", 1031], ["captured", 1037], ["cargo", 1046], ["to", 1052], ["the", 1055], ["proteasome", 1059], ["for", 1070], ["degradation", 1074], [",", 1085], ["which", 1087], ["presumably", 1093], ["leads", 1104], ["to", 1110], ["toxicity", 1113], [".", 1121], ["Quantification", 1123], ["of", 1138], ["cell", 1141], ["death", 1146], ["is", 1152], ["consistent", 1155], ["with", 1166], ["this", 1171], ["idea", 1176], [".", 1180], ["Measurement", 1182], ["of", 1194], ["protein", 1197], ["turnover", 1205], ["further", 1214], ["indicated", 1222], ["the", 1232], ["mutant", 1236], ["proteins", 1243], ["have", 1252], ["longer", 1257], ["half", 1264], ["-", 1268], ["lives", 1269], ["than", 1275], ["WT", 1280], ["ubiquilin-2", 1283], [".", 1294], ["Our", 1296], ["studies", 1300], ["provide", 1308], ["novel", 1316], ["insight", 1322], ["into", 1330], ["the", 1335], ["mechanism", 1339], ["by", 1349], ["which", 1352], ["ALS", 1358], ["-", 1361], ["linked", 1362], ["mutations", 1369], ["in", 1379], ["UBQLN2", 1382], ["interfere", 1389], ["with", 1399], ["protein", 1404], ["degradation", 1412], [".", 1423]]}
{"context": "The two major virulence factors of Bacillus anthracis are the tripartite toxin and the polyglutamate capsule, which are encoded by genes on the large plasmids, pXO1 and pXO2, respectively. The genes atxA, located on pXO1, and acpA, located on pXO2, encode positive trans-acting proteins that are involved in bicarbonate-mediated regulation of toxin and capsule production, respectively. A derivative strain cured of pXO1 produced less capsular substance than the parent strain harbouring both pXO1 and pXO2, and electroporation of the strain cured of pXO1 with a plasmid containing the cloned atxA gene resulted in an increased level of capsule production. An acpA-null mutant was complemented by not only acpA but also the atxA gene. The cap region, which is essential for encapsulation, contains three genes capB, capC, and capA, arranged in that order. The atxA gene stimulated capsule synthesis from the cloned cap region. Transcriptional analysis of cap by RNA slot-blot hybridization and primer-extension analysis revealed that atxA activated expression of cap in trans at the transcriptional level. These results indicate that cross-talk occurs, in which the pXO1-located gene, atxA, activates transcription of the cap region genes located on pXO2. We identified two major apparent transcriptional start sites, designated P1 and P2, located at positions 731 bp and 625 bp, respectively, upstream of the translation-initiation codon of capB. Transcription initiated from P1 and P2 was activated by both atxA and acpA, and activation appeared to be stimulated by bicarbonate. Deletion analysis of the upstream region of the cap promoter revealed that activation by both atxA and acpA required a DNA segment of 70 bp extending upstream of the P1 site. These results suggest that cross-talk by atxA to the genes encoding capsule synthesis is caused by the interaction of the atxA gene product with a regulatory sequence upstream of cap.", "qas": [{"question": "Which metabolite activates AtxA?", "answers": ["CO2", "bicarbonate"], "qid": "cf65aa1d62524b4690d8d12f1565be18", "question_tokens": [["Which", 0], ["metabolite", 6], ["activates", 17], ["AtxA", 27], ["?", 31]], "detected_answers": [{"text": "bicarbonate", "token_spans": [[281, 281], [58, 58]], "char_spans": [[1568, 1578], [308, 318]]}]}], "context_tokens": [["The", 0], ["two", 4], ["major", 8], ["virulence", 14], ["factors", 24], ["of", 32], ["Bacillus", 35], ["anthracis", 44], ["are", 54], ["the", 58], ["tripartite", 62], ["toxin", 73], ["and", 79], ["the", 83], ["polyglutamate", 87], ["capsule", 101], [",", 108], ["which", 110], ["are", 116], ["encoded", 120], ["by", 128], ["genes", 131], ["on", 137], ["the", 140], ["large", 144], ["plasmids", 150], [",", 158], ["pXO1", 160], ["and", 165], ["pXO2", 169], [",", 173], ["respectively", 175], [".", 187], ["The", 189], ["genes", 193], ["atxA", 199], [",", 203], ["located", 205], ["on", 213], ["pXO1", 216], [",", 220], ["and", 222], ["acpA", 226], [",", 230], ["located", 232], ["on", 240], ["pXO2", 243], [",", 247], ["encode", 249], ["positive", 256], ["trans", 265], ["-", 270], ["acting", 271], ["proteins", 278], ["that", 287], ["are", 292], ["involved", 296], ["in", 305], ["bicarbonate", 308], ["-", 319], ["mediated", 320], ["regulation", 329], ["of", 340], ["toxin", 343], ["and", 349], ["capsule", 353], ["production", 361], [",", 371], ["respectively", 373], [".", 385], ["A", 387], ["derivative", 389], ["strain", 400], ["cured", 407], ["of", 413], ["pXO1", 416], ["produced", 421], ["less", 430], ["capsular", 435], ["substance", 444], ["than", 454], ["the", 459], ["parent", 463], ["strain", 470], ["harbouring", 477], ["both", 488], ["pXO1", 493], ["and", 498], ["pXO2", 502], [",", 506], ["and", 508], ["electroporation", 512], ["of", 528], ["the", 531], ["strain", 535], ["cured", 542], ["of", 548], ["pXO1", 551], ["with", 556], ["a", 561], ["plasmid", 563], ["containing", 571], ["the", 582], ["cloned", 586], ["atxA", 593], ["gene", 598], ["resulted", 603], ["in", 612], ["an", 615], ["increased", 618], ["level", 628], ["of", 634], ["capsule", 637], ["production", 645], [".", 655], ["An", 657], ["acpA", 660], ["-", 664], ["null", 665], ["mutant", 670], ["was", 677], ["complemented", 681], ["by", 694], ["not", 697], ["only", 701], ["acpA", 706], ["but", 711], ["also", 715], ["the", 720], ["atxA", 724], ["gene", 729], [".", 733], ["The", 735], ["cap", 739], ["region", 743], [",", 749], ["which", 751], ["is", 757], ["essential", 760], ["for", 770], ["encapsulation", 774], [",", 787], ["contains", 789], ["three", 798], ["genes", 804], ["capB", 810], [",", 814], ["capC", 816], [",", 820], ["and", 822], ["capA", 826], [",", 830], ["arranged", 832], ["in", 841], ["that", 844], ["order", 849], [".", 854], ["The", 856], ["atxA", 860], ["gene", 865], ["stimulated", 870], ["capsule", 881], ["synthesis", 889], ["from", 899], ["the", 904], ["cloned", 908], ["cap", 915], ["region", 919], [".", 925], ["Transcriptional", 927], ["analysis", 943], ["of", 952], ["cap", 955], ["by", 959], ["RNA", 962], ["slot", 966], ["-", 970], ["blot", 971], ["hybridization", 976], ["and", 990], ["primer", 994], ["-", 1000], ["extension", 1001], ["analysis", 1011], ["revealed", 1020], ["that", 1029], ["atxA", 1034], ["activated", 1039], ["expression", 1049], ["of", 1060], ["cap", 1063], ["in", 1067], ["trans", 1070], ["at", 1076], ["the", 1079], ["transcriptional", 1083], ["level", 1099], [".", 1104], ["These", 1106], ["results", 1112], ["indicate", 1120], ["that", 1129], ["cross", 1134], ["-", 1139], ["talk", 1140], ["occurs", 1145], [",", 1151], ["in", 1153], ["which", 1156], ["the", 1162], ["pXO1-located", 1166], ["gene", 1179], [",", 1183], ["atxA", 1185], [",", 1189], ["activates", 1191], ["transcription", 1201], ["of", 1215], ["the", 1218], ["cap", 1222], ["region", 1226], ["genes", 1233], ["located", 1239], ["on", 1247], ["pXO2", 1250], [".", 1254], ["We", 1256], ["identified", 1259], ["two", 1270], ["major", 1274], ["apparent", 1280], ["transcriptional", 1289], ["start", 1305], ["sites", 1311], [",", 1316], ["designated", 1318], ["P1", 1329], ["and", 1332], ["P2", 1336], [",", 1338], ["located", 1340], ["at", 1348], ["positions", 1351], ["731", 1361], ["bp", 1365], ["and", 1368], ["625", 1372], ["bp", 1376], [",", 1378], ["respectively", 1380], [",", 1392], ["upstream", 1394], ["of", 1403], ["the", 1406], ["translation", 1410], ["-", 1421], ["initiation", 1422], ["codon", 1433], ["of", 1439], ["capB.", 1442], ["Transcription", 1448], ["initiated", 1462], ["from", 1472], ["P1", 1477], ["and", 1480], ["P2", 1484], ["was", 1487], ["activated", 1491], ["by", 1501], ["both", 1504], ["atxA", 1509], ["and", 1514], ["acpA", 1518], [",", 1522], ["and", 1524], ["activation", 1528], ["appeared", 1539], ["to", 1548], ["be", 1551], ["stimulated", 1554], ["by", 1565], ["bicarbonate", 1568], [".", 1579], ["Deletion", 1581], ["analysis", 1590], ["of", 1599], ["the", 1602], ["upstream", 1606], ["region", 1615], ["of", 1622], ["the", 1625], ["cap", 1629], ["promoter", 1633], ["revealed", 1642], ["that", 1651], ["activation", 1656], ["by", 1667], ["both", 1670], ["atxA", 1675], ["and", 1680], ["acpA", 1684], ["required", 1689], ["a", 1698], ["DNA", 1700], ["segment", 1704], ["of", 1712], ["70", 1715], ["bp", 1718], ["extending", 1721], ["upstream", 1731], ["of", 1740], ["the", 1743], ["P1", 1747], ["site", 1750], [".", 1754], ["These", 1756], ["results", 1762], ["suggest", 1770], ["that", 1778], ["cross", 1783], ["-", 1788], ["talk", 1789], ["by", 1794], ["atxA", 1797], ["to", 1802], ["the", 1805], ["genes", 1809], ["encoding", 1815], ["capsule", 1824], ["synthesis", 1832], ["is", 1842], ["caused", 1845], ["by", 1852], ["the", 1855], ["interaction", 1859], ["of", 1871], ["the", 1874], ["atxA", 1878], ["gene", 1883], ["product", 1888], ["with", 1896], ["a", 1901], ["regulatory", 1903], ["sequence", 1914], ["upstream", 1923], ["of", 1932], ["cap", 1935], [".", 1938]]}
{"context": "The Davidson Trauma Scale (DTS) was developed as a self-rating for use in diagnosing and measuring symptom severity and treatment outcome in post-traumatic stress disorder (PTSD); 630 subjects were identified by random digit dialing and evaluated for a history of trauma. Prevalence rates of PTSD and subthreshold PTSD with impairment were 2.2 and 4.1%, respectively. In this general population sample, 438 subjects endorsed at least one trauma, and four groups were generated: A) threshold PTSD (n = 13), B) subthreshold PTSD with impairment (n = 26), C) subthreshold PTSD without impairment (n = 78), and D) no PTSD (n = 321). Mean (SD) DTS score in the entire population was 11.0 +/- 18.1. Differences were found in four of the five pairwise between-group contrasts. In a second sample of 447 clinical trial participants from three SSRI vs. placebo studies, we assessed treatment effect size according to different measures. In all three clinical trials, effect size with the DTS was equal to, or better than, those found for the Impact of Event Scale (IES), Clinician Administered PTSD Scale (CAPS), and Structured Interview for PTSD (SIP). These results further affirm the utility of the DTS as a self-rating measure of PTSD symptom severity and in evaluating treatment response.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "73a1af5a2b084b75a3a2d56d9cdceaf4", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "post-traumatic stress disorder", "token_spans": [[26, 30]], "char_spans": [[141, 170]]}, {"text": "PTSD", "token_spans": [[32, 32], [91, 91], [101, 101], [54, 54], [253, 253], [57, 57], [222, 222], [232, 232], [126, 126], [113, 113]], "char_spans": [[173, 176], [491, 494], [522, 525], [292, 295], [1225, 1228], [314, 317], [1085, 1088], [1133, 1136], [613, 616], [569, 572]]}]}], "context_tokens": [["The", 0], ["Davidson", 4], ["Trauma", 13], ["Scale", 20], ["(", 26], ["DTS", 27], [")", 30], ["was", 32], ["developed", 36], ["as", 46], ["a", 49], ["self", 51], ["-", 55], ["rating", 56], ["for", 63], ["use", 67], ["in", 71], ["diagnosing", 74], ["and", 85], ["measuring", 89], ["symptom", 99], ["severity", 107], ["and", 116], ["treatment", 120], ["outcome", 130], ["in", 138], ["post", 141], ["-", 145], ["traumatic", 146], ["stress", 156], ["disorder", 163], ["(", 172], ["PTSD", 173], [")", 177], [";", 178], ["630", 180], ["subjects", 184], ["were", 193], ["identified", 198], ["by", 209], ["random", 212], ["digit", 219], ["dialing", 225], ["and", 233], ["evaluated", 237], ["for", 247], ["a", 251], ["history", 253], ["of", 261], ["trauma", 264], [".", 270], ["Prevalence", 272], ["rates", 283], ["of", 289], ["PTSD", 292], ["and", 297], ["subthreshold", 301], ["PTSD", 314], ["with", 319], ["impairment", 324], ["were", 335], ["2.2", 340], ["and", 344], ["4.1", 348], ["%", 351], [",", 352], ["respectively", 354], [".", 366], ["In", 368], ["this", 371], ["general", 376], ["population", 384], ["sample", 395], [",", 401], ["438", 403], ["subjects", 407], ["endorsed", 416], ["at", 425], ["least", 428], ["one", 434], ["trauma", 438], [",", 444], ["and", 446], ["four", 450], ["groups", 455], ["were", 462], ["generated", 467], [":", 476], ["A", 478], [")", 479], ["threshold", 481], ["PTSD", 491], ["(", 496], ["n", 497], ["=", 499], ["13", 501], [")", 503], [",", 504], ["B", 506], [")", 507], ["subthreshold", 509], ["PTSD", 522], ["with", 527], ["impairment", 532], ["(", 543], ["n", 544], ["=", 546], ["26", 548], [")", 550], [",", 551], ["C", 553], [")", 554], ["subthreshold", 556], ["PTSD", 569], ["without", 574], ["impairment", 582], ["(", 593], ["n", 594], ["=", 596], ["78", 598], [")", 600], [",", 601], ["and", 603], ["D", 607], [")", 608], ["no", 610], ["PTSD", 613], ["(", 618], ["n", 619], ["=", 621], ["321", 623], [")", 626], [".", 627], ["Mean", 629], ["(", 634], ["SD", 635], [")", 637], ["DTS", 639], ["score", 643], ["in", 649], ["the", 652], ["entire", 656], ["population", 663], ["was", 674], ["11.0", 678], ["+", 683], ["/-", 684], ["18.1", 687], [".", 691], ["Differences", 693], ["were", 705], ["found", 710], ["in", 716], ["four", 719], ["of", 724], ["the", 727], ["five", 731], ["pairwise", 736], ["between", 745], ["-", 752], ["group", 753], ["contrasts", 759], [".", 768], ["In", 770], ["a", 773], ["second", 775], ["sample", 782], ["of", 789], ["447", 792], ["clinical", 796], ["trial", 805], ["participants", 811], ["from", 824], ["three", 829], ["SSRI", 835], ["vs.", 840], ["placebo", 844], ["studies", 852], [",", 859], ["we", 861], ["assessed", 864], ["treatment", 873], ["effect", 883], ["size", 890], ["according", 895], ["to", 905], ["different", 908], ["measures", 918], [".", 926], ["In", 928], ["all", 931], ["three", 935], ["clinical", 941], ["trials", 950], [",", 956], ["effect", 958], ["size", 965], ["with", 970], ["the", 975], ["DTS", 979], ["was", 983], ["equal", 987], ["to", 993], [",", 995], ["or", 997], ["better", 1000], ["than", 1007], [",", 1011], ["those", 1013], ["found", 1019], ["for", 1025], ["the", 1029], ["Impact", 1033], ["of", 1040], ["Event", 1043], ["Scale", 1049], ["(", 1055], ["IES", 1056], [")", 1059], [",", 1060], ["Clinician", 1062], ["Administered", 1072], ["PTSD", 1085], ["Scale", 1090], ["(", 1096], ["CAPS", 1097], [")", 1101], [",", 1102], ["and", 1104], ["Structured", 1108], ["Interview", 1119], ["for", 1129], ["PTSD", 1133], ["(", 1138], ["SIP", 1139], [")", 1142], [".", 1143], ["These", 1145], ["results", 1151], ["further", 1159], ["affirm", 1167], ["the", 1174], ["utility", 1178], ["of", 1186], ["the", 1189], ["DTS", 1193], ["as", 1197], ["a", 1200], ["self", 1202], ["-", 1206], ["rating", 1207], ["measure", 1214], ["of", 1222], ["PTSD", 1225], ["symptom", 1230], ["severity", 1238], ["and", 1247], ["in", 1251], ["evaluating", 1254], ["treatment", 1265], ["response", 1275], [".", 1283]]}
{"context": "The objective of this guideline is to assist poison center personnel in the appropriate out-of-hospital triage and initial out-of-hospital management of patients with a suspected ingestion of dextromethorphan by 1) describing the process by which an ingestion of dextromethorphan might be managed, 2) identifying the key decision elements in managing cases of dextromethorphan ingestion, 3) providing clear and practical recommendations that reflect the current state of knowledge, and 4) identifying needs for research. This guideline applies to the ingestion of dextromethorphan alone. Co-ingestion of additional substances could require different referral and management recommendations depending on the combined toxicities of the substances. This guideline is based on an assessment of current scientific and clinical information. The expert consensus panel recognizes that specific patient care decisions might be at variance with this guideline and are the prerogative of the patient and the health professionals providing care, considering all of the circumstances involved. This guideline does not substitute for clinical judgment. The grade of recommendation is in parentheses. 1) All patients with suicidal intent, intentional abuse, or in cases in which a malicious intent is suspected (e.g., child abuse or neglect) should be referred to an emergency department (Grade D). 2) Patients who exhibit more than mild effects (e.g., infrequent vomiting or somnolence [lightly sedated and arousable with speaking voice or light touch]) after an acute dextromethorphan ingestion should be referred to an emergency department (Grade C). 3) Patients who have ingested 5-7.5 mg/kg should receive poison center-initiated follow-up approximately every 2 hours for up to 4 hours after ingestion. Refer to an emergency department if more than mild symptoms develop (Grade D). 4) Patients who have ingested more than 7.5 mg/kg should be referred to an emergency department for evaluation (Grade C). 5) If the patient is taking other medications likely to interact with dextromethorphan and cause serotonin syndrome, such as monoamine oxidase inhibitors or selective serotonin reuptake inhibitors, poison center-initiated follow-up every 2 hours for 8 hours is recommended (Grade D). 6) Patients who are asymptomatic and more than 4 hours have elapsed since the time of ingestion can be observed at home (Grade C). 7) Do not induce emesis (Grade D). 8) Do not use activated charcoal at home. Activated charcoal can be administered to asymptomatic patients who have ingested overdoses of dextromethorphan within the preceding hour. Its administration, if available, should only be carried out by health professionals and only if no contraindications are present. Do not delay transportation in order to administer activated charcoal (Grade D). 9) For patients who have ingested dextromethorphan and are sedated or comatose, naloxone, in the usual doses for treatment of opioid overdose, can be considered for prehospital administration, particularly if the patient has respiratory depression (Grade C). 10) Use intravenous benzodiazepines for seizures and benzodiazepines and external cooling measures for hyperthermia (>104 degrees F, >40 degrees C) for serotonin syndrome. This should be done in consultation with and authorized by EMS medical direction, by a written treatment protocol or policy, or with direct medical oversight (Grade C). 11) Carefully ascertain by history whether other drugs, such as acetaminophen, were involved in the incident and assess the risk for toxicity or for a drug interaction.", "qas": [{"question": "Which medication should be administered when managing patients with suspected acute opioid overdose?", "answers": ["naloxone"], "qid": "bb05ffd715264fdf8fc2a8c7edaf0d04", "question_tokens": [["Which", 0], ["medication", 6], ["should", 17], ["be", 24], ["administered", 27], ["when", 40], ["managing", 45], ["patients", 54], ["with", 63], ["suspected", 68], ["acute", 78], ["opioid", 84], ["overdose", 91], ["?", 99]], "detected_answers": [{"text": "naloxone", "token_spans": [[520, 520]], "char_spans": [[2918, 2925]]}]}], "context_tokens": [["The", 0], ["objective", 4], ["of", 14], ["this", 17], ["guideline", 22], ["is", 32], ["to", 35], ["assist", 38], ["poison", 45], ["center", 52], ["personnel", 59], ["in", 69], ["the", 72], ["appropriate", 76], ["out", 88], ["-", 91], ["of", 92], ["-", 94], ["hospital", 95], ["triage", 104], ["and", 111], ["initial", 115], ["out", 123], ["-", 126], ["of", 127], ["-", 129], ["hospital", 130], ["management", 139], ["of", 150], ["patients", 153], ["with", 162], ["a", 167], ["suspected", 169], ["ingestion", 179], ["of", 189], ["dextromethorphan", 192], ["by", 209], ["1", 212], [")", 213], ["describing", 215], ["the", 226], ["process", 230], ["by", 238], ["which", 241], ["an", 247], ["ingestion", 250], ["of", 260], ["dextromethorphan", 263], ["might", 280], ["be", 286], ["managed", 289], [",", 296], ["2", 298], [")", 299], ["identifying", 301], ["the", 313], ["key", 317], ["decision", 321], ["elements", 330], ["in", 339], ["managing", 342], ["cases", 351], ["of", 357], ["dextromethorphan", 360], ["ingestion", 377], [",", 386], ["3", 388], [")", 389], ["providing", 391], ["clear", 401], ["and", 407], ["practical", 411], ["recommendations", 421], ["that", 437], ["reflect", 442], ["the", 450], ["current", 454], ["state", 462], ["of", 468], ["knowledge", 471], [",", 480], ["and", 482], ["4", 486], [")", 487], ["identifying", 489], ["needs", 501], ["for", 507], ["research", 511], [".", 519], ["This", 521], ["guideline", 526], ["applies", 536], ["to", 544], ["the", 547], ["ingestion", 551], ["of", 561], ["dextromethorphan", 564], ["alone", 581], [".", 586], ["Co", 588], ["-", 590], ["ingestion", 591], ["of", 601], ["additional", 604], ["substances", 615], ["could", 626], ["require", 632], ["different", 640], ["referral", 650], ["and", 659], ["management", 663], ["recommendations", 674], ["depending", 690], ["on", 700], ["the", 703], ["combined", 707], ["toxicities", 716], ["of", 727], ["the", 730], ["substances", 734], [".", 744], ["This", 746], ["guideline", 751], ["is", 761], ["based", 764], ["on", 770], ["an", 773], ["assessment", 776], ["of", 787], ["current", 790], ["scientific", 798], ["and", 809], ["clinical", 813], ["information", 822], [".", 833], ["The", 835], ["expert", 839], ["consensus", 846], ["panel", 856], ["recognizes", 862], ["that", 873], ["specific", 878], ["patient", 887], ["care", 895], ["decisions", 900], ["might", 910], ["be", 916], ["at", 919], ["variance", 922], ["with", 931], ["this", 936], ["guideline", 941], ["and", 951], ["are", 955], ["the", 959], ["prerogative", 963], ["of", 975], ["the", 978], ["patient", 982], ["and", 990], ["the", 994], ["health", 998], ["professionals", 1005], ["providing", 1019], ["care", 1029], [",", 1033], ["considering", 1035], ["all", 1047], ["of", 1051], ["the", 1054], ["circumstances", 1058], ["involved", 1072], [".", 1080], ["This", 1082], ["guideline", 1087], ["does", 1097], ["not", 1102], ["substitute", 1106], ["for", 1117], ["clinical", 1121], ["judgment", 1130], [".", 1138], ["The", 1140], ["grade", 1144], ["of", 1150], ["recommendation", 1153], ["is", 1168], ["in", 1171], ["parentheses", 1174], [".", 1185], ["1", 1187], [")", 1188], ["All", 1190], ["patients", 1194], ["with", 1203], ["suicidal", 1208], ["intent", 1217], [",", 1223], ["intentional", 1225], ["abuse", 1237], [",", 1242], ["or", 1244], ["in", 1247], ["cases", 1250], ["in", 1256], ["which", 1259], ["a", 1265], ["malicious", 1267], ["intent", 1277], ["is", 1284], ["suspected", 1287], ["(", 1297], ["e.g.", 1298], [",", 1302], ["child", 1304], ["abuse", 1310], ["or", 1316], ["neglect", 1319], [")", 1326], ["should", 1328], ["be", 1335], ["referred", 1338], ["to", 1347], ["an", 1350], ["emergency", 1353], ["department", 1363], ["(", 1374], ["Grade", 1375], ["D", 1381], [")", 1382], [".", 1383], ["2", 1385], [")", 1386], ["Patients", 1388], ["who", 1397], ["exhibit", 1401], ["more", 1409], ["than", 1414], ["mild", 1419], ["effects", 1424], ["(", 1432], ["e.g.", 1433], [",", 1437], ["infrequent", 1439], ["vomiting", 1450], ["or", 1459], ["somnolence", 1462], ["[", 1473], ["lightly", 1474], ["sedated", 1482], ["and", 1490], ["arousable", 1494], ["with", 1504], ["speaking", 1509], ["voice", 1518], ["or", 1524], ["light", 1527], ["touch", 1533], ["]", 1538], [")", 1539], ["after", 1541], ["an", 1547], ["acute", 1550], ["dextromethorphan", 1556], ["ingestion", 1573], ["should", 1583], ["be", 1590], ["referred", 1593], ["to", 1602], ["an", 1605], ["emergency", 1608], ["department", 1618], ["(", 1629], ["Grade", 1630], ["C", 1636], [")", 1637], [".", 1638], ["3", 1640], [")", 1641], ["Patients", 1643], ["who", 1652], ["have", 1656], ["ingested", 1661], ["5", 1670], ["-", 1671], ["7.5", 1672], ["mg", 1676], ["/", 1678], ["kg", 1679], ["should", 1682], ["receive", 1689], ["poison", 1697], ["center", 1704], ["-", 1710], ["initiated", 1711], ["follow", 1721], ["-", 1727], ["up", 1728], ["approximately", 1731], ["every", 1745], ["2", 1751], ["hours", 1753], ["for", 1759], ["up", 1763], ["to", 1766], ["4", 1769], ["hours", 1771], ["after", 1777], ["ingestion", 1783], [".", 1792], ["Refer", 1794], ["to", 1800], ["an", 1803], ["emergency", 1806], ["department", 1816], ["if", 1827], ["more", 1830], ["than", 1835], ["mild", 1840], ["symptoms", 1845], ["develop", 1854], ["(", 1862], ["Grade", 1863], ["D", 1869], [")", 1870], [".", 1871], ["4", 1873], [")", 1874], ["Patients", 1876], ["who", 1885], ["have", 1889], ["ingested", 1894], ["more", 1903], ["than", 1908], ["7.5", 1913], ["mg", 1917], ["/", 1919], ["kg", 1920], ["should", 1923], ["be", 1930], ["referred", 1933], ["to", 1942], ["an", 1945], ["emergency", 1948], ["department", 1958], ["for", 1969], ["evaluation", 1973], ["(", 1984], ["Grade", 1985], ["C", 1991], [")", 1992], [".", 1993], ["5", 1995], [")", 1996], ["If", 1998], ["the", 2001], ["patient", 2005], ["is", 2013], ["taking", 2016], ["other", 2023], ["medications", 2029], ["likely", 2041], ["to", 2048], ["interact", 2051], ["with", 2060], ["dextromethorphan", 2065], ["and", 2082], ["cause", 2086], ["serotonin", 2092], ["syndrome", 2102], [",", 2110], ["such", 2112], ["as", 2117], ["monoamine", 2120], ["oxidase", 2130], ["inhibitors", 2138], ["or", 2149], ["selective", 2152], ["serotonin", 2162], ["reuptake", 2172], ["inhibitors", 2181], [",", 2191], ["poison", 2193], ["center", 2200], ["-", 2206], ["initiated", 2207], ["follow", 2217], ["-", 2223], ["up", 2224], ["every", 2227], ["2", 2233], ["hours", 2235], ["for", 2241], ["8", 2245], ["hours", 2247], ["is", 2253], ["recommended", 2256], ["(", 2268], ["Grade", 2269], ["D", 2275], [")", 2276], [".", 2277], ["6", 2279], [")", 2280], ["Patients", 2282], ["who", 2291], ["are", 2295], ["asymptomatic", 2299], ["and", 2312], ["more", 2316], ["than", 2321], ["4", 2326], ["hours", 2328], ["have", 2334], ["elapsed", 2339], ["since", 2347], ["the", 2353], ["time", 2357], ["of", 2362], ["ingestion", 2365], ["can", 2375], ["be", 2379], ["observed", 2382], ["at", 2391], ["home", 2394], ["(", 2399], ["Grade", 2400], ["C", 2406], [")", 2407], [".", 2408], ["7", 2410], [")", 2411], ["Do", 2413], ["not", 2416], ["induce", 2420], ["emesis", 2427], ["(", 2434], ["Grade", 2435], ["D", 2441], [")", 2442], [".", 2443], ["8)", 2445], ["Do", 2448], ["not", 2451], ["use", 2455], ["activated", 2459], ["charcoal", 2469], ["at", 2478], ["home", 2481], [".", 2485], ["Activated", 2487], ["charcoal", 2497], ["can", 2506], ["be", 2510], ["administered", 2513], ["to", 2526], ["asymptomatic", 2529], ["patients", 2542], ["who", 2551], ["have", 2555], ["ingested", 2560], ["overdoses", 2569], ["of", 2579], ["dextromethorphan", 2582], ["within", 2599], ["the", 2606], ["preceding", 2610], ["hour", 2620], [".", 2624], ["Its", 2626], ["administration", 2630], [",", 2644], ["if", 2646], ["available", 2649], [",", 2658], ["should", 2660], ["only", 2667], ["be", 2672], ["carried", 2675], ["out", 2683], ["by", 2687], ["health", 2690], ["professionals", 2697], ["and", 2711], ["only", 2715], ["if", 2720], ["no", 2723], ["contraindications", 2726], ["are", 2744], ["present", 2748], [".", 2755], ["Do", 2757], ["not", 2760], ["delay", 2764], ["transportation", 2770], ["in", 2785], ["order", 2788], ["to", 2794], ["administer", 2797], ["activated", 2808], ["charcoal", 2818], ["(", 2827], ["Grade", 2828], ["D", 2834], [")", 2835], [".", 2836], ["9", 2838], [")", 2839], ["For", 2841], ["patients", 2845], ["who", 2854], ["have", 2858], ["ingested", 2863], ["dextromethorphan", 2872], ["and", 2889], ["are", 2893], ["sedated", 2897], ["or", 2905], ["comatose", 2908], [",", 2916], ["naloxone", 2918], [",", 2926], ["in", 2928], ["the", 2931], ["usual", 2935], ["doses", 2941], ["for", 2947], ["treatment", 2951], ["of", 2961], ["opioid", 2964], ["overdose", 2971], [",", 2979], ["can", 2981], ["be", 2985], ["considered", 2988], ["for", 2999], ["prehospital", 3003], ["administration", 3015], [",", 3029], ["particularly", 3031], ["if", 3044], ["the", 3047], ["patient", 3051], ["has", 3059], ["respiratory", 3063], ["depression", 3075], ["(", 3086], ["Grade", 3087], ["C", 3093], [")", 3094], [".", 3095], ["10", 3097], [")", 3099], ["Use", 3101], ["intravenous", 3105], ["benzodiazepines", 3117], ["for", 3133], ["seizures", 3137], ["and", 3146], ["benzodiazepines", 3150], ["and", 3166], ["external", 3170], ["cooling", 3179], ["measures", 3187], ["for", 3196], ["hyperthermia", 3200], ["(", 3213], [">", 3214], ["104", 3215], ["degrees", 3219], ["F", 3227], [",", 3228], [">", 3230], ["40", 3231], ["degrees", 3234], ["C", 3242], [")", 3243], ["for", 3245], ["serotonin", 3249], ["syndrome", 3259], [".", 3267], ["This", 3269], ["should", 3274], ["be", 3281], ["done", 3284], ["in", 3289], ["consultation", 3292], ["with", 3305], ["and", 3310], ["authorized", 3314], ["by", 3325], ["EMS", 3328], ["medical", 3332], ["direction", 3340], [",", 3349], ["by", 3351], ["a", 3354], ["written", 3356], ["treatment", 3364], ["protocol", 3374], ["or", 3383], ["policy", 3386], [",", 3392], ["or", 3394], ["with", 3397], ["direct", 3402], ["medical", 3409], ["oversight", 3417], ["(", 3427], ["Grade", 3428], ["C", 3434], [")", 3435], [".", 3436], ["11", 3438], [")", 3440], ["Carefully", 3442], ["ascertain", 3452], ["by", 3462], ["history", 3465], ["whether", 3473], ["other", 3481], ["drugs", 3487], [",", 3492], ["such", 3494], ["as", 3499], ["acetaminophen", 3502], [",", 3515], ["were", 3517], ["involved", 3522], ["in", 3531], ["the", 3534], ["incident", 3538], ["and", 3547], ["assess", 3551], ["the", 3558], ["risk", 3562], ["for", 3567], ["toxicity", 3571], ["or", 3580], ["for", 3583], ["a", 3587], ["drug", 3589], ["interaction", 3594], [".", 3605]]}
{"context": "Ehlers-Danlos syndrome is a heterogeneous group of heritable connective tissue disorders characterized by increased fragility of various non-ossified tissues. It is usually ascertained due to abnormal skin texture, scarring complications, vascular fragility, or chronic symptoms, such as fatigue and musculoskeletal pain. Sometimes, Ehlers-Danlos syndrome remains undetected until the patient, usually in the pediatric age, shows extensive or severe mucocutaneous injuries after only minor traumas. In this scenario, the misdiagnosis of Ehlers-Danlos syndrome with child abuse is a possibility, as occasionally reported in the literature. Recently, more attention was posed by lay people between the possible association of Ehlers-Danlos syndrome and bone fragility. Literature and personal experience show a strong association between Ehlers-Danlos syndrome, generalized joint hypermobility and reduced bone mass density in older children and adults, especially fertile women. The existence of a true increased risk of fracture in Ehlers-Danlos syndrome is still a matter of debate in children and adults with little and conflicting evidence. In case of suspected child abuse, Ehlers-Danlos syndrome is certainly on the differential for bruising, especially in EDS types with marked cutaneous and capillary involvement. In suspected child abuse cases, careful examination of the index case and her/his extended family is routine, as well as exclusion of other disorders such as osteogenesis imperfecta. The hypothesis of Ehlers-Danlos syndrome as an alternative explanation for infantile fractures remains speculative.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "ea17a6333c81457d803d594917b8f0b9", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[10, 11]], "char_spans": [[61, 77]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndrome", 14], ["is", 23], ["a", 26], ["heterogeneous", 28], ["group", 42], ["of", 48], ["heritable", 51], ["connective", 61], ["tissue", 72], ["disorders", 79], ["characterized", 89], ["by", 103], ["increased", 106], ["fragility", 116], ["of", 126], ["various", 129], ["non", 137], ["-", 140], ["ossified", 141], ["tissues", 150], [".", 157], ["It", 159], ["is", 162], ["usually", 165], ["ascertained", 173], ["due", 185], ["to", 189], ["abnormal", 192], ["skin", 201], ["texture", 206], [",", 213], ["scarring", 215], ["complications", 224], [",", 237], ["vascular", 239], ["fragility", 248], [",", 257], ["or", 259], ["chronic", 262], ["symptoms", 270], [",", 278], ["such", 280], ["as", 285], ["fatigue", 288], ["and", 296], ["musculoskeletal", 300], ["pain", 316], [".", 320], ["Sometimes", 322], [",", 331], ["Ehlers", 333], ["-", 339], ["Danlos", 340], ["syndrome", 347], ["remains", 356], ["undetected", 364], ["until", 375], ["the", 381], ["patient", 385], [",", 392], ["usually", 394], ["in", 402], ["the", 405], ["pediatric", 409], ["age", 419], [",", 422], ["shows", 424], ["extensive", 430], ["or", 440], ["severe", 443], ["mucocutaneous", 450], ["injuries", 464], ["after", 473], ["only", 479], ["minor", 484], ["traumas", 490], [".", 497], ["In", 499], ["this", 502], ["scenario", 507], [",", 515], ["the", 517], ["misdiagnosis", 521], ["of", 534], ["Ehlers", 537], ["-", 543], ["Danlos", 544], ["syndrome", 551], ["with", 560], ["child", 565], ["abuse", 571], ["is", 577], ["a", 580], ["possibility", 582], [",", 593], ["as", 595], ["occasionally", 598], ["reported", 611], ["in", 620], ["the", 623], ["literature", 627], [".", 637], ["Recently", 639], [",", 647], ["more", 649], ["attention", 654], ["was", 664], ["posed", 668], ["by", 674], ["lay", 677], ["people", 681], ["between", 688], ["the", 696], ["possible", 700], ["association", 709], ["of", 721], ["Ehlers", 724], ["-", 730], ["Danlos", 731], ["syndrome", 738], ["and", 747], ["bone", 751], ["fragility", 756], [".", 765], ["Literature", 767], ["and", 778], ["personal", 782], ["experience", 791], ["show", 802], ["a", 807], ["strong", 809], ["association", 816], ["between", 828], ["Ehlers", 836], ["-", 842], ["Danlos", 843], ["syndrome", 850], [",", 858], ["generalized", 860], ["joint", 872], ["hypermobility", 878], ["and", 892], ["reduced", 896], ["bone", 904], ["mass", 909], ["density", 914], ["in", 922], ["older", 925], ["children", 931], ["and", 940], ["adults", 944], [",", 950], ["especially", 952], ["fertile", 963], ["women", 971], [".", 976], ["The", 978], ["existence", 982], ["of", 992], ["a", 995], ["true", 997], ["increased", 1002], ["risk", 1012], ["of", 1017], ["fracture", 1020], ["in", 1029], ["Ehlers", 1032], ["-", 1038], ["Danlos", 1039], ["syndrome", 1046], ["is", 1055], ["still", 1058], ["a", 1064], ["matter", 1066], ["of", 1073], ["debate", 1076], ["in", 1083], ["children", 1086], ["and", 1095], ["adults", 1099], ["with", 1106], ["little", 1111], ["and", 1118], ["conflicting", 1122], ["evidence", 1134], [".", 1142], ["In", 1144], ["case", 1147], ["of", 1152], ["suspected", 1155], ["child", 1165], ["abuse", 1171], [",", 1176], ["Ehlers", 1178], ["-", 1184], ["Danlos", 1185], ["syndrome", 1192], ["is", 1201], ["certainly", 1204], ["on", 1214], ["the", 1217], ["differential", 1221], ["for", 1234], ["bruising", 1238], [",", 1246], ["especially", 1248], ["in", 1259], ["EDS", 1262], ["types", 1266], ["with", 1272], ["marked", 1277], ["cutaneous", 1284], ["and", 1294], ["capillary", 1298], ["involvement", 1308], [".", 1319], ["In", 1321], ["suspected", 1324], ["child", 1334], ["abuse", 1340], ["cases", 1346], [",", 1351], ["careful", 1353], ["examination", 1361], ["of", 1373], ["the", 1376], ["index", 1380], ["case", 1386], ["and", 1391], ["her", 1395], ["/", 1398], ["his", 1399], ["extended", 1403], ["family", 1412], ["is", 1419], ["routine", 1422], [",", 1429], ["as", 1431], ["well", 1434], ["as", 1439], ["exclusion", 1442], ["of", 1452], ["other", 1455], ["disorders", 1461], ["such", 1471], ["as", 1476], ["osteogenesis", 1479], ["imperfecta", 1492], [".", 1502], ["The", 1504], ["hypothesis", 1508], ["of", 1519], ["Ehlers", 1522], ["-", 1528], ["Danlos", 1529], ["syndrome", 1536], ["as", 1545], ["an", 1548], ["alternative", 1551], ["explanation", 1563], ["for", 1575], ["infantile", 1579], ["fractures", 1589], ["remains", 1599], ["speculative", 1607], [".", 1618]]}
{"context": "A 29-year-old man with a history of elevated creatine kinase and necrotizing myopathy was reviewed. Prominent red cell acanthocytosis in association with reduced Kell antigen expression was present, findings consistent with the McLeod syndrome. Investigation of the patient's XK gene revealed a novel TGG- to-TAG transition at position 1023 in exon 3. This point mutation creates an in-frame stop codon (W314X), and predicts a truncated XK protein of 313 amino acids, compared with 444 amino acids in the normal XK protein. The mutation was not identified in the patient's mother or sister indicating that this mutation was spontaneous.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "d82fcc5243f04463a79983358c686ff9", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[44, 44], [79, 79], [94, 94]], "char_spans": [[276, 277], [437, 438], [512, 513]]}]}], "context_tokens": [["A", 0], ["29-year", 2], ["-", 9], ["old", 10], ["man", 14], ["with", 18], ["a", 23], ["history", 25], ["of", 33], ["elevated", 36], ["creatine", 45], ["kinase", 54], ["and", 61], ["necrotizing", 65], ["myopathy", 77], ["was", 86], ["reviewed", 90], [".", 98], ["Prominent", 100], ["red", 110], ["cell", 114], ["acanthocytosis", 119], ["in", 134], ["association", 137], ["with", 149], ["reduced", 154], ["Kell", 162], ["antigen", 167], ["expression", 175], ["was", 186], ["present", 190], [",", 197], ["findings", 199], ["consistent", 208], ["with", 219], ["the", 224], ["McLeod", 228], ["syndrome", 235], [".", 243], ["Investigation", 245], ["of", 259], ["the", 262], ["patient", 266], ["'s", 273], ["XK", 276], ["gene", 279], ["revealed", 284], ["a", 293], ["novel", 295], ["TGG-", 301], ["to", 306], ["-", 308], ["TAG", 309], ["transition", 313], ["at", 324], ["position", 327], ["1023", 336], ["in", 341], ["exon", 344], ["3", 349], [".", 350], ["This", 352], ["point", 357], ["mutation", 363], ["creates", 372], ["an", 380], ["in", 383], ["-", 385], ["frame", 386], ["stop", 392], ["codon", 397], ["(", 403], ["W314X", 404], [")", 409], [",", 410], ["and", 412], ["predicts", 416], ["a", 425], ["truncated", 427], ["XK", 437], ["protein", 440], ["of", 448], ["313", 451], ["amino", 455], ["acids", 461], [",", 466], ["compared", 468], ["with", 477], ["444", 482], ["amino", 486], ["acids", 492], ["in", 498], ["the", 501], ["normal", 505], ["XK", 512], ["protein", 515], [".", 522], ["The", 524], ["mutation", 528], ["was", 537], ["not", 541], ["identified", 545], ["in", 556], ["the", 559], ["patient", 563], ["'s", 570], ["mother", 573], ["or", 580], ["sister", 583], ["indicating", 590], ["that", 601], ["this", 606], ["mutation", 611], ["was", 620], ["spontaneous", 624], [".", 635]]}
{"context": "Cap analysis of gene expression (CAGE) is a high-throughput method for transcriptome analysis that provides a single base-pair resolution map of transcription start sites (TSS) and their relative usage. Despite their high resolution and functional significance, published CAGE data are still underused in promoter analysis due to the absence of tools that enable its efficient manipulation and integration with other genome data types. Here we present CAGEr, an R implementation of novel methods for the analysis of differential TSS usage and promoter dynamics, integrated with CAGE data processing and promoterome mining into a first comprehensive CAGE toolbox on a common analysis platform. Crucially, we provide collections of TSSs derived from most published CAGE datasets, as well as direct access to FANTOM5 resource of TSSs for numerous human and mouse cell/tissue types from within R, greatly increasing the accessibility of precise context-specific TSS data for integrative analyses. The CAGEr package is freely available from Bioconductor at http://www.bioconductor.org/packages/release/bioc/html/CAGEr.html.", "qas": [{"question": "Which tool is used for promoterome mining using CAGE data?", "answers": ["CAGEr"], "qid": "510b9aa3109f4e7c94f4cee443af85d9", "question_tokens": [["Which", 0], ["tool", 6], ["is", 11], ["used", 14], ["for", 19], ["promoterome", 23], ["mining", 35], ["using", 42], ["CAGE", 48], ["data", 53], ["?", 57]], "detected_answers": [{"text": "CAGEr", "token_spans": [[169, 169], [77, 77]], "char_spans": [[997, 1001], [452, 456]]}]}], "context_tokens": [["Cap", 0], ["analysis", 4], ["of", 13], ["gene", 16], ["expression", 21], ["(", 32], ["CAGE", 33], [")", 37], ["is", 39], ["a", 42], ["high", 44], ["-", 48], ["throughput", 49], ["method", 60], ["for", 67], ["transcriptome", 71], ["analysis", 85], ["that", 94], ["provides", 99], ["a", 108], ["single", 110], ["base", 117], ["-", 121], ["pair", 122], ["resolution", 127], ["map", 138], ["of", 142], ["transcription", 145], ["start", 159], ["sites", 165], ["(", 171], ["TSS", 172], [")", 175], ["and", 177], ["their", 181], ["relative", 187], ["usage", 196], [".", 201], ["Despite", 203], ["their", 211], ["high", 217], ["resolution", 222], ["and", 233], ["functional", 237], ["significance", 248], [",", 260], ["published", 262], ["CAGE", 272], ["data", 277], ["are", 282], ["still", 286], ["underused", 292], ["in", 302], ["promoter", 305], ["analysis", 314], ["due", 323], ["to", 327], ["the", 330], ["absence", 334], ["of", 342], ["tools", 345], ["that", 351], ["enable", 356], ["its", 363], ["efficient", 367], ["manipulation", 377], ["and", 390], ["integration", 394], ["with", 406], ["other", 411], ["genome", 417], ["data", 424], ["types", 429], [".", 434], ["Here", 436], ["we", 441], ["present", 444], ["CAGEr", 452], [",", 457], ["an", 459], ["R", 462], ["implementation", 464], ["of", 479], ["novel", 482], ["methods", 488], ["for", 496], ["the", 500], ["analysis", 504], ["of", 513], ["differential", 516], ["TSS", 529], ["usage", 533], ["and", 539], ["promoter", 543], ["dynamics", 552], [",", 560], ["integrated", 562], ["with", 573], ["CAGE", 578], ["data", 583], ["processing", 588], ["and", 599], ["promoterome", 603], ["mining", 615], ["into", 622], ["a", 627], ["first", 629], ["comprehensive", 635], ["CAGE", 649], ["toolbox", 654], ["on", 662], ["a", 665], ["common", 667], ["analysis", 674], ["platform", 683], [".", 691], ["Crucially", 693], [",", 702], ["we", 704], ["provide", 707], ["collections", 715], ["of", 727], ["TSSs", 730], ["derived", 735], ["from", 743], ["most", 748], ["published", 753], ["CAGE", 763], ["datasets", 768], [",", 776], ["as", 778], ["well", 781], ["as", 786], ["direct", 789], ["access", 796], ["to", 803], ["FANTOM5", 806], ["resource", 814], ["of", 823], ["TSSs", 826], ["for", 831], ["numerous", 835], ["human", 844], ["and", 850], ["mouse", 854], ["cell", 860], ["/", 864], ["tissue", 865], ["types", 872], ["from", 878], ["within", 883], ["R", 890], [",", 891], ["greatly", 893], ["increasing", 901], ["the", 912], ["accessibility", 916], ["of", 930], ["precise", 933], ["context", 941], ["-", 948], ["specific", 949], ["TSS", 958], ["data", 962], ["for", 967], ["integrative", 971], ["analyses", 983], [".", 991], ["The", 993], ["CAGEr", 997], ["package", 1003], ["is", 1011], ["freely", 1014], ["available", 1021], ["from", 1031], ["Bioconductor", 1036], ["at", 1049], ["http://www.bioconductor.org/packages/release/bioc/html/CAGEr.html", 1052], [".", 1117]]}
{"context": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) may be misidentified as intrinsically methicillin-resistant Staphylococcus aureus (MRSA) in the clinical laboratory. Under disk diffusion testing conditions designed to maximize detection of MRSA (incubation at 32 degrees C, pre-induction with methicillin, or plating on 4% NaCl-supplemented agar), BORSA strains also tend to appear resistant to semisynthetic penicillins. Under these conditions, ampicillin/sulbactam appears to be more accurate than amoxicillin/clavulanic acid for differentiating BORSA from MRSA.", "qas": [{"question": "What is BORSA?", "answers": ["Borderline oxacillin-resistant Staphylococcus aureus"], "qid": "a859d7dd48d14f7ba82f37892f524538", "question_tokens": [["What", 0], ["is", 5], ["BORSA", 8], ["?", 13]], "detected_answers": [{"text": "Borderline oxacillin-resistant Staphylococcus aureus", "token_spans": [[0, 5]], "char_spans": [[0, 51]]}]}], "context_tokens": [["Borderline", 0], ["oxacillin", 11], ["-", 20], ["resistant", 21], ["Staphylococcus", 31], ["aureus", 46], ["(", 53], ["BORSA", 54], [")", 59], ["may", 61], ["be", 65], ["misidentified", 68], ["as", 82], ["intrinsically", 85], ["methicillin", 99], ["-", 110], ["resistant", 111], ["Staphylococcus", 121], ["aureus", 136], ["(", 143], ["MRSA", 144], [")", 148], ["in", 150], ["the", 153], ["clinical", 157], ["laboratory", 166], [".", 176], ["Under", 178], ["disk", 184], ["diffusion", 189], ["testing", 199], ["conditions", 207], ["designed", 218], ["to", 227], ["maximize", 230], ["detection", 239], ["of", 249], ["MRSA", 252], ["(", 257], ["incubation", 258], ["at", 269], ["32", 272], ["degrees", 275], ["C", 283], [",", 284], ["pre", 286], ["-", 289], ["induction", 290], ["with", 300], ["methicillin", 305], [",", 316], ["or", 318], ["plating", 321], ["on", 329], ["4", 332], ["%", 333], ["NaCl", 335], ["-", 339], ["supplemented", 340], ["agar", 353], [")", 357], [",", 358], ["BORSA", 360], ["strains", 366], ["also", 374], ["tend", 379], ["to", 384], ["appear", 387], ["resistant", 394], ["to", 404], ["semisynthetic", 407], ["penicillins", 421], [".", 432], ["Under", 434], ["these", 440], ["conditions", 446], [",", 456], ["ampicillin", 458], ["/", 468], ["sulbactam", 469], ["appears", 479], ["to", 487], ["be", 490], ["more", 493], ["accurate", 498], ["than", 507], ["amoxicillin", 512], ["/", 523], ["clavulanic", 524], ["acid", 535], ["for", 540], ["differentiating", 544], ["BORSA", 560], ["from", 566], ["MRSA", 571], [".", 575]]}
{"context": "The Web site for the Anxiety Disorders Association of America (ADAA) receives more than 5 million visits per month and thus represents a unique medium for the study of anxiety disorders. ADAA Web site users from October 2002 to January 2003 were invited to complete a survey oriented toward trauma history and psychiatric sequelae. A diagnostic approximation of posttraumatic stress disorder (PTSD) was based on responses to the Trauma Questionnaire, the Davidson Trauma Scale, and questions about impairment. The Connor-Davidson Resilience Scale was also used. Variables were tested for their association with PTSD. Among 1558 participants, 87% had a history of trauma, and 38% had current PTSD. The population was comprised predominantly of white middle-class women, half of whom were married. More than 90% were first-time users of the site. Factors associated with PTSD included death of, or harm to, a loved one; personal history of incest, rape, or physical abuse; lower age; lower income; unemployment; missed work; increased medical care; dissatisfaction with psychotropic medication; depressive symptoms; and lower resilience. In this selective convenience sample, there were high rates of traumatization and PTSD. The demographics of this group are similar to those seen in previously studied populations that had contacted the ADAA. Furthermore, the factors associated with PTSD were like those in many community surveys. The ADAA Web site has the opportunity to benefit large numbers of highly distressed individuals.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "7b813fb8fbe444c2b8ed096bcfc51ca6", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[123, 123], [251, 251], [104, 104], [159, 159], [66, 66], [223, 223]], "char_spans": [[691, 694], [1385, 1388], [611, 614], [869, 872], [393, 396], [1218, 1221]]}]}], "context_tokens": [["The", 0], ["Web", 4], ["site", 8], ["for", 13], ["the", 17], ["Anxiety", 21], ["Disorders", 29], ["Association", 39], ["of", 51], ["America", 54], ["(", 62], ["ADAA", 63], [")", 67], ["receives", 69], ["more", 78], ["than", 83], ["5", 88], ["million", 90], ["visits", 98], ["per", 105], ["month", 109], ["and", 115], ["thus", 119], ["represents", 124], ["a", 135], ["unique", 137], ["medium", 144], ["for", 151], ["the", 155], ["study", 159], ["of", 165], ["anxiety", 168], ["disorders", 176], [".", 185], ["ADAA", 187], ["Web", 192], ["site", 196], ["users", 201], ["from", 207], ["October", 212], ["2002", 220], ["to", 225], ["January", 228], ["2003", 236], ["were", 241], ["invited", 246], ["to", 254], ["complete", 257], ["a", 266], ["survey", 268], ["oriented", 275], ["toward", 284], ["trauma", 291], ["history", 298], ["and", 306], ["psychiatric", 310], ["sequelae", 322], [".", 330], ["A", 332], ["diagnostic", 334], ["approximation", 345], ["of", 359], ["posttraumatic", 362], ["stress", 376], ["disorder", 383], ["(", 392], ["PTSD", 393], [")", 397], ["was", 399], ["based", 403], ["on", 409], ["responses", 412], ["to", 422], ["the", 425], ["Trauma", 429], ["Questionnaire", 436], [",", 449], ["the", 451], ["Davidson", 455], ["Trauma", 464], ["Scale", 471], [",", 476], ["and", 478], ["questions", 482], ["about", 492], ["impairment", 498], [".", 508], ["The", 510], ["Connor", 514], ["-", 520], ["Davidson", 521], ["Resilience", 530], ["Scale", 541], ["was", 547], ["also", 551], ["used", 556], [".", 560], ["Variables", 562], ["were", 572], ["tested", 577], ["for", 584], ["their", 588], ["association", 594], ["with", 606], ["PTSD", 611], [".", 615], ["Among", 617], ["1558", 623], ["participants", 628], [",", 640], ["87", 642], ["%", 644], ["had", 646], ["a", 650], ["history", 652], ["of", 660], ["trauma", 663], [",", 669], ["and", 671], ["38", 675], ["%", 677], ["had", 679], ["current", 683], ["PTSD", 691], [".", 695], ["The", 697], ["population", 701], ["was", 712], ["comprised", 716], ["predominantly", 726], ["of", 740], ["white", 743], ["middle", 749], ["-", 755], ["class", 756], ["women", 762], [",", 767], ["half", 769], ["of", 774], ["whom", 777], ["were", 782], ["married", 787], [".", 794], ["More", 796], ["than", 801], ["90", 806], ["%", 808], ["were", 810], ["first", 815], ["-", 820], ["time", 821], ["users", 826], ["of", 832], ["the", 835], ["site", 839], [".", 843], ["Factors", 845], ["associated", 853], ["with", 864], ["PTSD", 869], ["included", 874], ["death", 883], ["of", 889], [",", 891], ["or", 893], ["harm", 896], ["to", 901], [",", 903], ["a", 905], ["loved", 907], ["one", 913], [";", 916], ["personal", 918], ["history", 927], ["of", 935], ["incest", 938], [",", 944], ["rape", 946], [",", 950], ["or", 952], ["physical", 955], ["abuse", 964], [";", 969], ["lower", 971], ["age", 977], [";", 980], ["lower", 982], ["income", 988], [";", 994], ["unemployment", 996], [";", 1008], ["missed", 1010], ["work", 1017], [";", 1021], ["increased", 1023], ["medical", 1033], ["care", 1041], [";", 1045], ["dissatisfaction", 1047], ["with", 1063], ["psychotropic", 1068], ["medication", 1081], [";", 1091], ["depressive", 1093], ["symptoms", 1104], [";", 1112], ["and", 1114], ["lower", 1118], ["resilience", 1124], [".", 1134], ["In", 1136], ["this", 1139], ["selective", 1144], ["convenience", 1154], ["sample", 1166], [",", 1172], ["there", 1174], ["were", 1180], ["high", 1185], ["rates", 1190], ["of", 1196], ["traumatization", 1199], ["and", 1214], ["PTSD", 1218], [".", 1222], ["The", 1224], ["demographics", 1228], ["of", 1241], ["this", 1244], ["group", 1249], ["are", 1255], ["similar", 1259], ["to", 1267], ["those", 1270], ["seen", 1276], ["in", 1281], ["previously", 1284], ["studied", 1295], ["populations", 1303], ["that", 1315], ["had", 1320], ["contacted", 1324], ["the", 1334], ["ADAA", 1338], [".", 1342], ["Furthermore", 1344], [",", 1355], ["the", 1357], ["factors", 1361], ["associated", 1369], ["with", 1380], ["PTSD", 1385], ["were", 1390], ["like", 1395], ["those", 1400], ["in", 1406], ["many", 1409], ["community", 1414], ["surveys", 1424], [".", 1431], ["The", 1433], ["ADAA", 1437], ["Web", 1442], ["site", 1446], ["has", 1451], ["the", 1455], ["opportunity", 1459], ["to", 1471], ["benefit", 1474], ["large", 1482], ["numbers", 1488], ["of", 1496], ["highly", 1499], ["distressed", 1506], ["individuals", 1517], [".", 1528]]}
{"context": "In 1957, Simpson published a seminal paper defining the risk factors for recurrence following surgical treatment of intracranial meningiomas. Given that Simpson's study was published more than 50 years ago, preceding image guidance technology and MR imaging, the authors reviewed their own experience with surgical treatment of Grade I meningiomas to determine if Simpson's grading scale is still relevant to modern neurosurgical practice. From this cohort, the authors evaluated all patients undergoing craniotomy for resection of a histologically proven WHO Grade I meningioma as their initial therapy. Clinical information was retrospectively reconstructed using patient medical records and radiological data. Recurrence analysis was performed using the Kaplan-Meier method. The 5-year recurrence/progression-free survival for all patients receiving a Simpson Grade I, II, III, or IV resection was 95, 85, 88, and 81%, respectively (p = not significant, log-rank test). Kaplan-Meier analysis revealed no significant difference in recurrence-free survival between patients receiving a Simpson Grade I, II, III, or IV resection. Analysis limited to meningiomas arising from the skull base (excluding the cavernous sinus) similarly found no significant benefit to Simpson Grade I or II resection, and the survival curves were nearly superimposed. In this study of a cohort of patients undergoing surgery for WHO Grade I meningiomas, the authors demonstrate that the benefit of more aggressive attempts to resect the tumor with dura and underlying bone was negligible compared with simply removing the entire tumor, or even leaving small amounts of tumor attached to critical structures. The authors believe that these data reflect an evolution in the nature of meningioma surgery over the past 2 decades, and bring into question the relevance of using Simpson's grading system as the sole predictor of recurrence.", "qas": [{"question": "Simpson grading is used to describe resection of which brain tumor?", "answers": ["meningioma"], "qid": "2ae2864e473745f697faa29712bfb28c", "question_tokens": [["Simpson", 0], ["grading", 8], ["is", 16], ["used", 19], ["to", 24], ["describe", 27], ["resection", 36], ["of", 46], ["which", 49], ["brain", 55], ["tumor", 61], ["?", 66]], "detected_answers": [{"text": "meningioma", "token_spans": [[303, 303], [90, 90]], "char_spans": [[1761, 1770], [568, 577]]}]}], "context_tokens": [["In", 0], ["1957", 3], [",", 7], ["Simpson", 9], ["published", 17], ["a", 27], ["seminal", 29], ["paper", 37], ["defining", 43], ["the", 52], ["risk", 56], ["factors", 61], ["for", 69], ["recurrence", 73], ["following", 84], ["surgical", 94], ["treatment", 103], ["of", 113], ["intracranial", 116], ["meningiomas", 129], [".", 140], ["Given", 142], ["that", 148], ["Simpson", 153], ["'s", 160], ["study", 163], ["was", 169], ["published", 173], ["more", 183], ["than", 188], ["50", 193], ["years", 196], ["ago", 202], [",", 205], ["preceding", 207], ["image", 217], ["guidance", 223], ["technology", 232], ["and", 243], ["MR", 247], ["imaging", 250], [",", 257], ["the", 259], ["authors", 263], ["reviewed", 271], ["their", 280], ["own", 286], ["experience", 290], ["with", 301], ["surgical", 306], ["treatment", 315], ["of", 325], ["Grade", 328], ["I", 334], ["meningiomas", 336], ["to", 348], ["determine", 351], ["if", 361], ["Simpson", 364], ["'s", 371], ["grading", 374], ["scale", 382], ["is", 388], ["still", 391], ["relevant", 397], ["to", 406], ["modern", 409], ["neurosurgical", 416], ["practice", 430], [".", 438], ["From", 440], ["this", 445], ["cohort", 450], [",", 456], ["the", 458], ["authors", 462], ["evaluated", 470], ["all", 480], ["patients", 484], ["undergoing", 493], ["craniotomy", 504], ["for", 515], ["resection", 519], ["of", 529], ["a", 532], ["histologically", 534], ["proven", 549], ["WHO", 556], ["Grade", 560], ["I", 566], ["meningioma", 568], ["as", 579], ["their", 582], ["initial", 588], ["therapy", 596], [".", 603], ["Clinical", 605], ["information", 614], ["was", 626], ["retrospectively", 630], ["reconstructed", 646], ["using", 660], ["patient", 666], ["medical", 674], ["records", 682], ["and", 690], ["radiological", 694], ["data", 707], [".", 711], ["Recurrence", 713], ["analysis", 724], ["was", 733], ["performed", 737], ["using", 747], ["the", 753], ["Kaplan", 757], ["-", 763], ["Meier", 764], ["method", 770], [".", 776], ["The", 778], ["5-year", 782], ["recurrence", 789], ["/", 799], ["progression", 800], ["-", 811], ["free", 812], ["survival", 817], ["for", 826], ["all", 830], ["patients", 834], ["receiving", 843], ["a", 853], ["Simpson", 855], ["Grade", 863], ["I", 869], [",", 870], ["II", 872], [",", 874], ["III", 876], [",", 879], ["or", 881], ["IV", 884], ["resection", 887], ["was", 897], ["95", 901], [",", 903], ["85", 905], [",", 907], ["88", 909], [",", 911], ["and", 913], ["81", 917], ["%", 919], [",", 920], ["respectively", 922], ["(", 935], ["p", 936], ["=", 938], ["not", 940], ["significant", 944], [",", 955], ["log", 957], ["-", 960], ["rank", 961], ["test", 966], [")", 970], [".", 971], ["Kaplan", 973], ["-", 979], ["Meier", 980], ["analysis", 986], ["revealed", 995], ["no", 1004], ["significant", 1007], ["difference", 1019], ["in", 1030], ["recurrence", 1033], ["-", 1043], ["free", 1044], ["survival", 1049], ["between", 1058], ["patients", 1066], ["receiving", 1075], ["a", 1085], ["Simpson", 1087], ["Grade", 1095], ["I", 1101], [",", 1102], ["II", 1104], [",", 1106], ["III", 1108], [",", 1111], ["or", 1113], ["IV", 1116], ["resection", 1119], [".", 1128], ["Analysis", 1130], ["limited", 1139], ["to", 1147], ["meningiomas", 1150], ["arising", 1162], ["from", 1170], ["the", 1175], ["skull", 1179], ["base", 1185], ["(", 1190], ["excluding", 1191], ["the", 1201], ["cavernous", 1205], ["sinus", 1215], [")", 1220], ["similarly", 1222], ["found", 1232], ["no", 1238], ["significant", 1241], ["benefit", 1253], ["to", 1261], ["Simpson", 1264], ["Grade", 1272], ["I", 1278], ["or", 1280], ["II", 1283], ["resection", 1286], [",", 1295], ["and", 1297], ["the", 1301], ["survival", 1305], ["curves", 1314], ["were", 1321], ["nearly", 1326], ["superimposed", 1333], [".", 1345], ["In", 1347], ["this", 1350], ["study", 1355], ["of", 1361], ["a", 1364], ["cohort", 1366], ["of", 1373], ["patients", 1376], ["undergoing", 1385], ["surgery", 1396], ["for", 1404], ["WHO", 1408], ["Grade", 1412], ["I", 1418], ["meningiomas", 1420], [",", 1431], ["the", 1433], ["authors", 1437], ["demonstrate", 1445], ["that", 1457], ["the", 1462], ["benefit", 1466], ["of", 1474], ["more", 1477], ["aggressive", 1482], ["attempts", 1493], ["to", 1502], ["resect", 1505], ["the", 1512], ["tumor", 1516], ["with", 1522], ["dura", 1527], ["and", 1532], ["underlying", 1536], ["bone", 1547], ["was", 1552], ["negligible", 1556], ["compared", 1567], ["with", 1576], ["simply", 1581], ["removing", 1588], ["the", 1597], ["entire", 1601], ["tumor", 1608], [",", 1613], ["or", 1615], ["even", 1618], ["leaving", 1623], ["small", 1631], ["amounts", 1637], ["of", 1645], ["tumor", 1648], ["attached", 1654], ["to", 1663], ["critical", 1666], ["structures", 1675], [".", 1685], ["The", 1687], ["authors", 1691], ["believe", 1699], ["that", 1707], ["these", 1712], ["data", 1718], ["reflect", 1723], ["an", 1731], ["evolution", 1734], ["in", 1744], ["the", 1747], ["nature", 1751], ["of", 1758], ["meningioma", 1761], ["surgery", 1772], ["over", 1780], ["the", 1785], ["past", 1789], ["2", 1794], ["decades", 1796], [",", 1803], ["and", 1805], ["bring", 1809], ["into", 1815], ["question", 1820], ["the", 1829], ["relevance", 1833], ["of", 1843], ["using", 1846], ["Simpson", 1852], ["'s", 1859], ["grading", 1862], ["system", 1870], ["as", 1877], ["the", 1880], ["sole", 1884], ["predictor", 1889], ["of", 1899], ["recurrence", 1902], [".", 1912]]}
{"context": "Willis-Ekbom disease/restless legs syndrome (WED/RLS) seems to be a frequent cause of intractable chronic insomnia (ICI) but is under-recognized in children/adolescents with neurodevelopmental conditions (NDCs), as many patients do not have the ability to express the underlying \"urge-to-move\". In light of this, we aim to develop a protocol for behavioral observations supporting the diagnosis of WED/RLS. We investigated 26 pediatric patients (age 1-16 years, median 8) with NDCs, ICI and evidence of familial WED/RLS employing (1) \"emplotted narratives\" for description of the various \"urge-to-move\" presentations and (2) self-description and \"behavioral observations\" during a \"suggested clinical immobilization test\" (SCIT). Parental narratives reflected typical WED/RLS-related \"urge-to-move\" symptoms during day-, bed-, and nighttime in all patients. Fifteen out of 26 patients could describe the \"urge-to-move\" during the SCIT. Ten out of 26 patients, unable to describe their symptoms due to cognitive disabilities, showed patterns of \"relieving-movements\" upon observation. Sensory processing abnormalities were reported in all patients, with tactile sensitivities (26/26) (including shifted pain threshold) as the most common sensory domain. \"Emplotted narratives\" and structured \"behavioral observations\" support recognition of familial WED/RLS associated movement patterns and provide a useful tool for the diagnosis of WED/RLS in children with NDCs in a clinical office setting.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "b7c3669e630a465892c5b64dbd7a9d82", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[5, 7]], "char_spans": [[21, 42]]}]}], "context_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["/", 20], ["restless", 21], ["legs", 30], ["syndrome", 35], ["(", 44], ["WED", 45], ["/", 48], ["RLS", 49], [")", 52], ["seems", 54], ["to", 60], ["be", 63], ["a", 66], ["frequent", 68], ["cause", 77], ["of", 83], ["intractable", 86], ["chronic", 98], ["insomnia", 106], ["(", 115], ["ICI", 116], [")", 119], ["but", 121], ["is", 125], ["under", 128], ["-", 133], ["recognized", 134], ["in", 145], ["children", 148], ["/", 156], ["adolescents", 157], ["with", 169], ["neurodevelopmental", 174], ["conditions", 193], ["(", 204], ["NDCs", 205], [")", 209], [",", 210], ["as", 212], ["many", 215], ["patients", 220], ["do", 229], ["not", 232], ["have", 236], ["the", 241], ["ability", 245], ["to", 253], ["express", 256], ["the", 264], ["underlying", 268], ["\"", 279], ["urge", 280], ["-", 284], ["to", 285], ["-", 287], ["move", 288], ["\"", 292], [".", 293], ["In", 295], ["light", 298], ["of", 304], ["this", 307], [",", 311], ["we", 313], ["aim", 316], ["to", 320], ["develop", 323], ["a", 331], ["protocol", 333], ["for", 342], ["behavioral", 346], ["observations", 357], ["supporting", 370], ["the", 381], ["diagnosis", 385], ["of", 395], ["WED", 398], ["/", 401], ["RLS", 402], [".", 405], ["We", 407], ["investigated", 410], ["26", 423], ["pediatric", 426], ["patients", 436], ["(", 445], ["age", 446], ["1", 450], ["-", 451], ["16", 452], ["years", 455], [",", 460], ["median", 462], ["8)", 469], ["with", 472], ["NDCs", 477], [",", 481], ["ICI", 483], ["and", 487], ["evidence", 491], ["of", 500], ["familial", 503], ["WED", 512], ["/", 515], ["RLS", 516], ["employing", 520], ["(", 530], ["1", 531], [")", 532], ["\"", 534], ["emplotted", 535], ["narratives", 545], ["\"", 555], ["for", 557], ["description", 561], ["of", 573], ["the", 576], ["various", 580], ["\"", 588], ["urge", 589], ["-", 593], ["to", 594], ["-", 596], ["move", 597], ["\"", 601], ["presentations", 603], ["and", 617], ["(", 621], ["2", 622], [")", 623], ["self", 625], ["-", 629], ["description", 630], ["and", 642], ["\"", 646], ["behavioral", 647], ["observations", 658], ["\"", 670], ["during", 672], ["a", 679], ["\"", 681], ["suggested", 682], ["clinical", 692], ["immobilization", 701], ["test", 716], ["\"", 720], ["(", 722], ["SCIT", 723], [")", 727], [".", 728], ["Parental", 730], ["narratives", 739], ["reflected", 750], ["typical", 760], ["WED", 768], ["/", 771], ["RLS", 772], ["-", 775], ["related", 776], ["\"", 784], ["urge", 785], ["-", 789], ["to", 790], ["-", 792], ["move", 793], ["\"", 797], ["symptoms", 799], ["during", 808], ["day-", 815], [",", 819], ["bed-", 821], [",", 825], ["and", 827], ["nighttime", 831], ["in", 841], ["all", 844], ["patients", 848], [".", 856], ["Fifteen", 858], ["out", 866], ["of", 870], ["26", 873], ["patients", 876], ["could", 885], ["describe", 891], ["the", 900], ["\"", 904], ["urge", 905], ["-", 909], ["to", 910], ["-", 912], ["move", 913], ["\"", 917], ["during", 919], ["the", 926], ["SCIT", 930], [".", 934], ["Ten", 936], ["out", 940], ["of", 944], ["26", 947], ["patients", 950], [",", 958], ["unable", 960], ["to", 967], ["describe", 970], ["their", 979], ["symptoms", 985], ["due", 994], ["to", 998], ["cognitive", 1001], ["disabilities", 1011], [",", 1023], ["showed", 1025], ["patterns", 1032], ["of", 1041], ["\"", 1044], ["relieving", 1045], ["-", 1054], ["movements", 1055], ["\"", 1064], ["upon", 1066], ["observation", 1071], [".", 1082], ["Sensory", 1084], ["processing", 1092], ["abnormalities", 1103], ["were", 1117], ["reported", 1122], ["in", 1131], ["all", 1134], ["patients", 1138], [",", 1146], ["with", 1148], ["tactile", 1153], ["sensitivities", 1161], ["(", 1175], ["26/26", 1176], [")", 1181], ["(", 1183], ["including", 1184], ["shifted", 1194], ["pain", 1202], ["threshold", 1207], [")", 1216], ["as", 1218], ["the", 1221], ["most", 1225], ["common", 1230], ["sensory", 1237], ["domain", 1245], [".", 1251], ["\"", 1253], ["Emplotted", 1254], ["narratives", 1264], ["\"", 1274], ["and", 1276], ["structured", 1280], ["\"", 1291], ["behavioral", 1292], ["observations", 1303], ["\"", 1315], ["support", 1317], ["recognition", 1325], ["of", 1337], ["familial", 1340], ["WED", 1349], ["/", 1352], ["RLS", 1353], ["associated", 1357], ["movement", 1368], ["patterns", 1377], ["and", 1386], ["provide", 1390], ["a", 1398], ["useful", 1400], ["tool", 1407], ["for", 1412], ["the", 1416], ["diagnosis", 1420], ["of", 1430], ["WED", 1433], ["/", 1436], ["RLS", 1437], ["in", 1441], ["children", 1444], ["with", 1453], ["NDCs", 1458], ["in", 1463], ["a", 1466], ["clinical", 1468], ["office", 1477], ["setting", 1484], [".", 1491]]}
{"context": "Women in sub-Saharan Africa are a priority population for evaluation of new biomedical HIV-1 prevention strategies. Antiretroviral pre-exposure prophylaxis is a promising prevention approach; however, clinical trials among young women using daily or coitally-dependent products have found low adherence. Antiretroviral-containing vaginal microbicide rings, which release medication over a month or longer, may reduce these adherence challenges. ASPIRE (A Study to Prevent Infection with a Ring for Extended Use) is a phase III, randomized, double-blind, placebo-controlled trial testing the safety and effectiveness of a vaginal ring containing the non-nucleoside reverse transcriptase inhibitor dapivirine for prevention of HIV-1 infection. We describe the baseline characteristics of African women enrolled in the ASPIRE trial. Between August 2012 and June 2014, 5516 women were screened and 2629 HIV-1 seronegative women between 18-45 years of age were enrolled from 15 research sites in Malawi, South Africa, Uganda, and Zimbabwe. The median age was 26 years (IQR 22-31) and the majority (59%) were unmarried. Nearly 100% of participants reported having a primary sex partner in the prior three months but 43% did not know the HIV-1 status of their primary partner; 17% reported additional concurrent partners. Nearly two-thirds (64%) reported having disclosed to primary partners about planned vaginal ring use in the trial. Sexually transmitted infections were prevalent: 12% had Chlamydia trachomatis, 7% Trichomonas vaginalis, 4% Neisseria gonorrhoeae, and 1% syphilis. African HIV-1 seronegative women at risk of HIV -1 infection were successfully enrolled into a phase III trial of dapivirine vaginal ring for HIV-1 prevention.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "5c077ce1a2b84aa199040b93309cc5b6", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[294, 294]], "char_spans": [[1622, 1624]]}]}], "context_tokens": [["Women", 0], ["in", 6], ["sub", 9], ["-", 12], ["Saharan", 13], ["Africa", 21], ["are", 28], ["a", 32], ["priority", 34], ["population", 43], ["for", 54], ["evaluation", 58], ["of", 69], ["new", 72], ["biomedical", 76], ["HIV-1", 87], ["prevention", 93], ["strategies", 104], [".", 114], ["Antiretroviral", 116], ["pre", 131], ["-", 134], ["exposure", 135], ["prophylaxis", 144], ["is", 156], ["a", 159], ["promising", 161], ["prevention", 171], ["approach", 182], [";", 190], ["however", 192], [",", 199], ["clinical", 201], ["trials", 210], ["among", 217], ["young", 223], ["women", 229], ["using", 235], ["daily", 241], ["or", 247], ["coitally", 250], ["-", 258], ["dependent", 259], ["products", 269], ["have", 278], ["found", 283], ["low", 289], ["adherence", 293], [".", 302], ["Antiretroviral", 304], ["-", 318], ["containing", 319], ["vaginal", 330], ["microbicide", 338], ["rings", 350], [",", 355], ["which", 357], ["release", 363], ["medication", 371], ["over", 382], ["a", 387], ["month", 389], ["or", 395], ["longer", 398], [",", 404], ["may", 406], ["reduce", 410], ["these", 417], ["adherence", 423], ["challenges", 433], [".", 443], ["ASPIRE", 445], ["(", 452], ["A", 453], ["Study", 455], ["to", 461], ["Prevent", 464], ["Infection", 472], ["with", 482], ["a", 487], ["Ring", 489], ["for", 494], ["Extended", 498], ["Use", 507], [")", 510], ["is", 512], ["a", 515], ["phase", 517], ["III", 523], [",", 526], ["randomized", 528], [",", 538], ["double", 540], ["-", 546], ["blind", 547], [",", 552], ["placebo", 554], ["-", 561], ["controlled", 562], ["trial", 573], ["testing", 579], ["the", 587], ["safety", 591], ["and", 598], ["effectiveness", 602], ["of", 616], ["a", 619], ["vaginal", 621], ["ring", 629], ["containing", 634], ["the", 645], ["non", 649], ["-", 652], ["nucleoside", 653], ["reverse", 664], ["transcriptase", 672], ["inhibitor", 686], ["dapivirine", 696], ["for", 707], ["prevention", 711], ["of", 722], ["HIV-1", 725], ["infection", 731], [".", 740], ["We", 742], ["describe", 745], ["the", 754], ["baseline", 758], ["characteristics", 767], ["of", 783], ["African", 786], ["women", 794], ["enrolled", 800], ["in", 809], ["the", 812], ["ASPIRE", 816], ["trial", 823], [".", 828], ["Between", 830], ["August", 838], ["2012", 845], ["and", 850], ["June", 854], ["2014", 859], [",", 863], ["5516", 865], ["women", 870], ["were", 876], ["screened", 881], ["and", 890], ["2629", 894], ["HIV-1", 899], ["seronegative", 905], ["women", 918], ["between", 924], ["18", 932], ["-", 934], ["45", 935], ["years", 938], ["of", 944], ["age", 947], ["were", 951], ["enrolled", 956], ["from", 965], ["15", 970], ["research", 973], ["sites", 982], ["in", 988], ["Malawi", 991], [",", 997], ["South", 999], ["Africa", 1005], [",", 1011], ["Uganda", 1013], [",", 1019], ["and", 1021], ["Zimbabwe", 1025], [".", 1033], ["The", 1035], ["median", 1039], ["age", 1046], ["was", 1050], ["26", 1054], ["years", 1057], ["(", 1063], ["IQR", 1064], ["22", 1068], ["-", 1070], ["31", 1071], [")", 1073], ["and", 1075], ["the", 1079], ["majority", 1083], ["(", 1092], ["59", 1093], ["%", 1095], [")", 1096], ["were", 1098], ["unmarried", 1103], [".", 1112], ["Nearly", 1114], ["100", 1121], ["%", 1124], ["of", 1126], ["participants", 1129], ["reported", 1142], ["having", 1151], ["a", 1158], ["primary", 1160], ["sex", 1168], ["partner", 1172], ["in", 1180], ["the", 1183], ["prior", 1187], ["three", 1193], ["months", 1199], ["but", 1206], ["43", 1210], ["%", 1212], ["did", 1214], ["not", 1218], ["know", 1222], ["the", 1227], ["HIV-1", 1231], ["status", 1237], ["of", 1244], ["their", 1247], ["primary", 1253], ["partner", 1261], [";", 1268], ["17", 1270], ["%", 1272], ["reported", 1274], ["additional", 1283], ["concurrent", 1294], ["partners", 1305], [".", 1313], ["Nearly", 1315], ["two", 1322], ["-", 1325], ["thirds", 1326], ["(", 1333], ["64", 1334], ["%", 1336], [")", 1337], ["reported", 1339], ["having", 1348], ["disclosed", 1355], ["to", 1365], ["primary", 1368], ["partners", 1376], ["about", 1385], ["planned", 1391], ["vaginal", 1399], ["ring", 1407], ["use", 1412], ["in", 1416], ["the", 1419], ["trial", 1423], [".", 1428], ["Sexually", 1430], ["transmitted", 1439], ["infections", 1451], ["were", 1462], ["prevalent", 1467], [":", 1476], ["12", 1478], ["%", 1480], ["had", 1482], ["Chlamydia", 1486], ["trachomatis", 1496], [",", 1507], ["7", 1509], ["%", 1510], ["Trichomonas", 1512], ["vaginalis", 1524], [",", 1533], ["4", 1535], ["%", 1536], ["Neisseria", 1538], ["gonorrhoeae", 1548], [",", 1559], ["and", 1561], ["1", 1565], ["%", 1566], ["syphilis", 1568], [".", 1576], ["African", 1578], ["HIV-1", 1586], ["seronegative", 1592], ["women", 1605], ["at", 1611], ["risk", 1614], ["of", 1619], ["HIV", 1622], ["-1", 1626], ["infection", 1629], ["were", 1639], ["successfully", 1644], ["enrolled", 1657], ["into", 1666], ["a", 1671], ["phase", 1673], ["III", 1679], ["trial", 1683], ["of", 1689], ["dapivirine", 1692], ["vaginal", 1703], ["ring", 1711], ["for", 1716], ["HIV-1", 1720], ["prevention", 1726], [".", 1736]]}
{"context": "Protein methylation is a common posttranslational modification that mostly occurs on arginine and lysine residues. Arginine methylation has been reported to regulate RNA processing, gene transcription, DNA damage repair, protein translocation, and signal transduction. Lysine methylation is best known to regulate histone function and is involved in epigenetic regulation of gene transcription. To better study protein methylation, we have developed highly specific antibodies against monomethyl arginine; asymmetric dimethyl arginine; and monomethyl, dimethyl, and trimethyl lysine motifs. These antibodies were used to perform immunoaffinity purification of methyl peptides followed by LC-MS/MS analysis to identify and quantify arginine and lysine methylation sites in several model studies. Overall, we identified over 1000 arginine methylation sites in human cell line and mouse tissues, and \u223c160 lysine methylation sites in human cell line HCT116. The number of methylation sites identified in this study exceeds those found in the literature to date. Detailed analysis of arginine-methylated proteins observed in mouse brain compared with those found in mouse embryo shows a tissue-specific distribution of arginine methylation, and extends the types of proteins that are known to be arginine methylated to include many new protein types. Many arginine-methylated proteins that we identified from the brain, including receptors, ion channels, transporters, and vesicle proteins, are involved in synaptic transmission, whereas the most abundant methylated proteins identified from mouse embryo are transcriptional regulators and RNA processing proteins.", "qas": [{"question": "Name a method for enrichment of arginine-methylated peptides.", "answers": ["Immunoaffinity purification"], "qid": "d40f8b57b37941beac2d486723c72a73", "question_tokens": [["Name", 0], ["a", 5], ["method", 7], ["for", 14], ["enrichment", 18], ["of", 29], ["arginine", 32], ["-", 40], ["methylated", 41], ["peptides", 52], [".", 60]], "detected_answers": [{"text": "Immunoaffinity purification", "token_spans": [[95, 96]], "char_spans": [[629, 655]]}]}], "context_tokens": [["Protein", 0], ["methylation", 8], ["is", 20], ["a", 23], ["common", 25], ["posttranslational", 32], ["modification", 50], ["that", 63], ["mostly", 68], ["occurs", 75], ["on", 82], ["arginine", 85], ["and", 94], ["lysine", 98], ["residues", 105], [".", 113], ["Arginine", 115], ["methylation", 124], ["has", 136], ["been", 140], ["reported", 145], ["to", 154], ["regulate", 157], ["RNA", 166], ["processing", 170], [",", 180], ["gene", 182], ["transcription", 187], [",", 200], ["DNA", 202], ["damage", 206], ["repair", 213], [",", 219], ["protein", 221], ["translocation", 229], [",", 242], ["and", 244], ["signal", 248], ["transduction", 255], [".", 267], ["Lysine", 269], ["methylation", 276], ["is", 288], ["best", 291], ["known", 296], ["to", 302], ["regulate", 305], ["histone", 314], ["function", 322], ["and", 331], ["is", 335], ["involved", 338], ["in", 347], ["epigenetic", 350], ["regulation", 361], ["of", 372], ["gene", 375], ["transcription", 380], [".", 393], ["To", 395], ["better", 398], ["study", 405], ["protein", 411], ["methylation", 419], [",", 430], ["we", 432], ["have", 435], ["developed", 440], ["highly", 450], ["specific", 457], ["antibodies", 466], ["against", 477], ["monomethyl", 485], ["arginine", 496], [";", 504], ["asymmetric", 506], ["dimethyl", 517], ["arginine", 526], [";", 534], ["and", 536], ["monomethyl", 540], [",", 550], ["dimethyl", 552], [",", 560], ["and", 562], ["trimethyl", 566], ["lysine", 576], ["motifs", 583], [".", 589], ["These", 591], ["antibodies", 597], ["were", 608], ["used", 613], ["to", 618], ["perform", 621], ["immunoaffinity", 629], ["purification", 644], ["of", 657], ["methyl", 660], ["peptides", 667], ["followed", 676], ["by", 685], ["LC", 688], ["-", 690], ["MS", 691], ["/", 693], ["MS", 694], ["analysis", 697], ["to", 706], ["identify", 709], ["and", 718], ["quantify", 722], ["arginine", 731], ["and", 740], ["lysine", 744], ["methylation", 751], ["sites", 763], ["in", 769], ["several", 772], ["model", 780], ["studies", 786], [".", 793], ["Overall", 795], [",", 802], ["we", 804], ["identified", 807], ["over", 818], ["1000", 823], ["arginine", 828], ["methylation", 837], ["sites", 849], ["in", 855], ["human", 858], ["cell", 864], ["line", 869], ["and", 874], ["mouse", 878], ["tissues", 884], [",", 891], ["and", 893], ["\u223c160", 897], ["lysine", 902], ["methylation", 909], ["sites", 921], ["in", 927], ["human", 930], ["cell", 936], ["line", 941], ["HCT116", 946], [".", 952], ["The", 954], ["number", 958], ["of", 965], ["methylation", 968], ["sites", 980], ["identified", 986], ["in", 997], ["this", 1000], ["study", 1005], ["exceeds", 1011], ["those", 1019], ["found", 1025], ["in", 1031], ["the", 1034], ["literature", 1038], ["to", 1049], ["date", 1052], [".", 1056], ["Detailed", 1058], ["analysis", 1067], ["of", 1076], ["arginine", 1079], ["-", 1087], ["methylated", 1088], ["proteins", 1099], ["observed", 1108], ["in", 1117], ["mouse", 1120], ["brain", 1126], ["compared", 1132], ["with", 1141], ["those", 1146], ["found", 1152], ["in", 1158], ["mouse", 1161], ["embryo", 1167], ["shows", 1174], ["a", 1180], ["tissue", 1182], ["-", 1188], ["specific", 1189], ["distribution", 1198], ["of", 1211], ["arginine", 1214], ["methylation", 1223], [",", 1234], ["and", 1236], ["extends", 1240], ["the", 1248], ["types", 1252], ["of", 1258], ["proteins", 1261], ["that", 1270], ["are", 1275], ["known", 1279], ["to", 1285], ["be", 1288], ["arginine", 1291], ["methylated", 1300], ["to", 1311], ["include", 1314], ["many", 1322], ["new", 1327], ["protein", 1331], ["types", 1339], [".", 1344], ["Many", 1346], ["arginine", 1351], ["-", 1359], ["methylated", 1360], ["proteins", 1371], ["that", 1380], ["we", 1385], ["identified", 1388], ["from", 1399], ["the", 1404], ["brain", 1408], [",", 1413], ["including", 1415], ["receptors", 1425], [",", 1434], ["ion", 1436], ["channels", 1440], [",", 1448], ["transporters", 1450], [",", 1462], ["and", 1464], ["vesicle", 1468], ["proteins", 1476], [",", 1484], ["are", 1486], ["involved", 1490], ["in", 1499], ["synaptic", 1502], ["transmission", 1511], [",", 1523], ["whereas", 1525], ["the", 1533], ["most", 1537], ["abundant", 1542], ["methylated", 1551], ["proteins", 1562], ["identified", 1571], ["from", 1582], ["mouse", 1587], ["embryo", 1593], ["are", 1600], ["transcriptional", 1604], ["regulators", 1620], ["and", 1631], ["RNA", 1635], ["processing", 1639], ["proteins", 1650], [".", 1658]]}
{"context": "The aim of this study was to evaluate the efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder (PTSD). This 12-week, multicenter, double-blind study randomized patients to receive either tiagabine or placebo. Tiagabine (administered in divided doses) was initiated at 4 mg/d (2 mg BID) and individually titrated of up to 4 mg/d weekly to a maximum dose of 16 mg/d. Assessments included the Clinician-Administered PTSD Scale, Clinical Global Impressions of Change, Treatment Outcome PTSD Scale, Davidson Trauma Scale, Connor-Davidson Resilience Scale, Sheehan Disability Scale, Massachusetts General Hospital Sexual Functioning Questionnaire, and Montgomery-Asberg Depression Rating Scale. A total of 232 patients (tiagabine, n = 116; placebo, n = 116) were randomized. There were no significant differences in change from baseline in the Clinician-Administered PTSD Scale total score at final visit for tiagabine compared with placebo (P = 0.85). Similarly, no significant differences were observed with tiagabine on the other efficacy outcome measures (described above) compared with placebo. Tiagabine was generally well tolerated and not associated with weight gain, changes in sexual function, or worsening of depressive symptoms. Tiagabine was not significantly different from placebo in the treatment of symptoms of PTSD. Additional studies are needed to assess the role of drugs that target the gamma-aminobutyric acid system in the treatment of PTSD.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "b5c03080f08845128cbb48af0b93fc6d", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "post-traumatic stress disorder", "token_spans": [[18, 22]], "char_spans": [[104, 133]]}, {"text": "PTSD", "token_spans": [[91, 91], [246, 246], [102, 102], [169, 169], [24, 24], [270, 270]], "char_spans": [[453, 456], [1362, 1365], [522, 525], [901, 904], [136, 139], [1493, 1496]]}]}], "context_tokens": [["The", 0], ["aim", 4], ["of", 8], ["this", 11], ["study", 16], ["was", 22], ["to", 26], ["evaluate", 29], ["the", 38], ["efficacy", 42], ["and", 51], ["tolerability", 55], ["of", 68], ["tiagabine", 71], ["in", 81], ["adult", 84], ["patients", 90], ["with", 99], ["post", 104], ["-", 108], ["traumatic", 109], ["stress", 119], ["disorder", 126], ["(", 135], ["PTSD", 136], [")", 140], [".", 141], ["This", 143], ["12-week", 148], [",", 155], ["multicenter", 157], [",", 168], ["double", 170], ["-", 176], ["blind", 177], ["study", 183], ["randomized", 189], ["patients", 200], ["to", 209], ["receive", 212], ["either", 220], ["tiagabine", 227], ["or", 237], ["placebo", 240], [".", 247], ["Tiagabine", 249], ["(", 259], ["administered", 260], ["in", 273], ["divided", 276], ["doses", 284], [")", 289], ["was", 291], ["initiated", 295], ["at", 305], ["4", 308], ["mg", 310], ["/", 312], ["d", 313], ["(", 315], ["2", 316], ["mg", 318], ["BID", 321], [")", 324], ["and", 326], ["individually", 330], ["titrated", 343], ["of", 352], ["up", 355], ["to", 358], ["4", 361], ["mg", 363], ["/", 365], ["d", 366], ["weekly", 368], ["to", 375], ["a", 378], ["maximum", 380], ["dose", 388], ["of", 393], ["16", 396], ["mg", 399], ["/", 401], ["d", 402], [".", 403], ["Assessments", 405], ["included", 417], ["the", 426], ["Clinician", 430], ["-", 439], ["Administered", 440], ["PTSD", 453], ["Scale", 458], [",", 463], ["Clinical", 465], ["Global", 474], ["Impressions", 481], ["of", 493], ["Change", 496], [",", 502], ["Treatment", 504], ["Outcome", 514], ["PTSD", 522], ["Scale", 527], [",", 532], ["Davidson", 534], ["Trauma", 543], ["Scale", 550], [",", 555], ["Connor", 557], ["-", 563], ["Davidson", 564], ["Resilience", 573], ["Scale", 584], [",", 589], ["Sheehan", 591], ["Disability", 599], ["Scale", 610], [",", 615], ["Massachusetts", 617], ["General", 631], ["Hospital", 639], ["Sexual", 648], ["Functioning", 655], ["Questionnaire", 667], [",", 680], ["and", 682], ["Montgomery", 686], ["-", 696], ["Asberg", 697], ["Depression", 704], ["Rating", 715], ["Scale", 722], [".", 727], ["A", 729], ["total", 731], ["of", 737], ["232", 740], ["patients", 744], ["(", 753], ["tiagabine", 754], [",", 763], ["n", 765], ["=", 767], ["116", 769], [";", 772], ["placebo", 774], [",", 781], ["n", 783], ["=", 785], ["116", 787], [")", 790], ["were", 792], ["randomized", 797], [".", 807], ["There", 809], ["were", 815], ["no", 820], ["significant", 823], ["differences", 835], ["in", 847], ["change", 850], ["from", 857], ["baseline", 862], ["in", 871], ["the", 874], ["Clinician", 878], ["-", 887], ["Administered", 888], ["PTSD", 901], ["Scale", 906], ["total", 912], ["score", 918], ["at", 924], ["final", 927], ["visit", 933], ["for", 939], ["tiagabine", 943], ["compared", 953], ["with", 962], ["placebo", 967], ["(", 975], ["P", 976], ["=", 978], ["0.85", 980], [")", 984], [".", 985], ["Similarly", 987], [",", 996], ["no", 998], ["significant", 1001], ["differences", 1013], ["were", 1025], ["observed", 1030], ["with", 1039], ["tiagabine", 1044], ["on", 1054], ["the", 1057], ["other", 1061], ["efficacy", 1067], ["outcome", 1076], ["measures", 1084], ["(", 1093], ["described", 1094], ["above", 1104], [")", 1109], ["compared", 1111], ["with", 1120], ["placebo", 1125], [".", 1132], ["Tiagabine", 1134], ["was", 1144], ["generally", 1148], ["well", 1158], ["tolerated", 1163], ["and", 1173], ["not", 1177], ["associated", 1181], ["with", 1192], ["weight", 1197], ["gain", 1204], [",", 1208], ["changes", 1210], ["in", 1218], ["sexual", 1221], ["function", 1228], [",", 1236], ["or", 1238], ["worsening", 1241], ["of", 1251], ["depressive", 1254], ["symptoms", 1265], [".", 1273], ["Tiagabine", 1275], ["was", 1285], ["not", 1289], ["significantly", 1293], ["different", 1307], ["from", 1317], ["placebo", 1322], ["in", 1330], ["the", 1333], ["treatment", 1337], ["of", 1347], ["symptoms", 1350], ["of", 1359], ["PTSD", 1362], [".", 1366], ["Additional", 1368], ["studies", 1379], ["are", 1387], ["needed", 1391], ["to", 1398], ["assess", 1401], ["the", 1408], ["role", 1412], ["of", 1417], ["drugs", 1420], ["that", 1426], ["target", 1431], ["the", 1438], ["gamma", 1442], ["-", 1447], ["aminobutyric", 1448], ["acid", 1461], ["system", 1466], ["in", 1473], ["the", 1476], ["treatment", 1480], ["of", 1490], ["PTSD", 1493], [".", 1497]]}
{"context": "Centrosome forms the backbone of cell cycle progression mechanism. Recent debates have occurred regarding the essentiality of centrosome in cell cycle regulation. CEP family protein is the active component of centrosome and plays a vital role in centriole biogenesis and cell cycle progression control. A total of 31 proteins have been categorized into CEP family protein category and many more are under candidate evaluation. Furthermore, by the recent advancements in genomics and proteomics researches, several new CEP proteins have also been characterized. Here we have summarized the importance of CEP family proteins and their regulation mechanism involved in proper cell cycle progression. Further, we have reviewed the detailed molecular mechanism behind the associated pathological phenotypes and the possible therapeutic approaches. Proteins such as CEP57, CEP63, CEP152, CEP164, and CEP215 have been extensively studied with a detailed description of their molecular mechanisms, which are among the primary targets for drug discovery. Moreover, CEP27, CEP55, CEP70, CEP110, CEP120, CEP135, CEP192, CEP250, CEP290, and CEP350 also seem promising for future drug discovery approaches. Since the overview implicates that the overall researches on CEP proteins are not yet able to present significant details required for effective therapeutics development, thus, it is timely to discuss the importance of future investigations in this field.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "bc41177a6b044b729aab22fd26e9d225", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[0, 0], [32, 32], [18, 18]], "char_spans": [[0, 9], [209, 218], [126, 135]]}]}], "context_tokens": [["Centrosome", 0], ["forms", 11], ["the", 17], ["backbone", 21], ["of", 30], ["cell", 33], ["cycle", 38], ["progression", 44], ["mechanism", 56], [".", 65], ["Recent", 67], ["debates", 74], ["have", 82], ["occurred", 87], ["regarding", 96], ["the", 106], ["essentiality", 110], ["of", 123], ["centrosome", 126], ["in", 137], ["cell", 140], ["cycle", 145], ["regulation", 151], [".", 161], ["CEP", 163], ["family", 167], ["protein", 174], ["is", 182], ["the", 185], ["active", 189], ["component", 196], ["of", 206], ["centrosome", 209], ["and", 220], ["plays", 224], ["a", 230], ["vital", 232], ["role", 238], ["in", 243], ["centriole", 246], ["biogenesis", 256], ["and", 267], ["cell", 271], ["cycle", 276], ["progression", 282], ["control", 294], [".", 301], ["A", 303], ["total", 305], ["of", 311], ["31", 314], ["proteins", 317], ["have", 326], ["been", 331], ["categorized", 336], ["into", 348], ["CEP", 353], ["family", 357], ["protein", 364], ["category", 372], ["and", 381], ["many", 385], ["more", 390], ["are", 395], ["under", 399], ["candidate", 405], ["evaluation", 415], [".", 425], ["Furthermore", 427], [",", 438], ["by", 440], ["the", 443], ["recent", 447], ["advancements", 454], ["in", 467], ["genomics", 470], ["and", 479], ["proteomics", 483], ["researches", 494], [",", 504], ["several", 506], ["new", 514], ["CEP", 518], ["proteins", 522], ["have", 531], ["also", 536], ["been", 541], ["characterized", 546], [".", 559], ["Here", 561], ["we", 566], ["have", 569], ["summarized", 574], ["the", 585], ["importance", 589], ["of", 600], ["CEP", 603], ["family", 607], ["proteins", 614], ["and", 623], ["their", 627], ["regulation", 633], ["mechanism", 644], ["involved", 654], ["in", 663], ["proper", 666], ["cell", 673], ["cycle", 678], ["progression", 684], [".", 695], ["Further", 697], [",", 704], ["we", 706], ["have", 709], ["reviewed", 714], ["the", 723], ["detailed", 727], ["molecular", 736], ["mechanism", 746], ["behind", 756], ["the", 763], ["associated", 767], ["pathological", 778], ["phenotypes", 791], ["and", 802], ["the", 806], ["possible", 810], ["therapeutic", 819], ["approaches", 831], [".", 841], ["Proteins", 843], ["such", 852], ["as", 857], ["CEP57", 860], [",", 865], ["CEP63", 867], [",", 872], ["CEP152", 874], [",", 880], ["CEP164", 882], [",", 888], ["and", 890], ["CEP215", 894], ["have", 901], ["been", 906], ["extensively", 911], ["studied", 923], ["with", 931], ["a", 936], ["detailed", 938], ["description", 947], ["of", 959], ["their", 962], ["molecular", 968], ["mechanisms", 978], [",", 988], ["which", 990], ["are", 996], ["among", 1000], ["the", 1006], ["primary", 1010], ["targets", 1018], ["for", 1026], ["drug", 1030], ["discovery", 1035], [".", 1044], ["Moreover", 1046], [",", 1054], ["CEP27", 1056], [",", 1061], ["CEP55", 1063], [",", 1068], ["CEP70", 1070], [",", 1075], ["CEP110", 1077], [",", 1083], ["CEP120", 1085], [",", 1091], ["CEP135", 1093], [",", 1099], ["CEP192", 1101], [",", 1107], ["CEP250", 1109], [",", 1115], ["CEP290", 1117], [",", 1123], ["and", 1125], ["CEP350", 1129], ["also", 1136], ["seem", 1141], ["promising", 1146], ["for", 1156], ["future", 1160], ["drug", 1167], ["discovery", 1172], ["approaches", 1182], [".", 1192], ["Since", 1194], ["the", 1200], ["overview", 1204], ["implicates", 1213], ["that", 1224], ["the", 1229], ["overall", 1233], ["researches", 1241], ["on", 1252], ["CEP", 1255], ["proteins", 1259], ["are", 1268], ["not", 1272], ["yet", 1276], ["able", 1280], ["to", 1285], ["present", 1288], ["significant", 1296], ["details", 1308], ["required", 1316], ["for", 1325], ["effective", 1329], ["therapeutics", 1339], ["development", 1352], [",", 1363], ["thus", 1365], [",", 1369], ["it", 1371], ["is", 1374], ["timely", 1377], ["to", 1384], ["discuss", 1387], ["the", 1395], ["importance", 1399], ["of", 1410], ["future", 1413], ["investigations", 1420], ["in", 1435], ["this", 1438], ["field", 1443], [".", 1448]]}
{"context": "The rarity and the inconsistent criteria for defining atypical meningioma prior to the WHO 2007 classification made its management and prognostic factors poorly understood. Only few articles have addressed the survival rates of WHO-classified atypical meningiomas. The small number or the disproportionate representation of irradiated patients was a weakness for these articles. This study evaluated whether the extent of surgery and receiving adjuvant radiotherapy after an initial operation along with other patient characteristics influenced the recurrence and survival rates of atypical meningiomas. The clinical and surgical notes of the 79 patients with grade II atypical meningioma treated at our center over 13 years were retrospectively evaluated. The histology grading was consistent with WHO 2007 classification. The Simpson grading system was used to assess the extent of surgical resection. Kaplan Meier analysis, Cox multivariate regression analysis, and the Log-rank test were conducted using STATA\u00ae statistical package. The average age at the time of initial operation was 58 years, and 54 % were males. The mean follow-up period was 50 months. In Cox multivariate analysis, only Simpson grading was predictive of recurrence (hazard ratio = 2.22 / 1 increase in Simpson grade. p\u2009=\u20090.003). Simpson grade I patients had a relapse-free survival rate of 97 and 74 % at one and five years, respectively, compared with 88 and 32 % in the subtotal resection group (Simpson grades II to IV). There was no statistically significant correlation between recurrence and subjecting patients to postoperative radiotherapy. Apart from Simpson grade I patients, there was a general trend for worse outcome in irradiated patients. The most important prognostic factor in determining recurrence was Simpson grading. There was no statistically significant impact of adjuvant radiotherapy on the recurrence of atypical meningiomas. Meta-analysis for the existing literature is needed.", "qas": [{"question": "Simpson grading is used to describe resection of which brain tumor?", "answers": ["meningioma"], "qid": "8a4e9bb9b22a4d77b479e8ccadb64015", "question_tokens": [["Simpson", 0], ["grading", 8], ["is", 16], ["used", 19], ["to", 24], ["describe", 27], ["resection", 36], ["of", 46], ["which", 49], ["brain", 55], ["tumor", 61], ["?", 66]], "detected_answers": [{"text": "meningioma", "token_spans": [[9, 9], [101, 101]], "char_spans": [[63, 72], [678, 687]]}]}], "context_tokens": [["The", 0], ["rarity", 4], ["and", 11], ["the", 15], ["inconsistent", 19], ["criteria", 32], ["for", 41], ["defining", 45], ["atypical", 54], ["meningioma", 63], ["prior", 74], ["to", 80], ["the", 83], ["WHO", 87], ["2007", 91], ["classification", 96], ["made", 111], ["its", 116], ["management", 120], ["and", 131], ["prognostic", 135], ["factors", 146], ["poorly", 154], ["understood", 161], [".", 171], ["Only", 173], ["few", 178], ["articles", 182], ["have", 191], ["addressed", 196], ["the", 206], ["survival", 210], ["rates", 219], ["of", 225], ["WHO", 228], ["-", 231], ["classified", 232], ["atypical", 243], ["meningiomas", 252], [".", 263], ["The", 265], ["small", 269], ["number", 275], ["or", 282], ["the", 285], ["disproportionate", 289], ["representation", 306], ["of", 321], ["irradiated", 324], ["patients", 335], ["was", 344], ["a", 348], ["weakness", 350], ["for", 359], ["these", 363], ["articles", 369], [".", 377], ["This", 379], ["study", 384], ["evaluated", 390], ["whether", 400], ["the", 408], ["extent", 412], ["of", 419], ["surgery", 422], ["and", 430], ["receiving", 434], ["adjuvant", 444], ["radiotherapy", 453], ["after", 466], ["an", 472], ["initial", 475], ["operation", 483], ["along", 493], ["with", 499], ["other", 504], ["patient", 510], ["characteristics", 518], ["influenced", 534], ["the", 545], ["recurrence", 549], ["and", 560], ["survival", 564], ["rates", 573], ["of", 579], ["atypical", 582], ["meningiomas", 591], [".", 602], ["The", 604], ["clinical", 608], ["and", 617], ["surgical", 621], ["notes", 630], ["of", 636], ["the", 639], ["79", 643], ["patients", 646], ["with", 655], ["grade", 660], ["II", 666], ["atypical", 669], ["meningioma", 678], ["treated", 689], ["at", 697], ["our", 700], ["center", 704], ["over", 711], ["13", 716], ["years", 719], ["were", 725], ["retrospectively", 730], ["evaluated", 746], [".", 755], ["The", 757], ["histology", 761], ["grading", 771], ["was", 779], ["consistent", 783], ["with", 794], ["WHO", 799], ["2007", 803], ["classification", 808], [".", 822], ["The", 824], ["Simpson", 828], ["grading", 836], ["system", 844], ["was", 851], ["used", 855], ["to", 860], ["assess", 863], ["the", 870], ["extent", 874], ["of", 881], ["surgical", 884], ["resection", 893], [".", 902], ["Kaplan", 904], ["Meier", 911], ["analysis", 917], [",", 925], ["Cox", 927], ["multivariate", 931], ["regression", 944], ["analysis", 955], [",", 963], ["and", 965], ["the", 969], ["Log", 973], ["-", 976], ["rank", 977], ["test", 982], ["were", 987], ["conducted", 992], ["using", 1002], ["STATA", 1008], ["\u00ae", 1013], ["statistical", 1015], ["package", 1027], [".", 1034], ["The", 1036], ["average", 1040], ["age", 1048], ["at", 1052], ["the", 1055], ["time", 1059], ["of", 1064], ["initial", 1067], ["operation", 1075], ["was", 1085], ["58", 1089], ["years", 1092], [",", 1097], ["and", 1099], ["54", 1103], ["%", 1106], ["were", 1108], ["males", 1113], [".", 1118], ["The", 1120], ["mean", 1124], ["follow", 1129], ["-", 1135], ["up", 1136], ["period", 1139], ["was", 1146], ["50", 1150], ["months", 1153], [".", 1159], ["In", 1161], ["Cox", 1164], ["multivariate", 1168], ["analysis", 1181], [",", 1189], ["only", 1191], ["Simpson", 1196], ["grading", 1204], ["was", 1212], ["predictive", 1216], ["of", 1227], ["recurrence", 1230], ["(", 1241], ["hazard", 1242], ["ratio", 1249], ["=", 1255], ["2.22", 1257], ["/", 1262], ["1", 1264], ["increase", 1266], ["in", 1275], ["Simpson", 1278], ["grade", 1286], [".", 1291], ["p", 1293], ["=", 1295], ["0.003", 1297], [")", 1302], [".", 1303], ["Simpson", 1305], ["grade", 1313], ["I", 1319], ["patients", 1321], ["had", 1330], ["a", 1334], ["relapse", 1336], ["-", 1343], ["free", 1344], ["survival", 1349], ["rate", 1358], ["of", 1363], ["97", 1366], ["and", 1369], ["74", 1373], ["%", 1376], ["at", 1378], ["one", 1381], ["and", 1385], ["five", 1389], ["years", 1394], [",", 1399], ["respectively", 1401], [",", 1413], ["compared", 1415], ["with", 1424], ["88", 1429], ["and", 1432], ["32", 1436], ["%", 1439], ["in", 1441], ["the", 1444], ["subtotal", 1448], ["resection", 1457], ["group", 1467], ["(", 1473], ["Simpson", 1474], ["grades", 1482], ["II", 1489], ["to", 1492], ["IV", 1495], [")", 1497], [".", 1498], ["There", 1500], ["was", 1506], ["no", 1510], ["statistically", 1513], ["significant", 1527], ["correlation", 1539], ["between", 1551], ["recurrence", 1559], ["and", 1570], ["subjecting", 1574], ["patients", 1585], ["to", 1594], ["postoperative", 1597], ["radiotherapy", 1611], [".", 1623], ["Apart", 1625], ["from", 1631], ["Simpson", 1636], ["grade", 1644], ["I", 1650], ["patients", 1652], [",", 1660], ["there", 1662], ["was", 1668], ["a", 1672], ["general", 1674], ["trend", 1682], ["for", 1688], ["worse", 1692], ["outcome", 1698], ["in", 1706], ["irradiated", 1709], ["patients", 1720], [".", 1728], ["The", 1730], ["most", 1734], ["important", 1739], ["prognostic", 1749], ["factor", 1760], ["in", 1767], ["determining", 1770], ["recurrence", 1782], ["was", 1793], ["Simpson", 1797], ["grading", 1805], [".", 1812], ["There", 1814], ["was", 1820], ["no", 1824], ["statistically", 1827], ["significant", 1841], ["impact", 1853], ["of", 1860], ["adjuvant", 1863], ["radiotherapy", 1872], ["on", 1885], ["the", 1888], ["recurrence", 1892], ["of", 1903], ["atypical", 1906], ["meningiomas", 1915], [".", 1926], ["Meta", 1928], ["-", 1932], ["analysis", 1933], ["for", 1942], ["the", 1946], ["existing", 1950], ["literature", 1959], ["is", 1970], ["needed", 1973], [".", 1979]]}
{"context": "Mowat-Wilson syndrome (MWS) is a relatively newly described multiple congenital anomaly/mental retardation syndrome. Haploinsufficiency of a gene termed ZFHX1B (also known as SIP1) on chromosome 2 is responsible for this condition, and clinical genetic testing for MWS recently became available. The majority of reports in the literature originate from Northern Europe and Australia. Here we report our clinical experience with 12 patients diagnosed with MWS within a 2-year period of time in the United States, with particular emphasis on clinical characteristics and management strategies. Individuals with this condition have characteristic facial features, including microcephaly, hypertelorism, medially flared and broad eyebrows, prominent columella, pointed chin, and uplifted earlobes, which typically prompt the clinician to consider the diagnosis. Medical issues in our cohort of patients included seizures (75%) with no predeliction for any particular seizure type; agenesis of the corpus callosum (60% of our patients studied); congenital heart defects (75%), particularly involving the pulmonary arteries and/or valves; hypospadias (55% of males); severely impaired or absent speech (100% of individuals over 1 year of age) with relatively spared receptive language; and Hirschsprung disease (50%) or chronic constipation (25%). The incidence of MWS is unknown, but based on the number of patients identified in a short period of time within the US, it is likely greatly under recognized. MWS should be considered in any individual with severely impaired or absent speech, especially in the presence of seizures and anomalies involving the pulmonary arteries (particularly pulmonary artery sling) or pulmonary valves.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "ba508f5b8dfb4fbc83ecf9831706b686", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZFHX1B", "token_spans": [[25, 25]], "char_spans": [[153, 158]]}]}], "context_tokens": [["Mowat", 0], ["-", 5], ["Wilson", 6], ["syndrome", 13], ["(", 22], ["MWS", 23], [")", 26], ["is", 28], ["a", 31], ["relatively", 33], ["newly", 44], ["described", 50], ["multiple", 60], ["congenital", 69], ["anomaly", 80], ["/", 87], ["mental", 88], ["retardation", 95], ["syndrome", 107], [".", 115], ["Haploinsufficiency", 117], ["of", 136], ["a", 139], ["gene", 141], ["termed", 146], ["ZFHX1B", 153], ["(", 160], ["also", 161], ["known", 166], ["as", 172], ["SIP1", 175], [")", 179], ["on", 181], ["chromosome", 184], ["2", 195], ["is", 197], ["responsible", 200], ["for", 212], ["this", 216], ["condition", 221], [",", 230], ["and", 232], ["clinical", 236], ["genetic", 245], ["testing", 253], ["for", 261], ["MWS", 265], ["recently", 269], ["became", 278], ["available", 285], [".", 294], ["The", 296], ["majority", 300], ["of", 309], ["reports", 312], ["in", 320], ["the", 323], ["literature", 327], ["originate", 338], ["from", 348], ["Northern", 353], ["Europe", 362], ["and", 369], ["Australia", 373], [".", 382], ["Here", 384], ["we", 389], ["report", 392], ["our", 399], ["clinical", 403], ["experience", 412], ["with", 423], ["12", 428], ["patients", 431], ["diagnosed", 440], ["with", 450], ["MWS", 455], ["within", 459], ["a", 466], ["2-year", 468], ["period", 475], ["of", 482], ["time", 485], ["in", 490], ["the", 493], ["United", 497], ["States", 504], [",", 510], ["with", 512], ["particular", 517], ["emphasis", 528], ["on", 537], ["clinical", 540], ["characteristics", 549], ["and", 565], ["management", 569], ["strategies", 580], [".", 590], ["Individuals", 592], ["with", 604], ["this", 609], ["condition", 614], ["have", 624], ["characteristic", 629], ["facial", 644], ["features", 651], [",", 659], ["including", 661], ["microcephaly", 671], [",", 683], ["hypertelorism", 685], [",", 698], ["medially", 700], ["flared", 709], ["and", 716], ["broad", 720], ["eyebrows", 726], [",", 734], ["prominent", 736], ["columella", 746], [",", 755], ["pointed", 757], ["chin", 765], [",", 769], ["and", 771], ["uplifted", 775], ["earlobes", 784], [",", 792], ["which", 794], ["typically", 800], ["prompt", 810], ["the", 817], ["clinician", 821], ["to", 831], ["consider", 834], ["the", 843], ["diagnosis", 847], [".", 856], ["Medical", 858], ["issues", 866], ["in", 873], ["our", 876], ["cohort", 880], ["of", 887], ["patients", 890], ["included", 899], ["seizures", 908], ["(", 917], ["75", 918], ["%", 920], [")", 921], ["with", 923], ["no", 928], ["predeliction", 931], ["for", 944], ["any", 948], ["particular", 952], ["seizure", 963], ["type", 971], [";", 975], ["agenesis", 977], ["of", 986], ["the", 989], ["corpus", 993], ["callosum", 1000], ["(", 1009], ["60", 1010], ["%", 1012], ["of", 1014], ["our", 1017], ["patients", 1021], ["studied", 1030], [")", 1037], [";", 1038], ["congenital", 1040], ["heart", 1051], ["defects", 1057], ["(", 1065], ["75", 1066], ["%", 1068], [")", 1069], [",", 1070], ["particularly", 1072], ["involving", 1085], ["the", 1095], ["pulmonary", 1099], ["arteries", 1109], ["and/or", 1118], ["valves", 1125], [";", 1131], ["hypospadias", 1133], ["(", 1145], ["55", 1146], ["%", 1148], ["of", 1150], ["males", 1153], [")", 1158], [";", 1159], ["severely", 1161], ["impaired", 1170], ["or", 1179], ["absent", 1182], ["speech", 1189], ["(", 1196], ["100", 1197], ["%", 1200], ["of", 1202], ["individuals", 1205], ["over", 1217], ["1", 1222], ["year", 1224], ["of", 1229], ["age", 1232], [")", 1235], ["with", 1237], ["relatively", 1242], ["spared", 1253], ["receptive", 1260], ["language", 1270], [";", 1278], ["and", 1280], ["Hirschsprung", 1284], ["disease", 1297], ["(", 1305], ["50", 1306], ["%", 1308], [")", 1309], ["or", 1311], ["chronic", 1314], ["constipation", 1322], ["(", 1335], ["25", 1336], ["%", 1338], [")", 1339], [".", 1340], ["The", 1342], ["incidence", 1346], ["of", 1356], ["MWS", 1359], ["is", 1363], ["unknown", 1366], [",", 1373], ["but", 1375], ["based", 1379], ["on", 1385], ["the", 1388], ["number", 1392], ["of", 1399], ["patients", 1402], ["identified", 1411], ["in", 1422], ["a", 1425], ["short", 1427], ["period", 1433], ["of", 1440], ["time", 1443], ["within", 1448], ["the", 1455], ["US", 1459], [",", 1461], ["it", 1463], ["is", 1466], ["likely", 1469], ["greatly", 1476], ["under", 1484], ["recognized", 1490], [".", 1500], ["MWS", 1502], ["should", 1506], ["be", 1513], ["considered", 1516], ["in", 1527], ["any", 1530], ["individual", 1534], ["with", 1545], ["severely", 1550], ["impaired", 1559], ["or", 1568], ["absent", 1571], ["speech", 1578], [",", 1584], ["especially", 1586], ["in", 1597], ["the", 1600], ["presence", 1604], ["of", 1613], ["seizures", 1616], ["and", 1625], ["anomalies", 1629], ["involving", 1639], ["the", 1649], ["pulmonary", 1653], ["arteries", 1663], ["(", 1672], ["particularly", 1673], ["pulmonary", 1686], ["artery", 1696], ["sling", 1703], [")", 1708], ["or", 1710], ["pulmonary", 1713], ["valves", 1723], [".", 1729]]}
{"context": "Disease patterns in RA vary between the sexes; the condition is more commonly seen in women, who exhibit a more aggressive disease and a poorer long-term outcome. Men, however, are more likely than women to die from extra-articular complications of rheumatoid disease. This chapter discusses the outcome and mortality studies that substantiate these conclusions and then examines the possible mechanisms that may account for them, including the HLA system, seropositivity, compliance, response to therapy and pain threshold. In particular, sex and sex hormones emerge as independent risk factors in rheumatoid disease. The epidemiological evidence points towards a peak age of onset of RA at the time of the menopause in women and towards later in life in men. Premenopausal women may fare better than postmenopausal women with RA. The possible protective effects of the oral contraceptive pill and the dramatic amelioration with pregnancy are well documented. In vivo and in vitro studies have demonstrated that sex hormones interfere with a number of the putative processes involved in the pathogenesis of RA, including immunoregulation, interaction with inflammatory mediators and the cytokine system, and direct effects on cartilage itself. All these observations point towards the importance of gonadal hormones. However, trials on the potential therapeutic use of sex hormones in RA are limited and, as yet, disappointing. Further work is necessary to determine whether the roles of sex hormones are as central protagonists or just supporting cast in the complex arena of rheumatoid disease.", "qas": [{"question": "Is Rheumatoid Arthritis more common in men or women?", "answers": ["Women"], "qid": "dd55ff8b09a7433aa467295dae5b0c62", "question_tokens": [["Is", 0], ["Rheumatoid", 3], ["Arthritis", 14], ["more", 24], ["common", 29], ["in", 36], ["men", 39], ["or", 43], ["women", 46], ["?", 51]], "detected_answers": [{"text": "Women", "token_spans": [[16, 16], [127, 127], [137, 137], [40, 40], [143, 143]], "char_spans": [[86, 90], [721, 725], [775, 779], [198, 202], [817, 821]]}]}], "context_tokens": [["Disease", 0], ["patterns", 8], ["in", 17], ["RA", 20], ["vary", 23], ["between", 28], ["the", 36], ["sexes", 40], [";", 45], ["the", 47], ["condition", 51], ["is", 61], ["more", 64], ["commonly", 69], ["seen", 78], ["in", 83], ["women", 86], [",", 91], ["who", 93], ["exhibit", 97], ["a", 105], ["more", 107], ["aggressive", 112], ["disease", 123], ["and", 131], ["a", 135], ["poorer", 137], ["long", 144], ["-", 148], ["term", 149], ["outcome", 154], [".", 161], ["Men", 163], [",", 166], ["however", 168], [",", 175], ["are", 177], ["more", 181], ["likely", 186], ["than", 193], ["women", 198], ["to", 204], ["die", 207], ["from", 211], ["extra", 216], ["-", 221], ["articular", 222], ["complications", 232], ["of", 246], ["rheumatoid", 249], ["disease", 260], [".", 267], ["This", 269], ["chapter", 274], ["discusses", 282], ["the", 292], ["outcome", 296], ["and", 304], ["mortality", 308], ["studies", 318], ["that", 326], ["substantiate", 331], ["these", 344], ["conclusions", 350], ["and", 362], ["then", 366], ["examines", 371], ["the", 380], ["possible", 384], ["mechanisms", 393], ["that", 404], ["may", 409], ["account", 413], ["for", 421], ["them", 425], [",", 429], ["including", 431], ["the", 441], ["HLA", 445], ["system", 449], [",", 455], ["seropositivity", 457], [",", 471], ["compliance", 473], [",", 483], ["response", 485], ["to", 494], ["therapy", 497], ["and", 505], ["pain", 509], ["threshold", 514], [".", 523], ["In", 525], ["particular", 528], [",", 538], ["sex", 540], ["and", 544], ["sex", 548], ["hormones", 552], ["emerge", 561], ["as", 568], ["independent", 571], ["risk", 583], ["factors", 588], ["in", 596], ["rheumatoid", 599], ["disease", 610], [".", 617], ["The", 619], ["epidemiological", 623], ["evidence", 639], ["points", 648], ["towards", 655], ["a", 663], ["peak", 665], ["age", 670], ["of", 674], ["onset", 677], ["of", 683], ["RA", 686], ["at", 689], ["the", 692], ["time", 696], ["of", 701], ["the", 704], ["menopause", 708], ["in", 718], ["women", 721], ["and", 727], ["towards", 731], ["later", 739], ["in", 745], ["life", 748], ["in", 753], ["men", 756], [".", 759], ["Premenopausal", 761], ["women", 775], ["may", 781], ["fare", 785], ["better", 790], ["than", 797], ["postmenopausal", 802], ["women", 817], ["with", 823], ["RA", 828], [".", 830], ["The", 832], ["possible", 836], ["protective", 845], ["effects", 856], ["of", 864], ["the", 867], ["oral", 871], ["contraceptive", 876], ["pill", 890], ["and", 895], ["the", 899], ["dramatic", 903], ["amelioration", 912], ["with", 925], ["pregnancy", 930], ["are", 940], ["well", 944], ["documented", 949], [".", 959], ["In", 961], ["vivo", 964], ["and", 969], ["in", 973], ["vitro", 976], ["studies", 982], ["have", 990], ["demonstrated", 995], ["that", 1008], ["sex", 1013], ["hormones", 1017], ["interfere", 1026], ["with", 1036], ["a", 1041], ["number", 1043], ["of", 1050], ["the", 1053], ["putative", 1057], ["processes", 1066], ["involved", 1076], ["in", 1085], ["the", 1088], ["pathogenesis", 1092], ["of", 1105], ["RA", 1108], [",", 1110], ["including", 1112], ["immunoregulation", 1122], [",", 1138], ["interaction", 1140], ["with", 1152], ["inflammatory", 1157], ["mediators", 1170], ["and", 1180], ["the", 1184], ["cytokine", 1188], ["system", 1197], [",", 1203], ["and", 1205], ["direct", 1209], ["effects", 1216], ["on", 1224], ["cartilage", 1227], ["itself", 1237], [".", 1243], ["All", 1245], ["these", 1249], ["observations", 1255], ["point", 1268], ["towards", 1274], ["the", 1282], ["importance", 1286], ["of", 1297], ["gonadal", 1300], ["hormones", 1308], [".", 1316], ["However", 1318], [",", 1325], ["trials", 1327], ["on", 1334], ["the", 1337], ["potential", 1341], ["therapeutic", 1351], ["use", 1363], ["of", 1367], ["sex", 1370], ["hormones", 1374], ["in", 1383], ["RA", 1386], ["are", 1389], ["limited", 1393], ["and", 1401], [",", 1404], ["as", 1406], ["yet", 1409], [",", 1412], ["disappointing", 1414], [".", 1427], ["Further", 1429], ["work", 1437], ["is", 1442], ["necessary", 1445], ["to", 1455], ["determine", 1458], ["whether", 1468], ["the", 1476], ["roles", 1480], ["of", 1486], ["sex", 1489], ["hormones", 1493], ["are", 1502], ["as", 1506], ["central", 1509], ["protagonists", 1517], ["or", 1530], ["just", 1533], ["supporting", 1538], ["cast", 1549], ["in", 1554], ["the", 1557], ["complex", 1561], ["arena", 1569], ["of", 1575], ["rheumatoid", 1578], ["disease", 1589], [".", 1596]]}
{"context": "The spectrin heterodimer is formed by the antiparallel lateral association of an alpha and a beta subunit, each of which comprises largely a series of homologous triple-helical motifs. Initiation of dimer assembly involves strong binding between complementary motifs near the actin-binding end of the dimer. In this study, the mechanism of lateral spectrin association at this dimer nucleation site was investigated using the analytical ultracentrifuge to analyze heterodimers formed from recombinant peptides containing two or four homologous motifs from each subunit (alpha20-21/beta1-2; alpha18-21/beta1-4). Both the two-motif and four-motif dimer associations were weakened substantially with increasing salt concentration, indicating that electrostatic interactions are important for the dimer initiation process. Modeling of the electrostatic potential on the surface of the alpha20 and beta2 motifs showed that the side of the motifs comprising the A and B helices is the most favorable for association, with an area of positive electrostatic potential on the AB face of the beta2 motif opposite negative potential on the AB face of the alpha20 motif and vise versa. Protease protection analysis of the alpha20-21/beta1-2 dimer showed that multiple trypsin and proteinase K sites in the A helices of the beta2 and alpha21 motifs become buried upon dimer formation. Together, these data support a model where complementary long range electrostatic interactions on the AB faces of the triple-helical motifs in the dimer nucleation site initiate the correct pairing of motifs, i.e. alpha21-beta1 and alpha20-beta2. After initial docking of these complementary triple-helical motifs, this association is probably stabilized by subsequent formation of stronger hydrophobic interactions in a complex involving the A helices of both subunits and possibly most of the AB faces. The beta subunit A helix in particular appears to be buried in the dimer interface.", "qas": [{"question": "Alpha-spectrin and beta-spectrin subunits form parallel or antiparallel heterodimers?", "answers": ["antiparallel"], "qid": "341b721c73f64225b0bb8a8e9b4fdbef", "question_tokens": [["Alpha", 0], ["-", 5], ["spectrin", 6], ["and", 15], ["beta", 19], ["-", 23], ["spectrin", 24], ["subunits", 33], ["form", 42], ["parallel", 47], ["or", 56], ["antiparallel", 59], ["heterodimers", 72], ["?", 84]], "detected_answers": [{"text": "antiparallel", "token_spans": [[7, 7]], "char_spans": [[42, 53]]}]}], "context_tokens": [["The", 0], ["spectrin", 4], ["heterodimer", 13], ["is", 25], ["formed", 28], ["by", 35], ["the", 38], ["antiparallel", 42], ["lateral", 55], ["association", 63], ["of", 75], ["an", 78], ["alpha", 81], ["and", 87], ["a", 91], ["beta", 93], ["subunit", 98], [",", 105], ["each", 107], ["of", 112], ["which", 115], ["comprises", 121], ["largely", 131], ["a", 139], ["series", 141], ["of", 148], ["homologous", 151], ["triple", 162], ["-", 168], ["helical", 169], ["motifs", 177], [".", 183], ["Initiation", 185], ["of", 196], ["dimer", 199], ["assembly", 205], ["involves", 214], ["strong", 223], ["binding", 230], ["between", 238], ["complementary", 246], ["motifs", 260], ["near", 267], ["the", 272], ["actin", 276], ["-", 281], ["binding", 282], ["end", 290], ["of", 294], ["the", 297], ["dimer", 301], [".", 306], ["In", 308], ["this", 311], ["study", 316], [",", 321], ["the", 323], ["mechanism", 327], ["of", 337], ["lateral", 340], ["spectrin", 348], ["association", 357], ["at", 369], ["this", 372], ["dimer", 377], ["nucleation", 383], ["site", 394], ["was", 399], ["investigated", 403], ["using", 416], ["the", 422], ["analytical", 426], ["ultracentrifuge", 437], ["to", 453], ["analyze", 456], ["heterodimers", 464], ["formed", 477], ["from", 484], ["recombinant", 489], ["peptides", 501], ["containing", 510], ["two", 521], ["or", 525], ["four", 528], ["homologous", 533], ["motifs", 544], ["from", 551], ["each", 556], ["subunit", 561], ["(", 569], ["alpha20", 570], ["-", 577], ["21/beta1", 578], ["-", 586], ["2", 587], [";", 588], ["alpha18", 590], ["-", 597], ["21/beta1", 598], ["-", 606], ["4", 607], [")", 608], [".", 609], ["Both", 611], ["the", 616], ["two", 620], ["-", 623], ["motif", 624], ["and", 630], ["four", 634], ["-", 638], ["motif", 639], ["dimer", 645], ["associations", 651], ["were", 664], ["weakened", 669], ["substantially", 678], ["with", 692], ["increasing", 697], ["salt", 708], ["concentration", 713], [",", 726], ["indicating", 728], ["that", 739], ["electrostatic", 744], ["interactions", 758], ["are", 771], ["important", 775], ["for", 785], ["the", 789], ["dimer", 793], ["initiation", 799], ["process", 810], [".", 817], ["Modeling", 819], ["of", 828], ["the", 831], ["electrostatic", 835], ["potential", 849], ["on", 859], ["the", 862], ["surface", 866], ["of", 874], ["the", 877], ["alpha20", 881], ["and", 889], ["beta2", 893], ["motifs", 899], ["showed", 906], ["that", 913], ["the", 918], ["side", 922], ["of", 927], ["the", 930], ["motifs", 934], ["comprising", 941], ["the", 952], ["A", 956], ["and", 958], ["B", 962], ["helices", 964], ["is", 972], ["the", 975], ["most", 979], ["favorable", 984], ["for", 994], ["association", 998], [",", 1009], ["with", 1011], ["an", 1016], ["area", 1019], ["of", 1024], ["positive", 1027], ["electrostatic", 1036], ["potential", 1050], ["on", 1060], ["the", 1063], ["AB", 1067], ["face", 1070], ["of", 1075], ["the", 1078], ["beta2", 1082], ["motif", 1088], ["opposite", 1094], ["negative", 1103], ["potential", 1112], ["on", 1122], ["the", 1125], ["AB", 1129], ["face", 1132], ["of", 1137], ["the", 1140], ["alpha20", 1144], ["motif", 1152], ["and", 1158], ["vise", 1162], ["versa", 1167], [".", 1172], ["Protease", 1174], ["protection", 1183], ["analysis", 1194], ["of", 1203], ["the", 1206], ["alpha20", 1210], ["-", 1217], ["21/beta1", 1218], ["-", 1226], ["2", 1227], ["dimer", 1229], ["showed", 1235], ["that", 1242], ["multiple", 1247], ["trypsin", 1256], ["and", 1264], ["proteinase", 1268], ["K", 1279], ["sites", 1281], ["in", 1287], ["the", 1290], ["A", 1294], ["helices", 1296], ["of", 1304], ["the", 1307], ["beta2", 1311], ["and", 1317], ["alpha21", 1321], ["motifs", 1329], ["become", 1336], ["buried", 1343], ["upon", 1350], ["dimer", 1355], ["formation", 1361], [".", 1370], ["Together", 1372], [",", 1380], ["these", 1382], ["data", 1388], ["support", 1393], ["a", 1401], ["model", 1403], ["where", 1409], ["complementary", 1415], ["long", 1429], ["range", 1434], ["electrostatic", 1440], ["interactions", 1454], ["on", 1467], ["the", 1470], ["AB", 1474], ["faces", 1477], ["of", 1483], ["the", 1486], ["triple", 1490], ["-", 1496], ["helical", 1497], ["motifs", 1505], ["in", 1512], ["the", 1515], ["dimer", 1519], ["nucleation", 1525], ["site", 1536], ["initiate", 1541], ["the", 1550], ["correct", 1554], ["pairing", 1562], ["of", 1570], ["motifs", 1573], [",", 1579], ["i.e.", 1581], ["alpha21-beta1", 1586], ["and", 1600], ["alpha20-beta2", 1604], [".", 1617], ["After", 1619], ["initial", 1625], ["docking", 1633], ["of", 1641], ["these", 1644], ["complementary", 1650], ["triple", 1664], ["-", 1670], ["helical", 1671], ["motifs", 1679], [",", 1685], ["this", 1687], ["association", 1692], ["is", 1704], ["probably", 1707], ["stabilized", 1716], ["by", 1727], ["subsequent", 1730], ["formation", 1741], ["of", 1751], ["stronger", 1754], ["hydrophobic", 1763], ["interactions", 1775], ["in", 1788], ["a", 1791], ["complex", 1793], ["involving", 1801], ["the", 1811], ["A", 1815], ["helices", 1817], ["of", 1825], ["both", 1828], ["subunits", 1833], ["and", 1842], ["possibly", 1846], ["most", 1855], ["of", 1860], ["the", 1863], ["AB", 1867], ["faces", 1870], [".", 1875], ["The", 1877], ["beta", 1881], ["subunit", 1886], ["A", 1894], ["helix", 1896], ["in", 1902], ["particular", 1905], ["appears", 1916], ["to", 1924], ["be", 1927], ["buried", 1930], ["in", 1937], ["the", 1940], ["dimer", 1944], ["interface", 1950], [".", 1959]]}
{"context": "Previously, using a chromosomal reversion assay system, we established that an adaptive mutagenic process occurs in nongrowing Bacillus subtilis cells under stress, and we demonstrated that multiple mechanisms are involved in generating these mutations (41, 43). In an attempt to delineate how these mutations are generated, we began an investigation into whether or not transcription and transcription-associated proteins influence adaptive mutagenesis. In B. subtilis, the Mfd protein (transcription repair coupling factor) facilitates removal of RNA polymerase stalled at transcriptional blockages and recruitment of repair proteins to DNA lesions on the transcribed strand. Here we demonstrate that the loss of Mfd has a depressive effect on stationary-phase mutagenesis. An association between Mfd mutagenesis and aspects of transcription is discussed.", "qas": [{"question": "In which phase of cell cycle does  stress-induced transcription-associated mutagenesis (TAM) occur?", "answers": ["stationary phase", "stationary-phase"], "qid": "91db4f5a6e754a4889b60c8eb22bc009", "question_tokens": [["In", 0], ["which", 3], ["phase", 9], ["of", 15], ["cell", 18], ["cycle", 23], ["does", 29], [" ", 34], ["stress", 35], ["-", 41], ["induced", 42], ["transcription", 50], ["-", 63], ["associated", 64], ["mutagenesis", 75], ["(", 87], ["TAM", 88], [")", 91], ["occur", 93], ["?", 98]], "detected_answers": [{"text": "stationary phase", "token_spans": [[120, 122]], "char_spans": [[746, 761]]}]}], "context_tokens": [["Previously", 0], [",", 10], ["using", 12], ["a", 18], ["chromosomal", 20], ["reversion", 32], ["assay", 42], ["system", 48], [",", 54], ["we", 56], ["established", 59], ["that", 71], ["an", 76], ["adaptive", 79], ["mutagenic", 88], ["process", 98], ["occurs", 106], ["in", 113], ["nongrowing", 116], ["Bacillus", 127], ["subtilis", 136], ["cells", 145], ["under", 151], ["stress", 157], [",", 163], ["and", 165], ["we", 169], ["demonstrated", 172], ["that", 185], ["multiple", 190], ["mechanisms", 199], ["are", 210], ["involved", 214], ["in", 223], ["generating", 226], ["these", 237], ["mutations", 243], ["(", 253], ["41", 254], [",", 256], ["43", 258], [")", 260], [".", 261], ["In", 263], ["an", 266], ["attempt", 269], ["to", 277], ["delineate", 280], ["how", 290], ["these", 294], ["mutations", 300], ["are", 310], ["generated", 314], [",", 323], ["we", 325], ["began", 328], ["an", 334], ["investigation", 337], ["into", 351], ["whether", 356], ["or", 364], ["not", 367], ["transcription", 371], ["and", 385], ["transcription", 389], ["-", 402], ["associated", 403], ["proteins", 414], ["influence", 423], ["adaptive", 433], ["mutagenesis", 442], [".", 453], ["In", 455], ["B.", 458], ["subtilis", 461], [",", 469], ["the", 471], ["Mfd", 475], ["protein", 479], ["(", 487], ["transcription", 488], ["repair", 502], ["coupling", 509], ["factor", 518], [")", 524], ["facilitates", 526], ["removal", 538], ["of", 546], ["RNA", 549], ["polymerase", 553], ["stalled", 564], ["at", 572], ["transcriptional", 575], ["blockages", 591], ["and", 601], ["recruitment", 605], ["of", 617], ["repair", 620], ["proteins", 627], ["to", 636], ["DNA", 639], ["lesions", 643], ["on", 651], ["the", 654], ["transcribed", 658], ["strand", 670], [".", 676], ["Here", 678], ["we", 683], ["demonstrate", 686], ["that", 698], ["the", 703], ["loss", 707], ["of", 712], ["Mfd", 715], ["has", 719], ["a", 723], ["depressive", 725], ["effect", 736], ["on", 743], ["stationary", 746], ["-", 756], ["phase", 757], ["mutagenesis", 763], [".", 774], ["An", 776], ["association", 779], ["between", 791], ["Mfd", 799], ["mutagenesis", 803], ["and", 815], ["aspects", 819], ["of", 827], ["transcription", 830], ["is", 844], ["discussed", 847], [".", 856]]}
{"context": "Methicillin-resistant Staphylococcus aureus (MRSA) burden is increasing worldwide in hospitals [healthcare-associated (HA)-MRSA] and in communities [community-associated (CA)-MRSA]. However, the impact of CA-MRSA within hospitals remains limited, particularly in Latin America. A countrywide representative survey of S. aureus infections was performed in Argentina by analyzing 591 clinical isolates from 66 hospitals in a prospective cross-sectional, multicenter study (Nov-2009). This work involved healthcare-onset infections-(HAHO, >48 hospitalization hours) and community-onset (CO) infections [including both, infections (HACO) in patients with healthcare-associated risk-factors (HRFs) and infections (CACO) in those without HRFs]. MRSA strains were genetically typed as CA-MRSA and HA-MRSA genotypes (CA-MRSAG and HA-MRSAG) by SCCmec- and spa-typing, PFGE, MLST and virulence genes profile by PCR. Considering all isolates, 63% were from CO-infections and 55% were MRSA [39% CA-MRSAG and 16% HA-MRSAG]. A significantly higher MRSA proportion among CO- than HAHO-S. aureus infections was detected (58% vs 49%); mainly in children (62% vs 43%). The CA-MRSAG/HA-MRSAG have accounted for 16%/33% of HAHO-, 39%/13% of HACO- and 60.5%/0% of CACO-infections. Regarding the epidemiological associations identified in multivariate models for patients with healthcare-onset CA-MRSAG infections, CA-MRSAG behave like HA-MRSAG within hospitals but children were the highest risk group for healthcare-onset CA-MRSAG infections. Most CA-MRSAG belonged to two major clones: PFGE-type N-ST30-SCCmecIVc-t019-PVL(+) and PFGE-type I-ST5-IV-SCCmecIVa-t311-PVL(+) (45% each). The ST5-IV-PVL(+)/ST30-IV-PVL(+) clones have caused 31%/33% of all infections, 20%/4% of HAHO-, 43%/23% of HACO- and 35%/60% of CACO- infections, with significant differences by age groups (children/adults) and geographical regions. Importantly, an isolate belonging to USA300-0114-(ST8-SCCmecIVa-spat008-PVL(+)-ACME(+)) was detected for the first time in Argentina. Most of HA-MRSAG (66%) were related to the Cordobes/Chilean clone-(PFGE-type A-ST5-SCCmecI-t149) causing 18% of all infections (47% of HAHO- and 13% of HACO-infections). Results strongly suggest that the CA-MRSA clone ST5-IV-PVL(+) has begun to spread within hospitals, replacing the traditional Cordobes/Chilean-HA-MRSA clone ST5-I-PVL(-), mainly in children. Importantly, a growing MRSA reservoir in the community was associated with spreading of two CA-MRSA clones: ST5-IV-PVL(+), mainly in children with HRFs, and ST30-IV-PVL(+) in adults without HRFs. This is the first nationwide study in Argentina providing information about the molecular and clinical epidemiology of CA-MRSA, particularly within hospitals, which is essential for designing effective control measures in this country and worldwide.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "d454454df5fe41c28b4fd7ea8089ab83", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[464, 464], [139, 139], [131, 131], [37, 37], [6, 6], [186, 186], [202, 202], [486, 486], [501, 501], [557, 557], [514, 514], [143, 143]], "char_spans": [[2237, 2240], [781, 784], [739, 742], [208, 211], [45, 48], [973, 976], [1034, 1037], [2346, 2349], [2414, 2417], [2709, 2712], [2486, 2489], [793, 796]]}]}], "context_tokens": [["Methicillin", 0], ["-", 11], ["resistant", 12], ["Staphylococcus", 22], ["aureus", 37], ["(", 44], ["MRSA", 45], [")", 49], ["burden", 51], ["is", 58], ["increasing", 61], ["worldwide", 72], ["in", 82], ["hospitals", 85], ["[", 95], ["healthcare", 96], ["-", 106], ["associated", 107], ["(", 118], ["HA)-MRSA", 119], ["]", 127], ["and", 129], ["in", 133], ["communities", 136], ["[", 148], ["community", 149], ["-", 158], ["associated", 159], ["(", 170], ["CA)-MRSA].", 171], ["However", 182], [",", 189], ["the", 191], ["impact", 195], ["of", 202], ["CA", 205], ["-", 207], ["MRSA", 208], ["within", 213], ["hospitals", 220], ["remains", 230], ["limited", 238], [",", 245], ["particularly", 247], ["in", 260], ["Latin", 263], ["America", 269], [".", 276], ["A", 278], ["countrywide", 280], ["representative", 292], ["survey", 307], ["of", 314], ["S.", 317], ["aureus", 320], ["infections", 327], ["was", 338], ["performed", 342], ["in", 352], ["Argentina", 355], ["by", 365], ["analyzing", 368], ["591", 378], ["clinical", 382], ["isolates", 391], ["from", 400], ["66", 405], ["hospitals", 408], ["in", 418], ["a", 421], ["prospective", 423], ["cross", 435], ["-", 440], ["sectional", 441], [",", 450], ["multicenter", 452], ["study", 464], ["(", 470], ["Nov-2009", 471], [")", 479], [".", 480], ["This", 482], ["work", 487], ["involved", 492], ["healthcare", 501], ["-", 511], ["onset", 512], ["infections-(HAHO", 518], [",", 534], [">", 536], ["48", 537], ["hospitalization", 540], ["hours", 556], [")", 561], ["and", 563], ["community", 567], ["-", 576], ["onset", 577], ["(", 583], ["CO", 584], [")", 586], ["infections", 588], ["[", 599], ["including", 600], ["both", 610], [",", 614], ["infections", 616], ["(", 627], ["HACO", 628], [")", 632], ["in", 634], ["patients", 637], ["with", 646], ["healthcare", 651], ["-", 661], ["associated", 662], ["risk", 673], ["-", 677], ["factors", 678], ["(", 686], ["HRFs", 687], [")", 691], ["and", 693], ["infections", 697], ["(", 708], ["CACO", 709], [")", 713], ["in", 715], ["those", 718], ["without", 724], ["HRFs].", 732], ["MRSA", 739], ["strains", 744], ["were", 752], ["genetically", 757], ["typed", 769], ["as", 775], ["CA", 778], ["-", 780], ["MRSA", 781], ["and", 786], ["HA", 790], ["-", 792], ["MRSA", 793], ["genotypes", 798], ["(", 808], ["CA", 809], ["-", 811], ["MRSAG", 812], ["and", 818], ["HA", 822], ["-", 824], ["MRSAG", 825], [")", 830], ["by", 832], ["SCCmec-", 835], ["and", 843], ["spa", 847], ["-", 850], ["typing", 851], [",", 857], ["PFGE", 859], [",", 863], ["MLST", 865], ["and", 870], ["virulence", 874], ["genes", 884], ["profile", 890], ["by", 898], ["PCR", 901], [".", 904], ["Considering", 906], ["all", 918], ["isolates", 922], [",", 930], ["63", 932], ["%", 934], ["were", 936], ["from", 941], ["CO", 946], ["-", 948], ["infections", 949], ["and", 960], ["55", 964], ["%", 966], ["were", 968], ["MRSA", 973], ["[", 978], ["39", 979], ["%", 981], ["CA", 983], ["-", 985], ["MRSAG", 986], ["and", 992], ["16", 996], ["%", 998], ["HA", 1000], ["-", 1002], ["MRSAG].", 1003], ["A", 1011], ["significantly", 1013], ["higher", 1027], ["MRSA", 1034], ["proportion", 1039], ["among", 1050], ["CO-", 1056], ["than", 1060], ["HAHO", 1065], ["-", 1069], ["S.", 1070], ["aureus", 1073], ["infections", 1080], ["was", 1091], ["detected", 1095], ["(", 1104], ["58", 1105], ["%", 1107], ["vs", 1109], ["49", 1112], ["%", 1114], [")", 1115], [";", 1116], ["mainly", 1118], ["in", 1125], ["children", 1128], ["(", 1137], ["62", 1138], ["%", 1140], ["vs", 1142], ["43", 1145], ["%", 1147], [")", 1148], [".", 1149], ["The", 1151], ["CA", 1155], ["-", 1157], ["MRSAG", 1158], ["/", 1163], ["HA", 1164], ["-", 1166], ["MRSAG", 1167], ["have", 1173], ["accounted", 1178], ["for", 1188], ["16%/33", 1192], ["%", 1198], ["of", 1200], ["HAHO-", 1203], [",", 1208], ["39%/13", 1210], ["%", 1216], ["of", 1218], ["HACO-", 1221], ["and", 1227], ["60.5%/0", 1231], ["%", 1238], ["of", 1240], ["CACO", 1243], ["-", 1247], ["infections", 1248], [".", 1258], ["Regarding", 1260], ["the", 1270], ["epidemiological", 1274], ["associations", 1290], ["identified", 1303], ["in", 1314], ["multivariate", 1317], ["models", 1330], ["for", 1337], ["patients", 1341], ["with", 1350], ["healthcare", 1355], ["-", 1365], ["onset", 1366], ["CA", 1372], ["-", 1374], ["MRSAG", 1375], ["infections", 1381], [",", 1391], ["CA", 1393], ["-", 1395], ["MRSAG", 1396], ["behave", 1402], ["like", 1409], ["HA", 1414], ["-", 1416], ["MRSAG", 1417], ["within", 1423], ["hospitals", 1430], ["but", 1440], ["children", 1444], ["were", 1453], ["the", 1458], ["highest", 1462], ["risk", 1470], ["group", 1475], ["for", 1481], ["healthcare", 1485], ["-", 1495], ["onset", 1496], ["CA", 1502], ["-", 1504], ["MRSAG", 1505], ["infections", 1511], [".", 1521], ["Most", 1523], ["CA", 1528], ["-", 1530], ["MRSAG", 1531], ["belonged", 1537], ["to", 1546], ["two", 1549], ["major", 1553], ["clones", 1559], [":", 1565], ["PFGE", 1567], ["-", 1571], ["type", 1572], ["N", 1577], ["-", 1578], ["ST30-SCCmecIVc", 1579], ["-", 1593], ["t019-PVL(+", 1594], [")", 1604], ["and", 1606], ["PFGE", 1610], ["-", 1614], ["type", 1615], ["I", 1620], ["-", 1621], ["ST5-IV", 1622], ["-", 1628], ["SCCmecIVa", 1629], ["-", 1638], ["t311-PVL(+", 1639], [")", 1649], ["(", 1651], ["45", 1652], ["%", 1654], ["each", 1656], [")", 1660], [".", 1661], ["The", 1663], ["ST5-IV", 1667], ["-", 1673], ["PVL(+)/ST30-IV", 1674], ["-", 1688], ["PVL(+", 1689], [")", 1694], ["clones", 1696], ["have", 1703], ["caused", 1708], ["31%/33", 1715], ["%", 1721], ["of", 1723], ["all", 1726], ["infections", 1730], [",", 1740], ["20%/4", 1742], ["%", 1747], ["of", 1749], ["HAHO-", 1752], [",", 1757], ["43%/23", 1759], ["%", 1765], ["of", 1767], ["HACO-", 1770], ["and", 1776], ["35%/60", 1780], ["%", 1786], ["of", 1788], ["CACO-", 1791], ["infections", 1797], [",", 1807], ["with", 1809], ["significant", 1814], ["differences", 1826], ["by", 1838], ["age", 1841], ["groups", 1845], ["(", 1852], ["children", 1853], ["/", 1861], ["adults", 1862], [")", 1868], ["and", 1870], ["geographical", 1874], ["regions", 1887], [".", 1894], ["Importantly", 1896], [",", 1907], ["an", 1909], ["isolate", 1912], ["belonging", 1920], ["to", 1930], ["USA300", 1933], ["-", 1939], ["0114-(ST8-SCCmecIVa", 1940], ["-", 1959], ["spat008-PVL(+)-ACME(+", 1960], [")", 1981], [")", 1982], ["was", 1984], ["detected", 1988], ["for", 1997], ["the", 2001], ["first", 2005], ["time", 2011], ["in", 2016], ["Argentina", 2019], [".", 2028], ["Most", 2030], ["of", 2035], ["HA", 2038], ["-", 2040], ["MRSAG", 2041], ["(", 2047], ["66", 2048], ["%", 2050], [")", 2051], ["were", 2053], ["related", 2058], ["to", 2066], ["the", 2069], ["Cordobes", 2073], ["/", 2081], ["Chilean", 2082], ["clone-(PFGE", 2090], ["-", 2101], ["type", 2102], ["A", 2107], ["-", 2108], ["ST5-SCCmecI", 2109], ["-", 2120], ["t149", 2121], [")", 2125], ["causing", 2127], ["18", 2135], ["%", 2137], ["of", 2139], ["all", 2142], ["infections", 2146], ["(", 2157], ["47", 2158], ["%", 2160], ["of", 2162], ["HAHO-", 2165], ["and", 2171], ["13", 2175], ["%", 2177], ["of", 2179], ["HACO", 2182], ["-", 2186], ["infections", 2187], [")", 2197], [".", 2198], ["Results", 2200], ["strongly", 2208], ["suggest", 2217], ["that", 2225], ["the", 2230], ["CA", 2234], ["-", 2236], ["MRSA", 2237], ["clone", 2242], ["ST5-IV", 2248], ["-", 2254], ["PVL(+", 2255], [")", 2260], ["has", 2262], ["begun", 2266], ["to", 2272], ["spread", 2275], ["within", 2282], ["hospitals", 2289], [",", 2298], ["replacing", 2300], ["the", 2310], ["traditional", 2314], ["Cordobes", 2326], ["/", 2334], ["Chilean", 2335], ["-", 2342], ["HA", 2343], ["-", 2345], ["MRSA", 2346], ["clone", 2351], ["ST5-I", 2357], ["-", 2362], ["PVL(-", 2363], [")", 2368], [",", 2369], ["mainly", 2371], ["in", 2378], ["children", 2381], [".", 2389], ["Importantly", 2391], [",", 2402], ["a", 2404], ["growing", 2406], ["MRSA", 2414], ["reservoir", 2419], ["in", 2429], ["the", 2432], ["community", 2436], ["was", 2446], ["associated", 2450], ["with", 2461], ["spreading", 2466], ["of", 2476], ["two", 2479], ["CA", 2483], ["-", 2485], ["MRSA", 2486], ["clones", 2491], [":", 2497], ["ST5-IV", 2499], ["-", 2505], ["PVL(+", 2506], [")", 2511], [",", 2512], ["mainly", 2514], ["in", 2521], ["children", 2524], ["with", 2533], ["HRFs", 2538], [",", 2542], ["and", 2544], ["ST30-IV", 2548], ["-", 2555], ["PVL(+", 2556], [")", 2561], ["in", 2563], ["adults", 2566], ["without", 2573], ["HRFs", 2581], [".", 2585], ["This", 2587], ["is", 2592], ["the", 2595], ["first", 2599], ["nationwide", 2605], ["study", 2616], ["in", 2622], ["Argentina", 2625], ["providing", 2635], ["information", 2645], ["about", 2657], ["the", 2663], ["molecular", 2667], ["and", 2677], ["clinical", 2681], ["epidemiology", 2690], ["of", 2703], ["CA", 2706], ["-", 2708], ["MRSA", 2709], [",", 2713], ["particularly", 2715], ["within", 2728], ["hospitals", 2735], [",", 2744], ["which", 2746], ["is", 2752], ["essential", 2755], ["for", 2765], ["designing", 2769], ["effective", 2779], ["control", 2789], ["measures", 2797], ["in", 2806], ["this", 2809], ["country", 2814], ["and", 2822], ["worldwide", 2826], [".", 2835]]}
{"context": "Upon infection of a mammalian host, Bacillus anthracis responds to host cues, and particularly to elevated temperature (37\u00b0C) and bicarbonate/CO2 concentrations, with increased expression of virulence factors that include the anthrax toxins and extracellular capsular layer. This response requires the presence of the pXO1 virulence plasmid-encoded pleiotropic regulator AtxA. To better understand the genetic basis of this response, we utilized a controlled in vitro system and Next Generation sequencing to determine and compare RNA expression profiles of the parental strain and an isogenic AtxA-deficient strain in a 2 \u00d7 2 factorial design with growth environments containing or lacking carbon dioxide. We found 15 pXO1-encoded genes and 3 chromosomal genes that were strongly regulated by the separate or synergistic actions of AtxA and carbon dioxide. The majority of the regulated genes responded to both AtxA and carbon dioxide rather than to just one of these factors. Interestingly, we identified two previously unrecognized small RNAs that are highly expressed under physiological carbon dioxide concentrations in an AtxA-dependent manner. Expression levels of the two small RNAs were found to be higher than that of any other gene differentially expressed in response to these conditions. Secondary structure and small RNA-mRNA binding predictions for the two small RNAs suggest that they may perform important functions in regulating B. anthracis virulence. A majority of genes on the virulence plasmid pXO1 that are regulated by the presence of either CO2 or AtxA separately are also regulated synergistically in the presence of both. These results also elucidate novel pXO1-encoded small RNAs that are associated with virulence conditions.", "qas": [{"question": "Which metabolite activates AtxA?", "answers": ["CO2", "bicarbonate"], "qid": "2ef046659f484e2c81027f2213ef0759", "question_tokens": [["Which", 0], ["metabolite", 6], ["activates", 17], ["AtxA", 27], ["?", 31]], "detected_answers": [{"text": "CO2", "token_spans": [[27, 27], [258, 258]], "char_spans": [[142, 144], [1566, 1568]]}, {"text": "bicarbonate", "token_spans": [[25, 25]], "char_spans": [[130, 140]]}]}], "context_tokens": [["Upon", 0], ["infection", 5], ["of", 15], ["a", 18], ["mammalian", 20], ["host", 30], [",", 34], ["Bacillus", 36], ["anthracis", 45], ["responds", 55], ["to", 64], ["host", 67], ["cues", 72], [",", 76], ["and", 78], ["particularly", 82], ["to", 95], ["elevated", 98], ["temperature", 107], ["(", 119], ["37", 120], ["\u00b0", 122], ["C", 123], [")", 124], ["and", 126], ["bicarbonate", 130], ["/", 141], ["CO2", 142], ["concentrations", 146], [",", 160], ["with", 162], ["increased", 167], ["expression", 177], ["of", 188], ["virulence", 191], ["factors", 201], ["that", 209], ["include", 214], ["the", 222], ["anthrax", 226], ["toxins", 234], ["and", 241], ["extracellular", 245], ["capsular", 259], ["layer", 268], [".", 273], ["This", 275], ["response", 280], ["requires", 289], ["the", 298], ["presence", 302], ["of", 311], ["the", 314], ["pXO1", 318], ["virulence", 323], ["plasmid", 333], ["-", 340], ["encoded", 341], ["pleiotropic", 349], ["regulator", 361], ["AtxA.", 371], ["To", 377], ["better", 380], ["understand", 387], ["the", 398], ["genetic", 402], ["basis", 410], ["of", 416], ["this", 419], ["response", 424], [",", 432], ["we", 434], ["utilized", 437], ["a", 446], ["controlled", 448], ["in", 459], ["vitro", 462], ["system", 468], ["and", 475], ["Next", 479], ["Generation", 484], ["sequencing", 495], ["to", 506], ["determine", 509], ["and", 519], ["compare", 523], ["RNA", 531], ["expression", 535], ["profiles", 546], ["of", 555], ["the", 558], ["parental", 562], ["strain", 571], ["and", 578], ["an", 582], ["isogenic", 585], ["AtxA", 594], ["-", 598], ["deficient", 599], ["strain", 609], ["in", 616], ["a", 619], ["2", 621], ["\u00d7", 623], ["2", 625], ["factorial", 627], ["design", 637], ["with", 644], ["growth", 649], ["environments", 656], ["containing", 669], ["or", 680], ["lacking", 683], ["carbon", 691], ["dioxide", 698], [".", 705], ["We", 707], ["found", 710], ["15", 716], ["pXO1-encoded", 719], ["genes", 732], ["and", 738], ["3", 742], ["chromosomal", 744], ["genes", 756], ["that", 762], ["were", 767], ["strongly", 772], ["regulated", 781], ["by", 791], ["the", 794], ["separate", 798], ["or", 807], ["synergistic", 810], ["actions", 822], ["of", 830], ["AtxA", 833], ["and", 838], ["carbon", 842], ["dioxide", 849], [".", 856], ["The", 858], ["majority", 862], ["of", 871], ["the", 874], ["regulated", 878], ["genes", 888], ["responded", 894], ["to", 904], ["both", 907], ["AtxA", 912], ["and", 917], ["carbon", 921], ["dioxide", 928], ["rather", 936], ["than", 943], ["to", 948], ["just", 951], ["one", 956], ["of", 960], ["these", 963], ["factors", 969], [".", 976], ["Interestingly", 978], [",", 991], ["we", 993], ["identified", 996], ["two", 1007], ["previously", 1011], ["unrecognized", 1022], ["small", 1035], ["RNAs", 1041], ["that", 1046], ["are", 1051], ["highly", 1055], ["expressed", 1062], ["under", 1072], ["physiological", 1078], ["carbon", 1092], ["dioxide", 1099], ["concentrations", 1107], ["in", 1122], ["an", 1125], ["AtxA", 1128], ["-", 1132], ["dependent", 1133], ["manner", 1143], [".", 1149], ["Expression", 1151], ["levels", 1162], ["of", 1169], ["the", 1172], ["two", 1176], ["small", 1180], ["RNAs", 1186], ["were", 1191], ["found", 1196], ["to", 1202], ["be", 1205], ["higher", 1208], ["than", 1215], ["that", 1220], ["of", 1225], ["any", 1228], ["other", 1232], ["gene", 1238], ["differentially", 1243], ["expressed", 1258], ["in", 1268], ["response", 1271], ["to", 1280], ["these", 1283], ["conditions", 1289], [".", 1299], ["Secondary", 1301], ["structure", 1311], ["and", 1321], ["small", 1325], ["RNA", 1331], ["-", 1334], ["mRNA", 1335], ["binding", 1340], ["predictions", 1348], ["for", 1360], ["the", 1364], ["two", 1368], ["small", 1372], ["RNAs", 1378], ["suggest", 1383], ["that", 1391], ["they", 1396], ["may", 1401], ["perform", 1405], ["important", 1413], ["functions", 1423], ["in", 1433], ["regulating", 1436], ["B.", 1447], ["anthracis", 1450], ["virulence", 1460], [".", 1469], ["A", 1471], ["majority", 1473], ["of", 1482], ["genes", 1485], ["on", 1491], ["the", 1494], ["virulence", 1498], ["plasmid", 1508], ["pXO1", 1516], ["that", 1521], ["are", 1526], ["regulated", 1530], ["by", 1540], ["the", 1543], ["presence", 1547], ["of", 1556], ["either", 1559], ["CO2", 1566], ["or", 1570], ["AtxA", 1573], ["separately", 1578], ["are", 1589], ["also", 1593], ["regulated", 1598], ["synergistically", 1608], ["in", 1624], ["the", 1627], ["presence", 1631], ["of", 1640], ["both", 1643], [".", 1647], ["These", 1649], ["results", 1655], ["also", 1663], ["elucidate", 1668], ["novel", 1678], ["pXO1-encoded", 1684], ["small", 1697], ["RNAs", 1703], ["that", 1708], ["are", 1713], ["associated", 1717], ["with", 1728], ["virulence", 1733], ["conditions", 1743], [".", 1753]]}
{"context": "Selexipag is a novel, oral, selective prostacyclin (PGI2) receptor agonist in clinical development for the treatment of pulmonary arterial hypertension. Film-coated tablets with strength between 200 and 1,600 \u03bcg were used. Bioequivalence between 8 x 200 \u03bcg and a new 1,600 \u03bcg tablet was evaluated at steady state in healthy male subjects. This was an open-label, 2-treatment, 2-period, crossover, up-titration, phase 1 study. The treatments were selexipag at 1,600 \u03bcg b.i.d. for 4.5 days either as 8 x 200 \u03bcg tablets (reference: A) or 1 x 1,600 \u03bcg tablet (test: B), both preceded by an up-titration phase starting from 400 \u03bcg b.i.d. doses, in 200-\u03bcg steps every 4th day. Subjects were randomized 1 : 1 to the A-B or B-A sequence. The pharmacokinetics and tolerability of selexipag and its active metabolite, ACT-333679, were investigated. 80 subjects were enrolled in the study: 65 subjects completed the study according to protocol, and 15 subjects withdrew from the study. The most frequent adverse events (AEs) were headache (86%), myalgia (73%), and jaw pain (73%). There was no difference in nature and overall frequency of AEs between the two treatments. Steady state was attained within 3 days of the selexipag 1,600 \u00ce\u00bcg b.i.d. The 90% confidence intervals (CIs) of the geometric mean ratio (B/A) at steady state for AUC\u00cf\u0084 and Cmax,ss were within (0.80, 1.25) bioequivalence interval: (0.92, 1.06) and (0.95, 1.14), respectively, for selexipag and (0.95, 1.06) and (0.94, 1.07), respectively, for the active metabolite, ACT-333679. Bioequivalence was demonstrated between 8 x 200 \u03bcg and 1 x 1,600 \u03bcg selexipag at steady state.", "qas": [{"question": "Selexipag is used for which disease?", "answers": ["pulmonary arterial hypertension"], "qid": "990c3fbed6b34ba08dd9a7685e257613", "question_tokens": [["Selexipag", 0], ["is", 10], ["used", 13], ["for", 18], ["which", 22], ["disease", 28], ["?", 35]], "detected_answers": [{"text": "pulmonary arterial hypertension", "token_spans": [[21, 23]], "char_spans": [[120, 150]]}]}], "context_tokens": [["Selexipag", 0], ["is", 10], ["a", 13], ["novel", 15], [",", 20], ["oral", 22], [",", 26], ["selective", 28], ["prostacyclin", 38], ["(", 51], ["PGI2", 52], [")", 56], ["receptor", 58], ["agonist", 67], ["in", 75], ["clinical", 78], ["development", 87], ["for", 99], ["the", 103], ["treatment", 107], ["of", 117], ["pulmonary", 120], ["arterial", 130], ["hypertension", 139], [".", 151], ["Film", 153], ["-", 157], ["coated", 158], ["tablets", 165], ["with", 173], ["strength", 178], ["between", 187], ["200", 195], ["and", 199], ["1,600", 203], ["\u03bcg", 209], ["were", 212], ["used", 217], [".", 221], ["Bioequivalence", 223], ["between", 238], ["8", 246], ["x", 248], ["200", 250], ["\u03bcg", 254], ["and", 257], ["a", 261], ["new", 263], ["1,600", 267], ["\u03bcg", 273], ["tablet", 276], ["was", 283], ["evaluated", 287], ["at", 297], ["steady", 300], ["state", 307], ["in", 313], ["healthy", 316], ["male", 324], ["subjects", 329], [".", 337], ["This", 339], ["was", 344], ["an", 348], ["open", 351], ["-", 355], ["label", 356], [",", 361], ["2-treatment", 363], [",", 374], ["2-period", 376], [",", 384], ["crossover", 386], [",", 395], ["up", 397], ["-", 399], ["titration", 400], [",", 409], ["phase", 411], ["1", 417], ["study", 419], [".", 424], ["The", 426], ["treatments", 430], ["were", 441], ["selexipag", 446], ["at", 456], ["1,600", 459], ["\u03bcg", 465], ["b.i.d", 468], [".", 473], ["for", 475], ["4.5", 479], ["days", 483], ["either", 488], ["as", 495], ["8", 498], ["x", 500], ["200", 502], ["\u03bcg", 506], ["tablets", 509], ["(", 517], ["reference", 518], [":", 527], ["A", 529], [")", 530], ["or", 532], ["1", 535], ["x", 537], ["1,600", 539], ["\u03bcg", 545], ["tablet", 548], ["(", 555], ["test", 556], [":", 560], ["B", 562], [")", 563], [",", 564], ["both", 566], ["preceded", 571], ["by", 580], ["an", 583], ["up", 586], ["-", 588], ["titration", 589], ["phase", 599], ["starting", 605], ["from", 614], ["400", 619], ["\u03bcg", 623], ["b.i.d", 626], [".", 631], ["doses", 633], [",", 638], ["in", 640], ["200-\u03bcg", 643], ["steps", 650], ["every", 656], ["4th", 662], ["day", 666], [".", 669], ["Subjects", 671], ["were", 680], ["randomized", 685], ["1", 696], [":", 698], ["1", 700], ["to", 702], ["the", 705], ["A", 709], ["-", 710], ["B", 711], ["or", 713], ["B", 716], ["-", 717], ["A", 718], ["sequence", 720], [".", 728], ["The", 730], ["pharmacokinetics", 734], ["and", 751], ["tolerability", 755], ["of", 768], ["selexipag", 771], ["and", 781], ["its", 785], ["active", 789], ["metabolite", 796], [",", 806], ["ACT-333679", 808], [",", 818], ["were", 820], ["investigated", 825], [".", 837], ["80", 839], ["subjects", 842], ["were", 851], ["enrolled", 856], ["in", 865], ["the", 868], ["study", 872], [":", 877], ["65", 879], ["subjects", 882], ["completed", 891], ["the", 901], ["study", 905], ["according", 911], ["to", 921], ["protocol", 924], [",", 932], ["and", 934], ["15", 938], ["subjects", 941], ["withdrew", 950], ["from", 959], ["the", 964], ["study", 968], [".", 973], ["The", 975], ["most", 979], ["frequent", 984], ["adverse", 993], ["events", 1001], ["(", 1008], ["AEs", 1009], [")", 1012], ["were", 1014], ["headache", 1019], ["(", 1028], ["86", 1029], ["%", 1031], [")", 1032], [",", 1033], ["myalgia", 1035], ["(", 1043], ["73", 1044], ["%", 1046], [")", 1047], [",", 1048], ["and", 1050], ["jaw", 1054], ["pain", 1058], ["(", 1063], ["73", 1064], ["%", 1066], [")", 1067], [".", 1068], ["There", 1070], ["was", 1076], ["no", 1080], ["difference", 1083], ["in", 1094], ["nature", 1097], ["and", 1104], ["overall", 1108], ["frequency", 1116], ["of", 1126], ["AEs", 1129], ["between", 1133], ["the", 1141], ["two", 1145], ["treatments", 1149], [".", 1159], ["Steady", 1161], ["state", 1168], ["was", 1174], ["attained", 1178], ["within", 1187], ["3", 1194], ["days", 1196], ["of", 1201], ["the", 1204], ["selexipag", 1208], ["1,600", 1218], ["\u00ce\u00bcg", 1224], ["b.i.d", 1228], [".", 1233], ["The", 1235], ["90", 1239], ["%", 1241], ["confidence", 1243], ["intervals", 1254], ["(", 1264], ["CIs", 1265], [")", 1268], ["of", 1270], ["the", 1273], ["geometric", 1277], ["mean", 1287], ["ratio", 1292], ["(", 1298], ["B", 1299], ["/", 1300], ["A", 1301], [")", 1302], ["at", 1304], ["steady", 1307], ["state", 1314], ["for", 1320], ["AUC\u00cf\u0084", 1324], ["and", 1330], ["Cmax", 1334], [",", 1338], ["ss", 1339], ["were", 1342], ["within", 1347], ["(", 1354], ["0.80", 1355], [",", 1359], ["1.25", 1361], [")", 1365], ["bioequivalence", 1367], ["interval", 1382], [":", 1390], ["(", 1392], ["0.92", 1393], [",", 1397], ["1.06", 1399], [")", 1403], ["and", 1405], ["(", 1409], ["0.95", 1410], [",", 1414], ["1.14", 1416], [")", 1420], [",", 1421], ["respectively", 1423], [",", 1435], ["for", 1437], ["selexipag", 1441], ["and", 1451], ["(", 1455], ["0.95", 1456], [",", 1460], ["1.06", 1462], [")", 1466], ["and", 1468], ["(", 1472], ["0.94", 1473], [",", 1477], ["1.07", 1479], [")", 1483], [",", 1484], ["respectively", 1486], [",", 1498], ["for", 1500], ["the", 1504], ["active", 1508], ["metabolite", 1515], [",", 1525], ["ACT-333679", 1527], [".", 1537], ["Bioequivalence", 1539], ["was", 1554], ["demonstrated", 1558], ["between", 1571], ["8", 1579], ["x", 1581], ["200", 1583], ["\u03bcg", 1587], ["and", 1590], ["1", 1594], ["x", 1596], ["1,600", 1598], ["\u03bcg", 1604], ["selexipag", 1607], ["at", 1617], ["steady", 1620], ["state", 1627], [".", 1632]]}
{"context": "It is increasingly clear that the normal protein alpha-synuclein is in some manner closely associated with presynaptic components of select neuronal types within the adult human central nervous system (CNS) and, in addition, that in its pathologically altered state alpha-synuclein aggregates selectively in the form of filamentous inclusion bodies during certain progressive neurodegenerative disorders, such as familial and sporadic Parkinson's disease. By having the antibody AFshp raised specifically to alpha-synuclein to label Parkinson disease-specific Lewy bodies and Lewy neurites as well as synaptic boutons containing the unaltered protein, an initial attempt is made to map the overall distribution pattern and describe the staining behavior of the immunoreactive punctae in select regions of the prosencephalon. Neocortical immunolabeling is most prominent in the prodigious, but incompletely myelinated, association fields and faintest in the heavily myelinated primary motor and primary sensory fields, with the premotor and first order sensory association areas occupying an intermediate position. Of the thalamic grays evaluated, those containing powerfully myelinated fiber tracts (e.g. centrum medianum, habenular complex) show the weakest immunolabeling, whereas, less sturdily myelinated structures are highly immunoreactive. The fact that the immunostaining spectrum for normal alpha-synuclein is so broad, together with the fact that some thalamic sites actually are immunonegative leads to the following conclusions (1) alpha-synuclein, although present in the synaptic boutons of many nerve cells in the adult human CNS, is by no means ubiquitous there, and (2) neuronal types lacking the normal protein cannot generate the Parkinson's disease-specific filamentous pathology.", "qas": [{"question": "Against which protein is the antibody used for immonostaining of Lewy bodies raised?", "answers": ["alpha-Synuclein"], "qid": "2c9a3ae9437648e1834a87d46d29cd29", "question_tokens": [["Against", 0], ["which", 8], ["protein", 14], ["is", 22], ["the", 25], ["antibody", 29], ["used", 38], ["for", 43], ["immonostaining", 47], ["of", 62], ["Lewy", 65], ["bodies", 70], ["raised", 77], ["?", 83]], "detected_answers": [{"text": "alpha-Synuclein", "token_spans": [[80, 82], [45, 47], [8, 10], [216, 218], [242, 244]], "char_spans": [[508, 522], [266, 280], [49, 63], [1400, 1414], [1544, 1558]]}]}], "context_tokens": [["It", 0], ["is", 3], ["increasingly", 6], ["clear", 19], ["that", 25], ["the", 30], ["normal", 34], ["protein", 41], ["alpha", 49], ["-", 54], ["synuclein", 55], ["is", 65], ["in", 68], ["some", 71], ["manner", 76], ["closely", 83], ["associated", 91], ["with", 102], ["presynaptic", 107], ["components", 119], ["of", 130], ["select", 133], ["neuronal", 140], ["types", 149], ["within", 155], ["the", 162], ["adult", 166], ["human", 172], ["central", 178], ["nervous", 186], ["system", 194], ["(", 201], ["CNS", 202], [")", 205], ["and", 207], [",", 210], ["in", 212], ["addition", 215], [",", 223], ["that", 225], ["in", 230], ["its", 233], ["pathologically", 237], ["altered", 252], ["state", 260], ["alpha", 266], ["-", 271], ["synuclein", 272], ["aggregates", 282], ["selectively", 293], ["in", 305], ["the", 308], ["form", 312], ["of", 317], ["filamentous", 320], ["inclusion", 332], ["bodies", 342], ["during", 349], ["certain", 356], ["progressive", 364], ["neurodegenerative", 376], ["disorders", 394], [",", 403], ["such", 405], ["as", 410], ["familial", 413], ["and", 422], ["sporadic", 426], ["Parkinson", 435], ["'s", 444], ["disease", 447], [".", 454], ["By", 456], ["having", 459], ["the", 466], ["antibody", 470], ["AFshp", 479], ["raised", 485], ["specifically", 492], ["to", 505], ["alpha", 508], ["-", 513], ["synuclein", 514], ["to", 524], ["label", 527], ["Parkinson", 533], ["disease", 543], ["-", 550], ["specific", 551], ["Lewy", 560], ["bodies", 565], ["and", 572], ["Lewy", 576], ["neurites", 581], ["as", 590], ["well", 593], ["as", 598], ["synaptic", 601], ["boutons", 610], ["containing", 618], ["the", 629], ["unaltered", 633], ["protein", 643], [",", 650], ["an", 652], ["initial", 655], ["attempt", 663], ["is", 671], ["made", 674], ["to", 679], ["map", 682], ["the", 686], ["overall", 690], ["distribution", 698], ["pattern", 711], ["and", 719], ["describe", 723], ["the", 732], ["staining", 736], ["behavior", 745], ["of", 754], ["the", 757], ["immunoreactive", 761], ["punctae", 776], ["in", 784], ["select", 787], ["regions", 794], ["of", 802], ["the", 805], ["prosencephalon", 809], [".", 823], ["Neocortical", 825], ["immunolabeling", 837], ["is", 852], ["most", 855], ["prominent", 860], ["in", 870], ["the", 873], ["prodigious", 877], [",", 887], ["but", 889], ["incompletely", 893], ["myelinated", 906], [",", 916], ["association", 918], ["fields", 930], ["and", 937], ["faintest", 941], ["in", 950], ["the", 953], ["heavily", 957], ["myelinated", 965], ["primary", 976], ["motor", 984], ["and", 990], ["primary", 994], ["sensory", 1002], ["fields", 1010], [",", 1016], ["with", 1018], ["the", 1023], ["premotor", 1027], ["and", 1036], ["first", 1040], ["order", 1046], ["sensory", 1052], ["association", 1060], ["areas", 1072], ["occupying", 1078], ["an", 1088], ["intermediate", 1091], ["position", 1104], [".", 1112], ["Of", 1114], ["the", 1117], ["thalamic", 1121], ["grays", 1130], ["evaluated", 1136], [",", 1145], ["those", 1147], ["containing", 1153], ["powerfully", 1164], ["myelinated", 1175], ["fiber", 1186], ["tracts", 1192], ["(", 1199], ["e.g.", 1200], ["centrum", 1205], ["medianum", 1213], [",", 1221], ["habenular", 1223], ["complex", 1233], [")", 1240], ["show", 1242], ["the", 1247], ["weakest", 1251], ["immunolabeling", 1259], [",", 1273], ["whereas", 1275], [",", 1282], ["less", 1284], ["sturdily", 1289], ["myelinated", 1298], ["structures", 1309], ["are", 1320], ["highly", 1324], ["immunoreactive", 1331], [".", 1345], ["The", 1347], ["fact", 1351], ["that", 1356], ["the", 1361], ["immunostaining", 1365], ["spectrum", 1380], ["for", 1389], ["normal", 1393], ["alpha", 1400], ["-", 1405], ["synuclein", 1406], ["is", 1416], ["so", 1419], ["broad", 1422], [",", 1427], ["together", 1429], ["with", 1438], ["the", 1443], ["fact", 1447], ["that", 1452], ["some", 1457], ["thalamic", 1462], ["sites", 1471], ["actually", 1477], ["are", 1486], ["immunonegative", 1490], ["leads", 1505], ["to", 1511], ["the", 1514], ["following", 1518], ["conclusions", 1528], ["(", 1540], ["1", 1541], [")", 1542], ["alpha", 1544], ["-", 1549], ["synuclein", 1550], [",", 1559], ["although", 1561], ["present", 1570], ["in", 1578], ["the", 1581], ["synaptic", 1585], ["boutons", 1594], ["of", 1602], ["many", 1605], ["nerve", 1610], ["cells", 1616], ["in", 1622], ["the", 1625], ["adult", 1629], ["human", 1635], ["CNS", 1641], [",", 1644], ["is", 1646], ["by", 1649], ["no", 1652], ["means", 1655], ["ubiquitous", 1661], ["there", 1672], [",", 1677], ["and", 1679], ["(", 1683], ["2", 1684], [")", 1685], ["neuronal", 1687], ["types", 1696], ["lacking", 1702], ["the", 1710], ["normal", 1714], ["protein", 1721], ["can", 1729], ["not", 1732], ["generate", 1736], ["the", 1745], ["Parkinson", 1749], ["'s", 1758], ["disease", 1761], ["-", 1768], ["specific", 1769], ["filamentous", 1778], ["pathology", 1790], [".", 1799]]}
{"context": "Flumazenil, a specific benzodiazepine antagonist, was evaluated as adjunctive therapy in the management of benzodiazepine overdose. Thirteen emergency departments enrolled 326 patients in this double-blind, placebo-controlled trial; 162 patients were randomly allocated to receive flumazenil (maximum dose, 30 ml, providing 3 mg of flumazenil), and 164 were allocated to receive placebo (maximum dose, 30 ml). A successful response was the attainment of a score of 1 or 2 on the Clinical Global Impression Scale (CGIS), denoting a very much improved or much improved status, 10 minutes after the start of intravenous administration of the test drug. Among those patients whose drug screen revealed the presence of benzodiazepines, 75 (77%) of 97 patients given flumazenil and 13 (16%) of 83 given placebo attained such a response. The mean CGIS score at 10 minutes for benzodiazepine-positive patients treated with flumazenil was 1.95 versus 3.58 for those given placebo. As determined by the Neurobehavioral Assessment Scale, 61% of patients who initially responded became resedated; in these patients, the effect of flumazenil lasted a median of 90 minutes. At the investigator's discretion, patients who did not achieve a criterion response in the double-blind trial could receive open-label flumazenil, titrated as in the double-blind phase. Among the benzodiazepine-positive patients, 9 (53%) of 17 patients from the flumazenil group responded to the additional flumazenil, and 58 (81%) of patients previously given placebo responded. Safety was assessed in all 326 patients given the test drug. The most frequent adverse experiences after the administration of flumazenil were agitation (7%), vomiting (7%), abnormal crying (4%), and nausea (4%); these effects were observed with a lower frequency in the placebo group. Serious adverse experiences were reported in 4 patients; these included seizures and cardiac arrhythmias. Of the 3 patients with seizures, 2 had ingested large doses of cyclic antidepressants in addition to the benzodiazepine. The toxicology screen for 1 of the 2 showed 1900 ng/ml of amoxapine and 900 ng/ml of nortriptyline; the toxicology screen for the other, who also had ventricular tachycardia, showed 1928 ng/ml of loxapine and 301 ng/ml of amoxapine. The results of this study confirm published reports of the efficacy of flumazenil in reversing benzodiazepine-induced sedation in patients with benzodiazepine overdose. This was accomplished irrespective of the presence of coingested drugs. Flumazenil is not recommended for patients with serious cyclic antidepressant poisoning or those who use benzodiazepines therapeutically to control seizure disorders. When used as recommended, however, flumazenil has been shown to have an acceptable safety level.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "c0676b791a034e7e90ddf7a04c68ddd2", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[0, 0], [272, 272], [43, 43], [205, 205], [170, 170], [266, 266], [502, 502], [140, 140], [308, 308], [55, 55], [473, 473], [238, 238], [449, 449]], "char_spans": [[0, 9], [1467, 1476], [281, 290], [1118, 1127], [915, 924], [1422, 1431], [2729, 2738], [761, 770], [1667, 1676], [332, 341], [2527, 2536], [1295, 1304], [2357, 2366]]}]}], "context_tokens": [["Flumazenil", 0], [",", 10], ["a", 12], ["specific", 14], ["benzodiazepine", 23], ["antagonist", 38], [",", 48], ["was", 50], ["evaluated", 54], ["as", 64], ["adjunctive", 67], ["therapy", 78], ["in", 86], ["the", 89], ["management", 93], ["of", 104], ["benzodiazepine", 107], ["overdose", 122], [".", 130], ["Thirteen", 132], ["emergency", 141], ["departments", 151], ["enrolled", 163], ["326", 172], ["patients", 176], ["in", 185], ["this", 188], ["double", 193], ["-", 199], ["blind", 200], [",", 205], ["placebo", 207], ["-", 214], ["controlled", 215], ["trial", 226], [";", 231], ["162", 233], ["patients", 237], ["were", 246], ["randomly", 251], ["allocated", 260], ["to", 270], ["receive", 273], ["flumazenil", 281], ["(", 292], ["maximum", 293], ["dose", 301], [",", 305], ["30", 307], ["ml", 310], [",", 312], ["providing", 314], ["3", 324], ["mg", 326], ["of", 329], ["flumazenil", 332], [")", 342], [",", 343], ["and", 345], ["164", 349], ["were", 353], ["allocated", 358], ["to", 368], ["receive", 371], ["placebo", 379], ["(", 387], ["maximum", 388], ["dose", 396], [",", 400], ["30", 402], ["ml", 405], [")", 407], [".", 408], ["A", 410], ["successful", 412], ["response", 423], ["was", 432], ["the", 436], ["attainment", 440], ["of", 451], ["a", 454], ["score", 456], ["of", 462], ["1", 465], ["or", 467], ["2", 470], ["on", 472], ["the", 475], ["Clinical", 479], ["Global", 488], ["Impression", 495], ["Scale", 506], ["(", 512], ["CGIS", 513], [")", 517], [",", 518], ["denoting", 520], ["a", 529], ["very", 531], ["much", 536], ["improved", 541], ["or", 550], ["much", 553], ["improved", 558], ["status", 567], [",", 573], ["10", 575], ["minutes", 578], ["after", 586], ["the", 592], ["start", 596], ["of", 602], ["intravenous", 605], ["administration", 617], ["of", 632], ["the", 635], ["test", 639], ["drug", 644], [".", 648], ["Among", 650], ["those", 656], ["patients", 662], ["whose", 671], ["drug", 677], ["screen", 682], ["revealed", 689], ["the", 698], ["presence", 702], ["of", 711], ["benzodiazepines", 714], [",", 729], ["75", 731], ["(", 734], ["77", 735], ["%", 737], [")", 738], ["of", 740], ["97", 743], ["patients", 746], ["given", 755], ["flumazenil", 761], ["and", 772], ["13", 776], ["(", 779], ["16", 780], ["%", 782], [")", 783], ["of", 785], ["83", 788], ["given", 791], ["placebo", 797], ["attained", 805], ["such", 814], ["a", 819], ["response", 821], [".", 829], ["The", 831], ["mean", 835], ["CGIS", 840], ["score", 845], ["at", 851], ["10", 854], ["minutes", 857], ["for", 865], ["benzodiazepine", 869], ["-", 883], ["positive", 884], ["patients", 893], ["treated", 902], ["with", 910], ["flumazenil", 915], ["was", 926], ["1.95", 930], ["versus", 935], ["3.58", 942], ["for", 947], ["those", 951], ["given", 957], ["placebo", 963], [".", 970], ["As", 972], ["determined", 975], ["by", 986], ["the", 989], ["Neurobehavioral", 993], ["Assessment", 1009], ["Scale", 1020], [",", 1025], ["61", 1027], ["%", 1029], ["of", 1031], ["patients", 1034], ["who", 1043], ["initially", 1047], ["responded", 1057], ["became", 1067], ["resedated", 1074], [";", 1083], ["in", 1085], ["these", 1088], ["patients", 1094], [",", 1102], ["the", 1104], ["effect", 1108], ["of", 1115], ["flumazenil", 1118], ["lasted", 1129], ["a", 1136], ["median", 1138], ["of", 1145], ["90", 1148], ["minutes", 1151], [".", 1158], ["At", 1160], ["the", 1163], ["investigator", 1167], ["'s", 1179], ["discretion", 1182], [",", 1192], ["patients", 1194], ["who", 1203], ["did", 1207], ["not", 1211], ["achieve", 1215], ["a", 1223], ["criterion", 1225], ["response", 1235], ["in", 1244], ["the", 1247], ["double", 1251], ["-", 1257], ["blind", 1258], ["trial", 1264], ["could", 1270], ["receive", 1276], ["open", 1284], ["-", 1288], ["label", 1289], ["flumazenil", 1295], [",", 1305], ["titrated", 1307], ["as", 1316], ["in", 1319], ["the", 1322], ["double", 1326], ["-", 1332], ["blind", 1333], ["phase", 1339], [".", 1344], ["Among", 1346], ["the", 1352], ["benzodiazepine", 1356], ["-", 1370], ["positive", 1371], ["patients", 1380], [",", 1388], ["9", 1390], ["(", 1392], ["53", 1393], ["%", 1395], [")", 1396], ["of", 1398], ["17", 1401], ["patients", 1404], ["from", 1413], ["the", 1418], ["flumazenil", 1422], ["group", 1433], ["responded", 1439], ["to", 1449], ["the", 1452], ["additional", 1456], ["flumazenil", 1467], [",", 1477], ["and", 1479], ["58", 1483], ["(", 1486], ["81", 1487], ["%", 1489], [")", 1490], ["of", 1492], ["patients", 1495], ["previously", 1504], ["given", 1515], ["placebo", 1521], ["responded", 1529], [".", 1538], ["Safety", 1540], ["was", 1547], ["assessed", 1551], ["in", 1560], ["all", 1563], ["326", 1567], ["patients", 1571], ["given", 1580], ["the", 1586], ["test", 1590], ["drug", 1595], [".", 1599], ["The", 1601], ["most", 1605], ["frequent", 1610], ["adverse", 1619], ["experiences", 1627], ["after", 1639], ["the", 1645], ["administration", 1649], ["of", 1664], ["flumazenil", 1667], ["were", 1678], ["agitation", 1683], ["(", 1693], ["7", 1694], ["%", 1695], [")", 1696], [",", 1697], ["vomiting", 1699], ["(", 1708], ["7", 1709], ["%", 1710], [")", 1711], [",", 1712], ["abnormal", 1714], ["crying", 1723], ["(", 1730], ["4", 1731], ["%", 1732], [")", 1733], [",", 1734], ["and", 1736], ["nausea", 1740], ["(", 1747], ["4", 1748], ["%", 1749], [")", 1750], [";", 1751], ["these", 1753], ["effects", 1759], ["were", 1767], ["observed", 1772], ["with", 1781], ["a", 1786], ["lower", 1788], ["frequency", 1794], ["in", 1804], ["the", 1807], ["placebo", 1811], ["group", 1819], [".", 1824], ["Serious", 1826], ["adverse", 1834], ["experiences", 1842], ["were", 1854], ["reported", 1859], ["in", 1868], ["4", 1871], ["patients", 1873], [";", 1881], ["these", 1883], ["included", 1889], ["seizures", 1898], ["and", 1907], ["cardiac", 1911], ["arrhythmias", 1919], [".", 1930], ["Of", 1932], ["the", 1935], ["3", 1939], ["patients", 1941], ["with", 1950], ["seizures", 1955], [",", 1963], ["2", 1965], ["had", 1967], ["ingested", 1971], ["large", 1980], ["doses", 1986], ["of", 1992], ["cyclic", 1995], ["antidepressants", 2002], ["in", 2018], ["addition", 2021], ["to", 2030], ["the", 2033], ["benzodiazepine", 2037], [".", 2051], ["The", 2053], ["toxicology", 2057], ["screen", 2068], ["for", 2075], ["1", 2079], ["of", 2081], ["the", 2084], ["2", 2088], ["showed", 2090], ["1900", 2097], ["ng", 2102], ["/", 2104], ["ml", 2105], ["of", 2108], ["amoxapine", 2111], ["and", 2121], ["900", 2125], ["ng", 2129], ["/", 2131], ["ml", 2132], ["of", 2135], ["nortriptyline", 2138], [";", 2151], ["the", 2153], ["toxicology", 2157], ["screen", 2168], ["for", 2175], ["the", 2179], ["other", 2183], [",", 2188], ["who", 2190], ["also", 2194], ["had", 2199], ["ventricular", 2203], ["tachycardia", 2215], [",", 2226], ["showed", 2228], ["1928", 2235], ["ng", 2240], ["/", 2242], ["ml", 2243], ["of", 2246], ["loxapine", 2249], ["and", 2258], ["301", 2262], ["ng", 2266], ["/", 2268], ["ml", 2269], ["of", 2272], ["amoxapine", 2275], [".", 2284], ["The", 2286], ["results", 2290], ["of", 2298], ["this", 2301], ["study", 2306], ["confirm", 2312], ["published", 2320], ["reports", 2330], ["of", 2338], ["the", 2341], ["efficacy", 2345], ["of", 2354], ["flumazenil", 2357], ["in", 2368], ["reversing", 2371], ["benzodiazepine", 2381], ["-", 2395], ["induced", 2396], ["sedation", 2404], ["in", 2413], ["patients", 2416], ["with", 2425], ["benzodiazepine", 2430], ["overdose", 2445], [".", 2453], ["This", 2455], ["was", 2460], ["accomplished", 2464], ["irrespective", 2477], ["of", 2490], ["the", 2493], ["presence", 2497], ["of", 2506], ["coingested", 2509], ["drugs", 2520], [".", 2525], ["Flumazenil", 2527], ["is", 2538], ["not", 2541], ["recommended", 2545], ["for", 2557], ["patients", 2561], ["with", 2570], ["serious", 2575], ["cyclic", 2583], ["antidepressant", 2590], ["poisoning", 2605], ["or", 2615], ["those", 2618], ["who", 2624], ["use", 2628], ["benzodiazepines", 2632], ["therapeutically", 2648], ["to", 2664], ["control", 2667], ["seizure", 2675], ["disorders", 2683], [".", 2692], ["When", 2694], ["used", 2699], ["as", 2704], ["recommended", 2707], [",", 2718], ["however", 2720], [",", 2727], ["flumazenil", 2729], ["has", 2740], ["been", 2744], ["shown", 2749], ["to", 2755], ["have", 2758], ["an", 2763], ["acceptable", 2766], ["safety", 2777], ["level", 2784], [".", 2789]]}
{"context": "SET domain methyltransferases deposit methyl marks on specific histone tail lysine residues and play a major role in epigenetic regulation of gene transcription. We solved the structures of the catalytic domains of GLP, G9a, Suv39H2 and PRDM2, four of the eight known human H3K9 methyltransferases in their apo conformation or in complex with the methyl donating cofactor, and peptide substrates. We analyzed the structural determinants for methylation state specificity, and designed a G9a mutant able to tri-methylate H3K9. We show that the I-SET domain acts as a rigid docking platform, while induced-fit of the Post-SET domain is necessary to achieve a catalytically competent conformation. We also propose a model where long-range electrostatics bring enzyme and histone substrate together, while the presence of an arginine upstream of the target lysine is critical for binding and specificity. This article can also be viewed as an enhanced version in which the text of the article is integrated with interactive 3D representations and animated transitions. Please note that a web plugin is required to access this enhanced functionality. Instructions for the installation and use of the web plugin are available in Text S1.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "2a976c6394c14d34bced70aaed51880b", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[0, 1], [111, 112], [94, 95]], "char_spans": [[0, 9], [620, 629], [545, 554]]}]}], "context_tokens": [["SET", 0], ["domain", 4], ["methyltransferases", 11], ["deposit", 30], ["methyl", 38], ["marks", 45], ["on", 51], ["specific", 54], ["histone", 63], ["tail", 71], ["lysine", 76], ["residues", 83], ["and", 92], ["play", 96], ["a", 101], ["major", 103], ["role", 109], ["in", 114], ["epigenetic", 117], ["regulation", 128], ["of", 139], ["gene", 142], ["transcription", 147], [".", 160], ["We", 162], ["solved", 165], ["the", 172], ["structures", 176], ["of", 187], ["the", 190], ["catalytic", 194], ["domains", 204], ["of", 212], ["GLP", 215], [",", 218], ["G9a", 220], [",", 223], ["Suv39H2", 225], ["and", 233], ["PRDM2", 237], [",", 242], ["four", 244], ["of", 249], ["the", 252], ["eight", 256], ["known", 262], ["human", 268], ["H3K9", 274], ["methyltransferases", 279], ["in", 298], ["their", 301], ["apo", 307], ["conformation", 311], ["or", 324], ["in", 327], ["complex", 330], ["with", 338], ["the", 343], ["methyl", 347], ["donating", 354], ["cofactor", 363], [",", 371], ["and", 373], ["peptide", 377], ["substrates", 385], [".", 395], ["We", 397], ["analyzed", 400], ["the", 409], ["structural", 413], ["determinants", 424], ["for", 437], ["methylation", 441], ["state", 453], ["specificity", 459], [",", 470], ["and", 472], ["designed", 476], ["a", 485], ["G9a", 487], ["mutant", 491], ["able", 498], ["to", 503], ["tri", 506], ["-", 509], ["methylate", 510], ["H3K9", 520], [".", 524], ["We", 526], ["show", 529], ["that", 534], ["the", 539], ["I", 543], ["-", 544], ["SET", 545], ["domain", 549], ["acts", 556], ["as", 561], ["a", 564], ["rigid", 566], ["docking", 572], ["platform", 580], [",", 588], ["while", 590], ["induced", 596], ["-", 603], ["fit", 604], ["of", 608], ["the", 611], ["Post", 615], ["-", 619], ["SET", 620], ["domain", 624], ["is", 631], ["necessary", 634], ["to", 644], ["achieve", 647], ["a", 655], ["catalytically", 657], ["competent", 671], ["conformation", 681], [".", 693], ["We", 695], ["also", 698], ["propose", 703], ["a", 711], ["model", 713], ["where", 719], ["long", 725], ["-", 729], ["range", 730], ["electrostatics", 736], ["bring", 751], ["enzyme", 757], ["and", 764], ["histone", 768], ["substrate", 776], ["together", 786], [",", 794], ["while", 796], ["the", 802], ["presence", 806], ["of", 815], ["an", 818], ["arginine", 821], ["upstream", 830], ["of", 839], ["the", 842], ["target", 846], ["lysine", 853], ["is", 860], ["critical", 863], ["for", 872], ["binding", 876], ["and", 884], ["specificity", 888], [".", 899], ["This", 901], ["article", 906], ["can", 914], ["also", 918], ["be", 923], ["viewed", 926], ["as", 933], ["an", 936], ["enhanced", 939], ["version", 948], ["in", 956], ["which", 959], ["the", 965], ["text", 969], ["of", 974], ["the", 977], ["article", 981], ["is", 989], ["integrated", 992], ["with", 1003], ["interactive", 1008], ["3D", 1020], ["representations", 1023], ["and", 1039], ["animated", 1043], ["transitions", 1052], [".", 1063], ["Please", 1065], ["note", 1072], ["that", 1077], ["a", 1082], ["web", 1084], ["plugin", 1088], ["is", 1095], ["required", 1098], ["to", 1107], ["access", 1110], ["this", 1117], ["enhanced", 1122], ["functionality", 1131], [".", 1144], ["Instructions", 1146], ["for", 1159], ["the", 1163], ["installation", 1167], ["and", 1180], ["use", 1184], ["of", 1188], ["the", 1191], ["web", 1195], ["plugin", 1199], ["are", 1206], ["available", 1210], ["in", 1220], ["Text", 1223], ["S1", 1228], [".", 1230]]}
{"context": "Vascular Ehlers-Danlos Syndrome (VEDS), previously called Ehlers-Danlos syndrome type-IV, is a heterogeneous group of heritable connective tissue disorders characterized by thin, translucent skin, easy bruising, arterial, intestinal, and/or uterine fragility. There is large vessel involvement that leads to arterial rupture often preceded by aneurysm, arteriovenous fistulae, or dissection. Noninvasive imaging studies such as CT angiography and MR angiography are preferred as diagnostic studies for this condition. We are reporting a 4 years old girl who was presented with right sided unilateral convulsions and hypertension. CT angiogram showed stenosis with post-stenotic dilatation of coeliac and superior mesenteric arteries. There were extensive calcified plaques with atherosclerotic changes in the segment of right common iliac artery with aneurysmal dilatation of celiac, superior mesenteric and common iliac artery. Radiological findings were consistent with vascular Ehlers-Danlos syndrome. She was successfully managed with anti-hypertensive and anticonvulsants.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "c4aa033a18f745d98c38639082418fe4", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[25, 26]], "char_spans": [[128, 144]]}]}], "context_tokens": [["Vascular", 0], ["Ehlers", 9], ["-", 15], ["Danlos", 16], ["Syndrome", 23], ["(", 32], ["VEDS", 33], [")", 37], [",", 38], ["previously", 40], ["called", 51], ["Ehlers", 58], ["-", 64], ["Danlos", 65], ["syndrome", 72], ["type", 81], ["-", 85], ["IV", 86], [",", 88], ["is", 90], ["a", 93], ["heterogeneous", 95], ["group", 109], ["of", 115], ["heritable", 118], ["connective", 128], ["tissue", 139], ["disorders", 146], ["characterized", 156], ["by", 170], ["thin", 173], [",", 177], ["translucent", 179], ["skin", 191], [",", 195], ["easy", 197], ["bruising", 202], [",", 210], ["arterial", 212], [",", 220], ["intestinal", 222], [",", 232], ["and/or", 234], ["uterine", 241], ["fragility", 249], [".", 258], ["There", 260], ["is", 266], ["large", 269], ["vessel", 275], ["involvement", 282], ["that", 294], ["leads", 299], ["to", 305], ["arterial", 308], ["rupture", 317], ["often", 325], ["preceded", 331], ["by", 340], ["aneurysm", 343], [",", 351], ["arteriovenous", 353], ["fistulae", 367], [",", 375], ["or", 377], ["dissection", 380], [".", 390], ["Noninvasive", 392], ["imaging", 404], ["studies", 412], ["such", 420], ["as", 425], ["CT", 428], ["angiography", 431], ["and", 443], ["MR", 447], ["angiography", 450], ["are", 462], ["preferred", 466], ["as", 476], ["diagnostic", 479], ["studies", 490], ["for", 498], ["this", 502], ["condition", 507], [".", 516], ["We", 518], ["are", 521], ["reporting", 525], ["a", 535], ["4", 537], ["years", 539], ["old", 545], ["girl", 549], ["who", 554], ["was", 558], ["presented", 562], ["with", 572], ["right", 577], ["sided", 583], ["unilateral", 589], ["convulsions", 600], ["and", 612], ["hypertension", 616], [".", 628], ["CT", 630], ["angiogram", 633], ["showed", 643], ["stenosis", 650], ["with", 659], ["post", 664], ["-", 668], ["stenotic", 669], ["dilatation", 678], ["of", 689], ["coeliac", 692], ["and", 700], ["superior", 704], ["mesenteric", 713], ["arteries", 724], [".", 732], ["There", 734], ["were", 740], ["extensive", 745], ["calcified", 755], ["plaques", 765], ["with", 773], ["atherosclerotic", 778], ["changes", 794], ["in", 802], ["the", 805], ["segment", 809], ["of", 817], ["right", 820], ["common", 826], ["iliac", 833], ["artery", 839], ["with", 846], ["aneurysmal", 851], ["dilatation", 862], ["of", 873], ["celiac", 876], [",", 882], ["superior", 884], ["mesenteric", 893], ["and", 904], ["common", 908], ["iliac", 915], ["artery", 921], [".", 927], ["Radiological", 929], ["findings", 942], ["were", 951], ["consistent", 956], ["with", 967], ["vascular", 972], ["Ehlers", 981], ["-", 987], ["Danlos", 988], ["syndrome", 995], [".", 1003], ["She", 1005], ["was", 1009], ["successfully", 1013], ["managed", 1026], ["with", 1034], ["anti", 1039], ["-", 1043], ["hypertensive", 1044], ["and", 1057], ["anticonvulsants", 1061], [".", 1076]]}
{"context": "Chronic myeloid leukemia (CML) is arguably the best understood of all human malignancies. Its origins in the hematopoietic stem cell can be traced to a reciprocal translocation involving chromosomes 9 and 22, dubbed the Philadelphia chromosome, which is observed in essentially all patients. The resulting fusion gene, BCR/ABL, encodes an activated tyrosine kinase that can act alone to induce a CML-like syndrome in mouse models. These animal models have validated BCR/ABL as a target for the development of specific pharmaceutical inhibitors. The kinase inhibitor imatinib mesylate (Gleevec) is highly specific, effective, and minimally toxic, but may not effect cures as a single agent, particularly in patients with accelerated and blast-phase disease. Resistance to imatinib can confound therapy. Surprisingly, a high percentage of resistant cases manifest intact or augmented BCR/ABL signaling, suggesting that this oncoprotein, or signaling pathways emanating from it, remain viable targets. Combination chemotherapy is under active investigation, and among the most compelling strategies is dual treatment with agents that both target BCR/ABL signal transduction. BCR/ABL activates Ras, and compounds designed to antagonize Ras function called farnesyl transferase inhibitors (FTIs) have shown potent activity in vitro and in animal models of BCR/ABL-induced leukemia. Initial clinical trials in patients with refractory acute myeloid leukemia and CML in blast crisis have shown significant activity, suggesting that trials combining imatinib and FTIs are warranted.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "7ab997001a3a4c77a2cb4d78612ac48f", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[54, 56], [197, 199], [234, 236], [203, 205], [83, 85], [155, 157]], "char_spans": [[319, 325], [1143, 1149], [1351, 1357], [1172, 1178], [466, 472], [882, 888]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["arguably", 34], ["the", 43], ["best", 47], ["understood", 52], ["of", 63], ["all", 66], ["human", 70], ["malignancies", 76], [".", 88], ["Its", 90], ["origins", 94], ["in", 102], ["the", 105], ["hematopoietic", 109], ["stem", 123], ["cell", 128], ["can", 133], ["be", 137], ["traced", 140], ["to", 147], ["a", 150], ["reciprocal", 152], ["translocation", 163], ["involving", 177], ["chromosomes", 187], ["9", 199], ["and", 201], ["22", 205], [",", 207], ["dubbed", 209], ["the", 216], ["Philadelphia", 220], ["chromosome", 233], [",", 243], ["which", 245], ["is", 251], ["observed", 254], ["in", 263], ["essentially", 266], ["all", 278], ["patients", 282], [".", 290], ["The", 292], ["resulting", 296], ["fusion", 306], ["gene", 313], [",", 317], ["BCR", 319], ["/", 322], ["ABL", 323], [",", 326], ["encodes", 328], ["an", 336], ["activated", 339], ["tyrosine", 349], ["kinase", 358], ["that", 365], ["can", 370], ["act", 374], ["alone", 378], ["to", 384], ["induce", 387], ["a", 394], ["CML", 396], ["-", 399], ["like", 400], ["syndrome", 405], ["in", 414], ["mouse", 417], ["models", 423], [".", 429], ["These", 431], ["animal", 437], ["models", 444], ["have", 451], ["validated", 456], ["BCR", 466], ["/", 469], ["ABL", 470], ["as", 474], ["a", 477], ["target", 479], ["for", 486], ["the", 490], ["development", 494], ["of", 506], ["specific", 509], ["pharmaceutical", 518], ["inhibitors", 533], [".", 543], ["The", 545], ["kinase", 549], ["inhibitor", 556], ["imatinib", 566], ["mesylate", 575], ["(", 584], ["Gleevec", 585], [")", 592], ["is", 594], ["highly", 597], ["specific", 604], [",", 612], ["effective", 614], [",", 623], ["and", 625], ["minimally", 629], ["toxic", 639], [",", 644], ["but", 646], ["may", 650], ["not", 654], ["effect", 658], ["cures", 665], ["as", 671], ["a", 674], ["single", 676], ["agent", 683], [",", 688], ["particularly", 690], ["in", 703], ["patients", 706], ["with", 715], ["accelerated", 720], ["and", 732], ["blast", 736], ["-", 741], ["phase", 742], ["disease", 748], [".", 755], ["Resistance", 757], ["to", 768], ["imatinib", 771], ["can", 780], ["confound", 784], ["therapy", 793], [".", 800], ["Surprisingly", 802], [",", 814], ["a", 816], ["high", 818], ["percentage", 823], ["of", 834], ["resistant", 837], ["cases", 847], ["manifest", 853], ["intact", 862], ["or", 869], ["augmented", 872], ["BCR", 882], ["/", 885], ["ABL", 886], ["signaling", 890], [",", 899], ["suggesting", 901], ["that", 912], ["this", 917], ["oncoprotein", 922], [",", 933], ["or", 935], ["signaling", 938], ["pathways", 948], ["emanating", 957], ["from", 967], ["it", 972], [",", 974], ["remain", 976], ["viable", 983], ["targets", 990], [".", 997], ["Combination", 999], ["chemotherapy", 1011], ["is", 1024], ["under", 1027], ["active", 1033], ["investigation", 1040], [",", 1053], ["and", 1055], ["among", 1059], ["the", 1065], ["most", 1069], ["compelling", 1074], ["strategies", 1085], ["is", 1096], ["dual", 1099], ["treatment", 1104], ["with", 1114], ["agents", 1119], ["that", 1126], ["both", 1131], ["target", 1136], ["BCR", 1143], ["/", 1146], ["ABL", 1147], ["signal", 1151], ["transduction", 1158], [".", 1170], ["BCR", 1172], ["/", 1175], ["ABL", 1176], ["activates", 1180], ["Ras", 1190], [",", 1193], ["and", 1195], ["compounds", 1199], ["designed", 1209], ["to", 1218], ["antagonize", 1221], ["Ras", 1232], ["function", 1236], ["called", 1245], ["farnesyl", 1252], ["transferase", 1261], ["inhibitors", 1273], ["(", 1284], ["FTIs", 1285], [")", 1289], ["have", 1291], ["shown", 1296], ["potent", 1302], ["activity", 1309], ["in", 1318], ["vitro", 1321], ["and", 1327], ["in", 1331], ["animal", 1334], ["models", 1341], ["of", 1348], ["BCR", 1351], ["/", 1354], ["ABL", 1355], ["-", 1358], ["induced", 1359], ["leukemia", 1367], [".", 1375], ["Initial", 1377], ["clinical", 1385], ["trials", 1394], ["in", 1401], ["patients", 1404], ["with", 1413], ["refractory", 1418], ["acute", 1429], ["myeloid", 1435], ["leukemia", 1443], ["and", 1452], ["CML", 1456], ["in", 1460], ["blast", 1463], ["crisis", 1469], ["have", 1476], ["shown", 1481], ["significant", 1487], ["activity", 1499], [",", 1507], ["suggesting", 1509], ["that", 1520], ["trials", 1525], ["combining", 1532], ["imatinib", 1542], ["and", 1551], ["FTIs", 1555], ["are", 1560], ["warranted", 1564], [".", 1573]]}
{"context": "To evaluate the long-term impact of successive interventions on rates of methicillin-resistant Staphylococcus aureus (MRSA) colonization or infection and MRSA bacteremia in an endemic hospital-wide situation. Quasi-experimental, interrupted time-series analysis. The impact of the interventions was analyzed by use of segmented regression. Representative MRSA isolates were typed by use of pulsed-field gel electrophoresis. A 950-bed teaching hospital in Seville, Spain. All patients admitted to the hospital during the period from 1995 through 2008. Three successive interventions were studied: (1) contact precautions, with no active surveillance for MRSA; (2) targeted active surveillance for MRSA in patients and healthcare workers in specific wards, prioritized according to clinical epidemiology data; and (3) targeted active surveillance for MRSA in patients admitted from other medical centers. Neither the preintervention rate of MRSA colonization or infection (0.56 cases per 1,000 patient-days [95% confidence interval {CI}, 0.49-0.62 cases per 1,000 patient-days]) nor the slope for the rate of MRSA colonization or infection changed significantly after the first intervention. The rate decreased significantly to 0.28 cases per 1,000 patient-days (95% CI, 0.17-0.40 cases per 1,000 patient-days) after the second intervention and to 0.07 cases per 1,000 patient-days (95% CI, 0.06-0.08 cases per 1,000 patient-days) after the third intervention, and the rate remained at a similar level for 8 years. The MRSA bacteremia rate decreased by 80%, whereas the rate of bacteremia due to methicillin-susceptible S. aureus did not change. Eighty-three percent of the MRSA isolates identified were clonally related. All MRSA isolates obtained from healthcare workers were clonally related to those recovered from patients who were in their care. Our data indicate that long-term control of endemic MRSA is feasible in tertiary care centers. The use of targeted active surveillance for MRSA in patients and healthcare workers in specific wards (identified by means of analysis of clinical epidemiology data) and the use of decolonization were key to the success of the program.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "195e202a3f16414ebfc5916fde09ab66", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[351, 351], [112, 112], [160, 160], [59, 59], [19, 19], [283, 283], [25, 25], [121, 121], [199, 199], [313, 313], [146, 146], [321, 321], [366, 366]], "char_spans": [[1902, 1905], [653, 656], [939, 942], [355, 358], [118, 121], [1517, 1520], [154, 157], [696, 699], [1107, 1110], [1672, 1675], [849, 852], [1724, 1727], [1989, 1992]]}]}], "context_tokens": [["To", 0], ["evaluate", 3], ["the", 12], ["long", 16], ["-", 20], ["term", 21], ["impact", 26], ["of", 33], ["successive", 36], ["interventions", 47], ["on", 61], ["rates", 64], ["of", 70], ["methicillin", 73], ["-", 84], ["resistant", 85], ["Staphylococcus", 95], ["aureus", 110], ["(", 117], ["MRSA", 118], [")", 122], ["colonization", 124], ["or", 137], ["infection", 140], ["and", 150], ["MRSA", 154], ["bacteremia", 159], ["in", 170], ["an", 173], ["endemic", 176], ["hospital", 184], ["-", 192], ["wide", 193], ["situation", 198], [".", 207], ["Quasi", 209], ["-", 214], ["experimental", 215], [",", 227], ["interrupted", 229], ["time", 241], ["-", 245], ["series", 246], ["analysis", 253], [".", 261], ["The", 263], ["impact", 267], ["of", 274], ["the", 277], ["interventions", 281], ["was", 295], ["analyzed", 299], ["by", 308], ["use", 311], ["of", 315], ["segmented", 318], ["regression", 328], [".", 338], ["Representative", 340], ["MRSA", 355], ["isolates", 360], ["were", 369], ["typed", 374], ["by", 380], ["use", 383], ["of", 387], ["pulsed", 390], ["-", 396], ["field", 397], ["gel", 403], ["electrophoresis", 407], [".", 422], ["A", 424], ["950-bed", 426], ["teaching", 434], ["hospital", 443], ["in", 452], ["Seville", 455], [",", 462], ["Spain", 464], [".", 469], ["All", 471], ["patients", 475], ["admitted", 484], ["to", 493], ["the", 496], ["hospital", 500], ["during", 509], ["the", 516], ["period", 520], ["from", 527], ["1995", 532], ["through", 537], ["2008", 545], [".", 549], ["Three", 551], ["successive", 557], ["interventions", 568], ["were", 582], ["studied", 587], [":", 594], ["(", 596], ["1", 597], [")", 598], ["contact", 600], ["precautions", 608], [",", 619], ["with", 621], ["no", 626], ["active", 629], ["surveillance", 636], ["for", 649], ["MRSA", 653], [";", 657], ["(", 659], ["2", 660], [")", 661], ["targeted", 663], ["active", 672], ["surveillance", 679], ["for", 692], ["MRSA", 696], ["in", 701], ["patients", 704], ["and", 713], ["healthcare", 717], ["workers", 728], ["in", 736], ["specific", 739], ["wards", 748], [",", 753], ["prioritized", 755], ["according", 767], ["to", 777], ["clinical", 780], ["epidemiology", 789], ["data", 802], [";", 806], ["and", 808], ["(", 812], ["3", 813], [")", 814], ["targeted", 816], ["active", 825], ["surveillance", 832], ["for", 845], ["MRSA", 849], ["in", 854], ["patients", 857], ["admitted", 866], ["from", 875], ["other", 880], ["medical", 886], ["centers", 894], [".", 901], ["Neither", 903], ["the", 911], ["preintervention", 915], ["rate", 931], ["of", 936], ["MRSA", 939], ["colonization", 944], ["or", 957], ["infection", 960], ["(", 970], ["0.56", 971], ["cases", 976], ["per", 982], ["1,000", 986], ["patient", 992], ["-", 999], ["days", 1000], ["[", 1005], ["95", 1006], ["%", 1008], ["confidence", 1010], ["interval", 1021], ["{", 1030], ["CI", 1031], ["}", 1033], [",", 1034], ["0.49", 1036], ["-", 1040], ["0.62", 1041], ["cases", 1046], ["per", 1052], ["1,000", 1056], ["patient", 1062], ["-", 1069], ["days", 1070], ["]", 1074], [")", 1075], ["nor", 1077], ["the", 1081], ["slope", 1085], ["for", 1091], ["the", 1095], ["rate", 1099], ["of", 1104], ["MRSA", 1107], ["colonization", 1112], ["or", 1125], ["infection", 1128], ["changed", 1138], ["significantly", 1146], ["after", 1160], ["the", 1166], ["first", 1170], ["intervention", 1176], [".", 1188], ["The", 1190], ["rate", 1194], ["decreased", 1199], ["significantly", 1209], ["to", 1223], ["0.28", 1226], ["cases", 1231], ["per", 1237], ["1,000", 1241], ["patient", 1247], ["-", 1254], ["days", 1255], ["(", 1260], ["95", 1261], ["%", 1263], ["CI", 1265], [",", 1267], ["0.17", 1269], ["-", 1273], ["0.40", 1274], ["cases", 1279], ["per", 1285], ["1,000", 1289], ["patient", 1295], ["-", 1302], ["days", 1303], [")", 1307], ["after", 1309], ["the", 1315], ["second", 1319], ["intervention", 1326], ["and", 1339], ["to", 1343], ["0.07", 1346], ["cases", 1351], ["per", 1357], ["1,000", 1361], ["patient", 1367], ["-", 1374], ["days", 1375], ["(", 1380], ["95", 1381], ["%", 1383], ["CI", 1385], [",", 1387], ["0.06", 1389], ["-", 1393], ["0.08", 1394], ["cases", 1399], ["per", 1405], ["1,000", 1409], ["patient", 1415], ["-", 1422], ["days", 1423], [")", 1427], ["after", 1429], ["the", 1435], ["third", 1439], ["intervention", 1445], [",", 1457], ["and", 1459], ["the", 1463], ["rate", 1467], ["remained", 1472], ["at", 1481], ["a", 1484], ["similar", 1486], ["level", 1494], ["for", 1500], ["8", 1504], ["years", 1506], [".", 1511], ["The", 1513], ["MRSA", 1517], ["bacteremia", 1522], ["rate", 1533], ["decreased", 1538], ["by", 1548], ["80", 1551], ["%", 1553], [",", 1554], ["whereas", 1556], ["the", 1564], ["rate", 1568], ["of", 1573], ["bacteremia", 1576], ["due", 1587], ["to", 1591], ["methicillin", 1594], ["-", 1605], ["susceptible", 1606], ["S.", 1618], ["aureus", 1621], ["did", 1628], ["not", 1632], ["change", 1636], [".", 1642], ["Eighty", 1644], ["-", 1650], ["three", 1651], ["percent", 1657], ["of", 1665], ["the", 1668], ["MRSA", 1672], ["isolates", 1677], ["identified", 1686], ["were", 1697], ["clonally", 1702], ["related", 1711], [".", 1718], ["All", 1720], ["MRSA", 1724], ["isolates", 1729], ["obtained", 1738], ["from", 1747], ["healthcare", 1752], ["workers", 1763], ["were", 1771], ["clonally", 1776], ["related", 1785], ["to", 1793], ["those", 1796], ["recovered", 1802], ["from", 1812], ["patients", 1817], ["who", 1826], ["were", 1830], ["in", 1835], ["their", 1838], ["care", 1844], [".", 1848], ["Our", 1850], ["data", 1854], ["indicate", 1859], ["that", 1868], ["long", 1873], ["-", 1877], ["term", 1878], ["control", 1883], ["of", 1891], ["endemic", 1894], ["MRSA", 1902], ["is", 1907], ["feasible", 1910], ["in", 1919], ["tertiary", 1922], ["care", 1931], ["centers", 1936], [".", 1943], ["The", 1945], ["use", 1949], ["of", 1953], ["targeted", 1956], ["active", 1965], ["surveillance", 1972], ["for", 1985], ["MRSA", 1989], ["in", 1994], ["patients", 1997], ["and", 2006], ["healthcare", 2010], ["workers", 2021], ["in", 2029], ["specific", 2032], ["wards", 2041], ["(", 2047], ["identified", 2048], ["by", 2059], ["means", 2062], ["of", 2068], ["analysis", 2071], ["of", 2080], ["clinical", 2083], ["epidemiology", 2092], ["data", 2105], [")", 2109], ["and", 2111], ["the", 2115], ["use", 2119], ["of", 2123], ["decolonization", 2126], ["were", 2141], ["key", 2146], ["to", 2150], ["the", 2153], ["success", 2157], ["of", 2165], ["the", 2168], ["program", 2172], [".", 2179]]}
{"context": "NADPH oxidase (Nox) family enzymes are one of the main sources of cellular reactive oxygen species (ROS), which have been implicated in several physiological and pathophysiological processes. To date seven members of this family have been reported, including Nox1-5 and Duox1 and 2. With the exception of Nox2, the regulation of the Nox enzymes is still poorly understood. Nox1 is highly expressed in the colon, and requires two cytosolic regulators, the organizer subunit NoxO1 and the activator subunit NoxA1, as well as the binding of Rac1 GTPase, for its activity. Recently, we identified the c-Src substrate proteins Tks4 and Tks5 as functional members of a p47(phox)-related organizer superfamily. As a functional consequence of this interaction, Nox1 localizes to invadopodia, actin-rich membrane protrusions of cancer cells which facilitate pericellular proteolysis and invasive behavior. Here, we report that Tks4 and Tks5 directly bind to NoxA1. Moreover, the integrity of the N-terminal PRR of NoxA1 is essential for this direct interaction with the Tks proteins. When the PRR in NoxA1 is disrupted, Tks proteins cannot bind NoxA1 and lose their ability to support Nox1-dependent ROS generation. Consistent with this, Tks4 and Tks5 are unable to act as organizers for Nox2 because of their inability to interact with p67(phox), which lacks the N-terminal PRR, thus conferring a unique specificity to Tks4 and 5. Taken together, these results clarify the molecular basis for the interaction between NoxA1 and the Tks proteins and may provide new insights into the pharmacological design of a more effective anti-metastatic strategy.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "809980294d6346f88b44bf8f45d50ed7", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[137, 137], [45, 45], [70, 70]], "char_spans": [[753, 756], [259, 262], [373, 376]]}]}], "context_tokens": [["NADPH", 0], ["oxidase", 6], ["(", 14], ["Nox", 15], [")", 18], ["family", 20], ["enzymes", 27], ["are", 35], ["one", 39], ["of", 43], ["the", 46], ["main", 50], ["sources", 55], ["of", 63], ["cellular", 66], ["reactive", 75], ["oxygen", 84], ["species", 91], ["(", 99], ["ROS", 100], [")", 103], [",", 104], ["which", 106], ["have", 112], ["been", 117], ["implicated", 122], ["in", 133], ["several", 136], ["physiological", 144], ["and", 158], ["pathophysiological", 162], ["processes", 181], [".", 190], ["To", 192], ["date", 195], ["seven", 200], ["members", 206], ["of", 214], ["this", 217], ["family", 222], ["have", 229], ["been", 234], ["reported", 239], [",", 247], ["including", 249], ["Nox1", 259], ["-", 263], ["5", 264], ["and", 266], ["Duox1", 270], ["and", 276], ["2", 280], [".", 281], ["With", 283], ["the", 288], ["exception", 292], ["of", 302], ["Nox2", 305], [",", 309], ["the", 311], ["regulation", 315], ["of", 326], ["the", 329], ["Nox", 333], ["enzymes", 337], ["is", 345], ["still", 348], ["poorly", 354], ["understood", 361], [".", 371], ["Nox1", 373], ["is", 378], ["highly", 381], ["expressed", 388], ["in", 398], ["the", 401], ["colon", 405], [",", 410], ["and", 412], ["requires", 416], ["two", 425], ["cytosolic", 429], ["regulators", 439], [",", 449], ["the", 451], ["organizer", 455], ["subunit", 465], ["NoxO1", 473], ["and", 479], ["the", 483], ["activator", 487], ["subunit", 497], ["NoxA1", 505], [",", 510], ["as", 512], ["well", 515], ["as", 520], ["the", 523], ["binding", 527], ["of", 535], ["Rac1", 538], ["GTPase", 543], [",", 549], ["for", 551], ["its", 555], ["activity", 559], [".", 567], ["Recently", 569], [",", 577], ["we", 579], ["identified", 582], ["the", 593], ["c", 597], ["-", 598], ["Src", 599], ["substrate", 603], ["proteins", 613], ["Tks4", 622], ["and", 627], ["Tks5", 631], ["as", 636], ["functional", 639], ["members", 650], ["of", 658], ["a", 661], ["p47(phox)-related", 663], ["organizer", 681], ["superfamily", 691], [".", 702], ["As", 704], ["a", 707], ["functional", 709], ["consequence", 720], ["of", 732], ["this", 735], ["interaction", 740], [",", 751], ["Nox1", 753], ["localizes", 758], ["to", 768], ["invadopodia", 771], [",", 782], ["actin", 784], ["-", 789], ["rich", 790], ["membrane", 795], ["protrusions", 804], ["of", 816], ["cancer", 819], ["cells", 826], ["which", 832], ["facilitate", 838], ["pericellular", 849], ["proteolysis", 862], ["and", 874], ["invasive", 878], ["behavior", 887], [".", 895], ["Here", 897], [",", 901], ["we", 903], ["report", 906], ["that", 913], ["Tks4", 918], ["and", 923], ["Tks5", 927], ["directly", 932], ["bind", 941], ["to", 946], ["NoxA1", 949], [".", 954], ["Moreover", 956], [",", 964], ["the", 966], ["integrity", 970], ["of", 980], ["the", 983], ["N", 987], ["-", 988], ["terminal", 989], ["PRR", 998], ["of", 1002], ["NoxA1", 1005], ["is", 1011], ["essential", 1014], ["for", 1024], ["this", 1028], ["direct", 1033], ["interaction", 1040], ["with", 1052], ["the", 1057], ["Tks", 1061], ["proteins", 1065], [".", 1073], ["When", 1075], ["the", 1080], ["PRR", 1084], ["in", 1088], ["NoxA1", 1091], ["is", 1097], ["disrupted", 1100], [",", 1109], ["Tks", 1111], ["proteins", 1115], ["can", 1124], ["not", 1127], ["bind", 1131], ["NoxA1", 1136], ["and", 1142], ["lose", 1146], ["their", 1151], ["ability", 1157], ["to", 1165], ["support", 1168], ["Nox1-dependent", 1176], ["ROS", 1191], ["generation", 1195], [".", 1205], ["Consistent", 1207], ["with", 1218], ["this", 1223], [",", 1227], ["Tks4", 1229], ["and", 1234], ["Tks5", 1238], ["are", 1243], ["unable", 1247], ["to", 1254], ["act", 1257], ["as", 1261], ["organizers", 1264], ["for", 1275], ["Nox2", 1279], ["because", 1284], ["of", 1292], ["their", 1295], ["inability", 1301], ["to", 1311], ["interact", 1314], ["with", 1323], ["p67(phox", 1328], [")", 1336], [",", 1337], ["which", 1339], ["lacks", 1345], ["the", 1351], ["N", 1355], ["-", 1356], ["terminal", 1357], ["PRR", 1366], [",", 1369], ["thus", 1371], ["conferring", 1376], ["a", 1387], ["unique", 1389], ["specificity", 1396], ["to", 1408], ["Tks4", 1411], ["and", 1416], ["5", 1420], [".", 1421], ["Taken", 1423], ["together", 1429], [",", 1437], ["these", 1439], ["results", 1445], ["clarify", 1453], ["the", 1461], ["molecular", 1465], ["basis", 1475], ["for", 1481], ["the", 1485], ["interaction", 1489], ["between", 1501], ["NoxA1", 1509], ["and", 1515], ["the", 1519], ["Tks", 1523], ["proteins", 1527], ["and", 1536], ["may", 1540], ["provide", 1544], ["new", 1552], ["insights", 1556], ["into", 1565], ["the", 1570], ["pharmacological", 1574], ["design", 1590], ["of", 1597], ["a", 1600], ["more", 1602], ["effective", 1607], ["anti", 1617], ["-", 1621], ["metastatic", 1622], ["strategy", 1633], [".", 1641]]}
{"context": "Giant-cell tumor of bone is a rare, locally aggressive tumor that typically occurs in the bones of skeletally mature young adults in their second to fourth decades. Traditionally, surgery has been the mainstay of therapy for this disease, but the disease can recur even with optimal procedures. Furthermore, it may occur in locations where a surgical approach would be morbid. The maturation of the understanding of the role of the receptor activator of nuclear factor-\u03baB ligand (RANKL) in the pathophysiology of giant-cell tumor of bone has led to the use of denosumab, a monoclonal antibody against RANKL, in this disease. In 2013, the US Food and Drug Administration approved denosumab for use in patients with recurrent/unresectable/metastatic giant-cell tumor of bone or for patients in whom surgery would be morbid.", "qas": [{"question": "Which is the target of the drug Denosumab?", "answers": ["receptor activator of nuclear factor-\u03baB ligand", "RANKL"], "qid": "ce4f694e2894496cb11f3d96bd206a41", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["target", 13], ["of", 20], ["the", 23], ["drug", 27], ["Denosumab", 32], ["?", 41]], "detected_answers": [{"text": "receptor activator of nuclear factor-\u03baB ligand", "token_spans": [[79, 86]], "char_spans": [[432, 477]]}, {"text": "RANKL", "token_spans": [[88, 88], [112, 112]], "char_spans": [[480, 484], [601, 605]]}]}], "context_tokens": [["Giant", 0], ["-", 5], ["cell", 6], ["tumor", 11], ["of", 17], ["bone", 20], ["is", 25], ["a", 28], ["rare", 30], [",", 34], ["locally", 36], ["aggressive", 44], ["tumor", 55], ["that", 61], ["typically", 66], ["occurs", 76], ["in", 83], ["the", 86], ["bones", 90], ["of", 96], ["skeletally", 99], ["mature", 110], ["young", 117], ["adults", 123], ["in", 130], ["their", 133], ["second", 139], ["to", 146], ["fourth", 149], ["decades", 156], [".", 163], ["Traditionally", 165], [",", 178], ["surgery", 180], ["has", 188], ["been", 192], ["the", 197], ["mainstay", 201], ["of", 210], ["therapy", 213], ["for", 221], ["this", 225], ["disease", 230], [",", 237], ["but", 239], ["the", 243], ["disease", 247], ["can", 255], ["recur", 259], ["even", 265], ["with", 270], ["optimal", 275], ["procedures", 283], [".", 293], ["Furthermore", 295], [",", 306], ["it", 308], ["may", 311], ["occur", 315], ["in", 321], ["locations", 324], ["where", 334], ["a", 340], ["surgical", 342], ["approach", 351], ["would", 360], ["be", 366], ["morbid", 369], [".", 375], ["The", 377], ["maturation", 381], ["of", 392], ["the", 395], ["understanding", 399], ["of", 413], ["the", 416], ["role", 420], ["of", 425], ["the", 428], ["receptor", 432], ["activator", 441], ["of", 451], ["nuclear", 454], ["factor", 462], ["-", 468], ["\u03baB", 469], ["ligand", 472], ["(", 479], ["RANKL", 480], [")", 485], ["in", 487], ["the", 490], ["pathophysiology", 494], ["of", 510], ["giant", 513], ["-", 518], ["cell", 519], ["tumor", 524], ["of", 530], ["bone", 533], ["has", 538], ["led", 542], ["to", 546], ["the", 549], ["use", 553], ["of", 557], ["denosumab", 560], [",", 569], ["a", 571], ["monoclonal", 573], ["antibody", 584], ["against", 593], ["RANKL", 601], [",", 606], ["in", 608], ["this", 611], ["disease", 616], [".", 623], ["In", 625], ["2013", 628], [",", 632], ["the", 634], ["US", 638], ["Food", 641], ["and", 646], ["Drug", 650], ["Administration", 655], ["approved", 670], ["denosumab", 679], ["for", 689], ["use", 693], ["in", 697], ["patients", 700], ["with", 709], ["recurrent", 714], ["/", 723], ["unresectable", 724], ["/", 736], ["metastatic", 737], ["giant", 748], ["-", 753], ["cell", 754], ["tumor", 759], ["of", 765], ["bone", 768], ["or", 773], ["for", 776], ["patients", 780], ["in", 789], ["whom", 792], ["surgery", 797], ["would", 805], ["be", 811], ["morbid", 814], [".", 820]]}
{"context": "A significant role for IFN\u03b1 in the pathogenesis of systemic lupus erythematosus is well supported, and clinical trials of anti-IFN\u03b1 monoclonal antibodies are in progress in this disease. In other autoimmune diseases characterized by substantial inflammation and tissue destruction, the role of type I interferons is less clear. Gene expression analysis of peripheral blood cells from patients with rheumatoid arthritis and multiple sclerosis demonstrate an interferon signature similar to but less intense than that seen in patients with lupus. In both of those diseases, presence of the interferon signature has been associated with more significant clinical manifestations. At the same time, evidence supports an anti-inflammatory and beneficial role of IFN\u03b2 locally in the joints of patients with rheumatoid arthritis and in murine arthritis models, and many patients with multiple sclerosis show a clinical response to recombinant IFN\u03b2. As can also be proposed for type I diabetes mellitus, type I interferon appears to contribute to the development of autoimmunity and disease progression in multiple autoimmune diseases, while maintaining some capacity to control established disease - particularly at local sites of inflammation. Recent studies in both rheumatoid arthritis and multiple sclerosis suggest that quantification of type I interferon activity or target gene expression might be informative in predicting responses to distinct classes of therapeutic agents.", "qas": [{"question": "Which is the most common gene signature in Rheumatoid Arthritis patients?", "answers": ["Interferon signature", "IFN signature"], "qid": "ee9066e593e54642861b2b0705b2a15a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["common", 18], ["gene", 25], ["signature", 30], ["in", 40], ["Rheumatoid", 43], ["Arthritis", 54], ["patients", 64], ["?", 72]], "detected_answers": [{"text": "Interferon signature", "token_spans": [[71, 72], [95, 96]], "char_spans": [[457, 476], [588, 607]]}]}], "context_tokens": [["A", 0], ["significant", 2], ["role", 14], ["for", 19], ["IFN\u03b1", 23], ["in", 28], ["the", 31], ["pathogenesis", 35], ["of", 48], ["systemic", 51], ["lupus", 60], ["erythematosus", 66], ["is", 80], ["well", 83], ["supported", 88], [",", 97], ["and", 99], ["clinical", 103], ["trials", 112], ["of", 119], ["anti", 122], ["-", 126], ["IFN\u03b1", 127], ["monoclonal", 132], ["antibodies", 143], ["are", 154], ["in", 158], ["progress", 161], ["in", 170], ["this", 173], ["disease", 178], [".", 185], ["In", 187], ["other", 190], ["autoimmune", 196], ["diseases", 207], ["characterized", 216], ["by", 230], ["substantial", 233], ["inflammation", 245], ["and", 258], ["tissue", 262], ["destruction", 269], [",", 280], ["the", 282], ["role", 286], ["of", 291], ["type", 294], ["I", 299], ["interferons", 301], ["is", 313], ["less", 316], ["clear", 321], [".", 326], ["Gene", 328], ["expression", 333], ["analysis", 344], ["of", 353], ["peripheral", 356], ["blood", 367], ["cells", 373], ["from", 379], ["patients", 384], ["with", 393], ["rheumatoid", 398], ["arthritis", 409], ["and", 419], ["multiple", 423], ["sclerosis", 432], ["demonstrate", 442], ["an", 454], ["interferon", 457], ["signature", 468], ["similar", 478], ["to", 486], ["but", 489], ["less", 493], ["intense", 498], ["than", 506], ["that", 511], ["seen", 516], ["in", 521], ["patients", 524], ["with", 533], ["lupus", 538], [".", 543], ["In", 545], ["both", 548], ["of", 553], ["those", 556], ["diseases", 562], [",", 570], ["presence", 572], ["of", 581], ["the", 584], ["interferon", 588], ["signature", 599], ["has", 609], ["been", 613], ["associated", 618], ["with", 629], ["more", 634], ["significant", 639], ["clinical", 651], ["manifestations", 660], [".", 674], ["At", 676], ["the", 679], ["same", 683], ["time", 688], [",", 692], ["evidence", 694], ["supports", 703], ["an", 712], ["anti", 715], ["-", 719], ["inflammatory", 720], ["and", 733], ["beneficial", 737], ["role", 748], ["of", 753], ["IFN\u03b2", 756], ["locally", 761], ["in", 769], ["the", 772], ["joints", 776], ["of", 783], ["patients", 786], ["with", 795], ["rheumatoid", 800], ["arthritis", 811], ["and", 821], ["in", 825], ["murine", 828], ["arthritis", 835], ["models", 845], [",", 851], ["and", 853], ["many", 857], ["patients", 862], ["with", 871], ["multiple", 876], ["sclerosis", 885], ["show", 895], ["a", 900], ["clinical", 902], ["response", 911], ["to", 920], ["recombinant", 923], ["IFN\u03b2", 935], [".", 939], ["As", 941], ["can", 944], ["also", 948], ["be", 953], ["proposed", 956], ["for", 965], ["type", 969], ["I", 974], ["diabetes", 976], ["mellitus", 985], [",", 993], ["type", 995], ["I", 1000], ["interferon", 1002], ["appears", 1013], ["to", 1021], ["contribute", 1024], ["to", 1035], ["the", 1038], ["development", 1042], ["of", 1054], ["autoimmunity", 1057], ["and", 1070], ["disease", 1074], ["progression", 1082], ["in", 1094], ["multiple", 1097], ["autoimmune", 1106], ["diseases", 1117], [",", 1125], ["while", 1127], ["maintaining", 1133], ["some", 1145], ["capacity", 1150], ["to", 1159], ["control", 1162], ["established", 1170], ["disease", 1182], ["-", 1190], ["particularly", 1192], ["at", 1205], ["local", 1208], ["sites", 1214], ["of", 1220], ["inflammation", 1223], [".", 1235], ["Recent", 1237], ["studies", 1244], ["in", 1252], ["both", 1255], ["rheumatoid", 1260], ["arthritis", 1271], ["and", 1281], ["multiple", 1285], ["sclerosis", 1294], ["suggest", 1304], ["that", 1312], ["quantification", 1317], ["of", 1332], ["type", 1335], ["I", 1340], ["interferon", 1342], ["activity", 1353], ["or", 1362], ["target", 1365], ["gene", 1372], ["expression", 1377], ["might", 1388], ["be", 1394], ["informative", 1397], ["in", 1409], ["predicting", 1412], ["responses", 1423], ["to", 1433], ["distinct", 1436], ["classes", 1445], ["of", 1453], ["therapeutic", 1456], ["agents", 1468], [".", 1474]]}
{"context": "Opicapone is a novel third generation catechol-O-methyltransferase (COMT) inhibitor. The purpose of this study was to compare the levodopa pharmacokinetic profile throughout a day driven by the COMT inhibition either following repeated doses of opicapone or concomitant administration with entacapone. A randomized, double-blind, gender-balanced, parallel-group study was performed in 4 groups of 20 healthy subjects each. Four subjects in each group received placebo during the entire study. Sixteen subjects in one group received placebo once daily for 11 days and on day 12, 200 mg entacapone concomitantly with each levodopa/carbidopa dose (three times separated by a 5-h interval). Sixteen subjects in each of the remaining three groups received respectively 25, 50, and 75 mg opicapone once daily for 11 days and on day 12, placebo concomitantly with each levodopa/carbidopa dose. Levodopa minimum plasma concentration (Cmin) for each levodopa/carbidopa dose and for the mean of all levodopa/carbidopa doses increased substantially with all active treatments (entacapone and opicapone) when compared to the control group (placebo), with values ranging from 1.7-fold (200 mg entacapone) to 3.3-fold (75 mg opicapone). No statistical difference was found for levodopa peak of systemic exposure (as assessed by maximum observed plasma concentration (Cmax)) between all active treatments and placebo. A significant increase in the levodopa extent of systemic exposure (as assessed by concentration-time curve (AUC)) occurred with all opicapone treatments in relation to placebo. No statistical difference was found for levodopa AUC when entacapone was compared to placebo. When compared to entacapone, both 50 and 75 mg opicapone presented a significant increase for the levodopa AUC. All active treatments significantly inhibited both peak (as assessed by Emax) and extent (as assessed by effect-time curve (AUEC)) of the COMT activity in relation to placebo. When compared to entacapone, all opicapone treatments significantly decreased the extent (AUEC) of the COMT activity due to a long-lasting and sustained effect. The tolerability profile was favorable for all active treatments. Opicapone, a novel third generation COMT inhibitor, when compared to entacapone, provides a superior response upon the bioavailability of levodopa associated to more pronounced, long-lasting, and sustained COMT inhibition. The tolerability profile was favorable. On the basis of the results presented in this study and along with the earlier pharmacology studies, it is anticipated that opicapone adjunct therapy at the dosages of 25 and 50 mg will provide an enhancement in levodopa availability that will translate into clinical benefit for Parkinson's disease patients.", "qas": [{"question": "What enzyme is inhibied by Opicapone?", "answers": ["catechol-O-methyltransferase"], "qid": "0e5ff4402f1e44c1a1d80868713f9b9f", "question_tokens": [["What", 0], ["enzyme", 5], ["is", 12], ["inhibied", 15], ["by", 24], ["Opicapone", 27], ["?", 36]], "detected_answers": [{"text": "catechol-O-methyltransferase", "token_spans": [[6, 10]], "char_spans": [[38, 65]]}]}], "context_tokens": [["Opicapone", 0], ["is", 10], ["a", 13], ["novel", 15], ["third", 21], ["generation", 27], ["catechol", 38], ["-", 46], ["O", 47], ["-", 48], ["methyltransferase", 49], ["(", 67], ["COMT", 68], [")", 72], ["inhibitor", 74], [".", 83], ["The", 85], ["purpose", 89], ["of", 97], ["this", 100], ["study", 105], ["was", 111], ["to", 115], ["compare", 118], ["the", 126], ["levodopa", 130], ["pharmacokinetic", 139], ["profile", 155], ["throughout", 163], ["a", 174], ["day", 176], ["driven", 180], ["by", 187], ["the", 190], ["COMT", 194], ["inhibition", 199], ["either", 210], ["following", 217], ["repeated", 227], ["doses", 236], ["of", 242], ["opicapone", 245], ["or", 255], ["concomitant", 258], ["administration", 270], ["with", 285], ["entacapone", 290], [".", 300], ["A", 302], ["randomized", 304], [",", 314], ["double", 316], ["-", 322], ["blind", 323], [",", 328], ["gender", 330], ["-", 336], ["balanced", 337], [",", 345], ["parallel", 347], ["-", 355], ["group", 356], ["study", 362], ["was", 368], ["performed", 372], ["in", 382], ["4", 385], ["groups", 387], ["of", 394], ["20", 397], ["healthy", 400], ["subjects", 408], ["each", 417], [".", 421], ["Four", 423], ["subjects", 428], ["in", 437], ["each", 440], ["group", 445], ["received", 451], ["placebo", 460], ["during", 468], ["the", 475], ["entire", 479], ["study", 486], [".", 491], ["Sixteen", 493], ["subjects", 501], ["in", 510], ["one", 513], ["group", 517], ["received", 523], ["placebo", 532], ["once", 540], ["daily", 545], ["for", 551], ["11", 555], ["days", 558], ["and", 563], ["on", 567], ["day", 570], ["12", 574], [",", 576], ["200", 578], ["mg", 582], ["entacapone", 585], ["concomitantly", 596], ["with", 610], ["each", 615], ["levodopa", 620], ["/", 628], ["carbidopa", 629], ["dose", 639], ["(", 644], ["three", 645], ["times", 651], ["separated", 657], ["by", 667], ["a", 670], ["5-h", 672], ["interval", 676], [")", 684], [".", 685], ["Sixteen", 687], ["subjects", 695], ["in", 704], ["each", 707], ["of", 712], ["the", 715], ["remaining", 719], ["three", 729], ["groups", 735], ["received", 742], ["respectively", 751], ["25", 764], [",", 766], ["50", 768], [",", 770], ["and", 772], ["75", 776], ["mg", 779], ["opicapone", 782], ["once", 792], ["daily", 797], ["for", 803], ["11", 807], ["days", 810], ["and", 815], ["on", 819], ["day", 822], ["12", 826], [",", 828], ["placebo", 830], ["concomitantly", 838], ["with", 852], ["each", 857], ["levodopa", 862], ["/", 870], ["carbidopa", 871], ["dose", 881], [".", 885], ["Levodopa", 887], ["minimum", 896], ["plasma", 904], ["concentration", 911], ["(", 925], ["Cmin", 926], [")", 930], ["for", 932], ["each", 936], ["levodopa", 941], ["/", 949], ["carbidopa", 950], ["dose", 960], ["and", 965], ["for", 969], ["the", 973], ["mean", 977], ["of", 982], ["all", 985], ["levodopa", 989], ["/", 997], ["carbidopa", 998], ["doses", 1008], ["increased", 1014], ["substantially", 1024], ["with", 1038], ["all", 1043], ["active", 1047], ["treatments", 1054], ["(", 1065], ["entacapone", 1066], ["and", 1077], ["opicapone", 1081], [")", 1090], ["when", 1092], ["compared", 1097], ["to", 1106], ["the", 1109], ["control", 1113], ["group", 1121], ["(", 1127], ["placebo", 1128], [")", 1135], [",", 1136], ["with", 1138], ["values", 1143], ["ranging", 1150], ["from", 1158], ["1.7-fold", 1163], ["(", 1172], ["200", 1173], ["mg", 1177], ["entacapone", 1180], [")", 1190], ["to", 1192], ["3.3-fold", 1195], ["(", 1204], ["75", 1205], ["mg", 1208], ["opicapone", 1211], [")", 1220], [".", 1221], ["No", 1223], ["statistical", 1226], ["difference", 1238], ["was", 1249], ["found", 1253], ["for", 1259], ["levodopa", 1263], ["peak", 1272], ["of", 1277], ["systemic", 1280], ["exposure", 1289], ["(", 1298], ["as", 1299], ["assessed", 1302], ["by", 1311], ["maximum", 1314], ["observed", 1322], ["plasma", 1331], ["concentration", 1338], ["(", 1352], ["Cmax", 1353], [")", 1357], [")", 1358], ["between", 1360], ["all", 1368], ["active", 1372], ["treatments", 1379], ["and", 1390], ["placebo", 1394], [".", 1401], ["A", 1403], ["significant", 1405], ["increase", 1417], ["in", 1426], ["the", 1429], ["levodopa", 1433], ["extent", 1442], ["of", 1449], ["systemic", 1452], ["exposure", 1461], ["(", 1470], ["as", 1471], ["assessed", 1474], ["by", 1483], ["concentration", 1486], ["-", 1499], ["time", 1500], ["curve", 1505], ["(", 1511], ["AUC", 1512], [")", 1515], [")", 1516], ["occurred", 1518], ["with", 1527], ["all", 1532], ["opicapone", 1536], ["treatments", 1546], ["in", 1557], ["relation", 1560], ["to", 1569], ["placebo", 1572], [".", 1579], ["No", 1581], ["statistical", 1584], ["difference", 1596], ["was", 1607], ["found", 1611], ["for", 1617], ["levodopa", 1621], ["AUC", 1630], ["when", 1634], ["entacapone", 1639], ["was", 1650], ["compared", 1654], ["to", 1663], ["placebo", 1666], [".", 1673], ["When", 1675], ["compared", 1680], ["to", 1689], ["entacapone", 1692], [",", 1702], ["both", 1704], ["50", 1709], ["and", 1712], ["75", 1716], ["mg", 1719], ["opicapone", 1722], ["presented", 1732], ["a", 1742], ["significant", 1744], ["increase", 1756], ["for", 1765], ["the", 1769], ["levodopa", 1773], ["AUC", 1782], [".", 1785], ["All", 1787], ["active", 1791], ["treatments", 1798], ["significantly", 1809], ["inhibited", 1823], ["both", 1833], ["peak", 1838], ["(", 1843], ["as", 1844], ["assessed", 1847], ["by", 1856], ["Emax", 1859], [")", 1863], ["and", 1865], ["extent", 1869], ["(", 1876], ["as", 1877], ["assessed", 1880], ["by", 1889], ["effect", 1892], ["-", 1898], ["time", 1899], ["curve", 1904], ["(", 1910], ["AUEC", 1911], [")", 1915], [")", 1916], ["of", 1918], ["the", 1921], ["COMT", 1925], ["activity", 1930], ["in", 1939], ["relation", 1942], ["to", 1951], ["placebo", 1954], [".", 1961], ["When", 1963], ["compared", 1968], ["to", 1977], ["entacapone", 1980], [",", 1990], ["all", 1992], ["opicapone", 1996], ["treatments", 2006], ["significantly", 2017], ["decreased", 2031], ["the", 2041], ["extent", 2045], ["(", 2052], ["AUEC", 2053], [")", 2057], ["of", 2059], ["the", 2062], ["COMT", 2066], ["activity", 2071], ["due", 2080], ["to", 2084], ["a", 2087], ["long", 2089], ["-", 2093], ["lasting", 2094], ["and", 2102], ["sustained", 2106], ["effect", 2116], [".", 2122], ["The", 2124], ["tolerability", 2128], ["profile", 2141], ["was", 2149], ["favorable", 2153], ["for", 2163], ["all", 2167], ["active", 2171], ["treatments", 2178], [".", 2188], ["Opicapone", 2190], [",", 2199], ["a", 2201], ["novel", 2203], ["third", 2209], ["generation", 2215], ["COMT", 2226], ["inhibitor", 2231], [",", 2240], ["when", 2242], ["compared", 2247], ["to", 2256], ["entacapone", 2259], [",", 2269], ["provides", 2271], ["a", 2280], ["superior", 2282], ["response", 2291], ["upon", 2300], ["the", 2305], ["bioavailability", 2309], ["of", 2325], ["levodopa", 2328], ["associated", 2337], ["to", 2348], ["more", 2351], ["pronounced", 2356], [",", 2366], ["long", 2368], ["-", 2372], ["lasting", 2373], [",", 2380], ["and", 2382], ["sustained", 2386], ["COMT", 2396], ["inhibition", 2401], [".", 2411], ["The", 2413], ["tolerability", 2417], ["profile", 2430], ["was", 2438], ["favorable", 2442], [".", 2451], ["On", 2453], ["the", 2456], ["basis", 2460], ["of", 2466], ["the", 2469], ["results", 2473], ["presented", 2481], ["in", 2491], ["this", 2494], ["study", 2499], ["and", 2505], ["along", 2509], ["with", 2515], ["the", 2520], ["earlier", 2524], ["pharmacology", 2532], ["studies", 2545], [",", 2552], ["it", 2554], ["is", 2557], ["anticipated", 2560], ["that", 2572], ["opicapone", 2577], ["adjunct", 2587], ["therapy", 2595], ["at", 2603], ["the", 2606], ["dosages", 2610], ["of", 2618], ["25", 2621], ["and", 2624], ["50", 2628], ["mg", 2631], ["will", 2634], ["provide", 2639], ["an", 2647], ["enhancement", 2650], ["in", 2662], ["levodopa", 2665], ["availability", 2674], ["that", 2687], ["will", 2692], ["translate", 2697], ["into", 2707], ["clinical", 2712], ["benefit", 2721], ["for", 2729], ["Parkinson", 2733], ["'s", 2742], ["disease", 2745], ["patients", 2753], [".", 2761]]}
{"context": "Facioscapulohumeral dystrophy (FSHD) is characterized by chromatin relaxation of the D4Z4 macrosatellite array on chromosome 4 and expression of the D4Z4-encoded DUX4 gene in skeletal muscle. The more common form, autosomal dominant FSHD1, is caused by contraction of the D4Z4 array, whereas the genetic determinants and inheritance of D4Z4 array contraction-independent FSHD2 are unclear. Here, we show that mutations in SMCHD1 (encoding structural maintenance of chromosomes flexible hinge domain containing 1) on chromosome 18 reduce SMCHD1 protein levels and segregate with genome-wide D4Z4 CpG hypomethylation in human kindreds. FSHD2 occurs in individuals who inherited both the SMCHD1 mutation and a normal-sized D4Z4 array on a chromosome 4 haplotype permissive for DUX4 expression. Reducing SMCHD1 levels in skeletal muscle results in D4Z4 contraction-independent DUX4 expression. Our study identifies SMCHD1 as an epigenetic modifier of the D4Z4 metastable epiallele and as a causal genetic determinant of FSHD2 and possibly other human diseases subject to epigenetic regulation.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "1e975a42f37e4673a2b441a56ec1c446", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "Facioscapulohumeral dystrophy", "token_spans": [[0, 1]], "char_spans": [[0, 28]]}, {"text": "FSHD", "token_spans": [[3, 3]], "char_spans": [[31, 34]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["dystrophy", 20], ["(", 30], ["FSHD", 31], [")", 35], ["is", 37], ["characterized", 40], ["by", 54], ["chromatin", 57], ["relaxation", 67], ["of", 78], ["the", 81], ["D4Z4", 85], ["macrosatellite", 90], ["array", 105], ["on", 111], ["chromosome", 114], ["4", 125], ["and", 127], ["expression", 131], ["of", 142], ["the", 145], ["D4Z4-encoded", 149], ["DUX4", 162], ["gene", 167], ["in", 172], ["skeletal", 175], ["muscle", 184], [".", 190], ["The", 192], ["more", 196], ["common", 201], ["form", 208], [",", 212], ["autosomal", 214], ["dominant", 224], ["FSHD1", 233], [",", 238], ["is", 240], ["caused", 243], ["by", 250], ["contraction", 253], ["of", 265], ["the", 268], ["D4Z4", 272], ["array", 277], [",", 282], ["whereas", 284], ["the", 292], ["genetic", 296], ["determinants", 304], ["and", 317], ["inheritance", 321], ["of", 333], ["D4Z4", 336], ["array", 341], ["contraction", 347], ["-", 358], ["independent", 359], ["FSHD2", 371], ["are", 377], ["unclear", 381], [".", 388], ["Here", 390], [",", 394], ["we", 396], ["show", 399], ["that", 404], ["mutations", 409], ["in", 419], ["SMCHD1", 422], ["(", 429], ["encoding", 430], ["structural", 439], ["maintenance", 450], ["of", 462], ["chromosomes", 465], ["flexible", 477], ["hinge", 486], ["domain", 492], ["containing", 499], ["1", 510], [")", 511], ["on", 513], ["chromosome", 516], ["18", 527], ["reduce", 530], ["SMCHD1", 537], ["protein", 544], ["levels", 552], ["and", 559], ["segregate", 563], ["with", 573], ["genome", 578], ["-", 584], ["wide", 585], ["D4Z4", 590], ["CpG", 595], ["hypomethylation", 599], ["in", 615], ["human", 618], ["kindreds", 624], [".", 632], ["FSHD2", 634], ["occurs", 640], ["in", 647], ["individuals", 650], ["who", 662], ["inherited", 666], ["both", 676], ["the", 681], ["SMCHD1", 685], ["mutation", 692], ["and", 701], ["a", 705], ["normal", 707], ["-", 713], ["sized", 714], ["D4Z4", 720], ["array", 725], ["on", 731], ["a", 734], ["chromosome", 736], ["4", 747], ["haplotype", 749], ["permissive", 759], ["for", 770], ["DUX4", 774], ["expression", 779], [".", 789], ["Reducing", 791], ["SMCHD1", 800], ["levels", 807], ["in", 814], ["skeletal", 817], ["muscle", 826], ["results", 833], ["in", 841], ["D4Z4", 844], ["contraction", 849], ["-", 860], ["independent", 861], ["DUX4", 873], ["expression", 878], [".", 888], ["Our", 890], ["study", 894], ["identifies", 900], ["SMCHD1", 911], ["as", 918], ["an", 921], ["epigenetic", 924], ["modifier", 935], ["of", 944], ["the", 947], ["D4Z4", 951], ["metastable", 956], ["epiallele", 967], ["and", 977], ["as", 981], ["a", 984], ["causal", 986], ["genetic", 993], ["determinant", 1001], ["of", 1013], ["FSHD2", 1016], ["and", 1022], ["possibly", 1026], ["other", 1035], ["human", 1041], ["diseases", 1047], ["subject", 1056], ["to", 1064], ["epigenetic", 1067], ["regulation", 1078], [".", 1088]]}
{"context": "Neurological abnormalities associated with spiculated, \"acanthocytic\" red cells in blood have been described as neuroacanthocytosis. This is a heterogeneous group of conditions that can be clearly subdivided on the basis of recent genetic findings. The McLeod Syndrome, one of the core neuroacanthocytosis syndromes, is a rare X-linked disorder caused by mutations of the XK gene, an X-chromosomal gene of unknown function characterized by haemopoietic abnormalities and late-onset neurological and muscular defects. We report two Chilean brothers with the McLeod phenotype who showed important psychiatric features. The diagnosis may be elusive if the presence of acanthocytosis is not properly studied. We describe a method which allowed the diagnosis that unmasked acanthocytosis. Otherwise the condition could have remained undiagnosed as it had been for decades in this family. This syndrome must be considered when assessing a familial movement disorder, specially affecting males with relevant psychiatric features. A reliable test for acanthocytosis assessment is available.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "c79bc1f8f85548358708cf9eb729f140", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[62, 62]], "char_spans": [[372, 373]]}]}], "context_tokens": [["Neurological", 0], ["abnormalities", 13], ["associated", 27], ["with", 38], ["spiculated", 43], [",", 53], ["\"", 55], ["acanthocytic", 56], ["\"", 68], ["red", 70], ["cells", 74], ["in", 80], ["blood", 83], ["have", 89], ["been", 94], ["described", 99], ["as", 109], ["neuroacanthocytosis", 112], [".", 131], ["This", 133], ["is", 138], ["a", 141], ["heterogeneous", 143], ["group", 157], ["of", 163], ["conditions", 166], ["that", 177], ["can", 182], ["be", 186], ["clearly", 189], ["subdivided", 197], ["on", 208], ["the", 211], ["basis", 215], ["of", 221], ["recent", 224], ["genetic", 231], ["findings", 239], [".", 247], ["The", 249], ["McLeod", 253], ["Syndrome", 260], [",", 268], ["one", 270], ["of", 274], ["the", 277], ["core", 281], ["neuroacanthocytosis", 286], ["syndromes", 306], [",", 315], ["is", 317], ["a", 320], ["rare", 322], ["X", 327], ["-", 328], ["linked", 329], ["disorder", 336], ["caused", 345], ["by", 352], ["mutations", 355], ["of", 365], ["the", 368], ["XK", 372], ["gene", 375], [",", 379], ["an", 381], ["X", 384], ["-", 385], ["chromosomal", 386], ["gene", 398], ["of", 403], ["unknown", 406], ["function", 414], ["characterized", 423], ["by", 437], ["haemopoietic", 440], ["abnormalities", 453], ["and", 467], ["late", 471], ["-", 475], ["onset", 476], ["neurological", 482], ["and", 495], ["muscular", 499], ["defects", 508], [".", 515], ["We", 517], ["report", 520], ["two", 527], ["Chilean", 531], ["brothers", 539], ["with", 548], ["the", 553], ["McLeod", 557], ["phenotype", 564], ["who", 574], ["showed", 578], ["important", 585], ["psychiatric", 595], ["features", 607], [".", 615], ["The", 617], ["diagnosis", 621], ["may", 631], ["be", 635], ["elusive", 638], ["if", 646], ["the", 649], ["presence", 653], ["of", 662], ["acanthocytosis", 665], ["is", 680], ["not", 683], ["properly", 687], ["studied", 696], [".", 703], ["We", 705], ["describe", 708], ["a", 717], ["method", 719], ["which", 726], ["allowed", 732], ["the", 740], ["diagnosis", 744], ["that", 754], ["unmasked", 759], ["acanthocytosis", 768], [".", 782], ["Otherwise", 784], ["the", 794], ["condition", 798], ["could", 808], ["have", 814], ["remained", 819], ["undiagnosed", 828], ["as", 840], ["it", 843], ["had", 846], ["been", 850], ["for", 855], ["decades", 859], ["in", 867], ["this", 870], ["family", 875], [".", 881], ["This", 883], ["syndrome", 888], ["must", 897], ["be", 902], ["considered", 905], ["when", 916], ["assessing", 921], ["a", 931], ["familial", 933], ["movement", 942], ["disorder", 951], [",", 959], ["specially", 961], ["affecting", 971], ["males", 981], ["with", 987], ["relevant", 992], ["psychiatric", 1001], ["features", 1013], [".", 1021], ["A", 1023], ["reliable", 1025], ["test", 1034], ["for", 1039], ["acanthocytosis", 1043], ["assessment", 1058], ["is", 1069], ["available", 1072], [".", 1081]]}
{"context": "Reactive oxygen species (ROS) production by NADPH oxidase 1 (NOX1), which is mainly expressed in colon epithelial cells, requires the membrane-bound component p22(PHOX) and the cytosolic partners NOX organizer 1 (NOXO1), NOX activator 1 (NOXA1), and Rac1. Contrary to that of its phagocyte counterpart NOX2, the molecular basis of NOX1 regulation is not clear. Because NOXO1 lacks the phosphorylated region found in its homolog p47(PHOX), the current view is that NOX1 activation occurs without NOXO1 phosphorylation. Here, however, we demonstrate that phorbol myristate acetate (PMA) stimulates NOXO1 phosphorylation in a transfected human embryonic kidney (HEK) 293 epithelial cell model via protein kinase C and identify Ser-154 as the major phosphorylated site. Endogenous NOXO1 from T84 colon epithelial cells was also phosphorylated, suggesting that NOXO1 phosphorylation is physiologically relevant. In transfected HEK-293 cells, PMA-induced phosphorylation on Ser-154 enhanced NOXO1 binding to NOXA1 (+97%) and to the p22(PHOX) C-terminal region (+384%), increased NOXO1 colocalization with p22(PHOX), and allowed optimal ROS production by NOX1 as demonstrated by the use of S154A and S154D mutants compared with that by wild-type NOXO1 (P<0.05). Pulldown experiments revealed that phos-phorylation on Ser-154 was sufficient to markedly enhance NOXO1 binding to NOXA1, which in turn acts as a molecular switch, allowing optimal interaction of NOXO1 with p22(PHOX). This study unexpectedly revealed that full assembly and activation of NOX1 is a tightly regulated process in which NOXO1 phosphorylation on Ser-154 is the initial trigger.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "ce8e78ef06ed459386b6f776879b5c3c", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NADPH oxidase 1", "token_spans": [[8, 10]], "char_spans": [[44, 58]]}, {"text": "NOX1", "token_spans": [[275, 275], [205, 205], [90, 90], [12, 12], [66, 66]], "char_spans": [[1543, 1546], [1148, 1151], [464, 467], [61, 64], [331, 334]]}]}], "context_tokens": [["Reactive", 0], ["oxygen", 9], ["species", 16], ["(", 24], ["ROS", 25], [")", 28], ["production", 30], ["by", 41], ["NADPH", 44], ["oxidase", 50], ["1", 58], ["(", 60], ["NOX1", 61], [")", 65], [",", 66], ["which", 68], ["is", 74], ["mainly", 77], ["expressed", 84], ["in", 94], ["colon", 97], ["epithelial", 103], ["cells", 114], [",", 119], ["requires", 121], ["the", 130], ["membrane", 134], ["-", 142], ["bound", 143], ["component", 149], ["p22(PHOX", 159], [")", 167], ["and", 169], ["the", 173], ["cytosolic", 177], ["partners", 187], ["NOX", 196], ["organizer", 200], ["1", 210], ["(", 212], ["NOXO1", 213], [")", 218], [",", 219], ["NOX", 221], ["activator", 225], ["1", 235], ["(", 237], ["NOXA1", 238], [")", 243], [",", 244], ["and", 246], ["Rac1", 250], [".", 254], ["Contrary", 256], ["to", 265], ["that", 268], ["of", 273], ["its", 276], ["phagocyte", 280], ["counterpart", 290], ["NOX2", 302], [",", 306], ["the", 308], ["molecular", 312], ["basis", 322], ["of", 328], ["NOX1", 331], ["regulation", 336], ["is", 347], ["not", 350], ["clear", 354], [".", 359], ["Because", 361], ["NOXO1", 369], ["lacks", 375], ["the", 381], ["phosphorylated", 385], ["region", 400], ["found", 407], ["in", 413], ["its", 416], ["homolog", 420], ["p47(PHOX", 428], [")", 436], [",", 437], ["the", 439], ["current", 443], ["view", 451], ["is", 456], ["that", 459], ["NOX1", 464], ["activation", 469], ["occurs", 480], ["without", 487], ["NOXO1", 495], ["phosphorylation", 501], [".", 516], ["Here", 518], [",", 522], ["however", 524], [",", 531], ["we", 533], ["demonstrate", 536], ["that", 548], ["phorbol", 553], ["myristate", 561], ["acetate", 571], ["(", 579], ["PMA", 580], [")", 583], ["stimulates", 585], ["NOXO1", 596], ["phosphorylation", 602], ["in", 618], ["a", 621], ["transfected", 623], ["human", 635], ["embryonic", 641], ["kidney", 651], ["(", 658], ["HEK", 659], [")", 662], ["293", 664], ["epithelial", 668], ["cell", 679], ["model", 684], ["via", 690], ["protein", 694], ["kinase", 702], ["C", 709], ["and", 711], ["identify", 715], ["Ser-154", 724], ["as", 732], ["the", 735], ["major", 739], ["phosphorylated", 745], ["site", 760], [".", 764], ["Endogenous", 766], ["NOXO1", 777], ["from", 783], ["T84", 788], ["colon", 792], ["epithelial", 798], ["cells", 809], ["was", 815], ["also", 819], ["phosphorylated", 824], [",", 838], ["suggesting", 840], ["that", 851], ["NOXO1", 856], ["phosphorylation", 862], ["is", 878], ["physiologically", 881], ["relevant", 897], [".", 905], ["In", 907], ["transfected", 910], ["HEK-293", 922], ["cells", 930], [",", 935], ["PMA", 937], ["-", 940], ["induced", 941], ["phosphorylation", 949], ["on", 965], ["Ser-154", 968], ["enhanced", 976], ["NOXO1", 985], ["binding", 991], ["to", 999], ["NOXA1", 1002], ["(", 1008], ["+97", 1009], ["%", 1012], [")", 1013], ["and", 1015], ["to", 1019], ["the", 1022], ["p22(PHOX", 1026], [")", 1034], ["C", 1036], ["-", 1037], ["terminal", 1038], ["region", 1047], ["(", 1054], ["+384", 1055], ["%", 1059], [")", 1060], [",", 1061], ["increased", 1063], ["NOXO1", 1073], ["colocalization", 1079], ["with", 1094], ["p22(PHOX", 1099], [")", 1107], [",", 1108], ["and", 1110], ["allowed", 1114], ["optimal", 1122], ["ROS", 1130], ["production", 1134], ["by", 1145], ["NOX1", 1148], ["as", 1153], ["demonstrated", 1156], ["by", 1169], ["the", 1172], ["use", 1176], ["of", 1180], ["S154A", 1183], ["and", 1189], ["S154D", 1193], ["mutants", 1199], ["compared", 1207], ["with", 1216], ["that", 1221], ["by", 1226], ["wild", 1229], ["-", 1233], ["type", 1234], ["NOXO1", 1239], ["(", 1245], ["P<0.05", 1246], [")", 1252], [".", 1253], ["Pulldown", 1255], ["experiments", 1264], ["revealed", 1276], ["that", 1285], ["phos", 1290], ["-", 1294], ["phorylation", 1295], ["on", 1307], ["Ser-154", 1310], ["was", 1318], ["sufficient", 1322], ["to", 1333], ["markedly", 1336], ["enhance", 1345], ["NOXO1", 1353], ["binding", 1359], ["to", 1367], ["NOXA1", 1370], [",", 1375], ["which", 1377], ["in", 1383], ["turn", 1386], ["acts", 1391], ["as", 1396], ["a", 1399], ["molecular", 1401], ["switch", 1411], [",", 1417], ["allowing", 1419], ["optimal", 1428], ["interaction", 1436], ["of", 1448], ["NOXO1", 1451], ["with", 1457], ["p22(PHOX", 1462], [")", 1470], [".", 1471], ["This", 1473], ["study", 1478], ["unexpectedly", 1484], ["revealed", 1497], ["that", 1506], ["full", 1511], ["assembly", 1516], ["and", 1525], ["activation", 1529], ["of", 1540], ["NOX1", 1543], ["is", 1548], ["a", 1551], ["tightly", 1553], ["regulated", 1561], ["process", 1571], ["in", 1579], ["which", 1582], ["NOXO1", 1588], ["phosphorylation", 1594], ["on", 1610], ["Ser-154", 1613], ["is", 1621], ["the", 1624], ["initial", 1628], ["trigger", 1636], [".", 1643]]}
{"context": "The yeast Spt-Ada-Gcn5-acetyltransferase (SAGA) complex is a transcription coactivator that contains a histone H2B deubiquitination activity mediated by its Ubp8 subunit. Full enzymatic activity requires the formation of a quaternary complex, the deubiquitination module (DUBm) of SAGA, which is composed of Ubp8, Sus1, Sgf11, and Sgf73. The crystal structures of the DUBm have shed light on the structure/function relationship of this complex. Specifically, both Sgf11 and Sgf73 contain zinc finger domains (ZnF) that appear essential for the DUBm activity. Whereas Sgf73 N-terminal ZnF is important for DUBm stability, Sgf11 C-terminal ZnF appears to be involved in DUBm function. To further characterize the role of these two zinc fingers, we have solved their structure by NMR. We show that, contrary to the previously reported structures, Sgf73 ZnF adopts a C2H2 coordination with unusual tautomeric forms for the coordinating histidines. We further report that the Sgf11 ZnF, but not the Sgf73 ZnF, binds to nucleosomal DNA with a binding interface composed of arginine residues located within the ZnF \u03b1-helix. Mutational analyses both in vitro and in vivo provide evidence for the functional relevance of our structural observations. The combined interpretation of our results leads to an uncommon ZnF-DNA interaction between the SAGA DUBm and nucleosomes, thus providing further functional insights into SAGA's epigenetic modulation of the chromatin structure.", "qas": [{"question": "What does the SAGA complex acronym stands for?", "answers": ["Spt-Ada-Gcn5-acetyltransferase"], "qid": "c407bea87e58496cb312d3fd2e5eedc2", "question_tokens": [["What", 0], ["does", 5], ["the", 10], ["SAGA", 14], ["complex", 19], ["acronym", 27], ["stands", 35], ["for", 42], ["?", 45]], "detected_answers": [{"text": "Spt-Ada-Gcn5-acetyltransferase", "token_spans": [[2, 6]], "char_spans": [[10, 39]]}]}], "context_tokens": [["The", 0], ["yeast", 4], ["Spt", 10], ["-", 13], ["Ada", 14], ["-", 17], ["Gcn5-acetyltransferase", 18], ["(", 41], ["SAGA", 42], [")", 46], ["complex", 48], ["is", 56], ["a", 59], ["transcription", 61], ["coactivator", 75], ["that", 87], ["contains", 92], ["a", 101], ["histone", 103], ["H2B", 111], ["deubiquitination", 115], ["activity", 132], ["mediated", 141], ["by", 150], ["its", 153], ["Ubp8", 157], ["subunit", 162], [".", 169], ["Full", 171], ["enzymatic", 176], ["activity", 186], ["requires", 195], ["the", 204], ["formation", 208], ["of", 218], ["a", 221], ["quaternary", 223], ["complex", 234], [",", 241], ["the", 243], ["deubiquitination", 247], ["module", 264], ["(", 271], ["DUBm", 272], [")", 276], ["of", 278], ["SAGA", 281], [",", 285], ["which", 287], ["is", 293], ["composed", 296], ["of", 305], ["Ubp8", 308], [",", 312], ["Sus1", 314], [",", 318], ["Sgf11", 320], [",", 325], ["and", 327], ["Sgf73", 331], [".", 336], ["The", 338], ["crystal", 342], ["structures", 350], ["of", 361], ["the", 364], ["DUBm", 368], ["have", 373], ["shed", 378], ["light", 383], ["on", 389], ["the", 392], ["structure", 396], ["/", 405], ["function", 406], ["relationship", 415], ["of", 428], ["this", 431], ["complex", 436], [".", 443], ["Specifically", 445], [",", 457], ["both", 459], ["Sgf11", 464], ["and", 470], ["Sgf73", 474], ["contain", 480], ["zinc", 488], ["finger", 493], ["domains", 500], ["(", 508], ["ZnF", 509], [")", 512], ["that", 514], ["appear", 519], ["essential", 526], ["for", 536], ["the", 540], ["DUBm", 544], ["activity", 549], [".", 557], ["Whereas", 559], ["Sgf73", 567], ["N", 573], ["-", 574], ["terminal", 575], ["ZnF", 584], ["is", 588], ["important", 591], ["for", 601], ["DUBm", 605], ["stability", 610], [",", 619], ["Sgf11", 621], ["C", 627], ["-", 628], ["terminal", 629], ["ZnF", 638], ["appears", 642], ["to", 650], ["be", 653], ["involved", 656], ["in", 665], ["DUBm", 668], ["function", 673], [".", 681], ["To", 683], ["further", 686], ["characterize", 694], ["the", 707], ["role", 711], ["of", 716], ["these", 719], ["two", 725], ["zinc", 729], ["fingers", 734], [",", 741], ["we", 743], ["have", 746], ["solved", 751], ["their", 758], ["structure", 764], ["by", 774], ["NMR", 777], [".", 780], ["We", 782], ["show", 785], ["that", 790], [",", 794], ["contrary", 796], ["to", 805], ["the", 808], ["previously", 812], ["reported", 823], ["structures", 832], [",", 842], ["Sgf73", 844], ["ZnF", 850], ["adopts", 854], ["a", 861], ["C2H2", 863], ["coordination", 868], ["with", 881], ["unusual", 886], ["tautomeric", 894], ["forms", 905], ["for", 911], ["the", 915], ["coordinating", 919], ["histidines", 932], [".", 942], ["We", 944], ["further", 947], ["report", 955], ["that", 962], ["the", 967], ["Sgf11", 971], ["ZnF", 977], [",", 980], ["but", 982], ["not", 986], ["the", 990], ["Sgf73", 994], ["ZnF", 1000], [",", 1003], ["binds", 1005], ["to", 1011], ["nucleosomal", 1014], ["DNA", 1026], ["with", 1030], ["a", 1035], ["binding", 1037], ["interface", 1045], ["composed", 1055], ["of", 1064], ["arginine", 1067], ["residues", 1076], ["located", 1085], ["within", 1093], ["the", 1100], ["ZnF", 1104], ["\u03b1", 1108], ["-", 1109], ["helix", 1110], [".", 1115], ["Mutational", 1117], ["analyses", 1128], ["both", 1137], ["in", 1142], ["vitro", 1145], ["and", 1151], ["in", 1155], ["vivo", 1158], ["provide", 1163], ["evidence", 1171], ["for", 1180], ["the", 1184], ["functional", 1188], ["relevance", 1199], ["of", 1209], ["our", 1212], ["structural", 1216], ["observations", 1227], [".", 1239], ["The", 1241], ["combined", 1245], ["interpretation", 1254], ["of", 1269], ["our", 1272], ["results", 1276], ["leads", 1284], ["to", 1290], ["an", 1293], ["uncommon", 1296], ["ZnF", 1305], ["-", 1308], ["DNA", 1309], ["interaction", 1313], ["between", 1325], ["the", 1333], ["SAGA", 1337], ["DUBm", 1342], ["and", 1347], ["nucleosomes", 1351], [",", 1362], ["thus", 1364], ["providing", 1369], ["further", 1379], ["functional", 1387], ["insights", 1398], ["into", 1407], ["SAGA", 1412], ["'s", 1416], ["epigenetic", 1419], ["modulation", 1430], ["of", 1441], ["the", 1444], ["chromatin", 1448], ["structure", 1458], [".", 1467]]}
{"context": "Lewy body disease is a heterogeneous group of neurodegenerative disorders characterized by alpha-synuclein accumulation that includes dementia with Lewy bodies (DLB) and Parkinson's Disease (PD). Recent evidence suggests that impairment of lysosomal pathways (i.e. autophagy) involved in alpha-synuclein clearance might play an important role. For this reason, we sought to examine the expression levels of members of the autophagy pathway in brains of patients with DLB and Alzheimer's Disease (AD) and in alpha-synuclein transgenic mice. By immunoblot analysis, compared to controls and AD, in DLB cases levels of mTor were elevated and Atg7 were reduced. Levels of other components of the autophagy pathway such as Atg5, Atg10, Atg12 and Beclin-1 were not different in DLB compared to controls. In DLB brains, mTor was more abundant in neurons displaying alpha-synuclein accumulation. These neurons also showed abnormal expression of lysosomal markers such as LC3, and ultrastructural analysis revealed the presence of abundant and abnormal autophagosomes. Similar alterations were observed in the brains of alpha-synuclein transgenic mice. Intra-cerebral infusion of rapamycin, an inhibitor of mTor, or injection of a lentiviral vector expressing Atg7 resulted in reduced accumulation of alpha-synuclein in transgenic mice and amelioration of associated neurodegenerative alterations. This study supports the notion that defects in the autophagy pathway and more specifically in mTor and Atg7 are associated with neurodegeneration in DLB cases and alpha-synuclein transgenic models and supports the possibility that modulators of the autophagy pathway might have potential therapeutic effects.", "qas": [{"question": "Which disease of the central nervous system is characterized by the presence of Lewy bodies?", "answers": ["Parkinson's disease (PD)"], "qid": "2fa17a29be5d4cdb8b61ce90ede60e4a", "question_tokens": [["Which", 0], ["disease", 6], ["of", 14], ["the", 17], ["central", 21], ["nervous", 29], ["system", 37], ["is", 44], ["characterized", 47], ["by", 61], ["the", 64], ["presence", 68], ["of", 77], ["Lewy", 80], ["bodies", 85], ["?", 91]], "detected_answers": [{"text": "Parkinson's disease (PD)", "token_spans": [[26, 30]], "char_spans": [[170, 192]]}]}], "context_tokens": [["Lewy", 0], ["body", 5], ["disease", 10], ["is", 18], ["a", 21], ["heterogeneous", 23], ["group", 37], ["of", 43], ["neurodegenerative", 46], ["disorders", 64], ["characterized", 74], ["by", 88], ["alpha", 91], ["-", 96], ["synuclein", 97], ["accumulation", 107], ["that", 120], ["includes", 125], ["dementia", 134], ["with", 143], ["Lewy", 148], ["bodies", 153], ["(", 160], ["DLB", 161], [")", 164], ["and", 166], ["Parkinson", 170], ["'s", 179], ["Disease", 182], ["(", 190], ["PD", 191], [")", 193], [".", 194], ["Recent", 196], ["evidence", 203], ["suggests", 212], ["that", 221], ["impairment", 226], ["of", 237], ["lysosomal", 240], ["pathways", 250], ["(", 259], ["i.e.", 260], ["autophagy", 265], [")", 274], ["involved", 276], ["in", 285], ["alpha", 288], ["-", 293], ["synuclein", 294], ["clearance", 304], ["might", 314], ["play", 320], ["an", 325], ["important", 328], ["role", 338], [".", 342], ["For", 344], ["this", 348], ["reason", 353], [",", 359], ["we", 361], ["sought", 364], ["to", 371], ["examine", 374], ["the", 382], ["expression", 386], ["levels", 397], ["of", 404], ["members", 407], ["of", 415], ["the", 418], ["autophagy", 422], ["pathway", 432], ["in", 440], ["brains", 443], ["of", 450], ["patients", 453], ["with", 462], ["DLB", 467], ["and", 471], ["Alzheimer", 475], ["'s", 484], ["Disease", 487], ["(", 495], ["AD", 496], [")", 498], ["and", 500], ["in", 504], ["alpha", 507], ["-", 512], ["synuclein", 513], ["transgenic", 523], ["mice", 534], [".", 538], ["By", 540], ["immunoblot", 543], ["analysis", 554], [",", 562], ["compared", 564], ["to", 573], ["controls", 576], ["and", 585], ["AD", 589], [",", 591], ["in", 593], ["DLB", 596], ["cases", 600], ["levels", 606], ["of", 613], ["mTor", 616], ["were", 621], ["elevated", 626], ["and", 635], ["Atg7", 639], ["were", 644], ["reduced", 649], [".", 656], ["Levels", 658], ["of", 665], ["other", 668], ["components", 674], ["of", 685], ["the", 688], ["autophagy", 692], ["pathway", 702], ["such", 710], ["as", 715], ["Atg5", 718], [",", 722], ["Atg10", 724], [",", 729], ["Atg12", 731], ["and", 737], ["Beclin-1", 741], ["were", 750], ["not", 755], ["different", 759], ["in", 769], ["DLB", 772], ["compared", 776], ["to", 785], ["controls", 788], [".", 796], ["In", 798], ["DLB", 801], ["brains", 805], [",", 811], ["mTor", 813], ["was", 818], ["more", 822], ["abundant", 827], ["in", 836], ["neurons", 839], ["displaying", 847], ["alpha", 858], ["-", 863], ["synuclein", 864], ["accumulation", 874], [".", 886], ["These", 888], ["neurons", 894], ["also", 902], ["showed", 907], ["abnormal", 914], ["expression", 923], ["of", 934], ["lysosomal", 937], ["markers", 947], ["such", 955], ["as", 960], ["LC3", 963], [",", 966], ["and", 968], ["ultrastructural", 972], ["analysis", 988], ["revealed", 997], ["the", 1006], ["presence", 1010], ["of", 1019], ["abundant", 1022], ["and", 1031], ["abnormal", 1035], ["autophagosomes", 1044], [".", 1058], ["Similar", 1060], ["alterations", 1068], ["were", 1080], ["observed", 1085], ["in", 1094], ["the", 1097], ["brains", 1101], ["of", 1108], ["alpha", 1111], ["-", 1116], ["synuclein", 1117], ["transgenic", 1127], ["mice", 1138], [".", 1142], ["Intra", 1144], ["-", 1149], ["cerebral", 1150], ["infusion", 1159], ["of", 1168], ["rapamycin", 1171], [",", 1180], ["an", 1182], ["inhibitor", 1185], ["of", 1195], ["mTor", 1198], [",", 1202], ["or", 1204], ["injection", 1207], ["of", 1217], ["a", 1220], ["lentiviral", 1222], ["vector", 1233], ["expressing", 1240], ["Atg7", 1251], ["resulted", 1256], ["in", 1265], ["reduced", 1268], ["accumulation", 1276], ["of", 1289], ["alpha", 1292], ["-", 1297], ["synuclein", 1298], ["in", 1308], ["transgenic", 1311], ["mice", 1322], ["and", 1327], ["amelioration", 1331], ["of", 1344], ["associated", 1347], ["neurodegenerative", 1358], ["alterations", 1376], [".", 1387], ["This", 1389], ["study", 1394], ["supports", 1400], ["the", 1409], ["notion", 1413], ["that", 1420], ["defects", 1425], ["in", 1433], ["the", 1436], ["autophagy", 1440], ["pathway", 1450], ["and", 1458], ["more", 1462], ["specifically", 1467], ["in", 1480], ["mTor", 1483], ["and", 1488], ["Atg7", 1492], ["are", 1497], ["associated", 1501], ["with", 1512], ["neurodegeneration", 1517], ["in", 1535], ["DLB", 1538], ["cases", 1542], ["and", 1548], ["alpha", 1552], ["-", 1557], ["synuclein", 1558], ["transgenic", 1568], ["models", 1579], ["and", 1586], ["supports", 1590], ["the", 1599], ["possibility", 1603], ["that", 1615], ["modulators", 1620], ["of", 1631], ["the", 1634], ["autophagy", 1638], ["pathway", 1648], ["might", 1656], ["have", 1662], ["potential", 1667], ["therapeutic", 1677], ["effects", 1689], [".", 1696]]}
{"context": "Eukaryotic centromeres are maintained at specific chromosomal sites over many generations. In the budding yeast Saccharomyces cerevisiae, centromeres are genetic elements defined by a DNA sequence that is both necessary and sufficient for function; whereas, in most other eukaryotes, centromeres are maintained by poorly characterized epigenetic mechanisms in which DNA has a less definitive role. Here we use the pathogenic yeast Candida albicans as a model organism to study the DNA replication properties of centromeric DNA. By determining the genome-wide replication timing program of the C. albicans genome, we discovered that each centromere is associated with a replication origin that is the first to fire on its respective chromosome. Importantly, epigenetic formation of new ectopic centromeres (neocentromeres) was accompanied by shifts in replication timing, such that a neocentromere became the first to replicate and became associated with origin recognition complex (ORC) components. Furthermore, changing the level of the centromere-specific histone H3 isoform led to a concomitant change in levels of ORC association with centromere regions, further supporting the idea that centromere proteins determine origin activity. Finally, analysis of centromere-associated DNA revealed a replication-dependent sequence pattern characteristic of constitutively active replication origins. This strand-biased pattern is conserved, together with centromere position, among related strains and species, in a manner independent of primary DNA sequence. Thus, inheritance of centromere position is correlated with a constitutively active origin of replication that fires at a distinct early time. We suggest a model in which the distinct timing of DNA replication serves as an epigenetic mechanism for the inheritance of centromere position.", "qas": [{"question": "Do origins of replication close to yeast centromeres fire early or late?", "answers": ["Early"], "qid": "f86ba8d933b746bc9dcc170bdad24a09", "question_tokens": [["Do", 0], ["origins", 3], ["of", 11], ["replication", 14], ["close", 26], ["to", 32], ["yeast", 35], ["centromeres", 41], ["fire", 53], ["early", 58], ["or", 64], ["late", 67], ["?", 71]], "detected_answers": [{"text": "Early", "token_spans": [[268, 268]], "char_spans": [[1688, 1692]]}]}], "context_tokens": [["Eukaryotic", 0], ["centromeres", 11], ["are", 23], ["maintained", 27], ["at", 38], ["specific", 41], ["chromosomal", 50], ["sites", 62], ["over", 68], ["many", 73], ["generations", 78], [".", 89], ["In", 91], ["the", 94], ["budding", 98], ["yeast", 106], ["Saccharomyces", 112], ["cerevisiae", 126], [",", 136], ["centromeres", 138], ["are", 150], ["genetic", 154], ["elements", 162], ["defined", 171], ["by", 179], ["a", 182], ["DNA", 184], ["sequence", 188], ["that", 197], ["is", 202], ["both", 205], ["necessary", 210], ["and", 220], ["sufficient", 224], ["for", 235], ["function", 239], [";", 247], ["whereas", 249], [",", 256], ["in", 258], ["most", 261], ["other", 266], ["eukaryotes", 272], [",", 282], ["centromeres", 284], ["are", 296], ["maintained", 300], ["by", 311], ["poorly", 314], ["characterized", 321], ["epigenetic", 335], ["mechanisms", 346], ["in", 357], ["which", 360], ["DNA", 366], ["has", 370], ["a", 374], ["less", 376], ["definitive", 381], ["role", 392], [".", 396], ["Here", 398], ["we", 403], ["use", 406], ["the", 410], ["pathogenic", 414], ["yeast", 425], ["Candida", 431], ["albicans", 439], ["as", 448], ["a", 451], ["model", 453], ["organism", 459], ["to", 468], ["study", 471], ["the", 477], ["DNA", 481], ["replication", 485], ["properties", 497], ["of", 508], ["centromeric", 511], ["DNA", 523], [".", 526], ["By", 528], ["determining", 531], ["the", 543], ["genome", 547], ["-", 553], ["wide", 554], ["replication", 559], ["timing", 571], ["program", 578], ["of", 586], ["the", 589], ["C.", 593], ["albicans", 596], ["genome", 605], [",", 611], ["we", 613], ["discovered", 616], ["that", 627], ["each", 632], ["centromere", 637], ["is", 648], ["associated", 651], ["with", 662], ["a", 667], ["replication", 669], ["origin", 681], ["that", 688], ["is", 693], ["the", 696], ["first", 700], ["to", 706], ["fire", 709], ["on", 714], ["its", 717], ["respective", 721], ["chromosome", 732], [".", 742], ["Importantly", 744], [",", 755], ["epigenetic", 757], ["formation", 768], ["of", 778], ["new", 781], ["ectopic", 785], ["centromeres", 793], ["(", 805], ["neocentromeres", 806], [")", 820], ["was", 822], ["accompanied", 826], ["by", 838], ["shifts", 841], ["in", 848], ["replication", 851], ["timing", 863], [",", 869], ["such", 871], ["that", 876], ["a", 881], ["neocentromere", 883], ["became", 897], ["the", 904], ["first", 908], ["to", 914], ["replicate", 917], ["and", 927], ["became", 931], ["associated", 938], ["with", 949], ["origin", 954], ["recognition", 961], ["complex", 973], ["(", 981], ["ORC", 982], [")", 985], ["components", 987], [".", 997], ["Furthermore", 999], [",", 1010], ["changing", 1012], ["the", 1021], ["level", 1025], ["of", 1031], ["the", 1034], ["centromere", 1038], ["-", 1048], ["specific", 1049], ["histone", 1058], ["H3", 1066], ["isoform", 1069], ["led", 1077], ["to", 1081], ["a", 1084], ["concomitant", 1086], ["change", 1098], ["in", 1105], ["levels", 1108], ["of", 1115], ["ORC", 1118], ["association", 1122], ["with", 1134], ["centromere", 1139], ["regions", 1150], [",", 1157], ["further", 1159], ["supporting", 1167], ["the", 1178], ["idea", 1182], ["that", 1187], ["centromere", 1192], ["proteins", 1203], ["determine", 1212], ["origin", 1222], ["activity", 1229], [".", 1237], ["Finally", 1239], [",", 1246], ["analysis", 1248], ["of", 1257], ["centromere", 1260], ["-", 1270], ["associated", 1271], ["DNA", 1282], ["revealed", 1286], ["a", 1295], ["replication", 1297], ["-", 1308], ["dependent", 1309], ["sequence", 1319], ["pattern", 1328], ["characteristic", 1336], ["of", 1351], ["constitutively", 1354], ["active", 1369], ["replication", 1376], ["origins", 1388], [".", 1395], ["This", 1397], ["strand", 1402], ["-", 1408], ["biased", 1409], ["pattern", 1416], ["is", 1424], ["conserved", 1427], [",", 1436], ["together", 1438], ["with", 1447], ["centromere", 1452], ["position", 1463], [",", 1471], ["among", 1473], ["related", 1479], ["strains", 1487], ["and", 1495], ["species", 1499], [",", 1506], ["in", 1508], ["a", 1511], ["manner", 1513], ["independent", 1520], ["of", 1532], ["primary", 1535], ["DNA", 1543], ["sequence", 1547], [".", 1555], ["Thus", 1557], [",", 1561], ["inheritance", 1563], ["of", 1575], ["centromere", 1578], ["position", 1589], ["is", 1598], ["correlated", 1601], ["with", 1612], ["a", 1617], ["constitutively", 1619], ["active", 1634], ["origin", 1641], ["of", 1648], ["replication", 1651], ["that", 1663], ["fires", 1668], ["at", 1674], ["a", 1677], ["distinct", 1679], ["early", 1688], ["time", 1694], [".", 1698], ["We", 1700], ["suggest", 1703], ["a", 1711], ["model", 1713], ["in", 1719], ["which", 1722], ["the", 1728], ["distinct", 1732], ["timing", 1741], ["of", 1748], ["DNA", 1751], ["replication", 1755], ["serves", 1767], ["as", 1774], ["an", 1777], ["epigenetic", 1780], ["mechanism", 1791], ["for", 1801], ["the", 1805], ["inheritance", 1809], ["of", 1821], ["centromere", 1824], ["position", 1835], [".", 1843]]}
{"context": "The methylation of lysine residues of histones plays a pivotal role in the regulation of chromatin structure and gene expression. Here, we report two crystal structures of SET7/9, a histone methyltransferase (HMTase) that transfers methyl groups to Lys4 of histone H3, in complex with S-adenosyl-L-methionine (AdoMet) determined at 1.7 and 2.3 A resolution. The structures reveal an active site consisting of: (i) a binding pocket between the SET domain and a c-SET helix where an AdoMet molecule in an unusual conformation binds; (ii) a narrow substrate-specific channel that only unmethylated lysine residues can access; and (iii) a catalytic tyrosine residue. The methyl group of AdoMet is directed to the narrow channel where a substrate lysine enters from the opposite side. We demonstrate that SET7/9 can transfer two but not three methyl groups to unmodified Lys4 of H3 without substrate dissociation. The unusual features of the SET domain-containing HMTase discriminate between the un- and methylated lysine substrate, and the methylation sites for the histone H3 tail.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "56ed50d7657b481ea0e2512c19bb0438", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[85, 86], [176, 177]], "char_spans": [[443, 452], [937, 946]]}]}], "context_tokens": [["The", 0], ["methylation", 4], ["of", 16], ["lysine", 19], ["residues", 26], ["of", 35], ["histones", 38], ["plays", 47], ["a", 53], ["pivotal", 55], ["role", 63], ["in", 68], ["the", 71], ["regulation", 75], ["of", 86], ["chromatin", 89], ["structure", 99], ["and", 109], ["gene", 113], ["expression", 118], [".", 128], ["Here", 130], [",", 134], ["we", 136], ["report", 139], ["two", 146], ["crystal", 150], ["structures", 158], ["of", 169], ["SET7/9", 172], [",", 178], ["a", 180], ["histone", 182], ["methyltransferase", 190], ["(", 208], ["HMTase", 209], [")", 215], ["that", 217], ["transfers", 222], ["methyl", 232], ["groups", 239], ["to", 246], ["Lys4", 249], ["of", 254], ["histone", 257], ["H3", 265], [",", 267], ["in", 269], ["complex", 272], ["with", 280], ["S", 285], ["-", 286], ["adenosyl", 287], ["-", 295], ["L", 296], ["-", 297], ["methionine", 298], ["(", 309], ["AdoMet", 310], [")", 316], ["determined", 318], ["at", 329], ["1.7", 332], ["and", 336], ["2.3", 340], ["A", 344], ["resolution", 346], [".", 356], ["The", 358], ["structures", 362], ["reveal", 373], ["an", 380], ["active", 383], ["site", 390], ["consisting", 395], ["of", 406], [":", 408], ["(", 410], ["i", 411], [")", 412], ["a", 414], ["binding", 416], ["pocket", 424], ["between", 431], ["the", 439], ["SET", 443], ["domain", 447], ["and", 454], ["a", 458], ["c", 460], ["-", 461], ["SET", 462], ["helix", 466], ["where", 472], ["an", 478], ["AdoMet", 481], ["molecule", 488], ["in", 497], ["an", 500], ["unusual", 503], ["conformation", 511], ["binds", 524], [";", 529], ["(", 531], ["ii", 532], [")", 534], ["a", 536], ["narrow", 538], ["substrate", 545], ["-", 554], ["specific", 555], ["channel", 564], ["that", 572], ["only", 577], ["unmethylated", 582], ["lysine", 595], ["residues", 602], ["can", 611], ["access", 615], [";", 621], ["and", 623], ["(", 627], ["iii", 628], [")", 631], ["a", 633], ["catalytic", 635], ["tyrosine", 645], ["residue", 654], [".", 661], ["The", 663], ["methyl", 667], ["group", 674], ["of", 680], ["AdoMet", 683], ["is", 690], ["directed", 693], ["to", 702], ["the", 705], ["narrow", 709], ["channel", 716], ["where", 724], ["a", 730], ["substrate", 732], ["lysine", 742], ["enters", 749], ["from", 756], ["the", 761], ["opposite", 765], ["side", 774], [".", 778], ["We", 780], ["demonstrate", 783], ["that", 795], ["SET7/9", 800], ["can", 807], ["transfer", 811], ["two", 820], ["but", 824], ["not", 828], ["three", 832], ["methyl", 838], ["groups", 845], ["to", 852], ["unmodified", 855], ["Lys4", 866], ["of", 871], ["H3", 874], ["without", 877], ["substrate", 885], ["dissociation", 895], [".", 907], ["The", 909], ["unusual", 913], ["features", 921], ["of", 930], ["the", 933], ["SET", 937], ["domain", 941], ["-", 947], ["containing", 948], ["HMTase", 959], ["discriminate", 966], ["between", 979], ["the", 987], ["un-", 991], ["and", 995], ["methylated", 999], ["lysine", 1010], ["substrate", 1017], [",", 1026], ["and", 1028], ["the", 1032], ["methylation", 1036], ["sites", 1048], ["for", 1054], ["the", 1058], ["histone", 1062], ["H3", 1070], ["tail", 1073], [".", 1077]]}
{"context": "The major constituent of senile plaques in Alzheimer's disease is a 42-aa peptide, referred to as beta-amyloid (Abeta). Abeta is generated from a family of differentially spliced, type-1 transmembrane domain (TM)-containing proteins, called APP, by endoproteolytic processing. The major, relatively ubiquitous pathway of APP metabolism in cell culture involves cleavage by alpha-secretase, which cleaves within the Abeta sequence, thus precluding Abeta formation and deposition. An alternate secretory pathway, enriched in neurons and brain, leads to cleavage of APP at the N terminus of the Abeta peptide by beta-secretase, thus generating a cell-associated beta-C-terminal fragment (beta-CTF). A pathogenic mutation at codons 670/671 in APP (APP \"Swedish\") leads to enhanced cleavage at the beta-secretase scissile bond and increased Abeta formation. An inhibitor of vacuolar ATPases, bafilomycin, selectively inhibits the action of beta-secretase in cell culture, suggesting a requirement for an acidic intracellular compartment for effective beta-secretase cleavage of APP. beta-CTF is cleaved in the TM domain by gamma-secretase(s), generating both Abeta 1-40 (90%) and Abeta 1-42 (10%). Pathogenic mutations in APP at codon 717 (APP \"London\") lead to an increased proportion of Abeta 1-42 being produced and secreted. Missense mutations in PS-1, localized to chromosome 14, are pathogenic in the majority of familial Alzheimer's pedigrees. These mutations also lead to increased production of Abeta 1-42 over Abeta 1-40. Knockout of PS-1 in transgenic animals leads to significant inhibition of production of both Abeta 1-40 and Abeta 1-42 in primary cultures, indicating that PS-1 expression is important for gamma-secretase cleavages. Peptide aldehyde inhibitors that block Abeta production by inhibiting gamma-secretase cleavage of beta-CTF have been discovered.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "2e818059dd7c4f0d898f3266677d9a3c", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[7, 9]], "char_spans": [[43, 61]]}]}], "context_tokens": [["The", 0], ["major", 4], ["constituent", 10], ["of", 22], ["senile", 25], ["plaques", 32], ["in", 40], ["Alzheimer", 43], ["'s", 52], ["disease", 55], ["is", 63], ["a", 66], ["42-aa", 68], ["peptide", 74], [",", 81], ["referred", 83], ["to", 92], ["as", 95], ["beta", 98], ["-", 102], ["amyloid", 103], ["(", 111], ["Abeta", 112], [")", 117], [".", 118], ["Abeta", 120], ["is", 126], ["generated", 129], ["from", 139], ["a", 144], ["family", 146], ["of", 153], ["differentially", 156], ["spliced", 171], [",", 178], ["type-1", 180], ["transmembrane", 187], ["domain", 201], ["(", 208], ["TM)-containing", 209], ["proteins", 224], [",", 232], ["called", 234], ["APP", 241], [",", 244], ["by", 246], ["endoproteolytic", 249], ["processing", 265], [".", 275], ["The", 277], ["major", 281], [",", 286], ["relatively", 288], ["ubiquitous", 299], ["pathway", 310], ["of", 318], ["APP", 321], ["metabolism", 325], ["in", 336], ["cell", 339], ["culture", 344], ["involves", 352], ["cleavage", 361], ["by", 370], ["alpha", 373], ["-", 378], ["secretase", 379], [",", 388], ["which", 390], ["cleaves", 396], ["within", 404], ["the", 411], ["Abeta", 415], ["sequence", 421], [",", 429], ["thus", 431], ["precluding", 436], ["Abeta", 447], ["formation", 453], ["and", 463], ["deposition", 467], [".", 477], ["An", 479], ["alternate", 482], ["secretory", 492], ["pathway", 502], [",", 509], ["enriched", 511], ["in", 520], ["neurons", 523], ["and", 531], ["brain", 535], [",", 540], ["leads", 542], ["to", 548], ["cleavage", 551], ["of", 560], ["APP", 563], ["at", 567], ["the", 570], ["N", 574], ["terminus", 576], ["of", 585], ["the", 588], ["Abeta", 592], ["peptide", 598], ["by", 606], ["beta", 609], ["-", 613], ["secretase", 614], [",", 623], ["thus", 625], ["generating", 630], ["a", 641], ["cell", 643], ["-", 647], ["associated", 648], ["beta", 659], ["-", 663], ["C", 664], ["-", 665], ["terminal", 666], ["fragment", 675], ["(", 684], ["beta", 685], ["-", 689], ["CTF", 690], [")", 693], [".", 694], ["A", 696], ["pathogenic", 698], ["mutation", 709], ["at", 718], ["codons", 721], ["670/671", 728], ["in", 736], ["APP", 739], ["(", 743], ["APP", 744], ["\"", 748], ["Swedish", 749], ["\"", 756], [")", 757], ["leads", 759], ["to", 765], ["enhanced", 768], ["cleavage", 777], ["at", 786], ["the", 789], ["beta", 793], ["-", 797], ["secretase", 798], ["scissile", 808], ["bond", 817], ["and", 822], ["increased", 826], ["Abeta", 836], ["formation", 842], [".", 851], ["An", 853], ["inhibitor", 856], ["of", 866], ["vacuolar", 869], ["ATPases", 878], [",", 885], ["bafilomycin", 887], [",", 898], ["selectively", 900], ["inhibits", 912], ["the", 921], ["action", 925], ["of", 932], ["beta", 935], ["-", 939], ["secretase", 940], ["in", 950], ["cell", 953], ["culture", 958], [",", 965], ["suggesting", 967], ["a", 978], ["requirement", 980], ["for", 992], ["an", 996], ["acidic", 999], ["intracellular", 1006], ["compartment", 1020], ["for", 1032], ["effective", 1036], ["beta", 1046], ["-", 1050], ["secretase", 1051], ["cleavage", 1061], ["of", 1070], ["APP", 1073], [".", 1076], ["beta", 1078], ["-", 1082], ["CTF", 1083], ["is", 1087], ["cleaved", 1090], ["in", 1098], ["the", 1101], ["TM", 1105], ["domain", 1108], ["by", 1115], ["gamma", 1118], ["-", 1123], ["secretase(s", 1124], [")", 1135], [",", 1136], ["generating", 1138], ["both", 1149], ["Abeta", 1154], ["1", 1160], ["-", 1161], ["40", 1162], ["(", 1165], ["90", 1166], ["%", 1168], [")", 1169], ["and", 1171], ["Abeta", 1175], ["1", 1181], ["-", 1182], ["42", 1183], ["(", 1186], ["10", 1187], ["%", 1189], [")", 1190], [".", 1191], ["Pathogenic", 1193], ["mutations", 1204], ["in", 1214], ["APP", 1217], ["at", 1221], ["codon", 1224], ["717", 1230], ["(", 1234], ["APP", 1235], ["\"", 1239], ["London", 1240], ["\"", 1246], [")", 1247], ["lead", 1249], ["to", 1254], ["an", 1257], ["increased", 1260], ["proportion", 1270], ["of", 1281], ["Abeta", 1284], ["1", 1290], ["-", 1291], ["42", 1292], ["being", 1295], ["produced", 1301], ["and", 1310], ["secreted", 1314], [".", 1322], ["Missense", 1324], ["mutations", 1333], ["in", 1343], ["PS-1", 1346], [",", 1350], ["localized", 1352], ["to", 1362], ["chromosome", 1365], ["14", 1376], [",", 1378], ["are", 1380], ["pathogenic", 1384], ["in", 1395], ["the", 1398], ["majority", 1402], ["of", 1411], ["familial", 1414], ["Alzheimer", 1423], ["'s", 1432], ["pedigrees", 1435], [".", 1444], ["These", 1446], ["mutations", 1452], ["also", 1462], ["lead", 1467], ["to", 1472], ["increased", 1475], ["production", 1485], ["of", 1496], ["Abeta", 1499], ["1", 1505], ["-", 1506], ["42", 1507], ["over", 1510], ["Abeta", 1515], ["1", 1521], ["-", 1522], ["40", 1523], [".", 1525], ["Knockout", 1527], ["of", 1536], ["PS-1", 1539], ["in", 1544], ["transgenic", 1547], ["animals", 1558], ["leads", 1566], ["to", 1572], ["significant", 1575], ["inhibition", 1587], ["of", 1598], ["production", 1601], ["of", 1612], ["both", 1615], ["Abeta", 1620], ["1", 1626], ["-", 1627], ["40", 1628], ["and", 1631], ["Abeta", 1635], ["1", 1641], ["-", 1642], ["42", 1643], ["in", 1646], ["primary", 1649], ["cultures", 1657], [",", 1665], ["indicating", 1667], ["that", 1678], ["PS-1", 1683], ["expression", 1688], ["is", 1699], ["important", 1702], ["for", 1712], ["gamma", 1716], ["-", 1721], ["secretase", 1722], ["cleavages", 1732], [".", 1741], ["Peptide", 1743], ["aldehyde", 1751], ["inhibitors", 1760], ["that", 1771], ["block", 1776], ["Abeta", 1782], ["production", 1788], ["by", 1799], ["inhibiting", 1802], ["gamma", 1813], ["-", 1818], ["secretase", 1819], ["cleavage", 1829], ["of", 1838], ["beta", 1841], ["-", 1845], ["CTF", 1846], ["have", 1850], ["been", 1855], ["discovered", 1860], [".", 1870]]}
{"context": "Diamond-Blackfan anemia (DBA) is a congenital bone marrow failure syndrome characterized by a specific deficiency in erythroid progenitors. Forty percent of the patients are blood transfusion-dependent. Recent reports show that the ribosomal protein S19 (RPS19) gene is mutated in 25% of all patients with DBA. We constructed oncoretroviral vectors containing the RPS19 gene to develop gene therapy for RPS19-deficient DBA. These vectors were used to introduce the RPS19 gene into CD34(+) bone marrow (BM) cells from 4 patients with DBA with RPS19 gene mutations. Overexpression of the RPS19 transgene increased the number of erythroid colonies by almost 3-fold. High expression levels of the RPS19 transgene improved erythroid colony-forming ability substantially whereas low expression levels had no effect. Overexpression of RPS19 had no detrimental effect on granulocyte-macrophage colony formation. Therefore, these findings suggest that gene therapy for RPS19-deficient patients with DBA using viral vectors that express the RPS19 gene is feasible.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "0bede4582a9e40d4bb498c8ee7d6c64e", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[0, 3]], "char_spans": [[0, 22]]}, {"text": "DBA", "token_spans": [[5, 5], [164, 164], [55, 55], [71, 71], [95, 95]], "char_spans": [[25, 27], [990, 992], [306, 308], [419, 421], [533, 535]]}]}], "context_tokens": [["Diamond", 0], ["-", 7], ["Blackfan", 8], ["anemia", 17], ["(", 24], ["DBA", 25], [")", 28], ["is", 30], ["a", 33], ["congenital", 35], ["bone", 46], ["marrow", 51], ["failure", 58], ["syndrome", 66], ["characterized", 75], ["by", 89], ["a", 92], ["specific", 94], ["deficiency", 103], ["in", 114], ["erythroid", 117], ["progenitors", 127], [".", 138], ["Forty", 140], ["percent", 146], ["of", 154], ["the", 157], ["patients", 161], ["are", 170], ["blood", 174], ["transfusion", 180], ["-", 191], ["dependent", 192], [".", 201], ["Recent", 203], ["reports", 210], ["show", 218], ["that", 223], ["the", 228], ["ribosomal", 232], ["protein", 242], ["S19", 250], ["(", 254], ["RPS19", 255], [")", 260], ["gene", 262], ["is", 267], ["mutated", 270], ["in", 278], ["25", 281], ["%", 283], ["of", 285], ["all", 288], ["patients", 292], ["with", 301], ["DBA", 306], [".", 309], ["We", 311], ["constructed", 314], ["oncoretroviral", 326], ["vectors", 341], ["containing", 349], ["the", 360], ["RPS19", 364], ["gene", 370], ["to", 375], ["develop", 378], ["gene", 386], ["therapy", 391], ["for", 399], ["RPS19-deficient", 403], ["DBA", 419], [".", 422], ["These", 424], ["vectors", 430], ["were", 438], ["used", 443], ["to", 448], ["introduce", 451], ["the", 461], ["RPS19", 465], ["gene", 471], ["into", 476], ["CD34(+", 481], [")", 487], ["bone", 489], ["marrow", 494], ["(", 501], ["BM", 502], [")", 504], ["cells", 506], ["from", 512], ["4", 517], ["patients", 519], ["with", 528], ["DBA", 533], ["with", 537], ["RPS19", 542], ["gene", 548], ["mutations", 553], [".", 562], ["Overexpression", 564], ["of", 579], ["the", 582], ["RPS19", 586], ["transgene", 592], ["increased", 602], ["the", 612], ["number", 616], ["of", 623], ["erythroid", 626], ["colonies", 636], ["by", 645], ["almost", 648], ["3-fold", 655], [".", 661], ["High", 663], ["expression", 668], ["levels", 679], ["of", 686], ["the", 689], ["RPS19", 693], ["transgene", 699], ["improved", 709], ["erythroid", 718], ["colony", 728], ["-", 734], ["forming", 735], ["ability", 743], ["substantially", 751], ["whereas", 765], ["low", 773], ["expression", 777], ["levels", 788], ["had", 795], ["no", 799], ["effect", 802], [".", 808], ["Overexpression", 810], ["of", 825], ["RPS19", 828], ["had", 834], ["no", 838], ["detrimental", 841], ["effect", 853], ["on", 860], ["granulocyte", 863], ["-", 874], ["macrophage", 875], ["colony", 886], ["formation", 893], [".", 902], ["Therefore", 904], [",", 913], ["these", 915], ["findings", 921], ["suggest", 930], ["that", 938], ["gene", 943], ["therapy", 948], ["for", 956], ["RPS19-deficient", 960], ["patients", 976], ["with", 985], ["DBA", 990], ["using", 994], ["viral", 1000], ["vectors", 1006], ["that", 1014], ["express", 1019], ["the", 1027], ["RPS19", 1031], ["gene", 1037], ["is", 1042], ["feasible", 1045], [".", 1053]]}
{"context": "The purpose of this paper is to assess the reliability and validity of the Spanish version of the Davidson trauma scale (DTS-S) and to determine the prevalence and correlates of post-traumatic stress disorder (PTSD) symptoms in a non-clinical random sample of prison inmates. Probabilistic samples of 1,179 inmates from 26 penal institutions in Puerto Rico were selected using a multistage sampling design. Population estimates and correlations were obtained for PTSD, generalized anxiety and depression. The reliability, factor structure, and convergent validity of the DTS-S were assessed. Cross-validation was employed to confirm the results of the factor analyses. Using the cut-offs adopted by the scale's author, 136 (13.4 percent) of the inmates are likely to have current PTSD and 117 (11.6 percent) reach the cut-off for sub-threshold PTSD. Confirmatory factor analysis generated two factors explaining 53 percent of the variance. High reliabilities were obtained for the total scale (\u03b1=0.95) and for the frequency and severity scales (\u03b1=0.90 and 0.91). Significantly higher DTS-S scores were found for females (t=2.26, p<0.025), for inmates diagnosed with depression or anxiety (t=2.02, p<0.05), and those reporting suicide attempts (t=4.47, p<0.0001). Findings support that the DTS-S is a reliable and valid measure to assess PTSD symptoms in Latino inmate populations and to identify individuals at risk for the disorder that require confirmatory diagnosis and clinical interventions.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "b6a2b5c8312645a99ca848d823503319", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "post-traumatic stress disorder", "token_spans": [[34, 38]], "char_spans": [[178, 207]]}, {"text": "PTSD", "token_spans": [[160, 160], [144, 144], [40, 40], [254, 254], [81, 81]], "char_spans": [[844, 847], [780, 783], [210, 213], [1337, 1340], [463, 466]]}]}], "context_tokens": [["The", 0], ["purpose", 4], ["of", 12], ["this", 15], ["paper", 20], ["is", 26], ["to", 29], ["assess", 32], ["the", 39], ["reliability", 43], ["and", 55], ["validity", 59], ["of", 68], ["the", 71], ["Spanish", 75], ["version", 83], ["of", 91], ["the", 94], ["Davidson", 98], ["trauma", 107], ["scale", 114], ["(", 120], ["DTS", 121], ["-", 124], ["S", 125], [")", 126], ["and", 128], ["to", 132], ["determine", 135], ["the", 145], ["prevalence", 149], ["and", 160], ["correlates", 164], ["of", 175], ["post", 178], ["-", 182], ["traumatic", 183], ["stress", 193], ["disorder", 200], ["(", 209], ["PTSD", 210], [")", 214], ["symptoms", 216], ["in", 225], ["a", 228], ["non", 230], ["-", 233], ["clinical", 234], ["random", 243], ["sample", 250], ["of", 257], ["prison", 260], ["inmates", 267], [".", 274], ["Probabilistic", 276], ["samples", 290], ["of", 298], ["1,179", 301], ["inmates", 307], ["from", 315], ["26", 320], ["penal", 323], ["institutions", 329], ["in", 342], ["Puerto", 345], ["Rico", 352], ["were", 357], ["selected", 362], ["using", 371], ["a", 377], ["multistage", 379], ["sampling", 390], ["design", 399], [".", 405], ["Population", 407], ["estimates", 418], ["and", 428], ["correlations", 432], ["were", 445], ["obtained", 450], ["for", 459], ["PTSD", 463], [",", 467], ["generalized", 469], ["anxiety", 481], ["and", 489], ["depression", 493], [".", 503], ["The", 505], ["reliability", 509], [",", 520], ["factor", 522], ["structure", 529], [",", 538], ["and", 540], ["convergent", 544], ["validity", 555], ["of", 564], ["the", 567], ["DTS", 571], ["-", 574], ["S", 575], ["were", 577], ["assessed", 582], [".", 590], ["Cross", 592], ["-", 597], ["validation", 598], ["was", 609], ["employed", 613], ["to", 622], ["confirm", 625], ["the", 633], ["results", 637], ["of", 645], ["the", 648], ["factor", 652], ["analyses", 659], [".", 667], ["Using", 669], ["the", 675], ["cut", 679], ["-", 682], ["offs", 683], ["adopted", 688], ["by", 696], ["the", 699], ["scale", 703], ["'s", 708], ["author", 711], [",", 717], ["136", 719], ["(", 723], ["13.4", 724], ["percent", 729], [")", 736], ["of", 738], ["the", 741], ["inmates", 745], ["are", 753], ["likely", 757], ["to", 764], ["have", 767], ["current", 772], ["PTSD", 780], ["and", 785], ["117", 789], ["(", 793], ["11.6", 794], ["percent", 799], [")", 806], ["reach", 808], ["the", 814], ["cut", 818], ["-", 821], ["off", 822], ["for", 826], ["sub", 830], ["-", 833], ["threshold", 834], ["PTSD", 844], [".", 848], ["Confirmatory", 850], ["factor", 863], ["analysis", 870], ["generated", 879], ["two", 889], ["factors", 893], ["explaining", 901], ["53", 912], ["percent", 915], ["of", 923], ["the", 926], ["variance", 930], [".", 938], ["High", 940], ["reliabilities", 945], ["were", 959], ["obtained", 964], ["for", 973], ["the", 977], ["total", 981], ["scale", 987], ["(", 993], ["\u03b1=0.95", 994], [")", 1000], ["and", 1002], ["for", 1006], ["the", 1010], ["frequency", 1014], ["and", 1024], ["severity", 1028], ["scales", 1037], ["(", 1044], ["\u03b1=0.90", 1045], ["and", 1052], ["0.91", 1056], [")", 1060], [".", 1061], ["Significantly", 1063], ["higher", 1077], ["DTS", 1084], ["-", 1087], ["S", 1088], ["scores", 1090], ["were", 1097], ["found", 1102], ["for", 1108], ["females", 1112], ["(", 1120], ["t=2.26", 1121], [",", 1127], ["p<0.025", 1129], [")", 1136], [",", 1137], ["for", 1139], ["inmates", 1143], ["diagnosed", 1151], ["with", 1161], ["depression", 1166], ["or", 1177], ["anxiety", 1180], ["(", 1188], ["t=2.02", 1189], [",", 1195], ["p<0.05", 1197], [")", 1203], [",", 1204], ["and", 1206], ["those", 1210], ["reporting", 1216], ["suicide", 1226], ["attempts", 1234], ["(", 1243], ["t=4.47", 1244], [",", 1250], ["p<0.0001", 1252], [")", 1260], [".", 1261], ["Findings", 1263], ["support", 1272], ["that", 1280], ["the", 1285], ["DTS", 1289], ["-", 1292], ["S", 1293], ["is", 1295], ["a", 1298], ["reliable", 1300], ["and", 1309], ["valid", 1313], ["measure", 1319], ["to", 1327], ["assess", 1330], ["PTSD", 1337], ["symptoms", 1342], ["in", 1351], ["Latino", 1354], ["inmate", 1361], ["populations", 1368], ["and", 1380], ["to", 1384], ["identify", 1387], ["individuals", 1396], ["at", 1408], ["risk", 1411], ["for", 1416], ["the", 1420], ["disorder", 1424], ["that", 1433], ["require", 1438], ["confirmatory", 1446], ["diagnosis", 1459], ["and", 1469], ["clinical", 1473], ["interventions", 1482], [".", 1495]]}
{"context": "Persistent pain represents a major health problem, and most current therapeutic approaches are associated with unwanted effects and unsatisfactory pain relief. Therefore, an urgent need exists to develop more effective drugs that are directed toward new molecular targets. Nerve growth factor (NGF) is involved in pain transduction mechanisms, playing a key role as a master switch in many chronic and inflammatory pain states; the NGF ligand and its receptor TrkA constitute well-validated targets for pain therapy. Tanezumab (RN-624), a first-in-class recombinant humanized mAb targeting NGF, is being developed by Pfizer Inc for the potential treatment of pain associated with several conditions. In preclinical studies, tanezumab, and its murine precursor muMab-911, effectively targeted the NGF pathway in various chronic and inflammatory pain models. Phase I and II clinical trials in osteoarthritic pain and chronic lower back pain demonstrated good efficacy for the compound, as well as a good safety and tolerability profile. Given that tanezumab is an antibody, the drug demonstrates the general advantages of this class of products (including good specificity and favorable pharmacokinetics), and also appears to be particularly well suited for targeting the chronic and inflammatory-mediating pain actions of NGF and its receptor system.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "5e08c43eb8b64887bf868e17d62cc5c8", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[42, 44]], "char_spans": [[273, 291]]}, {"text": "NGF", "token_spans": [[102, 102], [136, 136], [72, 72], [46, 46], [223, 223]], "char_spans": [[590, 592], [796, 798], [432, 434], [294, 296], [1321, 1323]]}]}], "context_tokens": [["Persistent", 0], ["pain", 11], ["represents", 16], ["a", 27], ["major", 29], ["health", 35], ["problem", 42], [",", 49], ["and", 51], ["most", 55], ["current", 60], ["therapeutic", 68], ["approaches", 80], ["are", 91], ["associated", 95], ["with", 106], ["unwanted", 111], ["effects", 120], ["and", 128], ["unsatisfactory", 132], ["pain", 147], ["relief", 152], [".", 158], ["Therefore", 160], [",", 169], ["an", 171], ["urgent", 174], ["need", 181], ["exists", 186], ["to", 193], ["develop", 196], ["more", 204], ["effective", 209], ["drugs", 219], ["that", 225], ["are", 230], ["directed", 234], ["toward", 243], ["new", 250], ["molecular", 254], ["targets", 264], [".", 271], ["Nerve", 273], ["growth", 279], ["factor", 286], ["(", 293], ["NGF", 294], [")", 297], ["is", 299], ["involved", 302], ["in", 311], ["pain", 314], ["transduction", 319], ["mechanisms", 332], [",", 342], ["playing", 344], ["a", 352], ["key", 354], ["role", 358], ["as", 363], ["a", 366], ["master", 368], ["switch", 375], ["in", 382], ["many", 385], ["chronic", 390], ["and", 398], ["inflammatory", 402], ["pain", 415], ["states", 420], [";", 426], ["the", 428], ["NGF", 432], ["ligand", 436], ["and", 443], ["its", 447], ["receptor", 451], ["TrkA", 460], ["constitute", 465], ["well", 476], ["-", 480], ["validated", 481], ["targets", 491], ["for", 499], ["pain", 503], ["therapy", 508], [".", 515], ["Tanezumab", 517], ["(", 527], ["RN-624", 528], [")", 534], [",", 535], ["a", 537], ["first", 539], ["-", 544], ["in", 545], ["-", 547], ["class", 548], ["recombinant", 554], ["humanized", 566], ["mAb", 576], ["targeting", 580], ["NGF", 590], [",", 593], ["is", 595], ["being", 598], ["developed", 604], ["by", 614], ["Pfizer", 617], ["Inc", 624], ["for", 628], ["the", 632], ["potential", 636], ["treatment", 646], ["of", 656], ["pain", 659], ["associated", 664], ["with", 675], ["several", 680], ["conditions", 688], [".", 698], ["In", 700], ["preclinical", 703], ["studies", 715], [",", 722], ["tanezumab", 724], [",", 733], ["and", 735], ["its", 739], ["murine", 743], ["precursor", 750], ["muMab-911", 760], [",", 769], ["effectively", 771], ["targeted", 783], ["the", 792], ["NGF", 796], ["pathway", 800], ["in", 808], ["various", 811], ["chronic", 819], ["and", 827], ["inflammatory", 831], ["pain", 844], ["models", 849], [".", 855], ["Phase", 857], ["I", 863], ["and", 865], ["II", 869], ["clinical", 872], ["trials", 881], ["in", 888], ["osteoarthritic", 891], ["pain", 906], ["and", 911], ["chronic", 915], ["lower", 923], ["back", 929], ["pain", 934], ["demonstrated", 939], ["good", 952], ["efficacy", 957], ["for", 966], ["the", 970], ["compound", 974], [",", 982], ["as", 984], ["well", 987], ["as", 992], ["a", 995], ["good", 997], ["safety", 1002], ["and", 1009], ["tolerability", 1013], ["profile", 1026], [".", 1033], ["Given", 1035], ["that", 1041], ["tanezumab", 1046], ["is", 1056], ["an", 1059], ["antibody", 1062], [",", 1070], ["the", 1072], ["drug", 1076], ["demonstrates", 1081], ["the", 1094], ["general", 1098], ["advantages", 1106], ["of", 1117], ["this", 1120], ["class", 1125], ["of", 1131], ["products", 1134], ["(", 1143], ["including", 1144], ["good", 1154], ["specificity", 1159], ["and", 1171], ["favorable", 1175], ["pharmacokinetics", 1185], [")", 1201], [",", 1202], ["and", 1204], ["also", 1208], ["appears", 1213], ["to", 1221], ["be", 1224], ["particularly", 1227], ["well", 1240], ["suited", 1245], ["for", 1252], ["targeting", 1256], ["the", 1266], ["chronic", 1270], ["and", 1278], ["inflammatory", 1282], ["-", 1294], ["mediating", 1295], ["pain", 1305], ["actions", 1310], ["of", 1318], ["NGF", 1321], ["and", 1325], ["its", 1329], ["receptor", 1333], ["system", 1342], [".", 1348]]}
{"context": "The efficacy of RTS,S/AS01 as a vaccine for malaria is being tested in a phase 3 clinical trial. Early results show significant, albeit partial, protection against clinical malaria and severe malaria. To ascertain variations in vaccine efficacy according to covariates such as transmission intensity, choice of adjuvant, age at vaccination, and bednet use, we did an individual-participant pooled analysis of phase 2 clinical data. We analysed data from 11 different sites in Africa, including 4453 participants. We measured heterogeneity in vaccine efficacy by estimating the interactions between covariates and vaccination in pooled multivariable Cox regression and Poisson regression analyses. Endpoints for measurement of vaccine efficacy were infection, clinical malaria, severe malaria, and death. We defined transmission intensity levels according to the estimated local parasite prevalence in children aged 2-10 years (PrP\u2082\u208b\u2081\u2080), ranging from 5% to 80%. Choice of adjuvant was either AS01 or AS02. Vaccine efficacy against all episodes of clinical malaria varied by transmission intensity (p=0\u00b7001). At low transmission (PrP\u2082\u208b\u2081\u2080 10%) vaccine efficacy was 60% (95% CI 54 to 67), at moderate transmission (PrP\u2082\u208b\u2081\u2080 20%) it was 41% (21 to 57), and at high transmission (PrP\u2082\u208b\u2081\u2080 70%) the efficacy was 4% (-10 to 22). Vaccine efficacy also varied by adjuvant choice (p<0\u00b70001)--eg, at low transmission (PrP\u2082\u208b\u2081\u2080 10%), efficacy varied from 60% (95% CI 54 to 67) for AS01 to 47% (14 to 75) for AS02. Variations in efficacy by age at vaccination were of borderline significance (p=0\u00b7038), and bednet use and sex were not significant covariates. Vaccine efficacy (pooled across adjuvant choice and transmission intensity) varied significantly (p<0\u00b70001) according to time since vaccination, from 36% efficacy (95% CI 24 to 45) at time of vaccination to 0% (-38 to 38) after 3 years. Vaccine efficacy against clinical disease was of limited duration and was not detectable 3 years after vaccination. Furthermore, efficacy fell with increasing transmission intensity. Outcomes after vaccination cannot be gauged accurately on the basis of one pooled efficacy figure. However, predictions of public-health outcomes of vaccination will need to take account of variations in efficacy by transmission intensity and by time since vaccination. Medical Research Council (UK); Bill & Melinda Gates Foundation Vaccine Modelling Initiative; Wellcome Trust.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "fe31178b0e794792bab8b7ad3722944f", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[37, 37], [182, 182], [12, 12], [34, 34], [130, 130], [127, 127]], "char_spans": [[192, 198], [1055, 1061], [44, 50], [173, 179], [784, 790], [768, 774]]}]}], "context_tokens": [["The", 0], ["efficacy", 4], ["of", 13], ["RTS", 16], [",", 19], ["S", 20], ["/", 21], ["AS01", 22], ["as", 27], ["a", 30], ["vaccine", 32], ["for", 40], ["malaria", 44], ["is", 52], ["being", 55], ["tested", 61], ["in", 68], ["a", 71], ["phase", 73], ["3", 79], ["clinical", 81], ["trial", 90], [".", 95], ["Early", 97], ["results", 103], ["show", 111], ["significant", 116], [",", 127], ["albeit", 129], ["partial", 136], [",", 143], ["protection", 145], ["against", 156], ["clinical", 164], ["malaria", 173], ["and", 181], ["severe", 185], ["malaria", 192], [".", 199], ["To", 201], ["ascertain", 204], ["variations", 214], ["in", 225], ["vaccine", 228], ["efficacy", 236], ["according", 245], ["to", 255], ["covariates", 258], ["such", 269], ["as", 274], ["transmission", 277], ["intensity", 290], [",", 299], ["choice", 301], ["of", 308], ["adjuvant", 311], [",", 319], ["age", 321], ["at", 325], ["vaccination", 328], [",", 339], ["and", 341], ["bednet", 345], ["use", 352], [",", 355], ["we", 357], ["did", 360], ["an", 364], ["individual", 367], ["-", 377], ["participant", 378], ["pooled", 390], ["analysis", 397], ["of", 406], ["phase", 409], ["2", 415], ["clinical", 417], ["data", 426], [".", 430], ["We", 432], ["analysed", 435], ["data", 444], ["from", 449], ["11", 454], ["different", 457], ["sites", 467], ["in", 473], ["Africa", 476], [",", 482], ["including", 484], ["4453", 494], ["participants", 499], [".", 511], ["We", 513], ["measured", 516], ["heterogeneity", 525], ["in", 539], ["vaccine", 542], ["efficacy", 550], ["by", 559], ["estimating", 562], ["the", 573], ["interactions", 577], ["between", 590], ["covariates", 598], ["and", 609], ["vaccination", 613], ["in", 625], ["pooled", 628], ["multivariable", 635], ["Cox", 649], ["regression", 653], ["and", 664], ["Poisson", 668], ["regression", 676], ["analyses", 687], [".", 695], ["Endpoints", 697], ["for", 707], ["measurement", 711], ["of", 723], ["vaccine", 726], ["efficacy", 734], ["were", 743], ["infection", 748], [",", 757], ["clinical", 759], ["malaria", 768], [",", 775], ["severe", 777], ["malaria", 784], [",", 791], ["and", 793], ["death", 797], [".", 802], ["We", 804], ["defined", 807], ["transmission", 815], ["intensity", 828], ["levels", 838], ["according", 845], ["to", 855], ["the", 858], ["estimated", 862], ["local", 872], ["parasite", 878], ["prevalence", 887], ["in", 898], ["children", 901], ["aged", 910], ["2", 915], ["-", 916], ["10", 917], ["years", 920], ["(", 926], ["PrP\u2082\u208b\u2081\u2080", 927], [")", 934], [",", 935], ["ranging", 937], ["from", 945], ["5", 950], ["%", 951], ["to", 953], ["80", 956], ["%", 958], [".", 959], ["Choice", 961], ["of", 968], ["adjuvant", 971], ["was", 980], ["either", 984], ["AS01", 991], ["or", 996], ["AS02", 999], [".", 1003], ["Vaccine", 1005], ["efficacy", 1013], ["against", 1022], ["all", 1030], ["episodes", 1034], ["of", 1043], ["clinical", 1046], ["malaria", 1055], ["varied", 1063], ["by", 1070], ["transmission", 1073], ["intensity", 1086], ["(", 1096], ["p=0\u00b7001", 1097], [")", 1104], [".", 1105], ["At", 1107], ["low", 1110], ["transmission", 1114], ["(", 1127], ["PrP\u2082\u208b\u2081\u2080", 1128], ["10", 1136], ["%", 1138], [")", 1139], ["vaccine", 1141], ["efficacy", 1149], ["was", 1158], ["60", 1162], ["%", 1164], ["(", 1166], ["95", 1167], ["%", 1169], ["CI", 1171], ["54", 1174], ["to", 1177], ["67", 1180], [")", 1182], [",", 1183], ["at", 1185], ["moderate", 1188], ["transmission", 1197], ["(", 1210], ["PrP\u2082\u208b\u2081\u2080", 1211], ["20", 1219], ["%", 1221], [")", 1222], ["it", 1224], ["was", 1227], ["41", 1231], ["%", 1233], ["(", 1235], ["21", 1236], ["to", 1239], ["57", 1242], [")", 1244], [",", 1245], ["and", 1247], ["at", 1251], ["high", 1254], ["transmission", 1259], ["(", 1272], ["PrP\u2082\u208b\u2081\u2080", 1273], ["70", 1281], ["%", 1283], [")", 1284], ["the", 1286], ["efficacy", 1290], ["was", 1299], ["4", 1303], ["%", 1304], ["(", 1306], ["-10", 1307], ["to", 1311], ["22", 1314], [")", 1316], [".", 1317], ["Vaccine", 1319], ["efficacy", 1327], ["also", 1336], ["varied", 1341], ["by", 1348], ["adjuvant", 1351], ["choice", 1360], ["(", 1367], ["p<0\u00b70001)--eg", 1368], [",", 1381], ["at", 1383], ["low", 1386], ["transmission", 1390], ["(", 1403], ["PrP\u2082\u208b\u2081\u2080", 1404], ["10", 1412], ["%", 1414], [")", 1415], [",", 1416], ["efficacy", 1418], ["varied", 1427], ["from", 1434], ["60", 1439], ["%", 1441], ["(", 1443], ["95", 1444], ["%", 1446], ["CI", 1448], ["54", 1451], ["to", 1454], ["67", 1457], [")", 1459], ["for", 1461], ["AS01", 1465], ["to", 1470], ["47", 1473], ["%", 1475], ["(", 1477], ["14", 1478], ["to", 1481], ["75", 1484], [")", 1486], ["for", 1488], ["AS02", 1492], [".", 1496], ["Variations", 1498], ["in", 1509], ["efficacy", 1512], ["by", 1521], ["age", 1524], ["at", 1528], ["vaccination", 1531], ["were", 1543], ["of", 1548], ["borderline", 1551], ["significance", 1562], ["(", 1575], ["p=0\u00b7038", 1576], [")", 1583], [",", 1584], ["and", 1586], ["bednet", 1590], ["use", 1597], ["and", 1601], ["sex", 1605], ["were", 1609], ["not", 1614], ["significant", 1618], ["covariates", 1630], [".", 1640], ["Vaccine", 1642], ["efficacy", 1650], ["(", 1659], ["pooled", 1660], ["across", 1667], ["adjuvant", 1674], ["choice", 1683], ["and", 1690], ["transmission", 1694], ["intensity", 1707], [")", 1716], ["varied", 1718], ["significantly", 1725], ["(", 1739], ["p<0\u00b70001", 1740], [")", 1748], ["according", 1750], ["to", 1760], ["time", 1763], ["since", 1768], ["vaccination", 1774], [",", 1785], ["from", 1787], ["36", 1792], ["%", 1794], ["efficacy", 1796], ["(", 1805], ["95", 1806], ["%", 1808], ["CI", 1810], ["24", 1813], ["to", 1816], ["45", 1819], [")", 1821], ["at", 1823], ["time", 1826], ["of", 1831], ["vaccination", 1834], ["to", 1846], ["0", 1849], ["%", 1850], ["(", 1852], ["-38", 1853], ["to", 1857], ["38", 1860], [")", 1862], ["after", 1864], ["3", 1870], ["years", 1872], [".", 1877], ["Vaccine", 1879], ["efficacy", 1887], ["against", 1896], ["clinical", 1904], ["disease", 1913], ["was", 1921], ["of", 1925], ["limited", 1928], ["duration", 1936], ["and", 1945], ["was", 1949], ["not", 1953], ["detectable", 1957], ["3", 1968], ["years", 1970], ["after", 1976], ["vaccination", 1982], [".", 1993], ["Furthermore", 1995], [",", 2006], ["efficacy", 2008], ["fell", 2017], ["with", 2022], ["increasing", 2027], ["transmission", 2038], ["intensity", 2051], [".", 2060], ["Outcomes", 2062], ["after", 2071], ["vaccination", 2077], ["can", 2089], ["not", 2092], ["be", 2096], ["gauged", 2099], ["accurately", 2106], ["on", 2117], ["the", 2120], ["basis", 2124], ["of", 2130], ["one", 2133], ["pooled", 2137], ["efficacy", 2144], ["figure", 2153], [".", 2159], ["However", 2161], [",", 2168], ["predictions", 2170], ["of", 2182], ["public", 2185], ["-", 2191], ["health", 2192], ["outcomes", 2199], ["of", 2208], ["vaccination", 2211], ["will", 2223], ["need", 2228], ["to", 2233], ["take", 2236], ["account", 2241], ["of", 2249], ["variations", 2252], ["in", 2263], ["efficacy", 2266], ["by", 2275], ["transmission", 2278], ["intensity", 2291], ["and", 2301], ["by", 2305], ["time", 2308], ["since", 2313], ["vaccination", 2319], [".", 2330], ["Medical", 2332], ["Research", 2340], ["Council", 2349], ["(", 2357], ["UK", 2358], [")", 2360], [";", 2361], ["Bill", 2363], ["&", 2368], ["Melinda", 2370], ["Gates", 2378], ["Foundation", 2384], ["Vaccine", 2395], ["Modelling", 2403], ["Initiative", 2413], [";", 2423], ["Wellcome", 2425], ["Trust", 2434], [".", 2439]]}
{"context": "With the recent introduction of inhibitors of mammalian target of rapamycin (mTOR) in oncology, distinct cutaneous and oral adverse events have been identified. In fact, stomatitis and rash are documented as the most frequent and potentially dose-limiting side effects. Clinically, mTOR inhibitor-associated stomatitis (mIAS) more closely resembles aphthous stomatitis than oral mucositis due to conventional anticancer therapies. While most cases of mIAS are mild to moderate and self-limiting, more severe and persistent mIAS can become a dose-limiting toxicity. Small ulcerations may cause significant pain and mucosal sensitivity may occur in the absence of clinical changes. Use of clinical assessment tools that are primarily driven by ulceration size may underestimate mIAS, and assessment should include patient-reported outcomes. This article provides an up-to-date review of the clinical presentation, terminology, pathogenesis, assessment and management of mIAS and other mTOR inhibitor-associated oral adverse events. In addition, areas of future research are considered.", "qas": [{"question": "What does mTOR stands for?", "answers": ["mammalian target of rapamycin"], "qid": "51c0f6328c564f34adfee63c41eda084", "question_tokens": [["What", 0], ["does", 5], ["mTOR", 10], ["stands", 15], ["for", 22], ["?", 25]], "detected_answers": [{"text": "mammalian target of rapamycin", "token_spans": [[7, 10]], "char_spans": [[46, 74]]}]}], "context_tokens": [["With", 0], ["the", 5], ["recent", 9], ["introduction", 16], ["of", 29], ["inhibitors", 32], ["of", 43], ["mammalian", 46], ["target", 56], ["of", 63], ["rapamycin", 66], ["(", 76], ["mTOR", 77], [")", 81], ["in", 83], ["oncology", 86], [",", 94], ["distinct", 96], ["cutaneous", 105], ["and", 115], ["oral", 119], ["adverse", 124], ["events", 132], ["have", 139], ["been", 144], ["identified", 149], [".", 159], ["In", 161], ["fact", 164], [",", 168], ["stomatitis", 170], ["and", 181], ["rash", 185], ["are", 190], ["documented", 194], ["as", 205], ["the", 208], ["most", 212], ["frequent", 217], ["and", 226], ["potentially", 230], ["dose", 242], ["-", 246], ["limiting", 247], ["side", 256], ["effects", 261], [".", 268], ["Clinically", 270], [",", 280], ["mTOR", 282], ["inhibitor", 287], ["-", 296], ["associated", 297], ["stomatitis", 308], ["(", 319], ["mIAS", 320], [")", 324], ["more", 326], ["closely", 331], ["resembles", 339], ["aphthous", 349], ["stomatitis", 358], ["than", 369], ["oral", 374], ["mucositis", 379], ["due", 389], ["to", 393], ["conventional", 396], ["anticancer", 409], ["therapies", 420], [".", 429], ["While", 431], ["most", 437], ["cases", 442], ["of", 448], ["mIAS", 451], ["are", 456], ["mild", 460], ["to", 465], ["moderate", 468], ["and", 477], ["self", 481], ["-", 485], ["limiting", 486], [",", 494], ["more", 496], ["severe", 501], ["and", 508], ["persistent", 512], ["mIAS", 523], ["can", 528], ["become", 532], ["a", 539], ["dose", 541], ["-", 545], ["limiting", 546], ["toxicity", 555], [".", 563], ["Small", 565], ["ulcerations", 571], ["may", 583], ["cause", 587], ["significant", 593], ["pain", 605], ["and", 610], ["mucosal", 614], ["sensitivity", 622], ["may", 634], ["occur", 638], ["in", 644], ["the", 647], ["absence", 651], ["of", 659], ["clinical", 662], ["changes", 671], [".", 678], ["Use", 680], ["of", 684], ["clinical", 687], ["assessment", 696], ["tools", 707], ["that", 713], ["are", 718], ["primarily", 722], ["driven", 732], ["by", 739], ["ulceration", 742], ["size", 753], ["may", 758], ["underestimate", 762], ["mIAS", 776], [",", 780], ["and", 782], ["assessment", 786], ["should", 797], ["include", 804], ["patient", 812], ["-", 819], ["reported", 820], ["outcomes", 829], [".", 837], ["This", 839], ["article", 844], ["provides", 852], ["an", 861], ["up", 864], ["-", 866], ["to", 867], ["-", 869], ["date", 870], ["review", 875], ["of", 882], ["the", 885], ["clinical", 889], ["presentation", 898], [",", 910], ["terminology", 912], [",", 923], ["pathogenesis", 925], [",", 937], ["assessment", 939], ["and", 950], ["management", 954], ["of", 965], ["mIAS", 968], ["and", 973], ["other", 977], ["mTOR", 983], ["inhibitor", 988], ["-", 997], ["associated", 998], ["oral", 1009], ["adverse", 1014], ["events", 1022], [".", 1028], ["In", 1030], ["addition", 1033], [",", 1041], ["areas", 1043], ["of", 1049], ["future", 1052], ["research", 1059], ["are", 1068], ["considered", 1072], [".", 1082]]}
{"context": "Chronic myeloid leukemia (CML) is the first human malignancy for which the promise of targeted therapy has come true. CML is invariably associated with a specific genetic lesion--the t(9;22) chromosomal translocation. As a consequence of this translocation, a BCR-ABL fusion gene is formed on the 22q- derivative (traditionally known as the Philadelphia chromosome) and the deregulated tyrosine kinase activity of the protein encoded by this gene has been shown to be both necessary and sufficient for initiation and maintenance of the disease. Imatinib mesylate, an orally available tyrosine kinase inhibitor that targets Bcr-Abl, entered clinical evaluation in 1998. Its efficacy surpassed almost everyone's predictions, and the observation of high response rates and favorable toxicity profile associated with imatinib therapy led to its approval as first-line treatment for all newly diagnosed CML patients over an exceptionally short period of time. The 6-year results of the Phase III trial have recently been reported and confirm durability of responses and declining incidence of adverse events over time, although, at present, occurrence of unexpected side effects in the long term cannot be excluded. Although imatinib does not 'cure' CML and has to be administered chronically to patients, it has revolutionized both outcome and quality of life of CML patients.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "b84adc8ad62e42e3b5cd84477d1d0750", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[46, 48], [106, 108]], "char_spans": [[260, 266], [623, 629]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["the", 34], ["first", 38], ["human", 44], ["malignancy", 50], ["for", 61], ["which", 65], ["the", 71], ["promise", 75], ["of", 83], ["targeted", 86], ["therapy", 95], ["has", 103], ["come", 107], ["true", 112], [".", 116], ["CML", 118], ["is", 122], ["invariably", 125], ["associated", 136], ["with", 147], ["a", 152], ["specific", 154], ["genetic", 163], ["lesion", 171], ["--", 177], ["the", 179], ["t(9;22", 183], [")", 189], ["chromosomal", 191], ["translocation", 203], [".", 216], ["As", 218], ["a", 221], ["consequence", 223], ["of", 235], ["this", 238], ["translocation", 243], [",", 256], ["a", 258], ["BCR", 260], ["-", 263], ["ABL", 264], ["fusion", 268], ["gene", 275], ["is", 280], ["formed", 283], ["on", 290], ["the", 293], ["22q-", 297], ["derivative", 302], ["(", 313], ["traditionally", 314], ["known", 328], ["as", 334], ["the", 337], ["Philadelphia", 341], ["chromosome", 354], [")", 364], ["and", 366], ["the", 370], ["deregulated", 374], ["tyrosine", 386], ["kinase", 395], ["activity", 402], ["of", 411], ["the", 414], ["protein", 418], ["encoded", 426], ["by", 434], ["this", 437], ["gene", 442], ["has", 447], ["been", 451], ["shown", 456], ["to", 462], ["be", 465], ["both", 468], ["necessary", 473], ["and", 483], ["sufficient", 487], ["for", 498], ["initiation", 502], ["and", 513], ["maintenance", 517], ["of", 529], ["the", 532], ["disease", 536], [".", 543], ["Imatinib", 545], ["mesylate", 554], [",", 562], ["an", 564], ["orally", 567], ["available", 574], ["tyrosine", 584], ["kinase", 593], ["inhibitor", 600], ["that", 610], ["targets", 615], ["Bcr", 623], ["-", 626], ["Abl", 627], [",", 630], ["entered", 632], ["clinical", 640], ["evaluation", 649], ["in", 660], ["1998", 663], [".", 667], ["Its", 669], ["efficacy", 673], ["surpassed", 682], ["almost", 692], ["everyone", 699], ["'s", 707], ["predictions", 710], [",", 721], ["and", 723], ["the", 727], ["observation", 731], ["of", 743], ["high", 746], ["response", 751], ["rates", 760], ["and", 766], ["favorable", 770], ["toxicity", 780], ["profile", 789], ["associated", 797], ["with", 808], ["imatinib", 813], ["therapy", 822], ["led", 830], ["to", 834], ["its", 837], ["approval", 841], ["as", 850], ["first", 853], ["-", 858], ["line", 859], ["treatment", 864], ["for", 874], ["all", 878], ["newly", 882], ["diagnosed", 888], ["CML", 898], ["patients", 902], ["over", 911], ["an", 916], ["exceptionally", 919], ["short", 933], ["period", 939], ["of", 946], ["time", 949], [".", 953], ["The", 955], ["6-year", 959], ["results", 966], ["of", 974], ["the", 977], ["Phase", 981], ["III", 987], ["trial", 991], ["have", 997], ["recently", 1002], ["been", 1011], ["reported", 1016], ["and", 1025], ["confirm", 1029], ["durability", 1037], ["of", 1048], ["responses", 1051], ["and", 1061], ["declining", 1065], ["incidence", 1075], ["of", 1085], ["adverse", 1088], ["events", 1096], ["over", 1103], ["time", 1108], [",", 1112], ["although", 1114], [",", 1122], ["at", 1124], ["present", 1127], [",", 1134], ["occurrence", 1136], ["of", 1147], ["unexpected", 1150], ["side", 1161], ["effects", 1166], ["in", 1174], ["the", 1177], ["long", 1181], ["term", 1186], ["can", 1191], ["not", 1194], ["be", 1198], ["excluded", 1201], [".", 1209], ["Although", 1211], ["imatinib", 1220], ["does", 1229], ["not", 1234], ["'", 1238], ["cure", 1239], ["'", 1243], ["CML", 1245], ["and", 1249], ["has", 1253], ["to", 1257], ["be", 1260], ["administered", 1263], ["chronically", 1276], ["to", 1288], ["patients", 1291], [",", 1299], ["it", 1301], ["has", 1304], ["revolutionized", 1308], ["both", 1323], ["outcome", 1328], ["and", 1336], ["quality", 1340], ["of", 1348], ["life", 1351], ["of", 1356], ["CML", 1359], ["patients", 1363], [".", 1371]]}
{"context": "Community-associated methicillin resistant Staphylococcus aureus (CA-MRSA) has become a severe health concern because of its treatment difficulties. Herein, we report the synthesis and biological evaluation of two phenazine natural products and a series of phenazines that show promising activities against MRSA with MIC values in the low micromolar range. Basic studies revealed that these compounds are bacteriostatic agents. The most active compound also displayed promising IC50 values against HaCat cells. Finally, a QSAR model was developed to understand the key structural features of the molecules.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "939bd5a155c04ec9b5d6eb9c28071c9d", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[48, 48], [10, 10]], "char_spans": [[307, 310], [69, 72]]}]}], "context_tokens": [["Community", 0], ["-", 9], ["associated", 10], ["methicillin", 21], ["resistant", 33], ["Staphylococcus", 43], ["aureus", 58], ["(", 65], ["CA", 66], ["-", 68], ["MRSA", 69], [")", 73], ["has", 75], ["become", 79], ["a", 86], ["severe", 88], ["health", 95], ["concern", 102], ["because", 110], ["of", 118], ["its", 121], ["treatment", 125], ["difficulties", 135], [".", 147], ["Herein", 149], [",", 155], ["we", 157], ["report", 160], ["the", 167], ["synthesis", 171], ["and", 181], ["biological", 185], ["evaluation", 196], ["of", 207], ["two", 210], ["phenazine", 214], ["natural", 224], ["products", 232], ["and", 241], ["a", 245], ["series", 247], ["of", 254], ["phenazines", 257], ["that", 268], ["show", 273], ["promising", 278], ["activities", 288], ["against", 299], ["MRSA", 307], ["with", 312], ["MIC", 317], ["values", 321], ["in", 328], ["the", 331], ["low", 335], ["micromolar", 339], ["range", 350], [".", 355], ["Basic", 357], ["studies", 363], ["revealed", 371], ["that", 380], ["these", 385], ["compounds", 391], ["are", 401], ["bacteriostatic", 405], ["agents", 420], [".", 426], ["The", 428], ["most", 432], ["active", 437], ["compound", 444], ["also", 453], ["displayed", 458], ["promising", 468], ["IC50", 478], ["values", 483], ["against", 490], ["HaCat", 498], ["cells", 504], [".", 509], ["Finally", 511], [",", 518], ["a", 520], ["QSAR", 522], ["model", 527], ["was", 533], ["developed", 537], ["to", 547], ["understand", 550], ["the", 561], ["key", 565], ["structural", 569], ["features", 580], ["of", 589], ["the", 592], ["molecules", 596], [".", 605]]}
{"context": "Prominin-1 (CD133) is commonly used to isolate stem and progenitor cells from the developing and adult nervous system and to identify cancer stem cells in brain tumors. However, despite extensive characterization of Prominin-1(+) precursor cells from the adult subventricular zone, no information about the expression of Prominin-1 by precursor cells in the subgranular zone (SGZ) of the adult hippocampus has been available. We show here that Prominin-1 is expressed by a significant number of cells in the SGZ of adult mice in vivo and ex vivo, including postmitotic astrocytes. A small subset of Prominin-1(+) cells coexpressed the nonspecific precursor cell marker Nestin as well as GFAP and Sox2. Upon fluorescence-activated cell sorting, only Prominin-1/Nestin double-positive cells fulfilled the defining stem cell criteria of proliferation, self-renewal, and multipotentiality as assessed by a neurosphere assay. In addition, isolated primary Prominin-1(+) cells preferentially migrated to the neurogenic niche in the SGZ upon transplantation in vivo. Finally, despite its expression by various stem and progenitor cells, Prominin-1 turned out to be dispensable for precursor cell proliferation in vitro and in vivo. Nevertheless, a net decrease in hippocampal neurogenesis, by \u223c30% was found in Prominin-1 knock-out mice, suggesting other roles in controlling adult hippocampal neurogenesis. Remarkably, an upregulation of Prominin-2 was detected in Prominin-1-deficient mice highlighting a potential compensatory mechanism, which might explain the lack of severe symptoms in individuals carrying mutations in the Prom1 gene.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "6cc9877ac4fc485b8865be0daa1ae5a3", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[113, 113]], "char_spans": [[669, 674]]}]}], "context_tokens": [["Prominin-1", 0], ["(", 11], ["CD133", 12], [")", 17], ["is", 19], ["commonly", 22], ["used", 31], ["to", 36], ["isolate", 39], ["stem", 47], ["and", 52], ["progenitor", 56], ["cells", 67], ["from", 73], ["the", 78], ["developing", 82], ["and", 93], ["adult", 97], ["nervous", 103], ["system", 111], ["and", 118], ["to", 122], ["identify", 125], ["cancer", 134], ["stem", 141], ["cells", 146], ["in", 152], ["brain", 155], ["tumors", 161], [".", 167], ["However", 169], [",", 176], ["despite", 178], ["extensive", 186], ["characterization", 196], ["of", 213], ["Prominin-1(+", 216], [")", 228], ["precursor", 230], ["cells", 240], ["from", 246], ["the", 251], ["adult", 255], ["subventricular", 261], ["zone", 276], [",", 280], ["no", 282], ["information", 285], ["about", 297], ["the", 303], ["expression", 307], ["of", 318], ["Prominin-1", 321], ["by", 332], ["precursor", 335], ["cells", 345], ["in", 351], ["the", 354], ["subgranular", 358], ["zone", 370], ["(", 375], ["SGZ", 376], [")", 379], ["of", 381], ["the", 384], ["adult", 388], ["hippocampus", 394], ["has", 406], ["been", 410], ["available", 415], [".", 424], ["We", 426], ["show", 429], ["here", 434], ["that", 439], ["Prominin-1", 444], ["is", 455], ["expressed", 458], ["by", 468], ["a", 471], ["significant", 473], ["number", 485], ["of", 492], ["cells", 495], ["in", 501], ["the", 504], ["SGZ", 508], ["of", 512], ["adult", 515], ["mice", 521], ["in", 526], ["vivo", 529], ["and", 534], ["ex", 538], ["vivo", 541], [",", 545], ["including", 547], ["postmitotic", 557], ["astrocytes", 569], [".", 579], ["A", 581], ["small", 583], ["subset", 589], ["of", 596], ["Prominin-1(+", 599], [")", 611], ["cells", 613], ["coexpressed", 619], ["the", 631], ["nonspecific", 635], ["precursor", 647], ["cell", 657], ["marker", 662], ["Nestin", 669], ["as", 676], ["well", 679], ["as", 684], ["GFAP", 687], ["and", 692], ["Sox2", 696], [".", 700], ["Upon", 702], ["fluorescence", 707], ["-", 719], ["activated", 720], ["cell", 730], ["sorting", 735], [",", 742], ["only", 744], ["Prominin-1/Nestin", 749], ["double", 767], ["-", 773], ["positive", 774], ["cells", 783], ["fulfilled", 789], ["the", 799], ["defining", 803], ["stem", 812], ["cell", 817], ["criteria", 822], ["of", 831], ["proliferation", 834], [",", 847], ["self", 849], ["-", 853], ["renewal", 854], [",", 861], ["and", 863], ["multipotentiality", 867], ["as", 885], ["assessed", 888], ["by", 897], ["a", 900], ["neurosphere", 902], ["assay", 914], [".", 919], ["In", 921], ["addition", 924], [",", 932], ["isolated", 934], ["primary", 943], ["Prominin-1(+", 951], [")", 963], ["cells", 965], ["preferentially", 971], ["migrated", 986], ["to", 995], ["the", 998], ["neurogenic", 1002], ["niche", 1013], ["in", 1019], ["the", 1022], ["SGZ", 1026], ["upon", 1030], ["transplantation", 1035], ["in", 1051], ["vivo", 1054], [".", 1058], ["Finally", 1060], [",", 1067], ["despite", 1069], ["its", 1077], ["expression", 1081], ["by", 1092], ["various", 1095], ["stem", 1103], ["and", 1108], ["progenitor", 1112], ["cells", 1123], [",", 1128], ["Prominin-1", 1130], ["turned", 1141], ["out", 1148], ["to", 1152], ["be", 1155], ["dispensable", 1158], ["for", 1170], ["precursor", 1174], ["cell", 1184], ["proliferation", 1189], ["in", 1203], ["vitro", 1206], ["and", 1212], ["in", 1216], ["vivo", 1219], [".", 1223], ["Nevertheless", 1225], [",", 1237], ["a", 1239], ["net", 1241], ["decrease", 1245], ["in", 1254], ["hippocampal", 1257], ["neurogenesis", 1269], [",", 1281], ["by", 1283], ["\u223c30", 1286], ["%", 1289], ["was", 1291], ["found", 1295], ["in", 1301], ["Prominin-1", 1304], ["knock", 1315], ["-", 1320], ["out", 1321], ["mice", 1325], [",", 1329], ["suggesting", 1331], ["other", 1342], ["roles", 1348], ["in", 1354], ["controlling", 1357], ["adult", 1369], ["hippocampal", 1375], ["neurogenesis", 1387], [".", 1399], ["Remarkably", 1401], [",", 1411], ["an", 1413], ["upregulation", 1416], ["of", 1429], ["Prominin-2", 1432], ["was", 1443], ["detected", 1447], ["in", 1456], ["Prominin-1-deficient", 1459], ["mice", 1480], ["highlighting", 1485], ["a", 1498], ["potential", 1500], ["compensatory", 1510], ["mechanism", 1523], [",", 1532], ["which", 1534], ["might", 1540], ["explain", 1546], ["the", 1554], ["lack", 1558], ["of", 1563], ["severe", 1566], ["symptoms", 1573], ["in", 1582], ["individuals", 1585], ["carrying", 1597], ["mutations", 1606], ["in", 1616], ["the", 1619], ["Prom1", 1623], ["gene", 1629], [".", 1633]]}
{"context": "The ABL1 proto-oncogene encodes a cytoplasmic and nuclear protein tyrosine kinase (c-Abl) that has been implicated in processes of cell differentiation, cell division, cell adhesion and stress response. Alterations of ABL1 by chromosomal rearrangement or viral transduction can lead to malignant transformation. Activity of the c-Abl protein is negatively regulated by its SH3 domain through an unknown mechanism, and deletion of the SH3 domain turns ABL1 into an oncogene. We present evidence for an intramolecular inhibitory interaction of the SH3 domain with the catalytic domain and with the linker between the SH2 and catalytic domain (SH2-CD linker). Site-directed mutations in each of these three elements activate c-Abl. Mutations in the linker cause a conformational change of the molecule and increase binding of the SH3 domain to peptide ligands. Individual mutation of two charged residues in the SH3 and catalytic domain activates c-Abl, while inhibition is restored in the double reciprocal mutant. We propose that regulators of c-Abl will have opposite effects on its activity depending on their ability to favour or disrupt these intramolecular interactions.", "qas": [{"question": "What kind of enzyme is encoded by the proto-oncogene ABL1?", "answers": ["Nonreceptor tyrosine kinase", "Protein-Tyrosine Kinase", "protein tyrosine kinase"], "qid": "0e43309febce41e0bc84f3276562043b", "question_tokens": [["What", 0], ["kind", 5], ["of", 10], ["enzyme", 13], ["is", 20], ["encoded", 23], ["by", 31], ["the", 34], ["proto", 38], ["-", 43], ["oncogene", 44], ["ABL1", 53], ["?", 57]], "detected_answers": [{"text": "Protein-Tyrosine Kinase", "token_spans": [[10, 12]], "char_spans": [[58, 80]]}]}], "context_tokens": [["The", 0], ["ABL1", 4], ["proto", 9], ["-", 14], ["oncogene", 15], ["encodes", 24], ["a", 32], ["cytoplasmic", 34], ["and", 46], ["nuclear", 50], ["protein", 58], ["tyrosine", 66], ["kinase", 75], ["(", 82], ["c", 83], ["-", 84], ["Abl", 85], [")", 88], ["that", 90], ["has", 95], ["been", 99], ["implicated", 104], ["in", 115], ["processes", 118], ["of", 128], ["cell", 131], ["differentiation", 136], [",", 151], ["cell", 153], ["division", 158], [",", 166], ["cell", 168], ["adhesion", 173], ["and", 182], ["stress", 186], ["response", 193], [".", 201], ["Alterations", 203], ["of", 215], ["ABL1", 218], ["by", 223], ["chromosomal", 226], ["rearrangement", 238], ["or", 252], ["viral", 255], ["transduction", 261], ["can", 274], ["lead", 278], ["to", 283], ["malignant", 286], ["transformation", 296], [".", 310], ["Activity", 312], ["of", 321], ["the", 324], ["c", 328], ["-", 329], ["Abl", 330], ["protein", 334], ["is", 342], ["negatively", 345], ["regulated", 356], ["by", 366], ["its", 369], ["SH3", 373], ["domain", 377], ["through", 384], ["an", 392], ["unknown", 395], ["mechanism", 403], [",", 412], ["and", 414], ["deletion", 418], ["of", 427], ["the", 430], ["SH3", 434], ["domain", 438], ["turns", 445], ["ABL1", 451], ["into", 456], ["an", 461], ["oncogene", 464], [".", 472], ["We", 474], ["present", 477], ["evidence", 485], ["for", 494], ["an", 498], ["intramolecular", 501], ["inhibitory", 516], ["interaction", 527], ["of", 539], ["the", 542], ["SH3", 546], ["domain", 550], ["with", 557], ["the", 562], ["catalytic", 566], ["domain", 576], ["and", 583], ["with", 587], ["the", 592], ["linker", 596], ["between", 603], ["the", 611], ["SH2", 615], ["and", 619], ["catalytic", 623], ["domain", 633], ["(", 640], ["SH2-CD", 641], ["linker", 648], [")", 654], [".", 655], ["Site", 657], ["-", 661], ["directed", 662], ["mutations", 671], ["in", 681], ["each", 684], ["of", 689], ["these", 692], ["three", 698], ["elements", 704], ["activate", 713], ["c", 722], ["-", 723], ["Abl", 724], [".", 727], ["Mutations", 729], ["in", 739], ["the", 742], ["linker", 746], ["cause", 753], ["a", 759], ["conformational", 761], ["change", 776], ["of", 783], ["the", 786], ["molecule", 790], ["and", 799], ["increase", 803], ["binding", 812], ["of", 820], ["the", 823], ["SH3", 827], ["domain", 831], ["to", 838], ["peptide", 841], ["ligands", 849], [".", 856], ["Individual", 858], ["mutation", 869], ["of", 878], ["two", 881], ["charged", 885], ["residues", 893], ["in", 902], ["the", 905], ["SH3", 909], ["and", 913], ["catalytic", 917], ["domain", 927], ["activates", 934], ["c", 944], ["-", 945], ["Abl", 946], [",", 949], ["while", 951], ["inhibition", 957], ["is", 968], ["restored", 971], ["in", 980], ["the", 983], ["double", 987], ["reciprocal", 994], ["mutant", 1005], [".", 1011], ["We", 1013], ["propose", 1016], ["that", 1024], ["regulators", 1029], ["of", 1040], ["c", 1043], ["-", 1044], ["Abl", 1045], ["will", 1049], ["have", 1054], ["opposite", 1059], ["effects", 1068], ["on", 1076], ["its", 1079], ["activity", 1083], ["depending", 1092], ["on", 1102], ["their", 1105], ["ability", 1111], ["to", 1119], ["favour", 1122], ["or", 1129], ["disrupt", 1132], ["these", 1140], ["intramolecular", 1146], ["interactions", 1161], [".", 1173]]}
{"context": "The mechanism of neurodegeneration in CAG/polyglutamine repeat expansion diseases is unknown but is thought to occur at the protein level. Here, in studies of spinocerebellar ataxia type 3, also known as Machado-Joseph disease (SCA3/MJD), we show that the disease protein ataxin-3 accumulates in ubiquitinated intranuclear inclusions selectively in neurons of affected brain regions. We further provide evidence in vitro for a model of disease in which an expanded polyglutamine-containing fragment recruits full-length protein into insoluble aggregates. Together with recent findings from transgenic models, our results suggest that intranuclear aggregation of the expanded protein is a unifying feature of CAG/polyglutamine diseases and may be initiated or catalyzed by a glutamine-containing fragment of the disease protein.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "353a222964794361bdaaf8ea481c12ee", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[50, 50]], "char_spans": [[272, 279]]}]}], "context_tokens": [["The", 0], ["mechanism", 4], ["of", 14], ["neurodegeneration", 17], ["in", 35], ["CAG", 38], ["/", 41], ["polyglutamine", 42], ["repeat", 56], ["expansion", 63], ["diseases", 73], ["is", 82], ["unknown", 85], ["but", 93], ["is", 97], ["thought", 100], ["to", 108], ["occur", 111], ["at", 117], ["the", 120], ["protein", 124], ["level", 132], [".", 137], ["Here", 139], [",", 143], ["in", 145], ["studies", 148], ["of", 156], ["spinocerebellar", 159], ["ataxia", 175], ["type", 182], ["3", 187], [",", 188], ["also", 190], ["known", 195], ["as", 201], ["Machado", 204], ["-", 211], ["Joseph", 212], ["disease", 219], ["(", 227], ["SCA3/MJD", 228], [")", 236], [",", 237], ["we", 239], ["show", 242], ["that", 247], ["the", 252], ["disease", 256], ["protein", 264], ["ataxin-3", 272], ["accumulates", 281], ["in", 293], ["ubiquitinated", 296], ["intranuclear", 310], ["inclusions", 323], ["selectively", 334], ["in", 346], ["neurons", 349], ["of", 357], ["affected", 360], ["brain", 369], ["regions", 375], [".", 382], ["We", 384], ["further", 387], ["provide", 395], ["evidence", 403], ["in", 412], ["vitro", 415], ["for", 421], ["a", 425], ["model", 427], ["of", 433], ["disease", 436], ["in", 444], ["which", 447], ["an", 453], ["expanded", 456], ["polyglutamine", 465], ["-", 478], ["containing", 479], ["fragment", 490], ["recruits", 499], ["full", 508], ["-", 512], ["length", 513], ["protein", 520], ["into", 528], ["insoluble", 533], ["aggregates", 543], [".", 553], ["Together", 555], ["with", 564], ["recent", 569], ["findings", 576], ["from", 585], ["transgenic", 590], ["models", 601], [",", 607], ["our", 609], ["results", 613], ["suggest", 621], ["that", 629], ["intranuclear", 634], ["aggregation", 647], ["of", 659], ["the", 662], ["expanded", 666], ["protein", 675], ["is", 683], ["a", 686], ["unifying", 688], ["feature", 697], ["of", 705], ["CAG", 708], ["/", 711], ["polyglutamine", 712], ["diseases", 726], ["and", 735], ["may", 739], ["be", 743], ["initiated", 746], ["or", 756], ["catalyzed", 759], ["by", 769], ["a", 772], ["glutamine", 774], ["-", 783], ["containing", 784], ["fragment", 795], ["of", 804], ["the", 807], ["disease", 811], ["protein", 819], [".", 826]]}
{"context": "GATA-1 and the ets factor PU.1 have been reported to functionally antagonize one another in the regulation of erythroid versus myeloid gene transcription and development. The CCAAT enhancer binding protein epsilon (C/EBPepsilon) is expressed as multiple isoforms and has been shown to be essential to myeloid (granulocyte) terminal differentiation. We have defined a novel synergistic, as opposed to antagonistic, combinatorial interaction between GATA-1 and PU.1, and a unique repressor role for certain C/EBPepsilon isoforms in the transcriptional regulation of a model eosinophil granulocyte gene, the major basic protein (MBP). The eosinophil-specific P2 promoter of the MBP gene contains GATA-1, C/EBP, and PU.1 consensus sites that bind these factors in nuclear extracts of the eosinophil myelocyte cell line, AML14.3D10. The promoter is transactivated by GATA-1 alone but is synergistically transactivated by low levels of PU.1 in the context of optimal levels of GATA-1. The C/EBPepsilon(27) isoform strongly represses GATA-1 activity and completely blocks GATA-1/PU.1 synergy. In vitro mutational analyses of the MBP-P2 promoter showed that both the GATA-1/PU.1 synergy, and repressor activity of C/EBPepsilon(27) are mediated via protein-protein interactions through the C/EBP and/or GATA-binding sites but not the PU.1 sites. Co-immunoprecipitations using lysates of AML14.3D10 eosinophils show that both C/EBPepsilon(32/30) and epsilon(27) physically interact in vivo with PU.1 and GATA-1, demonstrating functional interactions among these factors in eosinophil progenitors. Our findings identify novel combinatorial protein-protein interactions for GATA-1, PU.1, and C/EBPepsilon isoforms in eosinophil gene transcription that include GATA-1/PU.1 synergy and repressor activity for C/EBPepsilon(27).", "qas": [{"question": "Which gene controls the expression of GATA-1 isoforms?", "answers": ["PU.1"], "qid": "301b11ff9a5742d3b24508da29ebffcd", "question_tokens": [["Which", 0], ["gene", 6], ["controls", 11], ["the", 20], ["expression", 24], ["of", 35], ["GATA-1", 38], ["isoforms", 45], ["?", 53]], "detected_answers": [{"text": "PU.1", "token_spans": [[229, 229], [5, 5], [74, 74], [124, 124], [281, 281], [158, 158], [255, 255]], "char_spans": [[1325, 1328], [26, 29], [459, 462], [712, 715], [1670, 1673], [930, 933], [1485, 1488]]}]}], "context_tokens": [["GATA-1", 0], ["and", 7], ["the", 11], ["ets", 15], ["factor", 19], ["PU.1", 26], ["have", 31], ["been", 36], ["reported", 41], ["to", 50], ["functionally", 53], ["antagonize", 66], ["one", 77], ["another", 81], ["in", 89], ["the", 92], ["regulation", 96], ["of", 107], ["erythroid", 110], ["versus", 120], ["myeloid", 127], ["gene", 135], ["transcription", 140], ["and", 154], ["development", 158], [".", 169], ["The", 171], ["CCAAT", 175], ["enhancer", 181], ["binding", 190], ["protein", 198], ["epsilon", 206], ["(", 214], ["C", 215], ["/", 216], ["EBPepsilon", 217], [")", 227], ["is", 229], ["expressed", 232], ["as", 242], ["multiple", 245], ["isoforms", 254], ["and", 263], ["has", 267], ["been", 271], ["shown", 276], ["to", 282], ["be", 285], ["essential", 288], ["to", 298], ["myeloid", 301], ["(", 309], ["granulocyte", 310], [")", 321], ["terminal", 323], ["differentiation", 332], [".", 347], ["We", 349], ["have", 352], ["defined", 357], ["a", 365], ["novel", 367], ["synergistic", 373], [",", 384], ["as", 386], ["opposed", 389], ["to", 397], ["antagonistic", 400], [",", 412], ["combinatorial", 414], ["interaction", 428], ["between", 440], ["GATA-1", 448], ["and", 455], ["PU.1", 459], [",", 463], ["and", 465], ["a", 469], ["unique", 471], ["repressor", 478], ["role", 488], ["for", 493], ["certain", 497], ["C", 505], ["/", 506], ["EBPepsilon", 507], ["isoforms", 518], ["in", 527], ["the", 530], ["transcriptional", 534], ["regulation", 550], ["of", 561], ["a", 564], ["model", 566], ["eosinophil", 572], ["granulocyte", 583], ["gene", 595], [",", 599], ["the", 601], ["major", 605], ["basic", 611], ["protein", 617], ["(", 625], ["MBP", 626], [")", 629], [".", 630], ["The", 632], ["eosinophil", 636], ["-", 646], ["specific", 647], ["P2", 656], ["promoter", 659], ["of", 668], ["the", 671], ["MBP", 675], ["gene", 679], ["contains", 684], ["GATA-1", 693], [",", 699], ["C", 701], ["/", 702], ["EBP", 703], [",", 706], ["and", 708], ["PU.1", 712], ["consensus", 717], ["sites", 727], ["that", 733], ["bind", 738], ["these", 743], ["factors", 749], ["in", 757], ["nuclear", 760], ["extracts", 768], ["of", 777], ["the", 780], ["eosinophil", 784], ["myelocyte", 795], ["cell", 805], ["line", 810], [",", 814], ["AML14.3D10", 816], [".", 826], ["The", 828], ["promoter", 832], ["is", 841], ["transactivated", 844], ["by", 859], ["GATA-1", 862], ["alone", 869], ["but", 875], ["is", 879], ["synergistically", 882], ["transactivated", 898], ["by", 913], ["low", 916], ["levels", 920], ["of", 927], ["PU.1", 930], ["in", 935], ["the", 938], ["context", 942], ["of", 950], ["optimal", 953], ["levels", 961], ["of", 968], ["GATA-1", 971], [".", 977], ["The", 979], ["C", 983], ["/", 984], ["EBPepsilon(27", 985], [")", 998], ["isoform", 1000], ["strongly", 1008], ["represses", 1017], ["GATA-1", 1027], ["activity", 1034], ["and", 1043], ["completely", 1047], ["blocks", 1058], ["GATA-1/PU.1", 1065], ["synergy", 1077], [".", 1084], ["In", 1086], ["vitro", 1089], ["mutational", 1095], ["analyses", 1106], ["of", 1115], ["the", 1118], ["MBP", 1122], ["-", 1125], ["P2", 1126], ["promoter", 1129], ["showed", 1138], ["that", 1145], ["both", 1150], ["the", 1155], ["GATA-1/PU.1", 1159], ["synergy", 1171], [",", 1178], ["and", 1180], ["repressor", 1184], ["activity", 1194], ["of", 1203], ["C", 1206], ["/", 1207], ["EBPepsilon(27", 1208], [")", 1221], ["are", 1223], ["mediated", 1227], ["via", 1236], ["protein", 1240], ["-", 1247], ["protein", 1248], ["interactions", 1256], ["through", 1269], ["the", 1277], ["C", 1281], ["/", 1282], ["EBP", 1283], ["and/or", 1287], ["GATA", 1294], ["-", 1298], ["binding", 1299], ["sites", 1307], ["but", 1313], ["not", 1317], ["the", 1321], ["PU.1", 1325], ["sites", 1330], [".", 1335], ["Co", 1337], ["-", 1339], ["immunoprecipitations", 1340], ["using", 1361], ["lysates", 1367], ["of", 1375], ["AML14.3D10", 1378], ["eosinophils", 1389], ["show", 1401], ["that", 1406], ["both", 1411], ["C", 1416], ["/", 1417], ["EBPepsilon(32/30", 1418], [")", 1434], ["and", 1436], ["epsilon(27", 1440], [")", 1450], ["physically", 1452], ["interact", 1463], ["in", 1472], ["vivo", 1475], ["with", 1480], ["PU.1", 1485], ["and", 1490], ["GATA-1", 1494], [",", 1500], ["demonstrating", 1502], ["functional", 1516], ["interactions", 1527], ["among", 1540], ["these", 1546], ["factors", 1552], ["in", 1560], ["eosinophil", 1563], ["progenitors", 1574], [".", 1585], ["Our", 1587], ["findings", 1591], ["identify", 1600], ["novel", 1609], ["combinatorial", 1615], ["protein", 1629], ["-", 1636], ["protein", 1637], ["interactions", 1645], ["for", 1658], ["GATA-1", 1662], [",", 1668], ["PU.1", 1670], [",", 1674], ["and", 1676], ["C", 1680], ["/", 1681], ["EBPepsilon", 1682], ["isoforms", 1693], ["in", 1702], ["eosinophil", 1705], ["gene", 1716], ["transcription", 1721], ["that", 1735], ["include", 1740], ["GATA-1/PU.1", 1748], ["synergy", 1760], ["and", 1768], ["repressor", 1772], ["activity", 1782], ["for", 1791], ["C", 1795], ["/", 1796], ["EBPepsilon(27", 1797], [")", 1810], [".", 1811]]}
{"context": "To compare tumor control rates after surgical resection or stereotactic radiosurgery for patients with small- to medium-size intracranial meningiomas. Between 1990 and 1997, 198 adult meningioma patients treated at our center underwent either surgical resection (n = 136) or radiosurgery (n = 62) as primary management for benign meningiomas <35 mm in average diameter. Tumor recurrence or progression rates were calculated by the Kaplan-Meier method according to an independent radiographic review. The mean follow-up was 64 months. The tumor resections were Simpson Grade 1 in 57 (42%), Grade 2 in 57 (42%), and Grade 3-4 in 22 (16%). The mean margin and maximal radiation dose at radiosurgery was 17.7 Gy and 34.9 Gy, respectively. Tumor recurrence/progression was more frequent in the surgical resection group (12%) than in the radiosurgical group (2%; p = 0.04). No statistically significant difference was detected in the 3- and 7-year actuarial progression-free survival (PFS) rate between patients with Simpson Grade 1 resections (100% and 96%, respectively) and patients who underwent radiosurgery (100% and 95%, respectively; p = 0.94). Radiosurgery provided a higher PFS rate compared with patients with Simpson Grade 2 (3- and 7-year PFS rate, 91% and 82%, respectively; p <0.05) and Grade 3-4 (3- and 7-year PFS rate, 68% and 34%, respectively; p <0.001) resections. Subsequent tumor treatments were more common after surgical resection (15% vs. 3%, p = 0.02). Complications occurred in 10% of patients after radiosurgery compared with 22% of patients after surgical resection (p = 0.06). The PFS rate after radiosurgery was equivalent to that after resection of a Simpson Grade 1 tumor and was superior to Grade 2 and 3-4 resections in our study. If long-term follow-up confirms the high tumor control rate and low morbidity of radiosurgery, this technique will likely become the preferred treatment for most patients with small- to moderate-size meningiomas without symptomatic mass effect.", "qas": [{"question": "Simpson grading is used to describe resection of which brain tumor?", "answers": ["meningioma"], "qid": "df74d144994648f89a2af1ac7f36e432", "question_tokens": [["Simpson", 0], ["grading", 8], ["is", 16], ["used", 19], ["to", 24], ["describe", 27], ["resection", 36], ["of", 46], ["which", 49], ["brain", 55], ["tumor", 61], ["?", 66]], "detected_answers": [{"text": "meningioma", "token_spans": [[29, 29]], "char_spans": [[184, 193]]}]}], "context_tokens": [["To", 0], ["compare", 3], ["tumor", 11], ["control", 17], ["rates", 25], ["after", 31], ["surgical", 37], ["resection", 46], ["or", 56], ["stereotactic", 59], ["radiosurgery", 72], ["for", 85], ["patients", 89], ["with", 98], ["small-", 103], ["to", 110], ["medium", 113], ["-", 119], ["size", 120], ["intracranial", 125], ["meningiomas", 138], [".", 149], ["Between", 151], ["1990", 159], ["and", 164], ["1997", 168], [",", 172], ["198", 174], ["adult", 178], ["meningioma", 184], ["patients", 195], ["treated", 204], ["at", 212], ["our", 215], ["center", 219], ["underwent", 226], ["either", 236], ["surgical", 243], ["resection", 252], ["(", 262], ["n", 263], ["=", 265], ["136", 267], [")", 270], ["or", 272], ["radiosurgery", 275], ["(", 288], ["n", 289], ["=", 291], ["62", 293], [")", 295], ["as", 297], ["primary", 300], ["management", 308], ["for", 319], ["benign", 323], ["meningiomas", 330], ["<", 342], ["35", 343], ["mm", 346], ["in", 349], ["average", 352], ["diameter", 360], [".", 368], ["Tumor", 370], ["recurrence", 376], ["or", 387], ["progression", 390], ["rates", 402], ["were", 408], ["calculated", 413], ["by", 424], ["the", 427], ["Kaplan", 431], ["-", 437], ["Meier", 438], ["method", 444], ["according", 451], ["to", 461], ["an", 464], ["independent", 467], ["radiographic", 479], ["review", 492], [".", 498], ["The", 500], ["mean", 504], ["follow", 509], ["-", 515], ["up", 516], ["was", 519], ["64", 523], ["months", 526], [".", 532], ["The", 534], ["tumor", 538], ["resections", 544], ["were", 555], ["Simpson", 560], ["Grade", 568], ["1", 574], ["in", 576], ["57", 579], ["(", 582], ["42", 583], ["%", 585], [")", 586], [",", 587], ["Grade", 589], ["2", 595], ["in", 597], ["57", 600], ["(", 603], ["42", 604], ["%", 606], [")", 607], [",", 608], ["and", 610], ["Grade", 614], ["3", 620], ["-", 621], ["4", 622], ["in", 624], ["22", 627], ["(", 630], ["16", 631], ["%", 633], [")", 634], [".", 635], ["The", 637], ["mean", 641], ["margin", 646], ["and", 653], ["maximal", 657], ["radiation", 665], ["dose", 675], ["at", 680], ["radiosurgery", 683], ["was", 696], ["17.7", 700], ["Gy", 705], ["and", 708], ["34.9", 712], ["Gy", 717], [",", 719], ["respectively", 721], [".", 733], ["Tumor", 735], ["recurrence", 741], ["/", 751], ["progression", 752], ["was", 764], ["more", 768], ["frequent", 773], ["in", 782], ["the", 785], ["surgical", 789], ["resection", 798], ["group", 808], ["(", 814], ["12", 815], ["%", 817], [")", 818], ["than", 820], ["in", 825], ["the", 828], ["radiosurgical", 832], ["group", 846], ["(", 852], ["2", 853], ["%", 854], [";", 855], ["p", 857], ["=", 859], ["0.04", 861], [")", 865], [".", 866], ["No", 868], ["statistically", 871], ["significant", 885], ["difference", 897], ["was", 908], ["detected", 912], ["in", 921], ["the", 924], ["3-", 928], ["and", 931], ["7-year", 935], ["actuarial", 942], ["progression", 952], ["-", 963], ["free", 964], ["survival", 969], ["(", 978], ["PFS", 979], [")", 982], ["rate", 984], ["between", 989], ["patients", 997], ["with", 1006], ["Simpson", 1011], ["Grade", 1019], ["1", 1025], ["resections", 1027], ["(", 1038], ["100", 1039], ["%", 1042], ["and", 1044], ["96", 1048], ["%", 1050], [",", 1051], ["respectively", 1053], [")", 1065], ["and", 1067], ["patients", 1071], ["who", 1080], ["underwent", 1084], ["radiosurgery", 1094], ["(", 1107], ["100", 1108], ["%", 1111], ["and", 1113], ["95", 1117], ["%", 1119], [",", 1120], ["respectively", 1122], [";", 1134], ["p", 1136], ["=", 1138], ["0.94", 1140], [")", 1144], [".", 1145], ["Radiosurgery", 1147], ["provided", 1160], ["a", 1169], ["higher", 1171], ["PFS", 1178], ["rate", 1182], ["compared", 1187], ["with", 1196], ["patients", 1201], ["with", 1210], ["Simpson", 1215], ["Grade", 1223], ["2", 1229], ["(", 1231], ["3-", 1232], ["and", 1235], ["7-year", 1239], ["PFS", 1246], ["rate", 1250], [",", 1254], ["91", 1256], ["%", 1258], ["and", 1260], ["82", 1264], ["%", 1266], [",", 1267], ["respectively", 1269], [";", 1281], ["p", 1283], ["<", 1285], ["0.05", 1286], [")", 1290], ["and", 1292], ["Grade", 1296], ["3", 1302], ["-", 1303], ["4", 1304], ["(", 1306], ["3-", 1307], ["and", 1310], ["7-year", 1314], ["PFS", 1321], ["rate", 1325], [",", 1329], ["68", 1331], ["%", 1333], ["and", 1335], ["34", 1339], ["%", 1341], [",", 1342], ["respectively", 1344], [";", 1356], ["p", 1358], ["<", 1360], ["0.001", 1361], [")", 1366], ["resections", 1368], [".", 1378], ["Subsequent", 1380], ["tumor", 1391], ["treatments", 1397], ["were", 1408], ["more", 1413], ["common", 1418], ["after", 1425], ["surgical", 1431], ["resection", 1440], ["(", 1450], ["15", 1451], ["%", 1453], ["vs.", 1455], ["3", 1459], ["%", 1460], [",", 1461], ["p", 1463], ["=", 1465], ["0.02", 1467], [")", 1471], [".", 1472], ["Complications", 1474], ["occurred", 1488], ["in", 1497], ["10", 1500], ["%", 1502], ["of", 1504], ["patients", 1507], ["after", 1516], ["radiosurgery", 1522], ["compared", 1535], ["with", 1544], ["22", 1549], ["%", 1551], ["of", 1553], ["patients", 1556], ["after", 1565], ["surgical", 1571], ["resection", 1580], ["(", 1590], ["p", 1591], ["=", 1593], ["0.06", 1595], [")", 1599], [".", 1600], ["The", 1602], ["PFS", 1606], ["rate", 1610], ["after", 1615], ["radiosurgery", 1621], ["was", 1634], ["equivalent", 1638], ["to", 1649], ["that", 1652], ["after", 1657], ["resection", 1663], ["of", 1673], ["a", 1676], ["Simpson", 1678], ["Grade", 1686], ["1", 1692], ["tumor", 1694], ["and", 1700], ["was", 1704], ["superior", 1708], ["to", 1717], ["Grade", 1720], ["2", 1726], ["and", 1728], ["3", 1732], ["-", 1733], ["4", 1734], ["resections", 1736], ["in", 1747], ["our", 1750], ["study", 1754], [".", 1759], ["If", 1761], ["long", 1764], ["-", 1768], ["term", 1769], ["follow", 1774], ["-", 1780], ["up", 1781], ["confirms", 1784], ["the", 1793], ["high", 1797], ["tumor", 1802], ["control", 1808], ["rate", 1816], ["and", 1821], ["low", 1825], ["morbidity", 1829], ["of", 1839], ["radiosurgery", 1842], [",", 1854], ["this", 1856], ["technique", 1861], ["will", 1871], ["likely", 1876], ["become", 1883], ["the", 1890], ["preferred", 1894], ["treatment", 1904], ["for", 1914], ["most", 1918], ["patients", 1923], ["with", 1932], ["small-", 1937], ["to", 1944], ["moderate", 1947], ["-", 1955], ["size", 1956], ["meningiomas", 1961], ["without", 1973], ["symptomatic", 1981], ["mass", 1993], ["effect", 1998], [".", 2004]]}
{"context": "Imatinib mesylate is a tyrosine kinase inhibitor with high affinity for the BCR-ABL fusion protein expressed by the hematopoietic cells in chronic myelogenous leukemia (CML). Some patients with chronic-phase or accelerated-phase CML either relapse after an initial response or are refractory to imatinib, prompting us to evaluate the efficacy of dose increase in such patients. Twelve chronic-phase patients initially receiving 400 mg/day and 4 patients with accelerated phase initially receiving either 400 mg/day (two patients) or 600 mg/day (two patients) had their dose increased (14 to 800 mg/day and 2 to 600 mg/day) because of progressive disease (usually clonal evolution) or inadequate cytogenetic response after at least 1 year of therapy. Six patients had major cytogenetic responses after dose increase (3 complete and 3 partial). Two others had minor cytogenetic responses. Two patients with clonal evolution transiently lost the additional clonal aberrations. Almost all of the responses occurred within 6 months, and were typically 3-6 months in duration. However, 3 patients have continuing major cytogenetic responses of >18 months duration. Dose increase was well tolerated, with thrombocytopenia, mild leukopenia, and exacerbation of prior edema being the most common adverse events. Although increasing the dose of imatinib can benefit a subgroup of patients with CML with either an inadequate cytogenetic response or disease progression, our results suggest the majority will not have a sustained meaningful response, and that other options, such as allogeneic stem cell transplant or investigational therapies, also need to be considered at the time of dose increase.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "52dc16109e66480083c5d9ca84eb049e", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[12, 14]], "char_spans": [[76, 82]]}]}], "context_tokens": [["Imatinib", 0], ["mesylate", 9], ["is", 18], ["a", 21], ["tyrosine", 23], ["kinase", 32], ["inhibitor", 39], ["with", 49], ["high", 54], ["affinity", 59], ["for", 68], ["the", 72], ["BCR", 76], ["-", 79], ["ABL", 80], ["fusion", 84], ["protein", 91], ["expressed", 99], ["by", 109], ["the", 112], ["hematopoietic", 116], ["cells", 130], ["in", 136], ["chronic", 139], ["myelogenous", 147], ["leukemia", 159], ["(", 168], ["CML", 169], [")", 172], [".", 173], ["Some", 175], ["patients", 180], ["with", 189], ["chronic", 194], ["-", 201], ["phase", 202], ["or", 208], ["accelerated", 211], ["-", 222], ["phase", 223], ["CML", 229], ["either", 233], ["relapse", 240], ["after", 248], ["an", 254], ["initial", 257], ["response", 265], ["or", 274], ["are", 277], ["refractory", 281], ["to", 292], ["imatinib", 295], [",", 303], ["prompting", 305], ["us", 315], ["to", 318], ["evaluate", 321], ["the", 330], ["efficacy", 334], ["of", 343], ["dose", 346], ["increase", 351], ["in", 360], ["such", 363], ["patients", 368], [".", 376], ["Twelve", 378], ["chronic", 385], ["-", 392], ["phase", 393], ["patients", 399], ["initially", 408], ["receiving", 418], ["400", 428], ["mg", 432], ["/", 434], ["day", 435], ["and", 439], ["4", 443], ["patients", 445], ["with", 454], ["accelerated", 459], ["phase", 471], ["initially", 477], ["receiving", 487], ["either", 497], ["400", 504], ["mg", 508], ["/", 510], ["day", 511], ["(", 515], ["two", 516], ["patients", 520], [")", 528], ["or", 530], ["600", 533], ["mg", 537], ["/", 539], ["day", 540], ["(", 544], ["two", 545], ["patients", 549], [")", 557], ["had", 559], ["their", 563], ["dose", 569], ["increased", 574], ["(", 584], ["14", 585], ["to", 588], ["800", 591], ["mg", 595], ["/", 597], ["day", 598], ["and", 602], ["2", 606], ["to", 608], ["600", 611], ["mg", 615], ["/", 617], ["day", 618], [")", 621], ["because", 623], ["of", 631], ["progressive", 634], ["disease", 646], ["(", 654], ["usually", 655], ["clonal", 663], ["evolution", 670], [")", 679], ["or", 681], ["inadequate", 684], ["cytogenetic", 695], ["response", 707], ["after", 716], ["at", 722], ["least", 725], ["1", 731], ["year", 733], ["of", 738], ["therapy", 741], [".", 748], ["Six", 750], ["patients", 754], ["had", 763], ["major", 767], ["cytogenetic", 773], ["responses", 785], ["after", 795], ["dose", 801], ["increase", 806], ["(", 815], ["3", 816], ["complete", 818], ["and", 827], ["3", 831], ["partial", 833], [")", 840], [".", 841], ["Two", 843], ["others", 847], ["had", 854], ["minor", 858], ["cytogenetic", 864], ["responses", 876], [".", 885], ["Two", 887], ["patients", 891], ["with", 900], ["clonal", 905], ["evolution", 912], ["transiently", 922], ["lost", 934], ["the", 939], ["additional", 943], ["clonal", 954], ["aberrations", 961], [".", 972], ["Almost", 974], ["all", 981], ["of", 985], ["the", 988], ["responses", 992], ["occurred", 1002], ["within", 1011], ["6", 1018], ["months", 1020], [",", 1026], ["and", 1028], ["were", 1032], ["typically", 1037], ["3", 1047], ["-", 1048], ["6", 1049], ["months", 1051], ["in", 1058], ["duration", 1061], [".", 1069], ["However", 1071], [",", 1078], ["3", 1080], ["patients", 1082], ["have", 1091], ["continuing", 1096], ["major", 1107], ["cytogenetic", 1113], ["responses", 1125], ["of", 1135], [">", 1138], ["18", 1139], ["months", 1142], ["duration", 1149], [".", 1157], ["Dose", 1159], ["increase", 1164], ["was", 1173], ["well", 1177], ["tolerated", 1182], [",", 1191], ["with", 1193], ["thrombocytopenia", 1198], [",", 1214], ["mild", 1216], ["leukopenia", 1221], [",", 1231], ["and", 1233], ["exacerbation", 1237], ["of", 1250], ["prior", 1253], ["edema", 1259], ["being", 1265], ["the", 1271], ["most", 1275], ["common", 1280], ["adverse", 1287], ["events", 1295], [".", 1301], ["Although", 1303], ["increasing", 1312], ["the", 1323], ["dose", 1327], ["of", 1332], ["imatinib", 1335], ["can", 1344], ["benefit", 1348], ["a", 1356], ["subgroup", 1358], ["of", 1367], ["patients", 1370], ["with", 1379], ["CML", 1384], ["with", 1388], ["either", 1393], ["an", 1400], ["inadequate", 1403], ["cytogenetic", 1414], ["response", 1426], ["or", 1435], ["disease", 1438], ["progression", 1446], [",", 1457], ["our", 1459], ["results", 1463], ["suggest", 1471], ["the", 1479], ["majority", 1483], ["will", 1492], ["not", 1497], ["have", 1501], ["a", 1506], ["sustained", 1508], ["meaningful", 1518], ["response", 1529], [",", 1537], ["and", 1539], ["that", 1543], ["other", 1548], ["options", 1554], [",", 1561], ["such", 1563], ["as", 1568], ["allogeneic", 1571], ["stem", 1582], ["cell", 1587], ["transplant", 1592], ["or", 1603], ["investigational", 1606], ["therapies", 1622], [",", 1631], ["also", 1633], ["need", 1638], ["to", 1643], ["be", 1646], ["considered", 1649], ["at", 1660], ["the", 1663], ["time", 1667], ["of", 1672], ["dose", 1675], ["increase", 1680], [".", 1688]]}
{"context": "We previously conducted a proof of principle; dose escalation study in Duchenne muscular dystrophy (DMD) patients using the morpholino splice-switching oligonucleotide AVI-4658 (eteplirsen) that induces skipping of dystrophin exon 51 in patients with relevant deletions, restores the open reading frame and induces dystrophin protein expression after intramuscular (i.m.) injection. We now show that this dystrophin expression was accompanied by an elevated expression of \u03b1-sarcoglycan, \u03b2-dystroglycan (BDG) and--in relevant cases--neuronal nitric oxide synthase (nNOS) at the sarcolemma, each of which is a component of a different subcomplex of the dystrophin-associated glycoprotein complex (DAPC). As expected, nNOS expression was relocalized to the sarcolemma in Duchenne patients in whom the dystrophin deletion left the nNOS-binding domain (exons 42-45) intact, whereas this did not occur in patients with deletions that involved this domain. Our results indicate that the novel internally deleted and shorter dystrophin induced by skipping exon 51 in patients with amenable deletions, can also restore the dystrophin-associated complex, further suggesting preserved functionality of the newly translated dystrophin.", "qas": [{"question": "What is the role of eteplirsen in DMD patients?", "answers": ["skipping of dystrophin exon 51"], "qid": "3d5eec0702a04e5a95da8cdd5d1454d8", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["role", 12], ["of", 17], ["eteplirsen", 20], ["in", 31], ["DMD", 34], ["patients", 38], ["?", 46]], "detected_answers": [{"text": "skipping of dystrophin exon 51", "token_spans": [[32, 36]], "char_spans": [[203, 232]]}]}], "context_tokens": [["We", 0], ["previously", 3], ["conducted", 14], ["a", 24], ["proof", 26], ["of", 32], ["principle", 35], [";", 44], ["dose", 46], ["escalation", 51], ["study", 62], ["in", 68], ["Duchenne", 71], ["muscular", 80], ["dystrophy", 89], ["(", 99], ["DMD", 100], [")", 103], ["patients", 105], ["using", 114], ["the", 120], ["morpholino", 124], ["splice", 135], ["-", 141], ["switching", 142], ["oligonucleotide", 152], ["AVI-4658", 168], ["(", 177], ["eteplirsen", 178], [")", 188], ["that", 190], ["induces", 195], ["skipping", 203], ["of", 212], ["dystrophin", 215], ["exon", 226], ["51", 231], ["in", 234], ["patients", 237], ["with", 246], ["relevant", 251], ["deletions", 260], [",", 269], ["restores", 271], ["the", 280], ["open", 284], ["reading", 289], ["frame", 297], ["and", 303], ["induces", 307], ["dystrophin", 315], ["protein", 326], ["expression", 334], ["after", 345], ["intramuscular", 351], ["(", 365], ["i.m", 366], [".", 369], [")", 370], ["injection", 372], [".", 381], ["We", 383], ["now", 386], ["show", 390], ["that", 395], ["this", 400], ["dystrophin", 405], ["expression", 416], ["was", 427], ["accompanied", 431], ["by", 443], ["an", 446], ["elevated", 449], ["expression", 458], ["of", 469], ["\u03b1", 472], ["-", 473], ["sarcoglycan", 474], [",", 485], ["\u03b2", 487], ["-", 488], ["dystroglycan", 489], ["(", 502], ["BDG", 503], [")", 506], ["and", 508], ["--", 511], ["in", 513], ["relevant", 516], ["cases", 525], ["--", 530], ["neuronal", 532], ["nitric", 541], ["oxide", 548], ["synthase", 554], ["(", 563], ["nNOS", 564], [")", 568], ["at", 570], ["the", 573], ["sarcolemma", 577], [",", 587], ["each", 589], ["of", 594], ["which", 597], ["is", 603], ["a", 606], ["component", 608], ["of", 618], ["a", 621], ["different", 623], ["subcomplex", 633], ["of", 644], ["the", 647], ["dystrophin", 651], ["-", 661], ["associated", 662], ["glycoprotein", 673], ["complex", 686], ["(", 694], ["DAPC", 695], [")", 699], [".", 700], ["As", 702], ["expected", 705], [",", 713], ["nNOS", 715], ["expression", 720], ["was", 731], ["relocalized", 735], ["to", 747], ["the", 750], ["sarcolemma", 754], ["in", 765], ["Duchenne", 768], ["patients", 777], ["in", 786], ["whom", 789], ["the", 794], ["dystrophin", 798], ["deletion", 809], ["left", 818], ["the", 823], ["nNOS", 827], ["-", 831], ["binding", 832], ["domain", 840], ["(", 847], ["exons", 848], ["42", 854], ["-", 856], ["45", 857], [")", 859], ["intact", 861], [",", 867], ["whereas", 869], ["this", 877], ["did", 882], ["not", 886], ["occur", 890], ["in", 896], ["patients", 899], ["with", 908], ["deletions", 913], ["that", 923], ["involved", 928], ["this", 937], ["domain", 942], [".", 948], ["Our", 950], ["results", 954], ["indicate", 962], ["that", 971], ["the", 976], ["novel", 980], ["internally", 986], ["deleted", 997], ["and", 1005], ["shorter", 1009], ["dystrophin", 1017], ["induced", 1028], ["by", 1036], ["skipping", 1039], ["exon", 1048], ["51", 1053], ["in", 1056], ["patients", 1059], ["with", 1068], ["amenable", 1073], ["deletions", 1082], [",", 1091], ["can", 1093], ["also", 1097], ["restore", 1102], ["the", 1110], ["dystrophin", 1114], ["-", 1124], ["associated", 1125], ["complex", 1136], [",", 1143], ["further", 1145], ["suggesting", 1153], ["preserved", 1164], ["functionality", 1174], ["of", 1188], ["the", 1191], ["newly", 1195], ["translated", 1201], ["dystrophin", 1212], [".", 1222]]}
{"context": "Notch3 is a single pass transmembrane protein belonging to the Notch receptor family. Notch proteins are involved in a very conserved signaling system (Notch signaling) with a broad spectrum of functions, from cell proliferation and differentiation to apoptosis. Mutations in Notch3 gene are linked to cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a disorder characterized by stroke and dementia in young adults. Studies evaluating Notch3 expression in human differentiated cells and adult tissues have shown high Notch3 levels only in vascular smooth muscle cells (VSMC). However, it has been hypothesized that Notch3 is ubiquitously expressed in adult human tissues. Our aim was to evaluate Notch3 expression in human peripheral blood lymphocytes (PBLs) and fibroblasts from normal healthy subjects. In both cell types, we examined the expression of Notch3 by reverse transcriptase-polymerase chain reaction (RT-PCR) and quantitative real-time polymerase chain reaction (qRT-PCR). Moreover, we assessed Notch3 protein expression by Western blot analysis. RT-PCR and qRT-PCR analysis showed the presence of Notch3 mRNA in both cell types. Western blot analysis confirmed Notch3 protein expression in PBLs and fibroblasts though showing different profiles. Our data support the expression of Notch3 in adult human cell types, and suggests that PBLs and fibroblasts could provide readily available cells for the study of the role of Notch3 expression in the pathogenetic mechanisms leading to different human disease.", "qas": [{"question": "Which gene is involved in CADASIL?", "answers": ["Notch3 gene"], "qid": "966839ca942444edadde10ae73c038bf", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["involved", 14], ["in", 23], ["CADASIL", 26], ["?", 33]], "detected_answers": [{"text": "Notch3 gene", "token_spans": [[45, 46]], "char_spans": [[276, 286]]}]}], "context_tokens": [["Notch3", 0], ["is", 7], ["a", 10], ["single", 12], ["pass", 19], ["transmembrane", 24], ["protein", 38], ["belonging", 46], ["to", 56], ["the", 59], ["Notch", 63], ["receptor", 69], ["family", 78], [".", 84], ["Notch", 86], ["proteins", 92], ["are", 101], ["involved", 105], ["in", 114], ["a", 117], ["very", 119], ["conserved", 124], ["signaling", 134], ["system", 144], ["(", 151], ["Notch", 152], ["signaling", 158], [")", 167], ["with", 169], ["a", 174], ["broad", 176], ["spectrum", 182], ["of", 191], ["functions", 194], [",", 203], ["from", 205], ["cell", 210], ["proliferation", 215], ["and", 229], ["differentiation", 233], ["to", 249], ["apoptosis", 252], [".", 261], ["Mutations", 263], ["in", 273], ["Notch3", 276], ["gene", 283], ["are", 288], ["linked", 292], ["to", 299], ["cerebral", 302], ["autosomal", 311], ["dominant", 321], ["arteriopathy", 330], ["with", 343], ["subcortical", 348], ["infarcts", 360], ["and", 369], ["leukoencephalopathy", 373], ["(", 393], ["CADASIL", 394], [")", 401], [",", 402], ["a", 404], ["disorder", 406], ["characterized", 415], ["by", 429], ["stroke", 432], ["and", 439], ["dementia", 443], ["in", 452], ["young", 455], ["adults", 461], [".", 467], ["Studies", 469], ["evaluating", 477], ["Notch3", 488], ["expression", 495], ["in", 506], ["human", 509], ["differentiated", 515], ["cells", 530], ["and", 536], ["adult", 540], ["tissues", 546], ["have", 554], ["shown", 559], ["high", 565], ["Notch3", 570], ["levels", 577], ["only", 584], ["in", 589], ["vascular", 592], ["smooth", 601], ["muscle", 608], ["cells", 615], ["(", 621], ["VSMC", 622], [")", 626], [".", 627], ["However", 629], [",", 636], ["it", 638], ["has", 641], ["been", 645], ["hypothesized", 650], ["that", 663], ["Notch3", 668], ["is", 675], ["ubiquitously", 678], ["expressed", 691], ["in", 701], ["adult", 704], ["human", 710], ["tissues", 716], [".", 723], ["Our", 725], ["aim", 729], ["was", 733], ["to", 737], ["evaluate", 740], ["Notch3", 749], ["expression", 756], ["in", 767], ["human", 770], ["peripheral", 776], ["blood", 787], ["lymphocytes", 793], ["(", 805], ["PBLs", 806], [")", 810], ["and", 812], ["fibroblasts", 816], ["from", 828], ["normal", 833], ["healthy", 840], ["subjects", 848], [".", 856], ["In", 858], ["both", 861], ["cell", 866], ["types", 871], [",", 876], ["we", 878], ["examined", 881], ["the", 890], ["expression", 894], ["of", 905], ["Notch3", 908], ["by", 915], ["reverse", 918], ["transcriptase", 926], ["-", 939], ["polymerase", 940], ["chain", 951], ["reaction", 957], ["(", 966], ["RT", 967], ["-", 969], ["PCR", 970], [")", 973], ["and", 975], ["quantitative", 979], ["real", 992], ["-", 996], ["time", 997], ["polymerase", 1002], ["chain", 1013], ["reaction", 1019], ["(", 1028], ["qRT", 1029], ["-", 1032], ["PCR", 1033], [")", 1036], [".", 1037], ["Moreover", 1039], [",", 1047], ["we", 1049], ["assessed", 1052], ["Notch3", 1061], ["protein", 1068], ["expression", 1076], ["by", 1087], ["Western", 1090], ["blot", 1098], ["analysis", 1103], [".", 1111], ["RT", 1113], ["-", 1115], ["PCR", 1116], ["and", 1120], ["qRT", 1124], ["-", 1127], ["PCR", 1128], ["analysis", 1132], ["showed", 1141], ["the", 1148], ["presence", 1152], ["of", 1161], ["Notch3", 1164], ["mRNA", 1171], ["in", 1176], ["both", 1179], ["cell", 1184], ["types", 1189], [".", 1194], ["Western", 1196], ["blot", 1204], ["analysis", 1209], ["confirmed", 1218], ["Notch3", 1228], ["protein", 1235], ["expression", 1243], ["in", 1254], ["PBLs", 1257], ["and", 1262], ["fibroblasts", 1266], ["though", 1278], ["showing", 1285], ["different", 1293], ["profiles", 1303], [".", 1311], ["Our", 1313], ["data", 1317], ["support", 1322], ["the", 1330], ["expression", 1334], ["of", 1345], ["Notch3", 1348], ["in", 1355], ["adult", 1358], ["human", 1364], ["cell", 1370], ["types", 1375], [",", 1380], ["and", 1382], ["suggests", 1386], ["that", 1395], ["PBLs", 1400], ["and", 1405], ["fibroblasts", 1409], ["could", 1421], ["provide", 1427], ["readily", 1435], ["available", 1443], ["cells", 1453], ["for", 1459], ["the", 1463], ["study", 1467], ["of", 1473], ["the", 1476], ["role", 1480], ["of", 1485], ["Notch3", 1488], ["expression", 1495], ["in", 1506], ["the", 1509], ["pathogenetic", 1513], ["mechanisms", 1526], ["leading", 1537], ["to", 1545], ["different", 1548], ["human", 1558], ["disease", 1564], [".", 1571]]}
{"context": "Chronic myeloid leukemia (CML) is a progressive and often fatal myeloproliferative neoplasm. The hallmark of CML is an acquired chromosomal translocation known as the Philadelphia chromosome (Ph), which results in the synthesis of the breakpoint cluster region-Abelson murine leukemia (BCR-ABL) fusion oncoprotein, a constitutively active tyrosine kinase. The introduction of imatinib, a tyrosine kinase inhibitor (TKI) that is specific for BCR-ABL, was a major breakthrough in CML therapy. Although most patients respond to first-line imatinib therapy, some experience loss of response (resistance) or require treatment discontinuation because of toxicity (intolerance). For patients with CML, failure on standard-dose imatinib therapy (400 mg daily), imatinib dose escalation (600-800 mg daily) is a second-line option. However, high-dose imatinib is not an appropriate approach for patients who experience drug toxicity, and there remain questions over the durability of responses achieved with this strategy. Alternative second-line options include the TKIs dasatinib and nilotinib. A substantial amount of long-term data for these agents is available. Although both are potent and specific BCR-ABL TKIs, dasatinib and nilotinib exhibit unique pharmacologic profiles and response patterns relative to different patient characteristics, such as disease stage and BCR-ABL mutation status. To optimize therapeutic benefit, clinicians should select treatment based on each patient's historic response, adverse-event tolerance, and risk factors.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "9f71ac936fe846a99b99d2e030c881b0", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[218, 220], [77, 79], [244, 246], [48, 50]], "char_spans": [[1195, 1201], [441, 447], [1366, 1372], [286, 292]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["a", 34], ["progressive", 36], ["and", 48], ["often", 52], ["fatal", 58], ["myeloproliferative", 64], ["neoplasm", 83], [".", 91], ["The", 93], ["hallmark", 97], ["of", 106], ["CML", 109], ["is", 113], ["an", 116], ["acquired", 119], ["chromosomal", 128], ["translocation", 140], ["known", 154], ["as", 160], ["the", 163], ["Philadelphia", 167], ["chromosome", 180], ["(", 191], ["Ph", 192], [")", 194], [",", 195], ["which", 197], ["results", 203], ["in", 211], ["the", 214], ["synthesis", 218], ["of", 228], ["the", 231], ["breakpoint", 235], ["cluster", 246], ["region", 254], ["-", 260], ["Abelson", 261], ["murine", 269], ["leukemia", 276], ["(", 285], ["BCR", 286], ["-", 289], ["ABL", 290], [")", 293], ["fusion", 295], ["oncoprotein", 302], [",", 313], ["a", 315], ["constitutively", 317], ["active", 332], ["tyrosine", 339], ["kinase", 348], [".", 354], ["The", 356], ["introduction", 360], ["of", 373], ["imatinib", 376], [",", 384], ["a", 386], ["tyrosine", 388], ["kinase", 397], ["inhibitor", 404], ["(", 414], ["TKI", 415], [")", 418], ["that", 420], ["is", 425], ["specific", 428], ["for", 437], ["BCR", 441], ["-", 444], ["ABL", 445], [",", 448], ["was", 450], ["a", 454], ["major", 456], ["breakthrough", 462], ["in", 475], ["CML", 478], ["therapy", 482], [".", 489], ["Although", 491], ["most", 500], ["patients", 505], ["respond", 514], ["to", 522], ["first", 525], ["-", 530], ["line", 531], ["imatinib", 536], ["therapy", 545], [",", 552], ["some", 554], ["experience", 559], ["loss", 570], ["of", 575], ["response", 578], ["(", 587], ["resistance", 588], [")", 598], ["or", 600], ["require", 603], ["treatment", 611], ["discontinuation", 621], ["because", 637], ["of", 645], ["toxicity", 648], ["(", 657], ["intolerance", 658], [")", 669], [".", 670], ["For", 672], ["patients", 676], ["with", 685], ["CML", 690], [",", 693], ["failure", 695], ["on", 703], ["standard", 706], ["-", 714], ["dose", 715], ["imatinib", 720], ["therapy", 729], ["(", 737], ["400", 738], ["mg", 742], ["daily", 745], [")", 750], [",", 751], ["imatinib", 753], ["dose", 762], ["escalation", 767], ["(", 778], ["600", 779], ["-", 782], ["800", 783], ["mg", 787], ["daily", 790], [")", 795], ["is", 797], ["a", 800], ["second", 802], ["-", 808], ["line", 809], ["option", 814], [".", 820], ["However", 822], [",", 829], ["high", 831], ["-", 835], ["dose", 836], ["imatinib", 841], ["is", 850], ["not", 853], ["an", 857], ["appropriate", 860], ["approach", 872], ["for", 881], ["patients", 885], ["who", 894], ["experience", 898], ["drug", 909], ["toxicity", 914], [",", 922], ["and", 924], ["there", 928], ["remain", 934], ["questions", 941], ["over", 951], ["the", 956], ["durability", 960], ["of", 971], ["responses", 974], ["achieved", 984], ["with", 993], ["this", 998], ["strategy", 1003], [".", 1011], ["Alternative", 1013], ["second", 1025], ["-", 1031], ["line", 1032], ["options", 1037], ["include", 1045], ["the", 1053], ["TKIs", 1057], ["dasatinib", 1062], ["and", 1072], ["nilotinib", 1076], [".", 1085], ["A", 1087], ["substantial", 1089], ["amount", 1101], ["of", 1108], ["long", 1111], ["-", 1115], ["term", 1116], ["data", 1121], ["for", 1126], ["these", 1130], ["agents", 1136], ["is", 1143], ["available", 1146], [".", 1155], ["Although", 1157], ["both", 1166], ["are", 1171], ["potent", 1175], ["and", 1182], ["specific", 1186], ["BCR", 1195], ["-", 1198], ["ABL", 1199], ["TKIs", 1203], [",", 1207], ["dasatinib", 1209], ["and", 1219], ["nilotinib", 1223], ["exhibit", 1233], ["unique", 1241], ["pharmacologic", 1248], ["profiles", 1262], ["and", 1271], ["response", 1275], ["patterns", 1284], ["relative", 1293], ["to", 1302], ["different", 1305], ["patient", 1315], ["characteristics", 1323], [",", 1338], ["such", 1340], ["as", 1345], ["disease", 1348], ["stage", 1356], ["and", 1362], ["BCR", 1366], ["-", 1369], ["ABL", 1370], ["mutation", 1374], ["status", 1383], [".", 1389], ["To", 1391], ["optimize", 1394], ["therapeutic", 1403], ["benefit", 1415], [",", 1422], ["clinicians", 1424], ["should", 1435], ["select", 1442], ["treatment", 1449], ["based", 1459], ["on", 1465], ["each", 1468], ["patient", 1473], ["'s", 1480], ["historic", 1483], ["response", 1492], [",", 1500], ["adverse", 1502], ["-", 1509], ["event", 1510], ["tolerance", 1516], [",", 1525], ["and", 1527], ["risk", 1531], ["factors", 1536], [".", 1543]]}
{"context": "Using a rat model of L-DOPA-induced dyskinesia (LID), the contributions of dopamine D1 and D2 receptors to axial, limb, and orolingual (ALO) abnormal involuntary movements (AIMs) elicited by L-DOPA were examined. Chronic L-DOPA-treated rats received the D1 receptor antagonist SCH23390 (0.01, 0.1, and 1.0 mg/kg; i.p.), the D2 receptor antagonist Eticlopride (0.01, 0.1, and 1.0 mg/kg; i.p.), a mixture of both antagonists (0.01, 0.1, 1.0 mg/kg each; i.p.), or vehicle 30 min prior to L-DOPA (6 mg/kg; i.p.)+Benserazide (15 mg/kg; i.p.). SCH23390 (0.1 and 1.0 mg/kg) significantly reduced axial and limb AIMs, while the same doses of Eticlopride significantly decreased axial, limb, and orolingual AIMs. Co-administration of SCH23390+Eticlopride significantly reduced axial (0.01, 0.1 and 1.0 mg/kg), limb (0.1 and 1.0 mg/kg), and orolingual (0.1 and 1.0 mg/kg) AIMs. These results indicate the importance of D1 and D2 receptors to LID and further validate the rat AIMs model.", "qas": [{"question": "Which drug is benserazide usually co-administered with?", "answers": ["L-Dopa"], "qid": "cef4a7fbb56948418ee4895ae79c5294", "question_tokens": [["Which", 0], ["drug", 6], ["is", 11], ["benserazide", 14], ["usually", 26], ["co", 34], ["-", 36], ["administered", 37], ["with", 50], ["?", 54]], "detected_answers": [{"text": "L-Dopa", "token_spans": [[121, 123], [5, 7], [48, 50], [41, 43]], "char_spans": [[485, 490], [21, 26], [221, 226], [191, 196]]}]}], "context_tokens": [["Using", 0], ["a", 6], ["rat", 8], ["model", 12], ["of", 18], ["L", 21], ["-", 22], ["DOPA", 23], ["-", 27], ["induced", 28], ["dyskinesia", 36], ["(", 47], ["LID", 48], [")", 51], [",", 52], ["the", 54], ["contributions", 58], ["of", 72], ["dopamine", 75], ["D1", 84], ["and", 87], ["D2", 91], ["receptors", 94], ["to", 104], ["axial", 107], [",", 112], ["limb", 114], [",", 118], ["and", 120], ["orolingual", 124], ["(", 135], ["ALO", 136], [")", 139], ["abnormal", 141], ["involuntary", 150], ["movements", 162], ["(", 172], ["AIMs", 173], [")", 177], ["elicited", 179], ["by", 188], ["L", 191], ["-", 192], ["DOPA", 193], ["were", 198], ["examined", 203], [".", 211], ["Chronic", 213], ["L", 221], ["-", 222], ["DOPA", 223], ["-", 227], ["treated", 228], ["rats", 236], ["received", 241], ["the", 250], ["D1", 254], ["receptor", 257], ["antagonist", 266], ["SCH23390", 277], ["(", 286], ["0.01", 287], [",", 291], ["0.1", 293], [",", 296], ["and", 298], ["1.0", 302], ["mg", 306], ["/", 308], ["kg", 309], [";", 311], ["i.p", 313], [".", 316], [")", 317], [",", 318], ["the", 320], ["D2", 324], ["receptor", 327], ["antagonist", 336], ["Eticlopride", 347], ["(", 359], ["0.01", 360], [",", 364], ["0.1", 366], [",", 369], ["and", 371], ["1.0", 375], ["mg", 379], ["/", 381], ["kg", 382], [";", 384], ["i.p", 386], [".", 389], [")", 390], [",", 391], ["a", 393], ["mixture", 395], ["of", 403], ["both", 406], ["antagonists", 411], ["(", 423], ["0.01", 424], [",", 428], ["0.1", 430], [",", 433], ["1.0", 435], ["mg", 439], ["/", 441], ["kg", 442], ["each", 445], [";", 449], ["i.p", 451], [".", 454], [")", 455], [",", 456], ["or", 458], ["vehicle", 461], ["30", 469], ["min", 472], ["prior", 476], ["to", 482], ["L", 485], ["-", 486], ["DOPA", 487], ["(", 492], ["6", 493], ["mg", 495], ["/", 497], ["kg", 498], [";", 500], ["i.p.)+Benserazide", 502], ["(", 520], ["15", 521], ["mg", 524], ["/", 526], ["kg", 527], [";", 529], ["i.p", 531], [".", 534], [")", 535], [".", 536], ["SCH23390", 538], ["(", 547], ["0.1", 548], ["and", 552], ["1.0", 556], ["mg", 560], ["/", 562], ["kg", 563], [")", 565], ["significantly", 567], ["reduced", 581], ["axial", 589], ["and", 595], ["limb", 599], ["AIMs", 604], [",", 608], ["while", 610], ["the", 616], ["same", 620], ["doses", 625], ["of", 631], ["Eticlopride", 634], ["significantly", 646], ["decreased", 660], ["axial", 670], [",", 675], ["limb", 677], [",", 681], ["and", 683], ["orolingual", 687], ["AIMs", 698], [".", 702], ["Co", 704], ["-", 706], ["administration", 707], ["of", 722], ["SCH23390+Eticlopride", 725], ["significantly", 746], ["reduced", 760], ["axial", 768], ["(", 774], ["0.01", 775], [",", 779], ["0.1", 781], ["and", 785], ["1.0", 789], ["mg", 793], ["/", 795], ["kg", 796], [")", 798], [",", 799], ["limb", 801], ["(", 806], ["0.1", 807], ["and", 811], ["1.0", 815], ["mg", 819], ["/", 821], ["kg", 822], [")", 824], [",", 825], ["and", 827], ["orolingual", 831], ["(", 842], ["0.1", 843], ["and", 847], ["1.0", 851], ["mg", 855], ["/", 857], ["kg", 858], [")", 860], ["AIMs", 862], [".", 866], ["These", 868], ["results", 874], ["indicate", 882], ["the", 891], ["importance", 895], ["of", 906], ["D1", 909], ["and", 912], ["D2", 916], ["receptors", 919], ["to", 929], ["LID", 932], ["and", 936], ["further", 940], ["validate", 948], ["the", 957], ["rat", 961], ["AIMs", 965], ["model", 970], [".", 975]]}
{"context": "We evaluated the adherence and acceptability of a vaginal ring containing dapivirine, maraviroc, or both drugs for 28\u00a0days during a Phase I placebo-controlled trial in 48 HIV-negative sexually abstinent U.S. women aged 18-40. Adherence was assessed weekly by clinical interview and computer-assisted self-interviewing; acceptability assessment occurred at the last product-use visit. Study retention was 98\u00a0% (47/48); 94\u00a0% (45/48) reported being fully adherent with ring use during the 28-day period. Two participants experienced the ring partially coming out. Analysis was blinded and behavioral data were combined across study groups. Most women reported being very comfortable having the ring in their vagina; 44\u00a0% preferred continuous use, whereas 51\u00a0% had no preference compared to episodic use. Although a range of minor ring concerns were expressed, few were actually experienced. High adherence to and acceptability of this vaginal ring in this Phase I trial contributes to its promise as a sustained mechanism for multidrug vaginal microbicide delivery.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "c1f471c321514f0caf736b5b44d25ecb", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[31, 31]], "char_spans": [[171, 173]]}]}], "context_tokens": [["We", 0], ["evaluated", 3], ["the", 13], ["adherence", 17], ["and", 27], ["acceptability", 31], ["of", 45], ["a", 48], ["vaginal", 50], ["ring", 58], ["containing", 63], ["dapivirine", 74], [",", 84], ["maraviroc", 86], [",", 95], ["or", 97], ["both", 100], ["drugs", 105], ["for", 111], ["28", 115], ["days", 118], ["during", 123], ["a", 130], ["Phase", 132], ["I", 138], ["placebo", 140], ["-", 147], ["controlled", 148], ["trial", 159], ["in", 165], ["48", 168], ["HIV", 171], ["-", 174], ["negative", 175], ["sexually", 184], ["abstinent", 193], ["U.S.", 203], ["women", 208], ["aged", 214], ["18", 219], ["-", 221], ["40", 222], [".", 224], ["Adherence", 226], ["was", 236], ["assessed", 240], ["weekly", 249], ["by", 256], ["clinical", 259], ["interview", 268], ["and", 278], ["computer", 282], ["-", 290], ["assisted", 291], ["self", 300], ["-", 304], ["interviewing", 305], [";", 317], ["acceptability", 319], ["assessment", 333], ["occurred", 344], ["at", 353], ["the", 356], ["last", 360], ["product", 365], ["-", 372], ["use", 373], ["visit", 377], [".", 382], ["Study", 384], ["retention", 390], ["was", 400], ["98", 404], ["%", 407], ["(", 409], ["47/48", 410], [")", 415], [";", 416], ["94", 418], ["%", 421], ["(", 423], ["45/48", 424], [")", 429], ["reported", 431], ["being", 440], ["fully", 446], ["adherent", 452], ["with", 461], ["ring", 466], ["use", 471], ["during", 475], ["the", 482], ["28-day", 486], ["period", 493], [".", 499], ["Two", 501], ["participants", 505], ["experienced", 518], ["the", 530], ["ring", 534], ["partially", 539], ["coming", 549], ["out", 556], [".", 559], ["Analysis", 561], ["was", 570], ["blinded", 574], ["and", 582], ["behavioral", 586], ["data", 597], ["were", 602], ["combined", 607], ["across", 616], ["study", 623], ["groups", 629], [".", 635], ["Most", 637], ["women", 642], ["reported", 648], ["being", 657], ["very", 663], ["comfortable", 668], ["having", 680], ["the", 687], ["ring", 691], ["in", 696], ["their", 699], ["vagina", 705], [";", 711], ["44", 713], ["%", 716], ["preferred", 718], ["continuous", 728], ["use", 739], [",", 742], ["whereas", 744], ["51", 752], ["%", 755], ["had", 757], ["no", 761], ["preference", 764], ["compared", 775], ["to", 784], ["episodic", 787], ["use", 796], [".", 799], ["Although", 801], ["a", 810], ["range", 812], ["of", 818], ["minor", 821], ["ring", 827], ["concerns", 832], ["were", 841], ["expressed", 846], [",", 855], ["few", 857], ["were", 861], ["actually", 866], ["experienced", 875], [".", 886], ["High", 888], ["adherence", 893], ["to", 903], ["and", 906], ["acceptability", 910], ["of", 924], ["this", 927], ["vaginal", 932], ["ring", 940], ["in", 945], ["this", 948], ["Phase", 953], ["I", 959], ["trial", 961], ["contributes", 967], ["to", 979], ["its", 982], ["promise", 986], ["as", 994], ["a", 997], ["sustained", 999], ["mechanism", 1009], ["for", 1019], ["multidrug", 1023], ["vaginal", 1033], ["microbicide", 1041], ["delivery", 1053], [".", 1061]]}
{"context": "The efficacy and safety of flumazenil were assessed in comparison to placebo in a double-blind randomised study of 31 adults intoxicated with benzodiazepines. The criteria of efficacy were the degree of sedation, and orientation in time and space. Patients who received flumazenil awoke within minutes but central depression returned partly one hour later, which reflects the short elimination half-life of the drug. Side effects were few and the results indicate that flumazenil is effective in the primary management of benzodiazepine overdose and in states where benzodiazepines have been taken with other drugs.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "6e6cc6752f9047989d4703ae6d6c8051", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[80, 80], [5, 5], [46, 46]], "char_spans": [[469, 478], [27, 36], [270, 279]]}]}], "context_tokens": [["The", 0], ["efficacy", 4], ["and", 13], ["safety", 17], ["of", 24], ["flumazenil", 27], ["were", 38], ["assessed", 43], ["in", 52], ["comparison", 55], ["to", 66], ["placebo", 69], ["in", 77], ["a", 80], ["double", 82], ["-", 88], ["blind", 89], ["randomised", 95], ["study", 106], ["of", 112], ["31", 115], ["adults", 118], ["intoxicated", 125], ["with", 137], ["benzodiazepines", 142], [".", 157], ["The", 159], ["criteria", 163], ["of", 172], ["efficacy", 175], ["were", 184], ["the", 189], ["degree", 193], ["of", 200], ["sedation", 203], [",", 211], ["and", 213], ["orientation", 217], ["in", 229], ["time", 232], ["and", 237], ["space", 241], [".", 246], ["Patients", 248], ["who", 257], ["received", 261], ["flumazenil", 270], ["awoke", 281], ["within", 287], ["minutes", 294], ["but", 302], ["central", 306], ["depression", 314], ["returned", 325], ["partly", 334], ["one", 341], ["hour", 345], ["later", 350], [",", 355], ["which", 357], ["reflects", 363], ["the", 372], ["short", 376], ["elimination", 382], ["half", 394], ["-", 398], ["life", 399], ["of", 404], ["the", 407], ["drug", 411], [".", 415], ["Side", 417], ["effects", 422], ["were", 430], ["few", 435], ["and", 439], ["the", 443], ["results", 447], ["indicate", 455], ["that", 464], ["flumazenil", 469], ["is", 480], ["effective", 483], ["in", 493], ["the", 496], ["primary", 500], ["management", 508], ["of", 519], ["benzodiazepine", 522], ["overdose", 537], ["and", 546], ["in", 550], ["states", 553], ["where", 560], ["benzodiazepines", 566], ["have", 582], ["been", 587], ["taken", 592], ["with", 598], ["other", 603], ["drugs", 609], [".", 614]]}
{"context": "Alzheimer's disease (AD) is the most common cause of dementia in humans. A pathological hallmark in the brain of an AD patient is extracellular amyloid plaques formed by accumulated beta-amyloid protein (Abeta), a metabolic product of amyloid precursor protein (APP). Studies have revealed a strong genetic linkage in the early-onset familial form (<60 years old) of AD. For example, some mutant APPs are transmitted dominantly and are segregated with inheritance of early onset AD. These mutants facilitate Abeta production. The \"Swedish\" mutations (APP(SW)) and the \"London\" mutation (APP(LON)) are examples of these mutants. Selective silencing of these mutant alleles holds therapeutic promise for AD. Here we show that the expression of the mutant APPs was selectively inhibited by RNA interference. The best selectivity was obtained when the mismatches were centrally placed in the antisense strand of small interfering RNAs. Introducing an additional mismatch in the antisense strand may improve the selectivity. The addition of a G at 5' end of the antisense strand may enhance the efficacy of gene silencing by RNA interference. Our results illustrate the guiding principles for selection of targeted sequences to achieve allele-specific silencing. The sequences that are effective to silence APP(SW) and APP(LON) as identified in this study may be useful in both in vivo and in vitro studies to investigate the pathophysiological role of APP(SW) and APP(LON) in AD development.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "7f2e06512c64492fae5b7778eda5946f", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[0, 2]], "char_spans": [[0, 18]]}, {"text": "AD", "token_spans": [[269, 269], [92, 92], [4, 4], [73, 73], [135, 135], [24, 24]], "char_spans": [[1472, 1473], [479, 480], [21, 22], [367, 368], [702, 703], [116, 117]]}]}], "context_tokens": [["Alzheimer", 0], ["'s", 9], ["disease", 12], ["(", 20], ["AD", 21], [")", 23], ["is", 25], ["the", 28], ["most", 32], ["common", 37], ["cause", 44], ["of", 50], ["dementia", 53], ["in", 62], ["humans", 65], [".", 71], ["A", 73], ["pathological", 75], ["hallmark", 88], ["in", 97], ["the", 100], ["brain", 104], ["of", 110], ["an", 113], ["AD", 116], ["patient", 119], ["is", 127], ["extracellular", 130], ["amyloid", 144], ["plaques", 152], ["formed", 160], ["by", 167], ["accumulated", 170], ["beta", 182], ["-", 186], ["amyloid", 187], ["protein", 195], ["(", 203], ["Abeta", 204], [")", 209], [",", 210], ["a", 212], ["metabolic", 214], ["product", 224], ["of", 232], ["amyloid", 235], ["precursor", 243], ["protein", 253], ["(", 261], ["APP", 262], [")", 265], [".", 266], ["Studies", 268], ["have", 276], ["revealed", 281], ["a", 290], ["strong", 292], ["genetic", 299], ["linkage", 307], ["in", 315], ["the", 318], ["early", 322], ["-", 327], ["onset", 328], ["familial", 334], ["form", 343], ["(", 348], ["<", 349], ["60", 350], ["years", 353], ["old", 359], [")", 362], ["of", 364], ["AD", 367], [".", 369], ["For", 371], ["example", 375], [",", 382], ["some", 384], ["mutant", 389], ["APPs", 396], ["are", 401], ["transmitted", 405], ["dominantly", 417], ["and", 428], ["are", 432], ["segregated", 436], ["with", 447], ["inheritance", 452], ["of", 464], ["early", 467], ["onset", 473], ["AD", 479], [".", 481], ["These", 483], ["mutants", 489], ["facilitate", 497], ["Abeta", 508], ["production", 514], [".", 524], ["The", 526], ["\"", 530], ["Swedish", 531], ["\"", 538], ["mutations", 540], ["(", 550], ["APP(SW", 551], [")", 557], [")", 558], ["and", 560], ["the", 564], ["\"", 568], ["London", 569], ["\"", 575], ["mutation", 577], ["(", 586], ["APP(LON", 587], [")", 594], [")", 595], ["are", 597], ["examples", 601], ["of", 610], ["these", 613], ["mutants", 619], [".", 626], ["Selective", 628], ["silencing", 638], ["of", 648], ["these", 651], ["mutant", 657], ["alleles", 664], ["holds", 672], ["therapeutic", 678], ["promise", 690], ["for", 698], ["AD", 702], [".", 704], ["Here", 706], ["we", 711], ["show", 714], ["that", 719], ["the", 724], ["expression", 728], ["of", 739], ["the", 742], ["mutant", 746], ["APPs", 753], ["was", 758], ["selectively", 762], ["inhibited", 774], ["by", 784], ["RNA", 787], ["interference", 791], [".", 803], ["The", 805], ["best", 809], ["selectivity", 814], ["was", 826], ["obtained", 830], ["when", 839], ["the", 844], ["mismatches", 848], ["were", 859], ["centrally", 864], ["placed", 874], ["in", 881], ["the", 884], ["antisense", 888], ["strand", 898], ["of", 905], ["small", 908], ["interfering", 914], ["RNAs", 926], [".", 930], ["Introducing", 932], ["an", 944], ["additional", 947], ["mismatch", 958], ["in", 967], ["the", 970], ["antisense", 974], ["strand", 984], ["may", 991], ["improve", 995], ["the", 1003], ["selectivity", 1007], [".", 1018], ["The", 1020], ["addition", 1024], ["of", 1033], ["a", 1036], ["G", 1038], ["at", 1040], ["5", 1043], ["'", 1044], ["end", 1046], ["of", 1050], ["the", 1053], ["antisense", 1057], ["strand", 1067], ["may", 1074], ["enhance", 1078], ["the", 1086], ["efficacy", 1090], ["of", 1099], ["gene", 1102], ["silencing", 1107], ["by", 1117], ["RNA", 1120], ["interference", 1124], [".", 1136], ["Our", 1138], ["results", 1142], ["illustrate", 1150], ["the", 1161], ["guiding", 1165], ["principles", 1173], ["for", 1184], ["selection", 1188], ["of", 1198], ["targeted", 1201], ["sequences", 1210], ["to", 1220], ["achieve", 1223], ["allele", 1231], ["-", 1237], ["specific", 1238], ["silencing", 1247], [".", 1256], ["The", 1258], ["sequences", 1262], ["that", 1272], ["are", 1277], ["effective", 1281], ["to", 1291], ["silence", 1294], ["APP(SW", 1302], [")", 1308], ["and", 1310], ["APP(LON", 1314], [")", 1321], ["as", 1323], ["identified", 1326], ["in", 1337], ["this", 1340], ["study", 1345], ["may", 1351], ["be", 1355], ["useful", 1358], ["in", 1365], ["both", 1368], ["in", 1373], ["vivo", 1376], ["and", 1381], ["in", 1385], ["vitro", 1388], ["studies", 1394], ["to", 1402], ["investigate", 1405], ["the", 1417], ["pathophysiological", 1421], ["role", 1440], ["of", 1445], ["APP(SW", 1448], [")", 1454], ["and", 1456], ["APP(LON", 1460], [")", 1467], ["in", 1469], ["AD", 1472], ["development", 1475], [".", 1486]]}
{"context": "In vivo brain microdialysis was used to assess the effects of tolcapone, a novel central and peripheral inhibitor of catechol-O-methyltransferase on striatal 3,4-dihydroxyphenyl-L-alanine (L-dopa) and dopamine metabolism. The oral administration of 30 mg/kg of tolcapone failed to change dopamine output but elicited a marked and long-lasting decrease of the extracellular levels of homovanillic acid (HVA) and 3-methoxytyramine with a concomitant increase of 3,4-dihydroxyphenylacetic acid (DOPAC). The administration of L-dopa (20 and 60 mg/kg p.o.) + benserazide (15 mg/kg p.o.) resulted in dose-dependent increase of dialysate levels of L-dopa and 3-O-methyl-DOPA. Tolcapone (30 mg/kg p.o.), given as adjunct to both doses of L-dopa, markedly enhanced the elevation or extracellular L-dopa, while it completely prevented the formation of 3-O-methyl-DOPA. In another experiment, the administration of L-dopa + benserazide (30 + 15 mg/kg p.o.) resulted in increased extracellular levels of dopamine, DOPAC, HVA and 3-methoxytyramine. The co-administration of tolcapone (30 mg/kg p.o.) further increased dopamine and DOPAC levels, whereas HVA and 3-methoxytyramine effluxes were reduced. These findings support the notion that tolcapone has the ability to enhance striatal dopamine neurotransmission by increasing L-dopa bioavailability through peripheral and central inhibition of L-dopa O-methylation, as well as by blocking the central conversion of dopamine into 3-methoxytyramine.", "qas": [{"question": "Which drug is benserazide usually co-administered with?", "answers": ["L-Dopa"], "qid": "08994280294d46b78596738f2a8bd39a", "question_tokens": [["Which", 0], ["drug", 6], ["is", 11], ["benserazide", 14], ["usually", 26], ["co", 34], ["-", 36], ["administered", 37], ["with", 50], ["?", 54]], "detected_answers": [{"text": "L-Dopa", "token_spans": [[33, 35], [161, 163], [124, 126], [91, 93], [260, 262], [270, 272], [185, 187], [151, 153]], "char_spans": [[189, 194], [787, 792], [641, 646], [522, 527], [1315, 1320], [1383, 1388], [904, 909], [730, 735]]}]}], "context_tokens": [["In", 0], ["vivo", 3], ["brain", 8], ["microdialysis", 14], ["was", 28], ["used", 32], ["to", 37], ["assess", 40], ["the", 47], ["effects", 51], ["of", 59], ["tolcapone", 62], [",", 71], ["a", 73], ["novel", 75], ["central", 81], ["and", 89], ["peripheral", 93], ["inhibitor", 104], ["of", 114], ["catechol", 117], ["-", 125], ["O", 126], ["-", 127], ["methyltransferase", 128], ["on", 146], ["striatal", 149], ["3,4-dihydroxyphenyl", 158], ["-", 177], ["L", 178], ["-", 179], ["alanine", 180], ["(", 188], ["L", 189], ["-", 190], ["dopa", 191], [")", 195], ["and", 197], ["dopamine", 201], ["metabolism", 210], [".", 220], ["The", 222], ["oral", 226], ["administration", 231], ["of", 246], ["30", 249], ["mg", 252], ["/", 254], ["kg", 255], ["of", 258], ["tolcapone", 261], ["failed", 271], ["to", 278], ["change", 281], ["dopamine", 288], ["output", 297], ["but", 304], ["elicited", 308], ["a", 317], ["marked", 319], ["and", 326], ["long", 330], ["-", 334], ["lasting", 335], ["decrease", 343], ["of", 352], ["the", 355], ["extracellular", 359], ["levels", 373], ["of", 380], ["homovanillic", 383], ["acid", 396], ["(", 401], ["HVA", 402], [")", 405], ["and", 407], ["3-methoxytyramine", 411], ["with", 429], ["a", 434], ["concomitant", 436], ["increase", 448], ["of", 457], ["3,4-dihydroxyphenylacetic", 460], ["acid", 486], ["(", 491], ["DOPAC", 492], [")", 497], [".", 498], ["The", 500], ["administration", 504], ["of", 519], ["L", 522], ["-", 523], ["dopa", 524], ["(", 529], ["20", 530], ["and", 533], ["60", 537], ["mg", 540], ["/", 542], ["kg", 543], ["p.o", 546], [".", 549], [")", 550], ["+", 552], ["benserazide", 554], ["(", 566], ["15", 567], ["mg", 570], ["/", 572], ["kg", 573], ["p.o", 576], [".", 579], [")", 580], ["resulted", 582], ["in", 591], ["dose", 594], ["-", 598], ["dependent", 599], ["increase", 609], ["of", 618], ["dialysate", 621], ["levels", 631], ["of", 638], ["L", 641], ["-", 642], ["dopa", 643], ["and", 648], ["3-O", 652], ["-", 655], ["methyl", 656], ["-", 662], ["DOPA", 663], [".", 667], ["Tolcapone", 669], ["(", 679], ["30", 680], ["mg", 683], ["/", 685], ["kg", 686], ["p.o", 689], [".", 692], [")", 693], [",", 694], ["given", 696], ["as", 702], ["adjunct", 705], ["to", 713], ["both", 716], ["doses", 721], ["of", 727], ["L", 730], ["-", 731], ["dopa", 732], [",", 736], ["markedly", 738], ["enhanced", 747], ["the", 756], ["elevation", 760], ["or", 770], ["extracellular", 773], ["L", 787], ["-", 788], ["dopa", 789], [",", 793], ["while", 795], ["it", 801], ["completely", 804], ["prevented", 815], ["the", 825], ["formation", 829], ["of", 839], ["3-O", 842], ["-", 845], ["methyl", 846], ["-", 852], ["DOPA", 853], [".", 857], ["In", 859], ["another", 862], ["experiment", 870], [",", 880], ["the", 882], ["administration", 886], ["of", 901], ["L", 904], ["-", 905], ["dopa", 906], ["+", 911], ["benserazide", 913], ["(", 925], ["30", 926], ["+", 929], ["15", 931], ["mg", 934], ["/", 936], ["kg", 937], ["p.o", 940], [".", 943], [")", 944], ["resulted", 946], ["in", 955], ["increased", 958], ["extracellular", 968], ["levels", 982], ["of", 989], ["dopamine", 992], [",", 1000], ["DOPAC", 1002], [",", 1007], ["HVA", 1009], ["and", 1013], ["3-methoxytyramine", 1017], [".", 1034], ["The", 1036], ["co", 1040], ["-", 1042], ["administration", 1043], ["of", 1058], ["tolcapone", 1061], ["(", 1071], ["30", 1072], ["mg", 1075], ["/", 1077], ["kg", 1078], ["p.o", 1081], [".", 1084], [")", 1085], ["further", 1087], ["increased", 1095], ["dopamine", 1105], ["and", 1114], ["DOPAC", 1118], ["levels", 1124], [",", 1130], ["whereas", 1132], ["HVA", 1140], ["and", 1144], ["3-methoxytyramine", 1148], ["effluxes", 1166], ["were", 1175], ["reduced", 1180], [".", 1187], ["These", 1189], ["findings", 1195], ["support", 1204], ["the", 1212], ["notion", 1216], ["that", 1223], ["tolcapone", 1228], ["has", 1238], ["the", 1242], ["ability", 1246], ["to", 1254], ["enhance", 1257], ["striatal", 1265], ["dopamine", 1274], ["neurotransmission", 1283], ["by", 1301], ["increasing", 1304], ["L", 1315], ["-", 1316], ["dopa", 1317], ["bioavailability", 1322], ["through", 1338], ["peripheral", 1346], ["and", 1357], ["central", 1361], ["inhibition", 1369], ["of", 1380], ["L", 1383], ["-", 1384], ["dopa", 1385], ["O", 1390], ["-", 1391], ["methylation", 1392], [",", 1403], ["as", 1405], ["well", 1408], ["as", 1413], ["by", 1416], ["blocking", 1419], ["the", 1428], ["central", 1432], ["conversion", 1440], ["of", 1451], ["dopamine", 1454], ["into", 1463], ["3-methoxytyramine", 1468], [".", 1485]]}
{"context": "Methylation of lysine residues of histones is an important epigenetic mark that correlates with functionally distinct regions of chromatin. We present here the crystal structure of a ternary complex of the enzyme Pr-Set7 (also known as Set8) that methylates Lys 20 of histone H4 (H4-K20). We show that the enzyme is exclusively a mono-methylase and is therefore responsible for a signaling role quite distinct from that established by other enzymes that target this histone residue. We provide evidence from NMR for the C-flanking domains of SET proteins becoming ordered upon addition of AdoMet cofactor and develop a model for the catalytic cycle of these enzymes. The crystal structure reveals the basis of the specificity of the enzyme for H4-K20 because a histidine residue within the substrate, close to the target lysine, is required for completion of the active site. We also show how a highly variable component of the SET domain is responsible for many of the enzymes' interactions with its target histone peptide and probably also how this part of the structure ensures that Pr-Set7 is nucleosome specific.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "f424eb5bb7c24c5185b12545eb402821", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[166, 167]], "char_spans": [[928, 937]]}]}], "context_tokens": [["Methylation", 0], ["of", 12], ["lysine", 15], ["residues", 22], ["of", 31], ["histones", 34], ["is", 43], ["an", 46], ["important", 49], ["epigenetic", 59], ["mark", 70], ["that", 75], ["correlates", 80], ["with", 91], ["functionally", 96], ["distinct", 109], ["regions", 118], ["of", 126], ["chromatin", 129], [".", 138], ["We", 140], ["present", 143], ["here", 151], ["the", 156], ["crystal", 160], ["structure", 168], ["of", 178], ["a", 181], ["ternary", 183], ["complex", 191], ["of", 199], ["the", 202], ["enzyme", 206], ["Pr", 213], ["-", 215], ["Set7", 216], ["(", 221], ["also", 222], ["known", 227], ["as", 233], ["Set8", 236], [")", 240], ["that", 242], ["methylates", 247], ["Lys", 258], ["20", 262], ["of", 265], ["histone", 268], ["H4", 276], ["(", 279], ["H4-K20", 280], [")", 286], [".", 287], ["We", 289], ["show", 292], ["that", 297], ["the", 302], ["enzyme", 306], ["is", 313], ["exclusively", 316], ["a", 328], ["mono", 330], ["-", 334], ["methylase", 335], ["and", 345], ["is", 349], ["therefore", 352], ["responsible", 362], ["for", 374], ["a", 378], ["signaling", 380], ["role", 390], ["quite", 395], ["distinct", 401], ["from", 410], ["that", 415], ["established", 420], ["by", 432], ["other", 435], ["enzymes", 441], ["that", 449], ["target", 454], ["this", 461], ["histone", 466], ["residue", 474], [".", 481], ["We", 483], ["provide", 486], ["evidence", 494], ["from", 503], ["NMR", 508], ["for", 512], ["the", 516], ["C", 520], ["-", 521], ["flanking", 522], ["domains", 531], ["of", 539], ["SET", 542], ["proteins", 546], ["becoming", 555], ["ordered", 564], ["upon", 572], ["addition", 577], ["of", 586], ["AdoMet", 589], ["cofactor", 596], ["and", 605], ["develop", 609], ["a", 617], ["model", 619], ["for", 625], ["the", 629], ["catalytic", 633], ["cycle", 643], ["of", 649], ["these", 652], ["enzymes", 658], [".", 665], ["The", 667], ["crystal", 671], ["structure", 679], ["reveals", 689], ["the", 697], ["basis", 701], ["of", 707], ["the", 710], ["specificity", 714], ["of", 726], ["the", 729], ["enzyme", 733], ["for", 740], ["H4-K20", 744], ["because", 751], ["a", 759], ["histidine", 761], ["residue", 771], ["within", 779], ["the", 786], ["substrate", 790], [",", 799], ["close", 801], ["to", 807], ["the", 810], ["target", 814], ["lysine", 821], [",", 827], ["is", 829], ["required", 832], ["for", 841], ["completion", 845], ["of", 856], ["the", 859], ["active", 863], ["site", 870], [".", 874], ["We", 876], ["also", 879], ["show", 884], ["how", 889], ["a", 893], ["highly", 895], ["variable", 902], ["component", 911], ["of", 921], ["the", 924], ["SET", 928], ["domain", 932], ["is", 939], ["responsible", 942], ["for", 954], ["many", 958], ["of", 963], ["the", 966], ["enzymes", 970], ["'", 977], ["interactions", 979], ["with", 992], ["its", 997], ["target", 1001], ["histone", 1008], ["peptide", 1016], ["and", 1024], ["probably", 1028], ["also", 1037], ["how", 1042], ["this", 1046], ["part", 1051], ["of", 1056], ["the", 1059], ["structure", 1063], ["ensures", 1073], ["that", 1081], ["Pr", 1086], ["-", 1088], ["Set7", 1089], ["is", 1094], ["nucleosome", 1097], ["specific", 1108], [".", 1116]]}
{"context": "Tanezumab is a humanized monoclonal antibody that specifically inhibits nerve growth factor as a treatment for chronic pain. This phase IIB study investigated the efficacy and safety of tanezumab for chronic low back pain vs placebo and naproxen. Patients (N=1347) received intravenous tanezumab (5, 10, or 20mg every 8weeks), naproxen (500mg twice daily), or placebo. The primary efficacy end point was mean change in daily average low back pain intensity (LBPI) from baseline to week 16. Secondary end points included mean change from baseline to week 16 in the Roland Morris Disability Questionnaire and Patient's Global Assessment (PGA) of low back pain. Tanezumab 10 and 20mg had similar efficacy profiles and significantly improved LBPI, Roland Morris Disability Questionnaire, and PGA scores vs both placebo and naproxen (P\u2a7d.05). Tanezumab 5mg provided improvement of PGA scores vs placebo (P\u2a7d.05), and naproxen resulted in significant improvement of LBPI vs placebo (P\u2a7d.05). Adverse event incidence was comparable across tanezumab doses but higher than with placebo or naproxen. Arthralgia, pain in extremity, headache, and paresthesia were the most commonly reported adverse events by tanezumab-treated patients. The most frequently reported adverse events resulting in discontinuation of tanezumab treatment were arthralgia and paresthesia; the highest frequency was observed with tanezumab 20mg (both 1.4%). Serious adverse event incidence was similar across treatments. In conclusion, tanezumab provided significantly greater improvement in pain, function, and global scores vs placebo and naproxen in patients with chronic low back pain.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "ccb9b1d3df6f45b2bb19557def943330", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[9, 11]], "char_spans": [[72, 90]]}]}], "context_tokens": [["Tanezumab", 0], ["is", 10], ["a", 13], ["humanized", 15], ["monoclonal", 25], ["antibody", 36], ["that", 45], ["specifically", 50], ["inhibits", 63], ["nerve", 72], ["growth", 78], ["factor", 85], ["as", 92], ["a", 95], ["treatment", 97], ["for", 107], ["chronic", 111], ["pain", 119], [".", 123], ["This", 125], ["phase", 130], ["IIB", 136], ["study", 140], ["investigated", 146], ["the", 159], ["efficacy", 163], ["and", 172], ["safety", 176], ["of", 183], ["tanezumab", 186], ["for", 196], ["chronic", 200], ["low", 208], ["back", 212], ["pain", 217], ["vs", 222], ["placebo", 225], ["and", 233], ["naproxen", 237], [".", 245], ["Patients", 247], ["(", 256], ["N=1347", 257], [")", 263], ["received", 265], ["intravenous", 274], ["tanezumab", 286], ["(", 296], ["5", 297], [",", 298], ["10", 300], [",", 302], ["or", 304], ["20", 307], ["mg", 309], ["every", 312], ["8weeks", 318], [")", 324], [",", 325], ["naproxen", 327], ["(", 336], ["500", 337], ["mg", 340], ["twice", 343], ["daily", 349], [")", 354], [",", 355], ["or", 357], ["placebo", 360], [".", 367], ["The", 369], ["primary", 373], ["efficacy", 381], ["end", 390], ["point", 394], ["was", 400], ["mean", 404], ["change", 409], ["in", 416], ["daily", 419], ["average", 425], ["low", 433], ["back", 437], ["pain", 442], ["intensity", 447], ["(", 457], ["LBPI", 458], [")", 462], ["from", 464], ["baseline", 469], ["to", 478], ["week", 481], ["16", 486], [".", 488], ["Secondary", 490], ["end", 500], ["points", 504], ["included", 511], ["mean", 520], ["change", 525], ["from", 532], ["baseline", 537], ["to", 546], ["week", 549], ["16", 554], ["in", 557], ["the", 560], ["Roland", 564], ["Morris", 571], ["Disability", 578], ["Questionnaire", 589], ["and", 603], ["Patient", 607], ["'s", 614], ["Global", 617], ["Assessment", 624], ["(", 635], ["PGA", 636], [")", 639], ["of", 641], ["low", 644], ["back", 648], ["pain", 653], [".", 657], ["Tanezumab", 659], ["10", 669], ["and", 672], ["20", 676], ["mg", 678], ["had", 681], ["similar", 685], ["efficacy", 693], ["profiles", 702], ["and", 711], ["significantly", 715], ["improved", 729], ["LBPI", 738], [",", 742], ["Roland", 744], ["Morris", 751], ["Disability", 758], ["Questionnaire", 769], [",", 782], ["and", 784], ["PGA", 788], ["scores", 792], ["vs", 799], ["both", 802], ["placebo", 807], ["and", 815], ["naproxen", 819], ["(", 828], ["P\u2a7d.05", 829], [")", 834], [".", 835], ["Tanezumab", 837], ["5", 847], ["mg", 848], ["provided", 851], ["improvement", 860], ["of", 872], ["PGA", 875], ["scores", 879], ["vs", 886], ["placebo", 889], ["(", 897], ["P\u2a7d.05", 898], [")", 903], [",", 904], ["and", 906], ["naproxen", 910], ["resulted", 919], ["in", 928], ["significant", 931], ["improvement", 943], ["of", 955], ["LBPI", 958], ["vs", 963], ["placebo", 966], ["(", 974], ["P\u2a7d.05", 975], [")", 980], [".", 981], ["Adverse", 983], ["event", 991], ["incidence", 997], ["was", 1007], ["comparable", 1011], ["across", 1022], ["tanezumab", 1029], ["doses", 1039], ["but", 1045], ["higher", 1049], ["than", 1056], ["with", 1061], ["placebo", 1066], ["or", 1074], ["naproxen", 1077], [".", 1085], ["Arthralgia", 1087], [",", 1097], ["pain", 1099], ["in", 1104], ["extremity", 1107], [",", 1116], ["headache", 1118], [",", 1126], ["and", 1128], ["paresthesia", 1132], ["were", 1144], ["the", 1149], ["most", 1153], ["commonly", 1158], ["reported", 1167], ["adverse", 1176], ["events", 1184], ["by", 1191], ["tanezumab", 1194], ["-", 1203], ["treated", 1204], ["patients", 1212], [".", 1220], ["The", 1222], ["most", 1226], ["frequently", 1231], ["reported", 1242], ["adverse", 1251], ["events", 1259], ["resulting", 1266], ["in", 1276], ["discontinuation", 1279], ["of", 1295], ["tanezumab", 1298], ["treatment", 1308], ["were", 1318], ["arthralgia", 1323], ["and", 1334], ["paresthesia", 1338], [";", 1349], ["the", 1351], ["highest", 1355], ["frequency", 1363], ["was", 1373], ["observed", 1377], ["with", 1386], ["tanezumab", 1391], ["20", 1401], ["mg", 1403], ["(", 1406], ["both", 1407], ["1.4", 1412], ["%", 1415], [")", 1416], [".", 1417], ["Serious", 1419], ["adverse", 1427], ["event", 1435], ["incidence", 1441], ["was", 1451], ["similar", 1455], ["across", 1463], ["treatments", 1470], [".", 1480], ["In", 1482], ["conclusion", 1485], [",", 1495], ["tanezumab", 1497], ["provided", 1507], ["significantly", 1516], ["greater", 1530], ["improvement", 1538], ["in", 1550], ["pain", 1553], [",", 1557], ["function", 1559], [",", 1567], ["and", 1569], ["global", 1573], ["scores", 1580], ["vs", 1587], ["placebo", 1590], ["and", 1598], ["naproxen", 1602], ["in", 1611], ["patients", 1614], ["with", 1623], ["chronic", 1628], ["low", 1636], ["back", 1640], ["pain", 1645], [".", 1649]]}
{"context": "High circulating levels of group IIA secretory phospholipase A2 (sPLA2-IIA) activity and mass are independent cardiovascular risk factors. Therefore, inhibition of sPLA2-IIA may be a target for the treatment of atherosclerotic cardiovascular disease. The present study evaluated the effects of sPLA2-IIA inhibition with varespladib acid in a novel mouse model, human apolipoprotein B (apoB)/human cholesteryl ester transfer protein (CETP)/human sPLA2-IIA triple transgenic mice (TTT) fed a Western-type diet. sPLA2-IIA expression increased atherosclerotic lesion formation in TTT compared with human apoB/human CETP double transgenic mice (P<0.01). Varespladib acid effectively inhibited plasma sPLA2-IIA activity. Surprisingly, however, administration of varespladib acid to TTT had no impact on atherosclerosis, which could be attributed to a proatherogenic plasma lipoprotein profile that appears in response to sPLA2-IIA inhibition because of increased plasma CETP activity. In the TTT model, sPLA2-IIA decreased CETP activity by reducing the acceptor properties of sPLA2-IIA-modified very low-density lipoproteins specifically because of a significantly lower apoE content. Increasing very low-density lipoprotein-apoE content by means of adenovirus-mediated gene transfer in sPLA2-IIA transgenic mice restored the acceptor properties for CETP. These data show that in a humanized triple transgenic mouse model with hypercholesterolemia, sPLA2-IIA inhibition increases CETP activity via increasing the very low-density lipoprotein-apoE content, resulting in a proatherogenic lipoprotein profile.", "qas": [{"question": "Which enzyme is inhibited by Varespladib?", "answers": ["secretory phospholipase A2"], "qid": "9f57803776af4b0bbe0deae68fbd40b0", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["Varespladib", 29], ["?", 40]], "detected_answers": [{"text": "secretory phospholipase A2", "token_spans": [[6, 8]], "char_spans": [[37, 62]]}]}], "context_tokens": [["High", 0], ["circulating", 5], ["levels", 17], ["of", 24], ["group", 27], ["IIA", 33], ["secretory", 37], ["phospholipase", 47], ["A2", 61], ["(", 64], ["sPLA2-IIA", 65], [")", 74], ["activity", 76], ["and", 85], ["mass", 89], ["are", 94], ["independent", 98], ["cardiovascular", 110], ["risk", 125], ["factors", 130], [".", 137], ["Therefore", 139], [",", 148], ["inhibition", 150], ["of", 161], ["sPLA2-IIA", 164], ["may", 174], ["be", 178], ["a", 181], ["target", 183], ["for", 190], ["the", 194], ["treatment", 198], ["of", 208], ["atherosclerotic", 211], ["cardiovascular", 227], ["disease", 242], [".", 249], ["The", 251], ["present", 255], ["study", 263], ["evaluated", 269], ["the", 279], ["effects", 283], ["of", 291], ["sPLA2-IIA", 294], ["inhibition", 304], ["with", 315], ["varespladib", 320], ["acid", 332], ["in", 337], ["a", 340], ["novel", 342], ["mouse", 348], ["model", 354], [",", 359], ["human", 361], ["apolipoprotein", 367], ["B", 382], ["(", 384], ["apoB)/human", 385], ["cholesteryl", 397], ["ester", 409], ["transfer", 415], ["protein", 424], ["(", 432], ["CETP)/human", 433], ["sPLA2-IIA", 445], ["triple", 455], ["transgenic", 462], ["mice", 473], ["(", 478], ["TTT", 479], [")", 482], ["fed", 484], ["a", 488], ["Western", 490], ["-", 497], ["type", 498], ["diet", 503], [".", 507], ["sPLA2-IIA", 509], ["expression", 519], ["increased", 530], ["atherosclerotic", 540], ["lesion", 556], ["formation", 563], ["in", 573], ["TTT", 576], ["compared", 580], ["with", 589], ["human", 594], ["apoB", 600], ["/", 604], ["human", 605], ["CETP", 611], ["double", 616], ["transgenic", 623], ["mice", 634], ["(", 639], ["P<0.01", 640], [")", 646], [".", 647], ["Varespladib", 649], ["acid", 661], ["effectively", 666], ["inhibited", 678], ["plasma", 688], ["sPLA2-IIA", 695], ["activity", 705], [".", 713], ["Surprisingly", 715], [",", 727], ["however", 729], [",", 736], ["administration", 738], ["of", 753], ["varespladib", 756], ["acid", 768], ["to", 773], ["TTT", 776], ["had", 780], ["no", 784], ["impact", 787], ["on", 794], ["atherosclerosis", 797], [",", 812], ["which", 814], ["could", 820], ["be", 826], ["attributed", 829], ["to", 840], ["a", 843], ["proatherogenic", 845], ["plasma", 860], ["lipoprotein", 867], ["profile", 879], ["that", 887], ["appears", 892], ["in", 900], ["response", 903], ["to", 912], ["sPLA2-IIA", 915], ["inhibition", 925], ["because", 936], ["of", 944], ["increased", 947], ["plasma", 957], ["CETP", 964], ["activity", 969], [".", 977], ["In", 979], ["the", 982], ["TTT", 986], ["model", 990], [",", 995], ["sPLA2-IIA", 997], ["decreased", 1007], ["CETP", 1017], ["activity", 1022], ["by", 1031], ["reducing", 1034], ["the", 1043], ["acceptor", 1047], ["properties", 1056], ["of", 1067], ["sPLA2-IIA", 1070], ["-", 1079], ["modified", 1080], ["very", 1089], ["low", 1094], ["-", 1097], ["density", 1098], ["lipoproteins", 1106], ["specifically", 1119], ["because", 1132], ["of", 1140], ["a", 1143], ["significantly", 1145], ["lower", 1159], ["apoE", 1165], ["content", 1170], [".", 1177], ["Increasing", 1179], ["very", 1190], ["low", 1195], ["-", 1198], ["density", 1199], ["lipoprotein", 1207], ["-", 1218], ["apoE", 1219], ["content", 1224], ["by", 1232], ["means", 1235], ["of", 1241], ["adenovirus", 1244], ["-", 1254], ["mediated", 1255], ["gene", 1264], ["transfer", 1269], ["in", 1278], ["sPLA2-IIA", 1281], ["transgenic", 1291], ["mice", 1302], ["restored", 1307], ["the", 1316], ["acceptor", 1320], ["properties", 1329], ["for", 1340], ["CETP", 1344], [".", 1348], ["These", 1350], ["data", 1356], ["show", 1361], ["that", 1366], ["in", 1371], ["a", 1374], ["humanized", 1376], ["triple", 1386], ["transgenic", 1393], ["mouse", 1404], ["model", 1410], ["with", 1416], ["hypercholesterolemia", 1421], [",", 1441], ["sPLA2-IIA", 1443], ["inhibition", 1453], ["increases", 1464], ["CETP", 1474], ["activity", 1479], ["via", 1488], ["increasing", 1492], ["the", 1503], ["very", 1507], ["low", 1512], ["-", 1515], ["density", 1516], ["lipoprotein", 1524], ["-", 1535], ["apoE", 1536], ["content", 1541], [",", 1548], ["resulting", 1550], ["in", 1560], ["a", 1563], ["proatherogenic", 1565], ["lipoprotein", 1580], ["profile", 1592], [".", 1599]]}
{"context": "The histone variant H2AZ is incorporated preferentially at specific locations in chromatin to modulate chromosome functions. In Saccharomyces cerevisiae, deposition of histone H2AZ is mediated by the multiprotein SWR1 complex, which catalyzes ATP-dependent exchange of nucleosomal histone H2A for H2AZ. Here, we define interactions between SWR1 components and H2AZ, revealing a link between the ATPase domain of Swr1 and three subunits required for the binding of H2AZ. We discovered that Swc2 binds directly to and is essential for transfer of H2AZ. Swc6 and Arp6 are necessary for the association of Swc2 and for nucleosome binding, whereas other subunits, Swc5 and Yaf9, are required for H2AZ transfer but neither H2AZ nor nucleosome binding. Finally, the C-terminal alpha-helix of H2AZ is crucial for its recognition by SWR1. These findings provide insight on the initial events of histone exchange.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "62476e02ad284ed2b1d1125d42c416a2", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[143, 143], [52, 52], [65, 65], [30, 30]], "char_spans": [[824, 827], [340, 343], [412, 415], [213, 216]]}]}], "context_tokens": [["The", 0], ["histone", 4], ["variant", 12], ["H2AZ", 20], ["is", 25], ["incorporated", 28], ["preferentially", 41], ["at", 56], ["specific", 59], ["locations", 68], ["in", 78], ["chromatin", 81], ["to", 91], ["modulate", 94], ["chromosome", 103], ["functions", 114], [".", 123], ["In", 125], ["Saccharomyces", 128], ["cerevisiae", 142], [",", 152], ["deposition", 154], ["of", 165], ["histone", 168], ["H2AZ", 176], ["is", 181], ["mediated", 184], ["by", 193], ["the", 196], ["multiprotein", 200], ["SWR1", 213], ["complex", 218], [",", 225], ["which", 227], ["catalyzes", 233], ["ATP", 243], ["-", 246], ["dependent", 247], ["exchange", 257], ["of", 266], ["nucleosomal", 269], ["histone", 281], ["H2A", 289], ["for", 293], ["H2AZ", 297], [".", 301], ["Here", 303], [",", 307], ["we", 309], ["define", 312], ["interactions", 319], ["between", 332], ["SWR1", 340], ["components", 345], ["and", 356], ["H2AZ", 360], [",", 364], ["revealing", 366], ["a", 376], ["link", 378], ["between", 383], ["the", 391], ["ATPase", 395], ["domain", 402], ["of", 409], ["Swr1", 412], ["and", 417], ["three", 421], ["subunits", 427], ["required", 436], ["for", 445], ["the", 449], ["binding", 453], ["of", 461], ["H2AZ", 464], [".", 468], ["We", 470], ["discovered", 473], ["that", 484], ["Swc2", 489], ["binds", 494], ["directly", 500], ["to", 509], ["and", 512], ["is", 516], ["essential", 519], ["for", 529], ["transfer", 533], ["of", 542], ["H2AZ", 545], [".", 549], ["Swc6", 551], ["and", 556], ["Arp6", 560], ["are", 565], ["necessary", 569], ["for", 579], ["the", 583], ["association", 587], ["of", 599], ["Swc2", 602], ["and", 607], ["for", 611], ["nucleosome", 615], ["binding", 626], [",", 633], ["whereas", 635], ["other", 643], ["subunits", 649], [",", 657], ["Swc5", 659], ["and", 664], ["Yaf9", 668], [",", 672], ["are", 674], ["required", 678], ["for", 687], ["H2AZ", 691], ["transfer", 696], ["but", 705], ["neither", 709], ["H2AZ", 717], ["nor", 722], ["nucleosome", 726], ["binding", 737], [".", 744], ["Finally", 746], [",", 753], ["the", 755], ["C", 759], ["-", 760], ["terminal", 761], ["alpha", 770], ["-", 775], ["helix", 776], ["of", 782], ["H2AZ", 785], ["is", 790], ["crucial", 793], ["for", 801], ["its", 805], ["recognition", 809], ["by", 821], ["SWR1", 824], [".", 828], ["These", 830], ["findings", 836], ["provide", 845], ["insight", 853], ["on", 861], ["the", 864], ["initial", 868], ["events", 876], ["of", 883], ["histone", 886], ["exchange", 894], [".", 902]]}
{"context": "Alpha-synuclein (alphaS) is the primary component of Lewy bodies, the pathological hallmark of Parkinson's Disease. Aggregation of alphaS is thought to proceed from a primarily disordered state with nascent secondary structure through intermediate conformations to oligomeric forms and finally to mature amyloid fibrils. Low pH conditions lead to conformational changes associated with increased alphaS fibril formation. Here we characterize these structural and dynamic changes using solution state NMR measurements of secondary chemical shifts, relaxation parameters, residual dipolar couplings, and paramagnetic relaxation enhancement. We find that the neutralization of negatively charged side-chains eliminates electrostatic repulsion in the C-terminal tail of alphaS and leads to a collapse of this region at low pH. Hydrophobic contacts between the compact C-terminal tail and the NAC (non-amyloid-beta component) region are maintained and may lead to the formation of a globular domain. Transient long-range contacts between the C-terminus of the protein and regions N-terminal to the NAC region are also preserved. Thus, the release of long-range contacts does not play a role in the increased aggregation of alphaS at low pH, which we instead attribute to the increased hydrophobicity of the protein.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "49df234dddfb4af6b70443ee0df3e00d", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[0, 2]], "char_spans": [[0, 14]]}]}], "context_tokens": [["Alpha", 0], ["-", 5], ["synuclein", 6], ["(", 16], ["alphaS", 17], [")", 23], ["is", 25], ["the", 28], ["primary", 32], ["component", 40], ["of", 50], ["Lewy", 53], ["bodies", 58], [",", 64], ["the", 66], ["pathological", 70], ["hallmark", 83], ["of", 92], ["Parkinson", 95], ["'s", 104], ["Disease", 107], [".", 114], ["Aggregation", 116], ["of", 128], ["alphaS", 131], ["is", 138], ["thought", 141], ["to", 149], ["proceed", 152], ["from", 160], ["a", 165], ["primarily", 167], ["disordered", 177], ["state", 188], ["with", 194], ["nascent", 199], ["secondary", 207], ["structure", 217], ["through", 227], ["intermediate", 235], ["conformations", 248], ["to", 262], ["oligomeric", 265], ["forms", 276], ["and", 282], ["finally", 286], ["to", 294], ["mature", 297], ["amyloid", 304], ["fibrils", 312], [".", 319], ["Low", 321], ["pH", 325], ["conditions", 328], ["lead", 339], ["to", 344], ["conformational", 347], ["changes", 362], ["associated", 370], ["with", 381], ["increased", 386], ["alphaS", 396], ["fibril", 403], ["formation", 410], [".", 419], ["Here", 421], ["we", 426], ["characterize", 429], ["these", 442], ["structural", 448], ["and", 459], ["dynamic", 463], ["changes", 471], ["using", 479], ["solution", 485], ["state", 494], ["NMR", 500], ["measurements", 504], ["of", 517], ["secondary", 520], ["chemical", 530], ["shifts", 539], [",", 545], ["relaxation", 547], ["parameters", 558], [",", 568], ["residual", 570], ["dipolar", 579], ["couplings", 587], [",", 596], ["and", 598], ["paramagnetic", 602], ["relaxation", 615], ["enhancement", 626], [".", 637], ["We", 639], ["find", 642], ["that", 647], ["the", 652], ["neutralization", 656], ["of", 671], ["negatively", 674], ["charged", 685], ["side", 693], ["-", 697], ["chains", 698], ["eliminates", 705], ["electrostatic", 716], ["repulsion", 730], ["in", 740], ["the", 743], ["C", 747], ["-", 748], ["terminal", 749], ["tail", 758], ["of", 763], ["alphaS", 766], ["and", 773], ["leads", 777], ["to", 783], ["a", 786], ["collapse", 788], ["of", 797], ["this", 800], ["region", 805], ["at", 812], ["low", 815], ["pH.", 819], ["Hydrophobic", 823], ["contacts", 835], ["between", 844], ["the", 852], ["compact", 856], ["C", 864], ["-", 865], ["terminal", 866], ["tail", 875], ["and", 880], ["the", 884], ["NAC", 888], ["(", 892], ["non", 893], ["-", 896], ["amyloid", 897], ["-", 904], ["beta", 905], ["component", 910], [")", 919], ["region", 921], ["are", 928], ["maintained", 932], ["and", 943], ["may", 947], ["lead", 951], ["to", 956], ["the", 959], ["formation", 963], ["of", 973], ["a", 976], ["globular", 978], ["domain", 987], [".", 993], ["Transient", 995], ["long", 1005], ["-", 1009], ["range", 1010], ["contacts", 1016], ["between", 1025], ["the", 1033], ["C", 1037], ["-", 1038], ["terminus", 1039], ["of", 1048], ["the", 1051], ["protein", 1055], ["and", 1063], ["regions", 1067], ["N", 1075], ["-", 1076], ["terminal", 1077], ["to", 1086], ["the", 1089], ["NAC", 1093], ["region", 1097], ["are", 1104], ["also", 1108], ["preserved", 1113], [".", 1122], ["Thus", 1124], [",", 1128], ["the", 1130], ["release", 1134], ["of", 1142], ["long", 1145], ["-", 1149], ["range", 1150], ["contacts", 1156], ["does", 1165], ["not", 1170], ["play", 1174], ["a", 1179], ["role", 1181], ["in", 1186], ["the", 1189], ["increased", 1193], ["aggregation", 1203], ["of", 1215], ["alphaS", 1218], ["at", 1225], ["low", 1228], ["pH", 1232], [",", 1234], ["which", 1236], ["we", 1242], ["instead", 1245], ["attribute", 1253], ["to", 1263], ["the", 1266], ["increased", 1270], ["hydrophobicity", 1280], ["of", 1295], ["the", 1298], ["protein", 1302], [".", 1309]]}
{"context": "Facio-scapulo-humeral dystrophy (FSHD) results from deletions in the subtelomeric macrosatellite D4Z4 array on the 4q35 region. Upregulation of the DUX4 retrogene from the last D4Z4 repeated unit is thought to underlie FSHD pathophysiology. However, no one knows what triggers muscle defect and when alteration arises. To gain further insights into the molecular mechanisms of the disease, we evaluated at the molecular level, the perturbation linked to the FSHD genotype with no a priori on disease onset, severity or penetrance and prior to any infiltration by fibrotic or adipose tissue in biopsies from fetuses carrying a short pathogenic D4Z4 array (n = 6) compared with fetuses with a non-pathogenic D4Z4 array (n = 21). By measuring expression of several muscle-specific markers and 4q35 genes including the DUX4 retrogene by an RT-PCR and western blotting, we observed a global dysregulation of genes involved in myogenesis including MYOD1 in samples with <11 D4Z4. The DUX4-fl pathogenic transcript was detected in FSHD biopsies but also in controls. Importantly, in FSHD fetuses, we mainly detected the non-spliced DUX4-fl isoform. In addition, several other genes clustered at the 4q35 locus are upregulated in FSHD fetuses. Our study is the first to examine fetuses carrying an FSHD-linked genotype and reveals an extensive dysregulation of several muscle-specific and 4q35 genes at early development stage at a distance from any muscle defect. Overall, our work suggests that even if FSHD is an adult-onset muscular dystrophy, the disease might also involve early molecular defects arising during myogenesis or early differentiation.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "4fc29c2642a542c698f2e6a566dc9c37", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[221, 221], [38, 38], [234, 234], [7, 7], [184, 184], [194, 194], [79, 79], [271, 271]], "char_spans": [[1222, 1225], [219, 222], [1290, 1293], [33, 36], [1024, 1027], [1076, 1079], [458, 461], [1497, 1500]]}]}], "context_tokens": [["Facio", 0], ["-", 5], ["scapulo", 6], ["-", 13], ["humeral", 14], ["dystrophy", 22], ["(", 32], ["FSHD", 33], [")", 37], ["results", 39], ["from", 47], ["deletions", 52], ["in", 62], ["the", 65], ["subtelomeric", 69], ["macrosatellite", 82], ["D4Z4", 97], ["array", 102], ["on", 108], ["the", 111], ["4q35", 115], ["region", 120], [".", 126], ["Upregulation", 128], ["of", 141], ["the", 144], ["DUX4", 148], ["retrogene", 153], ["from", 163], ["the", 168], ["last", 172], ["D4Z4", 177], ["repeated", 182], ["unit", 191], ["is", 196], ["thought", 199], ["to", 207], ["underlie", 210], ["FSHD", 219], ["pathophysiology", 224], [".", 239], ["However", 241], [",", 248], ["no", 250], ["one", 253], ["knows", 257], ["what", 263], ["triggers", 268], ["muscle", 277], ["defect", 284], ["and", 291], ["when", 295], ["alteration", 300], ["arises", 311], [".", 317], ["To", 319], ["gain", 322], ["further", 327], ["insights", 335], ["into", 344], ["the", 349], ["molecular", 353], ["mechanisms", 363], ["of", 374], ["the", 377], ["disease", 381], [",", 388], ["we", 390], ["evaluated", 393], ["at", 403], ["the", 406], ["molecular", 410], ["level", 420], [",", 425], ["the", 427], ["perturbation", 431], ["linked", 444], ["to", 451], ["the", 454], ["FSHD", 458], ["genotype", 463], ["with", 472], ["no", 477], ["a", 480], ["priori", 482], ["on", 489], ["disease", 492], ["onset", 500], [",", 505], ["severity", 507], ["or", 516], ["penetrance", 519], ["and", 530], ["prior", 534], ["to", 540], ["any", 543], ["infiltration", 547], ["by", 560], ["fibrotic", 563], ["or", 572], ["adipose", 575], ["tissue", 583], ["in", 590], ["biopsies", 593], ["from", 602], ["fetuses", 607], ["carrying", 615], ["a", 624], ["short", 626], ["pathogenic", 632], ["D4Z4", 643], ["array", 648], ["(", 654], ["n", 655], ["=", 657], ["6", 659], [")", 660], ["compared", 662], ["with", 671], ["fetuses", 676], ["with", 684], ["a", 689], ["non", 691], ["-", 694], ["pathogenic", 695], ["D4Z4", 706], ["array", 711], ["(", 717], ["n", 718], ["=", 720], ["21", 722], [")", 724], [".", 725], ["By", 727], ["measuring", 730], ["expression", 740], ["of", 751], ["several", 754], ["muscle", 762], ["-", 768], ["specific", 769], ["markers", 778], ["and", 786], ["4q35", 790], ["genes", 795], ["including", 801], ["the", 811], ["DUX4", 815], ["retrogene", 820], ["by", 830], ["an", 833], ["RT", 836], ["-", 838], ["PCR", 839], ["and", 843], ["western", 847], ["blotting", 855], [",", 863], ["we", 865], ["observed", 868], ["a", 877], ["global", 879], ["dysregulation", 886], ["of", 900], ["genes", 903], ["involved", 909], ["in", 918], ["myogenesis", 921], ["including", 932], ["MYOD1", 942], ["in", 948], ["samples", 951], ["with", 959], ["<", 964], ["11", 965], ["D4Z4", 968], [".", 972], ["The", 974], ["DUX4-fl", 978], ["pathogenic", 986], ["transcript", 997], ["was", 1008], ["detected", 1012], ["in", 1021], ["FSHD", 1024], ["biopsies", 1029], ["but", 1038], ["also", 1042], ["in", 1047], ["controls", 1050], [".", 1058], ["Importantly", 1060], [",", 1071], ["in", 1073], ["FSHD", 1076], ["fetuses", 1081], [",", 1088], ["we", 1090], ["mainly", 1093], ["detected", 1100], ["the", 1109], ["non", 1113], ["-", 1116], ["spliced", 1117], ["DUX4-fl", 1125], ["isoform", 1133], [".", 1140], ["In", 1142], ["addition", 1145], [",", 1153], ["several", 1155], ["other", 1163], ["genes", 1169], ["clustered", 1175], ["at", 1185], ["the", 1188], ["4q35", 1192], ["locus", 1197], ["are", 1203], ["upregulated", 1207], ["in", 1219], ["FSHD", 1222], ["fetuses", 1227], [".", 1234], ["Our", 1236], ["study", 1240], ["is", 1246], ["the", 1249], ["first", 1253], ["to", 1259], ["examine", 1262], ["fetuses", 1270], ["carrying", 1278], ["an", 1287], ["FSHD", 1290], ["-", 1294], ["linked", 1295], ["genotype", 1302], ["and", 1311], ["reveals", 1315], ["an", 1323], ["extensive", 1326], ["dysregulation", 1336], ["of", 1350], ["several", 1353], ["muscle", 1361], ["-", 1367], ["specific", 1368], ["and", 1377], ["4q35", 1381], ["genes", 1386], ["at", 1392], ["early", 1395], ["development", 1401], ["stage", 1413], ["at", 1419], ["a", 1422], ["distance", 1424], ["from", 1433], ["any", 1438], ["muscle", 1442], ["defect", 1449], [".", 1455], ["Overall", 1457], [",", 1464], ["our", 1466], ["work", 1470], ["suggests", 1475], ["that", 1484], ["even", 1489], ["if", 1494], ["FSHD", 1497], ["is", 1502], ["an", 1505], ["adult", 1508], ["-", 1513], ["onset", 1514], ["muscular", 1520], ["dystrophy", 1529], [",", 1538], ["the", 1540], ["disease", 1544], ["might", 1552], ["also", 1558], ["involve", 1563], ["early", 1571], ["molecular", 1577], ["defects", 1587], ["arising", 1595], ["during", 1603], ["myogenesis", 1610], ["or", 1621], ["early", 1624], ["differentiation", 1630], [".", 1645]]}
{"context": "Lack of specific antidotes is a major concern in intracerebral hemorrhage (ICH) related to direct anticoagulants including dabigatran (OAC-ICH). We examined the efficacy of idarucizumab, an antibody fragment binding to dabigatran, in a mouse model of OAC-ICH. Dabigatran etexilate (DE) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab. Pretreatment with DE increased intracerebral hematoma volume and cerebral hemoglobin content. Idarucizumab in equimolar dose prevented excess hematoma expansion for both DE doses. In more extensive ICH, idarucizumab significantly reduced mortality. Thus, idarucizumab prevents excess intracerebral hematoma formation in mice anticoagulated with dabigatran and reduces mortality.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "6aac3d7c2f5e40e09f41b4cb9a267ef5", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[121, 121], [19, 19], [49, 49], [38, 38]], "char_spans": [[746, 755], [123, 132], [260, 269], [219, 228]]}]}], "context_tokens": [["Lack", 0], ["of", 5], ["specific", 8], ["antidotes", 17], ["is", 27], ["a", 30], ["major", 32], ["concern", 38], ["in", 46], ["intracerebral", 49], ["hemorrhage", 63], ["(", 74], ["ICH", 75], [")", 78], ["related", 80], ["to", 88], ["direct", 91], ["anticoagulants", 98], ["including", 113], ["dabigatran", 123], ["(", 134], ["OAC", 135], ["-", 138], ["ICH", 139], [")", 142], [".", 143], ["We", 145], ["examined", 148], ["the", 157], ["efficacy", 161], ["of", 170], ["idarucizumab", 173], [",", 185], ["an", 187], ["antibody", 190], ["fragment", 199], ["binding", 208], ["to", 216], ["dabigatran", 219], [",", 229], ["in", 231], ["a", 234], ["mouse", 236], ["model", 242], ["of", 248], ["OAC", 251], ["-", 254], ["ICH", 255], [".", 258], ["Dabigatran", 260], ["etexilate", 271], ["(", 281], ["DE", 282], [")", 284], ["dose", 286], ["-", 290], ["dependently", 291], ["prolonged", 303], ["diluted", 313], ["thrombin", 321], ["time", 330], ["and", 335], ["tail", 339], ["-", 343], ["vein", 344], ["bleeding", 349], ["time", 358], [",", 362], ["which", 364], ["were", 370], ["reversed", 375], ["by", 384], ["idarucizumab", 387], [".", 399], ["Pretreatment", 401], ["with", 414], ["DE", 419], ["increased", 422], ["intracerebral", 432], ["hematoma", 446], ["volume", 455], ["and", 462], ["cerebral", 466], ["hemoglobin", 475], ["content", 486], [".", 493], ["Idarucizumab", 495], ["in", 508], ["equimolar", 511], ["dose", 521], ["prevented", 526], ["excess", 536], ["hematoma", 543], ["expansion", 552], ["for", 562], ["both", 566], ["DE", 571], ["doses", 574], [".", 579], ["In", 581], ["more", 584], ["extensive", 589], ["ICH", 599], [",", 602], ["idarucizumab", 604], ["significantly", 617], ["reduced", 631], ["mortality", 639], [".", 648], ["Thus", 650], [",", 654], ["idarucizumab", 656], ["prevents", 669], ["excess", 678], ["intracerebral", 685], ["hematoma", 699], ["formation", 708], ["in", 718], ["mice", 721], ["anticoagulated", 726], ["with", 741], ["dabigatran", 746], ["and", 757], ["reduces", 761], ["mortality", 769], [".", 778]]}
{"context": "Interleukin-1\u03b2 (IL-1\u03b2) is a potent mediator of inflammatory responses and plays a role in the differentiation of a number of lymphoid cells. In several inflammatory and autoimmune diseases, serum levels of IL-1\u03b2 are elevated and correlate with disease development and severity. The central role of the IL-1 pathway in several diseases has been validated by inhibitors currently in clinical development or approved by the FDA. However, the need to effectively modulate IL-1\u03b2-mediated local inflammation with the systemic delivery of an efficacious, safe and convenient drug still exists. To meet these challenges, we developed XOMA 052 (gevokizumab), a potent anti-IL-1\u03b2 neutralizing antibody that was designed in silico and humanized using Human Engineering\u2122 technology. XOMA 052 has a 300 femtomolar binding affinity for human IL-1\u03b2 and an in vitro potency in the low picomolar range. XOMA 052 binds to a unique IL-1\u03b2 epitope where residues critical for binding have been identified. We have previously reported that XOMA 052 is efficacious in vivo in a diet-induced obesity mouse model thought to be driven by low levels of chronic inflammation. We report here that XOMA 052 also reduces acute inflammation in vivo, neutralizing the effect of exogenously administered human IL-1\u03b2 and blocking peritonitis in a mouse model of acute gout. Based on its high potency, novel mechanism of action, long half-life, and high affinity, XOMA 052 provides a new strategy for the treatment of a number of inflammatory, autoimmune and metabolic diseases in which the role of IL-1\u03b2 is central to pathogenesis.", "qas": [{"question": "Which molecule is targeted by the drug Gevokizumab?", "answers": ["IL-1\u03b2"], "qid": "f129d78a420746cd9b0364aa8ac1fa28", "question_tokens": [["Which", 0], ["molecule", 6], ["is", 15], ["targeted", 18], ["by", 27], ["the", 30], ["drug", 34], ["Gevokizumab", 39], ["?", 50]], "detected_answers": [{"text": "IL-1\u03b2", "token_spans": [[141, 141], [35, 35], [115, 115], [2, 2], [220, 220], [276, 276], [78, 78], [159, 159]], "char_spans": [[828, 832], [206, 210], [664, 668], [16, 20], [1276, 1280], [1563, 1567], [468, 472], [913, 917]]}]}], "context_tokens": [["Interleukin-1\u03b2", 0], ["(", 15], ["IL-1\u03b2", 16], [")", 21], ["is", 23], ["a", 26], ["potent", 28], ["mediator", 35], ["of", 44], ["inflammatory", 47], ["responses", 60], ["and", 70], ["plays", 74], ["a", 80], ["role", 82], ["in", 87], ["the", 90], ["differentiation", 94], ["of", 110], ["a", 113], ["number", 115], ["of", 122], ["lymphoid", 125], ["cells", 134], [".", 139], ["In", 141], ["several", 144], ["inflammatory", 152], ["and", 165], ["autoimmune", 169], ["diseases", 180], [",", 188], ["serum", 190], ["levels", 196], ["of", 203], ["IL-1\u03b2", 206], ["are", 212], ["elevated", 216], ["and", 225], ["correlate", 229], ["with", 239], ["disease", 244], ["development", 252], ["and", 264], ["severity", 268], [".", 276], ["The", 278], ["central", 282], ["role", 290], ["of", 295], ["the", 298], ["IL-1", 302], ["pathway", 307], ["in", 315], ["several", 318], ["diseases", 326], ["has", 335], ["been", 339], ["validated", 344], ["by", 354], ["inhibitors", 357], ["currently", 368], ["in", 378], ["clinical", 381], ["development", 390], ["or", 402], ["approved", 405], ["by", 414], ["the", 417], ["FDA", 421], [".", 424], ["However", 426], [",", 433], ["the", 435], ["need", 439], ["to", 444], ["effectively", 447], ["modulate", 459], ["IL-1\u03b2", 468], ["-", 473], ["mediated", 474], ["local", 483], ["inflammation", 489], ["with", 502], ["the", 507], ["systemic", 511], ["delivery", 520], ["of", 529], ["an", 532], ["efficacious", 535], [",", 546], ["safe", 548], ["and", 553], ["convenient", 557], ["drug", 568], ["still", 573], ["exists", 579], [".", 585], ["To", 587], ["meet", 590], ["these", 595], ["challenges", 601], [",", 611], ["we", 613], ["developed", 616], ["XOMA", 626], ["052", 631], ["(", 635], ["gevokizumab", 636], [")", 647], [",", 648], ["a", 650], ["potent", 652], ["anti", 659], ["-", 663], ["IL-1\u03b2", 664], ["neutralizing", 670], ["antibody", 683], ["that", 692], ["was", 697], ["designed", 701], ["in", 710], ["silico", 713], ["and", 720], ["humanized", 724], ["using", 734], ["Human", 740], ["Engineering", 746], ["\u2122", 757], ["technology", 759], [".", 769], ["XOMA", 771], ["052", 776], ["has", 780], ["a", 784], ["300", 786], ["femtomolar", 790], ["binding", 801], ["affinity", 809], ["for", 818], ["human", 822], ["IL-1\u03b2", 828], ["and", 834], ["an", 838], ["in", 841], ["vitro", 844], ["potency", 850], ["in", 858], ["the", 861], ["low", 865], ["picomolar", 869], ["range", 879], [".", 884], ["XOMA", 886], ["052", 891], ["binds", 895], ["to", 901], ["a", 904], ["unique", 906], ["IL-1\u03b2", 913], ["epitope", 919], ["where", 927], ["residues", 933], ["critical", 942], ["for", 951], ["binding", 955], ["have", 963], ["been", 968], ["identified", 973], [".", 983], ["We", 985], ["have", 988], ["previously", 993], ["reported", 1004], ["that", 1013], ["XOMA", 1018], ["052", 1023], ["is", 1027], ["efficacious", 1030], ["in", 1042], ["vivo", 1045], ["in", 1050], ["a", 1053], ["diet", 1055], ["-", 1059], ["induced", 1060], ["obesity", 1068], ["mouse", 1076], ["model", 1082], ["thought", 1088], ["to", 1096], ["be", 1099], ["driven", 1102], ["by", 1109], ["low", 1112], ["levels", 1116], ["of", 1123], ["chronic", 1126], ["inflammation", 1134], [".", 1146], ["We", 1148], ["report", 1151], ["here", 1158], ["that", 1163], ["XOMA", 1168], ["052", 1173], ["also", 1177], ["reduces", 1182], ["acute", 1190], ["inflammation", 1196], ["in", 1209], ["vivo", 1212], [",", 1216], ["neutralizing", 1218], ["the", 1231], ["effect", 1235], ["of", 1242], ["exogenously", 1245], ["administered", 1257], ["human", 1270], ["IL-1\u03b2", 1276], ["and", 1282], ["blocking", 1286], ["peritonitis", 1295], ["in", 1307], ["a", 1310], ["mouse", 1312], ["model", 1318], ["of", 1324], ["acute", 1327], ["gout", 1333], [".", 1337], ["Based", 1339], ["on", 1345], ["its", 1348], ["high", 1352], ["potency", 1357], [",", 1364], ["novel", 1366], ["mechanism", 1372], ["of", 1382], ["action", 1385], [",", 1391], ["long", 1393], ["half", 1398], ["-", 1402], ["life", 1403], [",", 1407], ["and", 1409], ["high", 1413], ["affinity", 1418], [",", 1426], ["XOMA", 1428], ["052", 1433], ["provides", 1437], ["a", 1446], ["new", 1448], ["strategy", 1452], ["for", 1461], ["the", 1465], ["treatment", 1469], ["of", 1479], ["a", 1482], ["number", 1484], ["of", 1491], ["inflammatory", 1494], [",", 1506], ["autoimmune", 1508], ["and", 1519], ["metabolic", 1523], ["diseases", 1533], ["in", 1542], ["which", 1545], ["the", 1551], ["role", 1555], ["of", 1560], ["IL-1\u03b2", 1563], ["is", 1569], ["central", 1572], ["to", 1580], ["pathogenesis", 1583], [".", 1595]]}
{"context": "Circular RNAs (circRNAs) are a class of newly-identified non-coding RNA molecules. CircRNAs are conserved across different species and display specific organization, sequence, and expression in disease. Moreover, circRNAs' closed ring structure, insensitivity to RNase, and stability are advantages over linear RNAs in terms of development and application as a new kind of clinical marker. In addition, according to recent studies, circular RNA-7 (ciRS-7) acts as a sponge of miR-7 and thus inhibits its activity. Numerous evidences have confirmed expression of miR-7 is dysregulated in cancer tissues, however, whether ciRS-7 invovled in oncogenesis by acting as sponge of miR-7 remains unclear. Most recently, a study reported ciRS-7 acted as an oncogene in hepatocellular carcinoma through targeting miR-7 expression. This suggest ciRS-7/ miR-7 axis affects oncogenesis, and it provides a new perspective on the mechanisms of decreased miR-7 expression in cancer tissues. Discovery of sponge role of circRNAs caused researchers to more closely explore the underlying mechanism of carcinogenesis and has significant clinical implications, and may open a new chapter in research on the pathology and treatment of cancers. This review summarizes the structure and function of circRNAs and provides evidence for the impact of ciRS-7 in promoting the development of cancer by acting as sponge of miR-7.", "qas": [{"question": "Which miRNA is associated with the circular RNA ciRS-7?", "answers": ["miR-7"], "qid": "8d3460a44ce34647a536fc55cd18a4e1", "question_tokens": [["Which", 0], ["miRNA", 6], ["is", 12], ["associated", 15], ["with", 26], ["the", 31], ["circular", 35], ["RNA", 44], ["ciRS-7", 48], ["?", 54]], "detected_answers": [{"text": "miR-7", "token_spans": [[161, 161], [139, 139], [234, 234], [100, 100], [119, 119], [87, 87], [145, 145]], "char_spans": [[939, 943], [803, 807], [1394, 1398], [562, 566], [674, 678], [476, 480], [842, 846]]}]}], "context_tokens": [["Circular", 0], ["RNAs", 9], ["(", 14], ["circRNAs", 15], [")", 23], ["are", 25], ["a", 29], ["class", 31], ["of", 37], ["newly", 40], ["-", 45], ["identified", 46], ["non", 57], ["-", 60], ["coding", 61], ["RNA", 68], ["molecules", 72], [".", 81], ["CircRNAs", 83], ["are", 92], ["conserved", 96], ["across", 106], ["different", 113], ["species", 123], ["and", 131], ["display", 135], ["specific", 143], ["organization", 152], [",", 164], ["sequence", 166], [",", 174], ["and", 176], ["expression", 180], ["in", 191], ["disease", 194], [".", 201], ["Moreover", 203], [",", 211], ["circRNAs", 213], ["'", 221], ["closed", 223], ["ring", 230], ["structure", 235], [",", 244], ["insensitivity", 246], ["to", 260], ["RNase", 263], [",", 268], ["and", 270], ["stability", 274], ["are", 284], ["advantages", 288], ["over", 299], ["linear", 304], ["RNAs", 311], ["in", 316], ["terms", 319], ["of", 325], ["development", 328], ["and", 340], ["application", 344], ["as", 356], ["a", 359], ["new", 361], ["kind", 365], ["of", 370], ["clinical", 373], ["marker", 382], [".", 388], ["In", 390], ["addition", 393], [",", 401], ["according", 403], ["to", 413], ["recent", 416], ["studies", 423], [",", 430], ["circular", 432], ["RNA-7", 441], ["(", 447], ["ciRS-7", 448], [")", 454], ["acts", 456], ["as", 461], ["a", 464], ["sponge", 466], ["of", 473], ["miR-7", 476], ["and", 482], ["thus", 486], ["inhibits", 491], ["its", 500], ["activity", 504], [".", 512], ["Numerous", 514], ["evidences", 523], ["have", 533], ["confirmed", 538], ["expression", 548], ["of", 559], ["miR-7", 562], ["is", 568], ["dysregulated", 571], ["in", 584], ["cancer", 587], ["tissues", 594], [",", 601], ["however", 603], [",", 610], ["whether", 612], ["ciRS-7", 620], ["invovled", 627], ["in", 636], ["oncogenesis", 639], ["by", 651], ["acting", 654], ["as", 661], ["sponge", 664], ["of", 671], ["miR-7", 674], ["remains", 680], ["unclear", 688], [".", 695], ["Most", 697], ["recently", 702], [",", 710], ["a", 712], ["study", 714], ["reported", 720], ["ciRS-7", 729], ["acted", 736], ["as", 742], ["an", 745], ["oncogene", 748], ["in", 757], ["hepatocellular", 760], ["carcinoma", 775], ["through", 785], ["targeting", 793], ["miR-7", 803], ["expression", 809], [".", 819], ["This", 821], ["suggest", 826], ["ciRS-7/", 834], ["miR-7", 842], ["axis", 848], ["affects", 853], ["oncogenesis", 861], [",", 872], ["and", 874], ["it", 878], ["provides", 881], ["a", 890], ["new", 892], ["perspective", 896], ["on", 908], ["the", 911], ["mechanisms", 915], ["of", 926], ["decreased", 929], ["miR-7", 939], ["expression", 945], ["in", 956], ["cancer", 959], ["tissues", 966], [".", 973], ["Discovery", 975], ["of", 985], ["sponge", 988], ["role", 995], ["of", 1000], ["circRNAs", 1003], ["caused", 1012], ["researchers", 1019], ["to", 1031], ["more", 1034], ["closely", 1039], ["explore", 1047], ["the", 1055], ["underlying", 1059], ["mechanism", 1070], ["of", 1080], ["carcinogenesis", 1083], ["and", 1098], ["has", 1102], ["significant", 1106], ["clinical", 1118], ["implications", 1127], [",", 1139], ["and", 1141], ["may", 1145], ["open", 1149], ["a", 1154], ["new", 1156], ["chapter", 1160], ["in", 1168], ["research", 1171], ["on", 1180], ["the", 1183], ["pathology", 1187], ["and", 1197], ["treatment", 1201], ["of", 1211], ["cancers", 1214], [".", 1221], ["This", 1223], ["review", 1228], ["summarizes", 1235], ["the", 1246], ["structure", 1250], ["and", 1260], ["function", 1264], ["of", 1273], ["circRNAs", 1276], ["and", 1285], ["provides", 1289], ["evidence", 1298], ["for", 1307], ["the", 1311], ["impact", 1315], ["of", 1322], ["ciRS-7", 1325], ["in", 1332], ["promoting", 1335], ["the", 1345], ["development", 1349], ["of", 1361], ["cancer", 1364], ["by", 1371], ["acting", 1374], ["as", 1381], ["sponge", 1384], ["of", 1391], ["miR-7", 1394], [".", 1399]]}
{"context": "A novel 135 kDa centrosomal component (Cep135) was identified by immunoscreening of a mammalian expression library with monoclonal antibodies raised against clam centrosomes. It is predicted to be a highly coiled-coil protein with an extensive alpha-helix, suggesting that Cep135 is a structural component of the centrosome. To evaluate how the protein is arranged in the centrosomal structure, we overexpressed Cep135 polypeptides in CHO cells by transient transfection. HA- or GFP-tagged full (amino acids 1-1144) as well as truncated (#10, 29-1144; Delta3, 29-812) polypeptides become localized at the centrosome and induce cytoplasmic dots of various size and number in CHO cells. Centrosomes are associated with massive approximately 7 nm filaments and dense particles organized in a whorl-like arrangement in which parallel-oriented dense lines appear with a regular approximately 7 nm periodicity. The same filamentous aggregates are also detected in cytoplasmic dots, indicating that overexpressed Cep135 can assemble into elaborate higher-ordered structures in and outside the centrosome. Sf9 cells infected with baculovirus containing Cep135 sequences induce filamentous polymers which are distinctive from the whorl seen in CHO cells; #10 forms highly packed spheroids, but the Delta3-containing structure looks loose. Both structures show an internal repeating unit of dense and less dense stripes. Although the distance between the outer end of two adjacent dense lines is similar between two types of polymers ( approximately 120 nm), the dense stripe of Delta3 polymers ( approximately 40 nm) is wider than #10 ( approximately 30 nm). The light band of Delta3 ( approximately 40 nm) is thus narrower than #10 ( approximately 60 nm). Since thin fibers are frequently seen to extend from one dense line to the next, the coiled-coil rod of Cep135 may span the light band. These results suggest that overexpressed Cep135 assemble into distinctive polymers in a domain-specific manner.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "62f547c5c52345068b263ed7bbd85032", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[190, 190], [53, 53], [114, 114]], "char_spans": [[1086, 1095], [313, 322], [605, 614]]}]}], "context_tokens": [["A", 0], ["novel", 2], ["135", 8], ["kDa", 12], ["centrosomal", 16], ["component", 28], ["(", 38], ["Cep135", 39], [")", 45], ["was", 47], ["identified", 51], ["by", 62], ["immunoscreening", 65], ["of", 81], ["a", 84], ["mammalian", 86], ["expression", 96], ["library", 107], ["with", 115], ["monoclonal", 120], ["antibodies", 131], ["raised", 142], ["against", 149], ["clam", 157], ["centrosomes", 162], [".", 173], ["It", 175], ["is", 178], ["predicted", 181], ["to", 191], ["be", 194], ["a", 197], ["highly", 199], ["coiled", 206], ["-", 212], ["coil", 213], ["protein", 218], ["with", 226], ["an", 231], ["extensive", 234], ["alpha", 244], ["-", 249], ["helix", 250], [",", 255], ["suggesting", 257], ["that", 268], ["Cep135", 273], ["is", 280], ["a", 283], ["structural", 285], ["component", 296], ["of", 306], ["the", 309], ["centrosome", 313], [".", 323], ["To", 325], ["evaluate", 328], ["how", 337], ["the", 341], ["protein", 345], ["is", 353], ["arranged", 356], ["in", 365], ["the", 368], ["centrosomal", 372], ["structure", 384], [",", 393], ["we", 395], ["overexpressed", 398], ["Cep135", 412], ["polypeptides", 419], ["in", 432], ["CHO", 435], ["cells", 439], ["by", 445], ["transient", 448], ["transfection", 458], [".", 470], ["HA-", 472], ["or", 476], ["GFP", 479], ["-", 482], ["tagged", 483], ["full", 490], ["(", 495], ["amino", 496], ["acids", 502], ["1", 508], ["-", 509], ["1144", 510], [")", 514], ["as", 516], ["well", 519], ["as", 524], ["truncated", 527], ["(", 537], ["#", 538], ["10", 539], [",", 541], ["29", 543], ["-", 545], ["1144", 546], [";", 550], ["Delta3", 552], [",", 558], ["29", 560], ["-", 562], ["812", 563], [")", 566], ["polypeptides", 568], ["become", 581], ["localized", 588], ["at", 598], ["the", 601], ["centrosome", 605], ["and", 616], ["induce", 620], ["cytoplasmic", 627], ["dots", 639], ["of", 644], ["various", 647], ["size", 655], ["and", 660], ["number", 664], ["in", 671], ["CHO", 674], ["cells", 678], [".", 683], ["Centrosomes", 685], ["are", 697], ["associated", 701], ["with", 712], ["massive", 717], ["approximately", 725], ["7", 739], ["nm", 741], ["filaments", 744], ["and", 754], ["dense", 758], ["particles", 764], ["organized", 774], ["in", 784], ["a", 787], ["whorl", 789], ["-", 794], ["like", 795], ["arrangement", 800], ["in", 812], ["which", 815], ["parallel", 821], ["-", 829], ["oriented", 830], ["dense", 839], ["lines", 845], ["appear", 851], ["with", 858], ["a", 863], ["regular", 865], ["approximately", 873], ["7", 887], ["nm", 889], ["periodicity", 892], [".", 903], ["The", 905], ["same", 909], ["filamentous", 914], ["aggregates", 926], ["are", 937], ["also", 941], ["detected", 946], ["in", 955], ["cytoplasmic", 958], ["dots", 970], [",", 974], ["indicating", 976], ["that", 987], ["overexpressed", 992], ["Cep135", 1006], ["can", 1013], ["assemble", 1017], ["into", 1026], ["elaborate", 1031], ["higher", 1041], ["-", 1047], ["ordered", 1048], ["structures", 1056], ["in", 1067], ["and", 1070], ["outside", 1074], ["the", 1082], ["centrosome", 1086], [".", 1096], ["Sf9", 1098], ["cells", 1102], ["infected", 1108], ["with", 1117], ["baculovirus", 1122], ["containing", 1134], ["Cep135", 1145], ["sequences", 1152], ["induce", 1162], ["filamentous", 1169], ["polymers", 1181], ["which", 1190], ["are", 1196], ["distinctive", 1200], ["from", 1212], ["the", 1217], ["whorl", 1221], ["seen", 1227], ["in", 1232], ["CHO", 1235], ["cells", 1239], [";", 1244], ["#", 1246], ["10", 1247], ["forms", 1250], ["highly", 1256], ["packed", 1263], ["spheroids", 1270], [",", 1279], ["but", 1281], ["the", 1285], ["Delta3-containing", 1289], ["structure", 1307], ["looks", 1317], ["loose", 1323], [".", 1328], ["Both", 1330], ["structures", 1335], ["show", 1346], ["an", 1351], ["internal", 1354], ["repeating", 1363], ["unit", 1373], ["of", 1378], ["dense", 1381], ["and", 1387], ["less", 1391], ["dense", 1396], ["stripes", 1402], [".", 1409], ["Although", 1411], ["the", 1420], ["distance", 1424], ["between", 1433], ["the", 1441], ["outer", 1445], ["end", 1451], ["of", 1455], ["two", 1458], ["adjacent", 1462], ["dense", 1471], ["lines", 1477], ["is", 1483], ["similar", 1486], ["between", 1494], ["two", 1502], ["types", 1506], ["of", 1512], ["polymers", 1515], ["(", 1524], ["approximately", 1526], ["120", 1540], ["nm", 1544], [")", 1546], [",", 1547], ["the", 1549], ["dense", 1553], ["stripe", 1559], ["of", 1566], ["Delta3", 1569], ["polymers", 1576], ["(", 1585], ["approximately", 1587], ["40", 1601], ["nm", 1604], [")", 1606], ["is", 1608], ["wider", 1611], ["than", 1617], ["#", 1622], ["10", 1623], ["(", 1626], ["approximately", 1628], ["30", 1642], ["nm", 1645], [")", 1647], [".", 1648], ["The", 1650], ["light", 1654], ["band", 1660], ["of", 1665], ["Delta3", 1668], ["(", 1675], ["approximately", 1677], ["40", 1691], ["nm", 1694], [")", 1696], ["is", 1698], ["thus", 1701], ["narrower", 1706], ["than", 1715], ["#", 1720], ["10", 1721], ["(", 1724], ["approximately", 1726], ["60", 1740], ["nm", 1743], [")", 1745], [".", 1746], ["Since", 1748], ["thin", 1754], ["fibers", 1759], ["are", 1766], ["frequently", 1770], ["seen", 1781], ["to", 1786], ["extend", 1789], ["from", 1796], ["one", 1801], ["dense", 1805], ["line", 1811], ["to", 1816], ["the", 1819], ["next", 1823], [",", 1827], ["the", 1829], ["coiled", 1833], ["-", 1839], ["coil", 1840], ["rod", 1845], ["of", 1849], ["Cep135", 1852], ["may", 1859], ["span", 1863], ["the", 1868], ["light", 1872], ["band", 1878], [".", 1882], ["These", 1884], ["results", 1890], ["suggest", 1898], ["that", 1906], ["overexpressed", 1911], ["Cep135", 1925], ["assemble", 1932], ["into", 1941], ["distinctive", 1946], ["polymers", 1958], ["in", 1967], ["a", 1970], ["domain", 1972], ["-", 1978], ["specific", 1979], ["manner", 1988], [".", 1994]]}
{"context": "Molecular abnormalities caused by the hybrid Bcr-Abl gene are causally associated with the development and progression of Philadelphia chromosome-positive (Ph(+)) chronic myelogenous leukemia (CML). Imatinib mesylate (STI571), a specific Bcr-Abl tyrosine-kinase signal-transduction inhibitor, has shown encouraging activity in phase I and II studies of CML. Here, we describe the use of imatinib mesylate to treat 75 patients in blast-phase CML (median age, 53 years; 65 with nonlymphoid and 10 with lymphoid blasts), and compare the results with those of a historical control group treated with standard cytarabine-based therapy. Imatinib mesylate was given as oral doses at 300 to 1000 mg per day and was the first salvage therapy for 47 patients. The objective response rate was 52% (39 of 75 patients: 16 had complete and 3 had partial hematologic response; 12 had hematologic improvement; 7 returned to second chronic phase; and 1 had a complete response in extramedullary blastic disease). Response rates were not different between nonlymphoid and lymphoid groups. The cytogenetic response rate was 16% (12 patients: 5 complete, 3 partial [Ph(+) below 35%], and 4 minor [Ph(+), 34% to 90%]). The estimated median overall survival was 6.5 months; the estimated 1-year survival was 22%. Response to therapy (landmark analysis at 8 weeks) was associated with survival prolongation. Compared with standard cytarabine combinations, imatinib mesylate therapy was less toxic and produced a higher response rate (55% versus 29%, P =.001), longer median survival (7 versus 4 months, P =.04), and lower 4-week induction mortality (4% versus 15%, P =.07). Imatinib mesylate is currently being tested in combination with other drugs to improve the prognosis for blast-phase CML.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "130270c72b1842a69ae47929d7075090", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[42, 44], [6, 8]], "char_spans": [[238, 244], [45, 51]]}]}], "context_tokens": [["Molecular", 0], ["abnormalities", 10], ["caused", 24], ["by", 31], ["the", 34], ["hybrid", 38], ["Bcr", 45], ["-", 48], ["Abl", 49], ["gene", 53], ["are", 58], ["causally", 62], ["associated", 71], ["with", 82], ["the", 87], ["development", 91], ["and", 103], ["progression", 107], ["of", 119], ["Philadelphia", 122], ["chromosome", 135], ["-", 145], ["positive", 146], ["(", 155], ["Ph(+", 156], [")", 160], [")", 161], ["chronic", 163], ["myelogenous", 171], ["leukemia", 183], ["(", 192], ["CML", 193], [")", 196], [".", 197], ["Imatinib", 199], ["mesylate", 208], ["(", 217], ["STI571", 218], [")", 224], [",", 225], ["a", 227], ["specific", 229], ["Bcr", 238], ["-", 241], ["Abl", 242], ["tyrosine", 246], ["-", 254], ["kinase", 255], ["signal", 262], ["-", 268], ["transduction", 269], ["inhibitor", 282], [",", 291], ["has", 293], ["shown", 297], ["encouraging", 303], ["activity", 315], ["in", 324], ["phase", 327], ["I", 333], ["and", 335], ["II", 339], ["studies", 342], ["of", 350], ["CML", 353], [".", 356], ["Here", 358], [",", 362], ["we", 364], ["describe", 367], ["the", 376], ["use", 380], ["of", 384], ["imatinib", 387], ["mesylate", 396], ["to", 405], ["treat", 408], ["75", 414], ["patients", 417], ["in", 426], ["blast", 429], ["-", 434], ["phase", 435], ["CML", 441], ["(", 445], ["median", 446], ["age", 453], [",", 456], ["53", 458], ["years", 461], [";", 466], ["65", 468], ["with", 471], ["nonlymphoid", 476], ["and", 488], ["10", 492], ["with", 495], ["lymphoid", 500], ["blasts", 509], [")", 515], [",", 516], ["and", 518], ["compare", 522], ["the", 530], ["results", 534], ["with", 542], ["those", 547], ["of", 553], ["a", 556], ["historical", 558], ["control", 569], ["group", 577], ["treated", 583], ["with", 591], ["standard", 596], ["cytarabine", 605], ["-", 615], ["based", 616], ["therapy", 622], [".", 629], ["Imatinib", 631], ["mesylate", 640], ["was", 649], ["given", 653], ["as", 659], ["oral", 662], ["doses", 667], ["at", 673], ["300", 676], ["to", 680], ["1000", 683], ["mg", 688], ["per", 691], ["day", 695], ["and", 699], ["was", 703], ["the", 707], ["first", 711], ["salvage", 717], ["therapy", 725], ["for", 733], ["47", 737], ["patients", 740], [".", 748], ["The", 750], ["objective", 754], ["response", 764], ["rate", 773], ["was", 778], ["52", 782], ["%", 784], ["(", 786], ["39", 787], ["of", 790], ["75", 793], ["patients", 796], [":", 804], ["16", 806], ["had", 809], ["complete", 813], ["and", 822], ["3", 826], ["had", 828], ["partial", 832], ["hematologic", 840], ["response", 852], [";", 860], ["12", 862], ["had", 865], ["hematologic", 869], ["improvement", 881], [";", 892], ["7", 894], ["returned", 896], ["to", 905], ["second", 908], ["chronic", 915], ["phase", 923], [";", 928], ["and", 930], ["1", 934], ["had", 936], ["a", 940], ["complete", 942], ["response", 951], ["in", 960], ["extramedullary", 963], ["blastic", 978], ["disease", 986], [")", 993], [".", 994], ["Response", 996], ["rates", 1005], ["were", 1011], ["not", 1016], ["different", 1020], ["between", 1030], ["nonlymphoid", 1038], ["and", 1050], ["lymphoid", 1054], ["groups", 1063], [".", 1069], ["The", 1071], ["cytogenetic", 1075], ["response", 1087], ["rate", 1096], ["was", 1101], ["16", 1105], ["%", 1107], ["(", 1109], ["12", 1110], ["patients", 1113], [":", 1121], ["5", 1123], ["complete", 1125], [",", 1133], ["3", 1135], ["partial", 1137], ["[", 1145], ["Ph(+", 1146], [")", 1150], ["below", 1152], ["35", 1158], ["%", 1160], ["]", 1161], [",", 1162], ["and", 1164], ["4", 1168], ["minor", 1170], ["[", 1176], ["Ph(+", 1177], [")", 1181], [",", 1182], ["34", 1184], ["%", 1186], ["to", 1188], ["90", 1191], ["%", 1193], ["]", 1194], [")", 1195], [".", 1196], ["The", 1198], ["estimated", 1202], ["median", 1212], ["overall", 1219], ["survival", 1227], ["was", 1236], ["6.5", 1240], ["months", 1244], [";", 1250], ["the", 1252], ["estimated", 1256], ["1-year", 1266], ["survival", 1273], ["was", 1282], ["22", 1286], ["%", 1288], [".", 1289], ["Response", 1291], ["to", 1300], ["therapy", 1303], ["(", 1311], ["landmark", 1312], ["analysis", 1321], ["at", 1330], ["8", 1333], ["weeks", 1335], [")", 1340], ["was", 1342], ["associated", 1346], ["with", 1357], ["survival", 1362], ["prolongation", 1371], [".", 1383], ["Compared", 1385], ["with", 1394], ["standard", 1399], ["cytarabine", 1408], ["combinations", 1419], [",", 1431], ["imatinib", 1433], ["mesylate", 1442], ["therapy", 1451], ["was", 1459], ["less", 1463], ["toxic", 1468], ["and", 1474], ["produced", 1478], ["a", 1487], ["higher", 1489], ["response", 1496], ["rate", 1505], ["(", 1510], ["55", 1511], ["%", 1513], ["versus", 1515], ["29", 1522], ["%", 1524], [",", 1525], ["P", 1527], ["=", 1529], [".001", 1530], [")", 1534], [",", 1535], ["longer", 1537], ["median", 1544], ["survival", 1551], ["(", 1560], ["7", 1561], ["versus", 1563], ["4", 1570], ["months", 1572], [",", 1578], ["P", 1580], ["=", 1582], [".04", 1583], [")", 1586], [",", 1587], ["and", 1589], ["lower", 1593], ["4-week", 1599], ["induction", 1606], ["mortality", 1616], ["(", 1626], ["4", 1627], ["%", 1628], ["versus", 1630], ["15", 1637], ["%", 1639], [",", 1640], ["P", 1642], ["=", 1644], [".07", 1645], [")", 1648], [".", 1649], ["Imatinib", 1651], ["mesylate", 1660], ["is", 1669], ["currently", 1672], ["being", 1682], ["tested", 1688], ["in", 1695], ["combination", 1698], ["with", 1710], ["other", 1715], ["drugs", 1721], ["to", 1727], ["improve", 1730], ["the", 1738], ["prognosis", 1742], ["for", 1752], ["blast", 1756], ["-", 1761], ["phase", 1762], ["CML", 1768], [".", 1771]]}
{"context": "Lewy bodies, neuropathological hallmarks of Parkinson's disease and dementia with Lewy bodies, comprise alpha-synuclein filaments and other less defined proteins. Characterization of Lewy body proteins that interact with alpha-synuclein may provide insight into the mechanism of Lewy body formation. Double immunofluorescence labeling and confocal microscopy revealed approximately 80% of cortical Lewy bodies contained microtubule-associated protein 1B (MAP-1B) that overlapped with alpha-synuclein. Lewy bodies were isolated using an immunomagnetic technique from brain tissue of patients dying with dementia with Lewy bodies. Lewy body proteins were resolved by polyacrylamide gel electrophoresis. Immunoblotting confirmed the presence of MAP-1B and alpha-synuclein in purified Lewy bodies. Direct binding studies revealed a high affinity interaction (IC(50) approximately 20 nm) between MAP-1B and alpha-synuclein. The MAP-1B-binding sites were mapped to the last 45 amino acids of the alpha-synuclein C terminus. MAP-1B also bound in vitro assembled alpha-synuclein fibrils. Thus, MAP-1B may be involved in the pathogenesis of Lewy bodies via its interaction with monomeric and fibrillar alpha-synuclein.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "61399ac72d9a4c4397aa7b80ee902d25", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[172, 174], [196, 198], [141, 143], [74, 76], [16, 18], [160, 162], [34, 36], [115, 117]], "char_spans": [[1055, 1069], [1193, 1207], [902, 916], [484, 498], [104, 118], [990, 1004], [221, 235], [753, 767]]}]}], "context_tokens": [["Lewy", 0], ["bodies", 5], [",", 11], ["neuropathological", 13], ["hallmarks", 31], ["of", 41], ["Parkinson", 44], ["'s", 53], ["disease", 56], ["and", 64], ["dementia", 68], ["with", 77], ["Lewy", 82], ["bodies", 87], [",", 93], ["comprise", 95], ["alpha", 104], ["-", 109], ["synuclein", 110], ["filaments", 120], ["and", 130], ["other", 134], ["less", 140], ["defined", 145], ["proteins", 153], [".", 161], ["Characterization", 163], ["of", 180], ["Lewy", 183], ["body", 188], ["proteins", 193], ["that", 202], ["interact", 207], ["with", 216], ["alpha", 221], ["-", 226], ["synuclein", 227], ["may", 237], ["provide", 241], ["insight", 249], ["into", 257], ["the", 262], ["mechanism", 266], ["of", 276], ["Lewy", 279], ["body", 284], ["formation", 289], [".", 298], ["Double", 300], ["immunofluorescence", 307], ["labeling", 326], ["and", 335], ["confocal", 339], ["microscopy", 348], ["revealed", 359], ["approximately", 368], ["80", 382], ["%", 384], ["of", 386], ["cortical", 389], ["Lewy", 398], ["bodies", 403], ["contained", 410], ["microtubule", 420], ["-", 431], ["associated", 432], ["protein", 443], ["1B", 451], ["(", 454], ["MAP-1B", 455], [")", 461], ["that", 463], ["overlapped", 468], ["with", 479], ["alpha", 484], ["-", 489], ["synuclein", 490], [".", 499], ["Lewy", 501], ["bodies", 506], ["were", 513], ["isolated", 518], ["using", 527], ["an", 533], ["immunomagnetic", 536], ["technique", 551], ["from", 561], ["brain", 566], ["tissue", 572], ["of", 579], ["patients", 582], ["dying", 591], ["with", 597], ["dementia", 602], ["with", 611], ["Lewy", 616], ["bodies", 621], [".", 627], ["Lewy", 629], ["body", 634], ["proteins", 639], ["were", 648], ["resolved", 653], ["by", 662], ["polyacrylamide", 665], ["gel", 680], ["electrophoresis", 684], [".", 699], ["Immunoblotting", 701], ["confirmed", 716], ["the", 726], ["presence", 730], ["of", 739], ["MAP-1B", 742], ["and", 749], ["alpha", 753], ["-", 758], ["synuclein", 759], ["in", 769], ["purified", 772], ["Lewy", 781], ["bodies", 786], [".", 792], ["Direct", 794], ["binding", 801], ["studies", 809], ["revealed", 817], ["a", 826], ["high", 828], ["affinity", 833], ["interaction", 842], ["(", 854], ["IC(50", 855], [")", 860], ["approximately", 862], ["20", 876], ["nm", 879], [")", 881], ["between", 883], ["MAP-1B", 891], ["and", 898], ["alpha", 902], ["-", 907], ["synuclein", 908], [".", 917], ["The", 919], ["MAP-1B", 923], ["-", 929], ["binding", 930], ["sites", 938], ["were", 944], ["mapped", 949], ["to", 956], ["the", 959], ["last", 963], ["45", 968], ["amino", 971], ["acids", 977], ["of", 983], ["the", 986], ["alpha", 990], ["-", 995], ["synuclein", 996], ["C", 1006], ["terminus", 1008], [".", 1016], ["MAP-1B", 1018], ["also", 1025], ["bound", 1030], ["in", 1036], ["vitro", 1039], ["assembled", 1045], ["alpha", 1055], ["-", 1060], ["synuclein", 1061], ["fibrils", 1071], [".", 1078], ["Thus", 1080], [",", 1084], ["MAP-1B", 1086], ["may", 1093], ["be", 1097], ["involved", 1100], ["in", 1109], ["the", 1112], ["pathogenesis", 1116], ["of", 1129], ["Lewy", 1132], ["bodies", 1137], ["via", 1144], ["its", 1148], ["interaction", 1152], ["with", 1164], ["monomeric", 1169], ["and", 1179], ["fibrillar", 1183], ["alpha", 1193], ["-", 1198], ["synuclein", 1199], [".", 1208]]}
{"context": "To evaluate the usefulness of the periportal free air (PPFA) sign on computed tomography (CT) to distinguish upper from lower gastrointestinal (GI) tract perforation. During a 30-month period, we retrospectively analyzed abdominal CT images of 53 consecutive patients with surgically proven GI tract perforation. We divided the patients into two groups, i.e. upper and lower GI tract perforation groups. According to the distribution of free air, we divided the peritoneal cavity into supramesocolic compartment and inframesocolic compartment. We observed the presence or absence of free air in each compartment in each group. When there was free air in the periportal area, it was defined as periportal free air (PPFA) and the sign was positive. To evaluate the usefulness of the PPFA sign, we compared the PPFA sign with the falciform ligament sign and the ligamentum teres sign, both of which are well-known CT signs of pneumoperitoneum. Statistical analyses were performed with univariate and multivariate analyses using SPSS version 11.5 for significant findings among the CT signs. Free air was seen in supramesocolic compartment in 29 of 30 (97%) patients in the upper GI perforation group and in 17 of 23 (74%) in the lower GI perforation group. Free air in inframesocolic compartment did not show significant difference in either group (p=.16). The PPFA sign was seen in 28 of 30 (93%) patients with upper GI tract perforation, but in only 8 of 23 (35%) patients with lower GI tract perforation (p<.0001). The falciform ligament sign was seen in 24 of 30 (80%) patients with upper GI tract perforation and in 10 of 23 (43%) patients with lower GI tract perforation (p=.020). The ligamentum teres sign was seen in 16 of 30 (53%) patients with upper GI tract perforation and in 2 of 23 (8%) patients with lower GI tract perforation (p=.008). Multivariate logistic regression analysis showed that the PPFA sign was the only variable, which adjusted odds ratio of 15.5 (p=.002). The PPFA sign is a useful finding which can help to distinguish upper from lower GI tract perforation. When this sign is present, upper GI tract perforation is strongly suggested.", "qas": [{"question": "Falciform ligament sign is characteristic to which disease?", "answers": ["pneumoperitoneum"], "qid": "7b02cb46d87c4b849e37b82396d1c3b0", "question_tokens": [["Falciform", 0], ["ligament", 10], ["sign", 19], ["is", 24], ["characteristic", 27], ["to", 42], ["which", 45], ["disease", 51], ["?", 58]], "detected_answers": [{"text": "pneumoperitoneum", "token_spans": [[167, 167]], "char_spans": [[923, 938]]}]}], "context_tokens": [["To", 0], ["evaluate", 3], ["the", 12], ["usefulness", 16], ["of", 27], ["the", 30], ["periportal", 34], ["free", 45], ["air", 50], ["(", 54], ["PPFA", 55], [")", 59], ["sign", 61], ["on", 66], ["computed", 69], ["tomography", 78], ["(", 89], ["CT", 90], [")", 92], ["to", 94], ["distinguish", 97], ["upper", 109], ["from", 115], ["lower", 120], ["gastrointestinal", 126], ["(", 143], ["GI", 144], [")", 146], ["tract", 148], ["perforation", 154], [".", 165], ["During", 167], ["a", 174], ["30-month", 176], ["period", 185], [",", 191], ["we", 193], ["retrospectively", 196], ["analyzed", 212], ["abdominal", 221], ["CT", 231], ["images", 234], ["of", 241], ["53", 244], ["consecutive", 247], ["patients", 259], ["with", 268], ["surgically", 273], ["proven", 284], ["GI", 291], ["tract", 294], ["perforation", 300], [".", 311], ["We", 313], ["divided", 316], ["the", 324], ["patients", 328], ["into", 337], ["two", 342], ["groups", 346], [",", 352], ["i.e.", 354], ["upper", 359], ["and", 365], ["lower", 369], ["GI", 375], ["tract", 378], ["perforation", 384], ["groups", 396], [".", 402], ["According", 404], ["to", 414], ["the", 417], ["distribution", 421], ["of", 434], ["free", 437], ["air", 442], [",", 445], ["we", 447], ["divided", 450], ["the", 458], ["peritoneal", 462], ["cavity", 473], ["into", 480], ["supramesocolic", 485], ["compartment", 500], ["and", 512], ["inframesocolic", 516], ["compartment", 531], [".", 542], ["We", 544], ["observed", 547], ["the", 556], ["presence", 560], ["or", 569], ["absence", 572], ["of", 580], ["free", 583], ["air", 588], ["in", 592], ["each", 595], ["compartment", 600], ["in", 612], ["each", 615], ["group", 620], [".", 625], ["When", 627], ["there", 632], ["was", 638], ["free", 642], ["air", 647], ["in", 651], ["the", 654], ["periportal", 658], ["area", 669], [",", 673], ["it", 675], ["was", 678], ["defined", 682], ["as", 690], ["periportal", 693], ["free", 704], ["air", 709], ["(", 713], ["PPFA", 714], [")", 718], ["and", 720], ["the", 724], ["sign", 728], ["was", 733], ["positive", 737], [".", 745], ["To", 747], ["evaluate", 750], ["the", 759], ["usefulness", 763], ["of", 774], ["the", 777], ["PPFA", 781], ["sign", 786], [",", 790], ["we", 792], ["compared", 795], ["the", 804], ["PPFA", 808], ["sign", 813], ["with", 818], ["the", 823], ["falciform", 827], ["ligament", 837], ["sign", 846], ["and", 851], ["the", 855], ["ligamentum", 859], ["teres", 870], ["sign", 876], [",", 880], ["both", 882], ["of", 887], ["which", 890], ["are", 896], ["well", 900], ["-", 904], ["known", 905], ["CT", 911], ["signs", 914], ["of", 920], ["pneumoperitoneum", 923], [".", 939], ["Statistical", 941], ["analyses", 953], ["were", 962], ["performed", 967], ["with", 977], ["univariate", 982], ["and", 993], ["multivariate", 997], ["analyses", 1010], ["using", 1019], ["SPSS", 1025], ["version", 1030], ["11.5", 1038], ["for", 1043], ["significant", 1047], ["findings", 1059], ["among", 1068], ["the", 1074], ["CT", 1078], ["signs", 1081], [".", 1086], ["Free", 1088], ["air", 1093], ["was", 1097], ["seen", 1101], ["in", 1106], ["supramesocolic", 1109], ["compartment", 1124], ["in", 1136], ["29", 1139], ["of", 1142], ["30", 1145], ["(", 1148], ["97", 1149], ["%", 1151], [")", 1152], ["patients", 1154], ["in", 1163], ["the", 1166], ["upper", 1170], ["GI", 1176], ["perforation", 1179], ["group", 1191], ["and", 1197], ["in", 1201], ["17", 1204], ["of", 1207], ["23", 1210], ["(", 1213], ["74", 1214], ["%", 1216], [")", 1217], ["in", 1219], ["the", 1222], ["lower", 1226], ["GI", 1232], ["perforation", 1235], ["group", 1247], [".", 1252], ["Free", 1254], ["air", 1259], ["in", 1263], ["inframesocolic", 1266], ["compartment", 1281], ["did", 1293], ["not", 1297], ["show", 1301], ["significant", 1306], ["difference", 1318], ["in", 1329], ["either", 1332], ["group", 1339], ["(", 1345], ["p=.16", 1346], [")", 1351], [".", 1352], ["The", 1354], ["PPFA", 1358], ["sign", 1363], ["was", 1368], ["seen", 1372], ["in", 1377], ["28", 1380], ["of", 1383], ["30", 1386], ["(", 1389], ["93", 1390], ["%", 1392], [")", 1393], ["patients", 1395], ["with", 1404], ["upper", 1409], ["GI", 1415], ["tract", 1418], ["perforation", 1424], [",", 1435], ["but", 1437], ["in", 1441], ["only", 1444], ["8", 1449], ["of", 1451], ["23", 1454], ["(", 1457], ["35", 1458], ["%", 1460], [")", 1461], ["patients", 1463], ["with", 1472], ["lower", 1477], ["GI", 1483], ["tract", 1486], ["perforation", 1492], ["(", 1504], ["p<.0001", 1505], [")", 1512], [".", 1513], ["The", 1515], ["falciform", 1519], ["ligament", 1529], ["sign", 1538], ["was", 1543], ["seen", 1547], ["in", 1552], ["24", 1555], ["of", 1558], ["30", 1561], ["(", 1564], ["80", 1565], ["%", 1567], [")", 1568], ["patients", 1570], ["with", 1579], ["upper", 1584], ["GI", 1590], ["tract", 1593], ["perforation", 1599], ["and", 1611], ["in", 1615], ["10", 1618], ["of", 1621], ["23", 1624], ["(", 1627], ["43", 1628], ["%", 1630], [")", 1631], ["patients", 1633], ["with", 1642], ["lower", 1647], ["GI", 1653], ["tract", 1656], ["perforation", 1662], ["(", 1674], ["p=.020", 1675], [")", 1681], [".", 1682], ["The", 1684], ["ligamentum", 1688], ["teres", 1699], ["sign", 1705], ["was", 1710], ["seen", 1714], ["in", 1719], ["16", 1722], ["of", 1725], ["30", 1728], ["(", 1731], ["53", 1732], ["%", 1734], [")", 1735], ["patients", 1737], ["with", 1746], ["upper", 1751], ["GI", 1757], ["tract", 1760], ["perforation", 1766], ["and", 1778], ["in", 1782], ["2", 1785], ["of", 1787], ["23", 1790], ["(", 1793], ["8", 1794], ["%", 1795], [")", 1796], ["patients", 1798], ["with", 1807], ["lower", 1812], ["GI", 1818], ["tract", 1821], ["perforation", 1827], ["(", 1839], ["p=.008", 1840], [")", 1846], [".", 1847], ["Multivariate", 1849], ["logistic", 1862], ["regression", 1871], ["analysis", 1882], ["showed", 1891], ["that", 1898], ["the", 1903], ["PPFA", 1907], ["sign", 1912], ["was", 1917], ["the", 1921], ["only", 1925], ["variable", 1930], [",", 1938], ["which", 1940], ["adjusted", 1946], ["odds", 1955], ["ratio", 1960], ["of", 1966], ["15.5", 1969], ["(", 1974], ["p=.002", 1975], [")", 1981], [".", 1982], ["The", 1984], ["PPFA", 1988], ["sign", 1993], ["is", 1998], ["a", 2001], ["useful", 2003], ["finding", 2010], ["which", 2018], ["can", 2024], ["help", 2028], ["to", 2033], ["distinguish", 2036], ["upper", 2048], ["from", 2054], ["lower", 2059], ["GI", 2065], ["tract", 2068], ["perforation", 2074], [".", 2085], ["When", 2087], ["this", 2092], ["sign", 2097], ["is", 2102], ["present", 2105], [",", 2112], ["upper", 2114], ["GI", 2120], ["tract", 2123], ["perforation", 2129], ["is", 2141], ["strongly", 2144], ["suggested", 2153], [".", 2162]]}
{"context": "Puffy hand syndrome is an unrecognized complication of intravenous drug abuse. This painless syndrome appears during or after a long period of drug addiction. It involves the hands and sometimes the forearms, and may cause functional, aesthetic and social disturbances when the hand volume is important. Physiopathological mechanisms of the puffy hand syndrome are unclear and include venous and lymphatic insufficiencies, infectious complications and direct toxicity of injected drugs and their adulterants. Low-stretch bandage and elastic garment, usually used in lymphedema treatment, are proposed to treat the puffy hand syndrome.", "qas": [{"question": "What causes \"Puffy hand syndrome\"?", "answers": ["intravenous drug abuse"], "qid": "da08626bddab419dbddfc38db2657996", "question_tokens": [["What", 0], ["causes", 5], ["\"", 12], ["Puffy", 13], ["hand", 19], ["syndrome", 24], ["\"", 32], ["?", 33]], "detected_answers": [{"text": "intravenous drug abuse", "token_spans": [[8, 10]], "char_spans": [[55, 76]]}]}], "context_tokens": [["Puffy", 0], ["hand", 6], ["syndrome", 11], ["is", 20], ["an", 23], ["unrecognized", 26], ["complication", 39], ["of", 52], ["intravenous", 55], ["drug", 67], ["abuse", 72], [".", 77], ["This", 79], ["painless", 84], ["syndrome", 93], ["appears", 102], ["during", 110], ["or", 117], ["after", 120], ["a", 126], ["long", 128], ["period", 133], ["of", 140], ["drug", 143], ["addiction", 148], [".", 157], ["It", 159], ["involves", 162], ["the", 171], ["hands", 175], ["and", 181], ["sometimes", 185], ["the", 195], ["forearms", 199], [",", 207], ["and", 209], ["may", 213], ["cause", 217], ["functional", 223], [",", 233], ["aesthetic", 235], ["and", 245], ["social", 249], ["disturbances", 256], ["when", 269], ["the", 274], ["hand", 278], ["volume", 283], ["is", 290], ["important", 293], [".", 302], ["Physiopathological", 304], ["mechanisms", 323], ["of", 334], ["the", 337], ["puffy", 341], ["hand", 347], ["syndrome", 352], ["are", 361], ["unclear", 365], ["and", 373], ["include", 377], ["venous", 385], ["and", 392], ["lymphatic", 396], ["insufficiencies", 406], [",", 421], ["infectious", 423], ["complications", 434], ["and", 448], ["direct", 452], ["toxicity", 459], ["of", 468], ["injected", 471], ["drugs", 480], ["and", 486], ["their", 490], ["adulterants", 496], [".", 507], ["Low", 509], ["-", 512], ["stretch", 513], ["bandage", 521], ["and", 529], ["elastic", 533], ["garment", 541], [",", 548], ["usually", 550], ["used", 558], ["in", 563], ["lymphedema", 566], ["treatment", 577], [",", 586], ["are", 588], ["proposed", 592], ["to", 601], ["treat", 604], ["the", 610], ["puffy", 614], ["hand", 620], ["syndrome", 625], [".", 633]]}
{"context": "alpha-Synuclein and ubiquitin are two Lewy body protein components that may play antagonistic roles in the pathogenesis of Lewy bodies. We examined the relationship between alpha-synuclein, ubiquitin, and lipids in Lewy bodies of fixed brain sections or isolated from cortical tissues of dementia with Lewy bodies. Lewy bodies exhibited a range of labeling patterns for alpha-synuclein and ubiquitin, from a homogeneous pattern in which alpha-synuclein and ubiquitin were evenly distributed and overlapped across the inclusion body to a concentric pattern in which alpha-synuclein and ubiquitin were partially segregated, with alpha-synuclein labeling concentrated in the peripheral domain and ubiquitin in the central domain of the Lewy body. Lipids represented a significant component in both homogeneous and concentric Lewy bodies. These results suggest that Lewy bodies are heterogeneous in their subregional composition. The segregation of alpha-synuclein to Lewy body peripheral domain is consistent with the hypothesis that alpha-synuclein is continually deposited onto Lewy bodies.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "84268ced61744024a40b6f8d2316d275", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[63, 65], [28, 30], [154, 156], [168, 170], [95, 97], [105, 107], [0, 2], [75, 77]], "char_spans": [[370, 384], [173, 187], [945, 959], [1031, 1045], [565, 579], [627, 641], [0, 14], [437, 451]]}]}], "context_tokens": [["alpha", 0], ["-", 5], ["Synuclein", 6], ["and", 16], ["ubiquitin", 20], ["are", 30], ["two", 34], ["Lewy", 38], ["body", 43], ["protein", 48], ["components", 56], ["that", 67], ["may", 72], ["play", 76], ["antagonistic", 81], ["roles", 94], ["in", 100], ["the", 103], ["pathogenesis", 107], ["of", 120], ["Lewy", 123], ["bodies", 128], [".", 134], ["We", 136], ["examined", 139], ["the", 148], ["relationship", 152], ["between", 165], ["alpha", 173], ["-", 178], ["synuclein", 179], [",", 188], ["ubiquitin", 190], [",", 199], ["and", 201], ["lipids", 205], ["in", 212], ["Lewy", 215], ["bodies", 220], ["of", 227], ["fixed", 230], ["brain", 236], ["sections", 242], ["or", 251], ["isolated", 254], ["from", 263], ["cortical", 268], ["tissues", 277], ["of", 285], ["dementia", 288], ["with", 297], ["Lewy", 302], ["bodies", 307], [".", 313], ["Lewy", 315], ["bodies", 320], ["exhibited", 327], ["a", 337], ["range", 339], ["of", 345], ["labeling", 348], ["patterns", 357], ["for", 366], ["alpha", 370], ["-", 375], ["synuclein", 376], ["and", 386], ["ubiquitin", 390], [",", 399], ["from", 401], ["a", 406], ["homogeneous", 408], ["pattern", 420], ["in", 428], ["which", 431], ["alpha", 437], ["-", 442], ["synuclein", 443], ["and", 453], ["ubiquitin", 457], ["were", 467], ["evenly", 472], ["distributed", 479], ["and", 491], ["overlapped", 495], ["across", 506], ["the", 513], ["inclusion", 517], ["body", 527], ["to", 532], ["a", 535], ["concentric", 537], ["pattern", 548], ["in", 556], ["which", 559], ["alpha", 565], ["-", 570], ["synuclein", 571], ["and", 581], ["ubiquitin", 585], ["were", 595], ["partially", 600], ["segregated", 610], [",", 620], ["with", 622], ["alpha", 627], ["-", 632], ["synuclein", 633], ["labeling", 643], ["concentrated", 652], ["in", 665], ["the", 668], ["peripheral", 672], ["domain", 683], ["and", 690], ["ubiquitin", 694], ["in", 704], ["the", 707], ["central", 711], ["domain", 719], ["of", 726], ["the", 729], ["Lewy", 733], ["body", 738], [".", 742], ["Lipids", 744], ["represented", 751], ["a", 763], ["significant", 765], ["component", 777], ["in", 787], ["both", 790], ["homogeneous", 795], ["and", 807], ["concentric", 811], ["Lewy", 822], ["bodies", 827], [".", 833], ["These", 835], ["results", 841], ["suggest", 849], ["that", 857], ["Lewy", 862], ["bodies", 867], ["are", 874], ["heterogeneous", 878], ["in", 892], ["their", 895], ["subregional", 901], ["composition", 913], [".", 924], ["The", 926], ["segregation", 930], ["of", 942], ["alpha", 945], ["-", 950], ["synuclein", 951], ["to", 961], ["Lewy", 964], ["body", 969], ["peripheral", 974], ["domain", 985], ["is", 992], ["consistent", 995], ["with", 1006], ["the", 1011], ["hypothesis", 1015], ["that", 1026], ["alpha", 1031], ["-", 1036], ["synuclein", 1037], ["is", 1047], ["continually", 1050], ["deposited", 1062], ["onto", 1072], ["Lewy", 1077], ["bodies", 1082], [".", 1088]]}
{"context": "Oxidative stress activates the c-Jun N-terminal kinase (JNK) pathway. However, the exact mechanisms by which reactive oxygen species (ROS) activate JNK are unclear. We found that the ability of hydrogen peroxide (H(2)O(2)) to induce JNK activation varied in different cell types. Pyrrolidine dithiocarbamate (PDTC), a presumed antioxidant, induced JNK activation on its own and enhanced JNK activation by H(2)O(2) in many cell types, including Jurkat, HEK293, and LNCaP and Tsu-Pr1 prostate cancer cells. The activation of JNK by PDTC, in the presence or absence of exogenous H(2)O(2), was dependent on its chelating ability to metal ions, most likely copper ions. Despite the strong JNK-activating ability, H(2)O(2) plus PDTC did not induce significant activation of the upstream kinases, SEK1/MKK4 and MKK7. However, the JNK inactivation rate was slower in cells treated with H(2)O(2) plus PDTC compared with the rate in cells treated with ultraviolet C (UV-C). Treatment of H(2)O(2) plus PDTC significantly decreased the expression levels of a JNK phosphatase, M3/6 (also named hVH-5), but not the levels of other phosphatases (PP2A and PP4). In contrast, UV-C irradiation did not cause the down-regulation of M3/6. These results suggest that JNK activation by H(2)O(2) plus PDTC resulted from the down-regulation of JNK phosphatases. Our data also reveal a necessity to carefully evaluate the pharmacological and biochemical properties of PDTC.", "qas": [{"question": "Which protein is affected by dusp8 activation?", "answers": ["JNK"], "qid": "c5027f2833494601b4a79b125f0210f2", "question_tokens": [["Which", 0], ["protein", 6], ["is", 14], ["affected", 17], ["by", 26], ["dusp8", 29], ["activation", 35], ["?", 45]], "detected_answers": [{"text": "JNK", "token_spans": [[48, 48], [160, 160], [67, 67], [74, 74], [102, 102], [134, 134], [202, 202], [12, 12], [246, 246], [260, 260], [30, 30]], "char_spans": [[233, 235], [823, 825], [348, 350], [387, 389], [523, 525], [684, 686], [1047, 1049], [56, 58], [1246, 1248], [1320, 1322], [148, 150]]}]}], "context_tokens": [["Oxidative", 0], ["stress", 10], ["activates", 17], ["the", 27], ["c", 31], ["-", 32], ["Jun", 33], ["N", 37], ["-", 38], ["terminal", 39], ["kinase", 48], ["(", 55], ["JNK", 56], [")", 59], ["pathway", 61], [".", 68], ["However", 70], [",", 77], ["the", 79], ["exact", 83], ["mechanisms", 89], ["by", 100], ["which", 103], ["reactive", 109], ["oxygen", 118], ["species", 125], ["(", 133], ["ROS", 134], [")", 137], ["activate", 139], ["JNK", 148], ["are", 152], ["unclear", 156], [".", 163], ["We", 165], ["found", 168], ["that", 174], ["the", 179], ["ability", 183], ["of", 191], ["hydrogen", 194], ["peroxide", 203], ["(", 212], ["H(2)O(2", 213], [")", 220], [")", 221], ["to", 223], ["induce", 226], ["JNK", 233], ["activation", 237], ["varied", 248], ["in", 255], ["different", 258], ["cell", 268], ["types", 273], [".", 278], ["Pyrrolidine", 280], ["dithiocarbamate", 292], ["(", 308], ["PDTC", 309], [")", 313], [",", 314], ["a", 316], ["presumed", 318], ["antioxidant", 327], [",", 338], ["induced", 340], ["JNK", 348], ["activation", 352], ["on", 363], ["its", 366], ["own", 370], ["and", 374], ["enhanced", 378], ["JNK", 387], ["activation", 391], ["by", 402], ["H(2)O(2", 405], [")", 412], ["in", 414], ["many", 417], ["cell", 422], ["types", 427], [",", 432], ["including", 434], ["Jurkat", 444], [",", 450], ["HEK293", 452], [",", 458], ["and", 460], ["LNCaP", 464], ["and", 470], ["Tsu", 474], ["-", 477], ["Pr1", 478], ["prostate", 482], ["cancer", 491], ["cells", 498], [".", 503], ["The", 505], ["activation", 509], ["of", 520], ["JNK", 523], ["by", 527], ["PDTC", 530], [",", 534], ["in", 536], ["the", 539], ["presence", 543], ["or", 552], ["absence", 555], ["of", 563], ["exogenous", 566], ["H(2)O(2", 576], [")", 583], [",", 584], ["was", 586], ["dependent", 590], ["on", 600], ["its", 603], ["chelating", 607], ["ability", 617], ["to", 625], ["metal", 628], ["ions", 634], [",", 638], ["most", 640], ["likely", 645], ["copper", 652], ["ions", 659], [".", 663], ["Despite", 665], ["the", 673], ["strong", 677], ["JNK", 684], ["-", 687], ["activating", 688], ["ability", 699], [",", 706], ["H(2)O(2", 708], [")", 715], ["plus", 717], ["PDTC", 722], ["did", 727], ["not", 731], ["induce", 735], ["significant", 742], ["activation", 754], ["of", 765], ["the", 768], ["upstream", 772], ["kinases", 781], [",", 788], ["SEK1/MKK4", 790], ["and", 800], ["MKK7", 804], [".", 808], ["However", 810], [",", 817], ["the", 819], ["JNK", 823], ["inactivation", 827], ["rate", 840], ["was", 845], ["slower", 849], ["in", 856], ["cells", 859], ["treated", 865], ["with", 873], ["H(2)O(2", 878], [")", 885], ["plus", 887], ["PDTC", 892], ["compared", 897], ["with", 906], ["the", 911], ["rate", 915], ["in", 920], ["cells", 923], ["treated", 929], ["with", 937], ["ultraviolet", 942], ["C", 954], ["(", 956], ["UV", 957], ["-", 959], ["C", 960], [")", 961], [".", 962], ["Treatment", 964], ["of", 974], ["H(2)O(2", 977], [")", 984], ["plus", 986], ["PDTC", 991], ["significantly", 996], ["decreased", 1010], ["the", 1020], ["expression", 1024], ["levels", 1035], ["of", 1042], ["a", 1045], ["JNK", 1047], ["phosphatase", 1051], [",", 1062], ["M3/6", 1064], ["(", 1069], ["also", 1070], ["named", 1075], ["hVH-5", 1081], [")", 1086], [",", 1087], ["but", 1089], ["not", 1093], ["the", 1097], ["levels", 1101], ["of", 1108], ["other", 1111], ["phosphatases", 1117], ["(", 1130], ["PP2A", 1131], ["and", 1136], ["PP4", 1140], [")", 1143], [".", 1144], ["In", 1146], ["contrast", 1149], [",", 1157], ["UV", 1159], ["-", 1161], ["C", 1162], ["irradiation", 1164], ["did", 1176], ["not", 1180], ["cause", 1184], ["the", 1190], ["down", 1194], ["-", 1198], ["regulation", 1199], ["of", 1210], ["M3/6", 1213], [".", 1217], ["These", 1219], ["results", 1225], ["suggest", 1233], ["that", 1241], ["JNK", 1246], ["activation", 1250], ["by", 1261], ["H(2)O(2", 1264], [")", 1271], ["plus", 1273], ["PDTC", 1278], ["resulted", 1283], ["from", 1292], ["the", 1297], ["down", 1301], ["-", 1305], ["regulation", 1306], ["of", 1317], ["JNK", 1320], ["phosphatases", 1324], [".", 1336], ["Our", 1338], ["data", 1342], ["also", 1347], ["reveal", 1352], ["a", 1359], ["necessity", 1361], ["to", 1371], ["carefully", 1374], ["evaluate", 1384], ["the", 1393], ["pharmacological", 1397], ["and", 1413], ["biochemical", 1417], ["properties", 1429], ["of", 1440], ["PDTC", 1443], [".", 1447]]}
{"context": "Restless legs syndrome (RLS), also known as Willis-Ekbom disease, is a sensory-motor neurological disorder with a circadian component. RLS is characterized by uncomfortable sensations in the extremities, generally at night or during sleep, which often leads to an uncontrollable urge to move them for relief. Recently, genomic studies identified single-nucleotide polymorphisms in BTBD9, along with three other genes, as being associated with a higher risk of RLS. Little is known about the function of BTBD9 or its potential role in the pathophysiology of RLS. We therefore examined a line of Btbd9 mutant mice we recently generated for phenotypes similar to symptoms found in RLS patients. We observed that the Btbd9 mutant mice had motor restlessness, sensory alterations likely limited to the rest phase, and decreased sleep and increased wake times during the rest phase. Additionally, the Btbd9 mutant mice had altered serum iron levels and monoamine neurotransmitter systems. Furthermore, the sensory alterations in the Btbd9 mutant mice were relieved using ropinirole, a dopaminergic agonist widely used for RLS treatment. These results, taken together, suggest that the Btbd9 mutant mice model several characteristics similar to RLS and would therefore be the first genotypic mouse model of RLS. Furthermore, our data provide further evidence that BTBD9 is involved in RLS, and future studies of the Btbd9 mutant mice will help shine light on its role in the pathophysiology of RLS. Finally, our data argue for the utility of Btbd9 mutant mice to discover and screen novel therapeutics for RLS.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "79688e5fa4ba4c6f87957928ba8c86f4", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], [",", 28], ["also", 30], ["known", 35], ["as", 41], ["Willis", 44], ["-", 50], ["Ekbom", 51], ["disease", 57], [",", 64], ["is", 66], ["a", 69], ["sensory", 71], ["-", 78], ["motor", 79], ["neurological", 85], ["disorder", 98], ["with", 107], ["a", 112], ["circadian", 114], ["component", 124], [".", 133], ["RLS", 135], ["is", 139], ["characterized", 142], ["by", 156], ["uncomfortable", 159], ["sensations", 173], ["in", 184], ["the", 187], ["extremities", 191], [",", 202], ["generally", 204], ["at", 214], ["night", 217], ["or", 223], ["during", 226], ["sleep", 233], [",", 238], ["which", 240], ["often", 246], ["leads", 252], ["to", 258], ["an", 261], ["uncontrollable", 264], ["urge", 279], ["to", 284], ["move", 287], ["them", 292], ["for", 297], ["relief", 301], [".", 307], ["Recently", 309], [",", 317], ["genomic", 319], ["studies", 327], ["identified", 335], ["single", 346], ["-", 352], ["nucleotide", 353], ["polymorphisms", 364], ["in", 378], ["BTBD9", 381], [",", 386], ["along", 388], ["with", 394], ["three", 399], ["other", 405], ["genes", 411], [",", 416], ["as", 418], ["being", 421], ["associated", 427], ["with", 438], ["a", 443], ["higher", 445], ["risk", 452], ["of", 457], ["RLS", 460], [".", 463], ["Little", 465], ["is", 472], ["known", 475], ["about", 481], ["the", 487], ["function", 491], ["of", 500], ["BTBD9", 503], ["or", 509], ["its", 512], ["potential", 516], ["role", 526], ["in", 531], ["the", 534], ["pathophysiology", 538], ["of", 554], ["RLS", 557], [".", 560], ["We", 562], ["therefore", 565], ["examined", 575], ["a", 584], ["line", 586], ["of", 591], ["Btbd9", 594], ["mutant", 600], ["mice", 607], ["we", 612], ["recently", 615], ["generated", 624], ["for", 634], ["phenotypes", 638], ["similar", 649], ["to", 657], ["symptoms", 660], ["found", 669], ["in", 675], ["RLS", 678], ["patients", 682], [".", 690], ["We", 692], ["observed", 695], ["that", 704], ["the", 709], ["Btbd9", 713], ["mutant", 719], ["mice", 726], ["had", 731], ["motor", 735], ["restlessness", 741], [",", 753], ["sensory", 755], ["alterations", 763], ["likely", 775], ["limited", 782], ["to", 790], ["the", 793], ["rest", 797], ["phase", 802], [",", 807], ["and", 809], ["decreased", 813], ["sleep", 823], ["and", 829], ["increased", 833], ["wake", 843], ["times", 848], ["during", 854], ["the", 861], ["rest", 865], ["phase", 870], [".", 875], ["Additionally", 877], [",", 889], ["the", 891], ["Btbd9", 895], ["mutant", 901], ["mice", 908], ["had", 913], ["altered", 917], ["serum", 925], ["iron", 931], ["levels", 936], ["and", 943], ["monoamine", 947], ["neurotransmitter", 957], ["systems", 974], [".", 981], ["Furthermore", 983], [",", 994], ["the", 996], ["sensory", 1000], ["alterations", 1008], ["in", 1020], ["the", 1023], ["Btbd9", 1027], ["mutant", 1033], ["mice", 1040], ["were", 1045], ["relieved", 1050], ["using", 1059], ["ropinirole", 1065], [",", 1075], ["a", 1077], ["dopaminergic", 1079], ["agonist", 1092], ["widely", 1100], ["used", 1107], ["for", 1112], ["RLS", 1116], ["treatment", 1120], [".", 1129], ["These", 1131], ["results", 1137], [",", 1144], ["taken", 1146], ["together", 1152], [",", 1160], ["suggest", 1162], ["that", 1170], ["the", 1175], ["Btbd9", 1179], ["mutant", 1185], ["mice", 1192], ["model", 1197], ["several", 1203], ["characteristics", 1211], ["similar", 1227], ["to", 1235], ["RLS", 1238], ["and", 1242], ["would", 1246], ["therefore", 1252], ["be", 1262], ["the", 1265], ["first", 1269], ["genotypic", 1275], ["mouse", 1285], ["model", 1291], ["of", 1297], ["RLS", 1300], [".", 1303], ["Furthermore", 1305], [",", 1316], ["our", 1318], ["data", 1322], ["provide", 1327], ["further", 1335], ["evidence", 1343], ["that", 1352], ["BTBD9", 1357], ["is", 1363], ["involved", 1366], ["in", 1375], ["RLS", 1378], [",", 1381], ["and", 1383], ["future", 1387], ["studies", 1394], ["of", 1402], ["the", 1405], ["Btbd9", 1409], ["mutant", 1415], ["mice", 1422], ["will", 1427], ["help", 1432], ["shine", 1437], ["light", 1443], ["on", 1449], ["its", 1452], ["role", 1456], ["in", 1461], ["the", 1464], ["pathophysiology", 1468], ["of", 1484], ["RLS", 1487], [".", 1490], ["Finally", 1492], [",", 1499], ["our", 1501], ["data", 1505], ["argue", 1510], ["for", 1516], ["the", 1520], ["utility", 1524], ["of", 1532], ["Btbd9", 1535], ["mutant", 1541], ["mice", 1548], ["to", 1553], ["discover", 1556], ["and", 1565], ["screen", 1569], ["novel", 1576], ["therapeutics", 1582], ["for", 1595], ["RLS", 1599], [".", 1602]]}
{"context": "The development of novel oral anticoagulants (NOACs) has revolutionized oral anticoagulation. Rapid incorporation of NOACs into general practice has heightened the demand for directed reversal agents. Idarucizumab is a targeted reversal agent that is approved for the urgent reversal of the anticoagulant effects of dabigatran. While it is a welcome addition to reversal strategies of dabigatran, a number of clinical questions exist regarding its place in therapy. We describe controversies regarding the use of idarucizumab therapy in patients with dabigatran-associated bleeding. Although existing clinical studies show a rapid reversal of coagulation assays, these studies did not describe a corresponding improvement in mortality or rapid cessation of hemorrhage. It is questionable how heavily clinicians can rely upon the use of the surrogate endpoints in clinical studies, such as ecarin clotting time and dilute thrombin time. Another issue is whether patients exhibiting re-elevation of coagulation assays would benefit from an additional dose of idarucizumab, because this has not been studied. It is currently unclear if blood products must be given in addition to idarucizumab can be used as monotherapy. The initial data suggest a definite role for idarucizumab in treatment of bleeding associated with dabigatran. As more clinical practice experience is gained with the agent and the remaining data on its use are released, clinicians can better guide the clinical use of idarucizumab. At present, there is currently not enough evidence for idarucizumab to be used as monotherapy.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "dc40f38b59fd40f9bfc5fdd3040d8e0c", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[60, 60], [48, 48], [211, 211], [86, 86]], "char_spans": [[385, 394], [316, 325], [1317, 1326], [551, 560]]}]}], "context_tokens": [["The", 0], ["development", 4], ["of", 16], ["novel", 19], ["oral", 25], ["anticoagulants", 30], ["(", 45], ["NOACs", 46], [")", 51], ["has", 53], ["revolutionized", 57], ["oral", 72], ["anticoagulation", 77], [".", 92], ["Rapid", 94], ["incorporation", 100], ["of", 114], ["NOACs", 117], ["into", 123], ["general", 128], ["practice", 136], ["has", 145], ["heightened", 149], ["the", 160], ["demand", 164], ["for", 171], ["directed", 175], ["reversal", 184], ["agents", 193], [".", 199], ["Idarucizumab", 201], ["is", 214], ["a", 217], ["targeted", 219], ["reversal", 228], ["agent", 237], ["that", 243], ["is", 248], ["approved", 251], ["for", 260], ["the", 264], ["urgent", 268], ["reversal", 275], ["of", 284], ["the", 287], ["anticoagulant", 291], ["effects", 305], ["of", 313], ["dabigatran", 316], [".", 326], ["While", 328], ["it", 334], ["is", 337], ["a", 340], ["welcome", 342], ["addition", 350], ["to", 359], ["reversal", 362], ["strategies", 371], ["of", 382], ["dabigatran", 385], [",", 395], ["a", 397], ["number", 399], ["of", 406], ["clinical", 409], ["questions", 418], ["exist", 428], ["regarding", 434], ["its", 444], ["place", 448], ["in", 454], ["therapy", 457], [".", 464], ["We", 466], ["describe", 469], ["controversies", 478], ["regarding", 492], ["the", 502], ["use", 506], ["of", 510], ["idarucizumab", 513], ["therapy", 526], ["in", 534], ["patients", 537], ["with", 546], ["dabigatran", 551], ["-", 561], ["associated", 562], ["bleeding", 573], [".", 581], ["Although", 583], ["existing", 592], ["clinical", 601], ["studies", 610], ["show", 618], ["a", 623], ["rapid", 625], ["reversal", 631], ["of", 640], ["coagulation", 643], ["assays", 655], [",", 661], ["these", 663], ["studies", 669], ["did", 677], ["not", 681], ["describe", 685], ["a", 694], ["corresponding", 696], ["improvement", 710], ["in", 722], ["mortality", 725], ["or", 735], ["rapid", 738], ["cessation", 744], ["of", 754], ["hemorrhage", 757], [".", 767], ["It", 769], ["is", 772], ["questionable", 775], ["how", 788], ["heavily", 792], ["clinicians", 800], ["can", 811], ["rely", 815], ["upon", 820], ["the", 825], ["use", 829], ["of", 833], ["the", 836], ["surrogate", 840], ["endpoints", 850], ["in", 860], ["clinical", 863], ["studies", 872], [",", 879], ["such", 881], ["as", 886], ["ecarin", 889], ["clotting", 896], ["time", 905], ["and", 910], ["dilute", 914], ["thrombin", 921], ["time", 930], [".", 934], ["Another", 936], ["issue", 944], ["is", 950], ["whether", 953], ["patients", 961], ["exhibiting", 970], ["re", 981], ["-", 983], ["elevation", 984], ["of", 994], ["coagulation", 997], ["assays", 1009], ["would", 1016], ["benefit", 1022], ["from", 1030], ["an", 1035], ["additional", 1038], ["dose", 1049], ["of", 1054], ["idarucizumab", 1057], [",", 1069], ["because", 1071], ["this", 1079], ["has", 1084], ["not", 1088], ["been", 1092], ["studied", 1097], [".", 1104], ["It", 1106], ["is", 1109], ["currently", 1112], ["unclear", 1122], ["if", 1130], ["blood", 1133], ["products", 1139], ["must", 1148], ["be", 1153], ["given", 1156], ["in", 1162], ["addition", 1165], ["to", 1174], ["idarucizumab", 1177], ["can", 1190], ["be", 1194], ["used", 1197], ["as", 1202], ["monotherapy", 1205], [".", 1216], ["The", 1218], ["initial", 1222], ["data", 1230], ["suggest", 1235], ["a", 1243], ["definite", 1245], ["role", 1254], ["for", 1259], ["idarucizumab", 1263], ["in", 1276], ["treatment", 1279], ["of", 1289], ["bleeding", 1292], ["associated", 1301], ["with", 1312], ["dabigatran", 1317], [".", 1327], ["As", 1329], ["more", 1332], ["clinical", 1337], ["practice", 1346], ["experience", 1355], ["is", 1366], ["gained", 1369], ["with", 1376], ["the", 1381], ["agent", 1385], ["and", 1391], ["the", 1395], ["remaining", 1399], ["data", 1409], ["on", 1414], ["its", 1417], ["use", 1421], ["are", 1425], ["released", 1429], [",", 1437], ["clinicians", 1439], ["can", 1450], ["better", 1454], ["guide", 1461], ["the", 1467], ["clinical", 1471], ["use", 1480], ["of", 1484], ["idarucizumab", 1487], [".", 1499], ["At", 1501], ["present", 1504], [",", 1511], ["there", 1513], ["is", 1519], ["currently", 1522], ["not", 1532], ["enough", 1536], ["evidence", 1543], ["for", 1552], ["idarucizumab", 1556], ["to", 1569], ["be", 1572], ["used", 1575], ["as", 1580], ["monotherapy", 1583], [".", 1594]]}
{"context": "Fostamatinib (R788) is a prodrug rapidly converted to its active metabolite on oral administration. This (known as R406) is a potent inhibitor of spleen tyrosine kinase, required for the expression of a number of proinflammatory cytokines. Fostamatinib has shown significantly superior efficacy (when compared with placebo) in the control of patients with rheumatoid arthritis not responding to methotrexate in Phase II clinical trials. Treatment emergent adverse events with a higher frequency than in those on placebo included diarrhea, hypertension, urinary tract infections, neutropenia and elevated transaminases. The studied doses have shown a linear pharmacokinetic pattern and the administration of methotrexate does not affect it. Fostamatinib may have a role in the therapy of patients with rheumatoid arthritis with poor response to conventional therapy. If these results are confirmed once Phase III studies are completed, it may find a place in the evolving treatment algorithm for rheumatoid arthritis.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "7c88f7862dc74ae8bded750a958b2e65", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[28, 30]], "char_spans": [[146, 167]]}]}], "context_tokens": [["Fostamatinib", 0], ["(", 13], ["R788", 14], [")", 18], ["is", 20], ["a", 23], ["prodrug", 25], ["rapidly", 33], ["converted", 41], ["to", 51], ["its", 54], ["active", 58], ["metabolite", 65], ["on", 76], ["oral", 79], ["administration", 84], [".", 98], ["This", 100], ["(", 105], ["known", 106], ["as", 112], ["R406", 115], [")", 119], ["is", 121], ["a", 124], ["potent", 126], ["inhibitor", 133], ["of", 143], ["spleen", 146], ["tyrosine", 153], ["kinase", 162], [",", 168], ["required", 170], ["for", 179], ["the", 183], ["expression", 187], ["of", 198], ["a", 201], ["number", 203], ["of", 210], ["proinflammatory", 213], ["cytokines", 229], [".", 238], ["Fostamatinib", 240], ["has", 253], ["shown", 257], ["significantly", 263], ["superior", 277], ["efficacy", 286], ["(", 295], ["when", 296], ["compared", 301], ["with", 310], ["placebo", 315], [")", 322], ["in", 324], ["the", 327], ["control", 331], ["of", 339], ["patients", 342], ["with", 351], ["rheumatoid", 356], ["arthritis", 367], ["not", 377], ["responding", 381], ["to", 392], ["methotrexate", 395], ["in", 408], ["Phase", 411], ["II", 417], ["clinical", 420], ["trials", 429], [".", 435], ["Treatment", 437], ["emergent", 447], ["adverse", 456], ["events", 464], ["with", 471], ["a", 476], ["higher", 478], ["frequency", 485], ["than", 495], ["in", 500], ["those", 503], ["on", 509], ["placebo", 512], ["included", 520], ["diarrhea", 529], [",", 537], ["hypertension", 539], [",", 551], ["urinary", 553], ["tract", 561], ["infections", 567], [",", 577], ["neutropenia", 579], ["and", 591], ["elevated", 595], ["transaminases", 604], [".", 617], ["The", 619], ["studied", 623], ["doses", 631], ["have", 637], ["shown", 642], ["a", 648], ["linear", 650], ["pharmacokinetic", 657], ["pattern", 673], ["and", 681], ["the", 685], ["administration", 689], ["of", 704], ["methotrexate", 707], ["does", 720], ["not", 725], ["affect", 729], ["it", 736], [".", 738], ["Fostamatinib", 740], ["may", 753], ["have", 757], ["a", 762], ["role", 764], ["in", 769], ["the", 772], ["therapy", 776], ["of", 784], ["patients", 787], ["with", 796], ["rheumatoid", 801], ["arthritis", 812], ["with", 822], ["poor", 827], ["response", 832], ["to", 841], ["conventional", 844], ["therapy", 857], [".", 864], ["If", 866], ["these", 869], ["results", 875], ["are", 883], ["confirmed", 887], ["once", 897], ["Phase", 902], ["III", 908], ["studies", 912], ["are", 920], ["completed", 924], [",", 933], ["it", 935], ["may", 938], ["find", 942], ["a", 947], ["place", 949], ["in", 955], ["the", 958], ["evolving", 962], ["treatment", 971], ["algorithm", 981], ["for", 991], ["rheumatoid", 995], ["arthritis", 1006], [".", 1015]]}
{"context": "Calcineurin signaling has been implicated in a broad spectrum of developmental processes in a variety of organ systems. Calcineurin is a calmodulin-dependent, calcium-activated protein phosphatase composed of catalytic and regulatory subunits. The serine/threonine-specific phosphatase functions within a signal transduction pathway that regulates gene expression and biological responses in many developmentally important cell types. Calcineurin signaling was first defined in T lymphocytes as a regulator of nuclear factor of activated T cells (NFAT) transcription factor nuclear translocation and activation. Recent studies have demonstrated the vital nature of calcium/calcineurin/NFAT signaling in cardiovascular and skeletal muscle development in vertebrates. Inhibition, mutation, or forced expression of calcineurin pathway genes result in defects or alterations in cardiomyocyte maturation, heart valve formation, vascular development, skeletal muscle differentiation and fiber-type switching, and cardiac and skeletal muscle hypertrophy. Conserved calcineurin genes are found in invertebrates such as Drosophila and Caenorhabditis elegans, and genetic studies have demonstrated specific myogenic functions for the phosphatase in their development. The ability to investigate calcineurin signaling pathways in vertebrates and model genetic organisms provides a great potential to more fully comprehend the functions of calcineurin and its interacting genes in heart, blood vessel, and muscle development.", "qas": [{"question": "Which calcium/calmodulin dependent protein phosphatase is involved in the activation of the family of NFAT transcription factors (Nuclear Factors of Activated T cells)?", "answers": ["Calcineurin", "CaN", "phosphatase 2b"], "qid": "f5da104a83c341a2b668ac142d827213", "question_tokens": [["Which", 0], ["calcium", 6], ["/", 13], ["calmodulin", 14], ["dependent", 25], ["protein", 35], ["phosphatase", 43], ["is", 55], ["involved", 58], ["in", 67], ["the", 70], ["activation", 74], ["of", 85], ["the", 88], ["family", 92], ["of", 99], ["NFAT", 102], ["transcription", 107], ["factors", 121], ["(", 129], ["Nuclear", 130], ["Factors", 138], ["of", 146], ["Activated", 149], ["T", 159], ["cells", 161], [")", 166], ["?", 167]], "detected_answers": [{"text": "Calcineurin", "token_spans": [[0, 0], [160, 160], [19, 19], [192, 192], [124, 124], [212, 212], [103, 103], [65, 65]], "char_spans": [[0, 10], [1058, 1068], [120, 130], [1285, 1295], [812, 822], [1428, 1438], [673, 683], [435, 445]]}]}], "context_tokens": [["Calcineurin", 0], ["signaling", 12], ["has", 22], ["been", 26], ["implicated", 31], ["in", 42], ["a", 45], ["broad", 47], ["spectrum", 53], ["of", 62], ["developmental", 65], ["processes", 79], ["in", 89], ["a", 92], ["variety", 94], ["of", 102], ["organ", 105], ["systems", 111], [".", 118], ["Calcineurin", 120], ["is", 132], ["a", 135], ["calmodulin", 137], ["-", 147], ["dependent", 148], [",", 157], ["calcium", 159], ["-", 166], ["activated", 167], ["protein", 177], ["phosphatase", 185], ["composed", 197], ["of", 206], ["catalytic", 209], ["and", 219], ["regulatory", 223], ["subunits", 234], [".", 242], ["The", 244], ["serine", 248], ["/", 254], ["threonine", 255], ["-", 264], ["specific", 265], ["phosphatase", 274], ["functions", 286], ["within", 296], ["a", 303], ["signal", 305], ["transduction", 312], ["pathway", 325], ["that", 333], ["regulates", 338], ["gene", 348], ["expression", 353], ["and", 364], ["biological", 368], ["responses", 379], ["in", 389], ["many", 392], ["developmentally", 397], ["important", 413], ["cell", 423], ["types", 428], [".", 433], ["Calcineurin", 435], ["signaling", 447], ["was", 457], ["first", 461], ["defined", 467], ["in", 475], ["T", 478], ["lymphocytes", 480], ["as", 492], ["a", 495], ["regulator", 497], ["of", 507], ["nuclear", 510], ["factor", 518], ["of", 525], ["activated", 528], ["T", 538], ["cells", 540], ["(", 546], ["NFAT", 547], [")", 551], ["transcription", 553], ["factor", 567], ["nuclear", 574], ["translocation", 582], ["and", 596], ["activation", 600], [".", 610], ["Recent", 612], ["studies", 619], ["have", 627], ["demonstrated", 632], ["the", 645], ["vital", 649], ["nature", 655], ["of", 662], ["calcium", 665], ["/", 672], ["calcineurin", 673], ["/", 684], ["NFAT", 685], ["signaling", 690], ["in", 700], ["cardiovascular", 703], ["and", 718], ["skeletal", 722], ["muscle", 731], ["development", 738], ["in", 750], ["vertebrates", 753], [".", 764], ["Inhibition", 766], [",", 776], ["mutation", 778], [",", 786], ["or", 788], ["forced", 791], ["expression", 798], ["of", 809], ["calcineurin", 812], ["pathway", 824], ["genes", 832], ["result", 838], ["in", 845], ["defects", 848], ["or", 856], ["alterations", 859], ["in", 871], ["cardiomyocyte", 874], ["maturation", 888], [",", 898], ["heart", 900], ["valve", 906], ["formation", 912], [",", 921], ["vascular", 923], ["development", 932], [",", 943], ["skeletal", 945], ["muscle", 954], ["differentiation", 961], ["and", 977], ["fiber", 981], ["-", 986], ["type", 987], ["switching", 992], [",", 1001], ["and", 1003], ["cardiac", 1007], ["and", 1015], ["skeletal", 1019], ["muscle", 1028], ["hypertrophy", 1035], [".", 1046], ["Conserved", 1048], ["calcineurin", 1058], ["genes", 1070], ["are", 1076], ["found", 1080], ["in", 1086], ["invertebrates", 1089], ["such", 1103], ["as", 1108], ["Drosophila", 1111], ["and", 1122], ["Caenorhabditis", 1126], ["elegans", 1141], [",", 1148], ["and", 1150], ["genetic", 1154], ["studies", 1162], ["have", 1170], ["demonstrated", 1175], ["specific", 1188], ["myogenic", 1197], ["functions", 1206], ["for", 1216], ["the", 1220], ["phosphatase", 1224], ["in", 1236], ["their", 1239], ["development", 1245], [".", 1256], ["The", 1258], ["ability", 1262], ["to", 1270], ["investigate", 1273], ["calcineurin", 1285], ["signaling", 1297], ["pathways", 1307], ["in", 1316], ["vertebrates", 1319], ["and", 1331], ["model", 1335], ["genetic", 1341], ["organisms", 1349], ["provides", 1359], ["a", 1368], ["great", 1370], ["potential", 1376], ["to", 1386], ["more", 1389], ["fully", 1394], ["comprehend", 1400], ["the", 1411], ["functions", 1415], ["of", 1425], ["calcineurin", 1428], ["and", 1440], ["its", 1444], ["interacting", 1448], ["genes", 1460], ["in", 1466], ["heart", 1469], [",", 1474], ["blood", 1476], ["vessel", 1482], [",", 1488], ["and", 1490], ["muscle", 1494], ["development", 1501], [".", 1512]]}
{"context": "Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an autosomal dominant heart muscle disorder that causes arrhythmia, heart failure, and sudden death. Previously we mapped the genetic locus for the triad of autosomal recessive ARVC, palmoplantar keratoderma, and woolly hair (Naxos disease) to chromosome 17q21, in which the gene for plakoglobin is encoded. This protein is a key component of desmosomes and adherens junctions, and is important for the tight adhesion of many cell types, including those in the heart and skin. We studied 19 individuals with Naxos disease, as well as unaffected family members and unrelated individuals from the neighbouring Greek islands of Naxos and Milos. Gene sequence was determined by reverse transcriptase PCR from RNA isolated from the skin of an affected individual and mutations in other cases were confirmed by restriction-enzyme analysis. A homozygous 2 base pair deletion in the plakoglobin gene was identified only in the 19 affected individuals. This deletion caused a frameshift and premature termination of the protein, which was shown by western blot analysis. 29 clinically unaffected family members were heterozygous for the mutation; 20 unrelated individuals from Naxos and 43 autosomal dominant ARVC probands were homozygous for the normal allele. The finding of a deletion in plakoglobin in ARVC suggests that the proteins involved in cell-cell adhesion play an important part in maintaining myocyte integrity, and when junctions are disrupted, cell death, and fibrofatty replacement occur. Therefore, the discovery of a mutation in a protein with functions in maintaining cell junction integrity has important implications for other dominant forms of ARVC, related cardiomyopathies, and other cutaneous diseases.", "qas": [{"question": "Which gene is mutated in a subtype of arrhythmogenic right ventricular cardiomyopathy known as Naxos disease?", "answers": ["The Plakoglobin gene", "plakoglobin[jup]"], "qid": "204004adaf394da29332aa0a6d83a243", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["mutated", 14], ["in", 22], ["a", 25], ["subtype", 27], ["of", 35], ["arrhythmogenic", 38], ["right", 53], ["ventricular", 59], ["cardiomyopathy", 71], ["known", 86], ["as", 92], ["Naxos", 95], ["disease", 101], ["?", 108]], "detected_answers": [{"text": "The Plakoglobin gene", "token_spans": [[160, 161]], "char_spans": [[933, 948]]}]}], "context_tokens": [["Arrhythmogenic", 0], ["right", 15], ["ventricular", 21], ["cardiomyopathy", 33], ["(", 48], ["ARVC", 49], [")", 53], ["is", 55], ["an", 58], ["autosomal", 61], ["dominant", 71], ["heart", 80], ["muscle", 86], ["disorder", 93], ["that", 102], ["causes", 107], ["arrhythmia", 114], [",", 124], ["heart", 126], ["failure", 132], [",", 139], ["and", 141], ["sudden", 145], ["death", 152], [".", 157], ["Previously", 159], ["we", 170], ["mapped", 173], ["the", 180], ["genetic", 184], ["locus", 192], ["for", 198], ["the", 202], ["triad", 206], ["of", 212], ["autosomal", 215], ["recessive", 225], ["ARVC", 235], [",", 239], ["palmoplantar", 241], ["keratoderma", 254], [",", 265], ["and", 267], ["woolly", 271], ["hair", 278], ["(", 283], ["Naxos", 284], ["disease", 290], [")", 297], ["to", 299], ["chromosome", 302], ["17q21", 313], [",", 318], ["in", 320], ["which", 323], ["the", 329], ["gene", 333], ["for", 338], ["plakoglobin", 342], ["is", 354], ["encoded", 357], [".", 364], ["This", 366], ["protein", 371], ["is", 379], ["a", 382], ["key", 384], ["component", 388], ["of", 398], ["desmosomes", 401], ["and", 412], ["adherens", 416], ["junctions", 425], [",", 434], ["and", 436], ["is", 440], ["important", 443], ["for", 453], ["the", 457], ["tight", 461], ["adhesion", 467], ["of", 476], ["many", 479], ["cell", 484], ["types", 489], [",", 494], ["including", 496], ["those", 506], ["in", 512], ["the", 515], ["heart", 519], ["and", 525], ["skin", 529], [".", 533], ["We", 535], ["studied", 538], ["19", 546], ["individuals", 549], ["with", 561], ["Naxos", 566], ["disease", 572], [",", 579], ["as", 581], ["well", 584], ["as", 589], ["unaffected", 592], ["family", 603], ["members", 610], ["and", 618], ["unrelated", 622], ["individuals", 632], ["from", 644], ["the", 649], ["neighbouring", 653], ["Greek", 666], ["islands", 672], ["of", 680], ["Naxos", 683], ["and", 689], ["Milos", 693], [".", 698], ["Gene", 700], ["sequence", 705], ["was", 714], ["determined", 718], ["by", 729], ["reverse", 732], ["transcriptase", 740], ["PCR", 754], ["from", 758], ["RNA", 763], ["isolated", 767], ["from", 776], ["the", 781], ["skin", 785], ["of", 790], ["an", 793], ["affected", 796], ["individual", 805], ["and", 816], ["mutations", 820], ["in", 830], ["other", 833], ["cases", 839], ["were", 845], ["confirmed", 850], ["by", 860], ["restriction", 863], ["-", 874], ["enzyme", 875], ["analysis", 882], [".", 890], ["A", 892], ["homozygous", 894], ["2", 905], ["base", 907], ["pair", 912], ["deletion", 917], ["in", 926], ["the", 929], ["plakoglobin", 933], ["gene", 945], ["was", 950], ["identified", 954], ["only", 965], ["in", 970], ["the", 973], ["19", 977], ["affected", 980], ["individuals", 989], [".", 1000], ["This", 1002], ["deletion", 1007], ["caused", 1016], ["a", 1023], ["frameshift", 1025], ["and", 1036], ["premature", 1040], ["termination", 1050], ["of", 1062], ["the", 1065], ["protein", 1069], [",", 1076], ["which", 1078], ["was", 1084], ["shown", 1088], ["by", 1094], ["western", 1097], ["blot", 1105], ["analysis", 1110], [".", 1118], ["29", 1120], ["clinically", 1123], ["unaffected", 1134], ["family", 1145], ["members", 1152], ["were", 1160], ["heterozygous", 1165], ["for", 1178], ["the", 1182], ["mutation", 1186], [";", 1194], ["20", 1196], ["unrelated", 1199], ["individuals", 1209], ["from", 1221], ["Naxos", 1226], ["and", 1232], ["43", 1236], ["autosomal", 1239], ["dominant", 1249], ["ARVC", 1258], ["probands", 1263], ["were", 1272], ["homozygous", 1277], ["for", 1288], ["the", 1292], ["normal", 1296], ["allele", 1303], [".", 1309], ["The", 1311], ["finding", 1315], ["of", 1323], ["a", 1326], ["deletion", 1328], ["in", 1337], ["plakoglobin", 1340], ["in", 1352], ["ARVC", 1355], ["suggests", 1360], ["that", 1369], ["the", 1374], ["proteins", 1378], ["involved", 1387], ["in", 1396], ["cell", 1399], ["-", 1403], ["cell", 1404], ["adhesion", 1409], ["play", 1418], ["an", 1423], ["important", 1426], ["part", 1436], ["in", 1441], ["maintaining", 1444], ["myocyte", 1456], ["integrity", 1464], [",", 1473], ["and", 1475], ["when", 1479], ["junctions", 1484], ["are", 1494], ["disrupted", 1498], [",", 1507], ["cell", 1509], ["death", 1514], [",", 1519], ["and", 1521], ["fibrofatty", 1525], ["replacement", 1536], ["occur", 1548], [".", 1553], ["Therefore", 1555], [",", 1564], ["the", 1566], ["discovery", 1570], ["of", 1580], ["a", 1583], ["mutation", 1585], ["in", 1594], ["a", 1597], ["protein", 1599], ["with", 1607], ["functions", 1612], ["in", 1622], ["maintaining", 1625], ["cell", 1637], ["junction", 1642], ["integrity", 1651], ["has", 1661], ["important", 1665], ["implications", 1675], ["for", 1688], ["other", 1692], ["dominant", 1698], ["forms", 1707], ["of", 1713], ["ARVC", 1716], [",", 1720], ["related", 1722], ["cardiomyopathies", 1730], [",", 1746], ["and", 1748], ["other", 1752], ["cutaneous", 1758], ["diseases", 1768], [".", 1776]]}
{"context": "The enzyme telomerase is activated in 80-90% of all human malignancies and immortal cell lines, where it functions to maintain the integrity of chromosomal-end structures called telomeres. Telomerase enzyme activity can be detected in whole cell lysates by a polymerase chain reaction (PCR)-based method referred to as the telomeric repeat amplification protocol (TRAP). The TRAP assay involves extension of an oligonucleotide through telomerase-mediated enzymatic addition of telomeric DNA repeats and subsequent PCR amplification of the extension products. While the TRAP assay as originally developed utilizes radioactively labelled nucleotides, protocols are provided herein for nonradioactive versions of the TRAP assay, with options for either qualitative assessment of TRAP products by polyacrylamide gel electrophoresis (standard TRAP), or quantitative analysis by real-time PCR (Q-TRAP). The Q-TRAP method poses the additional advantages of exquisite sensitivity, rapidity, and potential for adoption to a high-throughput format.", "qas": [{"question": "What is the aim of the TRAP assay?", "answers": ["Telomerase enzyme activity can be detected in whole cell lysates by a polymerase chain reaction (PCR)-based method referred to as the telomeric repeat amplification protocol (TRAP)."], "qid": "8076404cfda8488c9fbc09080b95dccf", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["aim", 12], ["of", 16], ["the", 19], ["TRAP", 23], ["assay", 28], ["?", 33]], "detected_answers": [{"text": "Telomerase enzyme activity can be detected in whole cell lysates by a polymerase chain reaction (PCR)-based method referred to as the telomeric repeat amplification protocol (TRAP).", "token_spans": [[34, 61]], "char_spans": [[189, 367]]}]}], "context_tokens": [["The", 0], ["enzyme", 4], ["telomerase", 11], ["is", 22], ["activated", 25], ["in", 35], ["80", 38], ["-", 40], ["90", 41], ["%", 43], ["of", 45], ["all", 48], ["human", 52], ["malignancies", 58], ["and", 71], ["immortal", 75], ["cell", 84], ["lines", 89], [",", 94], ["where", 96], ["it", 102], ["functions", 105], ["to", 115], ["maintain", 118], ["the", 127], ["integrity", 131], ["of", 141], ["chromosomal", 144], ["-", 155], ["end", 156], ["structures", 160], ["called", 171], ["telomeres", 178], [".", 187], ["Telomerase", 189], ["enzyme", 200], ["activity", 207], ["can", 216], ["be", 220], ["detected", 223], ["in", 232], ["whole", 235], ["cell", 241], ["lysates", 246], ["by", 254], ["a", 257], ["polymerase", 259], ["chain", 270], ["reaction", 276], ["(", 285], ["PCR)-based", 286], ["method", 297], ["referred", 304], ["to", 313], ["as", 316], ["the", 319], ["telomeric", 323], ["repeat", 333], ["amplification", 340], ["protocol", 354], ["(", 363], ["TRAP", 364], [")", 368], [".", 369], ["The", 371], ["TRAP", 375], ["assay", 380], ["involves", 386], ["extension", 395], ["of", 405], ["an", 408], ["oligonucleotide", 411], ["through", 427], ["telomerase", 435], ["-", 445], ["mediated", 446], ["enzymatic", 455], ["addition", 465], ["of", 474], ["telomeric", 477], ["DNA", 487], ["repeats", 491], ["and", 499], ["subsequent", 503], ["PCR", 514], ["amplification", 518], ["of", 532], ["the", 535], ["extension", 539], ["products", 549], [".", 557], ["While", 559], ["the", 565], ["TRAP", 569], ["assay", 574], ["as", 580], ["originally", 583], ["developed", 594], ["utilizes", 604], ["radioactively", 613], ["labelled", 627], ["nucleotides", 636], [",", 647], ["protocols", 649], ["are", 659], ["provided", 663], ["herein", 672], ["for", 679], ["nonradioactive", 683], ["versions", 698], ["of", 707], ["the", 710], ["TRAP", 714], ["assay", 719], [",", 724], ["with", 726], ["options", 731], ["for", 739], ["either", 743], ["qualitative", 750], ["assessment", 762], ["of", 773], ["TRAP", 776], ["products", 781], ["by", 790], ["polyacrylamide", 793], ["gel", 808], ["electrophoresis", 812], ["(", 828], ["standard", 829], ["TRAP", 838], [")", 842], [",", 843], ["or", 845], ["quantitative", 848], ["analysis", 861], ["by", 870], ["real", 873], ["-", 877], ["time", 878], ["PCR", 883], ["(", 887], ["Q", 888], ["-", 889], ["TRAP", 890], [")", 894], [".", 895], ["The", 897], ["Q", 901], ["-", 902], ["TRAP", 903], ["method", 908], ["poses", 915], ["the", 921], ["additional", 925], ["advantages", 936], ["of", 947], ["exquisite", 950], ["sensitivity", 960], [",", 971], ["rapidity", 973], [",", 981], ["and", 983], ["potential", 987], ["for", 997], ["adoption", 1001], ["to", 1010], ["a", 1013], ["high", 1015], ["-", 1019], ["throughput", 1020], ["format", 1031], [".", 1037]]}
{"context": "Human selenoprotein P (HSelP) is unique protein that contains 10 selenocysteines encoded by 10 inframe UGA, which typically function as stop codon. The function of HSelP remains unclear, in part due to the inability to express it by gene recombinant technique. This study is to investigate expression and purification of recombinant HSelP in prokaryotic expression system, and its activity to induce apoptosis in vitro. The shorter HSelP isoform was cloned. After the selenocysteine (SeCys) at 40th position from N terminus of the HSelP shorter isoform was mutated into cysteine by PCR, it was expressed in E. coli. The expressed product was purified with DEAE column and identified by Western blot. Subsequently, its function on induction of mitochondrial apoptotic activity was studied. The mutant HSelP shorter isoform expressed in prokaryotic system was purified by DEAE column to 90% homogeneity. The purified product, HSelP280m, induced the opening of mitochondrial permeability transition pore (PTP) and decreased the transmembrane potential in a dose-dependent manner. These events could be abolished by PTP specific inhibitors. HSelP280m can induce the opening of mitochondrial PTP, which provides a basis for investigating the structure and function of recombinant HSelP.", "qas": [{"question": "Which is the human selenoprotein that contains several Se-Cys residues?", "answers": ["Selenoprotein P"], "qid": "c67a56187ba94d478fbc8c8608cabb52", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["human", 13], ["selenoprotein", 19], ["that", 33], ["contains", 38], ["several", 47], ["Se", 55], ["-", 57], ["Cys", 58], ["residues", 62], ["?", 70]], "detected_answers": [{"text": "Selenoprotein P", "token_spans": [[1, 2]], "char_spans": [[6, 20]]}]}], "context_tokens": [["Human", 0], ["selenoprotein", 6], ["P", 20], ["(", 22], ["HSelP", 23], [")", 28], ["is", 30], ["unique", 33], ["protein", 40], ["that", 48], ["contains", 53], ["10", 62], ["selenocysteines", 65], ["encoded", 81], ["by", 89], ["10", 92], ["inframe", 95], ["UGA", 103], [",", 106], ["which", 108], ["typically", 114], ["function", 124], ["as", 133], ["stop", 136], ["codon", 141], [".", 146], ["The", 148], ["function", 152], ["of", 161], ["HSelP", 164], ["remains", 170], ["unclear", 178], [",", 185], ["in", 187], ["part", 190], ["due", 195], ["to", 199], ["the", 202], ["inability", 206], ["to", 216], ["express", 219], ["it", 227], ["by", 230], ["gene", 233], ["recombinant", 238], ["technique", 250], [".", 259], ["This", 261], ["study", 266], ["is", 272], ["to", 275], ["investigate", 278], ["expression", 290], ["and", 301], ["purification", 305], ["of", 318], ["recombinant", 321], ["HSelP", 333], ["in", 339], ["prokaryotic", 342], ["expression", 354], ["system", 365], [",", 371], ["and", 373], ["its", 377], ["activity", 381], ["to", 390], ["induce", 393], ["apoptosis", 400], ["in", 410], ["vitro", 413], [".", 418], ["The", 420], ["shorter", 424], ["HSelP", 432], ["isoform", 438], ["was", 446], ["cloned", 450], [".", 456], ["After", 458], ["the", 464], ["selenocysteine", 468], ["(", 483], ["SeCys", 484], [")", 489], ["at", 491], ["40th", 494], ["position", 499], ["from", 508], ["N", 513], ["terminus", 515], ["of", 524], ["the", 527], ["HSelP", 531], ["shorter", 537], ["isoform", 545], ["was", 553], ["mutated", 557], ["into", 565], ["cysteine", 570], ["by", 579], ["PCR", 582], [",", 585], ["it", 587], ["was", 590], ["expressed", 594], ["in", 604], ["E.", 607], ["coli", 610], [".", 614], ["The", 616], ["expressed", 620], ["product", 630], ["was", 638], ["purified", 642], ["with", 651], ["DEAE", 656], ["column", 661], ["and", 668], ["identified", 672], ["by", 683], ["Western", 686], ["blot", 694], [".", 698], ["Subsequently", 700], [",", 712], ["its", 714], ["function", 718], ["on", 727], ["induction", 730], ["of", 740], ["mitochondrial", 743], ["apoptotic", 757], ["activity", 767], ["was", 776], ["studied", 780], [".", 787], ["The", 789], ["mutant", 793], ["HSelP", 800], ["shorter", 806], ["isoform", 814], ["expressed", 822], ["in", 832], ["prokaryotic", 835], ["system", 847], ["was", 854], ["purified", 858], ["by", 867], ["DEAE", 870], ["column", 875], ["to", 882], ["90", 885], ["%", 887], ["homogeneity", 889], [".", 900], ["The", 902], ["purified", 906], ["product", 915], [",", 922], ["HSelP280", 924], ["m", 932], [",", 933], ["induced", 935], ["the", 943], ["opening", 947], ["of", 955], ["mitochondrial", 958], ["permeability", 972], ["transition", 985], ["pore", 996], ["(", 1001], ["PTP", 1002], [")", 1005], ["and", 1007], ["decreased", 1011], ["the", 1021], ["transmembrane", 1025], ["potential", 1039], ["in", 1049], ["a", 1052], ["dose", 1054], ["-", 1058], ["dependent", 1059], ["manner", 1069], [".", 1075], ["These", 1077], ["events", 1083], ["could", 1090], ["be", 1096], ["abolished", 1099], ["by", 1109], ["PTP", 1112], ["specific", 1116], ["inhibitors", 1125], [".", 1135], ["HSelP280", 1137], ["m", 1145], ["can", 1147], ["induce", 1151], ["the", 1158], ["opening", 1162], ["of", 1170], ["mitochondrial", 1173], ["PTP", 1187], [",", 1190], ["which", 1192], ["provides", 1198], ["a", 1207], ["basis", 1209], ["for", 1215], ["investigating", 1219], ["the", 1233], ["structure", 1237], ["and", 1247], ["function", 1251], ["of", 1260], ["recombinant", 1263], ["HSelP.", 1275]]}
{"context": "Christianson syndrome (CS) is an X-linked neurodevelopmental and neurological disorder characterized in males by core symptoms that include non-verbal status, intellectual disability, epilepsy, truncal ataxia, postnatal microcephaly and hyperkinesis. CS is caused by mutations in the SLC9A6 gene, which encodes a multipass transmembrane sodium (potassium)-hydrogen exchanger 6 (NHE6) protein, functional in early recycling endosomes. The extent and variability of the CS phenotype in female heterozygotes, who presumably express the wild-type and mutant SLC9A6 alleles mosaically as a result of X-chromosome inactivation (XCI), have not yet been systematically characterized. Slc9a6 knockout mice (Slc9a6 KO) were generated by insertion of the bacterial lacZ/\u03b2-galactosidase (\u03b2-Gal) reporter into exon 6 of the X-linked gene. Mutant Slc9a6 KO male mice have been shown to develop late endosomal/lysosomal dysfunction associated with glycolipid accumulation in selected neuronal populations and patterned degeneration of Purkinje cells (PCs). In heterozygous female Slc9a6 KO mice, \u03b2-Gal serves as a transcriptional/XCI reporter and thus facilitates testing of effects of mosaic expression of the mutant allele on penetrance of the abnormal phenotype. Using \u03b2-Gal, we demonstrated mosaic expression of the mutant Slc9a6 allele and mosaically distributed lysosomal glycolipid accumulation and PC pathology in the brains of heterozygous Slc9a6 KO female mice. At the behavioral level, we showed that heterozygous female mice suffer from visuospatial memory and motor coordination deficits similar to but less severe than those observed in X-chromosome hemizygous mutant males. Our studies in heterozygous Slc9a6 KO female mice provide important clues for understanding the likely phenotypic range of Christianson syndrome among females heterozygous for SLC9A6 mutations and might improve diagnostic practice and genetic counseling by helping to characterize this presumably underappreciated patient/carrier group.", "qas": [{"question": "Mutation of which gene is implicated in the Christianson syndrome?", "answers": ["SLC9A6"], "qid": "d941cbf53efb4218a8348c71b146a2d2", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["implicated", 26], ["in", 37], ["the", 40], ["Christianson", 44], ["syndrome", 57], ["?", 65]], "detected_answers": [{"text": "SLC9A6", "token_spans": [[291, 291], [150, 150], [118, 118], [92, 92], [185, 185], [231, 231], [247, 247], [311, 311], [114, 114], [47, 47]], "char_spans": [[1702, 1707], [833, 838], [698, 703], [554, 559], [1065, 1070], [1312, 1317], [1434, 1439], [1850, 1855], [676, 681], [284, 289]]}]}], "context_tokens": [["Christianson", 0], ["syndrome", 13], ["(", 22], ["CS", 23], [")", 25], ["is", 27], ["an", 30], ["X", 33], ["-", 34], ["linked", 35], ["neurodevelopmental", 42], ["and", 61], ["neurological", 65], ["disorder", 78], ["characterized", 87], ["in", 101], ["males", 104], ["by", 110], ["core", 113], ["symptoms", 118], ["that", 127], ["include", 132], ["non", 140], ["-", 143], ["verbal", 144], ["status", 151], [",", 157], ["intellectual", 159], ["disability", 172], [",", 182], ["epilepsy", 184], [",", 192], ["truncal", 194], ["ataxia", 202], [",", 208], ["postnatal", 210], ["microcephaly", 220], ["and", 233], ["hyperkinesis", 237], [".", 249], ["CS", 251], ["is", 254], ["caused", 257], ["by", 264], ["mutations", 267], ["in", 277], ["the", 280], ["SLC9A6", 284], ["gene", 291], [",", 295], ["which", 297], ["encodes", 303], ["a", 311], ["multipass", 313], ["transmembrane", 323], ["sodium", 337], ["(", 344], ["potassium)-hydrogen", 345], ["exchanger", 365], ["6", 375], ["(", 377], ["NHE6", 378], [")", 382], ["protein", 384], [",", 391], ["functional", 393], ["in", 404], ["early", 407], ["recycling", 413], ["endosomes", 423], [".", 432], ["The", 434], ["extent", 438], ["and", 445], ["variability", 449], ["of", 461], ["the", 464], ["CS", 468], ["phenotype", 471], ["in", 481], ["female", 484], ["heterozygotes", 491], [",", 504], ["who", 506], ["presumably", 510], ["express", 521], ["the", 529], ["wild", 533], ["-", 537], ["type", 538], ["and", 543], ["mutant", 547], ["SLC9A6", 554], ["alleles", 561], ["mosaically", 569], ["as", 580], ["a", 583], ["result", 585], ["of", 592], ["X", 595], ["-", 596], ["chromosome", 597], ["inactivation", 608], ["(", 621], ["XCI", 622], [")", 625], [",", 626], ["have", 628], ["not", 633], ["yet", 637], ["been", 641], ["systematically", 646], ["characterized", 661], [".", 674], ["Slc9a6", 676], ["knockout", 683], ["mice", 692], ["(", 697], ["Slc9a6", 698], ["KO", 705], [")", 707], ["were", 709], ["generated", 714], ["by", 724], ["insertion", 727], ["of", 737], ["the", 740], ["bacterial", 744], ["lacZ", 754], ["/", 758], ["\u03b2", 759], ["-", 760], ["galactosidase", 761], ["(", 775], ["\u03b2", 776], ["-", 777], ["Gal", 778], [")", 781], ["reporter", 783], ["into", 792], ["exon", 797], ["6", 802], ["of", 804], ["the", 807], ["X", 811], ["-", 812], ["linked", 813], ["gene", 820], [".", 824], ["Mutant", 826], ["Slc9a6", 833], ["KO", 840], ["male", 843], ["mice", 848], ["have", 853], ["been", 858], ["shown", 863], ["to", 869], ["develop", 872], ["late", 880], ["endosomal", 885], ["/", 894], ["lysosomal", 895], ["dysfunction", 905], ["associated", 917], ["with", 928], ["glycolipid", 933], ["accumulation", 944], ["in", 957], ["selected", 960], ["neuronal", 969], ["populations", 978], ["and", 990], ["patterned", 994], ["degeneration", 1004], ["of", 1017], ["Purkinje", 1020], ["cells", 1029], ["(", 1035], ["PCs", 1036], [")", 1039], [".", 1040], ["In", 1042], ["heterozygous", 1045], ["female", 1058], ["Slc9a6", 1065], ["KO", 1072], ["mice", 1075], [",", 1079], ["\u03b2", 1081], ["-", 1082], ["Gal", 1083], ["serves", 1087], ["as", 1094], ["a", 1097], ["transcriptional", 1099], ["/", 1114], ["XCI", 1115], ["reporter", 1119], ["and", 1128], ["thus", 1132], ["facilitates", 1137], ["testing", 1149], ["of", 1157], ["effects", 1160], ["of", 1168], ["mosaic", 1171], ["expression", 1178], ["of", 1189], ["the", 1192], ["mutant", 1196], ["allele", 1203], ["on", 1210], ["penetrance", 1213], ["of", 1224], ["the", 1227], ["abnormal", 1231], ["phenotype", 1240], [".", 1249], ["Using", 1251], ["\u03b2", 1257], ["-", 1258], ["Gal", 1259], [",", 1262], ["we", 1264], ["demonstrated", 1267], ["mosaic", 1280], ["expression", 1287], ["of", 1298], ["the", 1301], ["mutant", 1305], ["Slc9a6", 1312], ["allele", 1319], ["and", 1326], ["mosaically", 1330], ["distributed", 1341], ["lysosomal", 1353], ["glycolipid", 1363], ["accumulation", 1374], ["and", 1387], ["PC", 1391], ["pathology", 1394], ["in", 1404], ["the", 1407], ["brains", 1411], ["of", 1418], ["heterozygous", 1421], ["Slc9a6", 1434], ["KO", 1441], ["female", 1444], ["mice", 1451], [".", 1455], ["At", 1457], ["the", 1460], ["behavioral", 1464], ["level", 1475], [",", 1480], ["we", 1482], ["showed", 1485], ["that", 1492], ["heterozygous", 1497], ["female", 1510], ["mice", 1517], ["suffer", 1522], ["from", 1529], ["visuospatial", 1534], ["memory", 1547], ["and", 1554], ["motor", 1558], ["coordination", 1564], ["deficits", 1577], ["similar", 1586], ["to", 1594], ["but", 1597], ["less", 1601], ["severe", 1606], ["than", 1613], ["those", 1618], ["observed", 1624], ["in", 1633], ["X", 1636], ["-", 1637], ["chromosome", 1638], ["hemizygous", 1649], ["mutant", 1660], ["males", 1667], [".", 1672], ["Our", 1674], ["studies", 1678], ["in", 1686], ["heterozygous", 1689], ["Slc9a6", 1702], ["KO", 1709], ["female", 1712], ["mice", 1719], ["provide", 1724], ["important", 1732], ["clues", 1742], ["for", 1748], ["understanding", 1752], ["the", 1766], ["likely", 1770], ["phenotypic", 1777], ["range", 1788], ["of", 1794], ["Christianson", 1797], ["syndrome", 1810], ["among", 1819], ["females", 1825], ["heterozygous", 1833], ["for", 1846], ["SLC9A6", 1850], ["mutations", 1857], ["and", 1867], ["might", 1871], ["improve", 1877], ["diagnostic", 1885], ["practice", 1896], ["and", 1905], ["genetic", 1909], ["counseling", 1917], ["by", 1928], ["helping", 1931], ["to", 1939], ["characterize", 1942], ["this", 1955], ["presumably", 1960], ["underappreciated", 1971], ["patient", 1988], ["/", 1995], ["carrier", 1996], ["group", 2004], [".", 2009]]}
{"context": "Myotonic dystrophy (DM), the most common form of muscular dystrophy in adults, is a clinically and genetically heterogeneous neuromuscular disorder. DM is characterized by autosomal dominant inheritance, muscular dystrophy, myotonia, and multisystem involvement. Type 1 DM (DM1) is caused by a (CTG)(n) expansion in the 3' untranslated region of DMPK in 19q13.3. Multiple families, predominantly of German descent and with clinically variable presentation that included proximal myotonic myopathy (PROMM) and type 2 DM (DM2) but without the DM1 mutation, showed linkage to the 3q21 region and were recently shown to segregate a (CCTG)(n) expansion mutation in intron 1 of ZNF9. Here, we present linkage to 3q21 and mutational confirmation in 17 kindreds of European origin with PROMM and proximal myotonic dystrophy, from geographically distinct populations. All patients have the DM2 (CCTG)(n) expansion. To study the evolution of this mutation, we constructed a comprehensive physical map of the DM2 region around ZNF9. High-resolution haplotype analysis of disease chromosomes with five microsatellite and 22 single-nucleotide polymorphism markers around the DM2 mutation identified extensive linkage disequilibrium and a single shared haplotype of at least 132 kb among patients from the different populations. With the exception of the (CCTG)(n) expansion, the available markers indicate that the DM2 haplotype is identical to the most common haplotype in normal individuals. This situation is reminiscent of that seen in DM1. Taken together, these data suggest a single founding mutation in DM2 patients of European origin. We estimate the age of the founding haplotype and of the DM2 (CCTG) expansion mutation to be approximately 200-540 generations.", "qas": [{"question": "How is myotonic dystrophy inherited?", "answers": ["autosomal dominant"], "qid": "3dff550077ca471a8137430b2d11722c", "question_tokens": [["How", 0], ["is", 4], ["myotonic", 7], ["dystrophy", 16], ["inherited", 26], ["?", 35]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[29, 30]], "char_spans": [[172, 189]]}]}], "context_tokens": [["Myotonic", 0], ["dystrophy", 9], ["(", 19], ["DM", 20], [")", 22], [",", 23], ["the", 25], ["most", 29], ["common", 34], ["form", 41], ["of", 46], ["muscular", 49], ["dystrophy", 58], ["in", 68], ["adults", 71], [",", 77], ["is", 79], ["a", 82], ["clinically", 84], ["and", 95], ["genetically", 99], ["heterogeneous", 111], ["neuromuscular", 125], ["disorder", 139], [".", 147], ["DM", 149], ["is", 152], ["characterized", 155], ["by", 169], ["autosomal", 172], ["dominant", 182], ["inheritance", 191], [",", 202], ["muscular", 204], ["dystrophy", 213], [",", 222], ["myotonia", 224], [",", 232], ["and", 234], ["multisystem", 238], ["involvement", 250], [".", 261], ["Type", 263], ["1", 268], ["DM", 270], ["(", 273], ["DM1", 274], [")", 277], ["is", 279], ["caused", 282], ["by", 289], ["a", 292], ["(", 294], ["CTG)(n", 295], [")", 301], ["expansion", 303], ["in", 313], ["the", 316], ["3", 320], ["'", 321], ["untranslated", 323], ["region", 336], ["of", 343], ["DMPK", 346], ["in", 351], ["19q13.3", 354], [".", 361], ["Multiple", 363], ["families", 372], [",", 380], ["predominantly", 382], ["of", 396], ["German", 399], ["descent", 406], ["and", 414], ["with", 418], ["clinically", 423], ["variable", 434], ["presentation", 443], ["that", 456], ["included", 461], ["proximal", 470], ["myotonic", 479], ["myopathy", 488], ["(", 497], ["PROMM", 498], [")", 503], ["and", 505], ["type", 509], ["2", 514], ["DM", 516], ["(", 519], ["DM2", 520], [")", 523], ["but", 525], ["without", 529], ["the", 537], ["DM1", 541], ["mutation", 545], [",", 553], ["showed", 555], ["linkage", 562], ["to", 570], ["the", 573], ["3q21", 577], ["region", 582], ["and", 589], ["were", 593], ["recently", 598], ["shown", 607], ["to", 613], ["segregate", 616], ["a", 626], ["(", 628], ["CCTG)(n", 629], [")", 636], ["expansion", 638], ["mutation", 648], ["in", 657], ["intron", 660], ["1", 667], ["of", 669], ["ZNF9", 672], [".", 676], ["Here", 678], [",", 682], ["we", 684], ["present", 687], ["linkage", 695], ["to", 703], ["3q21", 706], ["and", 711], ["mutational", 715], ["confirmation", 726], ["in", 739], ["17", 742], ["kindreds", 745], ["of", 754], ["European", 757], ["origin", 766], ["with", 773], ["PROMM", 778], ["and", 784], ["proximal", 788], ["myotonic", 797], ["dystrophy", 806], [",", 815], ["from", 817], ["geographically", 822], ["distinct", 837], ["populations", 846], [".", 857], ["All", 859], ["patients", 863], ["have", 872], ["the", 877], ["DM2", 881], ["(", 885], ["CCTG)(n", 886], [")", 893], ["expansion", 895], [".", 904], ["To", 906], ["study", 909], ["the", 915], ["evolution", 919], ["of", 929], ["this", 932], ["mutation", 937], [",", 945], ["we", 947], ["constructed", 950], ["a", 962], ["comprehensive", 964], ["physical", 978], ["map", 987], ["of", 991], ["the", 994], ["DM2", 998], ["region", 1002], ["around", 1009], ["ZNF9", 1016], [".", 1020], ["High", 1022], ["-", 1026], ["resolution", 1027], ["haplotype", 1038], ["analysis", 1048], ["of", 1057], ["disease", 1060], ["chromosomes", 1068], ["with", 1080], ["five", 1085], ["microsatellite", 1090], ["and", 1105], ["22", 1109], ["single", 1112], ["-", 1118], ["nucleotide", 1119], ["polymorphism", 1130], ["markers", 1143], ["around", 1151], ["the", 1158], ["DM2", 1162], ["mutation", 1166], ["identified", 1175], ["extensive", 1186], ["linkage", 1196], ["disequilibrium", 1204], ["and", 1219], ["a", 1223], ["single", 1225], ["shared", 1232], ["haplotype", 1239], ["of", 1249], ["at", 1252], ["least", 1255], ["132", 1261], ["kb", 1265], ["among", 1268], ["patients", 1274], ["from", 1283], ["the", 1288], ["different", 1292], ["populations", 1302], [".", 1313], ["With", 1315], ["the", 1320], ["exception", 1324], ["of", 1334], ["the", 1337], ["(", 1341], ["CCTG)(n", 1342], [")", 1349], ["expansion", 1351], [",", 1360], ["the", 1362], ["available", 1366], ["markers", 1376], ["indicate", 1384], ["that", 1393], ["the", 1398], ["DM2", 1402], ["haplotype", 1406], ["is", 1416], ["identical", 1419], ["to", 1429], ["the", 1432], ["most", 1436], ["common", 1441], ["haplotype", 1448], ["in", 1458], ["normal", 1461], ["individuals", 1468], [".", 1479], ["This", 1481], ["situation", 1486], ["is", 1496], ["reminiscent", 1499], ["of", 1511], ["that", 1514], ["seen", 1519], ["in", 1524], ["DM1", 1527], [".", 1530], ["Taken", 1532], ["together", 1538], [",", 1546], ["these", 1548], ["data", 1554], ["suggest", 1559], ["a", 1567], ["single", 1569], ["founding", 1576], ["mutation", 1585], ["in", 1594], ["DM2", 1597], ["patients", 1601], ["of", 1610], ["European", 1613], ["origin", 1622], [".", 1628], ["We", 1630], ["estimate", 1633], ["the", 1642], ["age", 1646], ["of", 1650], ["the", 1653], ["founding", 1657], ["haplotype", 1666], ["and", 1676], ["of", 1680], ["the", 1683], ["DM2", 1687], ["(", 1691], ["CCTG", 1692], [")", 1696], ["expansion", 1698], ["mutation", 1708], ["to", 1717], ["be", 1720], ["approximately", 1723], ["200", 1737], ["-", 1740], ["540", 1741], ["generations", 1745], [".", 1756]]}
{"context": "Mutations in the amyloid precursor protein gene were the first to be recognized as a cause of Alzheimer's disease (AD). We describe 2 Italian families showing the missense mutation in exon 17 of the amyloid precursor protein gene on chromosome 21 (Val717Ile), known as London mutation. In 1 family, this mutation was responsible for AD in 3 out of 7 siblings and it is also present in a fourth sibling who has only shown signs of executive dysfunction so far. Two subjects of the other family with AD diagnosis were carriers of the same mutation. All AD subjects showed a cognitive profile characterized by early impairment in long-term memory, shifting abilities and affective symptoms beginning in the fifth decade of life.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "f9dd23b8836640968364324126b3087b", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[17, 19]], "char_spans": [[94, 112]]}, {"text": "AD", "token_spans": [[107, 107], [63, 63], [21, 21], [97, 97]], "char_spans": [[551, 552], [333, 334], [115, 116], [498, 499]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["the", 13], ["amyloid", 17], ["precursor", 25], ["protein", 35], ["gene", 43], ["were", 48], ["the", 53], ["first", 57], ["to", 63], ["be", 66], ["recognized", 69], ["as", 80], ["a", 83], ["cause", 85], ["of", 91], ["Alzheimer", 94], ["'s", 103], ["disease", 106], ["(", 114], ["AD", 115], [")", 117], [".", 118], ["We", 120], ["describe", 123], ["2", 132], ["Italian", 134], ["families", 142], ["showing", 151], ["the", 159], ["missense", 163], ["mutation", 172], ["in", 181], ["exon", 184], ["17", 189], ["of", 192], ["the", 195], ["amyloid", 199], ["precursor", 207], ["protein", 217], ["gene", 225], ["on", 230], ["chromosome", 233], ["21", 244], ["(", 247], ["Val717Ile", 248], [")", 257], [",", 258], ["known", 260], ["as", 266], ["London", 269], ["mutation", 276], [".", 284], ["In", 286], ["1", 289], ["family", 291], [",", 297], ["this", 299], ["mutation", 304], ["was", 313], ["responsible", 317], ["for", 329], ["AD", 333], ["in", 336], ["3", 339], ["out", 341], ["of", 345], ["7", 348], ["siblings", 350], ["and", 359], ["it", 363], ["is", 366], ["also", 369], ["present", 374], ["in", 382], ["a", 385], ["fourth", 387], ["sibling", 394], ["who", 402], ["has", 406], ["only", 410], ["shown", 415], ["signs", 421], ["of", 427], ["executive", 430], ["dysfunction", 440], ["so", 452], ["far", 455], [".", 458], ["Two", 460], ["subjects", 464], ["of", 473], ["the", 476], ["other", 480], ["family", 486], ["with", 493], ["AD", 498], ["diagnosis", 501], ["were", 511], ["carriers", 516], ["of", 525], ["the", 528], ["same", 532], ["mutation", 537], [".", 545], ["All", 547], ["AD", 551], ["subjects", 554], ["showed", 563], ["a", 570], ["cognitive", 572], ["profile", 582], ["characterized", 590], ["by", 604], ["early", 607], ["impairment", 613], ["in", 624], ["long", 627], ["-", 631], ["term", 632], ["memory", 637], [",", 643], ["shifting", 645], ["abilities", 654], ["and", 664], ["affective", 668], ["symptoms", 678], ["beginning", 687], ["in", 697], ["the", 700], ["fifth", 704], ["decade", 710], ["of", 717], ["life", 720], [".", 724]]}
{"context": "Methylation of histone H3 lysine 4 (H3K4) in Saccharomyces cerevisiae is implemented by Set1/COMPASS, which was originally purified based on the similarity of yeast Set1 to human MLL1 and Drosophila melanogaster Trithorax (Trx). While humans have six COMPASS family members, Drosophila possesses a representative of the three subclasses within COMPASS-like complexes: dSet1 (human SET1A/SET1B), Trx (human MLL1/2), and Trr (human MLL3/4). Here, we report the biochemical purification and molecular characterization of the Drosophila COMPASS family. We observed a one-to-one similarity in subunit composition with their mammalian counterparts, with the exception of LPT (lost plant homeodomains [PHDs] of Trr), which copurifies with the Trr complex. LPT is a previously uncharacterized protein that is homologous to the multiple PHD fingers found in the N-terminal regions of mammalian MLL3/4 but not Drosophila Trr, indicating that Trr and LPT constitute a split gene of an MLL3/4 ancestor. Our study demonstrates that all three complexes in Drosophila are H3K4 methyltransferases; however, dSet1/COMPASS is the major monoubiquitination-dependent H3K4 di- and trimethylase in Drosophila. Taken together, this study provides a springboard for the functional dissection of the COMPASS family members and their role in the regulation of histone H3K4 methylation throughout development in Drosophila.", "qas": [{"question": "Which is the histone residue methylated by MLL1?", "answers": ["H3K4"], "qid": "3288fb6fd40c44d78d4fdd8b337240a0", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["histone", 13], ["residue", 21], ["methylated", 29], ["by", 40], ["MLL1", 43], ["?", 47]], "detected_answers": [{"text": "H3K4", "token_spans": [[203, 203], [191, 191], [7, 7], [235, 235]], "char_spans": [[1147, 1150], [1057, 1060], [36, 39], [1342, 1345]]}]}], "context_tokens": [["Methylation", 0], ["of", 12], ["histone", 15], ["H3", 23], ["lysine", 26], ["4", 33], ["(", 35], ["H3K4", 36], [")", 40], ["in", 42], ["Saccharomyces", 45], ["cerevisiae", 59], ["is", 70], ["implemented", 73], ["by", 85], ["Set1/COMPASS", 88], [",", 100], ["which", 102], ["was", 108], ["originally", 112], ["purified", 123], ["based", 132], ["on", 138], ["the", 141], ["similarity", 145], ["of", 156], ["yeast", 159], ["Set1", 165], ["to", 170], ["human", 173], ["MLL1", 179], ["and", 184], ["Drosophila", 188], ["melanogaster", 199], ["Trithorax", 212], ["(", 222], ["Trx", 223], [")", 226], [".", 227], ["While", 229], ["humans", 235], ["have", 242], ["six", 247], ["COMPASS", 251], ["family", 259], ["members", 266], [",", 273], ["Drosophila", 275], ["possesses", 286], ["a", 296], ["representative", 298], ["of", 313], ["the", 316], ["three", 320], ["subclasses", 326], ["within", 337], ["COMPASS", 344], ["-", 351], ["like", 352], ["complexes", 357], [":", 366], ["dSet1", 368], ["(", 374], ["human", 375], ["SET1A", 381], ["/", 386], ["SET1B", 387], [")", 392], [",", 393], ["Trx", 395], ["(", 399], ["human", 400], ["MLL1/2", 406], [")", 412], [",", 413], ["and", 415], ["Trr", 419], ["(", 423], ["human", 424], ["MLL3/4", 430], [")", 436], [".", 437], ["Here", 439], [",", 443], ["we", 445], ["report", 448], ["the", 455], ["biochemical", 459], ["purification", 471], ["and", 484], ["molecular", 488], ["characterization", 498], ["of", 515], ["the", 518], ["Drosophila", 522], ["COMPASS", 533], ["family", 541], [".", 547], ["We", 549], ["observed", 552], ["a", 561], ["one", 563], ["-", 566], ["to", 567], ["-", 569], ["one", 570], ["similarity", 574], ["in", 585], ["subunit", 588], ["composition", 596], ["with", 608], ["their", 613], ["mammalian", 619], ["counterparts", 629], [",", 641], ["with", 643], ["the", 648], ["exception", 652], ["of", 662], ["LPT", 665], ["(", 669], ["lost", 670], ["plant", 675], ["homeodomains", 681], ["[", 694], ["PHDs", 695], ["]", 699], ["of", 701], ["Trr", 704], [")", 707], [",", 708], ["which", 710], ["copurifies", 716], ["with", 727], ["the", 732], ["Trr", 736], ["complex", 740], [".", 747], ["LPT", 749], ["is", 753], ["a", 756], ["previously", 758], ["uncharacterized", 769], ["protein", 785], ["that", 793], ["is", 798], ["homologous", 801], ["to", 812], ["the", 815], ["multiple", 819], ["PHD", 828], ["fingers", 832], ["found", 840], ["in", 846], ["the", 849], ["N", 853], ["-", 854], ["terminal", 855], ["regions", 864], ["of", 872], ["mammalian", 875], ["MLL3/4", 885], ["but", 892], ["not", 896], ["Drosophila", 900], ["Trr", 911], [",", 914], ["indicating", 916], ["that", 927], ["Trr", 932], ["and", 936], ["LPT", 940], ["constitute", 944], ["a", 955], ["split", 957], ["gene", 963], ["of", 968], ["an", 971], ["MLL3/4", 974], ["ancestor", 981], [".", 989], ["Our", 991], ["study", 995], ["demonstrates", 1001], ["that", 1014], ["all", 1019], ["three", 1023], ["complexes", 1029], ["in", 1039], ["Drosophila", 1042], ["are", 1053], ["H3K4", 1057], ["methyltransferases", 1062], [";", 1080], ["however", 1082], [",", 1089], ["dSet1/COMPASS", 1091], ["is", 1105], ["the", 1108], ["major", 1112], ["monoubiquitination", 1118], ["-", 1136], ["dependent", 1137], ["H3K4", 1147], ["di-", 1152], ["and", 1156], ["trimethylase", 1160], ["in", 1173], ["Drosophila", 1176], [".", 1186], ["Taken", 1188], ["together", 1194], [",", 1202], ["this", 1204], ["study", 1209], ["provides", 1215], ["a", 1224], ["springboard", 1226], ["for", 1238], ["the", 1242], ["functional", 1246], ["dissection", 1257], ["of", 1268], ["the", 1271], ["COMPASS", 1275], ["family", 1283], ["members", 1290], ["and", 1298], ["their", 1302], ["role", 1308], ["in", 1313], ["the", 1316], ["regulation", 1320], ["of", 1331], ["histone", 1334], ["H3K4", 1342], ["methylation", 1347], ["throughout", 1359], ["development", 1370], ["in", 1382], ["Drosophila", 1385], [".", 1395]]}
{"context": "Increased expression of nerve growth factor in injured or inflamed tissue is associated with increased pain. This proof-of-concept study was designed to investigate the safety and analgesic efficacy of tanezumab, a humanized monoclonal antibody that binds and inhibits nerve growth factor. We randomly assigned 450 patients with osteoarthritis of the knee to receive tanezumab (administered at a dose of 10, 25, 50, 100, or 200 \u03bcg per kilogram of body weight) or placebo on days 1 and 56. The primary efficacy measures were knee pain while walking and the patient's global assessment of response to therapy. We also assessed pain, stiffness, and physical function using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC); the rate of response using the criteria of the Outcome Measures for Rheumatology Committee and Osteoarthritis Research Society International Standing Committee for Clinical Trials Response Criteria Initiative (OMERACT-OARSI); and safety. When averaged over weeks 1 through 16, the mean reductions from baseline in knee pain while walking ranged from 45 to 62% with various doses of tanezumab, as compared with 22% with placebo (P<0.001). Tanezumab, as compared with placebo, was also associated with significantly greater improvements in the response to therapy as assessed with the use of the patients' global assessment measure (mean increases in score of 29 to 47% with various doses of tanezumab, as compared with 19% with placebo; P\u22640.001). The rate of response according to the OMERACT-OARSI criteria ranged from 74 to 93% with tanezumab treatment, as compared with 44% with placebo (P<0.001). The rates of adverse events were 68% and 55% in the tanezumab and placebo groups, respectively. The most common adverse events among tanezumab-treated patients were headache (9% of the patients), upper respiratory tract infection (7%), and paresthesia (7%). In this proof-of-concept study, treatment with tanezumab was associated with a reduction in joint pain and improvement in function, with mild and moderate adverse events, among patients with moderate-to-severe osteoarthritis of the knee. (Funded by Rinat Neuroscience; ClinicalTrials.gov number, NCT00394563.).", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "cf8660626db24842b789111d454df139", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[44, 46], [3, 5]], "char_spans": [[269, 287], [24, 42]]}]}], "context_tokens": [["Increased", 0], ["expression", 10], ["of", 21], ["nerve", 24], ["growth", 30], ["factor", 37], ["in", 44], ["injured", 47], ["or", 55], ["inflamed", 58], ["tissue", 67], ["is", 74], ["associated", 77], ["with", 88], ["increased", 93], ["pain", 103], [".", 107], ["This", 109], ["proof", 114], ["-", 119], ["of", 120], ["-", 122], ["concept", 123], ["study", 131], ["was", 137], ["designed", 141], ["to", 150], ["investigate", 153], ["the", 165], ["safety", 169], ["and", 176], ["analgesic", 180], ["efficacy", 190], ["of", 199], ["tanezumab", 202], [",", 211], ["a", 213], ["humanized", 215], ["monoclonal", 225], ["antibody", 236], ["that", 245], ["binds", 250], ["and", 256], ["inhibits", 260], ["nerve", 269], ["growth", 275], ["factor", 282], [".", 288], ["We", 290], ["randomly", 293], ["assigned", 302], ["450", 311], ["patients", 315], ["with", 324], ["osteoarthritis", 329], ["of", 344], ["the", 347], ["knee", 351], ["to", 356], ["receive", 359], ["tanezumab", 367], ["(", 377], ["administered", 378], ["at", 391], ["a", 394], ["dose", 396], ["of", 401], ["10", 404], [",", 406], ["25", 408], [",", 410], ["50", 412], [",", 414], ["100", 416], [",", 419], ["or", 421], ["200", 424], ["\u03bcg", 428], ["per", 431], ["kilogram", 435], ["of", 444], ["body", 447], ["weight", 452], [")", 458], ["or", 460], ["placebo", 463], ["on", 471], ["days", 474], ["1", 479], ["and", 481], ["56", 485], [".", 487], ["The", 489], ["primary", 493], ["efficacy", 501], ["measures", 510], ["were", 519], ["knee", 524], ["pain", 529], ["while", 534], ["walking", 540], ["and", 548], ["the", 552], ["patient", 556], ["'s", 563], ["global", 566], ["assessment", 573], ["of", 584], ["response", 587], ["to", 596], ["therapy", 599], [".", 606], ["We", 608], ["also", 611], ["assessed", 616], ["pain", 625], [",", 629], ["stiffness", 631], [",", 640], ["and", 642], ["physical", 646], ["function", 655], ["using", 664], ["the", 670], ["Western", 674], ["Ontario", 682], ["and", 690], ["McMaster", 694], ["Universities", 703], ["Osteoarthritis", 716], ["Index", 731], ["(", 737], ["WOMAC", 738], [")", 743], [";", 744], ["the", 746], ["rate", 750], ["of", 755], ["response", 758], ["using", 767], ["the", 773], ["criteria", 777], ["of", 786], ["the", 789], ["Outcome", 793], ["Measures", 801], ["for", 810], ["Rheumatology", 814], ["Committee", 827], ["and", 837], ["Osteoarthritis", 841], ["Research", 856], ["Society", 865], ["International", 873], ["Standing", 887], ["Committee", 896], ["for", 906], ["Clinical", 910], ["Trials", 919], ["Response", 926], ["Criteria", 935], ["Initiative", 944], ["(", 955], ["OMERACT", 956], ["-", 963], ["OARSI", 964], [")", 969], [";", 970], ["and", 972], ["safety", 976], [".", 982], ["When", 984], ["averaged", 989], ["over", 998], ["weeks", 1003], ["1", 1009], ["through", 1011], ["16", 1019], [",", 1021], ["the", 1023], ["mean", 1027], ["reductions", 1032], ["from", 1043], ["baseline", 1048], ["in", 1057], ["knee", 1060], ["pain", 1065], ["while", 1070], ["walking", 1076], ["ranged", 1084], ["from", 1091], ["45", 1096], ["to", 1099], ["62", 1102], ["%", 1104], ["with", 1106], ["various", 1111], ["doses", 1119], ["of", 1125], ["tanezumab", 1128], [",", 1137], ["as", 1139], ["compared", 1142], ["with", 1151], ["22", 1156], ["%", 1158], ["with", 1160], ["placebo", 1165], ["(", 1173], ["P<0.001", 1174], [")", 1181], [".", 1182], ["Tanezumab", 1184], [",", 1193], ["as", 1195], ["compared", 1198], ["with", 1207], ["placebo", 1212], [",", 1219], ["was", 1221], ["also", 1225], ["associated", 1230], ["with", 1241], ["significantly", 1246], ["greater", 1260], ["improvements", 1268], ["in", 1281], ["the", 1284], ["response", 1288], ["to", 1297], ["therapy", 1300], ["as", 1308], ["assessed", 1311], ["with", 1320], ["the", 1325], ["use", 1329], ["of", 1333], ["the", 1336], ["patients", 1340], ["'", 1348], ["global", 1350], ["assessment", 1357], ["measure", 1368], ["(", 1376], ["mean", 1377], ["increases", 1382], ["in", 1392], ["score", 1395], ["of", 1401], ["29", 1404], ["to", 1407], ["47", 1410], ["%", 1412], ["with", 1414], ["various", 1419], ["doses", 1427], ["of", 1433], ["tanezumab", 1436], [",", 1445], ["as", 1447], ["compared", 1450], ["with", 1459], ["19", 1464], ["%", 1466], ["with", 1468], ["placebo", 1473], [";", 1480], ["P\u22640.001", 1482], [")", 1489], [".", 1490], ["The", 1492], ["rate", 1496], ["of", 1501], ["response", 1504], ["according", 1513], ["to", 1523], ["the", 1526], ["OMERACT", 1530], ["-", 1537], ["OARSI", 1538], ["criteria", 1544], ["ranged", 1553], ["from", 1560], ["74", 1565], ["to", 1568], ["93", 1571], ["%", 1573], ["with", 1575], ["tanezumab", 1580], ["treatment", 1590], [",", 1599], ["as", 1601], ["compared", 1604], ["with", 1613], ["44", 1618], ["%", 1620], ["with", 1622], ["placebo", 1627], ["(", 1635], ["P<0.001", 1636], [")", 1643], [".", 1644], ["The", 1646], ["rates", 1650], ["of", 1656], ["adverse", 1659], ["events", 1667], ["were", 1674], ["68", 1679], ["%", 1681], ["and", 1683], ["55", 1687], ["%", 1689], ["in", 1691], ["the", 1694], ["tanezumab", 1698], ["and", 1708], ["placebo", 1712], ["groups", 1720], [",", 1726], ["respectively", 1728], [".", 1740], ["The", 1742], ["most", 1746], ["common", 1751], ["adverse", 1758], ["events", 1766], ["among", 1773], ["tanezumab", 1779], ["-", 1788], ["treated", 1789], ["patients", 1797], ["were", 1806], ["headache", 1811], ["(", 1820], ["9", 1821], ["%", 1822], ["of", 1824], ["the", 1827], ["patients", 1831], [")", 1839], [",", 1840], ["upper", 1842], ["respiratory", 1848], ["tract", 1860], ["infection", 1866], ["(", 1876], ["7", 1877], ["%", 1878], [")", 1879], [",", 1880], ["and", 1882], ["paresthesia", 1886], ["(", 1898], ["7", 1899], ["%", 1900], [")", 1901], [".", 1902], ["In", 1904], ["this", 1907], ["proof", 1912], ["-", 1917], ["of", 1918], ["-", 1920], ["concept", 1921], ["study", 1929], [",", 1934], ["treatment", 1936], ["with", 1946], ["tanezumab", 1951], ["was", 1961], ["associated", 1965], ["with", 1976], ["a", 1981], ["reduction", 1983], ["in", 1993], ["joint", 1996], ["pain", 2002], ["and", 2007], ["improvement", 2011], ["in", 2023], ["function", 2026], [",", 2034], ["with", 2036], ["mild", 2041], ["and", 2046], ["moderate", 2050], ["adverse", 2059], ["events", 2067], [",", 2073], ["among", 2075], ["patients", 2081], ["with", 2090], ["moderate", 2095], ["-", 2103], ["to", 2104], ["-", 2106], ["severe", 2107], ["osteoarthritis", 2114], ["of", 2129], ["the", 2132], ["knee", 2136], [".", 2140], ["(", 2142], ["Funded", 2143], ["by", 2150], ["Rinat", 2153], ["Neuroscience", 2159], [";", 2171], ["ClinicalTrials.gov", 2173], ["number", 2192], [",", 2198], ["NCT00394563", 2200], [".", 2211], [")", 2212], [".", 2213]]}
{"context": "Natively disordered proteins are a growing class of anomalies to the structure-function paradigm. The natively disordered protein alpha-synuclein is the primary component of Lewy bodies, the cellular hallmark of Parkinson's disease. We noticed a dramatic difference in dilute solution 1H-15N Heteronuclear Single Quantum Coherence (HSQC) spectra of wild-type alpha-synuclein and two disease-related mutants (A30P and A53T), with spectra collected at 35 degrees C showing fewer cross-peaks than spectra acquired at 10 degrees C. Here, we show the change to be the result of a reversible conformational exchange linked to an increase in hydrodynamic radius and secondary structure as the temperature is raised. Combined with analytical ultracentrifugation data showing alpha-synuclein to be monomeric at both temperatures, we conclude that the poor quality of the 1H-15N HSQC spectra obtained at 35 degrees C is due to conformational fluctuations that occur on the proton chemical shift time scale. Using a truncated variant of alpha-synuclein, we show the conformational exchange occurs in the first 100 amino acids of the protein. Our data illustrate a key difference between globular and natively disordered proteins. The properties of globular proteins change little with solution conditions until they denature cooperatively, but the properties of natively disordered proteins can vary dramatically with solution conditions.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "8af93cd51edd4155854b8bc805023cf9", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[132, 134], [60, 62], [20, 22], [178, 180]], "char_spans": [[767, 781], [359, 373], [130, 144], [1026, 1040]]}]}], "context_tokens": [["Natively", 0], ["disordered", 9], ["proteins", 20], ["are", 29], ["a", 33], ["growing", 35], ["class", 43], ["of", 49], ["anomalies", 52], ["to", 62], ["the", 65], ["structure", 69], ["-", 78], ["function", 79], ["paradigm", 88], [".", 96], ["The", 98], ["natively", 102], ["disordered", 111], ["protein", 122], ["alpha", 130], ["-", 135], ["synuclein", 136], ["is", 146], ["the", 149], ["primary", 153], ["component", 161], ["of", 171], ["Lewy", 174], ["bodies", 179], [",", 185], ["the", 187], ["cellular", 191], ["hallmark", 200], ["of", 209], ["Parkinson", 212], ["'s", 221], ["disease", 224], [".", 231], ["We", 233], ["noticed", 236], ["a", 244], ["dramatic", 246], ["difference", 255], ["in", 266], ["dilute", 269], ["solution", 276], ["1H-15N", 285], ["Heteronuclear", 292], ["Single", 306], ["Quantum", 313], ["Coherence", 321], ["(", 331], ["HSQC", 332], [")", 336], ["spectra", 338], ["of", 346], ["wild", 349], ["-", 353], ["type", 354], ["alpha", 359], ["-", 364], ["synuclein", 365], ["and", 375], ["two", 379], ["disease", 383], ["-", 390], ["related", 391], ["mutants", 399], ["(", 407], ["A30P", 408], ["and", 413], ["A53", 417], ["T", 420], [")", 421], [",", 422], ["with", 424], ["spectra", 429], ["collected", 437], ["at", 447], ["35", 450], ["degrees", 453], ["C", 461], ["showing", 463], ["fewer", 471], ["cross", 477], ["-", 482], ["peaks", 483], ["than", 489], ["spectra", 494], ["acquired", 502], ["at", 511], ["10", 514], ["degrees", 517], ["C.", 525], ["Here", 528], [",", 532], ["we", 534], ["show", 537], ["the", 542], ["change", 546], ["to", 553], ["be", 556], ["the", 559], ["result", 563], ["of", 570], ["a", 573], ["reversible", 575], ["conformational", 586], ["exchange", 601], ["linked", 610], ["to", 617], ["an", 620], ["increase", 623], ["in", 632], ["hydrodynamic", 635], ["radius", 648], ["and", 655], ["secondary", 659], ["structure", 669], ["as", 679], ["the", 682], ["temperature", 686], ["is", 698], ["raised", 701], [".", 707], ["Combined", 709], ["with", 718], ["analytical", 723], ["ultracentrifugation", 734], ["data", 754], ["showing", 759], ["alpha", 767], ["-", 772], ["synuclein", 773], ["to", 783], ["be", 786], ["monomeric", 789], ["at", 799], ["both", 802], ["temperatures", 807], [",", 819], ["we", 821], ["conclude", 824], ["that", 833], ["the", 838], ["poor", 842], ["quality", 847], ["of", 855], ["the", 858], ["1H-15N", 862], ["HSQC", 869], ["spectra", 874], ["obtained", 882], ["at", 891], ["35", 894], ["degrees", 897], ["C", 905], ["is", 907], ["due", 910], ["to", 914], ["conformational", 917], ["fluctuations", 932], ["that", 945], ["occur", 950], ["on", 956], ["the", 959], ["proton", 963], ["chemical", 970], ["shift", 979], ["time", 985], ["scale", 990], [".", 995], ["Using", 997], ["a", 1003], ["truncated", 1005], ["variant", 1015], ["of", 1023], ["alpha", 1026], ["-", 1031], ["synuclein", 1032], [",", 1041], ["we", 1043], ["show", 1046], ["the", 1051], ["conformational", 1055], ["exchange", 1070], ["occurs", 1079], ["in", 1086], ["the", 1089], ["first", 1093], ["100", 1099], ["amino", 1103], ["acids", 1109], ["of", 1115], ["the", 1118], ["protein", 1122], [".", 1129], ["Our", 1131], ["data", 1135], ["illustrate", 1140], ["a", 1151], ["key", 1153], ["difference", 1157], ["between", 1168], ["globular", 1176], ["and", 1185], ["natively", 1189], ["disordered", 1198], ["proteins", 1209], [".", 1217], ["The", 1219], ["properties", 1223], ["of", 1234], ["globular", 1237], ["proteins", 1246], ["change", 1255], ["little", 1262], ["with", 1269], ["solution", 1274], ["conditions", 1283], ["until", 1294], ["they", 1300], ["denature", 1305], ["cooperatively", 1314], [",", 1327], ["but", 1329], ["the", 1333], ["properties", 1337], ["of", 1348], ["natively", 1351], ["disordered", 1360], ["proteins", 1371], ["can", 1380], ["vary", 1384], ["dramatically", 1389], ["with", 1402], ["solution", 1407], ["conditions", 1416], [".", 1426]]}
{"context": "The aim of the study was to determine the frequency and type of MRSA strains and antibiotic susceptibility in Al-Zahra Hospital, Isfahan, Iran. In an analytic descriptive survey in 2005 and early 2006, patients admitted to the hospital who contracted S. aureus nosocomial infections were enrolled in the study. All isolates were identified by the conventional laboratory tests. Minimal Inhibitory Concentration (MIC) of oxacillin on isolated bacteria was determined by E-Test method. According to Clinical and Laboratory Standard Institute (CLSI) criteria all strains with MIC of > or = 4 microg for oxacillin were identified as MRSA. Intrinsic high level resistance (mecA positive) and borderline oxacillin resistant Staphylococcus aureus (BORSA) were detected by amoxicillin-clavulanate E-test strips. Strains with MIC of > or = 4 microg for oxacillin and > or = 8 microg for amoxicillin-clavulanate were identified as mecA positive MRSA. Other staphylococcus with MIC > or = 4 microg for oxacillin and < or = 4 for amoxicillin-clavulanate were identified as mecA negative MRSA (BORSA). MIC of vancomycin also was determined on isolated bacteria. Data were analyzed by SPSS version 13 and Who net version 5. Out of 134 Staphylococcus aureus samples which were isolated from nosocomial infections 90 (67.2%) were MRSA. Sixty seven out of 90 (74.5%) MRSA were mecA positive and 23 out of 90 (25.5%) were mecA negative (BORSA). Although most of the MRSA strains were isolated from surgical site infections, there were no statistically significant differences between types of Staphylococcus aureus growing from variant sites of infections. Only one (1.49) of the mecA positive MRSA had reduced susceptibility to vancomycin but all of the mecA-negative MRSA (BORSA) were sensitive to it. Because one fourth of our staphylococcus strains are mecA negative BORSA and there is no alternative for vancomycin against mecA positive MRSA and Enterococcus spp. in our hospital, vancomycin should be reserved only for life threatening infections due to these organisms. Thus MRSA typing should be done to choose appropriate antibiotic for optimal treatment of MRSA infections.", "qas": [{"question": "What is BORSA?", "answers": ["borderline oxacillin resistant Staphylococcus aureus", "Borderline oxacillin-resistant Staphylococcus aureus"], "qid": "d3cb2ae20ed644fa9da62fd47344b395", "question_tokens": [["What", 0], ["is", 5], ["BORSA", 8], ["?", 13]], "detected_answers": [{"text": "Borderline oxacillin-resistant Staphylococcus aureus", "token_spans": [[122, 126]], "char_spans": [[687, 738]]}]}], "context_tokens": [["The", 0], ["aim", 4], ["of", 8], ["the", 11], ["study", 15], ["was", 21], ["to", 25], ["determine", 28], ["the", 38], ["frequency", 42], ["and", 52], ["type", 56], ["of", 61], ["MRSA", 64], ["strains", 69], ["and", 77], ["antibiotic", 81], ["susceptibility", 92], ["in", 107], ["Al", 110], ["-", 112], ["Zahra", 113], ["Hospital", 119], [",", 127], ["Isfahan", 129], [",", 136], ["Iran", 138], [".", 142], ["In", 144], ["an", 147], ["analytic", 150], ["descriptive", 159], ["survey", 171], ["in", 178], ["2005", 181], ["and", 186], ["early", 190], ["2006", 196], [",", 200], ["patients", 202], ["admitted", 211], ["to", 220], ["the", 223], ["hospital", 227], ["who", 236], ["contracted", 240], ["S.", 251], ["aureus", 254], ["nosocomial", 261], ["infections", 272], ["were", 283], ["enrolled", 288], ["in", 297], ["the", 300], ["study", 304], [".", 309], ["All", 311], ["isolates", 315], ["were", 324], ["identified", 329], ["by", 340], ["the", 343], ["conventional", 347], ["laboratory", 360], ["tests", 371], [".", 376], ["Minimal", 378], ["Inhibitory", 386], ["Concentration", 397], ["(", 411], ["MIC", 412], [")", 415], ["of", 417], ["oxacillin", 420], ["on", 430], ["isolated", 433], ["bacteria", 442], ["was", 451], ["determined", 455], ["by", 466], ["E", 469], ["-", 470], ["Test", 471], ["method", 476], [".", 482], ["According", 484], ["to", 494], ["Clinical", 497], ["and", 506], ["Laboratory", 510], ["Standard", 521], ["Institute", 530], ["(", 540], ["CLSI", 541], [")", 545], ["criteria", 547], ["all", 556], ["strains", 560], ["with", 568], ["MIC", 573], ["of", 577], [">", 580], ["or", 582], ["=", 585], ["4", 587], ["microg", 589], ["for", 596], ["oxacillin", 600], ["were", 610], ["identified", 615], ["as", 626], ["MRSA", 629], [".", 633], ["Intrinsic", 635], ["high", 645], ["level", 650], ["resistance", 656], ["(", 667], ["mecA", 668], ["positive", 673], [")", 681], ["and", 683], ["borderline", 687], ["oxacillin", 698], ["resistant", 708], ["Staphylococcus", 718], ["aureus", 733], ["(", 740], ["BORSA", 741], [")", 746], ["were", 748], ["detected", 753], ["by", 762], ["amoxicillin", 765], ["-", 776], ["clavulanate", 777], ["E", 789], ["-", 790], ["test", 791], ["strips", 796], [".", 802], ["Strains", 804], ["with", 812], ["MIC", 817], ["of", 821], [">", 824], ["or", 826], ["=", 829], ["4", 831], ["microg", 833], ["for", 840], ["oxacillin", 844], ["and", 854], [">", 858], ["or", 860], ["=", 863], ["8", 865], ["microg", 867], ["for", 874], ["amoxicillin", 878], ["-", 889], ["clavulanate", 890], ["were", 902], ["identified", 907], ["as", 918], ["mecA", 921], ["positive", 926], ["MRSA", 935], [".", 939], ["Other", 941], ["staphylococcus", 947], ["with", 962], ["MIC", 967], [">", 971], ["or", 973], ["=", 976], ["4", 978], ["microg", 980], ["for", 987], ["oxacillin", 991], ["and", 1001], ["<", 1005], ["or", 1007], ["=", 1010], ["4", 1012], ["for", 1014], ["amoxicillin", 1018], ["-", 1029], ["clavulanate", 1030], ["were", 1042], ["identified", 1047], ["as", 1058], ["mecA", 1061], ["negative", 1066], ["MRSA", 1075], ["(", 1080], ["BORSA", 1081], [")", 1086], [".", 1087], ["MIC", 1089], ["of", 1093], ["vancomycin", 1096], ["also", 1107], ["was", 1112], ["determined", 1116], ["on", 1127], ["isolated", 1130], ["bacteria", 1139], [".", 1147], ["Data", 1149], ["were", 1154], ["analyzed", 1159], ["by", 1168], ["SPSS", 1171], ["version", 1176], ["13", 1184], ["and", 1187], ["Who", 1191], ["net", 1195], ["version", 1199], ["5", 1207], [".", 1208], ["Out", 1210], ["of", 1214], ["134", 1217], ["Staphylococcus", 1221], ["aureus", 1236], ["samples", 1243], ["which", 1251], ["were", 1257], ["isolated", 1262], ["from", 1271], ["nosocomial", 1276], ["infections", 1287], ["90", 1298], ["(", 1301], ["67.2", 1302], ["%", 1306], [")", 1307], ["were", 1309], ["MRSA", 1314], [".", 1318], ["Sixty", 1320], ["seven", 1326], ["out", 1332], ["of", 1336], ["90", 1339], ["(", 1342], ["74.5", 1343], ["%", 1347], [")", 1348], ["MRSA", 1350], ["were", 1355], ["mecA", 1360], ["positive", 1365], ["and", 1374], ["23", 1378], ["out", 1381], ["of", 1385], ["90", 1388], ["(", 1391], ["25.5", 1392], ["%", 1396], [")", 1397], ["were", 1399], ["mecA", 1404], ["negative", 1409], ["(", 1418], ["BORSA", 1419], [")", 1424], [".", 1425], ["Although", 1427], ["most", 1436], ["of", 1441], ["the", 1444], ["MRSA", 1448], ["strains", 1453], ["were", 1461], ["isolated", 1466], ["from", 1475], ["surgical", 1480], ["site", 1489], ["infections", 1494], [",", 1504], ["there", 1506], ["were", 1512], ["no", 1517], ["statistically", 1520], ["significant", 1534], ["differences", 1546], ["between", 1558], ["types", 1566], ["of", 1572], ["Staphylococcus", 1575], ["aureus", 1590], ["growing", 1597], ["from", 1605], ["variant", 1610], ["sites", 1618], ["of", 1624], ["infections", 1627], [".", 1637], ["Only", 1639], ["one", 1644], ["(", 1648], ["1.49", 1649], [")", 1653], ["of", 1655], ["the", 1658], ["mecA", 1662], ["positive", 1667], ["MRSA", 1676], ["had", 1681], ["reduced", 1685], ["susceptibility", 1693], ["to", 1708], ["vancomycin", 1711], ["but", 1722], ["all", 1726], ["of", 1730], ["the", 1733], ["mecA", 1737], ["-", 1741], ["negative", 1742], ["MRSA", 1751], ["(", 1756], ["BORSA", 1757], [")", 1762], ["were", 1764], ["sensitive", 1769], ["to", 1779], ["it", 1782], [".", 1784], ["Because", 1786], ["one", 1794], ["fourth", 1798], ["of", 1805], ["our", 1808], ["staphylococcus", 1812], ["strains", 1827], ["are", 1835], ["mecA", 1839], ["negative", 1844], ["BORSA", 1853], ["and", 1859], ["there", 1863], ["is", 1869], ["no", 1872], ["alternative", 1875], ["for", 1887], ["vancomycin", 1891], ["against", 1902], ["mecA", 1910], ["positive", 1915], ["MRSA", 1924], ["and", 1929], ["Enterococcus", 1933], ["spp", 1946], [".", 1949], ["in", 1951], ["our", 1954], ["hospital", 1958], [",", 1966], ["vancomycin", 1968], ["should", 1979], ["be", 1986], ["reserved", 1989], ["only", 1998], ["for", 2003], ["life", 2007], ["threatening", 2012], ["infections", 2024], ["due", 2035], ["to", 2039], ["these", 2042], ["organisms", 2048], [".", 2057], ["Thus", 2059], ["MRSA", 2064], ["typing", 2069], ["should", 2076], ["be", 2083], ["done", 2086], ["to", 2091], ["choose", 2094], ["appropriate", 2101], ["antibiotic", 2113], ["for", 2124], ["optimal", 2128], ["treatment", 2136], ["of", 2146], ["MRSA", 2149], ["infections", 2154], [".", 2164]]}
{"context": "Flumazenil, a specific benzodiazepine antagonist, is useful in reversing the sedation and respiratory depression that often occur when benzodiazepines are administered to patients undergoing anesthesia or when patients have taken an intentional benzodiazepine overdose. Judicious use of flumazenil may provide useful diagnostic information and may obviate the need for mechanical ventilation and other invasive supportive measures. Although some controversy exists regarding the possible precipitation of seizure activity in the setting of mixed tricyclic antidepressant-benzodiazepine overdose, worldwide experience with flumazenil has validated its safety and efficacy.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "b4b16d825b304cf98373a45e742826da", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[0, 0], [85, 85], [40, 40]], "char_spans": [[0, 9], [622, 631], [287, 296]]}]}], "context_tokens": [["Flumazenil", 0], [",", 10], ["a", 12], ["specific", 14], ["benzodiazepine", 23], ["antagonist", 38], [",", 48], ["is", 50], ["useful", 53], ["in", 60], ["reversing", 63], ["the", 73], ["sedation", 77], ["and", 86], ["respiratory", 90], ["depression", 102], ["that", 113], ["often", 118], ["occur", 124], ["when", 130], ["benzodiazepines", 135], ["are", 151], ["administered", 155], ["to", 168], ["patients", 171], ["undergoing", 180], ["anesthesia", 191], ["or", 202], ["when", 205], ["patients", 210], ["have", 219], ["taken", 224], ["an", 230], ["intentional", 233], ["benzodiazepine", 245], ["overdose", 260], [".", 268], ["Judicious", 270], ["use", 280], ["of", 284], ["flumazenil", 287], ["may", 298], ["provide", 302], ["useful", 310], ["diagnostic", 317], ["information", 328], ["and", 340], ["may", 344], ["obviate", 348], ["the", 356], ["need", 360], ["for", 365], ["mechanical", 369], ["ventilation", 380], ["and", 392], ["other", 396], ["invasive", 402], ["supportive", 411], ["measures", 422], [".", 430], ["Although", 432], ["some", 441], ["controversy", 446], ["exists", 458], ["regarding", 465], ["the", 475], ["possible", 479], ["precipitation", 488], ["of", 502], ["seizure", 505], ["activity", 513], ["in", 522], ["the", 525], ["setting", 529], ["of", 537], ["mixed", 540], ["tricyclic", 546], ["antidepressant", 556], ["-", 570], ["benzodiazepine", 571], ["overdose", 586], [",", 594], ["worldwide", 596], ["experience", 606], ["with", 617], ["flumazenil", 622], ["has", 633], ["validated", 637], ["its", 647], ["safety", 651], ["and", 658], ["efficacy", 662], [".", 670]]}
{"context": "Hypospadias, when the urethra opens on the ventral side of the penis, is a common malformation seen in about 3 per 1,000 male births. It is a complex disorder associated with genetic and environmental factors and can be part of genetic syndromes. Mowat-Wilson syndrome (MWS) is a multiple congenital anomaly syndrome characterized by a distinct facial phenotype, Hirschsprung disease, microcephaly and mental retardation. It is caused by mutations in the zinc finger homeo box 1B gene, ZFHX1B (SIP1). To date, 68 deletion/mutation-positive cases have been reported. Genitourinary anomalies are common in MWS. Here we report that hypospadias is common in males with this syndrome. In 39 patients where this information was available, hypospadias was present in 46% of patients (18/39). In the 3 Italian male cases reported here, hypospadias was always present. MWS should be considered by endocrinologists in patients with hypospadias associated with developmental delays/mental retardation, in particular in the presence of a distinct facial phenotype.", "qas": [{"question": "Which gene is responsible for the development of the Mowat-Wilson syndrome?", "answers": ["ZFHX1B", "ZEB2", "SIP-1"], "qid": "ace3060b5e2147889d7d4709d6cd1e57", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["the", 49], ["Mowat", 53], ["-", 58], ["Wilson", 59], ["syndrome", 66], ["?", 74]], "detected_answers": [{"text": "ZFHX1B", "token_spans": [[88, 88]], "char_spans": [[486, 491]]}]}], "context_tokens": [["Hypospadias", 0], [",", 11], ["when", 13], ["the", 18], ["urethra", 22], ["opens", 30], ["on", 36], ["the", 39], ["ventral", 43], ["side", 51], ["of", 56], ["the", 59], ["penis", 63], [",", 68], ["is", 70], ["a", 73], ["common", 75], ["malformation", 82], ["seen", 95], ["in", 100], ["about", 103], ["3", 109], ["per", 111], ["1,000", 115], ["male", 121], ["births", 126], [".", 132], ["It", 134], ["is", 137], ["a", 140], ["complex", 142], ["disorder", 150], ["associated", 159], ["with", 170], ["genetic", 175], ["and", 183], ["environmental", 187], ["factors", 201], ["and", 209], ["can", 213], ["be", 217], ["part", 220], ["of", 225], ["genetic", 228], ["syndromes", 236], [".", 245], ["Mowat", 247], ["-", 252], ["Wilson", 253], ["syndrome", 260], ["(", 269], ["MWS", 270], [")", 273], ["is", 275], ["a", 278], ["multiple", 280], ["congenital", 289], ["anomaly", 300], ["syndrome", 308], ["characterized", 317], ["by", 331], ["a", 334], ["distinct", 336], ["facial", 345], ["phenotype", 352], [",", 361], ["Hirschsprung", 363], ["disease", 376], [",", 383], ["microcephaly", 385], ["and", 398], ["mental", 402], ["retardation", 409], [".", 420], ["It", 422], ["is", 425], ["caused", 428], ["by", 435], ["mutations", 438], ["in", 448], ["the", 451], ["zinc", 455], ["finger", 460], ["homeo", 467], ["box", 473], ["1B", 477], ["gene", 480], [",", 484], ["ZFHX1B", 486], ["(", 493], ["SIP1", 494], [")", 498], [".", 499], ["To", 501], ["date", 504], [",", 508], ["68", 510], ["deletion", 513], ["/", 521], ["mutation", 522], ["-", 530], ["positive", 531], ["cases", 540], ["have", 546], ["been", 551], ["reported", 556], [".", 564], ["Genitourinary", 566], ["anomalies", 580], ["are", 590], ["common", 594], ["in", 601], ["MWS", 604], [".", 607], ["Here", 609], ["we", 614], ["report", 617], ["that", 624], ["hypospadias", 629], ["is", 641], ["common", 644], ["in", 651], ["males", 654], ["with", 660], ["this", 665], ["syndrome", 670], [".", 678], ["In", 680], ["39", 683], ["patients", 686], ["where", 695], ["this", 701], ["information", 706], ["was", 718], ["available", 722], [",", 731], ["hypospadias", 733], ["was", 745], ["present", 749], ["in", 757], ["46", 760], ["%", 762], ["of", 764], ["patients", 767], ["(", 776], ["18/39", 777], [")", 782], [".", 783], ["In", 785], ["the", 788], ["3", 792], ["Italian", 794], ["male", 802], ["cases", 807], ["reported", 813], ["here", 822], [",", 826], ["hypospadias", 828], ["was", 840], ["always", 844], ["present", 851], [".", 858], ["MWS", 860], ["should", 864], ["be", 871], ["considered", 874], ["by", 885], ["endocrinologists", 888], ["in", 905], ["patients", 908], ["with", 917], ["hypospadias", 922], ["associated", 934], ["with", 945], ["developmental", 950], ["delays", 964], ["/", 970], ["mental", 971], ["retardation", 978], [",", 989], ["in", 991], ["particular", 994], ["in", 1005], ["the", 1008], ["presence", 1012], ["of", 1021], ["a", 1024], ["distinct", 1026], ["facial", 1035], ["phenotype", 1042], [".", 1051]]}
{"context": "Since the discovery of non-coding, small, highly structured, satellite RNAs (satRNAs) and viroids as subviral pathogens of plants , have been of great interest to molecular biologists as possible living fossils of pre-cellular evolution in an RNA world. Despite extensive studies performed in the last four decades, there is still mystery surrounding the origin and evolutionary relationship between these subviral pathogens. Recent technical advances revealed some commonly shared replication features between these two subviral pathogens. In this review, we discuss our current perception of replication and evolutionary origin of these petite RNA pathogens.", "qas": [{"question": "Which are the smallest known subviral pathogens of plants?", "answers": ["Viroids"], "qid": "0133a9c3b1f74db79d96f61d59105870", "question_tokens": [["Which", 0], ["are", 6], ["the", 10], ["smallest", 14], ["known", 23], ["subviral", 29], ["pathogens", 38], ["of", 48], ["plants", 51], ["?", 57]], "detected_answers": [{"text": "Viroids", "token_spans": [[19, 19]], "char_spans": [[90, 96]]}]}], "context_tokens": [["Since", 0], ["the", 6], ["discovery", 10], ["of", 20], ["non", 23], ["-", 26], ["coding", 27], [",", 33], ["small", 35], [",", 40], ["highly", 42], ["structured", 49], [",", 59], ["satellite", 61], ["RNAs", 71], ["(", 76], ["satRNAs", 77], [")", 84], ["and", 86], ["viroids", 90], ["as", 98], ["subviral", 101], ["pathogens", 110], ["of", 120], ["plants", 123], [",", 130], ["have", 132], ["been", 137], ["of", 142], ["great", 145], ["interest", 151], ["to", 160], ["molecular", 163], ["biologists", 173], ["as", 184], ["possible", 187], ["living", 196], ["fossils", 203], ["of", 211], ["pre", 214], ["-", 217], ["cellular", 218], ["evolution", 227], ["in", 237], ["an", 240], ["RNA", 243], ["world", 247], [".", 252], ["Despite", 254], ["extensive", 262], ["studies", 272], ["performed", 280], ["in", 290], ["the", 293], ["last", 297], ["four", 302], ["decades", 307], [",", 314], ["there", 316], ["is", 322], ["still", 325], ["mystery", 331], ["surrounding", 339], ["the", 351], ["origin", 355], ["and", 362], ["evolutionary", 366], ["relationship", 379], ["between", 392], ["these", 400], ["subviral", 406], ["pathogens", 415], [".", 424], ["Recent", 426], ["technical", 433], ["advances", 443], ["revealed", 452], ["some", 461], ["commonly", 466], ["shared", 475], ["replication", 482], ["features", 494], ["between", 503], ["these", 511], ["two", 517], ["subviral", 521], ["pathogens", 530], [".", 539], ["In", 541], ["this", 544], ["review", 549], [",", 555], ["we", 557], ["discuss", 560], ["our", 568], ["current", 572], ["perception", 580], ["of", 591], ["replication", 594], ["and", 606], ["evolutionary", 610], ["origin", 623], ["of", 630], ["these", 633], ["petite", 639], ["RNA", 646], ["pathogens", 650], [".", 659]]}
{"context": "Chronic myeloid leukemia (CML) originates from the hematopoietic stem cell and is characterized by the reciprocal translocation t(9;22)(q34;q11), which results in the BCR-ABL fusion gene on chromosome 22q-, also known as the Philadelphia chromosome. This chimeric gene codes for a cytoplasmic protein with constitutive tyrosine-kinase activity, responsible for cellular transformation and leukemogenesis in CML. The aim of this observational cohort study was to discriminate and quantify BCR-ABL transcripts in the peripheral blood of patients with CML who were treated with imatinib mesylate (Glivec, Novartis). Twenty-two patients were followed for six months during treatment. Quantitative real time polymerase chain reaction was performed before treatment and after 3 and 6 months from treatment initiation. As compared with the third month, there was a significant decrease in BCR-ABL expression in the sixth month of treatment (P = 0.0002). At the sixth month, there was a significant difference in the levels of the two major transcripts of BCR-ABL, B2A2 and B3A2 (P = 0.0347), indicating that B2A2 may be more sensitive to imatinib. The results of our study indicate that imatinib is able to modify the natural history of CML, and raise the hypothesis that patients who express the B2A2 transcript may have a better prognosis.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "e19160c7bb354a72b145aeab75882fde", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[78, 80], [182, 184], [26, 28], [147, 149]], "char_spans": [[488, 494], [1048, 1054], [167, 173], [882, 888]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["originates", 31], ["from", 42], ["the", 47], ["hematopoietic", 51], ["stem", 65], ["cell", 70], ["and", 75], ["is", 79], ["characterized", 82], ["by", 96], ["the", 99], ["reciprocal", 103], ["translocation", 114], ["t(9;22)(q34;q11", 128], [")", 143], [",", 144], ["which", 146], ["results", 152], ["in", 160], ["the", 163], ["BCR", 167], ["-", 170], ["ABL", 171], ["fusion", 175], ["gene", 182], ["on", 187], ["chromosome", 190], ["22q-", 201], [",", 205], ["also", 207], ["known", 212], ["as", 218], ["the", 221], ["Philadelphia", 225], ["chromosome", 238], [".", 248], ["This", 250], ["chimeric", 255], ["gene", 264], ["codes", 269], ["for", 275], ["a", 279], ["cytoplasmic", 281], ["protein", 293], ["with", 301], ["constitutive", 306], ["tyrosine", 319], ["-", 327], ["kinase", 328], ["activity", 335], [",", 343], ["responsible", 345], ["for", 357], ["cellular", 361], ["transformation", 370], ["and", 385], ["leukemogenesis", 389], ["in", 404], ["CML", 407], [".", 410], ["The", 412], ["aim", 416], ["of", 420], ["this", 423], ["observational", 428], ["cohort", 442], ["study", 449], ["was", 455], ["to", 459], ["discriminate", 462], ["and", 475], ["quantify", 479], ["BCR", 488], ["-", 491], ["ABL", 492], ["transcripts", 496], ["in", 508], ["the", 511], ["peripheral", 515], ["blood", 526], ["of", 532], ["patients", 535], ["with", 544], ["CML", 549], ["who", 553], ["were", 557], ["treated", 562], ["with", 570], ["imatinib", 575], ["mesylate", 584], ["(", 593], ["Glivec", 594], [",", 600], ["Novartis", 602], [")", 610], [".", 611], ["Twenty", 613], ["-", 619], ["two", 620], ["patients", 624], ["were", 633], ["followed", 638], ["for", 647], ["six", 651], ["months", 655], ["during", 662], ["treatment", 669], [".", 678], ["Quantitative", 680], ["real", 693], ["time", 698], ["polymerase", 703], ["chain", 714], ["reaction", 720], ["was", 729], ["performed", 733], ["before", 743], ["treatment", 750], ["and", 760], ["after", 764], ["3", 770], ["and", 772], ["6", 776], ["months", 778], ["from", 785], ["treatment", 790], ["initiation", 800], [".", 810], ["As", 812], ["compared", 815], ["with", 824], ["the", 829], ["third", 833], ["month", 839], [",", 844], ["there", 846], ["was", 852], ["a", 856], ["significant", 858], ["decrease", 870], ["in", 879], ["BCR", 882], ["-", 885], ["ABL", 886], ["expression", 890], ["in", 901], ["the", 904], ["sixth", 908], ["month", 914], ["of", 920], ["treatment", 923], ["(", 933], ["P", 934], ["=", 936], ["0.0002", 938], [")", 944], [".", 945], ["At", 947], ["the", 950], ["sixth", 954], ["month", 960], [",", 965], ["there", 967], ["was", 973], ["a", 977], ["significant", 979], ["difference", 991], ["in", 1002], ["the", 1005], ["levels", 1009], ["of", 1016], ["the", 1019], ["two", 1023], ["major", 1027], ["transcripts", 1033], ["of", 1045], ["BCR", 1048], ["-", 1051], ["ABL", 1052], [",", 1055], ["B2A2", 1057], ["and", 1062], ["B3A2", 1066], ["(", 1071], ["P", 1072], ["=", 1074], ["0.0347", 1076], [")", 1082], [",", 1083], ["indicating", 1085], ["that", 1096], ["B2A2", 1101], ["may", 1106], ["be", 1110], ["more", 1113], ["sensitive", 1118], ["to", 1128], ["imatinib", 1131], [".", 1139], ["The", 1141], ["results", 1145], ["of", 1153], ["our", 1156], ["study", 1160], ["indicate", 1166], ["that", 1175], ["imatinib", 1180], ["is", 1189], ["able", 1192], ["to", 1197], ["modify", 1200], ["the", 1207], ["natural", 1211], ["history", 1219], ["of", 1227], ["CML", 1230], [",", 1233], ["and", 1235], ["raise", 1239], ["the", 1245], ["hypothesis", 1249], ["that", 1260], ["patients", 1265], ["who", 1274], ["express", 1278], ["the", 1286], ["B2A2", 1290], ["transcript", 1295], ["may", 1306], ["have", 1310], ["a", 1315], ["better", 1317], ["prognosis", 1324], [".", 1333]]}
{"context": "This study aimed to explore retrospective childhood ADHD symptomatology, psychiatric comorbidity, rates of substance-use disorders (SUD), as well as their association with high-risk health behaviors in prison and adverse health outcomes. A randomly selected representative sample of inmates in the Puerto Rico correctional system (N = 1,179) was assessed with the Spanish-language Wender Utah Rating Scale (WURS); the Composite International Diagnostic Interview (CIDI) modules for lifetime/current major depression disorder (MDD), generalized anxiety disorder (GAD), and SUD; the Davidson Trauma Scale (DTS; posttraumatic stress disorder [PTSD]); and self-reports of in-site high-risk behaviors. Wald \u03c7(2) tests revealed significant associations of ADHD with MDD and PTSD, as well as increased risk for overdosing and intravenous drug use in prison. A logistic regression model adjusted for mood and anxiety comorbidity predicted lifetime SUD diagnosis (odds ratio = 2.38; 95% confidence interval = [1.15, 4.94]). Our results provide further evidence on the association of drug dependence and ADHD symptoms, and their overrepresentation among prison inmates.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "cb4d005ff43d41c896f0469ab1363b38", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[144, 144], [115, 115]], "char_spans": [[768, 771], [640, 643]]}]}], "context_tokens": [["This", 0], ["study", 5], ["aimed", 11], ["to", 17], ["explore", 20], ["retrospective", 28], ["childhood", 42], ["ADHD", 52], ["symptomatology", 57], [",", 71], ["psychiatric", 73], ["comorbidity", 85], [",", 96], ["rates", 98], ["of", 104], ["substance", 107], ["-", 116], ["use", 117], ["disorders", 121], ["(", 131], ["SUD", 132], [")", 135], [",", 136], ["as", 138], ["well", 141], ["as", 146], ["their", 149], ["association", 155], ["with", 167], ["high", 172], ["-", 176], ["risk", 177], ["health", 182], ["behaviors", 189], ["in", 199], ["prison", 202], ["and", 209], ["adverse", 213], ["health", 221], ["outcomes", 228], [".", 236], ["A", 238], ["randomly", 240], ["selected", 249], ["representative", 258], ["sample", 273], ["of", 280], ["inmates", 283], ["in", 291], ["the", 294], ["Puerto", 298], ["Rico", 305], ["correctional", 310], ["system", 323], ["(", 330], ["N", 331], ["=", 333], ["1,179", 335], [")", 340], ["was", 342], ["assessed", 346], ["with", 355], ["the", 360], ["Spanish", 364], ["-", 371], ["language", 372], ["Wender", 381], ["Utah", 388], ["Rating", 393], ["Scale", 400], ["(", 406], ["WURS", 407], [")", 411], [";", 412], ["the", 414], ["Composite", 418], ["International", 428], ["Diagnostic", 442], ["Interview", 453], ["(", 463], ["CIDI", 464], [")", 468], ["modules", 470], ["for", 478], ["lifetime", 482], ["/", 490], ["current", 491], ["major", 499], ["depression", 505], ["disorder", 516], ["(", 525], ["MDD", 526], [")", 529], [",", 530], ["generalized", 532], ["anxiety", 544], ["disorder", 552], ["(", 561], ["GAD", 562], [")", 565], [",", 566], ["and", 568], ["SUD", 572], [";", 575], ["the", 577], ["Davidson", 581], ["Trauma", 590], ["Scale", 597], ["(", 603], ["DTS", 604], [";", 607], ["posttraumatic", 609], ["stress", 623], ["disorder", 630], ["[", 639], ["PTSD", 640], ["]", 644], [")", 645], [";", 646], ["and", 648], ["self", 652], ["-", 656], ["reports", 657], ["of", 665], ["in", 668], ["-", 670], ["site", 671], ["high", 676], ["-", 680], ["risk", 681], ["behaviors", 686], [".", 695], ["Wald", 697], ["\u03c7(2", 702], [")", 705], ["tests", 707], ["revealed", 713], ["significant", 722], ["associations", 734], ["of", 747], ["ADHD", 750], ["with", 755], ["MDD", 760], ["and", 764], ["PTSD", 768], [",", 772], ["as", 774], ["well", 777], ["as", 782], ["increased", 785], ["risk", 795], ["for", 800], ["overdosing", 804], ["and", 815], ["intravenous", 819], ["drug", 831], ["use", 836], ["in", 840], ["prison", 843], [".", 849], ["A", 851], ["logistic", 853], ["regression", 862], ["model", 873], ["adjusted", 879], ["for", 888], ["mood", 892], ["and", 897], ["anxiety", 901], ["comorbidity", 909], ["predicted", 921], ["lifetime", 931], ["SUD", 940], ["diagnosis", 944], ["(", 954], ["odds", 955], ["ratio", 960], ["=", 966], ["2.38", 968], [";", 972], ["95", 974], ["%", 976], ["confidence", 978], ["interval", 989], ["=", 998], ["[", 1000], ["1.15", 1001], [",", 1005], ["4.94", 1007], ["]", 1011], [")", 1012], [".", 1013], ["Our", 1015], ["results", 1019], ["provide", 1027], ["further", 1035], ["evidence", 1043], ["on", 1052], ["the", 1055], ["association", 1059], ["of", 1071], ["drug", 1074], ["dependence", 1079], ["and", 1090], ["ADHD", 1094], ["symptoms", 1099], [",", 1107], ["and", 1109], ["their", 1113], ["overrepresentation", 1119], ["among", 1138], ["prison", 1144], ["inmates", 1151], [".", 1158]]}
{"context": "Neurofibromatosis type 1 (NF1) is the most common genetic disease affecting the nervous system. Patients typically develop many tumors over their lifetime, leading to increased morbidity and mortality. The NF1 gene, mutated in NF1, is also commonly mutated in sporadic glioblastoma multiforme (GBM). Because both NF1 and GBM are currently incurable, new therapeutic approaches are clearly needed. Natural products represent an opportunity to develop new therapies, as they have been evolutionarily selected to play targeted roles in organisms. Schweinfurthin A is a prenylated stilbene natural product that has previously shown specific inhibitory activity against brain and hematopoietic tumor lines. We show that patient-derived GBM and NF1 malignant peripheral nerve sheath tumor (MPNST) lines, as well as tumor lines derived from the Nf1-/+;Trp53-/+ (NPcis) mouse model of astrocytoma and MPNST are highly sensitive to inhibition by schweinfurthin A and its synthetic analogs. In contrast, primary mouse astrocytes are resistant to the growth inhibitory effects of schweinfurthin A, suggesting that schweinfurthin A may act specifically on tumor cells. Stable transfection of the GTPase-activating protein related domain of Nf1 into Nf1-/-;Trp53-/- astrocytoma cells confers resistance to schweinfurthin A. In addition, the profound effect of schweinfurthin A on dynamic reorganization of the actin cytoskeleton led us to discover that schweinfurthin A inhibits growth factor-stimulated Rho signaling. In summary, we have identified a class of small molecules that specifically inhibit growth of cells from both central and peripheral nervous system tumors and seem to act on NF1-deficient cells through cytoskeletal reorganization correlating to changes in Rho signaling.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "0d78800e67c54fad88dcb0110c4ca8f4", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[203, 203], [122, 122], [4, 4], [55, 55], [39, 39], [34, 34]], "char_spans": [[1228, 1230], [739, 741], [26, 28], [313, 315], [227, 229], [206, 208]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["(", 25], ["NF1", 26], [")", 29], ["is", 31], ["the", 34], ["most", 38], ["common", 43], ["genetic", 50], ["disease", 58], ["affecting", 66], ["the", 76], ["nervous", 80], ["system", 88], [".", 94], ["Patients", 96], ["typically", 105], ["develop", 115], ["many", 123], ["tumors", 128], ["over", 135], ["their", 140], ["lifetime", 146], [",", 154], ["leading", 156], ["to", 164], ["increased", 167], ["morbidity", 177], ["and", 187], ["mortality", 191], [".", 200], ["The", 202], ["NF1", 206], ["gene", 210], [",", 214], ["mutated", 216], ["in", 224], ["NF1", 227], [",", 230], ["is", 232], ["also", 235], ["commonly", 240], ["mutated", 249], ["in", 257], ["sporadic", 260], ["glioblastoma", 269], ["multiforme", 282], ["(", 293], ["GBM", 294], [")", 297], [".", 298], ["Because", 300], ["both", 308], ["NF1", 313], ["and", 317], ["GBM", 321], ["are", 325], ["currently", 329], ["incurable", 339], [",", 348], ["new", 350], ["therapeutic", 354], ["approaches", 366], ["are", 377], ["clearly", 381], ["needed", 389], [".", 395], ["Natural", 397], ["products", 405], ["represent", 414], ["an", 424], ["opportunity", 427], ["to", 439], ["develop", 442], ["new", 450], ["therapies", 454], [",", 463], ["as", 465], ["they", 468], ["have", 473], ["been", 478], ["evolutionarily", 483], ["selected", 498], ["to", 507], ["play", 510], ["targeted", 515], ["roles", 524], ["in", 530], ["organisms", 533], [".", 542], ["Schweinfurthin", 544], ["A", 559], ["is", 561], ["a", 564], ["prenylated", 566], ["stilbene", 577], ["natural", 586], ["product", 594], ["that", 602], ["has", 607], ["previously", 611], ["shown", 622], ["specific", 628], ["inhibitory", 637], ["activity", 648], ["against", 657], ["brain", 665], ["and", 671], ["hematopoietic", 675], ["tumor", 689], ["lines", 695], [".", 700], ["We", 702], ["show", 705], ["that", 710], ["patient", 715], ["-", 722], ["derived", 723], ["GBM", 731], ["and", 735], ["NF1", 739], ["malignant", 743], ["peripheral", 753], ["nerve", 764], ["sheath", 770], ["tumor", 777], ["(", 783], ["MPNST", 784], [")", 789], ["lines", 791], [",", 796], ["as", 798], ["well", 801], ["as", 806], ["tumor", 809], ["lines", 815], ["derived", 821], ["from", 829], ["the", 834], ["Nf1-/+;Trp53-/+", 838], ["(", 854], ["NPcis", 855], [")", 860], ["mouse", 862], ["model", 868], ["of", 874], ["astrocytoma", 877], ["and", 889], ["MPNST", 893], ["are", 899], ["highly", 903], ["sensitive", 910], ["to", 920], ["inhibition", 923], ["by", 934], ["schweinfurthin", 937], ["A", 952], ["and", 954], ["its", 958], ["synthetic", 962], ["analogs", 972], [".", 979], ["In", 981], ["contrast", 984], [",", 992], ["primary", 994], ["mouse", 1002], ["astrocytes", 1008], ["are", 1019], ["resistant", 1023], ["to", 1033], ["the", 1036], ["growth", 1040], ["inhibitory", 1047], ["effects", 1058], ["of", 1066], ["schweinfurthin", 1069], ["A", 1084], [",", 1085], ["suggesting", 1087], ["that", 1098], ["schweinfurthin", 1103], ["A", 1118], ["may", 1120], ["act", 1124], ["specifically", 1128], ["on", 1141], ["tumor", 1144], ["cells", 1150], [".", 1155], ["Stable", 1157], ["transfection", 1164], ["of", 1177], ["the", 1180], ["GTPase", 1184], ["-", 1190], ["activating", 1191], ["protein", 1202], ["related", 1210], ["domain", 1218], ["of", 1225], ["Nf1", 1228], ["into", 1232], ["Nf1-/-;Trp53-/-", 1237], ["astrocytoma", 1253], ["cells", 1265], ["confers", 1271], ["resistance", 1279], ["to", 1290], ["schweinfurthin", 1293], ["A.", 1308], ["In", 1311], ["addition", 1314], [",", 1322], ["the", 1324], ["profound", 1328], ["effect", 1337], ["of", 1344], ["schweinfurthin", 1347], ["A", 1362], ["on", 1364], ["dynamic", 1367], ["reorganization", 1375], ["of", 1390], ["the", 1393], ["actin", 1397], ["cytoskeleton", 1403], ["led", 1416], ["us", 1420], ["to", 1423], ["discover", 1426], ["that", 1435], ["schweinfurthin", 1440], ["A", 1455], ["inhibits", 1457], ["growth", 1466], ["factor", 1473], ["-", 1479], ["stimulated", 1480], ["Rho", 1491], ["signaling", 1495], [".", 1504], ["In", 1506], ["summary", 1509], [",", 1516], ["we", 1518], ["have", 1521], ["identified", 1526], ["a", 1537], ["class", 1539], ["of", 1545], ["small", 1548], ["molecules", 1554], ["that", 1564], ["specifically", 1569], ["inhibit", 1582], ["growth", 1590], ["of", 1597], ["cells", 1600], ["from", 1606], ["both", 1611], ["central", 1616], ["and", 1624], ["peripheral", 1628], ["nervous", 1639], ["system", 1647], ["tumors", 1654], ["and", 1661], ["seem", 1665], ["to", 1670], ["act", 1673], ["on", 1677], ["NF1-deficient", 1680], ["cells", 1694], ["through", 1700], ["cytoskeletal", 1708], ["reorganization", 1721], ["correlating", 1736], ["to", 1748], ["changes", 1751], ["in", 1759], ["Rho", 1762], ["signaling", 1766], [".", 1775]]}
{"context": "The clear connection between ribosome biogenesis dysfunction and specific hematopoiesis-related disorders prompted us to examine the role of critical lineage-specific transcription factors in the transcriptional regulation of ribosomal protein (RP) genes during terminal erythroid differentiation. By applying EMSA and ChIP methodologies in mouse erythroleukemia cells we show that GATA1 and PU.1 bind in vitro and in vivo the proximal promoter region of the RPS19 gene which is frequently mutated in Diamond-Blackfan Anemia. Moreover, ChIPseq data analysis also demonstrates that several RP genes are enriched as potential GATA1 and PU.1 gene targets in mouse and human erythroid cells, with GATA1 binding showing an association with higher ribosomal protein gene expression levels during terminal erythroid differentiation in human and mouse. Our results suggest that RP gene expression and hence balanced ribosome biosynthesis may be specifically and selectively regulated by lineage specific transcription factors during hematopoiesis, a finding which may be clinically relevant to ribosomopathies.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "35f2d4aeaa304a9d9c6fb6f5340d5589", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[77, 80]], "char_spans": [[501, 523]]}]}], "context_tokens": [["The", 0], ["clear", 4], ["connection", 10], ["between", 21], ["ribosome", 29], ["biogenesis", 38], ["dysfunction", 49], ["and", 61], ["specific", 65], ["hematopoiesis", 74], ["-", 87], ["related", 88], ["disorders", 96], ["prompted", 106], ["us", 115], ["to", 118], ["examine", 121], ["the", 129], ["role", 133], ["of", 138], ["critical", 141], ["lineage", 150], ["-", 157], ["specific", 158], ["transcription", 167], ["factors", 181], ["in", 189], ["the", 192], ["transcriptional", 196], ["regulation", 212], ["of", 223], ["ribosomal", 226], ["protein", 236], ["(", 244], ["RP", 245], [")", 247], ["genes", 249], ["during", 255], ["terminal", 262], ["erythroid", 271], ["differentiation", 281], [".", 296], ["By", 298], ["applying", 301], ["EMSA", 310], ["and", 315], ["ChIP", 319], ["methodologies", 324], ["in", 338], ["mouse", 341], ["erythroleukemia", 347], ["cells", 363], ["we", 369], ["show", 372], ["that", 377], ["GATA1", 382], ["and", 388], ["PU.1", 392], ["bind", 397], ["in", 402], ["vitro", 405], ["and", 411], ["in", 415], ["vivo", 418], ["the", 423], ["proximal", 427], ["promoter", 436], ["region", 445], ["of", 452], ["the", 455], ["RPS19", 459], ["gene", 465], ["which", 470], ["is", 476], ["frequently", 479], ["mutated", 490], ["in", 498], ["Diamond", 501], ["-", 508], ["Blackfan", 509], ["Anemia", 518], [".", 524], ["Moreover", 526], [",", 534], ["ChIPseq", 536], ["data", 544], ["analysis", 549], ["also", 558], ["demonstrates", 563], ["that", 576], ["several", 581], ["RP", 589], ["genes", 592], ["are", 598], ["enriched", 602], ["as", 611], ["potential", 614], ["GATA1", 624], ["and", 630], ["PU.1", 634], ["gene", 639], ["targets", 644], ["in", 652], ["mouse", 655], ["and", 661], ["human", 665], ["erythroid", 671], ["cells", 681], [",", 686], ["with", 688], ["GATA1", 693], ["binding", 699], ["showing", 707], ["an", 715], ["association", 718], ["with", 730], ["higher", 735], ["ribosomal", 742], ["protein", 752], ["gene", 760], ["expression", 765], ["levels", 776], ["during", 783], ["terminal", 790], ["erythroid", 799], ["differentiation", 809], ["in", 825], ["human", 828], ["and", 834], ["mouse", 838], [".", 843], ["Our", 845], ["results", 849], ["suggest", 857], ["that", 865], ["RP", 870], ["gene", 873], ["expression", 878], ["and", 889], ["hence", 893], ["balanced", 899], ["ribosome", 908], ["biosynthesis", 917], ["may", 930], ["be", 934], ["specifically", 937], ["and", 950], ["selectively", 954], ["regulated", 966], ["by", 976], ["lineage", 979], ["specific", 987], ["transcription", 996], ["factors", 1010], ["during", 1018], ["hematopoiesis", 1025], [",", 1038], ["a", 1040], ["finding", 1042], ["which", 1050], ["may", 1056], ["be", 1060], ["clinically", 1063], ["relevant", 1074], ["to", 1083], ["ribosomopathies", 1086], [".", 1101]]}
{"context": "Erythrasma is a superficial cutaneous infection caused by Corynebacterium minutissimum and is characterized by fluorescence under Wood's light (UV) because of the presence of porphyrins. These molecules are photosensitizing and we propose to assess efficacy of red light that activates porphyrins (photodynamic reaction) in treatment of this pathology. Assessment of effects of photodynamic action of red light for treatment of erythrasma without exogenous photosensitizing molecules. Thirteen patients with erythrasma were treated by one illumination (80 J/cm2) by red light (broad band, peak at 635 nm) without exogenous photosensitizing molecules. Disappearance or reduction of extent of lesions were observed 2 weeks later. If lesions were still present, a second irradiation was conducted with the same method. Preliminary results are presented. As a result of red light irradiation, we noticed a complete recovery for three patients and, in most other cases, reduction of extent of lesions (mean: -29% after one session). The treatment was well tolerated. We report first cases of photodynamic treatment of erythrasma. There are other reports of clinical applications of antimicrobial action of photodynamic therapy in dermatology (acne vulgaris, leishmaniasis, warts, etc.). But there are few applications without addition of exogenous photosensitizing agent. The originality and interest of our study is to use spontaneous presence of porphyrins in the lesions. This technique seems to be an interesting alternative, inexpensive and easy, for the treatment of this localized infection. But an optimal method is still to be determined to improve efficacy.", "qas": [{"question": "Which bacteria causes erythrasma?", "answers": ["Corynebacterium minutissimum"], "qid": "6216a4e8801a4b69bc9d147d4f205120", "question_tokens": [["Which", 0], ["bacteria", 6], ["causes", 15], ["erythrasma", 22], ["?", 32]], "detected_answers": [{"text": "Corynebacterium minutissimum", "token_spans": [[8, 9]], "char_spans": [[58, 85]]}]}], "context_tokens": [["Erythrasma", 0], ["is", 11], ["a", 14], ["superficial", 16], ["cutaneous", 28], ["infection", 38], ["caused", 48], ["by", 55], ["Corynebacterium", 58], ["minutissimum", 74], ["and", 87], ["is", 91], ["characterized", 94], ["by", 108], ["fluorescence", 111], ["under", 124], ["Wood", 130], ["'s", 134], ["light", 137], ["(", 143], ["UV", 144], [")", 146], ["because", 148], ["of", 156], ["the", 159], ["presence", 163], ["of", 172], ["porphyrins", 175], [".", 185], ["These", 187], ["molecules", 193], ["are", 203], ["photosensitizing", 207], ["and", 224], ["we", 228], ["propose", 231], ["to", 239], ["assess", 242], ["efficacy", 249], ["of", 258], ["red", 261], ["light", 265], ["that", 271], ["activates", 276], ["porphyrins", 286], ["(", 297], ["photodynamic", 298], ["reaction", 311], [")", 319], ["in", 321], ["treatment", 324], ["of", 334], ["this", 337], ["pathology", 342], [".", 351], ["Assessment", 353], ["of", 364], ["effects", 367], ["of", 375], ["photodynamic", 378], ["action", 391], ["of", 398], ["red", 401], ["light", 405], ["for", 411], ["treatment", 415], ["of", 425], ["erythrasma", 428], ["without", 439], ["exogenous", 447], ["photosensitizing", 457], ["molecules", 474], [".", 483], ["Thirteen", 485], ["patients", 494], ["with", 503], ["erythrasma", 508], ["were", 519], ["treated", 524], ["by", 532], ["one", 535], ["illumination", 539], ["(", 552], ["80", 553], ["J", 556], ["/", 557], ["cm2", 558], [")", 561], ["by", 563], ["red", 566], ["light", 570], ["(", 576], ["broad", 577], ["band", 583], [",", 587], ["peak", 589], ["at", 594], ["635", 597], ["nm", 601], [")", 603], ["without", 605], ["exogenous", 613], ["photosensitizing", 623], ["molecules", 640], [".", 649], ["Disappearance", 651], ["or", 665], ["reduction", 668], ["of", 678], ["extent", 681], ["of", 688], ["lesions", 691], ["were", 699], ["observed", 704], ["2", 713], ["weeks", 715], ["later", 721], [".", 726], ["If", 728], ["lesions", 731], ["were", 739], ["still", 744], ["present", 750], [",", 757], ["a", 759], ["second", 761], ["irradiation", 768], ["was", 780], ["conducted", 784], ["with", 794], ["the", 799], ["same", 803], ["method", 808], [".", 814], ["Preliminary", 816], ["results", 828], ["are", 836], ["presented", 840], [".", 849], ["As", 851], ["a", 854], ["result", 856], ["of", 863], ["red", 866], ["light", 870], ["irradiation", 876], [",", 887], ["we", 889], ["noticed", 892], ["a", 900], ["complete", 902], ["recovery", 911], ["for", 920], ["three", 924], ["patients", 930], ["and", 939], [",", 942], ["in", 944], ["most", 947], ["other", 952], ["cases", 958], [",", 963], ["reduction", 965], ["of", 975], ["extent", 978], ["of", 985], ["lesions", 988], ["(", 996], ["mean", 997], [":", 1001], ["-29", 1003], ["%", 1006], ["after", 1008], ["one", 1014], ["session", 1018], [")", 1025], [".", 1026], ["The", 1028], ["treatment", 1032], ["was", 1042], ["well", 1046], ["tolerated", 1051], [".", 1060], ["We", 1062], ["report", 1065], ["first", 1072], ["cases", 1078], ["of", 1084], ["photodynamic", 1087], ["treatment", 1100], ["of", 1110], ["erythrasma", 1113], [".", 1123], ["There", 1125], ["are", 1131], ["other", 1135], ["reports", 1141], ["of", 1149], ["clinical", 1152], ["applications", 1161], ["of", 1174], ["antimicrobial", 1177], ["action", 1191], ["of", 1198], ["photodynamic", 1201], ["therapy", 1214], ["in", 1222], ["dermatology", 1225], ["(", 1237], ["acne", 1238], ["vulgaris", 1243], [",", 1251], ["leishmaniasis", 1253], [",", 1266], ["warts", 1268], [",", 1273], ["etc", 1275], [".", 1278], [")", 1279], [".", 1280], ["But", 1282], ["there", 1286], ["are", 1292], ["few", 1296], ["applications", 1300], ["without", 1313], ["addition", 1321], ["of", 1330], ["exogenous", 1333], ["photosensitizing", 1343], ["agent", 1360], [".", 1365], ["The", 1367], ["originality", 1371], ["and", 1383], ["interest", 1387], ["of", 1396], ["our", 1399], ["study", 1403], ["is", 1409], ["to", 1412], ["use", 1415], ["spontaneous", 1419], ["presence", 1431], ["of", 1440], ["porphyrins", 1443], ["in", 1454], ["the", 1457], ["lesions", 1461], [".", 1468], ["This", 1470], ["technique", 1475], ["seems", 1485], ["to", 1491], ["be", 1494], ["an", 1497], ["interesting", 1500], ["alternative", 1512], [",", 1523], ["inexpensive", 1525], ["and", 1537], ["easy", 1541], [",", 1545], ["for", 1547], ["the", 1551], ["treatment", 1555], ["of", 1565], ["this", 1568], ["localized", 1573], ["infection", 1583], [".", 1592], ["But", 1594], ["an", 1598], ["optimal", 1601], ["method", 1609], ["is", 1616], ["still", 1619], ["to", 1625], ["be", 1628], ["determined", 1631], ["to", 1642], ["improve", 1645], ["efficacy", 1653], [".", 1661]]}
{"context": "In chronic myelogenous leukemia (CML), the development of chromosomal abnormalities in addition to the Philadelphia chromosome (clonal evolution) is considered by many to be a feature of accelerated phase (AP). Imatinib mesylate (STI571), a selective inhibitor of the Bcr-Abl tyrosine kinase, has significant activity in AP CML. As clonal evolution could allow Bcr-Abl independent proliferation, we analyzed its impact on the outcome of 71 AP patients treated with 600 mg of imatinib mesylate. Fifteen patients had clonal evolution alone (AP-CE), 32 had AP features but no evidence of clonal evolution (HEM-AP), and 24 had AP features plus clonal evolution (HEM-AP + CE). Of the AP-CE patients, 73% had a major cytogenetic response, compared with 31% of the HEM-AP patients (P =.043) and 12.5% of the HEM-AP + CE patients (P =.007). Complete cytogenetic responses were seen in 60% of AP-CE patients, compared with 31% of HEM-AP patients (P =.19) and 8% of HEM-AP + CE patients (P <.001). With mean follow-up of 11.2 months, 35% of all patients failed treatment. The lowest estimated rate of treatment failure at 1 year, 0%, was seen in AP-CE patients, compared with rates of 31% for HEM-AP patients and 69% for HEM-AP + CE patients (P =.0004). After 1 year, 100% of AP-CE patients were still alive, compared with 85% of HEM-AP patients and 67.5% of HEM-AP + CE patients (P =.01). In conclusion, in patients with clonal evolution as the sole criterion of disease acceleration, good responses to imatinib are still possible. Once patients have other signs of acceleration, clonal evolution predicts lower response rates and a shorter time to treatment failure.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "3cc897405a194e8f95127a9560586a7a", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[49, 51], [67, 69]], "char_spans": [[268, 274], [361, 367]]}]}], "context_tokens": [["In", 0], ["chronic", 3], ["myelogenous", 11], ["leukemia", 23], ["(", 32], ["CML", 33], [")", 36], [",", 37], ["the", 39], ["development", 43], ["of", 55], ["chromosomal", 58], ["abnormalities", 70], ["in", 84], ["addition", 87], ["to", 96], ["the", 99], ["Philadelphia", 103], ["chromosome", 116], ["(", 127], ["clonal", 128], ["evolution", 135], [")", 144], ["is", 146], ["considered", 149], ["by", 160], ["many", 163], ["to", 168], ["be", 171], ["a", 174], ["feature", 176], ["of", 184], ["accelerated", 187], ["phase", 199], ["(", 205], ["AP", 206], [")", 208], [".", 209], ["Imatinib", 211], ["mesylate", 220], ["(", 229], ["STI571", 230], [")", 236], [",", 237], ["a", 239], ["selective", 241], ["inhibitor", 251], ["of", 261], ["the", 264], ["Bcr", 268], ["-", 271], ["Abl", 272], ["tyrosine", 276], ["kinase", 285], [",", 291], ["has", 293], ["significant", 297], ["activity", 309], ["in", 318], ["AP", 321], ["CML", 324], [".", 327], ["As", 329], ["clonal", 332], ["evolution", 339], ["could", 349], ["allow", 355], ["Bcr", 361], ["-", 364], ["Abl", 365], ["independent", 369], ["proliferation", 381], [",", 394], ["we", 396], ["analyzed", 399], ["its", 408], ["impact", 412], ["on", 419], ["the", 422], ["outcome", 426], ["of", 434], ["71", 437], ["AP", 440], ["patients", 443], ["treated", 452], ["with", 460], ["600", 465], ["mg", 469], ["of", 472], ["imatinib", 475], ["mesylate", 484], [".", 492], ["Fifteen", 494], ["patients", 502], ["had", 511], ["clonal", 515], ["evolution", 522], ["alone", 532], ["(", 538], ["AP", 539], ["-", 541], ["CE", 542], [")", 544], [",", 545], ["32", 547], ["had", 550], ["AP", 554], ["features", 557], ["but", 566], ["no", 570], ["evidence", 573], ["of", 582], ["clonal", 585], ["evolution", 592], ["(", 602], ["HEM", 603], ["-", 606], ["AP", 607], [")", 609], [",", 610], ["and", 612], ["24", 616], ["had", 619], ["AP", 623], ["features", 626], ["plus", 635], ["clonal", 640], ["evolution", 647], ["(", 657], ["HEM", 658], ["-", 661], ["AP", 662], ["+", 665], ["CE", 667], [")", 669], [".", 670], ["Of", 672], ["the", 675], ["AP", 679], ["-", 681], ["CE", 682], ["patients", 685], [",", 693], ["73", 695], ["%", 697], ["had", 699], ["a", 703], ["major", 705], ["cytogenetic", 711], ["response", 723], [",", 731], ["compared", 733], ["with", 742], ["31", 747], ["%", 749], ["of", 751], ["the", 754], ["HEM", 758], ["-", 761], ["AP", 762], ["patients", 765], ["(", 774], ["P", 775], ["=", 777], [".043", 778], [")", 782], ["and", 784], ["12.5", 788], ["%", 792], ["of", 794], ["the", 797], ["HEM", 801], ["-", 804], ["AP", 805], ["+", 808], ["CE", 810], ["patients", 813], ["(", 822], ["P", 823], ["=", 825], [".007", 826], [")", 830], [".", 831], ["Complete", 833], ["cytogenetic", 842], ["responses", 854], ["were", 864], ["seen", 869], ["in", 874], ["60", 877], ["%", 879], ["of", 881], ["AP", 884], ["-", 886], ["CE", 887], ["patients", 890], [",", 898], ["compared", 900], ["with", 909], ["31", 914], ["%", 916], ["of", 918], ["HEM", 921], ["-", 924], ["AP", 925], ["patients", 928], ["(", 937], ["P", 938], ["=", 940], [".19", 941], [")", 944], ["and", 946], ["8", 950], ["%", 951], ["of", 953], ["HEM", 956], ["-", 959], ["AP", 960], ["+", 963], ["CE", 965], ["patients", 968], ["(", 977], ["P", 978], ["<", 980], [".001", 981], [")", 985], [".", 986], ["With", 988], ["mean", 993], ["follow", 998], ["-", 1004], ["up", 1005], ["of", 1008], ["11.2", 1011], ["months", 1016], [",", 1022], ["35", 1024], ["%", 1026], ["of", 1028], ["all", 1031], ["patients", 1035], ["failed", 1044], ["treatment", 1051], [".", 1060], ["The", 1062], ["lowest", 1066], ["estimated", 1073], ["rate", 1083], ["of", 1088], ["treatment", 1091], ["failure", 1101], ["at", 1109], ["1", 1112], ["year", 1114], [",", 1118], ["0", 1120], ["%", 1121], [",", 1122], ["was", 1124], ["seen", 1128], ["in", 1133], ["AP", 1136], ["-", 1138], ["CE", 1139], ["patients", 1142], [",", 1150], ["compared", 1152], ["with", 1161], ["rates", 1166], ["of", 1172], ["31", 1175], ["%", 1177], ["for", 1179], ["HEM", 1183], ["-", 1186], ["AP", 1187], ["patients", 1190], ["and", 1199], ["69", 1203], ["%", 1205], ["for", 1207], ["HEM", 1211], ["-", 1214], ["AP", 1215], ["+", 1218], ["CE", 1220], ["patients", 1223], ["(", 1232], ["P", 1233], ["=", 1235], [".0004", 1236], [")", 1241], [".", 1242], ["After", 1244], ["1", 1250], ["year", 1252], [",", 1256], ["100", 1258], ["%", 1261], ["of", 1263], ["AP", 1266], ["-", 1268], ["CE", 1269], ["patients", 1272], ["were", 1281], ["still", 1286], ["alive", 1292], [",", 1297], ["compared", 1299], ["with", 1308], ["85", 1313], ["%", 1315], ["of", 1317], ["HEM", 1320], ["-", 1323], ["AP", 1324], ["patients", 1327], ["and", 1336], ["67.5", 1340], ["%", 1344], ["of", 1346], ["HEM", 1349], ["-", 1352], ["AP", 1353], ["+", 1356], ["CE", 1358], ["patients", 1361], ["(", 1370], ["P", 1371], ["=", 1373], [".01", 1374], [")", 1377], [".", 1378], ["In", 1380], ["conclusion", 1383], [",", 1393], ["in", 1395], ["patients", 1398], ["with", 1407], ["clonal", 1412], ["evolution", 1419], ["as", 1429], ["the", 1432], ["sole", 1436], ["criterion", 1441], ["of", 1451], ["disease", 1454], ["acceleration", 1462], [",", 1474], ["good", 1476], ["responses", 1481], ["to", 1491], ["imatinib", 1494], ["are", 1503], ["still", 1507], ["possible", 1513], [".", 1521], ["Once", 1523], ["patients", 1528], ["have", 1537], ["other", 1542], ["signs", 1548], ["of", 1554], ["acceleration", 1557], [",", 1569], ["clonal", 1571], ["evolution", 1578], ["predicts", 1588], ["lower", 1597], ["response", 1603], ["rates", 1612], ["and", 1618], ["a", 1622], ["shorter", 1624], ["time", 1632], ["to", 1637], ["treatment", 1640], ["failure", 1650], [".", 1657]]}
{"context": "The secreted glycoprotein, sclerostin alters bone formation. To gain insights into the mechanism of action of sclerostin, we examined the interactions of sclerostin with bone proteins using a sclerostin affinity capture technique. Proteins from decalcified rat bone were captured on a sclerostin-maltose binding protein (MBP) amylose column, or on a MBP amylose column. The columns were extensively washed with low ionic strength buffer, and bound proteins were eluted with buffer containing 1M sodium chloride. Eluted proteins were separated by denaturing sodium-dodecyl sulfate gel electrophoresis and were identified by mass spectrometry. Several previously unidentified full-length sclerostin-interacting proteins such as alkaline phosphatase, carbonic anhydrase, gremlin-1, fetuin A, midkine, annexin A1 and A2, and collagen \u03b11, which have established roles in bone formation or resorption processes, were bound to the sclerostin-MBP amylose resin but not to the MBP amylose resin. Other full-length sclerostin-interacting proteins such as casein kinase II and secreted frizzled related protein 4 that modulate Wnt signaling were identified. Several peptides derived from proteins such as Phex, asporin and follistatin that regulate bone metabolism also bound sclerostin. Sclerostin interacts with multiple proteins that alter bone formation and resorption and is likely to function by altering several biologically relevant pathways in bone.", "qas": [{"question": "Sclerostin regulates what process?", "answers": ["bone metabolism"], "qid": "c769d26d6d6e49a8bccbfa8ca3020245", "question_tokens": [["Sclerostin", 0], ["regulates", 11], ["what", 21], ["process", 26], ["?", 33]], "detected_answers": [{"text": "bone metabolism", "token_spans": [[208, 209]], "char_spans": [[1238, 1252]]}]}], "context_tokens": [["The", 0], ["secreted", 4], ["glycoprotein", 13], [",", 25], ["sclerostin", 27], ["alters", 38], ["bone", 45], ["formation", 50], [".", 59], ["To", 61], ["gain", 64], ["insights", 69], ["into", 78], ["the", 83], ["mechanism", 87], ["of", 97], ["action", 100], ["of", 107], ["sclerostin", 110], [",", 120], ["we", 122], ["examined", 125], ["the", 134], ["interactions", 138], ["of", 151], ["sclerostin", 154], ["with", 165], ["bone", 170], ["proteins", 175], ["using", 184], ["a", 190], ["sclerostin", 192], ["affinity", 203], ["capture", 212], ["technique", 220], [".", 229], ["Proteins", 231], ["from", 240], ["decalcified", 245], ["rat", 257], ["bone", 261], ["were", 266], ["captured", 271], ["on", 280], ["a", 283], ["sclerostin", 285], ["-", 295], ["maltose", 296], ["binding", 304], ["protein", 312], ["(", 320], ["MBP", 321], [")", 324], ["amylose", 326], ["column", 334], [",", 340], ["or", 342], ["on", 345], ["a", 348], ["MBP", 350], ["amylose", 354], ["column", 362], [".", 368], ["The", 370], ["columns", 374], ["were", 382], ["extensively", 387], ["washed", 399], ["with", 406], ["low", 411], ["ionic", 415], ["strength", 421], ["buffer", 430], [",", 436], ["and", 438], ["bound", 442], ["proteins", 448], ["were", 457], ["eluted", 462], ["with", 469], ["buffer", 474], ["containing", 481], ["1", 492], ["M", 493], ["sodium", 495], ["chloride", 502], [".", 510], ["Eluted", 512], ["proteins", 519], ["were", 528], ["separated", 533], ["by", 543], ["denaturing", 546], ["sodium", 557], ["-", 563], ["dodecyl", 564], ["sulfate", 572], ["gel", 580], ["electrophoresis", 584], ["and", 600], ["were", 604], ["identified", 609], ["by", 620], ["mass", 623], ["spectrometry", 628], [".", 640], ["Several", 642], ["previously", 650], ["unidentified", 661], ["full", 674], ["-", 678], ["length", 679], ["sclerostin", 686], ["-", 696], ["interacting", 697], ["proteins", 709], ["such", 718], ["as", 723], ["alkaline", 726], ["phosphatase", 735], [",", 746], ["carbonic", 748], ["anhydrase", 757], [",", 766], ["gremlin-1", 768], [",", 777], ["fetuin", 779], ["A", 786], [",", 787], ["midkine", 789], [",", 796], ["annexin", 798], ["A1", 806], ["and", 809], ["A2", 813], [",", 815], ["and", 817], ["collagen", 821], ["\u03b11", 830], [",", 832], ["which", 834], ["have", 840], ["established", 845], ["roles", 857], ["in", 863], ["bone", 866], ["formation", 871], ["or", 881], ["resorption", 884], ["processes", 895], [",", 904], ["were", 906], ["bound", 911], ["to", 917], ["the", 920], ["sclerostin", 924], ["-", 934], ["MBP", 935], ["amylose", 939], ["resin", 947], ["but", 953], ["not", 957], ["to", 961], ["the", 964], ["MBP", 968], ["amylose", 972], ["resin", 980], [".", 985], ["Other", 987], ["full", 993], ["-", 997], ["length", 998], ["sclerostin", 1005], ["-", 1015], ["interacting", 1016], ["proteins", 1028], ["such", 1037], ["as", 1042], ["casein", 1045], ["kinase", 1052], ["II", 1059], ["and", 1062], ["secreted", 1066], ["frizzled", 1075], ["related", 1084], ["protein", 1092], ["4", 1100], ["that", 1102], ["modulate", 1107], ["Wnt", 1116], ["signaling", 1120], ["were", 1130], ["identified", 1135], [".", 1145], ["Several", 1147], ["peptides", 1155], ["derived", 1164], ["from", 1172], ["proteins", 1177], ["such", 1186], ["as", 1191], ["Phex", 1194], [",", 1198], ["asporin", 1200], ["and", 1208], ["follistatin", 1212], ["that", 1224], ["regulate", 1229], ["bone", 1238], ["metabolism", 1243], ["also", 1254], ["bound", 1259], ["sclerostin", 1265], [".", 1275], ["Sclerostin", 1277], ["interacts", 1288], ["with", 1298], ["multiple", 1303], ["proteins", 1312], ["that", 1321], ["alter", 1326], ["bone", 1332], ["formation", 1337], ["and", 1347], ["resorption", 1351], ["and", 1362], ["is", 1366], ["likely", 1369], ["to", 1376], ["function", 1379], ["by", 1388], ["altering", 1391], ["several", 1400], ["biologically", 1408], ["relevant", 1421], ["pathways", 1430], ["in", 1439], ["bone", 1442], [".", 1446]]}
{"context": "We report on maternal first cousins with bilateral microtia, micrognathia, cleft palate and hematologic findings of Diamond-Blackfan anemia (DBA). The similarity of findings shared between our cases and a female reported by Hasan and Inoue [1993] suggests that this is a distinctive syndrome, rather than a chance association. DBA is a heterogeneous disorder, caused in about 25% of cases by heterozygous mutations in the RPS19 gene (DBA1). Mutation analysis in our cases did not show an RPS19 mutation, and 2 alleles were present in each. Segregation analysis for DBA1 on chromosome 19 and DBA2 on 8p23 was not consistent with linkage. We conclude that this syndrome of microtia, cleft palate and DBA is not allelic to known DBA loci.", "qas": [{"question": "In which syndrome is the RPS19 gene most frequently mutated?", "answers": ["Diamond-Blackfan Anemia", "DBA"], "qid": "18ad572dfb52412caadfcb13edb5accd", "question_tokens": [["In", 0], ["which", 3], ["syndrome", 9], ["is", 18], ["the", 21], ["RPS19", 25], ["gene", 31], ["most", 36], ["frequently", 41], ["mutated", 52], ["?", 59]], "detected_answers": [{"text": "Diamond-Blackfan Anemia", "token_spans": [[18, 21]], "char_spans": [[116, 138]]}, {"text": "DBA", "token_spans": [[137, 137], [59, 59], [23, 23], [131, 131]], "char_spans": [[726, 728], [327, 329], [141, 143], [698, 700]]}]}], "context_tokens": [["We", 0], ["report", 3], ["on", 10], ["maternal", 13], ["first", 22], ["cousins", 28], ["with", 36], ["bilateral", 41], ["microtia", 51], [",", 59], ["micrognathia", 61], [",", 73], ["cleft", 75], ["palate", 81], ["and", 88], ["hematologic", 92], ["findings", 104], ["of", 113], ["Diamond", 116], ["-", 123], ["Blackfan", 124], ["anemia", 133], ["(", 140], ["DBA", 141], [")", 144], [".", 145], ["The", 147], ["similarity", 151], ["of", 162], ["findings", 165], ["shared", 174], ["between", 181], ["our", 189], ["cases", 193], ["and", 199], ["a", 203], ["female", 205], ["reported", 212], ["by", 221], ["Hasan", 224], ["and", 230], ["Inoue", 234], ["[", 240], ["1993", 241], ["]", 245], ["suggests", 247], ["that", 256], ["this", 261], ["is", 266], ["a", 269], ["distinctive", 271], ["syndrome", 283], [",", 291], ["rather", 293], ["than", 300], ["a", 305], ["chance", 307], ["association", 314], [".", 325], ["DBA", 327], ["is", 331], ["a", 334], ["heterogeneous", 336], ["disorder", 350], [",", 358], ["caused", 360], ["in", 367], ["about", 370], ["25", 376], ["%", 378], ["of", 380], ["cases", 383], ["by", 389], ["heterozygous", 392], ["mutations", 405], ["in", 415], ["the", 418], ["RPS19", 422], ["gene", 428], ["(", 433], ["DBA1", 434], [")", 438], [".", 439], ["Mutation", 441], ["analysis", 450], ["in", 459], ["our", 462], ["cases", 466], ["did", 472], ["not", 476], ["show", 480], ["an", 485], ["RPS19", 488], ["mutation", 494], [",", 502], ["and", 504], ["2", 508], ["alleles", 510], ["were", 518], ["present", 523], ["in", 531], ["each", 534], [".", 538], ["Segregation", 540], ["analysis", 552], ["for", 561], ["DBA1", 565], ["on", 570], ["chromosome", 573], ["19", 584], ["and", 587], ["DBA2", 591], ["on", 596], ["8p23", 599], ["was", 604], ["not", 608], ["consistent", 612], ["with", 623], ["linkage", 628], [".", 635], ["We", 637], ["conclude", 640], ["that", 649], ["this", 654], ["syndrome", 659], ["of", 668], ["microtia", 671], [",", 679], ["cleft", 681], ["palate", 687], ["and", 694], ["DBA", 698], ["is", 702], ["not", 705], ["allelic", 709], ["to", 717], ["known", 720], ["DBA", 726], ["loci", 730], [".", 734]]}
{"context": "Nucleotide excision repair (NER), which is arguably the most versatile DNA repair system, is strongly attenuated in human cells of the monocytic lineage when they differentiate into macrophages. Within active genes, however, both DNA strands continue to be proficiently repaired. The proficient repair of the nontranscribed strand cannot be explained by the dedicated subpathway of transcription-coupled repair (TCR), which is targeted to the transcribed strand in expressed genes. We now report that the previously termed differentiation-associated repair (DAR) depends upon transcription, but not simply upon RNA polymerase II (RNAPII) encountering a lesion: proficient repair of both DNA strands can occur in a part of a gene that the polymerase never reaches, and even if the translocation of RNAPII is blocked with transcription inhibitors. This suggests that DAR may be a subset of global NER, restricted to the subnuclear compartments or chromatin domains within which transcription occurs. Downregulation of selected NER genes with small interfering RNA has confirmed that DAR relies upon the same genes as global genome repair, rather than upon TCR-specific genes. Our findings support the general view that the genomic domains within which transcription is active are more accessible than the bulk of the genome to the recognition and repair of lesions through the global pathway and that TCR is superimposed upon that pathway of NER.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "84dfe31ea9704f369ff876aaf7937ab8", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[77, 78]], "char_spans": [[443, 460]]}]}], "context_tokens": [["Nucleotide", 0], ["excision", 11], ["repair", 20], ["(", 27], ["NER", 28], [")", 31], [",", 32], ["which", 34], ["is", 40], ["arguably", 43], ["the", 52], ["most", 56], ["versatile", 61], ["DNA", 71], ["repair", 75], ["system", 82], [",", 88], ["is", 90], ["strongly", 93], ["attenuated", 102], ["in", 113], ["human", 116], ["cells", 122], ["of", 128], ["the", 131], ["monocytic", 135], ["lineage", 145], ["when", 153], ["they", 158], ["differentiate", 163], ["into", 177], ["macrophages", 182], [".", 193], ["Within", 195], ["active", 202], ["genes", 209], [",", 214], ["however", 216], [",", 223], ["both", 225], ["DNA", 230], ["strands", 234], ["continue", 242], ["to", 251], ["be", 254], ["proficiently", 257], ["repaired", 270], [".", 278], ["The", 280], ["proficient", 284], ["repair", 295], ["of", 302], ["the", 305], ["nontranscribed", 309], ["strand", 324], ["can", 331], ["not", 334], ["be", 338], ["explained", 341], ["by", 351], ["the", 354], ["dedicated", 358], ["subpathway", 368], ["of", 379], ["transcription", 382], ["-", 395], ["coupled", 396], ["repair", 404], ["(", 411], ["TCR", 412], [")", 415], [",", 416], ["which", 418], ["is", 424], ["targeted", 427], ["to", 436], ["the", 439], ["transcribed", 443], ["strand", 455], ["in", 462], ["expressed", 465], ["genes", 475], [".", 480], ["We", 482], ["now", 485], ["report", 489], ["that", 496], ["the", 501], ["previously", 505], ["termed", 516], ["differentiation", 523], ["-", 538], ["associated", 539], ["repair", 550], ["(", 557], ["DAR", 558], [")", 561], ["depends", 563], ["upon", 571], ["transcription", 576], [",", 589], ["but", 591], ["not", 595], ["simply", 599], ["upon", 606], ["RNA", 611], ["polymerase", 615], ["II", 626], ["(", 629], ["RNAPII", 630], [")", 636], ["encountering", 638], ["a", 651], ["lesion", 653], [":", 659], ["proficient", 661], ["repair", 672], ["of", 679], ["both", 682], ["DNA", 687], ["strands", 691], ["can", 699], ["occur", 703], ["in", 709], ["a", 712], ["part", 714], ["of", 719], ["a", 722], ["gene", 724], ["that", 729], ["the", 734], ["polymerase", 738], ["never", 749], ["reaches", 755], [",", 762], ["and", 764], ["even", 768], ["if", 773], ["the", 776], ["translocation", 780], ["of", 794], ["RNAPII", 797], ["is", 804], ["blocked", 807], ["with", 815], ["transcription", 820], ["inhibitors", 834], [".", 844], ["This", 846], ["suggests", 851], ["that", 860], ["DAR", 865], ["may", 869], ["be", 873], ["a", 876], ["subset", 878], ["of", 885], ["global", 888], ["NER", 895], [",", 898], ["restricted", 900], ["to", 911], ["the", 914], ["subnuclear", 918], ["compartments", 929], ["or", 942], ["chromatin", 945], ["domains", 955], ["within", 963], ["which", 970], ["transcription", 976], ["occurs", 990], [".", 996], ["Downregulation", 998], ["of", 1013], ["selected", 1016], ["NER", 1025], ["genes", 1029], ["with", 1035], ["small", 1040], ["interfering", 1046], ["RNA", 1058], ["has", 1062], ["confirmed", 1066], ["that", 1076], ["DAR", 1081], ["relies", 1085], ["upon", 1092], ["the", 1097], ["same", 1101], ["genes", 1106], ["as", 1112], ["global", 1115], ["genome", 1122], ["repair", 1129], [",", 1135], ["rather", 1137], ["than", 1144], ["upon", 1149], ["TCR", 1154], ["-", 1157], ["specific", 1158], ["genes", 1167], [".", 1172], ["Our", 1174], ["findings", 1178], ["support", 1187], ["the", 1195], ["general", 1199], ["view", 1207], ["that", 1212], ["the", 1217], ["genomic", 1221], ["domains", 1229], ["within", 1237], ["which", 1244], ["transcription", 1250], ["is", 1264], ["active", 1267], ["are", 1274], ["more", 1278], ["accessible", 1283], ["than", 1294], ["the", 1299], ["bulk", 1303], ["of", 1308], ["the", 1311], ["genome", 1315], ["to", 1322], ["the", 1325], ["recognition", 1329], ["and", 1341], ["repair", 1345], ["of", 1352], ["lesions", 1355], ["through", 1363], ["the", 1371], ["global", 1375], ["pathway", 1382], ["and", 1390], ["that", 1394], ["TCR", 1399], ["is", 1403], ["superimposed", 1406], ["upon", 1419], ["that", 1424], ["pathway", 1429], ["of", 1437], ["NER", 1440], [".", 1443]]}
{"context": "Pannexin2 (Panx2) is the largest of three members of the pannexin proteins. Pannexins are topologically related to connexins and innexins, but serve different functional roles than forming gap junctions. We previously showed that pannexins form oligomeric channels but unlike connexins and innexins, they form only single membrane channels. High levels of Panx2 mRNA and protein in the Central Nervous System (CNS) have been documented. Whereas Pannexin1 (Panx1) is fairly ubiquitous and Pannexin3 (Panx3) is found in skin and connective tissue, both are fully glycosylated, traffic to the plasma membrane and have functions correlated with extracellular ATP release. Here, we describe trafficking and subcellular localizations of exogenous Panx2 and Panx1 protein expression in MDCK, HeLa, and HEK 293T cells as well as endogenous Panx1 and Panx2 patterns in the CNS. Panx2 was found in intracellular localizations, was partially N-glycosylated, and localizations were non-overlapping with Panx1. Confocal images of hippocampal sections immunolabeled for the astrocytic protein GFAP, Panx1 and Panx2 demonstrated that the two isoforms, Panx1 and Panx2, localized at different subcellular compartments in both astrocytes and neurons. Using recombinant fusions of Panx2 with appended genetic tags developed for correlated light and electron microscopy and then expressed in different cell lines, we determined that Panx2 is localized in the membrane of intracellular vesicles and not in the endoplasmic reticulum as initially indicated by calnexin colocalization experiments. Dual immunofluorescence imaging with protein markers for specific vesicle compartments showed that Panx2 vesicles are early endosomal in origin. In electron tomographic volumes, cross-sections of these vesicles displayed fine structural details and close proximity to actin filaments. Thus, pannexins expressed at different subcellular compartments likely exert distinct functional roles, particularly in the nervous system.", "qas": [{"question": "Where is the protein Pannexin1 located?", "answers": ["plasma membrane"], "qid": "08b59657cf0b4a05a3b821cb53bc7eeb", "question_tokens": [["Where", 0], ["is", 6], ["the", 9], ["protein", 13], ["Pannexin1", 21], ["located", 31], ["?", 38]], "detected_answers": [{"text": "plasma membrane", "token_spans": [[103, 104]], "char_spans": [[590, 604]]}]}], "context_tokens": [["Pannexin2", 0], ["(", 10], ["Panx2", 11], [")", 16], ["is", 18], ["the", 21], ["largest", 25], ["of", 33], ["three", 36], ["members", 42], ["of", 50], ["the", 53], ["pannexin", 57], ["proteins", 66], [".", 74], ["Pannexins", 76], ["are", 86], ["topologically", 90], ["related", 104], ["to", 112], ["connexins", 115], ["and", 125], ["innexins", 129], [",", 137], ["but", 139], ["serve", 143], ["different", 149], ["functional", 159], ["roles", 170], ["than", 176], ["forming", 181], ["gap", 189], ["junctions", 193], [".", 202], ["We", 204], ["previously", 207], ["showed", 218], ["that", 225], ["pannexins", 230], ["form", 240], ["oligomeric", 245], ["channels", 256], ["but", 265], ["unlike", 269], ["connexins", 276], ["and", 286], ["innexins", 290], [",", 298], ["they", 300], ["form", 305], ["only", 310], ["single", 315], ["membrane", 322], ["channels", 331], [".", 339], ["High", 341], ["levels", 346], ["of", 353], ["Panx2", 356], ["mRNA", 362], ["and", 367], ["protein", 371], ["in", 379], ["the", 382], ["Central", 386], ["Nervous", 394], ["System", 402], ["(", 409], ["CNS", 410], [")", 413], ["have", 415], ["been", 420], ["documented", 425], [".", 435], ["Whereas", 437], ["Pannexin1", 445], ["(", 455], ["Panx1", 456], [")", 461], ["is", 463], ["fairly", 466], ["ubiquitous", 473], ["and", 484], ["Pannexin3", 488], ["(", 498], ["Panx3", 499], [")", 504], ["is", 506], ["found", 509], ["in", 515], ["skin", 518], ["and", 523], ["connective", 527], ["tissue", 538], [",", 544], ["both", 546], ["are", 551], ["fully", 555], ["glycosylated", 561], [",", 573], ["traffic", 575], ["to", 583], ["the", 586], ["plasma", 590], ["membrane", 597], ["and", 606], ["have", 610], ["functions", 615], ["correlated", 625], ["with", 636], ["extracellular", 641], ["ATP", 655], ["release", 659], [".", 666], ["Here", 668], [",", 672], ["we", 674], ["describe", 677], ["trafficking", 686], ["and", 698], ["subcellular", 702], ["localizations", 714], ["of", 728], ["exogenous", 731], ["Panx2", 741], ["and", 747], ["Panx1", 751], ["protein", 757], ["expression", 765], ["in", 776], ["MDCK", 779], [",", 783], ["HeLa", 785], [",", 789], ["and", 791], ["HEK", 795], ["293", 799], ["T", 802], ["cells", 804], ["as", 810], ["well", 813], ["as", 818], ["endogenous", 821], ["Panx1", 832], ["and", 838], ["Panx2", 842], ["patterns", 848], ["in", 857], ["the", 860], ["CNS", 864], [".", 867], ["Panx2", 869], ["was", 875], ["found", 879], ["in", 885], ["intracellular", 888], ["localizations", 902], [",", 915], ["was", 917], ["partially", 921], ["N", 931], ["-", 932], ["glycosylated", 933], [",", 945], ["and", 947], ["localizations", 951], ["were", 965], ["non", 970], ["-", 973], ["overlapping", 974], ["with", 986], ["Panx1", 991], [".", 996], ["Confocal", 998], ["images", 1007], ["of", 1014], ["hippocampal", 1017], ["sections", 1029], ["immunolabeled", 1038], ["for", 1052], ["the", 1056], ["astrocytic", 1060], ["protein", 1071], ["GFAP", 1079], [",", 1083], ["Panx1", 1085], ["and", 1091], ["Panx2", 1095], ["demonstrated", 1101], ["that", 1114], ["the", 1119], ["two", 1123], ["isoforms", 1127], [",", 1135], ["Panx1", 1137], ["and", 1143], ["Panx2", 1147], [",", 1152], ["localized", 1154], ["at", 1164], ["different", 1167], ["subcellular", 1177], ["compartments", 1189], ["in", 1202], ["both", 1205], ["astrocytes", 1210], ["and", 1221], ["neurons", 1225], [".", 1232], ["Using", 1234], ["recombinant", 1240], ["fusions", 1252], ["of", 1260], ["Panx2", 1263], ["with", 1269], ["appended", 1274], ["genetic", 1283], ["tags", 1291], ["developed", 1296], ["for", 1306], ["correlated", 1310], ["light", 1321], ["and", 1327], ["electron", 1331], ["microscopy", 1340], ["and", 1351], ["then", 1355], ["expressed", 1360], ["in", 1370], ["different", 1373], ["cell", 1383], ["lines", 1388], [",", 1393], ["we", 1395], ["determined", 1398], ["that", 1409], ["Panx2", 1414], ["is", 1420], ["localized", 1423], ["in", 1433], ["the", 1436], ["membrane", 1440], ["of", 1449], ["intracellular", 1452], ["vesicles", 1466], ["and", 1475], ["not", 1479], ["in", 1483], ["the", 1486], ["endoplasmic", 1490], ["reticulum", 1502], ["as", 1512], ["initially", 1515], ["indicated", 1525], ["by", 1535], ["calnexin", 1538], ["colocalization", 1547], ["experiments", 1562], [".", 1573], ["Dual", 1575], ["immunofluorescence", 1580], ["imaging", 1599], ["with", 1607], ["protein", 1612], ["markers", 1620], ["for", 1628], ["specific", 1632], ["vesicle", 1641], ["compartments", 1649], ["showed", 1662], ["that", 1669], ["Panx2", 1674], ["vesicles", 1680], ["are", 1689], ["early", 1693], ["endosomal", 1699], ["in", 1709], ["origin", 1712], [".", 1718], ["In", 1720], ["electron", 1723], ["tomographic", 1732], ["volumes", 1744], [",", 1751], ["cross", 1753], ["-", 1758], ["sections", 1759], ["of", 1768], ["these", 1771], ["vesicles", 1777], ["displayed", 1786], ["fine", 1796], ["structural", 1801], ["details", 1812], ["and", 1820], ["close", 1824], ["proximity", 1830], ["to", 1840], ["actin", 1843], ["filaments", 1849], [".", 1858], ["Thus", 1860], [",", 1864], ["pannexins", 1866], ["expressed", 1876], ["at", 1886], ["different", 1889], ["subcellular", 1899], ["compartments", 1911], ["likely", 1924], ["exert", 1931], ["distinct", 1937], ["functional", 1946], ["roles", 1957], [",", 1962], ["particularly", 1964], ["in", 1977], ["the", 1980], ["nervous", 1984], ["system", 1992], [".", 1998]]}
{"context": "Interleukin-6 (IL-6) is a pleiotropic cytokine implicated in the pathogenesis of many immune-mediated disorders including several types of non-infectious uveitis. These uveitic conditions include Vogt-Koyanagi-Harada syndrome, uveitis associated with Beh\u00e7et disease, and sarcoidosis. This review summarizes the role of IL-6 in immunity, highlighting its effect on Th17, Th1, and plasmablast differentiation. It reviews the downstream mediators activated in the process of IL-6 binding to its receptor complex. This review also summarizes the biologics targeting either IL-6 or the IL-6 receptor, including tocilizumab, sarilumab, sirukumab, olokizumab, clazakizumab, and siltuximab. The target, dosage, potential side effects, and potential uses of these biologics are summarized in this article based on the existing literature. In summary, anti-IL-6 therapy for non-infectious uveitis shows promise in terms of efficacy and side effect profile.", "qas": [{"question": "Which interleukin is blocked by Siltuximab?", "answers": ["interleukin-6"], "qid": "a00c444bb61f44519190db6046039820", "question_tokens": [["Which", 0], ["interleukin", 6], ["is", 18], ["blocked", 21], ["by", 29], ["Siltuximab", 32], ["?", 42]], "detected_answers": [{"text": "interleukin-6", "token_spans": [[0, 0]], "char_spans": [[0, 12]]}]}], "context_tokens": [["Interleukin-6", 0], ["(", 14], ["IL-6", 15], [")", 19], ["is", 21], ["a", 24], ["pleiotropic", 26], ["cytokine", 38], ["implicated", 47], ["in", 58], ["the", 61], ["pathogenesis", 65], ["of", 78], ["many", 81], ["immune", 86], ["-", 92], ["mediated", 93], ["disorders", 102], ["including", 112], ["several", 122], ["types", 130], ["of", 136], ["non", 139], ["-", 142], ["infectious", 143], ["uveitis", 154], [".", 161], ["These", 163], ["uveitic", 169], ["conditions", 177], ["include", 188], ["Vogt", 196], ["-", 200], ["Koyanagi", 201], ["-", 209], ["Harada", 210], ["syndrome", 217], [",", 225], ["uveitis", 227], ["associated", 235], ["with", 246], ["Beh\u00e7et", 251], ["disease", 258], [",", 265], ["and", 267], ["sarcoidosis", 271], [".", 282], ["This", 284], ["review", 289], ["summarizes", 296], ["the", 307], ["role", 311], ["of", 316], ["IL-6", 319], ["in", 324], ["immunity", 327], [",", 335], ["highlighting", 337], ["its", 350], ["effect", 354], ["on", 361], ["Th17", 364], [",", 368], ["Th1", 370], [",", 373], ["and", 375], ["plasmablast", 379], ["differentiation", 391], [".", 406], ["It", 408], ["reviews", 411], ["the", 419], ["downstream", 423], ["mediators", 434], ["activated", 444], ["in", 454], ["the", 457], ["process", 461], ["of", 469], ["IL-6", 472], ["binding", 477], ["to", 485], ["its", 488], ["receptor", 492], ["complex", 501], [".", 508], ["This", 510], ["review", 515], ["also", 522], ["summarizes", 527], ["the", 538], ["biologics", 542], ["targeting", 552], ["either", 562], ["IL-6", 569], ["or", 574], ["the", 577], ["IL-6", 581], ["receptor", 586], [",", 594], ["including", 596], ["tocilizumab", 606], [",", 617], ["sarilumab", 619], [",", 628], ["sirukumab", 630], [",", 639], ["olokizumab", 641], [",", 651], ["clazakizumab", 653], [",", 665], ["and", 667], ["siltuximab", 671], [".", 681], ["The", 683], ["target", 687], [",", 693], ["dosage", 695], [",", 701], ["potential", 703], ["side", 713], ["effects", 718], [",", 725], ["and", 727], ["potential", 731], ["uses", 741], ["of", 746], ["these", 749], ["biologics", 755], ["are", 765], ["summarized", 769], ["in", 780], ["this", 783], ["article", 788], ["based", 796], ["on", 802], ["the", 805], ["existing", 809], ["literature", 818], [".", 828], ["In", 830], ["summary", 833], [",", 840], ["anti", 842], ["-", 846], ["IL-6", 847], ["therapy", 852], ["for", 860], ["non", 864], ["-", 867], ["infectious", 868], ["uveitis", 879], ["shows", 887], ["promise", 893], ["in", 901], ["terms", 904], ["of", 910], ["efficacy", 913], ["and", 922], ["side", 926], ["effect", 931], ["profile", 938], [".", 945]]}
{"context": "Dear sir, one of the most common entrapment neuropathy syndromes in clinical practice is \"Entrapment of median nerve in carpal tunnel\" also called \"Carpal tunnel syndrome (CTS)\" (Aydin et al., 2007; Huisstede et al., 2010). This syndrome is caused by entrapment of the median nerve in the wrist (Preston and Shapiro, 2005) when the pressure increases in the carpal tunnel. A high division of the median nerve proximal to the carpal tunnel, also known as a bifid median nerve, is a rare anatomic variation that may be associated with CTS and with persistent median vessels (Lanz, 1977). This anatomic variation has an incidence of 0,8% to 2,3% in patients with CTS. Lanz (1977) has characterized this anatomic condition of the median nerve in the carpal tunnel. These anatomic variants have been classified into four groups: - Group 0: extraligamentous thenar branch (standard anatomy); - Group 1: variations of the course of the thenar branch; - Group 2: accessory branches at the distal portion of the carpal tunnel; - Group 3: divided or duplicated median nerve inside the carpal tunnel; - Group 4: accessory branches proximal to the carpal tunnel. During dissection of the wrist performed for the treatment of a CTS under local anesthesia, we found an anatomical variation of the median nerve that was divided in two branches inside the carpal tunnel (Group 3 of Lanz Classification) and in which its radial branch passed through its own compartment. The two parts of the nerve seems to be unequal in size (Fig. 1). Moreover the nerve passed in carpal tunnel associated with a median artery, so we classified this variation in the group 3b of Lanz Classification (Fig. 2). The persistence of median artery coexisting with a bifid median nerve has been widely reported in surgical literature (Lanz, 1977; Barbe et al., 2005). Before surgical intervention clinical evaluation of patient and electrophysiological examination showed no differences compared to a non bifid median nerve entrapment syndrome. In conclusion the bifid median nerve may facilitate compression of median nerve in the carpal tunnel because of its increased cross sectional area even if it has no electrophysiological or clinical differential diagnosis in case of CTS. The aim of this letter is aware the physicians in order to borne in mind the possible presence of a median nerve variation during dissection of carpal tunnel in order to avoid the damage of this non common anatomical structures.", "qas": [{"question": "What nerve is involved in carpal tunnel syndrome?", "answers": ["median"], "qid": "0460fb3061fd40ec8e30bfca61c596bb", "question_tokens": [["What", 0], ["nerve", 5], ["is", 11], ["involved", 14], ["in", 23], ["carpal", 26], ["tunnel", 33], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "median", "token_spans": [[256, 256], [385, 385], [315, 315], [339, 339], [58, 58], [150, 150], [214, 214], [394, 394], [84, 84], [400, 400], [345, 345], [448, 448], [18, 18], [114, 114], [97, 97]], "char_spans": [[1283, 1288], [1971, 1976], [1580, 1585], [1695, 1700], [269, 274], [726, 731], [1051, 1056], [2029, 2034], [396, 401], [2072, 2077], [1733, 1738], [2342, 2347], [104, 109], [557, 562], [462, 467]]}]}], "context_tokens": [["Dear", 0], ["sir", 5], [",", 8], ["one", 10], ["of", 14], ["the", 17], ["most", 21], ["common", 26], ["entrapment", 33], ["neuropathy", 44], ["syndromes", 55], ["in", 65], ["clinical", 68], ["practice", 77], ["is", 86], ["\"", 89], ["Entrapment", 90], ["of", 101], ["median", 104], ["nerve", 111], ["in", 117], ["carpal", 120], ["tunnel", 127], ["\"", 133], ["also", 135], ["called", 140], ["\"", 147], ["Carpal", 148], ["tunnel", 155], ["syndrome", 162], ["(", 171], ["CTS", 172], [")", 175], ["\"", 176], ["(", 178], ["Aydin", 179], ["et", 185], ["al", 188], [".", 190], [",", 191], ["2007", 193], [";", 197], ["Huisstede", 199], ["et", 209], ["al", 212], [".", 214], [",", 215], ["2010", 217], [")", 221], [".", 222], ["This", 224], ["syndrome", 229], ["is", 238], ["caused", 241], ["by", 248], ["entrapment", 251], ["of", 262], ["the", 265], ["median", 269], ["nerve", 276], ["in", 282], ["the", 285], ["wrist", 289], ["(", 295], ["Preston", 296], ["and", 304], ["Shapiro", 308], [",", 315], ["2005", 317], [")", 321], ["when", 323], ["the", 328], ["pressure", 332], ["increases", 341], ["in", 351], ["the", 354], ["carpal", 358], ["tunnel", 365], [".", 371], ["A", 373], ["high", 375], ["division", 380], ["of", 389], ["the", 392], ["median", 396], ["nerve", 403], ["proximal", 409], ["to", 418], ["the", 421], ["carpal", 425], ["tunnel", 432], [",", 438], ["also", 440], ["known", 445], ["as", 451], ["a", 454], ["bifid", 456], ["median", 462], ["nerve", 469], [",", 474], ["is", 476], ["a", 479], ["rare", 481], ["anatomic", 486], ["variation", 495], ["that", 505], ["may", 510], ["be", 514], ["associated", 517], ["with", 528], ["CTS", 533], ["and", 537], ["with", 541], ["persistent", 546], ["median", 557], ["vessels", 564], ["(", 572], ["Lanz", 573], [",", 577], ["1977", 579], [")", 583], [".", 584], ["This", 586], ["anatomic", 591], ["variation", 600], ["has", 610], ["an", 614], ["incidence", 617], ["of", 627], ["0,8", 630], ["%", 633], ["to", 635], ["2,3", 638], ["%", 641], ["in", 643], ["patients", 646], ["with", 655], ["CTS", 660], [".", 663], ["Lanz", 665], ["(", 670], ["1977", 671], [")", 675], ["has", 677], ["characterized", 681], ["this", 695], ["anatomic", 700], ["condition", 709], ["of", 719], ["the", 722], ["median", 726], ["nerve", 733], ["in", 739], ["the", 742], ["carpal", 746], ["tunnel", 753], [".", 759], ["These", 761], ["anatomic", 767], ["variants", 776], ["have", 785], ["been", 790], ["classified", 795], ["into", 806], ["four", 811], ["groups", 816], [":", 822], ["-", 824], ["Group", 826], ["0", 832], [":", 833], ["extraligamentous", 835], ["thenar", 852], ["branch", 859], ["(", 866], ["standard", 867], ["anatomy", 876], [")", 883], [";", 884], ["-", 886], ["Group", 888], ["1", 894], [":", 895], ["variations", 897], ["of", 908], ["the", 911], ["course", 915], ["of", 922], ["the", 925], ["thenar", 929], ["branch", 936], [";", 942], ["-", 944], ["Group", 946], ["2", 952], [":", 953], ["accessory", 955], ["branches", 965], ["at", 974], ["the", 977], ["distal", 981], ["portion", 988], ["of", 996], ["the", 999], ["carpal", 1003], ["tunnel", 1010], [";", 1016], ["-", 1018], ["Group", 1020], ["3", 1026], [":", 1027], ["divided", 1029], ["or", 1037], ["duplicated", 1040], ["median", 1051], ["nerve", 1058], ["inside", 1064], ["the", 1071], ["carpal", 1075], ["tunnel", 1082], [";", 1088], ["-", 1090], ["Group", 1092], ["4", 1098], [":", 1099], ["accessory", 1101], ["branches", 1111], ["proximal", 1120], ["to", 1129], ["the", 1132], ["carpal", 1136], ["tunnel", 1143], [".", 1149], ["During", 1151], ["dissection", 1158], ["of", 1169], ["the", 1172], ["wrist", 1176], ["performed", 1182], ["for", 1192], ["the", 1196], ["treatment", 1200], ["of", 1210], ["a", 1213], ["CTS", 1215], ["under", 1219], ["local", 1225], ["anesthesia", 1231], [",", 1241], ["we", 1243], ["found", 1246], ["an", 1252], ["anatomical", 1255], ["variation", 1266], ["of", 1276], ["the", 1279], ["median", 1283], ["nerve", 1290], ["that", 1296], ["was", 1301], ["divided", 1305], ["in", 1313], ["two", 1316], ["branches", 1320], ["inside", 1329], ["the", 1336], ["carpal", 1340], ["tunnel", 1347], ["(", 1354], ["Group", 1355], ["3", 1361], ["of", 1363], ["Lanz", 1366], ["Classification", 1371], [")", 1385], ["and", 1387], ["in", 1391], ["which", 1394], ["its", 1400], ["radial", 1404], ["branch", 1411], ["passed", 1418], ["through", 1425], ["its", 1433], ["own", 1437], ["compartment", 1441], [".", 1452], ["The", 1454], ["two", 1458], ["parts", 1462], ["of", 1468], ["the", 1471], ["nerve", 1475], ["seems", 1481], ["to", 1487], ["be", 1490], ["unequal", 1493], ["in", 1501], ["size", 1504], ["(", 1509], ["Fig", 1510], [".", 1513], ["1", 1515], [")", 1516], [".", 1517], ["Moreover", 1519], ["the", 1528], ["nerve", 1532], ["passed", 1538], ["in", 1545], ["carpal", 1548], ["tunnel", 1555], ["associated", 1562], ["with", 1573], ["a", 1578], ["median", 1580], ["artery", 1587], [",", 1593], ["so", 1595], ["we", 1598], ["classified", 1601], ["this", 1612], ["variation", 1617], ["in", 1627], ["the", 1630], ["group", 1634], ["3b", 1640], ["of", 1643], ["Lanz", 1646], ["Classification", 1651], ["(", 1666], ["Fig", 1667], [".", 1670], ["2", 1672], [")", 1673], [".", 1674], ["The", 1676], ["persistence", 1680], ["of", 1692], ["median", 1695], ["artery", 1702], ["coexisting", 1709], ["with", 1720], ["a", 1725], ["bifid", 1727], ["median", 1733], ["nerve", 1740], ["has", 1746], ["been", 1750], ["widely", 1755], ["reported", 1762], ["in", 1771], ["surgical", 1774], ["literature", 1783], ["(", 1794], ["Lanz", 1795], [",", 1799], ["1977", 1801], [";", 1805], ["Barbe", 1807], ["et", 1813], ["al", 1816], [".", 1818], [",", 1819], ["2005", 1821], [")", 1825], [".", 1826], ["Before", 1828], ["surgical", 1835], ["intervention", 1844], ["clinical", 1857], ["evaluation", 1866], ["of", 1877], ["patient", 1880], ["and", 1888], ["electrophysiological", 1892], ["examination", 1913], ["showed", 1925], ["no", 1932], ["differences", 1935], ["compared", 1947], ["to", 1956], ["a", 1959], ["non", 1961], ["bifid", 1965], ["median", 1971], ["nerve", 1978], ["entrapment", 1984], ["syndrome", 1995], [".", 2003], ["In", 2005], ["conclusion", 2008], ["the", 2019], ["bifid", 2023], ["median", 2029], ["nerve", 2036], ["may", 2042], ["facilitate", 2046], ["compression", 2057], ["of", 2069], ["median", 2072], ["nerve", 2079], ["in", 2085], ["the", 2088], ["carpal", 2092], ["tunnel", 2099], ["because", 2106], ["of", 2114], ["its", 2117], ["increased", 2121], ["cross", 2131], ["sectional", 2137], ["area", 2147], ["even", 2152], ["if", 2157], ["it", 2160], ["has", 2163], ["no", 2167], ["electrophysiological", 2170], ["or", 2191], ["clinical", 2194], ["differential", 2203], ["diagnosis", 2216], ["in", 2226], ["case", 2229], ["of", 2234], ["CTS", 2237], [".", 2240], ["The", 2242], ["aim", 2246], ["of", 2250], ["this", 2253], ["letter", 2258], ["is", 2265], ["aware", 2268], ["the", 2274], ["physicians", 2278], ["in", 2289], ["order", 2292], ["to", 2298], ["borne", 2301], ["in", 2307], ["mind", 2310], ["the", 2315], ["possible", 2319], ["presence", 2328], ["of", 2337], ["a", 2340], ["median", 2342], ["nerve", 2349], ["variation", 2355], ["during", 2365], ["dissection", 2372], ["of", 2383], ["carpal", 2386], ["tunnel", 2393], ["in", 2400], ["order", 2403], ["to", 2409], ["avoid", 2412], ["the", 2418], ["damage", 2422], ["of", 2429], ["this", 2432], ["non", 2437], ["common", 2441], ["anatomical", 2448], ["structures", 2459], [".", 2469]]}
{"context": "Direct oral anticoagulants (DOACs) offer noninferior efficacy and improved safety compared to vitamin K antagonists (VKAs) for the prevention and treatment of venous thromboembolism and for the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation. Unlike VKAs, DOACs do not require routine laboratory monitoring of anticoagulant effect and dose adjustment. In certain situations, however, laboratory assessment of anticoagulant effect may be desirable. Here we review the utility of currently available assays for assessment of DOAC effect and recommend an optimal assessment strategy for each drug, including calibrated dilute thrombin time or ecarin-based assays for dabigatran and calibrated anti-Xa activity assays for the factor Xa inhibitors. We also discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and edoxaban.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "e6ccf71d79284970a5d7adfff0807ec8", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[148, 148], [109, 109]], "char_spans": [[924, 933], [694, 703]]}]}], "context_tokens": [["Direct", 0], ["oral", 7], ["anticoagulants", 12], ["(", 27], ["DOACs", 28], [")", 33], ["offer", 35], ["noninferior", 41], ["efficacy", 53], ["and", 62], ["improved", 66], ["safety", 75], ["compared", 82], ["to", 91], ["vitamin", 94], ["K", 102], ["antagonists", 104], ["(", 116], ["VKAs", 117], [")", 121], ["for", 123], ["the", 127], ["prevention", 131], ["and", 142], ["treatment", 146], ["of", 156], ["venous", 159], ["thromboembolism", 166], ["and", 182], ["for", 186], ["the", 190], ["prevention", 194], ["of", 205], ["stroke", 208], ["and", 215], ["systemic", 219], ["embolism", 228], ["in", 237], ["nonvalvular", 240], ["atrial", 252], ["fibrillation", 259], [".", 271], ["Unlike", 273], ["VKAs", 280], [",", 284], ["DOACs", 286], ["do", 292], ["not", 295], ["require", 299], ["routine", 307], ["laboratory", 315], ["monitoring", 326], ["of", 337], ["anticoagulant", 340], ["effect", 354], ["and", 361], ["dose", 365], ["adjustment", 370], [".", 380], ["In", 382], ["certain", 385], ["situations", 393], [",", 403], ["however", 405], [",", 412], ["laboratory", 414], ["assessment", 425], ["of", 436], ["anticoagulant", 439], ["effect", 453], ["may", 460], ["be", 464], ["desirable", 467], [".", 476], ["Here", 478], ["we", 483], ["review", 486], ["the", 493], ["utility", 497], ["of", 505], ["currently", 508], ["available", 518], ["assays", 528], ["for", 535], ["assessment", 539], ["of", 550], ["DOAC", 553], ["effect", 558], ["and", 565], ["recommend", 569], ["an", 579], ["optimal", 582], ["assessment", 590], ["strategy", 601], ["for", 610], ["each", 614], ["drug", 619], [",", 623], ["including", 625], ["calibrated", 635], ["dilute", 646], ["thrombin", 653], ["time", 662], ["or", 667], ["ecarin", 670], ["-", 676], ["based", 677], ["assays", 683], ["for", 690], ["dabigatran", 694], ["and", 705], ["calibrated", 709], ["anti", 720], ["-", 724], ["Xa", 725], ["activity", 728], ["assays", 737], ["for", 744], ["the", 748], ["factor", 752], ["Xa", 759], ["inhibitors", 762], [".", 772], ["We", 774], ["also", 777], ["discuss", 782], ["reversal", 790], ["strategies", 799], [",", 809], ["both", 811], ["specific", 816], ["and", 825], ["nonspecific", 829], [",", 840], ["for", 842], ["each", 846], ["drug", 851], [",", 855], ["including", 857], ["the", 867], ["preferential", 871], ["use", 884], ["of", 888], ["idarucizumab", 891], ["for", 904], ["the", 908], ["reversal", 912], ["of", 921], ["dabigatran", 924], ["and", 935], ["two", 939], ["agents", 943], [",", 949], ["andexanet", 951], ["and", 961], ["ciraparantag", 965], [",", 977], ["currently", 979], ["under", 989], ["development", 995], ["for", 1007], ["the", 1011], ["reversal", 1015], ["of", 1024], ["rivaroxaban", 1027], [",", 1038], ["apixaban", 1040], [",", 1048], ["and", 1050], ["edoxaban", 1054], [".", 1062]]}
{"context": "Machado-Joseph disease (MJD), also called spinocerebellar ataxia type 3, is caused by mutant ataxin-3 with a polyglutamine expansion. Although there is no treatment available at present to cure or delay the onset of MJD, mouse models have been generated to facilitate the development of a therapy. In this review, the published reports on mouse models of MJD and other polyglutamine spinocerebellar ataxias are compared. Based on these studies, the following approaches will be discussed as candidate treatments for MJD: 1) interfering with the formation of the mutant ataxin-3 cleavage fragment and possibly aggregate or inclusions, 2) reducing the disease protein nuclear localization, and 3) decreasing mutant ataxin-3 expression in neurons.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "e0187e9fdece45e5bba46192786ac6b4", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[124, 124], [19, 19], [101, 101]], "char_spans": [[713, 720], [93, 100], [569, 576]]}]}], "context_tokens": [["Machado", 0], ["-", 7], ["Joseph", 8], ["disease", 15], ["(", 23], ["MJD", 24], [")", 27], [",", 28], ["also", 30], ["called", 35], ["spinocerebellar", 42], ["ataxia", 58], ["type", 65], ["3", 70], [",", 71], ["is", 73], ["caused", 76], ["by", 83], ["mutant", 86], ["ataxin-3", 93], ["with", 102], ["a", 107], ["polyglutamine", 109], ["expansion", 123], [".", 132], ["Although", 134], ["there", 143], ["is", 149], ["no", 152], ["treatment", 155], ["available", 165], ["at", 175], ["present", 178], ["to", 186], ["cure", 189], ["or", 194], ["delay", 197], ["the", 203], ["onset", 207], ["of", 213], ["MJD", 216], [",", 219], ["mouse", 221], ["models", 227], ["have", 234], ["been", 239], ["generated", 244], ["to", 254], ["facilitate", 257], ["the", 268], ["development", 272], ["of", 284], ["a", 287], ["therapy", 289], [".", 296], ["In", 298], ["this", 301], ["review", 306], [",", 312], ["the", 314], ["published", 318], ["reports", 328], ["on", 336], ["mouse", 339], ["models", 345], ["of", 352], ["MJD", 355], ["and", 359], ["other", 363], ["polyglutamine", 369], ["spinocerebellar", 383], ["ataxias", 399], ["are", 407], ["compared", 411], [".", 419], ["Based", 421], ["on", 427], ["these", 430], ["studies", 436], [",", 443], ["the", 445], ["following", 449], ["approaches", 459], ["will", 470], ["be", 475], ["discussed", 478], ["as", 488], ["candidate", 491], ["treatments", 501], ["for", 512], ["MJD", 516], [":", 519], ["1", 521], [")", 522], ["interfering", 524], ["with", 536], ["the", 541], ["formation", 545], ["of", 555], ["the", 558], ["mutant", 562], ["ataxin-3", 569], ["cleavage", 578], ["fragment", 587], ["and", 596], ["possibly", 600], ["aggregate", 609], ["or", 619], ["inclusions", 622], [",", 632], ["2", 634], [")", 635], ["reducing", 637], ["the", 646], ["disease", 650], ["protein", 658], ["nuclear", 666], ["localization", 674], [",", 686], ["and", 688], ["3", 692], [")", 693], ["decreasing", 695], ["mutant", 706], ["ataxin-3", 713], ["expression", 722], ["in", 733], ["neurons", 736], [".", 743]]}
{"context": "Chronic myeloid leukemia (CML) is a pluripotent hematopoietic disorder that is currently considered incurable. The tyrosine kinase product of the Philadelphia chromosome, P210 BCR-ABL, provided a pathogenetic explanation for the initiation of the CML chronic phase and is the molecular therapeutic target for the disease. Imatinib mesylate, an orally available BCR-ABL kinase inhibitor, can induce haematologic and cytogenetic remission of CML. However, imatinib resistance occurs frequently, resulting in relapse. New treatment strategies are focusing on resistant CML stem cells and the bone marrow stroma. The identification of novel pathways and mechanisms in the bone marrow microenvironment could significantly contribute to the development of such strategies. In this work, we used a high-resolution label-free MS(E)  proteomic approach to identify differential protein expression in the CML bone marrow plasma of responsive and resistant patients. Oxidative lipid metabolism and regulation of the switch from canonical to noncanonical WNT signaling may contribute to CML resistance in the bone marrow compartment.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "c3ce02b73a0e40788ece57c69b7aafc1", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[59, 61], [27, 29]], "char_spans": [[361, 367], [176, 182]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["a", 34], ["pluripotent", 36], ["hematopoietic", 48], ["disorder", 62], ["that", 71], ["is", 76], ["currently", 79], ["considered", 89], ["incurable", 100], [".", 109], ["The", 111], ["tyrosine", 115], ["kinase", 124], ["product", 131], ["of", 139], ["the", 142], ["Philadelphia", 146], ["chromosome", 159], [",", 169], ["P210", 171], ["BCR", 176], ["-", 179], ["ABL", 180], [",", 183], ["provided", 185], ["a", 194], ["pathogenetic", 196], ["explanation", 209], ["for", 221], ["the", 225], ["initiation", 229], ["of", 240], ["the", 243], ["CML", 247], ["chronic", 251], ["phase", 259], ["and", 265], ["is", 269], ["the", 272], ["molecular", 276], ["therapeutic", 286], ["target", 298], ["for", 305], ["the", 309], ["disease", 313], [".", 320], ["Imatinib", 322], ["mesylate", 331], [",", 339], ["an", 341], ["orally", 344], ["available", 351], ["BCR", 361], ["-", 364], ["ABL", 365], ["kinase", 369], ["inhibitor", 376], [",", 385], ["can", 387], ["induce", 391], ["haematologic", 398], ["and", 411], ["cytogenetic", 415], ["remission", 427], ["of", 437], ["CML", 440], [".", 443], ["However", 445], [",", 452], ["imatinib", 454], ["resistance", 463], ["occurs", 474], ["frequently", 481], [",", 491], ["resulting", 493], ["in", 503], ["relapse", 506], [".", 513], ["New", 515], ["treatment", 519], ["strategies", 529], ["are", 540], ["focusing", 544], ["on", 553], ["resistant", 556], ["CML", 566], ["stem", 570], ["cells", 575], ["and", 581], ["the", 585], ["bone", 589], ["marrow", 594], ["stroma", 601], [".", 607], ["The", 609], ["identification", 613], ["of", 628], ["novel", 631], ["pathways", 637], ["and", 646], ["mechanisms", 650], ["in", 661], ["the", 664], ["bone", 668], ["marrow", 673], ["microenvironment", 680], ["could", 697], ["significantly", 703], ["contribute", 717], ["to", 728], ["the", 731], ["development", 735], ["of", 747], ["such", 750], ["strategies", 755], [".", 765], ["In", 767], ["this", 770], ["work", 775], [",", 779], ["we", 781], ["used", 784], ["a", 789], ["high", 791], ["-", 795], ["resolution", 796], ["label", 807], ["-", 812], ["free", 813], ["MS(E", 818], [")", 822], ["proteomic", 825], ["approach", 835], ["to", 844], ["identify", 847], ["differential", 856], ["protein", 869], ["expression", 877], ["in", 888], ["the", 891], ["CML", 895], ["bone", 899], ["marrow", 904], ["plasma", 911], ["of", 918], ["responsive", 921], ["and", 932], ["resistant", 936], ["patients", 946], [".", 954], ["Oxidative", 956], ["lipid", 966], ["metabolism", 972], ["and", 983], ["regulation", 987], ["of", 998], ["the", 1001], ["switch", 1005], ["from", 1012], ["canonical", 1017], ["to", 1027], ["noncanonical", 1030], ["WNT", 1043], ["signaling", 1047], ["may", 1057], ["contribute", 1061], ["to", 1072], ["CML", 1075], ["resistance", 1079], ["in", 1090], ["the", 1093], ["bone", 1097], ["marrow", 1102], ["compartment", 1109], [".", 1120]]}
{"context": "Adenosine-to-inosine RNA editing is a highly conserved process that post-transcriptionally modifies mRNA, generating proteomic diversity, particularly within the nervous system of metazoans. Transcripts encoding proteins involved in neurotransmission predominate as targets of such modifications. Previous reports suggest that RNA editing is responsive to environmental inputs in the form of temperature alterations. However, the molecular determinants underlying temperature-dependent RNA editing responses are not well understood. Using the poikilotherm Drosophila, we show that acute temperature alterations within a normal physiological range result in substantial changes in RNA editing levels. Our examination of particular sites reveals diversity in the patterns with which editing responds to temperature, and these patterns are conserved across five species of Drosophilidae representing over 10 million years of divergence. In addition, we show that expression of the editing enzyme, ADAR (adenosine deaminase acting on RNA), is dramatically decreased at elevated temperatures, partially, but not fully, explaining some target responses to temperature. Interestingly, this reduction in editing enzyme levels at elevated temperature is only partially reversed by a return to lower temperatures. Lastly, we show that engineered structural variants of the most temperature-sensitive editing site, in a sodium channel transcript, perturb thermal responsiveness in RNA editing profile for a particular RNA structure. Our results suggest that the RNA editing process responds to temperature alterations via two distinct molecular mechanisms: through intrinsic thermo-sensitivity of the RNA structures that direct editing, and due to temperature sensitive expression or stability of the RNA editing enzyme. Environmental cues, in this case temperature, rapidly reprogram the Drosophila transcriptome through RNA editing, presumably resulting in altered proteomic ratios of edited and unedited proteins.", "qas": [{"question": "Which is the major RNA editing enzyme in Drosophila melanogaster?", "answers": ["ADAR", "adenosine deaminase, RNA-specific"], "qid": "9ec37c93f75941a1a648eced56f60b4f", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["major", 13], ["RNA", 19], ["editing", 23], ["enzyme", 31], ["in", 38], ["Drosophila", 41], ["melanogaster", 52], ["?", 64]], "detected_answers": [{"text": "ADAR", "token_spans": [[151, 151]], "char_spans": [[994, 997]]}]}], "context_tokens": [["Adenosine", 0], ["-", 9], ["to", 10], ["-", 12], ["inosine", 13], ["RNA", 21], ["editing", 25], ["is", 33], ["a", 36], ["highly", 38], ["conserved", 45], ["process", 55], ["that", 63], ["post", 68], ["-", 72], ["transcriptionally", 73], ["modifies", 91], ["mRNA", 100], [",", 104], ["generating", 106], ["proteomic", 117], ["diversity", 127], [",", 136], ["particularly", 138], ["within", 151], ["the", 158], ["nervous", 162], ["system", 170], ["of", 177], ["metazoans", 180], [".", 189], ["Transcripts", 191], ["encoding", 203], ["proteins", 212], ["involved", 221], ["in", 230], ["neurotransmission", 233], ["predominate", 251], ["as", 263], ["targets", 266], ["of", 274], ["such", 277], ["modifications", 282], [".", 295], ["Previous", 297], ["reports", 306], ["suggest", 314], ["that", 322], ["RNA", 327], ["editing", 331], ["is", 339], ["responsive", 342], ["to", 353], ["environmental", 356], ["inputs", 370], ["in", 377], ["the", 380], ["form", 384], ["of", 389], ["temperature", 392], ["alterations", 404], [".", 415], ["However", 417], [",", 424], ["the", 426], ["molecular", 430], ["determinants", 440], ["underlying", 453], ["temperature", 464], ["-", 475], ["dependent", 476], ["RNA", 486], ["editing", 490], ["responses", 498], ["are", 508], ["not", 512], ["well", 516], ["understood", 521], [".", 531], ["Using", 533], ["the", 539], ["poikilotherm", 543], ["Drosophila", 556], [",", 566], ["we", 568], ["show", 571], ["that", 576], ["acute", 581], ["temperature", 587], ["alterations", 599], ["within", 611], ["a", 618], ["normal", 620], ["physiological", 627], ["range", 641], ["result", 647], ["in", 654], ["substantial", 657], ["changes", 669], ["in", 677], ["RNA", 680], ["editing", 684], ["levels", 692], [".", 698], ["Our", 700], ["examination", 704], ["of", 716], ["particular", 719], ["sites", 730], ["reveals", 736], ["diversity", 744], ["in", 754], ["the", 757], ["patterns", 761], ["with", 770], ["which", 775], ["editing", 781], ["responds", 789], ["to", 798], ["temperature", 801], [",", 812], ["and", 814], ["these", 818], ["patterns", 824], ["are", 833], ["conserved", 837], ["across", 847], ["five", 854], ["species", 859], ["of", 867], ["Drosophilidae", 870], ["representing", 884], ["over", 897], ["10", 902], ["million", 905], ["years", 913], ["of", 919], ["divergence", 922], [".", 932], ["In", 934], ["addition", 937], [",", 945], ["we", 947], ["show", 950], ["that", 955], ["expression", 960], ["of", 971], ["the", 974], ["editing", 978], ["enzyme", 986], [",", 992], ["ADAR", 994], ["(", 999], ["adenosine", 1000], ["deaminase", 1010], ["acting", 1020], ["on", 1027], ["RNA", 1030], [")", 1033], [",", 1034], ["is", 1036], ["dramatically", 1039], ["decreased", 1052], ["at", 1062], ["elevated", 1065], ["temperatures", 1074], [",", 1086], ["partially", 1088], [",", 1097], ["but", 1099], ["not", 1103], ["fully", 1107], [",", 1112], ["explaining", 1114], ["some", 1125], ["target", 1130], ["responses", 1137], ["to", 1147], ["temperature", 1150], [".", 1161], ["Interestingly", 1163], [",", 1176], ["this", 1178], ["reduction", 1183], ["in", 1193], ["editing", 1196], ["enzyme", 1204], ["levels", 1211], ["at", 1218], ["elevated", 1221], ["temperature", 1230], ["is", 1242], ["only", 1245], ["partially", 1250], ["reversed", 1260], ["by", 1269], ["a", 1272], ["return", 1274], ["to", 1281], ["lower", 1284], ["temperatures", 1290], [".", 1302], ["Lastly", 1304], [",", 1310], ["we", 1312], ["show", 1315], ["that", 1320], ["engineered", 1325], ["structural", 1336], ["variants", 1347], ["of", 1356], ["the", 1359], ["most", 1363], ["temperature", 1368], ["-", 1379], ["sensitive", 1380], ["editing", 1390], ["site", 1398], [",", 1402], ["in", 1404], ["a", 1407], ["sodium", 1409], ["channel", 1416], ["transcript", 1424], [",", 1434], ["perturb", 1436], ["thermal", 1444], ["responsiveness", 1452], ["in", 1467], ["RNA", 1470], ["editing", 1474], ["profile", 1482], ["for", 1490], ["a", 1494], ["particular", 1496], ["RNA", 1507], ["structure", 1511], [".", 1520], ["Our", 1522], ["results", 1526], ["suggest", 1534], ["that", 1542], ["the", 1547], ["RNA", 1551], ["editing", 1555], ["process", 1563], ["responds", 1571], ["to", 1580], ["temperature", 1583], ["alterations", 1595], ["via", 1607], ["two", 1611], ["distinct", 1615], ["molecular", 1624], ["mechanisms", 1634], [":", 1644], ["through", 1646], ["intrinsic", 1654], ["thermo", 1664], ["-", 1670], ["sensitivity", 1671], ["of", 1683], ["the", 1686], ["RNA", 1690], ["structures", 1694], ["that", 1705], ["direct", 1710], ["editing", 1717], [",", 1724], ["and", 1726], ["due", 1730], ["to", 1734], ["temperature", 1737], ["sensitive", 1749], ["expression", 1759], ["or", 1770], ["stability", 1773], ["of", 1783], ["the", 1786], ["RNA", 1790], ["editing", 1794], ["enzyme", 1802], [".", 1808], ["Environmental", 1810], ["cues", 1824], [",", 1828], ["in", 1830], ["this", 1833], ["case", 1838], ["temperature", 1843], [",", 1854], ["rapidly", 1856], ["reprogram", 1864], ["the", 1874], ["Drosophila", 1878], ["transcriptome", 1889], ["through", 1903], ["RNA", 1911], ["editing", 1915], [",", 1922], ["presumably", 1924], ["resulting", 1935], ["in", 1945], ["altered", 1948], ["proteomic", 1956], ["ratios", 1966], ["of", 1973], ["edited", 1976], ["and", 1983], ["unedited", 1987], ["proteins", 1996], [".", 2004]]}
{"context": "To assess whether vancomycin minimum inhibitory concentration (MIC) creeps among clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) in a regional hospital in China. Furthermore, to analyze the causes of vancomycin MIC creeps and the relationship between vancomycin MICs and the outcome among patients with MRSA infection. All clinical isolates of MRSA from 2006-2010 were retrieved and tested by the broth microdilution procedure to determine their vancomycin MIC. Meanwhile, related patient records were analyzed. While all isolates were susceptive to vancomycin, the percentage of isolates with a vancomycin MIC = 1 mg/L increased significantly from 2006 (37.0%) to 2010 (75.7%). Meanwhile, vancomycin usage density (DDDs/1000 bed-days) had increased significantly from 2006-2010. Mean linear correlation analysis showed a statistically significant positive correlation (r = 0.905, P < 0.05) between the consumption of vancomycin and the percentage of MRSA isolates with a vancomycin MIC = 1 mg/L. Clinical records revealed high vancomycin MIC was associated with a higher microbiologic failure rate in MRSA bloodstream infections. The data demonstrated vancomycin MIC creep among clinical isolates in our hospital, and the MIC creep may be caused by the increasing usage of vancomycin. Furthermore, the analysis strongly suggested this shift of vancomycin MIC within the susceptible range may be associated with an increasing probability of treatment failure.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "d121248484f240caaf83cd0a81473232", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[59, 59], [21, 21], [170, 170], [52, 52], [196, 196]], "char_spans": [[368, 371], [147, 150], [975, 978], [327, 330], [1126, 1129]]}]}], "context_tokens": [["To", 0], ["assess", 3], ["whether", 10], ["vancomycin", 18], ["minimum", 29], ["inhibitory", 37], ["concentration", 48], ["(", 62], ["MIC", 63], [")", 66], ["creeps", 68], ["among", 75], ["clinical", 81], ["isolates", 90], ["of", 99], ["methicillin", 102], ["-", 113], ["resistant", 114], ["Staphylococcus", 124], ["aureus", 139], ["(", 146], ["MRSA", 147], [")", 151], ["in", 153], ["a", 156], ["regional", 158], ["hospital", 167], ["in", 176], ["China", 179], [".", 184], ["Furthermore", 186], [",", 197], ["to", 199], ["analyze", 202], ["the", 210], ["causes", 214], ["of", 221], ["vancomycin", 224], ["MIC", 235], ["creeps", 239], ["and", 246], ["the", 250], ["relationship", 254], ["between", 267], ["vancomycin", 275], ["MICs", 286], ["and", 291], ["the", 295], ["outcome", 299], ["among", 307], ["patients", 313], ["with", 322], ["MRSA", 327], ["infection", 332], [".", 341], ["All", 343], ["clinical", 347], ["isolates", 356], ["of", 365], ["MRSA", 368], ["from", 373], ["2006", 378], ["-", 382], ["2010", 383], ["were", 388], ["retrieved", 393], ["and", 403], ["tested", 407], ["by", 414], ["the", 417], ["broth", 421], ["microdilution", 427], ["procedure", 441], ["to", 451], ["determine", 454], ["their", 464], ["vancomycin", 470], ["MIC", 481], [".", 484], ["Meanwhile", 486], [",", 495], ["related", 497], ["patient", 505], ["records", 513], ["were", 521], ["analyzed", 526], [".", 534], ["While", 536], ["all", 542], ["isolates", 546], ["were", 555], ["susceptive", 560], ["to", 571], ["vancomycin", 574], [",", 584], ["the", 586], ["percentage", 590], ["of", 601], ["isolates", 604], ["with", 613], ["a", 618], ["vancomycin", 620], ["MIC", 631], ["=", 635], ["1", 637], ["mg", 639], ["/", 641], ["L", 642], ["increased", 644], ["significantly", 654], ["from", 668], ["2006", 673], ["(", 678], ["37.0", 679], ["%", 683], [")", 684], ["to", 686], ["2010", 689], ["(", 694], ["75.7", 695], ["%", 699], [")", 700], [".", 701], ["Meanwhile", 703], [",", 712], ["vancomycin", 714], ["usage", 725], ["density", 731], ["(", 739], ["DDDs/1000", 740], ["bed", 750], ["-", 753], ["days", 754], [")", 758], ["had", 760], ["increased", 764], ["significantly", 774], ["from", 788], ["2006", 793], ["-", 797], ["2010", 798], [".", 802], ["Mean", 804], ["linear", 809], ["correlation", 816], ["analysis", 828], ["showed", 837], ["a", 844], ["statistically", 846], ["significant", 860], ["positive", 872], ["correlation", 881], ["(", 893], ["r", 894], ["=", 896], ["0.905", 898], [",", 903], ["P", 905], ["<", 907], ["0.05", 909], [")", 913], ["between", 915], ["the", 923], ["consumption", 927], ["of", 939], ["vancomycin", 942], ["and", 953], ["the", 957], ["percentage", 961], ["of", 972], ["MRSA", 975], ["isolates", 980], ["with", 989], ["a", 994], ["vancomycin", 996], ["MIC", 1007], ["=", 1011], ["1", 1013], ["mg", 1015], ["/", 1017], ["L.", 1018], ["Clinical", 1021], ["records", 1030], ["revealed", 1038], ["high", 1047], ["vancomycin", 1052], ["MIC", 1063], ["was", 1067], ["associated", 1071], ["with", 1082], ["a", 1087], ["higher", 1089], ["microbiologic", 1096], ["failure", 1110], ["rate", 1118], ["in", 1123], ["MRSA", 1126], ["bloodstream", 1131], ["infections", 1143], [".", 1153], ["The", 1155], ["data", 1159], ["demonstrated", 1164], ["vancomycin", 1177], ["MIC", 1188], ["creep", 1192], ["among", 1198], ["clinical", 1204], ["isolates", 1213], ["in", 1222], ["our", 1225], ["hospital", 1229], [",", 1237], ["and", 1239], ["the", 1243], ["MIC", 1247], ["creep", 1251], ["may", 1257], ["be", 1261], ["caused", 1264], ["by", 1271], ["the", 1274], ["increasing", 1278], ["usage", 1289], ["of", 1295], ["vancomycin", 1298], [".", 1308], ["Furthermore", 1310], [",", 1321], ["the", 1323], ["analysis", 1327], ["strongly", 1336], ["suggested", 1345], ["this", 1355], ["shift", 1360], ["of", 1366], ["vancomycin", 1369], ["MIC", 1380], ["within", 1384], ["the", 1391], ["susceptible", 1395], ["range", 1407], ["may", 1413], ["be", 1417], ["associated", 1420], ["with", 1431], ["an", 1436], ["increasing", 1439], ["probability", 1450], ["of", 1462], ["treatment", 1465], ["failure", 1475], [".", 1482]]}
{"context": "One of the primary criticismes of vestibular schwannoma (VS) radiosurgery is that the risk of surgical morbidity is increased for patients whose tumor progresses after the procedures. We reviewed the French experience of operated patients after failed Gamma Knife radiosurgery. From July 1992 to January 2002, 25 out of the 1000 treated patients underwent another treatment procedure for a gamma knife failure. Excluding the NF2 patients, 21 patients have been operated and the present study shows the data collected for 20 of them. In order to analyze the difficulties observed during the surgery, a questionnaire was filled by the surgeons. The mean interval between radiosurgery and removal was 36 Months, from 10 to 83 Months. The mean increase in Volume was 559% (37 to 3036%, median 160%). Evolution of the Koos grading was found from 8 grade II, 10 grade III et 2 grade IV to 10 grade III and 10 grade IV. Patients have been operated for radiological tumor growth in 7 cases and for clinico-radiological evolution in 13 cases. In 9 cases, the surgeon considered that he had to face unusual difficulties mainly because of adhesion of the tumor to neurovascular structures. Tumor removal was total in 14 cases, near total in 4 cases and subtotal in 2 cases. One case of venous infarction was noticed at the second day following surgery responsible of hemiparesis and aphasia that gradually recovered. At last follow-up examination, facial nerve was normal (House and Brackmann grade I and II) in 10 cases while it was a grade III in 7 cases and grade IV and V in 3 cases. We recommend that the decision for surgical removal of growing vestibular schwannoma after Gamma Knife treatment should be done after a sufficiently long follow-up period. Our results show that the quality of removal and of facial nerve preservation might be impaired by radiosurgery in half of cases. However these results do not support a change in our policy of radiosurgical treatment of small to medium size vestibular schwannoma.", "qas": [{"question": "Which disease can be categorized using the Koos grading system?", "answers": ["vestibular schwannoma"], "qid": "82b7ad0ac3da45f8850154988038abc3", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["categorized", 21], ["using", 33], ["the", 39], ["Koos", 43], ["grading", 48], ["system", 56], ["?", 62]], "detected_answers": [{"text": "vestibular schwannoma", "token_spans": [[312, 313], [6, 7], [372, 373]], "char_spans": [[1640, 1660], [34, 54], [1990, 2010]]}]}], "context_tokens": [["One", 0], ["of", 4], ["the", 7], ["primary", 11], ["criticismes", 19], ["of", 31], ["vestibular", 34], ["schwannoma", 45], ["(", 56], ["VS", 57], [")", 59], ["radiosurgery", 61], ["is", 74], ["that", 77], ["the", 82], ["risk", 86], ["of", 91], ["surgical", 94], ["morbidity", 103], ["is", 113], ["increased", 116], ["for", 126], ["patients", 130], ["whose", 139], ["tumor", 145], ["progresses", 151], ["after", 162], ["the", 168], ["procedures", 172], [".", 182], ["We", 184], ["reviewed", 187], ["the", 196], ["French", 200], ["experience", 207], ["of", 218], ["operated", 221], ["patients", 230], ["after", 239], ["failed", 245], ["Gamma", 252], ["Knife", 258], ["radiosurgery", 264], [".", 276], ["From", 278], ["July", 283], ["1992", 288], ["to", 293], ["January", 296], ["2002", 304], [",", 308], ["25", 310], ["out", 313], ["of", 317], ["the", 320], ["1000", 324], ["treated", 329], ["patients", 337], ["underwent", 346], ["another", 356], ["treatment", 364], ["procedure", 374], ["for", 384], ["a", 388], ["gamma", 390], ["knife", 396], ["failure", 402], [".", 409], ["Excluding", 411], ["the", 421], ["NF2", 425], ["patients", 429], [",", 437], ["21", 439], ["patients", 442], ["have", 451], ["been", 456], ["operated", 461], ["and", 470], ["the", 474], ["present", 478], ["study", 486], ["shows", 492], ["the", 498], ["data", 502], ["collected", 507], ["for", 517], ["20", 521], ["of", 524], ["them", 527], [".", 531], ["In", 533], ["order", 536], ["to", 542], ["analyze", 545], ["the", 553], ["difficulties", 557], ["observed", 570], ["during", 579], ["the", 586], ["surgery", 590], [",", 597], ["a", 599], ["questionnaire", 601], ["was", 615], ["filled", 619], ["by", 626], ["the", 629], ["surgeons", 633], [".", 641], ["The", 643], ["mean", 647], ["interval", 652], ["between", 661], ["radiosurgery", 669], ["and", 682], ["removal", 686], ["was", 694], ["36", 698], ["Months", 701], [",", 707], ["from", 709], ["10", 714], ["to", 717], ["83", 720], ["Months", 723], [".", 729], ["The", 731], ["mean", 735], ["increase", 740], ["in", 749], ["Volume", 752], ["was", 759], ["559", 763], ["%", 766], ["(", 768], ["37", 769], ["to", 772], ["3036", 775], ["%", 779], [",", 780], ["median", 782], ["160", 789], ["%", 792], [")", 793], [".", 794], ["Evolution", 796], ["of", 806], ["the", 809], ["Koos", 813], ["grading", 818], ["was", 826], ["found", 830], ["from", 836], ["8", 841], ["grade", 843], ["II", 849], [",", 851], ["10", 853], ["grade", 856], ["III", 862], ["et", 866], ["2", 869], ["grade", 871], ["IV", 877], ["to", 880], ["10", 883], ["grade", 886], ["III", 892], ["and", 896], ["10", 900], ["grade", 903], ["IV", 909], [".", 911], ["Patients", 913], ["have", 922], ["been", 927], ["operated", 932], ["for", 941], ["radiological", 945], ["tumor", 958], ["growth", 964], ["in", 971], ["7", 974], ["cases", 976], ["and", 982], ["for", 986], ["clinico", 990], ["-", 997], ["radiological", 998], ["evolution", 1011], ["in", 1021], ["13", 1024], ["cases", 1027], [".", 1032], ["In", 1034], ["9", 1037], ["cases", 1039], [",", 1044], ["the", 1046], ["surgeon", 1050], ["considered", 1058], ["that", 1069], ["he", 1074], ["had", 1077], ["to", 1081], ["face", 1084], ["unusual", 1089], ["difficulties", 1097], ["mainly", 1110], ["because", 1117], ["of", 1125], ["adhesion", 1128], ["of", 1137], ["the", 1140], ["tumor", 1144], ["to", 1150], ["neurovascular", 1153], ["structures", 1167], [".", 1177], ["Tumor", 1179], ["removal", 1185], ["was", 1193], ["total", 1197], ["in", 1203], ["14", 1206], ["cases", 1209], [",", 1214], ["near", 1216], ["total", 1221], ["in", 1227], ["4", 1230], ["cases", 1232], ["and", 1238], ["subtotal", 1242], ["in", 1251], ["2", 1254], ["cases", 1256], [".", 1261], ["One", 1263], ["case", 1267], ["of", 1272], ["venous", 1275], ["infarction", 1282], ["was", 1293], ["noticed", 1297], ["at", 1305], ["the", 1308], ["second", 1312], ["day", 1319], ["following", 1323], ["surgery", 1333], ["responsible", 1341], ["of", 1353], ["hemiparesis", 1356], ["and", 1368], ["aphasia", 1372], ["that", 1380], ["gradually", 1385], ["recovered", 1395], [".", 1404], ["At", 1406], ["last", 1409], ["follow", 1414], ["-", 1420], ["up", 1421], ["examination", 1424], [",", 1435], ["facial", 1437], ["nerve", 1444], ["was", 1450], ["normal", 1454], ["(", 1461], ["House", 1462], ["and", 1468], ["Brackmann", 1472], ["grade", 1482], ["I", 1488], ["and", 1490], ["II", 1494], [")", 1496], ["in", 1498], ["10", 1501], ["cases", 1504], ["while", 1510], ["it", 1516], ["was", 1519], ["a", 1523], ["grade", 1525], ["III", 1531], ["in", 1535], ["7", 1538], ["cases", 1540], ["and", 1546], ["grade", 1550], ["IV", 1556], ["and", 1559], ["V", 1563], ["in", 1565], ["3", 1568], ["cases", 1570], [".", 1575], ["We", 1577], ["recommend", 1580], ["that", 1590], ["the", 1595], ["decision", 1599], ["for", 1608], ["surgical", 1612], ["removal", 1621], ["of", 1629], ["growing", 1632], ["vestibular", 1640], ["schwannoma", 1651], ["after", 1662], ["Gamma", 1668], ["Knife", 1674], ["treatment", 1680], ["should", 1690], ["be", 1697], ["done", 1700], ["after", 1705], ["a", 1711], ["sufficiently", 1713], ["long", 1726], ["follow", 1731], ["-", 1737], ["up", 1738], ["period", 1741], [".", 1747], ["Our", 1749], ["results", 1753], ["show", 1761], ["that", 1766], ["the", 1771], ["quality", 1775], ["of", 1783], ["removal", 1786], ["and", 1794], ["of", 1798], ["facial", 1801], ["nerve", 1808], ["preservation", 1814], ["might", 1827], ["be", 1833], ["impaired", 1836], ["by", 1845], ["radiosurgery", 1848], ["in", 1861], ["half", 1864], ["of", 1869], ["cases", 1872], [".", 1877], ["However", 1879], ["these", 1887], ["results", 1893], ["do", 1901], ["not", 1904], ["support", 1908], ["a", 1916], ["change", 1918], ["in", 1925], ["our", 1928], ["policy", 1932], ["of", 1939], ["radiosurgical", 1942], ["treatment", 1956], ["of", 1966], ["small", 1969], ["to", 1975], ["medium", 1978], ["size", 1985], ["vestibular", 1990], ["schwannoma", 2001], [".", 2011]]}
{"context": "Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) is increasing in prevalence among asymptomatic carriers and in cases of paediatric soft-tissue infections alike. CA-MRSA may express virulence factors such as Panton-Valentine leukocidin, which makes soft-tissue and hard-tissue infections due to such organisms challenging to treat. We report a case of osteomyelitis of the proximal tibia in a 10-year-old boy and discuss its management in what is to the authors' knowledge the first case report of Panton-Valentine leukocidin-positive CA-MRSA osteomyelitis in a child in the UK.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "aee842a768df4abebce2612c194f1e62", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[33, 33], [104, 104], [11, 11]], "char_spans": [[191, 194], [564, 567], [69, 72]]}]}], "context_tokens": [["Community", 0], ["-", 9], ["associated", 10], ["methicillin", 21], ["-", 32], ["resistant", 33], ["Staphylococcus", 43], ["aureus", 58], ["(", 65], ["CA", 66], ["-", 68], ["MRSA", 69], [")", 73], ["is", 75], ["increasing", 78], ["in", 89], ["prevalence", 92], ["among", 103], ["asymptomatic", 109], ["carriers", 122], ["and", 131], ["in", 135], ["cases", 138], ["of", 144], ["paediatric", 147], ["soft", 158], ["-", 162], ["tissue", 163], ["infections", 170], ["alike", 181], [".", 186], ["CA", 188], ["-", 190], ["MRSA", 191], ["may", 196], ["express", 200], ["virulence", 208], ["factors", 218], ["such", 226], ["as", 231], ["Panton", 234], ["-", 240], ["Valentine", 241], ["leukocidin", 251], [",", 261], ["which", 263], ["makes", 269], ["soft", 275], ["-", 279], ["tissue", 280], ["and", 287], ["hard", 291], ["-", 295], ["tissue", 296], ["infections", 303], ["due", 314], ["to", 318], ["such", 321], ["organisms", 326], ["challenging", 336], ["to", 348], ["treat", 351], [".", 356], ["We", 358], ["report", 361], ["a", 368], ["case", 370], ["of", 375], ["osteomyelitis", 378], ["of", 392], ["the", 395], ["proximal", 399], ["tibia", 408], ["in", 414], ["a", 417], ["10-year", 419], ["-", 426], ["old", 427], ["boy", 431], ["and", 435], ["discuss", 439], ["its", 447], ["management", 451], ["in", 462], ["what", 465], ["is", 470], ["to", 473], ["the", 476], ["authors", 480], ["'", 487], ["knowledge", 489], ["the", 499], ["first", 503], ["case", 509], ["report", 514], ["of", 521], ["Panton", 524], ["-", 530], ["Valentine", 531], ["leukocidin", 541], ["-", 551], ["positive", 552], ["CA", 561], ["-", 563], ["MRSA", 564], ["osteomyelitis", 569], ["in", 583], ["a", 586], ["child", 588], ["in", 594], ["the", 597], ["UK", 601], [".", 603]]}
{"context": "Iron depletion is common in regular blood donors. The objective of the study was to investigate the frequency and severity of iron depletion in regular blood donors and whether IV iron is more effective than oral to avoid iron depletion and symptoms thereof, especially restless legs syndrome (RLS). One hundred and twenty blood donors with at least five previous whole blood donations were randomized to receive either IV iron sucrose (Venofer(\u00ae), RenaPharma/Vifor, Uppsala, Sweden), 200 mg, or to 20\u00d7100 mg of oral iron sulphate (Duroferon(\u00ae), GlaxoSmithKline, Stockholm, Sweden), after each blood donation during 1 year. Iron status and RLS incidence and severity were investigated. Iron status was generally poor among regular blood donors, especially in women, with a high incidence of iron depletion (>20%) and RLS (18%). The IV iron group increased storage iron to a greater extent than the oral iron group after 12 months (P=0\u00b70043). Female donors were more responsive to IV iron sucrose compared to oral iron sulphate, particularly female donors below 50 years of age. RLS severity scores were significantly lower in the IV iron group. The two treatments were safe. Iron status is poor in regular blood donors, restless legs syndrome is common, and the routine iron supplementation is insufficient. IV iron sucrose substitutes iron loss in blood donors more efficiently compared with oral iron sulphate, especially in women. Iron substitution to blood donors should be individualized and based on P-ferritin monitoring.", "qas": [{"question": "Which deficiency is the cause of restless leg syndrome?", "answers": ["iron"], "qid": "a118373d91094ae6aca3047edf9b0bac", "question_tokens": [["Which", 0], ["deficiency", 6], ["is", 17], ["the", 20], ["cause", 24], ["of", 30], ["restless", 33], ["leg", 42], ["syndrome", 46], ["?", 54]], "detected_answers": [{"text": "iron", "token_spans": [[171, 171], [179, 179], [122, 122], [267, 267], [248, 248], [195, 195], [132, 132], [254, 254], [257, 257], [0, 0], [230, 230], [39, 39], [167, 167], [99, 99], [221, 221], [22, 22], [73, 73], [151, 151], [200, 200], [274, 274], [31, 31]], "char_spans": [[864, 867], [903, 906], [624, 627], [1398, 1401], [1270, 1273], [983, 986], [686, 689], [1311, 1314], [1336, 1339], [0, 3], [1175, 1178], [222, 225], [835, 838], [517, 520], [1133, 1136], [126, 129], [423, 426], [791, 794], [1013, 1016], [1434, 1437], [180, 183]]}]}], "context_tokens": [["Iron", 0], ["depletion", 5], ["is", 15], ["common", 18], ["in", 25], ["regular", 28], ["blood", 36], ["donors", 42], [".", 48], ["The", 50], ["objective", 54], ["of", 64], ["the", 67], ["study", 71], ["was", 77], ["to", 81], ["investigate", 84], ["the", 96], ["frequency", 100], ["and", 110], ["severity", 114], ["of", 123], ["iron", 126], ["depletion", 131], ["in", 141], ["regular", 144], ["blood", 152], ["donors", 158], ["and", 165], ["whether", 169], ["IV", 177], ["iron", 180], ["is", 185], ["more", 188], ["effective", 193], ["than", 203], ["oral", 208], ["to", 213], ["avoid", 216], ["iron", 222], ["depletion", 227], ["and", 237], ["symptoms", 241], ["thereof", 250], [",", 257], ["especially", 259], ["restless", 270], ["legs", 279], ["syndrome", 284], ["(", 293], ["RLS", 294], [")", 297], [".", 298], ["One", 300], ["hundred", 304], ["and", 312], ["twenty", 316], ["blood", 323], ["donors", 329], ["with", 336], ["at", 341], ["least", 344], ["five", 350], ["previous", 355], ["whole", 364], ["blood", 370], ["donations", 376], ["were", 386], ["randomized", 391], ["to", 402], ["receive", 405], ["either", 413], ["IV", 420], ["iron", 423], ["sucrose", 428], ["(", 436], ["Venofer", 437], ["(", 444], ["\u00ae", 445], [")", 446], [",", 447], ["RenaPharma", 449], ["/", 459], ["Vifor", 460], [",", 465], ["Uppsala", 467], [",", 474], ["Sweden", 476], [")", 482], [",", 483], ["200", 485], ["mg", 489], [",", 491], ["or", 493], ["to", 496], ["20\u00d7100", 499], ["mg", 506], ["of", 509], ["oral", 512], ["iron", 517], ["sulphate", 522], ["(", 531], ["Duroferon", 532], ["(", 541], ["\u00ae", 542], [")", 543], [",", 544], ["GlaxoSmithKline", 546], [",", 561], ["Stockholm", 563], [",", 572], ["Sweden", 574], [")", 580], [",", 581], ["after", 583], ["each", 589], ["blood", 594], ["donation", 600], ["during", 609], ["1", 616], ["year", 618], [".", 622], ["Iron", 624], ["status", 629], ["and", 636], ["RLS", 640], ["incidence", 644], ["and", 654], ["severity", 658], ["were", 667], ["investigated", 672], [".", 684], ["Iron", 686], ["status", 691], ["was", 698], ["generally", 702], ["poor", 712], ["among", 717], ["regular", 723], ["blood", 731], ["donors", 737], [",", 743], ["especially", 745], ["in", 756], ["women", 759], [",", 764], ["with", 766], ["a", 771], ["high", 773], ["incidence", 778], ["of", 788], ["iron", 791], ["depletion", 796], ["(", 806], [">", 807], ["20", 808], ["%", 810], [")", 811], ["and", 813], ["RLS", 817], ["(", 821], ["18", 822], ["%", 824], [")", 825], [".", 826], ["The", 828], ["IV", 832], ["iron", 835], ["group", 840], ["increased", 846], ["storage", 856], ["iron", 864], ["to", 869], ["a", 872], ["greater", 874], ["extent", 882], ["than", 889], ["the", 894], ["oral", 898], ["iron", 903], ["group", 908], ["after", 914], ["12", 920], ["months", 923], ["(", 930], ["P=0\u00b70043", 931], [")", 939], [".", 940], ["Female", 942], ["donors", 949], ["were", 956], ["more", 961], ["responsive", 966], ["to", 977], ["IV", 980], ["iron", 983], ["sucrose", 988], ["compared", 996], ["to", 1005], ["oral", 1008], ["iron", 1013], ["sulphate", 1018], [",", 1026], ["particularly", 1028], ["female", 1041], ["donors", 1048], ["below", 1055], ["50", 1061], ["years", 1064], ["of", 1070], ["age", 1073], [".", 1076], ["RLS", 1078], ["severity", 1082], ["scores", 1091], ["were", 1098], ["significantly", 1103], ["lower", 1117], ["in", 1123], ["the", 1126], ["IV", 1130], ["iron", 1133], ["group", 1138], [".", 1143], ["The", 1145], ["two", 1149], ["treatments", 1153], ["were", 1164], ["safe", 1169], [".", 1173], ["Iron", 1175], ["status", 1180], ["is", 1187], ["poor", 1190], ["in", 1195], ["regular", 1198], ["blood", 1206], ["donors", 1212], [",", 1218], ["restless", 1220], ["legs", 1229], ["syndrome", 1234], ["is", 1243], ["common", 1246], [",", 1252], ["and", 1254], ["the", 1258], ["routine", 1262], ["iron", 1270], ["supplementation", 1275], ["is", 1291], ["insufficient", 1294], [".", 1306], ["IV", 1308], ["iron", 1311], ["sucrose", 1316], ["substitutes", 1324], ["iron", 1336], ["loss", 1341], ["in", 1346], ["blood", 1349], ["donors", 1355], ["more", 1362], ["efficiently", 1367], ["compared", 1379], ["with", 1388], ["oral", 1393], ["iron", 1398], ["sulphate", 1403], [",", 1411], ["especially", 1413], ["in", 1424], ["women", 1427], [".", 1432], ["Iron", 1434], ["substitution", 1439], ["to", 1452], ["blood", 1455], ["donors", 1461], ["should", 1468], ["be", 1475], ["individualized", 1478], ["and", 1493], ["based", 1497], ["on", 1503], ["P", 1506], ["-", 1507], ["ferritin", 1508], ["monitoring", 1517], [".", 1527]]}
{"context": "The nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 (Dapivirine) effectively prevented human immunodeficiency virus (HIV) infection in cocultures of monocyte-derived dendritic cells and T cells, representing primary targets in sexual transmission. Both drugs had a favorable therapeutic index. A 24-h treatment with 1,000 nM UC-781 or 100 nM TMC120-R147681 prevented cell-free HIV infection, whereas 10-fold-higher concentrations blocked cell-associated HIV.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "c3236d984bae4fe9a702753a63371250", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[74, 74], [17, 17], [62, 62]], "char_spans": [[479, 481], [142, 144], [402, 404]]}]}], "context_tokens": [["The", 0], ["nonnucleoside", 4], ["reverse", 18], ["transcriptase", 26], ["inhibitors", 40], ["UC-781", 51], ["and", 58], ["TMC120-R147681", 62], ["(", 77], ["Dapivirine", 78], [")", 88], ["effectively", 90], ["prevented", 102], ["human", 112], ["immunodeficiency", 118], ["virus", 135], ["(", 141], ["HIV", 142], [")", 145], ["infection", 147], ["in", 157], ["cocultures", 160], ["of", 171], ["monocyte", 174], ["-", 182], ["derived", 183], ["dendritic", 191], ["cells", 201], ["and", 207], ["T", 211], ["cells", 213], [",", 218], ["representing", 220], ["primary", 233], ["targets", 241], ["in", 249], ["sexual", 252], ["transmission", 259], [".", 271], ["Both", 273], ["drugs", 278], ["had", 284], ["a", 288], ["favorable", 290], ["therapeutic", 300], ["index", 312], [".", 317], ["A", 319], ["24-h", 321], ["treatment", 326], ["with", 336], ["1,000", 341], ["nM", 347], ["UC-781", 350], ["or", 357], ["100", 360], ["nM", 364], ["TMC120-R147681", 367], ["prevented", 382], ["cell", 392], ["-", 396], ["free", 397], ["HIV", 402], ["infection", 406], [",", 415], ["whereas", 417], ["10-fold", 425], ["-", 432], ["higher", 433], ["concentrations", 440], ["blocked", 455], ["cell", 463], ["-", 467], ["associated", 468], ["HIV", 479], [".", 482]]}
{"context": "CADASIL is a cerebrovascular disease caused by mutations in the NOTCH3 gene. Most mutations result in a gain or loss of cysteine residue in one of the 34 epidermal growth factor-like repeats in the extracellular domain of the Notch3 protein, thus sparing the number of cysteine residues. To date, more than 130 different mutations in the NOTCH3 gene have been reported in CADASIL patients, of which 95% are missense point mutations. Many polymorphisms have also been identified in the NOTCH3 coding sequence, some of them leading to amino acid substitutions. The aim of the present study was to analyze the NOTCH3 gene in a large group of patients affected by leukoencephalopathy and to investigate the presence of genetic variants. The molecular analysis revealed several nucleotide alterations. In particular, we identified 20 different mutations, 22 polymorphisms, and 8 genetic variants of unknown pathological significance never reported previously. We hope that this NOTCH3 gene mutational analysis, performed in such a significant number of unrelated and related patients affected by leukoencephalopathy, will help in molecular screening for the NOTCH3 gene, thus contributing to enlargement of the NOTCH3 gene variation database.", "qas": [{"question": "Which amino acid residue appears mutated in most of the cases reported with  cadasil syndrome?", "answers": ["Cysteine"], "qid": "3aa0a515baa742df87b15ccd76e1ea2d", "question_tokens": [["Which", 0], ["amino", 6], ["acid", 12], ["residue", 17], ["appears", 25], ["mutated", 33], ["in", 41], ["most", 44], ["of", 49], ["the", 52], ["cases", 56], ["reported", 62], ["with", 71], [" ", 76], ["cadasil", 77], ["syndrome", 85], ["?", 93]], "detected_answers": [{"text": "Cysteine", "token_spans": [[49, 49], [22, 22]], "char_spans": [[269, 276], [120, 127]]}]}], "context_tokens": [["CADASIL", 0], ["is", 8], ["a", 11], ["cerebrovascular", 13], ["disease", 29], ["caused", 37], ["by", 44], ["mutations", 47], ["in", 57], ["the", 60], ["NOTCH3", 64], ["gene", 71], [".", 75], ["Most", 77], ["mutations", 82], ["result", 92], ["in", 99], ["a", 102], ["gain", 104], ["or", 109], ["loss", 112], ["of", 117], ["cysteine", 120], ["residue", 129], ["in", 137], ["one", 140], ["of", 144], ["the", 147], ["34", 151], ["epidermal", 154], ["growth", 164], ["factor", 171], ["-", 177], ["like", 178], ["repeats", 183], ["in", 191], ["the", 194], ["extracellular", 198], ["domain", 212], ["of", 219], ["the", 222], ["Notch3", 226], ["protein", 233], [",", 240], ["thus", 242], ["sparing", 247], ["the", 255], ["number", 259], ["of", 266], ["cysteine", 269], ["residues", 278], [".", 286], ["To", 288], ["date", 291], [",", 295], ["more", 297], ["than", 302], ["130", 307], ["different", 311], ["mutations", 321], ["in", 331], ["the", 334], ["NOTCH3", 338], ["gene", 345], ["have", 350], ["been", 355], ["reported", 360], ["in", 369], ["CADASIL", 372], ["patients", 380], [",", 388], ["of", 390], ["which", 393], ["95", 399], ["%", 401], ["are", 403], ["missense", 407], ["point", 416], ["mutations", 422], [".", 431], ["Many", 433], ["polymorphisms", 438], ["have", 452], ["also", 457], ["been", 462], ["identified", 467], ["in", 478], ["the", 481], ["NOTCH3", 485], ["coding", 492], ["sequence", 499], [",", 507], ["some", 509], ["of", 514], ["them", 517], ["leading", 522], ["to", 530], ["amino", 533], ["acid", 539], ["substitutions", 544], [".", 557], ["The", 559], ["aim", 563], ["of", 567], ["the", 570], ["present", 574], ["study", 582], ["was", 588], ["to", 592], ["analyze", 595], ["the", 603], ["NOTCH3", 607], ["gene", 614], ["in", 619], ["a", 622], ["large", 624], ["group", 630], ["of", 636], ["patients", 639], ["affected", 648], ["by", 657], ["leukoencephalopathy", 660], ["and", 680], ["to", 684], ["investigate", 687], ["the", 699], ["presence", 703], ["of", 712], ["genetic", 715], ["variants", 723], [".", 731], ["The", 733], ["molecular", 737], ["analysis", 747], ["revealed", 756], ["several", 765], ["nucleotide", 773], ["alterations", 784], [".", 795], ["In", 797], ["particular", 800], [",", 810], ["we", 812], ["identified", 815], ["20", 826], ["different", 829], ["mutations", 839], [",", 848], ["22", 850], ["polymorphisms", 853], [",", 866], ["and", 868], ["8", 872], ["genetic", 874], ["variants", 882], ["of", 891], ["unknown", 894], ["pathological", 902], ["significance", 915], ["never", 928], ["reported", 934], ["previously", 943], [".", 953], ["We", 955], ["hope", 958], ["that", 963], ["this", 968], ["NOTCH3", 973], ["gene", 980], ["mutational", 985], ["analysis", 996], [",", 1004], ["performed", 1006], ["in", 1016], ["such", 1019], ["a", 1024], ["significant", 1026], ["number", 1038], ["of", 1045], ["unrelated", 1048], ["and", 1058], ["related", 1062], ["patients", 1070], ["affected", 1079], ["by", 1088], ["leukoencephalopathy", 1091], [",", 1110], ["will", 1112], ["help", 1117], ["in", 1122], ["molecular", 1125], ["screening", 1135], ["for", 1145], ["the", 1149], ["NOTCH3", 1153], ["gene", 1160], [",", 1164], ["thus", 1166], ["contributing", 1171], ["to", 1184], ["enlargement", 1187], ["of", 1199], ["the", 1202], ["NOTCH3", 1206], ["gene", 1213], ["variation", 1218], ["database", 1228], [".", 1236]]}
{"context": "Turner syndrome is a genetic disorder caused by the complete or partial absence of an X chromosome in affected women. Individuals with TS show characteristic difficulties with executive functions, visual-spatial and mathematical cognition, with relatively intact verbal skills, and congruent abnormalities in structural development of the posterior parietal cortex (PPC). The functionally heterogeneous PPC has recently been investigated using connectivity-based clustering methods, which sub-divide a given region into clusters of voxels showing similar structural or functional connectivity to other brain regions. In the present study, we extended this method to compare connectivity-based clustering between groups and investigate whether functional networks differentially recruit the PPC in TS. To this end, we parcellated the PPC into sub-regions based on temporal correlations with other regions of the brain. fMRI data were collected from 15 girls with TS and 14 typically developing (TD) girls, aged 7-14, while they performed a visual-spatial task. Temporal correlations between voxels in the PPC and a set of seed regions were calculated, and the PPC divided into clusters of voxels showing similar connectivity. It was found that in general the PPC parcellates similarly in TS and TD girls, but that regions in bilateral inferior parietal lobules, and posterior right superior parietal lobule, were reliably recruited by different networks in TS relative to TD participants. These regions showed weaker correlation in TS with a set of regions involved in visual processing. These results suggest that abnormal development of visuospatial functional networks in TS may relate to the well documented cognitive difficulties in this disorder.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "9aae75f96acc4b5ba4f5bc32a39f1e8f", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[15, 15]], "char_spans": [[86, 86]]}]}], "context_tokens": [["Turner", 0], ["syndrome", 7], ["is", 16], ["a", 19], ["genetic", 21], ["disorder", 29], ["caused", 38], ["by", 45], ["the", 48], ["complete", 52], ["or", 61], ["partial", 64], ["absence", 72], ["of", 80], ["an", 83], ["X", 86], ["chromosome", 88], ["in", 99], ["affected", 102], ["women", 111], [".", 116], ["Individuals", 118], ["with", 130], ["TS", 135], ["show", 138], ["characteristic", 143], ["difficulties", 158], ["with", 171], ["executive", 176], ["functions", 186], [",", 195], ["visual", 197], ["-", 203], ["spatial", 204], ["and", 212], ["mathematical", 216], ["cognition", 229], [",", 238], ["with", 240], ["relatively", 245], ["intact", 256], ["verbal", 263], ["skills", 270], [",", 276], ["and", 278], ["congruent", 282], ["abnormalities", 292], ["in", 306], ["structural", 309], ["development", 320], ["of", 332], ["the", 335], ["posterior", 339], ["parietal", 349], ["cortex", 358], ["(", 365], ["PPC", 366], [")", 369], [".", 370], ["The", 372], ["functionally", 376], ["heterogeneous", 389], ["PPC", 403], ["has", 407], ["recently", 411], ["been", 420], ["investigated", 425], ["using", 438], ["connectivity", 444], ["-", 456], ["based", 457], ["clustering", 463], ["methods", 474], [",", 481], ["which", 483], ["sub", 489], ["-", 492], ["divide", 493], ["a", 500], ["given", 502], ["region", 508], ["into", 515], ["clusters", 520], ["of", 529], ["voxels", 532], ["showing", 539], ["similar", 547], ["structural", 555], ["or", 566], ["functional", 569], ["connectivity", 580], ["to", 593], ["other", 596], ["brain", 602], ["regions", 608], [".", 615], ["In", 617], ["the", 620], ["present", 624], ["study", 632], [",", 637], ["we", 639], ["extended", 642], ["this", 651], ["method", 656], ["to", 663], ["compare", 666], ["connectivity", 674], ["-", 686], ["based", 687], ["clustering", 693], ["between", 704], ["groups", 712], ["and", 719], ["investigate", 723], ["whether", 735], ["functional", 743], ["networks", 754], ["differentially", 763], ["recruit", 778], ["the", 786], ["PPC", 790], ["in", 794], ["TS", 797], [".", 799], ["To", 801], ["this", 804], ["end", 809], [",", 812], ["we", 814], ["parcellated", 817], ["the", 829], ["PPC", 833], ["into", 837], ["sub", 842], ["-", 845], ["regions", 846], ["based", 854], ["on", 860], ["temporal", 863], ["correlations", 872], ["with", 885], ["other", 890], ["regions", 896], ["of", 904], ["the", 907], ["brain", 911], [".", 916], ["fMRI", 918], ["data", 923], ["were", 928], ["collected", 933], ["from", 943], ["15", 948], ["girls", 951], ["with", 957], ["TS", 962], ["and", 965], ["14", 969], ["typically", 972], ["developing", 982], ["(", 993], ["TD", 994], [")", 996], ["girls", 998], [",", 1003], ["aged", 1005], ["7", 1010], ["-", 1011], ["14", 1012], [",", 1014], ["while", 1016], ["they", 1022], ["performed", 1027], ["a", 1037], ["visual", 1039], ["-", 1045], ["spatial", 1046], ["task", 1054], [".", 1058], ["Temporal", 1060], ["correlations", 1069], ["between", 1082], ["voxels", 1090], ["in", 1097], ["the", 1100], ["PPC", 1104], ["and", 1108], ["a", 1112], ["set", 1114], ["of", 1118], ["seed", 1121], ["regions", 1126], ["were", 1134], ["calculated", 1139], [",", 1149], ["and", 1151], ["the", 1155], ["PPC", 1159], ["divided", 1163], ["into", 1171], ["clusters", 1176], ["of", 1185], ["voxels", 1188], ["showing", 1195], ["similar", 1203], ["connectivity", 1211], [".", 1223], ["It", 1225], ["was", 1228], ["found", 1232], ["that", 1238], ["in", 1243], ["general", 1246], ["the", 1254], ["PPC", 1258], ["parcellates", 1262], ["similarly", 1274], ["in", 1284], ["TS", 1287], ["and", 1290], ["TD", 1294], ["girls", 1297], [",", 1302], ["but", 1304], ["that", 1308], ["regions", 1313], ["in", 1321], ["bilateral", 1324], ["inferior", 1334], ["parietal", 1343], ["lobules", 1352], [",", 1359], ["and", 1361], ["posterior", 1365], ["right", 1375], ["superior", 1381], ["parietal", 1390], ["lobule", 1399], [",", 1405], ["were", 1407], ["reliably", 1412], ["recruited", 1421], ["by", 1431], ["different", 1434], ["networks", 1444], ["in", 1453], ["TS", 1456], ["relative", 1459], ["to", 1468], ["TD", 1471], ["participants", 1474], [".", 1486], ["These", 1488], ["regions", 1494], ["showed", 1502], ["weaker", 1509], ["correlation", 1516], ["in", 1528], ["TS", 1531], ["with", 1534], ["a", 1539], ["set", 1541], ["of", 1545], ["regions", 1548], ["involved", 1556], ["in", 1565], ["visual", 1568], ["processing", 1575], [".", 1585], ["These", 1587], ["results", 1593], ["suggest", 1601], ["that", 1609], ["abnormal", 1614], ["development", 1623], ["of", 1635], ["visuospatial", 1638], ["functional", 1651], ["networks", 1662], ["in", 1671], ["TS", 1674], ["may", 1677], ["relate", 1681], ["to", 1688], ["the", 1691], ["well", 1695], ["documented", 1700], ["cognitive", 1711], ["difficulties", 1721], ["in", 1734], ["this", 1737], ["disorder", 1742], [".", 1750]]}
{"context": "Fibrillar \u03b1-synuclein (AS) is the major component of Lewy bodies, the pathological hallmark of Parkinson's disease. Mouse AS (mAS) aggregates much faster than human AS (hAS), although mAS differs from hAS at only seven positions in its primary sequence. Currently, little is known about the site-specific structural differences between mAS and hAS fibrils. Here, we applied state-of-the-art solid-state nuclear magnetic resonance (ssNMR) methods to structurally characterize mAS fibrils. The assignment strategy employed a set of high-resolution 2D and 3D ssNMR spectra recorded on uniformly [(13)C, (15)N], [1-(13)C]glucose, and [2-(13)C]glucose labeled mAS fibrils. An almost complete resonance assignment (96% of backbone amide (15)N and 93% of all (13)C nuclei) was obtained for residues from Gly41 to Val95, which form the core of mAS fibrils. Six \u03b2-strands were identified to be within the fibril core of mAS based on a secondary chemical shift and NHHC analysis. Intermolecular (13)C:(15)N labeled restraints obtained from mixed 1:1 (13)C/(15)N-labeled mAS fibrils reveal a parallel, in-register supramolecular \u03b2-sheet arrangement. The results were compared in detail to recent structural studies on hAS fibrils and indicate the presence of a structurally conserved motif comprising residues Glu61-Lys80.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "0a1c02809201488c903f97ee1cd9280f", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[1, 3]], "char_spans": [[10, 20]]}]}], "context_tokens": [["Fibrillar", 0], ["\u03b1", 10], ["-", 11], ["synuclein", 12], ["(", 22], ["AS", 23], [")", 25], ["is", 27], ["the", 30], ["major", 34], ["component", 40], ["of", 50], ["Lewy", 53], ["bodies", 58], [",", 64], ["the", 66], ["pathological", 70], ["hallmark", 83], ["of", 92], ["Parkinson", 95], ["'s", 104], ["disease", 107], [".", 114], ["Mouse", 116], ["AS", 122], ["(", 125], ["mAS", 126], [")", 129], ["aggregates", 131], ["much", 142], ["faster", 147], ["than", 154], ["human", 159], ["AS", 165], ["(", 168], ["hAS", 169], [")", 172], [",", 173], ["although", 175], ["mAS", 184], ["differs", 188], ["from", 196], ["hAS", 201], ["at", 205], ["only", 208], ["seven", 213], ["positions", 219], ["in", 229], ["its", 232], ["primary", 236], ["sequence", 244], [".", 252], ["Currently", 254], [",", 263], ["little", 265], ["is", 272], ["known", 275], ["about", 281], ["the", 287], ["site", 291], ["-", 295], ["specific", 296], ["structural", 305], ["differences", 316], ["between", 328], ["mAS", 336], ["and", 340], ["hAS", 344], ["fibrils", 348], [".", 355], ["Here", 357], [",", 361], ["we", 363], ["applied", 366], ["state", 374], ["-", 379], ["of", 380], ["-", 382], ["the", 383], ["-", 386], ["art", 387], ["solid", 391], ["-", 396], ["state", 397], ["nuclear", 403], ["magnetic", 411], ["resonance", 420], ["(", 430], ["ssNMR", 431], [")", 436], ["methods", 438], ["to", 446], ["structurally", 449], ["characterize", 462], ["mAS", 475], ["fibrils", 479], [".", 486], ["The", 488], ["assignment", 492], ["strategy", 503], ["employed", 512], ["a", 521], ["set", 523], ["of", 527], ["high", 530], ["-", 534], ["resolution", 535], ["2D", 546], ["and", 549], ["3D", 553], ["ssNMR", 556], ["spectra", 562], ["recorded", 570], ["on", 579], ["uniformly", 582], ["[", 592], ["(", 593], ["13)C", 594], [",", 598], ["(", 600], ["15)N", 601], ["]", 605], [",", 606], ["[", 608], ["1-(13)C]glucose", 609], [",", 624], ["and", 626], ["[", 630], ["2-(13)C]glucose", 631], ["labeled", 647], ["mAS", 655], ["fibrils", 659], [".", 666], ["An", 668], ["almost", 671], ["complete", 678], ["resonance", 687], ["assignment", 697], ["(", 708], ["96", 709], ["%", 711], ["of", 713], ["backbone", 716], ["amide", 725], ["(", 731], ["15)N", 732], ["and", 737], ["93", 741], ["%", 743], ["of", 745], ["all", 748], ["(", 752], ["13)C", 753], ["nuclei", 758], [")", 764], ["was", 766], ["obtained", 770], ["for", 779], ["residues", 783], ["from", 792], ["Gly41", 797], ["to", 803], ["Val95", 806], [",", 811], ["which", 813], ["form", 819], ["the", 824], ["core", 828], ["of", 833], ["mAS", 836], ["fibrils", 840], [".", 847], ["Six", 849], ["\u03b2", 853], ["-", 854], ["strands", 855], ["were", 863], ["identified", 868], ["to", 879], ["be", 882], ["within", 885], ["the", 892], ["fibril", 896], ["core", 903], ["of", 908], ["mAS", 911], ["based", 915], ["on", 921], ["a", 924], ["secondary", 926], ["chemical", 936], ["shift", 945], ["and", 951], ["NHHC", 955], ["analysis", 960], [".", 968], ["Intermolecular", 970], ["(", 985], ["13)C:(15)N", 986], ["labeled", 997], ["restraints", 1005], ["obtained", 1016], ["from", 1025], ["mixed", 1030], ["1:1", 1036], ["(", 1040], ["13)C/(15)N", 1041], ["-", 1051], ["labeled", 1052], ["mAS", 1060], ["fibrils", 1064], ["reveal", 1072], ["a", 1079], ["parallel", 1081], [",", 1089], ["in", 1091], ["-", 1093], ["register", 1094], ["supramolecular", 1103], ["\u03b2", 1118], ["-", 1119], ["sheet", 1120], ["arrangement", 1126], [".", 1137], ["The", 1139], ["results", 1143], ["were", 1151], ["compared", 1156], ["in", 1165], ["detail", 1168], ["to", 1175], ["recent", 1178], ["structural", 1185], ["studies", 1196], ["on", 1204], ["hAS", 1207], ["fibrils", 1211], ["and", 1219], ["indicate", 1223], ["the", 1232], ["presence", 1236], ["of", 1245], ["a", 1248], ["structurally", 1250], ["conserved", 1263], ["motif", 1273], ["comprising", 1279], ["residues", 1290], ["Glu61-Lys80", 1299], [".", 1310]]}
{"context": "Erythrasma is a skin infection which is caused by Corynebacterium minutissimum. Interdigital erythrasma is the most common form. The aim of this study was to detect the frequency and risk factors of interdigital erythrasma in patients with clinically suspected tinea pedis. This study was conducted between June and December 2010 and included 122 patients who had interdigital foot lesions. All patients were examined using a Wood's lamp. The smears were stained using Gram's method. Direct examination was performed using 20% potassium hydroxide. Sabouraud dextrose agar and brain heart infusion agar were used for cultures. Moreover, the demographical characteristics of patients, concomitant diseases and clinical findings were also recorded. Cases that were found to be positive on Wood's lamp examination and/or Gram staining/culture were considered as erythrasma. The rate of erythrasma was found to be 46.7%. The mean age was 43.6 years, and the disease was more prevalent in men. The most common clinical finding was desquamation. Mycological examination was found as positive in 40.35% of the patients. No growth was observed in bacteriological cultures. It was found that using only Wood's lamp examination or Gram staining resulted in 11 (9%) and 19 positive patients (15.6%), respectively, whereas using both Wood's lamp examination and Gram staining concurrently resulted in 27 positive patients (22.1%). Interdigital erythrasma is a commonly seen condition and can clinically mimic tinea pedis. A Wood's lamp is a good diagnostic tool, but Gram staining, particularly in those with a negative Wood's lamp result, may be a useful method.", "qas": [{"question": "Which bacteria causes erythrasma?", "answers": ["Corynebacterium minutissimum"], "qid": "f259dac2d37f4a20997aff4a16f394eb", "question_tokens": [["Which", 0], ["bacteria", 6], ["causes", 15], ["erythrasma", 22], ["?", 32]], "detected_answers": [{"text": "Corynebacterium minutissimum", "token_spans": [[9, 10]], "char_spans": [[50, 77]]}]}], "context_tokens": [["Erythrasma", 0], ["is", 11], ["a", 14], ["skin", 16], ["infection", 21], ["which", 31], ["is", 37], ["caused", 40], ["by", 47], ["Corynebacterium", 50], ["minutissimum", 66], [".", 78], ["Interdigital", 80], ["erythrasma", 93], ["is", 104], ["the", 107], ["most", 111], ["common", 116], ["form", 123], [".", 127], ["The", 129], ["aim", 133], ["of", 137], ["this", 140], ["study", 145], ["was", 151], ["to", 155], ["detect", 158], ["the", 165], ["frequency", 169], ["and", 179], ["risk", 183], ["factors", 188], ["of", 196], ["interdigital", 199], ["erythrasma", 212], ["in", 223], ["patients", 226], ["with", 235], ["clinically", 240], ["suspected", 251], ["tinea", 261], ["pedis", 267], [".", 272], ["This", 274], ["study", 279], ["was", 285], ["conducted", 289], ["between", 299], ["June", 307], ["and", 312], ["December", 316], ["2010", 325], ["and", 330], ["included", 334], ["122", 343], ["patients", 347], ["who", 356], ["had", 360], ["interdigital", 364], ["foot", 377], ["lesions", 382], [".", 389], ["All", 391], ["patients", 395], ["were", 404], ["examined", 409], ["using", 418], ["a", 424], ["Wood", 426], ["'s", 430], ["lamp", 433], [".", 437], ["The", 439], ["smears", 443], ["were", 450], ["stained", 455], ["using", 463], ["Gram", 469], ["'s", 473], ["method", 476], [".", 482], ["Direct", 484], ["examination", 491], ["was", 503], ["performed", 507], ["using", 517], ["20", 523], ["%", 525], ["potassium", 527], ["hydroxide", 537], [".", 546], ["Sabouraud", 548], ["dextrose", 558], ["agar", 567], ["and", 572], ["brain", 576], ["heart", 582], ["infusion", 588], ["agar", 597], ["were", 602], ["used", 607], ["for", 612], ["cultures", 616], [".", 624], ["Moreover", 626], [",", 634], ["the", 636], ["demographical", 640], ["characteristics", 654], ["of", 670], ["patients", 673], [",", 681], ["concomitant", 683], ["diseases", 695], ["and", 704], ["clinical", 708], ["findings", 717], ["were", 726], ["also", 731], ["recorded", 736], [".", 744], ["Cases", 746], ["that", 752], ["were", 757], ["found", 762], ["to", 768], ["be", 771], ["positive", 774], ["on", 783], ["Wood", 786], ["'s", 790], ["lamp", 793], ["examination", 798], ["and/or", 810], ["Gram", 817], ["staining", 822], ["/", 830], ["culture", 831], ["were", 839], ["considered", 844], ["as", 855], ["erythrasma", 858], [".", 868], ["The", 870], ["rate", 874], ["of", 879], ["erythrasma", 882], ["was", 893], ["found", 897], ["to", 903], ["be", 906], ["46.7", 909], ["%", 913], [".", 914], ["The", 916], ["mean", 920], ["age", 925], ["was", 929], ["43.6", 933], ["years", 938], [",", 943], ["and", 945], ["the", 949], ["disease", 953], ["was", 961], ["more", 965], ["prevalent", 970], ["in", 980], ["men", 983], [".", 986], ["The", 988], ["most", 992], ["common", 997], ["clinical", 1004], ["finding", 1013], ["was", 1021], ["desquamation", 1025], [".", 1037], ["Mycological", 1039], ["examination", 1051], ["was", 1063], ["found", 1067], ["as", 1073], ["positive", 1076], ["in", 1085], ["40.35", 1088], ["%", 1093], ["of", 1095], ["the", 1098], ["patients", 1102], [".", 1110], ["No", 1112], ["growth", 1115], ["was", 1122], ["observed", 1126], ["in", 1135], ["bacteriological", 1138], ["cultures", 1154], [".", 1162], ["It", 1164], ["was", 1167], ["found", 1171], ["that", 1177], ["using", 1182], ["only", 1188], ["Wood", 1193], ["'s", 1197], ["lamp", 1200], ["examination", 1205], ["or", 1217], ["Gram", 1220], ["staining", 1225], ["resulted", 1234], ["in", 1243], ["11", 1246], ["(", 1249], ["9", 1250], ["%", 1251], [")", 1252], ["and", 1254], ["19", 1258], ["positive", 1261], ["patients", 1270], ["(", 1279], ["15.6", 1280], ["%", 1284], [")", 1285], [",", 1286], ["respectively", 1288], [",", 1300], ["whereas", 1302], ["using", 1310], ["both", 1316], ["Wood", 1321], ["'s", 1325], ["lamp", 1328], ["examination", 1333], ["and", 1345], ["Gram", 1349], ["staining", 1354], ["concurrently", 1363], ["resulted", 1376], ["in", 1385], ["27", 1388], ["positive", 1391], ["patients", 1400], ["(", 1409], ["22.1", 1410], ["%", 1414], [")", 1415], [".", 1416], ["Interdigital", 1418], ["erythrasma", 1431], ["is", 1442], ["a", 1445], ["commonly", 1447], ["seen", 1456], ["condition", 1461], ["and", 1471], ["can", 1475], ["clinically", 1479], ["mimic", 1490], ["tinea", 1496], ["pedis", 1502], [".", 1507], ["A", 1509], ["Wood", 1511], ["'s", 1515], ["lamp", 1518], ["is", 1523], ["a", 1526], ["good", 1528], ["diagnostic", 1533], ["tool", 1544], [",", 1548], ["but", 1550], ["Gram", 1554], ["staining", 1559], [",", 1567], ["particularly", 1569], ["in", 1582], ["those", 1585], ["with", 1591], ["a", 1596], ["negative", 1598], ["Wood", 1607], ["'s", 1611], ["lamp", 1614], ["result", 1619], [",", 1625], ["may", 1627], ["be", 1631], ["a", 1634], ["useful", 1636], ["method", 1643], [".", 1649]]}
{"context": "This study examined the accuracy of the 17-item Dutch version of the Davidson Trauma Scale (DTS) and the four-item SPAN (Startle, Physiological Arousal, Anger and Numbness) to detect survivors at risk for posttraumatic stress disorder (PTSD) within the first 2 weeks after the trauma. 203 civilian survivors of recent trauma with relatively mild symptoms completed the DTS a mean of 8.7 days after experiencing trauma. SPAN scores were computed from the DTS. At a mean of 64.6 days posttrauma, 160 respondents were assessed for diagnosis of PTSD with the Structured Interview for PTSD. Receiver operating characteristic curves showed that the DTS showed good overall screening accuracy (84%). At a cut-off value of 64, the DTS demonstrated a sensitivity of 0.86, a specificity of 0.70, a positive predictive value (PPV) of 0.12, and a negative predictive value (NPV) of 0.98. Overall accuracy of the SPAN was good (89%). At a cut-off of 10 the SPAN showed a sensitivity of 0.86, a specificity of 0.86, a PPV of 0.22, and a NPV of 0.98. The low PPVs were possibly due to the low of prevalence of PTSD in our sample (4.4%). This study shows that both the DTS and the SPAN are comparably accurate in screening early trauma survivors at risk for developing PTSD. The very brief four-item SPAN may be preferred over the longer 17-item DTS especially in settings in which time and resources are limited. Future studies should aim to cross-validate these results in random samples.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "f39ba0ef13d74fbbbee6b6a7495a7da1", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[224, 224], [106, 106], [44, 44], [100, 100], [255, 255]], "char_spans": [[1095, 1098], [580, 583], [236, 239], [541, 544], [1253, 1256]]}]}], "context_tokens": [["This", 0], ["study", 5], ["examined", 11], ["the", 20], ["accuracy", 24], ["of", 33], ["the", 36], ["17-item", 40], ["Dutch", 48], ["version", 54], ["of", 62], ["the", 65], ["Davidson", 69], ["Trauma", 78], ["Scale", 85], ["(", 91], ["DTS", 92], [")", 95], ["and", 97], ["the", 101], ["four", 105], ["-", 109], ["item", 110], ["SPAN", 115], ["(", 120], ["Startle", 121], [",", 128], ["Physiological", 130], ["Arousal", 144], [",", 151], ["Anger", 153], ["and", 159], ["Numbness", 163], [")", 171], ["to", 173], ["detect", 176], ["survivors", 183], ["at", 193], ["risk", 196], ["for", 201], ["posttraumatic", 205], ["stress", 219], ["disorder", 226], ["(", 235], ["PTSD", 236], [")", 240], ["within", 242], ["the", 249], ["first", 253], ["2", 259], ["weeks", 261], ["after", 267], ["the", 273], ["trauma", 277], [".", 283], ["203", 285], ["civilian", 289], ["survivors", 298], ["of", 308], ["recent", 311], ["trauma", 318], ["with", 325], ["relatively", 330], ["mild", 341], ["symptoms", 346], ["completed", 355], ["the", 365], ["DTS", 369], ["a", 373], ["mean", 375], ["of", 380], ["8.7", 383], ["days", 387], ["after", 392], ["experiencing", 398], ["trauma", 411], [".", 417], ["SPAN", 419], ["scores", 424], ["were", 431], ["computed", 436], ["from", 445], ["the", 450], ["DTS", 454], [".", 457], ["At", 459], ["a", 462], ["mean", 464], ["of", 469], ["64.6", 472], ["days", 477], ["posttrauma", 482], [",", 492], ["160", 494], ["respondents", 498], ["were", 510], ["assessed", 515], ["for", 524], ["diagnosis", 528], ["of", 538], ["PTSD", 541], ["with", 546], ["the", 551], ["Structured", 555], ["Interview", 566], ["for", 576], ["PTSD", 580], [".", 584], ["Receiver", 586], ["operating", 595], ["characteristic", 605], ["curves", 620], ["showed", 627], ["that", 634], ["the", 639], ["DTS", 643], ["showed", 647], ["good", 654], ["overall", 659], ["screening", 667], ["accuracy", 677], ["(", 686], ["84", 687], ["%", 689], [")", 690], [".", 691], ["At", 693], ["a", 696], ["cut", 698], ["-", 701], ["off", 702], ["value", 706], ["of", 712], ["64", 715], [",", 717], ["the", 719], ["DTS", 723], ["demonstrated", 727], ["a", 740], ["sensitivity", 742], ["of", 754], ["0.86", 757], [",", 761], ["a", 763], ["specificity", 765], ["of", 777], ["0.70", 780], [",", 784], ["a", 786], ["positive", 788], ["predictive", 797], ["value", 808], ["(", 814], ["PPV", 815], [")", 818], ["of", 820], ["0.12", 823], [",", 827], ["and", 829], ["a", 833], ["negative", 835], ["predictive", 844], ["value", 855], ["(", 861], ["NPV", 862], [")", 865], ["of", 867], ["0.98", 870], [".", 874], ["Overall", 876], ["accuracy", 884], ["of", 893], ["the", 896], ["SPAN", 900], ["was", 905], ["good", 909], ["(", 914], ["89", 915], ["%", 917], [")", 918], [".", 919], ["At", 921], ["a", 924], ["cut", 926], ["-", 929], ["off", 930], ["of", 934], ["10", 937], ["the", 940], ["SPAN", 944], ["showed", 949], ["a", 956], ["sensitivity", 958], ["of", 970], ["0.86", 973], [",", 977], ["a", 979], ["specificity", 981], ["of", 993], ["0.86", 996], [",", 1000], ["a", 1002], ["PPV", 1004], ["of", 1008], ["0.22", 1011], [",", 1015], ["and", 1017], ["a", 1021], ["NPV", 1023], ["of", 1027], ["0.98", 1030], [".", 1034], ["The", 1036], ["low", 1040], ["PPVs", 1044], ["were", 1049], ["possibly", 1054], ["due", 1063], ["to", 1067], ["the", 1070], ["low", 1074], ["of", 1078], ["prevalence", 1081], ["of", 1092], ["PTSD", 1095], ["in", 1100], ["our", 1103], ["sample", 1107], ["(", 1114], ["4.4", 1115], ["%", 1118], [")", 1119], [".", 1120], ["This", 1122], ["study", 1127], ["shows", 1133], ["that", 1139], ["both", 1144], ["the", 1149], ["DTS", 1153], ["and", 1157], ["the", 1161], ["SPAN", 1165], ["are", 1170], ["comparably", 1174], ["accurate", 1185], ["in", 1194], ["screening", 1197], ["early", 1207], ["trauma", 1213], ["survivors", 1220], ["at", 1230], ["risk", 1233], ["for", 1238], ["developing", 1242], ["PTSD", 1253], [".", 1257], ["The", 1259], ["very", 1263], ["brief", 1268], ["four", 1274], ["-", 1278], ["item", 1279], ["SPAN", 1284], ["may", 1289], ["be", 1293], ["preferred", 1296], ["over", 1306], ["the", 1311], ["longer", 1315], ["17-item", 1322], ["DTS", 1330], ["especially", 1334], ["in", 1345], ["settings", 1348], ["in", 1357], ["which", 1360], ["time", 1366], ["and", 1371], ["resources", 1375], ["are", 1385], ["limited", 1389], [".", 1396], ["Future", 1398], ["studies", 1405], ["should", 1413], ["aim", 1420], ["to", 1424], ["cross", 1427], ["-", 1432], ["validate", 1433], ["these", 1442], ["results", 1448], ["in", 1456], ["random", 1459], ["samples", 1466], [".", 1473]]}
{"context": "Ehlers-Danlos syndrome (EDS), a heterogeneous group of inheritable connective tissue disorders, is attributed to mutations in connective tissue genes. These mutations cause defects in collagen. Collagen, a connective tissue protein that acts like glue, gives strength to the body and provides support and elasticity for movement. Thus, the altered gene affects the mechanical properties of skin, joints, ligaments, and blood vessels. Ehlers-Danlos syndrome is transmitted through autosomal dominant, autosomal recessive, or x-linked patterns of inheritance. The life expectancy of an affected infant varies with the type of EDS. This article provides an overview of the 6 major classifications of EDS, their unique clinical presentations, a focused physical assessment guide, considerations for nursing care, and resources for parents. Ehlers-Danlos syndrome can be a potentially debilitating syndrome. It requires preventative and protective measures starting at birth to preserve joint function to improve infant outcomes. Caring for patients with EDS requires an understanding of the potential associated complications to help minimize the physical and emotional impact of the syndrome and improve the quality of life for affected individuals.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "10f8119b74f94e56b81c9c59ad105093", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[13, 14], [36, 37], [22, 23]], "char_spans": [[67, 83], [206, 222], [126, 142]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndrome", 14], ["(", 23], ["EDS", 24], [")", 27], [",", 28], ["a", 30], ["heterogeneous", 32], ["group", 46], ["of", 52], ["inheritable", 55], ["connective", 67], ["tissue", 78], ["disorders", 85], [",", 94], ["is", 96], ["attributed", 99], ["to", 110], ["mutations", 113], ["in", 123], ["connective", 126], ["tissue", 137], ["genes", 144], [".", 149], ["These", 151], ["mutations", 157], ["cause", 167], ["defects", 173], ["in", 181], ["collagen", 184], [".", 192], ["Collagen", 194], [",", 202], ["a", 204], ["connective", 206], ["tissue", 217], ["protein", 224], ["that", 232], ["acts", 237], ["like", 242], ["glue", 247], [",", 251], ["gives", 253], ["strength", 259], ["to", 268], ["the", 271], ["body", 275], ["and", 280], ["provides", 284], ["support", 293], ["and", 301], ["elasticity", 305], ["for", 316], ["movement", 320], [".", 328], ["Thus", 330], [",", 334], ["the", 336], ["altered", 340], ["gene", 348], ["affects", 353], ["the", 361], ["mechanical", 365], ["properties", 376], ["of", 387], ["skin", 390], [",", 394], ["joints", 396], [",", 402], ["ligaments", 404], [",", 413], ["and", 415], ["blood", 419], ["vessels", 425], [".", 432], ["Ehlers", 434], ["-", 440], ["Danlos", 441], ["syndrome", 448], ["is", 457], ["transmitted", 460], ["through", 472], ["autosomal", 480], ["dominant", 490], [",", 498], ["autosomal", 500], ["recessive", 510], [",", 519], ["or", 521], ["x", 524], ["-", 525], ["linked", 526], ["patterns", 533], ["of", 542], ["inheritance", 545], [".", 556], ["The", 558], ["life", 562], ["expectancy", 567], ["of", 578], ["an", 581], ["affected", 584], ["infant", 593], ["varies", 600], ["with", 607], ["the", 612], ["type", 616], ["of", 621], ["EDS", 624], [".", 627], ["This", 629], ["article", 634], ["provides", 642], ["an", 651], ["overview", 654], ["of", 663], ["the", 666], ["6", 670], ["major", 672], ["classifications", 678], ["of", 694], ["EDS", 697], [",", 700], ["their", 702], ["unique", 708], ["clinical", 715], ["presentations", 724], [",", 737], ["a", 739], ["focused", 741], ["physical", 749], ["assessment", 758], ["guide", 769], [",", 774], ["considerations", 776], ["for", 791], ["nursing", 795], ["care", 803], [",", 807], ["and", 809], ["resources", 813], ["for", 823], ["parents", 827], [".", 834], ["Ehlers", 836], ["-", 842], ["Danlos", 843], ["syndrome", 850], ["can", 859], ["be", 863], ["a", 866], ["potentially", 868], ["debilitating", 880], ["syndrome", 893], [".", 901], ["It", 903], ["requires", 906], ["preventative", 915], ["and", 928], ["protective", 932], ["measures", 943], ["starting", 952], ["at", 961], ["birth", 964], ["to", 970], ["preserve", 973], ["joint", 982], ["function", 988], ["to", 997], ["improve", 1000], ["infant", 1008], ["outcomes", 1015], [".", 1023], ["Caring", 1025], ["for", 1032], ["patients", 1036], ["with", 1045], ["EDS", 1050], ["requires", 1054], ["an", 1063], ["understanding", 1066], ["of", 1080], ["the", 1083], ["potential", 1087], ["associated", 1097], ["complications", 1108], ["to", 1122], ["help", 1125], ["minimize", 1130], ["the", 1139], ["physical", 1143], ["and", 1152], ["emotional", 1156], ["impact", 1166], ["of", 1173], ["the", 1176], ["syndrome", 1180], ["and", 1189], ["improve", 1193], ["the", 1201], ["quality", 1205], ["of", 1213], ["life", 1216], ["for", 1221], ["affected", 1225], ["individuals", 1234], [".", 1245]]}
{"context": "The organic cation transporter 3 (OCT3) is a widely expressed transporter for endogenous and exogenous organic cations. Of particular interest is OCT3 expression and function in the brain, where it plays a role in serotonin clearance and influences mood and behavior. Protein kinase signaling mediates rapid modulation of cerebral processes, but little is known about acute regulation of OCT3 by protein kinases. Therefore, we cloned mouse OCT3 (mOCT3) and generated a human embryonic kidney cell line stably expressing the transporter to study transport characteristics, acute regulation by protein kinases, and interaction with psychotropic drugs. Uptake measurement was performed using the fluorescent cation 4-(4-(dimethylamino)styryl)-N-methylpyridinium iodide (ASP(+), 1\u00a0\u03bcM) as a substrate. The translational value of these findings was determined by comparing results obtained with cloned mouse and human OCT3. mOCT3-mediated transport is membrane potential dependent and pH independent. ASP(+) uptake by mOCT3 and human OCT3 (hOCT3) was efficiently inhibited by 1-methyl-4-phenylpyridinium, tetrapentylammonium (TPA(+)), corticosterone, serotonin, and histamine and by the drugs ketamine, fluoxetine, and diazepam. The half maximal inhibitory concentrations of mOCT3 and hOCT3 for TPA(+), serotonin, diazepam, and ketamine are significantly different. Diazepam is a non-transported inhibitor. Furthermore, the activities of mOCT3 and hOCT3 are acutely regulated by the p56 (lck) tyrosine kinase by decreasing their V max. Studies with freshly isolated renal proximal tubules from mOCT1/2(-/-) mice, in which mOCT3 is the only OCT present, confirmed this regulation pathway. Only the activity of hOCT3 is regulated by calmodulin. These findings suggest that even though many transport properties of mOCT3 and hOCT3 are similar, there are also species-specific aspects of OCT3 function.", "qas": [{"question": "How is OCT3 associated with serotonin?", "answers": ["serotonin clearance"], "qid": "bf90e54a60234266b05dd70fed882e86", "question_tokens": [["How", 0], ["is", 4], ["OCT3", 7], ["associated", 12], ["with", 23], ["serotonin", 28], ["?", 37]], "detected_answers": [{"text": "serotonin clearance", "token_spans": [[38, 39]], "char_spans": [[214, 232]]}]}], "context_tokens": [["The", 0], ["organic", 4], ["cation", 12], ["transporter", 19], ["3", 31], ["(", 33], ["OCT3", 34], [")", 38], ["is", 40], ["a", 43], ["widely", 45], ["expressed", 52], ["transporter", 62], ["for", 74], ["endogenous", 78], ["and", 89], ["exogenous", 93], ["organic", 103], ["cations", 111], [".", 118], ["Of", 120], ["particular", 123], ["interest", 134], ["is", 143], ["OCT3", 146], ["expression", 151], ["and", 162], ["function", 166], ["in", 175], ["the", 178], ["brain", 182], [",", 187], ["where", 189], ["it", 195], ["plays", 198], ["a", 204], ["role", 206], ["in", 211], ["serotonin", 214], ["clearance", 224], ["and", 234], ["influences", 238], ["mood", 249], ["and", 254], ["behavior", 258], [".", 266], ["Protein", 268], ["kinase", 276], ["signaling", 283], ["mediates", 293], ["rapid", 302], ["modulation", 308], ["of", 319], ["cerebral", 322], ["processes", 331], [",", 340], ["but", 342], ["little", 346], ["is", 353], ["known", 356], ["about", 362], ["acute", 368], ["regulation", 374], ["of", 385], ["OCT3", 388], ["by", 393], ["protein", 396], ["kinases", 404], [".", 411], ["Therefore", 413], [",", 422], ["we", 424], ["cloned", 427], ["mouse", 434], ["OCT3", 440], ["(", 445], ["mOCT3", 446], [")", 451], ["and", 453], ["generated", 457], ["a", 467], ["human", 469], ["embryonic", 475], ["kidney", 485], ["cell", 492], ["line", 497], ["stably", 502], ["expressing", 509], ["the", 520], ["transporter", 524], ["to", 536], ["study", 539], ["transport", 545], ["characteristics", 555], [",", 570], ["acute", 572], ["regulation", 578], ["by", 589], ["protein", 592], ["kinases", 600], [",", 607], ["and", 609], ["interaction", 613], ["with", 625], ["psychotropic", 630], ["drugs", 643], [".", 648], ["Uptake", 650], ["measurement", 657], ["was", 669], ["performed", 673], ["using", 683], ["the", 689], ["fluorescent", 693], ["cation", 705], ["4-(4-(dimethylamino)styryl)-N", 712], ["-", 741], ["methylpyridinium", 742], ["iodide", 759], ["(", 766], ["ASP(+", 767], [")", 772], [",", 773], ["1", 775], ["\u03bcM", 777], [")", 779], ["as", 781], ["a", 784], ["substrate", 786], [".", 795], ["The", 797], ["translational", 801], ["value", 815], ["of", 821], ["these", 824], ["findings", 830], ["was", 839], ["determined", 843], ["by", 854], ["comparing", 857], ["results", 867], ["obtained", 875], ["with", 884], ["cloned", 889], ["mouse", 896], ["and", 902], ["human", 906], ["OCT3", 912], [".", 916], ["mOCT3-mediated", 918], ["transport", 933], ["is", 943], ["membrane", 946], ["potential", 955], ["dependent", 965], ["and", 975], ["pH", 979], ["independent", 982], [".", 993], ["ASP(+", 995], [")", 1000], ["uptake", 1002], ["by", 1009], ["mOCT3", 1012], ["and", 1018], ["human", 1022], ["OCT3", 1028], ["(", 1033], ["hOCT3", 1034], [")", 1039], ["was", 1041], ["efficiently", 1045], ["inhibited", 1057], ["by", 1067], ["1-methyl-4-phenylpyridinium", 1070], [",", 1097], ["tetrapentylammonium", 1099], ["(", 1119], ["TPA(+", 1120], [")", 1125], [")", 1126], [",", 1127], ["corticosterone", 1129], [",", 1143], ["serotonin", 1145], [",", 1154], ["and", 1156], ["histamine", 1160], ["and", 1170], ["by", 1174], ["the", 1177], ["drugs", 1181], ["ketamine", 1187], [",", 1195], ["fluoxetine", 1197], [",", 1207], ["and", 1209], ["diazepam", 1213], [".", 1221], ["The", 1223], ["half", 1227], ["maximal", 1232], ["inhibitory", 1240], ["concentrations", 1251], ["of", 1266], ["mOCT3", 1269], ["and", 1275], ["hOCT3", 1279], ["for", 1285], ["TPA(+", 1289], [")", 1294], [",", 1295], ["serotonin", 1297], [",", 1306], ["diazepam", 1308], [",", 1316], ["and", 1318], ["ketamine", 1322], ["are", 1331], ["significantly", 1335], ["different", 1349], [".", 1358], ["Diazepam", 1360], ["is", 1369], ["a", 1372], ["non", 1374], ["-", 1377], ["transported", 1378], ["inhibitor", 1390], [".", 1399], ["Furthermore", 1401], [",", 1412], ["the", 1414], ["activities", 1418], ["of", 1429], ["mOCT3", 1432], ["and", 1438], ["hOCT3", 1442], ["are", 1448], ["acutely", 1452], ["regulated", 1460], ["by", 1470], ["the", 1473], ["p56", 1477], ["(", 1481], ["lck", 1482], [")", 1485], ["tyrosine", 1487], ["kinase", 1496], ["by", 1503], ["decreasing", 1506], ["their", 1517], ["V", 1523], ["max", 1525], [".", 1528], ["Studies", 1530], ["with", 1538], ["freshly", 1543], ["isolated", 1551], ["renal", 1560], ["proximal", 1566], ["tubules", 1575], ["from", 1583], ["mOCT1/2(-/-", 1588], [")", 1599], ["mice", 1601], [",", 1605], ["in", 1607], ["which", 1610], ["mOCT3", 1616], ["is", 1622], ["the", 1625], ["only", 1629], ["OCT", 1634], ["present", 1638], [",", 1645], ["confirmed", 1647], ["this", 1657], ["regulation", 1662], ["pathway", 1673], [".", 1680], ["Only", 1682], ["the", 1687], ["activity", 1691], ["of", 1700], ["hOCT3", 1703], ["is", 1709], ["regulated", 1712], ["by", 1722], ["calmodulin", 1725], [".", 1735], ["These", 1737], ["findings", 1743], ["suggest", 1752], ["that", 1760], ["even", 1765], ["though", 1770], ["many", 1777], ["transport", 1782], ["properties", 1792], ["of", 1803], ["mOCT3", 1806], ["and", 1812], ["hOCT3", 1816], ["are", 1822], ["similar", 1826], [",", 1833], ["there", 1835], ["are", 1841], ["also", 1845], ["species", 1850], ["-", 1857], ["specific", 1858], ["aspects", 1867], ["of", 1875], ["OCT3", 1878], ["function", 1883], [".", 1891]]}
{"context": "Mutations in the CLN3 gene, which encodes a lysosomal membrane protein, are responsible for the neurodegenerative disorder juvenile Batten disease. A previous study on the yeast homolog to CLN3, designated Btn1p, revealed a potential role for CLN3 in the transport of arginine into the yeast vacuole, the equivalent organelle to the mammalian lysosome. Lysosomes isolated from lymphoblast cell lines, established from individuals with juvenile Batten disease-bearing mutations in CLN3, but not age-matched controls, demonstrate defective transport of arginine. Furthermore, we show that there is a depletion of arginine in cells derived from individuals with juvenile Batten disease. We have, therefore, characterized lysosomal arginine transport in normal lysosomes and show that it is ATP-, v-ATPase- and cationic-dependent. This and previous studies have shown that both arginine and lysine are transported by the same transport system, designated system c. However, we report that lysosomes isolated from juvenile Batten disease lymphoblasts are only defective for arginine transport. These results suggest that the CLN3 defect in juvenile Batten disease may affect how intracellular levels of arginine are regulated or distributed throughout the cell. This assertion is supported by two other experimental approaches. First, an antibody to CLN3 can block lysosomal arginine transport and second, expression of CLN3 in JNCL cells using a lentiviral vector can restore lysosomal arginine transport. CLN3 may have a role in regulating intracellular levels of arginine possibly through control of the transport of this amino acid into lysosomes.", "qas": [{"question": "What is the effect of a defective CLN3 gene?", "answers": ["Batten disease", "juvenile-onset neuronal ceroid lipofuscinosis", "JNCL"], "qid": "3dc4e3f9a1154fac800afd66066ee701", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["effect", 12], ["of", 19], ["a", 22], ["defective", 24], ["CLN3", 34], ["gene", 39], ["?", 43]], "detected_answers": [{"text": "Batten disease", "token_spans": [[20, 21], [172, 173], [191, 192], [72, 73], [111, 112]], "char_spans": [[132, 145], [1018, 1031], [1144, 1157], [444, 457], [668, 681]]}, {"text": "JNCL", "token_spans": [[236, 236]], "char_spans": [[1423, 1426]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["the", 13], ["CLN3", 17], ["gene", 22], [",", 26], ["which", 28], ["encodes", 34], ["a", 42], ["lysosomal", 44], ["membrane", 54], ["protein", 63], [",", 70], ["are", 72], ["responsible", 76], ["for", 88], ["the", 92], ["neurodegenerative", 96], ["disorder", 114], ["juvenile", 123], ["Batten", 132], ["disease", 139], [".", 146], ["A", 148], ["previous", 150], ["study", 159], ["on", 165], ["the", 168], ["yeast", 172], ["homolog", 178], ["to", 186], ["CLN3", 189], [",", 193], ["designated", 195], ["Btn1p", 206], [",", 211], ["revealed", 213], ["a", 222], ["potential", 224], ["role", 234], ["for", 239], ["CLN3", 243], ["in", 248], ["the", 251], ["transport", 255], ["of", 265], ["arginine", 268], ["into", 277], ["the", 282], ["yeast", 286], ["vacuole", 292], [",", 299], ["the", 301], ["equivalent", 305], ["organelle", 316], ["to", 326], ["the", 329], ["mammalian", 333], ["lysosome", 343], [".", 351], ["Lysosomes", 353], ["isolated", 363], ["from", 372], ["lymphoblast", 377], ["cell", 389], ["lines", 394], [",", 399], ["established", 401], ["from", 413], ["individuals", 418], ["with", 430], ["juvenile", 435], ["Batten", 444], ["disease", 451], ["-", 458], ["bearing", 459], ["mutations", 467], ["in", 477], ["CLN3", 480], [",", 484], ["but", 486], ["not", 490], ["age", 494], ["-", 497], ["matched", 498], ["controls", 506], [",", 514], ["demonstrate", 516], ["defective", 528], ["transport", 538], ["of", 548], ["arginine", 551], [".", 559], ["Furthermore", 561], [",", 572], ["we", 574], ["show", 577], ["that", 582], ["there", 587], ["is", 593], ["a", 596], ["depletion", 598], ["of", 608], ["arginine", 611], ["in", 620], ["cells", 623], ["derived", 629], ["from", 637], ["individuals", 642], ["with", 654], ["juvenile", 659], ["Batten", 668], ["disease", 675], [".", 682], ["We", 684], ["have", 687], [",", 691], ["therefore", 693], [",", 702], ["characterized", 704], ["lysosomal", 718], ["arginine", 728], ["transport", 737], ["in", 747], ["normal", 750], ["lysosomes", 757], ["and", 767], ["show", 771], ["that", 776], ["it", 781], ["is", 784], ["ATP-", 787], [",", 791], ["v", 793], ["-", 794], ["ATPase-", 795], ["and", 803], ["cationic", 807], ["-", 815], ["dependent", 816], [".", 825], ["This", 827], ["and", 832], ["previous", 836], ["studies", 845], ["have", 853], ["shown", 858], ["that", 864], ["both", 869], ["arginine", 874], ["and", 883], ["lysine", 887], ["are", 894], ["transported", 898], ["by", 910], ["the", 913], ["same", 917], ["transport", 922], ["system", 932], [",", 938], ["designated", 940], ["system", 951], ["c.", 958], ["However", 961], [",", 968], ["we", 970], ["report", 973], ["that", 980], ["lysosomes", 985], ["isolated", 995], ["from", 1004], ["juvenile", 1009], ["Batten", 1018], ["disease", 1025], ["lymphoblasts", 1033], ["are", 1046], ["only", 1050], ["defective", 1055], ["for", 1065], ["arginine", 1069], ["transport", 1078], [".", 1087], ["These", 1089], ["results", 1095], ["suggest", 1103], ["that", 1111], ["the", 1116], ["CLN3", 1120], ["defect", 1125], ["in", 1132], ["juvenile", 1135], ["Batten", 1144], ["disease", 1151], ["may", 1159], ["affect", 1163], ["how", 1170], ["intracellular", 1174], ["levels", 1188], ["of", 1195], ["arginine", 1198], ["are", 1207], ["regulated", 1211], ["or", 1221], ["distributed", 1224], ["throughout", 1236], ["the", 1247], ["cell", 1251], [".", 1255], ["This", 1257], ["assertion", 1262], ["is", 1272], ["supported", 1275], ["by", 1285], ["two", 1288], ["other", 1292], ["experimental", 1298], ["approaches", 1311], [".", 1321], ["First", 1323], [",", 1328], ["an", 1330], ["antibody", 1333], ["to", 1342], ["CLN3", 1345], ["can", 1350], ["block", 1354], ["lysosomal", 1360], ["arginine", 1370], ["transport", 1379], ["and", 1389], ["second", 1393], [",", 1399], ["expression", 1401], ["of", 1412], ["CLN3", 1415], ["in", 1420], ["JNCL", 1423], ["cells", 1428], ["using", 1434], ["a", 1440], ["lentiviral", 1442], ["vector", 1453], ["can", 1460], ["restore", 1464], ["lysosomal", 1472], ["arginine", 1482], ["transport", 1491], [".", 1500], ["CLN3", 1502], ["may", 1507], ["have", 1511], ["a", 1516], ["role", 1518], ["in", 1523], ["regulating", 1526], ["intracellular", 1537], ["levels", 1551], ["of", 1558], ["arginine", 1561], ["possibly", 1570], ["through", 1579], ["control", 1587], ["of", 1595], ["the", 1598], ["transport", 1602], ["of", 1612], ["this", 1615], ["amino", 1620], ["acid", 1626], ["into", 1631], ["lysosomes", 1636], [".", 1645]]}
{"context": "The objective was to determine the composition of the Cystic Fibrosis (CF) Population attending specialist UK CF centres in terms of age, gender, age at diagnosis, genotype and ethnicity. With the planned introduction of the national CF screening programme in the UK, cystic fibrosis transmembrane regulator (CFTR) mutations were compared between different ethnic groups enabling a UK-specific frequency of mutations to be defined. Data were analysed from the patient biographies held in the UK CF Database (see www.cystic-fibrosis.org.uk). The currently registered population of 5,274 CF patients is 96.3% Caucasian with a male preponderance that significantly increases with age. The majority of the 196 non-Caucasian CF patients are from the Indian Subcontinent (ISC), of which one in 84 UK CF patients are of Pakistani origin. The commonest CFTR mutation, deltaF508, is found in 74.1% of all CF chromosomes. In the Caucasian CF population, 57.5% are deltaF508 homozygotes but the UK ISC CF population with only 24.7%, has significantly fewer deltaF508 homozygotes patients (95% confidence interval (CI) 0.2-0.4). The distribution of Caucasian patients with deltaF508/deltaF508, deltaF508/Other and Other/Other does not fit the expected distribution with a Hardy-Weinberg model unless those patients without a detected mutation are excluded (P<0.001). The UK CF Database has shown the UK CF population to have distinct characteristics separate from the North American and European CF Registries. The ISC group contains many mutations not recognised by current genetic analysis, and one in four ISC patients have no CFTR mutations identified. The CFTR analysis proposed for the screening programme would detect 96% of patients registered in the database, but is unlikely to achieve the desired >80% detection rates in the ethnic minority groups. Screen-positive, non-Caucasian infants without an identifiable CFTR mutation should be referred for a sweat test and genetic counselling when serum trypsinogen concentrations remain elevated after birth.", "qas": [{"question": "Which is the most common CFTR mutation in Caucasians?", "answers": ["deltaF508"], "qid": "7d3f2b1fca4442a8ae60dafaeaa4cb04", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["common", 18], ["CFTR", 25], ["mutation", 30], ["in", 39], ["Caucasians", 42], ["?", 52]], "detected_answers": [{"text": "deltaF508", "token_spans": [[152, 152], [173, 173], [189, 189]], "char_spans": [[860, 868], [954, 962], [1046, 1054]]}]}], "context_tokens": [["The", 0], ["objective", 4], ["was", 14], ["to", 18], ["determine", 21], ["the", 31], ["composition", 35], ["of", 47], ["the", 50], ["Cystic", 54], ["Fibrosis", 61], ["(", 70], ["CF", 71], [")", 73], ["Population", 75], ["attending", 86], ["specialist", 96], ["UK", 107], ["CF", 110], ["centres", 113], ["in", 121], ["terms", 124], ["of", 130], ["age", 133], [",", 136], ["gender", 138], [",", 144], ["age", 146], ["at", 150], ["diagnosis", 153], [",", 162], ["genotype", 164], ["and", 173], ["ethnicity", 177], [".", 186], ["With", 188], ["the", 193], ["planned", 197], ["introduction", 205], ["of", 218], ["the", 221], ["national", 225], ["CF", 234], ["screening", 237], ["programme", 247], ["in", 257], ["the", 260], ["UK", 264], [",", 266], ["cystic", 268], ["fibrosis", 275], ["transmembrane", 284], ["regulator", 298], ["(", 308], ["CFTR", 309], [")", 313], ["mutations", 315], ["were", 325], ["compared", 330], ["between", 339], ["different", 347], ["ethnic", 357], ["groups", 364], ["enabling", 371], ["a", 380], ["UK", 382], ["-", 384], ["specific", 385], ["frequency", 394], ["of", 404], ["mutations", 407], ["to", 417], ["be", 420], ["defined", 423], [".", 430], ["Data", 432], ["were", 437], ["analysed", 442], ["from", 451], ["the", 456], ["patient", 460], ["biographies", 468], ["held", 480], ["in", 485], ["the", 488], ["UK", 492], ["CF", 495], ["Database", 498], ["(", 507], ["see", 508], ["www.cystic-fibrosis.org.uk", 512], [")", 538], [".", 539], ["The", 541], ["currently", 545], ["registered", 555], ["population", 566], ["of", 577], ["5,274", 580], ["CF", 586], ["patients", 589], ["is", 598], ["96.3", 601], ["%", 605], ["Caucasian", 607], ["with", 617], ["a", 622], ["male", 624], ["preponderance", 629], ["that", 643], ["significantly", 648], ["increases", 662], ["with", 672], ["age", 677], [".", 680], ["The", 682], ["majority", 686], ["of", 695], ["the", 698], ["196", 702], ["non", 706], ["-", 709], ["Caucasian", 710], ["CF", 720], ["patients", 723], ["are", 732], ["from", 736], ["the", 741], ["Indian", 745], ["Subcontinent", 752], ["(", 765], ["ISC", 766], [")", 769], [",", 770], ["of", 772], ["which", 775], ["one", 781], ["in", 785], ["84", 788], ["UK", 791], ["CF", 794], ["patients", 797], ["are", 806], ["of", 810], ["Pakistani", 813], ["origin", 823], [".", 829], ["The", 831], ["commonest", 835], ["CFTR", 845], ["mutation", 850], [",", 858], ["deltaF508", 860], [",", 869], ["is", 871], ["found", 874], ["in", 880], ["74.1", 883], ["%", 887], ["of", 889], ["all", 892], ["CF", 896], ["chromosomes", 899], [".", 910], ["In", 912], ["the", 915], ["Caucasian", 919], ["CF", 929], ["population", 932], [",", 942], ["57.5", 944], ["%", 948], ["are", 950], ["deltaF508", 954], ["homozygotes", 964], ["but", 976], ["the", 980], ["UK", 984], ["ISC", 987], ["CF", 991], ["population", 994], ["with", 1005], ["only", 1010], ["24.7", 1015], ["%", 1019], [",", 1020], ["has", 1022], ["significantly", 1026], ["fewer", 1040], ["deltaF508", 1046], ["homozygotes", 1056], ["patients", 1068], ["(", 1077], ["95", 1078], ["%", 1080], ["confidence", 1082], ["interval", 1093], ["(", 1102], ["CI", 1103], [")", 1105], ["0.2", 1107], ["-", 1110], ["0.4", 1111], [")", 1114], [".", 1115], ["The", 1117], ["distribution", 1121], ["of", 1134], ["Caucasian", 1137], ["patients", 1147], ["with", 1156], ["deltaF508/deltaF508", 1161], [",", 1180], ["deltaF508/Other", 1182], ["and", 1198], ["Other", 1202], ["/", 1207], ["Other", 1208], ["does", 1214], ["not", 1219], ["fit", 1223], ["the", 1227], ["expected", 1231], ["distribution", 1240], ["with", 1253], ["a", 1258], ["Hardy", 1260], ["-", 1265], ["Weinberg", 1266], ["model", 1275], ["unless", 1281], ["those", 1288], ["patients", 1294], ["without", 1303], ["a", 1311], ["detected", 1313], ["mutation", 1322], ["are", 1331], ["excluded", 1335], ["(", 1344], ["P<0.001", 1345], [")", 1352], [".", 1353], ["The", 1355], ["UK", 1359], ["CF", 1362], ["Database", 1365], ["has", 1374], ["shown", 1378], ["the", 1384], ["UK", 1388], ["CF", 1391], ["population", 1394], ["to", 1405], ["have", 1408], ["distinct", 1413], ["characteristics", 1422], ["separate", 1438], ["from", 1447], ["the", 1452], ["North", 1456], ["American", 1462], ["and", 1471], ["European", 1475], ["CF", 1484], ["Registries", 1487], [".", 1497], ["The", 1499], ["ISC", 1503], ["group", 1507], ["contains", 1513], ["many", 1522], ["mutations", 1527], ["not", 1537], ["recognised", 1541], ["by", 1552], ["current", 1555], ["genetic", 1563], ["analysis", 1571], [",", 1579], ["and", 1581], ["one", 1585], ["in", 1589], ["four", 1592], ["ISC", 1597], ["patients", 1601], ["have", 1610], ["no", 1615], ["CFTR", 1618], ["mutations", 1623], ["identified", 1633], [".", 1643], ["The", 1645], ["CFTR", 1649], ["analysis", 1654], ["proposed", 1663], ["for", 1672], ["the", 1676], ["screening", 1680], ["programme", 1690], ["would", 1700], ["detect", 1706], ["96", 1713], ["%", 1715], ["of", 1717], ["patients", 1720], ["registered", 1729], ["in", 1740], ["the", 1743], ["database", 1747], [",", 1755], ["but", 1757], ["is", 1761], ["unlikely", 1764], ["to", 1773], ["achieve", 1776], ["the", 1784], ["desired", 1788], [">", 1796], ["80", 1797], ["%", 1799], ["detection", 1801], ["rates", 1811], ["in", 1817], ["the", 1820], ["ethnic", 1824], ["minority", 1831], ["groups", 1840], [".", 1846], ["Screen", 1848], ["-", 1854], ["positive", 1855], [",", 1863], ["non", 1865], ["-", 1868], ["Caucasian", 1869], ["infants", 1879], ["without", 1887], ["an", 1895], ["identifiable", 1898], ["CFTR", 1911], ["mutation", 1916], ["should", 1925], ["be", 1932], ["referred", 1935], ["for", 1944], ["a", 1948], ["sweat", 1950], ["test", 1956], ["and", 1961], ["genetic", 1965], ["counselling", 1973], ["when", 1985], ["serum", 1990], ["trypsinogen", 1996], ["concentrations", 2008], ["remain", 2023], ["elevated", 2030], ["after", 2039], ["birth", 2045], [".", 2050]]}
{"context": "Many neurodegenerative diseases are associated with the aggregation of misfolded proteins into amyloid oligomers or fibrils that are deposited as pathological lesions within areas of the brain. An attractive therapeutic strategy for preventing or ameliorating amyloid formation is to identify agents that inhibit the onset or propagation of protein aggregation. Here we demonstrate how solid-state nuclear magnetic resonance (ssNMR) may be used to identify key residues within amyloidogenic protein sequences that may be targeted to inhibit the aggregation of the host protein. For alpha-synuclein, the major protein component of Lewy bodies associated with Parkinson's disease, we have used a combination of ssNMR and biochemical data to identify the key region for self-aggregation of the protein as residues 77-82 (VAQKTV). We used our new structural information to design a peptide derived from residues 77 to 82 of alpha-synuclein with an N-methyl group at the C-terminal residue, which was able to disrupt the aggregation of alpha-synuclein. Thus, we have shown how structural data obtained from ssNMR can guide the design of modified peptides for use as amyloid inhibitors, as a primary step toward developing therapeutic compounds for prevention and/or treatment of amyloid diseases.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "ec3fbfeea1b541fd86801d3f230fe7ac", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[179, 181], [90, 92], [155, 157]], "char_spans": [[1031, 1045], [582, 596], [920, 934]]}]}], "context_tokens": [["Many", 0], ["neurodegenerative", 5], ["diseases", 23], ["are", 32], ["associated", 36], ["with", 47], ["the", 52], ["aggregation", 56], ["of", 68], ["misfolded", 71], ["proteins", 81], ["into", 90], ["amyloid", 95], ["oligomers", 103], ["or", 113], ["fibrils", 116], ["that", 124], ["are", 129], ["deposited", 133], ["as", 143], ["pathological", 146], ["lesions", 159], ["within", 167], ["areas", 174], ["of", 180], ["the", 183], ["brain", 187], [".", 192], ["An", 194], ["attractive", 197], ["therapeutic", 208], ["strategy", 220], ["for", 229], ["preventing", 233], ["or", 244], ["ameliorating", 247], ["amyloid", 260], ["formation", 268], ["is", 278], ["to", 281], ["identify", 284], ["agents", 293], ["that", 300], ["inhibit", 305], ["the", 313], ["onset", 317], ["or", 323], ["propagation", 326], ["of", 338], ["protein", 341], ["aggregation", 349], [".", 360], ["Here", 362], ["we", 367], ["demonstrate", 370], ["how", 382], ["solid", 386], ["-", 391], ["state", 392], ["nuclear", 398], ["magnetic", 406], ["resonance", 415], ["(", 425], ["ssNMR", 426], [")", 431], ["may", 433], ["be", 437], ["used", 440], ["to", 445], ["identify", 448], ["key", 457], ["residues", 461], ["within", 470], ["amyloidogenic", 477], ["protein", 491], ["sequences", 499], ["that", 509], ["may", 514], ["be", 518], ["targeted", 521], ["to", 530], ["inhibit", 533], ["the", 541], ["aggregation", 545], ["of", 557], ["the", 560], ["host", 564], ["protein", 569], [".", 576], ["For", 578], ["alpha", 582], ["-", 587], ["synuclein", 588], [",", 597], ["the", 599], ["major", 603], ["protein", 609], ["component", 617], ["of", 627], ["Lewy", 630], ["bodies", 635], ["associated", 642], ["with", 653], ["Parkinson", 658], ["'s", 667], ["disease", 670], [",", 677], ["we", 679], ["have", 682], ["used", 687], ["a", 692], ["combination", 694], ["of", 706], ["ssNMR", 709], ["and", 715], ["biochemical", 719], ["data", 731], ["to", 736], ["identify", 739], ["the", 748], ["key", 752], ["region", 756], ["for", 763], ["self", 767], ["-", 771], ["aggregation", 772], ["of", 784], ["the", 787], ["protein", 791], ["as", 799], ["residues", 802], ["77", 811], ["-", 813], ["82", 814], ["(", 817], ["VAQKTV", 818], [")", 824], [".", 825], ["We", 827], ["used", 830], ["our", 835], ["new", 839], ["structural", 843], ["information", 854], ["to", 866], ["design", 869], ["a", 876], ["peptide", 878], ["derived", 886], ["from", 894], ["residues", 899], ["77", 908], ["to", 911], ["82", 914], ["of", 917], ["alpha", 920], ["-", 925], ["synuclein", 926], ["with", 936], ["an", 941], ["N", 944], ["-", 945], ["methyl", 946], ["group", 953], ["at", 959], ["the", 962], ["C", 966], ["-", 967], ["terminal", 968], ["residue", 977], [",", 984], ["which", 986], ["was", 992], ["able", 996], ["to", 1001], ["disrupt", 1004], ["the", 1012], ["aggregation", 1016], ["of", 1028], ["alpha", 1031], ["-", 1036], ["synuclein", 1037], [".", 1046], ["Thus", 1048], [",", 1052], ["we", 1054], ["have", 1057], ["shown", 1062], ["how", 1068], ["structural", 1072], ["data", 1083], ["obtained", 1088], ["from", 1097], ["ssNMR", 1102], ["can", 1108], ["guide", 1112], ["the", 1118], ["design", 1122], ["of", 1129], ["modified", 1132], ["peptides", 1141], ["for", 1150], ["use", 1154], ["as", 1158], ["amyloid", 1161], ["inhibitors", 1169], [",", 1179], ["as", 1181], ["a", 1184], ["primary", 1186], ["step", 1194], ["toward", 1199], ["developing", 1206], ["therapeutic", 1217], ["compounds", 1229], ["for", 1239], ["prevention", 1243], ["and/or", 1254], ["treatment", 1261], ["of", 1271], ["amyloid", 1274], ["diseases", 1282], [".", 1290]]}
{"context": "The McLeod syndrome is a rare X-linked recessive disorder characterized by blood group, neuromuscular and haematopoietic abnormalities. It is caused by XK gene defects and may include large deletions in the Xp21 region. Analysis of three unrelated McLeod patients for the presence of the XK, DMD, CYBB, ETX1, RPGR and OTC loci, as well as for the DXS709 marker, revealed deletions from the 39th exon of DMD to the ETX1 locus (patient Be), from the XK to RPGR loci (patient Bi) and from the XK to CYBB loci (patient Lh). All three patients normally expressed the Lutheran (Lu) red cell antigens, thus excluding the interval between the RPGR and DMD genes as site of the XS locus, previously mapped to the Xp21.2-Xq21.1 region and thought to regulate the expression of the LU blood group gene on chromosome 19.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "e6169de72a8e46a8bfd4b79a1daa5dc7", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[100, 100], [89, 89], [25, 25], [49, 49]], "char_spans": [[490, 491], [448, 449], [152, 153], [288, 289]]}]}], "context_tokens": [["The", 0], ["McLeod", 4], ["syndrome", 11], ["is", 20], ["a", 23], ["rare", 25], ["X", 30], ["-", 31], ["linked", 32], ["recessive", 39], ["disorder", 49], ["characterized", 58], ["by", 72], ["blood", 75], ["group", 81], [",", 86], ["neuromuscular", 88], ["and", 102], ["haematopoietic", 106], ["abnormalities", 121], [".", 134], ["It", 136], ["is", 139], ["caused", 142], ["by", 149], ["XK", 152], ["gene", 155], ["defects", 160], ["and", 168], ["may", 172], ["include", 176], ["large", 184], ["deletions", 190], ["in", 200], ["the", 203], ["Xp21", 207], ["region", 212], [".", 218], ["Analysis", 220], ["of", 229], ["three", 232], ["unrelated", 238], ["McLeod", 248], ["patients", 255], ["for", 264], ["the", 268], ["presence", 272], ["of", 281], ["the", 284], ["XK", 288], [",", 290], ["DMD", 292], [",", 295], ["CYBB", 297], [",", 301], ["ETX1", 303], [",", 307], ["RPGR", 309], ["and", 314], ["OTC", 318], ["loci", 322], [",", 326], ["as", 328], ["well", 331], ["as", 336], ["for", 339], ["the", 343], ["DXS709", 347], ["marker", 354], [",", 360], ["revealed", 362], ["deletions", 371], ["from", 381], ["the", 386], ["39th", 390], ["exon", 395], ["of", 400], ["DMD", 403], ["to", 407], ["the", 410], ["ETX1", 414], ["locus", 419], ["(", 425], ["patient", 426], ["Be", 434], [")", 436], [",", 437], ["from", 439], ["the", 444], ["XK", 448], ["to", 451], ["RPGR", 454], ["loci", 459], ["(", 464], ["patient", 465], ["Bi", 473], [")", 475], ["and", 477], ["from", 481], ["the", 486], ["XK", 490], ["to", 493], ["CYBB", 496], ["loci", 501], ["(", 506], ["patient", 507], ["Lh", 515], [")", 517], [".", 518], ["All", 520], ["three", 524], ["patients", 530], ["normally", 539], ["expressed", 548], ["the", 558], ["Lutheran", 562], ["(", 571], ["Lu", 572], [")", 574], ["red", 576], ["cell", 580], ["antigens", 585], [",", 593], ["thus", 595], ["excluding", 600], ["the", 610], ["interval", 614], ["between", 623], ["the", 631], ["RPGR", 635], ["and", 640], ["DMD", 644], ["genes", 648], ["as", 654], ["site", 657], ["of", 662], ["the", 665], ["XS", 669], ["locus", 672], [",", 677], ["previously", 679], ["mapped", 690], ["to", 697], ["the", 700], ["Xp21.2-Xq21.1", 704], ["region", 718], ["and", 725], ["thought", 729], ["to", 737], ["regulate", 740], ["the", 749], ["expression", 753], ["of", 764], ["the", 767], ["LU", 771], ["blood", 774], ["group", 780], ["gene", 786], ["on", 791], ["chromosome", 794], ["19", 805], [".", 807]]}
{"context": "The CRISPR-Cas (clustered regularly interspaced short palindromic repeats, CRISPR-associated genes) is an adaptive immunity system in bacteria and archaea that functions via a distinct self-non-self recognition mechanism that is partially analogous to the mechanism of eukaryotic RNA interference (RNAi). The CRISPR-Cas system incorporates fragments of virus or plasmid DNA into the CRISPR repeat cassettes and employs the processed transcripts of these spacers as guide RNAs to cleave the cognate foreign DNA or RNA. The Cas proteins, however, are not homologous to the proteins involved in RNAi and comprise numerous, highly diverged families. The majority of the Cas proteins contain diverse variants of the RNA recognition motif (RRM), a widespread RNA-binding domain. Despite the fast evolution that is typical of the cas genes, the presence of diverse versions of the RRM in most Cas proteins provides for a simple scenario for the evolution of the three distinct types of CRISPR-cas systems. In addition to several proteins that are directly implicated in the immune response, the cas genes encode a variety of proteins that are homologous to prokaryotic toxins that typically possess nuclease activity. The predicted toxins associated with CRISPR-Cas systems include the essential Cas2 protein, proteins of COG1517 that, in addition to a ligand-binding domain and a helix-turn-helix domain, typically contain different nuclease domains and several other predicted nucleases. The tight association of the CRISPR-Cas immunity systems with predicted toxins that, upon activation, would induce dormancy or cell death suggests that adaptive immunity and dormancy/suicide response are functionally coupled. Such coupling could manifest in the persistence state being induced and potentially providing conditions for more effective action of the immune system or in cell death being triggered when immunity fails.", "qas": [{"question": "Gene silencing can be achieved by RNA interference (RNAi) in eukaryotic organisms. What is the name of the analogous process in prokaryotic organisms?", "answers": ["CRISPR-Cas"], "qid": "c40581ee9c7a4286b6e7d0e14ece96df", "question_tokens": [["Gene", 0], ["silencing", 5], ["can", 15], ["be", 19], ["achieved", 22], ["by", 31], ["RNA", 34], ["interference", 38], ["(", 51], ["RNAi", 52], [")", 56], ["in", 58], ["eukaryotic", 61], ["organisms", 72], [".", 81], ["What", 83], ["is", 88], ["the", 91], ["name", 95], ["of", 100], ["the", 103], ["analogous", 107], ["process", 117], ["in", 125], ["prokaryotic", 128], ["organisms", 140], ["?", 149]], "detected_answers": [{"text": "CRISPR-Cas", "token_spans": [[1, 3], [268, 270], [54, 56], [220, 222], [176, 178]], "char_spans": [[4, 13], [1512, 1521], [309, 318], [1248, 1257], [979, 988]]}]}], "context_tokens": [["The", 0], ["CRISPR", 4], ["-", 10], ["Cas", 11], ["(", 15], ["clustered", 16], ["regularly", 26], ["interspaced", 36], ["short", 48], ["palindromic", 54], ["repeats", 66], [",", 73], ["CRISPR", 75], ["-", 81], ["associated", 82], ["genes", 93], [")", 98], ["is", 100], ["an", 103], ["adaptive", 106], ["immunity", 115], ["system", 124], ["in", 131], ["bacteria", 134], ["and", 143], ["archaea", 147], ["that", 155], ["functions", 160], ["via", 170], ["a", 174], ["distinct", 176], ["self", 185], ["-", 189], ["non", 190], ["-", 193], ["self", 194], ["recognition", 199], ["mechanism", 211], ["that", 221], ["is", 226], ["partially", 229], ["analogous", 239], ["to", 249], ["the", 252], ["mechanism", 256], ["of", 266], ["eukaryotic", 269], ["RNA", 280], ["interference", 284], ["(", 297], ["RNAi", 298], [")", 302], [".", 303], ["The", 305], ["CRISPR", 309], ["-", 315], ["Cas", 316], ["system", 320], ["incorporates", 327], ["fragments", 340], ["of", 350], ["virus", 353], ["or", 359], ["plasmid", 362], ["DNA", 370], ["into", 374], ["the", 379], ["CRISPR", 383], ["repeat", 390], ["cassettes", 397], ["and", 407], ["employs", 411], ["the", 419], ["processed", 423], ["transcripts", 433], ["of", 445], ["these", 448], ["spacers", 454], ["as", 462], ["guide", 465], ["RNAs", 471], ["to", 476], ["cleave", 479], ["the", 486], ["cognate", 490], ["foreign", 498], ["DNA", 506], ["or", 510], ["RNA", 513], [".", 516], ["The", 518], ["Cas", 522], ["proteins", 526], [",", 534], ["however", 536], [",", 543], ["are", 545], ["not", 549], ["homologous", 553], ["to", 564], ["the", 567], ["proteins", 571], ["involved", 580], ["in", 589], ["RNAi", 592], ["and", 597], ["comprise", 601], ["numerous", 610], [",", 618], ["highly", 620], ["diverged", 627], ["families", 636], [".", 644], ["The", 646], ["majority", 650], ["of", 659], ["the", 662], ["Cas", 666], ["proteins", 670], ["contain", 679], ["diverse", 687], ["variants", 695], ["of", 704], ["the", 707], ["RNA", 711], ["recognition", 715], ["motif", 727], ["(", 733], ["RRM", 734], [")", 737], [",", 738], ["a", 740], ["widespread", 742], ["RNA", 753], ["-", 756], ["binding", 757], ["domain", 765], [".", 771], ["Despite", 773], ["the", 781], ["fast", 785], ["evolution", 790], ["that", 800], ["is", 805], ["typical", 808], ["of", 816], ["the", 819], ["cas", 823], ["genes", 827], [",", 832], ["the", 834], ["presence", 838], ["of", 847], ["diverse", 850], ["versions", 858], ["of", 867], ["the", 870], ["RRM", 874], ["in", 878], ["most", 881], ["Cas", 886], ["proteins", 890], ["provides", 899], ["for", 908], ["a", 912], ["simple", 914], ["scenario", 921], ["for", 930], ["the", 934], ["evolution", 938], ["of", 948], ["the", 951], ["three", 955], ["distinct", 961], ["types", 970], ["of", 976], ["CRISPR", 979], ["-", 985], ["cas", 986], ["systems", 990], [".", 997], ["In", 999], ["addition", 1002], ["to", 1011], ["several", 1014], ["proteins", 1022], ["that", 1031], ["are", 1036], ["directly", 1040], ["implicated", 1049], ["in", 1060], ["the", 1063], ["immune", 1067], ["response", 1074], [",", 1082], ["the", 1084], ["cas", 1088], ["genes", 1092], ["encode", 1098], ["a", 1105], ["variety", 1107], ["of", 1115], ["proteins", 1118], ["that", 1127], ["are", 1132], ["homologous", 1136], ["to", 1147], ["prokaryotic", 1150], ["toxins", 1162], ["that", 1169], ["typically", 1174], ["possess", 1184], ["nuclease", 1192], ["activity", 1201], [".", 1209], ["The", 1211], ["predicted", 1215], ["toxins", 1225], ["associated", 1232], ["with", 1243], ["CRISPR", 1248], ["-", 1254], ["Cas", 1255], ["systems", 1259], ["include", 1267], ["the", 1275], ["essential", 1279], ["Cas2", 1289], ["protein", 1294], [",", 1301], ["proteins", 1303], ["of", 1312], ["COG1517", 1315], ["that", 1323], [",", 1327], ["in", 1329], ["addition", 1332], ["to", 1341], ["a", 1344], ["ligand", 1346], ["-", 1352], ["binding", 1353], ["domain", 1361], ["and", 1368], ["a", 1372], ["helix", 1374], ["-", 1379], ["turn", 1380], ["-", 1384], ["helix", 1385], ["domain", 1391], [",", 1397], ["typically", 1399], ["contain", 1409], ["different", 1417], ["nuclease", 1427], ["domains", 1436], ["and", 1444], ["several", 1448], ["other", 1456], ["predicted", 1462], ["nucleases", 1472], [".", 1481], ["The", 1483], ["tight", 1487], ["association", 1493], ["of", 1505], ["the", 1508], ["CRISPR", 1512], ["-", 1518], ["Cas", 1519], ["immunity", 1523], ["systems", 1532], ["with", 1540], ["predicted", 1545], ["toxins", 1555], ["that", 1562], [",", 1566], ["upon", 1568], ["activation", 1573], [",", 1583], ["would", 1585], ["induce", 1591], ["dormancy", 1598], ["or", 1607], ["cell", 1610], ["death", 1615], ["suggests", 1621], ["that", 1630], ["adaptive", 1635], ["immunity", 1644], ["and", 1653], ["dormancy", 1657], ["/", 1665], ["suicide", 1666], ["response", 1674], ["are", 1683], ["functionally", 1687], ["coupled", 1700], [".", 1707], ["Such", 1709], ["coupling", 1714], ["could", 1723], ["manifest", 1729], ["in", 1738], ["the", 1741], ["persistence", 1745], ["state", 1757], ["being", 1763], ["induced", 1769], ["and", 1777], ["potentially", 1781], ["providing", 1793], ["conditions", 1803], ["for", 1814], ["more", 1818], ["effective", 1823], ["action", 1833], ["of", 1840], ["the", 1843], ["immune", 1847], ["system", 1854], ["or", 1861], ["in", 1864], ["cell", 1867], ["death", 1872], ["being", 1878], ["triggered", 1884], ["when", 1894], ["immunity", 1899], ["fails", 1908], [".", 1913]]}
{"context": "To characterise activation of the type I interferon (IFN) pathway in patients with systemic lupus erythematosus (SLE), dermatomyositis (DM), polymyositis (PM), rheumatoid arthritis (RA) and systemic scleroderma (SSc) and to evaluate the potential to develop a molecular diagnostic tool from the peripheral blood that reflects this activation in disease-affected tissues. Overexpressed transcripts were identified in the whole blood (WB) of 262 patients with SLE, 44 with DM, 33 with PM, 28 with SSc and 89 with RA and compared with 24 healthy subjects using Affymetrix microarrays. A five gene type I IFN signature was assessed in these subjects to identify subpopulations showing both activation and concordance of the type I IFN pathway in the peripheral blood and disease-affected tissues of each disease and to correlate activation of this pathway in the WB with clinical measurements. A common set of 36 type I IFN inducible transcripts were identified among the most overexpressed in the WB of all subjects. Significant activation of the type I IFN pathway in subgroups of each of the five diseases studied was observed. Baseline disease activity measurements correlated with a type I IFN gene signature in the WB of subjects with SLE, PM and SSc, as did various serum autoantibody levels in subjects with SLE and DM. This signature was also well correlated between disease-affected tissue and WB in subjects with SLE, DM, PM and SSc. The results indicate that the type I IFN pathway is activated in patient subsets of five rheumatic diseases and suggest that these subsets may benefit from anti-IFN therapy.", "qas": [{"question": "Which is the most common gene signature in Rheumatoid Arthritis patients?", "answers": ["Interferon signature", "IFN signature"], "qid": "3d4407ef652d4c23ba87702480b6b50a", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["common", 18], ["gene", 25], ["signature", 30], ["in", 40], ["Rheumatoid", 43], ["Arthritis", 54], ["patients", 64], ["?", 72]], "detected_answers": [{"text": "IFN signature", "token_spans": [[115, 116]], "char_spans": [[601, 613]]}]}], "context_tokens": [["To", 0], ["characterise", 3], ["activation", 16], ["of", 27], ["the", 30], ["type", 34], ["I", 39], ["interferon", 41], ["(", 52], ["IFN", 53], [")", 56], ["pathway", 58], ["in", 66], ["patients", 69], ["with", 78], ["systemic", 83], ["lupus", 92], ["erythematosus", 98], ["(", 112], ["SLE", 113], [")", 116], [",", 117], ["dermatomyositis", 119], ["(", 135], ["DM", 136], [")", 138], [",", 139], ["polymyositis", 141], ["(", 154], ["PM", 155], [")", 157], [",", 158], ["rheumatoid", 160], ["arthritis", 171], ["(", 181], ["RA", 182], [")", 184], ["and", 186], ["systemic", 190], ["scleroderma", 199], ["(", 211], ["SSc", 212], [")", 215], ["and", 217], ["to", 221], ["evaluate", 224], ["the", 233], ["potential", 237], ["to", 247], ["develop", 250], ["a", 258], ["molecular", 260], ["diagnostic", 270], ["tool", 281], ["from", 286], ["the", 291], ["peripheral", 295], ["blood", 306], ["that", 312], ["reflects", 317], ["this", 326], ["activation", 331], ["in", 342], ["disease", 345], ["-", 352], ["affected", 353], ["tissues", 362], [".", 369], ["Overexpressed", 371], ["transcripts", 385], ["were", 397], ["identified", 402], ["in", 413], ["the", 416], ["whole", 420], ["blood", 426], ["(", 432], ["WB", 433], [")", 435], ["of", 437], ["262", 440], ["patients", 444], ["with", 453], ["SLE", 458], [",", 461], ["44", 463], ["with", 466], ["DM", 471], [",", 473], ["33", 475], ["with", 478], ["PM", 483], [",", 485], ["28", 487], ["with", 490], ["SSc", 495], ["and", 499], ["89", 503], ["with", 506], ["RA", 511], ["and", 514], ["compared", 518], ["with", 527], ["24", 532], ["healthy", 535], ["subjects", 543], ["using", 552], ["Affymetrix", 558], ["microarrays", 569], [".", 580], ["A", 582], ["five", 584], ["gene", 589], ["type", 594], ["I", 599], ["IFN", 601], ["signature", 605], ["was", 615], ["assessed", 619], ["in", 628], ["these", 631], ["subjects", 637], ["to", 646], ["identify", 649], ["subpopulations", 658], ["showing", 673], ["both", 681], ["activation", 686], ["and", 697], ["concordance", 701], ["of", 713], ["the", 716], ["type", 720], ["I", 725], ["IFN", 727], ["pathway", 731], ["in", 739], ["the", 742], ["peripheral", 746], ["blood", 757], ["and", 763], ["disease", 767], ["-", 774], ["affected", 775], ["tissues", 784], ["of", 792], ["each", 795], ["disease", 800], ["and", 808], ["to", 812], ["correlate", 815], ["activation", 825], ["of", 836], ["this", 839], ["pathway", 844], ["in", 852], ["the", 855], ["WB", 859], ["with", 862], ["clinical", 867], ["measurements", 876], [".", 888], ["A", 890], ["common", 892], ["set", 899], ["of", 903], ["36", 906], ["type", 909], ["I", 914], ["IFN", 916], ["inducible", 920], ["transcripts", 930], ["were", 942], ["identified", 947], ["among", 958], ["the", 964], ["most", 968], ["overexpressed", 973], ["in", 987], ["the", 990], ["WB", 994], ["of", 997], ["all", 1000], ["subjects", 1004], [".", 1012], ["Significant", 1014], ["activation", 1026], ["of", 1037], ["the", 1040], ["type", 1044], ["I", 1049], ["IFN", 1051], ["pathway", 1055], ["in", 1063], ["subgroups", 1066], ["of", 1076], ["each", 1079], ["of", 1084], ["the", 1087], ["five", 1091], ["diseases", 1096], ["studied", 1105], ["was", 1113], ["observed", 1117], [".", 1125], ["Baseline", 1127], ["disease", 1136], ["activity", 1144], ["measurements", 1153], ["correlated", 1166], ["with", 1177], ["a", 1182], ["type", 1184], ["I", 1189], ["IFN", 1191], ["gene", 1195], ["signature", 1200], ["in", 1210], ["the", 1213], ["WB", 1217], ["of", 1220], ["subjects", 1223], ["with", 1232], ["SLE", 1237], [",", 1240], ["PM", 1242], ["and", 1245], ["SSc", 1249], [",", 1252], ["as", 1254], ["did", 1257], ["various", 1261], ["serum", 1269], ["autoantibody", 1275], ["levels", 1288], ["in", 1295], ["subjects", 1298], ["with", 1307], ["SLE", 1312], ["and", 1316], ["DM", 1320], [".", 1322], ["This", 1324], ["signature", 1329], ["was", 1339], ["also", 1343], ["well", 1348], ["correlated", 1353], ["between", 1364], ["disease", 1372], ["-", 1379], ["affected", 1380], ["tissue", 1389], ["and", 1396], ["WB", 1400], ["in", 1403], ["subjects", 1406], ["with", 1415], ["SLE", 1420], [",", 1423], ["DM", 1425], [",", 1427], ["PM", 1429], ["and", 1432], ["SSc", 1436], [".", 1439], ["The", 1441], ["results", 1445], ["indicate", 1453], ["that", 1462], ["the", 1467], ["type", 1471], ["I", 1476], ["IFN", 1478], ["pathway", 1482], ["is", 1490], ["activated", 1493], ["in", 1503], ["patient", 1506], ["subsets", 1514], ["of", 1522], ["five", 1525], ["rheumatic", 1530], ["diseases", 1540], ["and", 1549], ["suggest", 1553], ["that", 1561], ["these", 1566], ["subsets", 1572], ["may", 1580], ["benefit", 1584], ["from", 1592], ["anti", 1597], ["-", 1601], ["IFN", 1602], ["therapy", 1606], [".", 1613]]}
{"context": "Neurofibromatosis type 1 (NF1) is a common disorder of dysregulated tissue growth secondary to mutations in the tumor suppressor gene NF1. Pulmonary arterial hypertension (PAH) in patients with NF1 is hypothesized to be secondary to an underlying vasculopathy. We describe the entity we term NF1-associated PAH (NF1-PAH) in four new patients and update the data on four previously published reports of patients with PAH and NF1. We performed genetic testing of the bone morphogenic protein receptor 2 (BMPR2) gene, which mutated in 70% of patients with familial PAH and approximately 25% of patients with idiopathic PAH. We report, for the first time, pathologic findings in the autopsy-obtained lung of one patient with NF1-PAH. Patients with NF1-PAH have a generally poor long-term prognosis. In four patients, we observed the mosaic pattern of lung attenuation on a CT scan of the chest, a radiographic finding that can be consistent with an underlying vasculopathy. No mutations or rearrangements in the BMPR2 gene were found. We observed complex plexiform lesions in the one available autopsy specimen. Similar lesions are a hallmark of plexogenic pulmonary arteriopathy and are associated with several severe types of PAH. (Plexiform lesions should not be confused with plexiform neurofibromas, which are distinctive tumors seen in NF1.) Our findings suggest that NF1 should be considered as being \"associated with PAH as outlined in the Revised Clinical Classification of Pulmonary Hypertension. Understanding the mechanism of PAH in NF1 may inform the pathogenesis of PAH, NF1-PAH itself, and other NF1-associated vasculopathies. The pulmonary vasculature should now be included among the arterial beds affected by NF1 vasculopathy.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "d0289ed00e594970840413f51ee34e30", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[243, 243], [299, 299], [22, 22], [236, 236], [4, 4], [73, 73], [270, 270], [33, 33]], "char_spans": [[1370, 1372], [1723, 1725], [134, 136], [1338, 1340], [26, 28], [424, 426], [1541, 1543], [194, 196]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["(", 25], ["NF1", 26], [")", 29], ["is", 31], ["a", 34], ["common", 36], ["disorder", 43], ["of", 52], ["dysregulated", 55], ["tissue", 68], ["growth", 75], ["secondary", 82], ["to", 92], ["mutations", 95], ["in", 105], ["the", 108], ["tumor", 112], ["suppressor", 118], ["gene", 129], ["NF1", 134], [".", 137], ["Pulmonary", 139], ["arterial", 149], ["hypertension", 158], ["(", 171], ["PAH", 172], [")", 175], ["in", 177], ["patients", 180], ["with", 189], ["NF1", 194], ["is", 198], ["hypothesized", 201], ["to", 214], ["be", 217], ["secondary", 220], ["to", 230], ["an", 233], ["underlying", 236], ["vasculopathy", 247], [".", 259], ["We", 261], ["describe", 264], ["the", 273], ["entity", 277], ["we", 284], ["term", 287], ["NF1-associated", 292], ["PAH", 307], ["(", 311], ["NF1-PAH", 312], [")", 319], ["in", 321], ["four", 324], ["new", 329], ["patients", 333], ["and", 342], ["update", 346], ["the", 353], ["data", 357], ["on", 362], ["four", 365], ["previously", 370], ["published", 381], ["reports", 391], ["of", 399], ["patients", 402], ["with", 411], ["PAH", 416], ["and", 420], ["NF1", 424], [".", 427], ["We", 429], ["performed", 432], ["genetic", 442], ["testing", 450], ["of", 458], ["the", 461], ["bone", 465], ["morphogenic", 470], ["protein", 482], ["receptor", 490], ["2", 499], ["(", 501], ["BMPR2", 502], [")", 507], ["gene", 509], [",", 513], ["which", 515], ["mutated", 521], ["in", 529], ["70", 532], ["%", 534], ["of", 536], ["patients", 539], ["with", 548], ["familial", 553], ["PAH", 562], ["and", 566], ["approximately", 570], ["25", 584], ["%", 586], ["of", 588], ["patients", 591], ["with", 600], ["idiopathic", 605], ["PAH", 616], [".", 619], ["We", 621], ["report", 624], [",", 630], ["for", 632], ["the", 636], ["first", 640], ["time", 646], [",", 650], ["pathologic", 652], ["findings", 663], ["in", 672], ["the", 675], ["autopsy", 679], ["-", 686], ["obtained", 687], ["lung", 696], ["of", 701], ["one", 704], ["patient", 708], ["with", 716], ["NF1-PAH", 721], [".", 728], ["Patients", 730], ["with", 739], ["NF1-PAH", 744], ["have", 752], ["a", 757], ["generally", 759], ["poor", 769], ["long", 774], ["-", 778], ["term", 779], ["prognosis", 784], [".", 793], ["In", 795], ["four", 798], ["patients", 803], [",", 811], ["we", 813], ["observed", 816], ["the", 825], ["mosaic", 829], ["pattern", 836], ["of", 844], ["lung", 847], ["attenuation", 852], ["on", 864], ["a", 867], ["CT", 869], ["scan", 872], ["of", 877], ["the", 880], ["chest", 884], [",", 889], ["a", 891], ["radiographic", 893], ["finding", 906], ["that", 914], ["can", 919], ["be", 923], ["consistent", 926], ["with", 937], ["an", 942], ["underlying", 945], ["vasculopathy", 956], [".", 968], ["No", 970], ["mutations", 973], ["or", 983], ["rearrangements", 986], ["in", 1001], ["the", 1004], ["BMPR2", 1008], ["gene", 1014], ["were", 1019], ["found", 1024], [".", 1029], ["We", 1031], ["observed", 1034], ["complex", 1043], ["plexiform", 1051], ["lesions", 1061], ["in", 1069], ["the", 1072], ["one", 1076], ["available", 1080], ["autopsy", 1090], ["specimen", 1098], [".", 1106], ["Similar", 1108], ["lesions", 1116], ["are", 1124], ["a", 1128], ["hallmark", 1130], ["of", 1139], ["plexogenic", 1142], ["pulmonary", 1153], ["arteriopathy", 1163], ["and", 1176], ["are", 1180], ["associated", 1184], ["with", 1195], ["several", 1200], ["severe", 1208], ["types", 1215], ["of", 1221], ["PAH", 1224], [".", 1227], ["(", 1229], ["Plexiform", 1230], ["lesions", 1240], ["should", 1248], ["not", 1255], ["be", 1259], ["confused", 1262], ["with", 1271], ["plexiform", 1276], ["neurofibromas", 1286], [",", 1299], ["which", 1301], ["are", 1307], ["distinctive", 1311], ["tumors", 1323], ["seen", 1330], ["in", 1335], ["NF1", 1338], [".", 1341], [")", 1342], ["Our", 1344], ["findings", 1348], ["suggest", 1357], ["that", 1365], ["NF1", 1370], ["should", 1374], ["be", 1381], ["considered", 1384], ["as", 1395], ["being", 1398], ["\"", 1404], ["associated", 1405], ["with", 1416], ["PAH", 1421], ["as", 1425], ["outlined", 1428], ["in", 1437], ["the", 1440], ["Revised", 1444], ["Clinical", 1452], ["Classification", 1461], ["of", 1476], ["Pulmonary", 1479], ["Hypertension", 1489], [".", 1501], ["Understanding", 1503], ["the", 1517], ["mechanism", 1521], ["of", 1531], ["PAH", 1534], ["in", 1538], ["NF1", 1541], ["may", 1545], ["inform", 1549], ["the", 1556], ["pathogenesis", 1560], ["of", 1573], ["PAH", 1576], [",", 1579], ["NF1-PAH", 1581], ["itself", 1589], [",", 1595], ["and", 1597], ["other", 1601], ["NF1-associated", 1607], ["vasculopathies", 1622], [".", 1636], ["The", 1638], ["pulmonary", 1642], ["vasculature", 1652], ["should", 1664], ["now", 1671], ["be", 1675], ["included", 1678], ["among", 1687], ["the", 1693], ["arterial", 1697], ["beds", 1706], ["affected", 1711], ["by", 1720], ["NF1", 1723], ["vasculopathy", 1727], [".", 1739]]}
{"context": "An outbreak of Clostridium difficile ribotype 027 infection (CDI) occurred at an university hospital, involving 19 departments. To determine what hospital-associated factors drove the outbreak of this particular strain we performed a case-control study. Cases (n = 79), diagnosed with CDI due to C. difficile ribotype 027 were matched for age and treating medical specialty to four control patients (n = 316). Patients diagnosed with CDI due to other ribotypes were included as a second control group. A random selection of C. difficile ribotype 027 strains (n = 10) was genotyped by Whole Genome Sequencing (WGS). WGS showed the outbreak was likely caused by a single strain of C. difficile (two or less single-nucleotide variants between isolates). Ninety-five percent of cases had used antibiotics, compared to 56% of controls. Previous admission to the intensive care unit (ICU) (OR: 2.4, 95% CI 1.0-5.6), longer length of stay (LOS), and recent hospital admission were associated with CDI ribotype 027. Cases were less likely to have been admitted to a ward with a known isolated CDI patient (OR: 0.2, 95% CI 0.1-0.6). Analysis of patients who stayed at the ICU (35 cases; 51 controls), indicated that the use of selective decontamination of the digestive tract (SDD) and a longer LOS in the ICU were associated with CDI risk. In this large outbreak, any antibiotic use, including SDD use, appeared as a prerequisite for acquisition of the outbreak strain. The role of use of SDD and prolonged stay on the ICU could not be disentangled, but both factors can play a biologically plausible role in C. difficile acquisition and infection.", "qas": [{"question": "Which main ribotype of Clostridium difficile is responsible of the recent outbreak?", "answers": ["Ribotype 027"], "qid": "3624fe9b9dca47c98be7dc8c2d2db870", "question_tokens": [["Which", 0], ["main", 6], ["ribotype", 11], ["of", 20], ["Clostridium", 23], ["difficile", 35], ["is", 45], ["responsible", 48], ["of", 60], ["the", 63], ["recent", 67], ["outbreak", 74], ["?", 82]], "detected_answers": [{"text": "Ribotype 027", "token_spans": [[5, 6], [57, 58], [199, 200], [99, 100]], "char_spans": [[37, 48], [309, 320], [994, 1005], [537, 548]]}]}], "context_tokens": [["An", 0], ["outbreak", 3], ["of", 12], ["Clostridium", 15], ["difficile", 27], ["ribotype", 37], ["027", 46], ["infection", 50], ["(", 60], ["CDI", 61], [")", 64], ["occurred", 66], ["at", 75], ["an", 78], ["university", 81], ["hospital", 92], [",", 100], ["involving", 102], ["19", 112], ["departments", 115], [".", 126], ["To", 128], ["determine", 131], ["what", 141], ["hospital", 146], ["-", 154], ["associated", 155], ["factors", 166], ["drove", 174], ["the", 180], ["outbreak", 184], ["of", 193], ["this", 196], ["particular", 201], ["strain", 212], ["we", 219], ["performed", 222], ["a", 232], ["case", 234], ["-", 238], ["control", 239], ["study", 247], [".", 252], ["Cases", 254], ["(", 260], ["n", 261], ["=", 263], ["79", 265], [")", 267], [",", 268], ["diagnosed", 270], ["with", 280], ["CDI", 285], ["due", 289], ["to", 293], ["C.", 296], ["difficile", 299], ["ribotype", 309], ["027", 318], ["were", 322], ["matched", 327], ["for", 335], ["age", 339], ["and", 343], ["treating", 347], ["medical", 356], ["specialty", 364], ["to", 374], ["four", 377], ["control", 382], ["patients", 390], ["(", 399], ["n", 400], ["=", 402], ["316", 404], [")", 407], [".", 408], ["Patients", 410], ["diagnosed", 419], ["with", 429], ["CDI", 434], ["due", 438], ["to", 442], ["other", 445], ["ribotypes", 451], ["were", 461], ["included", 466], ["as", 475], ["a", 478], ["second", 480], ["control", 487], ["group", 495], [".", 500], ["A", 502], ["random", 504], ["selection", 511], ["of", 521], ["C.", 524], ["difficile", 527], ["ribotype", 537], ["027", 546], ["strains", 550], ["(", 558], ["n", 559], ["=", 561], ["10", 563], [")", 565], ["was", 567], ["genotyped", 571], ["by", 581], ["Whole", 584], ["Genome", 590], ["Sequencing", 597], ["(", 608], ["WGS", 609], [")", 612], [".", 613], ["WGS", 615], ["showed", 619], ["the", 626], ["outbreak", 630], ["was", 639], ["likely", 643], ["caused", 650], ["by", 657], ["a", 660], ["single", 662], ["strain", 669], ["of", 676], ["C.", 679], ["difficile", 682], ["(", 692], ["two", 693], ["or", 697], ["less", 700], ["single", 705], ["-", 711], ["nucleotide", 712], ["variants", 723], ["between", 732], ["isolates", 740], [")", 748], [".", 749], ["Ninety", 751], ["-", 757], ["five", 758], ["percent", 763], ["of", 771], ["cases", 774], ["had", 780], ["used", 784], ["antibiotics", 789], [",", 800], ["compared", 802], ["to", 811], ["56", 814], ["%", 816], ["of", 818], ["controls", 821], [".", 829], ["Previous", 831], ["admission", 840], ["to", 850], ["the", 853], ["intensive", 857], ["care", 867], ["unit", 872], ["(", 877], ["ICU", 878], [")", 881], ["(", 883], ["OR", 884], [":", 886], ["2.4", 888], [",", 891], ["95", 893], ["%", 895], ["CI", 897], ["1.0", 900], ["-", 903], ["5.6", 904], [")", 907], [",", 908], ["longer", 910], ["length", 917], ["of", 924], ["stay", 927], ["(", 932], ["LOS", 933], [")", 936], [",", 937], ["and", 939], ["recent", 943], ["hospital", 950], ["admission", 959], ["were", 969], ["associated", 974], ["with", 985], ["CDI", 990], ["ribotype", 994], ["027", 1003], [".", 1006], ["Cases", 1008], ["were", 1014], ["less", 1019], ["likely", 1024], ["to", 1031], ["have", 1034], ["been", 1039], ["admitted", 1044], ["to", 1053], ["a", 1056], ["ward", 1058], ["with", 1063], ["a", 1068], ["known", 1070], ["isolated", 1076], ["CDI", 1085], ["patient", 1089], ["(", 1097], ["OR", 1098], [":", 1100], ["0.2", 1102], [",", 1105], ["95", 1107], ["%", 1109], ["CI", 1111], ["0.1", 1114], ["-", 1117], ["0.6", 1118], [")", 1121], [".", 1122], ["Analysis", 1124], ["of", 1133], ["patients", 1136], ["who", 1145], ["stayed", 1149], ["at", 1156], ["the", 1159], ["ICU", 1163], ["(", 1167], ["35", 1168], ["cases", 1171], [";", 1176], ["51", 1178], ["controls", 1181], [")", 1189], [",", 1190], ["indicated", 1192], ["that", 1202], ["the", 1207], ["use", 1211], ["of", 1215], ["selective", 1218], ["decontamination", 1228], ["of", 1244], ["the", 1247], ["digestive", 1251], ["tract", 1261], ["(", 1267], ["SDD", 1268], [")", 1271], ["and", 1273], ["a", 1277], ["longer", 1279], ["LOS", 1286], ["in", 1290], ["the", 1293], ["ICU", 1297], ["were", 1301], ["associated", 1306], ["with", 1317], ["CDI", 1322], ["risk", 1326], [".", 1330], ["In", 1332], ["this", 1335], ["large", 1340], ["outbreak", 1346], [",", 1354], ["any", 1356], ["antibiotic", 1360], ["use", 1371], [",", 1374], ["including", 1376], ["SDD", 1386], ["use", 1390], [",", 1393], ["appeared", 1395], ["as", 1404], ["a", 1407], ["prerequisite", 1409], ["for", 1422], ["acquisition", 1426], ["of", 1438], ["the", 1441], ["outbreak", 1445], ["strain", 1454], [".", 1460], ["The", 1462], ["role", 1466], ["of", 1471], ["use", 1474], ["of", 1478], ["SDD", 1481], ["and", 1485], ["prolonged", 1489], ["stay", 1499], ["on", 1504], ["the", 1507], ["ICU", 1511], ["could", 1515], ["not", 1521], ["be", 1525], ["disentangled", 1528], [",", 1540], ["but", 1542], ["both", 1546], ["factors", 1551], ["can", 1559], ["play", 1563], ["a", 1568], ["biologically", 1570], ["plausible", 1583], ["role", 1593], ["in", 1598], ["C.", 1601], ["difficile", 1604], ["acquisition", 1614], ["and", 1626], ["infection", 1630], [".", 1639]]}
{"context": "The susceptibility to arbekacin (ABK) of methicillin-resistant Staphylococcus aureus (MRSA) was investigated to find out how it related to aac(6')/aph(2\") gene. In 49 isolates of MRSA for which MIC of ABK ranged from 0.125 to 64 micrograms/ml, the MICs of ABK for 38 strains carrying aac(6')/aph(2\") gene were widely distributed from 0.25 to 64, whereas those for 11 strains without that gene were all < or = 0.5 microgram/ml. Residual rate of ABK activity was higher than that of gentamicin after the reaction with each crude enzyme preparation extracted from 3 isolates of MRSA, carrying aac(6')/aph(2\") and aad(4',4\") genes. Furthermore, 97 strains of MRSA isolated at Kanagawa prefecture in Japan in 1999 were all sensitive to ABK, although 28 strains of them carried aac(6')/aph(2\") gene. These results showed that ABK resistance was not necessarily related to carrying aac(6')/aph(2\") gene in clinical isolates of MRSA.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "c28f41488c09478c988e4e82f733d188", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[14, 14], [128, 128], [34, 34], [174, 174], [111, 111]], "char_spans": [[86, 89], [655, 658], [179, 182], [920, 923], [575, 578]]}]}], "context_tokens": [["The", 0], ["susceptibility", 4], ["to", 19], ["arbekacin", 22], ["(", 32], ["ABK", 33], [")", 36], ["of", 38], ["methicillin", 41], ["-", 52], ["resistant", 53], ["Staphylococcus", 63], ["aureus", 78], ["(", 85], ["MRSA", 86], [")", 90], ["was", 92], ["investigated", 96], ["to", 109], ["find", 112], ["out", 117], ["how", 121], ["it", 125], ["related", 128], ["to", 136], ["aac(6')/aph(2", 139], ["\"", 152], [")", 153], ["gene", 155], [".", 159], ["In", 161], ["49", 164], ["isolates", 167], ["of", 176], ["MRSA", 179], ["for", 184], ["which", 188], ["MIC", 194], ["of", 198], ["ABK", 201], ["ranged", 205], ["from", 212], ["0.125", 217], ["to", 223], ["64", 226], ["micrograms", 229], ["/", 239], ["ml", 240], [",", 242], ["the", 244], ["MICs", 248], ["of", 253], ["ABK", 256], ["for", 260], ["38", 264], ["strains", 267], ["carrying", 275], ["aac(6')/aph(2", 284], ["\"", 297], [")", 298], ["gene", 300], ["were", 305], ["widely", 310], ["distributed", 317], ["from", 329], ["0.25", 334], ["to", 339], ["64", 342], [",", 344], ["whereas", 346], ["those", 354], ["for", 360], ["11", 364], ["strains", 367], ["without", 375], ["that", 383], ["gene", 388], ["were", 393], ["all", 398], ["<", 402], ["or", 404], ["=", 407], ["0.5", 409], ["microgram", 413], ["/", 422], ["ml", 423], [".", 425], ["Residual", 427], ["rate", 436], ["of", 441], ["ABK", 444], ["activity", 448], ["was", 457], ["higher", 461], ["than", 468], ["that", 473], ["of", 478], ["gentamicin", 481], ["after", 492], ["the", 498], ["reaction", 502], ["with", 511], ["each", 516], ["crude", 521], ["enzyme", 527], ["preparation", 534], ["extracted", 546], ["from", 556], ["3", 561], ["isolates", 563], ["of", 572], ["MRSA", 575], [",", 579], ["carrying", 581], ["aac(6')/aph(2", 590], ["\"", 603], [")", 604], ["and", 606], ["aad(4',4", 610], ["\"", 618], [")", 619], ["genes", 621], [".", 626], ["Furthermore", 628], [",", 639], ["97", 641], ["strains", 644], ["of", 652], ["MRSA", 655], ["isolated", 660], ["at", 669], ["Kanagawa", 672], ["prefecture", 681], ["in", 692], ["Japan", 695], ["in", 701], ["1999", 704], ["were", 709], ["all", 714], ["sensitive", 718], ["to", 728], ["ABK", 731], [",", 734], ["although", 736], ["28", 745], ["strains", 748], ["of", 756], ["them", 759], ["carried", 764], ["aac(6')/aph(2", 772], ["\"", 785], [")", 786], ["gene", 788], [".", 792], ["These", 794], ["results", 800], ["showed", 808], ["that", 815], ["ABK", 820], ["resistance", 824], ["was", 835], ["not", 839], ["necessarily", 843], ["related", 855], ["to", 863], ["carrying", 866], ["aac(6')/aph(2", 875], ["\"", 888], [")", 889], ["gene", 891], ["in", 896], ["clinical", 899], ["isolates", 908], ["of", 917], ["MRSA", 920], [".", 924]]}
{"context": "Somatic mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene are reportedly associated with sensitivity of lung cancers to gefitinib (Iressa), kinase inhibitor. In-frame deletions occur in exon 19, whereas point mutations occur frequently in codon 858 (exon 21). We found from sequencing the EGFR TK domain that 7 of 10 gefitinib-sensitive tumors had similar types of alterations; no mutations were found in eight gefitinib-refractory tumors (P = 0.004). Five of seven tumors sensitive to erlotinib (Tarceva), a related kinase inhibitor for which the clinically relevant target is undocumented, had analogous somatic mutations, as opposed to none of 10 erlotinib-refractory tumors (P = 0.003). Because most mutation-positive tumors were adenocarcinomas from patients who smoked <100 cigarettes in a lifetime (\"never smokers\"), we screened EGFR exons 2-28 in 15 adenocarcinomas resected from untreated never smokers. Seven tumors had TK domain mutations, in contrast to 4 of 81 non-small cell lung cancers resected from untreated former or current smokers (P = 0.0001). Immunoblotting of lysates from cells transiently transfected with various EGFR constructs demonstrated that, compared to wild-type protein, an exon 19 deletion mutant induced diminished levels of phosphotyrosine, whereas the phosphorylation at tyrosine 1092 of an exon 21 point mutant was inhibited at 10-fold lower concentrations of drug. Collectively, these data show that adenocarcinomas from never smokers comprise a distinct subset of lung cancers, frequently containing mutations within the TK domain of EGFR that are associated with gefitinib and erlotinib sensitivity.", "qas": [{"question": "Mutations in which gene determine response to both erlotinib and gefitinib?", "answers": ["epidermal growth factor receptor (EGFR) gene"], "qid": "29f2855a4f1e49cabf0d468c74465cb7", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["determine", 24], ["response", 34], ["to", 43], ["both", 46], ["erlotinib", 51], ["and", 61], ["gefitinib", 65], ["?", 74]], "detected_answers": [{"text": "epidermal growth factor receptor (EGFR) gene", "token_spans": [[12, 19]], "char_spans": [[60, 103]]}]}], "context_tokens": [["Somatic", 0], ["mutations", 8], ["in", 18], ["the", 21], ["tyrosine", 25], ["kinase", 34], ["(", 41], ["TK", 42], [")", 44], ["domain", 46], ["of", 53], ["the", 56], ["epidermal", 60], ["growth", 70], ["factor", 77], ["receptor", 84], ["(", 93], ["EGFR", 94], [")", 98], ["gene", 100], ["are", 105], ["reportedly", 109], ["associated", 120], ["with", 131], ["sensitivity", 136], ["of", 148], ["lung", 151], ["cancers", 156], ["to", 164], ["gefitinib", 167], ["(", 177], ["Iressa", 178], [")", 184], [",", 185], ["kinase", 187], ["inhibitor", 194], [".", 203], ["In", 205], ["-", 207], ["frame", 208], ["deletions", 214], ["occur", 224], ["in", 230], ["exon", 233], ["19", 238], [",", 240], ["whereas", 242], ["point", 250], ["mutations", 256], ["occur", 266], ["frequently", 272], ["in", 283], ["codon", 286], ["858", 292], ["(", 296], ["exon", 297], ["21", 302], [")", 304], [".", 305], ["We", 307], ["found", 310], ["from", 316], ["sequencing", 321], ["the", 332], ["EGFR", 336], ["TK", 341], ["domain", 344], ["that", 351], ["7", 356], ["of", 358], ["10", 361], ["gefitinib", 364], ["-", 373], ["sensitive", 374], ["tumors", 384], ["had", 391], ["similar", 395], ["types", 403], ["of", 409], ["alterations", 412], [";", 423], ["no", 425], ["mutations", 428], ["were", 438], ["found", 443], ["in", 449], ["eight", 452], ["gefitinib", 458], ["-", 467], ["refractory", 468], ["tumors", 479], ["(", 486], ["P", 487], ["=", 489], ["0.004", 491], [")", 496], [".", 497], ["Five", 499], ["of", 504], ["seven", 507], ["tumors", 513], ["sensitive", 520], ["to", 530], ["erlotinib", 533], ["(", 543], ["Tarceva", 544], [")", 551], [",", 552], ["a", 554], ["related", 556], ["kinase", 564], ["inhibitor", 571], ["for", 581], ["which", 585], ["the", 591], ["clinically", 595], ["relevant", 606], ["target", 615], ["is", 622], ["undocumented", 625], [",", 637], ["had", 639], ["analogous", 643], ["somatic", 653], ["mutations", 661], [",", 670], ["as", 672], ["opposed", 675], ["to", 683], ["none", 686], ["of", 691], ["10", 694], ["erlotinib", 697], ["-", 706], ["refractory", 707], ["tumors", 718], ["(", 725], ["P", 726], ["=", 728], ["0.003", 730], [")", 735], [".", 736], ["Because", 738], ["most", 746], ["mutation", 751], ["-", 759], ["positive", 760], ["tumors", 769], ["were", 776], ["adenocarcinomas", 781], ["from", 797], ["patients", 802], ["who", 811], ["smoked", 815], ["<", 822], ["100", 823], ["cigarettes", 827], ["in", 838], ["a", 841], ["lifetime", 843], ["(", 852], ["\"", 853], ["never", 854], ["smokers", 860], ["\"", 867], [")", 868], [",", 869], ["we", 871], ["screened", 874], ["EGFR", 883], ["exons", 888], ["2", 894], ["-", 895], ["28", 896], ["in", 899], ["15", 902], ["adenocarcinomas", 905], ["resected", 921], ["from", 930], ["untreated", 935], ["never", 945], ["smokers", 951], [".", 958], ["Seven", 960], ["tumors", 966], ["had", 973], ["TK", 977], ["domain", 980], ["mutations", 987], [",", 996], ["in", 998], ["contrast", 1001], ["to", 1010], ["4", 1013], ["of", 1015], ["81", 1018], ["non", 1021], ["-", 1024], ["small", 1025], ["cell", 1031], ["lung", 1036], ["cancers", 1041], ["resected", 1049], ["from", 1058], ["untreated", 1063], ["former", 1073], ["or", 1080], ["current", 1083], ["smokers", 1091], ["(", 1099], ["P", 1100], ["=", 1102], ["0.0001", 1104], [")", 1110], [".", 1111], ["Immunoblotting", 1113], ["of", 1128], ["lysates", 1131], ["from", 1139], ["cells", 1144], ["transiently", 1150], ["transfected", 1162], ["with", 1174], ["various", 1179], ["EGFR", 1187], ["constructs", 1192], ["demonstrated", 1203], ["that", 1216], [",", 1220], ["compared", 1222], ["to", 1231], ["wild", 1234], ["-", 1238], ["type", 1239], ["protein", 1244], [",", 1251], ["an", 1253], ["exon", 1256], ["19", 1261], ["deletion", 1264], ["mutant", 1273], ["induced", 1280], ["diminished", 1288], ["levels", 1299], ["of", 1306], ["phosphotyrosine", 1309], [",", 1324], ["whereas", 1326], ["the", 1334], ["phosphorylation", 1338], ["at", 1354], ["tyrosine", 1357], ["1092", 1366], ["of", 1371], ["an", 1374], ["exon", 1377], ["21", 1382], ["point", 1385], ["mutant", 1391], ["was", 1398], ["inhibited", 1402], ["at", 1412], ["10-fold", 1415], ["lower", 1423], ["concentrations", 1429], ["of", 1444], ["drug", 1447], [".", 1451], ["Collectively", 1453], [",", 1465], ["these", 1467], ["data", 1473], ["show", 1478], ["that", 1483], ["adenocarcinomas", 1488], ["from", 1504], ["never", 1509], ["smokers", 1515], ["comprise", 1523], ["a", 1532], ["distinct", 1534], ["subset", 1543], ["of", 1550], ["lung", 1553], ["cancers", 1558], [",", 1565], ["frequently", 1567], ["containing", 1578], ["mutations", 1589], ["within", 1599], ["the", 1606], ["TK", 1610], ["domain", 1613], ["of", 1620], ["EGFR", 1623], ["that", 1628], ["are", 1633], ["associated", 1637], ["with", 1648], ["gefitinib", 1653], ["and", 1663], ["erlotinib", 1667], ["sensitivity", 1677], [".", 1688]]}
{"context": "MicroRNAs (miRNAs) are non-coding RNAs with important roles in regulating gene expression. Recent studies indicate that transcription and cleavage of miRNA are coupled, and that chromatin structure may influence miRNA transcription. However, little is known about the relationship between the chromatin structure and cleavage of pre-miRNA from pri-miRNA. By analysis of genome-wide nucleosome positioning data sets from human and Caenorhabditis elegans (C. elegans), we found an enrichment of positioned nucleosome on pre-miRNA genomic sequences, which is highly correlated with GC content within pre-miRNA. In addition, obvious enrichments of three histone modifications (H2BK5me1, H3K36me3 and H4K20me1) as well as RNA Polymerase II (RNAPII) were observed on pre-miRNA genomic sequences corresponding to the active-promoter miRNAs and expressed miRNAs. Our results revealed the chromatin structure characteristics of pre-miRNA genomic sequences, and implied potential mechanisms that can recognize these characteristics, thus improving pre-miRNA cleavage.", "qas": [{"question": "Which polymerase transcribes pri-miRNAs?", "answers": ["RNA polymerase II", "RNAPII"], "qid": "800083a0aff44406b0a95cb46cf7343b", "question_tokens": [["Which", 0], ["polymerase", 6], ["transcribes", 17], ["pri", 29], ["-", 32], ["miRNAs", 33], ["?", 39]], "detected_answers": [{"text": "RNA polymerase II", "token_spans": [[126, 128]], "char_spans": [[717, 733]]}, {"text": "RNAPII", "token_spans": [[130, 130]], "char_spans": [[736, 741]]}]}], "context_tokens": [["MicroRNAs", 0], ["(", 10], ["miRNAs", 11], [")", 17], ["are", 19], ["non", 23], ["-", 26], ["coding", 27], ["RNAs", 34], ["with", 39], ["important", 44], ["roles", 54], ["in", 60], ["regulating", 63], ["gene", 74], ["expression", 79], [".", 89], ["Recent", 91], ["studies", 98], ["indicate", 106], ["that", 115], ["transcription", 120], ["and", 134], ["cleavage", 138], ["of", 147], ["miRNA", 150], ["are", 156], ["coupled", 160], [",", 167], ["and", 169], ["that", 173], ["chromatin", 178], ["structure", 188], ["may", 198], ["influence", 202], ["miRNA", 212], ["transcription", 218], [".", 231], ["However", 233], [",", 240], ["little", 242], ["is", 249], ["known", 252], ["about", 258], ["the", 264], ["relationship", 268], ["between", 281], ["the", 289], ["chromatin", 293], ["structure", 303], ["and", 313], ["cleavage", 317], ["of", 326], ["pre", 329], ["-", 332], ["miRNA", 333], ["from", 339], ["pri", 344], ["-", 347], ["miRNA", 348], [".", 353], ["By", 355], ["analysis", 358], ["of", 367], ["genome", 370], ["-", 376], ["wide", 377], ["nucleosome", 382], ["positioning", 393], ["data", 405], ["sets", 410], ["from", 415], ["human", 420], ["and", 426], ["Caenorhabditis", 430], ["elegans", 445], ["(", 453], ["C.", 454], ["elegans", 457], [")", 464], [",", 465], ["we", 467], ["found", 470], ["an", 476], ["enrichment", 479], ["of", 490], ["positioned", 493], ["nucleosome", 504], ["on", 515], ["pre", 518], ["-", 521], ["miRNA", 522], ["genomic", 528], ["sequences", 536], [",", 545], ["which", 547], ["is", 553], ["highly", 556], ["correlated", 563], ["with", 574], ["GC", 579], ["content", 582], ["within", 590], ["pre", 597], ["-", 600], ["miRNA", 601], [".", 606], ["In", 608], ["addition", 611], [",", 619], ["obvious", 621], ["enrichments", 629], ["of", 641], ["three", 644], ["histone", 650], ["modifications", 658], ["(", 672], ["H2BK5me1", 673], [",", 681], ["H3K36me3", 683], ["and", 692], ["H4K20me1", 696], [")", 704], ["as", 706], ["well", 709], ["as", 714], ["RNA", 717], ["Polymerase", 721], ["II", 732], ["(", 735], ["RNAPII", 736], [")", 742], ["were", 744], ["observed", 749], ["on", 758], ["pre", 761], ["-", 764], ["miRNA", 765], ["genomic", 771], ["sequences", 779], ["corresponding", 789], ["to", 803], ["the", 806], ["active", 810], ["-", 816], ["promoter", 817], ["miRNAs", 826], ["and", 833], ["expressed", 837], ["miRNAs", 847], [".", 853], ["Our", 855], ["results", 859], ["revealed", 867], ["the", 876], ["chromatin", 880], ["structure", 890], ["characteristics", 900], ["of", 916], ["pre", 919], ["-", 922], ["miRNA", 923], ["genomic", 929], ["sequences", 937], [",", 946], ["and", 948], ["implied", 952], ["potential", 960], ["mechanisms", 970], ["that", 981], ["can", 986], ["recognize", 990], ["these", 1000], ["characteristics", 1006], [",", 1021], ["thus", 1023], ["improving", 1028], ["pre", 1038], ["-", 1041], ["miRNA", 1042], ["cleavage", 1048], [".", 1056]]}
{"context": "SET domain genes have been identified in numbers of bacterial genomes based on similarity to SET domains of eukaryotic histone methyltransferases. Herein, a Chlamydophila pneumoniae SET domain gene was clarified to be coincidently expressed with hctA and hctB genes encoding chlamydial histone H1-like proteins, Hc1 and Hc2, respectively. The SET domain protein (cpnSET) is localized in chlamydial cells and interacts with Hc1 and Hc2 through the C-terminal SET domain. As expected from conservation of catalytic sites in cpnSET, it functions as a protein methyltransferase to murine histone H3 and Hc1. However, little is known about protein methylation in the molecular pathogenesis of chlamydial infection. cpnSET may play an important role in chlamydial cell maturation due to modification of chlamydial histone H1-like proteins.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "bf4ddb3d39ae4a8ebc75f6c6b7218fbb", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[0, 1], [76, 77], [27, 28], [54, 55]], "char_spans": [[0, 9], [458, 467], [182, 191], [343, 352]]}]}], "context_tokens": [["SET", 0], ["domain", 4], ["genes", 11], ["have", 17], ["been", 22], ["identified", 27], ["in", 38], ["numbers", 41], ["of", 49], ["bacterial", 52], ["genomes", 62], ["based", 70], ["on", 76], ["similarity", 79], ["to", 90], ["SET", 93], ["domains", 97], ["of", 105], ["eukaryotic", 108], ["histone", 119], ["methyltransferases", 127], [".", 145], ["Herein", 147], [",", 153], ["a", 155], ["Chlamydophila", 157], ["pneumoniae", 171], ["SET", 182], ["domain", 186], ["gene", 193], ["was", 198], ["clarified", 202], ["to", 212], ["be", 215], ["coincidently", 218], ["expressed", 231], ["with", 241], ["hctA", 246], ["and", 251], ["hctB", 255], ["genes", 260], ["encoding", 266], ["chlamydial", 275], ["histone", 286], ["H1-like", 294], ["proteins", 302], [",", 310], ["Hc1", 312], ["and", 316], ["Hc2", 320], [",", 323], ["respectively", 325], [".", 337], ["The", 339], ["SET", 343], ["domain", 347], ["protein", 354], ["(", 362], ["cpnSET", 363], [")", 369], ["is", 371], ["localized", 374], ["in", 384], ["chlamydial", 387], ["cells", 398], ["and", 404], ["interacts", 408], ["with", 418], ["Hc1", 423], ["and", 427], ["Hc2", 431], ["through", 435], ["the", 443], ["C", 447], ["-", 448], ["terminal", 449], ["SET", 458], ["domain", 462], [".", 468], ["As", 470], ["expected", 473], ["from", 482], ["conservation", 487], ["of", 500], ["catalytic", 503], ["sites", 513], ["in", 519], ["cpnSET", 522], [",", 528], ["it", 530], ["functions", 533], ["as", 543], ["a", 546], ["protein", 548], ["methyltransferase", 556], ["to", 574], ["murine", 577], ["histone", 584], ["H3", 592], ["and", 595], ["Hc1", 599], [".", 602], ["However", 604], [",", 611], ["little", 613], ["is", 620], ["known", 623], ["about", 629], ["protein", 635], ["methylation", 643], ["in", 655], ["the", 658], ["molecular", 662], ["pathogenesis", 672], ["of", 685], ["chlamydial", 688], ["infection", 699], [".", 708], ["cpnSET", 710], ["may", 717], ["play", 721], ["an", 726], ["important", 729], ["role", 739], ["in", 744], ["chlamydial", 747], ["cell", 758], ["maturation", 763], ["due", 774], ["to", 778], ["modification", 781], ["of", 794], ["chlamydial", 797], ["histone", 808], ["H1-like", 816], ["proteins", 824], [".", 832]]}
{"context": "The conserved histone variant H2A.Z functions in euchromatin to antagonize the spread of heterochromatin. The mechanism by which histone H2A is replaced by H2A.Z in the nucleosome is unknown. We identified a complex containing 13 different polypeptides associated with a soluble pool of H2A.Z in Saccharomyces cerevisiae. This complex was designated SWR1-Com in reference to the Swr1p subunit, a Swi2/Snf2-paralog. Swr1p and six other subunits were found only in SWR1-Com, whereas six other subunits were also found in the NuA4 histone acetyltransferase and/or the Ino80 chromatin remodeling complex. H2A.Z and SWR1 were essential for viability of cells lacking the EAF1 component of NuA4, pointing to a close functional connection between these two complexes. Strikingly, chromatin immunoprecipitation analysis of cells lacking Swr1p, the presumed ATPase of the complex, revealed a profound defect in the deposition of H2A.Z at euchromatic regions that flank the silent mating type cassette HMR and at 12 other chromosomal sites tested. Consistent with a specialized role for Swr1p in H2A.Z deposition, the majority of the genome-wide transcriptional defects seen in swr1Delta cells were also found in htz1Delta cells. These studies revealed a novel role for a member of the ATP-dependent chromatin remodeling enzyme family in determining the region-specific histone subunit composition of chromatin in vivo and controlling the epigenetic state of chromatin. Metazoan orthologs of Swr1p (Drosophila Domino; human SRCAP and p400) may have analogous functions.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "30f3fe33aa974d54aa12ad555cb22644", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[97, 97]], "char_spans": [[611, 614]]}]}], "context_tokens": [["The", 0], ["conserved", 4], ["histone", 14], ["variant", 22], ["H2A.Z", 30], ["functions", 36], ["in", 46], ["euchromatin", 49], ["to", 61], ["antagonize", 64], ["the", 75], ["spread", 79], ["of", 86], ["heterochromatin", 89], [".", 104], ["The", 106], ["mechanism", 110], ["by", 120], ["which", 123], ["histone", 129], ["H2A", 137], ["is", 141], ["replaced", 144], ["by", 153], ["H2A.Z", 156], ["in", 162], ["the", 165], ["nucleosome", 169], ["is", 180], ["unknown", 183], [".", 190], ["We", 192], ["identified", 195], ["a", 206], ["complex", 208], ["containing", 216], ["13", 227], ["different", 230], ["polypeptides", 240], ["associated", 253], ["with", 264], ["a", 269], ["soluble", 271], ["pool", 279], ["of", 284], ["H2A.Z", 287], ["in", 293], ["Saccharomyces", 296], ["cerevisiae", 310], [".", 320], ["This", 322], ["complex", 327], ["was", 335], ["designated", 339], ["SWR1-Com", 350], ["in", 359], ["reference", 362], ["to", 372], ["the", 375], ["Swr1p", 379], ["subunit", 385], [",", 392], ["a", 394], ["Swi2/Snf2-paralog", 396], [".", 413], ["Swr1p", 415], ["and", 421], ["six", 425], ["other", 429], ["subunits", 435], ["were", 444], ["found", 449], ["only", 455], ["in", 460], ["SWR1-Com", 463], [",", 471], ["whereas", 473], ["six", 481], ["other", 485], ["subunits", 491], ["were", 500], ["also", 505], ["found", 510], ["in", 516], ["the", 519], ["NuA4", 523], ["histone", 528], ["acetyltransferase", 536], ["and/or", 554], ["the", 561], ["Ino80", 565], ["chromatin", 571], ["remodeling", 581], ["complex", 592], [".", 599], ["H2A.Z", 601], ["and", 607], ["SWR1", 611], ["were", 616], ["essential", 621], ["for", 631], ["viability", 635], ["of", 645], ["cells", 648], ["lacking", 654], ["the", 662], ["EAF1", 666], ["component", 671], ["of", 681], ["NuA4", 684], [",", 688], ["pointing", 690], ["to", 699], ["a", 702], ["close", 704], ["functional", 710], ["connection", 721], ["between", 732], ["these", 740], ["two", 746], ["complexes", 750], [".", 759], ["Strikingly", 761], [",", 771], ["chromatin", 773], ["immunoprecipitation", 783], ["analysis", 803], ["of", 812], ["cells", 815], ["lacking", 821], ["Swr1p", 829], [",", 834], ["the", 836], ["presumed", 840], ["ATPase", 849], ["of", 856], ["the", 859], ["complex", 863], [",", 870], ["revealed", 872], ["a", 881], ["profound", 883], ["defect", 892], ["in", 899], ["the", 902], ["deposition", 906], ["of", 917], ["H2A.Z", 920], ["at", 926], ["euchromatic", 929], ["regions", 941], ["that", 949], ["flank", 954], ["the", 960], ["silent", 964], ["mating", 971], ["type", 978], ["cassette", 983], ["HMR", 992], ["and", 996], ["at", 1000], ["12", 1003], ["other", 1006], ["chromosomal", 1012], ["sites", 1024], ["tested", 1030], [".", 1036], ["Consistent", 1038], ["with", 1049], ["a", 1054], ["specialized", 1056], ["role", 1068], ["for", 1073], ["Swr1p", 1077], ["in", 1083], ["H2A.Z", 1086], ["deposition", 1092], [",", 1102], ["the", 1104], ["majority", 1108], ["of", 1117], ["the", 1120], ["genome", 1124], ["-", 1130], ["wide", 1131], ["transcriptional", 1136], ["defects", 1152], ["seen", 1160], ["in", 1165], ["swr1Delta", 1168], ["cells", 1178], ["were", 1184], ["also", 1189], ["found", 1194], ["in", 1200], ["htz1Delta", 1203], ["cells", 1213], [".", 1218], ["These", 1220], ["studies", 1226], ["revealed", 1234], ["a", 1243], ["novel", 1245], ["role", 1251], ["for", 1256], ["a", 1260], ["member", 1262], ["of", 1269], ["the", 1272], ["ATP", 1276], ["-", 1279], ["dependent", 1280], ["chromatin", 1290], ["remodeling", 1300], ["enzyme", 1311], ["family", 1318], ["in", 1325], ["determining", 1328], ["the", 1340], ["region", 1344], ["-", 1350], ["specific", 1351], ["histone", 1360], ["subunit", 1368], ["composition", 1376], ["of", 1388], ["chromatin", 1391], ["in", 1401], ["vivo", 1404], ["and", 1409], ["controlling", 1413], ["the", 1425], ["epigenetic", 1429], ["state", 1440], ["of", 1446], ["chromatin", 1449], [".", 1458], ["Metazoan", 1460], ["orthologs", 1469], ["of", 1479], ["Swr1p", 1482], ["(", 1488], ["Drosophila", 1489], ["Domino", 1500], [";", 1506], ["human", 1508], ["SRCAP", 1514], ["and", 1520], ["p400", 1524], [")", 1528], ["may", 1530], ["have", 1534], ["analogous", 1539], ["functions", 1549], [".", 1558]]}
{"context": "A novel Ca2+/calmodulin-dependent protein kinase II (CaM Kinase II) inhibitor, KN-93 potently inhibits gastric acid secretion from parietal cells. As previously reported (1), treatment of parietal cells with a selective inhibitor of CaM kinase II, KN-62 resulted in the inhibition of cholinergic-stimulated rabbit parietal cell secretion, whereas it failed to inhibit the histamine and forskolin response. In contrast effects of carbachol, histamine and forskolin were significantly inhibited by KN-93 with an IC50 of 0.15, 0.3 and 1 microM, respectively; these effects occurred without any changes in intracellular cyclic AMP and Ca2+ levels. In the present study we investigated the mechanism by which KN-93 acts upon the acid-secreting machinery of gastric parietal cells. Neither redistribution of the proton pump activity nor the morphological transformation were affected by KN-93. The drug only weakly inhibited the H+, K(+)-ATPase activity but strongly dissipated the proton gradient formed in the gastric membrane vesicles and reduced the volume of luminal space. Thus KN-93 acts at pH gradient formation whereas KN-62 acts only at CaM Kinase II.", "qas": [{"question": "Which kinase is inhibited by the small molecule KN-93?", "answers": ["The calcium/calmodulin-dependent protein kinase-II", "CaM kinase II", "CAMK2"], "qid": "b747f9b082a644009fdd2023df633b19", "question_tokens": [["Which", 0], ["kinase", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["the", 29], ["small", 33], ["molecule", 39], ["KN-93", 48], ["?", 53]], "detected_answers": [{"text": "CaM kinase II", "token_spans": [[193, 195], [9, 11], [41, 43]], "char_spans": [[1141, 1153], [53, 65], [233, 245]]}]}], "context_tokens": [["A", 0], ["novel", 2], ["Ca2+/calmodulin", 8], ["-", 23], ["dependent", 24], ["protein", 34], ["kinase", 42], ["II", 49], ["(", 52], ["CaM", 53], ["Kinase", 57], ["II", 64], [")", 66], ["inhibitor", 68], [",", 77], ["KN-93", 79], ["potently", 85], ["inhibits", 94], ["gastric", 103], ["acid", 111], ["secretion", 116], ["from", 126], ["parietal", 131], ["cells", 140], [".", 145], ["As", 147], ["previously", 150], ["reported", 161], ["(", 170], ["1", 171], [")", 172], [",", 173], ["treatment", 175], ["of", 185], ["parietal", 188], ["cells", 197], ["with", 203], ["a", 208], ["selective", 210], ["inhibitor", 220], ["of", 230], ["CaM", 233], ["kinase", 237], ["II", 244], [",", 246], ["KN-62", 248], ["resulted", 254], ["in", 263], ["the", 266], ["inhibition", 270], ["of", 281], ["cholinergic", 284], ["-", 295], ["stimulated", 296], ["rabbit", 307], ["parietal", 314], ["cell", 323], ["secretion", 328], [",", 337], ["whereas", 339], ["it", 347], ["failed", 350], ["to", 357], ["inhibit", 360], ["the", 368], ["histamine", 372], ["and", 382], ["forskolin", 386], ["response", 396], [".", 404], ["In", 406], ["contrast", 409], ["effects", 418], ["of", 426], ["carbachol", 429], [",", 438], ["histamine", 440], ["and", 450], ["forskolin", 454], ["were", 464], ["significantly", 469], ["inhibited", 483], ["by", 493], ["KN-93", 496], ["with", 502], ["an", 507], ["IC50", 510], ["of", 515], ["0.15", 518], [",", 522], ["0.3", 524], ["and", 528], ["1", 532], ["microM", 534], [",", 540], ["respectively", 542], [";", 554], ["these", 556], ["effects", 562], ["occurred", 570], ["without", 579], ["any", 587], ["changes", 591], ["in", 599], ["intracellular", 602], ["cyclic", 616], ["AMP", 623], ["and", 627], ["Ca2", 631], ["+", 634], ["levels", 636], [".", 642], ["In", 644], ["the", 647], ["present", 651], ["study", 659], ["we", 665], ["investigated", 668], ["the", 681], ["mechanism", 685], ["by", 695], ["which", 698], ["KN-93", 704], ["acts", 710], ["upon", 715], ["the", 720], ["acid", 724], ["-", 728], ["secreting", 729], ["machinery", 739], ["of", 749], ["gastric", 752], ["parietal", 760], ["cells", 769], [".", 774], ["Neither", 776], ["redistribution", 784], ["of", 799], ["the", 802], ["proton", 806], ["pump", 813], ["activity", 818], ["nor", 827], ["the", 831], ["morphological", 835], ["transformation", 849], ["were", 864], ["affected", 869], ["by", 878], ["KN-93", 881], [".", 886], ["The", 888], ["drug", 892], ["only", 897], ["weakly", 902], ["inhibited", 909], ["the", 919], ["H+", 923], [",", 925], ["K(+)-ATPase", 927], ["activity", 939], ["but", 948], ["strongly", 952], ["dissipated", 961], ["the", 972], ["proton", 976], ["gradient", 983], ["formed", 992], ["in", 999], ["the", 1002], ["gastric", 1006], ["membrane", 1014], ["vesicles", 1023], ["and", 1032], ["reduced", 1036], ["the", 1044], ["volume", 1048], ["of", 1055], ["luminal", 1058], ["space", 1066], [".", 1071], ["Thus", 1073], ["KN-93", 1078], ["acts", 1084], ["at", 1089], ["pH", 1092], ["gradient", 1095], ["formation", 1104], ["whereas", 1114], ["KN-62", 1122], ["acts", 1128], ["only", 1133], ["at", 1138], ["CaM", 1141], ["Kinase", 1145], ["II", 1152], [".", 1154]]}
{"context": "The vitamin K antagonists (VKAs) have been the standard (and only) oral anticoagulants used for the long-term treatment or prevention of venous thromboembolism or stroke in patients with atrial fibrillation. The coagulopathy induced by VKAs can be reversed with vitamin K, and in urgent situations, the vitamin K-dependent coagulation factors can be replaced by transfusion. In the last decade, a new class of oral anticoagulants has been developed, direct oral anticoagulants that bind to a specific coagulation factor and neutralize it. These compounds were shown to be effective and safe compared with the VKAs and were licensed for specific indications, but without a specific reversal agent. The absence of a reversal agent is a barrier to more widespread use of these agents. Currently, for the management of major life-threatening bleeding with the direct oral anticoagulants, most authorities recommend the use of four factor prothrombin complex concentrates. There are now three reversal agents in development and poised to enter the market. Idarucizumab is a specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran, which was recently approved for use in the USA. Andexanet alfa is an antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor enoxaparin. Ciraparantag is an antidote targeted to reverse the direct thrombin and factor Xa inhibitors as well as the indirect inhibitor enoxaparin.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "708d81adb4e44a03ab3e302e8165cec5", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[197, 197]], "char_spans": [[1138, 1147]]}]}], "context_tokens": [["The", 0], ["vitamin", 4], ["K", 12], ["antagonists", 14], ["(", 26], ["VKAs", 27], [")", 31], ["have", 33], ["been", 38], ["the", 43], ["standard", 47], ["(", 56], ["and", 57], ["only", 61], [")", 65], ["oral", 67], ["anticoagulants", 72], ["used", 87], ["for", 92], ["the", 96], ["long", 100], ["-", 104], ["term", 105], ["treatment", 110], ["or", 120], ["prevention", 123], ["of", 134], ["venous", 137], ["thromboembolism", 144], ["or", 160], ["stroke", 163], ["in", 170], ["patients", 173], ["with", 182], ["atrial", 187], ["fibrillation", 194], [".", 206], ["The", 208], ["coagulopathy", 212], ["induced", 225], ["by", 233], ["VKAs", 236], ["can", 241], ["be", 245], ["reversed", 248], ["with", 257], ["vitamin", 262], ["K", 270], [",", 271], ["and", 273], ["in", 277], ["urgent", 280], ["situations", 287], [",", 297], ["the", 299], ["vitamin", 303], ["K", 311], ["-", 312], ["dependent", 313], ["coagulation", 323], ["factors", 335], ["can", 343], ["be", 347], ["replaced", 350], ["by", 359], ["transfusion", 362], [".", 373], ["In", 375], ["the", 378], ["last", 382], ["decade", 387], [",", 393], ["a", 395], ["new", 397], ["class", 401], ["of", 407], ["oral", 410], ["anticoagulants", 415], ["has", 430], ["been", 434], ["developed", 439], [",", 448], ["direct", 450], ["oral", 457], ["anticoagulants", 462], ["that", 477], ["bind", 482], ["to", 487], ["a", 490], ["specific", 492], ["coagulation", 501], ["factor", 513], ["and", 520], ["neutralize", 524], ["it", 535], [".", 537], ["These", 539], ["compounds", 545], ["were", 555], ["shown", 560], ["to", 566], ["be", 569], ["effective", 572], ["and", 582], ["safe", 586], ["compared", 591], ["with", 600], ["the", 605], ["VKAs", 609], ["and", 614], ["were", 618], ["licensed", 623], ["for", 632], ["specific", 636], ["indications", 645], [",", 656], ["but", 658], ["without", 662], ["a", 670], ["specific", 672], ["reversal", 681], ["agent", 690], [".", 695], ["The", 697], ["absence", 701], ["of", 709], ["a", 712], ["reversal", 714], ["agent", 723], ["is", 729], ["a", 732], ["barrier", 734], ["to", 742], ["more", 745], ["widespread", 750], ["use", 761], ["of", 765], ["these", 768], ["agents", 774], [".", 780], ["Currently", 782], [",", 791], ["for", 793], ["the", 797], ["management", 801], ["of", 812], ["major", 815], ["life", 821], ["-", 825], ["threatening", 826], ["bleeding", 838], ["with", 847], ["the", 852], ["direct", 856], ["oral", 863], ["anticoagulants", 868], [",", 882], ["most", 884], ["authorities", 889], ["recommend", 901], ["the", 911], ["use", 915], ["of", 919], ["four", 922], ["factor", 927], ["prothrombin", 934], ["complex", 946], ["concentrates", 954], [".", 966], ["There", 968], ["are", 974], ["now", 978], ["three", 982], ["reversal", 988], ["agents", 997], ["in", 1004], ["development", 1007], ["and", 1019], ["poised", 1023], ["to", 1030], ["enter", 1033], ["the", 1039], ["market", 1043], [".", 1049], ["Idarucizumab", 1051], ["is", 1064], ["a", 1067], ["specific", 1069], ["antidote", 1078], ["targeted", 1087], ["to", 1096], ["reverse", 1099], ["the", 1107], ["direct", 1111], ["thrombin", 1118], ["inhibitor", 1127], [",", 1136], ["dabigatran", 1138], [",", 1148], ["which", 1150], ["was", 1156], ["recently", 1160], ["approved", 1169], ["for", 1178], ["use", 1182], ["in", 1186], ["the", 1189], ["USA", 1193], [".", 1196], ["Andexanet", 1198], ["alfa", 1208], ["is", 1213], ["an", 1216], ["antidote", 1219], ["targeted", 1228], ["to", 1237], ["reverse", 1240], ["the", 1248], ["oral", 1252], ["direct", 1257], ["factor", 1264], ["Xa", 1271], ["inhibitors", 1274], ["as", 1285], ["well", 1288], ["as", 1293], ["the", 1296], ["indirect", 1300], ["inhibitor", 1309], ["enoxaparin", 1319], [".", 1329], ["Ciraparantag", 1331], ["is", 1344], ["an", 1347], ["antidote", 1350], ["targeted", 1359], ["to", 1368], ["reverse", 1371], ["the", 1379], ["direct", 1383], ["thrombin", 1390], ["and", 1399], ["factor", 1403], ["Xa", 1410], ["inhibitors", 1413], ["as", 1424], ["well", 1427], ["as", 1432], ["the", 1435], ["indirect", 1439], ["inhibitor", 1448], ["enoxaparin", 1458], [".", 1468]]}
{"context": "In patients with active rheumatoid arthritis despite therapy with DMARDS, treatment with a spleen tyrosine kinase inhibitor has achieved similar response rates to those achieved in clinical trials of other drugs, including biologic agents. Where might these agents fit in the current armamentarium against this disease?", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "6cdfaee03ce4412b9875775aca7ac48e", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[14, 16]], "char_spans": [[91, 112]]}]}], "context_tokens": [["In", 0], ["patients", 3], ["with", 12], ["active", 17], ["rheumatoid", 24], ["arthritis", 35], ["despite", 45], ["therapy", 53], ["with", 61], ["DMARDS", 66], [",", 72], ["treatment", 74], ["with", 84], ["a", 89], ["spleen", 91], ["tyrosine", 98], ["kinase", 107], ["inhibitor", 114], ["has", 124], ["achieved", 128], ["similar", 137], ["response", 145], ["rates", 154], ["to", 160], ["those", 163], ["achieved", 169], ["in", 178], ["clinical", 181], ["trials", 190], ["of", 197], ["other", 200], ["drugs", 206], [",", 211], ["including", 213], ["biologic", 223], ["agents", 232], [".", 238], ["Where", 240], ["might", 246], ["these", 252], ["agents", 258], ["fit", 265], ["in", 269], ["the", 272], ["current", 276], ["armamentarium", 284], ["against", 298], ["this", 306], ["disease", 311], ["?", 318]]}
{"context": "Restless legs syndrome (RLS), also known as Willis-Ekbom Disease (WED), is a sensorimotor disorder for which the exact pathophysiology remains unclear. Brain iron insufficiency and altered dopaminergic function appear to play important roles in the etiology of the disorder. This concept is based partly on extensive research studies using cerebrospinal fluid (CSF), autopsy material, and brain imaging indicating reduced regional brain iron and on the clinical efficacy of dopamine receptor agonists for alleviating RLS symptoms. Finding causal relations, linking low brain iron to altered dopaminergic function in RLS, has required however the use of animal models. These models have provided insights into how alterations in brain iron homeostasis and dopaminergic system may be involved in RLS. The results of animal models of RLS and biochemical, postmortem, and imaging studies in patients with the disease suggest that disruptions in brain iron trafficking lead to disturbances in striatal dopamine neurotransmission for at least some patients with RLS. This review examines the data supporting an iron deficiency-dopamine metabolic theory of RLS by relating the results from animal model investigations of the influence of brain iron deficiency on dopaminergic systems to data from clinical studies in patients with RLS.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "363dd991aef248d6b70acffea567a64a", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], ["(", 23], ["RLS", 24], [")", 27], [",", 28], ["also", 30], ["known", 35], ["as", 41], ["Willis", 44], ["-", 50], ["Ekbom", 51], ["Disease", 57], ["(", 65], ["WED", 66], [")", 69], [",", 70], ["is", 72], ["a", 75], ["sensorimotor", 77], ["disorder", 90], ["for", 99], ["which", 103], ["the", 109], ["exact", 113], ["pathophysiology", 119], ["remains", 135], ["unclear", 143], [".", 150], ["Brain", 152], ["iron", 158], ["insufficiency", 163], ["and", 177], ["altered", 181], ["dopaminergic", 189], ["function", 202], ["appear", 211], ["to", 218], ["play", 221], ["important", 226], ["roles", 236], ["in", 242], ["the", 245], ["etiology", 249], ["of", 258], ["the", 261], ["disorder", 265], [".", 273], ["This", 275], ["concept", 280], ["is", 288], ["based", 291], ["partly", 297], ["on", 304], ["extensive", 307], ["research", 317], ["studies", 326], ["using", 334], ["cerebrospinal", 340], ["fluid", 354], ["(", 360], ["CSF", 361], [")", 364], [",", 365], ["autopsy", 367], ["material", 375], [",", 383], ["and", 385], ["brain", 389], ["imaging", 395], ["indicating", 403], ["reduced", 414], ["regional", 422], ["brain", 431], ["iron", 437], ["and", 442], ["on", 446], ["the", 449], ["clinical", 453], ["efficacy", 462], ["of", 471], ["dopamine", 474], ["receptor", 483], ["agonists", 492], ["for", 501], ["alleviating", 505], ["RLS", 517], ["symptoms", 521], [".", 529], ["Finding", 531], ["causal", 539], ["relations", 546], [",", 555], ["linking", 557], ["low", 565], ["brain", 569], ["iron", 575], ["to", 580], ["altered", 583], ["dopaminergic", 591], ["function", 604], ["in", 613], ["RLS", 616], [",", 619], ["has", 621], ["required", 625], ["however", 634], ["the", 642], ["use", 646], ["of", 650], ["animal", 653], ["models", 660], [".", 666], ["These", 668], ["models", 674], ["have", 681], ["provided", 686], ["insights", 695], ["into", 704], ["how", 709], ["alterations", 713], ["in", 725], ["brain", 728], ["iron", 734], ["homeostasis", 739], ["and", 751], ["dopaminergic", 755], ["system", 768], ["may", 775], ["be", 779], ["involved", 782], ["in", 791], ["RLS", 794], [".", 797], ["The", 799], ["results", 803], ["of", 811], ["animal", 814], ["models", 821], ["of", 828], ["RLS", 831], ["and", 835], ["biochemical", 839], [",", 850], ["postmortem", 852], [",", 862], ["and", 864], ["imaging", 868], ["studies", 876], ["in", 884], ["patients", 887], ["with", 896], ["the", 901], ["disease", 905], ["suggest", 913], ["that", 921], ["disruptions", 926], ["in", 938], ["brain", 941], ["iron", 947], ["trafficking", 952], ["lead", 964], ["to", 969], ["disturbances", 972], ["in", 985], ["striatal", 988], ["dopamine", 997], ["neurotransmission", 1006], ["for", 1024], ["at", 1028], ["least", 1031], ["some", 1037], ["patients", 1042], ["with", 1051], ["RLS", 1056], [".", 1059], ["This", 1061], ["review", 1066], ["examines", 1073], ["the", 1082], ["data", 1086], ["supporting", 1091], ["an", 1102], ["iron", 1105], ["deficiency", 1110], ["-", 1120], ["dopamine", 1121], ["metabolic", 1130], ["theory", 1140], ["of", 1147], ["RLS", 1150], ["by", 1154], ["relating", 1157], ["the", 1166], ["results", 1170], ["from", 1178], ["animal", 1183], ["model", 1190], ["investigations", 1196], ["of", 1211], ["the", 1214], ["influence", 1218], ["of", 1228], ["brain", 1231], ["iron", 1237], ["deficiency", 1242], ["on", 1253], ["dopaminergic", 1256], ["systems", 1269], ["to", 1277], ["data", 1280], ["from", 1285], ["clinical", 1290], ["studies", 1299], ["in", 1307], ["patients", 1310], ["with", 1319], ["RLS", 1324], [".", 1327]]}
{"context": "alpha-Synuclein is a presynaptic protein recently identified as a specific component of Lewy bodies (LB) and Lewy neurites. The aim of this study was to assess the morphology and distribution of alpha-synuclein immunoreactivity in cases of dementia with LB (DLB), and to compare alpha-synuclein with ubiquitin immunostaining. We examined substantia nigra, paralimbic regions (entorhinal cortex, cingulate gyrus, insula and hippocampus), and neocortex (frontal and occipital association cortices) with double alpha-synuclein and ubiquitin immunostaining in 25 cases meeting neuropathological criteria for DLB. alpha-Synuclein immunostaining was more specific than ubiquitin immunostaining in that it differentiated LB from globose tangles. It was also slightly more sensitive, staining 4-5% more intracytoplasmic structures, especially diffuse alpha-synuclein deposits that were ubiquitin negative. In addition to LB, alpha-synuclein staining showed filiform and globose neurites in the substantia nigra, CA2-3 regions of the hippocampus, and entorhinal cortex. A spectrum of alpha-synuclein staining was seen in substantia nigra: from diffuse \"cloud-like\" inclusions to aggregated intracytoplasmic inclusions with variable ubiquitin staining to classic LB. We hypothesize that these represent different stages in LB formation.", "qas": [{"question": "Against which protein is the antibody used for immonostaining of Lewy bodies raised?", "answers": ["alpha-Synuclein"], "qid": "657d5d7eecf249cb96e36f5b3a818fcf", "question_tokens": [["Against", 0], ["which", 8], ["protein", 14], ["is", 22], ["the", 25], ["antibody", 29], ["used", 38], ["for", 43], ["immonostaining", 47], ["of", 62], ["Lewy", 65], ["bodies", 70], ["raised", 77], ["?", 83]], "detected_answers": [{"text": "alpha-Synuclein", "token_spans": [[36, 38], [142, 144], [156, 158], [53, 55], [90, 92], [105, 107], [185, 187], [0, 2]], "char_spans": [[195, 209], [843, 857], [917, 931], [279, 293], [508, 522], [609, 623], [1075, 1089], [0, 14]]}]}], "context_tokens": [["alpha", 0], ["-", 5], ["Synuclein", 6], ["is", 16], ["a", 19], ["presynaptic", 21], ["protein", 33], ["recently", 41], ["identified", 50], ["as", 61], ["a", 64], ["specific", 66], ["component", 75], ["of", 85], ["Lewy", 88], ["bodies", 93], ["(", 100], ["LB", 101], [")", 103], ["and", 105], ["Lewy", 109], ["neurites", 114], [".", 122], ["The", 124], ["aim", 128], ["of", 132], ["this", 135], ["study", 140], ["was", 146], ["to", 150], ["assess", 153], ["the", 160], ["morphology", 164], ["and", 175], ["distribution", 179], ["of", 192], ["alpha", 195], ["-", 200], ["synuclein", 201], ["immunoreactivity", 211], ["in", 228], ["cases", 231], ["of", 237], ["dementia", 240], ["with", 249], ["LB", 254], ["(", 257], ["DLB", 258], [")", 261], [",", 262], ["and", 264], ["to", 268], ["compare", 271], ["alpha", 279], ["-", 284], ["synuclein", 285], ["with", 295], ["ubiquitin", 300], ["immunostaining", 310], [".", 324], ["We", 326], ["examined", 329], ["substantia", 338], ["nigra", 349], [",", 354], ["paralimbic", 356], ["regions", 367], ["(", 375], ["entorhinal", 376], ["cortex", 387], [",", 393], ["cingulate", 395], ["gyrus", 405], [",", 410], ["insula", 412], ["and", 419], ["hippocampus", 423], [")", 434], [",", 435], ["and", 437], ["neocortex", 441], ["(", 451], ["frontal", 452], ["and", 460], ["occipital", 464], ["association", 474], ["cortices", 486], [")", 494], ["with", 496], ["double", 501], ["alpha", 508], ["-", 513], ["synuclein", 514], ["and", 524], ["ubiquitin", 528], ["immunostaining", 538], ["in", 553], ["25", 556], ["cases", 559], ["meeting", 565], ["neuropathological", 573], ["criteria", 591], ["for", 600], ["DLB", 604], [".", 607], ["alpha", 609], ["-", 614], ["Synuclein", 615], ["immunostaining", 625], ["was", 640], ["more", 644], ["specific", 649], ["than", 658], ["ubiquitin", 663], ["immunostaining", 673], ["in", 688], ["that", 691], ["it", 696], ["differentiated", 699], ["LB", 714], ["from", 717], ["globose", 722], ["tangles", 730], [".", 737], ["It", 739], ["was", 742], ["also", 746], ["slightly", 751], ["more", 760], ["sensitive", 765], [",", 774], ["staining", 776], ["4", 785], ["-", 786], ["5", 787], ["%", 788], ["more", 790], ["intracytoplasmic", 795], ["structures", 812], [",", 822], ["especially", 824], ["diffuse", 835], ["alpha", 843], ["-", 848], ["synuclein", 849], ["deposits", 859], ["that", 868], ["were", 873], ["ubiquitin", 878], ["negative", 888], [".", 896], ["In", 898], ["addition", 901], ["to", 910], ["LB", 913], [",", 915], ["alpha", 917], ["-", 922], ["synuclein", 923], ["staining", 933], ["showed", 942], ["filiform", 949], ["and", 958], ["globose", 962], ["neurites", 970], ["in", 979], ["the", 982], ["substantia", 986], ["nigra", 997], [",", 1002], ["CA2", 1004], ["-", 1007], ["3", 1008], ["regions", 1010], ["of", 1018], ["the", 1021], ["hippocampus", 1025], [",", 1036], ["and", 1038], ["entorhinal", 1042], ["cortex", 1053], [".", 1059], ["A", 1061], ["spectrum", 1063], ["of", 1072], ["alpha", 1075], ["-", 1080], ["synuclein", 1081], ["staining", 1091], ["was", 1100], ["seen", 1104], ["in", 1109], ["substantia", 1112], ["nigra", 1123], [":", 1128], ["from", 1130], ["diffuse", 1135], ["\"", 1143], ["cloud", 1144], ["-", 1149], ["like", 1150], ["\"", 1154], ["inclusions", 1156], ["to", 1167], ["aggregated", 1170], ["intracytoplasmic", 1181], ["inclusions", 1198], ["with", 1209], ["variable", 1214], ["ubiquitin", 1223], ["staining", 1233], ["to", 1242], ["classic", 1245], ["LB", 1253], [".", 1255], ["We", 1257], ["hypothesize", 1260], ["that", 1272], ["these", 1277], ["represent", 1283], ["different", 1293], ["stages", 1303], ["in", 1310], ["LB", 1313], ["formation", 1316], [".", 1325]]}
{"context": "To investigate the influence of age and gender on the components of the 28-joint Disease Activity Score (DAS28) in patients with rheumatoid arthritis (RA), and to clarify whether a high DAS28 can be equally interpreted in all age groups, independent of gender. A prospective cohort of 553 patients with RA was studied for approximately 20 years after diagnosis. The single measures of disease activity and the share of different components of the DAS28 (eg, erythrocyte sedimentation rate; ESR) were analysed and compared between three age groups (<45, 45-65 and >65 years) and per gender, using analysis of variance (ANOVA). The performance of the DAS28 and its components was explored in moderate to high and low DAS28 categories. Linear mixed model analysis was used to design the models best predicting ESR and the share of ESR. ESR significantly increased with age, independent of other variables of disease activity. This increase was more pronounced in male than in female patients. Nevertheless, the share of ESR increased with age only in male patients with a low DAS28 (<3.2). If the DAS28 score was >3.2, age and gender did not have a significant effect on any components of the DAS28. C-reactive protein (CRP) and DAS28(CRP) were not influenced by age. A high DAS28 was found to perform equally in all age groups, in men and women, despite the elevating effect of age on ESR. In elderly men with low disease activity, remission rate could be underestimated by an elevated ESR.", "qas": [{"question": "Is Rheumatoid Arthritis more common in men or women?", "answers": ["Women"], "qid": "a41b67e4e4004aa6a155ea9bb5d45fc4", "question_tokens": [["Is", 0], ["Rheumatoid", 3], ["Arthritis", 14], ["more", 24], ["common", 29], ["in", 36], ["men", 39], ["or", 43], ["women", 46], ["?", 51]], "detected_answers": [{"text": "Women", "token_spans": [[264, 264]], "char_spans": [[1337, 1341]]}]}], "context_tokens": [["To", 0], ["investigate", 3], ["the", 15], ["influence", 19], ["of", 29], ["age", 32], ["and", 36], ["gender", 40], ["on", 47], ["the", 50], ["components", 54], ["of", 65], ["the", 68], ["28-joint", 72], ["Disease", 81], ["Activity", 89], ["Score", 98], ["(", 104], ["DAS28", 105], [")", 110], ["in", 112], ["patients", 115], ["with", 124], ["rheumatoid", 129], ["arthritis", 140], ["(", 150], ["RA", 151], [")", 153], [",", 154], ["and", 156], ["to", 160], ["clarify", 163], ["whether", 171], ["a", 179], ["high", 181], ["DAS28", 186], ["can", 192], ["be", 196], ["equally", 199], ["interpreted", 207], ["in", 219], ["all", 222], ["age", 226], ["groups", 230], [",", 236], ["independent", 238], ["of", 250], ["gender", 253], [".", 259], ["A", 261], ["prospective", 263], ["cohort", 275], ["of", 282], ["553", 285], ["patients", 289], ["with", 298], ["RA", 303], ["was", 306], ["studied", 310], ["for", 318], ["approximately", 322], ["20", 336], ["years", 339], ["after", 345], ["diagnosis", 351], [".", 360], ["The", 362], ["single", 366], ["measures", 373], ["of", 382], ["disease", 385], ["activity", 393], ["and", 402], ["the", 406], ["share", 410], ["of", 416], ["different", 419], ["components", 429], ["of", 440], ["the", 443], ["DAS28", 447], ["(", 453], ["eg", 454], [",", 456], ["erythrocyte", 458], ["sedimentation", 470], ["rate", 484], [";", 488], ["ESR", 490], [")", 493], ["were", 495], ["analysed", 500], ["and", 509], ["compared", 513], ["between", 522], ["three", 530], ["age", 536], ["groups", 540], ["(", 547], ["<", 548], ["45", 549], [",", 551], ["45", 553], ["-", 555], ["65", 556], ["and", 559], [">", 563], ["65", 564], ["years", 567], [")", 572], ["and", 574], ["per", 578], ["gender", 582], [",", 588], ["using", 590], ["analysis", 596], ["of", 605], ["variance", 608], ["(", 617], ["ANOVA", 618], [")", 623], [".", 624], ["The", 626], ["performance", 630], ["of", 642], ["the", 645], ["DAS28", 649], ["and", 655], ["its", 659], ["components", 663], ["was", 674], ["explored", 678], ["in", 687], ["moderate", 690], ["to", 699], ["high", 702], ["and", 707], ["low", 711], ["DAS28", 715], ["categories", 721], [".", 731], ["Linear", 733], ["mixed", 740], ["model", 746], ["analysis", 752], ["was", 761], ["used", 765], ["to", 770], ["design", 773], ["the", 780], ["models", 784], ["best", 791], ["predicting", 796], ["ESR", 807], ["and", 811], ["the", 815], ["share", 819], ["of", 825], ["ESR", 828], [".", 831], ["ESR", 833], ["significantly", 837], ["increased", 851], ["with", 861], ["age", 866], [",", 869], ["independent", 871], ["of", 883], ["other", 886], ["variables", 892], ["of", 902], ["disease", 905], ["activity", 913], [".", 921], ["This", 923], ["increase", 928], ["was", 937], ["more", 941], ["pronounced", 946], ["in", 957], ["male", 960], ["than", 965], ["in", 970], ["female", 973], ["patients", 980], [".", 988], ["Nevertheless", 990], [",", 1002], ["the", 1004], ["share", 1008], ["of", 1014], ["ESR", 1017], ["increased", 1021], ["with", 1031], ["age", 1036], ["only", 1040], ["in", 1045], ["male", 1048], ["patients", 1053], ["with", 1062], ["a", 1067], ["low", 1069], ["DAS28", 1073], ["(", 1079], ["<", 1080], ["3.2", 1081], [")", 1084], [".", 1085], ["If", 1087], ["the", 1090], ["DAS28", 1094], ["score", 1100], ["was", 1106], [">", 1110], ["3.2", 1111], [",", 1114], ["age", 1116], ["and", 1120], ["gender", 1124], ["did", 1131], ["not", 1135], ["have", 1139], ["a", 1144], ["significant", 1146], ["effect", 1158], ["on", 1165], ["any", 1168], ["components", 1172], ["of", 1183], ["the", 1186], ["DAS28", 1190], [".", 1195], ["C", 1197], ["-", 1198], ["reactive", 1199], ["protein", 1208], ["(", 1216], ["CRP", 1217], [")", 1220], ["and", 1222], ["DAS28(CRP", 1226], [")", 1235], ["were", 1237], ["not", 1242], ["influenced", 1246], ["by", 1257], ["age", 1260], [".", 1263], ["A", 1265], ["high", 1267], ["DAS28", 1272], ["was", 1278], ["found", 1282], ["to", 1288], ["perform", 1291], ["equally", 1299], ["in", 1307], ["all", 1310], ["age", 1314], ["groups", 1318], [",", 1324], ["in", 1326], ["men", 1329], ["and", 1333], ["women", 1337], [",", 1342], ["despite", 1344], ["the", 1352], ["elevating", 1356], ["effect", 1366], ["of", 1373], ["age", 1376], ["on", 1380], ["ESR", 1383], [".", 1386], ["In", 1388], ["elderly", 1391], ["men", 1399], ["with", 1403], ["low", 1408], ["disease", 1412], ["activity", 1420], [",", 1428], ["remission", 1430], ["rate", 1440], ["could", 1445], ["be", 1451], ["underestimated", 1454], ["by", 1469], ["an", 1472], ["elevated", 1475], ["ESR", 1484], [".", 1487]]}
{"context": "SECIS elements are stem-loop structures located in the 3' untranslated regions (UTRs) of eukaryotic selenoprotein mRNAs that are required for directing cotranslational selenocysteine incorporation at UGA codons. In prokaryotes, stem-loops mediating selenocysteine incorporation are located immediately downstream of the UGA selenocysteine codon, in the coding region. Previous characterization studies of the mammalian SECIS elements of type 1 deiodinase, glutathione peroxidase, and selenoprotein P showed that conserved nucleotides in the loops and unpaired bulges, and base pairing in the stems are required for SECIS function. These initial studies utilized approximately 175-230-nt segments of the 3'UTRs of the selenoprotein mRNAs. Here we define the minimal functional rat type 1 deiodinase SECIS element, a 45-nt segment, the 5' boundary of which corresponds precisely to the 5'-most critical conserved nucleotide identified previously. We also define base pairing requirements in the stem of this element. In view of the presence of SECIS elements in the open reading frames (ORFs) of bacterial selenoproteins, we examine the effects in the type 1 deiodinase of extending the ORF into the SECIS element, and find that this dramatically inhibits SECIS function. Finally, we define a minimal spacing requirement of 51-111 nt between a eukaryotic UGA selenocysteine codon and SECIS element.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "5798e357ab44416ea1ecd5323e3e7ae4", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[0, 0], [96, 96], [198, 198], [230, 230], [169, 169], [126, 126], [63, 63], [207, 207]], "char_spans": [[0, 4], [615, 619], [1198, 1202], [1382, 1386], [1042, 1046], [798, 802], [419, 423], [1254, 1258]]}]}], "context_tokens": [["SECIS", 0], ["elements", 6], ["are", 15], ["stem", 19], ["-", 23], ["loop", 24], ["structures", 29], ["located", 40], ["in", 48], ["the", 51], ["3", 55], ["'", 56], ["untranslated", 58], ["regions", 71], ["(", 79], ["UTRs", 80], [")", 84], ["of", 86], ["eukaryotic", 89], ["selenoprotein", 100], ["mRNAs", 114], ["that", 120], ["are", 125], ["required", 129], ["for", 138], ["directing", 142], ["cotranslational", 152], ["selenocysteine", 168], ["incorporation", 183], ["at", 197], ["UGA", 200], ["codons", 204], [".", 210], ["In", 212], ["prokaryotes", 215], [",", 226], ["stem", 228], ["-", 232], ["loops", 233], ["mediating", 239], ["selenocysteine", 249], ["incorporation", 264], ["are", 278], ["located", 282], ["immediately", 290], ["downstream", 302], ["of", 313], ["the", 316], ["UGA", 320], ["selenocysteine", 324], ["codon", 339], [",", 344], ["in", 346], ["the", 349], ["coding", 353], ["region", 360], [".", 366], ["Previous", 368], ["characterization", 377], ["studies", 394], ["of", 402], ["the", 405], ["mammalian", 409], ["SECIS", 419], ["elements", 425], ["of", 434], ["type", 437], ["1", 442], ["deiodinase", 444], [",", 454], ["glutathione", 456], ["peroxidase", 468], [",", 478], ["and", 480], ["selenoprotein", 484], ["P", 498], ["showed", 500], ["that", 507], ["conserved", 512], ["nucleotides", 522], ["in", 534], ["the", 537], ["loops", 541], ["and", 547], ["unpaired", 551], ["bulges", 560], [",", 566], ["and", 568], ["base", 572], ["pairing", 577], ["in", 585], ["the", 588], ["stems", 592], ["are", 598], ["required", 602], ["for", 611], ["SECIS", 615], ["function", 621], [".", 629], ["These", 631], ["initial", 637], ["studies", 645], ["utilized", 653], ["approximately", 662], ["175", 676], ["-", 679], ["230-nt", 680], ["segments", 687], ["of", 696], ["the", 699], ["3'UTRs", 703], ["of", 710], ["the", 713], ["selenoprotein", 717], ["mRNAs", 731], [".", 736], ["Here", 738], ["we", 743], ["define", 746], ["the", 753], ["minimal", 757], ["functional", 765], ["rat", 776], ["type", 780], ["1", 785], ["deiodinase", 787], ["SECIS", 798], ["element", 804], [",", 811], ["a", 813], ["45-nt", 815], ["segment", 821], [",", 828], ["the", 830], ["5", 834], ["'", 835], ["boundary", 837], ["of", 846], ["which", 849], ["corresponds", 855], ["precisely", 867], ["to", 877], ["the", 880], ["5'-most", 884], ["critical", 892], ["conserved", 901], ["nucleotide", 911], ["identified", 922], ["previously", 933], [".", 943], ["We", 945], ["also", 948], ["define", 953], ["base", 960], ["pairing", 965], ["requirements", 973], ["in", 986], ["the", 989], ["stem", 993], ["of", 998], ["this", 1001], ["element", 1006], [".", 1013], ["In", 1015], ["view", 1018], ["of", 1023], ["the", 1026], ["presence", 1030], ["of", 1039], ["SECIS", 1042], ["elements", 1048], ["in", 1057], ["the", 1060], ["open", 1064], ["reading", 1069], ["frames", 1077], ["(", 1084], ["ORFs", 1085], [")", 1089], ["of", 1091], ["bacterial", 1094], ["selenoproteins", 1104], [",", 1118], ["we", 1120], ["examine", 1123], ["the", 1131], ["effects", 1135], ["in", 1143], ["the", 1146], ["type", 1150], ["1", 1155], ["deiodinase", 1157], ["of", 1168], ["extending", 1171], ["the", 1181], ["ORF", 1185], ["into", 1189], ["the", 1194], ["SECIS", 1198], ["element", 1204], [",", 1211], ["and", 1213], ["find", 1217], ["that", 1222], ["this", 1227], ["dramatically", 1232], ["inhibits", 1245], ["SECIS", 1254], ["function", 1260], [".", 1268], ["Finally", 1270], [",", 1277], ["we", 1279], ["define", 1282], ["a", 1289], ["minimal", 1291], ["spacing", 1299], ["requirement", 1307], ["of", 1319], ["51", 1322], ["-", 1324], ["111", 1325], ["nt", 1329], ["between", 1332], ["a", 1340], ["eukaryotic", 1342], ["UGA", 1353], ["selenocysteine", 1357], ["codon", 1372], ["and", 1378], ["SECIS", 1382], ["element", 1388], [".", 1395]]}
{"context": "Ataxin-3 (AT3) is the protein that triggers the inherited neurodegenerative disorder spinocerebellar ataxia type 3 when its polyglutamine (polyQ) stretch close to the C-terminus exceeds a critical length. AT3 consists of the N-terminal globular Josephin domain (JD) and the C-terminal disordered one. It cleaves isopeptide bonds between ubiquitin monomers, an event involved in protein quality control mechanisms. AT3 has been implicated in the pathway that sorts aggregated protein to aggresomes via microtubules, in which dynein and histone deacetylase 6 (HDAC6) also seem to be involved. By taking advantage of small angle X-ray scattering (SAXS) and surface plasmon resonance (SPR), we have investigated the interaction of AT3 with tubulin and HDAC6. Based on SAXS results, the AT3 oligomer, consisting of 6-7 subunits, tightly binds to the tubulin hexameric oligomer in a \"parallel\" fashion. By SPR analysis we have demonstrated that AT3 binds to tubulin dimer with a 50nM affinity. Binding fits with a Langmuir 1:1 model and involves a single binding interface. Nevertheless, the interaction surface consists of three distinct, discontinuous tubulin-binding regions (TBR), one located in the JD, and the two others in the disordered domain, upstream and downstream of the polyQ stretch. In the absence of any of the three TBRs, the affinity is drastically reduced. By SPR we have also provided the first evidence of direct binding of AT3 to HDAC6, with affinity in the range 0.1-1\u03bcM. These results shed light on the interactions among the components of the transport machinery that sorts aggregate protein to the aggresome, and pave the way to in vivo studies aimed at further clarifying their roles.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "ff352f0d6455402e93166f8e35e032b3", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[0, 0]], "char_spans": [[0, 7]]}]}], "context_tokens": [["Ataxin-3", 0], ["(", 9], ["AT3", 10], [")", 13], ["is", 15], ["the", 18], ["protein", 22], ["that", 30], ["triggers", 35], ["the", 44], ["inherited", 48], ["neurodegenerative", 58], ["disorder", 76], ["spinocerebellar", 85], ["ataxia", 101], ["type", 108], ["3", 113], ["when", 115], ["its", 120], ["polyglutamine", 124], ["(", 138], ["polyQ", 139], [")", 144], ["stretch", 146], ["close", 154], ["to", 160], ["the", 163], ["C", 167], ["-", 168], ["terminus", 169], ["exceeds", 178], ["a", 186], ["critical", 188], ["length", 197], [".", 203], ["AT3", 205], ["consists", 209], ["of", 218], ["the", 221], ["N", 225], ["-", 226], ["terminal", 227], ["globular", 236], ["Josephin", 245], ["domain", 254], ["(", 261], ["JD", 262], [")", 264], ["and", 266], ["the", 270], ["C", 274], ["-", 275], ["terminal", 276], ["disordered", 285], ["one", 296], [".", 299], ["It", 301], ["cleaves", 304], ["isopeptide", 312], ["bonds", 323], ["between", 329], ["ubiquitin", 337], ["monomers", 347], [",", 355], ["an", 357], ["event", 360], ["involved", 366], ["in", 375], ["protein", 378], ["quality", 386], ["control", 394], ["mechanisms", 402], [".", 412], ["AT3", 414], ["has", 418], ["been", 422], ["implicated", 427], ["in", 438], ["the", 441], ["pathway", 445], ["that", 453], ["sorts", 458], ["aggregated", 464], ["protein", 475], ["to", 483], ["aggresomes", 486], ["via", 497], ["microtubules", 501], [",", 513], ["in", 515], ["which", 518], ["dynein", 524], ["and", 531], ["histone", 535], ["deacetylase", 543], ["6", 555], ["(", 557], ["HDAC6", 558], [")", 563], ["also", 565], ["seem", 570], ["to", 575], ["be", 578], ["involved", 581], [".", 589], ["By", 591], ["taking", 594], ["advantage", 601], ["of", 611], ["small", 614], ["angle", 620], ["X", 626], ["-", 627], ["ray", 628], ["scattering", 632], ["(", 643], ["SAXS", 644], [")", 648], ["and", 650], ["surface", 654], ["plasmon", 662], ["resonance", 670], ["(", 680], ["SPR", 681], [")", 684], [",", 685], ["we", 687], ["have", 690], ["investigated", 695], ["the", 708], ["interaction", 712], ["of", 724], ["AT3", 727], ["with", 731], ["tubulin", 736], ["and", 744], ["HDAC6", 748], [".", 753], ["Based", 755], ["on", 761], ["SAXS", 764], ["results", 769], [",", 776], ["the", 778], ["AT3", 782], ["oligomer", 786], [",", 794], ["consisting", 796], ["of", 807], ["6", 810], ["-", 811], ["7", 812], ["subunits", 814], [",", 822], ["tightly", 824], ["binds", 832], ["to", 838], ["the", 841], ["tubulin", 845], ["hexameric", 853], ["oligomer", 863], ["in", 872], ["a", 875], ["\"", 877], ["parallel", 878], ["\"", 886], ["fashion", 888], [".", 895], ["By", 897], ["SPR", 900], ["analysis", 904], ["we", 913], ["have", 916], ["demonstrated", 921], ["that", 934], ["AT3", 939], ["binds", 943], ["to", 949], ["tubulin", 952], ["dimer", 960], ["with", 966], ["a", 971], ["50nM", 973], ["affinity", 978], [".", 986], ["Binding", 988], ["fits", 996], ["with", 1001], ["a", 1006], ["Langmuir", 1008], ["1:1", 1017], ["model", 1021], ["and", 1027], ["involves", 1031], ["a", 1040], ["single", 1042], ["binding", 1049], ["interface", 1057], [".", 1066], ["Nevertheless", 1068], [",", 1080], ["the", 1082], ["interaction", 1086], ["surface", 1098], ["consists", 1106], ["of", 1115], ["three", 1118], ["distinct", 1124], [",", 1132], ["discontinuous", 1134], ["tubulin", 1148], ["-", 1155], ["binding", 1156], ["regions", 1164], ["(", 1172], ["TBR", 1173], [")", 1176], [",", 1177], ["one", 1179], ["located", 1183], ["in", 1191], ["the", 1194], ["JD", 1198], [",", 1200], ["and", 1202], ["the", 1206], ["two", 1210], ["others", 1214], ["in", 1221], ["the", 1224], ["disordered", 1228], ["domain", 1239], [",", 1245], ["upstream", 1247], ["and", 1256], ["downstream", 1260], ["of", 1271], ["the", 1274], ["polyQ", 1278], ["stretch", 1284], [".", 1291], ["In", 1293], ["the", 1296], ["absence", 1300], ["of", 1308], ["any", 1311], ["of", 1315], ["the", 1318], ["three", 1322], ["TBRs", 1328], [",", 1332], ["the", 1334], ["affinity", 1338], ["is", 1347], ["drastically", 1350], ["reduced", 1362], [".", 1369], ["By", 1371], ["SPR", 1374], ["we", 1378], ["have", 1381], ["also", 1386], ["provided", 1391], ["the", 1400], ["first", 1404], ["evidence", 1410], ["of", 1419], ["direct", 1422], ["binding", 1429], ["of", 1437], ["AT3", 1440], ["to", 1444], ["HDAC6", 1447], [",", 1452], ["with", 1454], ["affinity", 1459], ["in", 1468], ["the", 1471], ["range", 1475], ["0.1", 1481], ["-", 1484], ["1\u03bcM.", 1485], ["These", 1490], ["results", 1496], ["shed", 1504], ["light", 1509], ["on", 1515], ["the", 1518], ["interactions", 1522], ["among", 1535], ["the", 1541], ["components", 1545], ["of", 1556], ["the", 1559], ["transport", 1563], ["machinery", 1573], ["that", 1583], ["sorts", 1588], ["aggregate", 1594], ["protein", 1604], ["to", 1612], ["the", 1615], ["aggresome", 1619], [",", 1628], ["and", 1630], ["pave", 1634], ["the", 1639], ["way", 1643], ["to", 1647], ["in", 1650], ["vivo", 1653], ["studies", 1658], ["aimed", 1666], ["at", 1672], ["further", 1675], ["clarifying", 1683], ["their", 1694], ["roles", 1700], [".", 1705]]}
{"context": "Facioscapulohumeral Disease (FSHD) is a dominantly inherited progressive myopathy associated with aberrant production of the transcription factor, Double Homeobox Protein 4 (DUX4). The expression of DUX4 depends on an open chromatin conformation of the D4Z4 macrosatellite array and a specific haplotype on chromosome 4. Even when these requirements are met, DUX4 transcripts and protein are only detectable in a subset of cells indicating that additional constraints govern DUX4 production. Since the direction of transcription, along with the production of non-coding antisense transcripts is an important regulatory feature of other macrosatellite repeats, we developed constructs that contain the non-coding region of a single D4Z4 unit flanked by genes that report transcriptional activity in the sense and antisense directions. We found that D4Z4 contains two promoters that initiate sense and antisense transcription within the array, and that antisense transcription predominates. Transcriptional start sites for the antisense transcripts, as well as D4Z4 regions that regulate the balance of sense and antisense transcripts were identified. We show that the choice of transcriptional direction is reversible but not mutually exclusive, since sense and antisense reporter activity was often present in the same cell and simultaneously upregulated during myotube formation. Similarly, levels of endogenous sense and antisense D4Z4 transcripts were upregulated in FSHD myotubes. These studies offer insight into the autonomous distribution of muscle weakness that is characteristic of FSHD.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "3ab6c2600b684e3c8863255de919f559", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[229, 229], [3, 3], [247, 247]], "char_spans": [[1470, 1473], [29, 32], [1591, 1594]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["Disease", 20], ["(", 28], ["FSHD", 29], [")", 33], ["is", 35], ["a", 38], ["dominantly", 40], ["inherited", 51], ["progressive", 61], ["myopathy", 73], ["associated", 82], ["with", 93], ["aberrant", 98], ["production", 107], ["of", 118], ["the", 121], ["transcription", 125], ["factor", 139], [",", 145], ["Double", 147], ["Homeobox", 154], ["Protein", 163], ["4", 171], ["(", 173], ["DUX4", 174], [")", 178], [".", 179], ["The", 181], ["expression", 185], ["of", 196], ["DUX4", 199], ["depends", 204], ["on", 212], ["an", 215], ["open", 218], ["chromatin", 223], ["conformation", 233], ["of", 246], ["the", 249], ["D4Z4", 253], ["macrosatellite", 258], ["array", 273], ["and", 279], ["a", 283], ["specific", 285], ["haplotype", 294], ["on", 304], ["chromosome", 307], ["4", 318], [".", 319], ["Even", 321], ["when", 326], ["these", 331], ["requirements", 337], ["are", 350], ["met", 354], [",", 357], ["DUX4", 359], ["transcripts", 364], ["and", 376], ["protein", 380], ["are", 388], ["only", 392], ["detectable", 397], ["in", 408], ["a", 411], ["subset", 413], ["of", 420], ["cells", 423], ["indicating", 429], ["that", 440], ["additional", 445], ["constraints", 456], ["govern", 468], ["DUX4", 475], ["production", 480], [".", 490], ["Since", 492], ["the", 498], ["direction", 502], ["of", 512], ["transcription", 515], [",", 528], ["along", 530], ["with", 536], ["the", 541], ["production", 545], ["of", 556], ["non", 559], ["-", 562], ["coding", 563], ["antisense", 570], ["transcripts", 580], ["is", 592], ["an", 595], ["important", 598], ["regulatory", 608], ["feature", 619], ["of", 627], ["other", 630], ["macrosatellite", 636], ["repeats", 651], [",", 658], ["we", 660], ["developed", 663], ["constructs", 673], ["that", 684], ["contain", 689], ["the", 697], ["non", 701], ["-", 704], ["coding", 705], ["region", 712], ["of", 719], ["a", 722], ["single", 724], ["D4Z4", 731], ["unit", 736], ["flanked", 741], ["by", 749], ["genes", 752], ["that", 758], ["report", 763], ["transcriptional", 770], ["activity", 786], ["in", 795], ["the", 798], ["sense", 802], ["and", 808], ["antisense", 812], ["directions", 822], [".", 832], ["We", 834], ["found", 837], ["that", 843], ["D4Z4", 848], ["contains", 853], ["two", 862], ["promoters", 866], ["that", 876], ["initiate", 881], ["sense", 890], ["and", 896], ["antisense", 900], ["transcription", 910], ["within", 924], ["the", 931], ["array", 935], [",", 940], ["and", 942], ["that", 946], ["antisense", 951], ["transcription", 961], ["predominates", 975], [".", 987], ["Transcriptional", 989], ["start", 1005], ["sites", 1011], ["for", 1017], ["the", 1021], ["antisense", 1025], ["transcripts", 1035], [",", 1046], ["as", 1048], ["well", 1051], ["as", 1056], ["D4Z4", 1059], ["regions", 1064], ["that", 1072], ["regulate", 1077], ["the", 1086], ["balance", 1090], ["of", 1098], ["sense", 1101], ["and", 1107], ["antisense", 1111], ["transcripts", 1121], ["were", 1133], ["identified", 1138], [".", 1148], ["We", 1150], ["show", 1153], ["that", 1158], ["the", 1163], ["choice", 1167], ["of", 1174], ["transcriptional", 1177], ["direction", 1193], ["is", 1203], ["reversible", 1206], ["but", 1217], ["not", 1221], ["mutually", 1225], ["exclusive", 1234], [",", 1243], ["since", 1245], ["sense", 1251], ["and", 1257], ["antisense", 1261], ["reporter", 1271], ["activity", 1280], ["was", 1289], ["often", 1293], ["present", 1299], ["in", 1307], ["the", 1310], ["same", 1314], ["cell", 1319], ["and", 1324], ["simultaneously", 1328], ["upregulated", 1343], ["during", 1355], ["myotube", 1362], ["formation", 1370], [".", 1379], ["Similarly", 1381], [",", 1390], ["levels", 1392], ["of", 1399], ["endogenous", 1402], ["sense", 1413], ["and", 1419], ["antisense", 1423], ["D4Z4", 1433], ["transcripts", 1438], ["were", 1450], ["upregulated", 1455], ["in", 1467], ["FSHD", 1470], ["myotubes", 1475], [".", 1483], ["These", 1485], ["studies", 1491], ["offer", 1499], ["insight", 1505], ["into", 1513], ["the", 1518], ["autonomous", 1522], ["distribution", 1533], ["of", 1546], ["muscle", 1549], ["weakness", 1556], ["that", 1565], ["is", 1570], ["characteristic", 1573], ["of", 1588], ["FSHD", 1591], [".", 1595]]}
